PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Rivkees, SA; Chen, M; Kulkarni, J; Browne, J; Zhao, ZY				Rivkees, SA; Chen, M; Kulkarni, J; Browne, J; Zhao, ZY			Characterization of the murine A1 adenosine receptor promoter, potent regulation by GATA-4 and Nkx2.5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-4; POLYMERASE CHAIN-REACTION; CENTRAL-NERVOUS-SYSTEM; DNA-BINDING TARGETS; EXPRESSION; GENE; NKX-2.5; LOCALIZATION; HOMEOBOX; ELEMENTS	Adenosine acts via A1 adenosine receptors (A1ARs) in the heart and brain to potently influence mammalian physiology. A1ARs are expressed very early in embryonic development, and A1ARs are among the earliest expressed G protein coupled receptors in the heart and brain, To understand the biologic basis of A1AR expression, a genomic fragment containing the murine A1AR promoter was cloned. Reporter assay studies using DDT1 MF2 cells that express A1ARs revealed that 500 base pairs of the proximal A1AR promoter contained essential elements for A1AR gene expression. Transgenic mice with A1AR proximal promoter coupled with the beta-galactosidase reporter gene had heavy labeling of the brain and atria, consistent with normal patterns of A1AR expression. Within the proximal A1AR promoter, putative binding sites for cardiac transcription factors GATA and Nkx2.5 were identified. Co-expression studies revealed that GATA-4 and Nkx2.5 could individually drive A1AR promoter activity and act synergistically to activate A1AR expression. These observations suggest that embryonic A1AR expression involves activation of the A1AR promoter by GATA-4 and Nkx2.5.	Yale Univ, Sch Med, Div Pediat Endocrinol, New Haven, CT 06520 USA	Yale University	Rivkees, SA (corresponding author), Yale Pediat, POB 208081, New Haven, CT 06520 USA.			Zhao, Zhiyong/0000-0002-6145-7464	NHLBI NIH HHS [R01-HL58442] Funding Source: Medline; NINDS NIH HHS [R01-NS33539] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033539] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; Brundege J M, 1997, Adv Pharmacol, V39, P353, DOI 10.1016/S1054-3589(08)60076-9; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; CHESKIS B, 1995, MOL ENDOCRINOL, V9, P1814, DOI 10.1210/me.9.12.1814; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; ENGELAND K, 1995, J BIOL CHEM, V270, P24572, DOI 10.1074/jbc.270.41.24572; Fenton SE, 1996, J BIOL CHEM, V271, P30870, DOI 10.1074/jbc.271.48.30870; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GUTKOWSKA J, 1993, ENDOCRINOLOGY, V132, P693, DOI 10.1210/en.132.2.693; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; HIGGINS MJ, 1994, PHARM WORLD SCI, V16, P62, DOI 10.1007/BF01880657; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofman PL, 1997, AM J PHYSIOL-REG I, V273, pR1374, DOI 10.1152/ajpregu.1997.273.4.R1374; HOYLE GW, 1994, J NEUROSCI, V14, P2455; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KRIANGKUM J, 1992, NUCLEIC ACIDS RES, V20, P3793, DOI 10.1093/nar/20.14.3793; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; LINTS TJ, 1993, DEVELOPMENT, V119, P969; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; REN HZ, 1994, P NATL ACAD SCI USA, V91, P4864, DOI 10.1073/pnas.91.11.4864; Ren HZ, 1995, MOL PHARMACOL, V48, P975; Ren HZ, 1998, MOL PHARMACOL, V53, P43, DOI 10.1124/mol.53.1.43; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; RIVKEES SA, 1995, DEV BRAIN RES, V89, P202, DOI 10.1016/0165-3806(95)00120-3; Scott V, 1994, Methods Mol Biol, V31, P339; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7	32	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14204	14209		10.1074/jbc.274.20.14204	http://dx.doi.org/10.1074/jbc.274.20.14204			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318839	hybrid			2022-12-25	WOS:000080322200068
J	Sokolov, M; Lu, L; Tucker, W; Gao, F; Gegenheimer, PA; Richter, ML				Sokolov, M; Lu, L; Tucker, W; Gao, F; Gegenheimer, PA; Richter, ML			The 20 C-terminal amino acid residues of the chloroplast ATP synthase gamma subunit are not essential for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; BINDING CHANGE MECHANISM; ESCHERICHIA-COLI; EPSILON-SUBUNIT; F1-ATPASE; STOICHIOMETRY; MITOCHONDRIA; RESOLUTION; EXPRESSION; CATALYSIS	It has been suggested that the last seven to nine amino acid residues at the C terminus of the gamma subunit of the ATP synthase act as a spindle for relation of the gamma subunit with respect to the c alpha beta subunits during catalysis (Abrahams, J. P,, Leslie, A. G. W., Lutter, R,, and Walker, J, E, (1994) Nature 370, 621-628), To test this hypothesis we selectively deleted C-terminal residues from the chloroplast gamma subunit, two at a time starting at the sixth residue from the end and finishing at the 20th residue from. the end. The mutant gamma genes were overexpressed in Escherichia coli and assembled with a native alpha(3)beta(3) complex, All the mutant forms of gamma assembled as effectively as the wild-type gamma. Deletion of the terminal 6 residues of gamma resulted in a significant increase (>50%) in the Ca-dependent ATPase activity when compared with the wildtype assembly. The increased activity persisted even after deletion of the C-terminal 14 residues, well beyond the seven residues proposed to form the spindle. Further deletions resulted in a decreased activity to similar to 19% of that of the wild-type enzyme after deleting all 20 C-terminal residues. The results indicate that the tip of the gamma C terminus is not essential for catalysis and raise questions about the role of the C terminus as a spindle for rotation.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of Kansas	Richter, ML (corresponding author), Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.	markl@kuhub.cc.ukans.edu	Gegenheimer, Peter Albert/E-2271-2013	Gegenheimer, Peter Albert/0000-0001-9863-1545				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANTHON GE, 1986, BIOCHIM BIOPHYS ACTA, V848, P92, DOI 10.1016/0005-2728(86)90164-7; Averboukh L, 1996, BIOTECHNIQUES, V20, P918; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZG, 1995, J BIOL CHEM, V270, P17124, DOI 10.1074/jbc.270.29.17124; CHEN ZG, 1992, FEBS LETT, V298, P69, DOI 10.1016/0014-5793(92)80024-B; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; GAO F, 1995, J BIOL CHEM, V270, P9763, DOI 10.1074/jbc.270.17.9763; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HU NM, 1993, J BIOL CHEM, V268, P8536; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1979, J BIOL CHEM, V254, P8951; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; RICHTER ML, 1996, ADV PHOTOSYNTH, V4, P453; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 2002, MOL CLONING LAB MANU; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	30	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13824	13829		10.1074/jbc.274.20.13824	http://dx.doi.org/10.1074/jbc.274.20.13824			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318787	hybrid			2022-12-25	WOS:000080322200016
J	Jimenez-Lara, AM; Aranda, A				Jimenez-Lara, AM; Aranda, A			Lysine 246 of the vitamin D receptor is crucial for ligand-dependent interaction with coactivators and transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; THYROID-HORMONE RECEPTOR; ACTIVATION FUNCTION AF-2; NUCLEAR-RECEPTOR; BINDING DOMAIN; HISTONE ACETYLTRANSFERASE; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; CONSERVED REGION; ACID RECEPTORS	Mutant R246A in the predicted helix 3 of the ligand-binding domain, as well as mutants L417S and E420Q in helix 12, which contains the core ligand-dependent transcriptional activation domain (AF-2), were generated to examine AF-2 activity of the vitamin D receptor (VDR), These mutations abolished vitamin D-dependent transactivation. In addition, VDR mediates a ligand-dependent repression of the response of the retinoic acid receptor beta 2 promoter to retinoic acid, and the helix 3 and helix 12 mutants were unable to mediate transrepression. Furthermore, the VDR mutants, but not the native receptor, enhanced phorbol ester induction of the activator protein-1-containing collagenase promoter. The helix 3 and helix 12 mutations strikingly reduced the ability of VDR to interact with the coactivators steroid receptor coactivator-1, ACTR, and the CREB-binding protein. As a consequence, overexpression of steroid receptor coactivator-1 increased vitamin D-dependent transactivation by VDR but not by the K246A mutant. These results indicate that the lysine 246 participates, together with residues in helix 12, in the recruitment of coactivators and that AF-2 activity is involved both in ligand dependent transactivation and in transrepression by VDR.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Aranda, Ana/ABG-8820-2020; Jiménez-Lara, Ana-María/ABF-5639-2020	Aranda, Ana/0000-0002-8338-9589; Jiménez-Lara, Ana-María/0000-0001-6471-9741				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Helmer EB, 1996, ENDOCRINOLOGY, V137, P390, DOI 10.1210/en.137.2.390; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; JIMENEZLARA AM, 1999, IN PRESS ENDOCRINOLO; Jin CH, 1996, MOL ENDOCRINOL, V10, P945, DOI 10.1210/me.10.8.945; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; MILBURN MV, 1997, EMBO WORKSH STRUCT F; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; ONATE SA, 1995, SCIENCE, V270, P1354; Palomino T, 1998, J BIOL CHEM, V273, P27541, DOI 10.1074/jbc.273.42.27541; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; SONE T, 1991, J BIOL CHEM, V266, P23296; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WAYS DK, 1993, MOL ENDOCRINOL, V7, P1112, DOI 10.1210/me.7.9.1112; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZHAO LJ, 1993, METHOD ENZYMOL, V217, P218	49	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13503	13510		10.1074/jbc.274.19.13503	http://dx.doi.org/10.1074/jbc.274.19.13503			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224118	Green Published, hybrid			2022-12-25	WOS:000080200400080
J	Richardson, TP; Trinkaus-Randall, V; Nugent, MA				Richardson, TP; Trinkaus-Randall, V; Nugent, MA			Regulation of basic fibroblast growth factor binding and activity by cell density and heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR RECEPTOR; ENDOTHELIAL-CELLS; CORNEAL SCARS; PROTEOGLYCANS; RELEASE; MYOFIBROBLASTS; MITOGENESIS; DEGRADATION; MECHANISM	The role of cell density in modulating basic fibroblast growth factor binding and activity was investigated. A primary corneal stromal fibroblast cell culture system was used, since these cells do not constitutively express heparan sulfate proteoglycans in vivo except after injury. A 3-5-fold reduction in bFGF binding per cell was observed as cell density increased from 1000 to 35,000 cells/cm(2). The cell density-dependent change in bFGF binding was not the result of altered FGFR expression as determined by equilibrium binding experiments and by immunoblot analysis. However, bFGF-cell surface receptor binding affinities were measured to be 10-20-fold higher at low cell densities than at intermediate and high cell density. bFGF-induced cell proliferation was also cell density-dependent, with maximal stimulation of proliferation 190-280% greater at intermediate densities (15,000 cells/cm(2)) than at other cell densities. This effect was specific to bFGF as serum, epidermal growth factor, and transforming growth factor-beta did not exhibit the same density-dependent profile. Further, heparan sulfate proteoglycans and, specifically, syndecan-4 were implicated as the modulator of bFGF binding and activity. Pretreatment of cell cultures with heparinase resulted in reduced bFGF binding to the cells and abrogated bFGF induced proliferation. These data suggest a mechanism by which cell density regulates heparan sulfate proteoglycan expression and modulates the cellular response to bFGF. Modulation of heparan sulfate proteoglycan expression might be an important aspect of the regulation of stromal cell migration and proliferation during wound healing.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA	Boston University; Boston University	Nugent, MA (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.			Trinkaus-Randall, Vickery/0000-0002-8573-9108; Nugent, Matthew/0000-0002-8630-4712	NEI NIH HHS [EY110004] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; BROWN CT, 1995, J CELL BIOCHEM, V59, P57, DOI 10.1002/jcb.240590108; Brown CT, 1999, J BIOL CHEM, V274, P7111, DOI 10.1074/jbc.274.11.7111; CINTRON C, 1990, INVEST OPHTH VIS SCI, V31, P1975; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; Guillonneau X, 1998, MOL BIOL CELL, V9, P2785, DOI 10.1091/mbc.9.10.2785; HANNEKEN A, 1995, INVEST OPHTH VIS SCI, V36, P1192; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Masur SK, 1996, P NATL ACAD SCI USA, V93, P4219, DOI 10.1073/pnas.93.9.4219; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; RAO RC, 1992, J OCUL PHARMACOL, V8, P77, DOI 10.1089/jop.1992.8.77; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rich CB, 1996, J BIOL CHEM, V271, P23043, DOI 10.1074/jbc.271.38.23043; Safaiyan F, 1998, EUR J BIOCHEM, V252, P576, DOI 10.1046/j.1432-1327.1998.2520576.x; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHMIDT A, 1990, EUR J CELL BIOL, V52, P229; SkaletzRorowski A, 1996, ARTERIOSCL THROM VAS, V16, P1063, DOI 10.1161/01.ATV.16.8.1063; Spanakis SG, 1998, INVEST OPHTH VIS SCI, V39, P1320; TRINKAUSRANDALL V, 1990, INVEST OPHTH VIS SCI, V31, P1321; TRIPATHI RC, 1992, EXP EYE RES, V54, P447, DOI 10.1016/0014-4835(92)90056-X; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; WATSKY MA, 1995, INVEST OPHTH VIS SCI, V36, P2568; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13534	13540		10.1074/jbc.274.19.13534	http://dx.doi.org/10.1074/jbc.274.19.13534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224122	hybrid			2022-12-25	WOS:000080200400084
J	DeFife, KM; Jenney, CR; Colton, E; Anderson, JM				DeFife, KM; Jenney, CR; Colton, E; Anderson, JM			Disruption of filamentous actin inhibits human macrophage fusion	FASEB JOURNAL			English	Article						microfilaments; foreign body giant cells; cytochalasins; macrophage mannose receptor	GIANT-CELL FORMATION; MANNOSE RECEPTOR ACTIVITY; HUMAN-MONOCYTES; BINDING-SITES; INTERLEUKIN-4; PHAGOCYTOSIS; EXPRESSION; ADHESION; RECOGNITION; CYTOCHALASINS	The foreign body reaction to implanted biomaterials, characterized by the presence of macrophages and foreign body giant cells (FBGC), can result in structural and functional failure of the implant. Recently, we have shown that interleukin-4 and interleukin-13 can independently induce human macrophage fusion to form FBGC via a macrophage mannose receptor (MR) -mediated pathway. The MR is believed to mediate both endocytosis of glycoproteins and phagocytosis of microorganisms, which bear terminal mannose, fucose, N-acetylglucosamine, or glucose residues. Polarization of microfilaments to closely apposed macrophage membranes as observed with fluorescence confocal microscopy led us to ask whether MR-mediated fusion occurred via a filamentous actin-dependent pathway. Cytochalasins B and D and latrunculin-A, agents that disrupt microfilaments, inhibited macrophage fusion in a concentration-dependent manner. The concentrations of cytochalasins D and B that inhibited fusion did not significantly decrease macrophage adhesion, spreading, or motility but did inhibit internalization of Candida albicans during interleukin-13-enhanced, MR-mediated phagocytosis, Very low concentrations of cytochalasin B (< 2 mu M) induced a slight enhancement of macrophage fusion, Taken together, the results of this study suggest that cytokine-induced, MR-mediated macrophage fusion requires an intact F-actin cytoskeleton and that the mechanism of fusion is similar to phagocytosis.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Anderson, JM (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.				NHLBI NIH HHS [HL 55714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATO PA, 1983, J CELL BIOL, V96, P750, DOI 10.1083/jcb.96.3.750; ANDERSON JM, 1993, CARDIOVASC PATHOL, V2, pS33; CHAMBERS TJ, 1982, IMMUNOBIOLOGY, V161, P283, DOI 10.1016/S0171-2985(82)80084-3; COLLIER TO, 1998, 71 SCI SESS AM HEART; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DARNELL J, 1990, MOL CELL BIOL, P554; DeFife KM, 1997, J IMMUNOL, V158, P3385; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; GIAIMIS J, 1992, J IMMUNOL METHODS, V154, P185, DOI 10.1016/0022-1759(92)90191-U; Greenberg Steven, 1993, P941; GREISLER HP, 1996, HUMAN BIOMATERIALS A; HASSAN NF, 1989, J IMMUNOL, V143, P2179; HE YW, 1995, J IMMUNOL, V155, P9; HEALY KE, 1994, BIOTECHNOL BIOENG, V43, P792, DOI 10.1002/bit.260430814; HENSON PM, 1988, INFLAMMATION BASIC P, P363; Jenney CR, 1998, J BIOMED MATER RES, V41, P171, DOI 10.1002/(SICI)1097-4636(199808)41:2<171::AID-JBM1>3.0.CO;2-F; KAO WYJ, 1995, J BIOMED MATER RES, V29, P1267, DOI 10.1002/jbm.820291014; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; KURACHI T, 1994, J BONE MINER RES, V9, pS179; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LEHTO VP, 1982, LAB INVEST, V47, P391; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MAHONEY EM, 1977, P NATL ACAD SCI USA, V74, P4895, DOI 10.1073/pnas.74.11.4895; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; McNally AK, 1996, AM J PATHOL, V149, P975; MCNALLY AK, 1995, AM J PATHOL, V147, P1487; MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119; MURCH AR, 1982, J PATHOL, V137, P177, DOI 10.1002/path.1711370302; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NEWMAN SL, 1991, J IMMUNOL, V146, P967; NORTON JM, 1980, J IMMUNOL, V125, P252; OHALLORAN TJ, 1992, J CELL BIOL, V118, P1371, DOI 10.1083/jcb.118.6.1371; ONO M, 1993, BIOL CELL, V77, P219, DOI 10.1016/S0248-4900(05)80191-1; RAMPAL AL, 1980, BIOCHEMISTRY-US, V19, P679, DOI 10.1021/bi00545a011; REAVEN EP, 1973, J CELL BIOL, V59, P12, DOI 10.1083/jcb.59.1.12; SCHREIBER S, 1990, CELL REGUL, V1, P403, DOI 10.1091/mbc.1.5.403; SHEPHERD VL, 1982, J RETICULOENDOTH SOC, V32, P423; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Smetana K, 1996, BIOMATERIALS, V17, P741, DOI 10.1016/0142-9612(96)86745-7; SOZZANI P, 1995, J BIOL CHEM, V270, P5084, DOI 10.1074/jbc.270.10.5084; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; STOKES K, 1995, J BIOMATER APPL, V9, P321, DOI 10.1177/088532829500900402; SUTTON JS, 1966, J CELL BIOL, V28, P303, DOI 10.1083/jcb.28.2.303; Tapper H, 1996, J LEUKOCYTE BIOL, V59, P613, DOI 10.1002/jlb.59.5.613; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WOODHOUSE KA, 1994, J COLLOID INTERF SCI, V164, P40, DOI 10.1006/jcis.1994.1141; YAHARA I, 1982, J CELL BIOL, V92, P69, DOI 10.1083/jcb.92.1.69; YIN HL, 1988, J CELL SCI, P169; ZHAO Q, 1991, J BIOMED MATER RES, V25, P177, DOI 10.1002/jbm.820250205	53	53	54	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					823	832		10.1096/fasebj.13.8.823	http://dx.doi.org/10.1096/fasebj.13.8.823			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224226				2022-12-25	WOS:000080372500006
J	Cooke, DW; Lane, MD				Cooke, DW; Lane, MD			The transcription factor nuclear factor I mediates repression of the GLUT4 promoter by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; GLUCOSE-TRANSPORTER GLUT4; TRANSGENIC MICE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; EUKARYOTIC TRANSCRIPTION; PROTEIN PROMOTER; BINDING PROTEIN; ADIPOSE-TISSUE; EXPRESSION; GENE	Insulin represses GLUT4 expression in 3T3-L1 adipocytes through an insulin response element located at bases -706 to -676 in the 5'-flanking sequence. Nuclear proteins related to the nuclear factor I (NF1) family of transcription factors bind to this insulin response element. Mutations that disrupt binding of NF1 proteins to the insulin response element impair the insulin response in reporter gene assays. Insulin treatment of 3T3-L1 adipocytes induces a rapid change in the level of phosphorylation of NF1 proteins, providing a potential mechanism for insulin's ability to regulate gene expression through NF1. Another as yet unidentified protein, not related to NF1, also binds to the GLUT4 insulin response element and is able to mediate partial repression of the GLUT4 promoter in reporter gene assays.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Cooke, DW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, 600 N Wolfe St, Baltimore, MD 21287 USA.				NIDDK NIH HHS [DK14575, DK02223] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002223, R01DK014575] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODEN G, 1996, DIABETES, V46, P3; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Cooke DW, 1998, J BIOL CHEM, V273, P6210, DOI 10.1074/jbc.273.11.6210; Darne CH, 1997, MOL CELL ENDOCRINOL, V132, P13, DOI 10.1016/S0303-7207(97)00116-0; DEEMS RO, 1994, DIABETOLOGIA, V37, P1097, DOI 10.1007/s001250050222; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; Fukuda H, 1997, FEBS LETT, V406, P243, DOI 10.1016/S0014-5793(97)00219-6; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P3096, DOI 10.1073/pnas.92.8.3096; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	40	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12917	12924		10.1074/jbc.274.18.12917	http://dx.doi.org/10.1074/jbc.274.18.12917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212282	hybrid			2022-12-25	WOS:000080056800102
J	Dupuy, F; Petit, JM; Mollicone, R; Oriol, R; Julien, R; Maftah, A				Dupuy, F; Petit, JM; Mollicone, R; Oriol, R; Julien, R; Maftah, A			A single amino acid in the hypervariable stem domain of vertebrate alpha 1,3/1,4-fucosyltransferases determines the type 1 type 2 transfer - Characterization of acceptor substrate specificity of the Lewis enzyme by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; HUMAN ALPHA-1,3/4-FUCOSYL-TRANSFERASES; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; HUMAN ALPHA-1,3-FUCOSYL-TRANSFERASE-V; HELICOBACTER-PYLORI; SEQUENCE ALIGNMENT; EXPRESSION CLONING; SELECTIN LIGANDS	Alignment of 15 vertebrate alpha 1,3-fucosyltransferases revealed one arginine conserved in all the enzymes employing exclusively type 2 acceptor substrates. At the equivalent position, a tryptophan was found in FUT3-encoded Lewis alpha 1,3/1,4-fucosyltransferase (Fuc-TIII) and FUT5-encoded alpha 1,3/1,4-fucosyltransferase, the only fucosyltransferases that can also transfer fucose in alpha 1,4-linkage, The single amino acid substitution Trp(111) --> Arg in Fuc-TIII was sufficient to change the specificity of fucose transfer from H-type 1 to H-type 2 accepters. The additional mutation of Asp(112) --> Glu increased the type 2 activity of the double mutant Fuc-TIII enzyme, but the single substitution of the acidic residue Asp(112) in Fuc-TIII by Glu decreased the activity of the enzyme and did not interfere with H-type 1/H-type 2 specificity. In contrast, substitution of Arg(115) in bovine futb-encoded alpha 1,3-fucosyltransferase (Fuc-Tb) by Trp generated a protein unable to transfer fucose either on H-type 1 or H-type 2 accepters. However, the double mutation Arg(115) --> TrP/Glu(116) --> Asp of Fuc-Tb slightly increased H-type 1 activity. The acidic residue adjacent to the candidate amino acid Trp/Arg seems to modulate the relative type 1/type 2 acceptor specificity, and its presence is necessary for enzyme activity since its substitution by the corresponding amide inactivated both Fuc-TIII and Fuc-Tb enzymes.	Univ Limoges, Fac Sci, Inst Biotechnol, F-87060 Limoges, France; Univ Paris 11, INSERM U504, F-94807 Villejuif, France	Universite de Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Maftah, A (corresponding author), Univ Limoges, Fac Sci, Inst Biotechnol, 123 Ave Albert Thomas, F-87060 Limoges, France.	maftah@unilim.fr						BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; Britten CJ, 1997, BBA-GEN SUBJECTS, V1334, P57, DOI 10.1016/S0304-4165(96)00076-1; CANDELIER JJ, 1993, LAB INVEST, V69, P449; CHANDRASEKARAN EV, 1995, BIOCHEMISTRY-US, V34, P4748, DOI 10.1021/bi00014a032; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; Du M, 1996, CARBOHYD RES, V286, P87, DOI 10.1016/0008-6215(96)00047-X; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GALLETPF, 1998, GLYCOBIOLOGY, V8, P919; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Hakomori S, 1997, CHEM BIOL, V4, P97, DOI 10.1016/S1074-5521(97)90253-2; HENDRICKSON TL, 1995, BIOCHEMISTRY-US, V34, P9444, DOI 10.1021/bi00029a020; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; Murray BW, 1997, BIOCHEMISTRY-US, V36, P823, DOI 10.1021/bi962284z; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Oriol R., 1995, BLOOD CEL B, P37; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Smith SL, 1997, BIOCHEM SOC T, V25, pS630, DOI 10.1042/bst025s630; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	45	64	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12257	12262		10.1074/jbc.274.18.12257	http://dx.doi.org/10.1074/jbc.274.18.12257			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212193	hybrid			2022-12-25	WOS:000080056800013
J	Pfennig, F; Schauwecker, F; Keller, U				Pfennig, F; Schauwecker, F; Keller, U			Molecular characterization of the genes of actinomycin synthetase I and of a 4-methyl-3-hydroxyanthranilic acid carrier protein involved in the assembly of the acylpeptide chain of actinomycin in Streptomyces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; YERSINIA-PESTIS; BIOSYNTHESIS; EXPRESSION; ENTEROBACTIN; PURIFICATION; CLONING; ENZYME; CHRYSOMALLUS	Actinomycin synthetase I (ACMS I) activates 4-methyl-3-hydroxyanthranilic acid, the precursor of the chromophoric moiety of the actinomycin, as adenylate, The gene acmA of ACMS I was identified upstream of the genes acmB and acmC encoding the two peptide synthetases ACMS II and ACMS III, respectively, which assemble the pentapeptide lactone rings of the antibiotic. Sequence analysis and expression of acmA in Streptomyces lividans as enzymatically active hexa-His-fusion confirmed the acmA gene product to be ACMS I. An open reading frame of 234 base pairs (acmD), which encodes a 78-amino acid protein with similarity to various acyl carrier proteins, is located downstream of acmA. The acmD gene was expressed in Escherichia coli as hexa-His-fusion protein (Acm acyl carrier protein (AcmACP)), ACMS I in the presence of ATP acylated the purified AcmACP with radioactive p-toluic acid, used as substrate in place of 4-MHA Only 10% of the AcmACP from E. coli was acylated, suggesting insufficient modification with 4'-phosphopantetheine cofactor. Incubation of this AcmACP with a holo-ACP synthase and coenzyme A quantitatively established the hole-form of AcmACP. Enzyme assays in the presence of ACMS II showed that toluyl-AcmACP directly acylated the thioester-bound threonine on ACMS II. Thus, AcmACP is a 4-MHA carrier protein in the peptide chain initiation of actinomycin synthesis.	Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, Fachgebiet Biochem & Mol Biol, D-10587 Berlin, Germany	Technical University of Berlin	Keller, U (corresponding author), Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, Fachgebiet Biochem & Mol Biol, Franklinstr 29, D-10587 Berlin, Germany.							August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Bearden SW, 1997, INFECT IMMUN, V65, P1659, DOI 10.1128/IAI.65.5.1659-1668.1997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Debabov DV, 1996, J BACTERIOL, V178, P3869, DOI 10.1128/jb.178.13.3869-3876.1996; deCrecyLagard V, 1997, J BACTERIOL, V179, P705, DOI 10.1128/jb.179.3.705-713.1997; FREI E, 1974, CANCER CHEMOTH REP 1, V58, P49; Gehring AM, 1997, BIOCHEMISTRY-US, V36, P8495, DOI 10.1021/bi970453p; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P2648, DOI 10.1021/bi9726584; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P11637, DOI 10.1021/bi9812571; GUILVOUT I, 1995, J BACTERIOL, V177, P1780, DOI 10.1128/jb.177.7.1780-1787.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; Hopwood D. A., 1985, GENETIC MANIPULATION; JONES GH, 1997, BIOTECHNOLOGY ANTIBI, P187; KATZ E, 1962, J BIOL CHEM, V237, P882; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; Katz E., 1967, ANTIBIOTICS, V2, P276; KELLER U, 1987, J BIOL CHEM, V262, P5852; KELLER U, 1984, BIOCHEMISTRY-US, V23, P1479, DOI 10.1021/bi00302a022; KELLER U, 1984, J BIOL CHEM, V259, P8226; KELLER U, 1992, J BIOL CHEM, V267, P11745; KELLER U, 1995, PETPIDOLACTONES, P71; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LI Y, 1990, GENE, V91, P9, DOI 10.1016/0378-1119(90)90156-L; LOYOZA E, 1988, EUR J BIOCHEM, V176, P661; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; Meienhofer J, 1973, Adv Appl Microbiol, V16, P203, DOI 10.1016/S0065-2164(08)70028-5; Motamedi H, 1998, EUR J BIOCHEM, V256, P528, DOI 10.1046/j.1432-1327.1998.2560528.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUSNAK F, 1991, BIOCHEMISTRY-US, V30, P2916, DOI 10.1021/bi00225a027; RUSNAK F, 1989, BIOCHEMISTRY-US, V28, P6827, DOI 10.1021/bi00443a008; RUSNAK F, 1990, BIOCHEMISTRY-US, V29, P1425, DOI 10.1021/bi00458a013; Sambrook J., 2002, MOL CLONING LAB MANU; Schauwecker F, 1998, J BACTERIOL, V180, P2468, DOI 10.1128/JB.180.9.2468-2474.1998; STAAB JF, 1989, FEMS MICROBIOL LETT, V59, P15; Staunton J, 1997, CHEM REV, V97, P2611, DOI 10.1021/cr9600316; STINDL A, 1994, BIOCHEMISTRY-US, V33, P9358, DOI 10.1021/bi00197a041; STINDL A, 1993, J BIOL CHEM, V268, P10612; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	32	34	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12508	12516		10.1074/jbc.274.18.12508	http://dx.doi.org/10.1074/jbc.274.18.12508			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212227	hybrid			2022-12-25	WOS:000080056800047
J	Togawa, A; Morinaga, N; Ogasawara, M; Moss, J; Vaughan, M				Togawa, A; Morinaga, N; Ogasawara, M; Moss, J; Vaughan, M			Purification and cloning of a brefeldin A-inhibited guanine nucleotide-exchange protein for ADP-ribosylation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GOLGI-APPARATUS; CHOLERA-TOXIN; HOMOLOGY DOMAINS; PHOSPHOLIPASE-D; SEC7 DOMAIN; ARF; CYTOHESIN-1; PLECKSTRIN; EXPRESSION; TRANSPORT	Activation of ADP-ribosylation factors (ARFs), similar to 20-kDa guanine nucleotide-binding proteins that play an important role in intracellular vesicular trafficking, depends on guanine nucleotide-exchange proteins (GEPs), which accelerate replacement of bound GDP with GTP. Two major families of ARF GEPs are known: similar to 200-kDa molecules that are inhibited by brefeldin A (BFA), a fungal metabolite that blocks protein secretion and causes apparent disintegration of Golgis structure, and similar to 50-kDa GEPs that are insensitive to BFA. We describe here two human brain cDNAs that encode BFA-inhibited GEPs. One is a similar to 209-kDa protein 99.5% identical in deduced amino acid sequence (1,849 residues) to a BFA-inhibited ARF GEP (p200) from bovine brain. The other smaller protein, which is similar to 74% identical (1,785 amino acids), represents a previously unknown gene. We propose that the former, p200, be named BIG1 for (brefeldin A-inhibited GEP1) and the second, which encodes a similar to 202-kDa protein, BIG2. A protein containing sequences found in BIG2 had been purified earlier from bovine brain. Human tissues contained a 7.5-kilobase BIG1 mRNA and a 9.4-kilobase BIG2 transcript. The BIG1 and BIG2 genes were localized, respectively, to chromosomes 8 and 20, BIG2, synthesized as a His, fusion protein in Sf9 cells, accelerated guanosine 5'-3-O-(thio)triphosphate binding by recombinant ARF1, ARF5, and ARF6, It activated native ARF (mixture of ARF1 and ARF3) more effectively than it did any of the nonmyristoylated recombinant ARFs, BIG2 activity was inhibited by BFA in a concentration-dependent manner but not by B17, a structural analog without effects on Golgi function. Although several clones for similar to 50-kDa BFA-insensitive ARF GEPs are known, these new clones for the similar to 200-kDa BIG1 and BIG2 should facilitate characterization of this rather different family of proteins as well as the elucidation of mechanisms of regulation of BFA-sensitive ARF function in Golgi transport.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Togawa, A (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000627, Z01HL000656, Z01HL000627, Z01HL000638] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; KAHN RA, 1984, J BIOL CHEM, V259, P6228; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Telemenakis I, 1997, EUR J CELL BIOL, V74, P143; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WELSH CF, 1994, MOL CELL BIOCHEM, V138, P157, DOI 10.1007/BF00928458	28	118	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12308	12315		10.1074/jbc.274.18.12308	http://dx.doi.org/10.1074/jbc.274.18.12308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212200	hybrid			2022-12-25	WOS:000080056800020
J	Imanaka, T; Aihara, K; Takano, T; Yamashita, A; Sato, R; Suzuki, Y; Yokota, S; Osumi, T				Imanaka, T; Aihara, K; Takano, T; Yamashita, A; Sato, R; Suzuki, Y; Yokota, S; Osumi, T			Characterization of the 70-kDa peroxisomal membrane protein, an ATP binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; CLOFIBRATE-TREATED RATS; FATTY-ACID OXIDATION; SACCHAROMYCES-CEREVISIAE; ABC-TRANSPORTER; BETA-OXIDATION; 3-KETOACYL-COA THIOLASE; ZELLWEGER-SYNDROME; LIVER PEROXISOMES; SIGNAL PEPTIDE	The 70-kDa peroxisomal membrane protein (PMP70) is one of the major components of rat liver peroxisomal membranes and belongs to a superfamily of proteins known as ATP binding cassette transporters. PMP70 is markedly induced by administration of hypolipidemic agents in parallel with peroxisome proliferation and induction of peroxisomal fatty acid beta-oxidation enzymes, To characterize the role of PMP70 in biogenesis and function of peroxisomes, we transfected the cDNA of rat PMP70 into Chinese hamster ovary cells and established cell lines stably expressing PMP70. The content of PMP70 in the transfectants increased about 5-fold when compared with the control cells. A subcellular fractionation study showed that overexpressed PMP70 was enriched in peroxisomes, This peroxisomal localization was confirmed by immunofluorescence and immunoelectron microscopy. The number of immune-gold particles corresponding to PMP70 on peroxisomes increased markedly in the transfectants, but the size and the number of peroxisomes were essentially the same in both the transfectants and the control cells. beta-Oxidation of palmitic acid increased about 2-3-fold in the transfectants, whereas the oxidation of lignoceric acid decreased about 30-40%. When intact peroxisomes prepared from both the cell lines were incubated with palmitoyl-CoA, oxidation was stimulated with ATP, but the degree of the stimulation was higher in the transfectants than in the control cells. Furthermore, we established three Chinese hamster ovary cell lines stably expressing mutant PMP70. In these cells, beta-oxidation of palmitic acid decreased markedly, These results suggest that PMP70 is involved in metabolic transport of long chain acyl-CoA across peroxisomal membranes and that increase of PMP70 is not associated with proliferation of peroxisomes.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Kanagawa 1990145, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Hyg Chem & Nutr, Kanagawa 1990145, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Biochem & Mol Biol Lab, Osaka 5650871, Japan; Gifu Univ, Sch Med, Dept Pediat, Gifu 5008076, Japan; Yamanashi Med Univ, Biol Lab, Yamanashi 4903898, Japan; Himeji Inst Technol, Dept Life Sci, Kamigori, Hyogo 6781297, Japan	University of Toyama; Teikyo University; Teikyo University; Osaka University; Gifu University; University of Yamanashi; University of Hyogo	Imanaka, T (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, 2630 Sugitani, Toyama 9300194, Japan.	imanaka@ms.toyama-mpu.ac.jp		Yamashita, Atsushi/0000-0002-2544-2134; Imanaka, Tsuneo/0000-0003-4677-1356				Aubourg P, 1996, ANN NY ACAD SCI, V804, P461, DOI 10.1111/j.1749-6632.1996.tb18637.x; BOSSIER P, 1994, YEAST, V10, P681, DOI 10.1002/yea.320100512; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DICZFALUSY U, 1990, J LIPID RES, V31, P307; DRAYE JP, 1988, EUR J BIOCHEM, V178, P183, DOI 10.1111/j.1432-1033.1988.tb14442.x; FARRANTS AKO, 1989, BIOCHIM BIOPHYS ACTA, V1002, P198, DOI 10.1016/0005-2760(89)90287-7; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HARTL FU, 1987, ARCH BIOCHEM BIOPHYS, V255, P109, DOI 10.1016/0003-9861(87)90300-6; HASHIMOTO T, 1986, J BIOCHEM-TOKYO, V100, P301, DOI 10.1093/oxfordjournals.jbchem.a121716; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V237, P152, DOI 10.1006/bbrc.1997.7102; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V239, P261, DOI 10.1006/bbrc.1997.7391; Imanaka T, 1996, J BIOL CHEM, V271, P3706; IMANAKA T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P264, DOI 10.1016/0005-2736(91)90401-S; JEDLITSCHKY G, 1991, J BIOL CHEM, V266, P24763; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KAMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323, DOI 10.1016/0167-4781(92)90510-7; Kawabe Y, 1998, CELL STRUCT FUNCT, V23, P187, DOI 10.1247/csf.23.187; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KOSTER W, 1992, MOL GEN GENET, V232, P399; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; OMOTE H, 1992, J BIOL CHEM, V267, P20571; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PAHAN K, 1995, J LIPID RES, V36, P986; Paton BC, 1997, AM J HUM GENET, V60, P1535; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Shan N, 1996, J BIOL CHEM, V271, P8725, DOI 10.1074/jbc.271.15.8725; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SUZUKI Y, 1991, BIOCHEM PHARMACOL, V41, P453, DOI 10.1016/0006-2952(91)90544-F; Swartzman EE, 1996, J CELL BIOL, V132, P549, DOI 10.1083/jcb.132.4.549; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; TURNBULL DM, 1984, BIOCHEM PHARMACOL, V33, P475, DOI 10.1016/0006-2952(84)90243-0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; Verhoeven NM, 1997, J LIPID RES, V38, P2062; Verleur N, 1997, EUR J BIOCHEM, V249, P657, DOI 10.1111/j.1432-1033.1997.00657.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOLVETANG EJ, 1990, BIOCHEM BIOPH RES CO, V170, P1135, DOI 10.1016/0006-291X(90)90511-K; YOKOTA S, 1982, ANN NY ACAD SCI, V386, P491, DOI 10.1111/j.1749-6632.1982.tb21460.x	50	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11968	11976		10.1074/jbc.274.17.11968	http://dx.doi.org/10.1074/jbc.274.17.11968			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207018	hybrid			2022-12-25	WOS:000079834800074
J	Kim, SY; Hwang, KY; Kim, SH; Sung, HC; Han, YS; Cho, YJ				Kim, SY; Hwang, KY; Kim, SH; Sung, HC; Han, YS; Cho, YJ			Structural basis for cold adaptation - Sequence, biochemical properties, and crystal structure of malate dehydrogenase from a psychrophile Aquaspirillium arcticum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE CITRATE SYNTHASE; ESCHERICHIA-COLI; LACTATE-DEHYDROGENASE; ANTARCTIC BACTERIUM; RESOLUTION; ENZYMES; THERMOSTABILITY; PURIFICATION; EXPRESSION; STABILITY	Aquaspillium arcticum is a psychrophilic bacterium that was isolated from arctic sediment and grows optimally at 4 degrees C, We have cloned, purified, and characterized malate dehydrogenase from A. arcticum (Aa MDH). We also have determined the crystal structures of apo-Aa MDH, Aa MDH.NADH binary complex, and Aa MDH.NAD.oxaloacetate ternary complex at 1.9-, 2.1-, and 2.5-Angstrom resolutions, respectively. The Aa MDH sequence is most closely related to the sequence of a thermophilic MDH from Thermus flavus (Tf MDH), showing 61% sequence identity and over 90% sequence similarity. Stability studies show that Aa MDH has a half-life of 10 min at 55 degrees C, whereas Tf MDH is fully active at 90 degrees C for 1 h. Aa MDH shows 2-3-fold higher catalytic efficiency compared with a mesophilic or a thermophilic MDH at the temperature range 4-10 degrees C. Structural comparison of Aa MDH and Tf MDH suggests that the increased relative flexibility of active site residues, favorable surface charge distribution for substrate and cofactor, and the reduced intersubunit ion pair interactions may be the major factors for the efficient catalytic activity of Aa MDH at low temperatures.	Korea Inst Sci & Technol, Struct Biol Ctr, Seoul 130650, South Korea; Korea Univ, Dept Biotechnol, Seoul, South Korea; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Korea Institute of Science & Technology (KIST); Korea University; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Cho, YJ (corresponding author), Korea Inst Sci & Technol, Struct Biol Ctr, POB 131, Seoul 130650, South Korea.							ABADZAPATERO C, 1987, J MOL BIOL, V198, P445, DOI 10.1016/0022-2836(87)90293-2; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; Bonisch H, 1996, ARCH BIOCHEM BIOPHYS, V333, P75, DOI 10.1006/abbi.1996.0366; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Danson MJ, 1997, COMP BIOCHEM PHYS A, V117, P307, DOI 10.1016/S0300-9629(96)00268-X; DAVAIL S, 1994, J BIOL CHEM, V269, P17448; DUNN CR, 1991, PHILOS T ROY SOC B, V332, P177, DOI 10.1098/rstb.1991.0047; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Feller G, 1997, CELL MOL LIFE SCI, V53, P830, DOI 10.1007/s000180050103; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; Feller G, 1996, FEMS MICROBIOL REV, V18, P189, DOI 10.1016/0168-6445(96)00011-3; Frolow F, 1996, NAT STRUCT BIOL, V3, P452, DOI 10.1038/nsb0596-452; Gerike U, 1997, EUR J BIOCHEM, V248, P49, DOI 10.1111/j.1432-1033.1997.00049.x; GLEASON WB, 1994, BIOCHEMISTRY-US, V33, P2078, DOI 10.1021/bi00174a014; Goldman A, 1995, STRUCTURE, V3, P1277, DOI 10.1016/S0969-2126(01)00263-5; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; HALL MD, 1993, J MOL BIOL, V232, P213, DOI 10.1006/jmbi.1993.1377; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; HERBERT RA, 1992, TRENDS BIOTECHNOL, V10, P395, DOI 10.1016/0167-7799(92)90282-Z; JORDAN DC, 1979, CAN J MICROBIOL, V25, P947, DOI 10.1139/m79-144; KELLY CA, 1993, BIOCHEMISTRY-US, V32, P3913, DOI 10.1021/bi00066a010; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; LETHERBARROW RJ, 1987, ENZFITTER NONLINEAR; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Russell RJM, 1998, STRUCTURE, V6, P351, DOI 10.1016/S0969-2126(98)00037-9; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SILVERSTEIN E, 1969, BIOCHEMISTRY-US, V8, P2543, DOI 10.1021/bi00834a042; Tsigos I, 1998, EUR J BIOCHEM, V254, P356, DOI 10.1046/j.1432-1327.1998.2540356.x; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	33	136	146	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11761	11767		10.1074/jbc.274.17.11761	http://dx.doi.org/10.1074/jbc.274.17.11761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206992	hybrid			2022-12-25	WOS:000079834800048
J	Okajima, T; Fukumoto, S; Miyazaki, H; Ishida, H; Kiso, M; Furukawa, K; Urano, T; Furukawa, K				Okajima, T; Fukumoto, S; Miyazaki, H; Ishida, H; Kiso, M; Furukawa, K; Urano, T; Furukawa, K			Molecular cloning of a novel alpha 2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; EXPRESSION CLONING; GAL-BETA-1,3GALNAC ALPHA-2,3-SIALYLTRANSFERASE; LEWIS-X; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; GALNAC ALPHA-2,6-SIALYLTRANSFERASE; SUBSTRATE SPECIFICITIES; MONOCLONAL-ANTIBODY; MASS-SPECTROMETRY; HUMAN CDNA	A novel member of the human CMP-NeuAc:beta-galacto side alpha 2,3-sialyltransferase (ST) subfamily, designated ST3Gal VI, was identified based on BLAST analysis of expressed sequence tags, and a cDNA clone was isolated from a human melanoma line library. The sequence of ST3Gal VI encoded a type II membrane protein with 2 amino acids of cytoplasmic domain, 32 amino acids of transmembrane region, and a large catalytic domain with 297 amino acids; and showed homology to previously cloned ST3Gal III, ST3Gal IV, and ST3Gal V at 34, 38, and 33%, respectively. Extracts from L cells transfected with ST3Gal VI cDNA in a expression vector and a fusion protein with protein A showed an enzyme activity of alpha 2,3-sialyltransferase toward Gal beta 1,4GlcNAc structure on glycoproteins and glycolipids, In contrast to ST3Gal III and ST3Gal IV, this enzyme exhibited restricted substrate specificity, i.e. it utilized Gal beta 1,4GlcNAc on glycoproteins, and neolactotetraosylceramide and neolactohexaosylceramide, but not lactotetraosylceramide, lactosylceramide, or asialo-GM1. Consequently, these data indicated that this enzyme is involved in the synthesis of sialyl-paragloboside, a precursor of sialyl-Lewis X determinant.	Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528501, Japan; Gifu Univ, Fac Agr, Dept Appl Bioorgan Chem, Gifu 5011193, Japan	Nagoya University; Nagasaki University; Gifu University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 466, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X; Fukumoto, Satoshi/0000-0002-5046-6891; Urano, Takeshi/0000-0003-3383-3554				DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; FURUKAWA K, 1988, J BIOL CHEM, V263, P14939; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; IUPAC-IUB Commission on Biochemical Nomenclature, 1977, LIPIDS, V12, P455; KAWASHIMA H, 1993, J BIOL CHEM, V268, P27118; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE YC, 1994, J BIOL CHEM, V269, P10028; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Miyamoto D, 1995, BIOCHEM BIOPH RES CO, V217, P852, DOI 10.1006/bbrc.1995.2850; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SASAKI S, 1994, EXP NEPHROL, V2, P269; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TAKI T, 1988, LIPIDS, V23, P192, DOI 10.1007/BF02535457; THAMPOE IJ, 1989, CANCER RES, V49, P6258; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; VALKI A, 1994, P NATL ACAD SCI USA, V91, P7390; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149	55	130	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11479	11486		10.1074/jbc.274.17.11479	http://dx.doi.org/10.1074/jbc.274.17.11479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206952	hybrid			2022-12-25	WOS:000079834800008
J	Suzuki, Y; Itakura, M; Kashiwagi, M; Nakamura, N; Matsuki, T; Sakuta, H; Naito, N; Takano, K; Fujita, T; Hirose, S				Suzuki, Y; Itakura, M; Kashiwagi, M; Nakamura, N; Matsuki, T; Sakuta, H; Naito, N; Takano, K; Fujita, T; Hirose, S			Identification by differential display of a hypertonicity-inducible inward rectifier potassium channel highly expressed in chloride cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNELS; ARBITRARILY PRIMED PCR; CLONING; REGION; RNA; EPITHELIUM; BRAIN; FISH	By using differential mRNA display to monitor the molecular alterations associated with adaptation of euryhaline eels to different salinities, we identified a cDNA fragment strongly induced in seawater eel gills. Cloning of a full-length cDNA and its expression in COS-7 cells indicated that the clone codes for an inward rectifier Rt channel (eKir) of 372 amino acid residues, which has two transmembrane segments and a typical pore-forming region (H5), Only low sequence similarities are present, except the H5 region, compared with other members of the inward rectifier K+ channel family (Kir), Consistent with this divergence in the amino acid sequence, a phylogenetic analysis indicated early divergence and independent evolution of eRir from other members; it is only distantly related to the Kir5.0 subfamily members. RNase protection analysis showed that eKir is highly expressed in the seawater eel gill, kidney, and posterior intestine but very weakly in freshwater eels. Immunohistochemistry of gill sections revealed dense localization of eKir in the chloride cells. Immunoelectron microscopy indicated that eKir is mainly present in the microtubular system in the chloride cell. This location and its salt-inducible nature suggest that the eKir channel cloned here is a novel member of the Kir5.0 subfamily in the Kir family and is implicated in osmoregulation.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Showa Univ, Coll Med Sci, Midori Ku, Yokohama, Kanagawa 2268555, Japan; Univ Tokyo, Sch Med, Dept Internal Med 4, Tokyo 1120015, Japan	Tokyo Institute of Technology; Showa University; University of Tokyo	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Nakamura, Nobuhiro/C-4265-2015	Nakamura, Nobuhiro/0000-0002-0249-2665; SUZUKI, YOSHIRO/0000-0003-0010-1867; Matsuki, Taizo/0000-0002-0591-4261				BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; BURRY RW, 1992, J HISTOCHEM CYTOCHEM, V40, P1849, DOI 10.1177/40.12.1453003; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; EVANS DH, 1990, ANNU REV PHYSIOL, V52, P43; Goksoyr A, 1995, Arch Toxicol Suppl, V17, P80; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; KATAFUCHI T, 1994, EUR J BIOCHEM, V222, P835, DOI 10.1111/j.1432-1033.1994.tb18930.x; KOBAYASHI T, 1995, BIOCHEM BIOPH RES CO, V208, P1166, DOI 10.1006/bbrc.1995.1456; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Kubo Y, 1996, J BIOL CHEM, V271, P15729, DOI 10.1074/jbc.271.26.15729; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Loretz C.A., 1995, CELLULAR MOL APPROAC, P25, DOI [10.1016/s1546-5098(08)60241-1, DOI 10.1016/S1546-5098(08)60241-1]; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; NAVARATNAM DS, 1995, J BIOL CHEM, V270, P19238, DOI 10.1074/jbc.270.33.19238; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; PISAM M, 1987, AM J ANAT, V179, P40, DOI 10.1002/aja.1001790106; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; SHIRAI N, 1972, Journal of the Faculty of Science University of Tokyo Section IV Zoology, V12, P385; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	31	52	57	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11376	11382		10.1074/jbc.274.16.11376	http://dx.doi.org/10.1074/jbc.274.16.11376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196230	hybrid			2022-12-25	WOS:000079751900098
J	FitzGerald, MJ; Arsura, M; Bellas, RE; Yang, W; Wu, M; Chin, L; Mann, KK; DePinho, RA; Sonenshein, GE				FitzGerald, MJ; Arsura, M; Bellas, RE; Yang, W; Wu, M; Chin, L; Mann, KK; DePinho, RA; Sonenshein, GE			Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc	ONCOGENE			English	Article						Max; Myc; Mad/Mxi; apoptosis; proliferation	HELIX-LOOP-HELIX; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; NEOPLASTIC TRANSFORMATION; GROWTH-FACTOR; CELL-GROWTH; B-CELLS; S-PHASE; HLA-A	dMax, a naturally occurring splice variant of the Myc binding protein Mas, lacks the DNA binding basic region and helix 1 of the Helix-Loop-Helix domain; dMax interacts with c-Myc in vitro and in vivo, and inhibits E-bos Myc site driven transcription in transient transfection assays, Here we have investigated the expression, function and interactions of dMax, RT/PCR analyses detected dmax mRNA in multiple tissues of the developing, newborn and adult mouse. Functionally, dMax reduced the ability of c-Myc to cooperate,vith the progression factor A-Myb to promote S phase entry of quiescent smooth muscle cells. In contrast, dMax failed to ablate inhibition of initiator element (Inr)-mediated transcription by c-Myc in Jurkat T cells. In in vitro protein:protein association assays, dMax interacted with c-Myc, N-Myc, L-Myc, Mad1, Mxi1, Mad3 and Mad4, but not,vith itself or wild-type Max, These interactions required an intact leucine zipper. Inhibition of E-box-mediated transactivation by induction of dMax overexpression resulted in apoptosis of WEHI 231 B cells. Thus, dMax is a widely expressed, naturally occurring protein, with the capacity to bind most members of the Myc/Max superfamily; dMax has little effect on Inr-mediated repression by c-Myc, but can significantly decrease E-bos-mediated events promoting proliferation and cell survival.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Boston University; Boston University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA36355, T32-CA64070] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA064070, R01CA036355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CROUCH DH, 1993, ONCOGENE, V8, P1849; DAVIS LJ, 1993, ONCOGENE, V8, P125; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; Hatton KS, 1996, MOL CELL BIOL, V16, P1794; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HINOSHITA F, 1992, TOXICOLOGY, V73, P203, DOI 10.1016/0300-483X(92)90103-L; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REDDY CD, 1992, ONCOGENE, V7, P2085; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEMSEI I, 1989, ONCOGENE, V4, P465; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TIBENSKY D, 1990, IMMUNOGENETICS, V32, P210, DOI 10.1007/BF02114976; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Wu M, 1996, MOL CELL BIOL, V16, P5015; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	62	14	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2489	2498		10.1038/sj.onc.1202611	http://dx.doi.org/10.1038/sj.onc.1202611			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229200				2022-12-25	WOS:000079703300009
J	Kawazoe, N; Watabe, M; Masuda, Y; Nakajo, S; Nakaya, K				Kawazoe, N; Watabe, M; Masuda, Y; Nakajo, S; Nakaya, K			Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells	ONCOGENE			English	Article						bufalin; apoptosis; Tiam1; leukemia	JNK/SAPK SIGNALING PATHWAY; PLECKSTRIN HOMOLOGY DOMAIN; HL-60 CELLS; KINASE ACTIVATION; ANTICANCER DRUGS; MAMMALIAN-CELLS; U937 CELLS; G-PROTEIN; DEATH; RAC	Bufalin, a component of the Chinese medicine chan'su, induces apoptosis in various lines of human tumor cells, such as leukemia HL60 and U937 cells, by altering the expression of apoptosis-related genes, for example, bcl-2 and c-myc. In this study, we characterized a gene that is involved in bufalin-induced apoptosis by the differential display (DD) technique, The partial nucleotide sequence of one of the differentially expressed clones obtained after treatment with bufalin was identical to that of the human gene for Tiam1, When U937 cells mere treated with 10(-7) M bufalin, expression of both Tiam1 mRNA and the protein was induced 1 h after the start of the treatment, The increase of Tiam1 mRNA was transient but the level of Tiam1 protein continued to increase at least for 6 h, In addition, the activities of Rad and p21-activated kinase (PAK) were also stimulated by bufalin treatment. To evaluate the role of Tiam1 in the apoptotic process, we examined the effects of the expression of sense and antisense RNA for Tiam1 in U937 cells, Apoptosis was strongly induced by bufalin in cells that expressed sense RNA for Tiam1 as compared to apoptosis in control cells treated with bufalin only, Cells expressing antisense RNA for Tiam1 were significantly more resistant than the control bufalin-treated cells to induction of DNA fragmentation in response to bufalin, Moreover, sense transformants had elevated activities of PAK and c-Jun NH2-terminal kinase (JNK). These results suggest that Tiam1 might play a critical role in bufalin-induced apoptosis through the activation of Rac1, PAK, and JNK pathway.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Nakaya, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.							BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BHALLA K, 1993, LEUKEMIA, V7, P563; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; DIDSBURY JR, 1987, FEBS LETT, V219, P259, DOI 10.1016/0014-5793(87)81228-0; Franklin CC, 1995, ONCOGENE, V11, P2365; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; JING YK, 1994, JPN J CANCER RES, V85, P645, DOI 10.1111/j.1349-7006.1994.tb02408.x; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANIATIS T, 1982, MOL CLONING LABORATO, P188; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MASUDA Y, 1995, LEUKEMIA RES, V19, P549, DOI 10.1016/0145-2126(95)00031-I; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOGUCHI K, 1995, JPN J CANCER RES, V86, P217, DOI 10.1111/j.1349-7006.1995.tb03042.x; NUMAZAWA S, 1994, J CELL PHYSIOL, V160, P113, DOI 10.1002/jcp.1041600114; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; ONISHI Y, 1993, BIOCHIM BIOPHYS ACTA, V1175, P147, DOI 10.1016/0167-4889(93)90017-J; PIERCE GB, 1989, P NATL ACAD SCI USA, V86, P3654, DOI 10.1073/pnas.86.10.3654; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WALKER PR, 1991, CANCER RES, V51, P1078; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG L, 1991, BIOCHEM BIOPH RES CO, V178, P686, DOI 10.1016/0006-291X(91)90162-Z	56	97	105	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2413	2421		10.1038/sj.onc.1202555	http://dx.doi.org/10.1038/sj.onc.1202555			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229192				2022-12-25	WOS:000079703300001
J	Bai, XM; Wei, G; Sinha, A; Esko, JD				Bai, XM; Wei, G; Sinha, A; Esko, JD			Chinese hamster ovary cell mutants defective in glycosaminoglycan assembly and glucuronosyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LINKAGE REGION; HUMAN SKIN FIBROBLASTS; HERPES-SIMPLEX VIRUS; N-DEACETYLASE/N-SULFOTRANSFERASE; HEPARAN-SULFATE PROTEOGLYCANS; SWARM RAT CHONDROSARCOMA; SAPORIN FUSION PROTEIN; CORE-LIKE MOLECULE; CHONDROITIN SULFATE; GOLGI-APPARATUS	The proteoglycans of animal cells typically contain one or more heparan sulfate or chondroitin sulfate chains. These glycosaminoglycans assemble on a tetrasaccharide primer, -GlcA beta 1,3Gal beta 1,3Gal beta 1,4Xyl beta-O-, attached to specific serine residues in the core protein. Studies of Chinese hamster ovary cell mutants defective in the first or second enzymes of the pathway (xylosyl-transferase and galactosyltransferase I) show that the assembly of the primer occurs by sequential transfer of single monosaccharide residues from the corresponding high energy nucleotide sugar donor to the non-reducing end of the growing chain. In order to study the other reactions involved in linkage tetrasaccharide assembly, we have devised a powerful selection method based on induced resistance to a mitotoxin composed of basic fibroblast growth factor-saporin. One class of mutants does not incorporate (SO4)-S-35 and [6-H-3]GlcN into glycosaminoglycan chains. Incubation of these cells with naphthol-beta-D-xyloside (Xyl beta-O-Np) resulted in accumulation of linkage region intermediates containing 1 or 2 mol of galactose (Gal beta 1, 4Xyl beta-O-Np and Gal beta 1, 3Gal beta 1, 4Xyl beta-O-Np) and sialic acid (Sia alpha 2,3Gal beta 1, 3Gal beta 1, 4Xyl beta-O-Np) but not any GlcA-containing oligosaccharides. Extracts of the mutants completely lacked UDP-glucluronic acid:Gal beta 1,3Gal-R glucuronosyltransferase (GlcAT-I) activity, as measured by the transfer of GlcA from UDP-GlcA to Gal beta 1,3Gal beta-O- naphthalenemethanol (<0.2 versus 3.6 pmol/min/mg). The mutation most likely lies in the structural gene encoding GlcAT-I since transfection of the mutant with a cDNA for GlcAT-I completely restored enzyme activity and glycosaminoglycan synthesis. These findings suggest that a single GlcAT effects the biosynthesis of common linkage region of both heparan sulfate and chondroitin sulfate in Chinese hamster ovary cells.	Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, Glycobiol Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Esko, JD (corresponding author), Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, Glycobiol Program, 9500 Gilman Dr,CMM E 1055, La Jolla, CA 92093 USA.	jesko@ucsd.edu						Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAKER JR, 1972, J BIOL CHEM, V247, P3838; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Cheng F, 1996, J BIOL CHEM, V271, P28572, DOI 10.1074/jbc.271.45.28572; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; Conrad H. E., 1998, HEPARIN BINDING PROT; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DeBeer T, 1996, EUR J BIOCHEM, V240, P789; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; DISTLER JJ, 1973, J BIOL CHEM, V248, P6772; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ELGAVISH A, 1988, J BIOL CHEM, V263, P18607; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; ESKO JD, 1996, CURRENT PROTOCOLS MO; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GLOSSL J, 1986, J BIOL CHEM, V261, P1920; GREVE H, 1988, GLYCOCONJUGATE J, V5, P175, DOI 10.1007/BF01061206; GRUENHEID S, 1993, J VIROL, V67, P93, DOI 10.1128/JVI.67.1.93-100.1993; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHN KV, 1977, J BIOL CHEM, V252, P6707; KATO M, 1994, J BIOL CHEM, V269, P18881; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P1175, DOI 10.1093/glycob/7.8.1175; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; Lidholt K, 1997, GLYCOCONJUGATE J, V14, P737, DOI 10.1023/A:1018525602197; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; MILLA ME, 1992, J BIOL CHEM, V267, P103; Miura Y, 1998, GLYCOBIOLOGY, V8, P813, DOI 10.1093/glycob/8.8.813; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; NAKAMURA T, 1994, BIOCHEM J, V304, P731, DOI 10.1042/bj3040731; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PRIETO I, 1991, ANN NY ACAD SCI, V638, P434, DOI 10.1111/j.1749-6632.1991.tb49062.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; ROUX L, 1988, J BIOL CHEM, V263, P8879; SALIMATH PV, 1995, J BIOL CHEM, V270, P9164, DOI 10.1074/jbc.270.16.9164; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SPEAR PG, 1992, ADV EXP MED BIOL, V313, P341; STOOLMILLER AC, 1972, J BIOL CHEM, V247, P3525; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; Takagaki K, 1996, J BIOCHEM-TOKYO, V119, P697; TEKOTTE H, 1994, J NEUROCHEM, V62, P1126; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; YAMADA S, 1995, GLYCOBIOLOGY, V5, P335, DOI 10.1093/glycob/5.3.335; YAMADA S, 1995, EUR J BIOCHEM, V233, P687, DOI 10.1111/j.1432-1033.1995.687_2.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	86	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13017	13024		10.1074/jbc.274.19.13017	http://dx.doi.org/10.1074/jbc.274.19.13017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224052	hybrid			2022-12-25	WOS:000080200400014
J	Chan, D; Freddi, S; Weng, YM; Bateman, JF				Chan, D; Freddi, S; Weng, YM; Bateman, JF			Interaction of collagen alpha 1(X) containing engineered NC1 mutations with normal alpha 1(X) in vitro - Implications for the molecular basis of schmid metaphyseal chondrodysplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL NONCOLLAGENOUS DOMAIN; X COLLAGEN; IN-VITRO; OSTEOGENESIS IMPERFECTA; NONSENSE CODONS; MESSENGER-RNA; GENE; SEQUENCE; CHAIN; CARTILAGE	Collagen X is a short-chain homotrimeric collagen expressed in the hypertrophic zone of calcifying cartilage. The clustering of mutations in the carboxyl-terminal nonhelical NC1 domain in Schmid metaphyseal chondrodysplasia (SMCD) suggests a critical role for NCI in collagen X structure and function. In vitro collagen X DNA expression, using T7-driven coupled transcription and translation, demonstrated that although alpha 1(X) containing normal NC1 domains can form electrophoretically stable trimers, engineered SMCD NC1 missense or premature termination mutations prevented the formation of electrophoretically stable homotrimers or heterotrimers when co-expressed with normal alpha 1(X), To allow the detection of more subtle interactions that may interfere with assembly but not produce SDS-stable final products, we have developed a competition-based in vitro co-expression and assembly approach. Our studies show that alpha 1(X) chains containing SMCD mutations reduce the efficiency of normal al(X) trimer assembly, indicating that interactions do occur between mutant and normal NC1 domains, which can impact on the formation of normal trimers, This finding has important implications for the molecular pathology of collagen X mutations in SMCD, Although we have previously demonstrated haploinsufficiency as one in vivo mechanism (Chan, D,, Weng, Y, M,, Hocking, A. M., Golub, S., McQuillan, D, J,, and Bateman, J, F, (1998) J, Clin. Invest, 101, 1490-1499), the current study suggests dominant interference is also possible if the mutant protein is expressed in vivo. Furthermore, we establish that a conserved 13-amino acid aromatic motif (amino acids 589-601) is critical for the interaction between the NCI domains, suggesting that this region may initiate assembly and the other NC1 mutations interfered with secondary interactions important in folding or in stabilizing the assembly process.	Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne	Bateman, JF (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.		Chan, Danny/C-4203-2009	Chan, Danny/0000-0003-3824-5778; Bateman, John/0000-0001-8542-0730				APTE SS, 1993, MATRIX, V13, P165, DOI 10.1016/S0934-8832(11)80075-2; Barber RE, 1996, BIOCHEM J, V320, P479, DOI 10.1042/bj3200479; Bateman J F, 1988, Ann N Y Acad Sci, V543, P95, DOI 10.1111/j.1749-6632.1988.tb55321.x; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BATEMAN JF, 1996, EXTRACELLULAR MATRIX, P23; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Byers Peter H., 1993, P317; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; Chan D, 1998, MATRIX BIOL, V17, P169, DOI 10.1016/S0945-053X(98)90056-7; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kielty Cay M., 1993, P103; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; LEES JF, 1994, J BIOL CHEM, V269, P24354; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MAQUAT LE, 1995, RNA, V1, P453; MASHIMA Y, 1992, AM J HUM GENET, V51, P81; MCINTOSH I, 1995, HUM MUTAT, V5, P121, DOI 10.1002/humu.1380050204; MCINTOSH I, 1994, HUM MOL GENET, V3, P303, DOI 10.1093/hmg/3.2.303; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; NERLICH AG, 1992, HISTOCHEMISTRY, V98, P275, DOI 10.1007/BF00270010; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; SCHMID TM, 1984, BIOCHEMISTRY-US, V23, P553, DOI 10.1021/bi00298a024; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; Wallis GA, 1996, J MED GENET, V33, P450, DOI 10.1136/jmg.33.6.450; Willing MC, 1996, AM J HUM GENET, V59, P799; ZHANG ZX, 1994, HUM MOL GENET, V3, P139, DOI 10.1093/hmg/3.1.139	34	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13091	13097		10.1074/jbc.274.19.13091	http://dx.doi.org/10.1074/jbc.274.19.13091			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224061	hybrid			2022-12-25	WOS:000080200400023
J	Gebhardt, F; Zanker, KS; Brandt, B				Gebhardt, F; Zanker, KS; Brandt, B			Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE; CELLS; EGFR; DNA; EXPRESSION; SEQUENCES; REGION; SITE; PCR	The influence of a highly polymorphic CA dinucleotide repeat in the epidermal growth factor receptor (EGFR) gene on transcription was examined with a quantitative nuclear run-off method. We could demonstrate that transcription of the EG;FR gene is inhibited by approximately 80% in alleles with 21 CA repeats. In experiments with polymerase chain reaction products that spanned a region of more than 4,000 base pairs and contained the promoter, two enhancers, and the polymorphic region in the first intron of the gene, we found that transcription activity declines with increasing numbers of CA dinucleotides. In vivo pre-mRNA expression data from cultured cell, lines support these findings, although other regulation mechanisms can outweigh this effect. In addition, we showed that under our experimental conditions RNA elongation terminates at a site closely downstream of the simple sequence repeat and that there are two separate major transcription start sites. Our results provide new insights in individually different EGFR gene expression and the role of the CA repeat in transcription of this proto-oncogene.	Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Witten Herdecke, Inst Immunol, D-58448 Witten, Germany	University of Munster; Witten Herdecke University	Brandt, B (corresponding author), Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany.			Brandt, Burkhard/0000-0003-3681-3049				ADAMSON ED, 1981, MOL CELL BIOCHEM, V34, P129, DOI 10.1007/BF02359619; BORNSTEIN P, 1988, MOL CELL BIOL, V8, P4851, DOI 10.1128/MCB.8.11.4851; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; Chi D. D., 1992, Human Molecular Genetics, V1, P135, DOI 10.1093/hmg/1.2.135; CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; Gabrielian A, 1996, FEBS LETT, V393, P65, DOI 10.1016/0014-5793(96)00855-1; Gabrielian A, 1996, FEBS LETT, V393, P124, DOI 10.1016/0014-5793(96)00837-X; HALEY JD, 1991, J BIOL CHEM, V266, P1746; HOU XY, 1994, J BIOL CHEM, V269, P4307; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; Roetger A, 1997, DNA CELL BIOL, V16, P443, DOI 10.1089/dna.1997.16.443; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SHEN WH, 1992, TRENDS GENET, V8, P227; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; TAE HJ, 1994, J BIOL CHEM, V269, P10475; TRAVERS AA, 1990, DNA TOPOLOGY ITS BIO; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308	24	318	331	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13176	13180		10.1074/jbc.274.19.13176	http://dx.doi.org/10.1074/jbc.274.19.13176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224073	hybrid			2022-12-25	WOS:000080200400035
J	Harvey, KF; Dinudom, A; Komwatana, P; Jolliffe, CN; Day, ML; Parasivam, G; Cook, DI; Kumar, S				Harvey, KF; Dinudom, A; Komwatana, P; Jolliffe, CN; Day, ML; Parasivam, G; Cook, DI; Kumar, S			All three WW domains of murine Nedd4 are involved in the regulation of epithelial sodium channels by intracellular Na+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OOCYTE EXPRESSION SYSTEM; LIDDLES-SYNDROME; CYTOSOLIC NA+; BETA-SUBUNIT; MISSENSE MUTATION; SALIVARY DUCTS; G-PROTEIN; PY MOTIF; HYPERTENSION; IDENTIFICATION	The amiloride-sensitive epithelial sodium channel (ENaC) plays a critical role in fluid and electrolyte homeostasis and consists of alpha, beta, and gamma subunits. The carboxyl terminus of each ENaC subunit contains a PPxY motif which is necessary for interaction with the WW domains of the ubiquitin-protein ligase, Nedd4, Disruption of this interaction, as in Liddle's syndrome where mutations delete or alter the PY motif of either the beta or gamma subunits, results in increased ENac activity. We have recently shown using the whole-cell patch clamp technique that Nedd4 mediates the ubiquitin dependent down-regulation of Na+ channel activity in response to increased intracellular Na+. In this paper, we demonstrate that WW domains 2 and 3 bind alpha-, beta-, and gamma-ENaC with varying degrees of affinity, whereas WW domain 1 does not bind to any of the subunits. We further show using whole-cell patch clamp techniques that Nedd4-mediated down-regulation of ENaC in mouse mandibular duct cells involves binding of the WW domains of Nedd4 to three distinct sites. We propose that Nedd4-mediated down-regulation of Na+ channels involves the binding of WW domains 2 and 3 to the Na+ channel and of WW domain 1 to an unknown associated protein.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia	Institute Medical & Veterinary Science Australia; University of Sydney	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.		Harvey, Kieran/AAD-5268-2022; Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814; Harvey, Kieran/0000-0001-7845-369X; Day, Margot/0000-0002-8689-7458				Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; DINUDOM A, 1995, J PHYSIOL-LONDON, V487, P549, DOI 10.1113/jphysiol.1995.sp020899; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; Farman N, 1997, AM J PHYSIOL-CELL PH, V272, pC131, DOI 10.1152/ajpcell.1997.272.1.C131; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Jeunemaitre X, 1997, J HYPERTENS, V15, P1091, DOI 10.1097/00004872-199715100-00007; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Komwatana P, 1998, J MEMBRANE BIOL, V162, P225, DOI 10.1007/s002329900360; Komwatana P, 1996, P NATL ACAD SCI USA, V93, P8107, DOI 10.1073/pnas.93.15.8107; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lehman AL, 1998, P NATL ACAD SCI USA, V95, P9436, DOI 10.1073/pnas.95.16.9436; Matsushita K, 1996, AM J PHYSIOL-LUNG C, V271, pL332, DOI 10.1152/ajplung.1996.271.2.L332; PLANT P, 1997, J BIOL CHEM, V472, P32329; PORONNIK P, 1995, PFLUG ARCH EUR J PHY, V429, P852, DOI 10.1007/BF00374810; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; XU X, 1995, J BIOL CHEM, V270, P19606, DOI 10.1074/jbc.270.33.19606	38	107	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12525	12530		10.1074/jbc.274.18.12525	http://dx.doi.org/10.1074/jbc.274.18.12525			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212229	hybrid			2022-12-25	WOS:000080056800049
J	Hernando, Y; Carter, AT; Parr, A; Hove-Jensen, B; Schweizer, M				Hernando, Y; Carter, AT; Parr, A; Hove-Jensen, B; Schweizer, M			Genetic analysis and enzyme activity suggest the existence of more than one minimal functional unit capable of synthesizing phosphoribosyl pyrophosphate in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETASE-ASSOCIATED PROTEIN; COMPLETE CDNA SEQUENCE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; RAT-LIVER; CATALYTIC SUBUNITS; MOLECULAR-CLONING; PURIFIED ENZYME; PRS; NUCLEOTIDE	The PRS gene family in Saccharomyces cerevisiae consists of five genes each capable of encoding a 5-phosphoribosyl-1(alpha)-pyrophosphate synthetase polypeptide, To gain insight into the functional organization of this gene family we have constructed a collection of strains containing all possible combinations of disruptions in the five PRS genes. Phenotypically these deletant strains can be classified into three groups: (i) a lethal phenotype that corresponds to strains containing a double disruption in PRS2 and PRS4 in combination with a disruption in either PRS1 or PRS3; simultaneous deletion of PRS1 and PRS5 or PRS3 and PRS5 are also lethal combinations; (ii) a second phenotype that is encountered in strains containing disruptions in PRS and PRS3 together or in combination with any of the other PRS genes manifests itself as a reduction in growth rate, enzyme activity, and nucleotide content; (iii) a third phenotype that corresponds to strains that, although affected in their phosphoribosyl pyrophosphate-synthesizing ability, are unimpaired for growth and have nucleotide profiles virtually the same as the mild type. Deletions of PRS2, PRS4, and PRS5 or combinations thereof cause this phenotype, These results suggest that the polypeptides encoded by the members of the PRS gene family may be organized into two functional entities, Evidence that these polypeptides interact with each other in vivo was obtained using the yeast two-hybrid system. Specifically PRS1 and PRS3 polypeptides interact strongly with each other, and there are significant interactions between the PRS5 polypeptide and either the PRS2 or PRS4 polypeptides. These data suggest that yeast phosphoribosyl pyrophosphate synthetase exists in vivo as multimeric complex(es).	Inst Food Res, Dept Genet & Microbiol, Norwich NR4 7UA, Norfolk, England; Univ Copenhagen, Inst Mol Biol, Ctr Enzyme Res, DK-1307 Copenhagen K, Denmark	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Copenhagen	Schweizer, M (corresponding author), Inst Food Res, Dept Genet & Microbiol, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	Michael.Schweizer@bbsrc.ac.uk	Hernando, Yolanda/D-2520-2014	Hernando, Yolanda/0000-0001-7378-9434				Bentsen AK, 1996, PROTEINS, V24, P238, DOI 10.1002/(SICI)1097-0134(199602)24:2<238::AID-PROT10>3.0.CO;2-O; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BOWER SG, 1988, J BACTERIOL, V170, P3243, DOI 10.1128/jb.170.7.3243-3248.1988; BOWER SG, 1989, J BIOL CHEM, V264, P10287; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER AT, 1994, YEAST, V10, P1031, DOI 10.1002/yea.320100805; Carter AT, 1997, MOL GEN GENET, V254, P148, DOI 10.1007/s004380050402; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gallois R, 1997, PLANT PHYSIOL, V115, P847, DOI 10.1104/pp.115.2.847; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENDRICKSON N, 1993, MOL BIOCHEM PARASIT, V59, P15, DOI 10.1016/0166-6851(93)90003-G; Hernando Y, 1998, J BACTERIOL, V180, P6404; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOVEJENSEN B, 1988, J BACTERIOL, V170, P1148, DOI 10.1128/jb.170.3.1148-1152.1988; HOVEJENSEN B, 1992, J BACTERIOL, V174, P6852, DOI 10.1128/JB.174.21.6852-6856.1992; IIZASA T, 1989, FEBS LETT, V244, P47, DOI 10.1016/0014-5793(89)81159-7; ISHIJIMA S, 1989, NUCLEIC ACIDS RES, V17, P8860, DOI 10.1093/nar/17.21.8860; ISHIJIMA S, 1989, NUCLEIC ACIDS RES, V17, P8859, DOI 10.1093/nar/17.21.8859; Ishizuka T, 1996, BBA-GENE STRUCT EXPR, V1306, P27, DOI 10.1016/0167-4781(96)00030-9; JARORI GK, 1995, EUR J BIOCHEM, V230, P517; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kaiser C., 1994, METHODS YEAST GENETI, P209; Katashima R, 1998, BBA-GENE STRUCT EXPR, V1396, P245, DOI 10.1016/S0167-4781(97)00217-0; KHORANA HG, 1958, J BIOL CHEM, V230, P941; KITA K, 1994, J BIOL CHEM, V269, P8334; KITA K, 1989, J BIOCHEM, V105, P736, DOI 10.1093/oxfordjournals.jbchem.a122737; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; Krath BN, 1999, PLANT PHYSIOL, V119, P497, DOI 10.1104/pp.119.2.497; NAGAYA M, 1993, BIOSCI BIOTECH BIOCH, V57, P1958, DOI 10.1271/bbb.57.1958; NILSSON D, 1989, MOL GEN GENET, V218, P565, DOI 10.1007/BF00332425; OCHI K, 1987, J GEN MICROBIOL, V133, P2787; ROESSLER BJ, 1990, NUCLEIC ACIDS RES, V18, P193, DOI 10.1093/nar/18.1.193; Sambrook J., 2002, MOL CLONING LAB MANU; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; SHIMADA H, 1990, J BIOL CHEM, V265, P3956; SIKORSKI RS, 1989, GENETICS, V122, P19; Sonoda T, 1997, BBA-GENE STRUCT EXPR, V1350, P6, DOI 10.1016/S0167-4781(96)00190-X; Sonoda T, 1997, J BIOCHEM-TOKYO, V122, P635; STRAUCH E, 1991, MOL MICROBIOL, V5, P289, DOI 10.1111/j.1365-2958.1991.tb02109.x; SWITZER RL, 1969, J BIOL CHEM, V244, P2854; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TAIRA M, 1987, J BIOL CHEM, V262, P14867; TAKEDA M, 1995, J BIOCHEM, V118, P607, DOI 10.1093/oxfordjournals.jbchem.a124953; TATIBANA M, 1995, ADV ENZYME REGUL, V35, P229, DOI 10.1016/0065-2571(94)00017-W; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	54	24	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12480	12487		10.1074/jbc.274.18.12480	http://dx.doi.org/10.1074/jbc.274.18.12480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212224	hybrid			2022-12-25	WOS:000080056800044
J	Puglielli, L; Mandon, EC; Hirschberg, CB				Puglielli, L; Mandon, EC; Hirschberg, CB			Identification, purification, and characterization of the rat liver Golgi membrane ATP transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; HEPARAN-SULFATE; NUCLEOTIDE SULFATE; MAMMARY-GLAND; APPARATUS; PROTEIN; PHOSPHORYLATION; PROTEOLIPOSOMES; RECONSTITUTION; TRANSLOCATION	Phosphorylation of secretory and integral membrane proteins and of proteoglycans also occurs in the lumen of the Golgi apparatus, ATP, the phosphate donor in these reactions, must first cross the Golgi membrane before it can serve as substrate. The existence of a specific ATP transporter in the Golgi membrane has been previously demonstrated in vitro using intact Golgi membrane vesicles from rat liver and mammary gland. We have now identified and purified the rat liver Golgi membrane ATP transporter. The transporter was purified to apparent homogeneity by a combination of conventional ion exchange, dye color, and affinity chromatography, An similar to 70,000-fold purification (2% yield) was achieved starting from crude rat liver Golgi membranes. A protein with an apparent molecular mass of 60 kDa was identified as the putative transporter by a combination of column chromatography, photoaffinity labeling with an analog of ATP, and native functional size determination on a glycerol gradient, The purified transporter appears to exist as a homodimer within the Golgi membrane, and when reconstituted into phosphatidylcholine liposomes, was active in ATP but not nucleotide sugar or adenosine 3'-phosphate 8'-phosphosulfate transport. The transport activity was saturable with an apparent K-m very similar to that of intact Golgi vesicles.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol W200, Boston, MA 02118 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01655 USA	Boston University; University of Massachusetts System; University of Massachusetts Worcester	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol W200, 715 Albany St, Boston, MA 02118 USA.			Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM34396] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BINGHAM EW, 1974, J BIOL CHEM, V249, P3647; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; GLOSSL J, 1986, J BIOL CHEM, V261, P1920; GUILLEN E, 1995, BIOCHEMISTRY-US, V34, P5472, DOI 10.1021/bi00016a018; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; HORWICH AL, 1995, CURR BIOL, V5, P455, DOI 10.1016/S0960-9822(95)00089-3; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MILLA ME, 1992, J BIOL CHEM, V267, P103; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P833; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; WANG SY, 1982, J BIOL CHEM, V257, P3837; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701	24	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12665	12669		10.1074/jbc.274.18.12665	http://dx.doi.org/10.1074/jbc.274.18.12665			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212247	hybrid			2022-12-25	WOS:000080056800067
J	Shimizu, N; Itoh, R; Hirono, Y; Otera, H; Ghaedi, K; Tateishi, K; Tamura, S; Okumoto, K; Harano, T; Mukai, S; Fujiki, Y				Shimizu, N; Itoh, R; Hirono, Y; Otera, H; Ghaedi, K; Tateishi, K; Tamura, S; Okumoto, K; Harano, T; Mukai, S; Fujiki, Y			The peroxin Pex14p - cDNA cloning by functional complementation on a Chinese hamster ovary cell mutant, characterization, and functional analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; RAT-LIVER PEROXISOMES; HUMAN PTS1 RECEPTOR; ASSEMBLY FACTOR-II; ACYL-COA OXIDASE; 3-KETOACYL-COA THIOLASE; BIOGENESIS DISORDERS; ZELLWEGER-SYNDROME; MEMBRANE-PROTEIN; TARGETING SIGNAL	Rat cDNA encoding a 376-amino acid peroxin was isolated by functional complementation of a peroxisome-deficient Chinese hamster ovary cell mutant, ZP110, of complementation group 14 (CG14), The primary sequence showed 28 and 24% amino acid identity with the yeast Pex14p from Hansenula polymorpha and Saccharomyces cerevisiae, respectively; therefore, we termed this cDNA rat PEX14 (RnPEX14). Human and Chinese hamster Pex14p showed 96 and 94% identity to rat Pex14p, except that both Pex14p comprised 377 amino acids. Pex14p was characterized as an integral membrane protein of peroxisomes, exposing its N- and C-terminal parts to the cytosol. Pex14p interacts with both Pex5p and Pex7p, the receptors for peroxisome targeting signal type 1 (PTS1) and PTS2, respectively, together with the receptors' cargoes, PTS1 and PTS2 proteins. Mutation in PEX14 from ZP161, the same CG as ZP110, was determined by reverse transcription-PCR as follows. A 133-base pair deletion at nucleotide residues 37-169 in one allele created a termination codon at 40-42; in addition to this mutation, 103 base pairs were deleted at positions 385-487, resulting in the second termination immediately downstream the second deletion site in the other allele. Neither of these two mutant forms of Pex14p restored peroxisome biogenesis in ZP110 and ZP161, thereby demonstrating PEX14 to be responsible for peroxisome deficiency in CG14.	Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1700013, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Ghaedi, Kamran/X-9824-2018	Ghaedi, Kamran/0000-0002-9790-5644				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; BODIER C, 1981, J BIOL CHEM, V256, P1604; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; Fujiki Y, 1997, BBA-MOL BASIS DIS, V1361, P235, DOI 10.1016/S0925-4439(97)00051-3; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Fukuda S, 1996, AM J HUM GENET, V59, P1210; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MIURA S, 1994, J BIOCHEM-TOKYO, V115, P1064, DOI 10.1093/oxfordjournals.jbchem.a124458; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MORAND OH, 1990, BIOCHIM BIOPHYS ACTA, V1034, P132, DOI 10.1016/0304-4165(90)90066-6; MOSER AB, 1995, J PEDIATR-US, V127, P13, DOI 10.1016/S0022-3476(95)70250-4; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; Okumoto K, 1997, EXP CELL RES, V233, P11, DOI 10.1006/excr.1997.3552; Okumoto K, 1997, NAT GENET, V17, P265, DOI 10.1038/ng1197-265; Okumoto K, 1998, HUM MOL GENET, V7, P1399, DOI 10.1093/hmg/7.9.1399; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Portsteffen H, 1997, NAT GENET, V17, P449, DOI 10.1038/ng1297-449; POULOS A, 1995, J PEDIATR-US, V127, P596, DOI 10.1016/S0022-3476(95)70121-4; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; RACHUBINSKI RA, 1984, J CELL BIOL, V99, P2241, DOI 10.1083/jcb.99.6.2241; Reuber BE, 1997, NAT GENET, V17, P445, DOI 10.1038/ng1297-445; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Tateishi K, 1997, EUR J CELL BIOL, V73, P352; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V230, P402, DOI 10.1006/bbrc.1996.5971; TSUKAMOTO T, 1994, MOL CELL BIOL, V14, P5458, DOI 10.1128/MCB.14.8.5458; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; WENDLAND M, 1993, J CLIN INVEST, V92, P2462, DOI 10.1172/JCI116854; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	58	135	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12593	12604		10.1074/jbc.274.18.12593	http://dx.doi.org/10.1074/jbc.274.18.12593			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212238	hybrid			2022-12-25	WOS:000080056800058
J	Menon, S; Ragsdale, SW				Menon, S; Ragsdale, SW			The role of an iron-sulfur cluster in an enzymatic methylation reaction - Methylation of CO dehydrogenase/acetyl-CoA synthase by the methylated corrinoid iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COENZYME-A; CARBON-MONOXIDE DEHYDROGENASE; COMPLETE GENOME SEQUENCE; CLOSTRIDIUM-THERMOACETICUM; METHIONINE SYNTHASE; REDUCTIVE ACTIVATION; MECHANISM; NICKEL; METHYLTETRAHYDROFOLATE; METHYLCOBALAMIN	This paper focuses on how a methyl group is transferred from a methyl-cobalt(III) species on one protein (the corrinoid iron-sulfur protein (CFeSP)) to a nickel iron-sulfur cluster on another protein (carbon monoxide dehydrogenase/acetyl-CoA synthase). This is an essential step in the Wood-Ljungdahl pathway of anaerobic CO and CO2 fixation. The results described here strongly indicate that transfer of methyl group to carbon monoxide dehydrogenase/acetyl-CoA synthase occurs by an S(N)2 pathway. They also provide convincing evidence that oxidative inactivation of Co(I) competes with methylation. Under the conditions of our anaerobic assay, Co(I) escapes from the catalytic cycle one in every 100 turnover cycles. Reductive activation of the CFeSP is required to regenerate Co(I) and recruit the protein back into the catalytic cycle. Our results strongly indicate that the [4Fe-4S] cluster of the CFeSP is required for reductive activation. They support the hypothesis that the [4Fe-4S] cluster of the CFeSP does not participate directly in the methyl transfer step but provides a conduit for electron flow from physiological reductants to the cobalt center.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039451, R29GM039451, R37GM039451] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBANAT DR, 1991, P NATL ACAD SCI USA, V88, P3272, DOI 10.1073/pnas.88.8.3272; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P11101, DOI 10.1021/bi00502a013; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; Barondeau DP, 1997, J AM CHEM SOC, V119, P3959, DOI 10.1021/ja963597k; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DIEKERT G, 1994, ANTON LEEUW INT J G, V66, P209, DOI 10.1007/BF00871640; Dixon MM, 1996, STRUCTURE, V4, P1263, DOI 10.1016/S0969-2126(96)00135-9; DRAKE HL, 1981, J BIOL CHEM, V256, P1137; ELLIOTT JI, 1982, J BACTERIOL, V151, P328, DOI 10.1128/JB.151.1.328-333.1982; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; GORST CM, 1991, J BIOL CHEM, V266, P20687; GRAHAME DA, 1995, BIOCHEMISTRY-US, V34, P4617, DOI 10.1021/bi00014a015; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; Jarrett JT, 1996, BIOCHEMISTRY-US, V35, P2464, DOI 10.1021/bi952389m; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KUMAR M, 1995, SCIENCE, V270, P628, DOI 10.1126/science.270.5236.628; LEBERTZ H, 1987, J AM CHEM SOC, V109, P3173, DOI 10.1021/ja00244a066; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; LU WP, 1991, J BIOL CHEM, V266, P3554; LU WP, 1990, J BIOL CHEM, V265, P3124; MARTIN BD, 1990, J AM CHEM SOC, V112, P2419, DOI 10.1021/ja00162a053; MATTHEWS R G, 1990, Biofactors, V2, P147; Menon S, 1998, BIOCHEMISTRY-US, V37, P5689, DOI 10.1021/bi9727996; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; Ragsdale SW, 1996, J BIOL INORG CHEM, V1, P489, DOI 10.1007/s007750050082; Ragsdale SW, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P191; Ragsdale SW, 1998, CURR OPIN CHEM BIOL, V2, P208, DOI 10.1016/S1367-5931(98)80062-8; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; RAGSDALE SW, 1994, ACETOGENESIS, P88; RAGSDALE SW, 1998, VITAMIN B12 B12 PROT, P167; RAGSDALE SW, 1997, BIOFACTORS, V9, P1; RAM MS, 1995, J AM CHEM SOC, V117, P2365, DOI 10.1021/ja00113a032; Ram MS, 1997, J AM CHEM SOC, V119, P1648, DOI 10.1021/ja963061z; ROBERTS JR, 1992, J BACTERIOL, V174, P4667, DOI 10.1128/JB.174.14.4667-4676.1992; Seravalli J, 1997, BIOCHEMISTRY-US, V36, P11241, DOI 10.1021/bi970590m; SHIN W, 1992, BIOCHEMISTRY-US, V31, P6003, DOI 10.1021/bi00141a007; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; ZHAO SY, 1995, BIOCHEMISTRY-US, V34, P15075, DOI 10.1021/bi00046a013; Zhao SY, 1996, BIOCHEMISTRY-US, V35, P2476, DOI 10.1021/bi952310d; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	44	50	52	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11513	11518		10.1074/jbc.274.17.11513	http://dx.doi.org/10.1074/jbc.274.17.11513			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206956	hybrid			2022-12-25	WOS:000079834800012
J	Rajotte, D; Ruoslahti, E				Rajotte, D; Ruoslahti, E			Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DEHYDROPEPTIDASE-I; FILAMENTOUS PHAGE; RAT BREAST; ADHESION; LIBRARIES; METASTASIS; INTEGRINS; CELLS; RGD	In vivo phage display is a powerful method to study organ- and tissue-specific vascular addresses. Using this approach, peptides capable of tissue-specific homing can be identified by performing a selection for that trait in vivo. We recently showed that the CGFECVRQCPERC (termed GFE-1) peptide can selectively bind to mouse lung vasculature after an intravenous injection, Our aim in the present study was to identify the receptor for this lung-homing peptide. By using affinity chromatography, we isolated a 55-kDa lung cell-surface protein that selectively binds to the GFE-1 peptide. Protein sequencing established the identity of the receptor as membrane dipeptidase (MDP), a cell-surface zinc metalloprotease involved in the metabolism of glutathione, leukotriene D-4, and certain beta-lactam antibiotics. Phage particles displaying the GFE-1 peptide selectively bind to COS-1 cells transfected with the murine MDP cDNA. Moreover, the synthetic GFE-1 peptide could inhibit MDP activity. By establishing MDP as the receptor for the GFE-1 peptide, our results suggest potential applications for both MDP and the GFE-1 peptide in delivery of compounds to the lungs. This work also demonstrates that cell-surface proteases can be involved in tissue-specific homing.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92093 USA.				NCI NIH HHS [CA 78804, CA 30199, CA 74238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA078804, R01CA074238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; AUERBACH R, 1987, CANCER RES, V47, P1492; Burritt JB, 1996, ANAL BIOCHEM, V238, P1, DOI 10.1006/abio.1996.0241; Cheng HC, 1998, J BIOL CHEM, V273, P24207, DOI 10.1074/jbc.273.37.24207; DelaFuente EK, 1997, AM J PHYSIOL-LUNG C, V272, pL461, DOI 10.1152/ajplung.1997.272.3.L461; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; GARDNER DJ, 1995, LAB ANIM SCI, V45, P199; Habib GM, 1996, J BIOL CHEM, V271, P16273, DOI 10.1074/jbc.271.27.16273; Habib GM, 1998, P NATL ACAD SCI USA, V95, P4859, DOI 10.1073/pnas.95.9.4859; HEYWOOD SP, 1995, ANAL BIOCHEM, V226, P10, DOI 10.1006/abio.1995.1184; HIROTA T, 1986, EUR J BIOCHEM, V160, P521, DOI 10.1111/j.1432-1033.1986.tb10070.x; Hooper NM, 1997, BIOCHEM J, V324, P151, DOI 10.1042/bj3240151; INAMURA T, 1994, PROSTAG LEUKOTR ESS, V50, P85, DOI 10.1016/0952-3278(94)90152-X; JOHNSON RC, 1991, CANCER RES, V51, P394; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; Keynan S, 1997, BIOCHEM J, V326, P47, DOI 10.1042/bj3260047; Keynan S, 1996, BIOCHEMISTRY-US, V35, P12511, DOI 10.1021/bi961193z; Keynan S, 1996, ZINC METALLOPROTEASE, P285; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PASQUALINI R, 1999, IN PRESS PHAGE DISPL; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Salmi M, 1997, ADV IMMUNOL, V64, P139, DOI 10.1016/S0065-2776(08)60889-5; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yamaya M, 1998, RESP PHYSIOL, V111, P101, DOI 10.1016/S0034-5687(97)00099-6	31	139	179	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11593	11598		10.1074/jbc.274.17.11593	http://dx.doi.org/10.1074/jbc.274.17.11593			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206967	hybrid			2022-12-25	WOS:000079834800023
J	Swantek, JL; Christerson, L; Cobb, MH				Swantek, JL; Christerson, L; Cobb, MH			Lipopolysaccharide-induced tumor necrosis factor-alpha promoter activity is inhibitor of nuclear factor-kappa B kinase-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; PRIMARY MACROPHAGES; FACTOR BIOSYNTHESIS; GENE-REGULATION; HUMAN MONOCYTES; ACTIVATION; CACHECTIN; ENDOTOXIN; COMPLEX; PATHWAY	The adverse effects of lipopolysaccharide (LPS) are primarily mediated by tumor necrosis factor-alpha (TNF-alpha). TNF-alpha production by LPS-stimulated macrophages is regulated both transcriptionally and post-transcriptionally. Transcriptional regulation of the TNF-alpha gene is dependent on nuclear factor-kappa B (NF-kappa B), We examined the signaling pathways involved in the regulation of NF-kappa B that lead to TNF-alpha promoter activity. We determined a role for one or both of the recently identified inhibitor of NF-kappa B kinases, I kappa B kinase-1 and I kappa B kinase-2, in LPS induction of an NF-kappa B reporter and of TNF-alpha promoter activity. I kappa B kinase activation is one of the earliest signaling events known to be induced by LPS. Furthermore, our results suggest roles for the I kappa B kinases NF-kappa B-inducing kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase I in the regulation of I kappa B kinase-2, as well as in LPS-induced TNF-alpha transcription.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM18550-01, GM53032] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018550] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DROUET C, 1991, J IMMUNOL, V147, P1694; GEPPERT TD, 1994, MOL MED, V1, P93; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Han J, 1990, Eur Cytokine Netw, V1, P71; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORRISON DC, 1979, ADV IMMUNOL, V294, P293; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	41	56	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11667	11671		10.1074/jbc.274.17.11667	http://dx.doi.org/10.1074/jbc.274.17.11667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206979	hybrid			2022-12-25	WOS:000079834800035
J	Palmer, HJ; Tuzon, CT; Paulson, KE				Palmer, HJ; Tuzon, CT; Paulson, KE			Age-dependent decline in mitogenic stimulation of hepatocytes - Reduced association between Shc and the epidermal growth factor receptor is coupled to decreased activation of Raf and extracellular signal-regulated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; AUTOPHOSPHORYLATION SITES; DIFFERENTIAL ACTIVATION; PHOSPHOTYROSINE-BINDING; TRANSDUCTION PATHWAY; INTACT-CELLS; IN-VIVO; T-CELLS; DOMAIN	The proliferative potential of the liver has been well documented to decline with age. However, the molecular mechanism of this phenomenon is not well understood. Cellular proliferation is the result of growth factor-receptor binding and activation of cellular signaling pathways to regulate specific gene transcription. To determine the mechanism of the age-related difference in proliferation, we evaluated extracellular signal-regulated kinase-mitogen-activated protein kinase activation and events upstream in the signaling pathway in epidermal growth factor (EGF)-stimulated hepatocytes isolated from young and old rats. We confirm the age-associated decrease in extracellular signal-regulated kinase-mitogen-activated protein kinase activation in response to EGF that has been previously reported. We also find that the activity of the upstream kinase, Raf kinase, is decreased in hepatocytes from old compared with young rats, An early age-related difference in the EGF-stimulated pathway is shown to be the decreased ability of the adapter protein, Shc, to associate with the EGF receptor through the Shc phosphotyrosine binding domain. To address the mechanism of decreased Shc/ EGF receptor interaction, we examined the phosphorylation of the EGF receptor at tyrosine 1173, a site recognized by the Shc phosphotyrosine binding domain, Tyrosine 1173 of the EGF receptor is underphosphorylated in the hepatocytes from old animals compared with young in a Western blot analysis using a phosphospecific antibody that recognizes phosphotyrosine 1173 of the EGF receptor. These data suggest that a molecular mechanism underlying the age-associated decrease in hepatocyte proliferation involves an age-dependent regulation of site-specific tyrosine residue phosphorylation on the EGF receptor.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University	Paulson, KE (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	kpaulson@hnrc.tufts.edu	Tuzon, Creighton/K-3398-2019	Tuzon, Creighton/0000-0001-9706-610X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R01DK050442] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34928, R01 DK50442] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BEYER HS, 1991, J LAB CLIN MED, V117, P101; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BUCHER NLR, 1964, CANCER RES, V24, P509; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; Garcia GG, 1997, CELL IMMUNOL, V175, P51, DOI 10.1006/cimm.1996.1040; GHOSH J, 1995, MECH AGEING DEV, V80, P171, DOI 10.1016/0047-6374(94)01568-7; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIGAMI A, 1993, BIOCHEM BIOPH RES CO, V196, P181, DOI 10.1006/bbrc.1993.2232; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LI NX, 1994, ONCOGENE, V9, P3457; Lim YP, 1997, J BIOL CHEM, V272, P29892, DOI 10.1074/jbc.272.47.29892; Liu YS, 1996, J BIOL CHEM, V271, P3604; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; Pahlavani MA, 1998, CELL IMMUNOL, V185, P39, DOI 10.1006/cimm.1998.1274; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; REENSTRA WR, 1993, EXP CELL RES, V209, P118, DOI 10.1006/excr.1993.1291; Reenstra WR, 1996, EXP CELL RES, V227, P252, DOI 10.1006/excr.1996.0274; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SALCINI AE, 1994, ONCOGENE, V9, P2827; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SOLER C, 1994, ONCOGENE, V9, P2207; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Tridandapani S, 1997, J IMMUNOL, V158, P1125; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIAO S, 1994, J BIOL CHEM, V269, P21244; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	57	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11424	11430		10.1074/jbc.274.16.11424	http://dx.doi.org/10.1074/jbc.274.16.11424			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196236	hybrid			2022-12-25	WOS:000079751900104
J	Tsubakimoto, K; Matsumoto, K; Abe, H; Ishii, J; Amano, M; Kaibuchi, K; Endo, T				Tsubakimoto, K; Matsumoto, K; Abe, H; Ishii, J; Amano, M; Kaibuchi, K; Endo, T			Small GTPase RhoD suppresses cell migration and cytokinesis	ONCOGENE			English	Article						small GTPase; Rho family; actin cytoskeleton; cell motility; cytokinesis	ACTIN STRESS FIBERS; PROTO-ONCOGENE PRODUCT; FOCAL ADHESIONS; BINDING PROTEIN; REGULATED EXPRESSION; HEMATOPOIETIC-CELLS; SMOOTH-MUSCLE; IN-VIVO; KINASE; GENE	Rho family small GTPases regulate organization of the actin cytoskeleton, Among them, RhoA plays essential roles in the formation of the actin stress fibers, the associated focal adhesions, and the contractile rings necessary for cytokinesis, Recently, RhoD, a novel member of Rho family has been identified. The amino acid sequences of its effector domain is distinct from those of the other Rho family proteins, suggesting its unique cellular functions. Introduction of the constitutively active form of RhoD(G26V) into fibroblasts by microinjection or transfection resulted in disassembly of the actin stress fibers and the focal adhesions, whereas the dominant negative form of RhoD(G26V) did not affect these structures. The degree of cell migration assessed by the phagokinetic tracks on a substrate covered with gold particles was diminished by the expression of RhoD(G26V) but not by RhoD(T31K). Thus, cytoskeletal alterations including the loss of stress fibers and focal adhesions by RhoD seems to lead to the retardation of cell migration. Transfection of RhoD(G26V) cDNA into cultured cells also induced multinucleation, Moreover, RhoD(G26V) microinjected into fertilized eggs and embryos of Xenopus laevis caused cleavage arrest only in the injected cells, and the uncleaved cells contained multiple nuclei. These results imply that RhoD does not affect nuclear division but can interfere with cytokinesis presumably by preventing the formation of the actin-based contractile ring. Enhancement of the stress fibers by RhoA or RhoA-activating lysophosphatidic acid was reversed by the transfection of RhoD cDNA, Accordingly, the cellular functions of RhoD are likely to be antagonistic to those of RhoA.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan	Chiba University; Nara Institute of Science & Technology	Endo, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; del Peso L, 1997, ONCOGENE, V15, P3047; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Dutartre H, 1996, J CELL SCI, V109, P367; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; Endo T, 1998, J CELL SCI, V111, P1081; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Foster R, 1996, MOL CELL BIOL, V16, P2689; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leung T, 1996, MOL CELL BIOL, V16, P5313; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MANSER E, 1995, METHOD ENZYMOL, V256, P130; Marks PW, 1996, GENOMICS, V38, P13, DOI 10.1006/geno.1996.0586; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOLL J, 1991, ONCOGENE, V6, P863; MORII N, 1995, METHOD ENZYMOL, V256, P196; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SEGADE F, 1995, J IMMUNOL, V154, P2384; SELF AJ, 1993, ONCOGENE, V8, P655; SHIRSAT NV, 1990, ONCOGENE, V5, P769; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	64	49	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2431	2440		10.1038/sj.onc.1202604	http://dx.doi.org/10.1038/sj.onc.1202604			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229194	Bronze			2022-12-25	WOS:000079703300003
J	Gatto, C; Lutsenko, S; Shin, JM; Sachs, G; Kaplan, JH				Gatto, C; Lutsenko, S; Shin, JM; Sachs, G; Kaplan, JH			Stabilization of the H,K-ATPase M5M6 membrane hairpin by K+ ions - Mechanistic significance for P-2-type ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; IN-VITRO TRANSLATION; ESCHERICHIA-COLI; CYTOPLASMIC LOOP; ATP-BINDING; IDENTIFICATION; CA2+-ATPASE; TOPOLOGY; PROTEINS; NA+,K+-ATPASE	The integral membrane protein, the gastric H,K-ATPase, is an alpha-beta heterodimer, with 10 putative transmembrane segments in the alpha-subunit and one such segment in the beta-subunit, All transmembrane segments remain within the membrane domain following trypsinization of the intact gastric H,K-ATPase in the presence of K+ ions, identified as M1M2, M3M4, M5M6, and M7, M8, M9, and M10, Removal of K+ ions from this digested preparation results in the selective loss of the M5M6 hairpin from the membrane. The release of the M5M6 fragment is directed to the extracellular phase as evidenced by the accumulation of the released M5M6 hairpin inside the sealed inside out vesicles. The stabilization of the M5M6 hairpin in the membrane phase by the transported cation as well as loss to the aqueous phase in the absence of the transported cation has been previously observed for another P-2-type ATPase, the Na,K-ATPase (Lutsenko, S., Anderko, R., and Kaplan, J. H. (1995) Proc. Natl, Acad. Sci. U. S. A. 92, 7936-7940). Thus, the effects of the counter-transported cation on retention of the M5M6 segment in the membrane as compared with the other membrane pairs may be a general feature of P-2-ATPase ion pumps, reflecting a flexibility of this region that relates to the mechanism of transport.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; W Los Angeles Vet Affairs Med Ctr, Ctr Ulcer Res, Los Angeles, CA 90073 USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Kaplan, JH (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	kaplanj@ohsu.edu		Kaplan, Jack/0000-0002-7048-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315, F32HL009972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30315, HL09972] Funding Source: Medline; NIGMS NIH HHS [GM39500] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Beggah AT, 1999, J BIOL CHEM, V274, P8217, DOI 10.1074/jbc.274.12.8217; Beguin P, 1997, ANN NY ACAD SCI, V834, P540, DOI 10.1111/j.1749-6632.1997.tb52312.x; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gatto C, 1999, BIOPHYS J, V76, pA450; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; Kaplan JH, 1997, ANN NY ACAD SCI, V834, P45, DOI 10.1111/j.1749-6632.1997.tb52224.x; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lambrecht N, 1998, J BIOL CHEM, V273, P13719, DOI 10.1074/jbc.273.22.13719; Lingrel JB, 1997, ANN NY ACAD SCI, V834, P194, DOI 10.1111/j.1749-6632.1997.tb52251.x; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; RABON EC, 1993, J BIOL CHEM, V268, P8012; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SACHS G, 1993, ALIMENT PHARM THER, V7, P4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIN JM, 1994, J BIOL CHEM, V269, P8642; Shin JM, 1997, ANN NY ACAD SCI, V834, P65, DOI 10.1111/j.1749-6632.1997.tb52226.x; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Vilsen B, 1997, ANN NY ACAD SCI, V834, P297, DOI 10.1111/j.1749-6632.1997.tb52260.x; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563	35	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13737	13740		10.1074/jbc.274.20.13737	http://dx.doi.org/10.1074/jbc.274.20.13737			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318774	hybrid			2022-12-25	WOS:000080322200003
J	Pan, CJ; Lin, BC; Chou, JY				Pan, CJ; Lin, BC; Chou, JY			Transmembrane topology of human glucose 6-phosphate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; PUTATIVE GLUCOSE-6-PHOSPHATE TRANSLOCASE; ASPARAGINE-LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; CHROMOSOME 11Q23; GENE; PROTEIN; IB; PHOSPHATE	Glycogen storage disease type 1b is caused by a deficiency in a glucose 6-phosphate transporter (G6PT) that translocates glucose 6-phosphate from the cytoplasm to the endoplasmic reticulum lumen where the active site of glucose 6-phosphatase is situated. Using amino- and carboxyl-terminal tagged G6PT, we demonstrate that proteolytic digestion of intact microsomes resulted in the cleavage of both tags, indicating that both termini of G6PT face the cytoplasm. This is consistent with ten and twelve transmembrane domain models for G6PT predicted by hydropathy analyses. A region of G6PT corresponding to amino acid residues 50-71, which constitute a transmembrane segment in the twelve-domain model, are situated in a 51-residue luminal loop in the ten-domain model. To determine which of these two models is correct, we generated two G6PT mutants, T53N and S55N, that created a potential Asn-linked glycosylation site at residues 53-55 ((NSS)-S-53) Or 55-57 (N(55)QS), respectively. (NSS)-S-53 Or N(55)QS would be glycosylated only if it is situated in a luminal loop larger than 33 residues as predicted by the ten-domain model. Whereas wild-type G6PT is not a glycoprotein, both T53N and S55N mutants are glycosylated, strongly supporting the ten-helical model for G6PT.	NICHHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.	chou@helix.nih.gov	Lin, Baochuan/A-8390-2009	Lin, Baochuan/0000-0002-9484-0785				Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; Arion W J, 1976, J Biol Chem, V251, P4891; ARION WJ, 1980, J BIOL CHEM, V255, P396; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; Chen Y-T, 1995, METABOLIC MOL BASES, P935; GERINI, 1997, FEBS LETT, V419, P235; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GUTZEMANN R, 1993, EUR J PEDIATR S1, V152, pS33; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; Kure S, 1998, BIOCHEM BIOPH RES CO, V248, P426, DOI 10.1006/bbrc.1998.8985; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; Marcolongo P, 1998, FEBS LETT, V436, P247, DOI 10.1016/S0014-5793(98)01129-6; NARISAWA K, 1978, BIOCHEM BIOPH RES CO, V83, P1360, DOI 10.1016/0006-291X(78)91371-2; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; Pan CJ, 1998, J BIOL CHEM, V273, P21658, DOI 10.1074/jbc.273.34.21658; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Veiga-da-Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590	29	62	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13865	13869		10.1074/jbc.274.20.13865	http://dx.doi.org/10.1074/jbc.274.20.13865			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318794	hybrid			2022-12-25	WOS:000080322200023
J	Perini, G; Oetjen, E; Green, MR				Perini, G; Oetjen, E; Green, MR			The hepatitis B pX protein promotes dimerization and DNA binding of cellular basic region leucine zipper proteins by targeting the conserved basic region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-X-PROTEIN; HTLV-I-TAX; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; GENE-EXPRESSION; BZIP PROTEINS; HBX PROTEIN; HEPATOCELLULAR-CARCINOMA; SEQUENCE REQUIREMENTS; TRANSACTIVATOR TAX	The hepatitis B virus pX protein is a potent transcriptional activator of viral and cellular genes whose mechanism of action is poorly understood. Here we show that pX dramatically stimulates in vitro DNA binding of a variety of cellular proteins that contain basic region/leucine zipper (bZIP) DNA binding domains. The basis for increased DNA binding is a direct interaction be tween pX and the conserved bZIP basic region, which promotes bZIP dimerization and the increased concentration of the bZIP homodimer then drives the DNA binding reaction. Unexpectedly, we found that the DNA binding specificity of various pX-bZIP complexes differs from one another and from that of the bZIP itself. Thus, through recognition of the conserved basic region, pX promotes dimerization, increases DNA binding, and alters DNA recognition. These properties-of pX are remarkably similar to those of the human T-cell lymphotrophic virus type I Tax protein. Although Tax and pX are not homologous, we show that the regions of the two proteins that stimulate bZIP binding contain apparent metal binding. sites. Finally, consistent with this in vitro activity, we provide evidence that both Tax and pX activate transcription in vivo, at least in part, by facilitating occupancy of bZIPs on target promoters.	Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.							ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ARII M, 1992, ONCOGENE, V7, P397; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; BEIMLING P, 1992, ONCOGENE, V7, P257; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DEMEDINA T, 1994, VIROLOGY, V202, P401, DOI 10.1006/viro.1994.1356; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FAKTOR O, 1990, ONCOGENE, V5, P867; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; HU KQ, 1992, P NATL ACAD SCI USA, V89, P11441, DOI 10.1073/pnas.89.23.11441; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIDDLJUNGGREN K, 1995, J GEN VIROL, V76, P2119, DOI 10.1099/0022-1317-76-9-2119; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOIKE K, 1989, MOL BIOL MED, V6, P151; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LOPEZCABRERA M, 1991, VIROLOGY, V183, P825, DOI 10.1016/0042-6822(91)91019-D; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Marriott SJ, 1996, VIROLOGY, V224, P206, DOI 10.1006/viro.1996.0522; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1994, ONCOGENE, V9, P2837; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Palmer CR, 1997, BIOCHEMISTRY-US, V36, P15349, DOI 10.1021/bi972076m; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; RENNER M, 1995, J HEPATOL, V23, P53, DOI 10.1016/0168-8278(95)80311-4; ROBINSON WS, 1994, ANNU REV MED, V45, P297; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHERKER AH, 1991, ANNU REV MICROBIOL, V45, P475; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1994, ONCOGENE, V9, P341; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; Xu X, 1996, VIROLOGY, V218, P362, DOI 10.1006/viro.1996.0205; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	75	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13970	13977		10.1074/jbc.274.20.13970	http://dx.doi.org/10.1074/jbc.274.20.13970			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318808	hybrid			2022-12-25	WOS:000080322200037
J	Basran, J; Jang, MH; Sutcliffe, MJ; Hille, R; Scrutton, NS				Basran, J; Jang, MH; Sutcliffe, MJ; Hille, R; Scrutton, NS			The role of Tyr-169 of trimethylamine dehydrogenase in substrate oxidation and magnetic interaction between FMN cofactor and the 4Fe/4S center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; COVALENTLY BOUND COENZYME; WILD-TYPE; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIUM; PROSTHETIC GROUPS; C30A MUTANT; FLAVOPROTEIN; KINETICS; FLAVIN	Tyr-169 in trimethylamine dehydrogenase is one component of a triad also comprising residues His-172 and Asp-267. Its role in catalysis and in mediating the magnetic interaction between FMN cofactor and the 4Fe/4S center have been investigated by stopped-flow and EPR spectroscopy of a Tyr-169 to Phe (Y169F) mutant of the enzyme. Tyr-169 is shown to play an important role in catalysis (mutation to phenylalanine reduces the limiting rate constant for bleaching of the active site flavin by about 100-fold) but does not serve as a general base in the course of catalysis. In addition, we are able to resolve two kinetically influential ionizations involved in both the reaction of free enzyme with free substrate (as reflected in k(lim)/K-d) and in the breakdown of the E-ox.S complex (as reflected in k(lim)). In EPR studies of the Y169F mutant, it is found that the ability of the Y169F enzyme to form the spin-interacting state between flavin semiquinone and reduced 4Fe/4S center characteristic of wild-type enzyme is significantly compromised. The present results are consistent with Tyr-169 representing the ionizable group of pK(a) similar to 9.5, previously identified in pH-jump studies of electron transfer, whose deprotonation must occur for the spin-interacting state to be established.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	University of Leicester; University of Leicester; University System of Ohio; Ohio State University	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.			Sutcliffe, Mike/0000-0003-0414-1700				Basran J, 1997, BIOCHEMISTRY-US, V36, P1989, DOI 10.1021/bi962623o; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; Falzon L, 1996, BIOCHEMISTRY-US, V35, P2445, DOI 10.1021/bi951550q; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; Huang LX, 1996, J BIOL CHEM, V271, P13401, DOI 10.1074/jbc.271.23.13401; HUANG LX, 1995, J BIOL CHEM, V270, P23958, DOI 10.1074/jbc.270.41.23958; Jang MH, 1999, J BIOL CHEM, V274, P13147, DOI 10.1074/jbc.274.19.13147; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LIM LW, 1986, J BIOL CHEM, V261, P5140; Mewies M, 1996, BIOCHEM J, V317, P267, DOI 10.1042/bj3170267; Mewies M, 1997, BIOCHEMISTRY-US, V36, P7162, DOI 10.1021/bi970621d; PACKMAN LC, 1995, J BIOL CHEM, V270, P13186, DOI 10.1074/jbc.270.22.13186; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; Sambrook J., 2002, MOL CLONING LAB MANU; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; WILSON EK, 1995, BIOCHEMISTRY-US, V34, P2584, DOI 10.1021/bi00008a024; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q	30	18	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13155	13161		10.1074/jbc.274.19.13155	http://dx.doi.org/10.1074/jbc.274.19.13155			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224070	hybrid			2022-12-25	WOS:000080200400032
J	Burmester, T				Burmester, T			Identification, molecular cloning, and phylogenetic analysis of a non-respiratory pseudo-hemocyanin of Homarus americanus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANULIRUS-INTERRUPTUS HEMOCYANIN; ARTHROPOD HEMOCYANINS; PHENOL OXIDASE; EVOLUTION; PROTEIN; SUBUNIT; SEQUENCE; CDNA; ARYLPHORIN; ELECTROPHORESIS	Copper-containing hemocyanins serve to transport oxygen in many arthropod species. Here I describe the identification and cDNA cloning of a structurally closely related non-respiratory pseudo-hemocyanin (PHc) of the American lobster, Homarus americanus, This protein has lost the ability to bind copper and, therefore, oxygen because a histidine residue in copper-binding site A is replaced by tyrosine, Like many arthropod hemocyanins, PHc forms a hexamer, It consists of two different subunit types of 660 and 661 amino acids, respectively, that share a 94.4% sequence identity. Whereas Homarus hemocyanin is produced in the hepatopancreas, PHc is synthesized by the ovaries and the heart tissue. Because different levels of PHc were observed in distinct individuals, I propose an association of the synthesis of this protein with the molting or reproduction cycle, similar to the hexamerins, insect storage proteins that are also related to the hemocyanins, However, phylogenetic analyses show that PHc derived independently from crustacean hemocyanins. Therefore, Homarus PHc is a member of a new class within the growing hemocyanin protein superfamily.	Univ Mainz, Inst Zool, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Burmester, T (corresponding author), Univ Mainz, Inst Zool, D-55099 Mainz, Germany.		Burmester, Thorsten/I-7225-2013	Burmester, Thorsten/0000-0002-5772-7863				BAK HJ, 1987, FEBS LETT, V204, P141; BEINTEMA JJ, 1994, MOL BIOL EVOL, V11, P493; Burmester T, 1998, J MOL EVOL, V47, P93, DOI 10.1007/PL00006366; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5; DEPLEDGE MH, 1989, HELGOLANDER MEERESUN, V43, P207, DOI 10.1007/BF02367900; Durstewitz G, 1997, MOL BIOL EVOL, V14, P266, DOI 10.1093/oxfordjournals.molbev.a025762; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FRIEDRICH M, 1995, NATURE, V376, P165, DOI 10.1038/376165a0; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HARRIS JR, 1970, J ULTRA MOL STRUCT R, V33, P219, DOI 10.1016/S0022-5320(70)90017-1; Jekel PA, 1996, COMP BIOCHEM PHYS B, V115, P243, DOI 10.1016/0305-0491(96)00119-8; JEKEL PA, 1988, EUR J BIOCHEM, V178, P403, DOI 10.1111/j.1432-1033.1988.tb14464.x; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MANGUM CP, 1983, BIOL CRUSTACEA, V5, P373; MARKL J, 1979, J COMP PHYSIOL, V130, P283, DOI 10.1007/BF00689845; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; MARKL J, 1986, BIOL BULL, V171, P90, DOI 10.2307/1541909; MARKL J, 1992, J COMP PHYSIOL B, V162, P665, DOI 10.1007/BF00301616; MARKL J, 1979, J COMP PHYSL, V133, P67; NEUTEBOOM B, 1992, EUR J BIOCHEM, V206, P243, DOI 10.1111/j.1432-1033.1992.tb16922.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sanchez D, 1998, MOL BIOL EVOL, V15, P415, DOI 10.1093/oxfordjournals.molbev.a025938; SCHELLER K, 1977, J INSECT PHYSIOL, V23, P285, DOI 10.1016/0022-1910(77)90043-9; Sellos D, 1997, FEBS LETT, V407, P153, DOI 10.1016/S0014-5793(97)00350-5; SENKBEIL EG, 1981, COMP BIOCHEM PHYS B, V68, P163, DOI 10.1016/0305-0491(81)90198-X; STOCKER W, 1988, J COMP PHYSIOL B, V158, P271, DOI 10.1007/BF00695326; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; Terwilliger NB, 1999, P NATL ACAD SCI USA, V96, P2013, DOI 10.1073/pnas.96.5.2013; TURBEVILLE JM, 1991, MOL BIOL EVOL, V8, P669; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WILLOTT E, 1989, J BIOL CHEM, V264, P19052	36	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13217	13222		10.1074/jbc.274.19.13217	http://dx.doi.org/10.1074/jbc.274.19.13217			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224079	hybrid			2022-12-25	WOS:000080200400041
J	Vegeto, E; Pollio, G; Pellicciari, C; Maggi, A				Vegeto, E; Pollio, G; Pellicciari, C; Maggi, A			Estrogen and progesterone induction of survival of monoblastoid cells undergoing TNF-alpha-induced apoptosis	FASEB JOURNAL			English	Article						estrogen receptor; progesterone receptor; U937 cells; TNF-alpha; apoptosis	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; MURINE MACROPHAGES; MESSENGER-RNA; GROWTH-FACTOR; MONONUCLEAR-CELLS; GENE-EXPRESSION; RECEPTOR; DEATH	Induction of apoptosis of mononucleated cells is a physiological process for regulating the intensity of the immune response. The female steroid hormones estrogen (E-2) and progesterone (Prog) are known to modulate the reactivity of the immune system; recently it has been demonstrated that they can regulate induction of apoptosis of endothelial cells and osteoblasts. TNF-alpha-mediated induction of apoptosis has been well characterized in myeloid cells. We investigated whether E-2 and Prog could interfere with TNF-alpha-induced apoptosis of the monoblastoid U937 cell line. Treatment with E-2 or Prog increased survival and prevented apoptosis induced by TNF-alpha in both undifferentiated and macrophage-like PMA-differentiated U937 cells, as assessed by trypan blue exclusion cell. counting, thymidine incorporation, AnnexinV labeling, followed by flow cytometry and DNA fragmentation studies. This effect can be associated with the activation of specific hormone receptors, since we observed the expression of the estrogen receptor alpha (ER-alpha), ER-beta, and progesterone receptor (PR) mRNAs; the ER-alpha protein expression was confirmed by immunocytochemical analysis. In addition, hormone-mediated survival against apoptosis was concentration dependent, reaching the half-maximal effect at 10 nM and blocked by the ER antagonist ICI 182,780 in undifferentiated cells, further supporting a receptor-mediated mechanism of cell survival. Other steroid receptor drugs such as Raloxifene, RU486, or the ICI 182,780 in PMA-differentiated cells displayed agonist activity by preventing TNF-alpha-induced apoptosis as efficiently as the hormones alone, providing further evidence to the notion that steroid receptor drugs may manifest agonist or antagonist activities depending on the cellular context in which they are studied. Treatment with E-2 was also associated with a time-dependent decrease in the mRNA level of the proapoptotic Nip-2 protein, supporting: the hypothesis that hormone responsiveness of U937 cells is mediated by target gene transcription. Together, these results demonstrate that ER and PR can be activated by endogenous or exogenous ligands to induce a genetic response that impairs TNF-alpha-induced apoptosis in U937 cells. The data presented here suggest that the female steroid receptors play a role in regulation of the immune response by preventing apoptosis of monoblastoid cells; this effect might have important consequences in the clinical use of steroid receptor drugs.	Univ Milan, Mol Pharmacol Lab, I-20133 Milan, Italy; Univ Pavia, Dept Biol Anim, I-27100 Pavia, Italy; Univ Pavia, CNR, Ctr Study Histochem, I-27100 Pavia, Italy	University of Milan; University of Pavia; Consiglio Nazionale delle Ricerche (CNR); University of Pavia	Maggi, A (corresponding author), Inst Pharmacol Sci, MPL, Via Balzaretti 9, I-20133 Milan, Italy.		Pellicciari, Carlo/Q-1481-2016	Pellicciari, Carlo/0000-0001-7684-0469; Maggi, Adriana/0000-0001-5700-5273	Telethon [E.0600] Funding Source: Medline	Telethon(Fondazione Telethon)		Anderson GP, 1996, TRENDS PHARMACOL SCI, V17, P438, DOI 10.1016/S0165-6147(96)01004-8; BENHUR H, 1995, AM J REPROD IMMUNOL, V34, P363, DOI 10.1111/j.1600-0897.1995.tb00965.x; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHAO TC, 1994, AM J REPROD IMMUNOL, V32, P43, DOI 10.1111/j.1600-0897.1994.tb00877.x; CIOCCA DR, 1995, ENDOCR REV, V16, P35, DOI 10.1210/er.16.1.35; CUTOLO M, 1995, CLIN EXP RHEUMATOL, V13, P217; DE M, 1990, J ENDOCRINOL, V126, P417, DOI 10.1677/joe.0.1260417; Deshpande R, 1997, AM J REPROD IMMUNOL, V38, P46; FOX HS, 1991, J IMMUNOL, V146, P4362; FRAZIERJESSEN MR, 1995, J IMMUNOL, V154, P1838; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Garnier M, 1997, J NEUROSCI, V17, P4591; GIRASOLE G, 1994, J CLIN INVEST, V95, P2886; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Hayashi T, 1998, J CARDIOVASC PHARM, V31, P292, DOI 10.1097/00005344-199802000-00016; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; HORWITZ KB, J STEROID BIOCH MOL, V53, P509; HU SK, 1988, INT J IMMUNOPHARMACO, V10, P247; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Legdeur MCJC, 1996, EXP HEMATOL, V24, P1530; LYNCH EA, 1994, J IMMUNOL, V153, P300; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; Marbaix E, 1996, P NATL ACAD SCI USA, V93, P9120, DOI 10.1073/pnas.93.17.9120; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815; Miller L, 1996, LIFE SCI, V59, P1, DOI 10.1016/0024-3205(96)00122-1; Miller L, 1996, J LEUKOCYTE BIOL, V59, P442, DOI 10.1002/jlb.59.3.442; Mitchinson MJ, 1996, CURR OPIN LIPIDOL, V7, P324, DOI 10.1097/00041433-199610000-00011; MOUNTZ JD, 1994, ARTHRITIS RHEUM, V37, P1415, DOI 10.1002/art.1780371002; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nathan L, 1997, ANNU REV PHARMACOL, V37, P477, DOI 10.1146/annurev.pharmtox.37.1.477; Olsen NJ, 1996, ENDOCR REV, V17, P369, DOI 10.1210/edrv-17-4-369; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; POLAN ML, 1989, J CLIN ENDOCR METAB, V69, P1200, DOI 10.1210/jcem-69-6-1200; POLLARD JW, 1987, CELL TISSUE RES, V249, P533; RICHER JK, 1998, P 80 ANN M END SOC; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; SHANKER G, 1995, LIFE SCI, V56, P499, DOI 10.1016/0024-3205(94)00479-C; SHANKER G, 1994, LYMPHOKINE CYTOK RES, V13, P377; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Thatte U, 1997, DRUGS, V54, P511, DOI 10.2165/00003495-199754040-00002; VANDELOOSDRECHT AA, 1993, EXP HEMATOL, V21, P461; Vegeto E, 1996, VITAM HORM, V52, P99, DOI 10.1016/S0083-6729(08)60408-2; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3	46	102	108	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					793	803		10.1096/fasebj.13.8.793	http://dx.doi.org/10.1096/fasebj.13.8.793			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224223				2022-12-25	WOS:000080372500003
J	Bendetowicz, AV; Wise, RJ; Gilbert, GE				Bendetowicz, AV; Wise, RJ; Gilbert, GE			Collagen-bound von Willebrand factor has reduced affinity for factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VWF CDNA; VONWILLEBRAND-FACTOR; BINDING-SITE; HETEROLOGOUS CELLS; FACTOR ASSOCIATION; PLATELET-ADHESION; ENDOTHELIAL-CELLS; LIGHT-CHAIN; PROTEIN; MULTIMERS	von Willebrand factor (vWf) is a multimeric adhesive glycoprotein that serves as a carrier for factor VIII in plasma. Although each vWf subunit displays a high affinity binding site for factor VIII in vitro, in plasma, only 2% of the vWf sites for factor VIII are occupied. We investigated whether interaction of plasma proteins with vWf or adhesion of vWf to collagen may alter the affinity or availability of factor VIII-binding sites on vWf, When vWf was immobilized on agarose-linked monoclonal antibody, factor VIII bound to vWf with high affinity, and neither the affinity nor binding site availability was influenced by the presence of 50% plasma. Therefore, plasma proteins do not alter the affinity or availability of factor Vm-binding sites. In contrast, when vWf was immobilized on agarose-linked collagen, its affinity for factor VIII was reduced 4-fold, with K-D increasing from 0.9 to 3.8 nM, However, one factor VIII-binding site remained available on each vWf subunit. A comparable reduction in affinity for factor VIII was observed when vWf was a constituent of the subendothelial cell matrix and when it was bound to purified type VI collagen. In parallel with the decreased affinity for factor VIII, collagen-bound vWf displayed a 6-fold lower affinity for monoclonal antibody W5-6A, with an epitope composed of residues 78-96 within the factor VIII-binding motif of vWf, We conclude that collagen induces a conformational change within the factor VIII-binding motif of vWf that lowers the affinity for factor VIII.	Brockton W Roxbury Vet Affairs Med Ctr, Dept Med, W Roxbury, MA 02132 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gilbert, GE (corresponding author), Brockton W Roxbury Vet Affairs Med Ctr, Dept Med, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.	ggilbert@massmed.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169; BARUCH D, 1991, BLOOD, V77, P519; Bendetowicz AV, 1998, BLOOD, V92, P529, DOI 10.1182/blood.V92.2.529.414k31_529_538; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CHOW TW, 1992, BLOOD, V80, P113; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; HITRAYA EG, 1995, LAB INVEST, V73, P393; HOUDIJK WPM, 1985, J CLIN INVEST, V75, P531, DOI 10.1172/JCI111729; HOYER LW, 1980, BLOOD, V55, P1056; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1987, J BIOL CHEM, V262, P17572; LOSCALZO J, 1986, J CLIN INVEST, V78, P1112, DOI 10.1172/JCI112668; MANN KG, 1990, BLOOD, V76, P1; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MAZURIER C, 1992, THROMB HAEMOSTASIS, V67, P391; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NISHINO M, 1989, BLOOD, V74, P1591; Rand JH, 1997, THROMB HAEMOSTASIS, V78, P445; RUGGERI ZM, 1981, BLOOD, V57, P1140; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; VLOT AJ, 1995, BLOOD, V85, P3150, DOI 10.1182/blood.V85.11.3150.bloodjournal85113150; Vlot AJ, 1996, BLOOD, V87, P1809; WAGNER DD, 1984, J CELL BIOL, V99, P2123, DOI 10.1083/jcb.99.6.2123; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WISE RJ, 1991, J BIOL CHEM, V266, P21948; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; ZUCKER MB, 1983, THROMB HAEMOSTASIS, V49, P37	43	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12300	12307		10.1074/jbc.274.18.12300	http://dx.doi.org/10.1074/jbc.274.18.12300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212199	hybrid			2022-12-25	WOS:000080056800019
J	Ni, L; Heard, TS; Weiner, H				Ni, L; Heard, TS; Weiner, H			In vivo mitochondrial import - A comparison of leader sequence charge and structural relationships with the in vitro model resulting in evidence for co-translational import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1-ATPASE BETA-SUBUNIT; MICROSOMAL ALDEHYDE DEHYDROGENASE; GREEN FLUORESCENT PROTEIN; YEAST MITOCHONDRIA; ORNITHINE TRANSCARBAMYLASE; ASPARTATE-AMINOTRANSFERASE; PHOSPHOLIPID-BILAYERS; PROCESSING PEPTIDASE; SYNTHESIZED PROTEINS; NEUROSPORA-CRASSA	The positive charges and structural properties of the mitochondrial leader sequence of aldehyde dehydrogenase have been extensively studied in vitro, The results of these studies showed that increasing the helicity of this leader would compensate for reduced import from positive charge substitutions of arginine with glutamine or the insertion of negative charged residues made in the native leader. In this in vivo study, utilizing the green fluorescent protein (GFP) as a passenger protein, import results showed the opposite effect with respect to helicity, but the results from mutations made within the native leader sequence were consistent between the in vitro and in vivo experiments. Leader mutations that reduced the efficiency of import resulted in a cytosolic accumulation of a truncated GFP chimera that was fluorescent but devoid of a mitochondrial leader. The native leader efficiently imported before GFP could achieve a stable, import-incompetent structure, suggesting that import was coupled with translation. As a test for a co-translational mechanism, a chimera of GFP that contained the native leader of aldehyde dehydrogenase attached at the N terminus and a C-terminal endoplasmic reticulum targeting signal attached to the C terminus of GFP was constructed. This chimera was localized exclusively to mitochondria, The import result with the dual signal chimera provides support for a co-translational mitochondrial import pathway.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Weiner, H (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.	weiner@biochem.purdue.edu			NIAAA NIH HHS [AA10795] Funding Source: Medline; NIGMS NIH HHS [GM53269] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010795] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADES IZ, 1980, J BIOL CHEM, V255, P9925; ADES IZ, 1980, J BIOL CHEM, V255, P9918; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; CHEN WJ, 1987, J BIOL CHEM, V262, P15598; Chupin V, 1996, BIOCHEMISTRY-US, V35, P3141, DOI 10.1021/bi952482a; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; Crowley KS, 1998, J BIOL CHEM, V273, P17278, DOI 10.1074/jbc.273.27.17278; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GASSER SM, 1982, J BIOL CHEM, V257, P3034; HALLERMAYER G, 1977, EUR J BIOCHEM, V81, P523, DOI 10.1111/j.1432-1033.1977.tb11978.x; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; Heard TS, 1998, J BIOL CHEM, V273, P29389, DOI 10.1074/jbc.273.45.29389; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1987, J CELL BIOL, V105, P669, DOI 10.1083/jcb.105.2.669; HORWICH AL, 1985, P NATL ACAD SCI USA, V82, P4930, DOI 10.1073/pnas.82.15.4930; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; JOHNSON MK, 1960, BIOCHEM J, V77, P610, DOI 10.1042/bj0770610; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KELLEMS RE, 1974, J BIOL CHEM, V249, P3297; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; KELLEMS RE, 1974, J BIOL CHEM, V249, P3304; King T.E., 1967, METHODS ENZYMOL, P216, DOI DOI 10.1016/0076-6879(67)10043-8; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; LAIN B, 1994, J BIOL CHEM, V269, P15588; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; Masters B, 1967, METHOD ENZYMOL, V10, P565; MATSUURA S, 1978, J CELL BIOL, V78, P503, DOI 10.1083/jcb.78.2.503; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MORITA T, 1982, EUR J BIOCHEM, V122, P501; MOYACAMARENA SY, 1995, PROTOPLASMA, V188, P151, DOI 10.1007/BF01280366; RAYMOND Y, 1979, J BIOL CHEM, V254, P9335; REID GA, 1982, J BIOL CHEM, V257, P3056; REID GA, 1982, J BIOL CHEM, V257, P3062; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; Segade F, 1996, J BIOL CHEM, V271, P12343, DOI 10.1074/jbc.271.21.12343; Sjoling S, 1996, EUR J BIOCHEM, V242, P114, DOI 10.1111/j.1432-1033.1996.0114r.x; SKERJANC IS, 1988, J BIOL CHEM, V263, P17233; SONDEREGGER P, 1982, J BIOL CHEM, V257, P3339; TERADA K, 1995, MOL CELL BIOL, V15, P3708; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG Y, 1994, BIOCHEMISTRY-US, V33, P12860, DOI 10.1021/bi00209a018; WANG Y, 1993, J BIOL CHEM, V268, P4759; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	61	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12685	12691		10.1074/jbc.274.18.12685	http://dx.doi.org/10.1074/jbc.274.18.12685			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212250	hybrid			2022-12-25	WOS:000080056800070
J	Boisfer, E; Lambert, G; Atger, V; Tran, NQ; Pastier, D; Benetollo, C; Trottier, JF; Beaucamps, I; Antonucci, M; Laplaud, M; Griglio, S; Chambaz, J; Kalopissis, AD				Boisfer, E; Lambert, G; Atger, V; Tran, NQ; Pastier, D; Benetollo, C; Trottier, JF; Beaucamps, I; Antonucci, M; Laplaud, M; Griglio, S; Chambaz, J; Kalopissis, AD			Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; HEPATIC LIPASE; TANGIER DISEASE; KNOCKOUT MICE; PLASMA; ATHEROSCLEROSIS; TRIGLYCERIDE; CHOLESTEROL; PARTICLES; HYPERCHOLESTEROLEMIA	Two lines of transgenic mice, hAIItg-delta and hAIItg-lambda, expressing human apolipoprotein (apo)A-II at 2 and 4 times the normal concentration, respectively, displayed on standard chow postprandial chylomicronemia, large quantities of very low density lipoprotein (VLDL) and low density lipoprotein (LDL) but greatly reduced high density lipoprotein (HDL), Hypertriglyceridemia may result from increased VLDL production, decreased VLDL catabolism, or both. Post-Triton VLDL production was comparable in transgenic and control mice. Postheparin lipoprotein lipase (LPL) and hepatic lipase activities decreased at most by 30% in transgenic mice, whereas adipose tissue and muscle LPL activities were unaffected, indicating normal LPL synthesis. However, VLDL-triglyceride hydrolysis by exogenous LPL was considerably slower in transgenic compared with control mice, with the apparent V-max of the reaction decreasing proportionately to human apoA-II expression. Human apoA-II was present in appreciable amounts in the VLDL of transgenic mice, which also carried apoC-II. The addition of purified apoA-II in postheparin plasma from control mice induced a dose-dependent decrease in LPL and hepatic lipase activities. In conclusion, overexpression of human apoA-II in transgenic mice induced the proatherogenic lipoprotein profile of low plasma HDL and postprandial hypertriglyceridemia because of decreased VLDL catabolism by LPL.	Inst Biomed Cordeliers, INSERM, U505, F-75006 Paris, France; Hop Broussais, Biochim Lab, F-75014 Paris, France; Hop La Pitie Salpetriere, INSERM, U321, F-75013 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Kalopissis, AD (corresponding author), Inst Biomed Cordeliers, INSERM, U505, 15 Rue Ecole Med, F-75006 Paris, France.			Lambert, Gilles/0000-0001-5632-0685				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Alaupovic P, 1997, ARTERIOSCL THROM VAS, V17, P715, DOI 10.1161/01.ATV.17.4.715; ALAUPOVIC P, 1991, J LIPID RES, V32, P9; Banka CL, 1996, CURR OPIN LIPIDOL, V7, P139, DOI 10.1097/00041433-199606000-00005; BEKAERT ED, 1993, J LIPID RES, V34, P111; Benlian P, 1996, NEW ENGL J MED, V335, P848, DOI 10.1056/NEJM199609193351203; BRASSEUR R, 1992, PROTEINS, V13, P246, DOI 10.1002/prot.340130307; Castellani LW, 1997, J CLIN INVEST, V100, P464, DOI 10.1172/JCI119554; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; Escola-Gil JC, 1998, J LIPID RES, V39, P457; FIELDING CJ, 1995, J LIPID RES, V36, P211; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANCONE OL, 1989, BIOCHIM BIOPHYS ACTA, V1002, P28, DOI 10.1016/0005-2760(89)90060-X; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KALOPISSIS AD, 1982, BIOCHIM BIOPHYS ACTA, V711, P33, DOI 10.1016/0005-2760(82)90006-6; Koren E, 1996, ATHEROSCLEROSIS, V122, P105, DOI 10.1016/0021-9150(95)05791-9; KUBO M, 1982, J BIOCHEM, V92, P865, DOI 10.1093/oxfordjournals.jbchem.a134000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; LOPEZ J, 1994, BIOCHEMISTRY-US, V33, P4056, DOI 10.1021/bi00179a034; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MarzalCasacuberta A, 1996, J BIOL CHEM, V271, P6720, DOI 10.1074/jbc.271.12.6720; Mowri HO, 1996, ARTERIOSCL THROM VAS, V16, P755, DOI 10.1161/01.ATV.16.6.755; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NILSSONEHLE P, 1977, ARTERY, V3, P194; OTWAY S, 1967, J PHYSIOL-LONDON, V190, P321, DOI 10.1113/jphysiol.1967.sp008211; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; Plump AS, 1997, J LIPID RES, V38, P1033; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rader DJ, 1996, CURR OPIN LIPIDOL, V7, P117, DOI 10.1097/00041433-199606000-00002; SCHMITZ G, 1983, J LIPID RES, V24, P1021; Schultz Joshua R., 1994, Current Opinion in Lipidology, V5, P126, DOI 10.1097/00041433-199404000-00009; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; Shachter NS, 1996, J CLIN INVEST, V98, P846, DOI 10.1172/JCI118857; SHINOMIYA M, 1982, BIOCHIM BIOPHYS ACTA, V713, P292; TALL AR, 1978, NEW ENGL J MED, V299, P1232, DOI 10.1056/NEJM197811302992207; THUREN T, 1991, J BIOL CHEM, V266, P4853; Vega GL, 1996, CURR OPIN LIPIDOL, V7, P209, DOI 10.1097/00041433-199608000-00007; WANG CS, 1987, BIOCHIM BIOPHYS ACTA, V920, P9, DOI 10.1016/0005-2760(87)90305-5; WANG CS, 1992, BIOCHIM BIOPHYS ACTA, V1123, P1, DOI 10.1016/0005-2760(92)90165-R; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; Weng W, 1996, P NATL ACAD SCI USA, V93, P14788, DOI 10.1073/pnas.93.25.14788; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; WU AL, 1981, J BIOL CHEM, V256, P3615; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	50	83	84	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11564	11572		10.1074/jbc.274.17.11564	http://dx.doi.org/10.1074/jbc.274.17.11564			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206963	hybrid			2022-12-25	WOS:000079834800019
J	Chan, PP; Lin, M; Faruqi, AF; Powell, J; Seidman, MM; Glazer, PM				Chan, PP; Lin, M; Faruqi, AF; Powell, J; Seidman, MM; Glazer, PM			Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-HELICAL DNA; HOMOLOGOUS RECOMBINATION; PSORALEN PHOTOADDUCTS; GENOMIC DNA; MUTAGENESIS; CLEAVAGE; REPAIR; SITE; EXPRESSION; NUCLEASE	Tripler-forming oligonucleotides (TFOs) can bind to polypurine/polypyrimidine regions in DNA in a sequence-specific manner and provoke DNA repair. We have coupled a TFO to a short donor fragment of DNA that shares homology to a selected gene as a strategy to mediate gene targeting and correction. In this bifunctional oligonucleotide, the TFO domain is designed to bind the target gene and stimulate repair and recombination, with the donor domain positioned for recombination and information transfer. A series of these tethered donor-TFO (TD-TFO) molecules with donor domains of 40-44 nucleotides and TFO domains in both the purine and pyrimidine tripler motifs were tested for their ability to mediate either gene correction or mutation of a supF reporter gene contained in a SV40 shuttle vector in mammalian cells. In vitro binding assays revealed that the attachment of the donor domain via a flexible linker did not significantly alter the binding affinity of the TFO domain for the polypurine site in the supF target DNA, with equilibrium dissociation constants in the 10(-8) M range. Experiments in which the target vector and the linked TD-TFOs were pre-incubated in vitro and co-transfected into cells led to conversion frequencies approaching 1%, 4-fold greater than with the two domains unlinked, When cells that had been previously transfected with the SV40 vector were electroporated with the TD-TFOs, frequencies of base pair-specific gene correction were seen in the range of 0.04%, up to 50-fold over background and at least 3-fold over either domain alone or in unlinked combinations. Sequence conversion by the TD-TFOs was achieved using either single- or double-stranded donor domains and either tripler motif, Substitution of either domain in the TD-TFO with control sequences yielded reagents with diminished activity, as did mixtures of unlinked TFO and donor DNA segments, The boost in activity provided by the attached TFO domain was reduced in cells deficient in the nucleotide excision repair factor XPA but was restored in a subclone of these cells expressing XPA cDNA, suggesting a role for nucleotide excision repair in the pathway of triple helix-stimulated gene conversion. The ability to correct or mutate a specific target site in mammalian cells using the TD-TFO strategy may provide a useful tool for research and possibly for therapeutic applications.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; NIA, NIH, Baltimore, MD 21224 USA	Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Glazer, PM (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, POB 206040, New Haven, CT 06520 USA.		Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205, R01GM054731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07205, GM54731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belousov ES, 1997, NUCLEIC ACIDS RES, V25, P3440, DOI 10.1093/nar/25.17.3440; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHENG AJ, 1994, NUCLEIC ACIDS RES, V22, P4742, DOI 10.1093/nar/22.22.4742; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; Faruqi AF, 1996, MOL CELL BIOL, V16, P6820; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; Gunther EJ, 1996, PHOTOCHEM PHOTOBIOL, V63, P207, DOI 10.1111/j.1751-1097.1996.tb03015.x; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; HAVRE PA, 1993, J VIROL, V67, P7324, DOI 10.1128/JVI.67.12.7324-7331.1993; Kunzelmann K, 1996, GENE THER, V3, P859; LANDGRAF R, 1994, BIOCHEMISTRY-US, V33, P10607, DOI 10.1021/bi00201a006; LEVY DD, 1995, CARCINOGENESIS, V16, P1557, DOI 10.1093/carcin/16.7.1557; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; POVSIC TJ, 1990, J AM CHEM SOC, V112, P9428, DOI 10.1021/ja00181a075; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; SEDIVY JM, 1992, GENE TARGETING; SEGAL DJ, 1995, P NATL ACAD SCI USA, V92, P806, DOI 10.1073/pnas.92.3.806; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; TAKASUGI M, 1991, P NATL ACAD SCI USA, V88, P5602, DOI 10.1073/pnas.88.13.5602; WANG G, 1995, J BIOL CHEM, V270, P22595, DOI 10.1074/jbc.270.38.22595; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196	27	105	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11541	11548		10.1074/jbc.274.17.11541	http://dx.doi.org/10.1074/jbc.274.17.11541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206960	hybrid			2022-12-25	WOS:000079834800016
J	Muller, HM; Dimopoulos, G; Blass, C; Kafatos, FC				Muller, HM; Dimopoulos, G; Blass, C; Kafatos, FC			A hemocyte-like cell line established from the malaria vector Anopheles gambiae expresses six prophenoloxidase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; MOLECULAR-CLONING; MELANOTIC ENCAPSULATION; ARMIGERES SUBALBATUS; IMMUNE-RESPONSE; MANDUCA-SEXTA; HOST-DEFENSE; BOMBYX-MORI; MOSQUITO; CDNA	Cell lines from the malaria vector Anopheles gambiae have been established as a tool for the study of the mosquito innate immune system in vitro. Here, we describe the first continuous insect cell line that produces prophenoloxidase (PPO), This cell line (4a-3B) expresses constitutively six PPO genes, three of which are novel (PPO4, PPO5, and PPO6), The PPO genes show distinct temporal expression profiles in the intact mosquito, spanning stages from the embryo to the adult in an overlapping manner. Transient induction of larva-specific PPO genes in blood-fed adult females suggests that the developmental hormone 20-hydroxyecdysone may be involved in PPO gene regulation. Indeed, exposure of 4a-3B cells to 20-hydroxyecdysone in culture results in induction of those PPO genes that are mainly expressed in early developmental stages, and repression of PPO5, which is preferentially expressed at the adult stage. The cell line shows bacteria-induced immune transcripts that encode defensin and Gram-negative bacteria-binding protein, but no induction of PPO transcripts. This cell line most likely derives from a hemocyte lineage, and represents an appropriate in vitro model for the study of the humoral and cellular immune defenses of A. gambiae.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Muller, HM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.			Muller, Hans-Michael/0000-0002-2384-7285; Dimopoulos, George/0000-0001-6755-8111				Ashida M., 1990, P239; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; ASHIDA M, 1988, TISSUE CELL, V20, P599, DOI 10.1016/0040-8166(88)90061-4; ASHIDA M, 1981, INSECT BIOCHEM, V11, P57, DOI 10.1016/0020-1790(81)90041-X; Ashida Masaaki, 1998, P135; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; Barillas-Mury C., 1996, EMBO Journal, V15, P4961; Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; Braun A, 1998, P NATL ACAD SCI USA, V95, P14337, DOI 10.1073/pnas.95.24.14337; BREY PT, 1991, ANAL BIOCHEM, V194, P359, DOI 10.1016/0003-2697(91)90241-K; BREY PT, 1995, EXP PARASITOL, V80, P654, DOI 10.1006/expr.1995.1081; Cho WL, 1998, INSECT MOL BIOL, V7, P31, DOI 10.1046/j.1365-2583.1998.71049.x; Clements AN., 1992, BIOL MOSQUITOES DEV; COLLINS FH, 1994, SCIENCE, V264, P1874, DOI 10.1126/science.8009215; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; COLUZZI M, 1992, PARASITOL TODAY, V8, P113, DOI 10.1016/0169-4758(92)90277-9; Dimopoulos G, 1998, EMBO J, V17, P6115, DOI 10.1093/emboj/17.21.6115; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; DRIF L, 1983, DEV COMP IMMUNOL, V7, P687, DOI 10.1016/0145-305X(83)90094-0; Foley D.A., 1978, Comparative Pathobiology, V4, P113; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; HARA T, 1993, COMP BIOCHEM PHYS B, V106, P287, DOI 10.1016/0305-0491(93)90302-L; HERNANDEZ VP, 1994, AM J TROP MED HYG, V50, P440, DOI 10.4269/ajtmh.1994.50.440; HIRUMA K, 1988, DEV BIOL, V130, P87, DOI 10.1016/0012-1606(88)90416-2; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P693, DOI 10.1016/S0965-1748(97)00045-3; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P835, DOI 10.1016/S0965-1748(97)00066-0; KAAYA GP, 1982, J MORPHOL, V173, P351, DOI 10.1002/jmor.1051730310; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; Komano H., 1988, P75; Kumar V., 1994, Insect Molecular Biology, V3, P41, DOI 10.1111/j.1365-2583.1994.tb00149.x; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee WJ, 1998, INSECT MOL BIOL, V7, P41, DOI 10.1046/j.1365-2583.1998.71047.x; LI JY, 1992, DEV COMP IMMUNOL, V16, P41, DOI 10.1016/0145-305X(92)90050-M; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Muller HM, 1995, EXP PARASITOL, V81, P371, DOI 10.1006/expr.1995.1128; NAPPI AJ, 1993, INSECT IMMUNITY, P131; Park DS, 1997, INSECT BIOCHEM MOLEC, V27, P983, DOI 10.1016/S0965-1748(97)00081-7; PASKEWITZ SM, 1989, J PARASITOL, V75, P594, DOI 10.2307/3282911; Perbal B., 1988, PRACTICAL GUIDE MOL; Pudney M., 1979, TCA (TISSUE CULTURE ASSOCIATION) MANUAL, V5, P997, DOI 10.1007/BF00919719; RICH V, 1995, PHYS WORLD, V8, P14; Richman AM, 1997, EMBO J, V16, P6114, DOI 10.1093/emboj/16.20.6114; Richman AM, 1996, INSECT MOL BIOL, V5, P203, DOI 10.1111/j.1365-2583.1996.tb00055.x; RIZKI TM, 1957, J MORPHOL, V100, P437; SALAZAR CE, 1993, NUCLEIC ACIDS RES, V21, P4147, DOI 10.1093/nar/21.17.4147; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; Sidjanski S, 1997, J PARASITOL, V83, P686, DOI 10.2307/3284247; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; Vernick Kenneth D., 1998, P261; ZHAO XL, 1995, DEV COMP IMMUNOL, V19, P205, DOI 10.1016/0145-305X(95)00005-E; Zheng LB, 1997, ARCH INSECT BIOCHEM, V34, P1, DOI 10.1002/(SICI)1520-6327(1997)34:1<1::AID-ARCH1>3.3.CO;2-R	55	223	246	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11727	11735		10.1074/jbc.274.17.11727	http://dx.doi.org/10.1074/jbc.274.17.11727			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206988	hybrid			2022-12-25	WOS:000079834800044
J	Wang, G; Yang, XM; Zhang, Y; Wang, QM; Chen, HP; Wei, HD; Xing, GC; Hu, ZY; Zhang, CG; Fang, DC; Wu, CT; He, FC				Wang, G; Yang, XM; Zhang, Y; Wang, QM; Chen, HP; Wei, HD; Xing, GC; Hu, ZY; Zhang, CG; Fang, DC; Wu, CT; He, FC			Identification and characterization of receptor for mammalian hepatopoietin that is homologous to yeast ERV1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGENERATIVE STIMULATOR SUBSTANCE; FETAL LIVER-CELLS; GROWTH-FACTOR; RAT-LIVER; PRIMARY CULTURES; HUMAN AUGMENTOR; DNA-SYNTHESIS; HEPATOCYTES; EXPRESSION; CLONING	Hepatopoietin (HPO) is a novel polypeptide mitogen specific for hepatocytes and hepatoma cell lines, which is derived from liver and supports its regeneration. To determine whether HPO acts via a receptor-based signal transduction, recombinant human hepatopoietin was labeled by iodination and used to characterize its binding activity by specific displacement test and Scatchard analysis in primarily cultured rat hepatocytes and human hepatoma Hep-G2 cells. The binding was saturable and specific because it was replaceable by HPO but not by epidermal growth factor, transforming growth factor-alpha, or insulin. Scatchard analysis indicated the presence of a single class of high affinity receptor with dissociation constant (K-d) of 2 and 0.7 pM, and a receptor density of about 10,000 sites/cell and 55,000 sites/cell in the rat hepatocytes and human hepatoma cells, respectively. The K-d values were consistent with the half-maximum dose of HPO activity. Affinity cross-linking of the receptor with I-125-HPO revealed a polypeptide of molecular mass approximately 90 kDa by SDS-polyacrylamide gel electrophoresis. Thus, the molecular mass of the HPO receptor was calculated to be about 75 kDa. These data demonstrated the existence of an HPO receptor in hepatocytes and hepatoma cells, which may account for biological effect.	Chinese Natl Human Genome Ctr, Beijing Inst Radiat Med, Beijing 100850, Peoples R China; Third Mil Med Coll, SW Hosp, Chongqing 400042, Peoples R China	Academy of Military Medical Sciences - China; Army Medical University	He, FC (corresponding author), Chinese Natl Human Genome Ctr, Beijing Inst Radiat Med, 27 Taiping Rd, Beijing 100850, Peoples R China.		Zhang, Chenggang/B-1480-2009	Zhang, Chenggang/0000-0002-4521-3304; Wang, Ge/0000-0003-0571-5745				Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; FREYCHET P, 1972, J BIOL CHEM, V247, P3953; HABIBULLAH CM, 1994, TRANSPLANTATION, V58, P951, DOI 10.1097/00007890-199410270-00016; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; He FC, 1997, CHINESE SCI BULL, V42, P1505; HE FC, 1992, HEPATOLOGY, V17, P225; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; LABRECQUE DR, 1991, DIGEST DIS SCI, V36, P669, DOI 10.1007/BF01297036; LABRECQUE DR, 1975, J PHYSIOL-LONDON, V248, P273, DOI 10.1113/jphysiol.1975.sp010973; LISOWSKY T, 1995, GENOMICS, V29, P690, DOI 10.1006/geno.1995.9950; MORLEY CGD, 1972, ANAL BIOCHEM, V45, P298, DOI 10.1016/0003-2697(72)90030-9; MOSHAGE H, 1992, J HEPATOL, V15, P404, DOI 10.1016/0168-8278(92)90078-4; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; PILCH PF, 1979, J BIOL CHEM, V254, P3375; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; TOMITA Y, 1981, EXP CELL RES, V135, P363, DOI 10.1016/0014-4827(81)90172-5; TU Q, 1991, J PATHOPHYSIOL, V7, P537; TU Q, 1990, CHIN J APPL PHYSL, V6, P199; TU Q, 1990, J CELL BIOCHEM, V14, P140; WU CT, 1987, THYMUS, V10, P109; XIE L, 1996, CHIN J APPL PHYSL, V12, P324; Yang XM, 1997, ACTA BIOCH BIOPH SIN, V29, P414; Yang XM, 1998, CHINESE SCI BULL, V43, P1026; Yang XM, 1997, SCI CHINA SER C, V40, P642, DOI 10.1007/BF02882695; YAO ZQ, 1990, HEPATOLOGY, V12, P1144; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, BIOCHEM BIOPH RES CO, V173, P1179, DOI 10.1016/S0006-291X(05)80910-6	28	60	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11469	11472		10.1074/jbc.274.17.11469	http://dx.doi.org/10.1074/jbc.274.17.11469			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206950	hybrid			2022-12-25	WOS:000079834800006
J	Murakami, H; Iwashita, T; Asai, N; Iwata, Y; Narumiya, S; Takahashi, M				Murakami, H; Iwashita, T; Asai, N; Iwata, Y; Narumiya, S; Takahashi, M			Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130(Cas) mediated by Ret kinase	ONCOGENE			English	Article						Ret; GDNF; focal adhesion kinase; paxillin; p130(Cas)	MEN 2B MUTATIONS; NEUROTROPHIC FACTOR; GROWTH-FACTOR; TRANSFORMING ACTIVITY; BIOLOGICAL PROPERTIES; DOPAMINERGIC-NEURONS; CELL-ADHESION; MOTOR-NEURONS; IN-VIVO; GDNF	Glial cell line-derived neurotrophic factor (GDNF) signals through a unique receptor system that includes Ret receptor tyrosine kinase and a glycosyl-phosphatidylinositol-linked cell surface protein. In the present study, we have identified several proteins in neuroblastoma cells that are phosphorylated on tyrosine in response to GDNF, The phosphorylated proteins include focal adhesion kinase (FAK), paxillin and Crk-associated substrate, p130(Cas), all of which are known to be associated with focal adhesions. Of these, paxillin and p130(Cas) interacted with Crk proteins in GDNF-treated neuroblastoma cells. GDNF also induced reorganization of the actin cytoskelton, Tyrosine phosphorylation of FAK, paxillin and p130(Cas) was inhibited by cytochalasin D or two specific inhibitors of phosphatidylinositol-3' kinase (PI-3' kinase), wortmannin and LY294002, indicating that their tyrosine phosphorylation depends on the formation of actin stress fiber and activation of PI-3' kinase. In addition, phosphorylation of FAK but not of paxillin and p130(Cas) was markedly impaired by the Clostridium botulinum C3 exoenzyme that specifically ADP-ribosylates and inactivates Rho, These results suggested the presence of Rho-dependent and -independent signaling pathways downstream of PI-3' kinase that mediate tyrosine phosphorylation of FAK, paxillin and p130(Cas) through Pet kinase.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 466, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan	Nagoya University; Kyoto University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.		TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; BORELLO MG, 1995, ONCOGENE, V11, P2419; BORRELLO MA, 1993, ONCOGENE, V9, P1661; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1996, ONCOGENE, V12, P481; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIAN X, 1991, NATURE, V352, P73; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	45	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1975	1982		10.1038/sj.onc.1202514	http://dx.doi.org/10.1038/sj.onc.1202514			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208419				2022-12-25	WOS:000079191300007
J	North, S; Espanel, X; Bantignies, F; Viollet, B; Vallet, V; Jalinot, P; Brun, G; Gillet, G				North, S; Espanel, X; Bantignies, F; Viollet, B; Vallet, V; Jalinot, P; Brun, G; Gillet, G			Regulation of cdc2 gene expression by the upstream stimulatory factors (USFs)	ONCOGENE			English	Article						cell cycle; differentiation; retina; cdc2; USF	TRANSCRIPTION FACTOR USF; HELIX-LOOP-HELIX; CELL-CYCLE REGULATION; MAMMALIAN-CELLS; IN-VIVO; PROMOTER; REGION; ACTIVATION; REPRESSION; IDENTIFICATION	cdc2 gene expression is under the control of multiple factors. Although E2F/DP proteins have been reported to play a central role, they cannot account for all aspects of the fine modulation of cdc2 gene expression during cell cycle and embryonic development. To characterize the transcription factors that control cdc2 gene expression during nerve cell differentiation in avians, we have previously cloned the quail cdc2 gene promoter region. We had identified an octamer (CAGGTGGC) containing an E-box, which has important activity in regulating cdc2 transcription. Using lit vivo genomic footprinting experiments, we show here that this motif, currently named TG, is the target of binding proteins at different stages of neuroretina development, confirming its importance as a regulatory response element for cdc2 gene expression. A subset of Helix-Loop-Helix family of transcription factors, known as Upstream Stimulatory Factors (USFs) specifically bind to this sequence as dimers, Moreover, our results indicate that USFs transactivate the promoter of cdc2 via the IG motif, These data may help to better understand the mechanisms that control cell division in differentiating nerve cells.	CNRS, Inst Biol & Chim Prot, UPR 412, F-69367 Lyon 07, France; CHU Cochin Port Royal, INSERM, U129, Unite Rech Genet & Pathol Mol, F-75014 Paris, France; Ecole Normale Super Lyon, UMR CNRS 49, Res Grp, Mol & Cellular Biol Lab, F-69364 Lyon 07, France; Ecole Normale Super Lyon, UMR CNRS 49, F-69364 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON)	Gillet, G (corresponding author), CNRS, Inst Biol & Chim Prot, UPR 412, 7 Passage Vercors, F-69367 Lyon 07, France.		Viollet, Benoit/O-6927-2017; Viollet, Benoit/N-2397-2019; gillet, germain/A-9095-2013	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; GILLET, Germain/0000-0002-1514-327X				BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Breen GAM, 1997, J BIOL CHEM, V272, P10538; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Espanel X, 1997, INT J DEV BIOL, V41, P469; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; GILLET G, 1993, ONCOGENE, V8, P565; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; Kenny JJ, 1997, VIROLOGY, V230, P381, DOI 10.1006/viro.1997.8501; KU DH, 1993, J BIOL CHEM, V268, P2255; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; North S, 1996, CELL GROWTH DIFFER, V7, P339; NURSE P, 1993, PHILOS T ROY SOC B, V341, P449, DOI 10.1098/rstb.1993.0127; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; Rippe RA, 1997, J BIOL CHEM, V272, P1753, DOI 10.1074/jbc.272.3.1753; SARDET C, 1997, E2FS RETINOBLASTOMA; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; SHIMIZU T, 1995, CANCER RES, V55, P228; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	39	26	26	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1945	1955		10.1038/sj.onc.1202506	http://dx.doi.org/10.1038/sj.onc.1202506			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208416				2022-12-25	WOS:000079191300004
J	Wang, LH; Kalb, RG; Strittmatter, SM				Wang, LH; Kalb, RG; Strittmatter, SM			A PDZ protein regulates the distribution of the transmembrane semaphorin, M-SemF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE GUIDANCE; PERIPHERAL-NERVE PROJECTION; NITRIC-OXIDE SYNTHASE; C-TERMINUS; GUANYLATE KINASES; FASCICLIN-II; FAMILY; DOMAIN; RECEPTOR; MOLECULES	M-SemF is a membrane-associated, neurally enriched member of the semaphorin family of axon guidance signals. We considered whether the cytoplasmic domain of M-SemF might possess a signaling function and/or might control the distribution of M-SemF on the cell surface. We identify a PDZ-containing neural protein as an M-SemF cytoplasmic domain-associated protein (SEMCAP-1), SEMCAP-2 is a closely related nonneuronal protein. SEMCAP-1 has recently also been identified as GIPC, by virtue of its interaction with the RGS protein GAIP in vitro (De Vries, L., Lou, X., Zhao, G., Zheng, B., and Farquhar, M.G. (1998) Proc. Natl, Acad, Sci, U. S. A, 95, 12340-12345), Expression studies support the notion that SEMCAP-1(GIPC) interacts with M-SemF, but not GAIP, in brain. Lung SEMCAP-2 and SEMCAP-1(GIPC) are potential partners for both GAIP and M-SemF. The protein interaction requires the single PDZ domain of SEMCAP-1(GIPC) and the carboxyl-terminal four residues of M-SemF, ESSV, While SEMCAP-1(GIPC) also interacts with SemC, it does not interact with other proteins containing a class I PDZ binding motif, nor does M-SemF interact with other class I PDZ proteins. Coexpression of SEMCAP-1(G;IPC) induces the redistribution of dispersed M-SemF into detergent-resistant aggregates in HEK293 cells. Thus, SEMCAP-1(GIPC) appears to regulate the subcellular distribution of M-SemF in brain, and SEMCAPs could link M-SemF to G protein signal transduction pathways.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA	Yale University	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, POB 208018,333 Cedar St, New Haven, CT 06520 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092	NINDS NIH HHS [NS29837, NS33020] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS033020, R01NS033020, R01NS029837] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Chiba A, 1996, DEV BIOL, V180, P424, DOI 10.1006/dbio.1996.0316; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Eckhardt F, 1997, MOL CELL NEUROSCI, V9, P409, DOI 10.1006/mcne.1997.0644; Elhabazi A, 1997, J BIOL CHEM, V272, P23515, DOI 10.1074/jbc.272.38.23515; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Jin Z, 1997, J NEUROSCI, V17, P6256; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Klostermann A, 1998, J BIOL CHEM, V273, P7326, DOI 10.1074/jbc.273.13.7326; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Koppel AM, 1998, J BIOL CHEM, V273, P15708, DOI 10.1074/jbc.273.25.15708; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Puschel AW, 1996, EUR J NEUROSCI, V8, P1317, DOI 10.1111/j.1460-9568.1996.tb01593.x; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Reichardt L. F., 1997, MOL CELLULAR APPROAC, P220; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Takahashi T, 1997, J NEUROSCI, V17, P9183; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Xu XM, 1998, J BIOL CHEM, V273, P22428, DOI 10.1074/jbc.273.35.22428; Yu HH, 1998, NEURON, V20, P207, DOI 10.1016/S0896-6273(00)80450-X; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	51	105	116	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14137	14146		10.1074/jbc.274.20.14137	http://dx.doi.org/10.1074/jbc.274.20.14137			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318831	hybrid			2022-12-25	WOS:000080322200060
J	Nyitrai, M; Hild, G; Belagyi, J; Somogyi, B				Nyitrai, M; Hild, G; Belagyi, J; Somogyi, B			The flexibility of actin filaments as revealed by fluorescence resonance energy transfer - The influence of divalent cations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; X-RAY-DIFFRACTION; LABELED F-ACTIN; CONFORMATIONAL CHANGE; ROTATIONAL-DYNAMICS; STRUCTURAL-CHANGES; HEAVY-MEROMYOSIN; MYOSIN-FILAMENTS; VARIABLE TWIST; CONTRACTION	The temperature profile of the fluorescence resonance energy transfer efficiency normalized by the fluorescence quantum yield of the donor in the presence of acceptor, f, was measured in a way allowing the independent investigation of (i) the strength of interaction between the adjacent protomers (intermonomer flexibility) and (ii) the flexibility of the protein matrix within actin protomers (intramonomer flexibility). In both cases the relative increase as a function of temperature in f is larger in calcium-F-actin than in magnesium-F-actin in the range of 5-40 degrees C, which indicates that both the intramonomer and the intermonomer flexibility of the actin filaments are larger in calcium-F-actin than those in magnesium-F-actin. The intermonomer flexibility was proved to be larger than the intramonomer one in both the calcium-F-actin and the magnesium-F-actin, The distance between Gln(41) and Cys(374) residues was found to be cation-independent and did not change during polymerization at 21 degrees C, The steady-state fluorescence anisotropy data of fluorophores attached to the Gln(41) or Cys(374) residues suggest that the microenvironments around these regions are more rigid in the magnesium-loaded actin filament than in the calcium-loaded form.	Univ Pecs, Sch Med, Hungarian Acad Sci, Res Grp, H-7601 Pecs, Hungary; Univ Pecs, Sch Med, Dept Biophys, H-7601 Pecs, Hungary; Univ Pecs, Sch Med, Cent Res Lab, H-7601 Pecs, Hungary	Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Pecs; University of Pecs; University of Pecs	Somogyi, B (corresponding author), Univ Pecs, Sch Med, Hungarian Acad Sci, Res Grp, POB 99, H-7601 Pecs, Hungary.			Nyitrai, Miklos/0000-0002-6229-4337				BADLEY RA, 1969, J MOL BIOL, V44, P71, DOI 10.1016/0022-2836(69)90405-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER B, 1987, BASIC RES CARDIOLO S; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; EGELMAN EH, 1995, CURR OPIN STRUC BIOL, V5, P172, DOI 10.1016/0959-440X(95)80072-7; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; Feuer G., 1948, HUNGARICA ACTA PHYSIOL, V1, P150; GALAZKIEWICZ B, 1989, EUR J BIOCHEM, V186, P233, DOI 10.1111/j.1432-1033.1989.tb15200.x; GEEVES MA, 1991, BIOCHEM J, V274, P1; GENNIS RB, 1972, BIOCHEMISTRY-US, V11, P2509, DOI 10.1021/bi00763a020; Heintz D, 1996, BIOCHEMISTRY-US, V35, P12686, DOI 10.1021/bi961159k; Hild G, 1998, BIOPHYS J, V75, P3015, DOI 10.1016/S0006-3495(98)77742-2; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY HE, 1994, BIOPHYS J, V67, P2411, DOI 10.1016/S0006-3495(94)80728-3; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOJIMA H, 1994, P NATL ACAD SCI USA, V91, P12962, DOI 10.1073/pnas.91.26.12962; KOUYAMA T, 1985, BIOPHYS J, V47, P43, DOI 10.1016/S0006-3495(85)83875-3; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; LORAND L, 1983, ANAL BIOCHEM, V131, P419, DOI 10.1016/0003-2697(83)90193-8; Maeda Y, 1988, Adv Exp Med Biol, V226, P381; MIKI M, 1982, BIOPHYS CHEM, V16, P165, DOI 10.1016/0301-4622(82)85019-9; MIKI M, 1991, BIOCHEMISTRY-US, V30, P10878, DOI 10.1021/bi00109a011; MIKI M, 1987, EUR J BIOCHEM, V168, P339, DOI 10.1111/j.1432-1033.1987.tb13425.x; MOSSAKOWSKA M, 1988, EUR J BIOCHEM, V175, P557, DOI 10.1111/j.1432-1033.1988.tb14228.x; Nyitrai M, 1998, BIOPHYS J, V74, P2474, DOI 10.1016/S0006-3495(98)77955-X; OOSAWA F, 1977, BIORHEOLOGY, V14, P11; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; PROCHNIEWICZ E, 1990, J MOL BIOL, V216, P761, DOI 10.1016/0022-2836(90)90397-5; PROCHNIEWICZNAKAYAMA E, 1983, J CELL BIOL, V97, P1663, DOI 10.1083/jcb.97.6.1663; SCHARF RE, 1995, BBA-PROTEIN STRUCT M, V1253, P129, DOI 10.1016/0167-4838(95)00186-5; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1995, BIOPHYS J, V68, pS12; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; STOKES DL, 1987, J CELL BIOL, V104, P1005, DOI 10.1083/jcb.104.4.1005; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; SUZUKI S, 1983, J GEN PHYSIOL, V81, P531, DOI 10.1085/jgp.81.4.531; TAKASHI R, 1979, BIOCHEMISTRY-US, V18, P5164, DOI 10.1021/bi00590a021; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; THOMAS DD, 1979, J MOL BIOL, V132, P257, DOI 10.1016/0022-2836(79)90259-6; THOMAS DD, 1995, BIOPHYS J, V68, pS135; WAKABAYASHI K, 1993, ADV EXP MED BIOL, V332, P451; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; YAGI N, 1989, J MOL BIOL, V208, P359, DOI 10.1016/0022-2836(89)90396-3; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; ZIMMERLE CT, 1987, BIOCHEMISTRY-US, V26, P6545, DOI 10.1021/bi00394a039	54	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12996	13001		10.1074/jbc.274.19.12996	http://dx.doi.org/10.1074/jbc.274.19.12996			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224049	hybrid			2022-12-25	WOS:000080200400011
J	Ohtani, K; Suzuki, Y; Eda, S; Kawai, T; Kase, T; Yamazaki, H; Shimada, T; Keshi, H; Sakai, Y; Fukuoh, A; Sakamoto, T; Wakamiya, N				Ohtani, K; Suzuki, Y; Eda, S; Kawai, T; Kase, T; Yamazaki, H; Shimada, T; Keshi, H; Sakai, Y; Fukuoh, A; Sakamoto, T; Wakamiya, N			Molecular cloning of a novel human collectin from liver (CL-L1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; INFLUENZA-A-VIRUS; CARBOHYDRATE-RECOGNITION DOMAINS; PULMONARY SURFACTANT APOPROTEIN; BOVINE CONGLUTININ; INHIBIT HEMAGGLUTINATION; BACTERICIDAL ACTIVITY; LECTINS; CDNA; PURIFICATION	Collectins are a C-lectin family with collagen-like sequences and carbohydrate recognition domains. These proteins can bind to carbohydrate antigens of microorganisms and inhibit their infection by direct neutralization and agglutination, the activation of complement through the lectin pathway, and opsonization by collectin receptors, Here we report the cloning of a cDNA encoding human collectin from liver (CL-L1 (collectin liver 1)) that has typical collectin structural characteristics, consisting of an N-terminal cysteine-rich domain, a collagen-like domain, a neck domain, and a carbohydrate recognition domain. The cDNA has an insert of 831 base pairs coding for a protein of 277 amino acid residues. The deduced amino acid sequence shows that this collectin has a unique repeat of four lysine residues in its C-terminal area. Northern blot, Western blot, and reverse tp anscription-polymerase chain reaction analyses showed that CL-L1 is present mainly in liver as a cytosolic protein and at low levels in placenta. More sensitive analyses by reverse transcription-polymerase chain reactions showed that most tissues (except skeletal muscle) have CL-L1 mRNA Zoo-blot analysis indicated that CL-L1 is limited to mammals and birds. A chromosomal localization study indicated that the CL-L1 gene localizes to chromosome 8q23-q24.1, different from chromosome 10 of other human collectin genes. Expression studies of fusion proteins lacking the collagen and N-terminal domains produced in Escherichia coli affirmed that CL-L1 binds mannose weakly. CL-L1 and recombinant CL-L1 fusion proteins do not bind to mannan columns. Analysis of the phylogenetic tree of CL-LI and other collectins indicated that CL-L1 belongs to a fourth subfamily of collectins following the mannan-binding protein, surfactant protein A, and surfactant protein D subfamilies including bovine conglutinin and collectin-43 (CL-43), These findings indicate that CL-LI may be involved in different biological functions.	Osaka Univ, Microbial Dis Res Inst, Dept Viral Infect, Suita, Osaka 565, Japan; Osaka Prefectural Inst Publ Hlth, Dept Pathol, Osaka 537, Japan; Osaka Prefectural Inst Publ Hlth, Dept Food Microbiol, Osaka 537, Japan; Osaka Prefectural Inst Publ Hlth, Dept Virol, Osaka 537, Japan; Osaka Prefectural Inst Publ Hlth, Dept Pharmaceut Affairs, Osaka 537, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Viral Infect, Suita, Osaka 565, Japan	Osaka University; Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health; Osaka University	Wakamiya, N (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Viral Infect, Suita, Osaka 565, Japan.	wakamiya@biken.osaka-u.ac.jp	Yamazaki, Hiroshi/A-6081-2011; Suzuki, Yasuhiko/F-6890-2012	Yamazaki, Hiroshi/0000-0002-1068-4261; Shimada, Tsutomu/0000-0003-2552-4348				DAVIS AE, 1984, BIOCHEMISTRY-US, V23, P2139, DOI 10.1021/bi00305a006; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; Eda S, 1996, BIOCHEM J, V316, P43, DOI 10.1042/bj3160043; Eda S, 1997, BIOCHEM J, V323, P393, DOI 10.1042/bj3230393; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; HARTLEY CA, 1992, J VIROL, V66, P4358, DOI 10.1128/JVI.66.7.4358-4363.1992; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Kamemura K, 1998, ANAL BIOCHEM, V258, P305, DOI 10.1006/abio.1998.2585; Kawai T, 1997, GENE, V186, P161, DOI 10.1016/S0378-1119(96)00664-6; Kawai T, 1998, GLYCOBIOLOGY, V8, P237, DOI 10.1093/glycob/8.3.237; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; Kodama T, 1996, CURR OPIN LIPIDOL, V7, P287, DOI 10.1097/00041433-199610000-00005; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LIM BL, 1994, J BIOL CHEM, V269, P11820; LIM BL, 1993, IMMUNOLOGY, V78, P159; Mogues T, 1996, GLYCOBIOLOGY, V6, P543, DOI 10.1093/glycob/6.5.543; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SASTRY K, 1989, J EXP MED, V170, P1175, DOI 10.1084/jem.170.4.1175; SASTRY K, 1991, J IMMUNOL, V147, P692; SCHWEINLE JE, 1989, J CLIN INVEST, V84, P1821, DOI 10.1172/JCI114367; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SHIMAMOTO A, 1997, SEIKAGAKU, V69, P574; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V191, P335, DOI 10.1006/bbrc.1993.1222; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1; VANIWAARDEN JF, 1992, J BIOL CHEM, V267, P25039; WAKAMIYA N, 1992, BIOCHEM BIOPH RES CO, V187, P1270, DOI 10.1016/0006-291X(92)90440-V; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0	37	114	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13681	13689		10.1074/jbc.274.19.13681	http://dx.doi.org/10.1074/jbc.274.19.13681			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224141	hybrid			2022-12-25	WOS:000080200400103
J	Reiske, HR; Kao, SC; Cary, LA; Guan, JL; Lai, JF; Chen, HC				Reiske, HR; Kao, SC; Cary, LA; Guan, JL; Lai, JF; Chen, HC			Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR-MATRIX; V-SRC; PHOSPHORYLATION; BINDING; ASSOCIATION; P130(CAS)	We have previously shown that overexpression of focal adhesion kinase (FAK) in Chinese hamster ovary (CHO) cells promoted their migration on fibronectin, This effect was dependent on the phosphorylation of FAK at Tyr-397, This residue was known to serve as a binding site for both Src and phosphatidylinositol 3-kinase (PI3K), implying that either one or both are required for FAR to promote cell migration. In this study, we have examined the role of PI3K in FAR-promoted cell migration. We have demonstrated that the PI3K inhibitors, wortmannin and LY294002, were able to inhibit FAR-promoted migration in a dose-dependent manner. Furthermore, a FAK mutant capable of binding Src but not PI3K was generated by a substitution of Asp residue 395 with Ala. When overexpressed in CHO cells, this differential binding mutant failed to promote cell migration although its association with Src was retained. Together, these results strongly suggest that PI3K binding is required for FAK to promote cell migration and that the binding of Src and p130(Cas) to FAK may not be sufficient for this event.	Natl Chung Hsing Univ, Inst Biochem, Taichung 402, Taiwan; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Natl Chung Hsing Univ, Dept Zool, Taichung 402, Taiwan	National Chung Hsing University; Cornell University; National Chung Hsing University	Chen, HC (corresponding author), Natl Chung Hsing Univ, Inst Biochem, Taichung 402, Taiwan.							BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; VOURI K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	38	225	234	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12361	12366		10.1074/jbc.274.18.12361	http://dx.doi.org/10.1074/jbc.274.18.12361			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212207	hybrid			2022-12-25	WOS:000080056800027
J	Zhang, YG; Dickman, MB; Jones, C				Zhang, YG; Dickman, MB; Jones, C			The mycotoxin fumonisin B-1 transcriptionally activates the p21 promoter through a cis-acting element containing two Sp1 binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; RNA-POLYMERASE-II; CELL-CYCLE; PROTEIN-KINASE; SP1-MEDIATED TRANSCRIPTION; P21(WAF1/CIP1) EXPRESSION; SPHINGOLIPID BIOSYNTHESIS; INHIBITOR P21(WAF1/CIP1); FUSARIUM-MONILIFORME; GROWTH	Fumonisin B-1 (FB1) is a food-borne mycotoxin produced by Fusarium moniliforme, Structurally FB1 resembles sphingoid bases, and ingestion of FB1 causes several animal diseases. FB1 will cause hepatic carcinoma in rats and is implicated as a cofactor in esophageal or hepatic carcinoma. Previous studies concluded that FB1 repressed cyclin-dependent kinase 2 (CDK2) activity but induced CDK inhibitors p21(Wafl/Cip1), P27(Kip1), and p57(Kip2) in monkey kidney cells (CV-1). In contrast, CV-1 cells transformed by simian virus 40 are resistant to the antiproliferative or apoptotic effects of FB1. Consequently, FB1 treatment of CV-1 cells leads to cell cycle arrest and apoptosis, In this study, we demonstrate that FB1 transcriptionally activates the p21 promoter. Functional analysis of the p21 promoter by reporter gene assays mapped the FB1-responsive region to -124 to -47. DNase I footprinting analysis revealed two protected motifs that span the FB1-responsive region, -124 to -101 (footprint II) and -89 to -67 (footprint III). Further studies demonstrated that DNA sequences from -124 to -101 were sufficient for FB1 stimulation. DNA sequences from -124 to -101 contain two Sp1 binding sites, and gel shift assays provided evidence that nuclear factors specifically bind to this region. Disruption of the two Sp1 binding sites abrogated the binding of nuclear proteins and prevented activation by FB1. Taken together, these results suggest that Sp1 or Sp1-related proteins mediate FB1-induced activation of the p21 promoter.	Univ Nebraska, Ctr Biotechnol, Dept Vet & Biomed Sci, Lincoln, NE 68503 USA; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68503 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Jones, C (corresponding author), Univ Nebraska, Ctr Biotechnol, Dept Vet & Biomed Sci, Lincoln, NE 68503 USA.	cj@unlinfo.unl.edu						Appella E, 1998, J PROTEIN CHEM, V17, P527; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHU FS, 1994, APPL ENVIRON MICROB, V60, P847, DOI 10.1128/AEM.60.3.847-852.1994; Ciacci-Zanella JR, 1998, FOOD CHEM TOXICOL, V36, P791, DOI 10.1016/S0278-6915(98)00034-9; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMBRINKKURTZMAN MA, 1994, J AOAC INT, V77, P512; DOYLE K, 1996, SOURCE DISCOVERY PRO, P241; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; GELDERBLOM WCA, 1988, APPL ENVIRON MICROB, V54, P1806, DOI 10.1128/AEM.54.7.1806-1811.1988; GELDERBLOM WCA, 1991, CARCINOGENESIS, V12, P1247, DOI 10.1093/carcin/12.7.1247; GELDERBLOM WCA, 1992, CARCINOGENESIS, V13, P433, DOI 10.1093/carcin/13.3.433; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gumprecht Laura A., 1995, Natural Toxins, V3, P395, DOI 10.1002/nt.2620030512; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HARPER JW, 1993, CELL, V75, P805; Harrison L R, 1990, J Vet Diagn Invest, V2, P217; HUANG CX, 1995, CANCER RES, V55, P1655; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KELLERMAN TS, 1990, ONDERSTEPOORT J VET, V57, P269; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAGRENADE CEF, 1990, BIODET RES, V3, P189; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Marasas W. F. O., 1982, CANCER ESOPHAGUS, V1, P29; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRILL AH, 1993, ADV LIPID RES, V26, P215; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIROCHA CJ, 1992, MYCOPATHOLOGIA, V117, P47, DOI 10.1007/BF00497278; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; QURESHI MA, 1992, POULTRY SCI, V71, P104, DOI 10.3382/ps.0710104; RILEY RT, 1994, J NUTR, V124, P594, DOI 10.1093/jn/124.4.594; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharma RP, 1997, J COMP PATHOL, V117, P371, DOI 10.1016/S0021-9975(97)80084-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIER WT, 1991, MYCOPATHOLOGIA, V116, P97, DOI 10.1007/BF00436371; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Siavoshian S, 1997, BIOCHEM BIOPH RES CO, V232, P169, DOI 10.1006/bbrc.1997.6255; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; THIEL PG, 1992, MYCOPATHOLOGIA, V117, P3, DOI 10.1007/BF00497272; Tolleson WH, 1996, ADV EXP MED BIOL, V392, P237; Voss Kenneth A., 1993, Natural Toxins, V1, P222, DOI 10.1002/nt.2620010404; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG E, 1991, J BIOL CHEM, V266, P14486; Wang H, 1996, P NATL ACAD SCI USA, V93, P3461, DOI 10.1073/pnas.93.8.3461; Wattenberg EV, 1996, BIOCHEM BIOPH RES CO, V227, P622, DOI 10.1006/bbrc.1996.1555; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	67	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12367	12371		10.1074/jbc.274.18.12367	http://dx.doi.org/10.1074/jbc.274.18.12367			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212208	hybrid			2022-12-25	WOS:000080056800028
J	Keene, RG; Luse, DS				Keene, RG; Luse, DS			Initially transcribed sequences strongly affect the extent of abortive initiation by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; ESCHERICHIA-COLI; TERNARY COMPLEX; CALF THYMUS; DNA HYBRID; IN-VITRO; ELONGATION; ATP; REQUIREMENT; INVITRO	We investigated transcript initiation and early elongation by RNA polymerase II using templates mismatched between -9 and +3 (bubble templates). Highly purified RNA polymerase II alone was able to initiate transcription specifically on these templates in the presence of dinucleotide primers. The length distribution of abortively initiated RNAs was similar for purified RNA polymerase II on bubble templates and polymerase II on double-stranded templates in HeLa nuclear extracts. Increasing the U content in the initial portion of the transcript caused similar increases in abortive initiation for transcription of bubble templates by pure polymerase and double-stranded templates in extracts. Thus, the level of abortive initiation by RNA polymerase II is at least partly determined by interactions of the polymerase with the transcript and/or the template, independent of the general transcription factors. Substitution of 5-bromo-UTP for UTP reduced abortive initiation on bubble templates, consistent with the idea that transcription complex stability during early elongation depends on the strength of the initial RNA-DNA hybrid. Interestingly, transcription of bubble templates in HeLa extracts gave very high levels of abortive initiation, suggesting that inability to reanneal the initially melted template segment inhibits transcript elongation in the presence of the initiation factors.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Luse, DS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave,NC20, Cleveland, OH 44195 USA.	lused@cesmtp.ccf.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biswas TK, 1997, ARCH BIOCHEM BIOPHYS, V340, P250, DOI 10.1006/abbi.1997.9917; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; COWIE A, 1982, J MOL BIOL, V159, P225, DOI 10.1016/0022-2836(82)90494-6; DAUBE SS, 1994, P NATL ACAD SCI USA, V91, P9539, DOI 10.1073/pnas.91.20.9539; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JACOB GA, 1994, J BIOL CHEM, V269, P3655; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUSE DS, 1987, J BIOL CHEM, V262, P289; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAN GH, 1994, J BIOL CHEM, V269, P30101; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINBERG D, 1987, J BIOL CHEM, V262, P3310; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; TANTIN D, 1994, J BIOL CHEM, V269, P17397; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133	45	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11526	11534		10.1074/jbc.274.17.11526	http://dx.doi.org/10.1074/jbc.274.17.11526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206958	hybrid			2022-12-25	WOS:000079834800014
J	Kohzuma, T; Inoue, T; Yoshizaki, F; Sasakawa, Y; Onodera, K; Nagatomo, S; Kitagawa, T; Uzawa, S; Isobe, Y; Sugimura, Y; Gotowda, M; Kai, Y				Kohzuma, T; Inoue, T; Yoshizaki, F; Sasakawa, Y; Onodera, K; Nagatomo, S; Kitagawa, T; Uzawa, S; Isobe, Y; Sugimura, Y; Gotowda, M; Kai, Y			The structure and unusual pH dependence of plastocyanin from the fern Dryopteris crassirhizoma - The protonation of an active site histidine is hindered by pi-pi interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER REACTION; RESOLUTION SOLUTION STRUCTURE; RESONANCE RAMAN-SPECTRA; AROMATIC RING STACKING; BLUE COPPER PROTEINS; GREEN-ALGA; CRYSTAL-STRUCTURE; CYTOCHROME-F; POPLAR PLASTOCYANIN; NEGATIVE CHARGE	Spectroscopic properties, amino acid sequence, electron transfer kinetics, and crystal structures of the oxidized (at 1.7 Angstrom resolution) and reduced form (at 1.8 Angstrom resolution) of a novel. plastocyanin from the fern Dryopteris crassirhizoma are presented. Kinetic studies show that the reduced form of Dryopteris plastocyanin remains redox-active at low pH, under conditions where the oxidation of the reduced form of other plastocyanins is inhibited by the protonation of a solvent-exposed active site residue, His(87) (equivalent to His(90) in Dryopteris plastocyanin), The x-ray crystal structure analysis of Dryopteris plastocyanin reveals pi-pi stacking between Phe(12) and His(90), suggesting that the active site is uniquely protected against inactivation. Like higher plant plastocyanins, Dryopteris plastocyanin has an acidic patch, but this patch is located closer to the solvent-exposed active site His residue, and the total number of acidic residues is smaller, In the reactions of Dryopteris plastocyanin with inorganic redox reagents, the acidic patch (the "remote" site) and the hydrophobic patch surrounding His(90) (the "adjacent" site) are equally efficient for electron transfer. These results indicate the significance of the lack of protonation at the active site of Dryopteris plastocyanin, the equivalence of the two electron transfer sites in this protein, and a possibility of obtaining a novel insight into the photosynthetic electron transfer system of the first vascular plant fern, including its molecular evolutionary aspects, This is the first report on the characterization of plastocyanin and the first three-dimensional protein structure from fern plant.	Ibaraki Univ, Fac Sci, Mito, Ibaraki 3108512, Japan; Osaka Univ, Grad Sch Engn, Osaka 5650871, Japan; Toho Univ, Fac Sci, Chiba 2748510, Japan; Inst Mol Sci, Aichi 4448585, Japan	Ibaraki University; Osaka University; Toho University	Kohzuma, T (corresponding author), Ibaraki Univ, Fac Sci, Mito, Ibaraki 3108512, Japan.	kohzuma@biomol.sci.ibaraki.ac.jp	Kohzuma, Takamitsu/U-2966-2019					Badsberg U, 1996, BIOCHEMISTRY-US, V35, P7021, DOI 10.1021/bi960621y; BAGBY S, 1994, BIOCHEMISTRY-US, V33, P6611, DOI 10.1021/bi00187a031; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P31, DOI 10.1093/nar/25.1.31; BLAIR DF, 1985, J AM CHEM SOC, V107, P5755, DOI 10.1021/ja00306a025; Boulter D., 1977, INT REV BIOCH PLANT, V13, P1; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHRISTENSEN HEM, 1990, INORG CHEM, V29, P2808, DOI 10.1021/ic00340a019; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; Crnogorac MM, 1996, BIOCHEMISTRY-US, V35, P16465, DOI 10.1021/bi961914u; DAVE BC, 1993, J AM CHEM SOC, V115, P12175, DOI 10.1021/ja00078a070; Dong SL, 1998, J AM CHEM SOC, V120, P10434, DOI 10.1021/ja974377p; GROSS EL, 1991, BIOCHIM BIOPHYS ACTA, V1056, P166, DOI 10.1016/S0005-2728(05)80283-X; GUCKERT JA, 1995, J AM CHEM SOC, V117, P2817, DOI 10.1021/ja00115a016; GUSS JM, 1983, J MOL BIOL, V169, P521; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KATOH S, 1961, NATURE, V189, P665, DOI 10.1038/189665a0; KOHZUMA T, 1995, J BIOL CHEM, V270, P25733, DOI 10.1074/jbc.270.43.25733; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARRSON S, 1995, J PHYS CHEM-US, V99, P4860; LOWERY MD, 1993, J AM CHEM SOC, V115, P3012, DOI 10.1021/ja00060a074; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERCHANT S, 1997, METAL IONS GENE REGU, P450; MOORE JM, 1991, J MOL BIOL, V221, P533, DOI 10.1016/0022-2836(91)80071-2; MOORE JM, 1988, SCIENCE, V240, P314, DOI 10.1126/science.3353725; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pierloot K, 1997, J AM CHEM SOC, V119, P218, DOI 10.1021/ja962381f; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; QIN L, 1992, BIOCHEMISTRY-US, V31, P5145, DOI 10.1021/bi00137a008; QIU D, 1995, J AM CHEM SOC, V117, P6443, DOI 10.1021/ja00129a005; REDINBO MR, 1993, BIOCHEMISTRY-US, V32, P10560, DOI 10.1021/bi00091a005; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Sasakawa Y, 1998, INORG CHIM ACTA, V283, P184, DOI 10.1016/S0020-1693(98)00228-X; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; Sugimori T, 1997, INORG CHEM, V36, P576, DOI 10.1021/ic9608556; Sykes A. G., 1990, STRUCT BOND, V75, P175; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; ULLMANN GM, 1995, J AM CHEM SOC, V117, P4766, DOI 10.1021/ja00122a005; VANPOUDEROYEN G, 1994, EUR J BIOCHEM, V222, P583; YAMAUCHI O, 1989, INORG CHEM, V28, P4066, DOI 10.1021/ic00321a006; YOSHIZAKI F, 1989, J BIOCHEM-TOKYO, V106, P282, DOI 10.1093/oxfordjournals.jbchem.a122845	47	72	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11817	11823		10.1074/jbc.274.17.11817	http://dx.doi.org/10.1074/jbc.274.17.11817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206999	hybrid			2022-12-25	WOS:000079834800055
J	Schuenemann, D; Amin, P; Hartmann, E; Hoffman, NE				Schuenemann, D; Amin, P; Hartmann, E; Hoffman, NE			Chloroplast SecY is complexed to SecE and involved in the translocation of the 33-kDa but not the 23-kDa subunit of the oxygen-evolving complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; THYLAKOID PRECURSOR PROTEIN; ESCHERICHIA-COLI; MEMBRANE INSERTION; ARABIDOPSIS-THALIANA; TARGETING PATHWAYS; NUCLEAR MUTATIONS; PEA-CHLOROPLASTS; EXPORT PATHWAY; TRANSPORT	SecY is a component of the protein-conducting channel for protein transport across the cytoplasmic membrane of prokaryotes. It is intimately associated with a second integral membrane protein, SecE, and together with SecA forms the minimal core of the preprotein translocase. A chloroplast homologue of SecY (cpSecY has previously been identified and determined to be localized to the thylakoid membrane. In the present work, we demonstrate that a SecE homologue is localized to the thylakoid membrane, where it forms a complex with cpSecY, Digitonin solubilization of thylakoid membranes releases the SecY/E complex in a 180-kDa form, indicating that other components are present and/or the complex is a higher order oligomer of the cpSecY/E dimer, To test whether cpSecY forms the protein-conducting channel of the thylakoid membrane, translocation assays were conducted with the SecA-dependent substrate OE33 and the SecA-independent substrate OE23, in the presence and absence of antibodies raised against cpSecY. The antibodies inhibited translocation of OE33 but not OE23, indicating that cpSecY comprises the protein-conducting channel used in the SecA-dependent pathway, whereas a distinct protein conducting channel is used to translocate OE23.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	Carnegie Institution for Science	Hoffman, NE (corresponding author), Carnegie Inst Sci, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	hoffman@andrew2.stanford.edu	Hartmann, Enno/C-5687-2013	Schuenemann, Danja/0000-0001-8894-7685; Hoffman, Neil/0000-0002-4057-555X				ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BEVAN M, 1998, NATURE, V391, P485; Brink S, 1997, EUR J BIOCHEM, V245, P340, DOI 10.1111/j.1432-1033.1997.00340.x; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EMANUELSSON O, 1999, IN PRESS PROTEIN SCI; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HENRY R, 1994, J BIOL CHEM, V269, P10189; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HULFORD A, 1994, J BIOL CHEM, V269, P3251; ITO K, 1990, J BIOENERG BIOMEMBR, V22, P353, DOI 10.1007/BF00763172; JAGENDORF AT, 1990, PLANT SCI, V71, P137, DOI 10.1016/0168-9452(90)90001-5; Jenkins BD, 1997, PLANT CELL, V9, P283, DOI 10.1105/tpc.9.3.283; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; Klimyuk VI, 1999, PLANT CELL, V11, P87, DOI 10.1105/tpc.11.1.87; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MOULD RM, 1991, J BIOL CHEM, V266, P12189; Mould RM, 1997, PLANT J, V11, P1051, DOI 10.1046/j.1365-313X.1997.11051051.x; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; NAKAI M, 1994, J BIOL CHEM, V269, P31338; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; Pilgrim ML, 1998, PLANT J, V13, P177, DOI 10.1046/j.1365-313X.1998.00021.x; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; Roy LM, 1998, J CELL BIOL, V141, P385, DOI 10.1083/jcb.141.2.385; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; Schnell DJ, 1998, ANNU REV PLANT PHYS, V49, P97, DOI 10.1146/annurev.arplant.49.1.97; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; Voelker R, 1997, GENETICS, V145, P467; Voelker R, 1995, MOL GEN GENET, V249, P507, DOI 10.1007/BF00290576; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 1998, FEBS LETT, V431, P339, DOI 10.1016/S0014-5793(98)00790-X; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wu GJ, 1997, PLANT CELL PHYSIOL, V38, P243, DOI 10.1093/oxfordjournals.pcp.a029159; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	66	74	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12177	12182		10.1074/jbc.274.17.12177	http://dx.doi.org/10.1074/jbc.274.17.12177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207046	hybrid			2022-12-25	WOS:000079834800102
J	Prasad, GL; Masuelli, L; Raj, MHG; Harindranath, N				Prasad, GL; Masuelli, L; Raj, MHG; Harindranath, N			Suppression of src-induced transformed phenotype by expression of tropomyosin-1	ONCOGENE			English	Article						tropomyosin; src; oncogenes; transformation; tumor suppression; cytoskeleton	MAMMARY EPITHELIAL-CELLS; PROTEIN-TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; RAT FIBROBLASTS; C-SRC; CDNA; ACTIN; ORGANIZATION; CYTOSKELETON; ONCOGENE	Suppression of high M-r tropomyosins (TMs) is a common feature of transformed cells. Previous work from this laboratory has demonstrated that the isoform 1 of TM, TM1, acts as an anti-oncogene in ras-transformed murine fibroblasts. In this study, we have investigated whether TM1 is a ras-specific suppressor, or a general suppressor protein of the cellular transformation. V-src transformed fibroblasts, which express decreased TM1, were transduced with a full-length cDNA to overexpress TM1. Both the control and the transduced cells expressed v-src kinase at comparable levels. TM1 expressing (src-T1) cells grew at a lower rate in monolayer, exhibited well spread, flat morphology than the control cells. Enhanced expression of TM1 resulted in improved microfilamental architecture. More significantly, src-T1 cells completely failed to grow under anchorage independent conditions. These data demonstrate that TM1 is as an anti-oncogene of functionally diverse oncogenes, and it is a class II tumor suppressor protein.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA; Univ La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Louisiana State Univ, Med Ctr, Dept Obgyn & Biochem, New Orleans, LA 70112 USA; US FDA, CBER, Div Hematol Prod, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Sapienza University Rome; Louisiana State University System; US Food & Drug Administration (FDA)	Prasad, GL (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA.		Masuelli, Laura/AGW-4259-2022	MASUELLI, Laura/0000-0001-8174-8034				BHATTACHARYA B, 1988, ONCOGENE RES, V3, P51; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; JAMMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KELLIE S, 1993, SYM SOC EXP BIOL, V47, P267; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MULLAUER L, 1993, ONCOGENE, V8, P2531; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OKAMURA H, 1994, ONCOGENE, V9, P2293; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; SCHAFER R, 1994, REV PHYSL BIOCH PHAR, V124, P30; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VANDEKERCKHOVE J, 1990, CURR OPIN CELL BIOL, V2, P241; Wang DZM, 1997, CANCER RES, V57, P2478; Wang FL, 1996, CANCER RES, V56, P3634; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; YAMASHIRO S, 1994, ADV EXP MED BIOL, V358, P113	45	52	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2027	2031		10.1038/sj.onc.1202264	http://dx.doi.org/10.1038/sj.onc.1202264			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208425				2022-12-25	WOS:000079191300013
J	Craig, AG; Norberg, T; Griffin, D; Hoeger, C; Akhtar, M; Schmidt, K; Low, W; Dykert, J; Richelson, E; Navarro, V; Mazella, J; Watkins, M; Hillyard, D; Imperial, J; Cruz, LJ; Olivera, BM				Craig, AG; Norberg, T; Griffin, D; Hoeger, C; Akhtar, M; Schmidt, K; Low, W; Dykert, J; Richelson, E; Navarro, V; Mazella, J; Watkins, M; Hillyard, D; Imperial, J; Cruz, LJ; Olivera, BM			Contulakin-G, an O-glycosylated invertebrate neurotensin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONUS-GEOGRAPHUS VENOM; MASS-SPECTROMETRY; GAMMA-CARBOXYGLUTAMATE; BINDING-PROPERTIES; PEPTIDE; RECEPTOR; IDENTIFICATION; EXPRESSION; TRYPTOPHAN; BROMINATION	We have purified contulakin-G, a 16-amino acid O-linked glycopeptide (pGlu-Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Lys-Pro-Tyr-Ile-Leu-OH, pGlu is pyroglutamate) from Conus geographus venom. The major glycosylated form of contulakin-G was found to incorporate the disaccharide beta-D-Galp-(1-->3)-alpha-D-GalpNAc-(1-->) attached to Thr(10). The C-terminal sequence of contulakin-G shows a high degree of similarity to the neurotensin family of peptides. Synthetic peptide replicates of Gal(beta-->3) GalNAc(alpha-->)Thr(10) contulakin-G and its nonglycosylated analog were prepared using an Fmoc (9-fluorenylmethoxycarbonyl) protected solid phase synthesis strategy. The synthetic glycosylated contulakin-G, when administered intracerebroventricular into mice, was found to result in motor control-associated dysfunction observed for the native peptide, Contulakin-G was found to be active at 10-fold lower doses than the nonglycosylated Thr(10) contulakin-G analog. The binding affinities of contulakin-G and the nonglycosylated Thr(10) contulakin-G for a number of neurotensin receptor types including the human neurotensin type 1 receptor (hNTR1), the rat neurotensin type 1 and type 2 receptors, and the mouse neurotensin type 3 receptor were determined. The binding affinity of the nonglycosylated Thr(10) contulakin-G was approximately an order of magnitude lower than that of neurotensin,,, for all the receptor types tested. In contrast, the glycosylated form of contulakin-G exhibited significantly weaker binding affinity for all of the receptors tested. However, both contulakin-G and nonglycosylated Thr(10) contulakin-G were found to be potent agonists of rat neurotensin receptor type 1. Based on these results, we conclude that O-linked glycosylation appears to be a highly unusual strategy for increasing the efficacy of toxins directed against neurotransmitter receptors.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Swedish Univ Agr Sci, Dept Chem, S-75007 Uppsala, Sweden; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Philippines, Inst Marine Sci, Quezon City 1101, Philippines	Utah System of Higher Education; University of Utah; Salk Institute; Swedish University of Agricultural Sciences; Mayo Clinic; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman	Olivera, BM (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.		Richelson, Elliott/A-9407-2012; Mazella, Jean/A-6767-2012		NIGMS NIH HHS [GM 48677] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI K, 1973, CHEM PHARM BULL, V21, P2801; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BARBER M, 1982, ANAL CHEM, V54, pA645; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; CHABRY J, 1994, J NEUROCHEM, V63, P19; COLLEDGE CJ, 1992, TOXICON, V30, P1111, DOI 10.1016/0041-0101(92)90056-B; COTTER RJ, 1989, BIOMED ENVIRON MASS, V18, P513, DOI 10.1002/bms.1200180803; CRAIG AG, 1994, BIOL MASS SPECTROM, V23, P519, DOI 10.1002/bms.1200230810; CRAIG AG, 1993, BIOL MASS SPECTROM, V22, P31, DOI 10.1002/bms.1200220105; Craig AG, 1998, BIOCHEMISTRY-US, V37, P16019, DOI 10.1021/bi981690a; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; CRUZ LJ, 1987, J BIOL CHEM, V262, P15821; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; CUSACK B, 1991, EUR J PHARM-MOLEC PH, V206, P339, DOI 10.1016/0922-4106(91)90119-3; CUSACK B, 1993, J RECEPTOR RES, V13, P123, DOI 10.3109/10799899309073650; FEURLE GE, 1992, J BIOL CHEM, V267, P22305; FISCHER WH, 1987, P NATL ACAD SCI USA, V84, P3628, DOI 10.1073/pnas.84.11.3628; GRAY WR, 1981, J BIOL CHEM, V256, P4734; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; LENGUYEN D, 1986, INT J PEPT PROT RES, V27, P285; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; LUNING B, 1989, GLYCOCONJUGATE J, V6, P5, DOI 10.1007/BF01047886; MAZELLA J, 1988, J BIOL CHEM, V263, P144; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MCLUCKEY SA, 1991, ANAL CHEM, V63, P375, DOI 10.1021/ac00004a015; MINAMINO N, 1984, BIOCHEM BIOPH RES CO, V122, P542, DOI 10.1016/S0006-291X(84)80067-4; MONJE VD, 1993, NEUROPHARMACOLOGY, V32, P1141, DOI 10.1016/0028-3908(93)90008-Q; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORBERG T, 1994, METHOD ENZYMOL, V247, P87; OLIVERA BM, 1985, TOXICON, V23, P277, DOI 10.1016/0041-0101(85)90150-3; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; SADOUL JL, 1984, BIOCHEM BIOPH RES CO, V120, P812, DOI 10.1016/S0006-291X(84)80179-5; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; Stewart J. M., 1984, SOLID PHASE PEPTIDE, P176; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; Tyler BM, 1998, BRAIN RES, V792, P246, DOI 10.1016/S0006-8993(98)00150-4; VANRENTERGHEM C, 1988, BIOCHEM BIOPH RES CO, V157, P977, DOI 10.1016/S0006-291X(88)80970-7; YOSHIDA H, 1976, BIOCHEMISTRY-US, V15, P61, DOI 10.1021/bi00646a010	46	172	178	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13752	13759		10.1074/jbc.274.20.13752	http://dx.doi.org/10.1074/jbc.274.20.13752			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318778	hybrid			2022-12-25	WOS:000080322200007
J	Della Rocca, GJ; Maudsley, S; Daaka, Y; Lefkowitz, RJ; Luttrell, LM				Della Rocca, GJ; Maudsley, S; Daaka, Y; Lefkowitz, RJ; Luttrell, LM			Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade - Role of focal adhesions and receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE CELLS; MAP KINASE; ANGIOTENSIN-II; EGF RECEPTOR; C-SRC; THROMBIN-RECEPTOR; DISTINCT PATHWAYS; ION-CHANNEL; PHOSPHORYLATION	G protein-coupled receptors (GPCRs)initiate Ras-dependent activation of the Erk 1/2 mitogen-activated protein kinase cascade by stimulating recruitment of Ras guanine nucleotide exchange factors to the plasma membrane. Both integrin-based focal adhesion complexes and receptor tyrosine kinases have been proposed as scaffolds upon which the GPCR-induced Ras activation complex may assemble. Using specific inhibitors of focal adhesion complex assembly and receptor tyrosine kinase activation, we have determined the relative contribution of each to activation of the Erk 1/2 cascade following stimulation of endogenous GPCRs in three different cell types. The tetrapeptide RGDS, which inhibits integrin dimerization, and cytochalasin D, which depolymerizes the actin cytoskeleton, disrupt the assembly of focal adhesions. In PC12 rat pheochromocytoma cells, both agents block lysophosphatidic acid (LPA)- and bradykinin-stimulated Erk 1/2 phosphorylation, suggesting that intact focal adhesion complexes are required for GPCR-induced mitogen-activated protein kinase activation in these cells, In Rat 1 fibroblasts, Erk 1/2 activation via LPA and thrombin receptors is completely insensitive to both agents. Conversely, the epidermal growth factor receptor-specific tyrphostin AG1478 inhibits GPCR-mediated Erk 1/2 activation in Rat 1 cells but has no effect in PC12 cells. In HEH-293 human embryonic kidney cells, LPA and thrombin receptor-mediated Erk 1/2 activation is partially sensitive to both the RGDS peptide and tyrphostin AG1478, suggesting that both focal adhesion and receptor tyrosine kinase scaffolds are employed in these cells. The dependence of GPCR-mediated Erk 1/2 activation on intact focal adhesions correlates with expression of the calcium-regulated focal adhesion kinase, Pyk2, In all three cell types, GPCR-stimulated Erk 1/2 activation is significantly inhibited by the Src kinase inhibitors, herbimycin A and 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyra-zolo-D-3,4-pyrimidine (PP1), suggesting that Src family nonreceptor tyrosine kinases represent a point of convergence for signals originating from either scaffold.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Della Rocca, Gregory/AAM-5281-2021; Lefkowitz, Robert/AAW-2649-2021; Maudsley, Stuart/AAV-9929-2021; Maudsley, Stuart/Q-4782-2019	Maudsley, Stuart/0000-0002-1868-184X; Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK02352, DK55524] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055524, K08DK002352, R56DK055524] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN YH, 1994, J BIOL CHEM, V269, P27372; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	36	223	224	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13978	13984		10.1074/jbc.274.20.13978	http://dx.doi.org/10.1074/jbc.274.20.13978			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318809	hybrid			2022-12-25	WOS:000080322200038
J	Odell, M; Shuman, S				Odell, M; Shuman, S			Footprinting of Chlorella virus DNA ligase bound at a nick in duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; ENZYME; SPECIFICITY; FIDELITY; DOMAIN; GENE; SITE	The 298-amino acid ATP-dependent DNA ligase of Chlorella virus PBCV-1 is the smallest eukaryotic DNA ligase known. The enzyme has intrinsic specificity for binding to nicked duplex DNA. To delineate the ligase-DNA interface, we have footprinted the enzyme binding site on DNA and the DNA binding site on Ligase, The size of the exonuclease III footprint of ligase bound a single nick in duplex DNA is 19-21 nucleotides. The footprint is asymmetric, extending 8-9 nucleotides on the 3'-OH side of the nick and 11-12 nucleotides on the 5'-phosphate side. The 5'-phosphate moiety is essential for the binding of Chlorella virus ligase to nicked DNA. Here we show that the 3'-OH moiety is not required for nick recognition. The Chlorella virus ligase binds to a nicked Ligand containing 2',3'-dideoxy and 5'-phosphate termini, but cannot catalyze adenylation of the 5'-end. Hence, the 3'-OH is important for step 2 chemistry even though it is not itself chemically transformed during DNA-adenylate formation. A 2'-OH cannot substitute for the essential 3'-OH in adenylation at a nick or even in strand closure at a preadenylated nick. The protein side of the ligase-DNA interface was probed by limited proteolysis of ligase with trypsin and chymotrypsin in the presence and absence of nicked DNA. Protease accessible sites are clustered within a short segment from amino acids 210-225 located distal to conserved motif V. The ligase is protected from proteolysis by nicked DNA. Protease cleavage of the native enzyme prior to DNA addition results in loss of DNA binding. These results suggest a bipartite domain structure in which the interdomain segment either comprises part of the DNA binding site or undergoes a conformational change upon DNA binding. The domain structure of Chlorella virus ligase inferred from the solution experiments is consistent with the structure of T7 DNA ligase determined by x-ray crystallography.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.							DOHERTY AJ, 1996, NUCLEIC ACIDS RES, V24, P2282; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 1997, J VIROL, V71, P1931, DOI 10.1128/JVI.71.3.1931-1937.1997; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LEHMAN IR, 1974, SCIENCE, V186, P790; MODRICH P, 1973, J BIOL CHEM, V248, P7502; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Sekiguchi J, 1997, BIOCHEMISTRY-US, V36, P9073, DOI 10.1021/bi970705m; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; Shuman S, 1996, STRUCTURE, V4, P653, DOI 10.1016/S0969-2126(96)00070-6; Shuman S, 1995, BIOCHEMISTRY-US, V34, P16138, DOI 10.1021/bi00049a029; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P3536, DOI 10.1093/nar/26.15.3536; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; YANG SW, 1992, J BIOL CHEM, V267, P8117	22	54	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14032	14039		10.1074/jbc.274.20.14032	http://dx.doi.org/10.1074/jbc.274.20.14032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318816	hybrid			2022-12-25	WOS:000080322200045
J	Ramanadham, S; Hsu, FF; Bohrer, A; Ma, ZM; Turk, J				Ramanadham, S; Hsu, FF; Bohrer, A; Ma, ZM; Turk, J			Studies of the role of group VI phospholipase A(2) in fatty acid incorporation, phospholipid remodeling, lysophosphatidylcholine generation, and secretagogue-inducecd arachidonic acid release in pancreatic islets and insulinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; MASS-SPECTROMETRIC CHARACTERIZATION; OXIDE-DEPENDENT MECHANISM; MACROPHAGE-LIKE CELLS; PROTEIN-KINASE-C; P388D(1) MACROPHAGES; PHOSPHATIDATE PHOSPHOHYDROLASE; BETA-CELLS; MEMBRANE PHOSPHOLIPIDS; SUBCELLULAR MEMBRANES	An 84-kDa group VI phospholipase A(2) (iPLA(2)) that does not require Ca2+ for catalysis has been cloned from Chinese hamster ovary cells, murine P388D1 cells, and pancreatic islet beta-cells, A housekeeping role for iPLA(2) in generating lysophosphatidylcholine (LPC) accepters for arachidonic acid incorporation into phosphatidylcholine (PC) has been proposed because iPLA(2) inhibition reduces LPC levels and suppresses arachidonate incorporation and phospholipid remodeling in P388D1 cells. Because islet beta-cell phospholipids are enriched in arachidonate, we have examined the role of iPLA(2) in arachidonate incorporation into islets and INS-1 insulinoma cells. Inhibition of iPLA(2) with a bromoenol lactone (BEL) suicide substrate did not suppress and generally enhanced [H-3]arachidonate incorporation into these cells in the presence or absence of extracellular calcium at varied time points and EEL concentrations. Arachidonate incorporation into islet phospholipids involved deacylation-reacylation and not de novo synthesis, as indicated by experiments with varied extracellular glucose concentrations and by examining [C-14]glucose incorporation into phospholipids. EEL also inhibited islet cytosolic phosphatidate phosphohydrolase (PAPH), but the PAPH inhibitor propranolol did not affect arachidonate incorporation into islet or INS-1 cell phospholipids. Inhibition of islet iPLA(2) did not alter the phospholipid head-group classes into which [H-3]arachidonate was initially incorporated or its subsequent transfer from PC to other lipids. Electrospray ionization mass spectrometric measurements indicated that inhibition of INS-1 cell iPLA(2) accelerated arachidonate incorporation into PC and that inhibition of islet iPLA(2) reduced LPC levels by 25%, suggesting that LPC mass does not limit arachidonate incorporation into islet PC. Gas chromatography/mass spectrometry measurements indicated that EEL but not propranolol suppressed insulin secretagogue-induced hydrolysis of arachidonate from islet phospholipids. In islets and INS-1 cells, iPLA(2) is thus not required for arachidonate incorporation or phospholipid remodeling and may play other roles in these cells.	Washington Univ, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA	Washington University (WUSTL)	Turk, J (corresponding author), Washington Univ, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, 660 S Euclid Ave,Box 8127, St Louis, MO 63110 USA.			Hsu, Fong-Fu/0000-0001-5368-0183	NIDDK NIH HHS [R37-DK-34388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; ASMIS R, 1994, ANN NY ACAD SCI, V744, P1, DOI 10.1111/j.1749-6632.1994.tb52718.x; AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BLANK ML, 1992, BIOCHIM BIOPHYS ACTA, V1124, P262, DOI 10.1016/0005-2760(92)90138-L; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Branch AD, 1998, TRENDS BIOCHEM SCI, V23, P45, DOI 10.1016/S0968-0004(97)01155-9; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CHILTON FH, 1987, BIOCHIM BIOPHYS ACTA, V917, P48, DOI 10.1016/0005-2760(87)90282-7; CORBETT JA, 1992, BIOCHEM J, V287, P220; Crooke ST, 1996, ANTISENSE NUCLEIC A, V6, P145, DOI 10.1089/oli.1.1996.6.145; DAVIS LG, 1994, BASIC METHODS MOL BI, P335; DAY CP, 1992, BIOCHIM BIOPHYS ACTA, V1127, P87, DOI 10.1016/0005-2760(92)90205-A; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1992, METHOD ENZYMOL, V209, P1; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dillon DA, 1997, J BIOL CHEM, V272, P10361; DUNLOP M, 1985, FEBS LETT, V193, P231, DOI 10.1016/0014-5793(85)80158-7; EDDLESTONE GT, 1995, AM J PHYSIOL-CELL PH, V268, pC181, DOI 10.1152/ajpcell.1995.268.1.C181; FARESE RV, 1983, METABOLISM, V32, P628, DOI 10.1016/0026-0495(83)90035-5; Forsell PKAL, 1998, FEBS LETT, V434, P295, DOI 10.1016/S0014-5793(98)00999-5; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Gijon MA, 1997, SEMIN CELL DEV BIOL, V8, P297, DOI 10.1006/scdb.1997.0151; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; Han XL, 1998, BBA-BIOMEMBRANES, V1414, P95, DOI 10.1016/S0005-2736(98)00154-0; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HILL EE, 1968, J BIOL CHEM, V243, P4440; Hsu FF, 1998, J AM SOC MASS SPECTR, V9, P516, DOI 10.1016/S1044-0305(98)00012-9; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KENNEDY C, 1994, BBA-LIPID LIPID MET, V1211, P326, DOI 10.1016/0005-2760(94)90157-0; KRONER EE, 1981, J BIOL CHEM, V256, P3690; KUWAE T, 1987, BIOCHEM BIOPH RES CO, V142, P86, DOI 10.1016/0006-291X(87)90454-2; KUWAE T, 1990, J BIOL CHEM, V265, P5002; Kuwae T, 1997, BBA-LIPID LIPID MET, V1344, P74, DOI 10.1016/S0005-2760(96)00135-X; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Ma ZM, 1997, J BIOL CHEM, V272, P17827, DOI 10.1074/jbc.272.28.17827; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P82; MESSINEO FC, 1984, J BIOL CHEM, V259, P1336; METZ SA, 1991, BIOCHEM PHARMACOL, V41, pR1, DOI 10.1016/0006-2952(91)90470-P; METZ SA, 1988, DIABETES, V37, P1453, DOI 10.2337/diabetes.37.11.1453; METZ SA, 1987, BIOCHEM BIOPH RES CO, V142, P251, DOI 10.1016/0006-291X(87)90478-5; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; PATTON GM, 1982, J LIPID RES, V23, P190; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 1998, BIOCHEMISTRY-US, V37, P4553, DOI 10.1021/bi9722507; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; SCHMID PC, 1991, J BIOL CHEM, V266, P13690; SCHMID PC, 1995, ARCH BIOCHEM BIOPHYS, V319, P168, DOI 10.1006/abbi.1995.1279; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; Sekine N, 1997, DIABETES, V46, P1424, DOI 10.2337/diabetes.46.9.1424; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; SUGIURA T, 1995, BBA-LIPID LIPID MET, V1255, P167, DOI 10.1016/0005-2760(94)00237-S; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TURK J, 1986, BIOCHIM BIOPHYS ACTA, V879, P399, DOI 10.1016/0005-2760(86)90232-8; TURK J, 1984, BIOCHIM BIOPHYS ACTA, V794, P125, DOI 10.1016/0005-2760(84)90305-9; WEIS MT, 1986, CIRC RES, V59, P694, DOI 10.1161/01.RES.59.6.694; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLF BA, 1986, J BIOL CHEM, V261, P3501; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; WU S, 1997, AM J PHYSIOL, V273, pL331; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	88	96	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13915	13927		10.1074/jbc.274.20.13915	http://dx.doi.org/10.1074/jbc.274.20.13915			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318801	hybrid			2022-12-25	WOS:000080322200030
J	Sekiya, F; Bae, YS; Jhon, DY; Hwang, SC; Rhee, SG				Sekiya, F; Bae, YS; Jhon, DY; Hwang, SC; Rhee, SG			AHNAK, a protein that binds and activates phospholipase C-gamma 1 in the presence of arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GENE AHNAK; STIMULATES PHOSPHOINOSITIDE HYDROLYSIS; PLACENTAL-LACTOGEN RELEASE; C-GAMMA; TAU-PROTEIN; PLASMA-MEMBRANE; KINASE-C; IN-SITU; CA-2+; CELLS	We have recently shown that phospholipase C-gamma (PLC-gamma) is activated by tau, a neuronal cell-specific microtubule-associated protein, in the presence of arachidonic acid, We now report that non-neuronal tissues also contain a protein that can activate PLC-gamma in the presence of arachidonic acid. Purification of this activator from bovine lung cytosol yielded several proteins with apparent molecular sizes of 70-130 kDa. They were identified as fragments derived from an unusually large protein (similar to 700 kDa) named AHNAK, which comprises about 30 repeated motifs each 128 amino acids in length. Two AHNAK fragments containing one and four of the repeated motifs, respectively, were expressed as glutathione S-transferase fusion proteins. Both recombinant proteins activated PLC-gamma 1 at nanomolar concentrations in the presence of arachidonic acid, suggesting that an intact AHNAK molecule contains multiple sites for PLC-gamma activation. The role of arachidonic acid was to promote a physical interaction between AHNAK and PLC-gamma 1, and the activation by AHNAK and arachidonic acid was mainly attributable to reduction in the enzyme's apparent K-m toward the substrate phosphatidylinositol 4,5-bisphosphate. Our results suggest that arachidonic acid liberated by phospholipase A(2) can act as an additional trigger for PLC-gamma activation, constituting an alternative mechanism that is independent of tyrosine phosphorylation.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 122, Bethesda, MD 20892 USA.	sgrhee@nih.gov		Hwang, Sung Chul/0000-0003-2401-619X				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CHOW SC, 1990, J BIOL CHEM, V265, P902; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Flanagan LA, 1997, BIOPHYS J, V73, P1440, DOI 10.1016/S0006-3495(97)78176-1; GERZER R, 1986, BIOCHIM BIOPHYS ACTA, V886, P383, DOI 10.1016/0167-4889(86)90173-4; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; HIEDA Y, 1989, J CELL BIOL, V109, P1511, DOI 10.1083/jcb.109.4.1511; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Jenkins SM, 1998, NEUROREPORT, V9, P67, DOI 10.1097/00001756-199801050-00014; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; JONES GA, 1993, J BIOL CHEM, V268, P20845; KUDOH J, 1995, CYTOGENET CELL GENET, V70, P218, DOI 10.1159/000134037; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LYNCH MA, 1990, J NEUROCHEM, V55, P215, DOI 10.1111/j.1471-4159.1990.tb08841.x; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; NEGISHI M, 1990, BIOCHEM BIOPH RES CO, V169, P773, DOI 10.1016/0006-291X(90)90398-7; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARK D, 1992, J BIOL CHEM, V267, P16048; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; SUH PG, 1988, J BIOL CHEM, V263, P14497; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; WAHL MI, 1992, J BIOL CHEM, V267, P10447; Wilson DM, 1997, AM J PATHOL, V150, P2181; WOLF BA, 1986, J BIOL CHEM, V261, P3501; ZEITLER P, 1985, MOL PHARMACOL, V28, P549; ZEITLER P, 1991, LIFE SCI, V48, P2089, DOI 10.1016/0024-3205(91)90166-9	39	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13900	13907		10.1074/jbc.274.20.13900	http://dx.doi.org/10.1074/jbc.274.20.13900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318799	hybrid			2022-12-25	WOS:000080322200028
J	Standaert, ML; Bandyopadhyay, G; Sajan, MP; Cong, L; Quon, MJ; Farese, RV				Standaert, ML; Bandyopadhyay, G; Sajan, MP; Cong, L; Quon, MJ; Farese, RV			Okadaic acid activates atypical protein kinase C (zeta/lambda) in rat and 3T3/L1 adipocytes - An apparent requirement for activation of GLUT4 translocation and glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED GLUCOSE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; POTENTIAL ROLE; AKT; CELLS; ZETA; ALPHA; PDK1	Okadaic acid, an inhibitor of protein phosphatases 1 and 2A, is known to provoke insulin-like effects on GLUT4 translocation and glucose transport, but the underlying mechanism is obscure. Presently, we found in both rat adipocytes and 3T3/L1 adipocytes that okadaic acid provoked partial insulin-like increases in glucose transport, which were inhibited by phosphatidylinositol (PI) 3-kinase inhibitors, wortmannin and LY294002, and inhibitors of atypical protein kinase C (PKC) isoforms, zeta and lambda. Moreover, in both cell types, okadaic acid provoked increases in the activity of immunoprecipitable PRC-zeta/lambda by a PI 3-kinase-dependent mechanism. In keeping with apparent PI 3-kinase dependence of stimulatory effects of okadaic acid on glucose transport and PKC-zeta/lambda activity, okadaic acid provoked insulin-like increases in membrane PI 3-kinase activity in rat adipocytes; the mechanism for PI 3-kinase activation was uncertain, however, because it was not apparent in phosphotyrosine immunoprecipitates. Of further note, okadaic acid provoked partial insulin-like increases in the translocation of hemagglutinin antigen-tagged GLUT4 to the plasma membrane in transiently transfected rat adipocytes, and these stimulatory effects on hemagglutinin antigen-tagged GLUT4 translocation were inhibited by eo-expression of kinase;inactive forms of PRC-zeta and PKC-lambda. but not by a double mutant (T308A, 5473A), activation-resistant form of protein kinase B, Our findings suggest that, as with insulin, PI 3-kinase-dependent atypical PKCs, zeta and lambda, are required for okadaic acid-induced increases in GLUT4 translocation and glucose transport in rat adipocytes and 3T3/L1 adipocytes.	Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA	State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Farese, RV (corresponding author), JA Haley VA Hosp, Res Serv VAR 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Quon, Michael/B-1970-2008; Farese, Robert/B-3605-2015	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065969, R01DK038079] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065969, 2R01DK38079-09A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; Standaert M, 1998, J BIOL CHEM, V273, P7470, DOI 10.1074/jbc.273.13.7470; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	20	59	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14074	14078		10.1074/jbc.274.20.14074	http://dx.doi.org/10.1074/jbc.274.20.14074			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318822	hybrid			2022-12-25	WOS:000080322200051
J	Varlamov, O; Wu, F; Shields, D; Fricker, LD				Varlamov, O; Wu, F; Shields, D; Fricker, LD			Biosynthesis and packaging of carboxypeptidase D into nascent secretory vesicles in pituitary cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; KEX2-LIKE PROCESSING ENDOPROTEASE; OBESE FAT/FAT MICE; ATT-20 CELLS; INTRACELLULAR TRAFFICKING; METALLOCARBOXYPEPTIDASE-D; PROPROTEIN CONVERTASE; PERMEABILIZED CELLS; TISSUE DISTRIBUTION; BOVINE PITUITARY	Metallocarboxypeptidase D (CPD) is a membrane-bound trans-Golgi network (TGN) protein. In AtT-20 cells, CPD is initially produced as a 170-kDa endoglycosidase H-sensitive glycoprotein. Within 30 min of chase, the CPD increases to 180 kDa and is resistant to endoglycosidase H as a result of carbohydrate maturation. CPD also undergoes an activation step required for binding to a substrate affinity resin. Blocking the protein exit from the endoplasmic reticulum inhibits the increase in molecular mass but not the step required for affinity column binding, suggesting that enzyme activation precedes carbohydrate maturation and that these reactions occur in distinct intracellular compartments. Only the higher molecular weight mature CPD enters nascent secretory vesicles, which bud from the TGN of permeabilized AtT-20 and GH(3) cells. The budding efficiency of CPD into vesicles is 2-3-fold lower than that of endogenous proopiomelanocortin in AtT-20 cells or prolactin in GH(3) cells. In contrast, the packaging of a truncated form of CPD, which lacks the cytoplasmic tail and transmembrane domain, was similar to that of proopiomelanocortin, Taken together, the results support the proposal that CPD functions in the TGN in the processing of proteins that transit the secretory pathway and that the C-terminal region plays a major role in TGN retention.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDA NIH HHS [K02 DA-00194] Funding Source: Medline; NIDDK NIH HHS [R37 DK21860, R01 DK-51271] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271, R37DK021860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; FRICKER LD, 1993, INNOVATIONS PROTEASE, P259; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KLEIN RS, 1992, J NEUROCHEM, V58, P2011, DOI 10.1111/j.1471-4159.1992.tb10941.x; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; Ling WLW, 1998, METHODS, V16, P141, DOI 10.1006/meth.1998.0661; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MITRA A, 1994, J BIOL CHEM, V269, P19876; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; Varlamov O, 1998, J CELL SCI, V111, P877; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169	44	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14040	14045		10.1074/jbc.274.20.14040	http://dx.doi.org/10.1074/jbc.274.20.14040			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318817	hybrid			2022-12-25	WOS:000080322200046
J	Rothery, RA; Trieber, CA; Weiner, JH				Rothery, RA; Trieber, CA; Weiner, JH			Interactions between the molybdenum cofactor and iron-sulfur clusters of Escherichia coli dimethylsulfoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; ELECTRON-PARAMAGNETIC-RESONANCE; FORMATE DEHYDROGENASE-H; SITE-DIRECTED MUTAGENESIS; ENGINEERED 3FE-4S CLUSTER; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; DMSO REDUCTASE; RHODOBACTER-SPHAEROIDES; EPR SPECTROSCOPY	We have used site-directed mutagenesis to study the interactions between the molybdo-bis(molybdopterin guanine dinucleotide) cofactor (Mo-bisMGD) and the other prosthetic groups of Escherichia coli Me2SO reductase (DmsABC), In redox-poised preparations, there is a significant spin-spin interaction between the reduced E-m,E-7 = -120 mV [4Fe-4S] cluster of DmsB and the Mo(V) of the Mo-bisMGD of DmsA, This interaction is significantly modified in a DmsA-C38S mutant that contains a [3Fe-4S] cluster in DmsA, suggesting that the [3Fe-4S] cluster is in close juxtaposition to the vector connecting the Mo(V) and the E-m,E-7 = -120 mV cluster of DmsB, In a DmsA-R77S mutant, the interaction is eliminated, indicating the importance of this residue in defining the interaction pathway. In ferricyanide-oxidized glycerol-inhibited DmsA(C38S)BC, there is no detectable interaction between the oxidized [3Fe-4S] cluster and the Mo-bisMGD, except for a minor broadening of the Mo(V) spectrum. In a double mutant, DmsA(S176A)B(C102S)C, which contains an engineered [3Fe-4S] cluster in DmsB, no significant paramagnetic interaction is detected between the oxidized [3Fe-4S] cluster and the Mo(V), These results have important implications for (i) understanding the magnetic interactions between the Mo(V) and other paramagnetic centers and (ii) delineating the electron transfer pathway from the [4Fe-4S] clusters of DmsB to the Mo-bisMGD of DmsA.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, MRC Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.			Rothery, Richard/0000-0003-3265-1783; Trieber, Catharine/0000-0002-1336-1126				BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P1648, DOI 10.1021/bi00536a027; BERG BL, 1991, J BIOL CHEM, V266, P22380; BERTRAND P, 1994, J AM CHEM SOC, V116, P3078, DOI 10.1021/ja00086a042; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; BRAY RC, 1991, BIOCHEM J, V280, P817, DOI 10.1042/bj2800817; BRETON J, 1994, FEBS LETT, V345, P76, DOI 10.1016/0014-5793(94)00445-5; CAMMACK R, 1994, BIOCHEM SOC T, V22, P721, DOI 10.1042/bst0220721; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; CONDON C, 1988, MOL MICROBIOL, V2, P43, DOI 10.1111/j.1365-2958.1988.tb00005.x; FINNEGAN MG, 1993, INORG CHEM, V32, P2616, DOI 10.1021/ic00064a005; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Gladyshev VN, 1996, J BIOL CHEM, V271, P8095, DOI 10.1074/jbc.271.14.8095; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; HEINZINGER NK, 1995, J BACTERIOL, V177, P2813, DOI 10.1128/jb.177.10.2813-2820.1995; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; INNES JB, 1989, BIOCHEMISTRY-US, V28, P1116, DOI 10.1021/bi00429a028; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; KRAFFT T, 1992, EUR J BIOCHEM, V206, P5456; LOWE DJ, 1978, BIOCHEM J, V169, P471, DOI 10.1042/bj1690471; LOWE DJ, 1972, BIOCHEM J, V130, P239, DOI 10.1042/bj1300239; Magalon A, 1997, J BACTERIOL, V179, P5037, DOI 10.1128/jb.179.16.5037-5045.1997; Magalon A, 1998, BIOCHEMISTRY-US, V37, P7363, DOI 10.1021/bi972858f; MATHEWS R, 1974, J BIOL CHEM, V249, P4326; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; PRINCE RC, 1987, J BIOL CHEM, V262, P5125; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambrook J., 2002, MOL CLONING LAB MANU; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; Trieber CA, 1996, J BIOL CHEM, V271, P27339, DOI 10.1074/jbc.271.44.27339; Trieber CA, 1996, J BIOL CHEM, V271, P4620; TRIEBER CA, 1994, J BIOL CHEM, V269, P7103; Turner RJ, 1997, PROTEIN ENG, V10, P285, DOI 10.1093/protein/10.3.285; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1993, J BIOL CHEM, V268, P3238; Zhao ZW, 1998, J BIOL CHEM, V273, P20758, DOI 10.1074/jbc.273.33.20758	49	26	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13002	13009		10.1074/jbc.274.19.13002	http://dx.doi.org/10.1074/jbc.274.19.13002			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224050	hybrid			2022-12-25	WOS:000080200400012
J	Scheele, JS; Bruner, E; Kharitonov, VG; Martasek, P; Roman, LJ; Masters, BSS; Sharma, VS; Magde, D				Scheele, JS; Bruner, E; Kharitonov, VG; Martasek, P; Roman, LJ; Masters, BSS; Sharma, VS; Magde, D			Kinetics of NO ligation with nitric-oxide synthase by flash photolysis and stopped-flow spectrophotometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; L-ARGININE; HEME-PROTEINS; SPECTRAL CHARACTERIZATION; DISSOCIATION; HEMOGLOBIN; MECHANISM; BINDING; CO; TETRAHYDROBIOPTERIN	Nitric-oxide synthase (NOS) catalyzes conversion of L-arginine to nitric oxide, which subsequently stimulates a host of physiological processes. Prior work suggests that NOS is inhibited by NO, providing opportunities for autoregulation, This contribution reports that NO reacts rapidly (k(a) congruent to 2 x 10(7) M-1 s(-1)) with neuronal NOS in both its ferric and ferrous oxidation states. Association kinetics are almost unaffected by L-arginine or the cofactor tetrahydrobiopterin, There is no evidence for the distinct two phases previously reported for association kinetics of CO. Small amounts of geminate recombination of NO trapped in a protein pocket can be observed over nanoseconds, and a much larger amount is inferred to take place at picosecond time scales. Dissociation rates are also very fast from the ferric form, in the neighborhood of 50 s(-1), when measured by extrapolating association rates to the zero NO concentration limit. Scavenging experiments give dissociation rate constants more than an order of magnitude slower: still quite fast. For the ferrous species, extrapolation is not distinguishable from zero, while scavenging experiments give a dissociation rate constant near 10(-4) s(-1). Implications of these results for interactions near the heme binding site are discussed.	Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Health San Antonio	Magde, D (corresponding author), Univ Calif San Diego, Dept Biochem & Chem, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Martasek, Pavel/G-6622-2017	Martasek, Pavel/0000-0001-6165-4444	NHLBI NIH HHS [HL40818] Funding Source: Medline; NIDDK NIH HHS [2T32DK07233] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; EICH RF, 1997, REACTIONS NITRIC OXI; Fan BC, 1997, BIOCHEMISTRY-US, V36, P12660, DOI 10.1021/bi9715369; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HOSHINO M, 1993, J AM CHEM SOC, V115, P9568, DOI 10.1021/ja00074a023; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; KHARITONOV VG, 1996, METHODS NITRIC OXIDE, P39; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Scheele JS, 1997, J BIOL CHEM, V272, P12523, DOI 10.1074/jbc.272.19.12523; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Tierney DL, 1998, J AM CHEM SOC, V120, P2983, DOI 10.1021/ja973648t; TSAI AL, 1994, FEBS LETT, V341, P141, DOI 10.1016/0014-5793(94)80445-1; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	33	49	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13105	13110		10.1074/jbc.274.19.13105	http://dx.doi.org/10.1074/jbc.274.19.13105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224063	hybrid			2022-12-25	WOS:000080200400025
J	Shi, XM; Yang, XL; Chen, D; Chang, ZJ; Cao, X				Shi, XM; Yang, XL; Chen, D; Chang, ZJ; Cao, X			Smad1 interacts with homeobox DNA-binding proteins in bone morphogenetic protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOX GENES; DIFFERENTIATION; EXPRESSION; TRANSCRIPTION; PROMOTER; FORELIMB; CELLS; MSX-1; BMP-4; LIMB	Bone morphogenetic proteins (BMP) transduce their signals into the cell through a family of mediator proteins known as Smads. Upon phosphorylation by the BMP receptors, Smad1 interacts with Smad4 and translocates into the nucleus where the complex recruits DNA-binding protein(s) to activate specific gene transcription. However, the DNA-binding protein(s) involved in BMP signaling has not been identified. Using a yeast two-hybrid approach, we found that Smad1 interacts with Hoxc-8, a homeodomain transcription factor. The interaction between Smad1 and Hoxc-8 was confined by a "pull-down" assay and a co-immunoprecipitation experiment in COS-l cells. Interestingly, purified Smad1 inhibited Hoxc-8 binding to the osteopontin Hoxc-8 site in a concentration-dependent manner. Transient transfection studies showed that native osteopontin promoter activity was elevated upon BMP stimulation. Consistent with the gel shift assay, overexpression of Hoxc-8 abolished the BMP stimulation. When a wild type or mutant Hoxc-8 binding element was linked to an SV40 promoter-driven reporter gene, the wild type but not the mutant Hoxc-8 binding site responded to BMP stimulation. Again, overexpression of Hoxc-8 suppressed the BMP-induced activity of the wild type reporter construct. Our findings suggest that Smad1 interaction with Hoxc-8 dislodges Hoxc-8 from its DNA binding element, resulting in the induction of gene expression.	Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL 35294 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Health San Antonio	Cao, X (corresponding author), 1670 Univ Blvd,BH G002, Birmingham, AL 35294 USA.	Cao@path.uab.edu	Chang, Zhijie/AAH-8109-2019	Elefteriou, Xiangli/0000-0002-2333-8747; Chang, Zhijie/0000-0003-1567-3227	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; BACHILLER D, 1994, EMBO J, V13, P1930, DOI 10.1002/j.1460-2075.1994.tb06462.x; CAO X, 1993, J BIOL CHEM, V268, P27371; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FromentalRamain C, 1996, DEVELOPMENT, V122, P461; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Izon DJ, 1998, BLOOD, V92, P383, DOI 10.1182/blood.V92.2.383.414k41_383_393; JOWETT AK, 1993, DEVELOPMENT, V117, P461; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Ladher R, 1996, DEVELOPMENT, V122, P2385; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; Lu HC, 1997, DEVELOPMENT, V124, P1643; Maconochie M, 1996, ANNU REV GENET, V30, P529, DOI 10.1146/annurev.genet.30.1.529; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; MOUELLIC HL, 1992, CELL, V69, P251; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; Shimamoto T, 1999, J EXP ZOOL, V283, P186; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Tang SJ, 1998, DEVELOPMENT, V125, P1877; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956; ZHANG N, 1993, ONCOGENE, V8, P3265; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	37	148	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13711	13717		10.1074/jbc.274.19.13711	http://dx.doi.org/10.1074/jbc.274.19.13711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224145	hybrid			2022-12-25	WOS:000080200400107
J	Budd, DC; Rae, A; Tobin, AB				Budd, DC; Rae, A; Tobin, AB			Activation of the mitogen-activated protein kinase pathway by a G(q/11)-coupled muscarinic receptor is independent of receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTORS; MEDIATED ENDOCYTOSIS; TYROSINE KINASE; BETA-ARRESTINS; GROWTH-FACTOR; PHOSPHORYLATION; DESENSITIZATION; STIMULATION	A number of recent studies have demonstrated an essential role for receptor endocytosis in the activation of the mitogen-activated protein (MAP) kinases, Erk-1 and Erk-2 (extracellular activated protein kinases 1 and 2), by growth factor receptors and the G-protein coupled beta(2)-adrenergic receptor, Because ligand-mediated receptor endocytosis and activation of the MAP kinase pathway are common phenomena among G-protein coupled receptors, it has been suggested that the essential role of endocytosis in MAP kinase activation identified for the beta(2)-adrenergic receptor may be universal for all G-protein coupled receptors (Daaka,Y,, Luttrell, L, M,, Ahn, S,, Della Rocca, G, J., Ferguson, S, S, G,, Caron, M. G,, and Lefkowitz, R, J, (1998) J, Biol, Chem, 273, 685-688), We tested this hypothesis using the G(q/11)-coupled m3-muscarinic receptor expressed in Chinese hamster ovary cells and an m3-muscarinic receptor mutant that does not undergo endocytosis. We demonstrate that inhibition of endocytosis by concanavalin A and cytochalasin D does not affect the ability of the wild type m3-muscarinic receptor to activate Erk-1/2, Furthermore, the mutant m3-muscarinic receptor that is unable to undergo endocytosis, activates the MAP kinase pathway in an identical manner to the wild type receptor. We conclude that receptor endocytosis is not universally essential for MAP kinase activation by G-protein coupled receptors, We discuss the possibility that the differential roles played by endocytosis in MAP kinase activation between various receptor subtypes may be linked to the mechanism of upstream activation of Raf-1.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Tobin, AB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	TBA@le.ac.uk						CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MORO O, 1993, J BIOL CHEM, V268, P6862; OFFERMANNS S, 1993, BIOCHEM J, V294, P545, DOI 10.1042/bj2940545; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	25	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12355	12360		10.1074/jbc.274.18.12355	http://dx.doi.org/10.1074/jbc.274.18.12355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212206	hybrid			2022-12-25	WOS:000080056800026
J	Hayashi, H; De Bellis, L; Ciurli, A; Kondo, M; Hayashi, M; Nishimura, R				Hayashi, H; De Bellis, L; Ciurli, A; Kondo, M; Hayashi, M; Nishimura, R			A novel acyl-CoA oxidase that can oxidize short-chain acyl-CoA in plant peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION ENZYMES; FATTY-ACID DEGRADATION; PUMPKIN COTYLEDONS; PURIFICATION; EXPRESSION; DEHYDROGENASE; PROTEIN; IDENTIFICATION; MITOCHONDRIAL; BIOSYNTHESIS	Short-chain acyl-CoA oxidases are beta-oxidation enzymes that are active on short-chain acyl-CoAs and that appear to be present in higher plant peroxisomes and absent in mammalian peroxisomes. Therefore, plant peroxisomes are capable of performing complete beta-oxidation of acyl-CoA chains, whereas mammalian peroxisomes can perform beta-oxidation of only those acyl-CoA chains that are larger than octanoyl-CoA (C-8), In this report, we have shown that a novel acyl-CoA oxidase can oxidize short-chain acyl-CoA in plant peroxisomes. A peroxisomal short-chain acyl-CoA oxidase from Arabidopsis was purified following the expression of the Arabidopsis cDNA in a baculovirus expression system, The purified enzyme was active on butyryl-CoA (C-4), hexanoyl-CoA (C-6), and octanoyl-CoA (C-8), Cell fractionation and immunocytochemical analysis revealed that the short-chain acyl-CoA oxidase is localized in peroxisomes, The expression pattern of the short-chain acyl-CoA oxidase was similar to that of peroxisomal 3-ketoacyl-CoA thiolase, a marker enzyme of fatty acid beta-oxidation, during post-germinative growth. Although the molecular structure and amino acid sequence of the enzyme are similar to those of mammalian mitochondrial acyl-CoA dehydrogenase, the purified enzyme has no activity as acyl-CoA dehydrogenase, These results indicate that the short-chain acyl-CoA oxidases function in fatty acid beta-oxidation in plant peroxisomes, and that by the cooperative action of long- and short-chain acyl-CoA oxidases, plant peroxisomes are capable of performing the complete beta-oxidation of acyl-CoA,	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Dipartimento Biol Piante Agr, I-56124 Pisa, Italy	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Nishimura, R (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.	mikosome@nibb.ac.jp	De Bellis, Luigi/I-2950-2019	De Bellis, Luigi/0000-0002-6047-3526; Nishimura, Mikio/0000-0001-7960-9721				Aebi H., 1974, METHODS ENZYMATIC AN, P673, DOI [10.1016/B978-0-12-091302-2.50032-3, DOI 10.1016/B978-0-12-091302-2.50032-3]; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; BEEVERS H, 1979, ANNU REV PLANT PHYS, V30, P159, DOI 10.1146/annurev.pp.30.060179.001111; BEEVERS H, 1982, ANN NY ACAD SCI, V386, P243, DOI 10.1111/j.1749-6632.1982.tb21420.x; BROSS P, 1990, J BIOL CHEM, V265, P7116; Do YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P295, DOI 10.1006/abbi.1997.0212; DOMMES V, 1976, ANAL BIOCHEM, V71, P571, DOI 10.1016/S0003-2697(76)80026-7; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Eccleston VS, 1998, PLANT CELL, V10, P613, DOI 10.1105/tpc.10.4.613; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; GERBLING H, 1987, PLANTA, V171, P386, DOI 10.1007/BF00398684; GERHARDT B, 1987, METHOD ENZYMOL, V148, P516; GERHARDT B, 1983, PLANTA, V159, P238, DOI 10.1007/BF00397531; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Hashimoto T, 1996, ANN NY ACAD SCI, V804, P86, DOI 10.1111/j.1749-6632.1996.tb18610.x; Hayashi H, 1998, J BIOL CHEM, V273, P8301, DOI 10.1074/jbc.273.14.8301; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; Hodges T K, 1974, Methods Enzymol, V32, P392; Hooks MA, 1996, BIOCHEM J, V320, P607, DOI 10.1042/bj3200607; Hoppe A, 1997, PLANTA, V202, P227, DOI 10.1007/s004250050123; HUANG AHC, 1983, JPLANT PEROXISOME; Kato A, 1996, PLANT MOL BIOL, V31, P843, DOI 10.1007/BF00019471; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KINDL H, 1993, BIOCHIMIE, V75, P225, DOI 10.1016/0300-9084(93)90080-C; Kleiter AE, 1998, PLANTA, V206, P125, DOI 10.1007/s004250050382; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MAESHIMA M, 1988, PLANT CELL PHYSIOL, V29, P381; MASTERSON C, 1990, PLANTA, V182, P129, DOI 10.1007/BF00239994; MIERNYK JA, 1991, PLANT PHYSIOL, V95, P564, DOI 10.1104/pp.95.2.564; NISHIMURA M, 1993, PROTOPLASMA, V175, P131, DOI 10.1007/BF01385011; PREISIGMULLER R, 1994, J BIOL CHEM, V269, P20475; PREISIGMULLER R, 1993, PLANT MOL BIOL, V22, P59, DOI 10.1007/BF00038995; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Srivastava DK, 1998, BIOCHEMISTRY-US, V37, P8446, DOI 10.1021/bi980380p; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V8, P4321; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; WOOD C, 1986, PLANTA, V167, P54, DOI 10.1007/BF00446368; YAMAGUCHI J, 1984, PLANT PHYSIOL, V74, P261, DOI 10.1104/pp.74.2.261	41	100	108	1	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12715	12721		10.1074/jbc.274.18.12715	http://dx.doi.org/10.1074/jbc.274.18.12715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212254	hybrid			2022-12-25	WOS:000080056800074
J	Hogue, DL; Kerby, L; Ling, V				Hogue, DL; Kerby, L; Ling, V			A mammalian lysosomal membrane protein confers multidrug resistance upon expression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CASSETTE TRANSPORTER; P-GLYCOPROTEIN; FUNCTIONAL EXPRESSION; ACID TRANSPORTERS; PLASMA-MEMBRANE; DRUG-RESISTANCE; YEAST; CELLS; CHOLESTEROL; STEROIDS	Mouse transporter protein (MTP) is a highly conserved polytopic membrane protein present in mammalian lysosomes and endosomes. The role of MTP in regulating the in vivo subcellular distribution of numerous structurally distinct small molecules has been examined in this study by its expression in a drug-sensitive strain of the yeast Saccharomyces cerevisiae. Surprisingly, the expression of MTP in membranes of an intracellular compartment resulted in a cellular resistance or hypersensitivity to a range of drugs that included nucleoside and nucleobase analogs, antibiotics, anthracyclines, ionophores, and steroid hormones. The intracellular bioavailability of steroid hormones was altered by MTP, as determined using an in vivo glucocorticoid receptor-driven reporter assay in yeast, suggesting that the MTP-regulated drug sensitivity arose due to a change in the subcellular compartmentalization of steroid hormones and other drugs. MTP-regulated drug sensitivity in yeast was blocked to varying degrees by compounds that inhibit lysosomal function, interfere with intracellular cholesterol transport, or modulate the multidrug resistance phenotype of mammalian cells. These results indicate that MTP is involved in the subcellular compartmentalization of diverse hydrophobic small molecules and contributes to the inherent drug sensitivity or resistance of the mammalian cell.	British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency	Hogue, DL (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.							AIKAWA K, 1994, BBA-LIPID LIPID MET, V1213, P127; BECHHANSEN NT, 1976, J CELL PHYSIOL, V88, P23, DOI 10.1002/jcp.1040880104; BECK WT, 1991, MOL CLIN ADV ANTICAN, P151; BERINSONE P, 1998, ANN NY ACAD SCI, V842, P91; BREUNINGER LM, 1995, CANCER RES, V55, P5342; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Cabrita M. A., 1996, Molecular Biology of the Cell, V7, p135A; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Gualix J, 1996, J BIOL CHEM, V271, P1957, DOI 10.1074/jbc.271.4.1957; Halliwell WH, 1997, TOXICOL PATHOL, V25, P53, DOI 10.1177/019262339702500111; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Huang PB, 1996, BBA-BIOMEMBRANES, V1281, P80, DOI 10.1016/0005-2736(96)00032-6; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; Ishizaki J, 1996, PHARMACEUT RES, V13, P902, DOI 10.1023/A:1016061330387; Kaiser C., 1994, METHODS YEAST GENETI; Kavallaris M, 1997, ANTI-CANCER DRUG, V8, P17, DOI 10.1097/00001813-199701000-00002; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; LEFSTIN JA, 1995, GENE DEV, V8, P2842; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LIPMAN BJ, 1990, J BIOL CHEM, V265, P2142; Lloyd J B, 1996, Subcell Biochem, V27, P361; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LUEBE RE, 1987, EMBO J, V6, P3261; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MAZZONE T, 1995, J LIPID RES, V36, P544; Moriyama Y, 1996, J EXP BIOL, V199, P1447; MOSELEY RH, 1995, AM J PHYSIOL-GASTR L, V268, pG480, DOI 10.1152/ajpgi.1995.268.3.G480; Ohkuma S, 1997, CELL STRUCT FUNCT, V22, P253, DOI 10.1247/csf.22.253; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PICARD D, 1990, GENE, V86, P257, DOI 10.1016/0378-1119(90)90287-2; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; PRITCHARD JB, 1994, AM J PHYSIOL, V266, pF966, DOI 10.1152/ajprenal.1994.266.6.F966; Pritchard JB, 1996, CELL PHYSIOL BIOCHEM, V6, P50, DOI 10.1159/000154794; RANGANATHAN S, 1984, BIOCHEM PHARMACOL, V33, P2377, DOI 10.1016/0006-2952(84)90709-3; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; REUTZ S, 1994, CELL, V77, P1071; ROOBOL C, 1984, BRIT J CANCER, V49, P739, DOI 10.1038/bjc.1984.116; SantoniRugiu E, 1997, CARCINOGENESIS, V18, P2255, DOI 10.1093/carcin/18.11.2255; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SEKLER I, 1995, J BIOL CHEM, V270, P21028, DOI 10.1074/jbc.270.36.21028; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Shapiro AB, 1998, INT J CANCER, V76, P857, DOI 10.1002/(SICI)1097-0215(19980610)76:6<857::AID-IJC15>3.0.CO;2-#; SHIRAISHI N, 1986, CANCER LETT, V30, P251, DOI 10.1016/0304-3835(86)90049-2; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; Sun-Wada GH, 1998, J BIOCHEM, V123, P912; TAYLOR V, 1995, J BIOL CHEM, V270, P28824, DOI 10.1074/jbc.270.48.28824; Thorens B, 1996, AM J PHYSIOL-GASTR L, V270, pG541, DOI 10.1152/ajpgi.1996.270.4.G541; VANDYKE RW, 1992, J PHARMACOL EXP THER, V261, P1; Verovski VN, 1996, BRIT J CANCER, V73, P596, DOI 10.1038/bjc.1996.103; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; WOHLHEUTER RM, 1980, INT REV CYTOL, V64, P174	67	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12877	12882		10.1074/jbc.274.18.12877	http://dx.doi.org/10.1074/jbc.274.18.12877			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212276	hybrid			2022-12-25	WOS:000080056800096
J	Huang, LQ; Wong, TYW; Lin, RCC; Furthmayr, H				Huang, LQ; Wong, TYW; Lin, RCC; Furthmayr, H			Replacement of threonine 558, a critical site of phosphorylation of moesin in vivo, with aspartate activates F-actin binding of moesin - Regulation by conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EZRIN/RADIXIN/MOESIN ERM PROTEINS; MEMBRANE-CYTOSKELETAL LINKER; TYROSINE KINASE SUBSTRATE; MICROVILLAR CORE PROTEIN; CELL-CELL CONTACTS; TERMINAL DOMAIN; HUMAN-PLATELETS; APICAL MICROVILLI; EPITHELIAL-CELLS; T-LYMPHOCYTES	Point and deletion mutants of moesin were examined for F-actin binding by blot overlay and co-sedimentation, and for intra- and intermolecular interactions with N- and C-terminal domains with yeast two-hybrid and in vitro binding assays, Wild-type moesin molecules interact poorly with F-actin and each other, and bind neither C- nor N-terminal fragments. Interaction with F-actin is strongly enhanced by replacement of Thr(558) With aspartate (T558D), by deletion of 11 N-terminal residues (DelN11), by deletion of the entire N-terminal membrane-binding domain of both wild type and T558D mutant molecules, and by exposure to phosphatidylinositol 4,5-diphosphate, Activation of F-actin binding is accompanied by changes in inter- and intramolecular domain interactions. The T558D mutation renders moesin capable of binding wild type but not mutated (T558D) C-terminal or wild type N-terminal fragments. The interaction between the latter two is prevented. DelN11 truncation enables binding of wild type N and C domain fragments. These changes suggest that the T558D mutation, mimicking phosphorylation of Thr(558), promotes F-actin binding by disruption of interdomain interactions between N and C domains and exposure of the high affinity F-actin binding site in the C-terminal domain. Oscillation between activated and resting state could thus provide the structural basis for transient interactions between moesin and the actin cytoskeleton in protruding and retracting microextensions.	Stanford Univ, Sch Med, Dept Pathol, Mol Mech Dis Lab, Stanford, CA 94305 USA	Stanford University	Furthmayr, H (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Mol Mech Dis Lab, Stanford, CA 94305 USA.	hfurthmayr@pathology.stanford.edu	Furthmayr, Heinz -/A-6295-2010					ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; Amieva MR, 1999, J CELL SCI, V112, P111; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CASELLA JF, 1994, J BIOL CHEM, V269, P6992; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Edwards KA, 1997, DEV BIOL, V191, P103, DOI 10.1006/dbio.1997.8707; FAZIOLI F, 1993, ONCOGENE, V8, P1335; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1998, BIOCHEM BIOPH RES CO, V248, P548, DOI 10.1006/bbrc.1998.9009; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LANKES WT, 1993, BIOCHIM BIOPHYS ACTA, V1216, P479, DOI 10.1016/0167-4781(93)90018-9; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Pearson M, 1998, MOL BIOL CELL, V9, p265A; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; SATO N, 1992, J CELL SCI, V103, P131; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WILSON DB, 1985, J BIOL CHEM, V260, P1046; Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	59	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12803	12810		10.1074/jbc.274.18.12803	http://dx.doi.org/10.1074/jbc.274.18.12803			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212266	hybrid			2022-12-25	WOS:000080056800086
J	Mason, DA; Moore, JD; Green, SA; Liggett, SB				Mason, DA; Moore, JD; Green, SA; Liggett, SB			A gain-of-function polymorphism in a G-protein coupling domain of the human beta(1)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA(2)-ADRENERGIC RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC-RECEPTOR; CONGESTIVE-HEART-FAILURE; TERNARY COMPLEX MODEL; BINDING; LOCALIZATION; MUTAGENESIS; MUTATION; LIGAND	The beta(1)-adrenergic receptor (beta(1)AR) is a key cell surface signaling protein expressed in the heart and other organs that mediates the actions of catecholamines of the sympathetic nervous system. A polymorphism in the intracellular cytoplasmic tail near the seventh transmembrane-spanning segment of the human beta(1)AR has been identified in a cohort of normal individuals. At amino acid position 389, Gly or Arg can be found (allele frequencies 0.26 and 0.74, respectively), the former previously considered as the human wild-type beta(1)AR. Using site-directed mutagenesis to mimic the two variants, CHW-1102 cells were permanently transfected to express the Gly-389 and Arg-389 receptors, In functional studies with matched expression, the Arg-389 receptors had slightly higher basal levels of adenylyl cyclase activities (10.7 +/- 1.2 versus 6.1 +/- 0.4 pmol/min/mg), However, maximal isoproterenol-stimulated levels were markedly higher for the Arg-389 as compared to the Gly-389 receptor (63.3 +/- 6.1 versus 20.9 +/- 2.0 pmol/min/mg), Agonist-promoted [S-35]guanosine 5'-O-(thiotriphosphate) binding was also increased with the Arg-389 receptor consistent with enhanced coupling to G(s) and increased adenylyl cyclase activation. In agonist competition studies carried out in the absence of guanosine 5'-(beta,gamma-imido)triphosphate, high affinity binding could not be resolved with the Gly-389 receptor, whereas Arg-389 displayed an accumulation of the agonist high affinity receptor complex (R-H = 26%). Taken together, these data indicate that this polymorphic variation of the human beta(1)AR results in alterations of receptor-G(s) interaction with functional signal transduction consequences, consistent with its localization in a putative G-protein binding domain. The genetic variation of beta(1)AR at this locus may be the basis of interindividual differences in pathophysiologic characteristics or in the response to therapeutic beta AR agonists and antagonists in cardiovascular and other diseases.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496, HL52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318, P01HL041496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Befort K, 1996, NEUROCHEM RES, V21, P1301, DOI 10.1007/BF02532371; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; COSTA T, 1992, MOL PHARMACOL, V41, P549; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; Flier J, 1996, NEW ENGL J MED, V334, P580, DOI 10.1056/NEJM199602293340907; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1992, MOL PHARMACOL, V41, P889; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; Green SA, 1996, J BIOL CHEM, V271, P24029, DOI 10.1074/jbc.271.39.24029; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; JONES AS, 1963, NATURE, V199, P280, DOI 10.1038/199280b0; KANNEL WB, 1991, AM HEART J, V121, P951, DOI 10.1016/0002-8703(91)90225-7; KRELL MJ, 1986, AM HEART J, V112, P787, DOI 10.1016/0002-8703(86)90475-8; LIGGETT SB, 1989, AM J PHYSIOL, V256, pE600, DOI 10.1152/ajpendo.1989.256.5.E600; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Rousseau G, 1996, MOL PHARMACOL, V49, P752; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; van Campen LCMC, 1998, J CARDIOVASC PHARM, V32, pS31, DOI 10.1097/00005344-199806321-00006; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	29	485	524	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12670	12674		10.1074/jbc.274.18.12670	http://dx.doi.org/10.1074/jbc.274.18.12670			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212248	hybrid			2022-12-25	WOS:000080056800068
J	Mechanic, LE; Hall, MC; Matson, SW				Mechanic, LE; Hall, MC; Matson, SW			Escherichia coli DNA helicase II is active as a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SIMPLEX VIRUS TYPE-1; UVRD GENE-PRODUCT; ORIGIN-BINDING PROTEIN; REP HELICASE; CONFORMATIONAL-CHANGES; OLIGOMERIC STRUCTURE; INDUCED DIMERIZATION; CRYSTAL-STRUCTURE; MISMATCH REPAIR	Helicases are thought to function as oligomers (generally dimers or hexamers), Here me demonstrate that although Escherichia coli DNA helicase II (UvrD) is capable of dimerization as evidenced by a positive interaction in the yeast two-hybrid system, gel filtration chromatography, and equilibrium sedimentation ultracentrifugation (K-d = 3.4 mu M), the protein is active in vivo and in vitro as a monomer, A mutant lacking the C-terminal 40 amino acids (UvrD Delta 40C) failed to dimerize and yet was as active as the wild-type protein in ATP hydrolysis and helicase assays. In addition, the uvrD Delta 40C allele fully complemented the loss of helicase II in both methyl-directed mismatch repair and excision repair of pyrimidine dimers, Biochemical inhibition experiments using wild-type UvrD and inactive UvrD point mutants provided further evidence for a functional monomer. This investigation provides the first direct demonstration of an active monomeric helicase, and a model for DNA unwinding by a monomer is presented.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Prot Engn & Mol Genet Training Program, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Mechanic, LE (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		Hall, Mark C./D-1698-2011	Hall, Mark/0000-0001-6429-2506	NIGMS NIH HHS [GM 33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; ARTHUR HM, 1980, MOL GEN GENET, V180, P185, DOI 10.1007/BF00267368; BLOOMFIELD V, 1967, BIOPOLYMERS, V5, P149, DOI 10.1002/bip.1967.360050203; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; Brosh RM, 1997, J BIOL CHEM, V272, P572; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Cantor C. R, 1980, BIOPHYSICAL CHEM 2, P591; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; Cole JL, 1996, BIOCHEMISTRY-US, V35, P15601, DOI 10.1021/bi961719f; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FEINSTEIN SI, 1986, GENETICS, V113, P13; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hall MC, 1997, J BIOL CHEM, V272, P18614, DOI 10.1074/jbc.272.30.18614; Hall MC, 1998, J MOL BIOL, V277, P257, DOI 10.1006/jmbi.1997.1614; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KUMURA K, 1984, J BIOL CHEM, V259, P1560; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue TM, 1995, METHOD ENZYMOL, V259, P427; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; Malik AK, 1996, J VIROL, V70, P7859, DOI 10.1128/JVI.70.11.7859-7866.1996; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MENDONCA VM, 1993, J BACTERIOL, V175, P4641, DOI 10.1128/JB.175.15.4641-4651.1993; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Phillips RJ, 1997, MOL GEN GENET, V254, P319, DOI 10.1007/PL00008605; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; VANHOLDE KE, 1975, PROTEINS, P226; WASHBURN BK, 1993, J BACTERIOL, V175, P341, DOI 10.1128/JB.175.2.341-350.1993; WESSEL R, 1990, EUR J BIOCHEM, V192, P695, DOI 10.1111/j.1432-1033.1990.tb19278.x; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; [No title captured]	68	83	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12488	12498		10.1074/jbc.274.18.12488	http://dx.doi.org/10.1074/jbc.274.18.12488			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212225	Green Published, hybrid			2022-12-25	WOS:000080056800045
J	Nelson, D; Potempa, J; Kordula, T; Travis, J				Nelson, D; Potempa, J; Kordula, T; Travis, J			Purification and characterization of a novel cysteine proteinase (periodontain) from Porphyromonas gingivalis - Evidence for a role in the inactivation of human alpha(1)-proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV-LIKE ACTIVITIES; CREVICULAR FLUID; BACTEROIDES-GINGIVALIS; PATHOGENIC MECHANISM; PROTEOLYTIC-ENZYMES; DISEASE; ELASTASE; GENE; ALPHA(1)-ANTITRYPSIN; DEGRADATION	Periodontal disease is characterized by inflammation of the periodontium manifested by recruitment of neutrophils, which can degranulate, releasing powerful proteinases responsible for destruction of connective tissues, and eventual loss of tooth attachment. Although the presence of host proteinase inhibitors (serpins) should minimize tissue damage by endogenous proteinases, this is not seen clinically, and it has been speculated that proteolytic inactivation of serpins may contribute to progression of the disease. A major pathogen associated with periodontal disease is the Gram-negative anaerobe Porphyromonas gingivalis, and in this report, we describe a novel proteinase that has been isolated from culture supernatants of this organism that is capable of inactivating the human serpin, alpha(1)-proteinase inhibitor, the primary endogenous regulator of human neutrophil elastase, This new enzyme, referred to as periodontain, belongs to the cysteine proteinase family based on inhibition studies and exists as a 75-kDa heterodimer, Furthermore, periodontain shares significant homology to streptopain, a proteinase from Streptococcus pyogenes, and prtT, a putative proteinase from P, gingivalis. Clearly, the presence of this enzyme, which rapidly inactivates alpha(1)-proteinase inhibitor, could result in elevated levels of human neutrophil elastase clinically detected in periodontal disease and should be considered as a potential virulence factor for P, gingivalis.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Dept Microbiol & Immunol, PL-31120 Krakow, Poland; Jagiellonian Univ, Dept Anim Biochem, PL-31120 Krakow, Poland	University System of Georgia; University of Georgia; Jagiellonian University; Jagiellonian University	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Life Sci Bldg, Athens, GA 30602 USA.		Nelson, Daniel C./I-2198-2012	Nelson, Daniel C./0000-0003-3248-4831	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09761] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banbula A, 1999, J BIOL CHEM, V274, P9246, DOI 10.1074/jbc.274.14.9246; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P657; CARLSSON J, 1984, INFECT IMMUN, V43, P644, DOI 10.1128/IAI.43.2.644-648.1984; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; COX SW, 1992, J CLIN PERIODONTOL, V19, P333, DOI 10.1111/j.1600-051X.1992.tb00655.x; COX SW, 1989, J PERIODONTAL RES, V24, P353, DOI 10.1111/j.1600-0765.1989.tb00882.x; CUTLER CW, 1993, J IMMUNOL, V151, P7016; DARANY DG, 1992, J PERIODONTOL, V63, P743, DOI 10.1902/jop.1992.63.9.743; Darveau RP, 1998, INFECT IMMUN, V66, P1660, DOI 10.1128/IAI.66.4.1660-1665.1998; Dashper SG, 1998, J DENT RES, V77, P1133; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Fokkema SJ, 1998, J CLIN PERIODONTOL, V25, P617, DOI 10.1111/j.1600-051X.1998.tb02497.x; Genco CA, 1998, INFECT IMMUN, V66, P4108; Grenier D, 1996, MICROBIOL-UK, V142, P955, DOI 10.1099/00221287-142-4-955; HUYNH C, 1992, J CLIN PERIODONTOL, V19, P187, DOI 10.1111/j.1600-051X.1992.tb00637.x; IMAMURA T, 1995, INFECT IMMUN, V63, P1999, DOI 10.1128/IAI.63.5.1999-2003.1995; Jagels MA, 1996, INFECT IMMUN, V64, P1984, DOI 10.1128/IAI.64.6.1984-1991.1996; KADOWAKI T, 1994, J BIOL CHEM, V269, P21371; Karunakaran T, 1997, J BACTERIOL, V179, P1898, DOI 10.1128/jb.179.6.1898-1908.1997; Kiyama M, 1998, BBA-GENE STRUCT EXPR, V1396, P39, DOI 10.1016/S0167-4781(97)00225-X; Kuramitsu HK, 1998, ORAL MICROBIOL IMMUN, V13, P263, DOI 10.1111/j.1399-302X.1998.tb00706.x; MADDEN TE, 1995, INFECT IMMUN, V63, P238, DOI 10.1128/IAI.63.1.238-247.1995; Madianos PN, 1997, INFECT IMMUN, V65, P3983, DOI 10.1128/IAI.65.10.3983-3990.1997; MAST AE, 1991, J BIOL CHEM, V266, P15810; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mikolajczyk-Pawlinska J, 1998, FEBS LETT, V440, P282, DOI 10.1016/S0014-5793(98)01461-6; MIYASAKI KT, 1991, J PERIODONTOL, V62, P761, DOI 10.1902/jop.1991.62.12.761; MOORE WEC, 1982, INFECT IMMUN, V38, P1137, DOI 10.1128/IAI.38.3.1137-1148.1982; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nelson D, 1998, ANAL BIOCHEM, V260, P230, DOI 10.1006/abio.1998.2708; OTOGOTO JI, 1993, INFECT IMMUN, V61, P117, DOI 10.1128/IAI.61.1.117-123.1993; PIKE R, 1994, J BIOL CHEM, V269, P406; Potempa J, 1998, J BIOL CHEM, V273, P21648, DOI 10.1074/jbc.273.34.21648; Potempa J, 1996, ACTA BIOCHIM POL, V43, P455; Potempa Jan, 1995, Perspectives in Drug Discovery and Design, V2, P445, DOI 10.1007/BF02172037; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENKEIN HA, 1995, J IMMUNOL, V154, P5331; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; Smalley JW, 1998, BIOCHEM J, V331, P681, DOI 10.1042/bj3310681; SMITH QT, 1994, ARCH ORAL BIOL, V39, P301, DOI 10.1016/0003-9969(94)90121-X; SOCRANSKY SS, 1992, J PERIODONTOL, V63, P322, DOI 10.1902/jop.1992.63.4s.322; Sugita N, 1998, INFLAMMATION, V22, P253, DOI 10.1023/A:1022344031223; Travis J, 1997, J PERIODONTAL RES, V32, P120, DOI 10.1111/j.1600-0765.1997.tb01392.x; TRAVIS J, 1994, AM J RESP CRIT CARE, V150, pS143, DOI 10.1164/ajrccm/150.6_Pt_2.S143; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Uitto VJ, 1996, J CLIN PERIODONTOL, V23, P30, DOI 10.1111/j.1600-051X.1996.tb00501.x; WHITE D, 1981, J PERIODONTAL RES, V16, P259, DOI 10.1111/j.1600-0765.1981.tb00974.x; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902	50	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12245	12251		10.1074/jbc.274.18.12245	http://dx.doi.org/10.1074/jbc.274.18.12245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212191	hybrid			2022-12-25	WOS:000080056800011
J	Therien, AG; Karlish, SJD; Blostein, R				Therien, AG; Karlish, SJD; Blostein, R			Expression and functional role of the gamma subunit of the Na,K-ATPase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL ACTIVITY; XENOPUS OOCYTES; SODIUM-PUMP; PURIFICATION; POLYPEPTIDE; MECHANISMS; ACTIVATION; COMPONENT; KINETICS; OUABAIN	The functional role of the gamma subunit of the Na,K-ATPase was studied using rat gamma cDNA-transfected HEK-293 cells and an antiserum (gamma C33) specific for gamma, Although the sequence for gamma was verified and shown to be larger (7237 Da) than first reported, it still comprises a single initiator methionine despite the expression of a gamma C33-reactive doublet on immunoblots. Kinetic analysis of the enzyme of transfected compared with control cells and of gamma C33-treated kidney pumps shows that gamma regulates the apparent affinity for ATP, Thus, gamma-transfected cells have a decreased K-ATP' as shown in measurements of (i) K-ATP' of Na,K-ATPase activity and (ii) K+ inhibition of Na-ATPase at 1 mu M ATP, Consistent with the behavior of gamma-transfected cells, gamma C33 pretreatment increases K-ATP' of the kidney enzyme and K+ inhibition (1 mu M ATP) of both kidney and gamma-transfected cells. These results are consistent with previous findings that an antiserum raised against the pig gamma subunit stabilizes the E-2(K) form of the enzyme (Therien, A. G., Goldshleger, R,, Karlish, S, J., and Blostein, R, (1997) J, Biol, Chem, 272, 32628-32634), Overall, our data demonstrate that gamma is a tissue (kidney)-specific regulator of the Na,K-ATPase that can increase the apparent affinity of the enzyme for ATP in a manner that is reversible by anti-gamma antiserum.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Weizmann Inst Sci, Dept Biochem, IL-76100 Rehovot, Israel	McGill University; Weizmann Institute of Science	Blostein, R (corresponding author), Montreal Gen Hosp, 1650 Cedar Ave,Rm L11-132, Montreal, PQ H3G 1A4, Canada.		Therien, Alex/AAS-8437-2021					ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; BREZIS M, 1993, ANNU REV MED, V44, P27, DOI 10.1146/annurev.me.44.020193.000331; CHOW DC, 1995, J EXP BIOL, V198, P1; COLLINS JH, 1982, BIOCHIM BIOPHYS ACTA, V686, P7, DOI 10.1016/0005-2736(82)90145-6; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; EISNER DA, 1981, J PHYSIOL-LONDON, V319, P403, DOI 10.1113/jphysiol.1981.sp013917; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; JONES H, 1997, J CELL BIOL, V139, P1545; Kim JW, 1997, BBA-GENE STRUCT EXPR, V1350, P133, DOI 10.1016/S0167-4781(96)00219-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; POST RL, 1972, J BIOL CHEM, V247, P6530; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628	24	120	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12252	12256		10.1074/jbc.274.18.12252	http://dx.doi.org/10.1074/jbc.274.18.12252			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212192	hybrid			2022-12-25	WOS:000080056800012
J	Jian, XY; Sainz, E; Clark, WA; Jensen, RT; Battey, JF; Northup, JK				Jian, XY; Sainz, E; Clark, WA; Jensen, RT; Battey, JF; Northup, JK			The bombesin receptor subtypes have distinct G protein specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C ISOZYMES; NEUROMEDIN-B RECEPTOR; HUMAN ORPHAN RECEPTOR; BETA-GAMMA-SUBUNITS; PEPTIDE RECEPTOR; ALPHA-SUBUNITS; HIGH-AFFINITY; GUANINE-NUCLEOTIDES; SF9 CELLS; KINASE-C	We used an in situ reconstitution assay to examine the receptor coupling to purified G protein alpha subunits by the bombesin receptor family, including gastrin-releasing peptide receptor (GRP-R), neuromedin B receptor (NMB-R), and bombesin receptor subtype 3 (BRS-3), Cells expressing GRP-R or NMB-R catalyzed the activation of squid retinal G alpha(q) and mouse G alpha(q) but not bovine retinal G alpha(t) or bovine brain G alpha(i/o). The GRP-R- and NMB-R-catalyzed activations of Ga, Were dependent upon and enhanced by different py dimers in the same rank order as follows: bovine brain beta gamma > beta(1)gamma(2) >> beta(1)gamma(1). Despite these qualitative similarities, GRP-R and NMB-R had distinct kinetic properties in receptor-G protein coupling. GRP-R had higher affinities for bovine brain beta gamma, beta(1)gamma(1), and beta(1)gamma(2) and squid retinal G alpha(q). In addition, GRP-R showed higher catalytic activity on squid G alpha(q). Like GRP-R and NMB-R, BRS-3 did not catalyze GTP gamma S binding to G alpha(i/o) or G alpha. However, BRS-3 showed little, if any, coupling with squid G alpha(q) but clearly activated mouse G alpha(q). GRP-R and NMB-R catalyzed GTP gamma S binding to squid and mouse G alpha(q), with GRP-R activating squid G alpha(q) more effectively, and NMB-R also showed slight preference for squid G alpha(q). These studies reveal that the structurally similar bombesin receptor subtypes, in particular BRS-3, possess distinct coupling preferences among members of the G alpha(q) family.	Natl Inst Deafness & Other Commun Disorders, Lab Cellular Biol, Rockville, MD 20850 USA; Natl Inst Deafness & Other Commun Disorders, Mol Biol Lab, Rockville, MD 20850 USA; NIDDKD, Digest Dis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Northup, JK (corresponding author), Natl Inst Deafness & Other Commun Disorders, Lab Cellular Biol, 5 Res Ct, Rockville, MD 20850 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000047, ZIADC000047] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; ASANO T, 1993, J BIOL CHEM, V268, P20512; BENYA RV, 1994, MOL PHARMACOL, V46, P495; BENYA RV, 1995, MOL PHARMACOL, V47, P10; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; FATHI Z, 1993, J BIOL CHEM, V268, P5979; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; KROOG GS, 1995, J BIOL CHEM, V270, P8217, DOI 10.1074/jbc.270.14.8217; KUSUI T, 1995, BIOCHEMISTRY-US, V34, P8061, DOI 10.1021/bi00025a012; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MANTEY S, 1993, MOL PHARMACOL, V43, P762; Mantey SA, 1997, J BIOL CHEM, V272, P26062, DOI 10.1074/jbc.272.41.26062; PARK DG, 1993, J BIOL CHEM, V268, P4573; Ryan RR, 1998, J BIOL CHEM, V273, P13613, DOI 10.1074/jbc.273.22.13613; RYBA NJ, 1993, BIOCHEM J, V292, P333, DOI 10.1042/bj2920333; Sainz E, 1998, J BIOL CHEM, V273, P15927, DOI 10.1074/jbc.273.26.15927; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049	37	57	58	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11573	11581		10.1074/jbc.274.17.11573	http://dx.doi.org/10.1074/jbc.274.17.11573			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206964	hybrid			2022-12-25	WOS:000079834800020
J	Li, JG; Luo, LY; Krupnick, JG; Benovic, JL; Liu-Chen, LY				Li, JG; Luo, LY; Krupnick, JG; Benovic, JL; Liu-Chen, LY			U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism - kappa receptor internalization is not required for mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; COATED VESICLE FORMATION; 3RD CYTOPLASMIC LOOP; HAMSTER OVARY CELLS; BETA(2)-ADRENERGIC RECEPTOR; DOWN-REGULATION; COUPLED RECEPTORS; OPIATE-RECEPTOR; MEDIATED ENDOCYTOSIS; THREONINE RESIDUES	Agonist-promoted internalization of some G protein coupled receptors has been shown to mediate receptor desensitization, resensitization, and down-regulation. In this study, we investigated whether opioids induced internalization of the human and rat kappa opioid receptors stably expressed in Chinese hamster ovary cells, the potential mechanisms involved in this process and its possible rob in activation of mitogen-activated protein (MAP) kinase, Exposure of the human kappa receptor to the agonists U50,488H, U69,593, ethylketocyclazocine, or tifluadom, but not etorphine, promoted receptor internalization. However, none of these agonists induced significant internalization of the rat kappa opioid receptor. U50,488H-induced human kappa receptor internalization was time- and concentration-dependent, with 30-40% of the receptors internalized following a 30-min exposure to 1 mu M U50,488H. Agonist removal resulted in the receptors gradually returning to the cell surface over a 60-min period, The antagonist naloxone blocked U50,488H-induced internalization without affecting internalization itself, while pretreatment with pertussis toxin had no effect on U50,488H-induced internalization. In contrast, incubation with sucrose (0.4-0.8 M) significantly reduced U50,488H-indueed internalization of the kappa receptor. While co-expression of the wild type GRK2, beta-arrestin, or dynamin I had no effect on kappa receptor internalization, co-expression of the dominant negative mutants GRK2-K220R, p-arrestin (319-418), or dynamin I-K44A significantly inhibited receptor internalization. Whether receptor internalization is critical for MAP kinase activation was next investigated. Co-expression of dominant negative mutants of beta-arrestin or dynamin I, which greatly reduced U50,488H-induced internalization, did not affect MAP kinase activation by the agonist, In addition, etorphine, which did not promote human kappa receptor internalization, was able to fully activate MAP kinase. Moreover, U50,488H or etorphine stimulation of the rat kappa receptor, which did not undergo internalization, also effectively activated MAP kinase, Thus, U50,488H-induced internalization of the human kappa opioid receptor in Chinese hamster ovary cells occurs via a GRK-, beta-arrestin-, and dynamin I-dependent process that likely involves clathrin-coated pits. In addition, internalization of the kappa receptor is not required for activation of MAP kinase.	Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Liu-Chen, LY (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	liuche@astro.temple.edu			NIDA NIH HHS [DA11263, DA06650, DA04745] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006650, R01DA011263, R29DA004745, R01DA004745] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Adler MW, 1993, HDB EXPT PHARM, P205; Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BHARGAVA HN, 1989, J PHARMACOL EXP THER, V251, P21; Bot G, 1997, MOL PHARMACOL, V52, P272, DOI 10.1124/mol.52.2.272; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105, DOI 10.1124/mol.52.1.105; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; JOSEPH DB, 1995, J PHARMACOL EXP THER, V272, P970; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MORRIS BJ, 1989, NEUROSCIENCE, V29, P433, DOI 10.1016/0306-4522(89)90070-5; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PASTERNAK GW, 1988, OPIATE RECEPTORS; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Segredo V, 1997, J NEUROCHEM, V68, P2395; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; TAUB DD, 1991, P NATL ACAD SCI USA, V88, P360, DOI 10.1073/pnas.88.2.360; TOLL L, 1992, J PHARMACOL EXP THER, V260, P9; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1993, MOL PHARMACOL, V44, P166; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YANG J, 1995, MOL PHARMACOL, V48, P477; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676; ZHU JM, 1995, LIFE SCI, V56, pPL201, DOI 10.1016/0024-3205(94)00507-O	64	134	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12087	12094		10.1074/jbc.274.17.12087	http://dx.doi.org/10.1074/jbc.274.17.12087			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207034	hybrid			2022-12-25	WOS:000079834800090
J	Schmitt, S; Glebe, D; Alving, K; Tolle, TK; Linder, M; Geyer, H; Linder, D; Peter-Katalinic, J; Gerlich, WH; Geyer, R				Schmitt, S; Glebe, D; Alving, K; Tolle, TK; Linder, M; Geyer, H; Linder, D; Peter-Katalinic, J; Gerlich, WH; Geyer, R			Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL GLYCOSYLATION SITES; MURINE LEUKEMIA-VIRUS; S-GENE-PRODUCTS; ENVELOPE PROTEIN; MASS-SPECTROMETRY; IMMUNE-RESPONSE; ANTIGEN; OLIGOSACCHARIDES; VACCINE; CELL	The surface antigen of hepatitis B virus comprises a nested set of small (S), middle (M), and large (L) proteins, all of which are partially glycosylated in their S domains. The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein. Since the pre-S2 N-glycan appears to play a crucial role in the secretion of viral particles, the M protein may be considered as a potential target for antiviral therapy. For characterization of the pre-S2 glycosylation, pre-SE (glyco)peptides were released from native, patient-derived hepatitis B virus subviral particles by tryptic digestion, separated from remaining particles, purified by reversed-phase high performance liquid chromatography, and identified by amino acid and N-terminal sequence analysis as well as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Pre-S2 N-glycans were characterized by anion exchange chromatography, methylation analysis, and on target sequential exoglycosidase digestions in combination with MALDI-TOF-MS, demonstrating the presence of partially sialylated diantennary complex-type oligosaccharides. In addition, the pre-Sa domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta 1-3)Gal-NAc alpha-, Neu5Ac(alpha 2-3)Gal(beta 1-3)GalNAc alpha-, or GalNAc alpha-residue. The respective O-glycosylation site was assigned to Thr-37 by digestion with carboxypeptidases in combination with MALDI-TOF-MS and by quadrupole time-of-flight electrospray mass spectrometry, Analytical data further revealed that about 90% of M protein is N-terminally acetylated.	Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Inst Med Virol, D-35392 Giessen, Germany; Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen; University of Munster	Geyer, R (corresponding author), Univ Giessen, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	Rudolf.Geyer@biochemie.med.uni-giessen.de						ALVING K, 1999, IN PRESS J MASS SPEC; BICHKO V, 1985, FEBS LETT, V185, P208, DOI 10.1016/0014-5793(85)80771-7; BLOCK TM, 1994, P NATL ACAD SCI USA, V91, P2235, DOI 10.1073/pnas.91.6.2235; Block TM, 1998, NAT MED, V4, P610, DOI 10.1038/nm0598-610; Bonetto V, 1997, J PROTEIN CHEM, V16, P371, DOI 10.1023/A:1026328520307; BRUSS V, 1994, EMBO J, V13, P2273, DOI 10.1002/j.1460-2075.1994.tb06509.x; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; Carman WF, 1997, J VIRAL HEPATITIS, V4, P11, DOI 10.1111/j.1365-2893.1997.tb00155.x; EMINI EA, 1989, J MED VIROL, V28, P7, DOI 10.1002/jmv.1890280103; Gerlich W, 1975, Dev Biol Stand, V30, P78; Geyer H, 1999, ANAL CHEM, V71, P476, DOI 10.1021/ac980712w; GEYER H, 1992, GLYCOBIOLOGY, V2, P299, DOI 10.1093/glycob/2.4.299; GEYER R, 1982, ANAL BIOCHEM, V121, P263, DOI 10.1016/0003-2697(82)90478-X; GEYER R, 1994, METHOD ENZYMOL, V230, P86; GEYER R, 1990, EUR J BIOCHEM, V187, P95, DOI 10.1111/j.1432-1033.1990.tb15281.x; GILLECECASTRO BL, 1987, ARCH BIOCHEM BIOPHYS, V256, P194, DOI 10.1016/0003-9861(87)90437-1; GRGACIC EVL, 1994, J VIROL, V68, P7344, DOI 10.1128/JVI.68.11.7344-7350.1994; GRUBER C, 1985, J GEN VIROL, V66, P417, DOI 10.1099/0022-1317-66-3-417; HANAOKA K, 1986, J BIOCHEM-TOKYO, V99, P1273, DOI 10.1093/oxfordjournals.jbchem.a135591; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Heermann KH, 1999, J CLIN MICROBIOL, V37, P68, DOI 10.1128/JCM.37.1.68-73.1999; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; Heermann KH, 1991, MOL BIOL HEPATITIS B, P109; Hildt E, 1996, HEPATOLOGY, V24, P502, DOI 10.1002/hep.510240306; HOLLINGER FB, 1995, FIELDS VIROLOGY, P2739; ITOH Y, 1986, P NATL ACAD SCI USA, V83, P9174, DOI 10.1073/pnas.83.23.9174; JUNGERS P, 1994, J INFECT DIS, V169, P399, DOI 10.1093/infdis/169.2.399; KANN M, 1998, TOPLEY WILSONS MICRO, P745; Lanford RE, 1998, P NATL ACAD SCI USA, V95, P5757, DOI 10.1073/pnas.95.10.5757; LerouxRoels G, 1997, VACCINE, V15, P1732, DOI 10.1016/S0264-410X(97)00118-7; LU XY, 1995, VIROLOGY, V213, P660, DOI 10.1006/viro.1995.0038; Mehta A, 1998, FEBS LETT, V430, P17, DOI 10.1016/S0014-5793(98)00525-0; Mehta A, 1997, P NATL ACAD SCI USA, V94, P1822, DOI 10.1073/pnas.94.5.1822; MILICH DR, 1990, J IMMUNOL, V144, P3535; MILICH DR, 1986, J IMMUNOL, V137, P2703; Moskovitz J, 1999, METHOD ENZYMOL, V300, P239; NAUMANN H, 1993, J GEN VIROL, V74, P1627, DOI 10.1099/0022-1317-74-8-1627; NEURATH AR, 1986, CELL, V46, P429, DOI 10.1016/0092-8674(86)90663-X; NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; PAZPARENTE J, 1985, CARBOHYD RES, V141, P41; PERSING DH, 1987, J VIROL, V61, P1672, DOI 10.1128/JVI.61.5.1672-1677.1987; PFEIFFER G, 1993, GLYCOCONJUGATE J, V10, P240, DOI 10.1007/BF00702206; PFEIFFER G, 1990, BIOMED CHROMATOGR, V4, P193, DOI 10.1002/bmc.1130040505; POL S, 1994, LANCET, V344, P342, DOI 10.1016/S0140-6736(94)91384-6; PONTISSO P, 1989, VIROLOGY, V173, P522, DOI 10.1016/0042-6822(89)90564-3; POULTER L, 1990, METHOD ENZYMOL, V193, P661, DOI 10.1016/0076-6879(90)93444-P; Pride MW, 1998, VACCINE, V16, P543, DOI 10.1016/S0264-410X(97)00242-9; Rothmann K, 1998, J VIROL, V72, P10138, DOI 10.1128/JVI.72.12.10138-10147.1998; Rutgers T, 1988, VIRAL HEPATITIS LIVE, P304; SCHLUTER M, 1985, CARBOHYD RES, V138, P305, DOI 10.1016/0008-6215(85)85113-2; SERAFINICESSI F, 1988, J GEN VIROL, V69, P869, DOI 10.1099/0022-1317-69-4-869; SHEU SY, 1994, J GEN VIROL, V75, P3031, DOI 10.1099/0022-1317-75-11-3031; SHIRAKI K, 1992, J GEN VIROL, V73, P1401, DOI 10.1099/0022-1317-73-6-1401; SHOUVAL D, 1994, VACCINE, V12, P1453, DOI 10.1016/0264-410X(94)90155-4; STIBBE W, 1983, DEV BIOL STAND, V54, P33; STIBBE W, 1983, J VIROL, V46, P626, DOI 10.1128/JVI.46.2.626-628.1983; Thomas HC, 1996, LANCET, V348, P1417, DOI 10.1016/S0140-6736(96)05409-8; Tolle TK, 1998, J VIROL, V72, P9978, DOI 10.1128/JVI.72.12.9978-9985.1998; Werr M, 1998, J VIROL, V72, P778, DOI 10.1128/JVI.72.1.778-782.1998; Zuckerman JN, 1997, BRIT MED J, V314, P329, DOI 10.1136/bmj.314.7077.329	61	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11945	11957		10.1074/jbc.274.17.11945	http://dx.doi.org/10.1074/jbc.274.17.11945			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207016	hybrid			2022-12-25	WOS:000079834800072
J	Sibinga, NES; Wang, H; Perrella, MA; Endege, WO; Patterson, C; Yoshizumi, M; Haber, E; Lee, ME				Sibinga, NES; Wang, H; Perrella, MA; Endege, WO; Patterson, C; Yoshizumi, M; Haber, E; Lee, ME			Interferon-gamma-mediated inhibition of cyclin A gene transcription is independent of individual cis-acting elements in the cyclin A promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SENSITIVE HEMATOPOIETIC-CELLS; DEPENDENT KINASE INHIBITOR; MAMMARY EPITHELIAL-CELLS; BARE LYMPHOCYTE SYNDROME; ALPHA-INTERFERON; GROWTH ARREST; TRANSFORMING GROWTH-FACTOR-BETA-1; RETINOBLASTOMA PROTEIN; DOWN-REGULATION	Interferons (IFNs) affect cellular functions by altering gene expression. The eukaryotic cell cycle is governed in part by the periodic transcription of cyclin genes, whose protein products associate with and positively regulate the cyclin-dependent kinases. To understand better the growth inhibitory effect of IFN-gamma on vascular smooth muscle cells (VSMCs), we compared the expression and activity of G(1) and S phase cyclins in control and IFN-gamma treated VSMCs, IFN-gamma treatment did not inhibit the G(1) cyclins but did decrease cyclin A protein, mRNA, and associated kinase activity by 85, 90, and 90%, respectively. Nuclear run-on and mRNA stability determinations indicated that this decrease was the result of transcriptional inhibition. To investigate the molecular basis of this inhibition, we examined protein-DNA interactions involving the cyclin A promoter, Electromobility shift assays showed little change with IFN-gamma treatment in the binding of nuclear proteins to isolated ATF, NF-Y, and CDE elements. In vivo genomic footprinting indicated that IFN-gamma treatment changed the occupancy of chromosomal NF-Y and CDE sites slightly and did not affect occupancy of the ATF site. In a previous study of transforming growth factor-beta 1-mediated inhibition of the cyclin A promoter, we mapped the inhibitory effect to the ATF site; in the present study of IFN-gamma treatment, functional analysis by transient transfection showed that inhibition of the cyclin A promoter persisted despite mutation of the ATF, NF-Y, or CDE elements. We hypothesize that IFN-gamma inhibits cyclin A transcription by modifying co-activators or general transcription factors within the complex that drives transcription of the cyclin A gene.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Sibinga, NES (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.		Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X	NHLBI NIH HHS [HL03194, HL03274] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALKWILL FR, 1984, EXP CELL RES, V155, P190, DOI 10.1016/0014-4827(84)90780-8; BARLAT I, 1995, ONCOGENE, V11, P1309; BENNETT MR, 1994, BIOCHEM J, V302, P701, DOI 10.1042/bj3020701; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BURKE LC, 1992, ONCOGENE, V7, P783; BYBEE A, 1992, BIOCHIM BIOPHYS ACTA, V1137, P73, DOI 10.1016/0167-4889(92)90102-H; Cao Y, 1998, J BIOL CHEM, V273, P4012, DOI 10.1074/jbc.273.7.4012; Cassatella MA, 1996, IMMUNOL LETT, V49, P79, DOI 10.1016/0165-2478(95)02484-0; CHAN YL, 1983, NUCLEIC ACIDS RES, V11, P7819, DOI 10.1093/nar/11.22.7819; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; COCKS BG, 1992, J BIOL CHEM, V267, P12307; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dickensheets HL, 1997, J IMMUNOL, V159, P6226; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Harper JW, 1997, CANCER SURV, V29, P91; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Horton MR, 1998, J IMMUNOL, V160, P3023; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUPPI K, 1994, ONCOGENE, V9, P3017; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KNAPEK DF, 1995, CANCER RES, V55, P1607; Kramer A, 1996, J BIOL CHEM, V271, P6579; LEE ME, 1990, J BIOL CHEM, V265, P10446; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Polentarutti N, 1998, EUR J IMMUNOL, V28, P496, DOI 10.1002/(SICI)1521-4141(199802)28:02<496::AID-IMMU496>3.0.CO;2-V; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; SEN GC, 1997, TRANSCRIPTIONAL REGU, P1; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVERMAN RH, 1994, J INTERFERON RES, V14, P101, DOI 10.1089/jir.1994.14.101; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; TAMAI K, 1995, J BIOL CHEM, V270, P392, DOI 10.1074/jbc.270.1.392; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; WATANABE Y, 1978, J GEN VIROL, V41, P411, DOI 10.1099/0022-1317-41-2-411; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	77	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12139	12146		10.1074/jbc.274.17.12139	http://dx.doi.org/10.1074/jbc.274.17.12139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207041	hybrid			2022-12-25	WOS:000079834800097
J	Soeder, KJ; Snedden, SK; Cao, WH; Della Rocca, GJ; Daniel, KW; Luttrell, LM; Collins, S				Soeder, KJ; Snedden, SK; Cao, WH; Della Rocca, GJ; Daniel, KW; Luttrell, LM; Collins, S			The beta(3)-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a G(i)-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATYPICAL BETA-ADRENOCEPTORS; ADENYLATE-CYCLASE ACTIVITY; A1 ADENOSINE RECEPTORS; COUPLED RECEPTORS; BETA-3-ADRENERGIC RECEPTOR; CYCLIC-AMP; ALPHA-SUBUNITS; UNCOUPLING PROTEIN; BROWN ADIPOCYTES; AZIDOANILIDO-GTP	Promiscuous coupling between G protein-coupled receptors and multiple species of heterotrimeric G; proteins provides a potential mechanism for expanding the diversity of G protein-coupled receptor signaling. We have examined the mechanism and functional consequences of dual G(s)/G(i) protein coupling of the beta(3)-adrenergic receptor (beta(3)AR) in 3T3-F442A adipocytes. The beta(3)AR selective agonist disodium (R,R)-5-[2[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL316,243) stimulated a dose-dependent increase in cAMP production in adipocyte plasma membrane preparations, and pretreatment of cells with pertussis toxin resulted in a further a-fold increase in cAMP production by CL316,243, CL316,243 (5 mu M) stimulated the incorporation of 8-azido-[P-32]GTP into G alpha(s) (1.57 +/- 0.12; n = 3) and G alpha(i) (1.68 +/- 0.13; n = 4) in adipocyte plasma membranes, directly demonstrating that beta(3)AR stimulation results in G(i)-GTP exchange. The beta(3)AR-stimulated increase in 8-azido-[P-32]GTP labeling of G alpha(i) was equivalent to that obtained with the A(1)-adenosine receptor agonist N-6-cyclopentyladenosine (1.56 +/- 0.07; n = 4), whereas inclusion of unlabeled GTP (100 mu M) eliminated all binding. Stimulation of the beta(3)AR in 3T3-F442A adipocytes led to a 2-3-fold activation of mitogen-activated protein (MAP) kinase, as measured by extracellular signal-regulated kinase-1 and -2 (ERK1/2) phosphorylation. Pretreatment of cells with pertussis toxin (PTX) eliminated MAP kinase activation by beta(3)AR, demonstrating that this response required receptor coupling to Gi, Expression of the human beta(3)AR in HEK-293 cells reconstituted the PTX-sensitive stimulation of MAP kinase, demonstrating that this phenomenon is not exclusive to adipocytes or to the rodent beta(3)AR, ERK1/2 activation by the beta(3)AR was insensitive to the cAMP-dependent protein kinase inhibitor H-89 but was abolished by genistein and AG1478. These data indicate that constitutive beta(3)AR coupling to G(i) proteins serves both to restrain G(s)-mediated activation of adenylyl cyclase and to initiate additional signal transduction pathways, including the ERK1/2 MAP kinase cascade.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Collins, S (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, POB 3557, Durham, NC 27710 USA.	colli008@mc.duke.edu	Della Rocca, Gregory/AAM-5281-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046793, R56DK053092, R01DK053092, K08DK002352] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46793, DK53092, DK02352] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BEGINHEICK N, 1987, MOL CELL ENDOCRINOL, V53, P1, DOI 10.1016/0303-7207(87)90185-7; BEGINHEICK N, 1995, J CELL BIOCHEM, V58, P464, DOI 10.1002/jcb.240580409; BEGINHEICK N, 1985, J BIOL CHEM, V260, P6187; BEGINHEICK N, 1990, BIOCHEM J, V268, P83, DOI 10.1042/bj2680083; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; CHANG KJ, 1988, P NATL ACAD SCI USA, V85, P4929, DOI 10.1073/pnas.85.13.4929; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; COOPER DMF, 1979, J BIOL CHEM, V254, P8927; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DJIAN P, 1985, J CELL PHYSIOL, V124, P554, DOI 10.1002/jcp.1041240327; FIELDS TA, 1994, BIOCHEMISTRY-US, V33, P6877, DOI 10.1021/bi00188a017; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; HINSCH KD, 1988, FEBS LETT, V238, P191, DOI 10.1016/0014-5793(88)80254-0; HOLLENGA C, 1991, EUR J PHARMACOL, V200, P325, DOI 10.1016/0014-2999(91)90590-M; HOLLENGA C, 1991, BRIT J PHARMACOL, V102, P577, DOI 10.1111/j.1476-5381.1991.tb12215.x; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARGIS EE, 1994, DRUG DEVELOP RES, V32, P69, DOI 10.1002/ddr.430320203; LARROUY D, 1991, EUR J PHARM-MOLEC PH, V206, P139, DOI 10.1016/0922-4106(91)90022-A; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Manara L, 1996, BRIT J PHARMACOL, V117, P435, DOI 10.1111/j.1476-5381.1996.tb15209.x; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NANTEL F, 1993, MOL PHARMACOL, V43, P548; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; PITTMAN RN, 1983, MOL PHARMACOL, V24, P398; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAVID K, 1988, BIOCHEM J, V249, P377, DOI 10.1042/bj2490377; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; ROUOT B, 1989, BIOCHEM J, V260, P307, DOI 10.1042/bj2600307; Sasaki N, 1998, J VET MED SCI, V60, P465, DOI 10.1292/jvms.60.465; SCHAFER R, 1988, BIOCHEM BIOPH RES CO, V155, P1051, DOI 10.1016/S0006-291X(88)80603-X; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANNUCCI SJ, 1989, AM J PHYSIOL, V257, pE871, DOI 10.1152/ajpendo.1989.257.6.E871; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WANGE RL, 1991, J BIOL CHEM, V266, P11409; YOSHIDA T, 1994, LIFE SCI, V54, P491, DOI 10.1016/0024-3205(94)00408-0	58	161	168	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12017	12022		10.1074/jbc.274.17.12017	http://dx.doi.org/10.1074/jbc.274.17.12017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207024	hybrid			2022-12-25	WOS:000079834800080
J	Russell, A; Thompson, MA; Hendley, J; Trute, L; Armes, J; Germain, D				Russell, A; Thompson, MA; Hendley, J; Trute, L; Armes, J; Germain, D			Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer	ONCOGENE			English	Article						D-type cyclin; breast cancer; proteolysis; SCF	CELL-CYCLE; ESTROGEN-RECEPTOR; EXPRESSION; GENE; DEGRADATION; PROTEIN; D2; DIFFERENTIATION; UBIQUITINATION; AMPLIFICATION	D-type cyclins are important cell cycle regulators that promote cellular proliferation in response to growth factors by inactivation of the retinoblastoma protein (Rb), Cyclin D1 has been shown to be overexpressed in several cancer types and to act as an oncogene in breast cancers. As D-type cyclins are rate limiting for progression into S phase, the level at which they accumulate must be carefully regulated. Several mechanisms leading to overexpression of cyclin D1 have been reported including amplification, translocation and stabilization of the mRNA, Here, we present data showing elevated cyclin D1 protein in breast cancer samples in the absence of elevated mRNA level. Further, we found that in these cases, cyclin D3 protein also accumulates and that the coordinate increase in cyclin D1 and D3 occurs in 15% (7/47) of breast cancers. In addition we show that blocking the activity of the 26S proteosome results in the accumulation of cyclin D1 and D3, that both D-type cyclins are abiquitinated and associate with Cul-1, a component of the SCF ubiquitin Ligase complex. Finally, we show that the coordinated elevation of cyclin D1 and D3 is also observed in the breast cell line MCF-7 and demonstrate that the degradation of cyclin D1 and D3 is deficient in this cell line. These results indicate that cyclin D1 and cyclin D3 share a common mechanism of degradation and we propose that the coordinate increase of D-type cyclins observed in primary breast cancers reflects a defect in their proteolysis.	Peter MacCallum Canc Inst, Trescowthick Res Lab, Melbourne, Vic 3000, Australia	Peter Maccallum Cancer Center	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Lab, Locked Bag 1,Abeckett St, Melbourne, Vic 3000, Australia.		Armes, Jane/D-6396-2012	Armes, Jane/0000-0002-2215-0347				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; GILLETT C, 1994, CANCER RES, V54, P1812; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HERBER B, 1994, ONCOGENE, V9, P1295; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1996, ONCOGENE, V13, P419; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	41	115	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1983	1991		10.1038/sj.onc.1202511	http://dx.doi.org/10.1038/sj.onc.1202511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208420				2022-12-25	WOS:000079191300008
J	Gonciarz-Swiatek, M; Wawrzynow, A; Um, SJ; Learn, BA; McMacken, R; Kelley, WL; Georgopoulos, C; Sliekers, O; Zylicz, M				Gonciarz-Swiatek, M; Wawrzynow, A; Um, SJ; Learn, BA; McMacken, R; Kelley, WL; Georgopoulos, C; Sliekers, O; Zylicz, M			Recognition, targeting, and hydrolysis of the lambda O replication protein by the ClpP ClpX protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-MU TRANSPOSASE; SINGLE-STRANDED-DNA; HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; SPECIFICITY COMPONENT; MUTATIONAL ANALYSIS; ATP HYDROLYSIS; BINDING SITES; HSP104	It has previously been established that sequences at the C termini of polypeptide substrates are critical for efficient hydrolysis by the ClpP/ClpX ATP-dependent protease, We report for the bacteriophage lambda O replication protein, however, that N-terminal sequences play the most critical role in facilitating proteolysis by ClpP/ClpX The N-terminal portion of lambda O is degraded at a rate comparable with that of wild type O protein, whereas the C-terminal domain of O is hydrolyzed at least 10-fold more slowly. Consistent with these results, deletion of the first 18 amino acids of lambda O blocks degradation of the N-terminal domain, whereas proteolysis of the O C-terminal domain is only slightly diminished as a result of deletion of the C-terminal 15 amino acids. We demonstrate that ClpX retains its capacity to bind to the N-terminal domain following removal of the first 18 amino acids of O, However, ClpX cannot efficiently promote the ATP-dependent binding of this truncated O polypeptide to ClpP, the catalytic subunit of the ClpP/ClpX protease, Based on our results with lambda O protein, we suggest that two distinct structural elements may be required in substrate polypeptides to enable efficient hydrolysis by the ClpP/ClpX protease: (i) a ClpX-binding site, which may be located remotely from substrate termini, and (ii) a proper N- or C-terminal sequence, whose exposure on the substrate surface may be induced by the binding of ClpX.	Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA; Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva 4, Switzerland	Fahrenheit Universities; University of Gdansk; Johns Hopkins University; University of Geneva	Zylicz, M (corresponding author), Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, Kladki 24, PL-80822 Gdansk, Poland.	zylicz@biotech.univ.gda.pl		Sliekers, Olav/0000-0002-8109-2431; Zylicz, Alicja/0000-0003-4174-3073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036526, R01GM032253] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32253, GM36526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEJARANO I, 1993, J BACTERIOL, V175, P7720, DOI 10.1128/JB.175.23.7720-7723.1993; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Frank EG, 1996, P NATL ACAD SCI USA, V93, P10291, DOI 10.1073/pnas.93.19.10291; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOTTESMAN S, 1981, CELL, V24, P225, DOI 10.1016/0092-8674(81)90518-3; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; LEBOWITZ JH, 1985, P NATL ACAD SCI USA, V82, P3988, DOI 10.1073/pnas.82.12.3988; LEBOWITZ JH, 1984, NUCLEIC ACIDS RES, V12, P3069, DOI 10.1093/nar/12.7.3069; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LIPINSKA B, 1980, BIOCHEM BIOPH RES CO, V92, P120, DOI 10.1016/0006-291X(80)91528-4; MCMACKEN R, 1983, MECHANISMS DNA REPLI, P819; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; ROBERTS JD, 1983, NUCLEIC ACIDS RES, V11, P7435, DOI 10.1093/nar/11.21.7435; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; SEOL JH, 1995, BIOCHEM BIOPH RES CO, V217, P41, DOI 10.1006/bbrc.1995.2743; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; UM SJ, 1993, THESIS J HOPKINS U; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WEGRZYN G, 1992, J MOL BIOL, V226, P675; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; WYATT WM, 1974, VIROLOGY, V58, P313, DOI 10.1016/0042-6822(74)90168-8; Zylicz M, 1998, P NATL ACAD SCI USA, V95, P15259, DOI 10.1073/pnas.95.26.15259	53	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13999	14005		10.1074/jbc.274.20.13999	http://dx.doi.org/10.1074/jbc.274.20.13999			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318812	hybrid			2022-12-25	WOS:000080322200041
J	McCarthy, JJ; Vyas, DR; Tsika, GL; Tsika, RW				McCarthy, JJ; Vyas, DR; Tsika, GL; Tsika, RW			Segregated regulatory elements direct beta-myosin heavy chain expression in response to altered muscle activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; DEVELOPMENTAL REGULATION; GENE-EXPRESSION; CARDIAC-MUSCLE; REGION; CELLS; DNA; TRANSCRIPTION; REPRESSOR; SEQUENCES	Our previous transgenic analyses revealed that a 600-base pair beta-myosin heavy chain (beta MyHC) promoter conferred mechanical overload (MOV) and non-weightbearing (NWB) responsiveness to a chloramphenicol acetyltransferase reporter gene. Whether the same DNA regulatory element(s) direct beta MyHC expression following MOV or NWB activity in vivo remains unknown. We now show that a 293-base pair beta MyHC promoter fused to chloramphenicol acetyltransferase (beta 293) responds to MOV, but not NWB activity, indicating a segregation of these two diverse elements. Inclusion of the beta MyHC negative regulatory element (-332 to -300; beta NRE) within transgene beta 350 repressed expression in all transgenic lines. Electrophoretic mobility shift assays showed highly enriched binding activity only in NWB soleus nuclear extracts that was specific to the distal region of the beta NRE sense strand (d beta NRE-S; -332 to -311). Supershift electrophoretic mobility shift assay revealed that the binding at the distal region of the beta NRE sense strand was antigenically distinct from cellular nucleic acid-binding protein and Y-box-binding factor 1, two proteins shown to bind this element, Two-dimensional UV cross-linking and shift Southwestern blotting analyses detected two proteins (50 and 52 kDa) that bind to this element. These in vivo results demonstrate that segregated beta MyHC promoter elements transcriptionally regulate beta MyHC transgene expression in response to two diverse modes of neuromuscular activity.	Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Tsika, RW (corresponding author), Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, 1600 E Rollins Ave,W112 VET Med Bldg, Columbia, MO 65211 USA.	tsikar@missouri.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041464, F32AR008412] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR41464, F32 AR08412] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; EDWARDS JG, 1992, BIOCHEM BIOPH RES CO, V189, P504, DOI 10.1016/0006-291X(92)91586-F; ERICKSON JM, 1981, GENE, V16, P1, DOI 10.1016/0378-1119(81)90055-X; FLINK IL, 1995, J BIOL CHEM, V270, P6959, DOI 10.1074/jbc.270.12.6959; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GORE MT, 1993, CIRCULATION, V88, P236; GRAY T A, 1990, Technique (Philadelphia), V2, P147; Hasegawa K, 1997, CIRCULATION, V96, P3943; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kingsley PD, 1996, DEV GROWTH DIFFER, V38, P697; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; McCarthy JJ, 1997, AM J PHYSIOL-REG I, V272, pR1552, DOI 10.1152/ajpregu.1997.272.5.R1552; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Pellizzoni L, 1997, J MOL BIOL, V267, P264, DOI 10.1006/jmbi.1996.0888; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RINDT H, 1993, J BIOL CHEM, V268, P5332; RUIZLOZANO P, 1994, GENE, V14, P243; Sapru MK, 1996, J BIOL CHEM, V271, P7203, DOI 10.1074/jbc.271.12.7203; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; Tsika GL, 1996, AM J PHYSIOL-CELL PH, V271, pC690, DOI 10.1152/ajpcell.1996.271.2.C690; Tsika R W, 1994, Exerc Sport Sci Rev, V22, P361; TSIKA RW, 1995, AM J PHYSIOL-CELL PH, V269, pC665, DOI 10.1152/ajpcell.1995.269.3.C665; WARDEN CH, 1994, GENOMICS, V24, P14, DOI 10.1006/geno.1994.1576; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	35	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14270	14279		10.1074/jbc.274.20.14270	http://dx.doi.org/10.1074/jbc.274.20.14270			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318848	hybrid			2022-12-25	WOS:000080322200077
J	Arakaki, N; Kajihara, T; Arakaki, R; Ohnishi, T; Kazi, JA; Nakashima, H; Daikuhara, Y				Arakaki, N; Kajihara, T; Arakaki, R; Ohnishi, T; Kazi, JA; Nakashima, H; Daikuhara, Y			Involvement of oxidative stress in tumor cytotoxic activity of hepatocyte growth factor scatter factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULMINANT HEPATIC-FAILURE; NECROSIS-FACTOR-ALPHA; C-MET RECEPTOR; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; HYDROGEN-PEROXIDE; HUMAN-FIBROBLASTS; RELAXING FACTOR	In this study, we show that N-acetylcysteine (NAC), a precursor of glutathione and an intracellular free radical scavenger, almost completely prevented hepatocyte growth factor (HGF)-suppressed growth of Sarcoma 180 and Meth A cells, and HGF-induced apoptosis, assessed by DNA fragmentation, and increase in caspase-3 activity, in Sarcoma 180 cells. The reduced form of glutathione also prevented HGF-suppressed growth of the cells as effective as NAG. Ascorbic acid partially prevented the effect of HGF, but other antioxidants such as superoxide dismutase, catalase, and vitamin E, and the free radical spin traps N-t-butyl-alpha-phenylnitrone and 3,3,5,5-tetramethyl-1-pyrroline-1-oxide did not have protective effects. HGF caused morphological changes of the cells, many cells showing condensation and rounding, and enhanced the generation of intracellular reactive oxygen species (ROS) as judged by flow cytometric analysis using 2',7'-dichlorofluorescein diacetate. NAC completely prevented both HGF-induced morphological changes and the enhancement of ROS generation in the cells. However, NAC did not prevent the HGF-induced scattering of Madin-Darby canine kidney cells. To our knowledge, this is the first report that HGF stimulates the production of ROS, and our results suggest the involvement of oxidative stress in the mechanism by which HGF induces growth suppression of tumor cells.	Kagoshima Univ, Sch Dent, Dept Biochem, Kagoshima 8908544, Japan; Kagoshima Univ, Sch Dent, Dept Immunol & Microbiol, Kagoshima 8908544, Japan	Kagoshima University; Kagoshima University	Daikuhara, Y (corresponding author), Kagoshima Univ, Sch Dent, Dept Biochem, 35-1 Sakuragaoka 8, Kagoshima 8908544, Japan.		Jamil, Kazi Ahsan/B-1057-2009	Jamil, Kazi Ahsan/0000-0001-5605-2211				Arakaki N, 1995, HEPATOLOGY, V22, P1728, DOI 10.1016/0270-9139(95)90198-1; Arakaki N, 1998, BIOCHEM BIOPH RES CO, V245, P211, DOI 10.1006/bbrc.1998.8397; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUROW S, 1987, EUR J CELL BIOL, V43, P128; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; DjavaheriMergny M, 1996, FEBS LETT, V384, P92, DOI 10.1016/0014-5793(96)00294-3; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; Gohda E, 1998, BIOCHEM BIOPH RES CO, V245, P278, DOI 10.1006/bbrc.1998.8416; GOHDA E, 1991, DIGEST DIS SCI, V36, P785, DOI 10.1007/BF01311238; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KYLE ME, 1988, J BIOL CHEM, V263, P3784; KYLE ME, 1987, BIOCHEM BIOPH RES CO, V149, P889, DOI 10.1016/0006-291X(87)90491-8; LASTER SM, 1988, J IMMUNOL, V141, P2629; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORITA M, 1995, HEPATOLOGY, V21, P1585, DOI 10.1016/0270-9139(95)90463-8; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, ONCOGENE, V6, P501; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHIMA N, 1991, CELL BIOL INT REP, V15, P397, DOI 10.1016/0309-1651(91)90128-6; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; Snedecor G.W., 1967, STAT METHODS, V6th, P1; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Yoshie Y, 1997, CARCINOGENESIS, V18, P1359, DOI 10.1093/carcin/18.7.1359; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; Zamora R, 1997, EUR J PHARMACOL, V321, P87, DOI 10.1016/S0014-2999(96)00918-1	65	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13541	13546		10.1074/jbc.274.19.13541	http://dx.doi.org/10.1074/jbc.274.19.13541			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224123	hybrid			2022-12-25	WOS:000080200400085
J	Kazlauskas, A; Poellinger, L; Pongratz, I				Kazlauskas, A; Poellinger, L; Pongratz, I			Evidence that the Co-chaperone p23 regulates ligand responsiveness of the dioxin (aryl hydrocarbon) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NUCLEAR TRANSLOCATOR PROTEIN; DNA-BINDING ACTIVITY; AH-RECEPTOR; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION FACTOR; PROGESTERONE-RECEPTOR; PAS DOMAIN; IN-VIVO; HSP90	The dioxin (aryl hydrocarbon) receptor is a ligand-dependent transcription factor that induces expression of a number of genes encoding drug metabolizing enzymes, In the absence of ligand the dioxin receptor is present in the cytoplasmic compartment of the cell associated with the molecular chaperone hsp90, which has been implicated in regulating the correct folding of the ligand binding domain of the receptor. In this study we have examined a potential role of the hsp90-associated p23 protein in the activation process of the dioxin receptor to a DNA binding form. In an in vitro model we show that addition of ligand alone to the dioxin receptor fails to induce release of hsp90 from the dioxin receptor. In the presence of ligand, this release was, however, induced upon addition of purified preparations of Arnt. Interestingly, p23 was also found to be associated with the nonactivated form of the dioxin receptor. Following fractionation on sucrose gradients p23 was dissociated from the receptor-hsp90 complex generating a receptor form, which showed ligand-independent release of hsp90 by Arnt and, consequently, ligand-independent activation of the DNA binding activity of the dioxin receptor. Ligand dependence was reconstituted in the presence of molybdate, a transition metal ion known to stabilize the interaction between the molecular chaperone hsp90 and p23, Taken together these experiments suggest a role of p23 in modulating ligand responsiveness in the activation process of the dioxin receptor.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Pongratz, I (corresponding author), Karolinska Inst, Dept Cellular & Mol Biol, S-17177 Stockholm, Sweden.	ingemar.pongratz@cmb.ki.se						BODINE PV, 1990, MOL CELL ENDOCRINOL, V74, pC77, DOI 10.1016/0303-7207(90)90199-I; BODINE PV, 1988, J BIOL CHEM, V263, P3501; BODINE PV, 1988, P NATL ACAD SCI USA, V85, P1462, DOI 10.1073/pnas.85.5.1462; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GRADIN K, 1993, J BIOL CHEM, V268, P4061; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; Ma Q, 1997, J BIOL CHEM, V272, P8878; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; POELLINGER L, 1993, PHARM SKIN, V5, P103; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Wang G L, 1996, Curr Opin Hematol, V3, P156; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	47	205	211	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13519	13524		10.1074/jbc.274.19.13519	http://dx.doi.org/10.1074/jbc.274.19.13519			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224120	hybrid			2022-12-25	WOS:000080200400082
J	Lee, KY; Chang, WT; Qiu, DM; Kao, PN; Rosen, GD				Lee, KY; Chang, WT; Qiu, DM; Kao, PN; Rosen, GD			PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRIPTERYGIUM-WILFORDII; TRANSCRIPTION; PHOSPHORYLATION; ACTIVATION; P65; INHIBITION; C-IAP2; DEATH	Progress in the treatment of solid tumors has been slow and sporadic. The efficacy of conventional chemotherapy in solid tumors is limited because tumors frequently have mutations in the p53 gene. Also, chemotherapy only kills rapidly dividing cells. Members of the tumor necrosis factor (TNF) family, however, induce apoptosis regardless of the p53 phenotype. Unfortunately, the cytotoxicity of TNF-alpha is limited by its activation of NF-kappa B and activation of NF-kappa B is proinflammatory, We have identified a compound called PG490, that is composed of purified triptolide, which induces apoptosis in tumor cells and sensitizes tumor cells to TNF-alpha-induced apoptosis, PG490 potently inhibited TNF-alpha-induced activation of NF-kappa B, PG490 also blocked TNF-alpha-mediated induction of c-IAP2 (hiap-1) and c-IAP1 (hiap-2), members of the inhibitor of apoptosis (IAP) family, interestingly, PG490 did not block DNA binding of NF-kappa B, but it blocked transactivation of NF-kappa B, Our identification of a compound that blocks TNF-alpha-induced activation of NP-kappa B may enhance the cytotoxicity of TNF-alpha on tumors in vivo and limit its proinflammatory effects.	Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA	Stanford University	Rosen, GD (corresponding author), Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, 300 Pasteur Dr, Stanford, CA 94305 USA.							Bauerle PA, 1996, CELL, V87, P13; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Burow ME, 1998, CANCER RES, V58, P4940; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gu WZ, 1998, INT J IMMUNOPHARMACO, V20, P389, DOI 10.1016/S0192-0561(98)00035-6; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; KUPCHAN SM, 1974, SCIENCE, V185, P791, DOI 10.1126/science.185.4153.791; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Shamon LA, 1997, CANCER LETT, V112, P113, DOI 10.1016/S0304-3835(96)04554-5; Tao XL, 1998, ARTHRITIS RHEUM-US, V41, P130, DOI 10.1002/1529-0131(199801)41:1<130::AID-ART16>3.3.CO;2-W; Tao XL, 1996, J PHARMACOL EXP THER, V276, P316; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wen LP, 1997, AM J PHYSIOL-LUNG C, V273, pL921, DOI 10.1152/ajplung.1997.273.5.L921; YANG SX, 1994, INT J IMMUNOPHARMACO, V16, P895, DOI 10.1016/0192-0561(94)90044-2; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	23	171	191	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13451	13455		10.1074/jbc.274.19.13451	http://dx.doi.org/10.1074/jbc.274.19.13451			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224110	hybrid			2022-12-25	WOS:000080200400072
J	Rodrigue, A; Chanal, A; Beck, K; Muller, M; Wu, LF				Rodrigue, A; Chanal, A; Beck, K; Muller, M; Wu, LF			Co-translocation of a periplasmic enzyme complex by a hitchhiker mechanism through the bacterial Tat pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN EXPORT; PLASMA-MEMBRANE; NICKEL; SYSTEM; GENES; HYDROGENASE-2; COMPONENTS; PRECURSOR; SEQUENCES	Bacterial periplasmic nickel-containing hydrogenases are composed of a small subunit containing a twin-arginine signal sequence and a large subunit devoid of an export signal. To understand how the large subunit is translocated into the periplasm, we cloned the hyb operon encoding the hydrogenase 2 of Escherichia coli constructed a deletion mutant, and studied the mechanism of translocation of hydrogenase 2, The small subunit (HybO) or the large subunit (HybC) accumulated in the cytoplasm as a precursor when either of them was expressed in the absence of the other subunit, Therefore, contrary to most classical secretory proteins, the signal sequence of the small subunit itself is not sufficient for membrane targeting and translocation if the large subunit is missing. On the other hand, the small subunit was required not only for membrane targeting of the large subunit, but also for the acquisition of nickel by the large subunit, Most interestingly, the signal sequence of the small subunit determines whether the large subunit follows the Sec or the twin-arginine translocation pathway. Taken together, these results provide for the first time compelling evidence for a naturally occurring hitchhiker co-translocation mechanism in bacteria.	UPR9043 CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille 20, France; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Wu, LF (corresponding author), UPR9043 CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Rodrigue, Agnès/AAD-5987-2020	Rodrigue, Agnes/0000-0002-8473-8103				BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BALLANTINE SP, 1986, EUR J BIOCHEM, V156, P277, DOI 10.1111/j.1432-1033.1986.tb09578.x; BARDONNET N, 1992, FEMS MICROBIOL LETT, V93, P243, DOI 10.1111/j.1574-6968.1992.tb05105.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Binder U, 1996, ARCH MICROBIOL, V165, P69, DOI 10.1007/s002030050299; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bouveret E, 1997, MOL MICROBIOL, V23, P909, DOI 10.1046/j.1365-2958.1997.2751640.x; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Harlow E, 1998, ANTIBODIES LAB MANUA; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MANEEWANNAKUL S, 1994, PLASMID, V31, P300, DOI 10.1006/plas.1994.1032; MENON NK, 1994, J BACTERIOL, V176, P4416, DOI 10.1128/jb.176.14.4416-4423.1994; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; Rodrigue A, 1996, FEBS LETT, V392, P81, DOI 10.1016/0014-5793(96)00788-0; Rodrigue A, 1996, J BACTERIOL, V178, P4453, DOI 10.1128/jb.178.15.4453-4460.1996; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1998, EUR J BIOCHEM, V255, P746, DOI 10.1046/j.1432-1327.1998.2550746.x; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VOORDOUW G, 1992, ADV INORG CHEM, V38, P397, DOI 10.1016/S0898-8838(08)60069-0; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243; WU LF, 1986, BIOCHIMIE, V68, P167, DOI 10.1016/S0300-9084(86)81081-1; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2	32	216	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13223	13228		10.1074/jbc.274.19.13223	http://dx.doi.org/10.1074/jbc.274.19.13223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224080	hybrid, Green Published			2022-12-25	WOS:000080200400042
J	Cheng, GM; Hagen, TP; Dawson, ML; Barnes, KV; Menick, DR				Cheng, GM; Hagen, TP; Dawson, ML; Barnes, KV; Menick, DR			The role of GATA, CArG, E-box, and a novel element in the regulation of cardiac expression of the Na+-Ca2+ exchanger gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; SODIUM-CALCIUM EXCHANGER; SERUM RESPONSE FACTOR; MUSCLE-SPECIFIC EXPRESSION; ALPHA-ACTIN PROMOTER; DEPENDENT REGULATION; PRESSURE-OVERLOAD; TINMAN HOMOLOG; CELLS; IDENTIFICATION	The cardiac Na+-Ca2+ exchanger (NCX1) is the principal Ca2+ efflux mechanism in cardiocytes, The exchanger is up-regulated in both cardiac hypertrophy and failure. In this report, we identify the cis-acting elements that control cardiac expression and ar-adrenergic up-regulation of the exchanger gene. Deletion analysis revealed that a minimal cardiac promoter fragment from -184 to +172 is sufficient for cardiac expression and alpha-adrenergic stimulation. Mutational analysis revealed that both the CArG element at -80 and the GATA element at -50 were required for cardiac expression. Gel mobility shift assay supershift analysis demonstrated that the serum response factor binds to the CArGr element and GATA-4 binds to the GATA element. Point mutations in the -172 E-box demonstrated that it was required for alpha-adrenergic induction. In addition, deletion analysis revealed one or more enhancer elements in the first intron (+103 to +134) that are essential for phenylephrine up-regulation but bear no homology to any known transcription element. Therefore, this work demonstrates that SRF and GATA-4 are critical for NCX1 expression in neonatal cardiomyocytes and that the -172 E-box in addition to a novel enhancer element(s) are required for phenylephrine up-regulation of NCX1 and may mediate its hypertrophic up-regulation.	Med Univ S Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Menick, DR (corresponding author), Med Univ S Carolina, Div Cardiol, Dept Med, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48788] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Cheng GM, 1998, CIRCULATION, V98, P609; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; FOSTER KA, 1990, AM J PHYSIOL, V259, pH432, DOI 10.1152/ajpheart.1990.259.2.H432; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; KURABAYASHI M, 1990, J BIOL CHEM, V265, P19271; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1991, J BIOL CHEM, V266, P1014; Mably JD, 1996, CIRC RES, V79, P4, DOI 10.1161/01.RES.79.1.4; MABLY JD, 1993, J BIOL CHEM, V268, P476; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; Menick DR, 1996, ANN NY ACAD SCI, V779, P489, DOI 10.1111/j.1749-6632.1996.tb44823.x; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; Nicholas SB, 1998, AM J PHYSIOL-HEART C, V274, pH217, DOI 10.1152/ajpheart.1998.274.1.H217; Ojamaa K, 1995, J BIOL CHEM, V270, P31276, DOI 10.1074/jbc.270.52.31276; PAPADOPOULOS N, 1993, MOL CELL BIOL, V13, P6907, DOI 10.1128/MCB.13.11.6907; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; RINDT H, 1993, J BIOL CHEM, V268, P5332; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; Scheller T, 1998, J BIOL CHEM, V273, P7643, DOI 10.1074/jbc.273.13.7643; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443	46	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12819	12826		10.1074/jbc.274.18.12819	http://dx.doi.org/10.1074/jbc.274.18.12819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212268	hybrid			2022-12-25	WOS:000080056800088
J	Schwartz, MP; Huang, SH; Matouschek, A				Schwartz, MP; Huang, SH; Matouschek, A			The structure of precursor proteins during import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-AMYLOLIQUEFACIENS BARNASE; SODIUM DODECYL-SULFATE; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; OUTER-MEMBRANE; MOLTEN-GLOBULE; CYTOCHROME-B2; TRANSLOCATION; RIBONUCLEASE; STABILITY	Precursor proteins must be at least partially unfolded during import into mitochondria, but their actual conformation during translocation is not known. Are proteins fully unfolded and threaded through the import machinery amino acid by amino acid, or do they retain some partial structure? The folding pathway of most proteins in vitro contains a partially folded intermediate known as the molten globule state, and it has been suggested that proteins are in the molten globule state during translocation across membranes. Here we show that precursors are normally fully unfolded during import into mitochondria, However, precursors containing residual structure can be imported, if less efficiently,	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Matouschek, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	matouschek@nwu.edu	Matouschek, Andreas/L-9379-2013	Matouschek, Andreas/0000-0001-6016-2341				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; CLARKE J, 1995, J MOL BIOL, V253, P493, DOI 10.1006/jmbi.1995.0568; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EISENBERG M, 1979, BIOCHEMISTRY-US, V18, P5213, DOI 10.1021/bi00590a028; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HARTLEY RW, 1975, BIOCHEMISTRY-US, V14, P2367, DOI 10.1021/bi00682a015; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026; Tzagoloff A, 1982, MITOCHONDRIA; Van Der Goot Francoise G., 1992, Trends in Cell Biology, V2, P343; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2045, DOI 10.1083/jcb.107.6.2045; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0; ZHANG XJ, 1995, J APPL CRYSTALLOGR, V28, P624, DOI 10.1107/S0021889895001063	30	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12759	12764		10.1074/jbc.274.18.12759	http://dx.doi.org/10.1074/jbc.274.18.12759			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212260	hybrid			2022-12-25	WOS:000080056800080
J	Kurz, LL; Klink, H; Jakob, I; Kuchenbecker, M; Benz, S; Lehmann-Horn, F; Rudel, R				Kurz, LL; Klink, H; Jakob, I; Kuchenbecker, M; Benz, S; Lehmann-Horn, F; Rudel, R			Identification of three cysteines as targets for the Zn2+ blockade of the human skeletal muscle chloride channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENCE; MYOTONIA; STOICHIOMETRY; MUTATIONS; MUTANT; CIC-1; CLC-1; RAT	Currents through the human skeletal muscle chloride channel hClC-1 can be blocked by external application of 1 mM. Zn2+ or the histidine-reactive compound diethyl pyrocarbonate (DEPC), The current block by Zn2+ strongly depends on the external pH (pK(a) near 6.9), whereas the block by DEPC is rather independent of the pH in the range of 5.5 to 8.5. To identify the target sites of these reagents, we constructed a total of twelve cysteine- and/or histidine-replacement mutants, transfected tsA201 cells with them, and investigated the resulting whole-cell chloride currents. The majority of the mutants exhibited a similar sensitivity toward Zn2+ or DEPC as wild type (WT) channels. Block by I mM Zn2+ was nearly absent only with the mutant C546A, Four mutants (C242A, C254A, H180A, and H451A) were slightly less sensitive to Zn2+ than WT. Tests with double, triple, and quadruple mutants yielded that, in addition to C546, C242 and C254 are also most likely participating in Zn2+-binding.	Univ Ulm, Dept Gen Physiol, D-89069 Ulm, Germany; Univ Ulm, Dept Appl Physiol, D-89069 Ulm, Germany	Ulm University; Ulm University	Kurz, LL (corresponding author), Univ Ulm, Dept Gen Physiol, D-89069 Ulm, Germany.							Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; Fahlke C, 1996, BIOPHYS J, V71, P695, DOI 10.1016/S0006-3495(96)79269-X; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; Kurz LL, 1997, PFLUG ARCH EUR J PHY, V433, P357; LehmannHorn F, 1996, REV PHYSIOL BIOCH P, V128, P195; Ludewig U, 1997, J PHYSIOL-LONDON, V498, P691, DOI 10.1113/jphysiol.1997.sp021893; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Miles E W, 1977, Methods Enzymol, V47, P431; Pusch M, 1995, NEURON, V15, P1455, DOI 10.1016/0896-6273(95)90023-3; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; Rychkov GY, 1997, J PHYSIOL-LONDON, V501, P355, DOI 10.1111/j.1469-7793.1997.355bn.x; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; TAINER JA, 1991, CURR OPIN BIOTECH, V2, P582, DOI 10.1016/0958-1669(91)90084-I; Wagner S, 1998, MUSCLE NERVE, V21, P1122, DOI 10.1002/(SICI)1097-4598(199809)21:9<1122::AID-MUS2>3.0.CO;2-9; Wollnik B, 1997, HUM MOL GENET, V6, P805, DOI 10.1093/hmg/6.5.805; Wooltorton JRA, 1997, J PHYSIOL-LONDON, V505, P633, DOI 10.1111/j.1469-7793.1997.633ba.x	26	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11687	11692		10.1074/jbc.274.17.11687	http://dx.doi.org/10.1074/jbc.274.17.11687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206982	hybrid			2022-12-25	WOS:000079834800038
J	Frank, RC; Sun, X; Berguido, FJ; Jakubowiak, A; Nimer, SD				Frank, RC; Sun, X; Berguido, FJ; Jakubowiak, A; Nimer, SD			The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1	ONCOGENE			English	Article						AML1/ETO; transformation; AP-1	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; DNA-BINDING; TRANSCRIPTION FACTOR; C-JUN; CHIMERIC ONCOPROTEIN; RETINOIC ACID; GENE	The 8;21 translocation is the most common cytogenetic abnormality in human acute myelogenous leukemia, joining the AML1 gene on chromosome 21, to the ETO gene on chromosome 8, forming the AML1/ETO fusion gene, The AML1/ETO fusion protein has been shown to function mainly as a transcriptional repressor of AML1 target genes and to block AML1 function in vitro and in vivo. However, AML1/ETO can also activate the BCL-2 promoter and cause enhanced hematopoietic progenitor self-renewal in vitro, suggesting gain-of-functions unique to the fusion protein. We used NIH3T3 cells to determine the transforming capacity of AML1/ETO, and to further characterize its mechanism of action. Expression of AML1/ETO in NIH3T3 cells caused cell-type specific cell death, and cellular transformation, characterized by phenotypic changes, anchorage-independent growth, and tumor formation in nude mice, In contrast, neither expression of AML1A, AML1B or ETO altered the normal growth pattern of the cells, To investigate the mechanism of transformation by AML1/ETO, we analysed the levels of activated, phosphorylated c-Jun (ser63) and other constituents of the AP-1 complex, in the presence of various AML1/ETO related proteins. Expression of AML1/ETO increased the level of c-Jun-P (ser63), and activated AP-1 dependent transcription, which was inhibited by expression of a dominant-negative c-Jun protein. Mutational analysis revealed that the runt homology domain (RHD) and a C-terminal transcriptional repression domain in AML1/ETO are required for transformation, activation of c-Jun and increased AP-1 activity, These results establish the transforming potential of the t(8;21) fusion protein and link this gain-of-function property to modulation of AP-1 activity.	Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, 1275 York Ave,H-701,Box 575, New York, NY 10021 USA.				NCI NIH HHS [K08 CA70388, CA09207] Funding Source: Medline; NIDDK NIH HHS [DK 43025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA070388, T32CA009207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKEW DS, 1991, ONCOGENE, V6, P1915; ASOU H, 1991, BLOOD, V77, P2031; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROWN PH, 1993, ONCOGENE, V8, P877; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; DOWNING JR, 1993, BLOOD, V81, P2860; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN PG, 1995, GENETICS, V140, P573; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Frank R, 1995, ONCOGENE, V11, P2667; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; KURIE JM, 1993, DIFFERENTIATION, V54, P115; Kurokawa M, 1996, ONCOGENE, V12, P883; KUROKAWA M, 1995, ONCOGENE, V11, P833; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MANDANAS RA, 1993, BLOOD, V82, P1838; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sawyers CL, 1997, LANCET, V349, P196, DOI 10.1016/S0140-6736(96)07535-6; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang J., 1997, Blood, V90, p245A; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247	64	41	44	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1701	1710		10.1038/sj.onc.1202459	http://dx.doi.org/10.1038/sj.onc.1202459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208431				2022-12-25	WOS:000079025000005
J	Li, L; Peterson, CA; Kanter-Smoler, G; Wei, YF; Ramagli, LS; Sunnerhagen, P; Siciliano, MJ; Legerski, RJ				Li, L; Peterson, CA; Kanter-Smoler, G; Wei, YF; Ramagli, LS; Sunnerhagen, P; Siciliano, MJ; Legerski, RJ			hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stimulates p53 accumulation	ONCOGENE			English	Article						cell cycle checkpoint; DNA damage; p53; fission yeast S-Pombe; RAD17; human homolog	DNA-DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; S-PHASE; PROTEIN-KINASE; BUDDING YEAST; ATAXIA-TELANGIECTASIA; ACCESSORY PROTEINS; REPAIR; REPLICATION	The RAD17 gene product of S. Pombe is an essential component of the checkpoint control pathway which responds to both DNA damage and disruption of replication. We have identified a human cDNA that encodes a polypeptide which is structurally conserved with the S, Pombe Rad17 protein. The human gene, designated hRAD17, predicts an encoded protein of 590 amino acids and a molecular weight of 69 kD. Amino acid sequence alignment revealed that hRad17 has 28.3% and 52.5% similarity with the S. Pombe Rad17 protein, and 21.8% identity and 45.8% similarity to the budding yeast cell cycle checkpoint protein, Rad 24. When introduced into the S. Pombe rad17 mutant, hRAD17 was able to partially revert its hydroxyurea and ionizing radiation hypersensitivity, but not its UV hypersensitivity. Permanent overexpression of the kRAD17 gene in human fibrosarcoma cells resulted in p53 activation and a significant reduction of S- and G2/M-phase cells accompanied by an accumulation of the G1-phase population, suggesting that hRAD17 may have a role in cell cycle checkpoint control, Immunostaining of HT-1080 cells transiently transfected with a hRAD17 construct confirmed the nuclear accumulation of p53, which mimics the induction caused by DNA damage. Using FISH analysis, we have mapped the hRAD17 locus to human chromosome 5q11.2.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Gothenburg, Dept Biol Mol, Lundberg Lab, SE-40530 Gothenburg, Sweden; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Gothenburg; GlaxoSmithKline; Human Genome Sciences Inc	Legerski, RJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Sunnerhagen, Per/G-1696-2012	Sunnerhagen, Per/0000-0002-0967-8729	NATIONAL CANCER INSTITUTE [R01CA076172, R29CA076172, P01CA034936, R01CA052461] Funding Source: NIH RePORTER; NCI NIH HHS [CA76172, CA52461, CA34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Barrett MT, 1996, ONCOGENE, V13, P1867; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; DAHLKVIST A, 1995, MOL GEN GENET, V246, P316, DOI 10.1007/BF00288604; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOWARD DL, 1998, GENE DEV, V12, P382; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; McAlear MA, 1996, GENETICS, V142, P65; MIURA I, 1992, CANCER RES, V52, P1322; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SIEDE W, 1994, GENETICS, V138, P271; STALLINGS RL, 1988, AM J HUM GENET, V43, P144; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	56	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1689	1699		10.1038/sj.onc.1202469	http://dx.doi.org/10.1038/sj.onc.1202469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208430				2022-12-25	WOS:000079025000004
J	Hopf, A; Schreiber, R; Mall, M; Greger, R; Kunzelmann, K				Hopf, A; Schreiber, R; Mall, M; Greger, R; Kunzelmann, K			Cystic fibrosis transmembrane conductance regulator inhibits epithelial Na+ channels carrying Liddle's syndrome mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; XENOPUS OOCYTES; CYTOSOLIC NA+; DUCT CELLS; PROTEIN; CFTR; EXPRESSION; SEQUENCE; SUBUNIT; ENAC	Epithelial Na+ channels (ENaC) are inhibited by the cystic fibrosis transmembrane conductance regulator (CFTR) upon activation by protein kinase A. It is, however, still unclear how CFTR regulates the activity of ENaC. In the present study we examined whether CFTR interacts with ENaC by interfering with the Nedd4- and ubiquitin-mediated endocytosis of ENaC. Various C-terminal mutations were introduced into the three alpha-, beta-, and gamma-subunits of the rat epithelial Na+ channel, thereby eliminating PY motifs, which are important binding domains for the ubiquitin ligase Nedd4. When expressed in Xenopus oocytes, most of the ENaC stop (alpha-H647X, beta-P565X, gamma-S608X) or point (alpha-P671A, beta-Y618A, gamma-P(624-626)A) mutations induced enhanced Na+ currents when compared with wild type alpha,beta,gamma-rENaC. However, ENaC currents formed by either of the mutant alpha-, beta-, or gamma-subunits were inhibited during activation of CFTR by forskolin (10 mu mol/l) and 3-isobutyl-1-methylxanthine (1 mmol/l), Antibodies to dynamin or ubiquitin enhanced alpha,beta,gamma-rENaC whole cell Na+ conductance but did not interfere with inhibition of ENaC by CFTR. Another mutant, beta-T592M,T593A-ENac, also showed enhanced Na+ currents, which were down-regulated by CFTR. Moreover, activation of ENaC by extracellular proteases and xCAP1 does not disturb CFTR-dependent inhibition of ENaC. We conclude that regulation of ENaC by CFTR is distal to other regulatory limbs and does not involve Nedd4-dependent ubiquitination.	Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany	University of Freiburg	Kunzelmann, K (corresponding author), Univ Freiburg, Inst Physiol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Kottgen, Anna/D-2920-2012; Mall, Marcus A./AAA-1498-2022; Schreiber, Robert/Q-7550-2019	Mall, Marcus A./0000-0002-4057-2199; Kunzelmann, Karl/0000-0002-4583-7037				Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Cui Y, 1997, P NATL ACAD SCI USA, V94, P9962, DOI 10.1073/pnas.94.18.9962; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Komwatana P, 1996, P NATL ACAD SCI USA, V93, P8107, DOI 10.1073/pnas.93.15.8107; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; STUTTS MJ, 1998, PEDIATR PULM, V17, P217; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5	25	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13894	13899		10.1074/jbc.274.20.13894	http://dx.doi.org/10.1074/jbc.274.20.13894			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318798	hybrid			2022-12-25	WOS:000080322200027
J	Arizmendi, C; Liu, S; Croniger, C; Poli, V; Friedman, JE				Arizmendi, C; Liu, S; Croniger, C; Poli, V; Friedman, JE			The transcription factor CCAAT/enhancer-binding protein beta regulates gluconeogenesis and phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ACID GLYCOPROTEIN GENE; LEUCINE-ZIPPER PROTEINS; GLUCOCORTICOID RECEPTOR; C/EBP-BETA; TARGETED DISRUPTION; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; SIGNAL-TRANSDUCTION; ENERGY HOMEOSTASIS; CELL-PROLIFERATION	CCAAT/enhancer-binding protein (C/EBP) beta and C/EBP alpha are members of the c/ebp gene family and are highly expressed in mammalian liver and adipose tissue. C/EBP alpha is essential for adipogenesis and neonatal gluconeogenesis, as shown by the C/EBP alpha knockout mouse. C/EBP beta binds to several sequences of the phosphoenolpyruvate carboxykinase (PEPCK) gene promoter with high affinity, and C/EBP beta protein is increased 200% in the livers of streptozotocin-diabetic mice, concurrent with increased PEPCK mRNA. To elucidate the role of C/EBP beta in the control of gluconeogenesis during diabetes, we studied the levels of plasma metabolites and hormones related to energy metabolism during diabetes in adult mice heterozygous and homozygous for a null mutation of the gene for C/EBP beta. We also examined the expression of PEPCK and glucose 6-phosphatase mRNAs and regulation of blood glucose, including the contribution of gluconeogenesis to blood glucose in c/ebp beta(-/-) mice. C/EBP beta was not essential to basal PEPCK mRNA levels. However, C/EBP beta deletion affected streptozotocin-diabetic response by: (a) delaying hyperglycemia, (b) preventing the increase of plasma free fatty acids, (c) limiting the full induction of PEPCK and glucose 6-phosphatase genes, and (d) preventing the increase in gluconeogenesis rate. Gel supershifts of transcription factor C/EBP alpha, bound to CRE, P3I, and AF-2 sites of the PEPCK promoter, was not increased in diabetic c/ebp beta(-/-) mouse liver nuclei, suggesting that C/EBP alpha does not substitute for C/EBP beta in the diabetic response of liver gene transcription. These results ling C/EBP beta to the metabolic and gene regulatory responses to diabetes and implicate C/EBP beta as an essential factor underlying glucocorticoid-dependent activation of PEPCK gene transcription in the intact animal.	Case Western Reserve Univ, Dept Nutr, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Sch Med, Cleveland, OH 44106 USA; Univ Salamanca, Sch Med, Dept Biochem & Mol Biol, E-37007 Salamanca, Spain; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	Case Western Reserve University; Case Western Reserve University; University of Salamanca; University of Dundee	Friedman, JE (corresponding author), Case Western Reserve Univ, Dept Nutr, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541, R29DK050272] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-50272, DK-25541, DK-07319] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; ALAM T, 1993, J BIOL CHEM, V268, P15681; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; BOSCH F, 1995, DIABETES, V44, P267, DOI 10.2337/diabetes.44.3.267; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Crosson SM, 1997, DIABETOLOGIA, V40, P1117, DOI 10.1007/s001250050796; CRYER PE, 1998, WILLIAMS TXB ENDOCRI, P939; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Friedman JE, 1997, J BIOL CHEM, V272, P31475, DOI 10.1074/jbc.272.50.31475; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HETENYI G, 1974, FED PROC, V33, pS44; Houssay BA, 1942, ENDOCRINOLOGY, V30, P884, DOI 10.1210/endo-30-6-884; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KADISH AH, 1968, CLIN CHEM, V14, P116; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; LIU JS, 1991, J BIOL CHEM, V266, P19095; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; LO S, 1970, J APPL PHYSIOL, V28, P234, DOI 10.1152/jappl.1970.28.2.234; Long CNH, 1936, J EXP MED, V63, P465, DOI 10.1084/jem.63.4.465; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; Massillon D, 1995, AM J PHYSIOL-ENDOC M, V269, pE1037, DOI 10.1152/ajpendo.1995.269.6.E1037; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; Nizielski SE, 1996, AM J PHYSIOL-REG I, V270, pR1005, DOI 10.1152/ajpregu.1996.270.5.R1005; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; TAE HJ, 1994, J BIOL CHEM, V269, P10475; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; UMEK RM, 1991, SCIENCE, V251, P283; Velho G, 1998, EUR J ENDOCRINOL, V138, P233, DOI 10.1530/eje.0.1380233; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Yang DW, 1998, ANAL BIOCHEM, V258, P315, DOI 10.1006/abio.1998.2632; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	66	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13033	13040		10.1074/jbc.274.19.13033	http://dx.doi.org/10.1074/jbc.274.19.13033			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224054	hybrid			2022-12-25	WOS:000080200400016
J	Drachman, JG; Millett, KM; Kaushansky, K				Drachman, JG; Millett, KM; Kaushansky, K			Thrombopoietin signal transduction requires functional JAK2, not TYK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MPL CYTOPLASMIC DOMAIN; C-MPL; CYTOKINE RECEPTOR; SHC PHOSPHORYLATION; GROWTH-FACTOR; DIFFERENTIATION; ACTIVATION; PATHWAY; CELLS	The Janus family of tyrosine kinases (JAKs) plays a critical role in signal transduction by members of the cytokine receptor superfamily. In response to ligand-receptor interaction, these nonreceptor tyrosine kinases are rapidly phosphorylated and activated, triggering tyrosine phosphorylation and activation of downstream signaling intermediates. Upon binding to its receptor, the product of the proto-oncogene c-mpl, thrombopoietin (TPO) activates both JAK2 and TYK2 in multiple cell lines as well as megakaryocytes and platelets. To study whether one or both of these kinases are essential for TPO signal transduction, we engineered a parental human sarcoma cell line (2C4) as well as sarcoma cell lines that are deficient in JAK2 expression (gamma 2A) or TYK2 expression (U1A) to express the wild-type Mpl receptor. The ability of TPO to induce tyrosine phosphorylation of Mpl and multiple intracellular substrates in each cell line was then examined. Our results demonstrate that JAK2-deficient cells (gamma 2A-Mpl) are unable to initiate TPO-mediated signaling. In contrast, cells that are TYK2-deficient (U1A-Mpl) are able to induce tyrosine phosphorylation of Mpl, JAK2, STAT3, and Shc as efficiently as parental cells (2C4-Mpl). These data indicate that JAK2 is an essential component of Mpl signaling and that, in the absence of JAK2, TYK2 is incapable of initiating TPO-induced tyrosine phosphorylation.	Puget Sound Blood Ctr & Program, Div Res, Seattle, WA 98104 USA; Univ Washington, Div Hematol, Seattle, WA 98195 USA	Puget Sound Blood Center; University of Washington; University of Washington Seattle	Drachman, JG (corresponding author), Puget Sound Blood Ctr & Program, Div Res, 921 Terry Ave, Seattle, WA 98104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003498] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL03498-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; Briscoe J, 1996, PHILOS T ROY SOC B, V351, P167, DOI 10.1098/rstb.1996.0013; Broudy VC, 1996, BLOOD, V88, P2026, DOI 10.1182/blood.V88.6.2026.bloodjournal8862026; COURTOIS G, 1995, J VIROL, V69, P2794, DOI 10.1128/JVI.69.5.2794-2800.1995; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; MORELLA KK, 1995, BLOOD, V86, P557, DOI 10.1182/blood.V86.2.557.bloodjournal862557; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Porteu F, 1996, MOL CELL BIOL, V16, P2473; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; Yamashita Y, 1997, EXP HEMATOL, V25, P211	30	98	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13480	13484		10.1074/jbc.274.19.13480	http://dx.doi.org/10.1074/jbc.274.19.13480			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224114	hybrid			2022-12-25	WOS:000080200400076
J	Ji, SN; Guan, R; Frank, SJ; Messina, JL				Ji, SN; Guan, R; Frank, SJ; Messina, JL			Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; RAT HEPATOMA-CELLS; RECEPTOR GENE-EXPRESSION; JAK2 TYROSINE KINASE; BINDING-PROTEIN; FACTOR-I; GH RECEPTOR; ERYTHROPOIETIN RECEPTOR; MESSENGER-RNA; IGF-I	Insulin is important for maintaining the responsive ness of the liver to growth hormone (GH). Insulin deficiency results in a decrease in liver GH receptor (GHR) expression, which can be reversed by insulin administration. In osteoblasts, continuous insulin treatment decreases the fraction of cellular GHR localized to the plasma membrane. Thus, it is not clear whether hyperinsulinemia results in an enhancement or inhibition of GH action. We asked whether continuous insulin stimulation, similar to what occurs in hyperinsulinemic states, results in GH resistance. Our present studies suggest that insulin treatment of hepatoma cells results in a time-dependent inhibition of acute GH-induced phosphorylation of STAT5B. Whereas total protein levels of JAK2 were not reduced after insulin pretreatment for 16 h, GH-induced JAK2 phosphorylation was inhibited. There was a concomitant decrease in GH binding and a reduction in immunoreactive GHR levels following pretreatment with insulin for 8-24 h. In summary, continuous insulin treatment in rat H4 hepatoma cells reduces GH binding, immunoreactive GHR, GH-induced phosphorylation of JAK2, and GH-induced tyrosine phosphorylation of STAT5B. These findings suggest that hepatic GH resistance may develop when a patient exhibits chronic hyperinsulinemia, a condition often observed in patients with obesity and in the early stage of Type 2 diabetes.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Birmingham Vet Adm Med Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Messina, JL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Volker Hall,G019,1670 Univ Blvd, Birmingham, AL 35294 USA.	messina@vh.path.uab.edu			NIDDK NIH HHS [DK40456, DK46395] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046395, R01DK040456, R29DK046395, R56DK046395] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angulo M, 1996, J PEDIATR ENDOCR MET, V9, P393; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASAKAWA K, 1986, BIOCHEM J, V238, P379, DOI 10.1042/bj2380379; BAUMANN G, 1995, EXP CLIN ENDOCR DIAB, V103, P2, DOI 10.1055/s-0029-1211322; BAXTER RC, 1980, ENDOCRINOLOGY, V107, P1176, DOI 10.1210/endo-107-4-1176; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P1312, DOI 10.1210/jc.80.4.1312; Bjorntorp P, 1997, NUTRITION, V13, P795, DOI 10.1016/S0899-9007(97)00191-3; Bjorntorp Per, 1997, Human Reproduction (Oxford), V12, P21; BLACKARD WG, 1970, DIABETES, V19, P302, DOI 10.2337/diab.19.5.302; BORNFELDT KE, 1989, J ENDOCRINOL, V122, P651, DOI 10.1677/joe.0.1220651; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Cerasi E, 1970, Horm Metab Res, V2, P302; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chen NY, 1997, ENDOCRINOLOGY, V138, P1988, DOI 10.1210/en.138.5.1988; CLAYTON KL, 1994, CLIN ENDOCRINOL, V41, P517, DOI 10.1111/j.1365-2265.1994.tb02584.x; Cuneo RC, 1998, J CLIN ENDOCR METAB, V83, P107, DOI 10.1210/jc.83.1.107; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Frick GP, 1998, ENDOCRINOLOGY, V139, P2824, DOI 10.1210/en.139.6.2824; GAVIN JR, 1982, ENDOCRINOLOGY, V110, P637, DOI 10.1210/endo-110-2-637; HanaireBroutin H, 1996, DIABETOLOGIA, V39, P1498, DOI 10.1007/s001250050604; HanaireBroutin H, 1996, DIABETES METAB, V22, P245; HO KK, 1996, ENDOCR J, V43, P63; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Kratzsch J, 1996, CLIN ENDOCRINOL, V44, P673, DOI 10.1046/j.1365-2265.1996.672494.x; KRETT NL, 1987, ENDOCRINOLOGY, V120, P401, DOI 10.1210/endo-120-1-401; LARON Z, 1995, J CLIN ENDOCR METAB, V80, P1526, DOI 10.1210/jc.80.5.1526; Leung KC, 1997, P NATL ACAD SCI USA, V94, P11381, DOI 10.1073/pnas.94.21.11381; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; LUGER A, 1990, EXP CLIN ENDOCRINOL, V95, P339, DOI 10.1055/s-0029-1210974; MAES M, 1983, DIABETES, V32, P1060, DOI 10.2337/diabetes.32.11.1060; Maheshwari H, 1996, J CLIN ENDOCR METAB, V81, P995, DOI 10.1210/jc.81.3.995; MALHERBE C, 1970, J CLIN ENDOCR METAB, V30, P535, DOI 10.1210/jcem-30-4-535; Martini JF, 1997, J BIOL CHEM, V272, P18951, DOI 10.1074/jbc.272.30.18951; MASSAGUE J, 1982, J BIOL CHEM, V257, P3958; MENON RK, 1992, J CLIN ENDOCR METAB, V74, P934, DOI 10.1210/jc.74.4.934; MENON RK, 1994, J ENDOCRINOL, V142, P453, DOI 10.1677/joe.0.1420453; MERCADO M, 1992, DIABETES, V41, P605, DOI 10.2337/diabetes.41.5.605; MESSINA JL, 1985, AM J PHYSIOL, V249, pE56, DOI 10.1152/ajpendo.1985.249.1.E56; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MESSINA JL, 1985, J BIOL CHEM, V260, P6418; Mullis PE, 1997, MOL CELL ENDOCRINOL, V131, P89, DOI 10.1016/S0303-7207(97)00096-8; Ochoa R, 1995, ARCH MED RES, V26, pS17; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; PITOT H, 1963, NATL CANCER I MONOGR, V13, P229; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; XU XO, 1995, ENDOCRINOLOGY, V136, P4551, DOI 10.1210/en.136.10.4551; Zhou YH, 1997, P NATL ACAD SCI USA, V94, P13215, DOI 10.1073/pnas.94.24.13215	57	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13434	13442		10.1074/jbc.274.19.13434	http://dx.doi.org/10.1074/jbc.274.19.13434			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224108	hybrid			2022-12-25	WOS:000080200400070
J	MacNicol, MC; MacNicol, AM				MacNicol, MC; MacNicol, AM			Nerve growth factor-stimulated B-Raf catalytic activity is refractory to inhibition by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATES MAP KINASE; NIH 3T3 CELLS; CYCLIC-AMP; PC12 CELLS; ADENOSINE-MONOPHOSPHATE; SUSTAINED ACTIVATION; SIGNAL-TRANSDUCTION; REGULATORY DOMAIN; GENE-EXPRESSION; PHOSPHORYLATION	The cAMP-dependent protein kinase (PKA) exhibits both inhibitory and stimulatory effects upon growth factor signaling mediated by the mitogen-activated protein kinase signaling pathway. PKA has been demonstrated to inhibit Raf-l-mediated cellular proliferation. PKA can both prevent Res-dependent Raf-l activation and directly inhibit Raf-l catalytic activity. In contrast to the inhibitory effect of PKA on Raf-l-dependent processes, PKA potentiates nerve growth factor-stimulated PC12 cell differentiation, a B-Raf mediated process. This potentiation, rather than inhibition, of PC12 cell differentiation is curious in light of the ability of PKA to inhibit Raf-l catalytic activity. The kinase domains of Raf-l and B-Raf are highly conserved, and it has been predicted that B-Raf catalytic activity would also be inhibited by PKA. In this study we examined the ability of PRA to regulate the kinase activity of the B-raf protooncogene, We report that nerve growth factor-stimulated B-Raf activity is not inhibited by PKA. By contrast, an N-terminally truncated, constitutively active form of B-Raf is inhibited by PKA both in vitro and in transfected PC12 cells. These results suggest that the N-terminal regulatory domain interferes with the ability of PRA to modulate B-Raf catalytic activity and provide an explanation for the observed resistance of B-Raf-dependent processes to PKA inhibition.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	MacNicol, AM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	amacnico@medicine.bsd.uchicago.edu			NCI NIH HHS [CA70846] Funding Source: Medline; NIDDK NIH HHS [P60 DK20595-18] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLY S, 1989, CANCER RES, V49, P5650; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; EYCHENE A, 1992, ONCOGENE, V7, P1315; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MacNicol MC, 1997, GENE, V196, P25, DOI 10.1016/S0378-1119(97)00171-6; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; PURUSHOTHAM KR, 1994, BIOCHEM BIOPH RES CO, V202, P743, DOI 10.1006/bbrc.1994.1993; RAPP UR, 1991, ONCOGENE, V6, P495; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STORM SM, 1990, ONCOGENE, V5, P345; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13193	13197		10.1074/jbc.274.19.13193	http://dx.doi.org/10.1074/jbc.274.19.13193			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224075	hybrid			2022-12-25	WOS:000080200400037
J	Tomlinson, MG; Kurosaki, T; Berson, AE; Fujii, GH; Johnston, JK; Bolen, JB				Tomlinson, MG; Kurosaki, T; Berson, AE; Fujii, GH; Johnston, JK; Bolen, JB			Reconstitution of Btk signaling by the atypical Tec family tyrosine kinases Bmx and Txk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE C-GAMMA-2; PREDOMINANT EXPRESSION; MEDIATED ACTIVATION; REGULATED KINASE; GENE; DOMAIN; PHOSPHORYLATION; IDENTIFICATION	Bruton's tyrosine kinase (Btk) is mutated in X-linked agammaglobulinemia patients and plays an essential role in B cell receptor signal transduction, Btk is a member of the Tec family of nonreceptor protein-tyrosine kinases that includes Bmx, Itk, Tec, and Txk. Cell lines deficient for Btk are impaired in phospholipase C-gamma 2 (PLC gamma 2)-dependent signaling. Itk and Tec have recently been shown to reconstitute PLC gamma 2-dependent signaling in Btk-deficient human cells, but it is not knows whether the atypical Tec family members, Bmx and Txk, can reconstitute function. Here we reconstitute Btk-deficient DT40 B cells with Bmx and Txk to compare their function with other Tec kinases, We show that in common with Itk and Tee, Bmx reconstituted PLC gamma 2-dependent responses including calcium mobilization, extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activation, and apoptosis, Txk also restored PLC gamma 2/calcium signaling but, unlike other Tec kinases, functioned in a phosphatidylinositol 3-kinase-independent manner and failed to reconstitute apoptosis. These results are consistent with a common role for Tec kinases as amplifiers of PLC gamma 2-dependent signal transduction, but suggest that the pleckstrin homology domain of Tec kinases, absent in Txk, is essential for apoptosis.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA; Kansai Med Univ, Dept Mol Genet, Moriguchi, Osaka 570, Japan	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Kansai Medical University	Tomlinson, MG (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Tomlinson, Michael/0000-0002-1189-0091				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, P1; Debnath J, 1999, MOL CELL BIOL, V19, P1498; Desiderio S, 1997, CURR OPIN IMMUNOL, V9, P534, DOI 10.1016/S0952-7915(97)80107-0; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Lu YL, 1998, J IMMUNOL, V161, P5404; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MANO H, 1995, BLOOD, V85, P343; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Satterthwaite AB, 1997, P NATL ACAD SCI USA, V94, P13152, DOI 10.1073/pnas.94.24.13152; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SOMMERS CL, 1995, ONCOGENE, V11, P245; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952-7915(94)90151-1; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	47	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13577	13585		10.1074/jbc.274.19.13577	http://dx.doi.org/10.1074/jbc.274.19.13577			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224128	hybrid			2022-12-25	WOS:000080200400090
J	He, C; Zhang, HL; Mirshahi, T; Logothetis, DE				He, C; Zhang, HL; Mirshahi, T; Logothetis, DE			Identification of a potassium channel site that interacts with G protein beta gamma subunits to mediate agonist-induced signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+-CHANNEL; GTP-BINDING PROTEINS; INWARD RECTIFIER; I-KACH; FUNCTIONAL EXPRESSION; ACTIVATION; CLONING; OOCYTES; CELLS; GIRK1	Activation of heterotrimeric GTP-binding (G) proteins by their coupled receptors, causes dissociation of the G protein alpha and beta gamma subunits, G(beta gamma) Subunits interact directly with G protein-gated inwardly rectifying K+ (GIRK) channels to stimulate their activity. In addition, free G(beta gamma) subunits, resulting from agonist-independent dissociation of G protein subunits, can account for a major component of the basal channel activity. Using a series of chimeric constructs between GIRK4 and a G(beta gamma)-insensitive K+ channel, IRK1, we have identified a critical site of interaction of GIRK with G(beta gamma). Mutation of Leu(339) to Glu within this site impaired agonist-induced sensitivity and decreased binding to G(beta gamma), without removing the G(beta gamma) contribution to basal currents. Mutation of the corresponding residue in GIRK1 (Leu(333)) resulted in a similar phenotype, Both the GIRK1 and GIRK4 subunits contributed equally to the agonist-induced sensitivity of the heteromultimeric channel. Thus, we have identified a channel site that interacts specifically with G(beta gamma) subunits released through receptor stimulation.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Logothetis, DE (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54185, HL07824] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Cohen NA, 1996, J BIOL CHEM, V271, P32301, DOI 10.1074/jbc.271.50.32301; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Inanobe A, 1995, BIOCHEM BIOPH RES CO, V217, P1238, DOI 10.1006/bbrc.1995.2901; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Kubo Y, 1996, BIOCHEM BIOPH RES CO, V227, P240, DOI 10.1006/bbrc.1996.1496; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; SUI JI, 1999, IN PRESS ADV 2 MESSE; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597	32	99	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12517	12524		10.1074/jbc.274.18.12517	http://dx.doi.org/10.1074/jbc.274.18.12517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212228	hybrid			2022-12-25	WOS:000080056800048
J	Kitchens, ME; Forsthoefel, AM; Rafique, Z; Spencer, HT; Berger, FG				Kitchens, ME; Forsthoefel, AM; Rafique, Z; Spencer, HT; Berger, FG			Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization - Implications for autoregulation of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; CELLS; BINDING; MECHANISM; ACID; 5-FLUOROURACIL; IDENTIFICATION; RESIDUE-33; SYNTHETASE; CANCER	Thymidylate synthase (TS) is indispensable in the de novo synthesis of dTMP. As such, it has been an important target at which anti-neoplastic drugs are directed. The fluoropyrimidines B-fluorouracil and 5-fluoro-2'-deoxyuridine are cytotoxic as a consequence of inhibition of TS by the metabolite 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP), This inhibition occurs through formation of a stable ternary complex among the enzyme, the nucleotide analog, and the co-substrate N-5,N-10-methylenetetrahydrofolate. Numerous studies have shown that cellular concentrations of TS undergo about a 2-4-fold induction following treatment with TS inhibitors. An extensive body of in vitro studies has led to the proposal that this induction occurs because of relief of the translational repression brought on by the binding of TS to its own mRNA. In the current study, we have tested several predictions of this autoregulatory translation model. In contrast to expectations, we find that fluoropyrimidines do not cause a change in the extent of ribosome binding to TS mRNA. Furthermore, mutations within the mRNA that abolish its ability to bind TS have no effect on the induction. Finally, enzyme turnover measurements show that the induction is associated with an increase in the stability of the TS polypeptide, Our results, in total, indicate that enzyme stabilization, rather than translational derepression, is the primary mechanism of TS induction by fluoropyrimidines and call into question the general applicability of the autoregulatory translation model.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; S Carolina Canc Ctr, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Kitchens, ME (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.							Ardalan B, 1980, Adv Pharmacol Chemother, V17, P289, DOI 10.1016/S1054-3589(08)60013-7; BARBOUR KW, 1992, MOL PHARMACOL, V42, P242; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; Chu E, 1996, BIOESSAYS, V18, P191, DOI 10.1002/bies.950180306; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1993, MOL PHARMACOL, V43, P527; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CISNEROS RJ, 1990, ANAL BIOCHEM, V186, P202, DOI 10.1016/0003-2697(90)90067-J; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; JOHANNES G, 1992, J BIOL CHEM, V267, P10108; KEYOMARSI K, 1988, J BIOL CHEM, V263, P14402; KEYOMARSI K, 1993, J BIOL CHEM, V268, P15142; MOHSEN AWA, 1995, BIOCHEMISTRY-US, V34, P1669; NUSSBAUM RL, 1985, AM J HUM GENET, V37, P1192; PALACIOS R, 1972, J BIOL CHEM, V247, P2316; Reilly RT, 1997, ARCH BIOCHEM BIOPHYS, V342, P338, DOI 10.1006/abbi.1997.0116; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SPEARS CP, 1982, CANCER RES, V42, P450; SWAIN SM, 1989, J CLIN ONCOL, V7, P890, DOI 10.1200/JCO.1989.7.7.890; Takemura Y, 1997, ANTI-CANCER DRUG, V8, P3, DOI 10.1097/00001813-199701000-00001; Touroutoglou N, 1996, CLIN CANCER RES, V2, P227; WASHTIEN WL, 1984, MOL PHARMACOL, V25, P171	22	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12544	12547		10.1074/jbc.274.18.12544	http://dx.doi.org/10.1074/jbc.274.18.12544			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212232	hybrid			2022-12-25	WOS:000080056800052
J	Lu, WQ; Luo, YD; Kan, MK; McKeehan, WL				Lu, WQ; Luo, YD; Kan, MK; McKeehan, WL			Fibroblast growth factor-10 - A second candidate stromal to epithelial cell andromedin in prostate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; MESSENGER-RNA; FACTOR FAMILY; HEPARAN-SULFATE; EXPRESSION; RAT; SPECIFICITY; BINDING; ACTIVATION; PROTEIN	Fibroblast growth factor (FGF)-10, a homologue of FGF-7, is expressed significantly in normal rat prostate tissue, well differentiated rat prostate tumors with an epithelial and stromal compartment and only in derived prostate stromal cells in culture. Similar to FGF-7, recombinant rat FGF-10 was a specific mitogen for prostate epithelial cells. In contrast to FGF-7 which is widely expressed among stromal cells in tissues, the expression of FGF-10 correlated with the presence of stromal cells of muscle origin. Radioreceptor binding assays and covalent cross-linking analysis revealed that FGF-10 binds with an affinity equal to FGF-7 to resident epithelial cell receptor, FGFR2IIIb, but unlike FGF-7 also binds the IIIb splice variant of FGFR1. Analysis of mRNA expression by RNase protection revealed that, similar to FGF-7, the expression of FGF-10 was responsive to androgen in stromal cells from normal prostate and nonmalignant differentiated tumors. Although FGF-10 cDNA exhibits a signal sequence for secretion, cultured stromal cells exhibit strictly a cell-associated FGF-10 antigen that correlates with an alternately translated intracellular isoform, FGF-10 requires 1.4 times higher NaCl for elution from immobilized heparin than does FGF-7 and binds to four times the number of sites on the pericellular matrix of epithelial cells. The results show that prostate stromal cell-derived FGF-10, like FGF-7, exhibits the properties of an andromedin which may indirectly mediate control of epithelial cell growth and function by androgen, Although FGF-10 and FGF-7 bind and activate the same resident epithelial cell receptor (FGFR2IIIb), differences in cell type of origin, compartmentation by alternate translation, the affinity for FGFR1IIIb, and access to FGFR by differential interaction with pericellular matrix heparan sulfate suggest they may play both independent and compensatory roles in prostate homeostasis.	Texas A&M Univ, Inst Biosci & Technol, Ctr Canc Biol & Nutr, Hlth Sci Ctr, Houston, TX 77080 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77080 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System	McKeehan, WL (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Canc Biol & Nutr, Hlth Sci Ctr, 2121 W Holcombe Blvd, Houston, TX 77080 USA.	wmckeeha@ibt.tamu.edu			NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK40739, DK35310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310, R01DK040739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; Feng SJ, 1997, CANCER RES, V57, P5369; FUKABORI Y, 1994, IN VITRO CELL DEV-AN, V30A, P745; Gerdes MJ, 1996, ENDOCRINOLOGY, V137, P864, DOI 10.1210/en.137.3.864; Hattori Y, 1997, MOL BRAIN RES, V47, P139, DOI 10.1016/S0169-328X(97)00044-2; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; ISAACS JT, 1987, CURRENT CONCEPTS APP, P573; Jang JH, 1997, IN VITRO CELL DEV-AN, V33, P819; KAN M, 1991, METHOD ENZYMOL, V198, P158; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN M, 1992, IN VITRO CELL DEV-AN, V28A, P515; KAN M, 1999, IN PRESS J BIOL CHEM; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Luo YD, 1998, BIOCHEMISTRY-US, V37, P16506, DOI 10.1021/bi9816599; MANSSON PE, 1989, CANCER RES, V49, P2485; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; XU JM, 1992, J BIOL CHEM, V267, P17792; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	27	154	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12827	12834		10.1074/jbc.274.18.12827	http://dx.doi.org/10.1074/jbc.274.18.12827			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212269	hybrid			2022-12-25	WOS:000080056800089
J	Maechler, P; Kennedy, ED; Sebo, E; Valeva, A; Pozzan, T; Wollheim, CB				Maechler, P; Kennedy, ED; Sebo, E; Valeva, A; Pozzan, T; Wollheim, CB			Secretagogues modulate the calcium concentration in the endoplasmic reticulum of insulin-secreting cells - Studies in aequorin-expressing intact and permeabilized INS-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; INDUCED CA2+ RELEASE; HELA-CELLS; IN-SITU; INOSITOL 1,4,5-TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; FLUORESCENT INDICATORS; CYTOPLASMIC CA2+; INTERNAL STORE; CYTOSOLIC CA2+	The precise regulation of the Ca2+ concentration in the endoplasmic reticulum ([Ca2+](er)) is important for protein processing and signal transduction, In the pancreatic beta-cell, dysregulation of [Ca2+](er) may cause impaired insulin secretion. The Ca2+-sensitive photoprotein aequorin mutated to lower its Ca2+ affinity was stably expressed in the endoplasmic reticulum (ER) of rat insulinoma INS-1 cells. The steady state [Ca2+](er) was 267 +/- 9 mu M. Both the Ca2+-ATPase inhibitor cyclopiazonic acid and 4-chloro-m-cresol, an activator of ryanodine receptors, caused an almost complete emptying of ER Ca2+. The inositol 1,4,5-trisphosphate generating agonists, carbachol, and ATP, reduced [Ca2+](er) by 20-25%, Insulin secretagogues that raise cytosolic [Ca2+] by membrane depolarization increased [Ca2+](er) in the potency order K+ much greater than glucose > leucine, paralleling their actions in the cytosolic compartment, Glucose, which augmented [Ca2+](er) by about 25%, potentiated the Ca2+-mobilizing effect of carbachol, explaining the corresponding observation in cytosolic [Ca2+]. The filling of ER Ca2+ by glucose is not directly mediated by ATP production as shown by the continuous monitoring of cytosolic ATP in luciferase expressing cells. Both glucose and K+ increase [Ca2+](er), but only the former generated whereas the latter consumed ATP, Nonetheless, drastic lowering of cellular ATP with a mitochondrial uncoupler resulted in a marked decrease in [Ca2+](er), emphasizing the requirement for mitochondrially derived ATP above a critical threshold concentration. Using alpha-toxin permeabilized cells in the presence of ATP, glucose 6-phosphate did not change [Ca2+](er), invalidating the hypothesis that glucose acts through this metabolite. Therefore, insulin secretagogues that primarily stimulate Ca2+ influx, elevate [Ca2+](er) to ensure beta-cell homeostasis.	Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem & Expt Diabetol, CH-1211 Geneva 4, Switzerland; Johannes Gutenberg Univ Mainz, Hochhaus, Inst Med Microbiol, D-55101 Mainz, Germany; Univ Padua, Natl Ctr Biomembranes, Dept Biomed Sci, I-35121 Padua, Italy	University of Geneva; Johannes Gutenberg University of Mainz; University of Padua	Wollheim, CB (corresponding author), Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem & Expt Diabetol, CH-1211 Geneva 4, Switzerland.	claes.wollheim@medecine.unige.ch		Maechler, Pierre/0000-0002-2005-1433				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; Chen W, 1996, J BIOL CHEM, V271, P7398, DOI 10.1074/jbc.271.13.7398; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Detimary P, 1998, BIOCHEM J, V333, P269, DOI 10.1042/bj3330269; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; Guest PC, 1997, BIOCHEM J, V323, P445, DOI 10.1042/bj3230445; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; GYLFE E, 1991, PFLUG ARCH EUR J PHY, V419, P639, DOI 10.1007/BF00370308; GYLFE E, 1988, J BIOL CHEM, V263, P13750; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HAMAKAWA N, 1995, CELL CALCIUM, V17, P21, DOI 10.1016/0143-4160(95)90099-3; HELLMAN B, 1986, BIOCHEM INT, V13, P383; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kendall JM, 1996, BIOCHEM J, V318, P383, DOI 10.1042/bj3180383; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V187, P1091, DOI 10.1016/0006-291X(92)91309-E; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Kennedy ED, 1998, DIABETES METAB, V24, P15; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Li GD, 1996, CELL CALCIUM, V19, P535, DOI 10.1016/S0143-4160(96)90063-9; LI GD, 1991, J BIOL CHEM, V266, P3449; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Miura Y, 1997, J PHYSIOL-LONDON, V503, P387, DOI 10.1111/j.1469-7793.1997.387bh.x; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROE MW, 1994, J BIOL CHEM, V269, P18279; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Shimomura O, 1997, BIOCHEM J, V326, P297, DOI 10.1042/bj3260297; Tengholm A, 1998, DIABETES, V47, P1224, DOI 10.2337/diabetes.47.8.1224; THELER JM, 1992, J BIOL CHEM, V267, P18110; TSE FW, 1994, P NATL ACAD SCI USA, V85, P1091; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; WILLMOTT NJ, 1995, FEBS LETT, V371, P99, DOI 10.1016/0014-5793(95)00848-4; WOLF BA, 1988, AM J PHYSIOL, V254, pE121, DOI 10.1152/ajpendo.1988.254.2.E121; WOLF BA, 1986, J BIOL CHEM, V261, P6284; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Zucchi R, 1997, PHARMACOL REV, V49, P1	59	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12583	12592		10.1074/jbc.274.18.12583	http://dx.doi.org/10.1074/jbc.274.18.12583			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212237	hybrid			2022-12-25	WOS:000080056800057
J	Malhotra, R; Brosius, FC				Malhotra, R; Brosius, FC			Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; PROGRAMMED CELL-DEATH; CYTOCHROME-C; CASPASE INHIBITOR; POTENTIAL ROLE; HEART-FAILURE; ELEGANS CED-4; BCL-2; MITOCHONDRIA; EXPRESSION	Myocardial ischemia/reperfusion is well recognized as a major cause of apoptotic or necrotic cell death. Neonatal rat cardiac myocytes are intrinsically resistant to hypoxia-induced apoptosis, suggesting a protective role of energy-generating substrates. In the present report, a model of sustained hypoxia of primary cultures of Percoll-enriched neonatal rat cardiac myocytes was used to study specifically the modulatory role of extracellular glucose and other intermediary substrates of energy metabolism (pyruvate, lactate, propionate) as well as glycolytic inhibitors (a-deoxyglucose and iodoacetate) on the induction and maintenance of apoptosis. In the absence of glucose and other substrates, hypoxia (5% CO2 and 95% N-2) caused apoptosis in 14% of cardiac myocytes at 3 h and in 22% of cells at 6-8 h of hypoxia, as revealed by sarcolemmal membrane blebbing, nuclear fragmentation, and chromatin condensation (Hoechst staining), terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining, and DNA laddering, This was accompanied by translocation of cytochrome c from the mitochondria to the cytosol and cleavage of the death substrate poly(ADP-ribose) polymerase, Cleavage of poly(ADP-ribose) polymerase and DNA laddering were prevented by preincubation with the caspase inhibitors benzyloxycarbonyl-val-Ala-Asp-fluoromethyl ketone (zVAD-fmk) and benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone (zDEVD-fmk), indicating activation of caspases in the apoptotic process. The caspase inhibitor zDEVD-fmk also partially inhibited cytochrome c translocation. The presence of as little as 1 mM glucose, but not pyruvate, lactate, or propionate, before hypoxia prevented apoptosis, Inhibiting glycolysis by 2-deoxyglucose or iodoacetate, in the presence of glucose, reversed the protective effect of glucose. This study demonstrates that glycolysis of extracellular glucose, and not other metabolic pathways, protects cardiac myocytes from hypoxic injury and subsequent apoptosis.	Univ Michigan, Med Ctr, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Brosius, FC (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Nephrol, 1560 MSRB 2, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060156] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL060156] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Anversa P, 1998, CIRC RES, V82, P1231, DOI 10.1161/01.RES.82.11.1231; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEKHEIT S, 1993, J AM COLL CARDIOL, V22, P1214, DOI 10.1016/0735-1097(93)90440-C; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bossenmeyer C, 1998, BRAIN RES, V787, P107, DOI 10.1016/S0006-8993(97)01527-8; Brosius FC, 1997, J MOL CELL CARDIOL, V29, P1675; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Chihab R, 1998, J NEUROCHEM, V71, P1177; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Doenst T, 1998, CIRCULATION, V97, P2454, DOI 10.1161/01.CIR.97.24.2454; EBERLI FR, 1991, CIRC RES, V68, P466, DOI 10.1161/01.RES.68.2.466; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; HEINEMAN FW, 1992, HEART CARDIOVASCULAR, P1641; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH G, 1995, AM J PATHOL, V146, P1325; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kajstura J, 1996, LAB INVEST, V74, P86; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Li ZH, 1997, AM J PHYSIOL-HEART C, V272, pH2313, DOI 10.1152/ajpheart.1997.272.5.H2313; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; OWEN P, 1990, CIRC RES, V66, P344, DOI 10.1161/01.RES.66.2.344; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Saraste A, 1997, CIRCULATION, V95, P320; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Sharov VG, 1996, AM J PATHOL, V148, P141; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUN DQ, 1994, CIRCULATION, V89, P793, DOI 10.1161/01.CIR.89.2.793; TAHILIANI AG, 1992, HEART CARDIOVASCULAR, P1599; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; TEIGER E, 1996, J CLIN INVEST, V96, P2247; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WHEELER TJ, 1994, BBA-BIOMEMBRANES, V1196, P191, DOI 10.1016/0005-2736(94)00211-8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Yue TL, 1998, CIRC RES, V82, P166; Yue TL, 1998, J MOL CELL CARDIOL, V30, P495, DOI 10.1006/jmcc.1997.0614; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	63	183	196	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12567	12575		10.1074/jbc.274.18.12567	http://dx.doi.org/10.1074/jbc.274.18.12567			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212235	hybrid			2022-12-25	WOS:000080056800055
J	Ogawa, H; Takusagawa, F; Wakaki, K; Kishi, H; Eskandarian, MR; Kobayashi, M; Date, T; Huh, NH; Pitot, HC				Ogawa, H; Takusagawa, F; Wakaki, K; Kishi, H; Eskandarian, MR; Kobayashi, M; Date, T; Huh, NH; Pitot, HC			Rat liver serine dehydratase - Bacterial expression and two folding domains as revealed by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC THREONINE DEAMINASE; GLYCINE N-METHYLTRANSFERASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; ASPARTIC-ACID; MESSENGER-RNA; ACTIVE-SITE; ENZYMES; PROTEIN	A pCW vector harboring rat liver serine dehydratase cDNA was expressed in Escherichia coli, The expressed level was about 5-fold higher in E. coli BL21 than in JM109 cell extract; the former lacked two kinds of proteases. Immunoblot analysis revealed the occurrence of a derivative other than serine dehydratase in the JM109 cell extract. The recombinant enzyme was purified to homogeneity. Staphylococcus aureus V8 protease and trypsin cleaved the enzyme at Glu-206 and Lys-220, respectively, with a concomitant loss of enzyme activity. Spectrophotometrically, the nicked enzyme showed a similar to 50% reduced capacity for binding of the coenzyme pyridoxal phosphate and no spectral change of circular dichroism in the region at 300-480 nm, whereas circular dichroism spectra of both enzymes in the far-UV region were similar, suggesting that proteolysis impairs the coenzyme binding without an accompanying gross change of the secondary structure. Whereas the nicked enzyme behaved like the intact enzyme on Sephadex G-75 column chromatography, it was dissociated into two fragments on the column containing 6 M urea. Upon the removal of urea, both fragments spontaneously refolded. These results suggest that serine dehydratase consists of two folding domains connected by a region that is very susceptible to proteases.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Biochem, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Pathol, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Immunol, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Internal Med, Toyama 9300194, Japan; Univ Kansas, Dept Biochem, Lawrence, KS 66045 USA; Kanazawa Med Univ, Dept Biochem, Uchinada, Ishikawa 9200293, Japan; Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Toyama; University of Toyama; University of Toyama; University of Toyama; University of Kansas; Kanazawa Medical University; University of Wisconsin System; University of Wisconsin Madison	Ogawa, H (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Biochem, Toyama 9300194, Japan.	hogawa@ms.toyama-mpu.ac.jp	HUH, Nam-ho/B-1613-2011					ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ANTSON AA, 1993, BIOCHEMISTRY-US, V32, P4195, DOI 10.1021/bi00067a006; ARME SA, 1986, BIOCHEMISTRY-US, V25, P3118; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BORISOV VV, 1980, NATURE, V284, P189, DOI 10.1038/284189a0; BORNAES C, 1992, GENETICS, V131, P531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Clausen T, 1996, J MOL BIOL, V262, P202, DOI 10.1006/jmbi.1996.0508; DATTA P, 1987, P NATL ACAD SCI USA, V84, P393, DOI 10.1073/pnas.84.2.393; Dunlop DS, 1997, BIOCHEM BIOPH RES CO, V235, P26, DOI 10.1006/bbrc.1997.6724; DUPOURQUE D, 1966, J BIOL CHEM, V241, P1233; EISENSTEIN E, 1995, BIOCHEMISTRY-US, V34, P9403, DOI 10.1021/bi00029a016; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GOMI T, 1989, J BIOL CHEM, V264, P16138; GRABOWSKI R, 1993, TRENDS BIOCHEM SCI, V18, P297, DOI 10.1016/0968-0004(93)90040-T; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Harlow E., 1988, ANTIBODIES LAB MANUA; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; HYDE CC, 1988, J BIOL CHEM, V263, P17857; INOUE H, 1971, J BIOL CHEM, V246, P2626; Isupov MN, 1998, J MOL BIOL, V276, P603, DOI 10.1006/jmbi.1997.1561; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; LABOW R, 1966, J BIOL CHEM, V241, P1239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONCINI R, 1990, J BIOCHEM BIOPH METH, V20, P97, DOI 10.1016/0165-022X(90)90068-N; LEONCINI R, 1990, ITAL J BIOCHEM, V39, P228; Maniatis T., 1982, MOL CLONING LAB MANU; MARCEAU M, 1988, J BIOL CHEM, V263, P16934; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; NAKAGAWA H, 1967, BIOCHEM BIOPH RES CO, V28, P359, DOI 10.1016/0006-291X(67)90318-X; NAKAGAWA H, 1969, J BIOCHEM-TOKYO, V66, P669; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; OBMOLOVA G, 1990, J MOL BIOL, V214, P641, DOI 10.1016/0022-2836(90)90282-Q; OGAWA H, 1990, J BIOL CHEM, V265, P14407; OGAWA H, 1988, P NATL ACAD SCI USA, V85, P5809, DOI 10.1073/pnas.85.16.5809; OGAWA H, 1989, J BIOL CHEM, V264, P15818; Ogawa H, 1997, BIOCHEM J, V327, P407, DOI 10.1042/bj3270407; OGAWA H, 1989, BIOCHIM BIOPHYS ACTA, V996, P139, DOI 10.1016/0167-4838(89)90106-4; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; SAMACH A, 1991, P NATL ACAD SCI USA, V88, P2678, DOI 10.1073/pnas.88.7.2678; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SIMON D, 1973, BIOCHIM BIOPHYS ACTA, V321, P361, DOI 10.1016/0005-2744(73)90091-0; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; TONG H, 1993, PROTEIN EXPRES PURIF, V4, P438, DOI 10.1006/prep.1993.1058; Wetlaufer D B, 1981, Adv Protein Chem, V34, P61, DOI 10.1016/S0065-3233(08)60518-5	48	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12855	12860		10.1074/jbc.274.18.12855	http://dx.doi.org/10.1074/jbc.274.18.12855			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212273	hybrid			2022-12-25	WOS:000080056800093
J	Rovere, C; Luis, J; Lissitzky, JC; Basak, A; Marvaldi, J; Chretien, M; Seidah, NG				Rovere, C; Luis, J; Lissitzky, JC; Basak, A; Marvaldi, J; Chretien, M; Seidah, NG			The RGD motif and the C-terminal segment of proprotein convertase 1 are critical for its cellular trafficking but not for its intracellular binding to integrin alpha(5)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASES; CHROMOSOMAL LOCALIZATION; SECRETORY PATHWAY; FURIN; CELLS; PROTEINS; PC1; BIOSYNTHESIS; CLEAVAGE; IDENTIFICATION	Cellular trafficking of subtilisin/kexin-like precursor convertases (PCs) may be regulated by a number of motifs, some of which are present within the P-domain and in the C-terminal sequence. Six of the seven known PCs contain a conserved RGD sequence within the P domain. In order to investigate the functional importance of this motif, we generated mutants of PC1 that contain a Myc tag epitope inserted between the prosegment and the catalytic subunit. Cellular expression of vaccinia virus recombinants revealed that this tag did not seem to influence the autocatalytic conversion of proPC1 into PC1 or its bioactivity, The two PC1 variants produced possess either the wild type RGD sequence or its RGE mutant. Stable transfectants of these variants in AtT20 cells revealed that similar to the wild type enzyme, PC1-RGD-Myc is sorted to secretory granules. In contrast, PC1-RGE-Mye exits the cell via the constitutive secretory pathway. In vitro, a 14-mer peptide spanning the RGD sequence of PC1, but not its RGE mutant, binds to cell surface vitronectin-binding integrins of Chinese hamster ovary cells. However, within the endoplasmic reticulum and in an RGD-independent fashion, integrin alpha(5)beta(1), associates primarily with the zymogens proPC1, proPC1-Delta C (missing the C-terminal 137 residues), as well as proPC(2). Thus, the observed discrimination between the secretion routes of PC1-RGD and PC1-RGE does not implicate integrins such as alpha(5)beta(1).	Univ Montreal, Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Clin Res Inst Montreal, Lab Mol Neuroendocrinol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Clin Res Inst Montreal, Prot Engn Network Ctr Excellence, Montreal, PQ H2W 1R7, Canada; CNRS, Biochim Cellulaire Lab, Unite Propre Rech Enseignement Super Associee 603, Fac Pharm, F-13385 Marseille 05, France; Hop St Marguerite, INSERM, U387, F-13009 Marseille 29, France	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Seidah, NG (corresponding author), Univ Montreal, Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	seidahn@irem.qc.ca	LUIS, José/M-3071-2013; Seidah, Nabil/I-3596-2013; Rovere-Jovene, Carole/O-4557-2016	Seidah, Nabil/0000-0001-6503-9342; Rovere-Jovene, Carole/0000-0001-9400-7972; CHRETIEN, Michel/0000-0002-8588-4460				BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENJANNET S, 1995, FEBS LETT, V362, P151, DOI 10.1016/0014-5793(95)00228-2; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1988, ENDOCRINOLOGY, V123, P874, DOI 10.1210/endo-123-2-874; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; Lipkind GM, 1998, P NATL ACAD SCI USA, V95, P7310, DOI 10.1073/pnas.95.13.7310; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Lusson J, 1997, BIOCHEM J, V326, P737, DOI 10.1042/bj3260737; Matter ML, 1998, J CELL BIOL, V141, P1019, DOI 10.1083/jcb.141.4.1019; MILGRAM SL, 1994, J CELL SCI, V107, P737; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SEIDAH NG, 1998, MOL B INT U, V2, P49; Steiner DF, 1996, DIABETES METAB, V22, P94; Taylor NA, 1997, BIOCHEM J, V321, P367, DOI 10.1042/bj3210367; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zhong M, 1996, FEBS LETT, V396, P31, DOI 10.1016/0014-5793(96)01059-9; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702	44	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12461	12467		10.1074/jbc.274.18.12461	http://dx.doi.org/10.1074/jbc.274.18.12461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212221	hybrid			2022-12-25	WOS:000080056800041
J	Tjernberg, LO; Callaway, DJE; Tjernberg, A; Hahne, S; Lilliehook, C; Terenius, L; Thyberg, J; Nordstedt, C				Tjernberg, LO; Callaway, DJE; Tjernberg, A; Hahne, S; Lilliehook, C; Terenius, L; Thyberg, J; Nordstedt, C			A molecular model of Alzheimer amyloid beta-peptide fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN INTERACTIONS; IN-VITRO; SECONDARY STRUCTURE; PROTEIN; DISEASE; AGGREGATION; AMYLOIDOGENICITY; NEUROTOXICITY; FRAGMENTS	Polymerization of the amyloid beta (A beta) peptide into protease-resistant fibrils is a significant step in the pathogenesis of Alzheimer's disease. It has not been possible to obtain detailed structural information about this process with conventional techniques because the peptide has limited solubility and does not form crystals. In this work, we present experimental results leading to a molecular level model for fibril formation. Systematically selected A beta-fragments containing the A beta(16-20) sequence, previously shown essential for A beta-A beta binding, were incubated in a physiological buffer. Electron microscopy revealed that the shortest fibril-forming sequence was A beta(14-23). Substitutions in this decapeptide impaired fibril formation and deletion of the decapeptide from A beta(1-42) inhibited fibril formation completely. All studied peptides that formed fibrils also formed stable dimers and/or tetramers, Molecular modeling of A beta(14-23) oligomers in an antiparallel beta-sheet conformation displayed favorable hydrophobic interactions stabilized by salt bridges between all charged residues. We propose that this decapeptide sequence forms the core of A beta-fibrils, with the hydrophobic C terminus folding over this core. The identification of this fundamental sequence and the implied molecular model could facilitate the design of potential inhibitors of amyloidogenesis.	Karolinska Hosp, Dept Clin Neurosci, Sect Drug Dependence Res, Lab Biochem & Mol Pharmacol, S-17176 Stockholm, Sweden; Picower Inst Med Res, Manhasset, NY 11030 USA; Pharmacia & Upjohn Inc, Dept Struct Chem, Mass Spectrometr Sect, S-11287 Stockholm, Sweden; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Northwell Health; Pfizer; Pharmacia Corporation; Karolinska Institutet	Tjernberg, LO (corresponding author), Karolinska Hosp, Dept Clin Neurosci, Sect Drug Dependence Res, Lab Biochem & Mol Pharmacol, CMM L8-01, S-17176 Stockholm, Sweden.	Lars.Tjernberg@cmm.ki.se						CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; FRASER PE, 1991, J NEUROSCI RES, V28, P474, DOI 10.1002/jnr.490280404; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Hughes SR, 1996, P NATL ACAD SCI USA, V93, P2065, DOI 10.1073/pnas.93.5.2065; Inouye H, 1996, CIBA F SYMP, V199, P22; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lundberg KM, 1997, CHEM BIOL, V4, P345, DOI 10.1016/S1074-5521(97)90125-3; MAURY CPJ, 1994, LAB INVEST, V70, P558; Naiki H, 1996, LAB INVEST, V74, P374; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1997, J BIOL CHEM, V272, P12601, DOI 10.1074/jbc.272.19.12601; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205; ZHANG SG, 1994, BIOPOLYMERS, V34, P663, DOI 10.1002/bip.360340508	35	325	348	0	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12619	12625		10.1074/jbc.274.18.12619	http://dx.doi.org/10.1074/jbc.274.18.12619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212241	hybrid			2022-12-25	WOS:000080056800061
J	Walker, D; Bichet, D; Geib, S; Mori, E; Cornet, V; Snutch, TP; Mori, Y; De Waard, M				Walker, D; Bichet, D; Geib, S; Mori, E; Cornet, V; Snutch, TP; Mori, Y; De Waard, M			A new beta subtype-specific interaction in alpha(1A) subunit controls P/Q-type Ca2+ channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; AMINO-TERMINUS; RAT-BRAIN; IDENTIFICATION; HETEROGENEITY; CLONING; BINDING; DOMAIN	The cytoplasmic beta subunit of voltage-dependent calcium channels modulates channel properties in a subtype-specific manner and is important in channel targeting. A high affinity interaction site between the alpha(1) interaction domain (AID) in the I-II cytoplasmic loop of alpha(1) and the beta interaction domain (BID) of the beta subunit is highly conserved among subunit subtypes. We describe a new subtype-specific interaction (Ss1) between the amino-terminal cytoplasmic domain of alpha(1A) (BI-2) and the carboxyl terminus of beta(4). Like the interaction identified previously (21) between the carboxyl termini of alpha(1A) and beta(4) (Ss2), the affinity of this interaction is lower than AID-BID, suggesting that these are secondary interactions. Ss1 and Ss2 involve overlapping sites on beta(4) and are competitive, but neither inhibits the interaction with AID. The interaction with the amino terminus of alpha(1) is isoform-dependent, suggesting a role in the specificity of alpha(1)-beta pairing. Coexpression of beta(4) in Xenopus oocytes produces a reduced hyperpolarizing shift in the I-V curve of the (alpha(1A) channel compared with beta(3) (not exhibiting this interaction). Replacing the amino terminus of alpha(1A) with that of alpha(1c) abolishes this difference. Our data contribute to our understanding of the molecular organization of calcium channels, providing a functional basis for variation in subunit composition of native P/Q-type channels.	INSERM, U464, Inst Federatif Jean Roche, Fac Med Nord, F-13916 Marseille 20, France; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 444, Japan; Univ British Columbia, Biotechnol Lab, Dept Zool, Vancouver, BC V6T 1Z3, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University of British Columbia	De Waard, M (corresponding author), INSERM, U464, Inst Federatif Jean Roche, Fac Med Nord, Bd Pierre Dramard, F-13916 Marseille 20, France.		Snutch, Terrance P/L-3464-2019; De Waard, Michel/G-7406-2014	Snutch, Terrance P/0000-0001-5182-1296; De Waard, Michel/0000-0002-2782-9615; Bichet, Delphine/0000-0002-9601-089X; Walker, Denise/0000-0003-1534-1679				BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Ludwig A, 1997, J NEUROSCI, V17, P1339; MCENERY MW, 1998, SOC NEUR ABSTR, V24, P81; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Page KM, 1998, J NEUROSCI, V18, P4815; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1994, J BIOL CHEM, V269, P1635; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	39	74	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12383	12390		10.1074/jbc.274.18.12383	http://dx.doi.org/10.1074/jbc.274.18.12383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212211	hybrid, Green Published			2022-12-25	WOS:000080056800031
J	Gingras, R; Richard, C; El-Alfy, M; Morales, CR; Potier, M; Pshezhetsky, AV				Gingras, R; Richard, C; El-Alfy, M; Morales, CR; Potier, M; Pshezhetsky, AV			Purification, cDNA cloning, and expression of a new human blood plasma glutamate carboxypeptidase homologous to N-acetyl-aspartyl-alpha-glutamate carboxypeptidase/prostate-specific membrane antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROMONAS-PROTEOLYTICA AMINOPEPTIDASE; LYSOSOMAL PROTECTIVE PROTEIN; LINKED ACIDIC DIPEPTIDASE; CATHEPSIN-A; BETA-GALACTOSIDASE; CRYSTAL-STRUCTURE; CLEAVAGE SITES; RAT; ACETYLASPARTYLGLUTAMATE; PEPTIDASE	We describe the identification, cDNA cloning, and biochemical characterization of a new human blood plasma glutamate carboxypeptidase (PGCP), PGCP was co-purified from human placenta with lysosomal carboxypeptidase, cathepsin A, lysosomal endopeptidase, cathepsin D, and a gamma-interferon-inducible protein, IP-30, using an affinity chromatography on a Phe-Leu-agarose column. A PC:CP cDNA was obtained as an expressed sequence tag clone and completed at 5'-end by rapid amplification of cDNA ends polymerase chain reaction. The cDNA contained a 1623-base pair open reading frame predicting a 541-amino acid protein, with five putative Asn glycosylation sites and a al-residue signal peptide. PGCP showed significant amino acid sequence homology to several cocatalytic metallopeptidases including a glutamate carboxypeptidase II also known as N-acetyl-aspartyl-alpha-glutamate carboxypeptidase or as prostate-specific membrane antigen and expressed glutamate carboxypeptidase activity. Expression of the PGCP cDNA in COS-l cells, followed by Western blotting and metabolic labeling showed that PGCP is synthesized as a 62-kDa precursor, which is processed to a 56-kDa mature form containing two Asn-linked oligosaccharide chains. The mature form of PGCP was secreted into the culture medium, which is consistent with its intracellular localization in secretion granules. In humans, PGCP is found principally in blood plasma, suggesting a potential role in the metabolism of secreted peptides.	Univ Montreal, Hop St Justine, Dept Pediat, Serv Genet Med, Montreal, PQ H3T 1C5, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Universite de Montreal; McGill University	Pshezhetsky, AV (corresponding author), Univ Montreal, Hop St Justine, Dept Pediat, Serv Genet Med, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	alex@jusine.umontreal.ca	Morales, Carlos R./H-1055-2011	A, Pshezhetsky/0000-0002-6612-1062				Ardaillou R, 1997, CURR OPIN NEPHROL HY, V6, P28, DOI 10.1097/00041552-199701000-00006; Ashmarin IP, 1997, NEUROSCI RES COMMUN, V21, P153; BARRETT AJ, 1970, BIOCHEM J, V117, P601, DOI 10.1042/bj1170601; Beinfeld MC, 1997, LIFE SCI, V61, P2359, DOI 10.1016/S0024-3205(97)00644-9; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BLAKELY RD, 1988, INT REV NEUROBIOL, V30, P39; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bzdega T, 1997, J NEUROCHEM, V69, P2270; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; COSTA E, 1987, FASEB J, V1, P16, DOI 10.1096/fasebj.1.1.3111927; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; Elsliger MA, 1996, BIOCHEMISTRY-US, V35, P14899, DOI 10.1021/bi952833l; Greenblatt HM, 1997, J MOL BIOL, V265, P620, DOI 10.1006/jmbi.1996.0729; HANNA WL, 1994, J IMMUNOL, V153, P4663; HERMO L, 1991, BIOL REPROD, V44, P1113, DOI 10.1095/biolreprod44.6.1113; Heston WDW, 1997, UROLOGY, V49, P104, DOI 10.1016/S0090-4295(97)00177-5; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HOOK VYH, 1988, CELL MOL NEUROBIOL, V8, P49, DOI 10.1007/BF00712911; ITOH K, 1995, J BIOL CHEM, V270, P515, DOI 10.1074/jbc.270.2.515; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; KAWAMURA Y, 1976, J BIOCH, V81, P435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUDA K, 1976, J BIOCHEM, V80, P659, DOI 10.1093/oxfordjournals.jbchem.a131325; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; PINTO T, 1996, CLIN CANCER RES, P1445; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; PSHEZHETSKY AV, 1994, ARCH BIOCHEM BIOPHYS, V313, P64, DOI 10.1006/abbi.1994.1359; PSHEZHETSKY AV, 1995, ANAL BIOCHEM, V230, P303, DOI 10.1006/abio.1995.1478; Rawlings ND, 1997, BBA-PROTEIN STRUCT M, V1339, P247, DOI 10.1016/S0167-4838(97)00008-3; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Rowsell S, 1997, STRUCTURE, V5, P337, DOI 10.1016/S0969-2126(97)00191-3; Shneider BL, 1997, J BIOL CHEM, V272, P31006, DOI 10.1074/jbc.272.49.31006; Skidgel RA, 1998, IMMUNOL REV, V161, P129, DOI 10.1111/j.1600-065X.1998.tb01577.x; SKIDGEL RA, 1992, J CARDIOVASC PHARM, V20, pS4, DOI 10.1097/00005344-199200209-00003; STAUCHSLUSHER B, 1990, J BIOL CHEM, V265, P21297; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	44	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11742	11750		10.1074/jbc.274.17.11742	http://dx.doi.org/10.1074/jbc.274.17.11742			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206990	hybrid			2022-12-25	WOS:000079834800046
J	Han, SK; Kim, KP; Koduri, R; Bittova, L; Munoz, NM; Leff, AR; Wilton, DC; Gelb, MH; Cho, WH				Han, SK; Kim, KP; Koduri, R; Bittova, L; Munoz, NM; Leff, AR; Wilton, DC; Gelb, MH; Cho, WH			Roles of Trp(31) in high membrane binding and proinflammatory activity of human group V phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIZED MIXED LIPOSOMES; SITE-DIRECTED MUTAGENESIS; INTERFACIAL CATALYSIS; ARACHIDONIC-ACID; CELL-MEMBRANES; COMPETITIVE INHIBITORS; IIA; EXPRESSION; RELEASE; SPECIFICITY	Group V phospholipase A(2) is a recently discovered secretory phospholipase A(2) (PLA(2)) that has been shown to be involved in eicosanoid formation in inflammatory cells, such as macrophages and mast cells. We have demonstrated that human group V PLA(2) (hsPL(2)-V) can bind phosphatidylcholine (PC) membranes and hydrolyze PC substrates much more efficiently than human group IIa PLA(2), which makes it better suited for acting on the outer plasma membrane (Han, S.-K., Yoon, E. T., and Cho, W. (1998) Biochem, J. 331, 353-357). In this study, we demonstrate that exogenous hsPLA(2)-V has much greater activity than does group IIa PLA(2) to release fatty acids from various mammalian cells and to elicit leukotriene B-4 formation from human neutrophils, To understand the molecular basis of these activities, we mutated two surface tryptophans of hsPLA(2)-V to alanine (W31A and W79A) and measured the effects of these mutations on the kinetic activity toward various substrates, on the binding affinity for vesicles and phospholipid-coated beads, on the penetration into phospholipid monolayers, and on the activity to release fatty acids and elicit eicosanoid formation from various mammalian cells. These studies show that the relatively high ability of hsPLA(2)-V to induce cellular eicosanoid formation derives from its high affinity for PC membranes and that Trp(31) on its putative interfacial binding surface plays an important role in its binding to PC vesicles and to the outer plasma membrane.	Univ Illinois, Dept Chem MC111, Chicago, IL 60607 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Chicago, Dept Med, Chicago, IL 60307 USA; Univ Southampton, Dept Biochem, Southampton SO9 3TU, Hants, England	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Chicago; University of Southampton	Cho, WH (corresponding author), Univ Illinois, Dept Chem MC111, 845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Bittova, Lenka/K-4375-2015	Bittova, Lenka/0000-0002-3556-5234; gelb, michael/0000-0001-7000-5219; Kim, Kwang Pyo/0000-0003-0095-3787	NHLBI NIH HHS [HL46368, HL36235] Funding Source: Medline; NIGMS NIH HHS [GM52598] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235, R37HL036235, R01HL046368, R23HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHEN J, 1994, J BIOL CHEM, V269, P2365; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DECHATELET LR, 1982, INFECT IMMUN, V35, P206, DOI 10.1128/IAI.35.1.206-212.1982; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Ghomashchi F, 1998, BIOCHEMISTRY-US, V37, P6697, DOI 10.1021/bi972525i; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Krischer SM, 1998, BIOCHEMISTRY-US, V37, P12884, DOI 10.1021/bi980696x; Lee BI, 1996, BIOCHEMISTRY-US, V35, P4231, DOI 10.1021/bi9524777; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; LIU XH, 1995, BIOCHEMISTRY-US, V34, P7322, DOI 10.1021/bi00022a005; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Othman R, 1996, BBA-LIPID LIPID MET, V1303, P92, DOI 10.1016/0005-2760(96)00083-5; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; ROGERS J, 1992, BIOCHEMISTRY-US, V31, P6056, DOI 10.1021/bi00141a014; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SHEN Z, 1994, BIOCHEMISTRY-US, V33, P11598, DOI 10.1021/bi00204a022; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WU SK, 1994, ANAL BIOCHEM, V221, P152, DOI 10.1006/abio.1994.1391; WU SK, 1993, BIOCHEMISTRY-US, V32, P13902, DOI 10.1021/bi00213a020; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; YUAN W, 1990, BIOCHEMISTRY-US, V29, P6082, DOI 10.1021/bi00477a028	43	163	163	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11881	11888		10.1074/jbc.274.17.11881	http://dx.doi.org/10.1074/jbc.274.17.11881			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207008	hybrid			2022-12-25	WOS:000079834800064
J	Kallen, KJ; Grotzinger, J; Lelievre, E; Vollmer, P; Aasland, D; Renne, C; Mullberg, J; zum Buschenfelde, KHM; Gascan, H; Rose-John, S				Kallen, KJ; Grotzinger, J; Lelievre, E; Vollmer, P; Aasland, D; Renne, C; Mullberg, J; zum Buschenfelde, KHM; Gascan, H; Rose-John, S			Receptor recognition sites of cytokines are organized as exchangeable modules - Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ONCOSTATIN-M; HEXAMERIC COMPLEX; CNTF RECEPTOR; IN-VITRO; GP130; FAMILY; ANTAGONIST; CELLS; IDENTIFICATION	Interleukin-6 (IL-6) and ciliary neurotrophic factor (CNTF) are "4-helical bundle" cytokines of the IL-6 type family of neuropoietic and hematopoietic cytokines, IL-6 signals by induction of a gp130 homodimer (eg. IL-6), whereas CNTF and leukemia inhibitory factor (LIF) signal via a heterodimer of gp130 and LIF receptor (LIFR). Despite binding to the same receptor component (gp130) and a similar protein structure, IL-6 and CNTF share only 6% sequence identity. Using molecular modeling we defined a putative LIFR binding epitope on CNTF that consists of three distinct regions (C-terminal A-helix/N-terminal AB loop, BC loop, C-terminal CD-loop/N-terminal D-helix), A corresponding gp130-binding site on IL-6 was exchanged with this epitope, The resulting IL-6/CNTF chimera lost the capacity to signal via gp130 on cells without LIFR, but acquired the ability to signal via the gp130/LIFR heterodimer and STATE on responsive cells. Besides identifying a specific LIFR binding epitope on CNTF, our results suggest that receptor recognition sites of cytokines are organized as modules that are exchangeable even between cytokines with limited sequence homology.	Johannes Gutenberg Univ Mainz, Abt Pathophysiol, Med Klin 1, D-55101 Mainz, Germany; Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52057 Aachen, Germany; CHU Angers, INSERM, F-49033 Angers, France	Johannes Gutenberg University of Mainz; RWTH Aachen University; RWTH Aachen University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Rose-John, S (corresponding author), Johannes Gutenberg Univ Mainz, Abt Pathophysiol, Med Klin 1, Obere Zahlbacher Str 63, D-55101 Mainz, Germany.	rosejohn@mail.uni-mainz.de	Rose-John, Stefan/A-7998-2010; Lelievre, Eric/M-2878-2015	Rose-John, Stefan/0000-0002-7519-3279; lelievre, eric/0000-0002-4132-4023				ALI SA, 1995, BIOTECHNIQUES, V18, P746; Anderson KD, 1996, P NATL ACAD SCI USA, V93, P7346, DOI 10.1073/pnas.93.14.7346; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; EHLERS M, 1994, J IMMUNOL, V153, P1744; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; Funakoshi H, 1998, P NATL ACAD SCI USA, V95, P5269, DOI 10.1073/pnas.95.9.5269; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; Grotzinger J, 1997, PROTEINS, V27, P96; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; Kallen K J, 1997, Expert Opin Investig Drugs, V6, P237, DOI 10.1517/13543784.6.3.237; Koshimizu U, 1996, DEVELOPMENT, V122, P1235; KRUTTGEN A, 1995, BIOCHEM J, V309, P215; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oppmann B, 1996, J IMMUNOL METHODS, V195, P153, DOI 10.1016/0022-1759(96)00110-X; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Renne C, 1998, J BIOL CHEM, V273, P27213, DOI 10.1074/jbc.273.42.27213; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WARD LD, 1994, J BIOL CHEM, V269, P23286; Xu GY, 1997, J MOL BIOL, V268, P468, DOI 10.1006/jmbi.1997.0933; Zhang JG, 1997, BIOCHEM J, V325, P693, DOI 10.1042/bj3250693; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	55	85	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11859	11867		10.1074/jbc.274.17.11859	http://dx.doi.org/10.1074/jbc.274.17.11859			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207005	hybrid			2022-12-25	WOS:000079834800061
J	Sipma, H; De Smet, P; Sienaert, I; Vanlingen, S; Missiaen, L; Parys, JB; De Smedt, H				Sipma, H; De Smet, P; Sienaert, I; Vanlingen, S; Missiaen, L; Parys, JB; De Smedt, H			Modulation of inositol 1,4,5-trisphosphate binding to the recombinant ligand-binding site of the type-1 inositol 1,4,5-trisphosphate receptor by Ca2+ and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; BASOPHILIC LEUKEMIA-CELLS; SMOOTH-MUSCLE CELLS; TRISPHOSPHATE RECEPTORS; CA2+-INDEPENDENT INHIBITION; CALCIUM RELEASE; CYTOSOLIC CA2+; PH; 1,4,5-TRIPHOSPHATE; MOBILIZATION	A recombinant protein (Lbs-1) containing the N-terminal 581 amino acids of the mouse type 1 inositol 1,4,5-trisphosphate receptor (IP3R-1), including the complete IP3-binding site, was expressed in the soluble fraction of E, coli, The characteristics of IP3 binding to this protein were similar as observed previously for the intact IP3R-1, Ca2+ dose-dependently inhibited IP3 binding to Lbs-1 with an IC50 of about 200 nM. This effect represented a decrease in the affinity of Lbs-1 for IP3, because the K-d increased from 115 +/- 15 nM in the absence to 196 +/- 18 nM in the presence of 5 mu M Ca2+, The maximal effect of Ca2+ on Lbs-1 (5 mu M Ca2+, 42.0 +/- 6.4% inhibition) was similar to the maximal inhibition observed for microsomes of insect Sf9 cells expressing full-length IP3R-1 (33.8 +/- 10.2%), Conceivably, the two contiguous Ca2+-binding sites (residues 304-450 of mouse IP3R-1) previously found by us (Sienaert, I., Missiaen, L., De Smedt, H, Parys, J.B., Sipma, H,, and Casteels, R, (1997) J, Biol Chem. 272, 25899-25906) mediate the effect of Ca2+ on IP3 binding to IP3R-1, Calmodulin also dose-dependently inhibited IP3 binding to Lbs-1 with an IC50 of about 3 mu M Maximal inhibition (10 mu M calmodulin, 43.1 +/- 5.9%) was similar as observed for Sf9-IP3R-1 microsomes (35.8 +/- 8.7%). Inhibition by calmodulin occurred independently of Ca2+ and was additive to the inhibitory effect of 5 mu M Ca2+ (together 74.5 +/- 5.1%). These results suggest that the N-terminal Ligand-binding region of IP3R-1 contains a calmodulin-binding domain that binds calmodulin independently of Ca2+ and that mediates the inhibition of IP3 binding to IP3R-1.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium	KU Leuven	De Smedt, H (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg O-N,Herestr 49, B-3000 Louvain, Belgium.	Humbert.DeSmedt@med.kuleuven.ac.be		Parys, Jan/0000-0002-3591-4967				AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1988, MOL ENDOCRINOL, V2, P1249, DOI 10.1210/mend-2-12-1249; HIROTA J, 1995, FEBS LETT, V368, P248, DOI 10.1016/0014-5793(95)00659-W; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Picard L, 1998, CELL CALCIUM, V23, P339, DOI 10.1016/S0143-4160(98)90029-X; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; Sienaert I, 1998, PFLUG ARCH EUR J PHY, V436, P40, DOI 10.1007/s004240050602; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; SINGH SV, 1987, BIOCHEM J, V246, P179, DOI 10.1042/bj2460179; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VANDELDEN C, 1993, J BIOL CHEM, V268, P12443; Vanlingen S, 1997, CELL CALCIUM, V22, P475, DOI 10.1016/S0143-4160(97)90075-0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	36	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12157	12162		10.1074/jbc.274.17.12157	http://dx.doi.org/10.1074/jbc.274.17.12157			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207043	hybrid			2022-12-25	WOS:000079834800099
J	Carroll, PE; Okuda, M; Horn, HF; Biddinger, P; Stambrook, PJ; Gleich, LL; Li, YQ; Tarapore, P; Fukasawa, K				Carroll, PE; Okuda, M; Horn, HF; Biddinger, P; Stambrook, PJ; Gleich, LL; Li, YQ; Tarapore, P; Fukasawa, K			Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression	ONCOGENE			English	Article						chromosome instability; p53; Mdm2; human cancer; centrosome hyperamplification	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; GENOMIC INSTABILITY; P53-DEFICIENT MICE; GAMMA-TUBULIN; BARRETTS-ESOPHAGUS; BREAST-CANCER; PROTEIN; AMPLIFICATION; CELLS	We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperamplification, which leads to aberrant mitosis and chromosome instability, Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperamplification, Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperamplification is frequent in both tumor types, Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperamplification. However, in some cases, me observed centrosome hyperamplification in tumors that retained wild-type p53, These tumors contained high levels of Mdm2, Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperamplification, We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperamplification and chromosome instability in cultured cells.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.		Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Okuda, Masaru/0000-0003-4690-8244; Horn, Henning/0000-0002-5885-8996				BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; BLOUNT PL, 1994, CANCER RES, V54, P2292; Bornens Michel, 1992, P1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CAHILLYSYNDER L, 1987, GENET, V13, P234; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG KC, 1993, ADV CANCER RES, V60, P121; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; EYFJORD JE, 1995, CANCER RES, V55, P646; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAPANY M, 1993, CANCER DETECT PREV, V17, P379; Gleich LL, 1996, LARYNGOSCOPE, V106, P1378, DOI 10.1097/00005537-199611000-00013; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1993, CANCER RES, V53, P16; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OSHIMURA M, 1986, ENVIRON MUTAGEN, V8, P129, DOI 10.1002/em.2860080112; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PAVELIC ZP, 1994, ANTICANCER RES, V14, P2259; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; PURDIE CA, 1994, ONCOGENE, V9, P603; RaybaudDiogene H, 1996, ORAL ONCOL, V32B, P143; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; VISSING H, 1987, NUCLEIC ACIDS RES, V15, P1363, DOI 10.1093/nar/15.4.1363; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	58	221	229	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1935	1944		10.1038/sj.onc.1202515	http://dx.doi.org/10.1038/sj.onc.1202515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208415				2022-12-25	WOS:000079191300003
J	Zwicker, J; Korner, K; Muller, R				Zwicker, J; Korner, K; Muller, R			The SV40 large T oncoprotein disrupts DNA-binding of the cell cycle-regulated transcriptional repressor CDF	ONCOGENE			English	Article						cell cycle; repression; transcriptional regulation; viral oncoproteins; SV40; cyclin A; cdc25C	CDC25C TRANSCRIPTION; GENE; PROTEIN; EXPRESSION; ANTIGEN; E2F; MODULATION; PATHWAY; PRODUCT; ELEMENT	A hallmark of neoplastic transformation by DNA tumor viruses is the deregulation of cell cycle genes. At least in some genes, this deregulation appears to be due to the oncoprotein-mediated disruption of complexes between E2F and pocket proteins and the ensuing generation of transcriptionally active free E2F. In the present study, we have analysed the effect of the SV40 large T oncoprotein (SV-LT) on the function of a different cell cycle-regulated transcriptional repressor, CDF, which is the principal regulator of the cdc25C, cyclin A and cdc2 genes, As shown by genomic footprinting of sorted G(1) and G(2) cell populations, transformation by SV-LT completely abrogated protection of the CDF binding site (CDE-CHR) in the cdc25C promoter. In agreement with this observation, expression of the SV-LT in fibroblasts led to a dramatic up-regulation of the cdc25C promoter in cells synchronized in G(0). These findings indicate that the oncoprotein-mediated dissociation of the CDF repressor protein from its cognate DNA-binding site is a major mechanism in virus-induced transcriptional deregulation.	Univ Marburg, IMT, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, IMT, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Boyer SN, 1996, CANCER RES, V56, P4620; BUCHOU T, 1993, ONCOGENE, V8, P1765; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; NEVINS JR, 1992, SCIENCE, V258, P424; OSHIMA J, 1993, ONCOGENE, V8, P2987; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	19	6	6	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2023	2025		10.1038/sj.onc.1202063	http://dx.doi.org/10.1038/sj.onc.1202063			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208424				2022-12-25	WOS:000079191300012
J	Lian, ZR; Pan, JB; Liu, J; Zhang, SM; Zhu, MH; Arbuthnot, P; Kew, M; Feitelson, MA				Lian, ZR; Pan, JB; Liu, J; Zhang, SM; Zhu, MH; Arbuthnot, P; Kew, M; Feitelson, MA			The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis	ONCOGENE			English	Article						translation initiation; hepatitis B X antigen; Sui1; hepatocellular carcinoma	VIRUS HBX PROTEIN; HEPATOCELLULAR-CARCINOMA; LIVER-CANCER; DNA-BINDING; TRANSACTIVATION FUNCTION; REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; INTEGRATED STATE; CARRIER PATIENTS; GENE PRODUCT(S)	The role of hepatitis B virus X antigen in the development of hepatocellular carcinoma was explored by stably transfecting HepG2 cells with an X antigen expression vector, and identifying the differences in gene expression that distinguish X positive from X negative cells by subtractive PCR, One differentially expressed gene, the human homolog of sdl (hu-sui1), encodes a translation initiation factor whose expression was suppressed by X antigen in HepG2 cells. Hu-Sui1 was also expressed in nontumor liver but not in tumor cells from patients with hepatocellular carcinoma. Introduction of hu-sui1 into HepG2 cells inhibited cell growth in culture, in soft agar, and partially inhibited tumor formation in nude mice. Hence, the suppression of hu-sui1 by X antigen may result in the abrogation of negative growth regulation and contribute to the development of hepatocellular carcinoma.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Witwatersrand, Dept Med, Mol Hepatol Res Unit, Johannesburg, South Africa; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Fourth Mil Med Coll, Dept Pathol, Xian, Shanxi, Peoples R China	Jefferson University; University of Witwatersrand; Jefferson University; Air Force Military Medical University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Arbuthnot, Patrick Brian/B-8163-2009; Lian, Zhaorui/AAW-2379-2020		NCI NIH HHS [CA66971, CA48656] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048656, R01CA048656, R01CA066971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AUTUNOVIC J, 1993, CELL MOL BIOL RES, V39, P463; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Bond J, 1996, ONCOGENE, V13, P2097; CEPKO CL, 1992, TRANSDUCTION GENES U; CHEN JY, 1988, HEPATOLOGY, V8, P518, DOI 10.1002/hep.1840080315; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; DANOS O, 1991, METHOD MOL BIOL, V8, P17; DUAN LX, 1995, HUM GENE THER, V6, P561; FEITELSON MA, 1988, J MED VIROL, V24, P121, DOI 10.1002/jmv.1890240202; FEITELSON MA, 1990, GASTROENTEROLOGY, V98, P1071, DOI 10.1016/0016-5085(90)90035-Y; FEITELSON MA, 1990, VIROLOGY, V177, P357, DOI 10.1016/0042-6822(90)90491-9; FEITELSON MA, 1986, HEPATOLOGY, V6, P191, DOI 10.1002/hep.1840060207; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEITELSON MA, 1990, VIROLOGY, V177, P367, DOI 10.1016/0042-6822(90)90492-A; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; HENSLER PJ, 1995, AM J PATHOL, V147, P1; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HORIIKE N, 1991, J INFECT DIS, V164, P1104, DOI 10.1093/infdis/164.6.1104; KASTAN MB, 1991, CANCER RES, V51, P6304; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Luber B, 1996, ONCOGENE, V12, P1597; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARAKAMI S, 1994, J BIOL CHEM, V269, P15118; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; Ozer A, 1996, GASTROENTEROLOGY, V110, P1519, DOI 10.1053/gast.1996.v110.pm8613059; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; ROBINSON WS, 1982, VIRAL HEPATITIS, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SEIFER M, 1991, J HEPATOL, V13, P61, DOI DOI 10.1016/0168-8278(91)90026-8; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; Shantz LM, 1996, CANCER RES, V56, P5136; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1995, J CANCER RES CLIN, V121, P593, DOI 10.1007/BF01197776; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TWU JS, 1989, J VIROL, V63, P2857, DOI 10.1128/JVI.63.6.2857-2860.1989; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; VILE R, 1991, VIRAL VECTORS GENE E, V8, P1; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU YZ, 1987, J NATL CANCER I, V79, P223; ZHU MH, 1993, INT J CANCER, V55, P571, DOI 10.1002/ijc.2910550409	81	55	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1677	1687		10.1038/sj.onc.1202470	http://dx.doi.org/10.1038/sj.onc.1202470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208429				2022-12-25	WOS:000079025000003
J	Krichevsky, AM; Metzer, E; Rosen, H				Krichevsky, AM; Metzer, E; Rosen, H			Translational control of specific genes during differentiation of HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; MESSENGER-RNA; RIBOSOMAL-RNA; 7SL RNA; EXPRESSION; PROTEIN; SEQUENCES; REPRESSION; FERRITIN; DOMAIN	Eukaryotic gene expression can be regulated through selective translation of specific mRNA species. Nevertheless, the limited number of known examples hampers the identification of common mechanisms that regulate translation of specific groups of genes in mammalian cells. We developed a method to identify translationally regulated genes. This method was used to examine the regulation of protein synthesis in HL-60 cells undergoing monocytic differentiation. A partial screening of cellular mRNAs identified five mRNAs whose translation was specifically inhibited and five others that were activated as was indicated by their mobilization onto polysomes, The specifically inhibited mRNAs encoded ribosomal proteins, identified as members of the 5'-terminal oligopyrimidine tract mRNA family. Most of the activated transcripts represented uncharacterized genes. The most actively mobilized transcript (termed TA-40) was an untranslated 1.3-kilobase polyadenylated RNA with unusual structural features, including two Alu-like elements. Following differentiation, a significant change in the cytoplasmic distribution of Alu-containing mRNAs was observed, namely, the enhancement of Alu-containing mRNAs in the polysomes. Our findings support the notion that protein synthesis is regulated during differentiation of HL-60 cells by both global and gene-specific mechanisms and that Alu-like sequences within cytoplasmic mRNAs are involved in such specific regulation.	Hebrew Univ Jerusalem, Fac Med, Dept Mol Virol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Rosen, H (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Mol Virol, POB 12272, IL-91120 Jerusalem, Israel.	hrose@md2.huji.ac.il		Krichevsky, Anna/0000-0002-5080-5507				AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; BIRNIE GD, 1988, BRIT J CANCER, V58, P41; Chang DY, 1997, NUCLEIC ACIDS RES, V25, P1117, DOI 10.1093/nar/25.6.1117; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Fan XHC, 1997, GENE DEV, V11, P2557, DOI 10.1101/gad.11.19.2557; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; GUNDELFINGER ED, 1983, NUCLEIC ACIDS RES, V11, P7363, DOI 10.1093/nar/11.21.7363; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; HOWARD B H, 1990, New Biologist, V2, P759; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, CURRENT PROTOCOLS MO; LORENI F, 1992, NUCLEIC ACIDS RES, V20, P1859, DOI 10.1093/nar/20.8.1859; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MATTIA E, 1986, J BIOL CHEM, V261, P4587; MATTIA E, 1989, P NATL ACAD SCI USA, V86, P1801, DOI 10.1073/pnas.86.6.1801; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas Oded, 1996, V30, P363; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; ROSEN H, 1989, DEV BRAIN RES, V46, P123, DOI 10.1016/0165-3806(89)90149-1; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ryoo HM, 1997, J CELL BIOCHEM, V64, P106, DOI 10.1002/(SICI)1097-4644(199701)64:1<106::AID-JCB13>3.0.CO;2-J; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; SIEGEL V, 1986, NATURE, V320, P81, DOI 10.1038/320081a0; Spahn CMT, 1996, J BIOL CHEM, V271, P32857, DOI 10.1074/jbc.271.51.32857; STRAUSS WM, 1995, CURRENT PROTOCOLS MO; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Tranque P, 1998, P NATL ACAD SCI USA, V95, P12238, DOI 10.1073/pnas.95.21.12238; TSIFTSOGLOU AS, 1985, INT J CELL CLONING, V3, P349, DOI 10.1002/stem.5530030602; ULLU E, 1984, NATURE, V312, P171, DOI 10.1038/312171a0; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; WICKERS M, 1996, TRANSLATIONAL CONTRO, P433; WINZEN R, 1992, J IMMUNOL, V148, P3454; YENOFSKY R, 1982, BIOCHEMISTRY-US, V21, P3909, DOI 10.1021/bi00260a001; YULUG IG, 1995, GENOMICS, V27, P544, DOI 10.1006/geno.1995.1090	51	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14295	14305		10.1074/jbc.274.20.14295	http://dx.doi.org/10.1074/jbc.274.20.14295			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318851	hybrid			2022-12-25	WOS:000080322200080
J	Zhou, TQ; Rosen, BP				Zhou, TQ; Rosen, BP			Asp(45) is a Mg2+ ligand in the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; NUCLEOTIDE-BINDING SITE; AZOTOBACTER-VINELANDII; CATALYTIC SUBUNIT; GTP-BINDING; PROTEIN; COMPLEX; PUMP; COORDINATION; MUTAGENESIS	The ATPase activity of ArsA, the catalytic subunit of the plasmid-encoded, ATP-dependent extrusion pump for arsenicals and antimonials in Escherichia coli, is allosterically activated by arsenite or antimonite. Magnesium is essential for ATPase activity. To examine the role of Asp(45) mutants were constructed in which Asp(45) was changed to Glu, Asn, or Ale. Cells expressing these mutated arsA genes lost arsenite resistance to varying degrees. Purified D45A and D45N enzymes were inactive, The purified D45E enzyme exhibited approximately 5% of the wild type activity with about a 5-fold decrease in affinity for Mg2+. Intrinsic tryptophan fluorescence was used to probe Mg2+ binding. ArsA containing only Trp(159) exhibited fluorescence enhancement upon the addition of MgATP, which was absent in D45N and D45A. As another measure of conformation, limited trypsin digestion was used to estimate the surface accessibility of residues in ArsA. ATP and Sb(III) synergistically protected wild type ArsA from trypsin digestion. Subsequent addition of Mg2+ increased trypsin sensitivity. D45N and D45A remained protected by ATP and Sb(III) but lost the Mg2+ effect. D45E exhibited an intermediate Mg2+ response. These results indicate that Asp(45) is a Mg2+-responsive residue, consistent with its function as a Mg2+ ligand.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM55424] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN CM, 1986, J BIOL CHEM, V261, P5030; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HARMARK K, 1992, BIOCHEMISTRY-US, V31, P7367, DOI 10.1021/bi00147a022; HSU CM, 1989, J BIOL CHEM, V264, P17349; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1992, J BIOL CHEM, V267, P19272; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; Li JX, 1996, J BIOL CHEM, V271, P25247, DOI 10.1074/jbc.271.41.25247; Miller J.H., 1992, SHORT COURSE BACTERI, P150; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Sambrook J., 2002, MOL CLONING LAB MANU; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Xu C, 1998, J BIOCHEM-TOKYO, V123, P16; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731	23	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13854	13858		10.1074/jbc.274.20.13854	http://dx.doi.org/10.1074/jbc.274.20.13854			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318792	hybrid			2022-12-25	WOS:000080322200021
J	Brower, CS; Shilatifard, A; Mather, T; Kamura, T; Takagi, Y; Haque, D; Treharne, A; Foundling, SI; Conaway, JW; Conaway, RC				Brower, CS; Shilatifard, A; Mather, T; Kamura, T; Takagi, Y; Haque, D; Treharne, A; Foundling, SI; Conaway, JW; Conaway, RC			The Elongin B ubiquitin homology domain - Identification of Elongin B sequences important for interaction with Elongin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTION FACTOR-SIII; NUCLEAR-PORE COMPLEX; MOLECULAR-CLONING; FACTOR-EPSILON; ELONGATION; BINDING; GENE; DEGRADATION	Mammalian Elongin B is a 118-amino acid protein composed of an 84-amino acid amino-terminal ubiquitin-like domain and a 34-amino acid carboxyl-terminal tail. Elongin B is found in cells as a subunit of the heterodimeric Elongin BC complex, which was originally identified as a positive regulator of RNA polymerase II elongation factor Elongin A and subsequently as a component of the multiprotein von Hippel-Lindau tumor suppressor and suppressor of cytokine signaling complexes, As part of our effort to understand how the Elongin BC complex regulates the activity of Elongin A, we are characterizing Elongin B functional domains, In this report, we show that the Elongin B ubiquitin-like domain is necessary and sufficient for interaction with Elongin C and for positive regulation of Elongin A transcriptional activity. In addition, by site-directed mutagenesis of the Elongin B ubiquitin-like domain, we identify a short Elongin B region that is important for its interaction with Elongin C, Finally, we observe that both the ubiquitin-like domain and carboxyl-terminal tail are conserved in Drosophila melanogaster and Caenorhabditis elegans Elongin B homologs that efficiently substitute for mammalian Elongin B in reconstitution of the transcriptionally active Elongin ABC complex, suggesting that the carboxyl-terminal tail performs an additional function not detected in our assays.	Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63104 USA; Oklahoma Med Res Fdn, Program Cardiovasc Biol, Oklahoma City, OK 73104 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Saint Louis University; Oklahoma Medical Research Foundation; Stanford University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Conaway, RC (corresponding author), Oklahoma Med Res Fdn, Program Mol & Cell Biol, 825 Ne 13Th St, Oklahoma City, OK 73104 USA.			Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Aso T, 1997, BIOCHEM BIOPH RES CO, V241, P334, DOI 10.1006/bbrc.1997.7819; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PETERSON MG, 1991, NATURE, V354, P369; Rao-Naik C, 1998, J BIOL CHEM, V273, P34976, DOI 10.1074/jbc.273.52.34976; Sambrook J., 2002, MOL CLONING LAB MANU; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Takagi Y, 1996, J BIOL CHEM, V271, P25562, DOI 10.1074/jbc.271.41.25562; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	36	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13629	13636		10.1074/jbc.274.19.13629	http://dx.doi.org/10.1074/jbc.274.19.13629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224134	hybrid			2022-12-25	WOS:000080200400096
J	De la Cerda, B; Diaz-Quintana, A; Navarro, JA; Hervas, M; De la Rosa, MA				De la Cerda, B; Diaz-Quintana, A; Navarro, JA; Hervas, M; De la Rosa, MA			Site-directed mutagenesis of cytochrome c(6) from Synechocystis sp. PCC6803 - The heme protein possesses a negatively charged area that may be isofunctional with the acidic patch of plastocyanin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; PHOTOSYSTEM-I; SPINACH PLASTOCYANIN; REACTION-MECHANISM; CRYSTAL-STRUCTURE; FLASH-PHOTOLYSIS; CYANOBACTERIUM; PCC-6803; MUTANT	This paper reports the first site-directed mutagenesis analysis of any cytochrome c(6), a heme protein that performs the same function as the copper-protein plastocyanin in the electron transport chain of photosynthetic organisms. Photosystem I reduction by the mutants of cytochrome c(6) from the cyanobacterium Synechocystis sp, PCC 6803 has been studied by laser flash absorption spectroscopy. Their kinetic efficiency and thermodynamic properties have been compared with those of plastocyanin mutants from the same organism. Such a comparative study reveals that aspartates at positions 70 and 72 in cytochrome c(6) are located in an acidic patch that may be isofunctional with the well known "south-east" patch of plastocyanin, Calculations of surface electrostatic potential distribution in the mutants of cytochrome c(6) and plastocyanin indicate that the changes in protein reactivity depend on the surface electrostatic potential pattern rather than on the net charge modification induced by mutagenesis, Phe-64, which is close to the heme group and may be the counterpart of Tyr-83 in plastocyanin, does not appear to be involved in the electron transfer to photosystem I, In contrast, Arg-67, which is at the edge of the cytochrome c(6) acidic area, seems to be crucial for the interaction with the reaction center.	Univ Sevilla, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Ctr Isla Cartuja, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	De la Rosa, MA (corresponding author), Univ Sevilla, Inst Bioquim Vegetal & Fotosintesis, Amer Vespucio S-N, Seville 41092, Spain.		Hervas, Manuel/K-9279-2014; De la Rosa, Miguel/B-2545-2014; Díaz-Quintana, Antonio/A-1946-2011; navarro, jose a/B-6354-2015; De la cerda, Berta/L-7039-2014	Hervas, Manuel/0000-0003-4523-8891; De la Rosa, Miguel/0000-0003-1187-5737; Díaz-Quintana, Antonio/0000-0001-8973-8009; navarro, jose a/0000-0002-0536-6074; De la cerda, Berta/0000-0001-5603-6473				CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; DelaCerda B, 1997, BIOCHEMISTRY-US, V36, P10125, DOI 10.1021/bi9708601; DIAZ A, 1994, EUR J BIOCHEM, V222, P1001, DOI 10.1111/j.1432-1033.1994.tb18951.x; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; GIAMMONA DA, 1984, THESIS U CALIFORNIA; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; HERVAS M, 1993, FEBS LETT, V319, P257, DOI 10.1016/0014-5793(93)80558-C; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; Kannt A, 1996, BBA-BIOENERGETICS, V1277, P115, DOI 10.1016/S0005-2728(96)00090-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MODI S, 1992, BIOCHIM BIOPHYS ACTA, V1102, P85, DOI 10.1016/0005-2728(92)90068-D; MODI S, 1992, BIOCHIM BIOPHYS ACTA, V1101, P64, DOI 10.1016/0167-4838(92)90467-R; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; PEARLMAN PA, 1995, AMBER 4 1; Romero A, 1998, J MOL BIOL, V275, P327, DOI 10.1006/jmbi.1997.1455; Sebban-Kreuzer C, 1998, BIOCHEMISTRY-US, V37, P8331, DOI 10.1021/bi980142u; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; Ullmann GM, 1997, BIOCHEMISTRY-US, V36, P16187, DOI 10.1021/bi971241v; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; WATKINS JA, 1994, PROTEIN SCI, V3, P2104, DOI 10.1002/pro.5560031124	27	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13292	13297		10.1074/jbc.274.19.13292	http://dx.doi.org/10.1074/jbc.274.19.13292			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224089	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000080200400051
J	Kachnic, LA; Wu, B; Wunsch, H; Mekeel, KL; DeFrank, JS; Tang, W; Powell, SN				Kachnic, LA; Wu, B; Wunsch, H; Mekeel, KL; DeFrank, JS; Tang, W; Powell, SN			The ability of p53 to activate downstream genes p21(WAF1/cip1) and MDM2, and cell cycle arrest following DNA damage is delayed and attenuated in scid cells deficient in the DNA-dependent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; SEVERE COMBINED IMMUNODEFICIENCY; V(D)J RECOMBINATION; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA; CHECKPOINT PATHWAY; KU-AUTOANTIGEN; G(1) ARREST; KINASE; MUTATION	scid mouse embryonic fibroblasts are deficient in DNA-dependent protein kinase activity due to a mutation in the C-terminal domain of the catalytic subunit (DNA-PKcs). when exposed to ionizing radiation, the increase in levels of p53 was the same as in normal mouse embryonic fibroblasts. However, the rise in p21(WAF1/cip1) and mdma was found to be delayed and attenuated, which ;correlated in time with delayed onset of G(1)/S arrest by now cytometric analysis. The p53-dependent G(1) checkpoint was not eliminated: inactivation of p53 by the E6 protein in scid cells resulted in the complete loss of detectable G(1)/S arrest after DNA damage, Immunofluorescence analysis of normal cells revealed p53 to be localized predominantly within the cytoplasm prior to irradiation and then translocate to the nucleus after irradiation. In contrast, scid cells show abnormal accumulation of p53 in the nucleus independent of irradiation, which was confirmed by immunoblot analysis of nuclear lysates. Taken together, these data suggest that loss of DNA-PK activity appears to attenuate the kinetics of p53 to activate downstream genes, implying that DNA-PK plays a role in post-translational modification of p53, without affecting the increase in levels of p53 in response to DNA damage.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Lab Mol & Cellular Radiat Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Powell, SN (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Lab Mol & Cellular Radiat Biol, Cox 302,100 Blossom St, Boston, MA 02114 USA.				NCI NIH HHS [CA58985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BUDACH W, 1992, CANCER RES, V52, P6292; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRIED LM, 1996, P NATL ACAD SCI USA, V93, P17382; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GANNON JV, 1991, NATURE, V349, P802; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; HARPER JW, 1993, CELL, V75, P805; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Huang LC, 1996, CANCER RES, V56, P2940; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Isaacs JS, 1997, CANCER RES, V57, P2986; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Jongmans W, 1996, ONCOGENE, V13, P1133; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; KASTAN MB, 1991, CANCER RES, V51, P6304; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mayo LD, 1997, CANCER RES, V57, P5013; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10790; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; OLSON DC, 1993, ONCOGENE, V8, P2353; POWELL SN, 1995, CANCER RES, V55, P1643; PRICE BD, 1993, ONCOGENE, V8, P3055; Rathmell WK, 1997, CANCER RES, V57, P68; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAN QM, 1994, CANCER RES, V54, P2755	66	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13111	13117		10.1074/jbc.274.19.13111	http://dx.doi.org/10.1074/jbc.274.19.13111			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224064	hybrid			2022-12-25	WOS:000080200400026
J	Ribeiro, SMF; Poczatek, M; Schultz-Cherry, S; Villain, M; Murphy-Ullrich, JE				Ribeiro, SMF; Poczatek, M; Schultz-Cherry, S; Villain, M; Murphy-Ullrich, JE			The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPATHIC COMPLEMENTARITY APPROACH; MOLECULAR-WEIGHT COMPLEX; BETA-1-LATENCY-ASSOCIATED PEPTIDE; MESSENGER-RNA; STRUCTURAL CHARACTERIZATION; EXTRACELLULAR-MATRIX; HUMAN-PLATELETS; TGF-BETA; BINDING; CELLS	One of the primary points of regulation of transforming growth factor-beta (TGF-beta) activity is control of its conversion from the latent precursor to the biologically active form. We have identified thrombospondin-l as a major physiological regulator of latent TGF-beta activation. Activation is dependent on the interaction of a specific sequence in thrombospondin-l ((KRFK415)-R-412) with the latent TGF-beta complex. Platelet thrombospondin-1 has TGF-beta activity and immunoreactive mature TGF-beta associated with it. We now report that the latency-associated peptide (LAP) of the latent TGF-beta complex also interacts with thrombospondin-l as part of a biologically active complex. Thrombospondin LAP complex formation involves the activation sequence of thrombospondin-l (KRFK) and a sequence (LSKL) near the amino terminus of LAP that is conserved in TGF-beta(1-5). The interactions of LAP with thrombospondin-l through the LSKL and KRFK sequences are important for thrombospondin-mediated activation of latent TGF-beta since LSKL peptides can competitively inhibit latent TGF-beta activation by thrombospondin or KRFK-containing peptides. In addition, the association of LAP with thrombospondin-1 may function to prevent the reformation of an inactive LAP TGF-beta complex since thrombospondin-bound LAP no longer confers latency on active TGF-beta. The mechanism of TGF-beta activation by thrombospondin-1 appears to be conserved among TGF-beta isoforms as latent TGF-beta(2) can also be activated by thrombospondin-1 or KRFK peptides in a manner that is sensitive to inhibition by LSKL peptides.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Ribeiro, SMF (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Volker Hall,G038,1670 Univ Blvd, Birmingham, AL 35294 USA.	ribeiro@path.uab.edu	Schultz-Cherry, Stacey/N-2506-2018		NHLBI NIH HHS [R01 HL050061, HL50061] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRENTANI RR, 1988, P NATL ACAD SCI USA, V85, P364, DOI 10.1073/pnas.85.2.364; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; BURT DW, 1992, MOL ENDOCRINOL, V6, P989, DOI 10.1210/me.6.6.989; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DERYNCK R, 1997, NUCLEIC ACIDS RES, V15, P3188; FASSINA G, 1994, GROWTH FACTORS, V10, P99, DOI 10.3109/08977199409010983; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; KONDAIAH P, 1990, J BIOL CHEM, V265, P1089; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; LIOUBIN MN, 1991, J CELL BIOCHEM, V45, P112, DOI 10.1002/jcb.240450118; Maier C C, 1994, Immunomethods, V5, P107, DOI 10.1006/immu.1994.1044; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1108, DOI 10.1210/mend-3-7-1108; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOSHER DF, 1990, ANNU REV MED, V41, P85; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; PASQUALINI R, 1989, J BIOL CHEM, V264, P14566; QIAN SW, 1990, NUCLEIC ACIDS RES, V18, P3059, DOI 10.1093/nar/18.10.3059; Roberts Anita B., 1995, Wound Repair and Regeneration, V3, P408, DOI 10.1046/j.1524-475X.1995.30405.x; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; SLATER M, 1995, EXPERIENTIA, V51, P235, DOI 10.1007/BF01931104; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; Yang YB, 1997, BIOCHEMISTRY-US, V36, P11923, DOI 10.1021/bi9710479	45	285	303	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13586	13593		10.1074/jbc.274.19.13586	http://dx.doi.org/10.1074/jbc.274.19.13586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224129	hybrid			2022-12-25	WOS:000080200400091
J	Zhou, XJ; Liao, J; Hu, LR; Feng, L; Omary, MB				Zhou, XJ; Liao, J; Hu, LR; Feng, L; Omary, MB			Characterization of the major physiologic phosphorylation site of human keratin 19 and its role in filament organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DEPENDENT PROTEIN-KINASE; INTERMEDIATE FILAMENTS; CULTURED-CELLS; OKADAIC ACID; IN-VITRO; EXPRESSION; CYTOKERATIN; DISEASE; MOUSE	Keratin polypeptide 19 (K19) is a type I intermediate filament protein that is expressed in stratified and simple-type epithelia, Little is known regarding K19 regulation or function, and the only other type I keratin that has been studied in terms of regulation is keratin 18 (K18), We characterized K19 phosphorylation as a handle to study its function. In vivo, serine is the major phosphorylated residue, and phosphopeptide mapping of (PO4)-P-32-labeled K19 generates one major phosphopeptide. Edman degradation suggested that the radiolabeled phosphopeptide represents K19 Ser-10 and/or Ser-35 phosphorylation, Mutation of Ser-10 or Ser-35 followed by transfection confirmed that Ser-35 is the major K19 phosphorylation site. Transfection of Ser-35 --> Ala K19 showed a filament assembly defect as compared with normal or with Ser-10 --> Ala K19, Comparison of K18 and K19 phosphorylation features in interphase cells showed that both are phosphorylated primarily at a single site, preferentially in the soluble versus the insoluble keratin fractions. K19 has higher basal phosphorylation, whereas K18 phosphorylation is far more sensitive to phosphatase type I and IIA inhibition. Our results demonstrate that Ser-35 is the major K19 interphase phosphorylation site and that it plays a role in keratin filament assembly. K19 and K18 phosphorylations share some features but also have distinct properties that suggest different regulation of type I keratins within the same cells.	Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94303 USA; Stanford Univ, Ctr Digest Dis, Palo Alto, CA 94304 USA; CLONTECH Labs, Palo Alto, CA 94303 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Omary, MB (corresponding author), Palo Alto Vet Affairs Med Ctr, 154J,3801 Miranda Ave, Palo Alto, CA 94304 USA.			Omary, Bishr/0000-0002-8624-2347	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007056, P30DK038707, R01DK047918] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47918, DK38707, DK07056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BERSHADSKY AD, 1988, CYTOSKELETON, P1; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOTTGER V, 1995, EUR J BIOCHEM, V231, P475, DOI 10.1111/j.1432-1033.1995.tb20721.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHOU CF, 1993, J BIOL CHEM, V268, P4465; ECKERT RL, 1988, P NATL ACAD SCI USA, V85, P1114, DOI 10.1073/pnas.85.4.1114; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; Fradette J, 1998, J BIOL CHEM, V273, P35176, DOI 10.1074/jbc.273.52.35176; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GILMARTIN ME, 1980, J INVEST DERMATOL, V75, P211, DOI 10.1111/1523-1747.ep12522887; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; KASAHARA K, 1993, J BIOL CHEM, V268, P23531; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 1997, J BIOL CHEM, V272, P7556, DOI 10.1074/jbc.272.11.7556; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; Ku NO, 1998, J CELL BIOL, V143, P2023, DOI 10.1083/jcb.143.7.2023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LEUBE RE, 1986, DIFFERENTIATION, V33, P69, DOI 10.1111/j.1432-0436.1986.tb00412.x; Liao J, 1996, ELECTROPHORESIS, V17, P1671, DOI 10.1002/elps.1150171104; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIAO J, 1995, J CELL BIOL, V131, P1291, DOI 10.1083/jcb.131.5.1291; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; LUSSIER M, 1989, GENE, V85, P435, DOI 10.1016/0378-1119(89)90437-X; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Michel M, 1996, J CELL SCI, V109, P1017; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; NARISAWA Y, 1994, J INVEST DERMATOL, V103, P191, DOI 10.1111/1523-1747.ep12392730; Omary M B, 1998, Subcell Biochem, V31, P105; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; OSHIMA RG, 1982, J BIOL CHEM, V257, P3414; OSHIMA RG, 1986, DIFFERENTIATION, V33, P61, DOI 10.1111/j.1432-0436.1986.tb00411.x; STASIAK PC, 1987, NUCLEIC ACIDS RES, V15, P10058, DOI 10.1093/nar/15.23.10058; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEINERT PM, 1982, BIOCHEMISTRY-US, V21, P177, DOI 10.1021/bi00530a030; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x	46	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12861	12866		10.1074/jbc.274.18.12861	http://dx.doi.org/10.1074/jbc.274.18.12861			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212274	hybrid			2022-12-25	WOS:000080056800094
J	Graether, SP; DeLuca, CI; Baardsnes, J; Hill, GA; Davies, PL; Jia, ZC				Graether, SP; DeLuca, CI; Baardsnes, J; Hill, GA; Davies, PL; Jia, ZC			Quantitative and qualitative analysis of type III antifreeze protein structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE; BINDING; IDENTIFICATION; SURFACE	Some cold water marine fishes avoid cellular damage because of freezing by expressing antifreeze proteins (AFPs) that bind to ice and inhibit its growth; one such protein is the globular type III AFP from eel pout. Despite several studies, the mechanism of ice binding remains unclear because of the difficulty in modeling the AFP-ice interaction. To further explore the mechanism, we have determined the x-ray crystallographic structure of 10 type III AFP mutants and combined that information with 7 previously determined structures to mainly analyze specific AFP-ice interactions such as hydrogen bonds. Quantitative assessment of binding was performed using a neural network with properties of the structure as input and predicted antifreeze activity as output. Using the cross-validation method, a correlation coefficient of 0.60 was obtained between measured and predicted activity, indicating successful learning and good predictive power. A large loss in the predictive power of the neural network occurred after properties related to the hydrophobic surface were left out, suggesting that van der Waal's interactions make a significant contribution to ice binding. By combining the analysis of the neural network with antifreeze activity and x-ray crystallographic structures of the mutants, we extend the existing ice-binding model to a two step process: 1) probing of the surface for the correct ice-binding plane by hydrogen-bonding side chains and 2) attractive van der Waal's interactions between the other residues of the ice-binding surface and the ice, which increases the strength of the protein-ice interaction.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Jia, ZC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.		Graether, Steffen P./AFU-0892-2022; Graether, Steffen P./AAR-8849-2021	Graether, Steffen P./0000-0002-2356-3936; Graether, Steffen P./0000-0002-2356-3936				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CHAO H, 1993, PROTEIN SCI, V2, P1411, DOI 10.1002/pro.5560020906; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; Chao HM, 1997, BIOCHEMISTRY-US, V36, P14652, DOI 10.1021/bi970817d; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DeLuca CI, 1998, J MOL BIOL, V275, P515, DOI 10.1006/jmbi.1997.1482; Haymet ADJ, 1998, FEBS LETT, V430, P301, DOI 10.1016/S0014-5793(98)00652-8; HINTZE J, 1998, NCSS STAT PACKAGE; Hotelling H, 1933, J EDUC PSYCHOL, V24, P417, DOI 10.1037/h0071325; Hotelling H, 1933, J EDUC PSYCHOL, V24, P498, DOI 10.1037/h0070888; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; JIA ZC, 1995, PROTEIN SCI, V4, P1236, DOI 10.1002/pro.5560040621; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Muller B., 1995, NEURAL NETWORKS INTR; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRESNELL SR, 1993, ANNU REV BIOPH BIOM, V22, P283, DOI 10.1146/annurev.bb.22.060193.001435; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SOENNICHSEN FD, 1996, STRUCTURE LOND, V4, P1325, DOI 10.1016/S0969-2126(96)00140-2; WISHART DS, 1994, VADAR COMPREHENSIVE; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; Ye QL, 1998, ACTA CRYSTALLOGR D, V54, P700, DOI 10.1107/S0907444997020040; ZELL A, 1991, INFORMATIK FACHBERIC, V285, P254	26	64	70	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11842	11847		10.1074/jbc.274.17.11842	http://dx.doi.org/10.1074/jbc.274.17.11842			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207002	hybrid			2022-12-25	WOS:000079834800058
J	Hashida-Okumura, A; Okumura, N; Iwamatsu, A; Buijs, RM; Romijn, HJ; Nagai, K				Hashida-Okumura, A; Okumura, N; Iwamatsu, A; Buijs, RM; Romijn, HJ; Nagai, K			Interaction of neuronal nitric-oxide synthase with alpha 1-syntrophin in rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; NERVOUS-SYSTEM; DYSTROPHIN; LOCALIZATION; SYNTROPHIN; PROTEIN; COLOCALIZATION; RELEASE	Neuronal nitric-oxide synthase (nNOS) has a PSD-95/ Dlg/ZO-1 (PDZ) domain that can interact with multiple proteins. nNOS has been known to interact with PSD-95 and a related protein, PSD-93, in brain and with alpha 1-syntrophin in skeletal muscle in mammals. In this study, we have purified an nNOS-interacting protein from bovine brain using an affinity column made of Sepharose conjugated with glutathione S-transferase-rat nNOS fusion protein and identified it as alpha 1-syntrophin by microsequencing. Immunostaining of primary cultures of rat embryonic brain neuronal cells with antibodies against these proteins showed that nNOS and alpha 1-syntrophin were colocalized in neuronal cell bodies and neurites. Immunohistochemical analysis indicated that the nNOS- and alpha 1-syntrophin-like immunoreactive substances were highly expressed in the rat hypothalamic suprachiasmatic nucleus (SCN) and paraventricular nucleus. In the SCN, nNOS- and alpha 1-syntrophin-like immunoreactive substances were colocalized in the same neurons as detected by confocal microscopy. These results indicate that nNOS in brain interacts with alpha 1-syntrophin in specific neurons of the SCN and paraventricular nucleus and that this interaction might play a physiological role in functions of these neurons.	Osaka Univ, Inst Prot Res, Div Prot Metab, Osaka 5650871, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Kanagawa 2360004, Japan; Netherlands Inst Res, NL-1105 AZ Amsterdam Zuidoost, Netherlands	Osaka University; Kirin Brewery Company Limited	Hashida-Okumura, A (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Metab, 3-2 Yamada Oka, Osaka 5650871, Japan.		Buijs, Rudolf/AAD-5707-2020					ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Gorecki DC, 1997, EUR J NEUROSCI, V9, P965, DOI 10.1111/j.1460-9568.1997.tb01447.x; HECKER M, 1994, J NEUROCHEM, V62, P1524; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; KALSBEEK A, 1992, BRAIN RES, V580, P62, DOI 10.1016/0006-8993(92)90927-2; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; MASUTANI H, 1994, BIOL RHYTHM RES, V25, P433, DOI 10.1080/09291019409360313; MATSUMINE A, 1996, SCIENCE, V272, P974; Nagai K, 1996, PROG BRAIN RES, V111, P253, DOI 10.1016/S0079-6123(08)60413-6; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; REUSS S, 1995, BRAIN RES, V695, P257, DOI 10.1016/0006-8993(95)00829-F; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; Zhang K, 1997, AM J PHYSIOL-REG I, V273, pR864, DOI 10.1152/ajpregu.1997.273.3.R864	25	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11736	11741		10.1074/jbc.274.17.11736	http://dx.doi.org/10.1074/jbc.274.17.11736			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206989	hybrid			2022-12-25	WOS:000079834800045
J	Hoth, S; Hedrich, R				Hoth, S; Hedrich, R			Distinct molecular bases for pH sensitivity of the guard cell K+ channels KST1 and KAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; INWARD RECTIFIER; ELECTROSTATIC INTERACTIONS; FUNCTIONAL EXPRESSION; IDENTIFICATION; SELECTIVITY; ACTIVATION; MUTATIONS; SUBUNITS; CURRENTS	Acid-induced potassium uptake through Kt channels is a prerequisite for stomatal opening. Our previous studies identified a pore histidine as a major component of the acid activation mechanism of the potato guard cell K+ channel KST1 (1), Although this histidine is highly conserved among all plant K+ uptake channels cloned so far, the pH-dependent gating of the Arabidopsis thaliana guard cell K+ channel KAT1 was not affected by mutations of this histidine, In both channels, KST1 and KAT1, aspartate mutants in the K+ channel consensus sequence GYGD adjacent to the histidine (KST1-D269N and KAT1-D265N) were inhibited by a rise in the extracellular proton concentration. pH changes affected the half-maximal activation voltage Vim of the KST1 mutant, whereas in the mutant channel KAT1-D265N an acid-induced decrease in the maximum conductance g(max) indicated the presence of a proton block. In contrast to the wild type KST1, the S4-mutant chan nel KST1-R181Q exhibited an activation upon alcalization of the extracellular solution. From our electrophysiological studies on channel mutants with respect to the pore histidine as well as the aspartate, we conclude that the common proton-supported shift in the voltage dependence of KST1 and KAT1 is based on distinct molecular elements.	Julius von Sachs Inst Biowissensch, Lehrstuhl Bot 1, D-97082 Wurzburg, Germany	University of Wurzburg	Hedrich, R (corresponding author), Julius von Sachs Inst Biowissensch, Lehrstuhl Bot 1, Julius von Sachs Pl 2, D-97082 Wurzburg, Germany.		Hoth, Stefan/E-8024-2017; Hedrich, Rainer/G-8771-2011	Hedrich, Rainer/0000-0003-3224-1362				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Becker D, 1996, P NATL ACAD SCI USA, V93, P8123, DOI 10.1073/pnas.93.15.8123; BLATT MR, 1992, J GEN PHYSIOL, V99, P615, DOI 10.1085/jgp.99.4.615; Bruggemann L, 1999, PLANTA, V207, P370, DOI 10.1007/s004250050494; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; Dietrich P, 1998, PLANTA, V205, P277, DOI 10.1007/s004250050322; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dreyer I, 1997, BIOPHYS J, V72, P2143, DOI 10.1016/S0006-3495(97)78857-X; Durell SR, 1996, NEUROPHARMACOLOGY, V35, P761, DOI 10.1016/0028-3908(96)00097-4; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; HEDRICH R, 1995, EUR BIOPHYS J, V66, P1061; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; Hoth S, 1997, J EXP BOT, V48, P415, DOI 10.1093/jxb/48.Special_Issue.415; Ichida AM, 1996, J MEMBRANE BIOL, V151, P53, DOI 10.1007/s002329900057; Ilan N, 1996, J MEMBRANE BIOL, V154, P169, DOI 10.1007/s002329900142; Ketchum KA, 1996, FEBS LETT, V378, P19, DOI 10.1016/0014-5793(95)01417-9; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Marten I, 1998, BIOPHYS J, V74, P2953, DOI 10.1016/S0006-3495(98)78002-6; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; Nakamura RL, 1997, J BIOL CHEM, V272, P1011, DOI 10.1074/jbc.272.2.1011; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; Sabirov RZ, 1997, PFLUG ARCH EUR J PHY, V433, P428, DOI 10.1007/s004240050296; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; UOZUMI N, 1995, J BIOL CHEM, V270, P24276, DOI 10.1074/jbc.270.41.24276; Uozumi N, 1998, P NATL ACAD SCI USA, V95, P9773, DOI 10.1073/pnas.95.17.9773; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; Zimmermann S, 1998, PLANT PHYSIOL, V116, P879, DOI 10.1104/pp.116.3.879	35	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11599	11603		10.1074/jbc.274.17.11599	http://dx.doi.org/10.1074/jbc.274.17.11599			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206968	hybrid			2022-12-25	WOS:000079834800024
J	Nakamura, T; Kambayashi, J; Okuma, M; Tandon, NN				Nakamura, T; Kambayashi, J; Okuma, M; Tandon, NN			Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both alpha(2)beta(1) integrin and GP VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-INDEPENDENT ADHESION; MEMBRANE GLYCOPROTEIN-VI; VON-WILLEBRAND-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-2; QUATERNARY STRUCTURE; INDUCED AGGREGATION; FLOW CONDITIONS; I COLLAGEN; C-SRC	alpha(2)beta(1) integrin, CD36, and GP VI have all been implicated in platelet-collagen adhesive interactions. We have investigated the role of these glycoproteins on activation of the GP IIb-IIIa complex induced by platelet adhesion to type I fibrillar and monomeric collagen under static conditions. In the presence of Mg2+, platelet adhesion to fibrillar collagen induced activation of the GP IIb-IIIa complex and complete spreading. Anti-alpha(2)beta(1) integrin and anti-GP VI antibodies inhibited the activation of the GP IIb-IIIa complex by about 40 and 50%, respectively, at 60 min although minimal inhibitory effects on adhesion were seen. Platelet spreading was markedly reduced by anti-alpha(2)beta(1) integrin antibody. The combination of anti-alpha(2)beta(1) integrin with anti-GP VI anti body completely inhibited both platelet adhesion and activation of the GP IIb-IIIa complex. Anti-CD36 antibody had no significant effects on platelet adhesion, spreading, and the activation of the GP IIb-IIIa complex at 60 min. Aspirin and the thromboxane A(2) receptor antagonist SQ29548 inhibited activation of the GP IIb-IIIa complex about 30% but had minimal inhibitory effect on adhesion. In the absence of Mg2+, there was significant activation of the GP IIb-IIIa complex brat minimal spreading was observed. Anti-GP VI antibody completely inhibited adhesion whereas no effect was observed with anti-alpha(2)beta(1) integrin antibody. Anti-CD36 antibody partially inhibited both adhesion and the activation of the GP IIb-IIIa complex. Platelet adhesion to monomeric collagen, which requires Mg2+ and is exclusively mediated by alpha(2)beta(1) integrin, resulted in partial activation of the GPIIb-IIIa complex and spreading. No significant effects were observed by anti-CD36 and anti-GP VI antibodies. These results suggest that both alpha(2)beta(1) integrin and GP VI are involved in inside-out signaling leading to activation of the GP IIb-IIIa complex after platelet adhesion to collagen and generation of thromboxane A(2) may further enhance expression of activated GP IIb-IIIa complexes.	Otsuka Amer Pharmaceut Inc, Maryland Res Labs, Rockville, MD 20850 USA; Takashima Gen Hosp, Shiga 5201121, Japan		Tandon, NN (corresponding author), Otsuka Amer Pharmaceut Inc, Maryland Res Labs, 9900 Med Ctr Dr, Rockville, MD 20850 USA.	narendrt@mrl.oapi.com						ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Asazuma N, 1996, THROMB HAEMOSTASIS, V75, P648; Barnes M J, 1998, Curr Opin Hematol, V5, P314, DOI 10.1097/00062752-199809000-00002; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; BEER JH, 1993, BLOOD, V82, P820; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BRASS LF, 1974, J CLIN INVEST, V54, P1480, DOI 10.1172/JCI107896; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; COLLER BS, 1989, BLOOD, V74, P182; COLLER BS, 1993, J CLIN INVEST, V92, P2796, DOI 10.1172/JCI116899; DECKMYN H, 1990, THROMB HAEMOSTASIS, V64, P74; DIAZRICART M, 1993, BLOOD, V82, P491; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; HAWIGER J, 1987, ANN NY ACAD SCI, V509, P131, DOI 10.1111/j.1749-6632.1987.tb30990.x; Ichinohe T, 1997, J BIOL CHEM, V272, P63; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; JAFFE R, 1974, J CLIN INVEST, V53, P875, DOI 10.1172/JCI107628; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kehrel B, 1998, BLOOD, V91, P491; KEHREL B, 1993, BLOOD, V82, P3364; KEHREL B, 1988, BLOOD, V71, P1074; KROLL MH, 1989, BLOOD, V74, P1181; MCKEOWN L, 1994, BLOOD, V83, P2866, DOI 10.1182/blood.V83.10.2866.2866; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; MUGGLI R, 1973, Thrombosis Research, V3, P715, DOI 10.1016/0049-3848(73)90018-2; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; POOLE AW, 1995, BRIT J PHARMACOL, V115, P101, DOI 10.1111/j.1476-5381.1995.tb16326.x; RAO GHR, 1994, J BIOL CHEM, V269, P13899; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; SUGIYAMA T, 1987, BLOOD, V69, P1712; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VANWILLIGEN G, 1992, BLOOD, V79, P82, DOI 10.1182/blood.V79.1.82.bloodjournal79182; Verkleij MW, 1998, BLOOD, V91, P3808; YAMAMOTO N, 1990, THROMB HAEMOSTASIS, V63, P97; YAMAMOTO N, 1992, BRIT J HAEMATOL, V81, P86, DOI 10.1111/j.1365-2141.1992.tb08177.x; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; ZIJENAH LS, 1990, BIOCHEM J, V268, P481, DOI 10.1042/bj2680481	50	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11897	11903		10.1074/jbc.274.17.11897	http://dx.doi.org/10.1074/jbc.274.17.11897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207010	hybrid			2022-12-25	WOS:000079834800066
J	Ochiai, M; Ashida, M				Ochiai, M; Ashida, M			A pattern recognition protein for peptidoglycan - Cloning the cDNA and the gene of the silkworm, Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; NF-KAPPA-B; MOLECULAR-CLONING; BACTERIAL PEPTIDOGLYCAN; HUMORAL LECTIN; HEMOLYMPH; PURIFICATION; CD14; ACTIVATION; DROSOPHILA	Peptidoglycan recognition protein (PGRP) specifically binds to peptidoglycan and is considered to be one of the pattern recognition proteins in the innate immunity of insect. The PGRP is an essential component for peptidoglycan to trigger the prophenoloxidase cascade that is now recognized to be an important insect defense mechanism, We cloned cDNA encoding PGRP from the silkworm fat body cDNA library. Northern blot analysis showed that the PGRP gene is constitutively expressed in the fat body, epithelial cell, and hemocytes of naive silkworms. Furthermore, a bacterial challenge intensified the gene expression, with the maximal period being from 6 to 36 h after infection. The upstream sequence of the cloned PGRP gene was shown to contain putative cis-regulatory elements similar to the NF-kappa B-like element, interferon-response half-element, and GATA motif element, which have been found in the promoters of the acute phase protein genes of mammals and insects. A homology search revealed that the homologs of silkworm PGRP are present in mice, nematodes, and bacteriophages, This suggests that the recognition of peptidoglycan as foreign is effected in both vertebrates and invertebrates by PGRP homologs with an evolutionally common origin.	Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Ochiai, M (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan.	ochiai@orange.lowtem.hokudai.ac.jp	Ochiai, Masanori/A-4372-2012	Ochiai, Masanori/0000-0002-0022-347X				AMANAI K, 1990, COMP BIOCHEM PHYS B, V97, P471, DOI 10.1016/0305-0491(90)90146-K; Ashida M., 1997, MOL MECH IMMUNE RESP, P135; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; ENGSTROM Y, 1997, MOL MECH IMMUNE RESP, P211; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JOMORI T, 1991, J BIOL CHEM, V266, P13318; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; KATO Y, 1993, INSECT BIOCHEM MOLEC, V23, P285, DOI 10.1016/0965-1748(93)90009-H; Kiselev SL, 1998, J BIOL CHEM, V273, P18633, DOI 10.1074/jbc.273.29.18633; Koizumi N, 1997, EUR J BIOCHEM, V248, P217, DOI 10.1111/j.1432-1033.1997.t01-1-00217.x; KOMANO H, 1985, DEV COMP IMMUNOL, V9, P31, DOI 10.1016/0145-305X(85)90057-6; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; PENDLAND JC, 1986, DEV COMP IMMUNOL, V10, P477, DOI 10.1016/0145-305X(86)90169-2; SCHMIDT O, 1993, DEV COMP IMMUNOL, V17, P195, DOI 10.1016/0145-305X(93)90038-R; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SODERHALL K, 1988, INSECT BIOCHEM, V18, P323, DOI 10.1016/0020-1790(88)90045-5; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	34	151	163	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11854	11858		10.1074/jbc.274.17.11854	http://dx.doi.org/10.1074/jbc.274.17.11854			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207004	hybrid			2022-12-25	WOS:000079834800060
J	Sun, YB; Sun, Y; Wenger, L; Rutter, JL; Brinckerhoff, CE; Cheung, HS				Sun, YB; Sun, Y; Wenger, L; Rutter, JL; Brinckerhoff, CE; Cheung, HS			p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; RHEUMATOID-ARTHRITIS SYNOVIUM; CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; GROWTH-FACTOR; DNA-BINDING; PROMOTER; REPRESSION	Recent studies show that the p53 tumor suppressor protein is overexpressed in rheumatoid arthritis (RA) synovium and that somatic mutations previously identified in human tumors are present in RA synovium (Firestein, G. S., Echeverri, F., Yeo, M., Zvaifler, N. J., and Green, D. R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10895-10900; Firestein, G. S., Nguyen, K., Aupperle, K. R, Yeo, M., Boyle, D. L., and Zvaifler, N. J. (1996) Am. J. Pathol. 149, 2143-2151; Reme, T., Travaglio, A., Gueydon, E., Adla, L, Jorgensen, C., and Sany, J. (1998) Clin. Exp. Immunol. 111, 353-3581). We hypothesize that the abnormality of p53 seen in RA synovium may contribute to joint degeneration through the regulation of human matrix metalloproteinase-1 (hMMP-1, collagenase-1) gene expression. Transcription assays were performed with luciferase reporters driven by the promoter of the hMMP-1 gene or by a minimal promoter containing tandem repeats of the consensus binding sequence for activator protein-1, cotransfected with p53-expressing plasmids, The results revealed that (i) wild-type (wt) p53 down-regulated the promoter activity of hMMP-1 in a dose-dependent fashion; (ii) four of six p53 mutants (commonly found in human cancers) lost this repression activity; and (iii) this p53 repression activity was mediated at least in part by the activator protein-1 sites found in the hMMP-1 promoter. These findings were further confirmed by Northern analysis. The down-regulation of hMMP-1 gene expression by endogenous wt-p53 was shown by treatment of U2-OS cells, a wt-p53-containing osteogenic sarcoma line, and Saos-2 cells, a p53-negative osteogenic sarcoma line, with etoposide, a potent inducer of p53 expression. p53, activated by etoposide, appears to block hMMP-1 promoter activity induced by etoposide in U2-OS cells. In summary, we have shown for the first time that the hMMP-1 gene is a p53 target gene, subject to p53 repression. Because MMP-1 is principally responsible for the irreversible destruction of collagen in articular tissue in RA, abnormality of p53 may contribute to joint degeneration through the regulation of MMP-1 expression.	Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33101 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Dartmouth Coll, Sch Med, Dept Pharmacol Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Med, Hanover, NH 03755 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; Pfizer; Dartmouth College; Dartmouth College	Cheung, HS (corresponding author), Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Rm NHCU 207G,1201 NW 16th St, Miami, FL 33125 USA.			Rutter, Joni/0000-0002-6502-2361	NIAMS NIH HHS [AR26599, AR38421, AR08662-33] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR026599, R01AR026599, R37AR008662, R01AR008662, R01AR038421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; AREND WP, 1993, TXB RHEUMATOLOGY, P227; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Aupperle KR, 1998, AM J PATHOL, V152, P1091; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRINCKERHOFF C E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P145; Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1; Cheung, 1980, J TISS CULT METHODS, V6, P39, DOI 10.1007/BF01665905; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Firestein GS, 1996, AM J PATHOL, V149, P2143; Firestein GS, 1997, P NATL ACAD SCI USA, V94, P10895, DOI 10.1073/pnas.94.20.10895; Garcia-Bermejo L, 1998, J CELL SCI, V111, P637; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARRIS DE, 1993, TXB RHEUMATOLOGY, P833; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; MARTELPELLETIER J, 1994, LAB INVEST, V70, P807; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Reme T, 1998, CLIN EXP IMMUNOL, V111, P353; RUTTER JL, 1997, J CELL BIOCHEM, V66, P1; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Steller MA, 1996, CANCER RES, V56, P5087; SUBLER MA, 1992, J VIROL, V66, P4754; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Wernicke D, 1996, J RHEUMATOL, V23, P590; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	54	114	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11535	11540		10.1074/jbc.274.17.11535	http://dx.doi.org/10.1074/jbc.274.17.11535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206959	hybrid			2022-12-25	WOS:000079834800015
J	Iben, S; Royer-Pokora, B				Iben, S; Royer-Pokora, B			Analysis of native WT1 protein from frozen human kidney and Wilms' tumors	ONCOGENE			English	Article						Wilms' tumor; WT1 protein; gelfiltration	DNA-BINDING; GENE WT1; TRANSCRIPTION; PHOSPHORYLATION; LOCALIZATION; INITIATION; EXPRESSION; INHIBITION; PRODUCT; P53	The Wilms' tumor susceptibility gene, WT1, is altered in a subset of Wilms' tumors and encodes a transcription factor with four zinc fingers. Here we describe the isolation of native WT1 protein from frozen normal human kidney and Wilms' tumor samples. Through size exclusion chromatography and Western blot analysis we determined the elution pattern of WT1, The majority of WT1 from adult kidney and Wilms' tumor specimens was found to elute at a size of approximately 120 kDa, consistent with a WT1 homodimer and some WT1 protein was also found in a higher molecular weight complex, In 14 week fetal kidney the majority of the WT1 protein eluted at a size of 80 kDa, suggesting that at this developmental stage the WT1 protein is not present as a homodimer, The identity of complexing partners can now be studied using this approach.	Univ Dusseldorf, Inst Human Genet & Anthropol, D-40001 Dusseldorf, Germany; Univ Heidelberg, Inst Human Genet & Anthropol, D-69120 Heidelberg, Germany	Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg	Royer-Pokora, B (corresponding author), Univ Dusseldorf, Inst Human Genet & Anthropol, Postfach 101007, D-40001 Dusseldorf, Germany.			Royer-Pokora, Brigitte/0000-0001-5114-7801				BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRENNER B, 1992, ONCOGENE, V7, P1431; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUBB GR, 1994, LAB INVEST, V71, P472; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; Schumacher V, 1997, P NATL ACAD SCI USA, V94, P3972, DOI 10.1073/pnas.94.8.3972; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	26	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2533	2536		10.1038/sj.onc.1202618	http://dx.doi.org/10.1038/sj.onc.1202618			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229205				2022-12-25	WOS:000079703300014
J	Hajnoczky, G; Hager, R; Thomas, AP				Hajnoczky, G; Hager, R; Thomas, AP			Mitochondria suppress local feedback activation of inositol 1,4,5-trisphosphate receptors by Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RAT-LIVER; CALCIUM OSCILLATIONS; PURKINJE-CELLS; RELEASE; TRISPHOSPHATE; MOBILIZATION; CEREBELLUM; METABOLISM; FRACTIONS	The concerted action of inositol 1,4,5-trisphosphate (IP3) and Ca2+ on the IP3 receptor Ca2+ release channel (IP3R) is a fundamental step in the generation of cytosolic Ca2+ oscillations and waves, which underlie Ca2+ signaling in many cells. Mitochondria appear in close association with regions of endoplasmic reticulum (ER) enriched in IP3R and are particularly responsive to IP3-induced increases of cytosolic Ca2+ ([Ca2+](c)). To determine whether feedback regulation of the IP3R by released Ca2+ is modulated by mitochondrial Ca2+ uptake, the interactions between ER and mitochondrial Ca2+ pools were examined by fluorescence imaging of compartmentalized Ca2+ indicators in permeabilized hepatocytes, IP3 decreased luminal ER Ca2+ ([Ca2+](ER)), and this was paralleled by an increase in mitochondrial matrix Ca2+ ([Ca2+](m)) and activation of Ca2+-sensitive mitochondrial metabolism. Remarkably, the decrease in [Ca2+](ER) evoked by submaximal IP3 was enhanced when mitochondrial Ca2+ uptake was blocked with ruthenium red or uncoupler. Moreover, subcellular regions that were relatively deficient in mitochondria demonstrated greater sensitivity to IP3 than regions of the cell with a high density of mitochondria. These data demonstrate that Ca2+ uptake by the mitochondria suppresses the local positive feedback effects of Ca2+ on the IP3R, giving rise to subcellular heterogeneity in IP3 sensitivity and IP3R excitability. Thus, mitochondria can play an important role in setting the threshold for activation and establishing the subcellular pattern of IP3-dependent [Ca2+](c) signaling.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	Thomas, AP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave,Univ Hts, Newark, NJ 07103 USA.	thomasap@umdnj.edu	Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422, R29DK038422, R01DK051526, R29DK051526] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38422, DK51526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Budd SL, 1996, J NEUROCHEM, V67, P2282; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DAWSON AP, 1984, BIOCHEM BIOPH RES CO, V120, P858, DOI 10.1016/S0006-291X(84)80186-2; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; Haugland RP, 1996, HDB FLUORESCENT PROB, P266; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; LUKACS GL, 1987, BIOCHIM BIOPHYS ACTA, V931, P251, DOI 10.1016/0167-4889(87)90213-8; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Michikawa T, 1996, CRIT REV NEUROBIOL, V10, P39, DOI 10.1615/CritRevNeurobiol.v10.i1.20; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHORE GC, 1977, J CELL BIOL, V72, P714, DOI 10.1083/jcb.72.3.714; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Tanimura A, 1996, J BIOL CHEM, V271, P30904, DOI 10.1074/jbc.271.48.30904; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296	35	219	222	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14157	14162		10.1074/jbc.274.20.14157	http://dx.doi.org/10.1074/jbc.274.20.14157			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318833	hybrid			2022-12-25	WOS:000080322200062
J	Huang, W; Dolmer, K; Gettins, PGW				Huang, W; Dolmer, K; Gettins, PGW			NMR solution structure of complement-like repeat CR8 from the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH REPEAT; TRIPLE-RESONANCE NMR; 3-DIMENSIONAL STRUCTURE; LIGAND-BINDING; CHEMICAL-SHIFTS; CALCIUM; DOMAIN; SENSITIVITY; DYNAMICS; SITE	The low density lipoprotein receptor-related protein is a member of the low density lipoprotein receptor family and contains clusters of cysteine-rich complement-like repeats of about 42 residues that are present in all members of this family of receptors, These clusters are thought to be the principal binding sites for protein ligands. We have expressed one complement-like repeat, CR8, from the cluster in lipoprotein receptor-related protein that binds certain proteinase inhibitor-proteinase complexes and used three-dimensional NMR on the C-13/N-15-labeled protein to determine the structure in solution of the calcium-hound form. The structure is very similar in overall fold to repeat 5 from the low density Lipoprotein receptor (LB5), with backbone root mean square deviation of 1.5 Angstrom. The calcium-binding. site also appears to be homologous, with four carboxyl and two backbone carbonyl ligands, However, differences in primary structure are such that equivalent surfaces that might represent the binding interfaces are very different from one another, indicating that different domains will have very different ligand specificities.	Univ Illinois, Dept Biochem & Mol Biol, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, Coll Med, M-C 536,1853 W Polk St, Chicago, IL 60612 USA.		Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkins AR, 1998, BIOCHEMISTRY-US, V37, P1662, DOI 10.1021/bi972529n; Biekofsky RR, 1998, BIOCHEMISTRY-US, V37, P7617, DOI 10.1021/bi9800449; BIERI S, 1995, BIOCHEMISTRY-US, V34, P13059, DOI 10.1021/bi00040a017; CASE DA, 1997, AMBER 5; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Dolmer K, 1998, BIOCHEMISTRY-US, V37, P17016, DOI 10.1021/bi982022s; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; [No title captured]	24	69	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14130	14136		10.1074/jbc.274.20.14130	http://dx.doi.org/10.1074/jbc.274.20.14130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318830	hybrid			2022-12-25	WOS:000080322200059
J	Saura, CA; Tomita, T; Davenport, F; Harris, CL; Iwatsubo, T; Thinakaran, G				Saura, CA; Tomita, T; Davenport, F; Harris, CL; Iwatsubo, T; Thinakaran, G			Evidence that intramolecular associations between presenilin domains are obligatory for endoproteolytic processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; TRANSFECTED CELLS; MISSENSE MUTATIONS; SENILE PLAQUES; APP MUTATIONS; WILD-TYPE; COMPLEX; GENE	Mutations in genes encoding presenilins (PS1 and PS2) cosegregate with the majority of early onset cases of familial. Alzheimer's disease. PS1 and PS2 are polytopic membrane proteins that undergo endoproteolytic cleavage to generate stable NH2- and COOH-terminal derivatives (NTF and CTF, respectively). Several lines of evidence suggest that the endoproteolytic derivatives are likely the functional units of PS in vivo. In the present report, we examine the disposition of PS NTF and CTF assemblies in stable mouse N2a neuroblastoma cell lines expressing human PS polypeptides. We show that exogenous expression of PS1 NTFs neither assemble with endogenous CTF nor exhibit dominant negative inhibitory effects on the endogenous PS1 cleavage and the accumulation of derivatives; In cells co-expressing PSI and PS2, PS1- and PS2-derived fragments do not form mixed assemblies. In contrast, cells expressing a chimeric PS1/PS2 polypeptide form stable PS1 NTF-PS2 CTF assemblies. Moreover, expression of chimeric PS1/ PS2 polypeptides harboring a familial early onset AD-linked mutation (M146L) elevates the production of A beta 42 peptides, Our results provide evidence that assembly of structural domains contained within NH2- and COOH-terminal regions of PS occur prior to endoproteolytic cleavage.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Neuropathol, Baltimore, MD 21205 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Tokyo 1130033, Japan	Johns Hopkins University; Johns Hopkins University; University of Tokyo	Thinakaran, G (corresponding author), Univ Chicago, Knapp Res Ctr, Dept Neurobiol Pharmacol & Physiol, 924 E 57th St, Chicago, IL 60637 USA.		Saura, Carlos A/D-2727-2011; Saura, Carlos A/AFM-9239-2022; Tomita, Taisuke/L-5427-2015	Saura, Carlos A/0000-0003-3692-5657; Tomita, Taisuke/0000-0002-0075-5943	NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER; NIA NIH HHS [1PO1 AG14248] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Busfield Frances, 1995, P59, DOI 10.1016/B978-012286965-5/50006-6; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lah JJ, 1997, J NEUROSCI, V17, P1971; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Mehta ND, 1998, ANN NEUROL, V43, P256, DOI 10.1002/ana.410430217; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; PEREZTUR J, 1995, NEUROREPORT, V7, P291; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SLUNT HH, 1995, AMYLOID, V2, P188, DOI 10.3109/13506129509036925; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; TOMITA T, 1983, J BIOL CHEM, V273, P2115; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Wisniewski HM, 1973, PROGR NEUROPATHOLOGY, V2, P1; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	43	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13818	13823		10.1074/jbc.274.20.13818	http://dx.doi.org/10.1074/jbc.274.20.13818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318786	hybrid			2022-12-25	WOS:000080322200015
J	Benard, V; Bohl, BP; Bokoch, GM				Benard, V; Bohl, BP; Bokoch, GM			Characterization of Rac and Cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; NADPH OXIDASE ACTIVITY; RESPIRATORY BURST OXIDASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HL-60 CELLS; PHOSPHOLIPASE-D; RHO-GTPASES; KINASE; INHIBITION	A major function of Rac2 in neutrophils is the regulation of oxidant production important in bacterial killing. Rac and the related GTPase Cdc42 also regulate the dynamics of the actin cytoskeleton, necessary for leukocyte chemotaxis and phagocytosis of microorganisms. Although these GTPases appear to be critical down stream components of chemoattractant receptor signaling in human neutrophils, the pathways involved in direct control of Rac/Cdc4a activation remain to be determined. We describe an assay that measures the formation of Rac-GTP and Cdc42-GTP based on their specific binding to the pal-binding domain of p21-activated kinase 1. A pal-binding domain glutathione S-transferase fusion protein specifically binds Rac and Cdc42 in their GTP-bound forms both in vitro and in cell samples. Binding is selective for Rac and Cdc42 versus RhoA. Using this assay, we investigated Rac and Cdc42 activation in neutrophils and differentiated HL-60 cells. The chemoattractant fMet-Leu-Phe and the phorbol ester phorbol myristate acetate stimulate formation of Rac-GTP and Cdc42-GTP with distinct time courses that parallel cell activation. We also show that the signaling pathways leading to Rac and Cdc42 activation in HL-60 cells involve G proteins sensitive to pertussis toxin, as well as tyrosine kinase and phosphatidylinositol 3-kinase activities.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Planat-Benard, Valerie/0000-0002-0712-4220	NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIGMS NIH HHS [GM39434, GM44428] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHUANG TH, 1993, J BIOL CHEM, V268, P775; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Houle MG, 1996, BIOCHEM CELL BIOL, V74, P459, DOI 10.1139/o96-050; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; OKADA T, 1994, J BIOL CHEM, V269, P3563; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	51	669	679	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13198	13204		10.1074/jbc.274.19.13198	http://dx.doi.org/10.1074/jbc.274.19.13198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224076	hybrid			2022-12-25	WOS:000080200400038
J	Hong, YL; Sarge, KD				Hong, YL; Sarge, KD			Regulation of protein phosphatase 2A activity by heat shock transcription factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; TUMOR-ANTIGENS; A-SUBUNIT; GENE-TRANSCRIPTION; CATALYTIC SUBUNIT; EXPRESSION; IDENTIFICATION; TYPE-2A; ACTIVATION; RABBIT	Heat shock transcription factor (HSF) mediates the stress-induced expression of heat shock protein genes (hsp), However, HSF is required for normal cell function even in the absence of stress and is important for cell cycle progression, but the mechanism that mediates these effects of HSF is unknown. Here, it is shown that a member of the HSF family, HSF2, interacts with the PR65 (A) subunit of protein phosphatase 2A (PP2A), HSF1 binding to PR65 blocks its interaction with the catalytic subunit, due to competition between HSF2 and catalytic subunit for the same binding site in PR65. In addition, overexpression of HSF2 stimulates PP2A activity in cells, indicating the relevance of HSF2 as a regulator of PP2A in vivo, These results identify HSF2 as a dual function protein, capable of regulating both hsp expression and PP2A activity. This could function as a mechanism by which hsp expression is integrated with the control of cell division or other PP2A-regulated pathways.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA	University of Kentucky	Sarge, KD (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA.	kdsarge@pop.uku.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD032008] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32008] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; CHEN SC, 1989, J BIOL CHEM, V264, P7267; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; James P, 1996, GENETICS, V144, P1425; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KINGSTON RE, 1991, HORMONAL CONTROL GEN, P377; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; Morimoto R I, 1996, EXS, V77, P139; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	45	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12967	12970		10.1074/jbc.274.19.12967	http://dx.doi.org/10.1074/jbc.274.19.12967			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224043	hybrid			2022-12-25	WOS:000080200400005
J	Stock, SD; Hama, H; DeWald, DB; Takemoto, JY				Stock, SD; Hama, H; DeWald, DB; Takemoto, JY			SEC14-dependent secretion in Saccharomyces cerevisiae - Nondependence on sphingolipid synthesis-coupled diacylglycerol production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; YEAST GOLGI-COMPLEX; VESICLE FORMATION; LIPID-SYNTHESIS; GENE; INOSITOL; TRANSPORT; 3-KINASE; IDENTIFICATION	The SEC14 gene in Saccharomyces cerevisiae encodes a phosphatidylinositol transfer protein required for secretory protein movement from the Golgi, Mutation of SAC1, a gene of unknown function, restores secretory now in sec14-1(ts) strains. The existing model for the bypass of the sec14-1(ts) defect by sac1-22 involves stimulation of sphingolipid biosynthesis and, in particular, the synthesis of mannosyl-diinositolphosphoryl-ceramide with concomitant increases in Golgi diacylglycerol levels. To test this model, we disrupted IPT1, the mannosyl-diinositolphosphoryl ceramide synthase of S, cerevisiae, Disruption of the IPT1 gene had no effect on the ability of sac1-22 to bypass sec14-1(ts). Furthermore, sphingolipid analysis of sec14-1(ts) and sec14-1(ts) sac1-22 strains showed that mannosyl-diinositolphosphoryl-ceramide synthesis was not stimulated in the bypass mutant. However, the sec14-1(ts) strain had elevated mannosyl-monoinositolphosphoryl-ceramide levels, and the sec14-1(ts) sac1-22 strain showed an 8-fold increase in phosphatidylinositol 4-phosphate along with a decrease in phosphatidylinositol 4,5-bisphosphate, Cellular diacylglycerol levels, measured by [C-14]acetate incorporation, did not differ between the sec14-1(ts) and the sec14-1 sac1-22 bypass strains, although disruption of IPT1 in the bypass strain resulted in reduced levels. These data indicate that phosphatidylinositol 4-phosphate, rather than mannosyl-diinositolphosphoryl-ceramide, accumulates in the sec14-1(ts) sac1-22 bypass strain, and that Golgi diacylglycerol accumulation is not required for bypass of the sec14-1(ts) growth and secretory phenotypes.	Utah State Univ, Dept Biol, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Takemoto, JY (corresponding author), Utah State Univ, Dept Biol, Logan, UT 84322 USA.	jon@biology.usu	Takemoto, Jon/A-5309-2011	Takemoto, Jon/0000-0001-9919-9168				BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BUTTKE TM, 1982, J BACTERIOL, V152, P747; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Kaiser C., 1994, METHODS YEAST GENETI; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Panaretou C, 1997, J BIOL CHEM, V272, P2477; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SMITH SW, 1974, J BIOL CHEM, V249, P3395; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Westphal V, 1996, J BIOL CHEM, V271, P11865, DOI 10.1074/jbc.271.20.11865; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346	32	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12979	12983		10.1074/jbc.274.19.12979	http://dx.doi.org/10.1074/jbc.274.19.12979			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224046	hybrid			2022-12-25	WOS:000080200400008
J	Zhang, N; Zhong, R; Deuel, TF				Zhang, N; Zhong, R; Deuel, TF			Domain structure of pleiotrophin required for transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING BRAIN; EXPRESSION; PROTEIN; CLONING; MIDKINE; CELLS	The pleiotrophin (PTN) gene (Ptn) is a potent proto-oncogene that is highly expressed in many primary human tumors and constitutively expressed in cell lines derived from these tumors. The product of the Ptn gene is a secreted 136-amino acid heparin binding cytokine with distinct lysine-rich clusters within both the N- and C-terminal domains. To seek domains of PTN functionally important in neoplastic transformation, we constructed a series of mutants and tested their transforming potential by four independent criteria. Our data establish that a domain within PTN residues 41 to 64 and either but not both the N- or C-terminal domains are required for transformation; deletion of both the N- and C termini abolishes the transformation potential of PTN. Furthermore, deletion of two internal 5-amino acid residue repeats enhances the transformation potency of PTN a-fold. Our data indicate that PTN residues 41-64 contain an essential domain for transformation and suggest the hypothesis that this domain requires an additional interaction of the highly basic clusters of the N or C terminus of PTN with a negatively charged "docking" site to enable the transforming domain itself to engage and initiate PTN signaling through its cognate receptor.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Growth Regulat, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Deuel, TF (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Growth Regulat, 330 Brookline Ave, Boston, MA 02215 USA.							CERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; FANG WJ, 1992, J BIOL CHEM, V267, P25889; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SilosSantiago I, 1996, J NEUROBIOL, V31, P283, DOI 10.1002/(SICI)1097-4695(199611)31:3<283::AID-NEU2>3.0.CO;2-6; TSUTSUI J, 1993, CANCER RES, V53, P1281; WALKER A, 1994, J BIOL CHEM, V269, P931; ZHANG N, 1997, J BIOL CHEM, V272, P16730	15	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12959	12962		10.1074/jbc.274.19.12959	http://dx.doi.org/10.1074/jbc.274.19.12959			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224041	hybrid			2022-12-25	WOS:000080200400003
J	Desrumaux, C; Deckert, V; Athias, A; Masson, D; Lizard, G; Palleau, V; Gambert, P; Lagrost, L				Desrumaux, C; Deckert, V; Athias, A; Masson, D; Lizard, G; Palleau, V; Gambert, P; Lagrost, L			Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells	FASEB JOURNAL			English	Article						acetylcholine; aorta; lipid transfer protein; oxidized LDL; vitamin E	LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-FED RABBITS; DEPENDENT ARTERIAL RELAXATION; ESTER TRANSFER PROTEIN; VITAMIN-E; LIPID-PEROXIDATION; OXIDIZED LDL; NITRIC-OXIDE; IN-VITRO; INHIBITION	alpha-tocopherol, the most potent antioxidant form of vitamin E, is mainly bound to lipoproteins in plasma and its incorporation into the vascular wall can prevent the endothelium dysfunction at an early stage of atherogenesis. In the present study, the plasma phospholipid transfer protein (PLTP) was shown to promote the net mass transfer of alpha-tocopherol from high density lipoproteins (HDL) and alpha-tocopherol-albumin complexes toward alpha-tocopherol-depleted, oxidized low density lipoproteins (LDL). The facilitated transfer reaction of alpha-tocopherol could be blocked by specific anti-PLTP antibodies. These observations indicate that PLTP may restore the antioxidant potential of plasma LDL at an early stage of the oxidation cascade that subsequently leads to cellular damages. In addition, the present study demonstrated that the PLTP-mediated net mass transfer of alpha-tocopherol can constitute a new mechanism for the incorporation of alpha-tocopherol into the vascular wall in addition to the previously recognized LDL receptor and lipoprotein lipase pathways. In ex vivo studies on rabbit aortic segments, the impairment of the endothelium-dependent arterial relaxation induced by oxidized LDL was found to be counteracted by a pretreatment with purified PLTP and alpha-tocopherol-albumin complexes, and both the maximal response and the sensitivity to acetylcholine were significantly improved. We conclude that PLTP, by supplying oxidized LDL and endothelial cells with alpha-tocopherol through a net mass transfer reaction may play at least two distinct beneficial roles in preventing endothelium damage, i.e., the antioxidant protection of LDL and the preservation of a normal relaxing function of vascular endothelial cells.	Hop Bocage, Lab Biochim Lipoprot, INSERM U498, F-21034 Dijon, France	CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lagrost, L (corresponding author), Hop Bocage, Lab Biochim Lipoprot, INSERM U498, BP 1542, F-21034 Dijon, France.		MASSON, David/AAC-8896-2022; Desrumaux, Catherine/O-1925-2018; Lizard, Gerard/B-2439-2012; Masson, David/R-6633-2019; MASSON, David/R-4557-2017	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; DECKERT, Valerie/0000-0001-5728-1710				ANDERSSON TLG, 1994, ATHEROSCLEROSIS, V111, P39, DOI 10.1016/0021-9150(94)90189-9; AZZI A, 1992, LIPID SOLUBLE ANTIOX, P122; BEHRENS WA, 1982, AM J CLIN NUTR, V35, P691, DOI 10.1093/ajcn/35.4.691; BOSCOBOINIK D, 1991, J CLIN INVEST, V98, P386; CHATELAIN E, 1993, BIOCHIM BIOPHYS ACTA, V1176, P83, DOI 10.1016/0167-4889(93)90181-N; Chow SE, 1998, FASEB J, V12, P823, DOI 10.1096/fasebj.12.10.823; DECKERT V, 1994, BRIT J PHARMACOL, V112, P939, DOI 10.1111/j.1476-5381.1994.tb13171.x; Deckert V, 1998, ARTERIOSCL THROM VAS, V18, P1054, DOI 10.1161/01.ATV.18.7.1054; Deckert V, 1997, CIRCULATION, V95, P723, DOI 10.1161/01.CIR.95.3.723; Desrumaux C, 1999, ARTERIOSCL THROM VAS, V19, P266, DOI 10.1161/01.ATV.19.2.266; ESTEBAN JM, 1991, MODERN PATHOL, V4, P53; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FARUQI R, 1994, J CLIN INVEST, V94, P592, DOI 10.1172/JCI117374; FRYER MJ, 1995, REDOX REP, V1, P159, DOI 10.1080/13510002.1995.11746975; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GALLE J, 1994, HYPERTENSION, V23, P556, DOI 10.1161/01.HYP.23.5.556; Goti D, 1998, BIOCHEM J, V332, P57, DOI 10.1042/bj3320057; GRANOT E, 1988, LIPIDS, V23, P17, DOI 10.1007/BF02535298; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; HENNIG B, 1987, NUTR RES, V7, P1253, DOI 10.1016/S0271-5317(87)80085-4; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; KAYDEN HJ, 1993, J LIPID RES, V34, P343; KEANEY JF, 1994, J CLIN INVEST, V93, P844, DOI 10.1172/JCI117039; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; Keaney JF, 1996, J CLIN INVEST, V98, P386, DOI 10.1172/JCI118804; KOSTNER GM, 1995, BIOCHEM J, V305, P659, DOI 10.1042/bj3050659; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LAGROST L, 1994, J LIPID RES, V35, P825; LEFER AM, 1991, FASEB J, V5, P2029, DOI 10.1096/fasebj.5.7.2010056; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P429, DOI 10.1161/01.ATV.17.3.429; MATSUDA Y, 1993, CIRC RES, V72, P1103, DOI 10.1161/01.RES.72.5.1103; MCCORMICK EC, 1960, J LIPID RES, V1, P221; MILLER KW, 1985, ANAL BIOCHEM, V145, P21, DOI 10.1016/0003-2697(85)90321-5; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Nishida HI, 1997, J BIOL CHEM, V272, P6959, DOI 10.1074/jbc.272.11.6959; OGIHARA T, 1988, CLIN CHIM ACTA, V174, P299, DOI 10.1016/0009-8981(88)90056-3; OHTA Y, 1997, AM J PHYSIOL, V273, pH1215; Rao R, 1997, BIOCHEMISTRY-US, V36, P3645, DOI 10.1021/bi962776b; REAVEN PD, 1995, ENDOCRINOLOGIST, V5, P44, DOI 10.1097/00019616-199501000-00007; ROMANCHIK JE, 1995, J NUTR, V125, P2610; SATO Y, 1991, FEBS LETT, V288, P41, DOI 10.1016/0014-5793(91)80999-J; SIMON BC, 1990, J CLIN INVEST, V86, P75, DOI 10.1172/JCI114718; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; STEWARTLEE AL, 1994, ARTERIOSCLER THROMB, V14, P494, DOI 10.1161/01.ATV.14.3.494; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TAKAHASHI Y, 1977, J NUTR SCI VITAMINOL, V23, P201; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TRABER MG, 1992, LIPIDS, V27, P657, DOI 10.1007/BF02536020; TRABER MG, 1984, AM J CLIN NUTR, V40, P747, DOI 10.1093/ajcn/40.4.747; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; YOKOYAMA M, 1990, BIOCHEM BIOPH RES CO, V168, P301, DOI 10.1016/0006-291X(90)91708-Z	60	74	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					883	892		10.1096/fasebj.13.8.883	http://dx.doi.org/10.1096/fasebj.13.8.883			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224231				2022-12-25	WOS:000080372500011
J	Ram, JL; Muller, CT; Beckmann, M; Hardege, JD				Ram, JL; Muller, CT; Beckmann, M; Hardege, JD			The spawning pheromone cysteine-glutathione disulfide ('nereithione') arouses a multicomponent nuptial behavior and electrophysiological activity in Nereis succinea males	FASEB JOURNAL			English	Article						cysteine-glutathione disulfide; pheromone; spawning behavior; sperm release	CILIATE EUPLOTES-RAIKOVI; OXIDIZED GLUTATHIONE; MONOCLONAL-ANTIBODIES; PHYSIOLOGICAL SLEEP; HYDRA; BINDING; ACID; CHEMORECEPTION; PURIFICATION; DEPRESS	The pheromone nereithione (cysteine-glutathione disulfide), which is released by swimming females of the polychaete Nereis succinea to activate spawning behavior of N. succinea males, has recently been identified and synthesized. Nereithione activates sperm release at less than 10(-6) M, one to two orders of magnitude less than oxidized glutathione or any other glutathione derivative tested. The glutathione fragment gamma-glu-cys inhibited sperm release. Nereithione aroused three components of the male nuptial behavior: circling, sperm release, and accelerated swimming. Electrophysiological activity elicited by nereithione near the sperm release site consisted of initial large spikes, cyclic bursting activity, and small spikes lasting up to a minute and was dose dependent, rapid, reversible, and repeatable. This preparation is an excellent model system for characterizing the receptors and functions of a marine pheromone.	Wayne State Univ, Dept Physiol, Gordon H Scott Hall Basic Med Sci, Detroit, MI 48201 USA; Univ Wales, Cardiff CF1 3TL, S Glam, Wales	Wayne State University; Cardiff University	Ram, JL (corresponding author), Wayne State Univ, Dept Physiol, Gordon H Scott Hall Basic Med Sci, 540 E Canfield Ave, Detroit, MI 48201 USA.		Beckmann, Manfred/AAX-9979-2021; Müller, Carsten T/A-7114-2010	Müller, Carsten T/0000-0003-0455-7132				BELLIS SL, 1991, BIOCHIM BIOPHYS ACTA, V1061, P89, DOI 10.1016/0005-2736(91)90272-A; BOILLYMARER Y, 1978, J EXP ZOOL, V205, P119, DOI 10.1002/jez.1402050114; BOILLYMARER Y, 1980, J EXP ZOOL, V213, P33, DOI 10.1002/jez.1402130106; COBB MH, 1982, MOL PHARMACOL, V21, P629; GROSVENOR W, 1992, BIOCHIM BIOPHYS ACTA, V1117, P120, DOI 10.1016/0304-4165(92)90068-6; HANAI K, 1986, COMP BIOCHEM PHYS A, V83, P313; HARDEGE JD, 1990, MAR BIOL, V104, P291, DOI 10.1007/BF01313270; HARDEGE JD, 1998, IN PRESS ECOSICNECE, V5; HCARDEGE JD, 1997, POLYCHAETE RES, V17, P18; HONDA K, 1994, BRAIN RES, V636, P253, DOI 10.1016/0006-8993(94)91024-3; HONDA K, 1991, SLEEP RES A, V20, P139; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; Kimura M, 1998, BRAIN RES BULL, V45, P545, DOI 10.1016/S0361-9230(97)00441-3; KOMODA Y, 1990, CHEM PHARM BULL, V38, P2057; LACH H, 1986, ACTA BIOL HUNG, V37, P93; LENHOFF HM, 1961, NATURE, V189, P486, DOI 10.1038/189486a0; Lillie FR, 1913, BIOL BULL-US, V24, P147, DOI 10.2307/1535996; OHTA K, 1992, BIOCHIM BIOPHYS ACTA, V1117, P136, DOI 10.1016/0304-4165(92)90071-2; Painter SD, 1998, BIOL BULL-US, V194, P120, DOI 10.2307/1543042; RAFFIONI S, 1987, EXP CELL RES, V172, P417, DOI 10.1016/0014-4827(87)90399-5; RAFFIONI S, 1988, J BIOL CHEM, V263, P18152; RAFFIONI S, 1989, BIOCHEMISTRY-US, V28, P5250, DOI 10.1021/bi00438a049; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P2071, DOI 10.1073/pnas.89.6.2071; ROELOFS WL, 1995, P NATL ACAD SCI USA, V92, P44, DOI 10.1073/pnas.92.1.44; SAKAGUCHI M, 1991, J COMP PHYSIOL A, V168, P409, DOI 10.1007/BF00199601; STEWART AE, 1992, PROTEIN SCI, V1, P777, DOI 10.1002/pro.5560010609; TOWNSEND G, 1939, THESIS U CHICAGO CHI; Zeeck E, 1998, J CHEM ECOL, V24, P13, DOI 10.1023/A:1022328610423; Zeeck E, 1996, NATURE, V382, P214, DOI 10.1038/382214a0; Zeeck E, 1998, CHEMOECOLOGY, V8, P33, DOI 10.1007/PL00001801	30	38	38	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					945	952		10.1096/fasebj.13.8.945	http://dx.doi.org/10.1096/fasebj.13.8.945			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224237				2022-12-25	WOS:000080372500017
J	Eickelberg, O; Pansky, A; Mussmann, R; Bihl, M; Tamm, M; Hildebrand, P; Perruchoud, AP; Roth, M				Eickelberg, O; Pansky, A; Mussmann, R; Bihl, M; Tamm, M; Hildebrand, P; Perruchoud, AP; Roth, M			Transforming growth factor-beta 1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; ALPHA-2(I) COLLAGEN; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; INDUCED PROLIFERATION; PULMONARY FIBROSIS; AP-1 COMPLEX; BINDING-SITE; RECEPTOR; PROMOTER	Transforming growth factor (TGF)-beta 1 induces extracellular matrix deposition and proliferation of mesenchymal cells. We recently reported that interleukin (IL)-6 is an essential mediator of growth factor-induced proliferation of lung fibroblasts. Here, we demonstrate by reverse transcriptase polymerase chain reaction and enzyme-linked immunoassay that TGF-beta 1 is a potent inducer of IL-6 mRNA and protein in primary human lung fibroblasts, Transient transfections of fibroblasts with a luciferase reporter gene construct containing nucleotides -651 to +1 of the human IL-6 promoter revealed that TGF-beta 1 also potently activated IL-6 promoter activity. Progressive 5'-deletions and site-directed mutagenesis of the parental construct located the TGF-pl-responsive cis-regulatory element to a known activating protein-1 (AP-1) sequence (nucleotides -284 to -276). Gel shift analyses revealed that AP-1 DNA binding activity in nuclear extracts was increased 30 min after stimulation with TGF-beta 1. In contrast, neither CCAAT enhancer-binding protein-beta, NF-kappa B, nor Spl were activated by TGF-beta 1, Supershift analyses demonstrated that the AP-1 complex induced by TGF-beta 1 was composed of Jun isoforms and absent of Fos isoforms, Moreover, this complex was found to be a JunD homodimer, Our data thus demonstrate that TGF-beta 1 is a potent inducer of IL-6 in primary human lung fibroblasts, The TGF-beta 1-activated JunD homodimer may be essential for a majority of the biological effects induced by TGF-beta 1 in this cell type, such as proliferation and extracellular matrix synthesis.	Univ Basel Hosp, Dept Res & Internal Med, CH-4031 Basel, Switzerland; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	University of Basel; Netherlands Cancer Institute	Eickelberg, O (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,LB 08, New Haven, CT 06520 USA.	oliver.eickelberg@yale.edu	Eickelberg, Oliver/A-5461-2013; Roth, Michael/H-8657-2019	Eickelberg, Oliver/0000-0001-7170-0360; Roth, Michael/0000-0002-8139-2821				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Bihl M, 1998, AM J RESP CELL MOL, V19, P606, DOI 10.1165/ajrcmb.19.4.3247; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Coker RK, 1998, EUR RESPIR J, V11, P1218, DOI 10.1183/09031936.98.11061218; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GAULDIE J, 1993, THORAX, V48, P931, DOI 10.1136/thx.48.9.931; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HSU JC, 1993, CANCER RES, V53, P3789; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Mazzarelli P, 1998, J NEUROIMMUNOL, V87, P185, DOI 10.1016/S0165-5728(98)00110-6; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; OSAWA H, 1995, NEPHROL DIAL TRANSPL, V10, P1592; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; ROTH M, 1995, P NATL ACAD SCI USA, V92, P1312, DOI 10.1073/pnas.92.5.1312; St-Arnaud Rene, 1998, Frontiers in Bioscience, V3, pD838; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; YAMASHITA I, 1994, BLOOD, V84, P1573; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369	46	155	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12933	12938		10.1074/jbc.274.18.12933	http://dx.doi.org/10.1074/jbc.274.18.12933			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212284	hybrid			2022-12-25	WOS:000080056800104
J	Majcherczyk, PA; Langen, H; Heumann, D; Fountoulakis, M; Glauser, MP; Moreillon, P				Majcherczyk, PA; Langen, H; Heumann, D; Fountoulakis, M; Glauser, MP; Moreillon, P			Digestion of Streptococcus pneumoniae cell walls with its major peptidoglycan hydrolase releases branched stem peptides carrying proinflammatory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-MONOCYTES; TEICHOIC-ACID; BACTERIAL PEPTIDOGLYCAN; FACTOR-ALPHA; LIPOPOLYSACCHARIDE LPS; PNEUMOCOCCAL AUTOLYSIN; BINDING-PROTEIN; CROSS-LINKING; ORGAN FAILURE	The peptidoglycan of Gram-positive bacteria is known to trigger cytokine release from peripheral blood mononuclear cells (PBMCs), However, it requires 100-1000 times more Gram-positive peptidoglycan than Gramnegative Lipopolysaccharide to release the same amounts of cytokines from target cells. Thus, either peptidoglycan is poorly active or only part of it is required for PBMC activation. To test this hypothesis, purified Streptococcus pneumoniae walls were digested with their major autolysin N-acetylmuramoyl-L-alanine amidase, and/or muramidase, Solubilized walls were separated by reverse phase high pressure chromatography, Individual fractions were tested for their PBMC-stimulating activity, and their composition was determined, Soluble components had a M-r between 600 and 1500, These primarily comprised stem peptides cross-linked to various extents. Simple stem peptides (M-r <750) were 10-fold less active than undigested peptidoglycan. In contrast, tripeptides (M-r >1000) were greater than or equal to 100-fold more potent than the native material. One dipeptide (inactive) and two tripeptides (active) were confirmed by post-source decay analysis. Complex branched peptides represented less than or equal to 2% of the total material, but their activity (w/w) was almost equal to that of LPS, This is the first observation suggesting that peptidoglycan stem peptides carry high tumor necrosis factor-stimulating activity. These types of structures are conserved among Gram-positive bacteria and will provide new material to help elucidate the mechanism of peptidoglycan-induced inflammation.	F Hoffmann La Roche & Co Ltd, Pharmaceut Res Gene Technol, CH-4070 Basel, Switzerland; CHU Vaudois, Div Infect Dis, Dept Internal Med, CH-1011 Lausanne, Switzerland	Roche Holding; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Moreillon, P (corresponding author), CHU Vaudois, Div Infect Dis, Dept Internal Med, CH-1011 Lausanne, Switzerland.				NCI NIH HHS [CA44013] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044013] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; AWADA A, 1992, CLIN INFECT DIS, V15, P33, DOI 10.1093/clinids/15.1.33; BAUMGARTNER JD, 1990, J EXP MED, V171, P889, DOI 10.1084/jem.171.3.889; BERRY AM, 1989, INFECT IMMUN, V57, P2324, DOI 10.1128/IAI.57.8.2324-2330.1989; BONE RC, 1993, J CRIT CARE, V8, P51, DOI 10.1016/0883-9441(93)90033-H; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CRASS BA, 1986, J INFECT DIS, V153, P918, DOI 10.1093/infdis/153.5.918; DESCH CE, 1989, LYMPHOKINE RES, V8, P141; DOKTER WHA, 1994, J BIOL CHEM, V269, P4201; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; ELLOUZ F, 1974, BIOCHEM BIOPH RES CO, V59, P1317, DOI 10.1016/0006-291X(74)90458-6; FISCHER H, 1985, J BACTERIOL, V163, P46, DOI 10.1128/JB.163.1.46-54.1985; Fountoulakis M, 1997, ELECTROPHORESIS, V18, P2968, DOI 10.1002/elps.1150181539; FOX A, 1982, INFECT IMMUN, V35, P1003, DOI 10.1128/IAI.35.3.1003-1010.1982; GARCIA E, 1985, MOL GEN GENET, V201, P225, DOI 10.1007/BF00425663; GARCIA JL, 1988, FEMS MICROBIOL LETT, V52, P133; GARCIA P, 1989, BIOCHEM BIOPH RES CO, V158, P251, DOI 10.1016/S0006-291X(89)80205-0; GARCIABUSTOS J, 1989, J BACTERIOL, V171, P114, DOI 10.1128/jb.171.1.114-119.1989; GARCIABUSTOS JF, 1988, J BACTERIOL, V170, P2143, DOI 10.1128/jb.170.5.2143-2147.1988; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, J BACTERIOL, V169, P447, DOI 10.1128/jb.169.2.447-453.1987; GLAUSER MP, 1994, CLIN INFECT DIS   S2, V18, P205; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; HOLTJE JV, 1976, J BIOL CHEM, V251, P4199; Kengatharan KM, 1998, J EXP MED, V188, P305, DOI 10.1084/jem.188.2.305; MATTSSON E, 1993, FEMS IMMUNOL MED MIC, V7, P281, DOI 10.1016/0928-8244(93)90023-W; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MOSSER JL, 1970, J BIOL CHEM, V245, P287; NATANSON C, 1986, J CLIN INVEST, V78, P259, DOI 10.1172/JCI112559; PARSONNET J, 1989, REV INFECT DIS S1, V11, P263; RIESENFELDORN I, 1989, INFECT IMMUN, V57, P1890, DOI 10.1128/IAI.57.7.1890-1893.1989; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SEVERIN A, 1995, FEMS MICROBIOL LETT, V130, P31; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Stevens DL, 1996, J INFECT DIS, V173, P619, DOI 10.1093/infdis/173.3.619; TIMMERMAN CP, 1993, INFECT IMMUN, V61, P4167, DOI 10.1128/IAI.61.10.4167-4172.1993; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; VAUDAUX P, 1992, J INFECT DIS, V166, P58, DOI 10.1093/infdis/166.1.58; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	45	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12537	12543		10.1074/jbc.274.18.12537	http://dx.doi.org/10.1074/jbc.274.18.12537			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212231	hybrid			2022-12-25	WOS:000080056800051
J	Urano, T; Yashiroda, H; Muraoka, M; Tanaka, K; Hosoi, T; Inoue, S; Ouchi, Y; Tanaka, K; Toyoshima, H				Urano, T; Yashiroda, H; Muraoka, M; Tanaka, K; Hosoi, T; Inoue, S; Ouchi, Y; Tanaka, K; Toyoshima, H			p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; CDK INHIBITOR; FACTOR-BETA; DIFFERENTIATION; EXPRESSION; P27; PHENOTYPE; P27(KIP1); BONE	Cyclin-dependent kinase inhibitory proteins are negative regulators of the cell cycle. Although all the cyclin-dependent kinase inhibitory proteins may be involved in cell cycle control during a differentiation process, only p57(Kip2) is shown to be essential for embryonic development. However, the role of p57 in the control of the cell cycle is poorly understood. Using osteoblasts derived from the calvaria of rat fetus, we show that p57 is accumulated in cells starved by low serum. Cyclin-dependent kinase 2 activity was suppressed in these cells with a significant amount bound to p57, Treatment of the cells with transforming growth factor beta 1 dramatically reduced the amount of p57, resulting in an activation of cyclin-dependent kinase 2 activity and the stimulation of cell proliferation. The decrease in p57 was inhibited by treating the cells with proteasome inhibitors, Z-Leu-Leu-Leu-aldehyde or lactacystin, but not with Z-Leu-Leu-aldehyde, which is an inhibitor of calpain, indicating that p57 is degraded through the proteasome pathway. p57 was also shown to be ubiquitinated in vitro, Because transforming growth factor beta 1 not only stimulates the growth but also inhibits the differentiation of the cells in this system, our results may suggest a possible involvement of p57 in the control of osteoblastic cell proliferation and differentiation.	Metropolitan Inst Mes Sci, Dept Tumor Biochem, Bunkyo Ku, Tokyo 1138613, Japan; Metropolitan Inst Mes Sci, Dept Chemotherapy & CREST, Japan Sci & Technol Corp, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan	Japan Science & Technology Agency (JST); University of Tokyo	Toyoshima, H (corresponding author), Metropolitan Inst Mes Sci, Dept Tumor Biochem, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Urano, Tomohiko/AFS-9574-2022; Yashiroda, Hideki/Y-7641-2019					BREEN EC, 1994, J CELL PHYSIOL, V160, P323, DOI 10.1002/jcp.1041600214; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	41	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12197	12200		10.1074/jbc.274.18.12197	http://dx.doi.org/10.1074/jbc.274.18.12197			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212182	hybrid			2022-12-25	WOS:000080056800002
J	Xu, F; Palmer, AE; Yaver, DS; Berka, RM; Gambetta, GA; Brown, SH; Solomon, EI				Xu, F; Palmer, AE; Yaver, DS; Berka, RM; Gambetta, GA; Brown, SH; Solomon, EI			Targeted mutations in a Trametes villosa laccase - Axial perturbations of the T1 copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGAL LACCASES; ASCORBATE OXIDASE; CRYSTAL-STRUCTURE; REDOX POTENTIALS; ACTIVE-SITE; PROTEINS; AZURIN; CERULOPLASMIN; RESOLUTION; INHIBITION	Trametes villosa laccase was mutated on a tetrapeptide segment near the type 1 site. The mutations F463M and F463L were at the position corresponding to the type 1 copper axial methionine (M517) ligand in Zucchini ascorbate oxidase, The mutations E460S and A461E were near the T1 copper site. The mutated Trametes laccases were expressed in an Aspergillus oryzae host and characterized. The E460S mutation failed to produce a transformant with meaningful expression. The F463L and A461E mutations did not significantly alter the molecular and enzymological properties of the laccase, In contrast, the F463M mutation resulted in a type 1 copper site with an EPR signal intermediate between that of the wild type laccase and plastocyanin, an altered UV-visible spectrum, and a decreased redox potential (by 0.1 V). In oxidizing phenolic substrate, the mutation led to a more basic optimal pH as well as an increase in h(cat) and K-m. These effects are attributed to a significant perturbation of the T1 copper center caused by the coordination of the axial methionine (M463) ligand.	Novo Nordisk Biotech, Davis, CA 95616 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Novo Nordisk; Stanford University	Xu, F (corresponding author), Novo Nordisk Biotech, 1445 Drew Ave, Davis, CA 95616 USA.	fengxu@nnbt.com; fb.eis@forsythe.stanford.edu		Yaver, Debbie/0000-0003-4150-6756; Solomon, Edward/0000-0003-0291-3199; Gambetta, Gregory/0000-0002-8838-5050	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031450, R01DK031450] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31450] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN JP, 1983, DNA-J MOLEC CELL BIO, V2, P183, DOI 10.1089/dna.1983.2.183; COLE JL, 1990, J AM CHEM SOC, V112, P2243, DOI 10.1021/ja00162a025; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Eggert C, 1998, APPL ENVIRON MICROB, V64, P1766; Gray H. B., 1983, COMMENTS INORG CHEM, V2, P203; GUCKERT JA, 1995, J AM CHEM SOC, V117, P2817, DOI 10.1021/ja00115a016; KARLSSON BG, 1989, FEBS LETT, V253, P99, DOI 10.1016/0014-5793(89)80938-X; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MAYER AM, 1987, PHYTOCHEMISTRY, V26, P11; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Messerschmidt A., 1997, MULTICOPPER OXIDASES; NAKAMURA T, 1958, BIOCHIM BIOPHYS ACTA, V30, P44, DOI 10.1016/0006-3002(58)90239-7; PASCHER T, 1993, EUR J BIOCHEM, V212, P289, DOI 10.1111/j.1432-1033.1993.tb17661.x; ROMERO A, 1993, J MOL BIOL, V229, P1007, DOI 10.1006/jmbi.1993.1101; SOLOMON EI, 1997, MULTICOPPER OXIDASES, P103; SPIRASOLOMON DJ, 1986, J AM CHEM SOC, V108, P5318, DOI 10.1021/ja00277a043; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; SYKES AG, 1991, ADV INORG CHEM, V36, P377, DOI 10.1016/S0898-8838(08)60044-6; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WERST MM, 1991, J AM CHEM SOC, V113, P1533, DOI 10.1021/ja00005a011; Xu F, 1996, BIOCHEMISTRY-US, V35, P7608, DOI 10.1021/bi952971a; Xu F, 1997, J BIOL CHEM, V272, P924, DOI 10.1074/jbc.272.2.924; Xu F, 1996, BBA-PROTEIN STRUCT M, V1292, P303, DOI 10.1016/0167-4838(95)00210-3; Xu F, 1998, BIOCHEM J, V334, P63, DOI 10.1042/bj3340063; Yaver DS, 1996, APPL ENVIRON MICROB, V62, P834, DOI 10.1128/AEM.62.3.834-841.1996; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	27	154	162	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12372	12375		10.1074/jbc.274.18.12372	http://dx.doi.org/10.1074/jbc.274.18.12372			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212209	hybrid			2022-12-25	WOS:000080056800029
J	Zimmermann, N; Conkright, JJ; Rothenberg, ME				Zimmermann, N; Conkright, JJ; Rothenberg, ME			CC chemokine receptor-3 undergoes prolonged ligand-induced internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG MODEL; EOTAXIN RECEPTOR; CHEMOATTRACTANT RECEPTORS; EOSINOPHIL RECRUITMENT; CHEMOTACTIC CYTOKINES; ALLERGIC INFLAMMATION; HIV-1 CORECEPTOR; IN-VIVO; EXPRESSION; PROTEIN	CC chemokine receptor-3 (CCR-3) is a major receptor involved in regulating eosinophil trafficking; therefore, elucidation of ligand-induced CCR-3 events has important implications in understanding the biological and pathological properties of eosinophils. Previous studies have demonstrated that unique receptor events occur in different cell types supporting investigation of CCR-3-mediated events in eosinophilic cells. We now report biochemical characterization of CCR-3 internalization following exposure of eosinophils to CCR-3 ligands, Treatment of freshly isolated human eosinophils with CCR-3 ligands resulted in marked and differential internalization of CCR-3 in a dose-dependent manner. Exposure to 100 ng/ml eotaxin reduced surface expression to 43, 43, and 76% at 15 min, 1 h, and 3 h, respectively. RANTES (reduced on activation T cell expressed and secreted) treatment induced more significant and prolonged internalization of CCR-3 than eotaxin; following 100 ng/ml of RANTES, 29, 24, and 47% of the receptor was expressed at 15 min, 3 h, and 18 h, respectively. Confocal microscopy demonstrated that receptor modulation involved receptor internalization by an endocytic pathway shared with the transferrin receptor. Receptor internalization was accompanied by partial degradation of CCR-3, and reexpression of CCR-3 was dependent in part upon de novo protein synthesis. Internalization was not blocked by pretreatment of eosinophils with pertussis toxin. Furthermore, staurosporine did not inhibit internalization although it blocked phorbol la-myristate 13-acetate-induced CCR-3 down-modulation. These results demonstrate that CCR-3 ligands induce differential receptor internalization that is not dependent upon G(i)-protein coupling, calcium transients, or protein kinase C.	Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Biol & Neonatol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Rothenberg, ME (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	rothm@chmcc.org						Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bates P, 1996, CELL, V86, P1, DOI 10.1016/S0092-8674(00)80070-7; Bohm SK, 1997, BIOCHEM J, V322, P1; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; ESKELINEN S, 1991, EUR J CELL BIOL, V56, P210; Forster R, 1998, J IMMUNOL, V160, P1522; Franci C, 1996, J IMMUNOL, V157, P5606; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MUELLER SG, 1995, J BIOL CHEM, V270, P10439, DOI 10.1074/jbc.270.18.10439; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Solari R, 1997, J BIOL CHEM, V272, P9617; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Tenscher K, 1996, BLOOD, V88, P3195, DOI 10.1182/blood.V88.8.3195.bloodjournal8883195; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; UHING RJ, 1992, BIOCHEM BIOPH RES CO, V183, P1033, DOI 10.1016/S0006-291X(05)80294-3; WELLER PF, 1991, NEW ENGL J MED, V324, P1110	41	112	117	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12611	12618		10.1074/jbc.274.18.12611	http://dx.doi.org/10.1074/jbc.274.18.12611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212240	hybrid			2022-12-25	WOS:000080056800060
J	Kim, DE; Shigesada, K; Patel, SS				Kim, DE; Shigesada, K; Patel, SS			Transcription termination factor rho contains three noncatalytic nucleotide binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-RHO; FUNCTIONAL INTERACTIONS; PHYSICAL-PROPERTIES; HELICASE ACTIVITY; LIGAND COFACTORS; CATALYTIC SITES; DNA HELICASE; RNA; F1-ATPASE; ATP	The active form of transcription termination factor rho from Escherichia coli is a homohexamer, but several studies suggest that the six subunits of the hexamer are not functionally identical. Rho has three tight and three weak ATP binding sites. Based on our findings, we propose that the tight nucleotide binding sites are noncatalytic and the weak sites are catalytic. In the presence of RNA, the rho-catalyzed ATPase rate is fast, close to 30 s(-1). However, under these conditions the three tightly bound nucleotides dissociate from the rho hexamer at a slow rate of 0.02 s(-1), indicating that the three tight nucleotide binding sites of rho do not participate in the fast ATPase turnover. These slowly exchanging nucleotide binding sites of rho are capable of hydrolyzing ATP, but the resulting products (ADP and pi) bind tightly and dissociate from rho about 1500 times slower than the fast ATPase turnover. Both RNA and excess ATP in solution are necessary for stabilizing nucleotide binding at these sites. In the absence of RNA or when solution ATP is hydrolyzed to ADP, a faster dissociation of nucleotides was observed. Based on these results, we pro pose that the rho hexamer is similar to the F-1-ATPase and T7 DNA helicase-containing noncatalytic sites that do not participate in the fast ATPase turnover. We propose that the three tight sites on rho are the noncatalytic sites and the three weak sites are the catalytic sites.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Kyoto Univ, Inst Virus Res, Dept Genet & Mol Biol, Sakyo Ku, Kyoto 606, Japan	Ohio State University; Kyoto University	Patel, SS (corresponding author), Ohio State Univ, Dept Biochem, 484 W 12th Ave, Columbus, OH 43210 USA.		Kim, Dong-Eun/D-8304-2011	Kim, Dong-Eun/0000-0001-6545-8387	NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BRENNAN CA, 1990, J BIOL CHEM, V265, P5440; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; CROSS RL, 1982, J BIOL CHEM, V257, P2874; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FINGER LR, 1981, BIOCHEMISTRY-US, V20, P1640, DOI 10.1021/bi00509a036; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Horiguchi T, 1997, J MOL BIOL, V269, P514, DOI 10.1006/jmbi.1997.1059; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; PAGAN J, 1990, FEBS LETT, V273, P147, DOI 10.1016/0014-5793(90)81071-U; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; SEIFRIED SE, 1991, J MOL BIOL, V221, P1139; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SHIGESADA K, 1980, NUCLEIC ACIDS RES, V8, P3355, DOI 10.1093/nar/8.15.3355; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477	28	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11623	11628		10.1074/jbc.274.17.11623	http://dx.doi.org/10.1074/jbc.274.17.11623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206972	hybrid			2022-12-25	WOS:000079834800028
J	Masuyama, N; Hanafusa, H; Kusakabe, M; Shibuya, H; Nishida, E				Masuyama, N; Hanafusa, H; Kusakabe, M; Shibuya, H; Nishida, E			Identification of two Smad4 proteins in Xenopus - Their common and distinct properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; TUMOR-SUPPRESSOR SMAD4; SIGNAL-TRANSDUCTION; MESODERM INDUCTION; KINASE CASCADE; RECEPTOR; PHOSPHORYLATION; EMBRYO; GENE	Smad family proteins have been identified as mediators of intracellular signal transduction by the transforming growth factor-beta (TGF-beta) superfamily. Each member of the pathway-restricted, receptor-activated Smad family cooperates and synergizes with Smad4, called co-Smad, to transduce the signals. Only Smad4 has been shown able to function as a common partner of the various pathway-restricted Smads in mammals. Here we have identified a novel Smad4-like molecule in Xenopus (XSmad4 beta) as well as a Xenopus homolog of a well established Smad4 (XSmad4 alpha). XSmad4 beta is 70% identical to XSmad4 alpha in amino acid sequence. Both of the Xenopus Smad4s can cooperate with Smad1 and Smad2, the pathway-restricted Smads specific for bone morphogenetic protein and TGF-beta, respectively. However, they show distinct properties in terms of their developmental expression patterns, subcellular localizations, and phosphorylation states. Moreover, XSmad4 beta, but not XSmad4 alpha, has the potent ability to induce ventralization when microinjected into the dorsal marginal region of the 4-cell stage of the embryos. These results suggest that the two Xenopus Smad4s have overlapping but distinct functions.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Kusakabe, Minoru/Q-3258-2019					Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; DAWID IB, 1994, J BIOL CHEM, V269, P6259; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heasman J, 1997, DEVELOPMENT, V124, P4179; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SMITH JC, 1995, CURR OPIN CELL BIOL, V7, P856, DOI 10.1016/0955-0674(95)80070-0; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	53	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12163	12170		10.1074/jbc.274.17.12163	http://dx.doi.org/10.1074/jbc.274.17.12163			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207044	hybrid			2022-12-25	WOS:000079834800100
J	Schreiber, R; Nitschke, R; Greger, R; Kunzelmann, K				Schreiber, R; Nitschke, R; Greger, R; Kunzelmann, K			The cystic fibrosis transmembrane conductance regulator activates aquaporin 3 in airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; NA+ CONDUCTANCE; WATER CHANNEL; COLLECTING DUCT; SODIUM-CHANNELS; RAT-KIDNEY; WILD-TYPE; CFTR; EXPRESSION; CL	Enhanced osmotic water permeability has been observed in Xenopus oocytes expressing cystic fibrosis transmembrane conductance regulator (CFTR) protein. Subsequent studies have shown that CFTR activates an endogenous water permeability in oocytes, but that CFTR itself is not the water channel. Here, we show CFTR dependent activation of endogenous water permeability in normal but not in cystic fibrosis human airway epithelial cells. Cell volume was measured by novel confocal x-z laser scanning microscopy, Glycerol uptake and antisense studies suggest CFTR-dependent regulation of aquaporin 3 (AQP3) water channels in airway epithelial cells. Regulatory interaction was confirmed by coexpression of CFTR and AQP3 cloned from human airways in Xenopus oocytes and of CFTR and rat AQP3 in Chinese hamster ovary cells. These findings indicate that CFTR is a regulator of AQP3 in airway epithelial cells.	Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany	University of Freiburg	Kunzelmann, K (corresponding author), Univ Freiburg, Inst Physiol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	kkunzel@sibm2.ruf.uni-freiburg.de	Nitschke, Roland/F-9525-2010; Schreiber, Robert/Q-7550-2019	Nitschke, Roland/0000-0002-9397-8475; Kunzelmann, Karl/0000-0002-4583-7037				BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; ECHEVARRIA M, 1993, J GEN PHYSIOL, V101, P827, DOI 10.1085/jgp.101.6.827; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; ENGELHARDT JF, 1994, J CLIN INVEST, V93, P737, DOI 10.1172/JCI117028; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; Greger R, 1996, J MOL MED-JMM, V74, P527; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HIPPER A, 1995, FEBS LETT, V374, P312, DOI 10.1016/0014-5793(95)01132-X; ISHIBASHI K, 1995, GENOMICS, V27, P352, DOI 10.1006/geno.1995.1055; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; KUNZELMANN K, 1995, PFLUG ARCH EUR J PHY, V431, P1, DOI 10.1007/BF00374371; Kunzelmann K, 1996, PFLUG ARCH EUR J PHY, V431, P578, DOI 10.1007/BF02191906; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Lei DC, 1996, GENE THER, V3, P427; LITTLEWOOD JM, 1992, BRIT MED BULL, V48, P847, DOI 10.1093/oxfordjournals.bmb.a072581; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; Nitschke R, 1997, PFLUG ARCH EUR J PHY, V434, P466, DOI 10.1007/s004240050422; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WIDDICOMBE JH, 1995, RESP PHYSIOL, V99, P3, DOI 10.1016/0034-5687(94)00095-H; Zhang YL, 1996, AM J PHYSIOL-CELL PH, V270, pC1326, DOI 10.1152/ajpcell.1996.270.5.C1326	35	91	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11811	11816		10.1074/jbc.274.17.11811	http://dx.doi.org/10.1074/jbc.274.17.11811			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206998	hybrid			2022-12-25	WOS:000079834800054
J	Ueda, H; Yamauchi, J; Itoh, H; Morishita, R; Kaziro, Y; Kato, K; Asano, T				Ueda, H; Yamauchi, J; Itoh, H; Morishita, R; Kaziro, Y; Kato, K; Asano, T			Phosphorylation of F-actin-associating G protein gamma(12) subunit enhances fibroblast motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; KINASE-C; GROWTH-FACTOR; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; CELL MOTILITY; BETA-SUBUNIT; PURIFICATION; CYTOSKELETON; CHEMOTAXIS	Eleven isoforms of G protein gamma subunit have been found thus far, but the precise roles of individual gamma subunits are not known. The gamma(12) subunit has two unique properties: phosphorylation by protein kinase C and association with F-actin. To elucidate the role of gamma(12), we overexpressed gamma(12) and other gamma subunits in NIH 3T3 cells together with the beta(1) subunit. The overexpressed gamma(12) as well as endogenous gamma(12), but not gamma(2), gamma(5), and gamma(7) subunits, associated with cytoskeletal components. Expression of gamma(12) induced remarkable changes including cell rounding, disruption of stress fibers, and enhancement of cell migration, but expression of other gamma subunits did not induce significant changes. Deletion of the N-terminal region of gamma(12) decreased the abilities of gamma(12) to associate with cytoskeletal fractions, to induce cell rounding, and to increase cell motility, Replacement by alanine of Ser(2) of gamma(12) (Ser(1) of a mature gamma(12) protein), a phosphorylation site for protein kinase C, eliminated these effects of y(12), whereas a mutant in which Ser(2) was replaced with glutamic acid showed effects equivalent to wild-type gamma(12), These results indicate that phosphorylation of gamma(12) at Ser(2) enhances the motility of cells.	Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Aichi 4800392, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Asano, T (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kamiya Cho, Aichi 4800392, Japan.							Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; ASANO T, 1995, J NEUROCHEM, V64, P1267; ASANO T, 1993, J BIOL CHEM, V268, P20512; Asano T, 1998, EUR J BIOCHEM, V251, P314, DOI 10.1046/j.1432-1327.1998.2510314.x; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CHIBA K, 1995, DEV BIOL, V169, P415, DOI 10.1006/dbio.1995.1157; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DAVIET I, 1990, FEBS LETT, V259, P315, DOI 10.1016/0014-5793(90)80035-H; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; SA G, 1994, J BIOL CHEM, V269, P3219; SARNDAHL E, 1993, P NATL ACAD SCI USA, V90, P6552, DOI 10.1073/pnas.90.14.6552; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Ueda H, 1997, J CELL SCI, V110, P1503; UEDA N, 1994, J BIOL CHEM, V269, P4388; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958	35	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12124	12128		10.1074/jbc.274.17.12124	http://dx.doi.org/10.1074/jbc.274.17.12124			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207039	hybrid			2022-12-25	WOS:000079834800095
J	Smith, PD; Crossland, S; Parker, G; Osin, P; Brooks, L; Waller, J; Philp, E; Crompton, MR; Gusterson, BA; Allday, MJ; Crook, T				Smith, PD; Crossland, S; Parker, G; Osin, P; Brooks, L; Waller, J; Philp, E; Crompton, MR; Gusterson, BA; Allday, MJ; Crook, T			Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	ONCOGENE			English	Article						p53; novel; mutation; breast; BRCA-1; BRCA-2	CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; DNA-REPAIR; CANCER; BREAST; GENE; MUTATION; MDM2; P21(WAF1/CIP1)	Inheritance of germ-line mutant alleles of BRCA1 and BRCA2 confers a markedly increased risk of breast cancer and we have previously reported a higher incidence of p53 mutations in these tumours than in grade matched sporadic tumours, We have now characterized these p53 mutants, The results of these studies identify a novel class of p53 mutants previously undescribed in human cancer Set with multiple occurrences in BRCA-associated tumours which retain a profile of p53-dependent activities in terms of transactivation, growth suppression and apoptosis induction which is close or equal to wild-type. However, these mutants fail to suppress transformation and exhibit gain of function transforming activity in rat embryo fibroblasts, These mutants therefore fall into a novel category of p53 mutants which dissociate transformation suppression from other wild-type functions. The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.	Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; London Sch Hyg & Trop Med, Div Clin Sci, London W1, England; Inst Canc Res, Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	University of London; Institute of Cancer Research - UK; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Crook, T (corresponding author), Inst Canc Res, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.		gusterson, barry a/D-3752-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakhani SR, 1997, LANCET, V349, P1505; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUDWIG T, 1997, GENE DEV, V11, P1126; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYASHITA T, 1995, CELL, V80, P293; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Parker GA, 1996, ONCOGENE, V13, P2541; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SMITH AP, 1992, HDB HUMAN PERFORMANC, V2, P2; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	82	87	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2451	2459		10.1038/sj.onc.1202565	http://dx.doi.org/10.1038/sj.onc.1202565			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229196				2022-12-25	WOS:000079703300005
J	Beullens, M; Van Eynde, A; Vulsteke, V; Connor, J; Shenolikar, S; Stalmans, W; Bollen, M				Beullens, M; Van Eynde, A; Vulsteke, V; Connor, J; Shenolikar, S; Stalmans, W; Bollen, M			Molecular determinants of nuclear protein phosphatase-1 regulation by NIPP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; INHIBITORY POLYPEPTIDES; PHOSPHORYLATION; BINDING; IDENTIFICATION; EXPRESSION; MECHANISM; GLYCOGEN; PEPTIDES; CLONING	NIPP-1 is a subunit of the major nuclear protein phosphatase-l (PP-1) in mammalian cells and potently inhibits PP-1 activity in vitro, Using yeast two-hybrid and co-sedimentation assays, we mapped a PP-1-binding site and the inhibition function to the central one-third domain of NIPP-1, Full-length NIPP-1 (351 residues) and the central domain, NIPP-1(143-217), were equally potent PP-1 inhibitors (IC50 = 0.3 mu M). Synthetic peptides spanning the central domain of NIPP-1 further narrowed the PP-1 inhibitory function to residues 191-200, A second, noninhibitory PP-1-binding site was identified by far-Western assays with digoxygenin-conjugated catalytic subunit (PP-1(C)) and included a consensus RVXF motif (residues 200-203) found in many other PP-1-binding proteins. The substitutions, V201A and/or F203A, in the RVXF motif, or phosphorylation of Ser(199) or Ser(204), which are established phosphorylation sites for protein kinase A and protein kinase CK2, respectively, prevented PP-1(C)-binding by NIPP-1(191-210) in the far-Western assay. NIPP-1(191-210) competed for PP-1 inhibition by full-length NIPP-1(1-351), inhibitor-1 and inhibitor-2, and dissociated PP-1(C) from inhibitor-1- and NIPP-1(143-217)-Sepharose but not from full-length NIPP-1(1-351)-Sepharose. Together, these data identified some of the key elements in the central domain of NIPP-1 that regulate PP-1 activity and suggested that the flanking sequences stabilize the association of NIPP-1 with PP-1(C).	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochim, B-3000 Louvain, Belgium; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	KU Leuven; Duke University	Bollen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochim, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.kuleuven.ac.be		Connor, John/0000-0002-8867-7256	NIDDK NIH HHS [DK52044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; ANTONIW JF, 1977, BIOCHEM J, V162, P423, DOI 10.1042/bj1620423; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Beullens M, 1998, METH MOL B, V93, P145; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIAND JP, 1985, J IMMUNOL METHODS, V78, P59, DOI 10.1016/0022-1759(85)90329-1; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Jagiello I, 1997, J BIOL CHEM, V272, P22067, DOI 10.1074/jbc.272.35.22067; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PARK IK, 1994, J BIOL CHEM, V269, P944; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Thompson LJ, 1997, J BIOL CHEM, V272, P29693, DOI 10.1074/jbc.272.47.29693; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Yang J, 1998, FASEB J, V12, pA1407; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	35	73	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14053	14061		10.1074/jbc.274.20.14053	http://dx.doi.org/10.1074/jbc.274.20.14053			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318819	hybrid			2022-12-25	WOS:000080322200048
J	Lewis, AL; Xia, Y; Datta, SK; McMillin, J; Kellems, RE				Lewis, AL; Xia, Y; Datta, SK; McMillin, J; Kellems, RE			Combinatorial interactions regulate cardiac expression of the murine adenylosuccinate synthetase 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE GENE; HEAVY-CHAIN GENE; POSITION-INDEPENDENT EXPRESSION; DNA-BINDING TARGETS; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; SKELETAL-MUSCLE; ELECTRICAL-STIMULATION; UPSTREAM ELEMENTS; TRANSCRIPTION	The mammalian heart begins contracting at the linear tube stage during embryogenesis and continuously pumps, nonstop, throughout the entire lifetime of the animal. Therefore, the cardiac energy metabolizing pathways must be properly established and efficiently functioning. While the biochemistry of these pathways is well defined, limited information regarding the regulation of cardiac metabolic genes is available. Previously, we reported that 1.9 kilobase pairs of murine adenylosuccinate synthetase 1 gene (Adss1) 5'-flanking DNA directs high levels of reporter expression to the adult transgenic heart, In this report, we define the 1.9-kilobase pair fragment as a cardiac-specific enhancer that controls correct spatiotemporal expression of a reporter similar to the endogenous Adss1 gene. A 700-base pair fragment within this region activates a heterologous promoter specifically in adult transgenic hearts. Proteins present in a cardiac nuclear extract interact with potential transcription factor binding sites of this region and these cia-acting sites play important regulatory roles in the cardiac expression of this reporter. Finally, we report that several different cardiac transcription factors trans-activate the 1.9HSCAT construct through these sites and that combinations result in enhanced reporter expression. Adss1 appears to be one of the first target genes identified for the bHLH factors Hand1 and Hand2.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; University of Texas System; Baylor College of Medicine	Kellems, RE (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA.							ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; FabreSuver C, 1996, J BIOL CHEM, V271, P4646, DOI 10.1074/jbc.271.9.4646; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KELLER A, 1992, MECH DEVELOP, V38, P41, DOI 10.1016/0925-4773(92)90037-K; KNOTTS S, 1995, NUCLEIC ACIDS RES, V23, P3301, DOI 10.1093/nar/23.16.3301; KRNACIK MJ, 1995, J BIOL CHEM, V270, P11119, DOI 10.1074/jbc.270.19.11119; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; Lewis AL, 1996, J BIOL CHEM, V271, P22647, DOI 10.1074/jbc.271.37.22647; LYONS GE, 1991, DEVELOPMENT, V113, P1017; MAHNKEZIZELMAN DK, 1992, J BIOL CHEM, V267, P20866; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; Sambrook J., 2002, MOL CLONING LAB MANU; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Shi DQ, 1998, J BIOL CHEM, V273, P27331, DOI 10.1074/jbc.273.42.27331; Shield MA, 1996, MOL CELL BIOL, V16, P5058; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P1; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Xu PA, 1999, J BIOL CHEM, V274, P10316, DOI 10.1074/jbc.274.15.10316	46	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14188	14197		10.1074/jbc.274.20.14188	http://dx.doi.org/10.1074/jbc.274.20.14188			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318837	hybrid			2022-12-25	WOS:000080322200066
J	Missiaen, L; Parys, JB; Weidema, AF; Sipma, H; Vanlingen, S; De Smet, P; Callewaert, G; De Smedt, H				Missiaen, L; Parys, JB; Weidema, AF; Sipma, H; Vanlingen, S; De Smet, P; Callewaert, G; De Smedt, H			The bell-shaped Ca2+ dependence of the inositol 1,4,5-trisphosphate-induced Ca2+ release is modulated by Ca2+/calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CYTOSOLIC CA2+; CA2+-INDEPENDENT INHIBITION; TRISPHOSPHATE RECEPTORS; LUMINAL CA2+; CALCIUM; CALMODULIN; MOBILIZATION; CEREBELLUM	Calmodulin inhibits inositol 1,4,5-trisphosphate (IP3) binding to the IP3 receptor in both a Ca2+-dependent and a Ca2+-independent way. Because there are no functional data on the modulation of the IP3-induced Ca2+ release by calmodulin at various Ca2+ concentrations, we have studied how cytosolic Ca2+ and Sr2+ interfere with the effects of calmodulin on the IP3-induced Ca2+ release in permeabilized A7r5 cells, We now report that calmodulin inhibited Ca2+ release through the IP3 receptor with an IC50 of 4.6 mu M if the cytosolic Ca2+ concentration was 0.3 mu M or higher. This inhibition was particularly pronounced at low IP3 concentrations. In contrast, calmodulin did not affect IP3-induced Ca2+ release if the cytosolic Ca2+ concentration was below 0.3 mu M. Calmodulin also inhibited Ca2+ release through the IP3 receptor in the presence of at least 10 mu M Sr2+. We conclude that cytosolic Ca2+ or Sr2+ are absolutely required for the calmodulin-induced inhibition of the IP,induced Ca2+ release and that this dependence represents the formation of the Ca2+/calmodulin or Sr2+/ calmodulin complex.	Catholic Univ Louvain, Fysiol Lab, B-3000 Louvain, Belgium	Universite Catholique Louvain	Missiaen, L (corresponding author), Catholic Univ Louvain, Fysiol Lab, Campus Gasthuisberg O-N,Herestr 49, B-3000 Louvain, Belgium.			Parys, Jan/0000-0002-3591-4967				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; COX JA, 1981, J BIOL CHEM, V256, P3218; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; Martell AE, 1989, CRITICAL STABILITY C; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; SIPMA H, 1999, IN PRESS J BIOL CHEM, V274; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	24	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13748	13751		10.1074/jbc.274.20.13748	http://dx.doi.org/10.1074/jbc.274.20.13748			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318777	hybrid			2022-12-25	WOS:000080322200006
J	Zhao, JM; Furukawa, K; Fukumoto, S; Okada, M; Furugen, R; Miyazaki, H; Takamiya, K; Aizawa, S; Shiku, H; Matsuyama, T; Furukawa, K				Zhao, JM; Furukawa, K; Fukumoto, S; Okada, M; Furugen, R; Miyazaki, H; Takamiya, K; Aizawa, S; Shiku, H; Matsuyama, T; Furukawa, K			Attenuation of interleukin 2 signal in the spleen cells of complex ganglioside-lacking mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LYMPHOCYTE SUBPOPULATIONS; VIRUS TYPE-I; SYNTHASE GENE; T-LYMPHOCYTES; ASIALO GM1; C-MYC; ACTIVATION; EXPRESSION; PROLIFERATION; ASSOCIATION	T cell development and function in complex ganglioside-lacking (GM2/GD2 synthase gene-disrupted) mice were analyzed, GM1, asialo-GM1, and GD1b were representative gangliosides expressed on T cells of the wild type mice and completely deleted on those of the mutant mice. The sizes and cell numbers of the mutant mice spleen and thymus were significantly reduced, Spleen cells from the mutant mice showed clearly reduced proliferation compared with the wild type when stimulated by interleukin 2 (IL-2) but not when treated with concanavalin A or anti-CD3 cross-linking Expression levels of IL-2 receptor alpha, beta, and gamma were almost equivalent, and up-regulation of a chain after T cell activation was also similar between the mutant and wild type mice. Activation of JAK1, JAK3, and SAT5 after IL-2 treatment was reduced, and c-fos expression was delayed and reduced in the mutant spleen cells, suggesting that the IL-2 signal was attenuated in the mutant mice probably due to the modulation of IL-2 receptors by the lack of complex gangliosides.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528102, Japan; Nagasaki Univ, Sch Dent, Dept Prevent Dent, Nagasaki 8528102, Japan; Nagasaki Univ, Sch Med, Dept Oncol, Nagasaki 8528102, Japan; Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 8528102, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Lab Morphogenesis, Kumamoto 8600811, Japan; Mie Univ, Sch Med, Dept Internal Med, Tsu, Mie 5140001, Japan	Nagoya University; Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Kumamoto University; Mie University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp		Shiku, Hiroshi/0000-0002-0362-755X; Zhao, Jinmin/0000-0002-1047-8820; Fukumoto, Satoshi/0000-0002-5046-6891; Takamiya, Kogo/0000-0001-7240-6307				BARLOZZARI T, 1983, J IMMUNOL, V131, P1024; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; FLOUTSIS G, 1989, INT J CANCER, V43, P6, DOI 10.1002/ijc.2910430103; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; FURUKAWA K, 1993, P NATL ACAD SCI USA, V90, P1972, DOI 10.1073/pnas.90.5.1972; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Ledeen RW, 1998, ANN NY ACAD SCI, V845, P161, DOI 10.1111/j.1749-6632.1998.tb09669.x; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NAKAMURA K, 1988, J BIOCHEM-TOKYO, V103, P201, DOI 10.1093/oxfordjournals.jbchem.a122232; OFFNER H, 1987, J IMMUNOL, V139, P3295; Okada M, 1996, CANCER RES, V56, P2844; PARKER J, 1984, FEBS LETT, V170, P391, DOI 10.1016/0014-5793(84)81351-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P4638; ROBB RJ, 1986, J IMMUNOL, V136, P971; SCHWARTING GA, 1983, J BIOL CHEM, V258, P5893; STEINDOUGLAS KE, 1976, J EXP MED, V143, P822, DOI 10.1084/jem.143.4.822; SUTTLES J, 1987, J IMMUNOL, V138, P364; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; TING CC, 1986, J IMMUNOL, V137, P2100; WELTE K, 1987, J IMMUNOL, V139, P1763; WHISLER RL, 1980, J IMMUNOL, V125, P2106; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YAMASHIRO S, 1995, GLYCOCONJUGATE J, V12, P894, DOI 10.1007/BF00731251; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	33	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13744	13747		10.1074/jbc.274.20.13744	http://dx.doi.org/10.1074/jbc.274.20.13744			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318776	hybrid			2022-12-25	WOS:000080322200005
J	Ellis, CA; Malik, AB; Gilchrist, A; Hamm, H; Sandoval, R; Voyno-Yasenetskaya, T; Tiruppathi, C				Ellis, CA; Malik, AB; Gilchrist, A; Hamm, H; Sandoval, R; Voyno-Yasenetskaya, T; Tiruppathi, C			Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of G(i)-linked Ras/mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; MESSENGER-RNA EXPRESSION; BETA-GAMMA-SUBUNITS; COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; TYROSINE KINASES; COS-7 CELLS; MAP KINASE; MECHANISM	We addressed the mechanisms of restoration of cell surface proteinase-activated receptor-1 (PAR-1) by investigating thrombin-activated signaling pathways involved in PAR-1 re-expression in endothelial cells. Exposure of endothelial cells transfected with PAR-I promoter-luciferase reporter construct to either thrombin or PAR-I activating peptide increased the steady-state PAR-1 mRNA and reporter activity, respectively. Pretreatment of reporter-transfected endothelial cells with pertussis toxin or co-expression of a minigene encoding Il-amino acid sequence of COOH-terminal Ga; prevented the thrombin-induced increase in reporter activity. Pertussis toxin treatment also prevented thrombin-induced MAPK phosphorylation, indicating a role of G alpha(i) in activating the downstream MAPK pathway. Expression of constitutively active G alpha(i2) mutant or G beta 1 gamma 2 subunits increased reporter activity 3-4-fold in the absence of thrombin stimulation. Go-expression of dominant negative mutants of either Ras or MEK1 with the reporter construct inhibited the thrombin-induced PAR-1 expression, whereas constitutively active forms of either Ras or MEK1 activated PAR-1 expression in the absence of thrombin stimulation. Expression of dominant negative Src kinase or inhibitors of phosphoinositide 3-kinase also prevented the MAPK activation and PAR-1 expression. We conclude that thrombin-induced activation of PAR-1 mediates PAR-1 expression by signaling through G(i1/2) coupled to Src and phosphoinositide 3-kinase, and thereby activating the downstream Ras/MAPK cascade.	Univ Illinois, Coll Med, Dept Pharmacol MC 868, Chicago, IL 60612 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University	Tiruppathi, C (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol MC 868, 835 S Wolcott Ave, Chicago, IL 60612 USA.	tiruc@uic.edu	voyno-yasenetskaya, tatyana/A-3171-2008; Hamm, Heidi E/G-2374-2014; Gilchrist, Annette/I-4465-2014	Gilchrist, Annette/0000-0003-2386-7646; Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027016, R01HL045638, R37HL027016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45638, HL27016] Funding Source: Medline; NIGMS NIH HHS [GM58531] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; FAURE M, 1994, J BIOL CHEM, V269, P7851; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRAVES JD, 1994, ANN REV N Y ACAD SCI, V320; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, J CELL SCI, V108, P1155; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; Molino M, 1997, J BIOL CHEM, V272, P11133; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; TIRUPPATHI C, 1992, AM J PHYSIOL, V263, pL595, DOI 10.1152/ajplung.1992.263.5.L595; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; ZACHARIAS U, 1995, J BIOL CHEM, V270, P545, DOI 10.1074/jbc.270.2.545	53	105	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13718	13727		10.1074/jbc.274.19.13718	http://dx.doi.org/10.1074/jbc.274.19.13718			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224146	hybrid			2022-12-25	WOS:000080200400108
J	English, MA; Licht, JD				English, MA; Licht, JD			Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENYS-DRASH SYNDROME; SUPPRESSOR GENE WT1; I RECEPTOR GENE; WILMS-TUMOR; PROTEIN WT1; DNA-BINDING; SUBNUCLEAR LOCALIZATION; UROGENITAL DEVELOPMENT; KIDNEY DEVELOPMENT; PROMOTER ACTIVITY	The WT1 gene encodes a zinc finger DNA binding transcription factor and is mutated in up to 15% of Wilms tumor cases. The WT1 protein binds to the promoters of many genes through GC- or TC-rich sequences and can function both as a transcriptional repressor and an activator in co-transfection assays depending on the cell type, the structure of the test promoter, and even the expression vectors used. Engineered expression of WT1 can lead to growth suppression by both cell cycle arrest and induction of apoptosis. However, the transcriptional activity of WT1 that is required for growth control was not defined. We found that three N-terminal tumor-associated missense mutations of WT1 were defective for activation of both a synthetic reporter containing WT1-binding sites as well as the promoter of a WT1 responsive gene, p21. These mutants failed to inhibit cell growth but still retain their ability to repress several putative WT1 target promoters. These results indicate that activation and not repression by WT1 is the critical transcriptional activity of the protein responsible for its growth suppressing properties.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.		Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369	NCI NIH HHS [R01 CA59998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; Beckwith JB, 1997, CANCER INVEST, V15, P153, DOI 10.3109/07357909709115768; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Cook DM, 1996, ONCOGENE, V13, P1789; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GOODYER P, 1995, ONCOGENE, V10, P1125; Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; Innis MA, 1990, PCR PROTOCOLS GUIDE; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LUO XN, 1995, ONCOGENE, V11, P743; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; Martinerie C, 1996, ONCOGENE, V12, P1479; MATSUNAGA E, 1981, HUM GENET, V57, P231; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; McConnell MJ, 1997, ONCOGENE, V14, P2689, DOI 10.1038/sj.onc.1201114; Menke AL, 1997, CANCER RES, V57, P1353; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; OGAWA O, 1993, HUM MOL GENET, V2, P203, DOI 10.1093/hmg/2.2.203; PARK S, 1993, CANCER RES, V53, P4757; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SHARMA PM, 1994, P NATL ACAD SCI USA, V91, P9931, DOI 10.1073/pnas.91.21.9931; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WERNER H, 1995, INT J BIOCHEM CELL B, V27, P987, DOI 10.1016/1357-2725(95)00074-Y	72	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13258	13263		10.1074/jbc.274.19.13258	http://dx.doi.org/10.1074/jbc.274.19.13258			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224085	hybrid			2022-12-25	WOS:000080200400047
J	Piecha, D; Muratoglu, S; Morgelin, M; Hauser, N; Studer, D; Kiss, I; Paulsson, M; Deak, F				Piecha, D; Muratoglu, S; Morgelin, M; Hauser, N; Studer, D; Kiss, I; Paulsson, M; Deak, F			Matrilin-2, a large, oligomeric matrix protein, is expressed by a great variety of cells and forms fibrillar networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; HELICAL COILED-COIL; C-TERMINAL DOMAIN; ENDOTHELIAL-CELLS; CARTILAGE; MOUSE; MUSCLE; LINE; ASSEMBLES; LAMININ	Matrilin-2 is a member of the protein superfamily with von Willebrand factor type A-like modules. Mouse matrilin-2 cDNA fragments were expressed in 293-EBNA cells, and the protein was purified, characterized, and used to immunize rabbits. The affinity-purified antiserum detects matrilin-2 in dense and loose connective tissue structures, subepithelial connective tissue of the skin and digestive tract, specialized cartilages, and blood vessel walls. In situ hybridization of S-35-labeled riboprobes localizes the matrilin-2 mRNA to fibroblasts of dermis, tendon, ligaments, perichondrium, and periosteum; connective tissue elements in the heart; smooth muscle cells; and epithelia and loose connective tissue cells of the alimentary canal and respiratory tract. RNA blot hybridization and immunoblotting revealed both matrilin-2 mRNA and protein in cultures of a variety of cell types, confirming the tissue distribution. Alternative splicing affects a module unique for matrilin-2 in all of the above RNA sources. SDS-polyacrylamide gel electrophoresis and electron microscopy reveals matrilin-2 from tissue extracts and cell line cultures as a mixture of mono-, di-, tri-, and tetramers, Matrilin-2 is substituted with N-linked oligosaccharides but not with glycosaminoglycans, Because of other, yet unidentified, cell-type dependent posttranslational modifications, the monomer is heterogeneous in size. Immunofluorescence showed that matrilin-2 functions by forming an extracellular, filamentous network.	Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary; Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany; Univ Lund, Dept Cell & Mol Biol, S-22100 Lund, Sweden; ME Muller Inst Biomech, CH-3010 Bern, Switzerland	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of Cologne; Lund University	Deak, F (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, POB 521, H-6701 Szeged, Hungary.		Studer, Daniel/F-8581-2012	Muratoglu Catania, Selen/0000-0002-1804-4875				AKITA M, 1993, PATHOBIOLOGY, V61, P98, DOI 10.1159/000163769; Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; BLANK RS, 1995, CIRC RES, V76, P742, DOI 10.1161/01.RES.76.5.742; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Deak F, 1997, J BIOL CHEM, V272, P9268; DEAK F, 1999, IN PRESS MATRIX BIOL, V18; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FOWLER WE, 1989, COAGULATION BLEEDING, P181; FUSENIG NE, 1978, B CANCER, V65, P271; HAUSER N, 1994, J BIOL CHEM, V269, P25747; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; SOROKIN L, 1994, EUR J BIOCHEM, V223, P603, DOI 10.1111/j.1432-1033.1994.tb19031.x; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; Wagener R, 1998, FEBS LETT, V436, P123, DOI 10.1016/S0014-5793(98)01111-9; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	29	73	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13353	13361		10.1074/jbc.274.19.13353	http://dx.doi.org/10.1074/jbc.274.19.13353			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224097	hybrid			2022-12-25	WOS:000080200400059
J	Bai, RL; Ewell, JB; Nguyen, NY; Hamel, E				Bai, RL; Ewell, JB; Nguyen, NY; Hamel, E			Direct photoaffinity labeling of cysteine 211 or a nearby amino acid residue of beta-tubulin by guanosine 5 '-diphosphate bound in the exchangeable site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP; BINDING; BRAIN	Tubulin with [8-C-14]GDP bound in the exchangeable site was exposed to ultraviolet light, and radiolabel was cross-linked to two peptide regions of the beta-subunit. Following enrichment for peptides cross-linked to guanosine by boronate chromatography, we confirmed that the cysteine 12 residue was the major site of crosslinking. However, significant radiolabel was also incorporated into a peptide containing amino acid residues 206 through 224. Although every amino acid in this peptide except cysteine 211 was identified by sequential Edman degradation, implying that this was the amino acid residue cross-linked to guanosine, radiolabel at C-8 was usually lost during peptide processing (probably during chromatography at pH 10). Consequently, the radiolabeled amino acid could not be unambiguously identified.	NCI, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, NIH, Frederick, MD 21702 USA; US FDA, Ctr Biol Evaluat & Res, Facil Biotechnol Resources, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Drug Discovery Res & Dev,NIH, Dev Therapeut Program,Div Canc Treatment & Diag, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Hamel, E (corresponding author), NIH, Lab Drug Discovery Res & Dev, Bldg 37,Rm 5D02,37 Convent Dr, Bethesda, MD 20892 USA.							BAI R, 1988, J BIOL CHEM, V273, P9894; GEAHLEN RL, 1977, P NATL ACAD SCI USA, V74, P4375, DOI 10.1073/pnas.74.10.4375; GROVER S, 1994, EUR J BIOCHEM, V222, P163, DOI 10.1111/j.1432-1033.1994.tb18854.x; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; KOBAYASH.T, 1974, J BIOCHEM-TOKYO, V76, P201, DOI 10.1093/oxfordjournals.jbchem.a130546; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; LEVI A, 1974, BIOCHIM BIOPHYS ACTA, V365, P450, DOI 10.1016/0005-2795(74)90022-1; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PENNINGROTH SM, 1977, J MOL BIOL, V115, P643, DOI 10.1016/0022-2836(77)90108-5; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P885, DOI 10.1021/bi00170a006; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; Stephens R.E., 1967, SCIENCE, V156, P1606; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WEISENBERG RC, 1976, BIOCHEMISTRY-US, V15, P4248, DOI 10.1021/bi00664a018	17	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12710	12714		10.1074/jbc.274.18.12710	http://dx.doi.org/10.1074/jbc.274.18.12710			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212253	hybrid			2022-12-25	WOS:000080056800073
J	Marino, M; Zheng, G; McCluskey, RT				Marino, M; Zheng, G; McCluskey, RT			Megalin (gp330) is an endocytic receptor for thyroglobulin on cultured Fisher rat thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; HEYMANN NEPHRITIS; LDL RECEPTOR; MEDIATES ENDOCYTOSIS; POTENTIAL ROLE; GENE FAMILY; PROTEIN; BINDING; INTERNALIZATION	We recently reported that megalin (gp330), an endocytic receptor found on the apical surface of thyroid cells, binds thyroglobulin (Tg) with high affinity in solid phase assays. Megalin-bound Tg was releasable by heparin, Here we show that Fisher rat thyroid (FRTL-5) cells, a differentiated rat thyroid cell line, can bind and endocytose Tg via megalin, We first demonstrated that FRTL-5 cells express megalin in a thyroid-stimulating hormone-dependent manner. Evidence of Tg binding to megalin on FRTL-5 cells and on an immortalized rat renal proximal tubule cell line (IRPT cells), was obtained by incubating the cells with I-125-Tg, followed by chemical cross-linking and immunoprecipitation of I-125-Tg with antibodies against megalin, To investigate cell binding further, we developed an assay in which cells were incubated with unlabeled Tg at 4 degrees C, followed by incubation with heparin, which released almost all of the cell-bound Tg into the medium. In solid phase experiments designed to illuminate the mechanism of heparin release, we demonstrated that Tg is a heparin-binding protein, as are several megalin ligands, The amount of Tg released by heparin from FRTL-5 and IRPT cells, measured by enzyme-linked immunosorbent assay (ELISA), was markedly reduced by two megalin competitors, receptor-associated protein (RAP) and 1H2 (monoclonal antibody against megalin), indicating that much of the Tg released by heparin had been bound to megalin (similar to 60-80%). The amount inhibited by RAP was considered to represent specific binding to megalin, which was saturable and of high affinity (K(d)similar to 11.2 nM), Tg endocytosis by FRTL-5 and IRPT cells was demonstrated in experiments in which cells were incubated with unlabeled Tg at 37 degrees C, followed by heparin to remove cell-bound Tg, The amount of Tg internalized (measured by ELISA in the cell lysates) was reduced by RAP and 1H2, indicating that Tg endocytosis is partially mediated by megalin.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Res Lab, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	McCluskey, RT (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Res Lab, 149 13th St, Charlestown, MA 02129 USA.				NIDDK NIH HHS [DK 46301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BERNIERVALENTIN F, 1990, J BIOL CHEM, V265, P17373; BERNIERVALENTIN F, 1991, ENDOCRINOLOGY, V129, P2194, DOI 10.1210/endo-129-4-2194; BIDEY SP, 1984, J ENDOCRINOL, V101, P269, DOI 10.1677/joe.0.1010269; CONSIGLIO E, 1981, J BIOL CHEM, V256, P592; CONSIGLIO E, 1979, J BIOL CHEM, V254, P5065; DUNN A, 1996, WERNER INGBARS THYRO, P81; EMOTO N, 1994, ENDOCRINOL METAB, V1, P123; ESQUIVEL PS, 1977, J EXP MED, V145, P1250, DOI 10.1084/jem.145.5.1250; FARQUHAR MG, 1994, ANN NY ACAD SCI, V737, P96, DOI 10.1111/j.1749-6632.1994.tb44304.x; Giraud A, 1997, ENDOCRINOLOGY, V138, P2325, DOI 10.1210/en.138.6.2325; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; GUTMANN EJ, 1989, AM J PHYSIOL, V257, pC397, DOI 10.1152/ajpcell.1989.257.2.C397; HERZ J, 1991, J BIOL CHEM, V266, P21232; JI ZS, 1993, J BIOL CHEM, V268, P10160; Jung FF, 1998, KIDNEY INT, V53, P358, DOI 10.1046/j.1523-1755.1998.00766.x; KOSTROUCH Z, 1993, ENDOCRINOLOGY, V132, P2645, DOI 10.1210/en.132.6.2645; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; LEMANSKY P, 1992, EUR J BIOCHEM, V209, P111, DOI 10.1111/j.1432-1033.1992.tb17267.x; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MULDER M, 1993, J BIOL CHEM, V268, P9369; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Raychowdhury R, 1996, AM J PATHOL, V148, P1613; ROITT IM, 1984, CLIN EXP IMMUNOL, V56, P129; ROUSSET B, 1991, MOL CELL ENDOCRINOL, V78, P89; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAXENA U, 1990, J BIOL CHEM, V265, P12880; STEFANSSON S, 1995, J CELL SCI, V108, P2361; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TANG SS, 1994, EXP NEPHROL, V2, P127; VANDENHOVE MF, 1982, EUR J BIOCHEM, V122, P415; Weaver AM, 1997, J LIPID RES, V38, P1841; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Zheng G, 1998, ENDOCRINOLOGY, V139, P1462, DOI 10.1210/en.139.3.1462; ZHENG G, 1994, ANN NY ACAD SCI, V737, P154, DOI 10.1111/j.1749-6632.1994.tb44309.x; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	44	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12898	12904		10.1074/jbc.274.18.12898	http://dx.doi.org/10.1074/jbc.274.18.12898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212279	hybrid			2022-12-25	WOS:000080056800099
J	Borgne, A; Ostvold, AC; Flament, S; Meijer, L				Borgne, A; Ostvold, AC; Flament, S; Meijer, L			Intra-M phase-promoting factor phosphorylation of cyclin B at the prophase/metaphase transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-CYCLE; FISSION YEAST; TYROSINE PHOSPHORYLATION; DEPENDENT KINASES; NUCLEAR-LOCALIZATION; OOCYTE MATURATION; STARFISH OOCYTES; CDC2; ACTIVATION	Activation of Cdc2-cyclin B (or M phase-promoting factor (MPF)) at the prophase/metaphase transition proceeds in two steps: dephosphorylation of Cdc2 and phosphorylation of cyclin B, We here investigated the regulation of cyclin B phosphorylation using the starfish oocyte model. Cyclin B phosphorylation is not required for Cdc2 kinase activity; both the prophase complex dephosphorylated on Cdc2 with Cdc25 and the metaphase complex dephosphorylated on cyclin B with protein phosphatase 2A display high kinase activities. An in vitro assay of cyclin B kinase activity closely mimics in vivo phosphorylation as shown by phosphopeptide maps of in vivo and in vitro phosphorylated cyclin B. We demonstrate that Cdc2 itself is the cyclin B kinase; cyclin B phosphorylation requires Cdc2 activity both in vivo (sensitivity to vitamin K-3, a Cdc25 inhibitor) and in vitro (copurification with Cdc2-cyclin B, requirement of Cdc2 dephosphorylation, and sensitivity to chemical inhibitors of cyclin-dependent kinases), Furthermore, cyclin B phosphorylation occurs as an intra-M phase-promoting factor reaction as shown by the following: 1) active Cdc2 is unable to phosphorylate cyclin B associated to phosphorylated Cdc2, and 2) cyclin B phosphorylation is insensitive to enzyme/substrate dilution. We conclude that, at the prophase/metaphase transition, cyclin B is mostly phosphorylated by its own associated Cdc2 subunit.	CNRS, Biol Stn, F-29682 Roscoff, France; Univ Oslo, Neurochem Lab, N-0317 Oslo, Norway; Univ Lille 1, Dev Biol Lab, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); University of Oslo; Universite de Lille - ISITE; Universite de Lille	Meijer, L (corresponding author), CNRS, Biol Stn, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr		, laurent/0000-0003-3511-4916				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AZZI L, 1994, J BIOL CHEM, V269, P13279; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Derua R, 1997, EXP CELL RES, V230, P310, DOI 10.1006/excr.1996.3436; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1997, METHOD ENZYMOL, V283, P677; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KERNS J, 1995, BIOORG CHEM, V23, P101, DOI 10.1006/bioo.1995.1008; KISHIMOTO T, 1994, INT J DEV BIOL, V38, P185; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEE MS, 1994, J BIOL CHEM, V269, P30530; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; Meijer L., 1995, PROGR CELL CYCLE RES, V1; MEIJER L, 1997, PROGR CELL CYCLE RES, V3; Meijer L., 1996, PROGR CELL CYCLE RES, V2; Meijer Laurent, 1994, Seminars in Developmental Biology, V5, P165, DOI 10.1006/sedb.1994.1022; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; Shapiro H, 1941, J CELL COMPAR PHYSL, V18, P61, DOI 10.1002/jcp.1030180108; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WALAAS SI, 1989, FEBS LETT, V258, P106, DOI 10.1016/0014-5793(89)81626-6; XU WL, 1992, P NATL ACAD SCI USA, V89, P4573, DOI 10.1073/pnas.89.10.4573; YAMASHITA M, 1995, DEV BIOL, V168, P62, DOI 10.1006/dbio.1995.1061	53	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11977	11986		10.1074/jbc.274.17.11977	http://dx.doi.org/10.1074/jbc.274.17.11977			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207019	hybrid			2022-12-25	WOS:000079834800075
J	Gong, LM; Yeh, ETH				Gong, LM; Yeh, ETH			Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; CELLULAR-REGULATION; HOMOLOG; SENTRIN; SYSTEM; ROLES; CDNA	NEDD8 is a ubiquitin-like molecule that can be covalently conjugated to a limited number of cellular proteins, such as Cdc53/cullin. We have previously reported that the C terminus of NEDD8 is efficiently processed to expose Gly-76, which is required for conjugation to target proteins. A combination of data base searches and polymerase chain reaction cloning was used to identify a cDNA encoding human UBA3, which is 38% identical to the yeast homologue, 22% identical to human UBA2, and 19% identical to the C-terminal region of human UBE1, The human UBA3 gene is located on chromosome 3p13 and gave rise to a 2.2-kilobase pair transcript that was detected in all tissues. Human UBA3 could be precipitated with glutathione S-transferase (GST)-NEDD8, but not with GST-ubiquitin or GST-sentrin-1. Moreover, human UBA3 could form a beta-mercaptoethanol-sensitive conjugate with NEDD8 in the presence of APP-BP1, a protein with sequence homology to the N-terminal half of ubiquitin-activating enzyme. We have also cloned human UBC12 and demonstrated that it could form a thiol ester linkage with NEDD8 in the presence of the activating enzyme complex. Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway should allow for a more detailed study of the role of NEDD8 modification in health and disease.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Yeh, ETH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, 6431 Fannin,Suite 4200, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Haas AL, 1997, FASEB J, V11, P1053, DOI 10.1096/fasebj.11.13.9367340; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LOEB KR, 1992, J BIOL CHEM, V267, P7806; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Okura T, 1996, J IMMUNOL, V157, P4277; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113	19	208	219	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12036	12042		10.1074/jbc.274.17.12036	http://dx.doi.org/10.1074/jbc.274.17.12036			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207026	hybrid			2022-12-25	WOS:000079834800082
J	Schweizer-Groyer, G; Jibard, N; Neau, E; Fortin, D; Cadepond, F; Baulieu, EE; Groyer, A				Schweizer-Groyer, G; Jibard, N; Neau, E; Fortin, D; Cadepond, F; Baulieu, EE; Groyer, A			The glucocorticoid response element II is functionally homologous in rat and human insulin-like growth factor-binding protein-1 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOZOTOCIN-DIABETIC RATS; TRANS-ACTING FACTORS; HUMAN GENE; HEPATOMA-CELLS; IGFBP-1 PROMOTER; MAMMALIAN-CELLS; MESSENGER-RNA; CIS-ELEMENTS; EXPRESSION; TRANSCRIPTION	In vivo, insulin-like growth factor-binding protein-1 (IGFBP-1) modulates the IGFs' bioavailability and may contribute to their delivery to peripheral tissues. In rat and human hepatocytes, glucocorticoids stimulate IG-FBP-1 gene transcription through homologous glucocorticoid response units (GRU). Transfection experiments have shown that one of these, GRUB (nucleotide (nt) -121 to -85 and nt -111 to -74 in human and rat promoters, respectively), was on its own able to mediate the glucocorticoid response in rat but not in human species (Suwanichkul, A., Allander, S., Morris, S. L. & Powell, D. R. (1994) J. Biol. Chem. 269, 30835-30841, Goswami, a, Lacson, R., Yang, E,, Sam, R. & Unterman, T. (1994) Endocrinology 134, 736-743, and Sub, D. S., Ooi, G. T, & Rechler, M. M. (1994) Mob Endocrinol. 8, 794-805), A close comparison of GRUB sequences has pointed out a C to A transition in the underlying GREII, which creates a GATC tetranucleotide in rat species. This tetranucleotide is submitted to adenosyl methylation (dam methylation) in most Escherichia coli bacterial strains, but not in eucaryotic cells. We showed (i) that on its own, the unmethylated rat GRUB (propagated in dam E. coli strains) was inactive, as is the case for its human counterpart (nonsignificant glucocorticoid inductions, 1.48 +/- 0.23 and 1.7 +/- 0.35-fold in Chinese hamster ovary cells, respectively) and (ii) that its adenosyl methylation in standard dam(+) bacterial strains yielded a functional GRU (6.5 +/- 1.1 and 13.1 +/- 3.9-fold glucocorticoid inductions in Chinese hamster ovary and HepG2 cells, respectively). Transient transfection in HepG2 hepatoma cells clearly showed that the interaction of liver-enriched trans-acting factor(s) with the 5'-overlapping insulin response element does not enable the unmethylated rat GRU2 or the human GRUB to become responsive to glucocorticoids (nonsignificant 2.21 +/- 0.48 and 1.20 +/- 0.06-fold induction, respectively). Furthermore, we have correlated these functional data with in vitro DNA-protein interaction studies: the dam methylated rat GREII displayed a 2.8-fold higher affinity for the glucocorticoid receptor than its unmethylated counterpart.	INSERM, U488, Lab Hormones, F-94276 Le Kremlin Bicetre, France; Hop St Antoine, INSERM, U142, F-75571 Paris 12, France; Univ Paris 07, INSERM, U327, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Schweizer-Groyer, G (corresponding author), INSERM, U488, Lab Hormones, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	groyer@kb.inserm.fr						BABAJKO S, 1993, P NATL ACAD SCI USA, V90, P272, DOI 10.1073/pnas.90.1.272; BABAJKO S, 1993, BIOCHEM BIOPH RES CO, V196, P480, DOI 10.1006/bbrc.1993.2275; BABAJKO S, 1993, ENDOCRINOLOGY, V132, P2586, DOI 10.1210/en.132.6.2586; BABAJKO S, 1993, GROWTH REGULAT, V3, P17; BAGCHI MK, 1992, ENDOCR REV, V13, P525, DOI 10.1210/er.13.3.525; BAR RS, 1990, ENDOCRINOLOGY, V127, P497, DOI 10.1210/endo-127-1-497; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P432, DOI 10.1210/jcem-65-3-432; CADEPOND F, 1994, J STEROID BIOCHEM, V48, P361, DOI 10.1016/0960-0760(94)90076-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; ERDOS T, 1970, ANAL BIOCHEM, V37, P244, DOI 10.1016/0003-2697(70)90044-8; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GRAHAM MW, 1995, TRANSGENIC RES, V4, P324, DOI 10.1007/BF01972529; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MURPHY LJ, 1991, ENDOCRINOLOGY, V128, P689, DOI 10.1210/endo-128-2-689; Nan XS, 1998, CIBA F SYMP, V214, P6; Neau Eric, 1995, Progress in Growth Factor Research, V6, P103, DOI 10.1016/0955-2235(95)00039-9; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OOI GT, 1992, MOL ENDOCRINOL, V6, P2219, DOI 10.1210/me.6.12.2219; OOI GT, 1993, J BIOL CHEM, V268, P16664; OOI GT, 1990, MOL ENDOCRINOL, V4, P321, DOI 10.1210/mend-4-2-321; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; PAO CI, 1992, MOL ENDOCRINOL, V6, P969, DOI 10.1210/me.6.6.969; POWELL DR, 1991, J BIOL CHEM, V266, P18868; POWELL DR, 1993, DNA CELL BIOL, V12, P283, DOI 10.1089/dna.1993.12.283; PRICE WA, 1992, ENDOCRINOLOGY, V130, P1424, DOI 10.1210/en.130.3.1424; Pristas P, 1998, J BASIC MICROB, V38, P283; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; ROBERTSON DG, 1994, BIOCHEM BIOPH RES CO, V200, P226, DOI 10.1006/bbrc.1994.1438; SCHULLER AGP, 1994, MOL CELL ENDOCRINOL, V104, P57, DOI 10.1016/0303-7207(94)90051-5; SchweizerGroyer G, 1997, BIOCHEM J, V324, P823, DOI 10.1042/bj3240823; SegardMaurel I, 1996, BIOCHEMISTRY-US, V35, P1634, DOI 10.1021/bi951369h; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; Suh DS, 1996, MOL ENDOCRINOL, V10, P1227, DOI 10.1210/me.10.10.1227; SUH DS, 1994, MOL ENDOCRINOL, V8, P794, DOI 10.1210/me.8.6.794; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; TAJIMA S, 1998, J BIOCHEM-TOKYO, V123, P998; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TRUSS M, 1992, NUCLEIC ACIDS RES, V20, P1483, DOI 10.1093/nar/20.7.1483; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; UNTERMAN TG, 1990, ENDOCRINOLOGY, V126, P2614, DOI 10.1210/endo-126-5-2614; UNTERMAN TG, 1993, ENDOCRINOLOGY, V133, P2531, DOI 10.1210/en.133.6.2531	52	4	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11679	11686		10.1074/jbc.274.17.11679	http://dx.doi.org/10.1074/jbc.274.17.11679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206981	hybrid			2022-12-25	WOS:000079834800037
J	Toshima, J; Tanaka, T; Mizuno, K				Toshima, J; Tanaka, T; Mizuno, K			Dual specificity protein kinase activity of testis-specific protein kinase 1 and its regulation by autophosphorylation of serine-215 within the activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; TYROSINE RESIDUES; PHOSPHORYLATION SITES; CONSERVED FEATURES; THREONINE KINASES; MAMMALIAN-CELLS; IDENTIFICATION; FAMILY; TESK1; TRANSFORMATION	TESK1 (testis-specific protein kinase 1) is a protein kinase with a structure composed of an N-terminal protein kinase domain and a C-terminal proline-rich domain. Whereas the 3.6-kilobase TESK1 mRNA is expressed predominantly in the testis, a faint 2.5-kilobase TESK1 mRNA is expressed ubiquitously. The kinase domain of TESK1 contains in the catalytic loop in subdomain VIE an unusual DLTSKN sequence, which is not related to the consensus sequence of either serine/threonine kinases or tyrosine kinases, In this study, we show that TESK1 has kinase activity with dual specificity on both serine/threonine and tyrosine residues. In an in vitro kinase reaction, the kinase domain of TESK1 underwent autophosphorylation on serine and tyrosine residues and catalyzed phosphorylation of histone H3 and myelin basic protein on serine, threonine, and tyrosine residues. Site-directed mutagenesis analyses revealed that Ser-215 within the "activation loop" of the kinase domain is the site of serine autophosphorylation of TESK1. Replacement of Ser-215 by alanine almost completely abolished serine autophosphorylation and histone H3 kinase activities. In contrast, replacement of Ser-215 by glutamic acid abolished serine autophosphorylation activity but retained histone H3 kinase activity. These results suggest that autophosphorylation of Ser-215 is an important step to positively regulate the kinase activity of TESK1.	Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Mizuno, K (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan.	kmizuscb@mbox.nc.kyushu-u.ac.jp	Mizuno, Kensaku/G-8631-2015					ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOUVILLE E, 1994, CANCER METAST REV, V13, P1, DOI 10.1007/BF00690414; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guesdon F, 1997, J BIOL CHEM, V272, P30017, DOI 10.1074/jbc.272.48.30017; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kentrup H, 1996, J BIOL CHEM, V271, P3488; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIZUNO K, 1994, ONCOGENE, V9, P1605; NUNOUE K, 1995, ONCOGENE, V11, P701; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; ORR JW, 1994, J BIOL CHEM, V269, P27715; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PROSCHEL C, 1995, ONCOGENE, V11, P1271; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Toshima J, 1998, BIOCHEM BIOPH RES CO, V249, P107, DOI 10.1006/bbrc.1998.9099; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; Toshima J, 1998, GENE, V206, P237, DOI 10.1016/S0378-1119(97)00591-X; WANG QM, 1994, J BIOL CHEM, V269, P14566; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	39	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12171	12176		10.1074/jbc.274.17.12171	http://dx.doi.org/10.1074/jbc.274.17.12171			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207045	hybrid			2022-12-25	WOS:000079834800101
J	Pettigrew, GW; Prazeres, S; Costa, C; Palma, N; Krippahl, L; Moura, I; Moura, JJG				Pettigrew, GW; Prazeres, S; Costa, C; Palma, N; Krippahl, L; Moura, I; Moura, JJG			The structure of an electron transfer complex containing a cytochrome c and a peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; CROSS-LINKING; LOW-AFFINITY; BINDING; RESOLUTION; SITE; NONCOVALENT; ASSIGNMENT	Efficient biological electron transfer may require a fluid association of redox partners. Two noncrystallographic methods (a new molecular docking program and H-1 NMR spectroscopy) have been used to study the electron transfer complex formed between the cytochrome c peroxidase (CCP) of Paracoccus denitrificans and cytochromes c, For the natural redox partner, cytochrome c(550), the results are consistent with a complex in which the heme of a single cytochrome lies above the exposed electron-transferring heme of the peroxidase. In contrast, two molecules of the nonphysiological but kinetically competent horse cytochrome bind between the two hemes of the peroxidase. These dramatically different patterns are consistent with a redox active surface on the peroxidase that may accommodate more than one cytochrome and allow lateral mobility.	Univ Edinburgh, Royal Dick Sch Vet Studies, Dept Preclin Vet Studies, Edinburgh EH9 1QH, Midlothian, Scotland; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, Ctr Quim Fina & Biotecnol, P-2825 Monte De Caparica, Portugal; Inst Super Ciencias Saude, P-2825 Monte De Caparica, Portugal	University of Edinburgh; Universidade Nova de Lisboa	Pettigrew, GW (corresponding author), Univ Edinburgh, Royal Dick Sch Vet Studies, Dept Preclin Vet Studies, Edinburgh EH9 1QH, Midlothian, Scotland.		Costa, Cristina/A-9966-2012; Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013	Costa, Cristina/0000-0002-8611-9023; Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Palma, Nuno/0000-0002-9396-2131; Krippahl, Ludwig/0000-0002-3774-8624				BENNING MM, 1994, ARCH BIOCHEM BIOPHYS, V310, P460, DOI 10.1006/abbi.1994.1193; BERATAN DN, 1987, J CHEM PHYS, V86, P4488, DOI 10.1063/1.452723; BETTS JN, 1992, J AM CHEM SOC, V114, P4043, DOI 10.1021/ja00037a004; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, P52; Boswell AP, 1980, BIOCHEM SOC T, V8, P637, DOI 10.1042/bst0080637b; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; ELLFOLK N, 1984, BIOCHIM BIOPHYS ACTA, V784, P62, DOI 10.1016/0167-4838(84)90173-0; Erman JE, 1997, BIOCHEMISTRY-US, V36, P4054, DOI 10.1021/bi962632x; FOOTE N, 1984, BIOCHEM J, V223, P369, DOI 10.1042/bj2230369; FULOP V, 1995, STRUCTURE, V3, P1225, DOI 10.1016/S0969-2126(01)00258-1; GILMOUR R, 1993, BIOCHEM J, V294, P745, DOI 10.1042/bj2940745; GUPTA RK, 1973, BIOCHIM BIOPHYS ACTA, V292, P502, DOI 10.1016/0005-2728(73)90056-X; Hu W, 1997, BIOCHEMISTRY-US, V36, P7958, DOI 10.1021/bi963131e; KANG CH, 1977, J BIOL CHEM, V252, P919; KELLER RM, 1978, BIOCHIM BIOPHYS ACTA, V533, P195, DOI 10.1016/0005-2795(78)90564-0; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; MAUK MR, 1994, BIOCHEMISTRY-US, V33, P12609, DOI 10.1021/bi00208a011; MOENCH SJ, 1992, BIOCHEMISTRY-US, V31, P3661, DOI 10.1021/bi00129a015; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; Pappa HS, 1996, BIOCHEMISTRY-US, V35, P4837, DOI 10.1021/bi952935b; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PETTIGREW GW, 1991, BIOCHIM BIOPHYS ACTA, V1058, P25, DOI 10.1016/S0005-2728(05)80261-0; STEMP EDA, 1993, BIOCHEMISTRY-US, V32, P10848, DOI 10.1021/bi00091a041; Sukits SF, 1997, BIOCHEMISTRY-US, V36, P5251, DOI 10.1021/bi970072b; TIMKOVICH R, 1984, BIOCHEMISTRY-US, V23, P3526, DOI 10.1021/bi00310a022; TIMKOVICH R, 1981, J MOL BIOL, V153, P95; WALDMEYER B, 1985, J BIOL CHEM, V260, P5184; WANG J, 1996, BIOCHEMISTRY-US, V335, P15107	29	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11383	11389		10.1074/jbc.274.16.11383	http://dx.doi.org/10.1074/jbc.274.16.11383			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196231	hybrid			2022-12-25	WOS:000079751900099
J	Furukawa, Y; Iwase, S; Kikuchi, J; Nakamura, M; Yamada, H; Matsuda, M				Furukawa, Y; Iwase, S; Kikuchi, J; Nakamura, M; Yamada, H; Matsuda, M			Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes	ONCOGENE			English	Article						interferon; transcription; E2F-1; E2F-4; pRB; p130	CELL-CYCLE REGULATION; SENSITIVE HEMATOPOIETIC-CELLS; DNA-BINDING ACTIVITY; GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; IN-VIVO; INTERLEUKIN-6 SUPPRESS; CDC2 GENE; EXPRESSION; ACTIVATION	E2F is a heterodimeric transcription factor composed of one of five E2F subunits (E2F-1 to E2F-5) and a DP subunit, E2F regulates the expression of several growth-promoting genes, and thus, can be a target of antiproliferative action of interferons (IFNs), In this study, me investigated the mechanisms whereby IFN-alpha suppresses transcription of the E2F-1 gene. Transfection studies revealed that E2F-1 promoter was functionally divided into two parts: upstream activation sequences (UAS) and a downstream negative-regulatory element (E2F-binding sites). When cells were proliferating, transcription of the E2F-1 gene was primarily driven by the UAS, while E2F sites were not involved in activation. IFN-alpha markedly reduced E2F-1 promoter activity, but introduction of non-binding mutation at the E2F sites completely abrogated the inhibition. Free E2F-1 was found to be the predominant species bound to the E2F sites in proliferating cells. IFN-alpha induced upregulation of E2F-4 along with dephosphorylation of PRE and p130, which resulted in the formation of E2F-4/pRB and E2F-4/p130 complexes on the E2F-1 promoter, These complexes function as transcriptional repressors to inhibit E2F-1 mRNA expression. Our findings indicate that E2F-4 is a critical regulator of E2F-1, which offer an excellent paradigm for understanding functional diversity within the E2F family.	Jichi Med Sch, Ctr Mol Med, Div Mol Hemopoiesis, Minamimaki, Tochigi 3290498, Japan; Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 3290498, Japan; Hitachi Ltd, Katsuta Res Lab, Katsuta, Ibaraki 312, Japan; Jikei Univ, Sch Med, DNA Res Inst, Dept Internal Med,Aoto, Tokyo 105, Japan; Jikei Univ, Sch Med, DNA Res Inst, Dept Genet, Tokyo 105, Japan	Jichi Medical University; Jichi Medical University; Hitachi Limited; Jikei University; Jikei University	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Mol Hemopoiesis, 3311-1 Yakushiji, Minamimaki, Tochigi 3290498, Japan.		Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Cress WD, 1996, MOL CELL BIOL, V16, P2119; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Geng Y, 1996, ONCOGENE, V12, P1173; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1994, J BIOL CHEM, V269, P6999; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KITAGAWA M, 1995, ONCOGENE, V10, P229; Kramer A, 1996, J BIOL CHEM, V271, P6579; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Moberg K, 1996, MOL CELL BIOL, V16, P1436; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Selleri C, 1996, BLOOD, V87, P4149, DOI 10.1182/blood.V87.10.4149.bloodjournal87104149; SEN GC, 1992, J BIOL CHEM, V267, P5017; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; THOMAS NSB, 1988, J BIOL CHEM, V264, P13697; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Williams CD, 1997, BRIT J HAEMATOL, V96, P688, DOI 10.1046/j.1365-2141.1997.d01-2086.x; Williams CD, 1997, BLOOD, V90, P194; XU JH, 1994, MOL CELL BIOL, V14, P8018, DOI 10.1128/MCB.14.12.8018; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					2003	2014		10.1038/sj.onc.1202500	http://dx.doi.org/10.1038/sj.onc.1202500			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208422				2022-12-25	WOS:000079191300010
J	Arrizubieta, MJ; Bandman, E				Arrizubieta, MJ; Bandman, E			Regulation of alpha-helical coiled-coil dimerization in chicken skeletal muscle light meromyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; INTERHELICAL IONIC INTERACTIONS; HEAVY-CHAIN FAMILY; MYOSIN HEAVY; AMINO-ACIDS; STABILITY; HETERODIMER; ISOFORMS; SPECIFICITY; PROTEINS	The dimerization specificity of the light meromyosin (LMM) domain of chicken neonatal and adult myosin isoforms was analyzed by metal chelation chromatography. Our results show that neonatal and adult LMMs associate preferentially, although not exclusively, as homodimeric coiled-coils. Using chimeric LMM constructs combining neonatal and adult sequences, we observed that a stretch of 183 amino acids of sequence identity at the N terminus of the LMM was sufficient to allow the adult LMM to dimerize in a non-selective manner. In contrast, sequence identity in the remaining C-terminal 465 amino acids had only a modest effect on the dimerization selectivity of the adult isoform. Sequence identity at the N terminus also promoted dimerization of the neonatal LMM to a greater degree than sequence identity at the C terminus. However, the N terminus had only a partial effect on the dimerization specificity of the neonatal sequence, and residues distributed throughout the LMM were capable of affecting dimerization selectivity of this isoform. These results indicated that dimerization preference of the neonatal and adult isoforms was affected to a different extent by sequence identity at a given region of the LMM.	Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA	University of California System; University of California Davis	Bandman, E (corresponding author), Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA.							Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arrizubieta MJ, 1998, BIOCHEM BIOPH RES CO, V244, P588, DOI 10.1006/bbrc.1998.8105; BANDMAN E, 1982, DEV BIOL, V93, P508, DOI 10.1016/0012-1606(82)90138-5; BANDMAN E, 1985, INT REV CYTOL, V97, P97, DOI 10.1016/S0074-7696(08)62349-9; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; GAUTHIER GF, 1990, J CELL BIOL, V110, P693, DOI 10.1083/jcb.110.3.693; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; GORDON DA, 1992, J MUSCLE RES CELL M, V13, P654, DOI 10.1007/BF01738255; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HOFFMAN S, 1988, FEBS LETT, V238, P245; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; JOHN M, 1994, J BIOL CHEM, V269, P16247; KERWIN B, 1991, J CELL BIOL, V113, P311, DOI 10.1083/jcb.113.2.311; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEHRER SS, 1989, SCIENCE, V246, P926, DOI 10.1126/science.2814515; LOWEY S, 1991, J CELL BIOL, V113, P303, DOI 10.1083/jcb.113.2.303; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MOORE LA, 1992, J MOL BIOL, V225, P1143, DOI 10.1016/0022-2836(92)90114-Y; MOORE LA, 1992, J MOL BIOL, V223, P383, DOI 10.1016/0022-2836(92)90741-2; Nozaki Y, 1972, Methods Enzymol, V26, P43; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PU WT, 1993, NUCLEIC ACIDS RES, V21, P4348, DOI 10.1093/nar/21.18.4348; RASHID DJ, 1995, J MOL BIOL, V252, P157, DOI 10.1006/jmbi.1995.0484; ROBBINS J, 1986, J BIOL CHEM, V261, P6606; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P734; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR LD, 1989, J CELL BIOL, V108, P533, DOI 10.1083/jcb.108.2.533; Tidyman WE, 1997, DEV DYNAM, V208, P491; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WALLER GS, 1985, J BIOL CHEM, V260, P4368; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365; ZHU BY, 1993, PROTEIN SCI, V2, P383	44	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13847	13853		10.1074/jbc.274.20.13847	http://dx.doi.org/10.1074/jbc.274.20.13847			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318791	hybrid			2022-12-25	WOS:000080322200020
J	Ivanov, VN; Ronai, Z				Ivanov, VN; Ronai, Z			Down-regulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FAS LIGAND EXPRESSION; C-JUN; TNF-ALPHA; SIGNAL-TRANSDUCTION; MALIGNANT-MELANOMA; T-CELLS; NEGATIVE REGULATION; RESPONSE ELEMENT; BINDING PROTEIN	To identify mechanisms whereby activating transcription factor 2 (ATF2) alters the radiation resistance of human melanoma cells, we examined the possible role of ATF2 in WC-induced apoptosis. Forced expression of full-length or truncated (Delta 1-195 amino acids) forms of ATF2 in LU1205, a late-stage human melanoma cell line, elevated the levels of UVC-induced apoptosis. At the same time, either truncated or full-length forms of ATF2 reduced UVC-induced activation of the tumor necrosis factor-alpha (TNF alpha) promoter and decreased expression of TNF alpha. Forced expression of c-Jun in ATF2-expressing melanoma cells restored TNF alpha expression, suggesting that both forms of ATF2 sequestered transcription factors that positively regulate TNF alpha expression in response to UV irradiation. Antagonistic antibodies to Fas, but not to TNFR1, efficiently suppressed UVC-induced apoptosis, suggesting that the Fas pathway mediates the primary apoptotic signal in melanoma cells whereas the TNFR1 pathway elicits a survival signal. Indeed, treatment of melanoma cells with TNF alpha before UVC irradiation partially suppressed WC-induced apoptosis, further supporting the protective role of TNF alpha in UVC-treated melanoma cells. Taken together, our findings suggest that ATF2 contributes to UVC-induced apoptosis through transcriptional silencing of TNF alpha, which balances Fas-mediated cell death in melanoma.	Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave,Rm 15-20, New York, NY 10029 USA.	ronaiz01@doc.mmsm.edu	Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA 51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Caricchio R, 1998, J IMMUNOL, V161, P241; CHATTON B, 1994, ONCOGENE, V9, P375; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; Cubillos S, 1997, ANTICANCER RES, V17, P2207; DECESARE D, 1995, ONCOGENE, V11, P365; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FUCHS SY, 1999, IN PRESS MOL CELL BI, V19; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hakansson A, 1997, MELANOMA RES, V7, P139, DOI 10.1097/00008390-199704000-00008; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KHOURY E, 1994, BLOOD, V84, P2506; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MIELE ME, 1994, EXP CELL RES, V214, P231, DOI 10.1006/excr.1994.1253; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OROSZ P, 1995, INT J CANCER, V60, P867, DOI 10.1002/ijc.2910600624; OROSZ P, 1993, J EXP MED, V177, P1391, DOI 10.1084/jem.177.5.1391; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; QIN ZH, 1993, J EXP MED, V178, P355, DOI 10.1084/jem.178.1.355; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; RODECK U, 1993, CANCER METAST REV, V12, P219, DOI 10.1007/BF00665954; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; RUSTEN LS, 1994, J CLIN INVEST, V94, P165, DOI 10.1172/JCI117303; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Stoelcker B, 1996, J INFLAMM, V46, P155; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsai EY, 1996, MOL CELL BIOL, V16, P459; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WU S, 1993, CANCER RES, V53, P1939; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; Yang YM, 1996, ONCOGENE, V12, P2223; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; ZUNIGAPFLUCKER JC, 1995, SCIENCE, V268, P1906, DOI 10.1126/science.7541554	88	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14079	14089		10.1074/jbc.274.20.14079	http://dx.doi.org/10.1074/jbc.274.20.14079			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318823	Green Published, hybrid			2022-12-25	WOS:000080322200052
J	Nakamura, K; Yahagi, S; Yamazaki, T; Yamane, K				Nakamura, K; Yahagi, S; Yamazaki, T; Yamane, K			Bacillus subtilis histone-like protein, HBsu, is an integral component of a SRP-like particle that can bind the Alu domain of small cytoplasmic RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; METHIONINE-RICH DOMAIN; COLI 4.5S RNA; ESCHERICHIA-COLI; 7S RNA; 54-KD PROTEIN; CDNA CLONE; SEQUENCE; SUBUNIT; HOMOLOG	Small cytoplasmic RNA (scRNA) is metabolically stable and abundant in Bacillus subtilis cells. Consisting of 271 nucleotides, it is structurally homologous to mammalian signal recognition particle RNA. In contrast to 4.5 S RNA of Escherichia coli, B. subtilis scRNA contains an Alu domain in addition to the evolutionarily conserved S domain. In this study, we show that a 10-kDa protein in B, subtilis cell extracts has scRNA binding activity at the Abu domain. The in vitro binding selectivity of the 10-kDa protein shows that it recognizes the higher structure of the Alu domain of scRNA caused by five consecutive complementary sequences in the two loops. Purification and subsequent analyses demonstrated that the 10-kDa protein is HBsu, which was originally identified as a member of the histone-like protein family. By constructing a HBsu-deficient B, subtilis mutant, we showed that HBsu is essential for normal growth. Immunoprecipitating cell lysates using anti-HBsu antibody yielded scRNA. Moreover, the eo-precipitation of HBsu with (His)(6)-tagged Ffh depended on the presence of scRNA, suggesting that HBsu, Ffh, and scRNA make a ternary complex and that scRNA serves as a functional unit for binding. These results demonstrated that HBsu is the third component of a signal recognition particle-like particle in B, subtilis that can bind the Alu domain of scRNA.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan	University of Tsukuba	Nakamura, K (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan.	nakamura.kouji@nifty.ne.jp						BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, TRENDS GENET, V6, P329, DOI 10.1016/0168-9525(90)90254-4; Birse DEA, 1997, EMBO J, V16, P3757, DOI 10.1093/emboj/16.13.3757; BOTT KF, 1967, J BACTERIOL, V94, P562, DOI 10.1128/JB.94.3.562-570.1967; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; Bunai K, 1996, BIOCHEM BIOPH RES CO, V227, P762, DOI 10.1006/bbrc.1996.1582; Bunai K, 1999, J BIOCHEM, V125, P151, DOI 10.1093/oxfordjournals.jbchem.a022252; Chang DY, 1996, NUCLEIC ACIDS RES, V24, P4165, DOI 10.1093/nar/24.21.4165; DANESE PN, 1995, J BACTERIOL, V177, P4969, DOI 10.1128/jb.177.17.4969-4973.1995; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; GARDEL C, 1990, EMBO J, V9, P4205, DOI 10.1002/j.1460-2075.1990.tb07645.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENNER DJ, 1990, METHOD ENZYMOL, V185, P223; HERZ J, 1990, FEBS LETT, V276, P103, DOI 10.1016/0014-5793(90)80518-N; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; HONDA K, 1993, J BACTERIOL, V175, P4885, DOI 10.1128/JB.175.15.4885-4894.1993; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; Kohler P, 1997, J BACTERIOL, V179, P2060; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; LUTCKE H, 1993, J CELL BIOL, V121, P977, DOI 10.1083/jcb.121.5.977; MICKA B, 1992, BIOCHIMIE, V74, P641, DOI 10.1016/0300-9084(92)90136-3; MICKA B, 1991, J BACTERIOL, V173, P3191, DOI 10.1128/JB.173.10.3191-3198.1991; NAKAMURA K, 1992, J BACTERIOL, V174, P2185, DOI 10.1128/JB.174.7.2185-2192.1992; NAKAMURA K, 1995, MICROBIOL-SGM, V141, P2965, DOI 10.1099/13500872-141-11-2965; NAKAMURA K, 1994, BIOCHEM BIOPH RES CO, V199, P1394, DOI 10.1006/bbrc.1994.1385; NISHIGUCHI M, 1994, J BACTERIOL, V176, P157, DOI 10.1128/JB.176.1.157-165.1994; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; Oguro A, 1996, GENE, V172, P17, DOI 10.1016/0378-1119(96)00181-3; Oguro A, 1998, J BIOL CHEM, V273, P19542, DOI 10.1074/jbc.273.31.19542; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; Shibata T, 1996, J BIOL CHEM, V271, P13162, DOI 10.1074/jbc.271.22.13162; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STRUB K, 1989, P NATL ACAD SCI USA, V86, P9747, DOI 10.1073/pnas.86.24.9747; STRUCK JCR, 1989, MOL GEN GENET, V215, P478, DOI 10.1007/BF00427046; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P2719, DOI 10.1093/nar/16.6.2719; Takamatsu H, 1997, EUR J BIOCHEM, V248, P575, DOI 10.1111/j.1432-1033.1997.00575.x; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WEINER AM, 1980, CELL, V22, P209, DOI 10.1016/0092-8674(80)90169-5; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	49	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13569	13576		10.1074/jbc.274.19.13569	http://dx.doi.org/10.1074/jbc.274.19.13569			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224127	hybrid			2022-12-25	WOS:000080200400089
J	Reinhard, M; Zumbrunn, J; Jaquemar, D; Kuhn, M; Walter, U; Trueb, B				Reinhard, M; Zumbrunn, J; Jaquemar, D; Kuhn, M; Walter, U; Trueb, B			An alpha-actinin binding site of zyxin is essential for subcellular zyxin localization and alpha-actinin recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROFILAMENT PROTEIN VASP; LISTERIA-MONOCYTOGENES; CYTOPLASMIC DOMAIN; FOCAL ADHESION; LIM DOMAIN; CYTOSKELETAL PROTEINS; ACTA PROTEIN; CELLS; PURIFICATION; LIGAND	The LIM domain protein zyxin is a component of adherens type junctions, stress fibers, and highly dynamic membrane areas and appears to be involved in microfilament organization. Chicken zyxin and its human counterpart display less than 60% sequence identity, raising concern about their functional identity. Here, we demonstrate that human zyxin, like the avian protein, specifically interacts with alpha-actinin. Furthermore, we map the interaction site to a motif of approximately 22 amino acids, present in the N-terminal domain of human zyxin, This motif is both necessary and sufficient for alpha-actinin binding, whereas a downstream region, which is related in sequence, appears to be dispensable. A synthetic peptide comprising human zyxin residues 21-42 specifically binds to alpha-actinin in solid phase binding assays. In contrast to full-length zyxin, constructs lacking this motif do not interact with alpha-actinin in blot overlays and fail to recruit alpha-actinin in living cells. When zyxin lacking the alpha actinin binding site is expressed as a fusion protein with green fluorescent protein, association of the recombinant protein with stress fibers is abolished, and targeting to focal adhesions is grossly impaired. Our results suggest a crucial role for the alpha-actinin-zyxin interaction in subcellular zyxin localization and microfilament organization.	Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97078 Wurzburg, Germany; Univ Bern, ME Muller Inst Biomech, CH-3010 Bern, Switzerland	University of Wurzburg; University of Bern	Reinhard, M (corresponding author), Univ Wurzburg, Inst Clin Biochem & Pathobiochem, Versbacher Str 5, D-97078 Wurzburg, Germany.		Reinhard, Martin/A-1006-2008; Walter, ulrich/W-2478-2017; Trueb, Beat/AAL-9621-2020	Reinhard, Martin/0000-0002-7833-6175; Walter, ulrich/0000-0001-6784-2307; Trueb, Beat/0000-0001-8684-6856				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; Balzar M, 1998, MOL CELL BIOL, V18, P4833, DOI 10.1128/MCB.18.8.4833; Bubeck P, 1997, J CELL SCI, V110, P1361; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRITCHLEY DR, 1999, IN PRESS GUIDEBOOK C; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Golsteyn RM, 1997, J CELL SCI, V110, P1893; Heiska L, 1996, J BIOL CHEM, V271, P26214, DOI 10.1074/jbc.271.42.26214; Hobert O, 1996, ONCOGENE, V12, P1577; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAVALKO FM, 1995, EXP CELL RES, V217, P534, DOI 10.1006/excr.1995.1119; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; SCHULZE H, 1989, EMBO J, V8, P3587, DOI 10.1002/j.1460-2075.1989.tb08531.x; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zigmond SH, 1998, CURR BIOL, V8, pR654, DOI 10.1016/S0960-9822(07)00415-0; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	44	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13410	13418		10.1074/jbc.274.19.13410	http://dx.doi.org/10.1074/jbc.274.19.13410			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224105	hybrid			2022-12-25	WOS:000080200400067
J	Smith, JJ; Rucknagel, KP; Schierhorn, A; Tang, J; Nemeth, A; Linder, M; Herschman, HR; Wahle, E				Smith, JJ; Rucknagel, KP; Schierhorn, A; Tang, J; Nemeth, A; Linder, M; Herschman, HR; Wahle, E			Unusual sites of arginine methylation in poly(A)-binding protein II and in vitro methylation by protein arginine methyltransferases PRMT1 and PRMT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; RNA-BINDING PROTEINS; SUBSTRATE-SPECIFICITY; N-METHYLTRANSFERASE; MESSENGER-RNA; ENZYMATIC METHYLATION; S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; MOLECULAR-WEIGHT; HNRNP PROTEINS	Arginine methylation is a post-translational modification found mostly in RNA-binding proteins. Poly(A) binding protein II from calf thymus was shown by mass spectrometry and sequencing to contain N-G-N-G-dimethylarginine at 13 positions in its amino acid sequence. Two additional arginine residues were partially methylated. Almost all of the modified residues were found in Arg-Xaa-Arg clusters in the C terminus of the protein. These motifs are distinct from Arg-Gly-Gly motifs that have been previously described as sites and specificity determinants for asymmetric arginine dimethylation. Poly(A)-binding protein II and deletion mutants expressed in Escherichia coli were in vitro substrates for two mammalian protein arginine methyltransferases, PRMT1 and PRMT3, with S-adenosyl-L-methionine as the methyl group donor. Both PRMT1 and PRMT3 specifically methylated arginines in the C-terminal domain corresponding to the naturally modified sites.	Univ Halle Wittenberg, Inst Biochem, D-06120 Halle, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Max Planck Forschungsstelle Enzymol Prot, D-06120 Halle, Germany; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	Martin Luther University Halle Wittenberg; Justus Liebig University Giessen; Max Planck Society; University of California System; University of California Los Angeles; Justus Liebig University Giessen	Wahle, E (corresponding author), Univ Halle Wittenberg, Inst Biochem, Kurt Mothes Str 3, D-06120 Halle, Germany.	ewahle@biochemtech.uni-halle.de		Wahle, Elmar/0000-0003-2504-0677	NIAID NIH HHS [AI34567] Funding Source: Medline; NIGMS NIH HHS [GM24797] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034567, U19AI034567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdulMana N, 1996, BIOCHEMISTRY-US, V35, P3545, DOI 10.1021/bi952298p; Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; Bagni C, 1998, J BIOL CHEM, V273, P10868, DOI 10.1074/jbc.273.18.10868; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURGESS WH, 1991, CELL REGUL, V2, P87, DOI 10.1091/mbc.2.2.87; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHOSH SK, 1990, BIOCHIM BIOPHYS ACTA, V1039, P142, DOI 10.1016/0167-4838(90)90179-J; Henry MF, 1996, MOL CELL BIOL, V16, P3668; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LEE TD, 1990, METHOD ENZYMOL, V193, P361, DOI 10.1016/0076-6879(90)93427-M; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1982, J BIOL CHEM, V257, P4600; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; SOMMER A, 1989, BIOCHEM BIOPH RES CO, V160, P1267, DOI 10.1016/S0006-291X(89)80140-8; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; WAHLE E, 1993, J BIOL CHEM, V268, P2937; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	48	121	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13229	13234		10.1074/jbc.274.19.13229	http://dx.doi.org/10.1074/jbc.274.19.13229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224081	hybrid			2022-12-25	WOS:000080200400043
J	Chen, G; Yuan, SSF; Liu, W; Xu, Y; Trujillo, K; Song, BW; Cong, F; Goff, SP; Wu, Y; Arlinghaus, R; Baltimore, D; Gasser, PJ; Park, MS; Sung, P; Lee, EYHP				Chen, G; Yuan, SSF; Liu, W; Xu, Y; Trujillo, K; Song, BW; Cong, F; Goff, SP; Wu, Y; Arlinghaus, R; Baltimore, D; Gasser, PJ; Park, MS; Sung, P; Lee, EYHP			Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA CELLS; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; TYROSINE KINASE; GENE-PRODUCT; REPAIR; PHOSPHORYLATION	Cells from individuals with the recessive cancer-prone disorder ataxia telangiectasia (A-T) are hypersensitive to ionizing radiation (I-R). ATM (mutated in A-T) is a protein kinase whose activity is stimulated by I-R. c-Abl, a nonreceptor tyrosine kinase, interacts with ATM and is activated by ATM following I-R. Rad51 is a homologue of bacterial RecA protein required for DNA recombination and repair. Here we demonstrate that there is an I-R-induced Rad51 tyrosine phosphorylation, and this induction is dependent on both ATM and c-Abl. ATM, c-Abl, and Rad51 can be co-immunoprecipitated from cell extracts. Consistent with the physical interaction, c-Abl phosphorylates Rad51 in vitro and in vivo. In assays using purified components, phosphorylation of Rad51 by c-Abl enhances complex formation between Rad51 and Rad52, which cooperates with Rad51 in recombination and repair. After I-R, an increase in association between Rad51 and Rad52 occurs in wild-type cells but not in cells with mutations that compromise ATM or c-Abl. Our data suggest signaling mediated through ATM, and c-Abl is required for the correct posttranslational modification of Rad51, which is critical for the assembly of Rad51 repair protein complex following I-R.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA	University of Texas System; University of Texas Health San Antonio; Massachusetts Institute of Technology (MIT); Columbia University; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Los Alamos National Laboratory	Lee, EYHP (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 7703 Floyd Curl Dr, San Antonio, TX 78245 USA.		Park, Min Sung/HCH-2207-2022; Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Xu, Yang/0000-0001-5574-921X; yuan, shyng-shiou/0000-0002-4753-788X; Gasser, Paul/0000-0002-2092-6068	NINDS NIH HHS [1RO1NS378381-01] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andoniou CE, 1996, ONCOGENE, V12, P1981; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; COX R, 1982, ATAXIA TELANGIECTASI; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; Foray N, 1997, INT J RADIAT BIOL, V71, P449; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Kanaar Roland, 1997, Genes and Function, V1, P165; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Luo CM, 1996, J BIOL CHEM, V271, P4497; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1995, CANCER RES, V55, P5991; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; THACKER J, 1994, INT J RADIAT BIOL, V66, P87; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799	40	216	222	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12748	12752		10.1074/jbc.274.18.12748	http://dx.doi.org/10.1074/jbc.274.18.12748			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212258	Green Accepted, hybrid			2022-12-25	WOS:000080056800078
J	Laderoute, KR; Mendonca, HL; Calaoagan, JM; Knapp, AM; Giaccia, AJ; Stork, PJS				Laderoute, KR; Mendonca, HL; Calaoagan, JM; Knapp, AM; Giaccia, AJ; Stork, PJS			Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments - A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; DUAL-SPECIFICITY PHOSPHATASE; NECROSIS-FACTOR-ALPHA; RAT MESANGIAL CELLS; C-JUN; TYROSINE-PHOSPHATASE; FACTOR-I; KAPPA-B; TRANSCRIPTION FACTORS; SIGNALING PATHWAY	Pathophysiological hypoxia is an important modulator of gene expression in solid tumors and other pathologic conditions. We observed that transcriptional activation of the c-jun proto oncogene in hypoxic tumor cells correlates with phosphorylation of the ATF2 transcription factor. This finding suggested that hypoxic signals transmitted to c-jun involve protein kinases that target AP-1 complexes (c-Jun and ATF2) that bind to its promoter region, Stress-inducible protein kinases capable of activating c-jun expression include stress-activated protein kinase/c-Jun N-terminal protein kinase (SAPK/JNK) and p38 members of the mitogen-activated protein kinase (MAPK) superfamily of signaling molecules. To investigate the potential role of MAPKs in the regulation of c-jun by tumor hypoxia, we focused on the activation SAPK/JNKs in SiHa human squamous carcinoma cells. Here, we describe the transient activation of SAPK/JNKs by tumor-like hypoxia, and the concurrent transcriptional activation of MKP-1, a stress-inducible member of the MAPK phosphatase (MKP) family of dual specificity protein-tyrosine phosphatases. MKP-1 antagonizes SAPK/JNK activation in response to diverse environmental stresses. Together, these findings identify MKP-1 as a hypoxia-responsive gene and suggest a critical role in the regulation of SAPK/JNK activity in the tumor microenvironment.	SRI Int, Div Pharmaceut Discovery, Menlo Park, CA 94025 USA; Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	SRI International; Stanford University; Oregon Health & Science University; Oregon Health & Science University	Laderoute, KR (corresponding author), SRI Int, Div Pharmaceut Discovery, 333 Ravenswood Ave, Menlo Park, CA 94025 USA.			, Keith/0000-0002-5121-8072	NATIONAL CANCER INSTITUTE [R01CA020329, R37CA020329, R01CA073807, P01CA067166] Funding Source: NIH RePORTER; NCI NIH HHS [CA67166, CA20329, CA73807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Anderson GR, 1995, J SURG RES, V59, P666, DOI 10.1006/jsre.1995.1221; AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brown JM, 1998, CANCER RES, V58, P1408; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Bunn HF, 1998, J EXP BIOL, V201, P1197; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kimura H, 1996, CANCER RES, V56, P5522; KOONG AC, 1994, CANCER RES, V54, P1; KOROMA BM, 1995, J CELL BIOCHEM, V59, P123, DOI 10.1002/jcb.240590114; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Laderoute KR, 1996, INT J ONCOL, V8, P875; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; LADEROUTE KR, 1992, INT J CANCER, V42, P1; Leav I, 1996, LAB INVEST, V75, P361; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1996, AM J PATHOL, V149, P1553; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Mazure NM, 1996, CANCER RES, V56, P3436; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Reynolds TY, 1996, CANCER RES, V56, P5754; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Sutherland RM, 1996, SEMIN RADIAT ONCOL, V6, P59, DOI 10.1016/S1053-4296(96)80036-1; TONKS NK, 1996, INTRACELLULAR SIGNAL, P91; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; Wenger RH, 1997, BIOL CHEM, V378, P609; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Woodgett JR, 1996, CANCER SURV, V27, P127; YANG DD, 1998, SCIENCE, V389, P865; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	78	115	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12890	12897		10.1074/jbc.274.18.12890	http://dx.doi.org/10.1074/jbc.274.18.12890			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212278	hybrid			2022-12-25	WOS:000080056800098
J	Waldow, A; Schmidt, B; Dierks, T; von Bulow, R; von Figura, K				Waldow, A; Schmidt, B; Dierks, T; von Bulow, R; von Figura, K			Amino acid residues forming the active site of arylsulfatase A - Role in catalytic activity and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MODIFICATION; FORMYLGLYCINE; SULFATASE; GENE; CONVERSION; CYSTEINE; CLONING	Arylsulfatase A belongs to the sulfatase family whose members carry a C alpha-formylglycine that is post-translationally generated by oxidation of a conserved cysteine or serine residue. The formylglycine acts as an aldehyde hydrate with two geminal hydroxyls being involved in catalysis of sulfate ester cleavage. In arylsulfatase A and N-acetylgalactosamine 4-sulfatase this formylglycine was found to form the active site together with a divalent cation and a number of polar residues, tightly interconnected by a net of hydrogen bonds. Most of these putative active site residues are highly conserved among the eukaryotic and prokaryotic members of the sulfatase family. To analyze their function in binding and cleaving sulfate esters, we substituted a total of nine putative active site residues of human ASA by alanine (Asp(29), Asp(30), Asp(281), Asn(282), His(125), His(229), Lys(123), Lys(302), and Ser(150)). In addition the Mg2+-complexing residues (Asp(29), Asp(30), Asp(281), and Asn(282)) were substituted conservatively by either asparagine or aspartate, In all mutants V-max was decreased to 1-26% of wild type activity. The K-m was more than 10-fold increased in K123A and K302A and up to B-fold in the other mutants, In all mutants the pH optimum was increased from 4.5 by 0.2-0.8 units. These results indicate that each of the nine residues examined is critical for catalytic activity, Lys(123) and Lys(302) by binding the substrate and the others by direct (His(125) and Asp(281)) Or indirect participation in catalysis. The shift in the pH optimum is explained by two deprotonation steps that have been proposed for sulfate ester cleavage.	Univ Gottingen, Biochem Abt 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Schmidt, B (corresponding author), Univ Gottingen, Biochem Abt 2, Zentrum Biochem & Mol Zellbiol, Gosslerstr 12D, D-37073 Gottingen, Germany.	bschmidt@uni-bc2.gwdg.de	Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Haag ES, 1998, DEV GENES EVOL, V208, P188, DOI 10.1007/s004270050173; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; Knaust A, 1998, BIOCHEMISTRY-US, V37, P13941, DOI 10.1021/bi9810205; Kyte J., 1995, STRUCTURE PROTEIN CH; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; Osteras M, 1998, P NATL ACAD SCI USA, V95, P11394, DOI 10.1073/pnas.95.19.11394; PAIETTA JV, 1989, MOL CELL BIOL, V9, P3630, DOI 10.1128/MCB.9.9.3630; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Recksiek R, 1998, J BIOL CHEM, V273, P6096, DOI 10.1074/jbc.273.11.6096; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; STEIN C, 1989, J BIOL CHEM, V264, P1252; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K	17	57	65	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12284	12288		10.1074/jbc.274.18.12284	http://dx.doi.org/10.1074/jbc.274.18.12284			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212197	hybrid			2022-12-25	WOS:000080056800017
J	Wang, DH; Sun, LZ; Zborowska, E; Willson, JKV; Gong, JG; Verraraghavan, J; Brattain, MG				Wang, DH; Sun, LZ; Zborowska, E; Willson, JKV; Gong, JG; Verraraghavan, J; Brattain, MG			Control of type II transforming growth factor-beta receptor expression by integrin ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; BREAST-CANCER CELLS; MCF-7 CELLS; TGF-BETA; DIFFERENTIAL SENSITIVITY; DNA-SYNTHESIS; FET CELLS; ALPHA(5)BETA(1); ADENOCARCINOMA; PHENOTYPE	Ectopic expression of the alpha(5) integrin subunit in cancer cells with little or no endogenous expression of this integrin often results in reduced proliferation as well as reduced malignancy, We now show that inhibition resulting from ectopic expression of alpha(5) integrin is due to induction of autocrine negative transforming growth factor-beta (TGF-beta) activity. MCF-7 breast cancer cells do not express either alpha(5) integrin or type II TGF-beta receptor and hence are unable to generate TGF-beta signal transduction. Ectopic expression of cy,integrin expression enhanced cell adhesion to fibronectin, reduced proliferation, and increased the expression of type II TGF-beta receptor mRNA and cell surface protein. Receptor expression was increased to a higher level in alpha(5) transfectants by growth on fibronectin-coated plates. Induction of type II TGF-beta receptor expression also resulted in the generation of autocrine negative TGF-beta activity because colony formation was increased after TGF-beta neutralizing antibody treatment. Transient transfection with a TGF-beta promoter response element in tandem with a luciferase cDNA into cells stably transfected with cu, integrin resulted in basal promoter activities 5-10-fold higher than those of control cells. Moreover, when alpha(5) transfectants were treated with a neutralizing antibody to either TGF-beta or integrin alpha(5), this increased basal promoter activity was blocked, Autocrine TGF-beta activity also induced 3-fold higher endogenous fibronectin expression in alpha(5) transfectants relative to that of control cells, Re-expression of type II receptor by alpha(5) transfection also restored the ability of the cells to respond to exogenous TGF-beta and led to reduced tumor growth in athymic nude mice. Taken together, these results show for the first time that TGF-beta type II receptor expression can be controlled by alpha(5)beta(1) ligation and integrin signal transduction, Moreover, TGF-beta and integrin signal transduction appear to cooperate in their tumor-suppressive functions.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Kentucky, Dept Pharmacol, Lexington, KY 40536 USA; Case Western Reserve Univ, Ireland Canc Ctr, Dept Med, Cleveland, OH 44106 USA; Sch Med, Cleveland, OH 44106 USA; Med Coll Ohio, Dept Biochem, Toledo, OH 43699 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Kentucky; Case Western Reserve University	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R37CA038173, R01CA038173, R01CA072001, R01CA050457] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72001, CA 50457, CA 38173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; ELLIOTT B, 1992, J CELL PHYSIOL, V152, P292, DOI 10.1002/jcp.1041520210; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; Gong JG, 1998, J BIOL CHEM, V273, P1662, DOI 10.1074/jbc.273.3.1662; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; KORETZ K, 1991, AM J PATHOL, V138, P741; Lee M, 1997, AM J PHYSIOL-LUNG C, V273, pL374, DOI 10.1152/ajplung.1997.273.2.L374; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SYMINGTON BE, 1992, J BIOL CHEM, V267, P25744; SYMINGTON BE, 1990, CELL REGUL, V1, P637, DOI 10.1091/mbc.1.9.637; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WANG DH, 1995, J CELL PHYSIOL, V164, P499, DOI 10.1002/jcp.1041640308; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WEINEL RJ, 1992, INT J CANCER, V52, P827, DOI 10.1002/ijc.2910520526; WESTERGRENTHORSSON G, 1991, J CELL PHYSIOL, V147, P523, DOI 10.1002/jcp.1041470319; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu GF, 1998, J BIOL CHEM, V273, P7749, DOI 10.1074/jbc.273.13.7749; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; ZUTTER MM, 1993, AM J PATHOL, V142, P1439; ZUTTER MM, 1990, AM J PATHOL, V137, P863	43	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12840	12847		10.1074/jbc.274.18.12840	http://dx.doi.org/10.1074/jbc.274.18.12840			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212271	hybrid			2022-12-25	WOS:000080056800091
J	Lai, MC; Teh, BH; Tarn, WY				Lai, MC; Teh, BH; Tarn, WY			A human papillomavirus E2 transcriptional activator - The interactions with cellular splicing factors and potential function in pre-mRNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; SR PROTEINS; CONSERVED FAMILY; GENE; CTD; PHOSPHORYLATION; LOCALIZATION; COACTIVATOR	The human papillomavirus (HPV) E2 protein plays an important role in transcriptional regulation of viral genes as well as in viral DNA replication. Unlike most types of HPV, the E2 protein of epidermodysplasia verruciformis (EV)-associated HPVs harbors a relatively long hinged region between the terminal, conserved transactivation and DNA binding/dimerization domains. The sequence of EV-HPV E2 hinge contains multiple arginine/serine (RS) dipeptide repeats which are characteristic of a family of pre-messenger RNA splicing factors, called SR proteins. Here we show that the HPV-5 (an EV-HPV) E2 protein can specifically interact with cellular splicing factors including a set of prototypical SR proteins and two snRNP-associated proteins. Transiently expressed HPV-5 E2 protein colocalizes with a nuclear matrix associated-splicing coactivator in nuclear speckled domains. The RS-rich hinge is essential for E2 transactivator interaction with splicing factors and for its subnuclear localization. Moreover, we present functional evidence for the HPV-B E2 transactivator, which shows that the RS-rich hinge domain of the E2 protein can facilitate the splicing of precursor messenger RNA made via transactivation by E2 itself. Our results, therefore, suggest that a DNA binding transactivator containing an RS-rich sequence can play a dual role in gene expression.	Acad Sinica, Inst Biomed Sci, Taipei 11526, Taiwan	Academia Sinica - Taiwan	Tarn, WY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11526, Taiwan.				NHLBI NIH HHS [DOH88-HR-812] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKSDALE SK, 1995, J VIROL, V69, P6553, DOI 10.1128/JVI.69.10.6553-6556.1995; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; BRIDGE E, 1995, J VIROL, V69, P281, DOI 10.1128/JVI.69.1.281-290.1995; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Fetzer S, 1997, RNA, V3, P344; FORTES P, 1995, J GEN VIROL, V76, P1001, DOI 10.1099/0022-1317-76-4-1001; FU XD, 1995, RNA, V1, P663; FUCHS PG, 1994, INTERVIROLOGY, V37, P159, DOI 10.1159/000150374; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; Harlow E., 1988, ANTIBODIES LAB MANUA; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; HOWLEY PM, 1990, VIROLOGY, P1625; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LEE CG, 1993, J BIOL CHEM, V268, P13472; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; NEUGEBAUER KM, 1995, J CELL BIOL, V129, P899, DOI 10.1083/jcb.129.4.899; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; Pfister H, 1992, Semin Cancer Biol, V3, P263; PHELAN A, 1993, P NATL ACAD SCI USA, V90, P9056, DOI 10.1073/pnas.90.19.9056; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Schoneich J, 1997, J IMMUNOL, V158, P4788; SHUMAN S, 1997, P NATL ACAD SCI USA, V94, P12898; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; Skiadopoulos MH, 1996, J VIROL, V70, P1117, DOI 10.1128/JVI.70.2.1117-1124.1996; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tanner S, 1997, BIOL CHEM, V378, P565; TARN WY, 1995, RNA, V1, P644; Teigelkamp S, 1997, RNA, V3, P1313; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zheng ZM, 1997, J VIROL, V71, P9096, DOI 10.1128/JVI.71.12.9096-9107.1997	53	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11832	11841		10.1074/jbc.274.17.11832	http://dx.doi.org/10.1074/jbc.274.17.11832			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207001	hybrid			2022-12-25	WOS:000079834800057
J	McPhee, I; Yarwood, SJ; Scotland, G; Huston, E; Beard, MB; Ross, AH; Houslay, ES; Houslay, MD				McPhee, I; Yarwood, SJ; Scotland, G; Huston, E; Beard, MB; Ross, AH; Houslay, ES; Houslay, MD			Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B - Consequences for rolipram inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; TERMINAL SPLICE REGION; MEMBRANE ASSOCIATION; MOLECULAR-CLONING; PROTEIN-KINASE; CHIMERIC CONSTRUCTS; RPDE-6 RNPDE4A5; SH3 DOMAIN; COS7 CELLS	The cAMP-specific phosphodiesterase (PDE) HSPDE 4A4B(pde46) selectively bound SH3 domains of SRC family tyrosyl kinases. Such an interaction profoundly changed the inhibition of PDE4 activity caused by the PDE4-selective inhibitor rolipram and mimicked the enhanced rolipram inhibition seen for particulate, compared with cytosolic pde46 expressed in COS7 cells. Particulate pde46 co-localized with LYN kinase in COS7 cells. The unique N-terminal and LR2 regions of pde46 contained the sites for SH3 binding. Altered rolipram inhibition was triggered by SH3 domain interaction with the LR2 region. Purified LYN SH3 and human PDE4A LR2 could be co immunoprecipitated, indicating a direct interaction. Protein kinase A-phosphorylated pde46 remained able to bind LYN SH3, pde46 was found to be associated with SRC kinase in the cytosol of COS1 cells, leading to aberrant kinetics of rolipram inhibition. It is suggested that pde46 may be associated with SRC family tyrosyl kinases in intact cells and that the ensuing SH3 domain interaction with the LR2 region of pde46 alters the conformation of the PDE catalytic unit, as detected by altered rolipram inhibition. Interaction between pde46 and SRC family tyrosyl kinases highlights a potentially novel regulatory system and point of signaling system cross-talk.	Univ Glasgow, IBLS, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Houslay, MD (corresponding author), Univ Glasgow, IBLS, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	M.Kouslay@bio.gla.ac.uk	Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Houslay, Miles/0000-0002-3826-8091; Yarwood, Stephen/0000-0001-9489-9253				ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4; Atienza JM, 1999, J BIOL CHEM, V274, P4839, DOI 10.1074/jbc.274.8.4839; Barnette MS, 1998, J PHARMACOL EXP THER, V284, P420; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Giembycz MA, 1996, TRENDS PHARMACOL SCI, V17, P331, DOI 10.1016/0165-6147(96)10039-0; HERRERAVELIT PRN, J IMMUNOL, V156, P1157; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Jacobitz S, 1996, MOL PHARMACOL, V50, P891; Juilfs DM, 1997, P NATL ACAD SCI USA, V94, P3388, DOI 10.1073/pnas.94.7.3388; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; Owens RJ, 1997, CELL SIGNAL, V9, P575, DOI 10.1016/S0898-6568(97)00072-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PILLAI R, 1994, J BIOL CHEM, V269, P30676; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SCHUDT C, 1995, EUR RESPIR J, V8, P1179, DOI 10.1183/09031936.95.08071179; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; SOUNESS JE, 1991, BIOCHEM PHARMACOL, V42, P937, DOI 10.1016/0006-2952(91)90056-B; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; SOUNESS JE, 1993, BIOCHEM J, V291, P389, DOI 10.1042/bj2910389; SULLIVAN M, 1994, CELL SIGNAL, V6, P793, DOI 10.1016/0898-6568(94)00039-5; Sullivan M, 1998, BIOCHEM J, V333, P693, DOI 10.1042/bj3330693; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TORPHY TJ, 1993, AGENT ACTION SUPPL, V43, P51; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; TORPHY TJ, 1994, ENVIRON HEALTH PERSP, V102, P79, DOI 10.2307/3432220; WILSON M, 1994, BIOCHEM J, V304, P407, DOI 10.1042/bj3040407; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	51	99	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11796	11810		10.1074/jbc.274.17.11796	http://dx.doi.org/10.1074/jbc.274.17.11796			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206997	hybrid			2022-12-25	WOS:000079834800053
J	Rajavashisth, TB; Liao, JK; Galis, ZS; Tripathi, S; Laufs, U; Tripathi, J; Chai, NN; Xu, XP; Jovinge, S; Shah, PK; Libby, P				Rajavashisth, TB; Liao, JK; Galis, ZS; Tripathi, S; Laufs, U; Tripathi, J; Chai, NN; Xu, XP; Jovinge, S; Shah, PK; Libby, P			Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; GENE-EXPRESSION; CDNA LIBRARY; MT-MMPS; ACTIVATION; INTERLEUKIN-1; MT1-MMP	We investigated whether inflammatory cytokines or oxidized low density lipoproteins (Ox-LDL) present in human atheroma modulate extracellular matrix degradation by inducing membrane type 1-matrix metalloproteinase (MT1-MMP) expression. Cultured human endothelial cells (EC) constitutively expressed MT1-MMP mRNA and protein with enzymatic activity, Tumor necrosis factor-alpha (TNF-alpha), interleukin-1 alpha, or interleukin-1 beta caused a time dependent increase in the steady-state MT1-MMP mRNA levels within 4 h of exposure, peaking about 4-fold by 6 h, and remaining elevated for 12 h, Increased MT1-MMP mRNA correlated with a 2.5-fold increase in MT1-MMP protein in EC membranes. Ox-LDL also increased MT1-MMP mRNA levels that varied with the duration of exposure and degree of LDL oxidation, The increase in MT1-MMP mRNA occurred within 6 h of exposure to Ox-LDL and peaked over 3 fold by 6 h, Ox-LDL, but not native LDL, increased MT1-MMP protein by a-fold in EC membranes. A combination of TNF-alpha and Ox-LDL was additive in increasing MT1-MMP expression. Nuclear run-on assays showed that TNF-alpha or Ox-LDL augmented steady-state mRNA levels by increased transcription of the MT1-MMP gene. These findings indicate that activation of EC by inflammatory cytokines and/or Ox-LDL increase MT1-MMP expression. Since MT1-MMP promotes matrix degradation by activating pro-MMP-2, these results suggest a novel mechanism whereby cytokines or Ox-LDL may influence extracellular matrix remodeling.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Atherosclerosis Res Ctr, Los Angeles, CA 90048 USA; Harbor UCLA Med Ctr, Torrance, CA 90502 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rajavashisth, TB (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Atherosclerosis Res Ctr, Los Angeles, CA 90048 USA.	rajavashisth@cshs.org	Libby, Peter/AAY-6404-2021; Rajavashisth, Tripathi/ABB-6379-2020	Libby, Peter/0000-0002-1502-502X; 	NHLBI NIH HHS [HL51980, HL58555, HL52233] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233, R01HL058555, R29HL051980, R01HL051980] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDECK MP, 1994, CIRC RES, V75, P539, DOI 10.1161/01.RES.75.3.539; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; Harlow E., 1988, ANTIBODIES LAB MANUA; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Imai K, 1996, CANCER RES, V56, P2707; Innis MA, 1990, PCR PROTOCOLS GUIDE; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1997, EUR J BIOCHEM, V248, P369, DOI 10.1111/j.1432-1033.1997.00369.x; Kolodgie FD, 1998, J AM COLL CARDIOL, V31, p419A, DOI 10.1016/S0735-1097(97)85524-6; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIBBY P, 1986, AM J PATHOL, V124, P179; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIBBY P, 1996, ATHEROSCLEROSIS CORO, V1, P585; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; Lin CY, 1997, J BIOL CHEM, V272, P9147; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; NAVAB M, 1988, J CLIN INVEST, V82, P1853, DOI 10.1172/JCI113802; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; RAJAVASHISTH TB, 1987, P NATL ACAD SCI USA, V84, P1157, DOI 10.1073/pnas.84.5.1157; RAJAVASHISTH TB, 1997, ENCY HUMAN BIOL, V1, P565; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sang Q X, 1998, Cell Res, V8, P171; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Springer TA., 1996, ATHEROSCLEROSIS CORO, VVol 1, P511; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; TIPPING PG, 1993, AM J PATHOL, V142, P1721; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZEMPO N, 1994, J VASC SURG, V20, P209, DOI 10.1016/0741-5214(94)90008-6	44	163	170	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11924	11929		10.1074/jbc.274.17.11924	http://dx.doi.org/10.1074/jbc.274.17.11924			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207013	hybrid			2022-12-25	WOS:000079834800069
J	Vishnivetskiy, SK; Paz, CL; Schubert, C; Hirsch, JA; Sigler, PB; Gurevich, VV				Vishnivetskiy, SK; Paz, CL; Schubert, C; Hirsch, JA; Sigler, PB; Gurevich, VV			How does arrestin respond to the phosphorylated state of rhodopsin?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; VISUAL ARRESTIN; 48-KDA PROTEIN; PHOTOEXCITED RHODOPSIN; BINDING; RECOGNITION; SELECTIVITY; ACTIVATION; ROLES	Visual arrestin quenches light-induced signaling by binding to light-activated, phosphorylated rhodopsin (P-Rh*). Here are present structure-function data, which in conjunction with the refined crystal structure of arrestin (Hirsch, J. A., Schubert, C., Gurevich, V. V., and Sigler, P.B. (1999) Cell, in press), support a model for the conversion of a basal or "inactive" conformation of free arrestin to one that can bind to and inhibit the light activated receptor. The trigger for this transition is an interaction of the phosphorylated COOH-terminal segment of the receptor with arrestin that disrupts intramolecular interactions, including a hydrogen-bonded network of buried, charged side chains, referred to as the "polar core." This disruption permits structural adjustments that allow arrestin to bind to the receptor. Our mutational survey identifies residues in arrestin (Arg(175), Asp(30), Asp(296), ASp(303), Arg(382)), which when altered bypass the need for the interaction with the receptor's phosphopeptide, enabling arrestin to bind to activated, nonphosphorylated rhodopsin (Rh*), These mutational changes disrupt interactions and substructures which the crystallographic model and previous biochemical studies have shown are responsible for maintaining the inactive state, The molecular basis for these disruptions was confirmed by successfully introducing structure-based second site substitutions that restored the critical interactions. The nearly absolute conservation of the mutagenically sensitive residues throughout the arrestin family suggests that this mechanism is likely to be applicable to arrestin-mediated desensitization of most G-protein-coupled receptors.	Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA; Yale Univ, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; Howard Hughes Medical Institute; Yale University	Gurevich, VV (corresponding author), Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, 10515 W Santa Fe Dr, Sun City, AZ 85372 USA.		Hirsch, Joel/AAC-8000-2021; Gurevich, Vsevolod/A-3236-2008	Hirsch, Joel/0000-0001-7544-8668; Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY11500] Funding Source: Medline; NIGMS NIH HHS [GM22324] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HIRSCH JA, 1999, IN PRESS CELL; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; Smith WC, 1999, BIOCHEMISTRY-US, V38, P2752, DOI 10.1021/bi982643l; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	20	141	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11451	11454		10.1074/jbc.274.17.11451	http://dx.doi.org/10.1074/jbc.274.17.11451			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206946	hybrid			2022-12-25	WOS:000079834800002
J	Blattner, C; Tobiasch, E; Litfen, M; Rahmsdorf, HJ; Herrlich, P				Blattner, C; Tobiasch, E; Litfen, M; Rahmsdorf, HJ; Herrlich, P			DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation	ONCOGENE			English	Article						ultraviolet irradiation; gamma irradiation; actinomycin D; p53 stabilization	CASEIN KINASE-II; TUMOR-SUPPRESSOR PROTEIN; ALTERNATIVELY SPLICED P53; FULL-LENGTH P53; IN-VIVO; BINDING FUNCTION; NUCLEAR ACCUMULATION; TERMINAL DOMAIN; CELL-CYCLE; RETROVIRAL VECTORS	Abundance and activity of p53 are predominantly regulated posttranslationally, Structural disturbance in transcribed genes induced by radiation, e.g. DNA damage, or by transcriptional inhibitors cause p53 protein stabilization by a yet unknown mechanism. Using stable and transient transfections for the analysis of p53 mutant proteins, we have ruled out a role in stabilization by UV, gamma irradiation or actinomycin C for the following putative phosphorylation sites in the p53 protein: serines 6, 9, 15, 33, 315 and 392, and threonine 18. By double mutation combinations of phosphorylations were also ruled out; 6,9; 15,18; 15,37, These mutations eliminate modifications by casein kinases I and II, DNA-PK, ATM, CDK and JNK, Also the 30 carboxyterminal amino acids are not required for induced p53 stabilization. Thus neither phosphorylations of individual amino acids nor interactions of the carboxyterminus of p53 with cellular macromolecules appear to play a role in the stabilization process. The only single prerequisite for induced stabilization of p53 is its prior destabilization by Mdm2, However, the level of active Mdm2 must be controlled carefully: overexpression of Mdm2 inhibits UV induced p53 stabilization.	Univ Karlsruhe, Forschungszentrum Karlsruhe, Genet Inst, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Herrlich, P (corresponding author), Univ Karlsruhe, Forschungszentrum Karlsruhe, Genet Inst, POB 3640, D-76021 Karlsruhe, Germany.		Blattner, Christine/ABI-2152-2020; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLATTNER C, 1994, ENVIRON MOL MUTAGEN, V24, P3, DOI 10.1002/em.2850240103; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Candeias SM, 1997, BIOCHIMIE, V79, P607, DOI 10.1016/S0300-9084(97)82010-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; COHEN PA, 1998, IN PRESS ONCOGENE; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRMANN CPE, 1991, ONCOGENE, V6, P877; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1991, CANCER RES, V51, P6304; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; Molinari M, 1996, ONCOGENE, V13, P2077; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RENZING J, 1995, ONCOGENE, V10, P1865; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	77	131	135	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1723	1732		10.1038/sj.onc.1202480	http://dx.doi.org/10.1038/sj.onc.1202480			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208433				2022-12-25	WOS:000079025000007
J	Habelhah, H; Okada, F; Kobayashi, M; Nakai, K; Choi, SK; Hamada, J; Moriuchi, T; Kaya, M; Yoshida, K; Fujinaga, K; Hosokawa, M				Habelhah, H; Okada, F; Kobayashi, M; Nakai, K; Choi, SK; Hamada, J; Moriuchi, T; Kaya, M; Yoshida, K; Fujinaga, K; Hosokawa, M			Increased E1AF expression in mouse fibrosarcoma promotes metastasis through induction of MT1-MMP expression	ONCOGENE			English	Article						mouse-fibrosarcoma; metastasis; MMP-2; MT1-MMP; E1AF	METALLOPROTEINASE GENE-EXPRESSION; TRANSFORMING GROWTH FACTOR-BETA-1; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; TRANSCRIPTION FACTORS; IV COLLAGENASE; GELATINASE-A; TUMOR-CELLS; 72-KDA GELATINASE; HUMAN FIBROBLASTS	In this study, we investigated the role of E1AF, a member of ets family transcription factor, in the acquisition of metastatic capacity by non-metastatic mouse fibrosarcoma cell clone, QR-32, The QR-32 cell clone grows progressively after co-implantation with gelatin sponge in syngeneic C57BL/6 mice. The cell lines (QRsP) established from arising tumors after the co-implantation exhibited enhanced tumorigenicity and pulmonary metastasis in vivo as compared with parent QR-32 cells. The enhanced pulmonary metastasis of QRsP cells was correlated well with augmented production of matrix metalloproteinase-2 (MMP-2) and increased expression of membrane-type 1-IMMP (MT1-MMP). The QRsP cells also acquired higher chemokinetic activities to fibronectin and higher invasive activities through a reconstituted basement membrane. Furthermore we observed the elevated mRNA expression of E1AF in QRsP cells compared to parent QR-32 cells. Therefore, we transfected QR-32 cells with E1AF cDNA. Overexpression of E1AF in the QR-32 cells resulted in the induction of MT1-MMP expression and converting an exogenously added precursor MMP-2 into active form. E1AF transfectants exhibited more motile and invasive activities, and moderately increased pulmonary metastatic activities than parental QR-32 cells in vivo, although their metastatic activities were lower than those of QRsP cells. These findings suggest that the increased expression of E1AF in fibrosarcoma contributes to invasive phenotypes including MT1-MIMP expression and enhanced cell migration, but not sufficient for exhibiting highly metastatic activity in vivo.	Hokkaido Univ, Sch Med, Inst Canc, Pathol Lab,Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Inst Canc, Div Cell Biol,Kita Ku, Sapporo, Hokkaido 0608638, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, Sapporo, Hokkaido 0600061, Japan	Hokkaido University; Hokkaido University; Sapporo Medical University	Hosokawa, M (corresponding author), Hokkaido Univ, Sch Med, Inst Canc, Pathol Lab,Kita Ku, Sapporo, Hokkaido 0608638, Japan.		Hamada, Jun-ichi/D-7452-2012	Okada, Futoshi/0000-0003-4733-1037; Habelhah, Hasem/0000-0003-4097-1007				ALBINI A, 1987, CANCER RES, V47, P3239; ASCHER NL, 1979, TRANSPLANTATION, V27, P254, DOI 10.1097/00007890-197904000-00010; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chen JH, 1996, ONCOGENE, V13, P1667; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Imai K, 1997, AM J PATHOL, V151, P245; Imai K, 1996, CANCER RES, V56, P2707; Kadono Y, 1998, CANCER RES, V58, P2240; Kaya M, 1996, ONCOGENE, V12, P221; KOHN EC, 1994, J BIOL CHEM, V269, P21505; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; OHagan RC, 1996, ONCOGENE, V13, P1323; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OKADA F, 1992, BRIT J CANCER, V66, P635, DOI 10.1038/bjc.1992.329; OVERALL CM, 1994, ANN NY ACAD SCI, V732, P51, DOI 10.1111/j.1749-6632.1994.tb24724.x; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; SALO T, 1991, J BIOL CHEM, V266, P11436; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Shindoh M, 1996, AM J PATHOL, V148, P693; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Taguchi K, 1997, JPN J CANCER RES, V88, P394, DOI 10.1111/j.1349-7006.1997.tb00395.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEITZMAN SA, 1990, BLOOD, V76, P655	40	53	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1771	1776		10.1038/sj.onc.1202465	http://dx.doi.org/10.1038/sj.onc.1202465			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208438				2022-12-25	WOS:000079025000012
J	Barbier, AJ; Poppleton, HM; Yigzaw, Y; Mullenix, JB; Wiepz, GJ; Bertics, PJ; Patel, TB				Barbier, AJ; Poppleton, HM; Yigzaw, Y; Mullenix, JB; Wiepz, GJ; Bertics, PJ; Patel, TB			Transmodulation of epidermal growth factor receptor function by cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEIN; CARDIAC ADENYLATE-CYCLASE; EGF RECEPTOR; TYROSINE KINASE; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; PC12 CELLS; PHOSPHORYLATION; CAMP	Binding of epidermal growth factor (EGF) to its receptor (EGFR) augments the tyrosine kinase activity of the receptor and autophosphorylation. Exposure of some tissues and cells to EGF also stimulates adenylyl cyclase activity and results in an increase in cyclic AMP (cAMP) levels. Because cAMP activates the cAMP-dependent protein kinase A (PKA), we investigated the effect of PKA on the EGFR, The purified catalytic subunit of PKA (PKAc) stoichiometrically phosphorylated the purified full-length wild type (WT) and kinase negative (K721M) forms of the EGFR. PKAc phosphorylated both WT-EGFR as well as a mutant truncated form of EGFR (Delta 1022-1186) exclusively on serine residues. Moreover, PKAc also phosphorylated the cytosolic domain of the EGFR (EGFRKD). Phosphorylation of the purified WT as well as EGFR Delta 1022-1186 and EGFRKD was accompanied by decreased autophosphorylation and diminished tyrosine kinase activity. Pretreatment of REF-52 cells with the nonhydrolyzable cAMP analog, 8-(4-chlorophenylthio)-cAMP, decreased EGF-induced tyrosine phosphorylation of cellular proteins as well as activation of the WT-EGFR. Similar effects were also observed in B82L cells transfected to express the Delta 1022-1186 form of EGFR. Furthermore, activation of PKAc in intact cells resulted in serine phosphorylation of the EGFR, The decreased phosphorylation of cellular proteins and diminished activation of the EGFR in cells treated with the cAMP analog was not the result of altered binding of EGF to its receptors or changes in receptor internalization. Therefore, we conclude that PKA phosphorylates the EGFR on Ser residues and decreases its tyrosine kinase activity and signal transduction both in vitro and in vivo.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Wisconsin System; University of Wisconsin Madison	Patel, TB (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053271] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48308] Funding Source: Medline; NIGMS NIH HHS [GM 53271] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUDNIK LT, 1991, J BIOL CHEM, V266, P13908; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GHOSHDASTIDAR P, 1984, J BIOL CHEM, V259, P3864; GILL GN, 1985, GROWTH FACTORS TRANS, P11; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HONNEGGER A, 1988, EMBO J, V7, P3045; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LIEBERMAN MD, 1996, SURGERY, V120, P345; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NAIR BG, 1993, BIOCHEM PHARMACOL, V46, P1239, DOI 10.1016/0006-2952(93)90473-A; NAIR BG, 1993, GROWTH FACTORS, V8, P41, DOI 10.3109/08977199309029133; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NAKAGAWA Y, 1991, BIOCHEM PHARMACOL, V42, P2333, DOI 10.1016/0006-2952(91)90238-Z; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; Poppleton H, 1996, J BIOL CHEM, V271, P6947, DOI 10.1074/jbc.271.12.6947; RACKOFF WR, 1984, MOL CELL ENDOCRINOL, V34, P113, DOI 10.1016/0303-7207(84)90062-5; RASHED SM, 1991, EUR J BIOCHEM, V197, P805, DOI 10.1111/j.1432-1033.1991.tb15975.x; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; STRYJEKKAMINSKA D, 1995, AM J PHYSIOL-GASTR L, V269, pG676, DOI 10.1152/ajpgi.1995.269.5.G676; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	42	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14067	14073		10.1074/jbc.274.20.14067	http://dx.doi.org/10.1074/jbc.274.20.14067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318821	hybrid			2022-12-25	WOS:000080322200050
J	El Hadj, NB; Popoff, MR; Marvaud, JC; Payrastre, B; Boquet, P; Geny, B				El Hadj, NB; Popoff, MR; Marvaud, JC; Payrastre, B; Boquet, P; Geny, B			G-protein-stimulated phospholipase D activity is inhibited by lethal toxin from Clostridium sordellii in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; PHOSPHATIDYLINOSITOL-TRANSFER PROTEIN; KINASE-C; D ACTIVATION; ACTIN-FILAMENTS; STREPTOLYSIN-O; RHO-PROTEINS; D DEFINES; V-SRC	Lethal toxin (LT) from Clostridium sordellii has been shown in HeLa cells to glucosylate and inactivate Has and Rac and, hence, to disorganize the actin cytoskeleton. In the present work, we demonstrate that LT treatment provokes the same effects in HL-60 cells. We show that guanosine 5'-O-(3-thiotriphosphate)-stimulated phospholipase D (PLD) activity is inhibited in a time- and dose-dependent manner after an overnight treatment with LT, A similar dose response to the toxin was found when PLD activity was stimulated by phorbol la-myristate 13-acetate via the protein kinase C pathway. The toxin effect on actin organization seemed unlikely to account directly for PLD inhibition as cytochalasin D and iota toxin from Clostridium perfringens E disorganize the actin cytoskeleton without modifying PLD activity. However, the enzyme inhibition and actin cytoskeleton disorganization could both be related to a major decrease observed in phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2). Likely in a relationship with this decrease, recombinant ADP-ribosylation factor, RhoA, Rac, and RalA were not able to reconstitute PLD activity in LT-treated cells permeabilized and depleted of cytosol. Studies of phosphoinositide kinase activities did not allow us to attribute the decrease in PtdIns(4,5)P-2 to inactivation of PtdIns4P 5-kinase. LT was also found to provoke a major inhibition in phosphatidylinositol 3-kinase that could not account for the inhibition of PLD activity because wortmannin, at doses that fully inhibit phosphatidylinositol 3-kinase, had no effect on the phospholipase activity. Among the three small G-proteins, Ras, Rac, and RalA, inactivated by LT and involved in PLD regulation, inactivation of Ral proteins appeared to be responsible for PLD inhibition as LT toxin (strain 9048) unable to glucosylate Ral proteins did not modify PLD activity. In HL-60 cells, LT treatment appeared also to modify cytosol components in relationship with PLD inhibition as a cytosol prepared from LT-treated cells was less efficient than one from control HL-60 cells in stimulating PLD activity. Phosphatidylinositol transfer proteins involved in the regulation of polyphosphoinositides and ADP-ribosylation factor, a major cytosolic PLD activator in HL-60 cells, were unchanged, whereas the level of cytosolic protein kinase C alpha was decreased after LT treatment, We conclude that in HL-60 cells, lethal toxin from C. sordellii, in inactivating small G-proteins involved in PLD regulation, provokes major modifications at the membrane and the cytosol levels that participate in the inhibition of PLD activity. Although Ral appeared to play an essential role in PLD activity, we discuss the role of other small G-proteins inactivated by LT in the different modifications observed in HL-60 cells.	Inst Cochin Genet Mol, INSERM, U332, F-75014 Paris, France; Inst Pasteur, Unite Toxines Microbiennes, F-75724 Paris 15, France; Hop Purpan, INSERM, U326, F-31059 Toulouse, France; Fac Med Nice, INSERM, U452, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Geny, B (corresponding author), Inst Cochin Genet Mol, INSERM, U332, 22 Rue Mechain, F-75014 Paris, France.			, Bernard/0000-0002-8693-0190				AKTORIES K, 1994, MOL CELL BIOCHEM, V138, P167, DOI 10.1007/BF00928459; Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Choudhury S, 1996, CANCER LETT, V109, P149, DOI 10.1016/S0304-3835(96)04439-4; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DAWSON RMC, 1967, BIOCHEM J, V102, P76, DOI 10.1042/bj1020076; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hofmann F, 1996, BIOCHEM BIOPH RES CO, V227, P77, DOI 10.1006/bbrc.1996.1470; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MARTINEZ RD, 1992, J MED MICROBIOL, V36, P30, DOI 10.1099/00222615-36-1-30; MORRIS JDH, 1989, ONCOGENE, V4, P27; Ohguchi K, 1996, INFECT IMMUN, V64, P4433, DOI 10.1128/IAI.64.11.4433-4437.1996; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; POLVERINO AJ, 1990, BIOCHEM J, V271, P309, DOI 10.1042/bj2710309; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Schmidt M, 1996, EUR J BIOCHEM, V240, P707, DOI 10.1111/j.1432-1033.1996.0707h.x; Singer WD, 1996, J BIOL CHEM, V271, P4504; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8	56	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14021	14031		10.1074/jbc.274.20.14021	http://dx.doi.org/10.1074/jbc.274.20.14021			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318815	hybrid			2022-12-25	WOS:000080322200044
J	Bearer, CF; Swick, AR; O'Riordan, MA; Cheng, GH				Bearer, CF; Swick, AR; O'Riordan, MA; Cheng, GH			Ethanol inhibits L1-mediated neurite outgrowth in postnatal rat cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE L1; ACTIVATED PROTEIN-KINASES; FETAL-ALCOHOL-SYNDROME; N-CADHERIN; HIPPOCAMPAL-NEURONS; L1-LIKE MOLECULE; GROWTH; FGF; PHOSPHORYLATION; MIGRATION	The neuropathology of the effects of ethanol on the developing central nervous system are similar to those of patients with mutations in L1, a neural cell adhesion molecule. This observation suggests that inhibition of L1 plays a role in the pathogenesis of alcohol-related neurodevelopmental disorders. Here we examine the effects of ethanol on L1 hemophilic binding and on L1 mediated neurite outgrowth. Ethanol had no effect on cell adhesion or aggregation in a myeloma cell line expressing full-length human L1. In contrast, the rate of L1-mediated neurite outgrowth of rat postnatal day 6 cerebellar granule cells grown on a substratum of Ng-CAM, the chick homologue of L1, was inhibited by 48.6% in the presence of ethanol with a half-maximal concentration of 4.7 mM, The same effect was found with soluble L1-Fc, thus showing that the inhibitory effect is not dependent on cell adhesion. In contrast, neither laminin nor N-cadherin-mediated neurite outgrowth was inhibited by physiologic concentrations of ethanol. We conclude that one mechanism of ethanol's toxicity to the developing central nervous system may be the inhibition of L1-mediated neurite outgrowth.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Bearer, CF (corresponding author), Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave,Suite 8100, Cleveland, OH 44106 USA.	cfb3@po.cwru.edu		Bearer, Cynthia/0000-0003-4809-2250	NATIONAL EYE INSTITUTE [R01EY005285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011839] Funding Source: NIH RePORTER; NEI NIH HHS [EY5285, R01 EY005285] Funding Source: Medline; NIAAA NIH HHS [R01 AA011839] Funding Source: Medline; NINDS NIH HHS [NS34252] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel E. L., 1990, FETAL ALCOHOL SYNDRO; ABEL EL, 1991, ALCOHOL CLIN EXP RES, V15, P514, DOI 10.1111/j.1530-0277.1991.tb00553.x; BEATTIE CE, 1993, J NEUROSCI, V13, P1784; BURDENGULLEY SM, 1995, J NEUROSCI, V15, P4370; CHARNESS ME, 1994, J BIOL CHEM, V269, P9304; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Dow K E, 1990, Neuroreport, V1, P111, DOI 10.1097/00001756-199010000-00007; DOW KE, 1985, SCIENCE, V228, P591, DOI 10.1126/science.3983644; DOW KE, 1990, BRAIN RES, V508, P40, DOI 10.1016/0006-8993(90)91114-V; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; HEATON MB, 1994, J NEUROSCI RES, V39, P305, DOI 10.1002/jnr.490390308; HEATON MB, 1995, DEV BRAIN RES, V89, P270, DOI 10.1016/0165-3806(95)00131-V; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; HOCKBERGER PE, 1987, J NEUROSCI, V7, P1370; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; *I MED, 1996, FET ALC SYNDR DIAGN; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; JONES KL, 1973, LANCET, V1, P1267; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kim JA, 1996, DEV BRAIN RES, V96, P1; Kunz S, 1996, J CELL BIOL, V135, P253, DOI 10.1083/jcb.135.1.253; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEMMON V, 1986, J NEUROSCI, V6, P2987; Lemoine P, 1968, OUEST MED, V21, P476; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; Matsuzawa M, 1996, INT J DEV NEUROSCI, V14, P283, DOI 10.1016/0736-5748(96)00014-7; MESSER A, 1977, BRAIN RES, V130, P13, DOI 10.1016/0006-8993(77)90839-3; MESSER A, 1977, BRAIN RES, V130, P1, DOI 10.1016/0006-8993(77)90838-1; MESSING RO, 1991, BRAIN RES, V565, P301, DOI 10.1016/0006-8993(91)91662-K; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MIURA M, 1992, J BIOL CHEM, V267, P10752; Ramanathan R, 1996, J CELL BIOL, V133, P381, DOI 10.1083/jcb.133.2.381; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; ROSENBERG A, 1994, ALCOHOL, V11, P565, DOI 10.1016/0741-8329(94)90084-1; STANESCU GL, 1991, J CLIN LAB ANAL, V5, P206, DOI 10.1002/jcla.1860050310; Swayze VW, 1997, PEDIATRICS, V99, P232, DOI 10.1542/peds.99.2.232; TRAUNECKER A, 1991, EMBO J, V10, P3655, DOI 10.1002/j.1460-2075.1991.tb04932.x; Vallejo Y, 1997, J BIOL CHEM, V272, P12244, DOI 10.1074/jbc.272.18.12244; WILKEMEYER MF, 1997, ALCOHOL CLIN EXP RES, V21, P85; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J NEUROCHEM, V62, P1231; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; WILLIAMS EJ, 1995, J CELL SCI, V108, P3523; Wong EV, 1996, J NEUROCHEM, V66, P779; Wong EV, 1995, NEUROSCI LETT, V200, P155, DOI 10.1016/0304-3940(95)12100-I; Wong EV, 1996, J BIOL CHEM, V271, P18217, DOI 10.1074/jbc.271.30.18217; ZOU JY, 1993, DEV BRAIN RES, V72, P75, DOI 10.1016/0165-3806(93)90161-3	54	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13264	13270		10.1074/jbc.274.19.13264	http://dx.doi.org/10.1074/jbc.274.19.13264			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224086	hybrid, Green Accepted			2022-12-25	WOS:000080200400048
J	Hulett, MD; Brinkworth, RI; McKenzie, IFC; Hogarth, PM				Hulett, MD; Brinkworth, RI; McKenzie, IFC; Hogarth, PM			Fine structure analysis of interaction of Fc epsilon RI with IgE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; IMMUNOGLOBULIN-BINDING REGIONS; EPIDERMAL LANGERHANS CELLS; GAMMA-RII; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; FUNCTIONAL DOMAINS; MOLECULAR-CLONING; IDENTIFICATION; CHAIN	The high affinity receptor for IgE (Fc epsilon RI) plays an integral role in triggering IgE-mediated hypersensitivity reactions. The IgE-interactive site of human Fc epsilon RI has previously been broadly mapped to several large regions in the second extracellular domain (D2) of the a-subunit (Fc epsilon RI alpha). In this study, the IgE binding site of human FceRIa has been further localized to subregions of D2, and key residues putatively involved in the interaction with IgE have been identified. Chimeric receptors generated between Fc epsilon RI alpha and the functionally distinct but structurally homologous low affinity receptor for IgG (Fc gamma RIIa) have been used to localize two IgE binding regions of Fc epsilon RI alpha to amino acid segments Tyr(129)-His(134) and Lys(154)-Glu(161). Both regions were capable of independently binding IgE upon placement into Fc gamma RIIa, Molecular modeling of the three-dimensional structure of Fc epsilon RI alpha-D2 has suggested that these binding regions correspond to the "exposed" C'-E and F-G loop regions at the membrane distal portion of the domain. A systematic site-directed mutagenesis strategy, whereby each residue in the Tyr(129)-His(134) and Lys(154)-Glu(161) regions of Fc epsilon RI alpha was replaced with alanine, has identified key residues putatively involved in the interaction with IgE, Substitution of Tyr(131), Glu(132), Val(155) and Asp(159) decreased the binding of IgE, whereas substitution of Trp(130), Trp(156) Tyr(160), and Glu(161) increased binding. In addition, mutagenesis of residues Trp(113), Val(115), and Tyr(116) in the B-C loop region, which lies adjacent to the C'-E and F-G loops, has suggested Trp(113) also contributes to IgE binding, since the substitution of this residue with alanine dramatically reduces binding. This information should prove valuable in the design of strategies to intervene in the Fc epsilon RI alpha-IgE interaction for the possible treatment of IgE-mediated allergic disease.	Austin Hosp, Austin Res Inst, Heidelberg, Vic 3084, Australia; Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Queensland	Hogarth, PM (corresponding author), Austin Hosp, Austin Res Inst, Studley Rd, Heidelberg, Vic 3084, Australia.		Hulett, Mark D/C-4160-2012	Hogarth, Mark/0000-0002-0360-7890; Hulett, Mark/0000-0003-2072-5968				BENHAMOU M, 1996, IGE RECEPTOR FCERI F, P32; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; GAVIN AL, 1995, IMMUNOLOGY, V86, P392; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HAAKFRENDSCHO M, 1993, J IMMUNOL, V151, P351; HARLOW E, 1988, ANTIBODIES LABORATOR, P328; Helm BA, 1996, J BIOL CHEM, V271, P7494, DOI 10.1074/jbc.271.13.7494; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HIBBS ML, 1994, J IMMUNOL, V152, P4466; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HULETT MD, 1995, J BIOL CHEM, V270, P21188, DOI 10.1074/jbc.270.36.21188; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HULETT MD, 1991, J IMMUNOL, V147, P1863; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; IERINO FL, 1993, J IMMUNOL, V150, P1794; LOPEZ AF, 1983, IMMUNOLOGY, V48, P503; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; McDonnell JM, 1996, NAT STRUCT BIOL, V3, P419, DOI 10.1038/nsb0596-419; NISSIM A, 1993, J IMMUNOL, V150, P1365; PARISH CR, 1974, PROC R SOC SER B-BIO, V187, P47, DOI 10.1098/rspb.1974.0060; PRESTA L, 1994, J BIOL CHEM, V269, P26368; RA C, 1993, INT IMMUNOL, V5, P47, DOI 10.1093/intimm/5.1.47; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RIGBY AJ, 1996, IGE RECEPTOR FCERI F, P7; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Tamm A, 1996, J BIOL CHEM, V271, P3659; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	40	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13345	13352		10.1074/jbc.274.19.13345	http://dx.doi.org/10.1074/jbc.274.19.13345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224096	hybrid			2022-12-25	WOS:000080200400058
J	Roychowdhury, S; Panda, D; Wilson, L; Rasenick, MM				Roychowdhury, S; Panda, D; Wilson, L; Rasenick, MM			G protein alpha subunits activate tubulin GTPase and modulate microtubule polymerization dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL SIGNAL-TRANSDUCTION; BINDING REGULATORY PROTEIN; ADENYLATE-CYCLASE; TRANSITION FREQUENCIES; KINETIC STABILIZATION; MITOTIC SPINDLE; LIVING CELLS; INTACT-CELLS; GROWTH CONES; INSTABILITY	G proteins serve many functions involving the transfer of signals from cell. surface receptors to intracellular effector molecules. Considerable evidence suggests that there is an interaction between G proteins and the cytoskeleton. In this report, G protein alpha subunits G(i1)alpha, G(B)alpha, and G(o)alpha are shown to activate the GTPase activity of tubulin, inhibit microtubule assembly, and accelerate microtubule dynamics. G(i)alpha inhibited polymerization of tubulin-GTP into microtubules by 80-90% in the absence of exogenous GTP, Addition of exogenous GTP, but not guanylylimidodiphosphate, which is resistant to hydrolysis, overcame the inhibition. Analysis of the dynamics of individual microtubules by video microscopy demonstrated that G(i1)alpha increases the catastrophe frequency, the frequency of transition from growth to shortening. Thus, G alpha may play a role in modulating microtubule dynamic instability, providing a mechanism for the modification of the cytoskeleton by extracellular signals.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Santa Barbara	Rasenick, MM (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, MC 901,835 S Wolcott Ave, Chicago, IL 60612 USA.	raz@uic.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER; NIA NIH HHS [AG 15482] Funding Source: Medline; NIMH NIH HHS [MH 39595] Funding Source: Medline; NINDS NIH HHS [NS13560] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULINSKI JC, 1991, BIOESSAYS, V13, P285, DOI 10.1002/bies.950130605; CARLIER MF, 1989, INT REV CYTOL, V115, P139; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHENG N, 1988, J BIOL CHEM, V263, P3935; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Cote M, 1997, ENDOCRINOLOGY, V138, P69, DOI 10.1210/en.138.1.69; Crouch MF, 1997, FASEB J, V11, P189, DOI 10.1096/fasebj.11.2.9039962; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; Gamblin TC, 1996, BIOCHEMISTRY-US, V35, P12576, DOI 10.1021/bi961135d; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LIN CT, 1992, LAB INVEST, V67, P770; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; MARGOLIS RL, 1986, P NATL ACAD SCI USA, V83, P639, DOI 10.1073/pnas.83.3.639; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Panda D, 1996, J BIOL CHEM, V271, P29807, DOI 10.1074/jbc.271.47.29807; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; Panda D, 1997, P NATL ACAD SCI USA, V94, P10560, DOI 10.1073/pnas.94.20.10560; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; RASENICK MM, 1988, J NEUROCHEM, V51, P300, DOI 10.1111/j.1471-4159.1988.tb04870.x; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; RASENICK MM, 1984, J NEUROCHEM, V43, P1447, DOI 10.1111/j.1471-4159.1984.tb05407.x; Ravindra R, 1996, J CELL BIOCHEM, V61, P392, DOI 10.1002/(SICI)1097-4644(19960601)61:3<392::AID-JCB6>3.3.CO;2-M; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; ROYCHOWDHURY S, 1986, BIOCHEMISTRY-US, V25, P7847, DOI 10.1021/bi00372a010; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WU HC, 1994, LAB INVEST, V71, P175	55	92	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13485	13490		10.1074/jbc.274.19.13485	http://dx.doi.org/10.1074/jbc.274.19.13485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224115	hybrid			2022-12-25	WOS:000080200400077
J	Thual, C; Komar, AA; Bousset, L; Fernandez-Bellot, E; Cullin, C; Melki, R				Thual, C; Komar, AA; Bousset, L; Fernandez-Bellot, E; Cullin, C; Melki, R			Structural characterization of Saccharomyces cerevisiae prion-like protein Ure2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; YEAST; BINDING; CONFORMATIONS; TRANSLATION; PROPAGATION; SYSTEM; DOMAIN; SUP35; GENE	Sacchromyces cerevisiae prion-like protein Urea was expressed in Escherichia coli and was purified to homogeneity, We show here that Ure2p is a soluble protein that can assemble into fibers that are similar to the fibers observed in the case of PrP in its scrapie prion filaments form or that form on Sup35 self-assembly. Ure2p self-assembly is a cooperative process where one can distinguish a lag phase followed by an elongation phase preceding a plateau. A combination of size exclusion chromatography, sedimentation velocity, and electron microscopy demonstrates that the soluble form of Ure2p consists at least of three forms of the protein as follows: a monomeric, dimeric, and tetrameric form whose abundance is concentration-dependent. By the use of limited proteolysis, intrinsic fluorescence, and circular dichroism measurements, we bring strong evidence for the existence of at least two structural domains in Ure2p molecules. Indeed, Ure2p NH2-terminal region is found poorly structured, whereas its COOH-terminal domain appears to be compactly folded. Finally, we show that only slight conformational changes accompany Ure2p assembly into insoluble high molecular weight oligomers, These changes essentially affect the COOH-terminal part of the molecule. The properties of Ure2p are compared in the discussion to that of other prion-like proteins such as Sup35 and mammalian prion protein PrP.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Melki, R (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.		cullin, christophe/AAM-2179-2020	cullin, christophe/0000-0003-4110-4677; Komar, Anton/0000-0003-4188-0633				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fernandez-Bellot E, 1999, BIOCHEM J, V338, P403, DOI 10.1042/0264-6021:3380403; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; JOHN ME, 1995, PLANT PHYSIOL, V108, P669, DOI 10.1104/pp.108.2.669; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; Komar AA, 1997, FEBS LETT, V415, P6, DOI 10.1016/S0014-5793(97)01082-X; KOMAR AA, 1995, FEBS LETT, V376, P195, DOI 10.1016/0014-5793(95)01275-0; Komar AA, 1998, BIOL CHEM, V379, P1295; KUNTZ ID, 1971, J AM CHEM SOC, V93, P516, DOI 10.1021/ja00731a037; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIN TH, 1991, J BIOL CHEM, V266, P1635; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; Melki R, 1996, BIOCHEMISTRY-US, V35, P10422, DOI 10.1021/bi960788r; Mihara H, 1998, BIOPOLYMERS, V47, P83, DOI 10.1002/(SICI)1097-0282(1998)47:1<83::AID-BIP9>3.0.CO;2-T; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIPE JD, 1994, CRIT REV CLIN LAB SC, V31, P352; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Thanaraj TA, 1996, PROTEIN SCI, V5, P1594, DOI 10.1002/pro.5560050814; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109; [No title captured]	40	115	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13666	13674		10.1074/jbc.274.19.13666	http://dx.doi.org/10.1074/jbc.274.19.13666			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224139	hybrid			2022-12-25	WOS:000080200400101
J	Vande Weghe, JG; Ow, DW				Vande Weghe, JG; Ow, DW			A fission yeast gene for mitochondrial sulfide oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE PHOTOTROPHIC BACTERIUM; SCHIZOSACCHAROMYCES-POMBE; QUINONE REDUCTASE; FLAVOCYTOCHROME-C; RHODOBACTER-CAPSULATUS; CYTOCHROME REDUCTION; TOLERANCE; DEHYDROGENASE; DETOXIFICATION; PURIFICATION	A cadmium-hypersensitive mutant of the fission yeast Schizosaccharomyces pombe was found to accumulate abnormally high levels of sulfide. The gene required for normal regulation of sulfide levels, hmt2(+), was cloned by complementation of the cadmium-hypersensitive phenotype of the mutant. Cell fractionation and immunocytochemistry indicated that HMT2 protein is localized to mitochondria, Sequence analysis revealed homology between HMT2 and sulfide dehydrogenases from photosynthetic bacteria. HMT2 protein, produced in and purified from Escherichia coli, was soluble, bound FAD, and catalyzed the reduction of quinone (coenzyme Q(2)) by sulfide. HMT2 activity was also detected in isolated fission yeast mitochondria. We propose that HMT2 functions as a sulfide:quinone oxidoreductase. Homologous enzymes may be widespread in higher organisms, as sulfide-oxidizing activities have been described previously in animal mitochondria, and genes of unknown function, but with similarity to hmt2(+), are present in the genomes of flies, worms, rats, mice, and humans.	USDA ARS, Ctr Plant Gene Express, Albany, CA 94710 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	United States Department of Agriculture (USDA); University of California System; University of California Berkeley	Ow, DW (corresponding author), USDA ARS, Ctr Plant Gene Express, 800 Buchanan St, Albany, CA 94710 USA.							ALFA C, 1993, EXPT FISSION YEAST L, P134; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIELI B, 1994, J BIOL CHEM, V269, P5705; BAGARINAO T, 1990, J COMP PHYSIOL B, V160, P519; BARTHOLOMEW TC, 1980, BIOCHEM PHARMACOL, V29, P2431, DOI 10.1016/0006-2952(80)90346-9; BAXTER CI, 1958, BIOCHIM BIOPHYS ACTA, V27, P584, DOI 10.1016/0006-3002(58)90390-1; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; Bergmeyer HU, 1974, METHOD ENZYMAT AN, P452; BRUNE DC, 1986, ARCH MICROBIOL, V145, P295, DOI 10.1007/BF00443662; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; DAUM G, 1982, J BIOL CHEM, V257, P3028; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; JAULT JM, 1994, J BIOENERG BIOMEMBR, V26, P447, DOI 10.1007/BF00762785; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; Lee RW, 1996, BIOL BULL, V191, P421, DOI 10.2307/1543015; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MEYER TE, 1991, BIOCHEMISTRY-US, V30, P8840, DOI 10.1021/bi00100a016; MOORE AL, 1992, YEAST, V8, P923, DOI 10.1002/yea.320081103; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; National Research Council Division of Medical Science subcommittee on Hydrogen Sulfide, 1979, HYDR SULF; OESCHGER R, 1992, MAR ECOL PROG SER, V86, P167, DOI 10.3354/meps086167; OESCHGER R, 1994, OPHELIA, V40, P147, DOI 10.1080/00785326.1994.10430581; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; Perego P, 1997, MOL PHARMACOL, V51, P12, DOI 10.1124/mol.51.1.12; POWELL MA, 1986, SCIENCE, V233, P563, DOI 10.1126/science.233.4763.563; ROST B, 1995, 3 INT C INT SYST MOL, P314; SCHNEPPENHEIM R, 1991, ELECTROPHORESIS, V12, P367, DOI 10.1002/elps.1150120508; Schutz M, 1997, J BIOL CHEM, V272, P9890; SHAHAK Y, 1994, PHOTOSYNTH RES, V39, P175, DOI 10.1007/BF00029384; SHAHAK Y, 1992, FEBS LETT, V299, P127, DOI 10.1016/0014-5793(92)80230-E; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; VANBEEUMEN J, 1990, J BIOL CHEM, V265, P9793; VanDriessche G, 1996, PROTEIN SCI, V5, P1753; Voelkel Susanne, 1996, European Journal of Biochemistry, V235, P231; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	36	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13250	13257		10.1074/jbc.274.19.13250	http://dx.doi.org/10.1074/jbc.274.19.13250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224084	hybrid			2022-12-25	WOS:000080200400046
J	Warnecke, D; Erdmannn, R; Fahl, A; Hube, B; Muller, F; Zank, T; Zahringer, U; Heinz, E				Warnecke, D; Erdmannn, R; Fahl, A; Hube, B; Muller, F; Zank, T; Zahringer, U; Heinz, E			Cloning and functional expression of UGT genes encoding sterol glucosyltransferases from Saccharomyces cerevisiae, Candida albicans, Pichia pastoris, and Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-GLUCOSYLTRANSFERASE; TRUE SLIME-MOLD; UDP-GLUCOSE; PHYSARUM-POLYCEPHALUM; PLASMA-MEMBRANE; PLANT STEROLS; ENDOPLASMIC-RETICULUM; STRUCTURAL-ANALYSIS; ESCHERICHIA-COLI; SINAPIS-ALBA	Sterol glucosides, typical membrane-bound lipids of many eukaryotes, are biosynthesized by a UDP-glucose: sterol glucosyltransferase (EC 2.4.1.173), We cloned genes from three different yeasts and from Dictyostelium discoideum, the deduced amino acid sequences of which all showed similarities with plant sterol glucosyltransferases (Ugt80A1, Ugt80A2), These genes from Sac charomyces cerevisiae (UGT51 = YLR189C), Pichia pas toris (UGT51B1), Candida albicans (UGT51C1), and Dictyostelium discoideum (ugt52) were expressed in Escherichia coli. In vitro enzyme assays with cell-free extracts of the transgenic E, coli strains showed that the genes encode UDP-glucose:sterol glucosyltransferases which can use different sterols such as cholesterol, sitosterol, and ergosterol as sugar accepters. An S. cerevisiae null mutant of UGT51 had lost its ability to synthesize sterol glucoside but exhibited normal growth under various culture conditions. Expression of either UGT51 or UGT51B1 in this null mutant under the control of a galactose-induced promoter restored sterol glucoside synthesis in vitro, Lipid extracts of these cells contained a novel glycolipid, This lipid was purified and identified as ergosterol-beta-D-glucopyranoside by nuclear magnetic resonance spectroscopy. These data prove that the cloned genes encode sterol-beta-D-glucosyltransferases and that sterol glucoside synthesis is an inherent feature of eukaryotic microorganisms.	Univ Hamburg, Inst Allgemeine Bot, D-22609 Hamburg, Germany; Free Univ Berlin, Inst Biochem, D-12203 Berlin, Germany; Forschungszentrum Borstel, D-23845 Borstel, Germany	University of Hamburg; Free University of Berlin; Forschungszentrum Borstel	Warnecke, D (corresponding author), Univ Hamburg, Inst Allgemeine Bot, Ohnhorststr 18, D-22609 Hamburg, Germany.	warnecke@botanik.uni-hamburg.de		Hube, Bernhard/0000-0002-6028-0425				ABRAHAM W, 1987, J LIPID RES, V28, P446; ALTSCHUL SF, 1990, J MOL BIOL, V215, P408; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bach TJ, 1997, PROG LIPID RES, V36, P197, DOI 10.1016/S0163-7827(97)00009-X; BARAUD J, 1970, B SOC CHIM BIOL, V52, P421; BOUVIERNAVE P, 1995, PLANT SCI, V110, P11, DOI 10.1016/0168-9452(95)04181-S; BouvierNave P, 1997, EUR J BIOCHEM, V246, P518, DOI 10.1111/j.1432-1033.1997.t01-1-00518.x; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; DUPERON R, 1980, BIOGENESIS FUNCTION, P445; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ESDERS TW, 1972, J BIOL CHEM, V247, P248; GHANNOUM MA, 1986, J GEN MICROBIOL, V132, P2367; GHANNOUM MA, 1990, J MED VET MYCOL, V28, P103; GRUNWALD C, 1971, PLANT PHYSIOL, V48, P653, DOI 10.1104/pp.48.5.653; Haque M, 1996, J BACTERIOL, V178, P2065, DOI 10.1128/jb.178.7.2065-2070.1996; Hartmann MA, 1998, TRENDS PLANT SCI, V3, P170, DOI 10.1016/S1360-1385(98)01233-3; HASE A, 1981, ARCH BIOCHEM BIOPHYS, V210, P280, DOI 10.1016/0003-9861(81)90191-0; HIRAI Y, 1995, J BACTERIOL, V177, P5327, DOI 10.1128/jb.177.18.5327-5333.1995; HUNGUND BL, 1994, CHEM PHYS LIPIDS, V69, P167, DOI 10.1016/0009-3084(94)90038-8; Jorasch P, 1998, MOL MICROBIOL, V29, P419, DOI 10.1046/j.1365-2958.1998.00930.x; KALINOWSKA M, 1986, Phytochemistry (Oxford), V25, P45, DOI 10.1016/S0031-9422(00)94498-4; KASTELICSUHADOLC T, 1980, BIOCHIM BIOPHYS ACTA, V620, P322, DOI 10.1016/0005-2760(80)90213-1; KIMMEL AR, 1985, MOL CELL BIOL, V5, P2123, DOI 10.1128/MCB.5.8.2123; KIMMEL AR, 1979, CELL, V16, P787, DOI 10.1016/0092-8674(79)90094-1; KIRK DN, 1990, J CHEM SOC PERK T 2, P1567, DOI 10.1039/p29900001567; Klahre U, 1998, PLANT CELL, V10, P1677, DOI 10.1105/tpc.10.10.1677; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEHLE L, 1980, EUR J BIOCHEM, V109, P589, DOI 10.1111/j.1432-1033.1980.tb04832.x; LENART U, 1995, ACTA BIOCHIM POL, V42, P269; LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940; LIVERMORE BP, 1978, INFECT IMMUN, V20, P215, DOI 10.1128/IAI.20.1.215-220.1978; LORCH Y, 1985, J MOL BIOL, V186, P821, DOI 10.1016/0022-2836(85)90400-0; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MAYBERRY WR, 1983, BIOCHIM BIOPHYS ACTA, V752, P434, DOI 10.1016/0005-2760(83)90273-4; MCKERSIE BD, 1979, PLANT PHYSIOL, V63, P802, DOI 10.1104/pp.63.5.802; MCMORRIS TC, 1977, BIOCHIM BIOPHYS ACTA, V486, P308, DOI 10.1016/0005-2760(77)90026-1; Moehs CP, 1997, PLANT J, V11, P227, DOI 10.1046/j.1365-313X.1997.11020227.x; MUDD JB, 1980, PLANT PHYSIOL, V65, P78, DOI 10.1104/pp.65.1.78; MUHIUDEEN IA, 1984, J LIPID RES, V25, P1117; MURAKAMIMUROFUSHI K, 1987, J BIOL CHEM, V262, P16719; MurakamiMurofushi K, 1997, J BIOL CHEM, V272, P486; MURAKAMIMUROFUSHI K, 1989, BIOCHIM BIOPHYS ACTA, V992, P412, DOI 10.1016/0304-4165(89)90108-6; Ness F, 1998, J BACTERIOL, V180, P1913, DOI 10.1128/JB.180.7.1913-1919.1998; OEKERS P, 1998, J BIOL CHEM, V273, P26765; Palermo LM, 1997, CURR GENET, V32, P93, DOI 10.1007/s002940050252; PARKS LW, 1978, LIPIDS, V13, P730, DOI 10.1007/BF02533753; PARODI AJ, 1976, ACTA PHYSIOL LAT AM, V26, P430; PATEL KR, 1978, J BACTERIOL, V136, P829, DOI 10.1128/JB.136.2.829-831.1978; Rahier A, 1997, BIOCHEM BIOPH RES CO, V236, P434, DOI 10.1006/bbrc.1997.6974; Schaller H, 1998, PLANT PHYSIOL, V118, P461, DOI 10.1104/pp.118.2.461; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; SHAW DR, 1989, MOL GEN GENET, V218, P453, DOI 10.1007/BF00332409; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH PF, 1971, J BACTERIOL, V108, P986, DOI 10.1128/JB.108.3.986-991.1971; SMITH WB, 1977, ORG MAGN RESONANCE, V9, P644, DOI 10.1002/mrc.1270091108; Sweigard JA, 1998, MOL PLANT MICROBE IN, V11, P404, DOI 10.1094/MPMI.1998.11.5.404; Tomeo ME, 1997, YEAST, V13, P449; TYORINOJA K, 1974, BIOCHEM J, V141, P133; ULLMANN P, 1993, BIOCHIMIE, V75, P713, DOI 10.1016/0300-9084(93)90102-X; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Veron B, 1996, LIPIDS, V31, P989, DOI 10.1007/BF02522694; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Warnecke DC, 1997, PLANT MOL BIOL, V35, P597, DOI 10.1023/A:1005806119807; WARNECKE DC, 1994, PLANT PHYSIOL, V105, P1067, DOI 10.1104/pp.105.4.1067; WEBB MS, 1995, BBA-BIOMEMBRANES, V1239, P226, DOI 10.1016/0005-2736(95)00147-U; WERTZ PW, 1986, J LIPID RES, V27, P427; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WOJCIECHOWSKI ZA, 1979, BIOCHIM BIOPHYS ACTA, V570, P363, DOI 10.1016/0005-2744(79)90156-6; WOJCIECHOWSKI ZA, 1979, PHYTOCHEMISTRY, V18, P39, DOI 10.1016/S0031-9422(00)90911-7; WOJCIECHOWSKI ZA, 1991, PHYSL BIOCH STEROLS; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	78	102	114	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13048	13059		10.1074/jbc.274.19.13048	http://dx.doi.org/10.1074/jbc.274.19.13048			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224056	hybrid			2022-12-25	WOS:000080200400018
J	Yen, FT; Masson, M; Clossais-Besnard, N; Andre, P; Grosset, JM; Bougueleret, L; Dumas, JB; Guerassimenko, O; Bihain, BE				Yen, FT; Masson, M; Clossais-Besnard, N; Andre, P; Grosset, JM; Bougueleret, L; Dumas, JB; Guerassimenko, O; Bihain, BE			Molecular cloning of a lipolysis-stimulated remnant receptor expressed in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DI-LEUCINE MOTIF; CHYLOMICRON REMNANTS; LDL RECEPTOR; APOLIPOPROTEIN-E; DOWN-REGULATION; PATHWAY; GENE; PROTEIN; METABOLISM	The lipolysis-stimulated receptor (LSR) is a lipoprotein receptor primarily expressed in the liver and activated by free fatty acids. Antibodies inhibiting LSR functions showed that the receptor is a heterotrimer or tetramer consisting of 68-kDa (alpha) and 56-kDa (beta) sub units associated through disulfide bridges. Screening of expression libraries with these antibodies led to identification of mRNAs derived by alternate splicing from a single gene and coding for proteins with molecular masses matching that of LSR alpha and beta, Antibodies directed against a synthetic peptide of LSR alpha and beta putative ligand binding domains inhibited LSR activity. Western blotting identified two liver proteins with the same apparent molecular mass as that of LSR alpha and beta. Transient transfections of LSR alpha alone in Chinese hamster ovary cells increased oleate-induced binding and uptake of lipoproteins, while cotransfection of both LSR alpha and beta increased oleate-induced proteolytic degradation of the particles. The ligand specificity of LSR expressed in cotransfected Chinese hamster ovary cells closely matched that previously described using fibroblasts from subjects lacking the low density lipoprotein receptor. LSR affinity is highest for the triglyceride-rich lipoproteins, chylomicrons, and very low density lipoprotein. We speculate that LSR is a rate-limiting step for the clearance of dietary triglycerides and plays a role in determining their partitioning between the liver and peripheral tissues.	INSERM U391, F-35043 Rennes, France; Genset SA, F-75000 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Bihain, BE (corresponding author), Genset Corp, 875 Prospect St,Suite 206, La Jolla, CA 92037 USA.		André, Patrice/M-8139-2014; Yen, Frances T/G-9175-2014	André, Patrice/0000-0002-5834-7395; Yen, Frances T/0000-0001-8740-4304				ATTIE AD, 1982, HEPATOLOGY, V2, P269; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BEISIEGEL U, 1988, ARTERIOSCLEROSIS, V8, P288, DOI 10.1161/01.ATV.8.3.288; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; Bihain BE, 1998, CURR OPIN LIPIDOL, V9, P221, DOI 10.1097/00041433-199806000-00006; BIHAIN BE, 1992, BIOCHEMISTRY-US, V31, P4628, DOI 10.1021/bi00134a013; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Cooper AD, 1997, J LIPID RES, V38, P2173; DEARIA E, 1996, J LIPID RES, V37, P197; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HOEG JM, 1986, BIOCHIM BIOPHYS ACTA, V876, P13, DOI 10.1016/0005-2760(86)90312-7; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUYNH TV, 1984, DNA CLONING TECHNIQU; Ishibashi S, 1996, J BIOL CHEM, V271, P22422, DOI 10.1074/jbc.271.37.22422; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KHALLOU J, 1996, CIRCULATION S, V94, P37; KOSAK M, 1990, P NATL ACAD SCI USA, V87, P8301; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MAHLEY RW, 1989, ARTERIOSCLER, V9, P114; Mann CJ, 1997, J BIOL CHEM, V272, P31348, DOI 10.1074/jbc.272.50.31348; MANN CJ, 1995, BIOCHEMISTRY-US, V34, P10421, DOI 10.1021/bi00033a014; Oukka M, 1997, EUR J IMMUNOL, V27, P855, DOI 10.1002/eji.1830270408; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; Sambrook J., 2002, MOL CLONING LAB MANU; Shepherd J, 1986, Methods Enzymol, V129, P566; SHIN JY, 1991, J BIOL CHEM, V266, P10658; TROUSSARD AA, 1995, J BIOL CHEM, V270, P17068, DOI 10.1074/jbc.270.29.17068; Via D P, 1986, Methods Enzymol, V129, P848; VILARO S, 1988, BIOCHIM BIOPHYS ACTA, V959, P106, DOI 10.1016/0005-2760(88)90021-5; VILARO S, 1988, AM J PHYSIOL, V254, pG711, DOI 10.1152/ajpgi.1988.254.5.G711; Ware Carl F., 1998, P549; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; YEN FT, 1994, BIOCHEMISTRY-US, V33, P1172, DOI 10.1021/bi00171a017; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	39	56	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13390	13398		10.1074/jbc.274.19.13390	http://dx.doi.org/10.1074/jbc.274.19.13390			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224102	hybrid			2022-12-25	WOS:000080200400064
J	Jovanovic, N; Jovanovic, S; Jovanovic, A; Terzic, A				Jovanovic, N; Jovanovic, S; Jovanovic, A; Terzic, A			Gene delivery of Kir6.2/SUR2A in conjunction with pinacidil handles intracellular Ca2+ homeostasis under metabolic stress	FASEB JOURNAL			English	Article						K-ATP channels; ischemia; gene therapy; potassium channel opener	SENSITIVE K+ CHANNEL; MAMMALIAN-CELL LINE; ATP-CHANNEL; SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; INSULIN-SECRETION; CARDIAC-CELLS; PHARMACOLOGICAL APPROACH; SARCOPLASMIC-RETICULUM; HYPOXIA-REOXYGENATION	Metabolic injury is a complex process affecting various tissues, with intracellular Ca2+ loading recognized as a common precipitating event leading to cell death. We have recently observed that cells overexpressing recombinant ATP-sensitive K+ (K-ATP) channel subunits may acquire resistance against metabolic stress, To examine whether, under metabolic challenge, intracellular Ca2+ homeostasis can be maintained by an activator of channel proteins, we delivered Kir6.2 and SUR2A genes, which encode K-ATP channel subunits, into a somatic cell line lacking native K-ATP channels, Hypoxia-reoxygenation was simulated by application and removal of the mitochondrial poison 2,4 dinitrophenol, Under such metabolic stress, Ca2+ loading was induced by Ca2+ influx during hypoxia and release of Ca2+ from intracellular stores during reoxygenation. Delivery of Kir6.2/SUR2A genes, in conjunction with the K-ATP channel activator pinacidil, prevented intracellular Ca2+ loading irrespective of whether the channel opener was applied throughout the duration of hypoxia-reoxygenation or transiently during the hypoxic or reoxygenation stage, In all stages of injury, the effect of pinacidil was inhibited by the selective antagonist of K-ATP channel, 5-hydroxydecanoate. The present study provides evidence that combined use of gene delivery and pharmacological targeting of recombinant proteins can handle intracellular Ca2+ homeostasis under hypoxia-reoxygenation irrespective of the stage of the metabolic insult.	Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Terzic, A (corresponding author), Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Guggenheim 7F,200 1st St SW, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alekseev AE, 1997, J MEMBRANE BIOL, V159, P161, DOI 10.1007/s002329900279; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; BALESTRINO M, 1995, J NEUROSCI METH, V59, P99, DOI 10.1016/0165-0270(94)00199-Q; BEHLING RW, 1995, J MOL CELL CARDIOL, V27, P1809, DOI 10.1016/0022-2828(95)90004-7; Brady PA, 1996, EUR J PHARMACOL, V308, P343, DOI 10.1016/0014-2999(96)00327-5; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; French BA, 1998, CURR OPIN CARDIOL, V13, P205; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; Grover GJ, 1997, CAN J PHYSIOL PHARM, V75, P309, DOI 10.1139/cjpp-75-4-309; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HEARSE DJ, 1995, CARDIOVASC RES, V30, P1; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567, DOI 10.1152/ajpheart.1998.275.5.H1567; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Ishii T, 1996, J PHYSIOL-LONDON, V493, P371, DOI 10.1113/jphysiol.1996.sp021389; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jovanovic A, 1998, LAB INVEST, V78, P1101; Jovanovic A, 1996, EUR J PHARMACOL, V298, P63, DOI 10.1016/0014-2999(95)00738-5; Jovanovic A, 1997, ANN THORAC SURG, V63, P153; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; JUEDES MJ, 1992, FEBS LETT, V313, P39, DOI 10.1016/0014-5793(92)81179-P; Kim JS, 1998, TRANSPLANTATION, V65, P369, DOI 10.1097/00007890-199802150-00012; KIRBY MS, 1992, J BIOL CHEM, V267, P12545; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kusuoka H, 1998, JPN CIRC J, V62, P611, DOI 10.1253/jcj.62.611; Lauritzen I, 1997, J NEUROCHEM, V69, P1570; Levitsky J, 1998, J CLIN PHARMACOL, V38, P887, DOI 10.1002/j.1552-4604.1998.tb04383.x; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Lopez JR, 1996, J THORAC CARDIOV SUR, V112, P820, DOI 10.1016/S0022-5223(96)70070-3; LOPEZ JR, 1995, BIOCHEM BIOPH RES CO, V214, P781, DOI 10.1006/bbrc.1995.2354; Lorenz E, 1998, MOL CELL BIOL, V18, P1652, DOI 10.1128/MCB.18.3.1652; Maxwell SRJ, 1997, INT J CARDIOL, V58, P95, DOI 10.1016/S0167-5273(96)02854-9; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; MILLER TW, 1995, CARDIOVASC RES, V29, P85, DOI 10.1016/S0008-6363(96)88551-8; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOTSU T, 1992, J PHARMACOL EXP THER, V260, P702; Okuyama Y, 1998, PFLUG ARCH EUR J PHY, V435, P595, DOI 10.1007/s004240050559; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; WATTS JA, 1986, J MOL CELL CARDIOL, V18, P71, DOI 10.1016/S0022-2828(86)80030-X; YANAGISAWA T, 1990, BRIT J PHARMACOL, V101, P157, DOI 10.1111/j.1476-5381.1990.tb12106.x; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	45	53	53	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					923	929		10.1096/fasebj.13.8.923	http://dx.doi.org/10.1096/fasebj.13.8.923			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224235				2022-12-25	WOS:000080372500015
J	Long, WP; Chen, X; Perdew, GH				Long, WP; Chen, X; Perdew, GH			Protein kinase C modulates aryl hydrocarbon receptor nuclear translocator protein-mediated transactivation potential in a dimer context	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; HELIX-LOOP-HELIX; AH RECEPTOR; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAINS; ACTIVATION DOMAINS; GENE-EXPRESSION; SIM GENE; ARNT; DNA	Protein kinase C (PKC)- and protein kinase A (PKA)mediated modulation of the transactivation potential of human aryl hydrocarbon receptor nuclear translocator (hARNT), a basic helix-loop-helix (bHLH)-PAS transcription factor, and the bHLH-ZIP transcription factors USF-1 (for upstream regulatory factor 1) and c-Myc were examined, An 81 nM dose of the PKC activator phorbol-12-myristate-13-acetate (PMA), shown here to specifically activate PKC in COS-l cells, or a 1 nM dose of the PKA activator 8-bromoadenosine-3',5'-cyclic monophosphate (8-Br-cAMP) results in 2.6- and 1.9-fold enhancements, respectively, in hARNT-mediated transactivation of the class B, E-box-driven reporter pMyc3E1bLuc relative to identically transfected, carrier solvent-treated COS-l cells. In contrast, 81 nM PMA and 1 nM 8-Br-cAMP did not enhance transactivation of pMyc3E1bLuc-driven by USF-1 and c-Myc expression relative to identically transfected, carrier-treated COS-1 cells. Co-transfection of pcDNA3/ARNT-474-Flag, expressing a hARNT carboxyl-terminal transactivation domain deletion, and pMyc3E1bLuc does not result in induction of reporter activity, suggesting PMA's effects do not involve formation of unknown hARNT-protein heterodimers. Additionally, PMA had no effect on hARNT expression relative to Me2SO-treated cells. Metabolic P-32 labeling of hARNT in cells treated with carrier solvent or 81 nM PMA demonstrates that PMA does not increase the overall phosphorylation level of hARNT. These results demonstrate, for the first time, that the transactivation potential of ARNT in a dimer context can be specifically modulated by PKC or PKA stimulation and that the bHLH-PAS and bHLH-ZIP transcription factors are differentially regulated by these pathways in COS-1 cells.	Penn State Univ, Ctr Mol Toxicol, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Grad Program Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Perdew, GH (corresponding author), Penn State Univ, Ctr Mol Toxicol, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009272, R01ES004869, R29ES004869] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04869, ES09272] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; CZERNIECKI BJ, 1989, CANCER LETT, V48, P29, DOI 10.1016/0304-3835(89)90199-7; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIFAGAGNA FD, 1995, J VIROL, V69, P2765, DOI 10.1128/JVI.69.5.2765-2775.1995; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Ema M, 1996, MOL CELL BIOL, V16, P5865; Galibert MD, 1997, J IMMUNOL, V159, P6176; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HEI YJ, 1991, MOL PHARMACOL, V39, P233; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HORD NG, 1994, MOL PHARMACOL, V46, P618; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kobayashi M, 1996, BIOTECHNIQUES, V21, P398; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Long WP, 1998, MOL PHARMACOL, V53, P691, DOI 10.1124/mol.53.4.691; Luo X, 1996, MOL CELL BIOL, V16, P1367; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SETH A, 1992, J BIOL CHEM, V267, P24796; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; SOGAWA K, 1989, EUR J BIOCHEM, V181, P539, DOI 10.1111/j.1432-1033.1989.tb14757.x; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WILSON C, 1998, J SOC TOXICOL, V42, P247; Yamaki A, 1996, GENOMICS, V35, P136, DOI 10.1006/geno.1996.0332	37	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12391	12400		10.1074/jbc.274.18.12391	http://dx.doi.org/10.1074/jbc.274.18.12391			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212212	hybrid			2022-12-25	WOS:000080056800032
J	Marcinkiewicz, C; Calvete, JJ; Marcinkiewicz, MM; Raida, M; Vijay-Kumar, S; Huang, ZW; Lobb, RR; Niewiarowski, S				Marcinkiewicz, C; Calvete, JJ; Marcinkiewicz, MM; Raida, M; Vijay-Kumar, S; Huang, ZW; Lobb, RR; Niewiarowski, S			EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits alpha 4 and alpha 5 integrins in an RGD-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; PLATELET-AGGREGATION INHIBITOR; SNAKE-VENOM; STRUCTURAL REQUIREMENTS; LIGAND-BINDING; VIPER VENOMS; RECEPTOR; IIIA; FIBRONECTIN; PEPTIDE	EC3, a heterodimeric disintegrin (M-r = 14,762) isolated from Echis carinatus venom is a potent antagonist of alpha 4 integrins, Two subunits called EC3A and EC3B were isolated from reduced and alkylated EC3 by reverse phase high performance liquid chromatography, Each subunit contained 67 residues, including 10 cysteines, and displayed a high degree of homology to each other and to other disintegrins, EC3 inhibited adhesion of cells expressing alpha 4 beta 1 and alpha 4 beta 7 integrins to natural ligands vascular cell adhesion molecule 1 (VCAM-1) and mucosal addressin cell adhesion molecule 1 (MadCAM-1) with IC50 = 630 nM, adhesion of K562 cells (alpha 5 beta 1) to fibronectin with IC50 = 150 nM, and adhesion of alpha IIb beta 3 Chinese hamster ovary cells to fibrinogen with IC50 500 nM; it did not inhibit adhesion of alpha v beta 3 Chinese hamster ovary cells to vitronectin, Ethylpyridylethylated EC3B inhibited adhesion of Jurkat cells to immobilized VCAM-1 (IC50 = 6 mu M), whereas EC3A was inactive in this system. The MLDG motif appeared to be essential for activity of EC3B, Linear MLDG peptide inhibited the adhesion of Jurkat to VCAM-1 in a dose-dependent manner (IC50 = 4 mM), whereas RGDS peptide was not active at the same concentration. MLDG partially inhibited adhesion of K562 cells to fibronectin (5-10 mM) in contrast to RGDS peptide (IC50 = 3 mM), inhibiting completely at 10 mM.	Temple Univ, Sch Med, Dept Physiol, Sol Sherry Thrombosis Res Ctr,Fels Canc Res Inst, Philadelphia, PA 19140 USA; Biogen Inc, Cambridge, MA 02142 USA; Inst Peptide Res, D-30559 Hannover, Germany; CSIC, Inst Biomed, E-46010 Valencia, Spain; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Biogen; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Jefferson University	Niewiarowski, S (corresponding author), Temple Univ, Sch Med, Dept Physiol, Sol Sherry Thrombosis Res Ctr,Fels Canc Res Inst, 3400 N Broad St, Philadelphia, PA 19140 USA.		Calvete, Juan J/K-9619-2014; Calvete, Juan/P-2555-2019	Calvete, Juan J/0000-0001-5026-3122; Calvete, Juan/0000-0001-5026-3122	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE011844] Funding Source: NIH RePORTER; NIDCR NIH HHS [R03 DE11844] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADLER M, 1992, BIOCHEMISTRY-US, V31, P1031, DOI 10.1021/bi00119a011; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Briskin MJ, 1996, J IMMUNOL, V156, P719; CALVETE JJ, 1992, FEBS LETT, V309, P316, DOI 10.1016/0014-5793(92)80797-K; CALVETE JJ, 1991, BIOCHEMISTRY-US, V30, P5225, DOI 10.1021/bi00235a016; CHAO BH, 1989, P NATL ACAD SCI USA, V86, P8050, DOI 10.1073/pnas.86.20.8050; CLARK EA, 1994, J BIOL CHEM, V269, P21940; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; HUANG TF, 1987, J BIOL CHEM, V262, P16157; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; MADSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; MARCINKIEWICZ C, 1996, BIOCHEM J, V371, P118; MCLANE MA, 1994, BIOCHEM J, V301, P429, DOI 10.1042/bj3010429; McMurray RW, 1996, SEMIN ARTHRITIS RHEU, V25, P215, DOI 10.1016/S0049-0172(96)80034-5; MOULD AP, 1994, J BIOL CHEM, V269, P27224; Moyano JV, 1997, J BIOL CHEM, V272, P24832, DOI 10.1074/jbc.272.40.24832; Munoz M, 1996, J BIOL CHEM, V271, P2696, DOI 10.1074/jbc.271.5.2696; MUSIAL J, 1990, CIRCULATION, V82, P261, DOI 10.1161/01.CIR.82.1.261; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Satoh T, 1997, J BIOL CHEM, V272, P12175, DOI 10.1074/jbc.272.18.12175; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; Siigur E, 1996, BIOCHEM BIOPH RES CO, V224, P229, DOI 10.1006/bbrc.1996.1012; TRIKHA M, 1994, CANCER RES, V54, P4993; Tselepis VH, 1997, J BIOL CHEM, V272, P21341, DOI 10.1074/jbc.272.34.21341; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321	40	94	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12468	12473		10.1074/jbc.274.18.12468	http://dx.doi.org/10.1074/jbc.274.18.12468			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212222	hybrid			2022-12-25	WOS:000080056800042
J	Petersen, F; Brandt, E; Lindahl, U; Spillmann, D				Petersen, F; Brandt, E; Lindahl, U; Spillmann, D			Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; FACTOR-IV; POLYMORPHONUCLEAR NEUTROPHILS; PROTEOGLYCAN CARRIER; CHONDROITIN SULFATE; CHEMOKINES; PLATELET-FACTOR-4; CLEAVAGE; PROTEINS; RESIDUES	Platelet factor 4 (PF-4) is a platelet-derived alpha-chemokine that binds to and activates human neutrophils to undergo specific functions like exocytosis or adhesion. PF-4 binding has been shown to be independent of interleukin-8 receptors and could be inhibited by soluble chondroitin sulfate type glycosaminoglycans or by pretreatment of cells with chondroitinase ABC. Here we present evidence that surface-expressed neutrophil glycosaminoglycans are of chondroitin sulfate type and that this species binds to the tetrameric form of PF-4, The glycosaminoglycans consist of a single type of chain with an average molecular mass of similar to 23 kDa and are composed of similar to 85-90% chondroitin 8-sulfate disaccharide units type CSA (-->4GlcA beta 1-->3GalNAc(4-O-sulfate)beta 1-->) and of similar to 10-15% di-O-sulfated disaccharide units. A major part of these di-O-sulfated disaccharide units are CSE units (-->4GlcA beta 1-->3GaLNAc(4,6-O-sulfate)beta 1-->). Binding studies revealed that the interaction of chondroitin sulfate with PF-4 required at least 20 monosaccharide units for significant binding. The di-O-sulfated disaccharide units in neutrophil glycosaminoglycans clearly promoted the affinity to PF-4, which showed a K-d similar to 0.8 mu M as the affinities of bovine cartilage chondroitin sulfate A, porcine skin dermatan sulfate, or bovine cartilage chondroitin sulfate C, all consisting exclusively of monosulfated disaccharide units, were found to be 3-5-fold lower. Taken together, our data indicate that chondroitin sulfate chains function as physiologically relevant binding sites for PF-4 on neutrophils and that the affinity of these chains for PF-4 is controlled by their degree of sulfation.	Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany	Uppsala University; Forschungszentrum Borstel	Spillmann, D (corresponding author), Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.							BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARBER AJ, 1972, BIOCHIM BIOPHYS ACTA, V286, P312, DOI 10.1016/0304-4165(72)90267-X; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BRANDT E, 1991, CYTOKINE, V3, P311, DOI 10.1016/1043-4666(91)90499-4; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Dudek AZ, 1997, J BIOL CHEM, V272, P31785, DOI 10.1074/jbc.272.50.31785; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; FILES JC, 1981, BLOOD, V58, P607; GARDINER EE, 1994, EUR J BIOCHEM, V221, P871, DOI 10.1111/j.1432-1033.1994.tb18802.x; GARDINER EE, 1992, BIOCHEM J, V288, P577, DOI 10.1042/bj2880577; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; HUANG SS, 1982, J BIOL CHEM, V257, P1546; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; LEVINE SP, 1977, THROMB RES, V11, P673, DOI 10.1016/0049-3848(77)90025-1; LEVITT D, 1986, MOL IMMUNOL, V23, P1125, DOI 10.1016/0161-5890(86)90011-8; LIDHOLT K, 1995, BIOCHEM J, V311, P233, DOI 10.1042/bj3110233; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; MCLAREN KM, 1982, THROMB RES, V19, P293; OLSSON I, 1967, BIOCHIM BIOPHYS ACTA, V141, P348, DOI 10.1016/0304-4165(67)90109-2; OLSSON I, 1968, BIOCHIM BIOPHYS ACTA, V165, P309, DOI 10.1016/0304-4165(68)90209-2; Petersen F, 1996, J IMMUNOL, V156, P1954; PETERSEN F, 1994, J IMMUNOL, V152, P2467; Petersen F, 1998, J IMMUNOL, V161, P4347; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	41	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12376	12382		10.1074/jbc.274.18.12376	http://dx.doi.org/10.1074/jbc.274.18.12376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212210	hybrid			2022-12-25	WOS:000080056800030
J	Graf, GA; Connell, PM; van der Westhuyzen, DR; Smart, EJ				Graf, GA; Connell, PM; van der Westhuyzen, DR; Smart, EJ			The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CAVEOLAE; APOPROTEIN-A-I; SR-BI; RAT; TRANSPORT; PROTEIN; CELLS; INTERNALIZATION; METABOLISM; EXPRESSION	The uptake of cholesterol esters from high density lipoproteins (HDLs) is characterized by the initial movement of cholesterol esters into a reversible plasma membrane pool. Cholesterol esters are subsequently internalized to a nonreversible pool. Unlike the uptake of cholesterol from low density lipoproteins, cholesterol ester uptake from HDL does not involve the internalization and degradation of the particle and is therefore termed selective. The class B, type I scavenger receptor (SR-BI) has been identified as an HDL receptor and shown to mediate selective cholesterol ester uptake. SR-BI is localized to cholesterol- and sphingomyelin-rich microdomains called caveolae, Caveolae are directly involved in cholesterol trafficking. Therefore, we tested the hypothesis that caveolae are accepters for HDL-derived cholesterol ether (CE), Our studies demonstrate that in Chinese hamster ovary cells expressing SR-BI, >80% of the plasma membrane associated CE is present in caveolae after 7.5 min of selective cholesterol ether uptake. We also show that excess, unlabeled HDL can extract the radiolabeled CE from caveolae, demonstrating that caveolae constitute a reversible plasma membrane pool of CE. Furthermore, 50% of the caveolae-associated CE can be chased into a nonreversible pool. We conclude that caveolae are accepters for HDL-derived cholesterol ethers, and that caveolae constitute a reversible, plasma membrane pool of cholesterol ethers.	Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Smart, EJ (corresponding author), Univ Kentucky, Dept Physiol, 800 Rose St,MSC 508C, Lexington, KY 40536 USA.		Eckhardt, Erik/G-1567-2010	Graf, Gregory/0000-0002-0130-9929	NHLBI NIH HHS [R01HL59376, R26HL58475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058475, R01HL058475, R01HL059376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSEN JM, 1978, J BIOL CHEM, V253, P9024; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KNETCH TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; MURPHY BD, 1985, ENDOCRINOLOGY, V116, P1587, DOI 10.1210/endo-116-4-1587; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Smart EJ, 1995, COLD SPRING HARB SYM, V60, P243, DOI 10.1101/SQB.1995.060.01.028; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Webb NR, 1997, J LIPID RES, V38, P1490	46	150	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12043	12048		10.1074/jbc.274.17.12043	http://dx.doi.org/10.1074/jbc.274.17.12043			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207027	hybrid			2022-12-25	WOS:000079834800083
J	Wang, WY; Poovaiah, BW				Wang, WY; Poovaiah, BW			Interaction of plant chimeric calcium/calmodulin-dependent protein kinase with a homolog of eukaryotic elongation factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINOACYL-TRANSFER-RNA; FACTOR 1-ALPHA; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; TRANSLATIONAL ELONGATION; CALCIUM-CALMODULIN; TYROSINE KINASE; PHOSPHORYLATION; DOMAIN	A chimeric Ca2+/calmodulin-dependent protein kinase (CCaMK) was previously cloned and characterized in this laboratory. To investigate the biological functions of CCaMK, the yeast two-hybrid system was used to isolate genes encoding proteins that interact with CCaMK, One of the cDNA clones obtained from the screening (LlEF-1 alpha 1) has high similarity with the eukaryotic elongation factor-1 alpha (EF-1 alpha). CCaMK phosphorylated LlEF-1 alpha 1 in a Ca2+/calmodulin-dependent manner. The phosphorylation site for CCaMK (Thr-257) was identified by site-directed mutagenesis. Interestingly, Thr-257 is located in the putative tRNA-binding region of LlEF-1 alpha 1. An isoform of Ca2+-dependent protein kinase (CDPK) phosphorylated multiple sites of LlEF-1 alpha 1 in a Ca2+-dependent but calmodulin-independent manner. Unlike CDPK, CCaMK phosphorylated only one site, and this site is different from CDPK phosphorylation sites, This suggests that the phosphorylation of EF-1 alpha by these two kinases may have different functional significance. Although the phosphorylation of LlEF-1 alpha 1 by CCaMK is Ca2+/calmodulin-dependent, in vitro binding assays revealed that CCaMK binds to LlEF-1 alpha 1 in a Ca2+-independent manner. This was further substantiated by coimmunoprecipitation of CCaMK and EF-1 alpha using the protein extract from lily anthers. Dissociation of CCaMK from EF-1 alpha by Ca2+ and phosphorylation of EF-1 alpha by CCaMK in a Ca2+/calmodulin-dependent manner suggests that these interactions may play a role in regulating the biological functions of EF-1 alpha.	Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA	Washington State University	Poovaiah, BW (corresponding author), Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA.							BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; Chang YWE, 1997, J BIOL CHEM, V272, P28252, DOI 10.1074/jbc.272.45.28252; Clore AM, 1996, PLANT CELL, V8, P2003, DOI 10.2307/3870408; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DURSO NA, 1994, PLANT CELL, V6, P893, DOI 10.1105/tpc.6.6.893; DURSO NA, 1994, PROTOPLASMA, V180, P99, DOI 10.1007/BF01507846; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; HARMON AC, 1994, BIOCHEMISTRY-US, V33, P7278, DOI 10.1021/bi00189a032; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; KAUR KJ, 1994, J BIOL CHEM, V269, P23045; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Kumagai F, 1995, BOT ACTA, V108, P467, DOI 10.1111/j.1438-8677.1995.tb00523.x; Kurasawa Y, 1996, J BIOCHEM-TOKYO, V119, P791; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Lu YT, 1996, PLANTA, V199, P18; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Moore RC, 1998, CELL MOTIL CYTOSKEL, V41, P168, DOI 10.1002/(SICI)1097-0169(1998)41:2<168::AID-CM7>3.0.CO;2-A; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; Negrutskii BS, 1996, FEBS LETT, V382, P18, DOI 10.1016/0014-5793(96)00128-7; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Ramachandiran S, 1997, J BIOCHEM-TOKYO, V121, P984; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; Sambrook J., 2002, MOL CLONING LAB MANU; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Takezawa D, 1996, J PLANT PHYSIOL, V149, P329, DOI 10.1016/S0176-1617(96)80130-1; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; TANG WJY, 1993, METHOD CELL BIOL, V37, P95, DOI 10.1016/S0091-679X(08)60245-9; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; WANG CS, 1992, AM J BOT, V79, P118, DOI 10.2307/2445097; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YANG W, 1994, J BIOL CHEM, V269, P3852; ZHU JK, 1994, PLANT CELL, V6, P393, DOI 10.1105/tpc.6.3.393; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	45	28	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12001	12008		10.1074/jbc.274.17.12001	http://dx.doi.org/10.1074/jbc.274.17.12001			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207022	hybrid			2022-12-25	WOS:000079834800078
J	Boesen-de Cock, JGR; Tepper, AD; de Vries, E; van Blitterswijk, WJ; Borst, J				Boesen-de Cock, JGR; Tepper, AD; de Vries, E; van Blitterswijk, WJ; Borst, J			Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APO-1/FAS RECEPTOR/LIGAND SYSTEM; DAUNORUBICIN-INDUCED APOPTOSIS; FAS/FAS LIGAND INTERACTIONS; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; INDUCED CELL-DEATH; ACID SPHINGOMYELINASE; CERAMIDE FORMATION; LYMPHOID-CELLS; COMPLEX DISC	The death receptor CD95 (APO-1/Fas), the anticancer drug etoposide, and gamma-radiation induce apoptosis in the human T cell line Jurkat. Variant clones selected for resistance to CD95-induced apoptosis proved cross-resistant to etoposide- and radiation-induced apoptosis, suggesting that the apoptosis pathways induced by these distinct stimuli have critical component(s) in common. The pathways do not converge at the level of CD95 ligation or caspase-8 signaling. Whereas caspase-8 function was required for CD95-mediated cytochrome c release, effector caspase activation, and apoptosis, these responses were unaffected in etoposide-treated and irradiated cells when caspase-8 was inhibited by FLIPL. Both effector caspase processing and cytochrome c release were inhibited in the resistant variant cells as well as in Bcl-2 transfectants, suggesting that, in Jurkat cells, the apoptosis signaling pathways activated by CD95, etoposide, and gamma-radiation are under common mitochondrial control. All three stimuli induced ceramide production in wild-type cells, but not in resistant variant cells. Exogenous ceramide bypassed apoptosis resistance in the variant cells, but not in Bcl-2-transfected cells, suggesting that apoptosis signaling induced by CD95, etoposide, and gamma-radiation is subject to common regulation at a level different from that targeted by Bcl-2.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jborst@nki.nl		Borst, Jannie/0000-0002-8043-5009				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chmura SJ, 1997, CANCER RES, V57, P1270; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEJONG D, 1994, CANCER RES, V54, P256; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hu SM, 1997, J BIOL CHEM, V272, P9621; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Michael JM, 1997, CANCER RES, V57, P3600; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	57	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14255	14261		10.1074/jbc.274.20.14255	http://dx.doi.org/10.1074/jbc.274.20.14255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318846	hybrid			2022-12-25	WOS:000080322200075
J	Egawa, K; Sharma, PM; Nakashima, N; Huang, Y; Huver, E; Boss, GR; Olefsky, JM				Egawa, K; Sharma, PM; Nakashima, N; Huang, Y; Huver, E; Boss, GR; Olefsky, JM			Membrane-targeted phosphatidylinositol 3-kinase mimics insulin actions and induces a state of cellular insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; GLUCOSE-TRANSPORT ACTIVITY; RECEPTOR SUBSTRATE FAMILY; 3T3-L1 ADIPOCYTES; GLUT4 TRANSLOCATION; DNA-SYNTHESIS; 1-PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOTYROSINE PROTEIN	Phosphatidylinositol (PI) 3-kinase plays an important role in various insulin-stimulated biological responses including glucose transport, glycogen synthesis, and protein synthesis. However, the molecular link between PI 3-kinase and these biological responses is still unclear. We have investigated whether targeting of the catalytic p110 subunit of PI 3-kinase to cellular membranes is sufficient and necessary to induce PI 3-kinase dependent signaling responses, characteristic of insulin action. We overexpressed Myc-tagged, membrane-targeted p110 (p110(CAAX)), and wild-type p110 (p110(WT)) in 3T3-L1 adipocytes by adenovirus-mediated gene transfer. Overexpressed p110(CAAX) exhibited similar to 2-fold increase in basal kinase activity in p110 immunoprecipitates, that further increased to similar to 4-fold with insulin. Even at this submaximal PI 3-kinase activity, p110(CAAX) fully stimulated p70 S6 kinase, Akt, 2-deoxyglucose uptake, and Ras, whereas, p110(WT) had little or no effect on these downstream effects, Interestingly p110(CAAX) did not activate MAP kinase, despite its stimulation of p21(ras). Surprisingly, p110(CAAX) did not increase basal glycogen synthase activity, and inhibited insulin stimulated activity, indicative of cellular resistance to this action of insulin, p110(CAAX) also inhibited insulin stimulated, but not platelet-derived growth factor-stimulated mitogen-activated protein kinase phosphorylation, demonstrating that the p110(CAAX) induced inhibition of mitogen-activated protein kinase and insulin signaling is specific, and not due to some toxic or nonspecific effect on the cells. Moreover, p110(CAAX) stimulated IRS-1 Ser/Thr phosphorylation, and inhibited IRS-1 associated PI 3-kinase activity, without affecting insulin receptor tyrosine phosphorylation, suggesting that it may play an important role as a negative regulator for insulin signaling. In conclusion, our studies show that membrane-targeted PI S-kinase can mimic a number of biologic effects normally induced by insulin. In addition, the persistent activation of PI 3-kinase induced by p110(CAAX) expression leads to desensitization of specific signaling pathways. Interestingly, the state of cellular insulin resistance is not global, in that some of insulin's actions are inhibited, whereas others are intact.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Whittier Diabet Inst, La Jolla, CA 92093 USA; Vet Adm Res Serv, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NIDDK NIH HHS [R01 DK 36651] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brownell HL, 1997, DNA CELL BIOL, V16, P103, DOI 10.1089/dna.1997.16.103; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GLUZMAN Y, 1982, VIRAL VECTORS, P187; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; LAM K, 1994, J BIOL CHEM, V269, P20648; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444	58	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14306	14314		10.1074/jbc.274.20.14306	http://dx.doi.org/10.1074/jbc.274.20.14306			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318852	hybrid			2022-12-25	WOS:000080322200081
J	Kim, HS; Maeda, N; Oh, GT; Fernandez, LG; Gomez, RA; Smithies, O				Kim, HS; Maeda, N; Oh, GT; Fernandez, LG; Gomez, RA; Smithies, O			Homeostasis in mice with genetically decreased angiotensinogen is primarily by an increased number of renin-producing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CONVERTING ENZYME; BLOOD-PRESSURE; NUCLEOTIDE-SEQUENCE; EXPRESSING CELLS; GENE DUPLICATION; MESSENGER-RNA; MOUSE; KIDNEY; HYPERTENSION	Here we investigate the biochemical, molecular, and cellular changes directed toward blood pressure homeostasis that occur in the endocrine branch of the renin-angiotensin system of mice having one angiotensinogen gene inactivated. No compensatory up-regulation of the remaining normal allele occurs in tbe liver, the main tissue of angiotensinogen synthesis. No significant changes occur in expression of the genes coding for the angiotensin converting enzyme or the major pressor-mediating receptor for angiotensin, but plasma renin concentration in the mice having only one copy of the angiotensinogen gene is greater than twice wild-type, This increase is mediated primarily by a modest increase in the proportion of renal glomeruli producing renin in their juxtaglomerular apparatus and by four times wild-type numbers of renin-producing cells along afferent arterioles of the glomeruli rather than by upregulating renin production in cells already committed to its synthesis.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ Virginia, Hlth Sci Ctr, Dept Pediat, Charlottesville, VA 22908 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Virginia	Kim, HS (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.		Oh, Goo Taeg/AAQ-9995-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49277] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; AZROLAN N, 1990, J LIPID RES, V31, P1141; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BURT DW, 1989, GENE, V84, P91, DOI 10.1016/0378-1119(89)90143-1; CANTIN M, 1977, AM J PATHOL, V87, P581; CASELLAS D, 1993, AM J PHYSIOL, V265, pF151, DOI 10.1152/ajprenal.1993.265.1.F151; Chen XM, 1997, AM J PHYSIOL-RENAL, V272, pF299, DOI 10.1152/ajprenal.1997.272.3.F299; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; DICKINSON DP, 1984, GENETICS, V108, P651; DZAU VJ, 1988, AM J PHYSIOL, V255, pF563, DOI 10.1152/ajprenal.1988.255.4.F563; EPSTEIN CJ, 1986, CONSEQUENCES CHROMOS, P65; FABIAN JR, 1989, J BIOL CHEM, V264, P17589; FIELD LJ, 1985, P NATL ACAD SCI USA, V82, P6196, DOI 10.1073/pnas.82.18.6196; GERBER H, 1987, ENDOCRINOLOGY, V120, P91, DOI 10.1210/endo-120-1-91; GOMEZ RA, 1990, AM J PHYSIOL, V259, pF660, DOI 10.1152/ajprenal.1990.259.4.F660; GOMEZ RA, 1988, AM J PHYSIOL, V254, pF900, DOI 10.1152/ajprenal.1988.254.6.F900; HERMANN K, 1988, CLIN CHEM, V34, P1046; Hilgers KF, 1997, HYPERTENSION, V29, P216, DOI 10.1161/01.HYP.29.1.216; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KIM WS, 1989, NUCLEIC ACIDS RES, V17, P9480, DOI 10.1093/nar/17.22.9279; KOHARA K, 1991, PEPTIDES, V12, P1135, DOI 10.1016/0196-9781(91)90070-6; Krege JH, 1997, HYPERTENSION, V29, P150, DOI 10.1161/01.HYP.29.1.150; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; LIN CT, 1986, ENDOCRINOLOGY, V118, P538, DOI 10.1210/endo-118-2-538; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; NARUSE K, 1981, P NATL ACAD SCI-BIOL, V78, P7579, DOI 10.1073/pnas.78.12.7579; NASJLETTI A, 1971, CAN J PHYSIOL PHARM, V49, P931, DOI 10.1139/y71-129; NG KKF, 1967, NATURE, V216, P762, DOI 10.1038/216762a0; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Oliverio MI, 1998, P NATL ACAD SCI USA, V95, P15496, DOI 10.1073/pnas.95.26.15496; Oliverio MI, 1997, AM J PHYSIOL-RENAL, V272, pF515, DOI 10.1152/ajprenal.1997.272.4.F515; PAUL M, 1993, J CLIN INVEST, V91, P2058, DOI 10.1172/JCI116428; PICCINI N, 1982, CELL, V30, P205, DOI 10.1016/0092-8674(82)90026-5; Reddi V, 1998, J AM SOC NEPHROL, V9, P63; ROMANO LA, 1994, HYPERTENSION, V23, P889, DOI 10.1161/01.HYP.23.6.889; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; Sealey J E, 1980, Endocr Rev, V1, P365; SEALEY JE, 1991, CLIN CHEM, V37, P1811; SEALEY JE, 1989, AM J HYPERTENS, V2, P358, DOI 10.1093/ajh/2.5.358; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; TAUGNER R, 1982, KLIN WOCHENSCHR, V60, P1218, DOI 10.1007/BF01716726; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5	53	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14210	14217		10.1074/jbc.274.20.14210	http://dx.doi.org/10.1074/jbc.274.20.14210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318840	hybrid			2022-12-25	WOS:000080322200069
J	Liu, XS; Zou, H; Widlak, P; Garrard, W; Wang, XD				Liu, XS; Zou, H; Widlak, P; Garrard, W; Wang, XD			Activation of the apoptotic endonuclease DFF40 (caspase-activated DNase or nuclease) - Oligomerization and direct interaction with histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN CONDENSATION; FRAGMENTATION; INHIBITOR; SPECIFICITIES; PROTEASES; CLEAVAGE; FAMILY	DNA fragmentation factor (DFF) is a heterodimeric protein composed of 45-kDa (DFF45) and 40-kDa (DFF40) subunits, a protein that mediates regulated DNA fragmentation and chromatin condensation in response to apoptotic signals. DFF45 is a specific molecular chaperone and an inhibitor for the nuclease activity of DFF40. Previous studies have shown that upon cleavage of DFF45 by caspase-3, the nuclease activity of DFF40 is relieved of inhibition. Here we further investigate the mechanism of DFF40 activation. We demonstrate that DFF45 can also be cleaved and inactivated by caspase-7 but not by caspase-6 and caspase-8. The cleaved DFF45 fragments dissociate from DFF40, allowing DFF40 to oligomerize to form a large functional complex that cleaves DNA by introducing double strand breaks. Histone H1 directly interacts with DFF, confers DNA binding ability to DFF, and stimulates the nuclease activity of DFF40 by increasing its K-cat, and decreasing its K-m.	Univ Texas, SW Med Ctr, Dept Biochem, HHMI, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, HHMI, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Widlak, Piotr/AAL-8075-2021	Widlak, Piotr/0000-0001-5099-4726; Wang, Xiaodong/0000-0001-9885-356X	NIGMS NIH HHS [GMRO1-29935, GMRO1-55942, GMRO1-51585] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029935, R01GM051585] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CAMPBELL VW, 1980, J BIOL CHEM, V255, P3726; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KUNITZ M, 1950, J GEN PHYSIOL, V33, P349, DOI 10.1085/jgp.33.4.349; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Toh SY, 1998, BIOCHEM BIOPH RES CO, V250, P598, DOI 10.1006/bbrc.1998.9369; VANHOLDE KE, 1989, CHROMATIN, P198; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	18	156	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13836	13840		10.1074/jbc.274.20.13836	http://dx.doi.org/10.1074/jbc.274.20.13836			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318789	hybrid			2022-12-25	WOS:000080322200018
J	Mziaut, H; Korza, G; Hand, AR; Gerard, C; Ozols, J				Mziaut, H; Korza, G; Hand, AR; Gerard, C; Ozols, J			Targeting proteins to the lumen of endoplasmic reticulum using N-terminal domains of 11 beta-hydroxysteroid dehydrogenase and the 50-kDa esterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GREEN FLUORESCENT PROTEIN; NADH-CYTOCHROME-B5 REDUCTASE; MEMBRANE-PROTEINS; HEMAGGLUTININ-NEURAMINIDASE; INTRACELLULAR-TRANSPORT; MICROSOMAL MEMBRANE; GOLGI LOCALIZATION; COVALENT STRUCTURE; SIMIAN VIRUS-5	Previous studies identified two intrinsic endoplasmic reticulum (EB) proteins, 11 beta-hydroxysteroid dehydrogenase, isozyme 1 (11 beta-HSD) and the 50-kDa esterase (E3), sharing some amino acid sequence motifs in their N-terminal transmembrane (TM) domains. Both are type II membrane proteins with the C terminus projecting into the lumen of the ER, This finding implied that the N-terminal TM domains of 11 beta-HSD and E3 may constitute a lumenal targeting signal (LTS). To investigate this hypothesis we created chimeric fusions using the putative targeting sequences and the reporter gene, Aequorea victoria green fluorescent protein, Transfected COS cells expressing LTS-green fluorescent protein chimeras were examined by fluorescent microscopy and electron microscopic immunogold labeling The orientation of expressed chimeras was established by immunocytofluorescent staining of selectively permeabilized COS cells. In addition, protease protection assays of membranes in the presence and absence of detergents was used to confirm lumenal or the cytosolic orientation of the constructed chimeras. To investigate the general applicability of the proposed LTS, we fused the N terminus of E3 to the N terminus of the NADH-cytochrome b5 reductase lacking the myristoyl group and N-terminal 30-residue membrane anchor. The orientation of the cytochrome b5 reductase was reversed, from cytosolic to lumenal projection of the active domain. These observations establish that an amino acid sequence consisting of short basic or neutral residues at the N terminus, followed by a specific array of hydrophobic residues terminating with acidic residues, is sufficient for lumenal targeting of single-pass proteins that are structurally and functionally unrelated.	Univ Connecticut, Ctr Hlth, Sch Med, Dept Electron Microscopy, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Sch Med, Dept Biochem, Farmington, CT 06030 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA	University of Connecticut; University of Connecticut; Harvard University; Boston Children's Hospital; Harvard Medical School	Ozols, J (corresponding author), Univ Connecticut, Ctr Hlth, Sch Med, Dept Biochem, Farmington, CT 06030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026351] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-26351] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Hand Arthur R., 1995, P205, DOI 10.1016/B978-012286230-4/50006-7; Haynes RL, 1997, J BIOL CHEM, V272, P17126, DOI 10.1074/jbc.272.27.17126; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; HEIN WR, 1993, EMBO J, V12, P715, DOI 10.1002/j.1460-2075.1993.tb05705.x; HEINEMANN FS, 1982, J BIOL CHEM, V257, P4988; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; HEINEMANN FS, 1984, J BIOL CHEM, V259, P797; HIEBERT SW, 1985, J VIROL, V54, P1; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KUMAR V, 1994, J BIOL CHEM, V269, P13451; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MORI M, 1981, P NATL ACAD SCI-BIOL, V78, P6056, DOI 10.1073/pnas.78.10.6056; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; OTTO JC, 1994, J BIOL CHEM, V269, P19868; OZOLS J, 1986, J BIOL CHEM, V261, P3965; Ozols J, 1998, BIOCHEMISTRY-US, V37, P10336, DOI 10.1021/bi9807916; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302; OZOLS J, 1985, J BIOL CHEM, V260, P5427; OZOLS J, 1977, P NATL ACAD SCI USA, V74, P3725, DOI 10.1073/pnas.74.9.3725; OZOLS J, 1994, BIOCHEMISTRY-US, V33, P3751, DOI 10.1021/bi00178a035; OZOLS J, 1989, J BIOL CHEM, V264, P12533; OZOLS J, 1985, J BIOL CHEM, V260, P1953; OZOLS J, 1984, J BIOL CHEM, V259, P3349; Parks GD, 1996, J BIOL CHEM, V271, P7187, DOI 10.1074/jbc.271.12.7187; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Scheel AA, 1996, BIOCHEMISTRY-US, V35, P10203, DOI 10.1021/bi960807x; SCHULZ I, 1990, METHOD ENZYMOL, V192, P280; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STRITTMATTER P, 1992, J BIOL CHEM, V267, P2519; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459	45	33	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14122	14129		10.1074/jbc.274.20.14122	http://dx.doi.org/10.1074/jbc.274.20.14122			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318829	hybrid			2022-12-25	WOS:000080322200058
J	Santamaria, I; Velasco, G; Pendas, AM; Paz, A; Lopez-Otin, C				Santamaria, I; Velasco, G; Pendas, AM; Paz, A; Lopez-Otin, C			Molecular cloning and structural and functional characterization of human cathepsin F, a new cysteine proteinase of the papain family with a long propeptide domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; HUMAN BLEOMYCIN HYDROLASE; CHROMOSOMAL LOCALIZATION; PROCATHEPSIN-L; GENE CHARACTERIZATION; EXPRESSION ANALYSIS; TISSUE DISTRIBUTION; GENOMIC STRUCTURE; PROTEASES; BREAST	A cDNA encoding a new cysteine proteinase belonging to the papain family and called cathepsin F has been cloned from a human prostate cDNA library. This cDNA encodes a polypeptide of 484 amino acids, with the same domain organization as other cysteine proteinases, in; eluding a hydrophobic signal sequence, a prodomain, and a catalytic region. However, this propeptide domain is unusually long and distinguishes cathepsin F from other proteinases of the papain family. Cathepsin F also shows all structural motifs characteristic of these proteinases, including the essential cysteine residue of the active site. Consistent with these structural features, cathepsin F produced in Escherichia coli as a fusion protein with glutathione S-transferase degrades the synthetic peptide benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin, a substrate commonly used for functional characterization of cysteine proteinases, Furthermore, this proteolytic activity is blocked by transepoxysuccinyl-L-leucylamido-(4-guanidino an inhibitor of cysteine proteinases. The gene encoding cathepsin F maps to chromosome 11q13, close to that encoding cathepsin W, Cathepsin F is widely expressed in human tissues, suggesting a role in normal protein catabolism. Northern blot analysis also revealed a significant level of expression in some cancer cell lines opening the possibility that this enzyme could be involved in degradative processes occurring during tumor progression.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.		Pendas, Alberto M/L-1017-2014; Velasco, Gloria/AAS-5842-2021; Santamaria, Inigo/H-6727-2015; López-Otín, Carlos/AAB-2106-2020	Velasco, Gloria/0000-0001-8032-5056; Santamaria, Inigo/0000-0001-8718-5359; López-Otín, Carlos/0000-0001-6964-1904; Paz-Aparicio, Ana/0000-0001-5112-7333; Pendas, Alberto M/0000-0001-9264-3721				BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; CHAUHAN SS, 1991, CANCER RES, V51, P1478; Chuaqui RF, 1997, AM J PATHOL, V150, P297; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Ferrando AA, 1997, J BIOL CHEM, V272, P33298, DOI 10.1074/jbc.272.52.33298; Ferrando AA, 1996, CANCER RES, V56, P1746; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; HESITERKAMP N, 1982, NATURE, V299, P747; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KIMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P454, DOI 10.1073/pnas.78.1.454; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KUHNER MK, 1994, MOL BIOL EVOL, V11, P459; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; Maniatis T., 1982, MOL CLONING LAB MANU; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MASON RW, 1985, BIOCHEM J, V226, P233, DOI 10.1042/bj2260233; Mathur PP, 1997, BIOCHEM MOL BIOL INT, V42, P217; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; Newsham IF, 1998, AM J PATHOL, V153, P5, DOI 10.1016/S0002-9440(10)65538-1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; PENDAS AM, 1994, CYTOGENET CELL GENET, V66, P263, DOI 10.1159/000133708; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; Rao NV, 1997, J BIOL CHEM, V272, P10260; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; Rood JA, 1997, GENOMICS, V41, P169, DOI 10.1006/geno.1997.4614; Santamaria I, 1998, CANCER RES, V58, P1624; Santamaria I, 1998, J BIOL CHEM, V273, P16816, DOI 10.1074/jbc.273.27.16816; Santamaria I, 1998, GENOMICS, V53, P231, DOI 10.1006/geno.1997.5180; SHI GP, 1992, J BIOL CHEM, V267, P7258; SHI GP, 1994, J BIOL CHEM, V269, P11530; Sloane B F, 1990, Semin Cancer Biol, V1, P137; TAKEDA A, 1992, BIOCHEM J, V288, P643, DOI 10.1042/bj2880643; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; Tsujinaka T, 1996, J CLIN INVEST, V97, P244, DOI 10.1172/JCI118398; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000; WANG X, 1987, CYTOGENET CELL GENET, V46, P710; Wex T, 1998, BIOCHEM BIOPH RES CO, V248, P255, DOI 10.1006/bbrc.1998.8954; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708	65	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13800	13809		10.1074/jbc.274.20.13800	http://dx.doi.org/10.1074/jbc.274.20.13800			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318784	hybrid			2022-12-25	WOS:000080322200013
J	Zhao, LY; Helms, JB; Brunner, J; Wieland, FT				Zhao, LY; Helms, JB; Brunner, J; Wieland, FT			GTP-dependent binding of ADP-ribosylation factor to coatomer in close proximity to the binding site for dilysine retrieval motifs and p23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MEMBRANES; GUANINE-NUCLEOTIDE; TRANSPORT VESICLES; EXCHANGE FACTOR; BREFELDIN-A; SECRETORY PATHWAY; COATED VESICLES; PROTEIN COMPLEX; PHOSPHOLIPASE-D; ARF PROTEIN	A site-directed photocross-linking approach was employed to determine components that act downstream of ADP-ribosylation factor (ARF). To this end, a photolabile phenylalanine analog was incorporated at various positions of the putative effector region of the ARF molecule. Depending on the position of incorporation, we find specific and GTP-dependent interactions of ARF with two subunits of the coatomer complex, beta-COP and gamma-COP, as well as an interaction with a cytosolic protein (similar to 185 kDa). In addition, we observe homodimer formation of ARF molecules at the Golgi membrane. These data suggest that the binding site of ARF to coatomer is at the interface of its beta- and gamma-subunits, and this is in close proximity to the second site of interaction of coatomer with the Golgi membrane, the binding site within gamma-COP for cytosolic dibasic/diphenylalanine motifs.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; Swiss Fed Inst Technol, Biochem Lab, CH-8092 Zurich, Switzerland	Ruprecht Karls University Heidelberg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Helms, JB (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	helms@urz.uni-heidelberg.de						AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BECKERS CJM, 1992, METHOD ENZYMOL, V219, P5; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNNER J, 1993, CHEM SOC REV, V22, P183, DOI 10.1039/cs9932200183; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; HARTER C, 1993, FEBS LETT, V332, P71, DOI 10.1016/0014-5793(93)80487-F; Harter C, 1996, BBA-REV BIOMEMBRANES, V1286, P75, DOI 10.1016/0304-4157(96)00003-2; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; Reinhard C, 1999, P NATL ACAD SCI USA, V96, P1224, DOI 10.1073/pnas.96.4.1224; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	52	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14198	14203		10.1074/jbc.274.20.14198	http://dx.doi.org/10.1074/jbc.274.20.14198			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318838	hybrid			2022-12-25	WOS:000080322200067
J	Cox, GA; Johnson, RB; Cook, JA; Wakulchik, M; Johnson, MG; Villarreal, EC; Wang, QM				Cox, GA; Johnson, RB; Cook, JA; Wakulchik, M; Johnson, MG; Villarreal, EC; Wang, QM			Identification and characterization of human rhinovirus-14 3C protease deamidation isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; VIRUS-REPLICATION; RNA-BINDING; POLIOVIRUS; INHIBITION; TRANSCRIPTION; POLYPROTEIN; CLEAVAGE; PROTEINS; 3C(PRO)	A purified recombinant human rhinovirus-14 3C protease preparation contained only similar to 50% active enzyme as titrated using specifically designed irreversible 3C protease inhibitors. Analysis of the purified 3C protein by isoelectric focusing showed differently charged 3C isoforms that had isoelectric points (pI) of 8.3 (55%) and 9.0 (45%), with the latter one being consistent with the predicted pi of the human rhinovirus-14 3C protein. Further analysis indicated that the pi 8.3 protein was the deamidated form of 3C, and it displayed similar to 10-fold reduced cleavage activity relative to the original 3C protease sample. Peptide mapping followed by sequence analysis revealed that a single asparagine, Asn-164, was deamidated to aspartic acid in the pi 8.3 isoform, Converting Asn-164 to Asp by site-directed mutagenesis resulted in a mutated 3C protease with extremely low activity, as seen with the pi 8.3 isoform, indicating a role of Asn-164 in substrate recognition and binding, In addition, the deamidated 3C protease was found to be present in vivo, and its abundance was related to the viral replication cycle, Moreover, mutant virus carrying Asp-164 showed reduced viability in infected cells. Taken together, our data suggest that 3C protein deamidation plays a role in the regulation of its enzymatic activity.	Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Villarreal, EC (corresponding author), Eli Lilly & Co, Lilly Res Labs, Drop Code 0438, Indianapolis, IN 46285 USA.							BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BECKER GW, 1988, BIOTECHNOL APPL BIOC, V10, P326; BIRCH GM, 1995, PROTEIN EXPRES PURIF, V6, P609, DOI 10.1006/prep.1995.1080; CLARK ME, 1991, EMBO J, V10, P2941, DOI 10.1002/j.1460-2075.1991.tb07844.x; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; Couch RB, 1996, VIROLOGY, P713; DIDONATO A, 1993, J BIOL CHEM, V268, P4745; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; HEINZ BA, 1995, J VIROL, V69, P4189, DOI 10.1128/JVI.69.7.4189-4197.1995; Higuchi R., 1989, PCR TECHNOLOGY, P61; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; Kong JS, 1998, J MED CHEM, V41, P2579, DOI 10.1021/jm980114+; LEONG LEC, 1993, J BIOL CHEM, V268, P25735; MALCOLM BA, 1995, PROTEIN SCI, V4, P1439, DOI 10.1002/pro.5560040801; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; ORR DC, 1989, J GEN VIROL, V70, P2931, DOI 10.1099/0022-1317-70-11-2931; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PORTER AG, 1993, J VIROL, V67, P6917, DOI 10.1128/JVI.67.12.6917-6921.1993; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SELVESEN G, 1993, PROTEOLYTIC ENZYMES, P83; Wang QM, 1998, EXPERT OPIN THER PAT, V8, P1151, DOI 10.1517/13543776.8.9.1151; Wang QM, 1997, ANAL BIOCHEM, V252, P238, DOI 10.1006/abio.1997.2315; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; Yalamanchili P, 1997, J VIROL, V71, P1220, DOI 10.1128/JVI.71.2.1220-1226.1997	24	7	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13211	13216		10.1074/jbc.274.19.13211	http://dx.doi.org/10.1074/jbc.274.19.13211			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224078	hybrid			2022-12-25	WOS:000080200400040
J	Gibson, MA; Leavesley, DI; Ashman, LK				Gibson, MA; Leavesley, DI; Ashman, LK			Microfibril-associated glycoprotein-2 specifically interacts with a range of bovine and human cell types via alpha(v)beta(3) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; FIBRILLIN-CONTAINING MICROFIBRILS; MOLECULAR-CLONING; EXTRACELLULAR MICROFIBRILS; DEVELOPMENTAL EXPRESSION; VITRONECTIN RECEPTOR; PROTEIN-COMPONENTS; FIBER MICROFIBRILS; B-CELL; ADHESION	Microfibril-associated glycoprotein (MAGP)-1 and MAGP-2 are small structurally related glycoproteins that are specifically associated with fibrillin-containing microfibrils, MAGP-2, unlike MAGP-1, contains an RGD motif with potential for integrin binding. To determine if the RGD sequence is active, a series of cell binding assays was performed. MAGP-2 was shown to promote the attachment and spreading of bovine nuchal ligament fibroblasts when coated onto plastic wells in molar quantities similar to those of fibronectin, In contrast, similar to 10-fold more MAGP-1 was required to support comparable levels of cell adhesion. The fibroblast binding to MAGP-2 was completely inhibited if the peptide GRGDSP or the MAGP-2-specific peptide GVSGQRGDDVTTVTSET was added to the reaction medium at a 10 mu M final concentration. The control peptide GRGESP had no effect on the interaction. These findings indicate that the cell interaction with MAGP-2 is an RGD-mediated event. A monoclonal antibody to human alpha(V)beta(3) integrin (LM609) almost completely blocked cell attachment to MAGP-2 when added to the medium at 0.5 mu g/ml, whereas two monoclonal antibodies specific for the human beta(1) integrin subunit, 4B4 (blocking) and QE2.E5 (activating), had no effect even at 10 mu g/ml. Fetal bovine aortic smooth muscle cells, ear cartilage chondrocytes, and arterial endothelial cells and human skin fibroblasts and osteoblasts were also observed to adhere strongly to MAGP-2. In addition, each cell type was able to spread on MAGP-2 substrate, with the exception of the endothelial cells, which remained spherical after 2 h of incubation. The binding of each cell type was blocked when the anti-alpha(V)beta(3) integrin antibody was included in the assay, indicating that alpha(V)beta(3) integrin is the major receptor for MAGP-2 on several cell types. Thus, MAGP-2 may mediate interactions between fibrillin-containing microfibrils and cell surfaces during the development of a variety of tissues.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Royal Adelaide Hosp, Renal Unit, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	University of Adelaide; Royal Adelaide Hospital; Institute Medical & Veterinary Science Australia	Gibson, MA (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA 5005, Australia.		ASHMAN, LEONIE/G-7631-2013; Leavesley, David/C-9532-2009	ASHMAN, LEONIE/0000-0003-3559-3611; Leavesley, David/0000-0002-1033-5459				ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BRIZZI MF, 1990, BRIT J HAEMATOL, V76, P203, DOI 10.1111/j.1365-2141.1990.tb07872.x; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; Cleary E. G., 1996, EXTRACELLULAR MATRIX, V2, P95; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; D'Arrigo C, 1998, CONNECT TISSUE RES, V37, P29, DOI 10.3109/03008209809028898; DAVIS LS, 1990, J IMMUNOL, V145, P785; DIETZ HC, 1994, ADV HUM GENET, V22, P153; Faull RJ, 1996, J BIOL CHEM, V271, P25099, DOI 10.1074/jbc.271.41.25099; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; Gibson MA, 1998, EUR J BIOCHEM, V256, P221, DOI 10.1046/j.1432-1327.1998.2560221.x; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOSHI P, 1993, J CELL SCI, V106, P389; Karonen T, 1997, BRIT J DERMATOL, V137, P51, DOI 10.1046/j.1365-2133.1997.17671859.x; KIELTY CM, 1995, INT J BIOCHEM CELL B, V27, P747, DOI 10.1016/1357-2725(95)00028-N; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805; MARIENCHECK MC, 1995, CONNECT TISSUE RES, V31, P87, DOI 10.3109/03008209509028396; MECHAM RP, 1988, BIOCHEM BIOPH RES CO, V151, P822, DOI 10.1016/S0006-291X(88)80355-3; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MINOWADA J, 1977, CANCER RES, V37, P3096; MIYOSHI I, 1977, NATURE, V267, P843, DOI 10.1038/267843a0; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; Pfaff M, 1996, FEBS LETT, V384, P247, DOI 10.1016/0014-5793(96)00325-0; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; RUBIN K, 1996, EXTRACELLULAR MATRIX, V2, P262; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAITO T, 1994, J ORTHOP RES, V12, P384, DOI 10.1002/jor.1100120311; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; WALL RT, 1978, J CELL PHYSIOL, V96, P203, DOI 10.1002/jcp.1040960209; YEH H, 1994, GENOMICS, V23, P443, DOI 10.1006/geno.1994.1521; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHAO Z, 1995, HUM MOL GENET, V4, P58	56	57	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13060	13065		10.1074/jbc.274.19.13060	http://dx.doi.org/10.1074/jbc.274.19.13060			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224057	hybrid			2022-12-25	WOS:000080200400019
J	Kennedy, HJ; Pouli, AE; Ainscow, EK; Jouaville, LS; Rizzuto, R; Rutter, GA				Kennedy, HJ; Pouli, AE; Ainscow, EK; Jouaville, LS; Rizzuto, R; Rutter, GA			Glucose generates sub-plasma membrane ATP microdomains in single islet beta-cells - Potential role for strategically located mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETING CELLS; GLYCEROL-PHOSPHATE DEHYDROGENASE; GREEN FLUORESCENT PROTEIN; MOUSE PANCREATIC-ISLETS; RAT-HEART MITOCHONDRIA; SENSITIVE K+ CHANNELS; FIREFLY LUCIFERASE; ADENINE-NUCLEOTIDES; INTACT-CELLS; LACTATE-DEHYDROGENASE	Increases in the concentration of free ATP within the islet beta-cell may couple elevations in blood glucose to insulin release by closing ATP sensitive K+ (K-ATP) channels and activating Ca2+ influx. Here, we use recombinant targeted luciferases and photon counting imaging to monitor changes in free [ATP] in subdomains of single living MING and primary beta-cells. Resting [ATP] in the cytosol ([ATP](c)), in the mitochondrial matrix ([ATP](m)), and beneath the plasma membrane ([ATP](pm)) were similar (similar to 1 mM). Elevations in extracellular glucose concentration (3-30 mM) increased free [ATP] in each domain with distinct kinetics. Thus, sustained increases in [ATP](m) and [ATP](pm) were observed, but only a transient increase in [ATP](c). However, detectable increases in [ATP](c) and [ATP](pm), but not [ATP](m), required extracellular Ca2+. Enhancement of glucose-induced Ca2+ influx with high [K+] had little effect on the apparent [ATP](c) and [ATP](m) increases but augmented the [ATP](pm) increase. Underlying these changes, glucose increased the mitochondrial proton motive force, an effect mimicked by high [K+]. These data support a model in which glucose increases [ATP](m) both through enhanced substrate supply and by progressive Ca2+ dependent activation of mitochondrial enzymes. This may then lead to a privileged elevation of [ATP](pm), which may be essential for the sustained closure of K-ATP channels. Luciferase imaging would appear to be a useful new tool for dynamic in vivo imaging of free ATP concentration.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Padua, Dept Biomed Sci, I-35121 Padua 17, Italy; Univ Padua, CNR, Ctr Study Biol Membranes, I-35121 Padua 17, Italy	University of Bristol; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Rutter, GA (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.		Rizzuto, Rosario/B-6312-2008	Rutter, Guy/0000-0001-6360-0343; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [850] Funding Source: Medline	Telethon(Fondazione Telethon)		ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BOWERS KC, 1992, J MOL CELL CARDIOL, V24, P213, DOI 10.1016/0022-2828(92)93159-H; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; Civelek VN, 1996, BIOCHEM J, V315, P1015, DOI 10.1042/bj3151015; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CRAIG FF, 1991, BIOCHEM J, V276, P637, DOI 10.1042/bj2760637; DELUCA M, 1979, ANAL BIOCHEM, V95, P194, DOI 10.1016/0003-2697(79)90204-5; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; Detimary P, 1996, ENDOCRINOLOGY, V137, P4671, DOI 10.1210/en.137.11.4671; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; Detimary P, 1998, BIOCHEM J, V333, P269, DOI 10.1042/bj3330269; FORD SR, 1995, BBA-PROTEIN STRUCT M, V1252, P180, DOI 10.1016/0167-4838(95)00150-S; Gribble FM, 1998, DIABETOLOGIA, V41, pA13; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HALESTRAP AP, 1982, BIOCHEM J, V204, P37, DOI 10.1042/bj2040037; HESS DT, 1992, J NEUROSCI, V12, P4634; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; KENNEDY HJ, 1997, DIABETIC MED, V14, pS8; KLINGENBERG M, 1979, TRENDS BIOCHEM SCI, V4, P249, DOI 10.1016/0968-0004(79)90215-9; KOOP A, 1993, BIOCHEM J, V295, P165, DOI 10.1042/bj2950165; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; LANG DA, 1981, DIABETES, V30, P435, DOI 10.2337/diabetes.30.5.435; LEMASTERS JJ, 1977, BIOCHEMISTRY-US, V16, P445, DOI 10.1021/bi00622a016; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MEGLASSON MD, 1989, METABOLISM, V38, P1188, DOI 10.1016/0026-0495(89)90158-3; MEGLASSON MD, 1989, AM J PHYSIOL, V256, pE173, DOI 10.1152/ajpendo.1989.256.1.E173; Nakazaki M, 1998, DIABETOLOGIA, V41, P279, DOI 10.1007/s001250050904; Nicholls D.G., 1982, BIOENERGETICS INTRO; OHTA M, 1993, J PHARMACOL EXP THER, V264, P35; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PANTEN U, 1982, ENDOCRINOLOGY, V111, P1595, DOI 10.1210/endo-111-5-1595; Panten U., 1988, ENERGETICS SECRETION, P109; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PIPELEERS D, 1994, DIABETOLOGIA, V37, pS57, DOI 10.1007/BF00400827; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; Pouli AE, 1998, BIOCHEM J, V330, P1399; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, BBA-BIOENERGETICS, V1366, P17, DOI 10.1016/S0005-2728(98)00118-2; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; RUTTER GA, 1990, INT J BIOCHEM, V22, P1081, DOI 10.1016/0020-711X(90)90105-C; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; RUTTER GA, 1999, IMAGING LIVING CELLS, P286; SCHOLZ TD, 1995, AM J PHYSIOL-HEART C, V268, pH82, DOI 10.1152/ajpheart.1995.268.1.H82; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SENER A, 1992, J BIOL CHEM, V267, P13251; Sherf BA, 1994, PROMEGA NOTES, V49, P14; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; Szewczyk A, 1998, BBA-BIOENERGETICS, V1365, P333, DOI 10.1016/S0005-2728(98)00094-2; Tagaya M, 1996, FEBS LETT, V394, P83, DOI 10.1016/0014-5793(96)00932-5; Wang X, 1996, AM J PHYSIOL-HEART C, V270, pH476, DOI 10.1152/ajpheart.1996.270.2.H476; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WOODWARD RH, 1972, STAT METHODS RES PRO, P178; Zhao C, 1998, FEBS LETT, V430, P213, DOI 10.1016/S0014-5793(98)00600-0	84	265	269	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13281	13291		10.1074/jbc.274.19.13281	http://dx.doi.org/10.1074/jbc.274.19.13281			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224088	hybrid			2022-12-25	WOS:000080200400050
J	Qiu, DM; Zhao, GH; Aoki, Y; Shi, LF; Uyei, A; Nazarian, S; Ng, JCH; Kao, PN				Qiu, DM; Zhao, GH; Aoki, Y; Shi, LF; Uyei, A; Nazarian, S; Ng, JCH; Kao, PN			Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappa B transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE HERBAL REMEDY; TUMOR-NECROSIS-FACTOR; WILFORDII HOOK-F; TRIPTERYGIUM-WILFORDII; GENE-EXPRESSION; NUCLEAR FACTOR; IMMUNE-SYSTEM; P65 SUBUNIT; DNA-BINDING; LYMPHOCYTE	PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes stimulated with phorbol 12-myristate 13-acetate (PMA) and antibody to CD3 (IC50 of 10 ng/ml), and with PMA and ionomycin (Iono, IC50 of 40 ng/ml). In Jurkat T-cells, PG490 inhibits PMA/Iono-stimulated IL-2 transcription. PG490 inhibits the induction of DNA binding activity at the purine-box/antigen receptor response element (ARRE)/nuclear factor of activated T-cells (NF-AT) target sequence but not at the NF-kappa B site. PG490 can completely inhibit transcriptional activation at the purine-box/ARRE/NF-AT and NF-kappa B target DNA sequences triggered by all stimuli examined (PMA, PMA/Iono, tumor necrosis factor-alpha). PG490 also inhibits PMA-stimulated activation of a chimeric transcription factor in which the C-terminal TA1 transactivation domain of NF-kappa B p65 is fused to the DNA binding domain of GAL4. In 16HBE human bronchial epithelial cells, IL-8 expression is regulated predominantly by NF-kappa B, and PG490 but not cyclosporin A can completely inhibit expression of IL-8. The mechanism of PG490 inhibition of cytokine gene expression differs from cyclosporin A and involves nuclear inhibition of transcriptional activation of NF-kappa B and the purine-box regulator operating at the ARRE/NF-AT site at a step after specific DNA binding.	Stanford Univ, Med Ctr, Stanford, CA 94305 USA	Stanford University	Kao, PN (corresponding author), Stanford Univ, Med Ctr, Stanford, CA 94305 USA.				NIAID NIH HHS [R01-AI39624] Funding Source: Medline; PHS HHS [K04-01147] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039624] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Aoki Y, 1997, BIOCHEM BIOPH RES CO, V234, P424, DOI 10.1006/bbrc.1997.6658; AOKI Y, 1997, AM J PHYSIOL, V272, pL272; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAO PN, 1994, J BIOL CHEM, V269, P20691; Kincaid RL, 1995, J ALLERGY CLIN IMMUN, V96, P1170, DOI 10.1016/S0091-6749(95)70202-4; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; KUPCHAN SM, 1974, SCIENCE, V185, P791, DOI 10.1126/science.185.4153.791; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; SCHMITZ ML, 1995, IMMUNOBIOLOGY, V193, P116, DOI 10.1016/S0171-2985(11)80534-6; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; Shamon LA, 1997, CANCER LETT, V112, P113, DOI 10.1016/S0304-3835(96)04554-5; TAO XL, 1989, CHINESE MED J-PEKING, V102, P327; TAO XL, 1995, J PHARMACOL EXP THER, V272, P1305; Tao XL, 1996, J PHARMACOL EXP THER, V276, P316; TAO XL, 1991, ARTHRITIS RHEUM, V34, P1274, DOI 10.1002/art.1780341011; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WEI YS, 1991, ACTA PHARM SINIC, V12, P406; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YANG SX, 1994, INT J IMMUNOPHARMACO, V16, P895, DOI 10.1016/0192-0561(94)90044-2; Yang YL, 1998, IMMUNOPHARMACOLOGY, V40, P139, DOI 10.1016/S0162-3109(98)00036-8; ZHENG JR, 1987, CHUNG KUO I HSUEH KO, V9, P317; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	46	247	277	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13443	13450		10.1074/jbc.274.19.13443	http://dx.doi.org/10.1074/jbc.274.19.13443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224109	hybrid			2022-12-25	WOS:000080200400071
J	Ramos-DeSimone, N; Hahn-Dantona, E; Sipley, J; Nagase, H; French, DL; Quigley, JP				Ramos-DeSimone, N; Hahn-Dantona, E; Sipley, J; Nagase, H; French, DL; Quigley, JP			Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; EXTRACELLULAR-MATRIX; PROGELATINASE-B; GELATINASE-B; 4-AMINOPHENYLMERCURIC ACETATE; 92-KDA GELATINASE; TERMINAL DOMAIN; PLASMIN SYSTEM	Matrix metalloproteinase-g (MMP-9) may play a critical catalytic role in tissue remodeling in vivo, but it is secreted by cells as a stable, inactive zymogen, pro MMP-9, and requires activation for catalytic function. A number of proteolytic enzymes activate pro-MIMP-9 in vitro, but the natural activator(s) of MMP-9 is unknown. To examine MMP-9 activation in a cellular setting we employed cultures of human tumor cells (MDA-MB-231 breast carcinoma cells) that were induced to produce MMP-9 over a 200-fold concentration range (0.03-8.1 nM). The levels of tissue inhibitors of metalloproteinase (TIMPs) in the induced cultures remain relatively constant at 1-4 nM. Quantitation of the zymogen/active enzyme status of MMP-9 in the MDA-MB-231 cultures indicates that even in the presence of potential activators, the molar ratio of endogenous MMP-9 to TIMP dictates whether pro-MMP-9 activation can progress. When the MMP-9/TIMP ratio exceeds 1.0, MMP-9 activation progresses, but through an interacting protease cascade involving plasmin and stromelysin 1 (MMP-3). Plasmin, generated by the endogenous urokinase-type plasminogen activator, is not an efficient activator of pro-MMP-9, neither the secreted pro-MMP-9 nor the very low levels of pro-MMP-9 associated with intact cells. Although plasmin can proteolytically process pro-MMP-9, this limited action does not yield an enzymatically active MMP-9, nor does it cause the MMP-9 to be more susceptible to activation. Plasmin, however, is very efficient at generating active MMP-3 (stromelysin-l) from exogenously added pro-MMP-3. The activated MMP-3 becomes a potent activator of the 92-kDa pro-MMP-9, yielding an 82-kDa species that is enzymatically active in solution and represents up to 50-75% conversion of the zymogen, The activated MMP-9 enhances the invasive phenotype of the cultured cells as their ability to both degrade extracellular matrix and transverse basement membrane is significantly increased following zymogen activation. That this enhanced tissue remodelling capability is due to the activation of MMP-9 is demonstrated through the use of a specific anti-MMP-9 blocking monoclonal antibody.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Icahn School of Medicine at Mount Sinai; University of Kansas; University of Kansas Medical Center	Quigley, JP (corresponding author), Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA055852, R01CA076039] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA76039, R01CA55852] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahrens D, 1996, ARTHRITIS RHEUM, V39, P1576, DOI 10.1002/art.1780390919; AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Aimes RT, 1998, J CELL PHYSIOL, V174, P342, DOI 10.1002/(SICI)1097-4652(199803)174:3<342::AID-JCP8>3.3.CO;2-K; Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN PD, 1990, CANCER RES, V50, P6184; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; DESRIVIERES S, 1993, J CELL PHYSIOL, V157, P587, DOI 10.1002/jcp.1041570319; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; FRIDMAN R, 1995, CANCER RES, V55, P2548; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; Heppner KJ, 1996, AM J PATHOL, V149, P273; Hewitt R, 1996, ENZYME PROTEIN, V49, P163, DOI 10.1159/000468623; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Hua J, 1996, CANCER RES, V56, P5279; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Knauper V, 1997, EUR J BIOCHEM, V248, P369, DOI 10.1111/j.1432-1033.1997.00369.x; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; Lijnen HR, 1998, BLOOD, V91, P2045, DOI 10.1182/blood.V91.6.2045.2045_2045_2053; LOWELL S, 1998, BIOCHEM J, V331, P453; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOLL UM, 1990, CANCER RES, V50, P6162; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; MOOKHTIAR KA, 1986, ANAL BIOCHEM, V158, P322, DOI 10.1016/0003-2697(86)90557-9; NAGASE H, 1994, J BIOL CHEM, V269, P20952; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; Nguyen M, 1998, J BIOL CHEM, V273, P5400, DOI 10.1074/jbc.273.9.5400; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1995, LAB INVEST, V72, P311; Partridge CA, 1997, AM J PHYSIOL-LUNG C, V272, pL813, DOI 10.1152/ajplung.1997.272.5.L813; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; Sipley JD, 1997, P NATL ACAD SCI USA, V94, P2933, DOI 10.1073/pnas.94.7.2933; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; Toth M, 1997, CANCER RES, V57, P3159; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; von Bredow DC, 1998, BIOCHEM J, V331, P965, DOI 10.1042/bj3310965; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WISEN JF, 1996, ENZYME PROTEIN, V49, P174; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	63	477	497	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13066	13076		10.1074/jbc.274.19.13066	http://dx.doi.org/10.1074/jbc.274.19.13066			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224058	hybrid			2022-12-25	WOS:000080200400020
J	Richardson, M; Robishaw, JD				Richardson, M; Robishaw, JD			The alpha(2A)-adrenergic receptor discriminates between G(i) heterotrimers of different beta gamma subunit composition in Sf9 insect cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A(1) ADENOSINE RECEPTORS; RECOMBINANT G-PROTEINS; RHODOPSIN; RECONSTITUTION; PURIFICATION; SPECIFICITY; INHIBITION; PHOSPHORYLATION; PRENYLATION; EXPRESSION	In view of the expanding roles of the beta gamma subunits of the G proteins in signaling, the possibility was raised that the rich diversity of beta gamma subunit combinations might contribute to the specificity of signaling at the level of the receptor. To test this possibility, Sf9 cell membranes expressing the recombinant alpha(2A)-adrenergic receptor were used to assess the contribution of the beta gamma subunit composition. Reconstituted coupling between the receptor and heterotrimeric G(i) protein was assayed by high affinity, guanine nucleotide-sensitive binding of the alpha(2)-adrenergic agonist, [H-3]UK-14,304. Supporting this hypothesis, the present study showed clear differences in the abilities of the various beta gamma dimers, including those containing the beta(3) subtype and the newly described gamma(4), gamma(10), and gamma(11) subtypes, to promote interaction of the same alpha(i) subunit with the alpha(2A)-adrenergic receptor.	Penn State Univ, Coll Med, Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Robishaw, JD (corresponding author), Penn State Univ, Coll Med, Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA.				NIGMS NIH HHS [GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039867, R29GM039867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; Figler RA, 1997, BIOCHEMISTRY-US, V36, P16288, DOI 10.1021/bi972000q; Figler RA, 1996, MOL PHARMACOL, V50, P1587; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JANSSON CC, 1995, EUR J PHARM-MOLEC PH, V290, P75, DOI 10.1016/0922-4106(95)90019-5; KALMAN VK, 1995, J BIOL CHEM, V270, P14835, DOI 10.1074/jbc.270.24.14835; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LIMBIRD L, 1988, ALPHA 2 ADRENERGIC R, P22; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; PARKER EM, 1991, J BIOL CHEM, V266, P519; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Ray K, 1996, TRENDS CARDIOVAS MED, V6, P115, DOI 10.1016/1050-1738(96)00021-7; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; ROBISHAW JD, 1993, ANAL BIOCHEM, V208, P283, DOI 10.1006/abio.1993.1047; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Taylor JM, 1996, J BIOL CHEM, V271, P3336; UEDA N, 1994, J BIOL CHEM, V269, P4388; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	35	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13525	13533		10.1074/jbc.274.19.13525	http://dx.doi.org/10.1074/jbc.274.19.13525			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224121	hybrid			2022-12-25	WOS:000080200400083
J	Saint-Pol, A; Codogno, P; Moore, SEH				Saint-Pol, A; Codogno, P; Moore, SEH			Cytosol-to-lysosome transport of free polymannose-type oligosaccharides - Kinetic and specificity studies using rat liver lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THY-1-NEGATIVE MUTANT LYMPHOMAS; LIPID-LINKED OLIGOSACCHARIDES; ALPHA-D-MANNOSIDASE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; GLYCOPEPTIDE EXPORT; DIPHOSPHO-DOLICHOL; CATABOLIC PATHWAY; SIALIC-ACID	In hepatocellular carcinoma HepG2 cells, free polymannose-type oligosaccharides appearing in the cytosol during the biosynthesis and quality control of glycoproteins are rapidly translocated into lysosomes by an as yet pearly defined process (Saint-Pol, A., Bauvy, C., Codogno, P., and Moore, S. E. H. (1997) J. Cell Biol. 136, 45-59), Here, we demonstrate an ATP-dependent association of [2-H-3]mannose-labeled Man(5)GlcNAc with isolated rat liver lysosomes, This association was only observed in the presence of swainsonine, a mannosidase inhibitor, which was required for the protection of sedimentable, but not nonsedimentable, Man(5)GlcNAc from degradation, indicating that oligosaccharides were transported into lysosomes, Saturable high affinity transport (K-uptake, 22.3 mu M, V-max, 7.1 fmol/min/unit of P hexosaminidase) was dependent upon the hydrolysis of ATP but independent of vacuolar H+/ATPase activity. Transport. was inhibited strongly by NEM and weakly by vanadate but not by sodium azide, and, in addition, the sugar transport inhibitors phloretin, phloridzin, and cytochalasin B were without effect on transport. Oligosaccharide import did not show absolute specificity but was selective toward partially demannosylated and dephosphorylated oligosaccharides, and, furthermore, inhibition studies revealed that the free reducing GlcNAc residue of the oligosaccharide was of critical importance for its interaction with the transporter. These results demonstrate the presence of a novel lysosomal free oligosaccharide transporter that must work in concert with cytosolic hydrolases in order to clear the cytosol of endoplasmic reticulum-generated free oligosaccharides.	Fac Med Xavier Bichat, INSERM U410, Unite Neuroendocrinol & Biol Cellulaire Digest, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Moore, SEH (corresponding author), Fac Med Xavier Bichat, INSERM U410, Unite Neuroendocrinol & Biol Cellulaire Digest, 16 Rue Henri Huchard, F-75018 Paris, France.		Moore, Stuart/AAF-3920-2021; Codogno, Patrice/G-1384-2013	Moore, Stuart/0000-0002-1020-2242; Codogno, Patrice/0000-0002-5492-3180				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ALLEN AK, 1973, BIOCHEM J, V131, P155, DOI 10.1042/bj1310155; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; BARRUECO JR, 1991, J BIOL CHEM, V266, P11732; BAUR H, 1977, EUR J BIOCHEM, V74, P397, DOI 10.1111/j.1432-1033.1977.tb11404.x; BEINTEMA JJ, 1994, FEBS LETT, V350, P159, DOI 10.1016/0014-5793(94)00753-5; BELARD M, 1988, BIOCHEM J, V255, P235; Cacan R, 1996, BIOCHEM J, V313, P597, DOI 10.1042/bj3130597; CACAN R, 1987, EUR J BIOCHEM, V166, P469, DOI 10.1111/j.1432-1033.1987.tb13539.x; Cacan R, 1997, TRENDS GLYCOSCI GLYC, V9, P365, DOI 10.4052/tigg.9.365; CACAN R, 1989, EUR J BIOCHEM, V185, P173, DOI 10.1111/j.1432-1033.1989.tb15099.x; CHAPMAN A, 1979, CELL, V17, P509, DOI 10.1016/0092-8674(79)90259-9; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; Chou HF, 1997, BIOCHEM J, V327, P781, DOI 10.1042/bj3270781; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FOHR KJ, 1989, BIOCHEM J, V262, P83; HAEUW JF, 1991, EUR J BIOCHEM, V202, P1257, DOI 10.1111/j.1432-1033.1991.tb16498.x; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; Kato T, 1997, J BIOCHEM, V122, P1167, DOI 10.1093/oxfordjournals.jbchem.a021877; Lee RT, 1998, GLYCOCONJUGATE J, V15, P649, DOI 10.1023/A:1006976129458; LEE WS, 1994, J BIOL CHEM, V269, P12032; Lloyd J B, 1996, Subcell Biochem, V27, P361; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; Moore SEH, 1998, GLYCOBIOLOGY, V8, P373, DOI 10.1093/glycob/8.4.373; MOORE SEH, 1995, EMBO J, V14, P6034, DOI 10.1002/j.1460-2075.1995.tb00292.x; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; OKU H, 1991, J BIOCHEM-TOKYO, V110, P982, DOI 10.1093/oxfordjournals.jbchem.a123700; OPHEIM DJ, 1977, J BIOL CHEM, V252, P739; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PIERCE RJ, 1979, BIOCHEM J, V180, P673, DOI 10.1042/bj1800673; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; SaintPol A, 1997, J CELL BIOL, V136, P45, DOI 10.1083/jcb.136.1.45; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHOUP VA, 1976, J BIOL CHEM, V251, P3845; Smythe E, 1996, Subcell Biochem, V27, P51; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; STRECKER G, 1976, BIOCHIMIE, V58, P579, DOI 10.1016/S0300-9084(76)80227-1; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; SUZUKI T, 1994, GLYCOCONJUGATE J, V11, P469, DOI 10.1007/BF00731283; TIETZE F, 1989, J BIOL CHEM, V264, P15316; TROWBRIDGE IS, 1979, CELL, V17, P503, DOI 10.1016/0092-8674(79)90258-7; Varki A, 1996, P NATL ACAD SCI USA, V93, P4523, DOI 10.1073/pnas.93.10.4523; VILLERS C, 1994, BIOCHEM J, V298, P135, DOI 10.1042/bj2980135; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WOO JT, 1992, J ANTIBIOT, V45, P1108, DOI 10.7164/antibiotics.45.1108; YAMASHITA K, 1980, J BIOL CHEM, V255, P5126	56	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13547	13555		10.1074/jbc.274.19.13547	http://dx.doi.org/10.1074/jbc.274.19.13547			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224124	hybrid			2022-12-25	WOS:000080200400086
J	Todd, JL; Tanner, KG; Denu, JM				Todd, JL; Tanner, KG; Denu, JM			Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR - A novel role in down-regulating the ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAP KINASE; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; IN-VIVO; REDOX REGULATION; PC12 CELLS; REVERSIBLE INACTIVATION; VACCINIA VIRUS	The mammalian dual-specificity protein-tyrosine phosphatase VHR (for VH1-related) has been identified as a novel regulator of extracellular regulated kinases (ERKs), To identify potential cellular substrates of VHR, covalently immobilized mutant VHR protein was employed as an affinity trap. A tyrosine-phosphorylated protein(s) of similar to 42 kDa was specifically adsorbed by the affinity column and identified as ERK1 and ERK2. Subsequent kinetic analyses and transfection studies demonstrated that VHR specifically dephosphorylates and inactivates ERK1 and ERK2 in vitro and in vivo, Only the native structure of phosphorylated ERK was recognized by VHR and was inactivated with a second-order rate constant of 40,000 M-1 s(-1). VHR was found to dephosphorylate endogenous ERK, but not p38 and JNK, Immunodepletion of endogenous VHR eliminated the dephosphorylation of cellular ERK. Transfection studies in COS-l cells demonstrated that in vivo phosphorylation of epidermal growth factor-stimulated ERK depended on VHR protein levels. Overexpression above endogenous levels of VHR led to accelerated ERK inactivation, but did not alter the normal activation of ERK. Unique among reported mitogen activated protein kinase phosphatases, VHR is constitutively expressed, localized to the nucleus, and tyrosine-specific. This study is the first to report the identification of authentic substrates of dual-specificity phosphatases utilizing affinity absorbents and is the first to identify a nuclear, constitutively expressed, and tyrosine-specific ERK phosphatase. The data strongly suggest that VHR is responsible for the rapid inactivation of ERK following stimulation and for its repression in quiescent cells.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol L224, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol L224, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Boglari G, 1998, EUR J CELL BIOL, V75, P54, DOI 10.1016/S0171-9335(98)80046-0; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Branch AD, 1998, TRENDS BIOCHEM SCI, V23, P45, DOI 10.1016/S0968-0004(97)01155-9; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chajry N, 1996, EUR J BIOCHEM, V235, P97, DOI 10.1111/j.1432-1033.1996.00097.x; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Dorfman K, 1996, ONCOGENE, V13, P925; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Leclerc P, 1997, FREE RADICAL BIO MED, V22, P643, DOI 10.1016/S0891-5849(96)00379-6; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LIU K, 1995, J VIROL, V69, P7823, DOI 10.1128/JVI.69.12.7823-7834.1995; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Pende M, 1997, J NEUROSCI, V17, P1291; PERALDI P, 1993, EUR J BIOCHEM, V218, P815, DOI 10.1111/j.1432-1033.1993.tb18436.x; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Rao GN, 1996, ONCOGENE, V13, P713; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schramek H, 1996, AM J PHYSIOL-RENAL, V271, pF423, DOI 10.1152/ajprenal.1996.271.2.F423; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Watson RWG, 1996, SURGERY, V120, P150; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; WNG X, 1998, J BIOL CHEM, V273, P9973; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG WY, 1995, J CELL PHYSIOL, V162, P348, DOI 10.1002/jcp.1041620307; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	75	142	148	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13271	13280		10.1074/jbc.274.19.13271	http://dx.doi.org/10.1074/jbc.274.19.13271			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224087	hybrid			2022-12-25	WOS:000080200400049
J	Vig, E; Green, M; Liu, YW; Donner, DB; Mukaida, N; Goebl, MG; Harrington, MA				Vig, E; Green, M; Liu, YW; Donner, DB; Mukaida, N; Goebl, MG; Harrington, MA			Modulation of tumor necrosis factor and interleukin-1-dependent NF-kappa B activity by mPLK IRAK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; ACCESSORY PROTEIN; DEATH DOMAIN; CELL-DEATH; TNF; IL-1; COMPLEX; FAMILY	The innate immune response is an important defense against pathogenic agents. A component of this response is the NF-kappa B-dependent activation of genes encoding inflammatory cytokines such as interleukin-8 (IL-8) and cell adhesion molecules like E-selectin. Members of the serine/threonine innate immune kinase family of proteins have been proposed to mediate the innate immune response. One serine/threonine innate immune kinase family member, the mouse Pelle-like kinase/human interleukin-l receptor-associated kinase (mPLK/IRAK), has been proposed to play an obligate role in promoting IL-l-mediated inflammation. However, it is currently unknown whether mPLK/IRAK catalytic activity is required for IL-l-dependent NF-kappa B activation. The present study demonstrates that mPLK/IRAK catalytic activity is not required for IL-l-mediated activation of an NF-kappa B-dependent signal. Intriguingly, catalytically inactive mPLK/IRAK inhibits type 1 tumor necrosis factor (TNF) receptor-dependent NF-kappa B activation, The pathway through which mPLK/IRAK mediates this TNF response is TRADD- and TRAF2-independent. Our data suggest that in addition to its role in IL-1 signaling, mPLK/IRAK is a component of a novel signal transduction pathway through which TNF R1 activates NF-kappa B-dependent gene expression.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Canc Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Kanazawa Univ, Canc Res Inst, Dept Pharmacol, Kanazawa 920, Japan	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Kanazawa University	Harrington, MA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 1044 W Walnut St, Indianapolis, IN 46202 USA.		Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851	NCI NIH HHS [CA67891, CA73023] Funding Source: Medline; NIAID NIH HHS [AI42798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA067891, R01CA067891, R01CA073023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chun KT, 1997, MOL GEN GENET, V256, P365, DOI 10.1007/s004380050580; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hedin KE, 1997, J IMMUNOL, V159, P5431; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; YANG L, 1994, J BIOL CHEM, V269, P32732; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	50	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13077	13084		10.1074/jbc.274.19.13077	http://dx.doi.org/10.1074/jbc.274.19.13077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224059	hybrid			2022-12-25	WOS:000080200400021
J	Steegborn, C; Clausen, T; Sondermann, P; Jacob, U; Worbs, M; Marinkovic, S; Huber, R; Wahl, MC				Steegborn, C; Clausen, T; Sondermann, P; Jacob, U; Worbs, M; Marinkovic, S; Huber, R; Wahl, MC			Kinetics and inhibition of recombinant human cystathionine gamma-lyase - Toward the rational control of transsulfuration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITORS; ESCHERICHIA-COLI; BETA-LYASE; SLOW-BINDING; ENZYMATIC AMPLIFICATION; X-RAY; INACTIVATION; MECHANISM; PROPARGYLGLYCINE; PURIFICATION	The gene encoding human cystathionine gamma-lyase was cloned from total cellular Rep G2 RNA. Fusion to a T7 promoter allowed expression in Escherichia coli, representing the first mammalian cystathionine gamma-lyase overproduced in a bacterial system. About 90% of the heterologous gene product was insoluble, and renaturation experiments from purified inclusion bodies met with limited success. About 5 mg/liter culture of human cystathionine gamma-lyase could also be extracted from the soluble lysis fraction, employing a three-step native procedure. While the enzyme showed high gamma-lyase activity toward L-cystathionine (K-m = 0.5 mM, V-max = 2.5 units/mg) with an optimum pH of 8.2, no residual cystathionine beta-lyase behavior and only marginal reactivity toward L-cystine and L-cysteine were detected. Inhibition studies were performed with the mechanism-based inactivators propargylglycine, trifluoroalanine, and aminoethoxyvinylglycine. Propargylglycine inactivated human cystathionine gamma-lyase much more strongly than trifluoroalanine, in agreement with the enzyme's preference for C-gamma-S bonds. Aminoethoxyvinylglycine showed slow and tight binding characteristics with a K-i of 10.5 mu M, comparable with its effect on cystathionine beta-lyase, The results have important implications for the design of specific inhibitors for transsulfuration components.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Planegg Martinsried, Germany	Max Planck Society	Wahl, MC (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.		Wahl, Markus C./D-6365-2017	Wahl, Markus C./0000-0002-2811-5307; Clausen, Tim/0000-0003-1582-6924				ABELES RH, 1973, J AM CHEM SOC, V95, P6124, DOI 10.1021/ja00799a053; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ALSTON AT, 1981, FEBS LETT, V128, P293; ALTING AC, 1995, APPL ENVIRON MICROB, V61, P4037, DOI 10.1128/AEM.61.11.4037-4042.1995; BRZOVIC P, 1990, BIOCHEMISTRY-US, V29, P442, DOI 10.1021/bi00454a020; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCHICH JE, 1975, J BIOL CHEM, V250, P7722; Clausen T, 1998, EMBO J, V17, P6827, DOI 10.1093/emboj/17.23.6827; Clausen T, 1996, J MOL BIOL, V262, P202, DOI 10.1006/jmbi.1996.0508; Clausen T, 1997, BIOCHEMISTRY-US, V36, P12633, DOI 10.1021/bi970630m; Dudman NPB, 1996, J NUTR, V126, pS1295, DOI 10.1093/jn/126.suppl_4.1295S; Eadie GS, 1942, J BIOL CHEM, V146, P85; FEARON CW, 1982, BIOCHEMISTRY-US, V21, P3790, DOI 10.1021/bi00259a011; FLAVIN M, 1964, J BIOL CHEM, V239, P2212; FLAVIN M, 1971, METHODS ENZYMOL B, V17, P416; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; GLODE LM, 1981, BIOCHEMISTRY-US, V20, P1306, DOI 10.1021/bi00508a041; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P367; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; JOHNSTON M, 1979, BIOCHEMISTRY-US, V18, P4691; KITZ R, 1962, J BIOL CHEM, V237, P3245; KREFT BD, 1994, PLANT PHYSIOL, V104, P1215, DOI 10.1104/pp.104.4.1215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU Y, 1992, BIOCHEM BIOPH RES CO, V189, P749, DOI 10.1016/0006-291X(92)92265-Y; MARTEL A, 1987, BIOCH VITAMIN B6, P341; MATSUO Y, 1958, J BIOL CHEM, V230, P545; MATSUO Y, 1958, J BIOL CHEM, V230, P561; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NAGASAWA T, 1984, J BIOL CHEM, V259, P10398; OWENS LD, 1968, BIOCHIM BIOPHYS ACTA, V158, P219, DOI 10.1016/0304-4165(68)90134-7; PRUESS DL, 1974, J ANTIBIOT, V27, P229, DOI 10.7164/antibiotics.27.229; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240; SILVERMAN RB, 1977, BIOCHEMISTRY-US, V16, P5515, DOI 10.1021/bi00644a019; SILVERMAN RB, 1976, BIOCHEMISTRY-US, V15, P4718, DOI 10.1021/bi00666a028; SILVERMAN RB, 1988, MECH BASED ENZYME IN, V2; STURMAN JA, 1980, J BIOL CHEM, V255, P4763; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; UREN JR, 1978, BIOCHEM PHARMACOL, V27, P2807, DOI 10.1016/0006-2952(78)90194-6; UREN JR, 1987, METHOD ENZYMOL, V143, P483; Wahl MC, 1997, FEBS LETT, V414, P492, DOI 10.1016/S0014-5793(97)01057-0; WASHTIEN W, 1977, BIOCHEMISTRY-US, V16, P2485, DOI 10.1021/bi00630a026; YAMAGATA S, 1993, J BACTERIOL, V175, P4800, DOI 10.1128/JB.175.15.4800-4808.1993; [No title captured]	49	78	94	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12675	12684		10.1074/jbc.274.18.12675	http://dx.doi.org/10.1074/jbc.274.18.12675			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212249	hybrid			2022-12-25	WOS:000080056800069
J	Murphy, MP; Hickman, LJ; Eckman, CB; Uljon, SN; Wang, R; Golde, TE				Murphy, MP; Hickman, LJ; Eckman, CB; Uljon, SN; Wang, R; Golde, TE			gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSMEMBRANE DOMAIN; CULTURED-CELLS; SENILE PLAQUES; A-BETA; CLEAVAGE; A-BETA-42(43); MUTATION; RELEASE	gamma-Secretase activity is the final cleavage event that releases the amyloid beta peptide (A beta) from the beta-secretase cleaved carboxyl-terminal fragment of the amyloid beta protein precursor (APP). No protease responsible for this highly unusual, purportedly intramembranous, cleavage has been definitively identified, We examined the substrate specificity of gamma-secretase by mutating various residues within or adjacent to the transmembrane domain of the APP and then analyzing A beta production from cells transfected with these mutant APPs by enzyme-linked immunosorbent assay and mass spectrometry. A beta production was also analyzed from a subset of transmembrane domain APP mutants that showed dramatic shifts in gamma-secretase cleavage in the presence or absence of pepstatin, an inhibitor of gamma-secretase activity. These studies demonstrate that gamma-secretase's cleavage specificity is primarily determined by location of the gamma-secretase cleavage site of APP with respect to the membrane, and that gamma-secretase activity is due to the action of multiple proteases exhibiting both a pepstatin-sensitive activity and a pepstatin-insensitive activity. Given that gamma-secretase is a major therapeutic target in Alzheimer's disease these studies provide important information with respect to the mechanism of A beta production that will direct efforts to isolate the gamma-secretases and potentially to develop effective therapeutic inhibitors of pathologically relevant gamma-secretase activities.	Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19010 USA; Rockefeller Univ, Lab Mass Spectrometry, New York, NY 10021 USA	Mayo Clinic; University of Pennsylvania; Rockefeller University	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Pharmacol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Wang, Rong/A-8721-2009		NATIONAL INSTITUTE ON AGING [R03AG016065] Funding Source: NIH RePORTER; NIA NIH HHS [AG-16065] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BROMME D, 1986, ARCH BIOCHEM BIOPHYS, V244, P439, DOI 10.1016/0003-9861(86)90611-9; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DEAN RT, 1979, BIOCHEM J, V180, P339, DOI 10.1042/bj1800339; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Eckman CB, 1997, HUM MOL GENET, V6, P2087, DOI 10.1093/hmg/6.12.2087; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FELSENSTEIN KM, 1994, NEUROSCI LETT, V174, P173, DOI 10.1016/0304-3940(94)90014-0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Paganetti PA, 1996, J NEUROSCI RES, V46, P283, DOI 10.1002/(SICI)1097-4547(19961101)46:3<283::AID-JNR1>3.0.CO;2-G; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; USAMI M, 1993, J NEUROCHEM, V61, P239, DOI 10.1111/j.1471-4159.1993.tb03560.x; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WHITTAKER RG, 1994, ANAL BIOCHEM, V220, P238, DOI 10.1006/abio.1994.1333; WIEDEMANN A, 1989, CELL, V57, P115; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b	46	149	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11914	11923		10.1074/jbc.274.17.11914	http://dx.doi.org/10.1074/jbc.274.17.11914			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207012				2022-12-25	WOS:000079834800068
J	Page, S; Fischer, C; Baumgartner, B; Haas, M; Kreusel, U; Loidl, G; Hayn, M; Ziegler-Heitbrock, HWL; Neumeier, D; Brand, K				Page, S; Fischer, C; Baumgartner, B; Haas, M; Kreusel, U; Loidl, G; Hayn, M; Ziegler-Heitbrock, HWL; Neumeier, D; Brand, K			4-hydroxynonenal prevents NF-kappa B activation and tumor necrosis factor expression by inhibiting I kappa B phosphorylation and subsequent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIPID-PEROXIDATION; KINASE COMPLEX; OXIDIZED LDL; CELL-LINE; ATHEROSCLEROTIC LESION; SIGNAL-TRANSDUCTION; CYTOKINE PRODUCTION; MONOCYTIC CELLS; MESSENGER-RNA	Extensively oxidized low density lipoprotein (ox-LDL), a modulator of atherogenesis, down-regulates the lipopolysaccharide (LPS)-induced activation of transcription factor NF-kappa B. We investigated whether 4-hydroxynonenal (HNE), a prominent aldehyde component of on-LDL, represents one of the inhibitory substances. NF-kappa B activation by stimuli such as LPS, interleukin (IL)-1 beta, and phorbol ester, but not tumor necrosis factor (TNF), was reversibly inhibited by HNE in a dose-dependent manner in human monocytic cells, whereas AP-1 binding was unaffected. Using similar HNE concentrations, LPS-induced kappa B- and TNF or IL-8 promoter-dependent transcription was prevented. Furthermore, pretreatment with HNE suppressed TNF production but not lactate dehydrogenase levels. Under these conditions the binding of LPS to monocytic cells was not significantly affected, However, induced proteolysis of the inhibitory proteins I kappa B-alpha, I kappa B-beta, and, at a later time point, I kappa B-epsilon was prevented. This is not due to inhibition of the proteasome, the major proteolytic activities of which remain unaffected, but rather to a specific prevention of the activation-dependent phosphorylation of I kappa B-alpha. This is the first report which demonstrates that HNE specifically inhibits the NF-kappa B/Rel system. Downmodulation of NF-kappa B-regulated gene expression may contribute at certain stages of atherosclerosis to low levels of chronic inflammation and may also be involved in other inflammatory/degenerative diseases.	Tech Univ Munich, Klinikum Rechts Isar, Inst Clin Chem & Pathobiochem, D-81675 Munich, Germany; Max Planck Inst Biochem, Dept Bioorgan Chem, D-82152 Martinsried, Germany; Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria; Univ Munich, Inst Immunol, D-80336 Munich, Germany	Technical University of Munich; Max Planck Society; Graz University of Technology; University of Munich	Brand, K (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Inst Clin Chem & Pathobiochem, Ismaninger Str 22, D-81675 Munich, Germany.			Page, Sharon/0000-0003-0228-3609				ARES MPS, 1995, ARTERIOSCL THROM VAS, V15, P1584, DOI 10.1161/01.ATV.15.10.1584; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Blanc EM, 1997, J NEUROCHEM, V69, P570; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BRAND K, 1993, J CLIN INVEST, V91, P2031, DOI 10.1172/JCI116425; BRAND K, 1994, ARTERIOSCLER THROMB, V14, P790, DOI 10.1161/01.ATV.14.5.790; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; Brand K, 1997, EXP PHYSIOL, V82, P297, DOI 10.1113/expphysiol.1997.sp004025; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Camandola S, 1997, BIOFACTORS, V6, P173, DOI 10.1002/biof.5520060211; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; COLLINS T, 1993, LAB INVEST, V68, P499; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FONG LG, 1991, J LIPID RES, V32, P1899; GRILLI M, 1993, INT REV CYTOL, V143, P1; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; Heinemann M, 1996, INFECT IMMUN, V64, P4872, DOI 10.1128/IAI.64.11.4872-4875.1996; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; INGALLS RR, 1995, INFECT IMMUN, V63, P3125, DOI 10.1128/IAI.63.8.3125-3130.1995; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kol A, 1998, TRENDS CARDIOVAS MED, V8, P191, DOI 10.1016/S1050-1738(98)00010-3; Kruman I, 1997, J NEUROSCI, V17, P5089; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; LIBBY P, 1991, LAB INVEST, V64, P5; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mattila KJ, 1998, CLIN INFECT DIS, V26, P719, DOI 10.1086/514570; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Muller K, 1996, FEBS LETT, V388, P165, DOI 10.1016/0014-5793(96)00559-5; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; Paradis V, 1997, HEPATOLOGY, V26, P135; Parthasarathy Sampath, 1994, Current Opinion in Lipidology, V5, P371, DOI 10.1097/00041433-199410000-00009; PEDRON T, 1995, J IMMUNOL, V155, P1460; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Schmidt M, 1997, FASEB J, V11, P1235, DOI 10.1096/fasebj.11.14.9409542; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHACKELFORD RE, 1995, J BIOL CHEM, V270, P3475, DOI 10.1074/jbc.270.8.3475; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THAI SF, 1995, J LEUKOCYTE BIOL, V57, P427, DOI 10.1002/jlb.57.3.427; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	67	137	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11611	11618		10.1074/jbc.274.17.11611	http://dx.doi.org/10.1074/jbc.274.17.11611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206970	hybrid			2022-12-25	WOS:000079834800026
J	Sastry, S; Linderoth, N				Sastry, S; Linderoth, N			Molecular mechanisms of peptide loading by the tumor rejection antigen heat shock chaperone gp96 (GRP94)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONFORMATIONAL CHANGE; PYRENE EXCIMER FLUORESCENCE; CYTOTOXIC T-LYMPHOCYTES; STRESS-INDUCED PROTEINS; ENDOPLASMIC-RETICULUM; IMMUNE-RESPONSE; IN-VIVO; BINDING; CANCER; TAP	Complexes of gp96/GRP94 and peptides have been shows to elicit immunogenicity. We used fluorescence to understand peptide association with gp96, A pyrene-peptide conjugate was complexed with gp96 under a variety of conditions. At room temperature in low salt (20 mM NaCl), the peptide binds gp96 with a strong affinity (similar to 100-150 nM) and forms pyrene excimers, suggesting that the peptides were assembled as dimers. In high salt (2.2 at NaCl), although peptide binding was stronger (K-a approximate to 55 nM) than in low salt, pyrene excimers were absent, implying that peptides were farther apart in the complex. Heat shock-activated peptide binding exhibited characteristics of both low salt and high salt modes of binding. Anisotropy and average lifetime of the bound pyrene suggested that peptides were probably located in a solvent-accessible hydrophobic binding pocket in low salt, whereas in high salt, the peptide may be buried in a less hydrophobic (more hydrophilic) environment. These results suggested that peptide-gp96 complexes were assembled in several different ways, depending on the assembly conditions. Resonance energy transfer between the intrinsic tryptophan(s) in gp96 and pyrene suggested that one or more tryptophan residues were within the critical Forster distance of 27-30 Angstrom from the pyrene in the bound peptide. It is proposed that peptides are assembled within higher order gp96 complexes (dimers, etc.) in a hydrophobic pocket and that there may be a conformational change in gp96 leading to an open configuration for peptide loading.	Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA	Rockefeller University	Sastry, S (corresponding author), Rockefeller Univ, Mol Genet Lab, 1230 York Ave, New York, NY 10021 USA.	sastrys@rockvax.rockefeller.edu						ANDERSON SL, 1994, J EXP MED, V180, P1565, DOI 10.1084/jem.180.4.1565; Arnold D, 1997, J EXP MED, V186, P461, DOI 10.1084/jem.186.3.461; BARRANTES FJ, 1975, P NATL ACAD SCI USA, V72, P3097, DOI 10.1073/pnas.72.8.3097; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; Breloer M, 1998, EUR J IMMUNOL, V28, P1016, DOI 10.1002/(SICI)1521-4141(199803)28:03<1016::AID-IMMU1016>3.0.CO;2-G; Ciupitu AMT, 1998, J EXP MED, V187, P685, DOI 10.1084/jem.187.5.685; CREIGHTON, 1993, PROTEINS STRUCTURE M, P270; EGUSA S, 1985, MACROMOLECULES, V18, P882, DOI 10.1021/ma00147a011; ENGELKE M, 1994, CHEM PHYS LIPIDS, V72, P35, DOI 10.1016/0009-3084(94)90015-9; Engelke M, 1996, J MEMBRANE BIOL, V153, P117, DOI 10.1007/s002329900115; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GOROVITS BM, 1995, J BIOL CHEM, V270, P13057, DOI 10.1074/jbc.270.22.13057; Grosso VN, 1998, PHOTOCHEM PHOTOBIOL, V68, P481, DOI 10.1111/j.1751-1097.1998.tb02503.x; HAUGLAND RA, 1996, HDB FLUORESCENT PROB, P36; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; Janetzki S, 1998, J IMMUNOTHER, V21, P269, DOI 10.1097/00002371-199807000-00004; KNOPP JA, 1969, J BIOL CHEM, V244, P6309; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P75; Lammert E, 1997, EUR J IMMUNOL, V27, P923, DOI 10.1002/eji.1830270418; Lehrer S S, 1995, Subcell Biochem, V24, P115; Lehrer SS, 1997, METHOD ENZYMOL, V278, P286; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Marusina K, 1997, BIOCHEMISTRY-US, V36, P856, DOI 10.1021/bi9619738; Nicchitta CV, 1998, CURR OPIN IMMUNOL, V10, P103, DOI 10.1016/S0952-7915(98)80039-3; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; PAP EHW, 1995, J BIOL CHEM, V270, P1254, DOI 10.1074/jbc.270.3.1254; Przepiorka D, 1998, MOL MED TODAY, V4, P478, DOI 10.1016/S1357-4310(98)01345-8; Roman E, 1996, IMMUNOLOGY, V88, P487, DOI 10.1046/j.1365-2567.1996.d01-697.x; Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944; Srivastava P K, 1991, Semin Immunol, V3, P57; Srivastava P. K., 1993, ADV CANCER RES, V62, P154; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; SRIVASTAVA PK, 1994, EXPERIENTIA, V50, P1054, DOI 10.1007/BF01923461; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Srivastava PK, 1997, METHODS, V12, P165, DOI 10.1006/meth.1997.0464; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; TURRO NJ, 1991, MODERN MOL PHOTOCHEM, P141; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1994, J IMMUNOL, V152, P5398; VONHIPPEL PH, 1989, BIOL MACROMOL, P417; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WINNIK FM, 1993, CHEM REV, V93, P587, DOI 10.1021/cr00018a001	50	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12023	12035		10.1074/jbc.274.17.12023	http://dx.doi.org/10.1074/jbc.274.17.12023			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207025	hybrid			2022-12-25	WOS:000079834800081
J	Sato, H; Tamba, M; Ishii, T; Bannai, S				Sato, H; Tamba, M; Ishii, T; Bannai, S			Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; HUMAN-DIPLOID FIBROBLASTS; MOUSE PERITONEAL-MACROPHAGES; XENOPUS-LAEVIS OOCYTES; HEAVY-CHAIN; CYSTINE; GLUTAMATE; INDUCTION; ANTIGEN; IDENTIFICATION	Transport system x(c)(-) found in plasma membrane of cultured mammalian cells is an exchange agency for anionic amino acids with high specificity for anionic form of cystine and glutamate, We have isolated cDNA encoding the transporter for system x(c)(-) from mouse activated macrophages by expression in Xenopus oocytes. The expression of system x(c)(-) activity in oocytes required two cDNA transcripts, and the sequence analysis revealed that one is identical with the heavy chain of 4F2 cell surface antigen (4F2hc) and the other is a novel protein of 502 amino acids with 12 putative transmembrane domains. The latter protein, named xCT, showed a significant homology with those recently reported to mediate cationic or zwitterionic amino acid transport when co-expressed with 4F2hc, Thus xCT is a new member of a family of amino acid transporters that form heteromultimeric complex with 4F2hc, with a striking difference in substrate specificity. The expression of system x(c)(-) was highly regulated, and Northern blot analysis demonstrated that the expression of both 4F2hc and xCT was enhanced in macrophages stimulated by lipopolysaccharide or an electrophilic agent. However, the expression of xCT was more directly correlated with the system x(c)(-), activity.	Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba	Bannai, S (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan.							BANNAI S, 1989, J BIOL CHEM, V264, P18480; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BANNAI S, 1984, NATURE, V311, P308; BANNAI S, 1986, J BIOL CHEM, V261, P2256; BANNAI S, 1982, J CELL PHYSIOL, V112, P265, DOI 10.1002/jcp.1041120216; BANNAI S, 1981, J BIOL CHEM, V256, P5770; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Droge W, 1997, FASEB J, V11, P1077, DOI 10.1096/fasebj.11.13.9367343; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; ISHII T, 1992, ANN NY ACAD SCI, V663, P497, DOI 10.1111/j.1749-6632.1992.tb38714.x; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; TAYLOR MA, 1987, DEV BIOL, V124, P287, DOI 10.1016/0012-1606(87)90480-5; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628; WELLS RG, 1992, J BIOL CHEM, V267, P15285	23	688	727	8	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11455	11458		10.1074/jbc.274.17.11455	http://dx.doi.org/10.1074/jbc.274.17.11455			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206947	hybrid			2022-12-25	WOS:000079834800003
J	Yao, I; Hata, Y; Ide, N; Hirao, K; Deguchi, M; Nishioka, H; Mizoguchi, A; Takai, Y				Yao, I; Hata, Y; Ide, N; Hirao, K; Deguchi, M; Nishioka, H; Mizoguchi, A; Takai, Y			MAGUIN, a novel neuronal membrane-associated guanylate kinase-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; POSTSYNAPTIC DENSITY; PDZ DOMAIN; BINDING; FAMILY; PSD-95; RAS; RECOGNITION; NETWORKS	Postsynaptic density (PSD)-95/Synapse-associated protein (SAP) 90 and synaptic scaffolding molecule (S-SCAM) are neuronal membrane-associated guanylate kinases. Because PSD-95/SAP90 and S-SCAM function as synaptic scaffolding proteins, identification of ligands for these proteins is important to elucidate the structure of synaptic junctions. Here, we report a novel protein interacting with the PDZ domains of PSD-95/SAP90 and S-SCAM and named it MAGUIN-1 (membrane-associated guanylate kinase-interacting protein-1). MAGUIN-1 has one sterile alpha motif, one PDZ, and one plekstrin homology domain. MAGUIN-1 is localized at the plasma membrane via the plekstrin homology domain and the C-terminal region and interacts with PSD-95/SAP90 and S-SCAM via a C-terminal PDZ domain-binding moth, MAGUIN-1 has a short isoform, MAGUIN-2, which lacks a PDZ domain-binding motif, MAGUINs are expressed in neurons and localized in the cell body and neurites and are coimmunoprecipitated with PSD-95/SAP90 and S-SCAM hom rat crude synaptosome. MAGUIN-1 may play an important role with PSD-95/SAP90 and S-SCAM to assemble the components of synaptic junctions.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, Takai Biotimer Project Exploratory Res Adv Techno, Nishi Ku, Kobe, Hyogo 6512241, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 6068315, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Kyoto University; Osaka University	Takai, Y (corresponding author), JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, Takai Biotimer Project Exploratory Res Adv Techno, Nishi Ku, 2-2-10 Murotani, Kobe, Hyogo 6512241, Japan.							Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GARNER C, 1996, TRENDS CELL BIOL, V19, P429; HAMMOND C, 1996, CELLULAR MOL NEUROBI, P20; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOMAU HC, 1995, SCIENCE, V269, P1737; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; RAMEZANI RM, 1992, MOL GEN GENET, V236, P145; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schultz J, 1997, PROTEIN SCI, V6, P249; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Telemenakis I, 1997, EUR J CELL BIOL, V74, P143; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	47	61	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11889	11896		10.1074/jbc.274.17.11889	http://dx.doi.org/10.1074/jbc.274.17.11889			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207009	hybrid			2022-12-25	WOS:000079834800065
J	Zeng, WR; Watson, P; Lin, J; Jothy, S; Lidereau, R; Park, M; Nepveu, A				Zeng, WR; Watson, P; Lin, J; Jothy, S; Lidereau, R; Park, M; Nepveu, A			Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; chromosome 7q22; CUTL1; human Cut homeobox gene; loss of heterozygosity	CCAAT DISPLACEMENT PROTEIN; HOMEODOMAIN PROTEIN; UTERINE LEIOMYOMATA; DROSOPHILA CUT; SUSCEPTIBILITY; EXPRESSION; PROMOTER; DELETION; 7Q31; LOCALIZATION	In breast cancer, loss of heterozygosity (LOH) has been described on the long arm of chromosome 7, at band q31, suggesting the presence of a tumor suppressor gene in this region, In this study, we have identified a second region of LOH on 7q, at band 7q22. Deletion of genetic material at 7q22 was found in all tumor types and grades and was associated with increased tumor size. The region of LOH at 7q22 in every case included one or more of three polymorphic markers that are located within the CUTL1 gene. LOH of 7q22 has also been documented in the case of human uterine leiomyomas (Zeng et al., 1997; Ishmad et al., 1997), Interestingly, in both leiomyomas and mammary tumors induced in transgenic mice expressing the Polyomavirus (PyV) large T (LT) antigen, immunocomplexes of CUTL1 and PyV LT antigen were detected (Webster et al., 1998), Altogether, genetic data in human breast cancer and biochemical analyses in breast tumors from transgenic mice suggest that CUTL1 is a candidate tumor suppressor gene.	McGill Univ, Mol Oncol Grp, Dept Med, Montreal, PQ, Canada; McGill Univ, Mol Oncol Grp, Dept Oncol, Montreal, PQ, Canada; Univ Manitoba, Fac Med, Dept Pathol & Physiol, Winnipeg, MB R3T 2N2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France	McGill University; McGill University; University of Manitoba; University of Toronto; Rene Huguenin Hospital	Nepveu, A (corresponding author), McGill Univ, Mol Oncol Grp, Dept Med, Montreal, PQ, Canada.		/AAB-8315-2020	Watson, Peter/0000-0002-1642-0638				ANDRES V, 1992, DEVELOPMENT, V116, P321; Berker-Karauzum S, 1998, CANCER GENET CYTOGEN, V100, P114, DOI 10.1016/S0165-4608(96)00422-0; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bieche I, 1997, CLIN CANCER RES, V3, P1009; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CALLAHAN R, 1993, CLIN CHIM ACTA, V217, P63, DOI 10.1016/0009-8981(93)90238-Y; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DAVE BJ, 1995, CANCER EPIDEM BIOMAR, V4, P743; DENG G, 1994, CANCER RES, V54, P499; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; Fischer K, 1998, RECENT RESULTS CANC, V144, P46; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HARADA R, 1994, J BIOL CHEM, V269, P2062; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; Kerangueven F, 1997, CANCER RES, V57, P5469; Kristjansson AK, 1997, ANTICANCER RES, V17, P93; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; Lin JC, 1996, ONCOGENE, V13, P2001; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; LUNDGREN R, 1991, SCAND J UROL NEPHROL, P1; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; Mertens F, 1997, CANCER RES, V57, P2765; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; OZISIK YY, 1993, CANCER GENET CYTOGEN, V71, P1, DOI 10.1016/0165-4608(93)90195-R; Quaggin SE, 1996, J BIOL CHEM, V271, P22624, DOI 10.1074/jbc.271.37.22624; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SATO T, 1990, CANCER RES, V50, P7184; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SolinasToldo S, 1996, CANCER RES, V56, P3803; STORTO PD, 1990, GENE CHROMOSOME CANC, V2, P300, DOI 10.1002/gcc.2870020408; Tougas L, 1996, CLIN INVEST MED, V19, P222; VALARCHE I, 1993, DEVELOPMENT, V119, P881; Watson PH, 1996, CAN MED ASSOC J, V155, P281; WATSON PH, 1993, J NATL CANCER I, V85, P902, DOI 10.1093/jnci/85.11.902; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xing YP, 1997, CANCER GENET CYTOGEN, V98, P69; YOON SO, 1994, J BIOL CHEM, V269, P18453; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155	48	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					2015	2021		10.1038/sj.onc.1202519	http://dx.doi.org/10.1038/sj.onc.1202519			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208423				2022-12-25	WOS:000079191300011
J	Middleton, SA; Barbone, FP; Johnson, DL; Thurmond, RL; You, Y; McMahon, FJ; Jin, RZ; Livnah, O; Tullai, J; Farrell, FX; Goldsmith, MA; Wilson, IA; Jolliffe, LK				Middleton, SA; Barbone, FP; Johnson, DL; Thurmond, RL; You, Y; McMahon, FJ; Jin, RZ; Livnah, O; Tullai, J; Farrell, FX; Goldsmith, MA; Wilson, IA; Jolliffe, LK			Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-HORMONE RECEPTOR; HUMAN TISSUE FACTOR; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; LIGAND-BINDING; HIGH-AFFINITY; HEMATOPOIETIC RECEPTORS; ANGSTROM RESOLUTION; PROTEIN HORMONE	We have shown previously that Phe(93) in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO. Substitution of Phe(93) with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells. Remarkably, Phe(93) forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe(93) is also important for EMP1 binding. We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding. The three largest hydrophobic contacts at Phe(93) Met(150), and Phe(205) and a hydrogen bonding interaction at Thr(151) were examined. Our results indicate that Phe(93) and Phe(205) are important for both EPO and EMP1 binding, Met(150) is not important for EPO binding but is critical for EMP1 binding, and Thr(151) is not important for binding either ligand. Thus, Phe(93) and Phe(205) are important binding determinants for both EPO and EMP1, even though these ligands share no sequence or structural homology, suggesting that these residues mag represent a minimum epitope on the EPOR for productive ligand binding.	RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA; Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Scripps Research Institute; Scripps Research Institute	Middleton, SA (corresponding author), RW Johnson Pharmaceut Res Inst, 1000 Route 202,POB 300, Raritan, NJ 08869 USA.	smiddlet@prius.jnj.com	McMahon, Francis J/A-7290-2009	McMahon, Francis J/0000-0002-9469-305X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049497, R01GM054351] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54351, GM49497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbone FP, 1997, J BIOL CHEM, V272, P4985, DOI 10.1074/jbc.272.8.4985; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONG YJ, 1993, EXP HEMATOL, V21, P483; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HERMINE O, 1994, BLOOD, V84, P811; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JONES SS, 1990, BLOOD, V76, P31; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klein BK, 1997, J BIOL CHEM, V272, P22630, DOI 10.1074/jbc.272.36.22630; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KRANTZ SB, 1991, BLOOD, V77, P419; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; Muller YA, 1996, J MOL BIOL, V256, P144, DOI 10.1006/jmbi.1996.0073; NAGAO M, 1993, BLOOD, V81, P2503; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WELLS JA, 1995, BIO-TECHNOL, V13, P647, DOI 10.1038/nbt0795-647; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; Zdanov A, 1996, PROTEIN SCI, V5, P1955, DOI 10.1002/pro.5560051001	47	43	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14163	14169		10.1074/jbc.274.20.14163	http://dx.doi.org/10.1074/jbc.274.20.14163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318834	hybrid			2022-12-25	WOS:000080322200063
J	Pullen, SS; Dang, TTA; Crute, JJ; Kehry, MR				Pullen, SS; Dang, TTA; Crute, JJ; Kehry, MR			CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs) - Binding site specificity and activation of downstream pathways by distinct TRAFs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CROSS-LINKING CD40; TERMINAL KINASE; PROTEIN-KINASES; CELL-DEATH; P38 MAPK; IDENTIFICATION; DOMAIN; PROLIFERATION; INDUCTION	Tumor necrosis factor receptor-associated factors (TRAFs) associate with the CD40 cytoplasmic domain and initiate signaling after CD40 receptor multimerization by its ligand. We used saturating peptide-based mutational analyses of the TRAF1/TRAF2/TRAF3 and TRAF6 binding sequences in CD40 to finely map residues involved in CD40-TRAF interactions, The core binding site for TRAF1, TRAF2, and TRAF3 in CD40 could be minimally substituted. The TRAF6 binding site demonstrated more amino acid sequence flexibility and could be optimized. Point mutations that eliminated or enhanced binding of TRAFs to one or both sites were made in CD40 and tested in quantitative CD40-TRAF binding assays. Sequences flanking the core TRAF binding sites were found to modulate TRAF binding, and the two TRAF binding sites were not independent. Cloned stable transfectants of human embryonic kidney 293 cells that expressed wild type CD40 or individual CD40 mutations were used to demonstrate that both TRAF binding sites were required for optimal NF-kappa B and c-Jun N-terminal kinase activation. in contrast, p38 mitogen-activated protein kinase activation was primarily dependent upon TRAF6 binding, These studies suggest a role in CD40 signaling for competitive TRAF binding and imply that CD40 responses reflect an integration of signals from individual TRAFs.	Boehringer Ingelheim Pharmaceut Inc, Dept Biol, Ridgefield, CT 06877 USA	Boehringer Ingelheim	Kehry, MR (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Dept Biol, 900 Ridgebury Rd,POB 368,Mail Code R6-5, Ridgefield, CT 06877 USA.							Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; CHENG C, 1996, GENE DEV, V10, P963; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Craxton A, 1998, J IMMUNOL, V161, P3225; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldstein MD, 1996, J IMMUNOL, V157, P2837; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARDY RR, 1986, HDB EXPT IMMUNOLOGY, V13, P1; HODGKIN PD, 1990, J IMMUNOL, V145, P2025; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hsing Y, 1997, J IMMUNOL, V159, P4898; HU HM, 1994, J BIOL CHEM, V269, P30069; ISHIDA T, 1995, J IMMUNOL, V155, P5527; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; JACKSON S, 1982, J IMMUNOL METHODS, V48, P299, DOI 10.1016/0022-1759(82)90331-3; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kehry MR, 1996, J IMMUNOL, V156, P2345; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Purkerson JM, 1998, J IMMUNOL, V160, P2121; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Salmon RA, 1997, J IMMUNOL, V159, P5309; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Sutherland CL, 1996, J IMMUNOL, V157, P3381; vanKooten C, 1997, INT ARCH ALLERGY IMM, V113, P393, DOI 10.1159/000237614; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	46	147	165	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14246	14254		10.1074/jbc.274.20.14246	http://dx.doi.org/10.1074/jbc.274.20.14246			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318845	hybrid			2022-12-25	WOS:000080322200074
J	Webb, Y; Zhou, XB; Ngo, L; Cornish, V; Stahl, J; Erdjument-Bromage, H; Tempst, P; Rifkind, RA; Marks, PA; Breslow, R; Richon, VM				Webb, Y; Zhou, XB; Ngo, L; Cornish, V; Stahl, J; Erdjument-Bromage, H; Tempst, P; Rifkind, RA; Marks, PA; Breslow, R; Richon, VM			Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED-CELL DIFFERENTIATION; MURINE ERYTHROLEUKEMIA-CELLS; SEQUENCE DATABASES; RAT-LIVER; DNA; INDUCERS; SUBUNIT; CROSSLINKING; SUPPRESSION; CONTAINS	The ability of a novel class of hybrid polar compounds (HPCs) to induce differentiation and consequent cessation of proliferation of transformed cells has led to their development as potential chemotherapeutic agents in the treatment of cancer. Suberoylanilide hydroxamic acid (SAHA) is a prototype of a family of hydroxamic acid based compounds (SAHA-like HPCs) that can, at micromolar concentrations, induce a variety of transformed cell lines to differentiate. The mechanism of action of the HPCs is not entirely understood. Searching for a cellular target of the SAHA-like HPCs, we synthesized a photoaffinity labeling reagent structurally based on SAHA, and probed for SAHA-binding proteins in murine erythroleukemia (MEL) cells. Photoaffinity labeling in cell free extracts identified a 32-kDa protein (p32) that was specifically labeled by the photoaffinity reagent. Cell fractionation assays localized p32 to the P100 fraction, p32 was partially purified and identified by mass spectrometry as the 40 S ribosomal protein S3. Expression of epitope-tagged S3 in bacterial lysates followed by photoaffinity labeling confirmed its specific labeling. Identification of a cytodifferentiation agent target may shed light on the mechanism by which the SAHA-like HPCs exert their antitumor effects.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	Memorial Sloan Kettering Cancer Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Memorial Sloan Kettering Cancer Center; Columbia University	Richon, VM (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594; Zhou, Xianbo/0000-0003-3544-7497	NCI NIH HHS [CA-0974823, P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM18754-35A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018754, R37GM018754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FA, 1998, CURRENT PROTOCALS MO; Bayley H, 1983, LAB TECHNIQUES BIOCH, V12; BOMMER UA, 1991, BIOCHIMIE, V73, P1007, DOI 10.1016/0300-9084(91)90142-N; BRESLOW R, 1991, P NATL ACAD SCI USA, V88, P5542, DOI 10.1073/pnas.88.13.5542; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; COREY EJ, 1977, TETRAHEDRON LETT, P3529; Deutsch WA, 1997, J BIOL CHEM, V272, P32857, DOI 10.1074/jbc.272.52.32857; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fenyo D, 1996, ANAL CHEM, V68, pA721, DOI 10.1021/ac9621579; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; Geromanos S, 1998, RAPID COMMUN MASS SP, V12, P551, DOI 10.1002/(SICI)1097-0231(19980515)12:9<551::AID-RCM198>3.3.CO;2-P; GRABOWSKI DT, 1991, NUCLEIC ACIDS RES, V19, P4297, DOI 10.1093/nar/19.15.4297; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; MARKS PA, 1989, P NATL ACAD SCI USA, V86, P6358, DOI 10.1073/pnas.86.16.6358; Marks PA, 1996, INT J HEMATOL, V63, P1; MARKS PA, 1992, CONCISE REV CLIN EXP, P91; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; NOMURA S, 1986, CELL, V44, P663, DOI 10.1016/0092-8674(86)90275-8; PALAI S, 1988, CHEM FUNCTIONAL GROU; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; REUBEN RC, 1978, J BIOL CHEM, V253, P4214; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; RICHON V, 1992, MOL CELLULAR APPROAC, P243; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; RICHON VM, 1994, CELL BIOL LAB HDB, V1, P213; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; SAUDIN RB, 1943, ORG SYN, V2, P196; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302; WESTERMANN P, 1979, FEBS LETT, V97, P101, DOI 10.1016/0014-5793(79)80061-7; WILLGERODT C, 1904, CHEM BERICHTE, V3351; WILSON DM, 1994, J BIOL CHEM, V269, P25359; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101	43	37	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14280	14287		10.1074/jbc.274.20.14280	http://dx.doi.org/10.1074/jbc.274.20.14280			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318849	hybrid			2022-12-25	WOS:000080322200078
J	Chutkow, WA; Makielski, JC; Nelson, DJ; Burant, CF; Fan, Z				Chutkow, WA; Makielski, JC; Nelson, DJ; Burant, CF; Fan, Z			Alternative splicing of sur2 exon 17 regulates nucleotide sensitivity of the ATP-sensitive potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PIG VENTRICULAR MYOCYTES; HEART CELL-MEMBRANE; PANCREATIC B-CELLS; K+ CHANNEL; SULFONYLUREA RECEPTOR; SKELETAL-MUSCLE; SMOOTH-MUSCLE; FUNCTIONAL SIMILARITIES; DISTINCT FUNCTIONS	ATP-sensitive potassium channels (K-ATP) are implicated in a diverse array of physiological functions. Previous work has shown that alternative usage of exons 14, 39, and 40 of the muscle-specific K-ATP channel regulatory subunit,, sur2, occurs in tissue-specific patterns. Here, we show that exon 17 of the first nucleotide binding fold of sur2 is also alternatively spliced. RNase protection demonstrates that SUR2(Delta 17) predominates in skeletal muscle and gut and is also expressed in bladder, fat, heart, lung, liver, and kidney. Polymerase chain reaction and restriction digest analysis of sur2 cDNA demonstrate the existence of at least five sur2 splice variants as follows: SUR2(39), SUR2(40), SUR2(Delta 17/39), SUR2(Delta 17/40), and SUR2(Delta 14/39). Electrophysiological recordings of excised, inside-out patches from COS cells cotransfected with Kir6.2 and the sur2 variants demonstrated that exon 17 splicing alters KATP sensitivity to ATP block, by a;fold hom;approximate to 40 to approximate to 90 mu M for exon 17 and Delta 17, respectively. Single channel kinetic analysis of SUR2(39) and SUR2(Delta 17/39) demonstrated that both exhibited characteristic K-ATP kinetics but that SUR2(Delta 17/39) exhibited longer mean burst durations and shorter mean interburst dwell times. In sum, alternative splicing of sur2 enhances the observed diversity of K-ATP and may contribute to tissue-specific modulation of ATP sensitivity.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Univ Wisconsin, Dept Med, Madison, WI 53792 USA	University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison	Burant, CF (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058133, R01HL057414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002170] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL58133-01, R01-HL57414] Funding Source: Medline; NIDDK NIH HHS [DK-K08-02170] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Akao M, 1997, J CLIN INVEST, V100, P3053, DOI 10.1172/JCI119860; Alekseev AE, 1998, J GEN PHYSIOL, V111, P381, DOI 10.1085/jgp.111.2.381; Alekseev AE, 1997, J MEMBRANE BIOL, V159, P161, DOI 10.1007/s002329900279; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BEECH DJ, 1993, BRIT J PHARMACOL, V110, P573, DOI 10.1111/j.1476-5381.1993.tb13849.x; BLEICH M, 1990, PFLUG ARCH EUR J PHY, V415, P449, DOI 10.1007/BF00373623; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Carson MR, 1995, BIOPHYS J, V69, P2443, DOI 10.1016/S0006-3495(95)80113-X; Chutkow WA, 1996, DIABETES, V45, P1439, DOI 10.2337/diabetes.45.10.1439; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DUNNE MJ, 1986, FEBS LETT, V208, P59, DOI 10.1016/0014-5793(86)81532-0; FAN Z, 1990, PFLUG ARCH EUR J PHY, V415, P387, DOI 10.1007/BF00373613; FAN Z, 1990, J PHYSIOL-LONDON, V430, P273, DOI 10.1113/jphysiol.1990.sp018291; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; GILLIS KD, 1989, AM J PHYSIOL, V257, pC1119, DOI 10.1152/ajpcell.1989.257.6.C1119; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HIRAOKA M, 1989, J PHARMACOL EXP THER, V250, P278; HIRAOKA M, 1993, CARDIOVASC DRUG THER, V7, P593, DOI 10.1007/BF00877625; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; KAJIOKA S, 1991, J PHYSIOL-LONDON, V444, P397, DOI 10.1113/jphysiol.1991.sp018885; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; MANAVALAN P, 1995, FEBS LETT, V366, P87, DOI 10.1016/0014-5793(95)00463-J; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Qin F, 1997, P ROY SOC B-BIOL SCI, V264, P375, DOI 10.1098/rspb.1997.0054; Quast U, 1996, N-S ARCH PHARMACOL, V354, P213; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P659, DOI 10.1113/jphysiol.1984.sp015089; Sambrook J., 1989, MOL CLONING; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; SPRUCE AE, 1985, NATURE, V316, P736, DOI 10.1038/316736a0; SPRUCE AE, 1987, J PHYSIOL-LONDON, V382, P213, DOI 10.1113/jphysiol.1987.sp016364; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; Tokuyama Y, 1996, BIOCHEM BIOPH RES CO, V220, P532, DOI 10.1006/bbrc.1996.0439; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7	54	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13656	13665		10.1074/jbc.274.19.13656	http://dx.doi.org/10.1074/jbc.274.19.13656			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224138	hybrid			2022-12-25	WOS:000080200400100
J	Holinger, EP; Chittenden, T; Lutz, RJ				Holinger, EP; Chittenden, T; Lutz, RJ			Bak BH3 peptides antagonize Bcl-x(L) function and induce apoptosis through cytochrome c-independent activation of caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; INDUCED CELL-DEATH; SURVIVAL-PROMOTING PROTEINS; POLY(ADP-RIBOSE) POLYMERASE; PERMEABILITY TRANSITION; FAMILY PROTEINS; ION-CHANNEL; HETERODIMERIZATION; INHIBITION; DOMAIN	The Bcl-2 homology 3 (BH3) domain is crucial for the death-inducing and dimerization properties of pro-apoptotic members of the Bcl-2 protein family, including Bak, Bar, and Bad. Here we report that synthetic peptides corresponding to the BH3 domain of Bak bind to Bcl-x(L), antagonize its anti-apoptotic function, and rapidly induce apoptosis when delivered into intact cells via fusion to the Antennapedia homeoprotein internalization domain. Treatment of HeLa cells with the Antennapedia-BH3 fusion peptide resulted in peptide internalization and induction of apoptosis within 2-3 h, as indicated by caspase activation and subsequent poly(ADP-ribose) polymerase cleavage, as well as morphological characteristics of apoptosis, A point mutation within the BH3 peptide that blocks its ability to bind to Bcl-x(L) abolished its apoptotic activity, suggesting that interaction of the BH3 peptide with Eel-a-related death suppressors, such as Bcl-x(L), may be critical for its activity in cells. While overexpression of Bcl-x(L) can block BH3-induced apoptosis, treatment with BH3 peptides resensitized Bcl-x(L)-expressing cells to Fas-mediated apoptosis, BH3-induced apoptosis was blocked by caspase inhibitors, demonstrating a dependence on caspase activation, but was not accompanied by a dramatic early loss of mitochondrial membrane potential or detectable translocation of cytochrome c from mitochondria to cytosol, These findings demonstrate that the BH3 domain itself is capable of inducing apoptosis in whole cells, possibly by antagonizing the function of Eel-a-related death suppressors.	Apoptosis Technol Inc, Cambridge, MA 02139 USA		Lutz, RJ (corresponding author), Apoptosis Technol Inc, 148 Sidney St, Cambridge, MA 02139 USA.							Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BALL KL, 1996, CURR BIOL, V7, P71; Bonfanti M, 1997, CANCER RES, V57, P1442; BOYD JM, 1995, ONCOGENE, V11, P1921; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; LABEZNIK YA, 1994, NATURE, V371, P346; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THEODORE L, 1995, J NEUROSCI, V15, P7158; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	59	235	280	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13298	13304		10.1074/jbc.274.19.13298	http://dx.doi.org/10.1074/jbc.274.19.13298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224090	hybrid			2022-12-25	WOS:000080200400052
J	Kondejewski, LH; Jelokhani-Niaraki, M; Farmer, SW; Lix, B; Kay, CM; Sykes, BD; Hancock, REW; Hodges, RS				Kondejewski, LH; Jelokhani-Niaraki, M; Farmer, SW; Lix, B; Kay, CM; Sykes, BD; Hancock, REW; Hodges, RS			Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PROTEIN SECONDARY STRUCTURE; ALPHA-HELICAL PEPTIDES; GRAMICIDIN-S ANALOGS; PSEUDOMONAS-AERUGINOSA; BETA-SHEET; HYDROPHOBIC MOMENT; CIRCULAR-DICHROISM; LIPID BILAYERS; OUTER-MEMBRANE	We have investigated the role of amphipathicity in a homologous series of head-to-tail cyclic antimicrobial peptides in efforts to delineate features resulting in high antimicrobial activity coupled with low hemolytic activity (Le. a high therapeutic index). The peptide GS14, cyclo(VKLKVd-YPLKVKLd-YP), designed on the basis of gramicidin S (GS), exists in a preformed highly amphipathic beta-sheet conformation and was used as the base compound for this study. Fourteen diastereomers of GS14 were synthesized; each contained a different single enantiomeric substitution within the framework of GS14, The beta-sheet structure of all GS14 diastereomers was disrupted as determined by CD and NMR spectroscopy under aqueous conditions; however, all diastereomers exhibited differential structure inducibility in hydrophobic environments. Because the diastereomers all have the same composition, sequence, and intrinsic hydrophobicity, the amphipathicity of the diastereomers could be ranked based upon retention time from reversed-phase high performance liquid chromatography, There was a clear correlation showing that high amphipathicity resulted in high hemolytic activity and low antimicrobial activity in the diastereomers, The latter may be the result of increased affinity of highly amphipathic peptides to outer membrane components of Gram-negative microorganisms. The diastereomers possessing the most favorable therapeutic indices possessed some of the lowest amphipathicities, although there was a threshold value below which antimicrobial activity decreased. The best diastereomer exhibited 130-fold less hemolytic activity compared with GS14, as well as greatly increased antimicrobial activities, resulting in improvement in therapeutic indices of between 1,000- and 10,000 fold for a number of microorganisms. The therapeutic indices of this peptide were between 16- and 32-fold greater than GS for Gram-negative microorganisms and represents a significant improvement in specificity over GS, Our findings show that a highly amphipathic nature is not desirable in the design of constrained cyclic antimicrobial peptides and that an optimum amphipathicity can be defined by systematic enantiomeric substitutions.	Univ Alberta, Ctr Excellence, Prot Engn Network, Edmonton, AB T6G 2S2, Canada; Univ British Columbia, Canadian Bacterial Dis Network, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada	University of Alberta; University of British Columbia; University of British Columbia	Hodges, RS (corresponding author), Univ Alberta, Ctr Excellence, Prot Engn Network, Edmonton, AB T6G 2S2, Canada.		Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503; Farmer, Susan/0000-0002-6712-7810				BLANCO FJ, 1994, BIOCHEMISTRY-US, V33, P6004, DOI 10.1021/bi00185a041; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; CAGAS PM, 1995, PROT STRUCT FUNCT GE, V21, P141; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P171; Dathe M, 1996, BIOCHEMISTRY-US, V35, P12612, DOI 10.1021/bi960835f; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Gause GF, 1944, NATURE, V154, P703, DOI 10.1038/154703a0; Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284; GUO DC, 1986, J CHROMATOGR, V359, P499, DOI 10.1016/0021-9673(86)80102-9; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; HANCOCK REW, 1981, J ANTIMICROB CHEMOTH, V8, P429, DOI 10.1093/jac/8.6.429; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HULL SE, 1978, NATURE, V275, P206, DOI 10.1038/275206a0; IZUMIYA N, 1979, SYNTHETIC ASPECTS BI, P49; KATAYAMA T, 1994, J PHARM SCI, V83, P1357, DOI 10.1002/jps.2600830930; Kondejewski LH, 1996, J BIOL CHEM, V271, P25261, DOI 10.1074/jbc.271.41.25261; Krause E, 1996, INT J PEPT PROT RES, V48, P559; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; Mant CT, 1998, J CHROMATOGR A, V816, P65, DOI 10.1016/S0021-9673(98)00507-X; Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; NICAS TI, 1983, J GEN MICROBIOL, V129, P509; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; OVCHINNIKOV YA, 1975, TETRAHEDRON, V31, P2177, DOI 10.1016/0040-4020(75)80216-X; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PATHAK N, 1995, PROTEINS, V22, P182, DOI 10.1002/prot.340220210; Prenner EJ, 1997, BIOCHEMISTRY-US, V36, P7906, DOI 10.1021/bi962785k; RACKOVSKY S, 1980, P NATL ACAD SCI USA, V77, P6965, DOI 10.1073/pnas.77.12.6965; Rothemund S, 1996, PEPTIDE RES, V9, P79; SEREDA TJ, 1994, J CHROMATOGR A, V676, P139, DOI 10.1016/0021-9673(94)00371-8; Shai Y, 1996, J BIOL CHEM, V271, P7305, DOI 10.1074/jbc.271.13.7305; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; TAMAKI M, 1987, J CHROMATOGR-BIOMED, V413, P287, DOI 10.1016/0378-4347(87)80241-4; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; Wieprecht T, 1997, BIOCHEMISTRY-US, V36, P6124, DOI 10.1021/bi9619987; Wishart DS, 1996, LETT PEPT SCI, V3, P53, DOI 10.1007/BF00131086; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; ZHOU N E, 1990, Peptide Research, V3, P8	41	228	239	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13181	13192		10.1074/jbc.274.19.13181	http://dx.doi.org/10.1074/jbc.274.19.13181			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224074	hybrid			2022-12-25	WOS:000080200400036
J	Munz, B; Wiedmann, M; Lochmuller, H; Werner, S				Munz, B; Wiedmann, M; Lochmuller, H; Werner, S			Cloning of novel injury-regulated genes - Implications for an important role of the muscle-specific protein skNAC in muscle repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGENERATING SKELETAL-MUSCLE; SATELLITE CELLS; ENDOPLASMIC-RETICULUM; MYOGENIN; COMPLEX; GROWTH; MOUSE; EXPRESSION; ACTIN; MYOD	To gain insight into the molecular mechanisms underlying the wound repair process, we searched for genes that are regulated by skin injury. Using the differential display reverse transcription-polymerase chain reaction technique, we identified a gene that was strongly induced as early as 12 h after wounding. Sequence analysis revealed the identity of the corresponding protein with skeletal muscle nascent polypeptide-associated complex (skNAC), a recently identified muscle-specific transcription factor. By in situ hybridization and immunohistochemistry, we demonstrated the specific expression of skNAC in skeletal muscle cells of the panniculus carnosus at the wound edge. Furthermore, in vitro studies with cultured myoblasts revealed expression of skNAC in differentiating and differentiated, but not in proliferating, nondifferentiated cells. Differentiation of cultured myoblasts was accompanied by simultaneous expression of skNAC and the muscle-specific transcription factor myogenin. Our results provide the first evidence for a role of skNAC in muscle repair processes. Furthermore, they demonstrate the usefulness of our approach in identifying new players in wound repair.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Munich, Genzentrum, D-81377 Munich, Germany; Univ Munich, Friedrich Baur Inst, D-80336 Munich, Germany	Max Planck Society; Memorial Sloan Kettering Cancer Center; University of Munich; University of Munich	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland.			Werner, Sabine/0000-0001-7397-8710; Lochmuller, Hanns/0000-0003-2324-8001				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAUER D, 1994, PCR METH APPL, V4, P97; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK RAF, 1996, MOL CELLULAR BIOL WO, P8; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Franke WW, 1996, DIFFERENTIATION, V60, P245, DOI 10.1046/j.1432-0436.1996.6040245.x; FUCHTBAUER EM, 1992, DEV DYNAM, V193, P34; Gal-Levi R, 1998, BBA-MOL CELL RES, V1402, P39, DOI 10.1016/S0167-4889(97)00124-9; GROUNDS MD, 1992, CELL TISSUE RES, V267, P99, DOI 10.1007/BF00318695; HAM RG, 1988, IN VITRO CELL DEV B, V24, P833; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; ROSENTHAL A, 1987, EMBO J, V6, P3641, DOI 10.1002/j.1460-2075.1987.tb02696.x; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yotov WV, 1996, GENE DEV, V10, P1763, DOI 10.1101/gad.10.14.1763	19	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13305	13310		10.1074/jbc.274.19.13305	http://dx.doi.org/10.1074/jbc.274.19.13305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224091	hybrid			2022-12-25	WOS:000080200400053
J	Spiridonov, NA; Wilson, DB				Spiridonov, NA; Wilson, DB			Characterization and cloning of CelR, a transcriptional regulator of cellulase genes from Thermomonospora fusca	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-LIVIDANS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; LAC REPRESSORS; DNA-SEQUENCES; PROTEIN; EXPRESSION; IDENTIFICATION; ENDOGLUCANASE; AVICELASE	CelR, a protein that regulates transcription of cellulase genes in Thermomonospora fusca (Actinomycetaceae) was purified to homogeneity. A B-kilobase NotI-SacI fragment of T. fusca DNA containing the celR gene was cloned into Esherichia coli and sequenced. The celR gene encodes a 340-residue polypeptide that is highly homologous to members of the GalR-LacI family of bacterial transcriptional regulators. CelR specifically binds to a Ii-base pair inverted repeat, which has sequence similarity to the binding sites of other family members. This site is present in regions upstream of all six cellulase genes in T. fusca. The binding of CelR to the celE promoter is inhibited specifically by low concentrations of cellobiose (0.2-0.5 mM), the major end product of cellulases. The other sugars tested did not affect binding at equivalent or 50-fold higher concentrations. The results suggest that CelR may act as a repressor, and that the mechanism of induction involves a direct interaction of CelR with cellobiose.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University	Wilson, DB (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, 458 Biotechnol Bldg,, Ithaca, NY 14853 USA.	dbw3@cornell.edu	Spiridonov, Nikolay/B-6287-2014					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barr BK, 1996, BIOCHEMISTRY-US, V35, P586, DOI 10.1021/bi9520388; Blanco J, 1997, APPL MICROBIOL BIOT, V48, P208, DOI 10.1007/s002530051040; FERNANDEZABALOS JM, 1992, J BACTERIOL, V174, P6368; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAGERDAL BGR, 1978, APPL ENVIRON MICROB, V36, P606; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Ilmen M, 1996, MOL GEN GENET, V251, P451, DOI 10.1007/s004380050189; IRWIN DC, 1993, BIOTECHNOL BIOENG, V42, P1002, DOI 10.1002/bit.260420811; JUNG ED, 1993, APPL ENVIRON MICROB, V59, P3032, DOI 10.1128/AEM.59.9.3032-3043.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAO G, 1991, J BACTERIOL, V173, P3397, DOI 10.1128/jb.173.11.3397-3407.1991; LIN E, 1987, APPL ENVIRON MICROB, V53, P1352, DOI 10.1128/AEM.53.6.1352-1357.1987; LIN E, 1988, J BACTERIOL, V170, P3843, DOI 10.1128/jb.170.9.3843-3846.1988; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; NAKAI R, 1988, GENE, V65, P229; Nguyen J, 1997, J BACTERIOL, V179, P6383, DOI 10.1128/jb.179.20.6383-6390.1997; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; Saloheimo A., 1998, CARBOHYDRASES TRICHO, P267; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOCHTERMEIER A, 1992, MOL MICROBIOL, V6, P3611, DOI 10.1111/j.1365-2958.1992.tb01797.x; Spiridonov NA, 1998, J BACTERIOL, V180, P3529, DOI 10.1128/JB.180.14.3529-3532.1998; THEBERGE M, 1992, APPL ENVIRON MICROB, V58, P815; Walter S, 1996, MOL GEN GENET, V251, P186, DOI 10.1007/s004380050156; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WILSON DB, 1992, CRIT REV BIOTECHNOL, V12, P45, DOI 10.3109/07388559209069187; WILSON DB, 1999, IN PRESS RECENT PROG; ZHANG S, 1995, BIOCHEMISTRY-US, V34, P3386, DOI 10.1021/bi00010a030	30	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13127	13132		10.1074/jbc.274.19.13127	http://dx.doi.org/10.1074/jbc.274.19.13127			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224066	hybrid			2022-12-25	WOS:000080200400028
J	Alvarez-Dominguez, C; Stahl, PD				Alvarez-Dominguez, C; Stahl, PD			Increased expression of Rab5a correlates directly with accelerated maturation of Listeria monocytogenes phagosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY ENDOCYTIC PATHWAY; GAMMA-INTERFERON; FUSION; CELLS; YEAST; MACROPHAGES; MECHANISMS; ACTIVATION; ENDOSOMES; ISOFORMS	Previous studies have shown that Listeria monocytogenes (LM) modulates phagocytic membrane traffic. Here we explore whether Rab5a, a GTPase associated with phagosome-endosome fusion, is related to phagosome maturation and to the intracellular survival of LM. Stable transfection of Rab5a cDNA into macrophages accelerates intracellular degradation of LM. Morphological studies confirmed that phagosome maturation and phagosome-lysosome fusion is enhanced by overexpression of Rab5a. Down-regulation experiments using antisense oligonucleotides targeted to the Rab5a mRNA efficiently reduced RabBa synthesis, reduced phagosome-endosome traffic, blocked phagosome-lysosome fusion, and extended intraphagosomal survival of LM. Down-regulation of Rab5a had no effect on LM internalization. Down-regulation of Rab5c had no effect on phagosome maturation and phagosome-lysosome fusion. The results indicate that RabBa controls early phagosome-endosome interactions and governs the maturation of the early phagosome leading to phagosome-lysosome fusion.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.		Alvarez-Dominguez, Carmen/J-4675-2014	Alvarez-Dominguez, Carmen/0000-0002-4585-6959				Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; Alvarez-Dominguez C., 1995, Immunology and Infectious Diseases (Oxford), V5, P127; Alvarez-Dominguez C, 1998, J BIOL CHEM, V273, P33901, DOI 10.1074/jbc.273.51.33901; ALVAREZDOMINGUE.C, 1998, PHAGOCYTOSIS PATHOGE; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; AlvarezDominguez C, 1997, J CELL SCI, V110, P731; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BERMUDEZ LE, 1993, CLIN EXP IMMUNOL, V91, P277; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Field H, 1998, J BIOL CHEM, V273, P32102, DOI 10.1074/jbc.273.48.32102; HARDING CV, 1992, EUR J IMMUNOL, V22, P1865, DOI 10.1002/eji.1830220728; HIGGINBOTHAM JN, 1992, CLIN EXP IMMUNOL, V88, P492; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; JONES S, 1994, INFECT IMMUN, V62, P5608, DOI 10.1128/IAI.62.12.5608-5613.1994; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; Pontow SE, 1996, J BIOL CHEM, V271, P30736, DOI 10.1074/jbc.271.48.30736; PORTNOY DA, 1992, CURR OPIN IMMUNOL, V4, P20, DOI 10.1016/0952-7915(92)90118-X; PORTNOY DA, 1989, J EXP MED, V170, P2141, DOI 10.1084/jem.170.6.2141; Scorneaux B, 1996, ANTIMICROB AGENTS CH, V40, P1225, DOI 10.1128/AAC.40.5.1225; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; STEINC A, 1989, OLIGODEOXYNUCLEOTIDE, P97; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Zerlauth G, 1996, INFECT IMMUN, V64, P2666, DOI 10.1128/IAI.64.7.2666-2672.1996	30	68	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11459	11462		10.1074/jbc.274.17.11459	http://dx.doi.org/10.1074/jbc.274.17.11459			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206948	hybrid			2022-12-25	WOS:000079834800004
J	Rudolph, AE; Stuckey, JA; Zhao, Y; Matthews, HR; Patton, WA; Moss, J; Dixon, JE				Rudolph, AE; Stuckey, JA; Zhao, Y; Matthews, HR; Patton, WA; Moss, J; Dixon, JE			Expression, characterization, and mutagenesis of the Yersinia pestis murine toxin, a phospholipase D superfamily member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; D DEFINES; PHOSPHATASE; PHOSPHATIDYLCHOLINE; FAMILY; GENE; PHOSPHOHISTIDINE; IDENTIFICATION; INTERMEDIATE; PURIFICATION	A phospholipase D (PLD) superfamily was recently identified that contains proteins of highly diverse functions with the conserved motif HXKX(4)DX(6)G(G/S). The superfamily includes a bacterial nuclease, human and plant PLD enzymes, cardiolipin synthases, phosphatidylserine synthases, and the murine toxin from Yersinia pestis (Ymt), Ymt is particularly effective as a prototype for family members containing two conserved motifs, because it is smaller than many other two-domain superfamily enzymes, and it can be overexpressed, Large quantities of pure recombinant Ymt allowed the formation of diffraction-quality crystals for x-ray structure determination, Dimeric Ymt was shown to have PLD-like activity as demonstrated by the hydrolysis of phosphatidylcholine. Ymt also used bis(para-nitrophenol) phosphate as a substrate. Using these substrates, the amino acids essential for Ymt function were determined. Specifically, substitution of histidine or lysine in the conserved motifs reduced the turnover rate of bis(para-nitrophenol) phosphate by a factor of 10(4) and phospholipid turnover to an undetectable level. The role of the conserved residues in catalysis was further defined by the isolation of a radiolabeled phosphoenzyme intermediate, which identified a conserved histidine residue as the nucleophile in the catalytic reaction. Based on these data, a unifying two-step catalytic mechanism is proposed for this diverse family of enzymes.	Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Dixon, JE (corresponding author), Univ Michigan, Dept Biol Chem, Sch Med, M5416 Med Sci Bldg I, Ann Arbor, MI 48109 USA.	jedixon@umich.edu			NIDDK NIH HHS [NIDDKD 18849] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYER PD, 1962, J BIOL CHEM, V237, P3306; Brubaker R R, 1972, Curr Top Microbiol Immunol, V57, P111; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; BRUZIK K, 1984, BIOCHEMISTRY-US, V23, P1656, DOI 10.1021/bi00303a012; BURLAND V, 1995, NUCLEIC ACIDS RES, V23, P2105, DOI 10.1093/nar/23.12.2105; Butler T, 1983, PLAGUE OTHER YERSINI; Cao JX, 1997, VIRUS RES, V48, P11, DOI 10.1016/S0168-1702(96)01422-0; Cherepanov P A, 1991, Mol Gen Mikrobiol Virusol, P19; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HIRAOKA S, 1991, J BIOCHEM, V110, P443, DOI 10.1093/oxfordjournals.jbchem.a123600; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; POHLMAN RF, 1993, NUCLEIC ACIDS RES, V21, P4867, DOI 10.1093/nar/21.21.4867; Ponting CP, 1996, PROTEIN SCI, V5, P914; RAETZ CRH, 1987, BIOCHEMISTRY-US, V26, P4022, DOI 10.1021/bi00387a042; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TROPP BE, 1995, J BACTERIOL, V177, P5155, DOI 10.1128/jb.177.17.5155-5157.1995; VANETTEN RL, 1978, P NATL ACAD SCI USA, V75, P4784; WANG XM, 1994, J BIOL CHEM, V269, P20312; WEI YF, 1991, METHOD ENZYMOL, V200, P388; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679; YANG SF, 1967, J BIOL CHEM, V242, P477; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 1997, PROTEIN SCI, V6, P2655	34	93	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11824	11831		10.1074/jbc.274.17.11824	http://dx.doi.org/10.1074/jbc.274.17.11824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207000	hybrid			2022-12-25	WOS:000079834800056
J	Schmidt, BZ; Fowler, NL; Hidvegi, T; Perlmutter, DH; Colten, HR				Schmidt, BZ; Fowler, NL; Hidvegi, T; Perlmutter, DH; Colten, HR			Disruption of disulfide bonds is responsible for impaired secretion in human complement factor H deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM DEGRADATION; CONSENSUS REPEAT UNITS; HOMOZYGOUS FACTOR-H; CYSTEINE RESIDUES; MENINGOCOCCAL DISEASE; REGULATORY PROTEINS; MEMBRANE-PROTEIN; HUMAN LYSOZYME; C2 DEFICIENCY; CDNA SEQUENCE	Factor H, a secretory glycoprotein composed of 20 short consensus repeat modules, is an inhibitor of the complement system. Previous studies of inherited factor H deficiency revealed single amino acid substitutions at conserved cysteine residues, on one allele arginine for cysteine 518 (C518R) and on the other tyrosine for cysteine 941 (C941Y) (Ault, B. H,, Schmidt, B, Z,, Fowler, N, L., Kashtan, C, E,, Ahmed, A. E,, Vogt, B, A., and Colten, H, R, (1997) J, Biol. Chem, 272, 25168-25175), To ascertain if the phenotype, impaired secretion of factor H, is due to the C518R substitution or the C941Y substitution and to ascertain the mechanism by which secretion is impaired, we studied COS-1 and HepG2 cells transfected with wild type and several mutant factor H molecules, The results showed markedly impaired secretion of both C518R and C941Y factor H as well as that of factor H molecules bearing alanine or arginine substitutions at the Cys(518)-Cys(546) disulfide bond (C518A, C546A, C546R, C518A-C546A), In each case, mutant factor H was retained in the endoplasmic reticulum and degraded relatively slowly as compared with most other mutant secretory and membrane proteins that are retained in the endoplasmic reticulum, These data indicate that impaired secretion of the naturally occurring C518R and C941Y mutant factor H proteins is due to disruption of framework-specific disulfide bonds in factor H short consensus repeat modules.	Washington Univ, Sch Med, Childrens Hosp, Dept Pediat,Div Gastroenterol & Nutr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Childrens Hosp, Dept Cell Biol,Div Gastroenterol & Nutr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Childrens Hosp, Dept Physiol,Div Gastroenterol & Nutr, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Perlmutter, DH (corresponding author), Washington Univ, Sch Med, Childrens Hosp, Dept Pediat,Div Gastroenterol & Nutr, 1 Childrens Pl, St Louis, MO 63110 USA.		Hidvegi, Tunda/A-8041-2008	Schmidt, Bela Z/0000-0003-1085-9372	NHLBI NIH HHS [HL37784] Funding Source: Medline; NIAID NIH HHS [AI24836] Funding Source: Medline; NIDDK NIH HHS [DK52526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BRAI M, 1988, J CLIN IMMUNOL, V8, P50, DOI 10.1007/BF00915156; DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; Eikenboom JCJ, 1996, BLOOD, V88, P2433, DOI 10.1182/blood.V88.7.2433.bloodjournal8872433; Ernst SC, 1996, J IMMUNOL, V157, P405; FIJEN CAP, 1989, LANCET, V2, P585; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Harlow E, 1988, ANTIBODIES LAB MANUA, P418; HASHIGUCHI T, 1995, J CLIN INVEST, V95, P1002, DOI 10.1172/JCI117744; HAVILAND DL, 1991, J IMMUNOL, V146, P362; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; Horton R M, 1997, Methods Mol Biol, V67, P141; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KULICS J, 1994, IMMUNOLOGY, V82, P509; LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOPEZLARREA C, 1987, BIOCHEM SOC T, V15, P648, DOI 10.1042/bst0150648; MCCORMACK AL, 1995, J BIOL CHEM, V270, P3212, DOI 10.1074/jbc.270.7.3212; MIYAZAKI JI, 1986, P NATL ACAD SCI USA, V83, P757, DOI 10.1073/pnas.83.3.757; Nabil K, 1997, BIOCHEM J, V326, P377, DOI 10.1042/bj3260377; NAKANO Y, 1992, BIOCHIM BIOPHYS ACTA, V1116, P235, DOI 10.1016/0304-4165(92)90016-N; NIELSEN HE, 1989, SCAND J IMMUNOL, V30, P711, DOI 10.1111/j.1365-3083.1989.tb02480.x; NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277; OMURA F, 1992, EUR J BIOCHEM, V205, P551, DOI 10.1111/j.1432-1033.1992.tb16812.x; PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULZ TF, 1986, EUR J IMMUNOL, V16, P1351, DOI 10.1002/eji.1830161107; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SUGAHARA Y, 1994, THROMB HAEMOSTASIS, V72, P814; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; THOMPSON RA, 1981, CLIN EXP IMMUNOL, V46, P110; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VIK DP, 1989, CURR TOP MICROBIOL I, V153, P147; VOGT BA, 1995, PEDIATR NEPHROL, V9, P11, DOI 10.1007/BF00858956; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Warwicker P, 1997, IMMUNOGENETICS, V46, P437, DOI 10.1007/s002510050300; Wetsel RA, 1996, J BIOL CHEM, V271, P5824, DOI 10.1074/jbc.271.10.5824; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; YUK MH, 1995, J BIOL CHEM, V270, P20169, DOI 10.1074/jbc.270.34.20169; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	58	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11782	11788		10.1074/jbc.274.17.11782	http://dx.doi.org/10.1074/jbc.274.17.11782			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206995	hybrid			2022-12-25	WOS:000079834800051
J	Taylor, VC; Buckley, CD; Douglas, M; Cody, AJ; Simmons, DL; Freeman, SD				Taylor, VC; Buckley, CD; Douglas, M; Cody, AJ; Simmons, DL; Freeman, SD			The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOGENOUS LEUKEMIA; IMMUNOGLOBULIN SUPERFAMILY; INHIBITORY RECEPTOR; CRYSTAL-STRUCTURE; PROGENITOR CELLS; SH2 DOMAIN; ANTIBODY; ANTIGEN; FAMILY; SIALOADHESIN	The myeloid restricted membrane glycoprotein, CD33, is a member of the recently characterized "sialic acid-binding immunoglobulin-related lectin" family. Although CD33 can mediate sialic acid-dependent cell interactions as a recombinant protein, its function in myeloid cells has yet to be determined. Since CD33 contains two potential immunoreceptor tyrosine-based inhibition motifs in its cytoplasmic tail, we investigated whether it might act as a signaling receptor in myeloid cells. Tyrosine phosphorylation of CD33 in myeloid cell lines was stimulated by cell surface cross-linking or by pervanadate, and inhibited by PP2, a specific inhibitor of Src family tyrosine kinases, Phosphorylated CD33 recruited both the protein-tyrosine phosphatases, SHP-1 and SHP-8. CD33 was dephosphorylated in vitro by the co-immunoprecipitated tyrosine phosphatases, suggesting that it might also be an in vivo substrate. The first CD33 phosphotyrosine motif is dominant in CD33-SHP-1/SHP-2 interactions, since mutating tyrosine 340 in a CD33-cytoplasmic tail fusion protein significantly reduced binding to SHP-1 and SHP-2 in THP-1 lysates, while mutation of tyrosine 358 had no effect. Furthermore, the NH2-terminal Src homology 2 domain of SHP-1 and SHP-8, believed to be essential for phosphatase activation, selectively bound a CD33 phosphopeptide containing tyrosine 340 but not one containing tyrosine 358, Finally, mutation of tyrosine 340 increased red blood cell binding by CD33 expressed in COS cells. Hence, CD33 signaling through selective recruitment of SHP-1/SHP-8 may modulate its ligand(s) binding activity.	John Radcliffe Hosp, Inst Mol Med, Cell Adhes Lab, Oxford OX3 9DU, England; Univ Birmingham, Dept Rheumatol, Birmingham B15 2TT, W Midlands, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England	University of Oxford; University of Birmingham; GlaxoSmithKline	Freeman, SD (corresponding author), John Radcliffe Hosp, Inst Mol Med, Cell Adhes Lab, Oxford OX3 9DU, England.	freemans@icrf.icnet.uk		Cody, Alison/0000-0002-2868-6580; Freeman, Sylvie/0000-0003-1869-180X				APPELBAUM FR, 1992, TRANSPLANTATION, V54, P829, DOI 10.1097/00007890-199211000-00012; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Burshtyn DN, 1997, TRENDS CELL BIOL, V7, P473, DOI 10.1016/S0962-8924(97)01167-7; CARON PC, 1994, CANCER, V73, P1049, DOI 10.1002/1097-0142(19940201)73:3+<1049::AID-CNCR2820731344>3.0.CO;2-1; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; GRIFFIN JD, 1984, LEUKEMIA RES, V8, P521, DOI 10.1016/0145-2126(84)90001-8; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Huyer G, 1998, BIOCHEMISTRY-US, V37, P2741, DOI 10.1021/bi9722913; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; MATUTES E, 1985, HEMATOL ONCOL, V3, P179, DOI 10.1002/hon.2900030306; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; ROBERTSON MJ, 1992, BLOOD, V79, P2229; SIMMONS D, 1988, J IMMUNOL, V141, P2797; Takei Y, 1997, CYTOGENET CELL GENET, V78, P295, DOI 10.1159/000134676; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6	30	132	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11505	11512		10.1074/jbc.274.17.11505	http://dx.doi.org/10.1074/jbc.274.17.11505			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206955	Green Published, hybrid			2022-12-25	WOS:000079834800011
J	Gupta, D; Wang, QL; Vinson, C; Dziarski, R				Gupta, D; Wang, QL; Vinson, C; Dziarski, R			Bacterial peptidoglycan induces CD14-dependent activation of transcription factors CREB ATF and AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SIGNAL-REGULATED KINASE; LPS-BINDING-PROTEIN; LIPOPOLYSACCHARIDE LPS; SOLUBLE PEPTIDOGLYCAN; MONOCYTIC CELLS; CROSS-LINKING; C-JUN; CD14; GENE	Peptidoglycan (PGN), the major cell wall component of Gram-positive bacteria, induces secretion of cytokines in macrophages through CD14, the pattern recognition receptor that binds lipopolysaccharide and other microbial products. To begin to elucidate the mechanisms that regulate the transcription of cytokine genes, we wanted to determine which transcription factors are activated by PGN in mouse RAW264.7 and human THP-1 macrophage cells. Our results demonstrated that: (i) PGN induced phosphorylation of the transcription factors ATF-1 and CREB; (ii) ATF-1 and CREB bound DNA asa dimer and induced transcriptional activation of a CRE reporter plasmid, which was inhibited by dominant negative CREB and ATF-1; (iii) PGN induced phosphorylation of c-Jun, protein synthesis of JunB and c-Fos, and transcriptional activation of the AP-1 reporter plasmid, which was inhibited by dominant negative c-Fos; and (iv) PGN-induced activation of CREB/ATF and AP-1 was mediated through CD14. This is the first study to demonstrate activation of CREB/ATF and AP-1 transcription factors by PGN or by any other component of Gram-positive bacteria.	Indiana Univ, Sch Med, NW Ctr Med Educ, Gary, IN 46408 USA; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	Indiana University System; Indiana University Northwest; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gupta, D (corresponding author), Indiana Univ, Sch Med, NW Ctr Med Educ, 3400 Broadway, Gary, IN 46408 USA.				NIAID NIH HHS [AI28797] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, V3; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; CHANDRA G, 1995, J IMMUNOL, V155, P4535; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; DENT T, 1993, GENE DEV, V7, P479; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; DZIARSKI R, 1999, GLYCOMICROBIOLOGY; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; GUPTA D, 1995, J IMMUNOL, V155, P2620; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Heymer B., 1985, IMMUNOLOGY BACTERIAL, P11; Jin YP, 1998, J INFECT DIS, V177, P1629, DOI 10.1086/515318; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pan JL, 1998, J BIOL CHEM, V273, P10068, DOI 10.1074/jbc.273.16.10068; PROFFITT J, 1995, GENE, V152, P173, DOI 10.1016/0378-1119(94)00701-S; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	39	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14012	14020		10.1074/jbc.274.20.14012	http://dx.doi.org/10.1074/jbc.274.20.14012			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318814	hybrid			2022-12-25	WOS:000080322200043
J	Rosenblat, M; Belinky, P; Vaya, J; Levy, R; Hayek, T; Coleman, R; Merchav, S; Aviram, M				Rosenblat, M; Belinky, P; Vaya, J; Levy, R; Hayek, T; Coleman, R; Merchav, S; Aviram, M			Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell-mediated oxidation of low density lipoprotein - A possible role for protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-DEFICIENT MICE; CHRONIC GRANULOMATOUS-DISEASE; LIPID-PEROXIDATION; HUMAN-NEUTROPHILS; RESPIRATORY BURST; HUMAN-MONOCYTES; LDL OXIDATION; IN-VITRO; ANTIOXIDANT ACTIVITY; STRUCTURAL ASPECTS	Macrophage-mediated oxidation of low density lipoprotein (LDL) is considered to be of major importance in early atherogenesis; therefore, intervention means to inhibit this process are being extensively studied. In the present study, we questioned the ability of the isoflavan glabridin (from licorice) to accumulate in macrophages and to affect cell-mediated oxidation of LDL, We first performed in vitro studies, using mouse peritoneal macrophages (MPMs) and the J-774 A.1 macrophage-like cell line. Both cells accumulated up to 1.5 mu g of glabridin/mg of cell protein after 2 h of incubation, and this process was time- and glabridin dose-dependent. In parallel, in glabridin-enriched cells, macrophage-mediated oxidation of LDL was inhibited by up to 80% in comparison with control cells. Glabridin inhibited superoxide release from MPMs in response to phorbol 12-myristate 13-acetate, or to LDL when added together with copper ions, by up to 60%, Translocation of P-47, a cytosolic component of NADPH oxidase to the plasma membrane was substantially inhibited, In glabridin-enriched macrophages, protein kinase C activity reduced by similar to 70%. All of the above effects of glabridin required the presence of the two hydroxyl groups on the flavonoid's B phenol ring, In order to assess the physiological significance of these results, we next performed in vivo studies, using the atherosclerotic apolipoprotein E-deficient (E-0) mice. MPMs harvested from glabridin-treated E-0 mice (20 mu g/mouse/day for a period of 6 weeks) demonstrated reduced capability to oxidize LDL by 80% in comparison with placebo-treated mice. This latter phenomenon was associated with a reduction in the lesion oxysterols and a 50% reduction in the aortic lesion size. We thus conclude that glabridin accumulation in macrophages is associated with reduced cell-mediated oxidation of LDL and decreased activation of the NADPH oxidase system. These phenomena could be responsible for the attenuation of atherosclerosis in E-0 mice, induced by glabridin.	Rambam Med Ctr, Lipid Res Lab, Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Lipid Res Lab, Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Anat & Cell Biol,Haemopoiesis Unit, Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Div Morphol Sci, Haifa, Israel; Galilee Technol Ctr, Lab Nat Cpds Med Use, Kiryat Shmona, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Fac Hlth Sci, Infect Dis Lab, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center	Aviram, M (corresponding author), Rambam Med Ctr, Lipid Res Lab, Haifa, Israel.	aviram@tx.technion.ac.il						AEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43; Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Aviram M, 1998, MOL CELL BIOCHEM, V188, P149, DOI 10.1023/A:1006841011201; AVIRAM M, 1993, ANN NUTR METAB, V37, P75, DOI 10.1159/000177753; AVIRAM M, 1983, BIOCHEM MED METAB B, V30, P111, DOI 10.1016/0006-2944(83)90013-3; Aviram M, 1996, EUR J CLIN CHEM CLIN, V34, P599; Aviram M, 1996, METABOLISM, V45, P1069, DOI 10.1016/S0026-0495(96)90005-0; Aviram M, 1998, ATHEROSCLEROSIS, V137, pS45, DOI 10.1016/S0021-9150(97)00306-7; AVIRAM M, 1989, ARTERIOSCLEROSIS, V9, P67, DOI 10.1161/01.ATV.9.1.67; AVIRAM M, 1992, J BIOL CHEM, V267, P218; AVIRAM M, 1994, J LIPID RES, V35, P385; AVIRAM M, 1999, CURR INT CARDIOL REP, V1, P66; Baoutina A, 1998, J LIPID RES, V39, P114; Belinky PA, 1998, ATHEROSCLEROSIS, V137, P49, DOI 10.1016/S0021-9150(97)00251-7; Belinky PA, 1998, FREE RADICAL BIO MED, V24, P1419, DOI 10.1016/S0891-5849(98)00006-9; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Buege J A, 1978, Methods Enzymol, V52, P302; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CHANG WS, 1993, ANTICANCER RES, V13, P2165; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ELLIOTT AJ, 1992, BIOCHEM PHARMACOL, V44, P1603, DOI 10.1016/0006-2952(92)90478-2; FERRIOLA PC, 1989, BIOCHEM PHARMACOL, V38, P1617, DOI 10.1016/0006-2952(89)90309-2; FUHRMAN B, 1995, AM J CLIN NUTR, V61, P549, DOI 10.1093/ajcn/61.3.549; Fuhrman B, 1997, AM J CLIN NUTR, V66, P267, DOI 10.1093/ajcn/66.2.267; GOCKE N, 1996, J CARDIOVASC RISK, V3, P352; HATANO T, 1991, YAKUGAKU ZASSHI, V111, P311, DOI 10.1248/yakushi1947.111.6_311; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; Hayek T, 1997, ARTERIOSCL THROM VAS, V17, P2744, DOI 10.1161/01.ATV.17.11.2744; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIRAMATSU K, 1987, ARTERIOSCLEROSIS, V7, P55, DOI 10.1161/01.ATV.7.1.55; Jaiswal AS, 1996, INDIAN J BIOCHEM BIO, V33, P116; JARVIS WD, 1994, CANCER RES, V54, P1707; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LEVY R, 1994, BBA-MOL CELL RES, V1220, P253, DOI 10.1016/0167-4889(94)90146-5; LEVY R, 1991, J IMMUNOL, V147, P3066; LEVY R, 1990, J IMMUNOL, V145, P2595; LI Q, 1994, J BIOL CHEM, V269, P17508; LIMASSET B, 1993, BIOCHEM PHARMACOL, V46, P1257, DOI 10.1016/0006-2952(93)90476-D; LINDAHL M, 1993, INFLAMMATION, V17, P573, DOI 10.1007/BF00914195; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGIAPANE H, 1992, BIOCHEM PHARMACOL, V43, P445, DOI 10.1016/0006-2952(92)90562-W; Muldoon MF, 1996, BRIT MED J, V312, P458, DOI 10.1136/bmj.312.7029.458; NARDINI M, 1995, FREE RADICAL BIO MED, V19, P541, DOI 10.1016/0891-5849(95)00052-Y; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; PAGONIS C, 1986, BIOCHEM PHARMACOL, V35, P237, DOI 10.1016/0006-2952(86)90520-4; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARK JW, 1995, BIOCHEM BIOPH RES CO, V211, P410, DOI 10.1006/bbrc.1995.1829; PARTHASARATHY S, 1992, CURR OPIN LIPIDOL, V3, P313; Pearson DA, 1997, J AGR FOOD CHEM, V45, P578, DOI 10.1021/jf9603893; Pierpoint W S, 1986, Prog Clin Biol Res, V213, P125; PINCEMAIL J, 1987, EXPERIENTIA, V43, P181, DOI 10.1007/BF01942843; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; ROBAK J, 1988, POL J PHARMACOL PHAR, V40, P451; ROBAK J, 1988, BIOCHEM PHARMACOL, V37, P837, DOI 10.1016/0006-2952(88)90169-4; Rosenblat M, 1998, FREE RADICAL BIO MED, V24, P305, DOI 10.1016/S0891-5849(97)00231-1; SUZUKAWA M, 1994, ATHEROSCLEROSIS, V110, P77, DOI 10.1016/0021-9150(94)90070-1; vanAcker SABE, 1996, FREE RADICAL BIO MED, V20, P331, DOI 10.1016/0891-5849(95)02047-0; Vaya J, 1997, FREE RADICAL BIO MED, V23, P302, DOI 10.1016/S0891-5849(97)00089-0; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	69	103	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13790	13799		10.1074/jbc.274.20.13790	http://dx.doi.org/10.1074/jbc.274.20.13790			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318783	hybrid			2022-12-25	WOS:000080322200012
J	Thoidis, G; Kupriyanova, T; Cunningham, JM; Chen, P; Cadel, S; Foulon, T; Cohen, P; Fine, RE; Kandror, KV				Thoidis, G; Kupriyanova, T; Cunningham, JM; Chen, P; Cadel, S; Foulon, T; Cohen, P; Fine, RE; Kandror, KV			Glucose transporter Glut3 is targeted to secretory vesicles in neurons and PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOPEPTIDASE-B; HUMAN PLATELETS; INSULIN; TRANSLOCATION; MEMBRANE; PROTEINS; TISSUE; BRAIN	In rat brain and cultured neuroendocrine PC12 cells, Glut3 is localized at the cell surface and, also, in a distinct population of homogenous synaptic-like vesicles. Glut3-containing vesicles co-purify with "classical" synaptic vesicles, but can be separated from the latter by sucrose gradient centrifugation. Unlike classical synaptic vesicles, Glut3-containing vesicles possess a high level of aminopeptidase activity, which has been identified as aminopeptidase B. This enzyme has recently been shown to be a marker of the secretory pathway in PC12 cells (Balogh, A., Cadel, S., Foulon, T., Picart, R., Der Garabedian, A., Rousselet, A., Tougard, C., and Cohen, P. (1998) J. Cell Sci. 111, 161-169). We, therefore, conclude that Glut3 is targeted to secretory vesicles in both neurons and PC12 cells.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Edith Nourse Rodgers Mem Vet Hosp, Bedford, MA 01730 USA; Univ Paris 06, CNRS, UMR 7631, F-75006 Paris, France	Boston University; Boston University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K121,715 Albany St, Boston, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007201, R01DK052057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG005894] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG-05894] Funding Source: Medline; NIDDK NIH HHS [T32DK07201, R01DK52057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balogh A, 1998, J CELL SCI, V111, P161; BILAN PJ, 1992, BIOCHEM BIOPH RES CO, V186, P1129, DOI 10.1016/0006-291X(92)90864-H; Cadel S, 1997, P NATL ACAD SCI USA, V94, P2963, DOI 10.1073/pnas.94.7.2963; CADEL S, 1995, MOL CELL ENDOCRINOL, V110, P149, DOI 10.1016/0303-7207(95)03529-G; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; Heijnen HFG, 1997, J CELL BIOL, V138, P323, DOI 10.1083/jcb.138.2.323; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Sorbara LR, 1997, BIOCHEM J, V328, P511; Thoidis G, 1998, P NATL ACAD SCI USA, V95, P183, DOI 10.1073/pnas.95.1.183	19	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14062	14066		10.1074/jbc.274.20.14062	http://dx.doi.org/10.1074/jbc.274.20.14062			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318820	hybrid			2022-12-25	WOS:000080322200049
J	Cai, H; Clarke, S				Cai, H; Clarke, S			A novel methyltransferase catalyzes the methyl esterification of trans-aconitate in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR METHYLTRANSFERASE; STATIONARY-PHASE; RUMINAL FERMENTATION; RNA-POLYMERASE; SURVIVAL; COMMON; IDENTIFICATION; ACCUMULATION; EXPRESSION; RESISTANCE	We have identified a new type of S-adenosyl-L-methionine-dependent methyltransferase in the cytosol of Escherichia coli that is expressed in early stationary phase under the control of the RpoS a factor. This enzyme catalyzes the monomethyl esterification of trans-aconitate at high affinity (K-m = 0.32 mat) and cis-aconitate, isocitrate, and citrate at lower velocities and affinities. We have purified the enzyme to homogeneity by gel-filtration, anion-exchange, and hydrophobic chromatography, The N-terminal amino acid sequence was found to match that expected for the o252 open reading frame at 34.57 min on the E. coli genomic sequence whose deduced amino acid sequence contains the signature sequence motifs of the major class of S-adenosyl-L-methionine-dependent methyltransferases, Overexpression of the o252 gene resulted in an overexpression of the methyltransferase activity, and we have now designated it tom for trans-aconitate methyltransferase. We have generated a knock-out strain off. coli lacking this activity, and we find that its growth and stationary phase survival are similar to that of the parent strain. We demonstrate the endogenous formation of trans-aconitate methyl ester in extracts of wild type but not tam(-) mutant cells indicating that trans-aconitate is present in E. coli, Since trans-aconitate does not appear to be a metabolic intermediate in these cells but forms spontaneously from the key citric acid cycle intermediate cis-aconitate, we suggest that its methylation may limit its potential interference in normal metabolic pathways. We have detected trans-aconitate methyltransferase activity in extracts of the yeast Saccharomyces cerevisiae, whereas no activity has been found in extracts of Caenorhabditis elegans or mouse brain.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Box 951570, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERLUND T, 1995, J BACTERIOL, V177, P6791, DOI 10.1128/jb.177.23.6791-6797.1995; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMBLER JA, 1948, J ORG CHEM, V13, P399, DOI 10.1021/jo01161a013; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; BURAU R, 1965, SCIENCE, V150, P766, DOI 10.1126/science.150.3697.766; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CLARKE S, 1999, S ADENOSYLMETHIONINE; COIC Y., 1961, ANN INST NATL RECH AGRON SER A ANN PHYSIOL VEG, V3, P87; COOK GM, 1994, APPL ENVIRON MICROB, V60, P2533, DOI 10.1128/AEM.60.7.2533-2537.1994; GARY JD, 1995, J BIOL CHEM, V270, P4076, DOI 10.1074/jbc.270.8.4076; GAWRON O, 1977, BIOCHIM BIOPHYS ACTA, V484, P453, DOI 10.1016/0005-2744(77)90101-2; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HALL BG, 1982, J BACTERIOL, V151, P269, DOI 10.1128/JB.151.1.269-273.1982; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kagan RM, 1997, ARCH BIOCHEM BIOPHYS, V348, P320, DOI 10.1006/abbi.1997.0362; KIM E, 1997, P NATL ACAD SCI USA, V94, P3132; Krebs HA, 1944, BIOCHEM J, V38, P426, DOI 10.1042/bj0380426; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malachowski R, 1928, BER DTSCH CHEM GES, V61, P2521, DOI 10.1002/cber.19280611119; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; OTTEN JG, 1970, ANAL BIOCHEM, V35, P302, DOI 10.1016/0003-2697(70)90041-2; REBHOLZ KL, 1994, ARCH BIOCHEM BIOPHYS, V312, P227, DOI 10.1006/abbi.1994.1303; ROSE IA, 1993, BIOCHEMISTRY-US, V32, P8504, DOI 10.1021/bi00084a016; RUSSELL JB, 1984, APPL ENVIRON MICROB, V47, P155, DOI 10.1128/AEM.47.1.155-159.1984; Sambrook J., 2002, MOL CLONING LAB MANU; Silhavy T. J., 1984, EXPT GENE FUSIONS, P107; STOUT PR, 1967, AGRON J, V59, P21, DOI 10.2134/agronj1967.00021962005900010006x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOMPSON JF, 1990, ANAL BIOCHEM, V184, P39, DOI 10.1016/0003-2697(90)90008-W; Visick JE, 1998, FEMS MICROBIOL LETT, V167, P19, DOI 10.1111/j.1574-6968.1998.tb13202.x; Visick JE, 1997, J BACTERIOL, V179, P4158, DOI 10.1128/jb.179.13.4158-4163.1997; Visick JE, 1998, J BACTERIOL, V180, P2623, DOI 10.1128/JB.180.10.2623-2629.1998; Watanabe K, 1997, CURR MICROBIOL, V35, P97, DOI 10.1007/s002849900219; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985	42	26	29	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13470	13479		10.1074/jbc.274.19.13470	http://dx.doi.org/10.1074/jbc.274.19.13470			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224113	hybrid			2022-12-25	WOS:000080200400075
J	Lin, KI; Pasinelli, P; Brown, RH; Hardwick, JM; Ratan, RR				Lin, KI; Pasinelli, P; Brown, RH; Hardwick, JM; Ratan, RR			Decreased intracellular superoxide levels activate Sindbis virus-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; PROGRAMMED CELL-DEATH; ALPHAVIRUS-INDUCED APOPTOSIS; NF-KAPPA-B; OXIDATIVE STRESS; NEURONAL APOPTOSIS; HYDROGEN-PEROXIDE; TRANSGENIC MICE; MAMMALIAN-CELLS; INFECTED-CELLS	Infection of many cultured cell types with Sindbis virus (SV), an alphavirus, triggers apoptosis through a commonly utilized caspase activation pathway. However, the upstream signals by which SV activates downstream apoptotic effecters, including caspases, remain unclear. Here we report that in AT-3 prostate carcinoma cells, SV infection decreases superoxide (O-radical anion) levels within minutes of infection as monitored by an aconitase activity assay. This SV-induced decrease in O-radical anion levels appears to activate or modulate cell death, as a recombinant SV expressing the O-radical anion scavenging enzyme, copper/zinc superoxide dismutase (SOD), potentiates SV-induced apoptosis. A recombinant SV expressing a mutant form of SOD, which has reduced SOD activity, has no effect. The potentiation of SV-induced apoptosis by wild type SOD is because of its ability to scavenge intracellular OX rather than its ability to promote the generation of hydrogen peroxide. Pyruvate, a peroxide scavenger, does not affect the ability of wild type SOD to potentiate cell death; and increasing the intracellular catalase activity via a recombinant SV vector has no effect on SV-induced apoptosis, Moreover, increasing intracellular O-radical anion by treatment of 3T3 cells with paraquat protects them from SV-induced death. Altogether, our results suggest that SV may activate apoptosis by reducing intracellular superoxide levels and define a novel redox signaling pathway by which viruses can trigger cell death.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02129 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Johns Hopkins University	Ratan, RR (corresponding author), Harvard Univ, Sch Med, Dept Neurol, 77 Ave Louis Pasteur,Rm 857, Boston, MA 02115 USA.	rratan@caregroup.harvard.edu		Pasinelli, Piera/0000-0002-3385-2707	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034943, K08NS001951] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; BarPeled O, 1996, P NATL ACAD SCI USA, V93, P8530, DOI 10.1073/pnas.93.16.8530; BISHAI WR, 1994, J BACTERIOL, V176, P2914, DOI 10.1128/JB.176.10.2914-2921.1994; BROWN RH, 1995, CELL, V80, P687, DOI 10.1016/0092-8674(95)90346-1; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Desagher S, 1997, J NEUROSCI, V17, P9060; Eleouet JF, 1998, J VIROL, V72, P4918, DOI 10.1128/JVI.72.6.4918-4924.1998; Esch F, 1998, J NEUROSCI, V18, P4083; ESOLEN LM, 1995, J VIROL, V69, P3955, DOI 10.1128/JVI.69.6.3955-3958.1995; Fariello R G, 1988, Funct Neurol, V3, P407; FERRARI G, 1995, J NEUROSCI, V15, P2857; FREEMAN BA, 1982, LAB INVEST, V47, P412; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GRIFFIN DE, 1994, ARCH VIROL, P31; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HINSHAW VS, 1994, J VIROL, V68, P3667, DOI 10.1128/JVI.68.6.3667-3673.1994; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAWANISHI M, 1993, J VIROL, V67, P7654, DOI 10.1128/JVI.67.12.7654-7658.1993; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Levine B, 1996, P NATL ACAD SCI USA, V93, P4810, DOI 10.1073/pnas.93.10.4810; Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MCCORD JM, 1988, OXYRADICALS MOL BIOL, P27; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MOREY AL, 1993, J PATHOL, V169, P213, DOI 10.1002/path.1711690207; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Nava VE, 1998, J VIROL, V72, P452, DOI 10.1128/JVI.72.1.452-459.1998; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; PELEDKAMAR M, 1995, EMBO J, V14, P4985, DOI 10.1002/j.1460-2075.1995.tb00181.x; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; PORTERACALLIAU C, 1995, J NEUROSCI, V13, P3669; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; RATAN RR, 1994, J NEUROSCI, V14, P4385; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOLSKAYA EA, 1995, J VIROL, V69, P1181, DOI 10.1128/JVI.69.2.1181-1189.1995; TSUDA T, 1994, NEURON, V13, P727, DOI 10.1016/0896-6273(94)90039-6; Tucker PC, 1996, J VIROL, V70, P3972, DOI 10.1128/JVI.70.6.3972-3977.1996; Wang JF, 1996, FREE RADICAL BIO MED, V20, P533, DOI 10.1016/0891-5849(95)02085-3; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	63	30	31	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13650	13655		10.1074/jbc.274.19.13650	http://dx.doi.org/10.1074/jbc.274.19.13650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224137	hybrid			2022-12-25	WOS:000080200400099
J	Nierras, CR; Warner, JR				Nierras, CR; Warner, JR			Protein kinase C enables the regulatory circuit that connects membrane synthesis to ribosome synthesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SECRETORY PATHWAY; TRANSMEMBRANE PROTEIN; GENE-TRANSCRIPTION; ESCHERICHIA-COLI; S-CEREVISIAE; CELL-GROWTH; YEAST-CELLS; CYCLIC-AMP; EXPRESSION	The balanced growth of a cell requires the integration of major systems such as DNA replication, membrane biosynthesis, and ribosome formation. An example of such integration is evident from our recent finding that, in Saccharomyces cerevisiae, any failure in the secretory pathway leads to severe repression of transcription of both rRNA and ribosomal protein genes. We have attempted to determine the regulatory circuit(s) that connects the secretory pathway with the transcription of ribosomal genes. Experiments show that repression does not occur through the circuit that responds to misfolded proteins in the endoplasmic reticulum, nor does it occur through circuits known to regulate ribosome synthesis, e.g. the stringent response, or the cAMP pathway. Rather, it appears to depend on a stress response at the plasma membrane that is transduced through protein kinase C (PKC), Deletion of PKC1 relieves the repression of both ribosomal protein and rRNA genes that occurs in response to a defect in the secretory pathway. We propose that failure of the secretory pathway prevents the synthesis of new plasma membrane. As protein synthesis continues, stress develops in the plasma membrane. This stress is monitored by Pkc1p, which initiates a signal transduction pathway that leads to repression of transcription of the rRNA and ribosomal protein genes. The importance of the transcription of the 137 ribosomal protein genes to the economy of the cell is apparent from the existence of at least three distinct pathways that can effect the repression of this set of genes.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Warner, JR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	warner@aecom.yu.edu			NCI NIH HHS [CA13330] Funding Source: Medline; NIGMS NIH HHS [GM25532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; GRIFFIOEN G, 1994, FEMS MICROBIOL LETT, V123, P137, DOI 10.1111/j.1574-6968.1994.tb07213.x; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; Helliwell SB, 1998, GENETICS, V148, P99; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERRUER MH, 1989, NUCLEIC ACIDS RES, V17, P7427, DOI 10.1093/nar/17.18.7427; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JU QD, 1994, YEAST, V10, P151, DOI 10.1002/yea.320100203; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KIEF DR, 1981, MOL CELL BIOL, V1, P1007, DOI 10.1128/MCB.1.11.1007; KIM CH, 1983, MOL CELL BIOL, V3, P457, DOI 10.1128/MCB.3.3.457; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KRAAKMAN LS, 1993, MOL GEN GENET, V239, P196, DOI 10.1007/BF00281618; Ktistakis NT, 1998, BIOESSAYS, V20, P495; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Meyuhas Oded, 1996, V30, P363; Mizuta K, 1998, NUCLEIC ACIDS RES, V26, P1063, DOI 10.1093/nar/26.4.1063; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1993, CELL, V74, P743; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; Planta RJ, 1997, YEAST, V13, P1505, DOI 10.1002/(SICI)1097-0061(199712)13:16<1505::AID-YEA229>3.0.CO;2-I; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WARNER JR, 1977, CELL, V11, P201, DOI 10.1016/0092-8674(77)90331-2; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WARNER JR, 1978, NATURE, V275, P338, DOI 10.1038/275338a0; WARNER JR, 1976, J BACTERIOL, V125, P887, DOI 10.1128/JB.125.3.887-891.1976; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; WOUDT LP, 1986, EMBO J, V5, P1037, DOI 10.1002/j.1460-2075.1986.tb04319.x; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1	78	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13235	13241		10.1074/jbc.274.19.13235	http://dx.doi.org/10.1074/jbc.274.19.13235			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224082	hybrid			2022-12-25	WOS:000080200400044
J	Zhang, LJ; Kim, M; Choi, YH; Goemans, B; Yeung, C; Hu, ZY; Zhan, SL; Seth, P; Helman, LJ				Zhang, LJ; Kim, M; Choi, YH; Goemans, B; Yeung, C; Hu, ZY; Zhan, SL; Seth, P; Helman, LJ			Diminished G(1) checkpoint after gamma-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR P21 GENE; NIH 3T3 CELLS; P53-INDEPENDENT EXPRESSION; DEPENDENT KINASES; PHASE-TRANSITION; PROTEIN-KINASES; CANCER CELLS; D1; PROGRESSION; DIFFERENTIATION	High levels of insulin-like growth factor II (IGFII) mRNA expression are detected in many human tumors of different origins including rhabdomyosarcoma, a tumor of skeletal muscle origin. To investigate the role of IGFII in tumorigenesis, we have compared the mouse myoblast cell line C2C12-2.7, which was stably transfected with human IGFII cDNA and expressed high and constant amounts of IGFII, to a control cell line C2C12-1.1, A rhabdomyosarcoma cell line, RH30, which expresses high levels of IGFII and contains mutated p53, was also used in these studies. IGFII overexpression in mouse myoblast C2C12 cells causes a reduced cycling time and higher growth rate. After gamma-irradiation treatment, C2C12-1.1 cells were arrested mainly in G(0)/G(1) phase. However, C2C12-2.7 and RH30 cells went through a very short G(1) phase and then were arrested in an extended G(2)/M phase. To verify further the effect of IGFII on the cell cycle, we developed a Chinese hamster ovary (CHO) cell line with tetracycline-controlled IGFII expression. We found that CHO cells with high expression of IGFII have a shortened cycling time and a diminished G(1) checkpoint after treatment with methylmethane sulfonate (MMS), a DNA base-damaging agent, when compared with CHO cells with very low IGFII expression, It was also found that IGFII overexpression in C2C12 cells was associated with increases in cyclin D1, p21, and p53 protein levels, as well as mitogen-activated protein kinase activity, These studies suggest that IGFII overexpression shortens cell cycling time and diminishes the G(1) checkpoint after DNA damage despite an intact p53/p21 induction. In addition, IGFII overexpression is also associated with multiple changes in the levels and activities of cell cycle regulatory components following gamma-irradiation, Taken together, these changes may contribute to the high growth rate and genetic alterations that occur during tumorigenesis.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; NCI, Med Breast Canc Sect, NIH, Bethesda, MD 20892 USA; NCI, Cell Signalling & Oncogenesis Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Helman, LJ (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bldg 10,Rm 13N240, Bethesda, MD 20892 USA.							BHATAVDEKAR JM, 1994, NEOPLASMA, V41, P101; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FIORENTINO M, 1994, DIAGN MOL PATHOL, V3, P59, DOI 10.1097/00019606-199403010-00010; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu Y, 1996, CANCER RES, V56, P31; LOVEC H, 1994, ONCOGENE, V9, P323; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Marchetti A, 1996, ONCOGENE, V12, P1319; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MINNITI CP, 1995, CELL GROWTH DIFFER, V6, P263; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY A, 1993, CELL CYCLE, P3; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHUURING E, 1992, ONCOGENE, V7, P355; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Winston JT, 1996, ONCOGENE, V12, P127; Xu FH, 1997, BRIT J HAEMATOL, V97, P429, DOI 10.1046/j.1365-2141.1997.592708.x; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	57	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13118	13126		10.1074/jbc.274.19.13118	http://dx.doi.org/10.1074/jbc.274.19.13118			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224065	hybrid			2022-12-25	WOS:000080200400027
J	Clark, RSB; Kochanek, PM; Chen, MZ; Watkins, SC; Marion, DW; Chen, J; Hamilton, RL; Loeffert, JE; Graham, SH				Clark, RSB; Kochanek, PM; Chen, MZ; Watkins, SC; Marion, DW; Chen, J; Hamilton, RL; Loeffert, JE; Graham, SH			Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury	FASEB JOURNAL			English	Article						apoptosis; Bax; Bclx(L); Cpp32; interleukin-1 beta converting enzyme	INTERLEUKIN-1-BETA CONVERTING-ENZYME; CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; CEREBRAL-ISCHEMIA; TRANSGENIC MICE; RAT-BRAIN; REGULATING APOPTOSIS; PROTOONCOGENE BCL-2; ALZHEIMERS-DISEASE; GLOBAL-ISCHEMIA	The bcl-2 and caspase families are important regulators of programmed cell death in experimental models of ischemic, excitotoxic, and traumatic brain injury. The Bcl-2 family members Bcl-2 and Bcl-x(L) suppress programmed cell death, whereas Bax promotes programmed cell death. Activated caspase-1 (interleukin-1 beta converting enzyme) and caspase-3 (Yama/Apopain/Cpp32) cleave proteins that are important in maintaining cytoskeletal integrity and DNA repair, and activate deoxyribonucleases, producing cell death with morphological features of apoptosis. To address the question of whether these Bcl-2 and caspase family members participate in the process of delayed neuronal death in humans, we examined brain tissue samples removed from adult patients during surgical decompression for intracranial hypertension in the acute phase after traumatic brain injury (n=8) and com pared these samples to brain tissue obtained at autopsy from non-trauma patients (n=6). An increase in Bcl-2 but not Bcl-x(L) or Bax, cleavage of caspase-1, up-regulation and cleavage of caspase-3, and evidence for DNA fragmentation with both apoptotic and necrotic morphologies were found in tissue from traumatic brain injury patients compared with controls. These findings are the first to demonstrate that programmed cell death occurs in human brain after acute injury, and identify potential pharmacological and molecular targets for the treatment of human head injury.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Dept Vet Affairs Med Ctr, Neurol Serv 127, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave Pittsburgh, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021; Watkins, Simon/ABG-2590-2021	Kochanek, Patrick M/0000-0002-2627-913X; Watkins, Simon/0000-0003-4092-1552; Chen, Jun/0000-0002-8077-3403	NICHD NIH HHS [5P30 HD28836] Funding Source: Medline; NINDS NIH HHS [1KO8 NS01946, 1RO1 NS 38620-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001946, R01NS038620] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Ashkenas J, 1996, J EXP MED, V183, P1947, DOI 10.1084/jem.183.5.1947; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Hayasaki K, 1997, ACT NEUR S, V70, P75; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JENNETT B, 1985, LANCET, V1, P480; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Mogi M, 1996, NEUROSCI LETT, V215, P137, DOI 10.1016/S0304-3940(96)12961-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; SHAW K, 1998, J NEUROTRAUM, V15, P871; Smith F. M., 1998, Journal of Neurotrauma, V15, P54; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	51	180	191	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					813	821		10.1096/fasebj.13.8.813	http://dx.doi.org/10.1096/fasebj.13.8.813			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224225				2022-12-25	WOS:000080372500005
J	Frank, S; Zacharowski, K; Wray, GM; Thiemermann, C; Pfeilschifter, J				Frank, S; Zacharowski, K; Wray, GM; Thiemermann, C; Pfeilschifter, J			Identification of copper zinc superoxide dismutase as a novel nitric oxide-regulated gene in rat glomerular mesangial cells and kidneys of endotoxemic rats	FASEB JOURNAL			English	Article						gene expression regulation; glomerular mesangium; superoxide anion; endotoxemia	SYNTHASE MESSENGER-RNA; L-ARGININE; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; GROWTH-FACTOR; CYCLIC-AMP; EXPRESSION; INDUCTION; ACTIVATION; ALPHA	To define the mechanism of nitric oxide (NO) action in the glomerulus, we attempted to identify genes that are regulated by NO in rat glomerular mesangial cells, We identified a Cu/Zn superoxide dismutase (SOD) that was strongly induced in these cells by treatment with S-nitroso-glutathione as a NO-donating agent. Bacterial lipopolysaccharide (LPS) acutely decreased Cu/Zn SOD mRNA levels, The LPS-mediated decrease in Cu/Zn SOD is reversed by endogenously produced NO, as LPS also induced a delayed strong iNOS expression in these cells in vitro, which is accompanied by increased Cu/Zn SOD expression. NO dependency of Cu/Zn SOD mRNA recovery could be demonstrated by inhibition of this process by L-N-G-monomethylarginine, an inhibitor of NOS enzymatic activity, To demonstrate the in vivo relevance of our observations, we have chosen LPS-treated rats as a model for induction of a systemic inflammatory response. In these animals, we demonstrate a direct coupling of Cu/Zn SOD expression levels to the presence of NO, as Cu/Zn SOD mRNA levels declined during acute inflammation in the presence of a selective inhibitor of iNOS, We propose that the up-regulation of Cu/Zn SOD by endogenous NO may serve as an adaptive, protective mechanism to prevent the formation of toxic quantities of per oxynitrite in conditions associated with iNOS induction during endotoxic shock.	Univ Frankfurt Klinikum, Inst Allgemeine Pharmakol & Toxikol, Zentrum Pharmakol, D-60590 Frankfurt, Germany; St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, London EC1 6BD, England	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of London; Queen Mary University London	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Inst Allgemeine Pharmakol & Toxikol, Zentrum Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Pfeilschifter@em.uni-frankfurt.de		Thiemermann, Christoph/0000-0003-4228-9722				BAUD L, 1992, J AM SOC NEPHROL, V2, pS132; BAUD L, 1986, AM J PHYSIOL, V251, pF765, DOI 10.1152/ajprenal.1986.251.5.F765; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; CAMUSSI G, 1995, J IMMUNOL, V155, P316; CATTELL V, 1993, EXP NEPHROL, V1, P265; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROW JP, 1995, NITRIC OXIDE BIOCH M, P17; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DUQUE I, 1992, AM J PHYSIOL, V263, pF466, DOI 10.1152/ajprenal.1992.263.3.F466; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GWINNER W, 1995, KIDNEY INT, V48, P354, DOI 10.1038/ki.1995.303; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; KASHGARIAN M, 1992, KIDNEY INT, V41, P524, DOI 10.1038/ki.1992.74; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; KUNZ D, 1994, BIOCHEM J, V304, P337, DOI 10.1042/bj3040337; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; MUHL H, 1994, BRIT J PHARMACOL, V112, P1; MUHL H, 1995, J CLIN INVEST, V95, P1941, DOI 10.1172/JCI117876; Muhl H, 1996, EUR J PHARMACOL, V317, P137, DOI 10.1016/S0014-2999(96)00701-7; Nitsch DD, 1997, AM J PATHOL, V150, P889; PFEILSCHIFTER J, 1995, KIDNEY INT, V48, pS50; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; PFEILSCHIFTER J, 1994, NEWS PHYSIOL SCI, V9, P271, DOI 10.1152/physiologyonline.1994.9.6.271; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; PFEILSCHIFTER J, 1993, NEPHRON, V64, P518, DOI 10.1159/000187394; Pluss C, 1996, BIOCHEM J, V318, P665; Puga A, 1987, Free Radic Res Commun, V3, P337, DOI 10.3109/10715768709088074; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; Sandau K, 1997, J IMMUNOL, V158, P4938; SAURA M, 1995, KIDNEY INT, V47, P500, DOI 10.1038/ki.1995.63; Schlondorff D, 1996, KIDNEY INT, V49, P1583, DOI 10.1038/ki.1996.229; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHULTZ PJ, 1994, KIDNEY INT, V46, P683, DOI 10.1038/ki.1994.321; Stephanz GB, 1996, EXP NEPHROL, V4, P151; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wray GM, 1998, SHOCK, V9, P329, DOI 10.1097/00024382-199805000-00003; XIE QW, 1994, J BIOL CHEM, V269, P4705; YOSHIOKA T, 1994, KIDNEY INT, V46, P405, DOI 10.1038/ki.1994.288	54	51	53	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					869	882		10.1096/fasebj.13.8.869	http://dx.doi.org/10.1096/fasebj.13.8.869			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224230				2022-12-25	WOS:000080372500010
J	Cociancich, SO; Park, SS; Fidock, DA; Shahabuddin, M				Cociancich, SO; Park, SS; Fidock, DA; Shahabuddin, M			Vesicular ATPase-overexpressing cells determine the distribution of malaria parasite oocysts on the midguts of mosquitoes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; B-SUBUNIT; PLASMODIUM-GALLINACEUM; PROTON PUMP; CLONING; TUBULES; FAMILY	In Plasmodium-infected mosquitoes, oocysts are preferentially located at the posterior half of the posterior midgut, Because mosquitoes rest vertically after feeding, the effect of gravity on the ingested blood has been proposed as the cause of such a biased distribution. In this paper, we examined the oocyst distribution on the midguts of mosquitoes that were continuously rotated to nullify the effect of gravity and found that the typical pattern of oocyst distribution did not change, Invasion of the midgut epithelium by ookinetes was similarly found to be biased toward the posterior part of the posterior midgut, We examined whether the distribution of oocysts depends on the distribution of vesicular ATPase (V-ATPase)-overexpressing cells that Plasmodium ookinetes preferentially use to cross the midgut epithelium. An antiserum raised against recombinant Aedes aegypti V-ATPase B subunit indicated that the majority of VATPase-overexpressing cells in Ae. aegypti and Anopheles gambiae are localized at the posterior part of the posterior midgut, We propose that the typical distribution of oocysts on the mosquito midgut is attributable to the presence and the spatial distribution of the V-ATPase-overexpressing cells in the midgut epithelium.	NIAID, Parasit Dis Lab, Malaria Genet Sect, NIH, Bethesda, MD 20892 USA; NIAID, Parasit Dis Lab, Med Entomol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Shahabuddin, M (corresponding author), NIAID, Parasit Dis Lab, Malaria Genet Sect, NIH, 9000 Rockville Pike,Bldg 4,Rm B2-39, Bethesda, MD 20892 USA.		COCIANCICH, Stéphane/C-4267-2014	COCIANCICH, Stéphane/0000-0001-8601-3598; Fidock, David/0000-0001-6753-8938	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000811] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLEMENTS AN, 1992, BIOL MOSQUITOES, V1, P304; CLEMENTS AN, 1992, BIOL MOSQUITOES, V1, P263; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; DUFFY PE, 1993, J EXP MED, V177, P505, DOI 10.1084/jem.177.2.505; Filippova M, 1998, INSECT MOL BIOL, V7, P223, DOI 10.1111/j.1365-2583.1998.00069.x; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; GILL SS, 1991, ARCH BIOCHEM BIOPHYS, V291, P92, DOI 10.1016/0003-9861(91)90109-V; Huff CG, 1934, AM J HYG, V19, P123, DOI 10.1093/oxfordjournals.aje.a117980; HUFF CG, 1965, EXP PARASITOL, V16, P107, DOI 10.1016/0014-4894(65)90036-6; LICHKO LP, 1985, FEBS LETT, V187, P349, DOI 10.1016/0014-5793(85)81274-6; MADDRELL SHP, 1992, J EXP BIOL, V172, P417; Neumann R. O., 1908, Archiv fuer Protistenkunde, V13; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; Shahabuddin M, 1998, P NATL ACAD SCI USA, V95, P3385, DOI 10.1073/pnas.95.7.3385; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Shahabuddin M, 1998, PARASITOLOGY, V116, pS83, DOI 10.1017/S0031182000084973; Shute P. G., 1938, Archives Roumaines de Pathologie Experimentale et de Microbiologie, V11, P351; SIEBER KP, 1991, EXP PARASITOL, V72, P145, DOI 10.1016/0014-4894(91)90132-G; WATERS AP, 1991, P NATL ACAD SCI USA, V88, P3140, DOI 10.1073/pnas.88.8.3140; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143	20	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12650	12655		10.1074/jbc.274.18.12650	http://dx.doi.org/10.1074/jbc.274.18.12650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212245	hybrid			2022-12-25	WOS:000080056800065
J	Goncharov, I; Palfi, Z; Bindereif, A; Michaeli, S				Goncharov, I; Palfi, Z; Bindereif, A; Michaeli, S			Purification of the spliced leader ribonucleoprotein particle from Leptomonas collosoma revealed the existence of an Sm protein in trypanosomes - Cloning the SmE homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; SNRNP E-PROTEIN; MESSENGER-RNA; BRUCEI; GENE; U2; U6; IDENTIFICATION; COMPONENTS; SEQUENCE	Trans-splicing in trypanosomes involves the addition of a common spliced leader (SL) sequence, which is derived from a small RNA, the SL RNA, to all mRNA precursors. The SL RNA is present in the cell in the form of a ribonucleoprotein, the SL RNP, Using conventional chromatography and affinity selection with 2'-O-methylated RNA oligonucleotides at high ionic strength, five proteins of 70, 16, 13, 12, and 8 kDa were co-selected with the SL RNA from Leptomonas collosoma, representing the SL RNP core particle. Under conditions of lower ionic strength, additional proteins of 28 and 20 kDa were revealed. On the basis of peptide sequences, the gene coding for a protein with a predicted molecular weight of 11.9 kDa was cloned and identified as homologue of the cis-spliceosomal SmE. The protein carries the Sm motifs 1 and 2 characteristic of Sm antigens that bind to all known cis-spliceosomal uridylic acid-rich small nuclear RNAs (U snRNAs), suggesting the existence of Sm proteins in trypanosomes, This finding is of special interest because trypanosome snRNPs are the only snRNPs examined to date that are not recognized by anti-Sm antibodies. Because of the early divergence of trypanosomes from the eukaryotic lineage, the trypanosome SmE protein represents one of the primordial Sm proteins in nature.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Humboldt Univ, Inst Biochem, D-10117 Berlin, Germany	Weizmann Institute of Science; Humboldt University of Berlin	Michaeli, S (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Michaeli, Shulamit/AAC-8255-2022					AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Bordonne R, 1996, GENE, V176, P111, DOI 10.1016/0378-1119(96)00230-2; BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; Camasses A, 1998, MOL CELL BIOL, V18, P1956, DOI 10.1128/MCB.18.4.1956; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; CROSS M, 1993, EMBO J, V12, P1239, DOI 10.1002/j.1460-2075.1993.tb05765.x; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; FAUTSCH MP, 1992, GENOMICS, V14, P883, DOI 10.1016/S0888-7543(05)80109-0; GOLDRING A, 1995, GENE, V156, P139, DOI 10.1016/0378-1119(95)00048-B; GOLDRING A, 1995, EXPT PARASITOLOGY, V80, P333; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Judd R C, 1994, Methods Mol Biol, V32, P49; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Lucke S, 1997, EMBO J, V16, P4433, DOI 10.1093/emboj/16.14.4433; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; PALFI Z, 1992, J BIOL CHEM, V267, P20159; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; STANFORD DR, 1988, NUCLEIC ACIDS RES, V16, P10593, DOI 10.1093/nar/16.22.10593; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; ULLU E, 1995, J BIOL CHEM, V270, P20365, DOI 10.1074/jbc.270.35.20365; ULLU E, 1995, MOL BIOL PARASITIC P, P115; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473	28	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12217	12221		10.1074/jbc.274.18.12217	http://dx.doi.org/10.1074/jbc.274.18.12217			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212187	hybrid			2022-12-25	WOS:000080056800007
J	Jourdan-Le Saux, C; Tronecker, H; Bogic, L; Bryant-Greenwood, GD; Boyd, CD; Csiszar, K				Jourdan-Le Saux, C; Tronecker, H; Bogic, L; Bryant-Greenwood, GD; Boyd, CD; Csiszar, K			The LOXL2 gene encodes a new lysyl oxidase-like protein and is expressed at high levels in reproductive tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS RECISION GENE; MESSENGER-RNA; AMINE OXIDASES; IN-SITU; H-RAS; LOCALIZATION; SEQUENCE; IDENTIFICATION; REVERTANTS; ASSIGNMENT	We have reported in this paper the complete cDNA sequence, gene structure, and tissue-specific expression of LOXL2, a new amine oxidase and a member of an emerging family of human lysyl oxidases, The predicted amino acid sequence, from several overlapping cDNA clones isolated from placenta and spleen cDNA libraries, shared extensive sequence homology with the conserved copper-binding and catalytic domains of both lysyl oxidase (LOX) and the lysyl oxidase-like (LOXL) protein. These conserved domains are encoded by five consecutive exons within the LOX, LOXL, and LOXL2 genes that also maintained exon-intron structure conservation. In contrast, six exons encoding the aminoterminal domains diverged both in sequence and structure. Exon 1 of the LOXL2 gene does not encode a signal sequence that is present in LOX and LOXL, suggesting a different processing and intracellular localization for this new protein. Expression of the LOXL2 gene was detected in almost all tissues with the highest steady state mRNA levels in the reproductive tissues, placenta, uterus and prostate. In situ hybridization identified placental syncytial and cytotrophoblasts responsible for the synthesis of LOXL2 mRNA and demonstrated a spatial and temporal expression pattern unique to the LOXL2 gene.	Univ Hawaii, Pacific Biomed Res Ctr, Honolulu, HI 96822 USA	University of Hawaii System	Csiszar, K (corresponding author), Univ Hawaii, Pacific Biomed Res Ctr, 1960 E West Rd, Honolulu, HI 96822 USA.	kciszar@aol.com			NCI NIH HHS [CA766580] Funding Source: Medline; NCRR NIH HHS [RR03061] Funding Source: Medline; NICHD NIH HHS [HD24314] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024314] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BACCARANICONTRI M, 1990, MATRIX, V9, P428, DOI 10.1016/S0934-8832(11)80011-9; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOGIC LV, 1995, J CLIN ENDOCR METAB, V80, P130, DOI 10.1210/jc.80.1.130; BOYD CD, 1995, MOL BIOL REP, V21, P95, DOI 10.1007/BF00986499; BUTLER E, 1987, EXP CELL RES, V173, P174, DOI 10.1016/0014-4827(87)90343-0; Casey ML, 1997, J CLIN ENDOCR METAB, V82, P167, DOI 10.1210/jc.82.1.167; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Csiszar K, 1996, MOL BIOL REP, V23, P97, DOI 10.1007/BF00424435; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; Dove JE, 1996, FEBS LETT, V398, P231, DOI 10.1016/S0014-5793(96)01245-8; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; Jourdan-Le Saux C, 1998, GENOMICS, V51, P305, DOI 10.1006/geno.1998.5356; KAGAN HM, 1994, MOL BIOL PATHOL ELAS; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Kim YH, 1999, J CELL BIOCHEM, V72, P181, DOI 10.1002/(SICI)1097-4644(19990201)72:2<181::AID-JCB3>3.0.CO;2-D; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; KREBS CJ, 1993, BIOCHIM BIOPHYS ACTA, V1202, P7, DOI 10.1016/0167-4838(93)90056-W; KUIVANIEMI H, 1984, J BIOL CHEM, V259, P6996; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; Lyles GA, 1996, INT J BIOCHEM CELL B, V28, P259, DOI 10.1016/1357-2725(95)00130-1; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; MELLO MLS, 1995, EXP CELL RES, V220, P374, DOI 10.1006/excr.1995.1328; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; Peyrol S, 1997, AM J PATHOL, V150, P497; Ren CZ, 1998, CANCER RES, V58, P1285; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Szabo Z, 1997, HUM GENET, V101, P198, DOI 10.1007/s004390050613; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; WAKASAKI H, 1990, LAB INVEST, V63, P377	34	81	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12939	12944						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212285				2022-12-25	WOS:000080056800105
J	Szabo, K; Szakacs, G; Hegedus, T; Sarkadi, B				Szabo, K; Szakacs, G; Hegedus, T; Sarkadi, B			Nucleotide occlusion in the human cystic fibrosis transmembrane conductance regulator - Different patterns in the two nucleotide binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN ATPASE ACTIVITY; HUMAN MULTIDRUG TRANSPORTER; P-GLYCOPROTEIN; CHLORIDE CHANNELS; INSECT CELLS; CL CHANNELS; CFTR; HYDROLYSIS; SITES; EXPRESSION	The function of the human cystic fibrosis transmembrane conductance regulator (CFTR) protein as a chloride channel or transport regulator involves cellular ATP binding and cleavage. Here we describe that human CFTR expressed in insect (Sf9) cell membranes shows specific, Mg2+-dependent nucleotide occlusion, detected by covalent labeling with 8-azido-[alpha-P-32]ATP. Nucleotide occlusion in CFTR requires incubation at 37 degrees C, and the occluded nucleotide can not be removed by repeated washings of the membranes with cold MgATP-containing medium. By using limited tryptic digestion of the labeled CFTR protein we found that the adenine nucleotide occlusion preferentially occurred in the N-terminal nucleotide binding domain (NBD). Addition of the ATPase inhibitor vanadate, which stabilizes an open state of the CFTR chloride channel, produced an increased nucleotide occlusion and resulted in the labeling of both the N-terminal and C-terminal NBDs, Protein modification with N-ethylmaleimide prevented both vanadate-dependent and -independent nucleotide occlusion in CFTR, The pattern of nucleotide occlusion indicates significant differences in the ATP hydrolyzing activities of the two NBDs, which may explain their different roles in the CFTR channel regulation.	Hungarian Acad Sci, Natl Inst Haematol & Immunol, Membrane Res Grp, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Sarkadi, B (corresponding author), Hungarian Acad Sci, Natl Inst Haematol & Immunol, Membrane Res Grp, Daroczi U24, H-1113 Budapest, Hungary.		Sarkadi, Balazs/I-5024-2013; Szakacs, Gergely/A-2580-2009; Hegedus, Tamas/P-8625-2015	Szakacs, Gergely/0000-0002-9311-7827; Hegedus, Tamas/0000-0002-5195-749X				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Cotten JF, 1997, J BIOL CHEM, V272, P25617, DOI 10.1074/jbc.272.41.25617; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; ISKANDER II, 1996, J BIOL CHEM, V271, P4725; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Larsen EH, 1996, PFLUG ARCH EUR J PHY, V432, P528, DOI 10.1007/s004240050166; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SARKADI B, 1994, EUR CYST FIBR C; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; YOUNG HK, 1995, J BIOL CHEM, V270, P22093	39	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12209	12212		10.1074/jbc.274.18.12209	http://dx.doi.org/10.1074/jbc.274.18.12209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212185	hybrid			2022-12-25	WOS:000080056800005
J	Rietveld, A; Neutz, S; Simons, K; Eaton, S				Rietveld, A; Neutz, S; Simons, K; Eaton, S			Association of sterol- and glycosylphosphatidylinositol-linked proteins with Drosophila raft lipid microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; EPITHELIAL-CELLS; PHASE-SEPARATION; CHOLESTEROL; HEDGEHOG; IDENTIFICATION; TRANSPORT; GLYCOSPHINGOLIPIDS; SPHINGOMYELIN; MONOLAYERS	In vertebrates, the formation of raft lipid microdomains plays an important part in both polarized protein sorting and signal transduction, To establish a system in which raft-dependent processes could be studied genetically, we have analyzed the protein and lipid composition of these microdomains in Drosophila melanogaster, Using mass spectrometry, we identified the phospholipids, sphingolipids, and sterols present in Drosophila membranes. Despite chemical differences between Drosophila and mammalian lipids, their structure suggests that the biophysical properties that allow raft formation have been preserved. Consistent with this, we have identified a detergent-insoluble fraction of Drosophila membranes that, like mammalian rafts, is rich in sterol, sphingolipids, and glycosylphosphatidylinositol-linked proteins. We show that the sterol-linked Hedgehog N-terminal fragment associates specifically with this detergent-insoluble membrane fraction. Our findings demonstrate that raft formation is preserved across widely separated phyla in organisms with different lipid structures. They further suggest sterol modification as a novel mechanism for targeting proteins to raft membranes and raise the possibility that signaling and polarized intracellular transport of Hedgehog are based on raft association.	European Mol Biol Lab, Cell Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Eaton, S (corresponding author), European Mol Biol Lab, Cell Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Eaton, Suzanne/D-7698-2017	Eaton, Suzanne/0000-0002-8319-284X; Simons, Kai/0000-0002-9231-9996				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONDARENKO L V, 1989, Ontogenez, V20, P141; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FOLCH J, 1957, J BIOL CHEM, V226, P497; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KLENK HD, 1970, VIROLOGY, V40, P939, DOI 10.1016/0042-6822(70)90140-6; KLENK HD, 1969, VIROLOGY, V38, P255, DOI 10.1016/0042-6822(69)90367-5; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SCHULER I, 1990, BIOCHIM BIOPHYS ACTA, V1028, P82, DOI 10.1016/0005-2736(90)90268-S; SHAFFER CD, 1994, METHOD CELL BIOL, V44, P99, DOI 10.1016/S0091-679X(08)60908-5; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SILBERKANG M, 1983, J BIOL CHEM, V258, P8503; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOTTE JP, 1992, BIOCHEMISTRY-US, V31, P5472, DOI 10.1021/bi00139a008; SUGITA M, 1989, J BIOL CHEM, V264, P15028; SVOBODA JA, 1995, LIPIDS, V30, P91, DOI 10.1007/BF02537047; URBINA JA, 1995, BBA-BIOMEMBRANES, V1238, P163, DOI 10.1016/0005-2736(95)00117-L; VANHELVOORT A, 1995, FEBS LETT, V369, P18, DOI 10.1016/0014-5793(95)00616-H; WIEGANDT H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P117, DOI 10.1016/0005-2760(92)90101-Z; Xiao Z, 1997, MOL BIOL CELL, V8, P855, DOI 10.1091/mbc.8.5.855	43	237	245	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12049	12054		10.1074/jbc.274.17.12049	http://dx.doi.org/10.1074/jbc.274.17.12049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207028	hybrid			2022-12-25	WOS:000079834800084
J	Saxena, M; Williams, S; Brockdorff, J; Gilman, J; Mustelin, T				Saxena, M; Williams, S; Brockdorff, J; Gilman, J; Mustelin, T			Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; MAP KINASE; TRANSCRIPTIONAL REGULATION; NEGATIVE REGULATION; GENETIC-EVIDENCE; FAMILY KINASES; IL-2 GENE; LC-PTP; TRANSDUCTION; PHOSPHORYLATION	Activation of T lymphocytes to produce cytokines is regulated by the counterbalance of protein-tyrosine kinases and protein-tyrosine phosphatases, many of which have a high degree of substrate specificity because of physical association with their targets. Overexpression of hematopoietic protein-tyrosine phosphatase (HePTP) results in suppression of T lymphocyte activation as measured by T cell antigen receptor-induced activation of transcription factors binding to the 5' promoter of the interleukin-2 gene. Efforts to pinpoint the exact site of action and specificity of HePTP in the signaling cascade revealed that HePTP acts directly on the mitogen-activated protein (MAP) kinases Erk1 and 2 and consequently reduces the magnitude and duration of their catalytic activation in intact T cells. In contrast, HePTP had no effects on N-terminal c-Jun kinase or on events upstream of the MAP kinases, The specificity of HePTP correlated with its physical association through its noncatalytic N terminus with Erk and another MAP kinase, p38, but not Jnk or other proteins. We propose that HePTP plays a negative role in antigen receptor signaling by specifically regulating MAP kinases in the cytosol and at early time points of T cell activation before the activation-induced expression of nuclear dual-specific MAP kinase phosphatases.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Mustelin, T (corresponding author), Sidney Kimmel Canc Ctr, Lab Signal Transduct, 10835 Altman Row, San Diego, CA 92121 USA.			Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI35603, AI41481] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603, R01AI041481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1994, FEBS LETT, V338, P47, DOI 10.1016/0014-5793(94)80114-2; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Egerton M, 1996, EUR J IMMUNOL, V26, P2279, DOI 10.1002/eji.1830261002; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; FONATSCH C, 1991, CANCER GENET CYTOGEN, V56, P243, DOI 10.1016/0165-4608(91)90177-V; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; LUO K, 1990, ONCOGENE, V5, P921; MAMAEV N, 1988, CANCER GENET CYTOGEN, V35, P21, DOI 10.1016/0165-4608(88)90116-1; MITELMAN F, 1991, CYTOGENET CELL GENET, V58, P1503; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1998, FRONT BIOSCI, V3, P1066; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; SESILVA DR, 1998, J IMMUNOL, V160, P4175; SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49; SHIOZUKA K, 1995, GENE, V162, P279, DOI 10.1016/0378-1119(95)00306-Q; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SWEITER M, 1995, J BIOL CHEM, V270, P21902; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; ZANKE B, 1994, LEUKEMIA, V8, P236; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	49	124	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11693	11700		10.1074/jbc.274.17.11693	http://dx.doi.org/10.1074/jbc.274.17.11693			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206983	hybrid			2022-12-25	WOS:000079834800039
J	Avisar, N; Shiftan, L; Ben-Dror, I; Havazelet, N; Vardimon, L				Avisar, N; Shiftan, L; Ben-Dror, I; Havazelet, N; Vardimon, L			A silencer element in the regulatory region of glutamine synthetase controls cell type-specific repression of gene induction by glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC NEURAL RETINA; RECEPTOR TRANSCRIPTIONAL ACTIVITY; SODIUM-CHANNEL GENE; MAMMALIAN-CELLS; TARGET GENES; EXPRESSION; IDENTIFICATION; LOCALIZATION; INDUCIBILITY; INVOLVEMENT	Glutamine synthetase is a key enzyme in the recycling of the neurotransmitter glutamate, Expression of this enzyme is regulated by glucocorticoids, which induce a high level of glutamine synthetase in neural but not in various non-neural tissues, This is despite the fact that non-neural cells express functional glucocorticoid receptor molecules capable of inducing other target genes. Sequencing and functional analysis of the upstream region of the glutamine synthetase gene identified, 5' to the glucocorticoid response element (GRE), a 21-base pair glutamine synthetase silencer element (GSSE), which showed considerable homology with the neural restrictive silencer element NRSE. The GSSE was able to markedly repress the induction of gene transcription by glucocorticoids in non-neural cells and in embryonic neural retina. The repressive activity of the GSSE could be conferred on a heterologous GRE promoter and was orientation- and position-independent with respect to the transcriptional start site, but appeared to depend on a location proximal to the GRE, Gel-shift assays revealed that non-neural cells and cells of early embryonic retina contain a high level of GSSE binding activity and that this level declines progressively with age. Our results suggest that the GSSE might be involved in the restriction of glutamine synthetase induction by glucocorticoids to differentiated neural tissues.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Vardimon, L (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.							BENDROR I, 1993, P NATL ACAD SCI USA, V90, P1117, DOI 10.1073/pnas.90.3.1117; BENOR S, 1993, MOL CELL BIOL, V13, P331, DOI 10.1128/MCB.13.1.331; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; BULMER M, 1987, MOL BIOL EVOL, V4, P395; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOROVITS R, 1994, P NATL ACAD SCI USA, V91, P4786, DOI 10.1073/pnas.91.11.4786; Gorovits R, 1996, MOL BRAIN RES, V43, P321, DOI 10.1016/S0169-328X(96)00213-6; GROSSMAN R, 1994, MOL BRAIN RES, V21, P312, DOI 10.1016/0169-328X(94)90262-3; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; KENNEDY AJ, 1974, NATURE, V252, P50, DOI 10.1038/252050a0; Kimura MA, 1985, NEUTRAL THEORY MOL E; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LINSER P, 1979, P NATL ACAD SCI USA, V76, P6476, DOI 10.1073/pnas.76.12.6476; LINSER PJ, 1981, DEV BRAIN RES, V1, P103, DOI 10.1016/0165-3806(81)90097-3; MAGNUSON SR, 1988, DEV BIOL, V130, P536, DOI 10.1016/0012-1606(88)90348-X; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Mieda M, 1996, J BIOL CHEM, V271, P5177; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Moran D, 1997, GENE, V194, P201, DOI 10.1016/S0378-1119(97)00148-0; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MOSCONA AA, 1983, PROGR RETINAL RES, P111; MOSCONA M, 1979, DIFFERENTIATION, V13, P165, DOI 10.1111/j.1432-0436.1979.tb01579.x; PATEJUNAS G, 1987, MOL CELL BIOL, V7, P1070, DOI 10.1128/MCB.7.3.1070; PATEJUNAS G, 1990, J BIOL CHEM, V265, P15280; PU HF, 1990, GENE, V89, P259, DOI 10.1016/0378-1119(90)90014-I; PUPKO T, 1999, IN PRESS J MOL EVOL, V48; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SHARP PM, 1987, MOL BIOL EVOL, V4, P222; VANDENBERG CJ, 1970, HDB NEUROCHEMISTRY, P355; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; VARDIMON L, 1988, P NATL ACAD SCI USA, V85, P5981, DOI 10.1073/pnas.85.16.5981; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221; ZHANG HY, 1993, J BIOL CHEM, V268, P2850; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	43	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11399	11407		10.1074/jbc.274.16.11399	http://dx.doi.org/10.1074/jbc.274.16.11399			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196233	hybrid			2022-12-25	WOS:000079751900101
J	Hubbs, AE; Majidi, M; Lichy, JH				Hubbs, AE; Majidi, M; Lichy, JH			Expression of an isoform of the novel signal transduction protein ST5 is linked to cell morphology	ONCOGENE			English	Article						ST5; signal transduction; cytoskeleton; contact-inhibition	KINASE-ACTIVITY; IDENTIFICATION; MICROTUBULES; INVOLVEMENT; DISRUPTION; HYBRIDS; LINES; GENE	The human ST5 gene is expressed as 4.6, 3.1 and 2.8 kb transcripts encoding putative 126, 82 and 70 kDa proteins that function in the MAP kinase signaling pathway in transient expression assays, Expression of the 2.8 kb transcript correlates with reduced tumorigenicity in HeLa-fibroblast hybrids, suggesting a role in tumor suppression. We now report the detection of ST5 proteins in cellular extracts, demonstrate specific expression of p70 in non-tumorigenic HeLa-fibroblast hybrids, extend the correlation between p70 expression and cellular morphology to a wide variety of cell lines, and provide direct evidence that p70 can effect changes in cell growth and morphology. ST5 proteins were identified in extracts of human, mouse and simian epithelial cells and fibroblasts, but were absent from lymphoid cells. Transfection of the 2.8 kb cDNA into a p70-negative mouse fibroblast line yielded stable transfectants with a Battened, less refractile morphology relative to controls. The p70 expressing clones had initial growth rates similar to those of control cells but their saturation density was reduced threefold, suggesting a restoration of contact-regulated growth. In conjunction with previous findings, these results suggest that ST5 proteins participate directly in events affecting cytoskeletal organization and tumorigenicity.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	United States Department of Defense	Lichy, JH (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA.				NATIONAL CANCER INSTITUTE [R01CA064114] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA64114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V1, pCH9; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; KAJSTURA J, 1993, CELL BIOL INT, V17, P1023, DOI 10.1006/cbir.1993.1032; Lichy JH, 1996, NUCLEIC ACIDS RES, V24, P4700, DOI 10.1093/nar/24.23.4700; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; Lu Q, 1998, MOL CELL BIOL, V18, P3257, DOI 10.1128/MCB.18.6.3257; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Majidi M, 1998, J BIOL CHEM, V273, P16608, DOI 10.1074/jbc.273.26.16608; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; STANBRIDGE EJ, 1980, INT J CANCER, V26, P1, DOI 10.1002/ijc.2910260102; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; Taubenberger JK, 1996, CELL IMMUNOL, V171, P41, DOI 10.1006/cimm.1996.0170; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	19	10	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2519	2525		10.1038/sj.onc.1202554	http://dx.doi.org/10.1038/sj.onc.1202554			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229203				2022-12-25	WOS:000079703300012
J	Kitagawa, H; Shimakawa, H; Sugahara, K				Kitagawa, H; Shimakawa, H; Sugahara, K			The tumor suppressor EXT-like gene EXTL2 encodes an alpha 1, 4-N-acetylhexosaminyltransferase that transfers N-acetylgalactosamine and N-acetylglucosamine to the common glycosaminoglycan-protein linkage region - The key enzyme for the chain initiation of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; IN-VITRO; IDENTIFICATION; BIOSYNTHESIS; FAMILY; CHROMOSOME-11; EXPRESSION; GLYCOSYLTRANSFERASES; TETRASACCHARIDES; HETEROZYGOSITY	We previously demonstrated a unique alpha-N-acetylgalactosaminyltransferase that transferred N-acetylgalactosamine (GalNAc) to the tetrasaccharide-serine, GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser (GlcA represents glucuronic acid), derived from the common glycosaminoglycan-protein linkage region, through an alpha 1,4-linkage. In this study, we purified the enzyme from the serum-free culture medium of a human sarcoma cell line. Peptide sequence analysis of the purified enzyme revealed 100% identity to the multiple exostoses-like gene EXTL2/EXTR1, a member of the hereditary multiple exostoses (EXT) gene family of tumor suppressors. The expression of a soluble recombinant form of the protein produced an active enzyme, which transferred alpha-GalNAc from UDP-[H-3]GalNAc to various acceptor substrates including GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser. Interestingly, the enzyme also catalyzed the transfer of N-acetylglucosamine (GlcNAc) from UDP-[H-3]GlcNAc to GlcA beta 1-3Gal beta 1-O-naphthalenemethanol, which was the acceptor substrate for the previously described GlcNAc transferase I involved in the biosynthetic initiation of heparan sulfate. The GlcNAc transferase reaction product was sensitive to the action of heparitinase I, establishing the identity of the enzyme to be alpha 1,4-GlcNAc transferase. These results altogether indicate that EXTL2/EXTR2 encodes the alpha 1,4-N-acetylhexosaminyl-transferase that transfers GalNAc/GlcNAc to the tetrasaccharide representing the common glycosaminoglycan-protein linkage region and that is most likely the critical enzyme that determines and initiates the heparin/heparan sulfate synthesis, separating it from the chondroitin sulfate/dermatan sulfate synthesis.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita-machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Binari RC, 1997, DEVELOPMENT, V124, P2623; COOK A, 1993, AM J HUM GENET, V53, P71; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Fritz TA, 1997, GLYCOBIOLOGY, V7, P587, DOI 10.1093/glycob/7.5.587-c; GOTO F, 1993, PURE APPL CHEM, V65, P793, DOI 10.1351/pac199365040793; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1999, IN PRESS GLYCOBIOLOG, V9; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; Lidholt K, 1997, GLYCOCONJUGATE J, V14, P737, DOI 10.1023/A:1018525602197; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; Miura Y, 1998, GLYCOBIOLOGY, V8, P813, DOI 10.1093/glycob/8.8.813; Murch SH, 1996, LANCET, V347, P1299, DOI 10.1016/S0140-6736(96)90941-1; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; SCHMALE GA, 1994, J BONE JOINT SURG AM, V76A, P986, DOI 10.2106/00004623-199407000-00005; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SOLOMON L, 1964, AM J HUM GENET, V16, P351; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796	30	161	169	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13933	13937		10.1074/jbc.274.20.13933	http://dx.doi.org/10.1074/jbc.274.20.13933			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318803	hybrid			2022-12-25	WOS:000080322200032
J	Liu, RY; Fan, C; Olashaw, NE; Wang, X; Zuckerman, KS				Liu, RY; Fan, C; Olashaw, NE; Wang, X; Zuckerman, KS			Tumor necrosis factor-alpha-induced proliferation of human Mo7e leukemic cells occurs via activation of nuclear factor kappa B transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; PROTEIN-KINASE ACTIVATION; BREAST-CANCER CELLS; TNF-ALPHA; INDUCED APOPTOSIS; LYMPHOMA PATIENTS; U937 CELLS; HEL CELLS; LINE; INHIBITION	Tumor necrosis factor-alpha (TNF-alpha) stimulates proliferation of Mo7e, CMK, HU-3, and M-MOK human leukemic cell lines. We report here the signal transduction pathway involved in TNF-alpha-induced Mo7e cell proliferation. Mo7e cells spontaneously die in the absence of growth factors, but treating the cells with interleukin (IL)-3, IL-6, thrombopoietin, granulocyte/macrophage colony-stimulating factor, or TNF-alpha promotes their survival and proliferation. Although most of these factors activate MAP kinase and Jun NH2-terminal kinase/signal transducer and activators of transcription signaling pathways, TNF-alpha fails to activate either pathway. When Mo7e cells were treated with TNF-alpha, nuclear factor kappa B (NF-kappa B) was activated transiently. The activated NF-kappa B consisted of heterodimers of p65 and p50 subunits. The degradation of I kappa B alpha coincided with activation of NF-kappa B in TNF-alpha-treated cells. To investigate the role of activated NF-kappa B in TNF-alpha-induced Mo7e proliferation, a cell-permeable peptide (SN50) carrying the nuclear localization sequence of p50 NF-KB was used to block nuclear translocation of activated NF-kappa B, Pretreating Mo7e cells with SN50 blocked TNF-alpha-induced nuclear translocation of NF-kappa B and inhibited TNF-alpha-induced Mo7e cell survival and proliferation. A mutant SN50 peptide did not affect TNF-alpha-induced Mo7e cell growth. SN50 had no effects on IL-3- or granulocyte/macrophage colony-stimulating factor-induced Mo7e cell proliferation. The results indicate that activation of NF-kappa B is involved in TNF-alpha-induced Mo7e cell survival and proliferation.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Hematol & Med Oncol, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Dept Anat, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Liu, RY (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Hematol & Med Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA056072, P30CA076292] Funding Source: NIH RePORTER; NCI NIH HHS [CA56072, P30 CA76292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSSON J, 1993, AM J PEDIAT HEMATOL, V15, P364; ADERKA D, 1993, BLOOD, V81, P2076; AKIYAMA Y, 1992, JPN J CANCER RES, V83, P989, DOI 10.1111/j.1349-7006.1992.tb02012.x; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Blagosklonny MV, 1998, INT J CANCER, V78, P511, DOI 10.1002/(SICI)1097-0215(19981109)78:4<511::AID-IJC19>3.0.CO;2-8; BRACH MA, 1993, LEUKEMIA, V7, pS22; BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CIMINO G, 1991, LEUKEMIA, V5, P32; DIGEL W, 1989, BLOOD, V73, P1242; Drexler HG, 1997, LEUKEMIA, V11, P701, DOI 10.1038/sj.leu.2400633; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; GREENBERG SM, 1988, BLOOD, V72, P1968; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; ISHII E, 1991, INT J HEMATOL, V54, P79; KALMANTI M, 1993, INT J HEMATOL, V57, P147; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu RY, 1999, BLOOD, V93, P2369, DOI 10.1182/blood.V93.7.2369.407k18_2369_2379; Liu RY, 1998, CANCER RES, V58, P2217; LIU RY, 1992, CANCER RES, V52, P3667; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu G, 1997, NEUROCHEM INT, V30, P401, DOI 10.1016/S0197-0186(96)00075-7; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MIURA K, 1992, LEUKEMIA RES, V16, P281, DOI 10.1016/0145-2126(92)90066-G; MUNKER R, 1993, ACTA HAEMATOL-BASEL, V90, P77; OGURA M, 1985, BLOOD, V66, P1384; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Olashaw NE, 1996, J BIOL CHEM, V271, P30307; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Ozaki K, 1997, FEBS LETT, V410, P297, DOI 10.1016/S0014-5793(97)00653-4; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; SAARINEN UM, 1990, CANCER RES, V50, P592; Salles G, 1996, BRIT J HAEMATOL, V93, P352, DOI 10.1046/j.1365-2141.1996.5181059.x; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wadhwa M, 1996, CYTOKINE, V8, P900, DOI 10.1006/cyto.1996.0121; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Warzocha K, 1997, J CLIN ONCOL, V15, P499, DOI 10.1200/JCO.1997.15.2.499; Warzocha Krzysztof, 1997, Leukemia (Basingstoke), V11, P441; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1997, CANCER RES, V57, P3097; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614	48	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13877	13885		10.1074/jbc.274.20.13877	http://dx.doi.org/10.1074/jbc.274.20.13877			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318796	hybrid			2022-12-25	WOS:000080322200025
J	Norris, JL; Baldwin, AS				Norris, JL; Baldwin, AS			Oncogenic Ras enhances NF-kappa B transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELLULAR-TRANSFORMATION; GENE-EXPRESSION; REQUIRES RAF-1; FACTOR-ALPHA; HA-RAS; C-JUN; CASCADES; STRESS; PHOSPHORYLATION	Tumors frequently contain mutations in ras genes, resulting in constitutive activation of Ras-activated signaling pathways. The ultimate targets of these signal transduction cascades are transcription factors required for cellular proliferation. Understanding how constitutive activation of Ras contributes to tumorigenesis requires an understanding of both the signaling pathways that Ras activates and how these pathways in turn regulate gene expression. Gene expression from kappa B sites is enhanced in cells transformed with activated Ras and NF-kappa B activity is required for oncogenic Ras to transform NIH-3T3 and Rat-1 fibroblasts. Both dominant negative and constitutively active components of signaling pathways have been tested for their ability to regulate NF-kappa B. These experiments show that Ras utilizes Raf-dependent and Raf-independent pathways to activate NF-kappa B transcriptional activity, both of which require the stress-activated kinase p38 or a related kinase. In the case of Raf, activation of NF-kappa B by an autocrine factor stimulates kappa B-dependent transcriptional activity.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA073756, F32CA073487] Funding Source: NIH RePORTER; NCI NIH HHS [CA73756, 5F32 CA73487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOEDERT M, 1997, EMBO J, V16, P3663; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; OLSEN MF, 1995, SCIENCE, V269, P1270; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TROPPMAIR J, 1997, ONCOGENE, V17, P4454; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	41	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13841	13846		10.1074/jbc.274.20.13841	http://dx.doi.org/10.1074/jbc.274.20.13841			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318790	hybrid			2022-12-25	WOS:000080322200019
J	Rehault, S; Brillard-Bourdet, M; Juliano, MA; Juliano, L; Gauthier, F; Moreau, T				Rehault, S; Brillard-Bourdet, M; Juliano, MA; Juliano, L; Gauthier, F; Moreau, T			New, sensitive fluorogenic substrates for human cathepsin G based on the sequence of serpin-reactive site loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; CHYMOTRYPSIN-LIKE ENZYMES; PROTEINASE-INHIBITORS; CRYSTAL-STRUCTURE; HUMAN CHYMASE; PEPTIDE; ELASTASE; LEUKOCYTE; PROTEASES; TISSUE	Cathepsin G has both trypsin- and chymotrypsin-like activity, but studies on its enzymatic properties have been limited by a lack of sensitive synthetic substrates. Cathepsin G activity is physiologically controlled by the fast acting serpin inhibitors alpha(1)-antichymotrypsin and alpha(1)-proteinase inhibitor, in which the reactive site loops are cleaved during interaction with their target enzymes. We therefore synthesized a series of intramolecularly quenched fluorogenic peptides based on the sequence of various serpin loops. Those peptides were assayed as substrates for cathepsin G and other chymotrypsin-like enzymes including chymotrypsin and chymase. Peptide substrates derived from the alpha(1)-antichymotrypsin loop were the most sensitive for cathepsin G; with k(cat)/K-m values of 5-20 mM(-1) s(-1). Substitutions were introduced at positions P-1 and P-2 in alpha(1)-antichymotrypsin-derived substrates to tentatively improve their sensitivity. Replacement of Leu-Leu in ortho-aminobenzoyl (Abz)-Thr-Leu-Leu-Ser-Ala-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine (EDDnp) by Pro-Phe in Abz-Thr-Pro-Phe-Ser-Ala-Leu-Gln-EDDnp produced the most sensitive substrate of cathepsin G ever reported. It was cleaved with a specificity constant k(cat)/K-m of 150 mM(-1) s(-1). Analysis by molecular modeling of a peptide substrate bound into the cathepsin G active site revealed that, in addition to the protease S-1 subsite, subsites S-1' and S-2' significantly contribute to the definition of the substrate specificity of cathepsin G.	Univ Tours, Enzymol & Prot Chem Lab, F-37032 Tours, France; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Universite de Tours; Universidade Federal de Sao Paulo (UNIFESP)	Moreau, T (corresponding author), Univ Tours, Enzymol & Prot Chem Lab, 2bis Blvd Tonnelle, F-37032 Tours, France.		REHAULT-GODBERT, Sophie/Y-3890-2019; Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822; Rehault-Godbert, Sophie/0000-0003-2800-3417				ALLEN DH, 1995, J BIOL CHEM, V270, P1408, DOI 10.1074/jbc.270.3.1408; AVRIL LE, 1995, FEBS LETT, V367, P251, DOI 10.1016/0014-5793(95)00571-P; BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; BAUER CA, 1976, BIOCHEMISTRY-US, V15, P1291, DOI 10.1021/bi00651a019; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BIETH JG, 1986, BIOL EXTRACELLULAR M, V1, P217; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; CHAGAS JR, 1991, ANAL BIOCHEM, V192, P419, DOI 10.1016/0003-2697(91)90558-B; Chertov O, 1997, J EXP MED, V186, P739, DOI 10.1084/jem.186.5.739; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; Fitzpatrick PA, 1996, PROTEIN ENG, V9, P585, DOI 10.1093/protein/9.7.585; HARPER JW, 1981, ANAL BIOCHEM, V118, P382, DOI 10.1016/0003-2697(81)90597-2; HARVIMA IT, 1994, ARCH DERMATOL RES, V287, P61, DOI 10.1007/BF00370720; Hayem A, 1988, Adv Exp Med Biol, V240, P97; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; LAROSA CA, 1994, J VASC SURG, V19, P306, DOI 10.1016/S0741-5214(94)70106-7; LEVY H, 1979, BIOCHIM BIOPHYS ACTA, V567, P35, DOI 10.1016/0005-2744(79)90169-4; LOMAS DA, 1995, J BIOL CHEM, V270, P23437, DOI 10.1074/jbc.270.40.23437; MAISON CM, 1991, J IMMUNOL, V147, P921; McGrath ME, 1997, BIOCHEMISTRY-US, V36, P14318, DOI 10.1021/bi971403n; MCRAE B, 1980, BIOCHEMISTRY-US, V19, P3973, DOI 10.1021/bi00558a013; OLIVEIRA MCF, 1992, ANAL BIOCHEM, V203, P39, DOI 10.1016/0003-2697(92)90040-E; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, BIOCHEMISTRY-US, V36, P5381, DOI 10.1021/bi9617522; Polanowska J, 1998, BBA-PROTEIN STRUCT M, V1386, P189, DOI 10.1016/S0167-4838(98)00085-5; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; Sanker S, 1997, J BIOL CHEM, V272, P2963, DOI 10.1074/jbc.272.5.2963; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SENIOR RM, 1984, J IMMUNOL, V132, P2547; SHAFER WM, 1991, J BIOL CHEM, V266, P112; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; TANAKA T, 1985, BIOCHEMISTRY-US, V24, P2040, DOI 10.1021/bi00329a036; Tsu CA, 1997, BIOCHEMISTRY-US, V36, P5393, DOI 10.1021/bi961753u; WANG MC, 1979, INVEST UROL, V17, P159; Watorek W, 1988, Adv Exp Med Biol, V240, P23; Yamazaki T, 1998, IMMUNOLOGY, V93, P115	46	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13810	13817		10.1074/jbc.274.20.13810	http://dx.doi.org/10.1074/jbc.274.20.13810			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318785	hybrid			2022-12-25	WOS:000080322200014
J	Tomura, H; Nishigori, H; Sho, K; Yamagata, K; Inoue, I; Takeda, J				Tomura, H; Nishigori, H; Sho, K; Yamagata, K; Inoue, I; Takeda, J			Loss-of-function and dominant-negative mechanisms associated with hepatocyte nuclear factor-1 beta mutations in familial type 2 diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEINS; GLUCOSE-TRANSPORTER; GENE; TRANSCRIPTION; HOMEOPROTEIN; MODY; HETERODIMERS; MEMBER; GLUT2; CELL	Hepatocyte nuclear factor (HNF)-1 beta, a homeodomain-containing transcription factor, regulates gene expression in a dimerized form in pancreas, liver, and some other tissues. Recent genetic studies have identified two HNF-1 beta mutations, R177X and A263fsinsGG, in subjects with a monogenic form of type 2 diabetes. Despite the defects being in the same gene, diverse severities of disease are observed in the affected subjects. To investigate the molecular mechanism by which mutations might cause various phenotypic features, wild type and mutant proteins were transiently expressed in insulin-producing (MIN6) and hepatic (HepG2) cells. Luciferase reporter assay showed that both mutations resulted in a marked reduction of transactivation activity. Because their dimerization activity was found to be intact by the yeast two-hybrid system, it was possible that they were dominant-negative to wild type activity. When co-expressed with wild type, both of the mutants significantly decreased wild type activity in HepG2 cells. In contrast, although A263fsinsGG functioned similarly in MIN6 cells, R177X failed to affect wild type activity in this cell line. Immunohistochemical analysis of the mutants suggests that this functional divergence might be generated by the modification of nuclear localization. These results suggest that HNF-1 beta mutations may impair pancreatic beta-cell function by loss-of-function and dominant-negative mechanisms.	Gunma Univ, Dept Cell Biol, Inst Mol & Cellular Regulat, Mol Genet Lab, Maebashi, Gumma 3718512, Japan; Osaka Univ, Sch Med, Dept Internal Med 2, Osaka 5650871, Japan	Gunma University; Osaka University	Takeda, J (corresponding author), Gunma Univ, Dept Cell Biol, Inst Mol & Cellular Regulat, Mol Genet Lab, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.							BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Nishigori H, 1998, DIABETES, V47, P1354, DOI 10.2337/diabetes.47.8.1354; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; TAKEDA J, 1993, DIABETES, V42, P773, DOI 10.2337/diabetes.42.5.773; TREISMAN J, 1989, CELL, V59, P553; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; Yamada S, 1999, DIABETES, V48, P645, DOI 10.2337/diabetes.48.3.645; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	20	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12975	12978		10.1074/jbc.274.19.12975	http://dx.doi.org/10.1074/jbc.274.19.12975			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224045	hybrid			2022-12-25	WOS:000080200400007
J	Niederberger, V; Hayek, B; Vrtala, S; Laffer, S; Twardosz, A; Vangelista, L; Sperr, WR; Valent, P; Rumpold, H; Kraft, D; Ehrenberger, K; Valenta, R; Spitzauer, S				Niederberger, V; Hayek, B; Vrtala, S; Laffer, S; Twardosz, A; Vangelista, L; Sperr, WR; Valent, P; Rumpold, H; Kraft, D; Ehrenberger, K; Valenta, R; Spitzauer, S			Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7	FASEB JOURNAL			English	Article						Type I allergy; allergen; EF-hand protein; conformational epitopes; circular dichroism spectroscopy; cross-reactivity; pollen-specific expression	IMMUNOGOLD ELECTRON-MICROSCOPY; CYTOSOLIC-FREE CALCIUM; ACTIN-BINDING PROTEIN; BIRCH POLLEN; IGE-BINDING; MOLECULAR CHARACTERIZATION; PRATENSE POLLEN; IMMUNOLOGICAL CHARACTERIZATION; RECOMBINANT ALLERGENS; CRYSTAL-STRUCTURE	Type I allergy, an immunodisorder that affects almost 20% of the population worldwide, is based on the immunoglobulin E (IgE) recognition of per se innocuous antigens (allergens). Pollen from wind-pollinated plants belong to the most potent allergen sources. We report the isolation of a cDNA coding for a 8.6 kDa two EF-hand calcium binding allergen, Phl p 7, from a timothy grass (Phleum pratense) pollen expression cDNA library, using serum IgE from a grass pollen allergic patient. Sequence analysis identified Phl p 7 as a member of a recently discovered subfamily of pollen-specific calcium binding proteins. Recombinant Phl p 7 was expressed in Escherichia coli and purified to homogeneity as determined by mass spectroscopy. Approximately 10% of pollen allergic patients displayed IgE reactivity to rPhl p 7 and Phl p 7-homologous allergens present in pollens of monocotyledonic and dicotyledonic plants. Circular dichroism analysis of the calcium-bound and apo-rPhl p 7 indicated that differences in IgE recognition may be due to calcium-induced changes in the protein conformation. The fact that patients mount IgE antibodies against different protein conformations is interpreted as a footprint of a preferential sensitization against either form. The biological activity of rPhl p 7 was demonstrated by its ability to induce basophil histamine release and immediate type skin reactions in sensitized individuals. In conclusion, IgE binding to Phl p 7 represents an example for the conformation-dependent IgE recognition of an allergen. Recombinant Phl p 7 may be used for diagnosis and perhaps treatment of a group of patients who suffer from allergy to pollens of many unrelated plant species.	Univ Vienna, Mol Immunopathol Grp, Inst Gen & Expt Pathol, AKH,Med Sch, A-1090 Vienna, Austria; Univ Vienna, Dept Otorhinolaryngol, AKH, A-1090 Vienna, Austria; Univ Vienna, Inst Med & Chem Lab Diagnost, AKH, A-1090 Vienna, Austria; European Mol Biol Lab, Heidelberg, Germany; Univ Vienna, Dept Internal Med 1, Div Hematol, AKH, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; European Molecular Biology Laboratory (EMBL); University of Vienna	Valenta, R (corresponding author), Univ Vienna, Mol Immunopathol Grp, Inst Gen & Expt Pathol, AKH,Med Sch, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Valent, Peter/B-8533-2016; Sperr, Mast/V-4767-2019; Test, PV/U-9451-2019	Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Vangelista, Luca/0000-0003-0764-5031; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243				Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BLUM HE, 1977, J BIOL CHEM, V252, P2834; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BREWBAKE JL, 1963, AM J BOT, V50, P859, DOI 10.2307/2439772; Bufe A, 1996, PLANTA, V199, P413, DOI 10.1007/BF00195733; Bugajska-Schretter A, 1998, J ALLERGY CLIN IMMUN, V101, P67, DOI 10.1016/S0091-6749(98)70195-2; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; DROBAK BK, 1994, PLANT J, V6, P389, DOI 10.1046/j.1365-313X.1994.06030389.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; FRANKLINTONG VE, 1993, PLANT J, V4, P163, DOI 10.1046/j.1365-313X.1993.04010163.x; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Grote M, 1998, J ALLERGY CLIN IMMUN, V101, P60, DOI 10.1016/S0091-6749(98)70194-0; GROTE M, 1993, J HISTOCHEM CYTOCHEM, V41, P745, DOI 10.1177/41.5.8468456; GROTE M, 1994, J HISTOCHEM CYTOCHEM, V42, P427, DOI 10.1177/42.3.8308259; Hayek B, 1998, J IMMUNOL, V161, P7031; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; Kay A.B., 1997, ALLERGY ALLERGIC DIS; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, J IMMUNOL, V157, P4953; MALHO R, 1994, PLANT J, V5, P331, DOI 10.1111/j.1365-313X.1994.00331.x; Messerli M, 1997, J CELL SCI, V110, P1269; MILLER DD, 1992, J CELL SCI, V101, P7; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Smith PM, 1997, INT ARCH ALLERGY IMM, V114, P265, DOI 10.1159/000237678; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; Suphioglu C, 1997, FEBS LETT, V402, P167, DOI 10.1016/S0014-5793(96)01520-7; Thorn KS, 1997, STRUCTURE, V5, P19, DOI 10.1016/S0969-2126(97)00163-9; Tinghino R, 1998, J ALLERGY CLIN IMMUN, V101, P772, DOI 10.1016/S0091-6749(98)70306-9; Toriyama K, 1995, PLANT MOL BIOL, V29, P1157, DOI 10.1007/BF00020459; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVE G, 1995, EMBO J, V14, P4922, DOI 10.1002/j.1460-2075.1995.tb00175.x; Twardosz A, 1997, BIOCHEM BIOPH RES CO, V239, P197, DOI 10.1006/bbrc.1997.6860; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567	62	89	98	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					843	856		10.1096/fasebj.13.8.843	http://dx.doi.org/10.1096/fasebj.13.8.843			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224228				2022-12-25	WOS:000080372500008
J	Hasegawa, M; Cuenda, A; Spillantini, MG; Thomas, GM; Buee-Scherrer, V; Cohen, P; Goedert, M				Hasegawa, M; Cuenda, A; Spillantini, MG; Thomas, GM; Buee-Scherrer, V; Cohen, P; Goedert, M			Stress-activated protein kinase-3 interacts with the PDZ domain of alpha 1-syntrophin - A mechanism for specific substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS VULVAR INDUCTION; DYSTROPHIN-ASSOCIATED PROTEIN; MAP KINASE; CELLULAR STRESSES; SKELETAL-MUSCLE; MOLECULAR-CLONING; MAMMALIAN-CELLS; SODIUM-CHANNELS; SAP KINASES; P38 GROUP	Mechanisms for selective targeting to unique subcellular sites play an important role in determining the substrate specificities of protein kinases, Here we show that stress-activated protein kinase-3 (SAPK3, also called ERK6 and p38 gamma), a member of the mitogen-activated protein kinase family that is abundantly expressed in skeletal muscle, binds through its carboxyl-terminal sequence -KETXL to the PDZ domain of alpha 1-syntrophin, SAPK3 phosphorylates alpha 1-syntrophin at serine residues 193 and 201 in vitro and phosphorylation is dependent on binding 60 the PDZ domain of alpha 1-syntrophin, In skeletal muscle SAPK3 and alpha 1-syntrophin co-localize at the neuromuscular junction, and both proteins can be co-immunoprecipitated from transfected COS cell lysates, Phosphorylation of a PDZ domain-containing protein by an associated protein kinase is a novel mechanism for determining both the localization and the substrate specificity of a protein kinase.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Cambridge, Dept Neurol, Cambridge CB2 2PY, England	MRC Laboratory Molecular Biology; University of Dundee; University of Cambridge	Goedert, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Buee-Scherrer, Valerie/0000-0002-6107-1289				ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gee SH, 1998, J NEUROSCI, V18, P128; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hoskins R, 1996, DEVELOPMENT, V122, P97; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909	51	133	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12626	12631		10.1074/jbc.274.18.12626	http://dx.doi.org/10.1074/jbc.274.18.12626			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212242	hybrid			2022-12-25	WOS:000080056800062
J	Hunter, GA; Ferreira, GC				Hunter, GA; Ferreira, GC			Pre-steady-state reaction of 8-aminolevulinate synthase - Evidence for a rate-determining product release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE COFACTOR; AMINO-ACID AMINOTRANSFERASE; 5-AMINOLEVULINATE SYNTHASE; ASPARTATE-AMINOTRANSFERASE; HEME-BIOSYNTHESIS; ESCHERICHIA-COLI; AMINOLEVULINATE SYNTHASE; CRYSTAL-STRUCTURES; BINDING; CATALYSIS	5-Aminolevulinate synthase (ALAS) is the first enzyme of the heme biosynthetic pathway in non-plant eukaryotes and the a-subclass of purple bacteria. The pyridoxal 5'-phosphate cofactor at the active site undergoes changes in absorptive properties during substrate binding and catalysis that have allowed us to study the kinetics of these reactions spectroscopically, Rapid scanning stopped-flow experiments of murine erythroid B-aminolevulinate synthase demonstrate that reaction with glycine plus succinyl-CoA results in a pre-steady-state burst of quinonoid intermediate formation. Thus, a step following binding of substrates and initial quinonoid intermediate formation is rate-determining. The steady-state spectrum of the enzyme is similar to that formed in the presence of Ei-aminolevulinate, suggesting that release of this product limits the overall rate. Reaction of either glycine or B-aminolevulinate with ALAS is slow (k(f) = 0.15 s(-1)) and approximates k(cat). The rate constant for reaction with glycine is increased at least 90-fold in the presence of succinyl-CoA and most likely represents a slow conformational change of the enzyme that is accelerated by succinyl-CoA The slow rate of reaction of B-aminolevulinate with ALAS is 8-aminolevulinate-independent, suggesting that it also represents a slow isomerization of the enzyme. Reaction of succinyl-CoA with the enzyme-glycine complex to form a quinonoid intermediate is a biphasic process and may be irreversible. Taken together, the data suggest that turnover is limited by release of 5-aminolevulinate or a conformational change associated with B-aminolevulinate release.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Inst Biomol Sci, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Ferreira, GC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA.		Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052053] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52053] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOUD MM, 1974, J CHEM SOC CHEM COMM, P643, DOI 10.1039/c39740000643; AHKTAR M, 1979, COMPREHENSIVE ORGANI, V5, P1121; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Berndt MC, 1996, BBA-PROTEIN STRUCT M, V1298, P159, DOI 10.1016/S0167-4838(96)00117-3; BOTTOMLEY SS, 1995, J BIOENERG BIOMEMBR, V27, P161, DOI 10.1007/BF02110031; DURBIN J, 1950, BIOMETRIKA, V37, P409, DOI 10.1093/biomet/37.3-4.409; FANICAGA.M, 1973, EUR J BIOCHEM, V40, P19, DOI 10.1111/j.1432-1033.1973.tb03164.x; FERREIRA GC, 1993, PROTEIN SCI, V2, P1959, DOI 10.1002/pro.5560021117; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P151, DOI 10.1007/BF02110030; FERREIRA GC, 1993, J BIOL CHEM, V268, P584; FERREIRA GC, 1995, PROTEIN SCI, V4, P1001; Gong J, 1998, BIOCHEMISTRY-US, V37, P3509, DOI 10.1021/bi9719298; HUNTER GA, 1995, ANAL BIOCHEM, V226, P221, DOI 10.1006/abio.1995.1217; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; KIKUCHI G, 1958, J BIOL CHEM, V233, P1214; KIRSCH JF, 1966, BIOCHEMISTRY-US, V5, P783, DOI 10.1021/bi00866a053; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGHAI A, 1977, BIOCHEM SOC T, V5, P299, DOI 10.1042/bst0050299; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MILES EW, 1994, ADV LIF SCI-SERIES, P113; NANDI DL, 1978, J BIOL CHEM, V253, P8872; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; Peisach D, 1998, BIOCHEMISTRY-US, V37, P4958, DOI 10.1021/bi972884d; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; ShoolinginJordan PM, 1997, METHOD ENZYMOL, V281, P309; Tan DW, 1996, BIOCHEMISTRY-US, V35, P8934, DOI 10.1021/bi952918m; Tan DW, 1998, PROTEIN SCI, V7, P1208, DOI 10.1002/pro.5560070516; Tan DW, 1998, BIOCHEMISTRY-US, V37, P1478, DOI 10.1021/bi971928f; Wang W, 1997, BIOCHEMISTRY-US, V36, P8479, DOI 10.1021/bi970226n; YONAHA K, 1975, J BIOL CHEM, V250, P6983; ZAMAN Z, 1973, BIOCHEM J, V135, P257, DOI 10.1042/bj1350257; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006	36	56	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12222	12228		10.1074/jbc.274.18.12222	http://dx.doi.org/10.1074/jbc.274.18.12222			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212188	hybrid			2022-12-25	WOS:000080056800008
J	Kao, R; Davies, J				Kao, R; Davies, J			Molecular dissection of mitogillin reveals that the fungal ribotoxins are a family of natural genetically engineered ribonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA IDENTITY ELEMENTS; AMINO-ACID-SEQUENCE; ALPHA-SARCIN; EUKARYOTIC RIBOSOMES; TOXIN RESTRICTOCIN; SPECIFICITY; CLEAVAGE; RICIN; SITE; RECOGNITION	Mitogillin and the related fungal ribotoxins are highly specific ribonucleases which inactivate the ribosome enzymatically by cleaving the 23-28 S RNA of the large ribosomal subunit at a single phosphodiester bond. The site of cleavage occurs between G(4325) and A(4326) (rat ribosome numbering) which are present in one of the most conserved sequences (the alpha-sarcin loop) among the large subunit ribosomal RNAs of all living species. Amino acid sequence comparison of ribotoxins and guanyl/purine ribonucleases have identified domains or residues likely involved in ribonucleolytic activity or cleavage specificity. Fifteen deletion mutants (each 4 to 8 amino acid deletions) in motifs of mitogillin showing little amino acid sequence homology with guanyl/purine ribonucleases were constructed by site-directed mutagenesis, Analyses of the purified mutant proteins identified those regions in fungal ribotoxins contributing to ribosome targeting and modulating the catalytic activity of the toxin; some of the identified motifs are homologous to sequences in ribosomal proteins and elongation factors. This mutational study of mitogillin together with the recently published x-ray structure of restrictocin (a close relative of mitogillin) supports the hypothesis that the specific cleavage properties of ribotoxins are the result of natural genetic engineering in which the ribosomal targeting elements of ribosome-associated proteins were inserted into nonessential regions of T1-like ribonucleases.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Kao, R (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Kao, Richard Yi Tsun/C-4289-2009	Kao, Richard Y/0000-0001-8703-4980				ARNI R, 1988, J BIOL CHEM, V263, P15358; BETTER M, 1992, J BIOL CHEM, V267, P16712; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; CamposOlivas R, 1996, FEBS LETT, V399, P163, DOI 10.1016/S0014-5793(96)01320-8; CONDE FP, 1989, EUR J BIOCHEM, V178, P795, DOI 10.1111/j.1432-1033.1989.tb14511.x; ENDO Y, 1982, J BIOL CHEM, V257, P9054; ENDO Y, 1988, J BIOL CHEM, V263, P7917; FANDO JL, 1985, EUR J BIOCHEM, V149, P29, DOI 10.1111/j.1432-1033.1985.tb08888.x; FERNANDEZLUNA JL, 1985, BIOCHEMISTRY-US, V24, P861, DOI 10.1021/bi00325a008; Gluck A, 1996, J MOL BIOL, V256, P838, DOI 10.1006/jmbi.1996.0130; GLUCK A, 1994, NUCLEIC ACIDS RES, V22, P321, DOI 10.1093/nar/22.3.321; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; Kao R, 1998, MOL MICROBIOL, V29, P1019, DOI 10.1046/j.1365-2958.1998.00987.x; Kao R, 1995, BIOCHEM CELL BIOL, V73, P1151, DOI 10.1139/o95-124; Lacadena J, 1998, FEBS LETT, V424, P46, DOI 10.1016/S0014-5793(98)00137-9; Lamy B., 1992, GENETICALLY ENG TOXI, P237; LOPEZOTIN C, 1984, EUR J BIOCHEM, V143, P621, DOI 10.1111/j.1432-1033.1984.tb08415.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; OLSON BH, 1965, APPL MICROBIOL, V13, P322, DOI 10.1128/AEM.13.3.322-326.1965; OLSON BH, 1965, APPL MICROBIOL, V13, P314, DOI 10.1128/AEM.13.3.314-321.1965; ORLANDI R, 1988, CANC IMMUNOL IMMUNOT, V26, P1714; RODRIGUEZ R, 1982, BIOCHEM BIOPH RES CO, V108, P315, DOI 10.1016/0006-291X(82)91868-X; SACCO G, 1983, J BIOL CHEM, V258, P5811; SCHINDLER DG, 1977, NUCLEIC ACIDS RES, V4, P1097, DOI 10.1093/nar/4.4.1097; Shapiro R, 1998, BIOCHEMISTRY-US, V37, P6847, DOI 10.1021/bi9800146; TAKEDA E, 1997, NUCL ACIDS S SER, V37, P131; WAWRZYNCZAK EJ, 1991, EUR J BIOCHEM, V196, P203, DOI 10.1111/j.1432-1033.1991.tb15805.x; Yang XJ, 1996, STRUCTURE, V4, P837, DOI 10.1016/S0969-2126(96)00090-1	28	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12576	12582		10.1074/jbc.274.18.12576	http://dx.doi.org/10.1074/jbc.274.18.12576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212236	hybrid			2022-12-25	WOS:000080056800056
J	Li, SS; Smerdon, MJ				Li, SS; Smerdon, MJ			Base excision repair of N-methylpurines in a yeast minichromosome - Effects of transcription, DNA sequence, and nucleosome positioning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; NUCLEOTIDE LEVEL; DAMAGE; GENE; STRAND; METHYLATION; ENZYME	Base excision repair of dimethyl sulfate induced N-methylpurines (NMPs) was measured in a yeast minichromosome that has a galactose-inducible GAL1: URA3 fusion gene, a constitutively expressed HIS3 gene, and varied regions of chromatin structure. Removal rates of NMPs varied dramatically (>20-fold) at different sites along three selected fragments encompassing a total length of 1775 base pairs. Repair of NMPs was not coupled to transcription, because the transcribed strands of HIS3 and induced GAL1:URA3 were not repaired faster than the nontranscribed strands. However, the repair rate of NMPs was significantly affected by the nearest neighbor nucleotides, Slow repair occurred at NMPs between purines, especially guanines, whereas fast repair occurred at NMPs between pyrimidines. NMPs between a purine and pyrimidine were repaired at moderate rates. Moreover, a rough correlation between nucleosome positions and repair rates exists in some but not all regions that were analyzed.	Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA.	smerdon@mail.wsu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004106] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABANOBI SE, 1980, BIOCHEMISTRY-US, V19, P1382, DOI 10.1021/bi00548a018; CHEN J, 1989, P NATL ACAD SCI USA, V86, P7961, DOI 10.1073/pnas.86.20.7961; FRIEDMAN RA, 1995, BIOPHYS J, V69, P1528, DOI 10.1016/S0006-3495(95)80023-8; Krokan HE, 1997, BIOCHEM J, V325, P1; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEDOUX SP, 1990, J BIOL CHEM, V265, P14875; LI S, 1999, IN PRESS METHODS COM; Li SS, 1996, CARCINOGENESIS, V17, P1549, DOI 10.1093/carcin/17.8.1549; Maxam A M, 1980, Methods Enzymol, V65, P499; Mullen GP, 1997, BIOCHEMISTRY-US, V36, P4713, DOI 10.1021/bi962363a; OMARI S, 1990, THESIS SWISS FEDERAL; Pieper RO, 1998, CONT CANC RES, P33; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; SCICCHITANO DA, 1990, MUTAT RES, V233, P31, DOI 10.1016/0027-5107(90)90148-W; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SMERDON MJ, 1993, ALFRED BENZON SYMP S, V35, P258; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; Smerdon MJ, 1998, CONT CANC RES, P199; WASSERMANN K, 1990, J BIOL CHEM, V265, P13906; Xiao W, 1998, CURR GENET, V33, P92, DOI 10.1007/s002940050313; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; Ye N, 1998, J MOL BIOL, V284, P269, DOI 10.1006/jmbi.1998.2138	26	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12201	12204		10.1074/jbc.274.18.12201	http://dx.doi.org/10.1074/jbc.274.18.12201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212183	hybrid			2022-12-25	WOS:000080056800003
J	Morimoto, T; Hasegawa, K; Kaburagi, S; Kakita, T; Masutani, H; Kitsis, RN; Matsumori, A; Sasayama, S				Morimoto, T; Hasegawa, K; Kaburagi, S; Kakita, T; Masutani, H; Kitsis, RN; Matsumori, A; Sasayama, S			GATA-5 is involved in leukemia inhibitory factor-responsive transcription of the beta-myosin heavy chain gene in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCING RECEPTOR COMPONENT; PROTEIN-KINASE-C; MYOCARDIAL-CELL HYPERTROPHY; MUSCLE-SPECIFIC EXPRESSION; ATRIAL-NATRIURETIC-FACTOR; IL-6 SIGNAL TRANSDUCER; ENHANCER FACTOR-I; M-CAT; INDUCIBLE EXPRESSION; DEPENDENT PATHWAYS	Leukemia inhibitory factor is a member of a family of structurally related cytokines sharing the receptor component gp130, Activation of gp130 by leukemia inhibitory factor is sufficient to induce myocardial cell hypertrophy accompanied by specific changes in the pattern of gene expression. However, the molecular mechanisms that link gp130 activation to these changes have not been clarified. The present study investigated the transcriptional pathways by which leukemia inhibitory factor activates P-myosin heavy chain expression during myocardial cell hypertrophy. Mutation of the GATA motif in the P-myosin heavy chain promoter totally abolished leukemia inhibitory factor-responsive transcription without changing basal transcriptional activity. In contrast, endothelin-l responsiveness was unaffected by the GATA mutation. Among members of the cardiac GATA transcription factor subfamily (GATA-4, -5, and -6), GATA-5 was the sole and potent transactivator for the beta-myosin heavy chain promoter. This transactivation was dependent on sequence-specific binding of GATA-5 to the beta-myosin heavy chain GATA element, Cardiac nuclear factors that bind to to the beta-myosin heavy chain GATA element were induced by leukemia inhibitory factor stimulation. Last, leukemia inhibitory factor stimulation markedly increased transcripts of cardiac GATA-5, the expression of which is normally restricted to the early embryo. Thus, GATA-5 may be involved in gp130 signaling in cardiac myocytes.	Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Biol Responses, Inst Virus Res, Kyoto 6068507, Japan; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Kyoto University; Kyoto University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Hasegawa, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.	koj@kuhp.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; BUTTRICK PM, 1993, CIRC RES, V72, P1211, DOI 10.1161/01.RES.72.6.1211; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cooper G, 1997, ANNU REV MED, V48, P13, DOI 10.1146/annurev.med.48.1.13; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Hasegawa K, 1997, CIRCULATION, V96, P3943; HASEGAWA K, 1997, MOL BIOL CARDIOVASCU, P67; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Heim MH, 1996, EUR J CLIN INVEST, V26, P1, DOI 10.1046/j.1365-2362.1996.103248.x; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Ishikawa M, 1996, BIOCHEM BIOPH RES CO, V219, P377, DOI 10.1006/bbrc.1996.0241; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; KURABAYASHI M, 1990, JPN CIRC J, V54, P1192, DOI 10.1253/jcj.54.1192; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; MACLELLAN WR, 1997, MOL BIOL CARDIOVASCU, P327; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MERCADIER JJ, 1993, B ACAD NAT MED PARIS, V177, P917; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; Shioi T, 1996, CIRCULATION, V94, P2930, DOI 10.1161/01.CIR.94.11.2930; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; Taga T, 1996, J NEUROCHEM, V67, P1; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; THORBURN A, 1993, J BIOL CHEM, V268, P2244; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; YIN TG, 1993, J IMMUNOL, V151, P2555; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	63	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12811	12818		10.1074/jbc.274.18.12811	http://dx.doi.org/10.1074/jbc.274.18.12811			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212267	Green Submitted, hybrid			2022-12-25	WOS:000080056800087
J	Zamir, LO; Nikolakakis, A; Huang, LR; St-Pierre, P; Sauriol, F; Sparace, S; Mamer, O				Zamir, LO; Nikolakakis, A; Huang, LR; St-Pierre, P; Sauriol, F; Sparace, S; Mamer, O			Biosynthesis of 3-acetyldeoxynivalenol and sambucinol - Identification of the two oxygenation steps after trichodiene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-CULMORUM; POST-TRICHODIENE; TRICHOTHECENE 3-ACETYLDEOXYNIVALENOL; ISOTRICHODERMIN; PRECURSOR; INTERMEDIATE; METABOLITES; MYCOTOXINS; COMPLEXES	The first two oxygenation steps post-trichodiene in the biosyntheses of the trichothecenes 3-acetyldeoxynivalenol and sambucinol were investigated. The plausible intermediates 2-hydroxytrichodiene (2 alpha- and 2 beta-) and 12,13-epoxytrichodiene and the dioxygenated compounds 12,13-epoxy-9,10-trichoene-2-ol (2 alpha- and 2 beta-) were prepared specifically labeled with stable isotopes. They were then fed separately and/or together to Fusarium culmorum cultures, and the derived trichothecenes were isolated, purified, and analyzed. The stable isotopes enable easy localization of the labels in the products by H-2 NMR, C-13 MMR, and mass spectrometry. We found that 2 alpha-hydroxytrichodiene is the first oxygenated step in the biosynthesis of both 3-acetyldeoxynivalenol and sambucinol. The stereoisomer 2 beta-hydroxytrichodiene and 12,13-epoxytrichodiene are not biosynthetic intermediates and have not been isolated as metabolites. We also demonstrated that the dioxygenated 12,13-epoxy-9,10-trichoene-2 alpha-ol is a biosynthetic precursor to trichothecenes as had been suggested in a preliminary work. Its stereoisomer was not found in the pathway. A further confirmation of our results was the isolation of both oxygenated trichodiene derivatives 2 alpha-hydroxytrichodiene and 12,13-epoxy-9,10-trichoene-2 alpha-ol as natural metabolites in F. culmorum cultures.	Univ Quebec, Inst Armand Frappier, Ctr Rech Microbiol Appl, Laval, PQ H7N 4Z3, Canada; McGill Univ, Dept Chem, Montreal, PQ H3Z 2K6, Canada; McGill Univ, Dept Plant Sci, St Anne De Bellevue, PQ H9X 3V9, Canada; McGill Univ, Biomed Mass Spectrometry Unit, Montreal, PQ H3A 1A3, Canada	University of Quebec; McGill University; McGill University; McGill University	Zamir, LO (corresponding author), Univ Quebec, Inst Armand Frappier, Ctr Rech Microbiol Appl, 531 Blvd Prairies, Laval, PQ H7N 4Z3, Canada.							COLVIN EW, 1973, J CHEM SOC PERK T, V18, P1989; DeNijs M, 1997, J FOOD SAFETY, V17, P161; GREENHALGH R, 1984, J AGR FOOD CHEM, V32, P945, DOI 10.1021/jf00124a060; HESKETH AR, 1990, J CHEM SOC CHEM COMM, P1184, DOI 10.1039/c39900001184; HESKETH AR, 1993, PHYTOCHEMISTRY, V32, P93, DOI 10.1016/0031-9422(92)80113-S; HESKETH AR, 1991, PHYTOCHEMISTRY, V30, P2237, DOI 10.1016/0031-9422(91)83621-Q; HUFFMAN JW, 1983, SYNTHETIC COMMUN, V13, P553, DOI 10.1080/00397918308059528; KAZLAUSKAS RJ, 1991, J ORG CHEM, V56, P2656, DOI 10.1021/jo00008a016; Liu WZ, 1997, EUR J PLANT PATHOL, V103, P589, DOI 10.1023/A:1008693213656; MARASAAS WFD, 1984, TOXIGENIC FUSARIUMS, P147; MCCORMICK SP, 1990, APPL ENVIRON MICROB, V56, P702, DOI 10.1128/AEM.56.3.702-706.1990; Muller HM, 1997, MYCOPATHOLOGIA, V137, P185, DOI 10.1023/A:1006805717043; PEARSON AJ, 1989, J ORG CHEM, V54, P4663, DOI 10.1021/jo00280a039; Rotter BA, 1996, J TOXICOL ENV HEALTH, V48, P1, DOI 10.1080/009841096161447; Sharpless K. B., 1979, ALDRICHIM ACTA, V12, P63; SHARPLESS KB, 1972, J AM CHEM SOC, V94, P6538, DOI 10.1021/ja00773a045; THOMPSON DJ, 1976, J ORGANOMET CHEM, V108, P381, DOI 10.1016/S0022-328X(00)92017-5; ZAMIR LO, 1992, J LABELLED COMPD RAD, V31, P915, DOI 10.1002/jlcr.2580311110; ZAMIR LO, 1989, J CHEM SOC CHEM COMM, P598, DOI 10.1039/c39890000598; Zamir LO, 1996, J BIOL CHEM, V271, P27353, DOI 10.1074/jbc.271.44.27353; ZAMIR LO, 1991, J BIOL CHEM, V266, P14992; ZAMIR LO, 1990, J BIOL CHEM, V265, P6713; ZAMIR LO, 1987, J BIOL CHEM, V262, P15348; ZAMIR LO, 1991, J CHEM SOC CHEM COMM, P1033, DOI 10.1039/c39910001033; ZAMIR LO, 1999, IN PRESS J AGR FOOD	25	10	10	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12269	12277		10.1074/jbc.274.18.12269	http://dx.doi.org/10.1074/jbc.274.18.12269			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212195	hybrid			2022-12-25	WOS:000080056800015
J	Gardiner, EE; D'Souza, SE				Gardiner, EE; D'Souza, SE			Sequences within fibrinogen and intercellular adhesion molecule-1 (ICAM-1) modulate signals required for mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LYN TYROSINE KINASE; LEUKOCYTE ADHESION; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; REGULATED KINASE; CROSS-LINKING; IN-VIVO; PATHWAY; PHOSPHORYLATION	The interaction of fibrinogen (Fg) with intercellular adhesion molecule-1 (ICAM) on B-lymphoid Raji cells results in mitogenesis (Gardiner, E. E., and D'Souza, S. E. (1997) J. Biol. Chem, 272, 15474-15480). Incubation of Raji with Fg resulted in the increased tyrosine phosphorylation of the receptor-associated tyrosine kinase, pp60(Src) and extracellular signal-regulated kinase-1 (ERK), The increase in ERK-1 phosphorylation was blocked by a peptide with sequence matching ICAM-1 (8-22) and corresponded to a decrease in ERK-1 enzymatic activity. 100 mu M amounts of Fg peptide gamma-(117-133) caused an increase in tyrosine phosphorylation of ERK-1, These results are consistent with our previous report wherein ICAM-1-(8-22) blocked Fg-induced mitogenesis and Fg-gamma-(117-133) induced proliferation in Raji, The specific inhibitor of MEK, PD98059 (25 mu M), abrogated the increased phosphorylation of ERK-1 and blocked Raji mitogenesis by >50%, Inhibitors of pp60(Src), geldanamycin (62 nm), and herbimycin A (2.5 mu M) blocked >50% of Raji proliferation. These results indicate that the proliferation induced by Fg interactions with ICAM-1 is mediated in part by receptor-associated tyrosine kinases and ERK-1, and that the recognition sequences within Fg and ICAM-1 participate in the signaling process.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	D'Souza, SE (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Gardiner, Elizabeth/E-7774-2011; Gardiner, Elizabeth/P-8716-2019	Gardiner, Elizabeth/0000-0001-9453-9688	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043721, R29HL043721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bokemeyer D, 1997, J CLIN INVEST, V100, P582, DOI 10.1172/JCI119568; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CHIRATHAWORN C, 1995, J IMMUNOL, V155, P5479; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DSouza SE, 1996, J BIOL CHEM, V271, P24270, DOI 10.1074/jbc.271.39.24270; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Gardiner EE, 1997, J BIOL CHEM, V272, P15474, DOI 10.1074/jbc.272.24.15474; Hicks RCJ, 1996, NATURE, V379, P818, DOI 10.1038/379818a0; Holland J, 1997, J BIOL CHEM, V272, P9108; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lai KH, 1996, J CLIN INVEST, V98, P1560, DOI 10.1172/JCI118949; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEVESQUE JP, 1986, P NATL ACAD SCI USA, V83, P6494, DOI 10.1073/pnas.83.17.6494; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; POUDRIER J, 1994, J EXP MED, V179, P1417, DOI 10.1084/jem.179.5.1417; REILLY PL, 1995, J IMMUNOL, V155, P529; ROTHLEIN R, 1994, J IMMUNOL, V152, P2488; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; Shainoff JR, 1996, J BIOL CHEM, V271, P24129, DOI 10.1074/jbc.271.39.24129; SPORN LA, 1995, BLOOD, V86, P1802, DOI 10.1182/blood.V86.5.1802.bloodjournal8651802; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Sriramarao P, 1996, BLOOD, V88, P3416, DOI 10.1182/blood.V88.9.3416.bloodjournal8893416; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; UEHARA Y, 1989, CANCER RES, V49, P780; VANHORSSEN M, 1995, EUR J IMMUNOL, V25, P154, DOI 10.1002/eji.1830250126; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442	40	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11930	11936		10.1074/jbc.274.17.11930	http://dx.doi.org/10.1074/jbc.274.17.11930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207014	hybrid			2022-12-25	WOS:000079834800070
J	Peloponese, JM; Collette, Y; Gregoire, C; Bailly, C; Campese, D; Meurs, EF; Olive, D; Loret, EP				Peloponese, JM; Collette, Y; Gregoire, C; Bailly, C; Campese, D; Meurs, EF; Olive, D; Loret, EP			Full peptide synthesis, purification, and characterization of six Tat variants - Differences observed between HIV-1 isolates from Africa and other continents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT PROTEIN-KINASE; CIRCULAR-DICHROISM; TRANS-ACTIVATION; RNA; TYPE-1; GENE; PKR; LYMPHOCYTES; INDUCTION	AIDS in Africa is characterized by the equal distribution of mortality between the two genders because of highly virulent human immunodeficiency virus type I (HIV-1) strains. The viral protein Tat trans-activates viral gene expression and is essential for HIV-1 replication. We chemically synthesized six different Tat proteins, with sizes ranging from 86 to 101 residues, from HIV-1 isolates located in different parts of the world including highly virulent African strains. Protein purification, mass spectroscopy, and amino acid analysis showed that the synthesis was successful in each case but with different yields. We show that all have the ability to bind the HIV long terminal repeat (LTR) RNA trans-activation response element (TAR) region, involved in Tat-mediated trans-activation, but structural heterogeneities are revealed by circular dichroism. These Tat synthetic proteins cross membranes but differ in their ability to trans-activate an HIV LTR-reporter gene in stably transfected HeLa cells. Two Tat proteins from virulent African HIV-1 strains were much more active than those from Europe and the United States. The interferon-induced kinase (PKR), involved in cell antiviral defense, phosphorylates only Tat variants corresponding to less or nonvirulent HIV-1 isolates. Our results indicate that the high virulence of some African HN-I strains could be related to Tat activity.	Inst Biol Struct & Microbiol, Lab Ingn Syst Macromol, CNRS,UPR 9027, F-13402 Marseille, France; INSERM, U119, Unite Cancerol Expt, F-13009 Marseille, France; Inst Rech Canc, INSERM, U124, F-59045 Lille, France; Inst Pasteur, Unite Virol & Immunol Cellulaire, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Loret, EP (corresponding author), Inst Biol Struct & Microbiol, Lab Ingn Syst Macromol, CNRS,UPR 9027, 31 Chem Joseph Aiguier, F-13402 Marseille, France.		COLLETTE, Yves/F-2270-2013	COLLETTE, Yves/0000-0001-5359-7099; Peloponese, Jean-Marie/0000-0002-9677-9703				ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BERKHOUT B, 1990, CELL, V62, P7257; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; CHUN R, 1990, J VIROL, V64, P3074, DOI 10.1128/JVI.64.6.3074-3077.1990; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Gregoire CJ, 1996, J BIOL CHEM, V271, P22641, DOI 10.1074/jbc.271.37.22641; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; HUET T, 1989, AIDS, V3, P707, DOI 10.1097/00002030-198911000-00004; Jeang K., 1996, HUMAN RETROVIRUSES A, P3; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; URRY DW, 1972, BIOCHIM BIOPHYS ACTA, V265, P115, DOI 10.1016/0304-4157(72)90021-4; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	34	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11473	11478		10.1074/jbc.274.17.11473	http://dx.doi.org/10.1074/jbc.274.17.11473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206951	hybrid			2022-12-25	WOS:000079834800007
J	Roymoulik, I; Chen, HP; Marsh, ENG				Roymoulik, I; Chen, HP; Marsh, ENG			The reaction of the substrate analog 2-ketoglutarate with adenosylcobalamin-dependent glutamate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-ATOM ABSTRACTION; METHYLMALONYL-COA MUTASE; CARBON BOND HOMOLYSIS; CLOSTRIDIUM-COCHLEARIUM; ESCHERICHIA-COLI; ENZYME; REARRANGEMENT; PURIFICATION; CATALYSIS; MECHANISM	Glutamate mutase is one of several adenosylcobalamin-dependent enzymes that catalyze unusual rearrangements that proceed through a mechanism involving free radical intermediates. The enzyme exhibits remarkable specificity, and so far no molecules other than L-glutamate and L-threo-3-methylaspartate have been found to be substrates. Here we describe the reaction of glutamate mutase with the substrate analog, 2-ketoglutarate. Binding of 2-ketoglutarate (or its hydrate) to the holoenzyme elicits a change in the UV-visible spectrum consistent with the formation of cob(II)alamin on the enzyme, 2-ketoglutarate undergoes rapid exchange of tritium between the 5'-position of the coenzyme and C-4 of 2-ketoglutarate, consistent with the formation of a 2-ketoglutaryl radical analogous to that formed with glutamate, Under aerobic conditions this leads to the slow inactivation of the enzyme, presumably through reaction of free radical species with oxygen. Despite the formation of a substrate-like radical, no rearrangement of 2-ketoglutarate to 3-methyloxalacetate could be detected. The results indicate that formation of the C-4 radical of 2-ketoglutarate is a facile process but that it does not undergo further reactions, suggesting that this may be a useful substrate analog with which to investigate the mechanism of coenzyme homolysis.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Marsh, ENG (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.		Chen, Hao-Ping/Q-3283-2019; Marsh, Neil/G-7553-2016	Chen, Hao-Ping/0000-0002-6491-2178; Marsh, Neil/0000-0003-1713-1683	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055163] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55163] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; BARKER HA, 1964, J BIOL CHEM, V239, P3260; BEATRIX B, 1994, EUR J BIOCHEM, V266, P577; Bothe H, 1998, BIOCHEMISTRY-US, V37, P4105, DOI 10.1021/bi971393q; BUCKEL W, 1996, CHEM SOC REV, P329; Chen HP, 1997, BIOCHEMISTRY-US, V36, P7884, DOI 10.1021/bi970169y; CHEN HP, 1997, BIOCHEMISTRY-US, V36, P14393; FINKE RG, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P244; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HARTZOULAKIS B, 1994, P INDIAN AS-CHEM SCI, V106, P1165; HAY BP, 1986, J AM CHEM SOC, V108, P4820, DOI 10.1021/ja00276a020; HOLLOWAY DE, 1994, J BIOL CHEM, V269, P20425; HSIANG MW, 1967, J BIOL CHEM, V242, P3079; LEUTBECHER U, 1992, EUR J BIOCHEM, V205, P759, DOI 10.1111/j.1432-1033.1992.tb16840.x; MARSH ENG, 1995, BIOCHEMISTRY-US, V34, P7542, DOI 10.1021/bi00022a030; Marsh ENG, 1998, BIOCHEMISTRY-US, V37, P11864, DOI 10.1021/bi980512e; MARSH ENG, 1995, BIOESSAYS, V17, P431, DOI 10.1002/bies.950170511; MICHENFELDER M, 1986, ANGEW CHEM INT EDIT, V25, P366, DOI 10.1002/anie.198603661; Padmakumar R, 1997, BIOCHEMISTRY-US, V36, P3713, DOI 10.1021/bi962503g; SWITZER RL, 1969, J BIOL CHEM, V244, P5263; ZELDER O, 1994, EUR J BIOCHEM, V226, P577, DOI 10.1111/j.1432-1033.1994.tb20083.x	21	15	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11619	11622		10.1074/jbc.274.17.11619	http://dx.doi.org/10.1074/jbc.274.17.11619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206971	hybrid			2022-12-25	WOS:000079834800027
J	Kim, YB; Lee, KH; Sugita, K; Yoshida, M; Horinouchi, S				Kim, YB; Lee, KH; Sugita, K; Yoshida, M; Horinouchi, S			Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase	ONCOGENE			English	Article						histone acetylation; cell cycle; p21(WAF1/cip1); antitumor	CHROMOBACTERIUM-VIOLACEUM NO-968; TRICHOSTATIN-A; TRANSCRIPTIONAL REPRESSION; MORPHOLOGICAL TRANSFORMATION; GELSOLIN EXPRESSION; CHROMATIN STRUCTURE; SODIUM-BUTYRATE; CARCINOMA CELL; NIH3T3 CELLS; ACETYLTRANSFERASE	Oxamflatin [(2E)-5-[3-](phenylsufonyl)amino]phenyl]pent-2-en-4-ynohydroxamic acid] induces transcriptional activation of junD and morphological reversion in various NIH3T3-dtrived transformed cell lines. We found that oxamflatin showed in vitro antiproliferative activity against various mouse and human tumor cell lines with drastic changes in the cell morphology and in vivo antitumor activity against B16 melanoma, Oxamflatin caused an elongated cell shape with filamentous protrusions as well as arrest of the cell cycle at the G1 phase in HeLa cells, These phenotypic changes of HeLa cells were apparently similar to those by trichostatin A (TSA), a specific inhibitor of histone deacetylase (HDAC), The effect of oxamflatin on the transcriptional activity of the cytomegalovirus (CMV) promoter was examined and compared with known HDAC inhibitors, TSA, sodium n-butyrate, and FR901228, Oxamflatin as well as all these inhibitors greatly enhanced the transcriptional activity of the CMV promoter in a dose-dependent manner. Oxamflatin, like TSA, inhibited intracellular HDAC activity, as a result of which marked amounts of acetylated histone species accumulated. Finally, effects on expression of several endogenous genes in,oh td in cell morphology and cell cycle control in HeLa cells were analysed. Expression of gelsolin, cyclin E and Cdk inhibitors including p21(WAF1/Cip1) was highly augmented, while that of cyclin A and cyclin D1 was decreased by oxamflatin. These results suggest that changes in the expression pattern of the genes regulating cell morphology and the cell cycle due to histone hyperacetylation are responsible for the antitumor activity, the morphological change and the cell cycle arrest induced by oxamflatin.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Shionogi & Co Ltd, Shionogi Res Labs, Hukushima Ku, Osaka 533, Japan	University of Tokyo; Shionogi & Company Limited	Yoshida, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 113, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Dion LD, 1997, VIROLOGY, V231, P201, DOI 10.1006/viro.1997.8538; FALLON RJ, 1979, J CELL PHYSIOL, V100, P251, DOI 10.1002/jcp.1041000206; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GOLBERG YP, 1992, J CELL BIOCHEM, V49, P74; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; INOUE A, 1970, BIOCHIM BIOPHYS ACTA, V220, P307, DOI 10.1016/0005-2744(70)90015-X; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Khochbin S, 1997, FEBS LETT, V419, P157, DOI 10.1016/S0014-5793(97)01423-3; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Kwon HJ, 1997, ONCOGENE, V15, P2625, DOI 10.1038/sj.onc.1201443; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MORIYA S, 1994, INT J ONCOL, V5, P1347; MORIYA S, 1996, CELL, V87, P1261; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLAUER L, 1993, ONCOGENE, V8, P2531; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOGUCHI PD, 1978, J HISTOCHEM CYTOCHEM, V26, P761, DOI 10.1177/26.9.361885; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PORTER RM, 1993, J PATHOL, V170, P435, DOI 10.1002/path.1711700406; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Sonoda H, 1996, ONCOGENE, V13, P143; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; SUGITA K, 1992, CANCER RES, V52, P168; Supuran CT, 1997, J ENZYM INHIB, V12, P175, DOI 10.3109/14756369709029313; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; TANAKA J, 1991, VIROLOGY, V185, P271, DOI 10.1016/0042-6822(91)90774-6; TANAKA M, 1995, CANCER RES, V55, P3228; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; UEDA H, 1994, J ANTIBIOT, V47, P301; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	64	229	261	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	1999	18	15					2461	2470		10.1038/sj.onc.1202564	http://dx.doi.org/10.1038/sj.onc.1202564			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229197				2022-12-25	WOS:000079703300006
J	Sakanaka, C; Williams, LT				Sakanaka, C; Williams, LT			Functional domains of axin - Importance of the C terminus as an oligomerization domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; GLYCOGEN-SYNTHASE KINASE-3; BETA-CATENIN; ADENOMATOUS POLYPOSIS; NEGATIVE REGULATOR; XENOPUS EMBRYOS; TRANSCRIPTION; ACTIVATION; MUTATIONS; COMPLEX	To understand the mechanism of how Axin acts as an inhibitory molecule in the Wnt pathway, we generated a series of mutated forms of Axin. From the binding experiments, we defined the domains of Axin that bind glycogen synthase kinase-3 beta (GSK-3 beta) and beta-catenin. We also examined the ability of each Axin mutant to inhibit lymphoid enhancer factor-1 (Lef-1) reporter activity in a cell line expressing high levels of beta-catenin. Axin mutants that did not bind GSK-3 beta or beta-catenin were ineffective in suppressing Lef-1 reporter activity. Binding GSK-3 beta and beta-catenin was not sufficient for this inhibitory effect of Axin. Axin mutants with C-terminal truncations lacked the ability to inhibit Lef-1 reporter activity, even though they bound GSH-3 beta and beta-catenin. The C-terminal region was required for binding to Axin itself. Substitution of the C-terminal, region with an unrelated dimerizing molecule, the retinoid X receptor restored its inhibitory effect on Lef-1-dependent, transcription. The oligomerization of Axin through its C terminus is important for its function in regulation of beta-catenin-mediated response.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Chiron Corp, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; Novartis	Williams, LT (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; Vasicek TJ, 1997, GENETICS, V147, P777; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	23	61	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14090	14093		10.1074/jbc.274.20.14090	http://dx.doi.org/10.1074/jbc.274.20.14090			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318824	hybrid			2022-12-25	WOS:000080322200053
J	Brame, CJ; Salomon, RG; Morrow, JD; Roberts, LJ				Brame, CJ; Salomon, RG; Morrow, JD; Roberts, LJ			Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PROSTAGLANDIN ENDOPEROXIDES; GENERATION; F-2-ISOPROSTANES; LEVUGLANDIN-E2; FRAGMENTATION; GLUTATHIONE; DISEASE; HEXANE; VITRO	Isoprostanes are prostaglandin-like compounds produced by non enzymatic peroxidation of arachidonic acid. The cyclooxygenase-derived endoperoxide, prostaglandin H-2, can undergo rearrangement to highly reactive gamma-ketoaldehyde secoprostanoids (levuglandin E-2 and D-2), We explored whether isoprostane endoperoxide intermediates also rearrange to levuglandin-like compounds (isolevuglandins), Formation of a series of isolevuglandins during oxidation of arachidonic acid in vitro was established utilizing a number of mass spectrometric analyses. However, these compounds could not be detected in free form in protein-containing biological systems, which we hypothesized was due to extremely rapid adduction to amines. This was supported by the finding that >60% of levuglandin E-2 adducted to albumin within 20 s, whereas -50% of 4-hydroxynonenal still remained unadducted after 1 h. By utilizing electro spray tandem mass spectrometry, we established that these compounds form oxidized pyrrole adducts (lactams and hydroxylactams) with lysine, Formation of isolevuglandin-lysine adducts on apolipoprotein B was readily detected during oxidation of low density lipoprotein following enzymatic digestion of the protein to single amino acids, These studies identify a novel series of extremely reactive products of the isoprostane pathway that rapidly form covalent adducts with lysine residues on proteins. This provides the basis to explore the formation of isolevuglandins in vivo to investigate the potential biological ramifications of their formation in settings of oxidant injury.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Vanderbilt University; Vanderbilt University; Case Western Reserve University	Roberts, LJ (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.		Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056, P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48831] Funding Source: Medline; NIGMS NIH HHS [GM 15431, GM 42056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CURZIO M, 1986, BIOL CHEM H-S, V367, P321, DOI 10.1515/bchm3.1986.367.1.321; DECAPRIO AP, 1982, TOXICOL APPL PHARM, V65, P440, DOI 10.1016/0041-008X(82)90389-1; DEMKOWICZDOBRZANSKI K, 1992, CARCINOGENESIS, V13, P1447, DOI 10.1093/carcin/13.8.1447; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GRAHAM DG, 1995, CRIT REV TOXICOL, V25, P91, DOI 10.3109/10408449509021609; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMBERG M, 1966, J AM CHEM SOC, V88, P2349, DOI 10.1021/ja00962a068; IYER RS, 1994, J ORG CHEM, V59, P6038, DOI 10.1021/jo00099a039; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; IYER RS, 1990, J ORG CHEM, V55, P3171; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MILLER DB, 1990, J ORG CHEM, V55, P3164, DOI 10.1021/jo00297a036; MILLS GL, 1984, GUIDEBOOK LIPOPROTEI, P87; Montine TJ, 1998, ANN NEUROL, V44, P410, DOI 10.1002/ana.410440322; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; Morrow JD, 1996, J BIOL CHEM, V271, P23185, DOI 10.1074/jbc.271.38.23185; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9883; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; SALOMON RG, 1984, J AM CHEM SOC, V106, P6049, DOI 10.1021/ja00332a049; SMITH EB, 1967, J ORG CHEM, V32, P3330, DOI 10.1021/jo01286a012; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; ZIRROLLI JA, 1990, J AM SOC MASS SPECTR, V1, P325, DOI 10.1016/1044-0305(90)85009-B	24	144	153	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13139	13146		10.1074/jbc.274.19.13139	http://dx.doi.org/10.1074/jbc.274.19.13139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224068	hybrid			2022-12-25	WOS:000080200400030
J	Kusuhara, H; Sekine, T; Utsunomiya-Tate, N; Tsuda, M; Kojima, R; Cha, SH; Sugiyama, Y; Kanai, Y; Endou, H				Kusuhara, H; Sekine, T; Utsunomiya-Tate, N; Tsuda, M; Kojima, R; Cha, SH; Sugiyama, Y; Kanai, Y; Endou, H			Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOROID-PLEXUS INVITRO; CATION TRANSPORTER; EXPRESSION CLONING; BARRIER; PROTEIN; KIDNEY; LIVER; CIMETIDINE; MECHANISMS; CELLS	A cDNA encoding the new member of the multispecific organic anion transporter family, OAT3, was isolated by the reverse transcription polymerase chain reaction cloning method. Degenerate primers were designed based on the sequences conserved among OAT1, OAT2, and organic cation transporter 1 (OCT1), and reverse transcription-polymerase chain reaction was performed using rat brain poly(A)(+) RNA. The 536-amino acid protein sequence encoded by OAT3 showed 49, 39, and 36% identity to those of OAT1, OAT2, and OCT1, respectively. Northern blot analysis revealed that rat OAT3 mRNA is expressed in the liver, brain, kidney, and eye. When expressed in Xenopus laevis oocytes, OAT3 mediated the uptake of organic anions, such asp-aminohippurate (K-m = 65 mu M), ochratoxin A (K-m = 0.74 Emr), and estrone sulfate (K-m = 2.3 mu M) and a cationic compound, cimetidine. OAT3-mediated uptake of [H-3]estrone sulfate was sodium-independent. para-Aminohippuric acid, estrone sulfate or ochratoxin A did not show any trans-stimulatory effect on either influx or efflux of [H-3]estrone sulfate via OAT3. Organic anions such as sulfobromophthalein, probenecid, indocyanine green, bumetanide, piroxicam, furosemide, azidodeoxythymidine, 4,4'-diisothiocyanostilbene-3,3'-disulfonic acid, and benzylpenicillin inhibited OAT3-mediated estrone sulfate uptake, while ouabain and digoxin did not. Organic cations such as tetraethylammonium, guanidine, verapamil, and quinidine did not interact with OAT3, Acidic metabolites of neurotransmitters derived from dopamine, epinephrine, norepinephrine, and serotonin inhibited the uptake of estrone sulfate via OAT3, These results suggest an important role of OAT3 in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Tokyo 1130033, Japan; Meijo Univ, Fac Pharm, Dept Pharmacol, Tempaku Ku, Nagoya, Tokyo 4688503, Japan	Kyorin University; University of Tokyo; Meijo University	Endou, H (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	endouh@kyorin-u.ac.jp						Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; BOOM SPA, 1993, J PHARMACOL EXP THER, V267, P1039; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; CORNFORD EM, 1985, J NEUROCHEM, V44, P1541, DOI 10.1111/j.1471-4159.1985.tb08793.x; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Hakvoort A, 1998, BRAIN RES, V795, P247, DOI 10.1016/S0006-8993(98)00284-4; Heaney C, 1998, HUM MOL GENET, V7, P1407, DOI 10.1093/hmg/7.9.1407; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kakee A, 1997, J PHARMACOL EXP THER, V283, P1018; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEININGER B, 1991, J NEUROCHEM, V56, P1163, DOI 10.1111/j.1471-4159.1991.tb11406.x; MASEREEUW R, 1994, PHARMACEUT RES, V11, P324, DOI 10.1023/A:1018932213953; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; Moller J. V., 1983, PHARMACOL REV, V34, P315; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Pardridge WM., 1991, PEPTIDE DRUG DELIVER; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Rapoport SI, 1976, BLOOD BRAIN BARRIER; Schomig E, 1998, FEBS LETT, V425, P79, DOI 10.1016/S0014-5793(98)00203-8; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMONSON GD, 1994, J CELL SCI, V107, P1065; SUZUKI H, 1987, J PHARMACOL EXP THER, V242, P660; SUZUKI H, 1986, J PHARMACOL EXP THER, V239, P927; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Takasawa K, 1997, BIOPHARM DRUG DISPOS, V18, P611, DOI 10.1002/(SICI)1099-081X(199710)18:7<611::AID-BDD45>3.0.CO;2-2; ULLRICH KJ, 1993, CLIN INVESTIGATOR, V71, P843; ULLRICH KJ, 1993, PFLUG ARCH EUR J PHY, V425, P280, DOI 10.1007/BF00374179	31	406	416	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13675	13680		10.1074/jbc.274.19.13675	http://dx.doi.org/10.1074/jbc.274.19.13675			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224140	hybrid			2022-12-25	WOS:000080200400102
J	Linnemann, T; Geyer, M; Jaitner, BK; Block, C; Kalbitzer, HR; Wittinghofer, A; Herrmann, C				Linnemann, T; Geyer, M; Jaitner, BK; Block, C; Kalbitzer, HR; Wittinghofer, A; Herrmann, C			Thermodynamic and kinetic characterization of the interaction between the Ras binding domain of AF6 and members of the Ras subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE ACTIVATION; SIGNALING PATHWAY; STRUCTURAL BASIS; IN-VITRO; R-RAS; PROTEIN; TRANSFORMATION; EFFECTORS; YEAST; IDENTIFICATION	Cellular signaling downstream of Ras is highly diversified and may involve many different effector molecules. A potential candidate is AF6 which was originally identified as a fusion to ALL-1 in acute myeloid leukemia. In the present work the interaction between Ras and AF6 is characterized and compared with other effecters. The binding characteristics are quite similar to Raf and RalGEF, i.e. nucleotide dissociation as well as GTPase-activating protein activity are inhibited, whereas the intrinsic GTPase activity of Ras is unperturbed by AF6 binding. Particularly, the dynamics of interaction are similar to Raf and RalGEF with a lifetime of the Ras.AF6 complex in the millisecond range. As probed by P-31 NMR spectroscopy one of two major conformational states of Ras is stabilized by the interaction with AF6, Looking at the affinities of AF6 to a number of Pas mutants in the effector region, a specificity profile emerges distinct from that of other effector molecules. This finding may be useful in defining the biological function of AF6 by selectively switching off other pathways downstream of Ras using the appropriate effector mutant. Notably, among the Ras-related proteins AF6 binds most tightly to Rap1A which could imply a role of Rap1A in AF6 regulation.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44026 Dortmund, Germany; Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany	Max Planck Society; University of Regensburg	Herrmann, C (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Postfach 102664, D-44026 Dortmund, Germany.			Geyer, Matthias/0000-0002-7718-5002; Kalbitzer, Hans Robert/0000-0002-6514-2355				Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Bork P, 1997, TRENDS BIOCHEM SCI, V22, P296, DOI 10.1016/S0968-0004(97)01084-0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COX AD, 1994, ONCOGENE, V9, P3281; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ito S, 1997, MOL GEN GENET, V255, P429, DOI 10.1007/s004380050515; Jaitner BK, 1997, J BIOL CHEM, V272, P29927, DOI 10.1074/jbc.272.47.29927; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; PRASAD R, 1993, CANCER RES, V53, P5624; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; SHIROUZU M, 1994, ONCOGENE, V9, P2153; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	55	117	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13556	13562		10.1074/jbc.274.19.13556	http://dx.doi.org/10.1074/jbc.274.19.13556			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224125	hybrid			2022-12-25	WOS:000080200400087
J	Loechel, F; Overgaard, MT; Oxvig, C; Albrechtsen, R; Wewer, UM				Loechel, F; Overgaard, MT; Oxvig, C; Albrechtsen, R; Wewer, UM			Regulation of human ADAM 12 protease by the prodomain - Evidence for a functional, cysteine switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HUMAN FIBROBLAST COLLAGENASE; ACTIVE-SITE; TISSUE INHIBITORS; MUTATIONAL ANALYSIS; CONVERTING-ENZYME; CATALYTIC DOMAIN; LYTIC PROTEASE; MELTRIN-ALPHA; IN-VIVO	The ADAMs (a disintegrin and metalloprotease) are a family of multidomain proteins that are believed to play key roles in cell-cell and cell-matrix interactions, We have shown recently that human ADAM 12-S (meltrin alpha) is an active metalloprotease. It is synthesized as a zymogen, with the prodomain maintaining the protease in a latent form. We now provide evidence that the latency mechanism of ADAM 12 can be explained by the cysteine switch model, in which coordination of Zn2+ in the active site of the catalytic domain by a cysteine residue in the prodomain is critical for inhibition of the protease. Replacing Cys(179) with other amino acids results in an ADAM 12 preform that is proteolytically active, but latency can be restored by placing cysteine at other positions in the propeptide, None of the amino acids adjacent to the crucial cysteine residue is essential for blocking activity of the protease domain. In addition to its latency function, the prodomain is required for exit of ADAM 12 protease from the endoplasmic reticulum, Tissue inhibitor of metalloprotease-l, -2, and -3 were not found to block proteolytic activity of ADAM 12, hence a physiological inhibitor of ADAM 12 protease in the extracellular environment remains to be identified.	Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus, Denmark	University of Copenhagen; Aarhus University	Wewer, UM (corresponding author), Univ Copenhagen, Inst Mol Pathol, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.		Overgaard, Michael Toft/E-1354-2011	Overgaard, Michael Toft/0000-0002-1423-2481; Oxvig, Claus/0000-0002-4715-9719; Albrechtsen, Reidar/0000-0003-4180-1827				Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; DOLMER K, 1995, FEBS LETT, V372, P93, DOI 10.1016/0014-5793(95)00960-H; FEINMAN RD, 1994, ANN NY ACAD SCI, V737, P245, DOI 10.1111/j.1749-6632.1994.tb44316.x; FOX JW, 1996, ZINC METALLOPROTEINA, P47; FREIMARK BD, 1994, J BIOL CHEM, V269, P26982; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Khan AR, 1998, PROTEIN SCI, V7, P815; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NAGASE H, 1994, ANN NY ACAD SCI, V732, P294, DOI 10.1111/j.1749-6632.1994.tb24744.x; Nagase H, 1996, ZINC METALLOPROTEASE, P153; PARK AJ, 1991, J BIOL CHEM, V266, P1584; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; Phillips MA, 1996, BIOCHEMISTRY-US, V35, P6771, DOI 10.1021/bi960113o; RAMOS C, 1994, J BIOL CHEM, V269, P7006; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Sambrook J., 2002, MOL CLONING LAB MANU; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sohl JL, 1997, BIOCHEMISTRY-US, V36, P3894, DOI 10.1021/bi962341o; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1995, PROTEIN SCI, V4, P823; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313	36	118	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13427	13433		10.1074/jbc.274.19.13427	http://dx.doi.org/10.1074/jbc.274.19.13427			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224107	hybrid			2022-12-25	WOS:000080200400069
J	Weston, WM; LeClair, EE; Trzyna, W; McHugh, KM; Nugent, P; Lafferty, CM; Ma, L; Tuan, RS; Greene, RM				Weston, WM; LeClair, EE; Trzyna, W; McHugh, KM; Nugent, P; Lafferty, CM; Ma, L; Tuan, RS; Greene, RM			Differential display identification of plunc, a novel gene expressed in embryonic palate, nasal epithelium, and adult lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MESSENGER-RNA; SALIVARY PROTEIN; N-GLYCOSYLATION; LEUCINE ZIPPER; PEPTIDES; SITES	We have identified a novel gene transcript of approximately 1.1 kilobases in length that is expressed in the presumptive nasal epithelium of the mouse embryo. In situ hybridization analysis shows discrete regions of expression associated with the palate, nasal septum, and nasal conchae, This transcript is also expressed strongly in the trachea and bronchi of the adult lung, Screening of a mouse heart cDNA library yielded several overlapping clones to give a continuous sequence of 1113 bases, containing an open reading frame of 278 codons comprising the complete mRNA. No significant homologies with known genes were observed at the nucleotide level; limited amino acid homology with two salivary gland-specific proteins was noted. A search for functionally significant protein motifs revealed consensus sequences for N-glycosylation, protein kinase C and casein kinase phosphorylation, and a leucine zipper. Additionally, we observed a unique amino acid sequence pattern, consisting of the residues Gly-(Leu/Pro/Gln)-(Pro/Leu)-Leu-Pro-Leu, repeated four times near the amino-terminal portion of the protein with two amino acid residues separating the repeats. Based on these observations, we propose that we have identified a new gene, which we call plunc (for palate, lung, and nasal epithelium clone; GenBank(TM) accession number U69172).	Thomas Jefferson Univ, Orthopaed Res Lab, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Louisville, Sch Dent, Dept Biol & Biophys Sci, Louisville, KY 40292 USA; Allegheny Univ Hlth Sci, Dept Pathol, Philadelphia, PA 19102 USA	Jefferson University; Jefferson University; University of Louisville; Drexel University	LeClair, EE (corresponding author), Thomas Jefferson Univ, Orthopaed Res Lab, 501 Curtis Bldg,1015 Walnut St, Philadelphia, PA 19107 USA.		McHugh, Kirk/E-3640-2011		NICHD NIH HHS [HD08368] Funding Source: Medline; NIDCR NIH HHS [DE05550, DE11176] Funding Source: Medline; NIDDK NIH HHS [R01 DK055791] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE011176, R01DE005550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055791] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; GEETHAHABIB M, 1990, J BIOL CHEM, V265, P13655; GREENE RM, 1994, MASTERY PLASTIC RECO, P459; Kaufman M.H., 1992, ATLAS MOUSE DEV; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; MADSEN HO, 1985, NUCLEIC ACIDS RES, V13, P1, DOI 10.1093/nar/13.1.1; MIRELS L, 1992, J BIOL CHEM, V267, P2679; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PROVENZA DV, 1972, FUNDAMENTALS ORAL HI; Rajan GH, 1996, ANIM GENET, V27, P407, DOI 10.1111/j.1365-2052.1996.tb00507.x; RONIN C, 1978, FEBS LETT, V96, P179, DOI 10.1016/0014-5793(78)81089-8; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; WAWERSIK S, 1999, DEV BIOL PROTOCOLS; Wilkinson DG., 1992, SITU HYBRIDIZATION P, P75; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	23	109	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13698	13703		10.1074/jbc.274.19.13698	http://dx.doi.org/10.1074/jbc.274.19.13698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224143	hybrid			2022-12-25	WOS:000080200400105
J	Andrejewski, N; Punnonen, EL; Guhde, G; Tanaka, Y; Lullmann-Rauch, R; Hartmann, D; von Figura, K; Saftig, P				Andrejewski, N; Punnonen, EL; Guhde, G; Tanaka, Y; Lullmann-Rauch, R; Hartmann, D; von Figura, K; Saftig, P			Normal lysosomal morphology and function in LAMP-1-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; HAMSTER-KIDNEY CELLS; ASN-LINKED OLIGOSACCHARIDES; POLY-N-ACETYLLACTOSAMINE; MEMBRANE-GLYCOPROTEINS; ACID-PHOSPHATASE; CATHEPSIN-D; KDA SIALOGLYCOPROTEIN; EXON ORGANIZATION; CULTURED-CELLS	Lysosomal membranes contain two highly glycosylated proteins, designated LAMP-1 and LAMP-2, as major components. LAMP-1 and LAMP-S are structurally related, To investigate the physiological role of LAMP-1, we have generated mice deficient for this protein. LAMP-l-deficient mice are viable and fertile. In LAMP-1-deficient brain, a mild regional astrogliosis and altered immunoreactivity against cathepsin-D was observed. Histological and ultrastructural analyses of all other tissues did not reveal abnormalities. Lysosomal properties, such as enzyme activities, lysosomal pH, osmotic stability, density, shape, and subcellular distribution were not changed in comparison with controls. Western blot analyses of LAMP-1-deficient and heterozygote tissues revealed an up-regulation of the LAR IP-S protein pointing to a compensatory effect of LAMP-S in response to the LAMP-1 deficiency. The increase of LAMP-2 was neither correlated with an increase in the level of lamp-2 mRNAs nor with increased half-life time of LAMP-2, This findings suggest a translational regulation of LAMP-2 expression.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Univ Helsinki, Inst Biochem & Electron Microscopy, FIN-00014 Helsinki, Finland; Univ Kiel, Inst Anat, D-24043 Kiel, Germany	University of Gottingen; University of Helsinki; University of Kiel	Saftig, P (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, Gosslerstr 12D, D-37073 Gottingen, Germany.		Saftig, Paul/A-7966-2010					AcevedoSchermerhorn C, 1997, EXP CELL RES, V236, P510, DOI 10.1006/excr.1997.3752; Bresciani R, 1996, EUR J BIOCHEM, V238, P669, DOI 10.1111/j.1432-1033.1996.0669w.x; CARLSSON SR, 1989, J BIOL CHEM, V264, P20526; CHA Y, 1990, J BIOL CHEM, V265, P5008; CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1; CHEN JW, 1988, J BIOL CHEM, V263, P8754; DAHLGREN C, 1995, BIOCHEM J, V311, P667, DOI 10.1042/bj3110667; DOCHERTY K, 1979, BIOCHEM J, V178, P361, DOI 10.1042/bj1780361; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FEBBRAIO M, 1990, J BIOL CHEM, V265, P18531; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HEFFERNAN M, 1989, CANCER RES, V49, P6077; HIMENO M, 1989, FEBS LETT, V244, P351, DOI 10.1016/0014-5793(89)80561-7; HONING S, 1995, J CELL BIOL, V128, P464; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; ISBRANDT D, 1994, AM J HUM GENET, V54, P454; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KORNFELD S, 1989, ANN REV CELL BIOL, V5, P488; KOSTER A, 1994, EUR J BIOCHEM, V224, P685, DOI 10.1111/j.1432-1033.1994.00685.x; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LEE N, 1990, J BIOL CHEM, V265, P20476; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LEMANSKY P, 1984, J BIOL CHEM, V259, P129; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; OKAZAKI I, 1992, J BIOCHEM, V111, P763, DOI 10.1093/oxfordjournals.jbchem.a123833; PETERS C, 1994, FEBS LETT, V346, P108, DOI 10.1016/0014-5793(94)00499-4; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; PIERCE M, 1986, J BIOL CHEM, V261, P772; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; PORTER MT, 1969, P NATL ACAD SCI USA, V62, P887, DOI 10.1073/pnas.62.3.887; Saftig P, 1997, J BIOL CHEM, V272, P18628, DOI 10.1074/jbc.272.30.18628; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; SAWADA R, 1993, J BIOL CHEM, V268, P9014; SCHULZEGARG C, 1993, J CELL BIOL, V122, P541, DOI 10.1083/jcb.122.3.541; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOUAKIM A, 1989, CANCER RES, V49, P6889; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; ZOT AS, 1990, J BIOL CHEM, V265, P20988	50	136	141	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12692	12701		10.1074/jbc.274.18.12692	http://dx.doi.org/10.1074/jbc.274.18.12692			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212251	hybrid			2022-12-25	WOS:000080056800071
J	Leisner, TM; Wencel-Drake, JD; Wang, W; Lam, SCT				Leisner, TM; Wencel-Drake, JD; Wang, W; Lam, SCT			Bidirectional transmembrane modulation of integrin alpha(IIb)beta(3) conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IIB; GROWTH-FACTOR RECEPTOR; PLATELET GPIIB-IIIA; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODY; LIGAND-BINDING; CHEMICAL SYNTHESIS; STRUCTURAL MODEL; CELL-ADHESION	Activation of blood platelets by physiological stimuli (e.g, thrombin, ADP) at sites of vascular injury induces inside-out signaling, resulting in a conformational change of the prototype integrin alpha(IIb)beta(3) from an inactive to an active state competent to bind soluble fibrinogen. Furthermore, ligand occupancy of alpha(IIb)beta(3) initiates outside-in signaling and additional conformational changes of the receptor, leading to the exposure of extracellular neoepitopes termed ligand-induced binding sites (LIBS), which are recognized by anti-LIES monoclonal antibodies. To date, the mechanism of bidirectional transmembrane signaling of alpha(IIb)beta(3) has not been established, In this study, using our newly developed anti-LIBS(cyt)1 monoclonal antibody, we showed that extracellular ligand binding to alpha(IIb)beta(3) on blood platelets induces a transmembrane conformational change in alpha(IIb)beta(3), thereby exposing the LIBS(cyt)1 epitope in the alpha(IIb), cytoplasmic sequence between Lys(994) and Asp(1003), In addition, a point mutation at this site (P998A/P999A) renders alpha(IIb)beta(3) constitutively active to bind extracellular ligands, resulting in fibrinogen-dependent cell-cell aggregation. Taken collectively, these results demonstrated that the extracellular ligand-binding site and a cytoplasmic LIBS epitope in integrin alpha(IIb)beta(3) are conformationally and functionally coupled. Such bidirectional modulation of alpha(IIb)beta(3) conformation across the cell membrane may play a key role in inside-out and outside-in signaling via this integrin.	Univ Illinois, Dept Pharmacol MC868, Chicago, IL 60612 USA; Univ Illinois, Sch Biomed & Hlth Informat Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lam, SCT (corresponding author), Univ Illinois, Dept Pharmacol MC868, 835 S Wolcott Ave, Chicago, IL 60612 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052755, R01HL041793, R29HL041793] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41793, HL-52755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DU XP, 1993, J BIOL CHEM, V268, P23087; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; HARRISON P, 1989, J CLIN INVEST, V84, P1320, DOI 10.1172/JCI114300; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IUPAC-IUB commission on biochemical nomenclature, 1968, J BIOL CHEM, V243, P3557; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LAM SCT, 1992, J BIOL CHEM, V267, P5649; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; Nurden P, 1996, BLOOD, V88, P887, DOI 10.1182/blood.V88.3.887.bloodjournal883887; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PIDARD D, 1983, J BIOL CHEM, V258, P2582; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; WencelDrake JD, 1996, BLOOD, V87, P602, DOI 10.1182/blood.V87.2.602.bloodjournal872602	42	59	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12945	12949		10.1074/jbc.274.18.12945	http://dx.doi.org/10.1074/jbc.274.18.12945			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212286	hybrid			2022-12-25	WOS:000080056800106
J	Maeda, N; Ichihara-Tanaka, K; Kimura, T; Kadomatsu, K; Muramatsu, T; Noda, M				Maeda, N; Ichihara-Tanaka, K; Kimura, T; Kadomatsu, K; Muramatsu, T; Noda, M			A receptor-like protein-tyrosine phosphatase PTP zeta/RPTP beta binds a heparin-binding growth factor midkine - Involvement of arginine 78 of midkine in the high affinity binding to PTP zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; MOLECULE HB-GAM; NEURITE OUTGROWTH; 6B4 PROTEOGLYCAN/PHOSPHACAN; EXTRACELLULAR VARIANT; PROMOTING ACTIVITY; CELL-ADHESION; BRAIN; CLONING; LIGAND	Midkine is a 13-kDa heparin-binding growth factor with 45% sequence identity to pleiotrophin. Pleiotrophin has been demonstrated to bind to protein-tyrosine phosphatase zeta (PTP zeta) with high affinity. In this study, we examined the binding of midkine to PTP zeta by solid-phase binding assay. Midkine and pleiotrophin binding to PTP zeta were equally inhibited by soluble pleiotrophin and also by some specific glycosaminoglycans. For both bindings, Scatchard analysis revealed low (3.0 nM) and high (0.58 nM) affinity binding sites. These results suggested that PTP zeta is a common receptor for midkine and pleiotrophin. Midkine is structurally divided into the N- and C-terminal halves, and the latter exhibited full activity for PTP zeta binding and neuronal migration induction. The C-terminal half contains two heparin-binding sites consisting of clusters of basic amino acids, Clusters I and II. A mutation at Arg(78) in Cluster I resulted in loss of the high affinity binding and reduced neuronal migration-inducing activity, while mutations at Lys(83) and Lys(84) in Cluster II showed almost no effect on either activity. Chondroitinase ABC-treated PTP zeta exhibited similar low affinity binding both to the native midkine and midkine mutants at Arg(78). These results suggested that Arg(78) in midkine plays an essential role in high affinity binding to PTP zeta by interacting with the chondroitin sulfate portion of this receptor.	Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Peptide Inst Inc, Osaka 5620015, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Nagoya University	Noda, M (corresponding author), Natl Inst Basic Biol, Div Mol Neurobiol, 38 Nishigonaka,Myodaiji Cho, Okazaki, Aichi 4448585, Japan.		Kadomatsu, Kenji/G-8083-2012; Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X				Akhter S, 1998, J BIOCHEM-TOKYO, V123, P1127; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P66, DOI 10.1006/bbrc.1997.6905; BARNEA G, 1994, J BIOL CHEM, V269, P14349; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; FABRI L, 1993, J CHROMATOGR, V646, P213, DOI 10.1016/S0021-9673(99)87023-X; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Inui T, 1996, J PEPT SCI, V2, P28; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; KOJIMA S, 1995, J BIOL CHEM, V270, P9590, DOI 10.1074/jbc.270.16.9590; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; MURAMATSU T, 1994, DEV GROWTH DIFFER, V36, P1; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nishiwaki T, 1998, J BIOCHEM-TOKYO, V123, P458; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x	30	255	265	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12474	12479		10.1074/jbc.274.18.12474	http://dx.doi.org/10.1074/jbc.274.18.12474			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212223	hybrid			2022-12-25	WOS:000080056800043
J	Sinniger, V; Merton, RE; Fabregas, P; Felez, J; Longstaff, C				Sinniger, V; Merton, RE; Fabregas, P; Felez, J; Longstaff, C			Regulation of tissue plasminogen activator activity by cells - Domains responsible for binding and mechanism of stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-PA; FACTOR-X; CELLULAR RECEPTORS; KINETIC-PARAMETERS; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; HIGH-AFFINITY; UROKINASE; CHAIN; SITE	A number of cell types have previously been shown to bind tissue plasminogen activator (tPA), which in some cases can remain active on the cell surface resulting in enhanced plasminogen activation kinetics. We have investigated several cultured cell lines, U937, THP1, K562, Molt4, and Nalm6 and shown that they bind both tPA and plasminogen and are able to act as promoters of plasminogen activation in kinetic assays. To understand what structural features of tPA are involved in cell surface interactions, we performed kinetic assays with a range of tPA domain deletion mutants consisting of full-length glycosylated and nonglycosylated tPA (F-G-K1-K2-P), Delta FtPA (G-K1-K2-P), K2-P tPA (BM 06.022 or Reteplase), and protease domain (P), Deletion variants were made in Escherichia coli and were nonglycosylated, Plasminogen activation rates were compared with and without cells, over a range of cell densities at physiological tPA concentrations, and produced maximum levels of stimulation up to 80-fold with full-length, glycosylated tPA, Stimulation for nonglycosylated full-length tPA dropped to 45-60% of this value. Loss of N-terminal domains as in Delta FtPA and K2P resulted in a further loss of stimulation to 15-30% of the full-length glycosylated value. The protease domain alone was stimulated at very low levels of up to a-fold. Thus, a number of different sites are involved in cell interactions especially within finger and kringle domains, which is similar to the regulation of tPA activity by fibrin, A model was developed to explain the mechanism of stimulation and compared with actual data collected with varying cell, plasminogen, or tPA concentrations and different tPA variants. Experimental data and model predictions were generally in good agreement and suggest that stimulation is well explained by the concentration of reactants by cells.	Natl Inst Biol Stand & Controls, Blanche Lane, S Mimms EN6 3QG, Herts, England; Hosp Duran Reynals, Inst Recersa Oncol, Barcelona 08907, Spain	National Institute for Biological Standards & Control; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals	Longstaff, C (corresponding author), Natl Inst Biol Stand & Controls, Blanche Lane, S Mimms EN6 3QG, Herts, England.	clongstaff@nibsc.ac.uk	Longstaff, Colin/D-2413-2013	Longstaff, Colin/0000-0001-7608-208X				BAKKER AHF, 1995, J BIOL CHEM, V270, P12355, DOI 10.1074/jbc.270.21.12355; BARNATHAN ES, 1988, J BIOL CHEM, V263, P7792; BEEBE DP, 1989, BLOOD, V74, P2034; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BU GJ, 1994, BLOOD, V83, P3427; CORNISHBOWDEN A, 1996, FUNDAMENTALS ENZYME, P112; CUMMINGS HS, 1985, ARCH BIOCHEM BIOPHYS, V236, P612, DOI 10.1016/0003-9861(85)90665-4; DEVRIES C, 1991, THROMB HAEMOSTASIS, V65, P280; Ellis V, 1997, BLOOD, V90, P2312, DOI 10.1182/blood.V90.6.2312.2312_2312_2322; FELEZ J, 1993, BLOOD, V82, P2433, DOI 10.1182/blood.V82.8.2433.bloodjournal8282433; Felez J, 1996, THROMB HAEMOSTASIS, V76, P577; FELEZ J, 1991, BLOOD, V78, P2318; FRIEDEN C, 1964, J BIOL CHEM, V239, P3522; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P252; GENTRY R, 1995, BIOPHYS J, V69, P362, DOI 10.1016/S0006-3495(95)79908-8; GENTRY R, 1995, BIOPHYS J, V69, P356, DOI 10.1016/S0006-3495(95)79907-6; GEPPERT AG, 1992, ARCH BIOCHEM BIOPHYS, V297, P205, DOI 10.1016/0003-9861(92)90663-H; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; HAJJAR KA, 1995, THROMB HAEMOSTASIS, V74, P294; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HIGGINS DL, 1990, ANNU REV PHARMACOL, V30, P91; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; Jardi M, 1996, THROMB HAEMOSTASIS, V76, P1009; JONES AJS, 1990, THROMB HAEMOSTASIS, V64, P455; KALYAN NK, 1988, J BIOL CHEM, V263, P3971; KOHNERT U, 1992, PROTEIN ENG, V5, P93, DOI 10.1093/protein/5.1.93; LEATHERBARROW RJ, 1998, GRAFT VERSION 4 0; LEVITZKI A, 1997, PROTEIN FUNCTION PRA, P104; LIJNEN HR, 1984, EUR J BIOCHEM, V144, P541, DOI 10.1111/j.1432-1033.1984.tb08499.x; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LONGSTAFF C, 1992, J BIOL CHEM, V267, P173; LONGSTAFF C, 1995, FIBRINOLYSIS, V9, P178, DOI 10.1016/S0268-9499(95)80009-3; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Machovich R, 1997, THROMB HAEMOSTASIS, V77, P1041; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; POWER RF, 1990, J BIOL CHEM, V265, P1419; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; Rijken DC, 1996, BLOOD COAGUL FIBRIN, V7, P561, DOI 10.1097/00001721-199607000-00008; SARMIENTOS P, 1989, BIO-TECHNOL, V7, P495, DOI 10.1038/nbt0589-495; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8903, DOI 10.1021/bi9525031; STOCKINGER H, 1992, THROMB RES, V67, P589, DOI 10.1016/0049-3848(92)90019-7; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; YE J, 1995, BIOCHEMISTRY-US, V34, P6448, DOI 10.1021/bi00019a026	50	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12414	12422		10.1074/jbc.274.18.12414	http://dx.doi.org/10.1074/jbc.274.18.12414			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212215	hybrid			2022-12-25	WOS:000080056800035
J	Amendt, BA; Sutherland, LB; Russo, AF				Amendt, BA; Sutherland, LB; Russo, AF			Transcriptional antagonism between Hmx1 and Nkx2.5 for a shared DNA-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENE; HOMEODOMAIN PROTEINS; EXPRESSION; RECOGNITION; NKX-2.5; SPECIFICITY; ACTIVATION; IDENTIFICATION; CONSERVATION; REPRESSION	The recently described Hmx family of homeodomain proteins is predominately expressed in discrete regions of developing sensory tissues. In this report, we have identified the preferred DNA-binding site of the murine Hmx3 homeodomain protein by the selection and amplification binding (SAAB) technique. The consensus Hmx-binding site contained the sequence 5'-CAAGTG-3', which differs from the 5'-TAAT-3' motif commonly associated with homeodomain proteins. Instead, the Hmx consensus is similar to the B'-CAAGTG-3'-binding sites of Nkx2.1 and Nkx2.5 homeodomain proteins. Based on mutation studies, both the 5'-CAAG-3' core and the 3'-TG dinucleotide are required for high affinity binding by Hmx3 and the homologous Hmx1 protein. A critical determinant of this specificity is the glutamine at position 50 in the third helix of the Hmx homeodomain. Hmx1 binds to the 5'-CAAGTG-3' element with an apparent dissociation constant of 20 nM. Unexpectedly, the human Hmx1 protein specifically repressed transcription from a luciferase reporter gene containing 3 copies of the 5'-CAAGTG-3' sequence. In contrast, the Nkx2.5 protein transactivated this luciferase reporter. Interestingly, co-expression of Hmx1 and Nkx2.5 attenuated each others activity, suggesting that genes containing the CAAGTG element can integrate signals from these proteins. Therefore, Hmx1 and Nkx2.5 proteins bind a unique DNA sequence and act as transcriptional antagonists.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Amendt, BA (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	brad-amendt@uiowa.edu		Amendt, Brad A./0000-0001-6524-1006; Russo, Andrew/0000-0002-8156-5649	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE009170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25969] Funding Source: Medline; NIDCR NIH HHS [DE09170] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amendt BA, 1998, J BIOL CHEM, V273, P20066, DOI 10.1074/jbc.273.32.20066; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOBER E, 1994, DEV BIOL, V162, P288, DOI 10.1006/dbio.1994.1086; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen YP, 1996, DEVELOPMENT, V122, P3035; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEITCHER DL, 1994, J NEUROSCI, V14, P486; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; Hadrys T, 1998, DEVELOPMENT, V125, P33; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; RINKWITZBRANDT S, 1995, MECH DEVELOP, V52, P371, DOI 10.1016/0925-4773(95)00414-V; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; STADLER HS, 1992, P NATL ACAD SCI USA, V89, P11579, DOI 10.1073/pnas.89.23.11579; STADLER HS, 1995, MAMM GENOME, V6, P383, DOI 10.1007/BF00355637; STADLER HS, 1994, DEV BIOL, V161, P251, DOI 10.1006/dbio.1994.1025; TREISMAN J, 1989, CELL, V59, P553; TVERBERG LA, 1993, J BIOL CHEM, V268, P15965; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	40	41	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11635	11642		10.1074/jbc.274.17.11635	http://dx.doi.org/10.1074/jbc.274.17.11635			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206974	hybrid			2022-12-25	WOS:000079834800030
J	Chan, WK; Yao, G; Gu, YZ; Bradfield, CA				Chan, WK; Yao, G; Gu, YZ; Bradfield, CA			Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways - Demonstration of competition and compensation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; AH-RECEPTOR; TRANSDUCTION PATHWAYS; NUCLEAR TRANSLOCATOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; HEPATOMA-CELLS; ARNT; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; DIFFERENTIATION	The aryl hydrocarbon receptor (AHR) and the alpha-class hypoxia inducible factors (HIF1 alpha, HIF2 alpha, and HIF3 alpha) are basic helix-loop-helix PAS (bHLH-PAS) proteins that heterodimerize with ARNT, In response to 2,3,7,8-tetrachlorodibenzo-p-dioxin, the AHR . ARNT complex binds to "dioxin responsive enhancers" (DREs) and activates genes involved in the metabolism of xenobiotics, e.g. cytochrome P4501A1 (Cyp1a1), The HIF1 alpha . ARNT complex binds to "hypoxia responsive enhancers" and activates the transcription of genes that regulate adaptation to low oxygen, e.g, erythropoietin (Epo), We postulated that activation of one pathway would inhibit the other due to competition for ARNT or other limiting cellular factors. Using pathway specific reporters in transient transfection assays, we observed that DRE driven transcription was markedly inhibited by hypoxia and that hypoxia responsive enhancer driven transcription was inhibited by AHR agonists, When we attempted to support this cross-talk model using endogenous loci, we observed that activation of the hypoxia pathway inhibited Cyp1a1 up-regulation, but that activation of the AHR actually enhanced the induction of Epo by hypoxia. To explain this unexpected additivity, we examined the Epo gene and found that its promoter harbors DREs immediately upstream of its transcriptional start site. These experiments outline conditions where inhibitory and additive cross-talk occur between the hypoxia and dioxin signal transduction pathways and identify Epo as an AHR-regulated gene.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Pacific, Sch Pharm & Hlth Sci, Dept Pharmaceut & Med Chem, Stockton, CA 95211 USA	University of Wisconsin System; University of Wisconsin Madison; University of the Pacific	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	bradfield@ontology.wisc.edu		, Guang/0000-0003-0167-777X	NATIONAL CANCER INSTITUTE [P30CA007175, R01CA098681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005703] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA098681, P30-CA07175] Funding Source: Medline; NIEHS NIH HHS [R01-ES05703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; CARVER LA, 1996, THESIS; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CHEN YH, 1995, J BIOL CHEM, V270, P22548, DOI 10.1074/jbc.270.38.22548; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DEVORE J, 1986, STAT EXPLORATION ANA; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HANKINSON O, 1993, ARCH BIOCHEM BIOPHYS, V300, P1, DOI 10.1006/abbi.1993.1001; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; KNUTSON JC, 1984, J CELL PHYSIOL, V121, P143, DOI 10.1002/jcp.1041210118; Kuil CW, 1998, J BIOL CHEM, V273, P8829, DOI 10.1074/jbc.273.15.8829; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; NEBERT DW, 1978, POLYCYCLIC HYDROCARB, V2, P345; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; POSTLIND H, 1993, TOXICOLOGY, V18, P255; RIDDICK DS, 1994, J BIOL CHEM, V269, P12118; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SKEATH JB, 1994, FASEB J, V8, P714, DOI 10.1096/fasebj.8.10.8050670; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003	34	170	173	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12115	12123		10.1074/jbc.274.17.12115	http://dx.doi.org/10.1074/jbc.274.17.12115			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207038	hybrid			2022-12-25	WOS:000079834800094
J	Lee, YC; Kaufmannn, M; Kitazume-Kawaguchi, S; Kono, M; Takashima, S; Kurosawa, N; Liu, H; Pircher, H; Tsujii, S				Lee, YC; Kaufmannn, M; Kitazume-Kawaguchi, S; Kono, M; Takashima, S; Kurosawa, N; Liu, H; Pircher, H; Tsujii, S			Molecular cloning and functional expression of two members of mouse NeuAc alpha 2,3Gal beta 1,3GalNAc GalNAc alpha 2,6-sialyltransferase family, ST6GalNAc III and IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL-BETA-1,3GALNAC-SPECIFIC GALNAC ALPHA-2,6-SIALYLTRANSFERASE; BETA-GALACTOSIDE ALPHA-2,6-SIALYTRANSFERASE; DEVELOPMENTALLY-REGULATED MEMBER; SIALYLTRANSFERASE GENE FAMILY; N-LINKED OLIGOSACCHARIDES; POLYMERASE CHAIN-REACTION; CARBOHYDRATE STRUCTURES; G(D3) SYNTHASE; ACID-RESIDUES; ALPHA-2,3-SIALYLTRANSFERASE	Two cDNA clones encoding NeuAc alpha 2,3Gal beta 1,3GalNAc GalNAc alpha 2,6-sialyltransferase have been isolated from mouse brain cDNA libraries. One of the cDNA clones is a homologue of previously reported rat ST6GalNAc III according to the amino acid sequence identity (94.4%) and the substrate specificity of the expressed recombinant enzyme, while the other cDNA clone includes an open reading frame coding for 302 amino acids. The deduced amino acid sequence is not identical to those of other cloned mouse sialyltransferases, although it shows the highest sequence similarity with mouse ST6GalNAc III (43.0%). The expressed soluble recombinant enzyme exhibited activity toward NeuAc alpha 2, 3Gal beta 1,3GalNAc, fetuin, and GM1b, while no significant activity was detected toward Gal beta 1,3GalNAc or asialofetuin, or the other glycoprotein substrates tested. The sialidase sensitivity of the C-14-sialylated residue of fetuin, which was sialylated by this enzyme with CMP-[C-14]NeuAc, was the same as that of ST6GalNAc III. These results indicate that the expressed enzyme is a new type of GalNAc alpha 2,6-sialyltransferase, which requires sialic acid residues linked to Gal beta 1,3GalNAc residues for its activity; therefore, we designated it mouse ST6GalNAc TV. Although the substrate specificity of this enzyme is similar to that of ST6GalNAc III, ST6GalNAc IV prefers O-glycans to glycolipids, Glycolipids, however, are better substrates for ST6GalNAc III.	RIKEN, Inst Phys & Chem Res, Frontier Res Program, Wako, Saitama 3510198, Japan; Univ Freiburg, Inst Med Microbiol & Hyg, Dept Immunol, D-79104 Freiburg, Germany	RIKEN; University of Freiburg	Tsujii, S (corresponding author), RIKEN, Inst Phys & Chem Res, Frontier Res Program, Wako, Saitama 3510198, Japan.			Kono, Mari/0000-0003-2447-4350; Kurosawa, Nobuyuki/0000-0002-1548-4541				AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FURUYA S, 1994, J BIOL CHEM, V269, P32418; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hamamoto T, 1993, Bioorg Med Chem, V1, P141, DOI 10.1016/S0968-0896(00)82111-2; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; ISHIKAWA D, 1995, GLYCOCONJUGATE J, V12, P523; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; Kim YJ, 1997, BIOCHEM BIOPH RES CO, V235, P327, DOI 10.1006/bbrc.1997.6725; KIMBER SJ, 1989, BIOCHEM SOC T, V17, P23, DOI 10.1042/bst0170023; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KOJIMA N, 1994, BIOCHEMISTRY-US, V33, P5772, DOI 10.1021/bi00185a014; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KUROSAWA N, 1995, BBA-GEN SUBJECTS, V1244, P216, DOI 10.1016/0304-4165(95)00012-Z; KUROSAWA N, 1994, EUR J BIOCHEM, V219, P375, DOI 10.1111/j.1432-1033.1994.tb19949.x; KUROSAWA N, 1999, IN PRESS J BIOCH TOK; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WEIGANDT H, 1967, J NEUROCHEM, V14, P671; WEN DX, 1992, J BIOL CHEM, V267, P21011; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Zeng GC, 1997, GENE, V187, P131, DOI 10.1016/S0378-1119(96)00735-4; Zeng GC, 1996, BIOCHEM BIOPH RES CO, V226, P319, DOI 10.1006/bbrc.1996.1354	61	58	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11958	11967		10.1074/jbc.274.17.11958	http://dx.doi.org/10.1074/jbc.274.17.11958			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207017	hybrid			2022-12-25	WOS:000079834800073
J	Musante, L; Zegarra-Moran, O; Montaldo, PG; Ponzoni, M; Galietta, LJV				Musante, L; Zegarra-Moran, O; Montaldo, PG; Ponzoni, M; Galietta, LJV			Autocrine regulation of volume-sensitive anion channels in airway epithelial cells by adenosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EXTRACELLULAR ATP; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; ION-TRANSPORT; RECEPTORS; ANTAGONISTS; INHIBITION; MECHANISM	The activity of volume-sensitive Cl- channels was studied in human tracheal epithelial cells (9HTEo-) by taurine efflux experiments. The efflux elicited by a hypotonic shock was partially inhibited by adenosine receptor antagonists, by alpha,beta-methyleneadenosine 5'-diphosphate (alpha beta MeADP), an inhibitor of the 5'-ectonucleotidase, and by adenosine deaminase, On the other hand, dipyridamole, a nucleoside transporter inhibitor, increased the swelling-induced taurine efflux, Extracellular ATP and adenosine increased taurine efflux by potentiating the effect of hypotonic shock. alpha beta MeADP strongly inhibited the effect of extracellular ATP but not that of adenosine, These results suggest that anion channel activation involves the release of intracellular ATP, which is then degraded to adenosine by specific ectoenzymes. Adenosine then binds to purinergic receptors, causing the activation of the channels. To directly demonstrate ATP efflux, cells were loaded with [H-3]AMP, and the release of radiolabeled molecules was analyzed by high performance liquid chromatography, During hypotonic shock, cell supernatants showed the presence of ATP, ADP, and adenosine, alpha beta MeADP inhibited adenosine formation and caused the appearance of AMP. Under hypotonic conditions, elevation of intracellular Ca2+ by ionomycin caused an increase of ATP and adenosine in the extracellular solution. Our results demonstrate that volume-sensitive anion channels are regulated with an autocrine mechanism involving swelling-induced ATP release and then hydrolysis to adenosine.	Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy; Ist Giannina Gaslini, Lab Oncol, I-16148 Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini	Galietta, LJV (corresponding author), Ist Giannina Gaslini, Genet Mol Lab, Largo Gerolamo Gaslini 5, I-16148 Genoa, Italy.		Ponzoni, Mirco/J-7713-2016; Galietta, Luis JV/HCG-8692-2022; Musante, Luciana/AAA-5726-2021	Ponzoni, Mirco/0000-0002-6164-4286; Musante, Luciana/0000-0002-2742-1484; Galietta, Luis/0000-0001-8686-3461	Telethon [E.0593] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Basavappa S, 1996, MOL NEUROBIOL, V13, P137, DOI 10.1007/BF02740638; Cunha RA, 1998, J NEUROSCI, V18, P1987; Galietta LJV, 1997, AM J PHYSIOL-CELL PH, V273, pC57, DOI 10.1152/ajpcell.1997.273.1.C57; GALIETTA LJV, 1992, FEBS LETT, V304, P61, DOI 10.1016/0014-5793(92)80589-9; GARCIAPEREZ A, 1990, HYPERTENSION, V16, P595, DOI 10.1161/01.HYP.16.6.595; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; Harris RA, 1997, AM J PHYSIOL-LUNG C, V273, pL363, DOI 10.1152/ajplung.1997.273.2.L363; HOFFMANN EK, 1991, ADV COMP ENV PHYSL, V9, P140; Kim HD, 1996, AM J PHYSIOL-CELL PH, V270, pC86, DOI 10.1152/ajpcell.1996.270.1.C86; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kirk K, 1997, J MEMBRANE BIOL, V158, P1, DOI 10.1007/s002329900239; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MEGHJI P, 1995, BIOCHEM J, V308, P725, DOI 10.1042/bj3080725; MEGHJI P, 1995, LIFE SCI, V57, P763, DOI 10.1016/0024-3205(95)02004-3; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; Rugolo M, 1996, AM J PHYSIOL-LUNG C, V271, pL665, DOI 10.1152/ajplung.1996.271.4.L665; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; SHIMADA J, 1992, J MED CHEM, V35, P924, DOI 10.1021/jm00083a018; SIEGFRIED G, 1995, ENDOCRINOLOGY, V136, P1267, DOI 10.1210/en.136.3.1267; Silver SM, 1997, KIDNEY INT, V51, P1237, DOI 10.1038/ki.1997.169; SMALLRIDGE RC, 1992, ENDOCRINOLOGY, V131, P1883, DOI 10.1210/en.131.4.1883; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; UKENA D, 1986, LIFE SCI, V39, P743, DOI 10.1016/0024-3205(86)90023-8; Vandenberg JI, 1996, CARDIOVASC RES, V32, P85, DOI 10.1016/S0008-6363(96)00048-X; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wright AR, 1997, TRENDS PHARMACOL SCI, V18, P224, DOI 10.1016/S0165-6147(97)90627-1; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	32	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11701	11707		10.1074/jbc.274.17.11701	http://dx.doi.org/10.1074/jbc.274.17.11701			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206984	hybrid			2022-12-25	WOS:000079834800040
J	Pace, AJ; Gama, L; Breitwieser, GE				Pace, AJ; Gama, L; Breitwieser, GE			Dimerization of the calcium-sensing receptor occurs within the extracellular domain and is eliminated by Cys -> Ser mutations at Cys(101) and Cys(236)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; PUTATIVE PHEROMONE RECEPTORS; CELL-SURFACE EXPRESSION; HUMAN CA2+ RECEPTOR; MUSCARINIC RECEPTORS; SIGNAL-TRANSDUCTION; MULTIGENE FAMILY; SF9 CELLS; BINDING; PHOSPHORYLATION	Calcium-sensing receptors are present in membranes as dimers that can be reduced to monomers with sufhydryl reagents. All studies were carried out on the human calcium-sensing receptor tagged at the carboxyl terminus with green fluorescent protein (hCaR-GFP) to permit identification and localization of expressed proteins. Truncations containing either the extracellular agonist binding domain plus transmembrane helix 1 (ECD/TMH1-GFP) or the transmembrane domain plus the intracellular carboxyl terminus (TMD/carboxyl terminus-GFP) were used to identify the dimerization domain. ECD/TMH1-GFP was a dimer in the absence of reducing reagents, whereas TMD/carboxyl-terminal GFP was a monomer in the absence or presence of reducing agents, suggesting that dimerization occurs via the ECD. To identify the residue(s) involved in dimerization within the ECD, cysteine --> serine point mutations were made in residues that are conserved between hCaR and metabotropic glutamate receptors. Mutations at positions 60 and 131 were expressed at levels comparable to wild type in HEK 293 cells, had minimal effects on hCaR function, and did not eliminate dimerization, whereas mutations at positions 101 and 236 greatly decreased receptor expression and resulted in significant amounts of monomer in the absence of reducing agents. The double point mutant hCaR(C101S/C236S)-GFP was expressed more robustly than either C101S or C236S and covalent dimerization was eliminated. hCaR(C101S/ C236S)-GFP had a decreased affinity for extracellular Ca2+ and slower response kinetics upon increases or decreases in agonist concentration. These results suggest that covalent, disulfide bond-mediated dimerization of the calcium-sensing receptor contributes to stabilization of the ECD and to acceleration of the transitions between inactive and active receptor conformations.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Breitwieser, GE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.			Gama, Lucio/0000-0001-9511-012X; Breitwieser, Gerda/0000-0001-9081-0362	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI H, 1994, J BIOL CHEM, V269, P24557; AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1991, J BONE MINER RES, V6, P1217; Chattopadhyay N, 1996, ENDOCR REV, V17, P289, DOI 10.1210/er.17.4.289; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; HARTIG P, 1990, NEUROPSYCHOPHARMACOL, V3, P335; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; Hermans E, 1998, J NEUROCHEM, V70, P1772; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; LEE TWT, 1986, BIOCHEMISTRY-US, V25, P7009, DOI 10.1021/bi00370a038; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MATTERA R, 1985, J BIOL CHEM, V260, P7410; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pearce SHS, 1997, J ENDOCRINOL, V154, P371, DOI 10.1677/joe.0.1540371; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; POTTER LT, 1991, MOL PHARMACOL, V39, P211; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SCHREURS J, 1995, J NEUROCHEM, V64, P1622; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256; VIGNES M, 1992, NEUROCHEM INT, V21, P229, DOI 10.1016/0197-0186(92)90152-H; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; Ye CP, 1997, J NEUROSCI RES, V47, P547, DOI 10.1002/(SICI)1097-4547(19970301)47:5<547::AID-JNR10>3.0.CO;2-V	44	98	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11629	11634		10.1074/jbc.274.17.11629	http://dx.doi.org/10.1074/jbc.274.17.11629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206973	hybrid			2022-12-25	WOS:000079834800029
J	Mengubas, K; Riordan, FA; Bravery, CA; Lewin, J; Owens, DL; Mehta, AB; Hoffbrand, AV; Wickremasinghe, RG				Mengubas, K; Riordan, FA; Bravery, CA; Lewin, J; Owens, DL; Mehta, AB; Hoffbrand, AV; Wickremasinghe, RG			Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism	ONCOGENE			English	Article						ceramide; leukaemia; apoptosis; necrosis	RADIATION-INDUCED APOPTOSIS; DAUNORUBICIN-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASES; CELL-DEATH; HL-60 CELLS; DNA-DAMAGE; IN-VITRO; B-CELL; LEUKEMIA; RESISTANCE	Synthetic ceramides induce apoptotic death of Jurkat and HL60 leukaemia cell lines. By contrast we show here that ceramide induces non-apoptotic killing of malignant cells from patients with B-chronic lymphocytic leukaemia (B-CLL) and of normal B lymphocytes, The protein phosphatase inhibitor okadaic acid readily induces apoptosis of B-CLL cells, indicating that this death pathway is fully functional in these cells. The ability of ceramide to activate the apoptotic protease caspase 3 in HL60 cells but not in B-CLL cells, as well as the lack of correlation of ceramide-mediated killing of different B-CLL isolates with expression of the apoptosis-regulating proteins bcl-2 and bax reinforce the conclusion that ceramide killing of B-CLL cells is by a non-apoptotic mechanism. Fludarabine treatment or gamma-irradiation of B-CLL cells resulted in ceramide elevation and in killing by both apoptotic and non-apoptotic mechanisms, suggesting that a ceramide-triggered non-apoptotic mechanism may play a role in the killing of these cells. Therefore, the results here show that ceramide can induce either apoptotic or non-apoptotic death, depending on the cellular conte it. The inability of synthetic dihydroceramide to kill B-CLL cells or normal B lymphocytes suggests that non-apoptotic killing by ceramide is via interaction with a specific, but unidentified, cellular target.	UCL Royal Free & Univ Coll Sch Med, Dept Hematol, London NW3 2PF, England; UCL Royal Free & Univ Coll Sch Med, Dept Histopathol, London NW3 2PF, England; UCL Royal Free & Univ Coll Sch Med, Hemophilia Ctr, London NW3 2PF, England	University of London; University College London; University of London; University College London; University of London; University College London	Wickremasinghe, RG (corresponding author), UCL Royal Free & Univ Coll Sch Med, Dept Hematol, Rowland Hill St, London NW3 2PF, England.		Mehta, Atul/GPC-7364-2022					Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chmura SJ, 1997, CANCER RES, V57, P1270; Consoli U, 1998, BLOOD, V91, P1742, DOI 10.1182/blood.V91.5.1742.1742_1742_1748; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Eguchi Y, 1997, CANCER RES, V57, P1835; FernandezSanchez MT, 1996, FEBS LETT, V398, P106, DOI 10.1016/S0014-5793(96)01192-1; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kojima H, 1996, ONCOL RES, V8, P497; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Michael JM, 1997, CANCER RES, V57, P3600; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohmori M, 1997, CANCER RES, V57, P4714; PANAYIOTIDIS P, 1993, BRIT J HAEMATOL, V85, P439; Panayiotidis P., 1995, Blood, V86, p607A; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; PUSHKAREVA M, 1995, BIOCHEMISTRY-US, V34, P1885, DOI 10.1021/bi00006a009; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimizu S, 1996, ONCOGENE, V12, P2045; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tay DLM, 1996, EXP HEMATOL, V24, P277; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Thomas A, 1996, ONCOGENE, V12, P1055; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	48	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2499	2506		10.1038/sj.onc.1202622	http://dx.doi.org/10.1038/sj.onc.1202622			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229201				2022-12-25	WOS:000079703300010
J	Sawamoto, K; Yamada, C; Kishida, S; Hirota, Y; Taguchi, A; Kikuchi, A; Okano, H				Sawamoto, K; Yamada, C; Kishida, S; Hirota, Y; Taguchi, A; Kikuchi, A; Okano, H			Ectopic expression of constitutively activated Ral GTPase inhibits cell shape changes during Drosophila eye development	ONCOGENE			English	Article						actin; cell shape; Drosophila; Ra1	NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN TYROSINE KINASE; C-FOS PROMOTER; PUTATIVE EFFECTOR; FATE; MEMBRANE; GROWTH; IDENTIFICATION; TRANSFORMATION; MELANOGASTER	The small GTP-binding protein Ral is activated by RalGDS, one of the effector molecules for Ras. Active Ral binds to a GTPase activating protein for CDC42 and Rac. Although previous studies suggest a role for Ral in the regulation of CDC42 and Rac, which are involved in arranging the cytoskeleton, its in vivo function is largely unknown. To examine the effect of overexpressing Ral on development, transgenic Drosophila were generated that overexpress wild-type or mutated Ral during eye development. While wild-type Ral caused no developmental defects, expression of a constitutively activated protein resulted in a rough eye phenotype, Activated Ral did not affect cell fate determination in the larval eye discs but caused severe disruption of the ommatidial organization later in pupal development. Phalloidin staining showed that activated Ral perturbed the cytoskeletal structure and cell shape changes during pupal development. This phenotype is similar to that caused by RhoA overexpression. In addition, the phenotype was synergistically enhanced by the coexpression of RhoA, These results suggest that Ral functions to control the cytoskeletal structure required for cell shape changes during Drosophila development.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Suita, Osaka 5650871, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7340037, Japan; JST, CREST, Minato Ku, Tokyo 1050011, Japan	Osaka University; Hiroshima University; Japan Science & Technology Agency (JST)	Okano, H (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Okano, Hideyuki/I-7584-2019; Hirota, Yuki/A-9736-2015	Hirota, Yuki/0000-0001-9629-0038; Sawamoto, Kazunobu/0000-0003-1984-5129; kishida, shosei/0000-0003-0405-851X				Aelst L, 1997, GENE DEV, V11, P2295; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FRECH M, 1990, J BIOL CHEM, V265, P6353; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HAY BA, 1994, DEVELOPMENT, V120, P2121; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Karim FD, 1998, DEVELOPMENT, V125, P1; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Lee T, 1996, DEVELOPMENT, V122, P409; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LONGLEY RL, 1995, DEV BIOL, V171, P415, DOI 10.1006/dbio.1995.1292; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsuo T, 1997, DEVELOPMENT, V124, P2671; Miller DT, 1998, DEVELOPMENT, V125, P2327; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Park SH, 1995, ONCOGENE, V11, P2349; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; WASSARMAN DA, 1997, ADV DEV BIO, V5, P1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff T, 1993, DEV DROSOPHILA MELAN; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	58	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1967	1974		10.1038/sj.onc.1202522	http://dx.doi.org/10.1038/sj.onc.1202522			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208418				2022-12-25	WOS:000079191300006
J	Jonas, JC; Sharma, A; Hasenkamp, W; Ilkova, H; Patane, G; Laybutt, R; Bonner-Weir, S; Weir, GC				Jonas, JC; Sharma, A; Hasenkamp, W; Ilkova, H; Patane, G; Laybutt, R; Bonner-Weir, S; Weir, GC			Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL PHOSPHATE DEHYDROGENASE; INSULIN GENE-TRANSCRIPTION; LACTATE-DEHYDROGENASE; FATTY RATS; PANCREATECTOMIZED RATS; ISOLATED ISLETS; GLUCOSE; EXPRESSION; SECRETION; GLUCOKINASE	Differentiated pancreatic beta cells are unique in their ability to secrete insulin in response to a rise in plasma glucose. We have proposed that the unique constellation of genes they express may be lost in diabetes due to the deleterious effect of chronic hyperglycemia. To test this hypothesis, Sprague-Dawley rats were submitted to a 85-95% pancreatectomy or sham pancreatectomy. One week later, the animals developed mild to severe chronic hyperglycemia that was stable for the next 3 weeks, without significant alteration of plasma nonesterified fatty acid levels. Expression of many genes important for glucose-induced insulin release decreased progressively with increasing hyperglycemia, in parallel with a reduction of several islet transcription factors involved in beta cell development and differentiation. In contrast, genes barely expressed in sham islets (lactate dehydrogenase A and hexokinase I) were markedly increased, in parallel with an increase in the transcription factor c-Myc, a potent stimulator of cell growth. These abnormalities were accompanied by beta cell hypertrophy. Changes in gene expression were fully developed 2 weeks after pancreatectomy. Correction of blood glucose by phlorizin for the next 2 weeks normalized islet gene expression and beta cell volume without affecting plasma nonesterified fatty acid levels, strongly suggesting Chat hyperglycemia triggers these abnormalities. In conclusion, chronic hyperglycemia leads to beta cell hypertrophy and loss of beta cell differentiation that is correlated with changes in c-Myc and other key transcription factors. A similar change in beta cell differentiation could contribute to the profound derangement of insulin secretion in human diabetes.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.	Weir, GC (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl,Rm 535, Boston, MA 02215 USA.	weirg@joslab.harvard.edu	Jonas, Jean-Christophe/C-6766-2011	Jonas, Jean-Christophe/0000-0001-9882-5438; Bonner-Weir, Susan/0000-0003-4682-0656	NIDDK NIH HHS [DK-44523, DK-36836, DK-35449] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK035449, R01DK044523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BarreraHernandez G, 1996, DIABETES, V45, P1217, DOI 10.2337/diabetes.45.9.1217; Baumgart E, 1996, J BIOL CHEM, V271, P3846; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; BROCKENBROUGH JS, 1988, DIABETES, V37, P232, DOI 10.2337/diabetes.37.2.232; Cockburn BN, 1997, DIABETES, V46, P1434, DOI 10.2337/diabetes.46.9.1434; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fleischer N, 1998, DIABETES, V47, P1419, DOI 10.2337/diabetes.47.9.1419; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GIROIX MH, 1993, DIABETOLOGIA, V36, P305, DOI 10.1007/BF00400232; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; HENQUIN JC, 1994, JOSLINS DIABETES MEL, P56; HOSOKAWA H, 1995, DIABETES, V44, P1328, DOI 10.2337/diabetes.44.11.1328; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; Leahy Jack L., 1996, P103; LEAHY JL, 1988, J CLIN INVEST, V81, P1407, DOI 10.1172/JCI113470; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; MacDonald MJ, 1996, DIABETES, V45, P1626, DOI 10.2337/diabetes.45.11.1626; Madsen OD, 1997, HORM METAB RES, V29, P265, DOI 10.1055/s-2007-979035; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; PHILIPPE J, 1987, MOL CELL BIOL, V7, P560, DOI 10.1128/MCB.7.1.560; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Roche E, 1998, DIABETOLOGIA, V41, pA130; ROE MW, 1994, J BIOL CHEM, V269, P18279; Roe MW, 1996, AM J PHYSIOL-ENDOC M, V270, pE133, DOI 10.1152/ajpendo.1996.270.1.E133; ROSSETTI L, 1987, J CLIN INVEST, V80, P1037, DOI 10.1172/JCI113157; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Seufert J, 1998, J CLIN INVEST, V101, P2528, DOI 10.1172/JCI2401; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; Tokuyama Y, 1996, BIOCHEM BIOPH RES CO, V220, P532, DOI 10.1006/bbrc.1996.0439; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; VALERA A, 1994, J BIOL CHEM, V269, P28543; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; YAMASHITA S, 1988, ENDOCRINOLOGY, V123, P1825, DOI 10.1210/endo-123-4-1825; ZAMBON A, 1993, J LIPID RES, V34, P1021; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258; Zhao C, 1998, FEBS LETT, V430, P213, DOI 10.1016/S0014-5793(98)00600-0	54	451	481	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14112	14121		10.1074/jbc.274.20.14112	http://dx.doi.org/10.1074/jbc.274.20.14112			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318828	hybrid			2022-12-25	WOS:000080322200057
J	Le Bonniec, S; Deregnaucourt, C; Redeker, V; Banerjee, R; Grellier, P; Goldberg, DE; Schrevel, J				Le Bonniec, S; Deregnaucourt, C; Redeker, V; Banerjee, R; Grellier, P; Goldberg, DE; Schrevel, J			Plasmepsin II, an acidic hemoglobinase from the Plasmodium falciparum food vacuole, is active at neutral pH on the host erythrocyte membrane skeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC PROTEINASE; PROTEASES; PURIFICATION; DEGRADATION; EXPRESSION; SEPARATION; SPECTRIN; PATHWAY; CULTURE; CELLS	Plasmepsin II, an aspartic protease from the human intraerythrocytic parasite Plasmodium falciparum, is involved in degradation of the host cell hemoglobin within the acidic food vacuole of the parasite. Previous characterization of enzymatic activities from Plasmodium soluble extracts, responsible for in vitro hydrolysis of erythrocyte spectrin, had shown that the hydrolysis process occurred at pH 5.0 and involved aspartic protease(s) cleaving mainly within the SH3 motif of the spectrin alpha-subunit. Therefore, we used a recombinant construct of the erythroid SH3 motif as substrate to investigate the involvement of plasmepsins in spectrin hydrolysis, Using specific anti-plasmepsin II antibodies in Western blotting experiments, plasmepsin II was detected in chromatographic fractions enriched in the parasite SH3 hydrolase activity. Involvement of plasmepsin II in hydrolysis was demonstrated by mass spectrometry identification of cleavage sites in the SH3 motif, upon hydrolysis by Plasmodium extract enzymatic activity, and by recombinant plasmepsin II, Furthermore, recombinant plasmepsin II digested native spectrin at pH 6.8, either purified or situated in erythrocyte ghosts, Additional degradation of actin and protein 4.1 from ghosts was observed. Specific antibodies were used in confocal imaging of schizont-infected erythrocytes to localize plasmepsin II in mature stages of the parasite development cycle; antibodies clearly labeled the periphery of the parasites. Taken together, these results strongly suggest that, in addition to hemoglobin degradation, plasmepsin II might be involved in cytoskeleton cleavage of infected erythrocytes.	Museum Natl Hist Nat, Lab Biol Parasitaire, CNRS, F-75231 Paris 05, France; Ecole Super Phys & Chim Ind Ville Paris, Neurobiol Lab, CNRS, UMR 7637, F-75231 Paris, France; Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, Howard Hughes Med Inst, St Louis, MO 63110 USA	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Deregnaucourt, C (corresponding author), Museum Natl Hist Nat, Lab Biol Parasitaire, CNRS, EP 1790,61 Rue Buffon, F-75231 Paris 05, France.		Redeker, Virginie/L-8929-2018; Schrevel, Joseph/AAG-7085-2020	Redeker, Virginie/0000-0003-2694-8388; 	NIAID NIH HHS [AI31615] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031615] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; DEGUERCY A, 1990, MOL BIOCHEM PARASIT, V38, P233, DOI 10.1016/0166-6851(90)90026-I; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Francis SE, 1997, J BIOL CHEM, V272, P14961, DOI 10.1074/jbc.272.23.14961; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; GRELLIER P, 1994, BIOL CELL, V82, P129, DOI 10.1016/S0248-4900(94)80015-4; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LeBonniec S, 1996, CR ACAD SCI III-VIE, V319, P1011; Luker KE, 1996, MOL BIOCHEM PARASIT, V79, P71, DOI 10.1016/0166-6851(96)02651-5; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; ROSENTHAL PJ, 1989, MOL BIOCHEM PARASIT, V35, P177, DOI 10.1016/0166-6851(89)90120-5; ROSENTHAL PJ, 1992, MOL BIOCHEM PARASIT, V51, P143, DOI 10.1016/0166-6851(92)90209-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREVEL J, 1990, BLOOD CELLS, V16, P563; SHERMAN IW, 1983, MOL BIOCHEM PARASIT, V8, P207, DOI 10.1016/0166-6851(83)90044-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WEIDEKAMM E, 1973, BIOCHIM BIOPHYS ACTA, V323, P539, DOI 10.1016/0005-2736(73)90162-4	24	85	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14218	14223		10.1074/jbc.274.20.14218	http://dx.doi.org/10.1074/jbc.274.20.14218			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318841	hybrid			2022-12-25	WOS:000080322200070
J	Bennett, MK; Ngo, TT; Athanikar, JN; Rosenfeld, JM; Osborne, TF				Bennett, MK; Ngo, TT; Athanikar, JN; Rosenfeld, JM; Osborne, TF			Co-stimulation of promoter for low density lipoprotein receptor gene by sterol regulatory element-binding protein and Sp1 is specifically disrupted by the yin yang 1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; SERUM RESPONSE FACTOR; CHOLESTEROL-SYNTHESIS; SYNTHASE PROMOTER; FATTY-ACIDS; EXPRESSION; REPRESSION; LIVER; CELLS; SITES	Sterol regulation of gene expression in mammalian cells is mediated by an interaction between the cholesterol-sensitive sterol regulatory element-binding proteins (SREBPs) and promoter-specific but generic co-regulatory transcription factors such as Spl and NF-Y/CBF, Thus, sterol-regulated promoters that require different co-regulatory factors could be regulated independently through targeting the specific interaction between the SREBPs and the individual co-regulatory proteins. In the present studies we demonstrate that transiently expressed yin yang 1 protein (YY1) inhibits the SREBP-mediated activation of the low density lipoprotein (LDL) receptor in a sensitive and dose dependent manner. The inhibition is independent of YY1 binding directly to the LDL receptor promoter, and we show that the same region of YY1 that interacts in solution with Spl also interacts with SREBP. Furthermore, other SREBP-regulated genes that are not co-regulated by Spl are either not affected at all or are not as sensitive to the repression. Thus, the specific interaction that occurs between SREBPs and Spl to stimulate the LDL receptor promoter is a specific target for inhibition by the YY1 protein, and we provide evidence that the mechanism can be at least partially explained by the ability of YY1 to inhibit the interaction between SREBP and Spl in solution in vitro, The LDL receptor is the key gene of cholesterol uptake, and the rate-controlling genes of cholesterol synthesis are stimulated by the concerted action of SREBPs along with coregulators that are distinct from Spl, Therefore, repression of gene expression through specifically targeting the interaction between SREBP and Spl would provide a molecular mechanism to explain how cholesterol uptake can be regulated independently from cholesterol biosynthesis in mammalian cells.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 19172 Jamboree Rd, Irvine, CA 92697 USA.				NHLBI NIH HHS [HL48044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DIETSCHY JM, 1983, BIOCHEM SOC T, V11, P639, DOI 10.1042/bst0110639; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Guan GM, 1997, J BIOL CHEM, V272, P10295; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LIU R, 1994, NUCLEIC ACIDS RES, V22, P2453, DOI 10.1093/nar/22.13.2453; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MILLINDERVALLET.S, 1996, J BIOL CHEM, V271, P12247; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Osborne TF, 1998, METHODS, V16, P42, DOI 10.1006/meth.1998.0643; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; Osborne TF, 1997, CURR BIOL, V7, pR172, DOI 10.1016/S0960-9822(97)70081-2; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SODOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SPADY DK, 1985, J LIPID RES, V26, P465; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TURLEY SD, 1981, J LIPID RES, V22, P551; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Yokoyama C., 1993, CELL, V75, P185; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	40	63	75	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13025	13032		10.1074/jbc.274.19.13025	http://dx.doi.org/10.1074/jbc.274.19.13025			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224053	hybrid			2022-12-25	WOS:000080200400015
J	Renard, S; Olivier, A; Granger, P; Avenet, P; Graham, D; Sevrin, M; George, P; Besnard, F				Renard, S; Olivier, A; Granger, P; Avenet, P; Graham, D; Sevrin, M; George, P; Besnard, F			Structural elements of the gamma-aminobutyric acid type A receptor conferring subtype selectivity for benzodiazepine site ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA(A) RECEPTORS; BINDING-SITE; ALPHA-SUBUNIT; A RECEPTOR; POINT MUTATION; PHARMACOLOGY; MODULATION; AFFINITY	gamma-aminobutyric acid type A (GABA(A)) receptors comprise a subfamily of ligand-gated ion channels whose activity can be modulated by ligands acting at the benzodiazepine binding site on the receptor. The benzodiazepine binding site was characterized using a site-directed mutagenesis strategy in which amino acids of the alpha(5) subunit were substituted by their corresponding alpha(1) residues. Given the high affinity and selectivity of alpha(1)-containing compared with alpha(5)-containing GABA(A) receptors for zolpidem, mutated alpha(5) subunits were co-expressed with beta(2) and gamma(2) subunits, and the affinity of recombinant receptors for zolpidem was measured. One alpha(5) mutant (bearing P162T, E200G, and T204S) exhibited properties similar to that of the alpha(1) subunit, notably high affinity zolpidem binding and potentiation by zolpidem of GABA-induced chloride current. Two of these mutations, alpha(5)P162T and alpha(5)E200G, might alter binding pocket conformation, whereas alpha(5)T204S probably permits formation of a hydrogen bond with a proton acceptor in zolpidem, These three amino acid substitutions also influenced receptor affinity for CL218872, Our data thus suggest that corresponding amino acids of the alpha(1) subunit, particularly alpha(1)-Ser(204), are the crucial residues influencing ligand selectivity at the binding pocket of alpha(1)-containing receptors, and a model of this binding pocket is presented.	Synthelabo, Dept Genom Biol, F-92500 Rueil Malmaison, France; CNS Res Dept, F-92225 Bagneux, France	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Besnard, F (corresponding author), Synthelabo, Dept Genom Biol, 10 Rue Carrieres, F-92500 Rueil Malmaison, France.			Renard, Stephane/0000-0002-1374-4960				Amin J, 1997, MOL PHARMACOL, V51, P833, DOI 10.1124/mol.51.5.833; Besnard F, 1997, J RECEPT SIGNAL TR R, V17, P99, DOI 10.3109/10799899709036596; Buhr A, 1997, P NATL ACAD SCI USA, V94, P8824, DOI 10.1073/pnas.94.16.8824; Buhr A, 1997, J BIOL CHEM, V272, P11799, DOI 10.1074/jbc.272.18.11799; Buhr A, 1996, MOL PHARMACOL, V49, P1080; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUCIC I, 1995, J PHARMACOL EXP THER, V272, P438; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; FAUREHALLEY C, 1993, EUR J PHARM-MOLEC PH, V246, P283, DOI 10.1016/0922-4106(93)90043-9; GARDNER CR, 1992, PROG NEURO-PSYCHOPH, V16, P755, DOI 10.1016/0278-5846(92)90099-Z; Graham D, 1996, EUR NEUROPSYCHOPHARM, V6, P119, DOI 10.1016/0924-977X(95)00072-W; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; LANGER SZ, 1988, FUND CLIN PHARMACOL, V2, P159, DOI 10.1111/j.1472-8206.1988.tb00629.x; McKernan RM, 1998, MOL PHARMACOL, V54, P33, DOI 10.1124/mol.54.1.33; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Olivier A, 1997, BIOORG MED CHEM LETT, V7, P2277, DOI 10.1016/S0960-894X(97)00404-6; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; Schaerer MT, 1998, EUR J PHARMACOL, V354, P283, DOI 10.1016/S0014-2999(98)00456-7; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; STEPHENSON FA, 1995, BIOCHEM J, V310, P1; WIELAND HA, 1994, J MED CHEM, V37, P4576, DOI 10.1021/jm00052a019; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	26	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13370	13374		10.1074/jbc.274.19.13370	http://dx.doi.org/10.1074/jbc.274.19.13370			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224099	hybrid			2022-12-25	WOS:000080200400061
J	Harpur, AG; Layton, MJ; Das, P; Bottomley, MJ; Panayotou, G; Driscoll, PC; Waterfield, MD				Harpur, AG; Layton, MJ; Das, P; Bottomley, MJ; Panayotou, G; Driscoll, PC; Waterfield, MD			Intermolecular interactions of the p85 alpha regulatory subunit of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; SH3 DOMAIN; P85 SUBUNIT; CATALYTIC SUBUNIT; BETA-RECEPTOR; PI 3-KINASE; ACTIVATION; BINDING; PROTEINS	The regulatory subunit of phosphatidylinositol 3-kinase, p85, contains a number of well defined domains involved in protein-protein interactions, including an SH3 domain and two SH2 domains. In order to investigate in detail the nature of the interactions of these domains with each other and with other binding partners, a series of deletion and point mutants was constructed, and their binding characteristics and apparent molecular masses under native conditions were analyzed. The SH3 domain and the first proline-rich motif bound each other, and variants of p85 containing the SH3 and BH domains and the first proline-rich motif were dimeric, Analysis of the apparent molecular mass of the deletion mutants indicated that each of these domains contributed residues to the dimerization interface, and competition experiments revealed that there were intermolecular SH3 domain-proline-rich motif interactions and BH-BH domain interactions mediating dimerization of p85 alpha both in vitro and in vivo. Binding of SH2 domain ligands did not affect the dimeric state of p85a. Recently, roles for the p85 subunit have been postulated that do not involve the catalytic subunit, and if p85 exists on its own we propose that it would be dimeric.	Ludwig Inst Canc Res, London W1P 8BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Biomed Sci Res Ctr A Fleming, Inst Mol Oncol, Vari 16672, Greece	Ludwig Institute for Cancer Research; University of London; University College London; Alexander Fleming Biomedical Sciences Research Center	Harpur, AG (corresponding author), Imperial Canc Res Fund, Cell Biophys Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	A.Harpur@icrf.icnet.uk	Layton, Meredith/E-9171-2014; Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950				Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CHEN JK, 1994, BIOORG MED CHEM LETT, V4, P1755, DOI 10.1016/S0960-894X(00)80375-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; END P, 1993, J BIOL CHEM, V268, P10066; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NOBES CD, 1995, J CELL SCI, V108, P225; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONS S, 1995, MOL CELL BIOL, V15, P4453; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shepherd PR, 1997, J BIOL CHEM, V272, P19000, DOI 10.1074/jbc.272.30.19000; SHIBASAKI F, 1993, BIOCHEM J, V289, P227, DOI 10.1042/bj2890227; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	44	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12323	12332		10.1074/jbc.274.18.12323	http://dx.doi.org/10.1074/jbc.274.18.12323			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212202	hybrid			2022-12-25	WOS:000080056800022
J	Heitmeier, MR; Scarim, AL; Corbett, JA				Heitmeier, MR; Scarim, AL; Corbett, JA			Double-stranded RNA inhibits beta-cell function and induces islet damage by stimulating beta-cell production of nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; BB RAT; SYNTHASE EXPRESSION; DIABETES-MELLITUS; LANGERHANS; INTERFERON; INTERLEUKIN-1-BETA; MACROPHAGES; DESTRUCTION; ACTIVATION	Viral infection has been implicated as a triggering event that may initiate beta-cell damage during the development of autoimmune diabetes. In this study, the effects of the viral replicative intermediate, double-stranded RNA (dsRNA) (in the form of synthetic polyinosinic-polycytidylic acid (poly IC)) on islet expression of inducible nitric oxide synthase (iNOS), production of nitric oxide, and islet function and viability were investigated. Treatment of rat islets with poly(IC) + interferon-gamma (IFN-gamma) stimulates the time- and concentration-dependent expression of iNOS and production of nitrite by rat islets, iNOS expression and nitrite production by rat islets in response to poly(IC) + IFN-gamma correlate with an inhibition of insulin secretion and islet degeneration, effects that are prevented by the iNOS inhibitor aminoguanidine (AG), We have previously shown that poly(IC) + IFN-gamma activates resident macrophages, stimulating iNOS expression, nitric oxide production and interleukin-1 (IL-1) release. In addition, in response to tumor necrosis factor-alpha (TNF-alpha) + lipopolysaccharide, activated resident macrophages mediate beta-cell damage via intraislet IL-1 release followed by IL-1-induced iNOS expression by p-cells, The inhibitory and destructive effects of poly(IC) + IFN-gamma, however, do not appear to require resident macrophages. Treatment of macrophage-depleted rat islets for 40 h with poly(IC) + IFN-gamma results in the expression of iNOS, production of nitrite, and inhibition of insulin secretion. The destructive effects of dsRNA + IFN-gamma on islets appear to be mediated by a direct interaction with beta-cells. Poly IC + IFN-gamma stimulates iNOS expression and inhibits insulin secretion by primary beta-cells purified by fluorescence-activated cell sorting. In addition, AG prevents the inhibitory effects of poly(IC) + IFN-gamma on glucose-stimulated insulin secretion by beta-cells, These results indicate that dsRNA + IFN-gamma interacts directly with beta-cells stimulating iNOS expression and inhibiting insulin secretion in a nitric oxide-dependent manner. These findings provide biochemical evidence for a novel mechanism by which viral infection may directly mediate the initial destruction of beta-cells during the development of autoimmune diabetes.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NIAID NIH HHS [AI44458] Funding Source: Medline; NIDDK NIH HHS [DK-52194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER P, 1971, NATURE-NEW BIOL, V232, P76, DOI 10.1038/newbio232076a0; Arnush M, 1998, J IMMUNOL, V160, P2684; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; CORBETT JA, 1994, BIOCHEM J, V299, P719, DOI 10.1042/bj2990719; CORBETT JA, 1995, DIABET ANN, V9, P265; EWEL CH, 1992, DIABETES, V41, P1016, DOI 10.2337/diabetes.41.8.1016; Faruqi TR, 1997, AM J PHYSIOL-HEART C, V273, pH2490, DOI 10.1152/ajpheart.1997.273.5.H2490; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; Hirasawa K, 1996, J GEN VIROL, V77, P737, DOI 10.1099/0022-1317-77-4-737; HOPCROFT DW, 1985, IN VITRO CELL DEV B, V21, P421; HUANG XJ, 1994, IMMUNITY, V1, P469, DOI 10.1016/1074-7613(94)90089-2; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERR IM, 1992, J INTERFERON RES, V12, P237, DOI 10.1089/jir.1992.12.237; LACY PE, 1991, AM J PATHOL, V138, P1183; LENGYEL P, 1987, J INTERFERON RES, V7, P511, DOI 10.1089/jir.1987.7.511; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NEURP J, 1994, DIABETOLOG, V37, P82; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; Scarim AL, 1997, ENDOCRINOLOGY, V138, P5301, DOI 10.1210/en.138.12.5301; SELDEN RF, 1991, CURRENT PROTOCOLS MO, V1; Snell JC, 1997, J LEUKOCYTE BIOL, V62, P369, DOI 10.1002/jlb.62.3.369; SOBEL DO, 1992, DIABETES, V41, P515, DOI 10.2337/diabetes.41.4.515; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; Takamura T, 1998, J BIOL CHEM, V273, P2493, DOI 10.1074/jbc.273.5.2493; vonHerrath MG, 1996, IMMUNOL REV, V152, P111; vonHerrath MG, 1997, BIOCHEM SOC T, V25, P630, DOI 10.1042/bst0250630; WANG JL, 1993, J BIOL CHEM, V268, P7785; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WRIGHT PH, 1971, DIABETES, V20, P33, DOI 10.2337/diab.20.1.33; YOON JW, 1995, DIABETES METAB REV, V11, P83, DOI 10.1002/dmr.5610110202; YOON JW, 1997, TXB DIABETES; YOON JW, 1996, DIABETES MELLITUS, P3339	43	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12531	12536		10.1074/jbc.274.18.12531	http://dx.doi.org/10.1074/jbc.274.18.12531			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212230	hybrid			2022-12-25	WOS:000080056800050
J	Norcum, MT; Dignam, JD				Norcum, MT; Dignam, JD			Immunoelectron microscopic localization of glutamyl-/prolyl-tRNA synthetase within the eukaryotic multisynthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; STRUCTURAL ORGANIZATION; COMPONENT; SUBUNIT; FORM	A high molecular mass complex of aminoacyl-tRNA synthetases is readily isolated from a variety of eukaryotes. Although its composition is well characterized, knowledge of its structure and organization is still quite limited. This study uses antibodies directed against prolyl-tRNA synthetase for immunoelectron microscopic localization of the bifunctional glutamyl-/prolyl-tRNA synthetase. This is the first visualization of a specific site within the multisynthetase complex. Images of immunocomplexes are presented in the characteristic views of negatively stained multisynthetase complex from rabbit reticulocytes. As described in terms of a three domain working model of the structure, in "front" views of the particle and "intermediate" views, the primary antibody binding site is near the intersection between the "base" and one "arm," In "side" views, where the particle is rotated about its long axis, the binding site is near the midpoint. "Top" and "bottom" views, which appear as square projections, are also consistent with the central location of the binding site. These data place the glutamyl-/prolyl-tRNA synthetase polypeptide in a defined area of the particle, which encompasses portions of two domains, yet is consistent with the previous structural model.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA	University of Mississippi; University of Mississippi Medical Center	Norcum, MT (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.							BIANCHI C, 1992, BIOCHEM BIOPH RES CO, V187, P1071, DOI 10.1016/0006-291X(92)91306-B; DANG CV, 1979, J BIOL CHEM, V254, P5350; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; GODAR DE, 1988, BIOCHEMISTRY-US, V27, P6921, DOI 10.1021/bi00418a038; KERJAN P, 1992, BIOCHIMIE, V74, P195, DOI 10.1016/0300-9084(92)90046-H; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; NORCUM MT, 1991, J BIOL CHEM, V266, P15398; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; TARGOFF IN, 1994, RHEUM DIS CLIN N AM, V20, P857; TING SM, 1992, J BIOL CHEM, V267, P17701; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	18	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12205	12208		10.1074/jbc.274.18.12205	http://dx.doi.org/10.1074/jbc.274.18.12205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212184	hybrid			2022-12-25	WOS:000080056800004
J	Ogata, M; Takada, T; Mori, Y; Oh-hora, M; Uchida, Y; Kosugi, A; Miyake, K; Hamaoka, T				Ogata, M; Takada, T; Mori, Y; Oh-hora, M; Uchida, Y; Kosugi, A; Miyake, K; Hamaoka, T			Effects of overexpression of PTP36, a putative protein tyrosine phosphatase, on cell adhesion, cell growth, and cytoskeletons in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; INTEGRIN-MEDIATED ADHESION; SEQUENCE HOMOLOGY; MOLECULAR-CLONING; BAND-4.1 FAMILY; KINASE-ACTIVITY; EXPRESSION; DOMAIN; BINDING; MEMBER	Non-receptor-type putative protein tyrosine phosphatase-36 (PTP36), also known as PTPD2/Pez, possesses a domain homologous to the N-terminal half of band 4.1 protein. To gain insight into the biological function of PTP36, we established a HeLa cell line, HtTA/P36-9, in which the overexpression of PTP36 was inducible. PTP36 expressed in HeLa cells was enriched in the cytoskeleton near the plasma membrane. There was little endogenous PTP36 detectable in uninduced HtTA/P36-9 cells or in the parental HeLa cells. Upon induction of PTP36 overexpression, HtTA/P36-9 cells spread less well, grew more slowly, and adhered to the extracellular matrix proteins less well than uninduced cells. Moreover, decreases in the actin stress fibers and the number of focal adhesions were observed. The tyrosine phosphorylation of the focal adhesion kinase induced by lysophosphatidic acid was suppressed in the HtTA/P36-9 cells overexpressing PTP36. These results indicate that PTP36 affects cytoskeletons, cell adhesion, and cell growth, thus suggesting that PTP36 is involved in their regulatory processes.	Osaka Univ, Sch Med C6, Ctr Biomed Res, Dept Oncol, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Suita, Osaka 5650871, Japan; Saga Med Sch, Dept Immunol, Saga 849, Japan	Osaka University; Osaka University; Saga University	Ogata, M (corresponding author), Osaka Univ, Sch Med C6, Ctr Biomed Res, Dept Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							ARAI M, 1994, J NEUROSCI RES, V38; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu MX, 1996, J BIOL CHEM, V271, P27751, DOI 10.1074/jbc.271.44.27751; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Gu MX, 1996, P NATL ACAD SCI USA, V93, P12980, DOI 10.1073/pnas.93.23.12980; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; JINNO Y, 1989, J BIOL CHEM, V264, P15953; LABBE D, 1994, FEBS LETT, V356, P351, DOI 10.1016/0014-5793(94)01305-5; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; OGATA M, 1997, KINASES PHOSPHATASES, P322; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SARAS J, 1994, J BIOL CHEM, V269, P24082; SAWADA M, 1994, BIOCHEM BIOPH RES CO, V203, P479, DOI 10.1006/bbrc.1994.2207; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; TOYAMASORIMACHI N, 1993, EUR J IMMUNOL, V23, P439, DOI 10.1002/eji.1830230221; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	34	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12905	12909		10.1074/jbc.274.18.12905	http://dx.doi.org/10.1074/jbc.274.18.12905			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212280	hybrid			2022-12-25	WOS:000080056800100
J	Smas, CM; Chen, L; Zhao, L; Latasa, MJ; Sul, HS				Smas, CM; Chen, L; Zhao, L; Latasa, MJ; Sul, HS			Transcriptional repression of pref-1 by glucocorticoids promotes 3T3-L1 adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; EPIDERMAL-GROWTH-FACTOR; PPAR-GAMMA; GENE-EXPRESSION; OXIDIZED LDL; CELLS; PREADIPOCYTE; ALPHA; ADIPOGENESIS; ACTIVATION	Pref-1 is an epidermal growth factor-like domain-containing transmembrane protein that is cleaved to generate a soluble factor. It is abundant in 3T3-L1 preadipocytes but absent in mature adipocytes, Constitutive expression of pref-1 or the addition of its ectodomain inhibits adipogenesis, We find that the pref-1 gene is an early target of dexamethasone, a component of the dexamethasone/methylisobutylxanthine differentiation mixture used routinely for adipoconversion. The time course of the decrease in pref-1 mRNA by dexamethasone reflected the pref-1 mRNA half-life determined by actinomycin D treatment. Nuclear run-on assays showed that dexamethasone attenuates pref-1 transcription. We demonstrate a correlation between pref-1 down regulation and adipoconversion by varying the time period and concentration of dexamethasone, Increasing the dexamethasone treatment from 2 to 4 days resulted in a time-dependent pref-1 down-regulation and increased differentiation as measured by adipocyte marker mRNAs, The dexamethasone concentration between 1 and 10 nM showed a dose-dependent decrease in pref-1 mRNA and an enhancement of adipogenesis. To test the hypothesis that dexamethasone initiation of adipoconversion may be via down-regulation of pref-1, we lowered endogenous pref-1 mRNA levels by stably transfecting 3T3-L1 preadipocytes with antisense pref-1, At 1 mu M, antisense cells had enhanced adipose conversion; a similar degree of differentiation occurred with 2 nM dexamethasone, a concentration that does not support differentiation of control 3T3-L1 cells. We conclude that dexamethasone-mediated repression of pref-1 contributes to the mechanisms whereby glucocorticoids promote adipogenesis.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA.		Han, Zaiqi/AAI-2233-2019; Latasa, Maria-Jesus/M-8704-2014	Latasa, Maria-Jesus/0000-0003-2840-8692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ailhaud G, 1996, BIOCHEM SOC T, V24, P400, DOI 10.1042/bst0240400; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Boney CM, 1996, ENDOCRINOLOGY, V137, P2923, DOI 10.1210/en.137.7.2923; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623-199707000-00012; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; Hansen LH, 1998, MOL ENDOCRINOL, V12, P1140, DOI 10.1210/me.12.8.1140; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; HELMAN LJ, 1990, NUCLEIC ACIDS RES, V18, P685; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; Micheal LF, 1997, ENDOCRINOLOGY, V138, P3695, DOI 10.1210/en.138.9.3695; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SHUGART EC, 1995, CELL GROWTH DIFFER, V6, P1541; Smas CM, 1996, INT J OBESITY, V20, pS65; Smas CM, 1998, J BIOL CHEM, V273, P31751, DOI 10.1074/jbc.273.48.31751; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1994, BIOCHEMISTRY-US, V33, P9257, DOI 10.1021/bi00197a029; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Smas CM, 1997, CRIT REV EUKAR GENE, V7, P281, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.10; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YOUNG HE, 1995, DEV DYNAM, V202, P137, DOI 10.1002/aja.1002020205	42	127	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12632	12641		10.1074/jbc.274.18.12632	http://dx.doi.org/10.1074/jbc.274.18.12632			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212243	hybrid			2022-12-25	WOS:000080056800063
J	Koenderink, JB; Swarts, HGP; Hermsen, HPH; De Pont, JJHHM				Koenderink, JB; Swarts, HGP; Hermsen, HPH; De Pont, JJHHM			The beta-subunits of Na+,K+-ATPase and gastric H+,K+-ATPase have a high preference for their own alpha-subunit and affect the K+ affinity of these enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE COMPLEXES; AMINO-ACID-SEQUENCE; FUNCTIONAL EXPRESSION; INTRACELLULAR-TRANSPORT; EXTRACELLULAR DOMAIN; DISULFIDE BONDS; INSECT CELLS; H+/K+-ATPASE; NA,K-ATPASE; H,K-ATPASE	The alpha- and beta-subunits of Na+,K+-ATPase and H+,K+ ATPase were expressed in Sf9 cells in different combinations. Immunoprecipitation of the alpha-subunits resulted in coprecipitation of the accompanying beta-subunit independent of the type of beta-subunit, This indicates cross-assembly of the subunits of the different ATPases, The hybrid ATPase with the catalytic subunit of Na+,K+- ATPase and the beta-subunit of H+,K+-ATPase (NaK alpha HK beta) showed an ATPase activity, which was only 12 +/- 4% of the activity of the Na+,K+-ATPase with its own beta-subunit. Likewise, the complementary hybrid ATPase with the catalytic subunit of H+,K+-ATPase and the beta-subunit of Na+,K+-ATPase (HK alpha NaK beta) showed an ATPase activity which was 9 +/- 2% of that of the recombinant H+,K+ ATPase, In addition, the apparent K+ affinity of hybrid NaK alpha HK beta was decreased, while the apparent K+ affinity of the opposite hybrid HK alpha NaK beta was increased. The hybrid NaK alpha HK beta could be phosphorylated by ATP to a level of 21 +/- 7% of that of Na+,K+-ATPase, These values, together with the ATPase activity gave turnover numbers for NaK alpha beta and NaK alpha HK beta of 8800 +/- 310 min(-1) and 4800 +/- 160 min(-1), respectively. Measurements of phosphorylation of the HK alpha NaK beta and HK alpha beta enzymes are consistent with a higher turnover of the former. These findings suggest a role of the beta-subunit in the catalytic turnover. In conclusion, although both Na+,K+-ATPase and H+,K+-ATPase have a high preference for their own beta-subunit, they can function with the beta-subunit of the other enzyme, in which case the K+ affinity and turnover number are modified.	Catholic Univ Nijmegen, Dept Biochem, Inst Cellular Signaling, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Catholic Univ Nijmegen, Dept Biochem, Inst Cellular Signaling, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.dePont@bioch.kun.nl	Koenderink, Jan/N-3578-2014					ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; Beggah AT, 1997, J BIOL CHEM, V272, P10318; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; Caplan MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1304, DOI 10.1152/ajpgi.1997.272.6.G1304; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; DEPONT JJHHM, 1992, ANN NY ACAD SCI, V671, P446; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; Dunbar LA, 1997, ANN NY ACAD SCI, V834, P514, DOI 10.1111/j.1749-6632.1997.tb52309.x; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GEERING K, 1993, AM J PHYSIOL, V265, pC1169, DOI 10.1152/ajpcell.1993.265.4.C1169; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; KLAASSEN CHW, 1995, BIOCHEM BIOPH RES CO, V210, P907, DOI 10.1006/bbrc.1995.1743; Klaassen CHW, 1997, BIOCHEM J, V321, P419, DOI 10.1042/bj3210419; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; Liu JY, 1997, BBA-GEN SUBJECTS, V1336, P370, DOI 10.1016/S0304-4165(96)00153-5; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NING G, 1993, FEBS LETT, V336, P521, DOI 10.1016/0014-5793(93)80868-U; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; SWARTS HGP, 1991, BIOCHIM BIOPHYS ACTA, V1070, P283, DOI 10.1016/0005-2736(91)90068-J; SWARTS HGP, 1994, BBA-BIOMEMBRANES, V1189, P143, DOI 10.1016/0005-2736(94)90059-0; TYAGARAJAN K, 1995, BBA-BIOMEMBRANES, V1236, P105, DOI 10.1016/0005-2736(95)00044-4; Ueno S, 1997, BBA-BIOMEMBRANES, V1330, P217, DOI 10.1016/S0005-2736(97)00167-3; UENO S, 1995, J BIOCHEM, V117, P591, DOI 10.1093/oxfordjournals.jbchem.a124749; Wang SG, 1997, AM J PHYSIOL-CELL PH, V272, pC923, DOI 10.1152/ajpcell.1997.272.3.C923	54	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11604	11610		10.1074/jbc.274.17.11604	http://dx.doi.org/10.1074/jbc.274.17.11604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206969	Green Published, hybrid			2022-12-25	WOS:000079834800025
J	Miyamoto, A; Yang, SX; Laufs, U; Ruan, XL; Liao, JK				Miyamoto, A; Yang, SX; Laufs, U; Ruan, XL; Liao, JK			Activation of guanine nucleotide-binding proteins and induction of endothelial tissue-type plasminogen activator gene transcription by alcohol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; RELAXING FACTOR; CORONARY-DISEASE; PHORBOL ESTER; NITRIC-OXIDE; PC12 CELLS; ETHANOL; EXPRESSION; RELEASE; CONSUMPTION	The mechanism by which moderate alcohol ingestion lowers the risk of cardiovascular disease is unknown but may be due, in part, to the ability of alcohol to increase the level of tissue-type plasminogen activator (t-PA), Human endothelial cells were treated with low concentrations of ethanol (0.25-25 mM, 0-24 h), which are associated with moderate alcohol consumption. Although treatment with ethanol alone did not affect t-PA gene transcription or mRNA expression, it augmented isoproterenol (LSO)-stimulated t-PA gene transcription and mRNA levels by 3.4- and 2.8-fold, respectively, and decreased plasminogen activator inhibitor-1 mRNA levels by 65%. These effects of ethanol correlated with 2.5- and 6.9-fold increases in ISO-stimulated cyclic AMP levels and 4x-cyclic AMP response element heterologous promoter activity, respectively. To determine whether alcohol-induced changes in agonist-stimulated cyclic AMP levels were because of modulation of guanine nucleotide-binding proteins (G proteins), we assessed the effects of ethanol on G alpha(s) and G alpha(i2). Although ethanol did not affect the expression of G alpha(s) or G alpha(i2), it increased ISO-stimulated G alpha(s) GTPase and GTP binding activity by 2.2 and 2.9-fold and decreased UK14304-stimulated G alpha(i2) GTPase and GTP binding activity by 38 and 80%, These results indicate that treatment with relatively low concentrations of ethanol enhances agonist-stimulated cyclic AMP-dependent t-PA gene transcription in vascular endothelial cells through differential modulation of G protein.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Kagoshima Univ, Dept Vet Pharmacol, Kagoshima 8900065, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kagoshima University	Liao, JK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, 221 Longwood Ave,LMRC-322, Boston, MA 02115 USA.	jliao@rics.bwh.harvard.edu			NHLBI NIH HHS [HL-52233] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DE CR, 1995, J CLIN INVEST, V96, P60; Gorinstein S, 1997, J INTERN MED, V241, P47, DOI 10.1046/j.1365-2796.1997.77888000.x; Grenett HE, 1998, ALCOHOL CLIN EXP RES, V22, P849, DOI 10.1111/j.1530-0277.1998.tb03878.x; HOFFMAN PL, 1990, FASEB J, V4, P2612, DOI 10.1096/fasebj.4.9.2161371; HU G, 1993, J BIOL CHEM, V268, P23441; LAUG WE, 1983, JAMA-J AM MED ASSOC, V250, P772, DOI 10.1001/jama.250.6.772; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1993, J BIOL CHEM, V268, P19528; LIAO JK, 1994, J BIOL CHEM, V269, P12987; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; MEDCALF RL, 1991, MOL ENDOCRINOL, V5, P1773, DOI 10.1210/mend-5-12-1773; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MOCHLYROSEN D, 1988, NATURE, V333, P848, DOI 10.1038/333848a0; NAGAMINE Y, 1985, P NATL ACAD SCI USA, V82, P4606, DOI 10.1073/pnas.82.14.4606; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; Pellegrini N, 1996, EUR J CLIN NUTR, V50, P209; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; RABE CS, 1990, BIOCHEM PHARMACOL, V40, P565, DOI 10.1016/0006-2952(90)90557-2; RABIN RA, 1988, J NEUROCHEM, V51, P1148, DOI 10.1111/j.1471-4159.1988.tb03080.x; Ramanathan R, 1996, J CELL BIOL, V133, P381, DOI 10.1083/jcb.133.2.381; RASBAND W, 1993, NIH IMAGE PROGRAM VE; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SANTELL L, 1988, J BIOL CHEM, V263, P16802; Sloan LS, 1998, BIOCHEMISTRY-US, V37, P7113, DOI 10.1021/bi972009s; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Sumpio BE, 1997, AM J PHYSIOL-CELL PH, V273, pC1441, DOI 10.1152/ajpcell.1997.273.5.C1441; Uno S, 1998, J BIOCHEM, V123, P806; WAND GS, 1993, J BIOL CHEM, V268, P2595; WIGLER M, 1976, NATURE, V259, P232, DOI 10.1038/259232a0	33	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12055	12060		10.1074/jbc.274.17.12055	http://dx.doi.org/10.1074/jbc.274.17.12055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207029	hybrid			2022-12-25	WOS:000079834800085
J	VanValkenburgh, C; Chen, XM; Mullins, C; Fang, H; Green, N				VanValkenburgh, C; Chen, XM; Mullins, C; Fang, H; Green, N			The catalytic mechanism of endoplasmic reticulum signal peptidase appears to be distinct from most eubacterial signal peptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; POTENTIAL ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; BACILLUS-SUBTILIS; SHUTTLE VECTORS; AMINO-ACIDS; YEAST; PROTEIN; GENE; IDENTIFICATION	Many type I signal peptidases from eubacterial cells appear to contain a serine/lysine catalytic dyad. In contrast, our data show that the signal peptidase complex from the endoplasmic reticulum lacks an apparent catalytic lysine. Instead, a serine, histidine, and two aspartic acids are important for signal peptidase activity by the Sec11p subunit of the yeast signal peptidase complex. Amino acids critical to the eubacterial signal peptidases and Sec11p are, however, positioned similarly along their primary sequences, suggesting the presence of a common structural element(s) near the catalytic sites of these enzymes.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	VanValkenburgh, C (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.				NCI NIH HHS [2 T32 CA09385-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; Fang H, 1996, J BIOL CHEM, V271, P16460, DOI 10.1074/jbc.271.28.16460; Fang H, 1997, J BIOL CHEM, V272, P13152, DOI 10.1074/jbc.272.20.13152; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; Meyer HA, 1997, J BIOL CHEM, V272, P13159, DOI 10.1074/jbc.272.20.13159; Mullins C, 1996, J BIOL CHEM, V271, P29094, DOI 10.1074/jbc.271.46.29094; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANDERSON CM, 1991, J BIOL CHEM, V266, P13423; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SUNG M, 1992, J BIOL CHEM, V267, P13154; TALMADGE K, 1980, P NATL ACAD SCI-BIOL, V77, P3988, DOI 10.1073/pnas.77.7.3988; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WEI YY, 1995, NAT STRUCT BIOL, V2, P218, DOI 10.1038/nsb0395-218; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	39	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11519	11525		10.1074/jbc.274.17.11519	http://dx.doi.org/10.1074/jbc.274.17.11519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206957	hybrid			2022-12-25	WOS:000079834800013
J	Fujimoto, A; Morita, R; Hatta, N; Takehara, K; Takata, M				Fujimoto, A; Morita, R; Hatta, N; Takehara, K; Takata, M			p16(INK4a) inactivation is not frequent in uncultured sporadic primary cutaneous melanoma	ONCOGENE			English	Article						loss of heterozygosity; microsatellites; gene mutation; tumour suppressor gene; immunohistochemistry	TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; ACRAL LENTIGINOUS MELANOMA; CHROMOSOME 9P DELETIONS; KINASE-4 INHIBITOR GENE; HOMOZYGOUS DELETIONS; GERMLINE MUTATIONS; DELETED REGION; OVARIAN-TUMORS; METHYLATION	In an attempt to examine whether the inactivation of p16(INK4a) is an important early event in the development of sporadic melanoma in vivo, we have systematically analysed 46 uncultured primary cutaneous melanomas, Loss of heterozygosity (LOH) of chromosome region 9p21-22 (where the p16(INK4a) resides) was detected in II tumours (24%) by PCR-based LOH analyses. Direct sequencing of all three exons of the p16(INK4a) gene in these 11 tumours revealed no somatic mutation although germline mutations which have not been reported previously as common polymorphisms were detected in two patients. Further sequencing analyses of the p16(INK4a) gene exon 2 in 19 additional tumours with no evidence of LOH on 9p21-22 identified only one heterozygous C->T mutation at codon 81 altering a proline to a leucine. A sensitive methylation-specific PCR assay did not reveal ne novo methylation of the 5'CpG island in exon 1 of the p16(INK4a) gene in any of the tumours showing 9p21-22 allelic loss or a heterozygous p16(INK4a) mutation. Complete loss of p16(INK4a) protein, most likely due to homozygous deletion of the p16(INK4a) gene, was observed in 6 (15%) out of 39 evaluable cases by immunohistochemical analyses on frozen sections using two different anti-p16(INK4a) antibodies. The results show that inactivation of p16(INK4a) is not as frequent in primary melanoma as has been reported in cell lines, and warrant further search for another tumour suppressor on 9p21-22. This study also emphasizes the importance of examining uncultured primary tumours rather than cell lines to define early events in tumorigenesis.	Kanazawa Univ, Sch Med, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University	Takata, M (corresponding author), Kanazawa Univ, Sch Med, Dept Dermatol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.			HATTA, NAOHITO/0000-0003-1590-8348				Biden K, 1997, HEPATOLOGY, V25, P593, DOI 10.1002/hep.510250317; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Castellano M, 1997, CANCER RES, V57, P4868; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Farrell WE, 1997, CANCER RES, V57, P2703; Flores JF, 1996, CANCER RES, V56, P5023; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Gonzalgo ML, 1997, CANCER RES, V57, P5336; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HERMAN JG, 1995, CANCER RES, V55, P4525; Hermann RC, 1996, HARVARD REV PSYCHIAT, V4, P98, DOI 10.3109/10673229609030529; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAGESHITA T, 1991, CANCER RES, V51, P1726; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kim SK, 1997, CANCER RES, V57, P400; Kinoshita I, 1996, CANCER RES, V56, P5557; KREMENTZ ET, 1982, ANN SURG, V195, P632, DOI 10.1097/00000658-198205000-00013; LIU Q, 1995, ONCOGENE, V10, P1061; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morita R, 1998, J INVEST DERMATOL, V111, P919, DOI 10.1046/j.1523-1747.1998.00458.x; Myohanen SK, 1998, CANCER RES, V58, P591; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; POLLOCK PM, 1995, ONCOGENE, V11, P663; PUIG S, 1995, AM J HUM GENET, V57, P395; REED JA, 1995, CANCER RES, V55, P2713; Schmidt EE, 1997, BRIT J CANCER, V75, P2, DOI 10.1038/bjc.1997.2; SEIJI M, 1979, PIGMENT CELL, V5, P95; Shih YC, 1997, INT J CANCER, V70, P508, DOI 10.1002/(SICI)1097-0215(19970304)70:5<508::AID-IJC3>3.3.CO;2-6; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; Wiest JS, 1997, CANCER RES, V57, P1	47	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2527	2532		10.1038/sj.onc.1202803	http://dx.doi.org/10.1038/sj.onc.1202803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229204				2022-12-25	WOS:000079703300013
J	Wasylyk, C; Salvi, R; Argentini, M; Dureuil, C; Delumeau, I; Abecassis, J; Debussche, L; Wasylyk, B				Wasylyk, C; Salvi, R; Argentini, M; Dureuil, C; Delumeau, I; Abecassis, J; Debussche, L; Wasylyk, B			p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53	ONCOGENE			English	Article						p21(WAF1/CIP1); E2F; E6; cell cycle; apoptosis; antisense	WILD-TYPE P53; HUMAN TUMOR-CELLS; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2	The p53 tumour suppressor is frequently inactivated in human tumours, One form of inactivation results from overexpression of MDM2, that normally forms a negative auto-regulatory loop with p53 and inhibits its activity through complex formation, We have investigated whether disrupting the MDM2-p53 complex in cells that overexpress MDM2 is sufficient to trigger p53 mediated cell death. We find that expression of a peptide homologue of p53 that binds to MDM2 leads to increased p53 levels and transcriptional activity. The consequences are increased expression of the downstream effecters MDM2 and p21(WAF1/CIP1), inhibition of colony formation, cell cycle arrest and cell death. There is also a decrease in E2F activity, that might have been due to the known physical and functional interactions of MDM2 with E2F1/DP1, However, this decrease is p53 dependent, as are also colony formation, cell cycle arrest and cell death, These results show that a peptide homologue of p53 is sufficient to induce p53 dependent cell death in cells overexpressing MDM2, and support the notion that disruption of the p53-MDM2 complex is a target for the development of therapeutic agents.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, F-94403 Vitry, France; Lab Biol Tumorale, F-67085 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Sanofi-Aventis	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALKHALAF M, 1998, IN PRESS ONCOGENE; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bernards R, 1997, BBA-REV CANCER, V1333, pM33, DOI 10.1016/S0304-419X(97)00027-9; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; CASEY G, 1991, ONCOGENE, V6, P1791; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Conseiller E, 1998, J CLIN INVEST, V101, P120, DOI 10.1172/JCI1140; CORDONCARDO C, 1994, CANCER RES, V54, P794; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1991, CANCER RES, V51, P6304; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, ONCOGENE, V10, P2001; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leveillard T, 1998, MECH DEVELOP, V74, P189, DOI 10.1016/S0925-4773(98)00074-4; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 1997, CANCER RES, V57, P5013; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SAKAI E, 1992, ONCOGENE, V7, P927; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Teoh G, 1997, BLOOD, V90, P1982, DOI 10.1182/blood.V90.5.1982; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wubah JA, 1996, CURR BIOL, V6, P60, DOI 10.1016/S0960-9822(02)00422-0; Wurl P, 1998, ONCOGENE, V16, P1183, DOI 10.1038/sj.onc.1201646; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAGINUMA Y, 1991, CANCER RES, V51, P6506; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	96	111	119	1	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1921	1934		10.1038/sj.onc.1202528	http://dx.doi.org/10.1038/sj.onc.1202528			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208414				2022-12-25	WOS:000079191300002
J	Srivastava, RK; Srivastava, AR; Cho-Chung, YS; Longo, DL				Srivastava, RK; Srivastava, AR; Cho-Chung, YS; Longo, DL			Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells	ONCOGENE			English	Article						retinoic acid; caspase protein kinase A; cytochrome c; apoptosis	DEPENDENT PROTEIN-KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION; RECEPTOR-BETA; POLY(ADP-RIBOSE) POLYMERASE; CATALYTIC SUBUNIT; UP-REGULATION; CYTOCHROME-C; ELEMENT; SUPPRESSION; GROWTH	We investigated the intracellular mechanisms of retinoic acid (9-cis-RA, 13-cis-RA or all-trans-RA) and a cyclic AMP analog 8-Cl-cAMP on growth-inhibition and apoptosis in human ovarian cancer NIH: OVCAR-3 and OVCGR-8 cells, The cyclic AMP analog, 8-Cl-cAMP, acted synergistically with RA in inducing and activating retinoic acid receptor beta (RAR beta) which correlated with the growth inhibition, cell cycle arrest, and apoptosis in both cell types. In addition, combined treatment of cells with RA plus 8-Cl-cAMP resulted in the release of cytochrome c, loss in mitochondrial membrane potential and activation of caspase-3 followed by cleavage of anti-poly(ADP-ribose)polymerase and DNA-dependent protein kinase (catalytic subunit), Interestingly, inhibition of caspase-3 activation blocked RA plus 8-Cl-cAMP induced apoptosis, Furthermore, mutations in a CRE-related motif within the RAR beta promoter resulted in loss of both transcriptional activation of RAR beta and synergy between RA and 8-Cl-cAMP, Thus, RAR beta can mediate RA and/or cyclic AMP action in ovarian cancer cells by promoting apoptosis, Loss of RAR beta expression, therefore, may contribute to the tumorigenicity of human ovarian cancer cells, These findings suggest that RA and 8-Cl-cAMP act in a synergistic fashion in inducing apoptosis via caspase-3 activation, and may have potential for combination biotherapy for the treatment of malignant disease such as ovarian cancer.	NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA; NCI, Med Branch, Bethesda, MD 20892 USA; NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Srivastava, RK (corresponding author), NIA, Immunol Lab, NIH, Box 28,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Longo, Dan L./F-6022-2011					ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Heiden MGV, 1997, CELL, V91, P627; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hong Waun Ki, 1994, P597; Hong WK, 1995, CLIN CANCER RES, V1, P677; HOULE B, 1993, EXP CELL RES, V195, P163; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Srivastava RK, 1998, BREAST CANCER RES TR, V49, P97, DOI 10.1023/A:1005905723550; Srivastava RK, 1998, CLIN CANCER RES, V4, P755; SRIVASTAVA RK, 1998, IN PRESS MOL CELL BI; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TORTORA G, 1995, CLIN CANCER RES, V1, P377; VAVSSIARE JL, 1994, P NATL ACAD SCI USA, V91, P11752; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; ZHANG XK, 1994, CANCER RES, V54, P5663	45	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1755	1763		10.1038/sj.onc.1202464	http://dx.doi.org/10.1038/sj.onc.1202464			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208436				2022-12-25	WOS:000079025000010
J	Gardner, TG; Kearse, KP				Gardner, TG; Kearse, KP			Modification of the T cell antigen-receptor (TCR) complex by UDP-glucose : glycoprotein glucosyltransferase - TCR folding is finalized convergent with formation of alpha beta delta epsilon gamma epsilon complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; LINKED OLIGOSACCHARIDES; SCHIZOSACCHAROMYCES-POMBE; MOLECULAR CHAPERONE; INITIAL STEP; CLASS-I; CALNEXIN; PROTEINS; DEGRADATION; CHAINS	Most T lymphocytes express on their surfaces a multisubunit receptor complex, the T cell antigen receptor (TCR) containing alpha, beta, gamma, delta, epsilon, and zeta molecules, that has been widely studied as a model system for protein quality control. Although the parameters of TCR assembly are relatively well established, little information exists regarding the stage(s) of TCR oligomerization where folding of TCR proteins is completed. Here we evaluated the modification of TCR glycoproteins by the endoplasmic reticulum folding sensor enzyme UDP-glucose:glycoprotein glucosyltransferase (GT) as a unique and sensitive indicator of how TCR subunits assembled into multisubunit; complexes are perceived by the endoplasmic reticulum quality control system. These results demonstrate that all TCR subunits containing N-glycan were modified by GT and that TCR proteins were differentially reglucosylated during their assembly with partner TCR chains. importantly, these data show that GT modification of most TCR subunits persisted until as; sembly of CD3 alpha beta chains and formation of CD3-associated, disulfide-linked alpha beta heterodimers. These studies provide a novel evaluation of the folding status of TCR glycoproteins during their assembly into multisubunit complexes and are consistent with the concept that TCR folding is finalized convergent with formation of alpha beta delta epsilon gamma epsilon complexes.	E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27848 USA	University of North Carolina; East Carolina University	Kearse, KP (corresponding author), E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27848 USA.			Gardner, Terrence/0000-0002-6018-2083	NIAID NIH HHS [R29 AI42104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042104] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balow JP, 1996, J IMMUNOL METHODS, V189, P251, DOI 10.1016/0022-1759(95)00255-3; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; Dietrich J, 1998, J BIOL CHEM, V273, P26281, DOI 10.1074/jbc.273.41.26281; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Exley M, 1991, Semin Immunol, V3, P283; Fanchiotti S, 1998, J CELL BIOL, V143, P625, DOI 10.1083/jcb.143.3.625; Fernandez F, 1998, EMBO J, V17, P5877, DOI 10.1093/emboj/17.20.5877; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; GANNAN S, 1991, BIOCHEMISTRY-US, V30, P3098; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KEARSE KP, 1995, IMMUNITY, V2, P391; KEARSE KP, 1993, P NATL ACAD SCI USA, V90, P2348; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEE O, 1987, P NATL ACAD SCI USA, V84, P1374; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; Solheim JC, 1997, J IMMUNOL, V158, P541; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; VARKI A, 1994, METHOD ENZYMOL, V230, P16; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; Wu WY, 1996, J EXP MED, V184, P759, DOI 10.1084/jem.184.2.759; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	44	17	17	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14094	14099		10.1074/jbc.274.20.14094	http://dx.doi.org/10.1074/jbc.274.20.14094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318825	hybrid			2022-12-25	WOS:000080322200054
J	Abuin, G; Freitas, LHG; Colli, W; Alves, MJM; Schenkman, S				Abuin, G; Freitas, LHG; Colli, W; Alves, MJM; Schenkman, S			Expression of trans-sialidase and 85-kDa glycoprotein genes in Trypanosoma cruzi is differentially regulated at the post-transcriptional level by labile protein factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL INVASION; MESSENGER-RNA; SURFACE PROTEIN; BLOOD-STREAM; CYCLIC-AMP; DEVELOPMENTAL REGULATION; 3'-UNTRANSLATED REGION; TRYPOMASTIGOTE FORMS; SIGNAL-TRANSDUCTION; ADHESION MOLECULE	To adapt to different environments, Trypanosoma cruzi, the protozoan parasite that causes Chagas' disease, expresses a different set of proteins during development, To bean to understand the mechanism that controls this differential gene expression, we have analyzed the levels of amastin and trans-sialidase mRNAs and the mRNAs encoding members of the 85-kDa glycoprotein gene family, which are differentially expressed in the T, cruzi stages found in the mammalian host. Amastin mRNA is expressed predominantly in intracellular and proliferative amastigotes. trans-Sialidase mRNAs are found mostly in forms undergoing transformation from amastigotes to trypomastigotes inside infected cells, whereas mRNAs encoding the 85-kDa glycoproteins appear only in the infective trypomastigotes released from the cells. The genes coding for these mRNA species are constitutively transcribed in all stages of T, cruzi cells, suggesting that expression is controlled post-transcriptionally during differentiation. Inhibition of transcription by actinomycin D revealed that each mRNA species has a relatively long half-life in stages where it accumulates. In the case of the trans-sialidase and 85-kDa glycoprotein genes, mRNA accumulation was induced by treatment with the protein synthesis inhibitor cycloheximide at the stages that preceded the normal accumulation. Therefore, mRNA stabilization may account for mRNA accumulation. mRNA degradation could be promoted by proteins with high turnover, or stabilization could be promoted by forming a complex with the translational machinery at defined times in development. Identification of the factors that induce mRNA degradation or stabilization is essential to the understanding of control of gene expression in these organisms.	Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Immunol & Parasitol, BR-04023062 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo	Schenkman, S (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Immunol & Parasitol, Rua Botucatu 862 8 A, BR-04023062 Sao Paulo, Brazil.	sergio@ecb.epm.br	Schenkman, Sergio/A-9227-2013; Freitas-Junior, Lucio H/C-8677-2011; Alves, Maria Julia/K-8976-2012; Colli, Walter/ABA-5440-2021; Colli, Walter/G-1188-2012; Colli, Walter/AAW-7649-2021	Schenkman, Sergio/0000-0001-9353-8480; Freitas-Junior, Lucio H/0000-0002-8904-7897; Alves, Maria Julia/0000-0001-7211-9631; Colli, Walter/0000-0001-7305-4673				ABUIN G, 1989, MOL BIOCHEM PARASIT, V35, P229, DOI 10.1016/0166-6851(89)90209-0; ALVES MJM, 1986, MOL BIOCHEM PARASIT, V21, P75, DOI 10.1016/0166-6851(86)90081-2; AMORIM MI, 1993, ACTA TROP, V53, P99, DOI 10.1016/0001-706X(93)90022-4; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349; BORDA ES, 1991, MOL BIOCHEM PARASIT, V47, P91, DOI 10.1016/0166-6851(91)90151-U; BOSCHETTI MA, 1987, MOL BIOCHEM PARASIT, V24, P175, DOI 10.1016/0166-6851(87)90104-6; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUENKOVA M, 1995, J EXP MED, V181, P1693, DOI 10.1084/jem.181.5.1693; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; COSO OA, 1992, BIOCHEM J, V287, P443, DOI 10.1042/bj2870443; CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P385, DOI 10.1146/annurev.mi.47.100193.002125; DACRUZ MQ, 1991, EXPERIENTIA, V47, P89, DOI 10.1007/BF02041263; DIETRICH P, 1993, GENE, V125, P103, DOI 10.1016/0378-1119(93)90753-P; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; DOCAMPO R, 1993, MOL BIOCHEM PARASIT, V59, P305, DOI 10.1016/0166-6851(93)90228-P; Egima CM, 1996, MOL BIOCHEM PARASIT, V77, P115, DOI 10.1016/0166-6851(96)02582-0; FLINN HM, 1992, NUCLEIC ACIDS RES, V20, P755, DOI 10.1093/nar/20.4.755; FRAIDENRAICH D, 1993, P NATL ACAD SCI USA, V90, P10140, DOI 10.1073/pnas.90.21.10140; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Garcia ES, 1995, EXP PARASITOL, V81, P255, DOI 10.1006/expr.1995.1116; GIORDANO R, 1994, MOL BIOCHEM PARASIT, V65, P85, DOI 10.1016/0166-6851(94)90117-1; Giordano R, 1999, J BIOL CHEM, V274, P3461, DOI 10.1074/jbc.274.6.3461; GONZALESPERDOMO M, 1988, EXP PARASITOL, V66, P205, DOI 10.1016/0014-4894(88)90092-6; Gonzalez J, 1996, J EXP MED, V184, P1909, DOI 10.1084/jem.184.5.1909; GRAHAM SV, 1995, MOL CELL BIOL, V15, P5945; Graham SV, 1996, MOL BIOCHEM PARASIT, V80, P179, DOI 10.1016/0166-6851(96)02674-6; HALL BF, 1992, J EXP MED, V176, P313, DOI 10.1084/jem.176.2.313; HEATH S, 1990, MOL BIOCHEM PARASIT, V43, P133, DOI 10.1016/0166-6851(90)90138-C; Hotz HR, 1997, NUCLEIC ACIDS RES, V25, P3017, DOI 10.1093/nar/25.15.3017; HUANG J, 1991, MOL CELL BIOL, V11, P3180, DOI 10.1128/MCB.11.6.3180; LEGUIZAMON MS, 1994, INFECT IMMUN, V62, P3441; LIMA MF, 1989, MOL BIOCHEM PARASIT, V33, P159, DOI 10.1016/0166-6851(89)90030-3; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; MORRIS SA, 1992, EXP PARASITOL, V74, P69, DOI 10.1016/0014-4894(92)90140-6; Nozaki T, 1995, MOL BIOCHEM PARASIT, V75, P55, DOI 10.1016/0166-6851(95)02512-X; OCHATT CM, 1993, MOL BIOCHEM PARASIT, V57, P73, DOI 10.1016/0166-6851(93)90245-S; OLIVEIRA MM, 1993, MOL CELL BIOCHEM, V124, P91, DOI 10.1007/BF00929200; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PEREIRA IS, 1982, ACTA TROP, V39, P275; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; RAMIREZ MI, 1993, INFECT IMMUN, V61, P3636, DOI 10.1128/IAI.61.9.3636-3641.1993; Ribeirao M, 1997, GLYCOBIOLOGY, V7, P1237, DOI 10.1093/glycob/7.8.1237; ROLIN S, 1993, MOL BIOCHEM PARASIT, V61, P115, DOI 10.1016/0166-6851(93)90164-S; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1994, J BIOL CHEM, V269, P7970; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SCHENKMAN S, 1993, PARASITOL TODAY, V9, P218, DOI 10.1016/0169-4758(93)90017-A; Silva LHP, 1953, FOLIA CLIN BIOL, V20, P191; Stojdl DF, 1996, EXP PARASITOL, V83, P134, DOI 10.1006/expr.1996.0057; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; TSCHUDI C, 1994, INFECT AGENT DIS, V3, P181; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; WILSON ME, 1993, J BIOL CHEM, V268, P15731; ZINGALES B, 1987, MOL BIOCHEM PARASIT, V26, P135, DOI 10.1016/0166-6851(87)90137-X	62	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13041	13047		10.1074/jbc.274.19.13041	http://dx.doi.org/10.1074/jbc.274.19.13041			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224055	hybrid			2022-12-25	WOS:000080200400017
J	DeLuca, C; Petropoulos, L; Zmeureanu, D; Hiscott, J				DeLuca, C; Petropoulos, L; Zmeureanu, D; Hiscott, J			Nuclear I kappa B beta maintains persistent NF-kappa B activation in HIV-1-infected myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TUMOR-NECROSIS-FACTOR; PERIPHERAL-BLOOD MONOCYTES; CYTOKINE GENE-EXPRESSION; KINASE COMPLEX; MYELOMONOBLASTIC CELLS; TRANSCRIPTION FACTOR; ALPHA DEGRADATION; INDUCED APOPTOSIS; DNA-BINDING	Monocytic cells exhibit constitutive NF-kappa B activation upon infection with human immunodeficiency virus-1 (HIV-1). Because I kappa B beta has been implicated in maintaining NF-kappa B DNA binding, we sought to investigate whether I kappa B beta was involved in maintaining persistent NF-kappa B activation in HN-l-infected monocytic cell lines. I kappa B beta was present in the nucleus of HIV-l-infected cells and participated in the ternary complex formation with NF-kappa B and DNA. In contrast to uninfected cells, the addition of recombinant glutathione S-transferase-I kappa B alpha protein to preformed NF-kappa B DNA complexes from HIV-1-infected cell extracts did not completely dissociate the complexes, suggesting that I kappa B beta may protect NF-kappa B complexes from I kappa B alpha-mediated dissociation. Immunodepletion of I kappa B beta resulted in an NF-kappa B.DNA binding complex that was sensitive to I kappa B alpha-mediated dissociation, thus demonstrating the protective role of I kappa B beta. In addition, co-transfection studies with an NF-kappa B-dependent reporter construct demonstrated that I kappa B beta co-expression partially alleviated inhibition of NF-kappa B-mediated gene expression by I kappa B alpha, implying that I kappa B beta can maintain transcriptionally active NF-kappa B.DNA complexes. Furthermore, constitutive phosphorylation of I kappa B alpha was observed. Immunoprecipitation of the I kappa B kinase (IKK) complex followed by in vitro analysis of kinase activity demonstrated that IKK was constitutively activated in HIV-1-infected myeloid cells. Thus, virus-induced constitutive IKK activation, coupled with the maintenance of a ternary NF-kappa B.DNA complex by I kappa B beta, maintains persistent NF-kappa B activity in HN-l-infected myeloid cells.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.							ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; CROWE SM, 1994, J LEUKOCYTE BIOL, V56, P215, DOI 10.1002/jlb.56.3.215; DADDARIO M, 1992, J IMMUNOL, V148, P1222; DADDARIO M, 1990, J VIROL, V64, P6080, DOI 10.1128/JVI.64.12.6080-6089.1990; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; DeLuca C, 1996, J VIROL, V70, P5183, DOI 10.1128/JVI.70.8.5183-5193.1996; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; KORNBLUTH RS, 1994, J LEUKOCYTE BIOL, V56, P247, DOI 10.1002/jlb.56.3.247; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOLINA JM, 1990, J INFECT DIS, V161, P888, DOI 10.1093/infdis/161.5.888; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Perno CF, 1997, J LEUKOCYTE BIOL, V62, P1; PETERS AMJ, 1991, CLIN IMMUNOL IMMUNOP, V61, P343, DOI 10.1016/S0090-1229(05)80006-6; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; ROULSTON A, 1992, J EXP MED, V175, P751, DOI 10.1084/jem.175.3.751; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	54	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13010	13016		10.1074/jbc.274.19.13010	http://dx.doi.org/10.1074/jbc.274.19.13010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224051	hybrid			2022-12-25	WOS:000080200400013
J	Tanaka, K; Nigg, EA				Tanaka, K; Nigg, EA			Cloning and characterization of the murine Nek3 protein kinase, a novel member of the NIMA family of putative cell cycle regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; CHROMATIN CONDENSATION; MITOTIC REGULATOR; PHOSPHORYLATION SITES; EXPRESSION PATTERN; VERTEBRATE CELLS; P34CDC2 KINASE; ACTIVATION; MITOSIS; GENE	We have cloned and characterized murine Nek3 (NIMA-related kinase 3), a novel mammalian gene product structurally related to the cell cycle-regulatory kinase NIMA of Aspergillus nidulans. By RNase protection, low levels of Nek3 expression could be detected in all organs examined, regardless of proliferative index. In contrast to Nek1 and Nek2, Nek3 levels were not particularly elevated in either the male or the female germ line. Nek3 levels showed at most marginal variations through the cell cycle, but they were elevated in G(0)-arrested, quiescent fibroblasts. Furthermore, no cell cycle-dependent changes in Nek3 activity could be detected, and no effects upon cell cycle progression could be observed upon antibody microinjection or overexpression of either wild-type or catalytically inactive Nek3. Finally, Nek3 was found to be a predominantly cytoplasmic enzyme. These data indicate that Nek3 differs from previously characterized Neks with regard to all parameters investigated, including organ specificity of expression, cell cycle dependence of expression and activity, and subcellular localization. Hence, the structural similarity between mammalian Neks may not necessarily be indicative of a common function, and it is possible that some members of this kinase family may perform functions that are not directly related to cell cycle control.	Univ Geneva, Dept Mol Biol Sci 2, CH-1211 Geneva 4, Switzerland	University of Geneva	Nigg, EA (corresponding author), Univ Geneva, Dept Mol Biol Sci 2, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.			nigg, erich/0000-0003-4835-5719; Tanaka, Kayoko/0000-0002-2905-3603				Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; BERGEN LG, 1984, J BACTERIOL, V159, P114, DOI 10.1128/JB.159.1.114-119.1984; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1997, METHOD ENZYMOL, V283, P270; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Krien MJE, 1998, J CELL SCI, V111, P967; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1993, J BIOL CHEM, V268, P8769; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; REUTER R, 1986, FEBS LETT, V201, P25, DOI 10.1016/0014-5793(86)80564-6; Rhee K, 1997, DEVELOPMENT, V124, P2167; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SCHWEITZER B, 1992, MOL GEN GENET, V234, P164, DOI 10.1007/BF00272358; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; Wu L, 1998, J CELL BIOL, V141, P1575, DOI 10.1083/jcb.141.7.1575; Ye X S, 1997, Prog Cell Cycle Res, V3, P221; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	42	32	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13491	13497		10.1074/jbc.274.19.13491	http://dx.doi.org/10.1074/jbc.274.19.13491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224116	Green Published, hybrid			2022-12-25	WOS:000080200400078
J	Thomas, F; Serratrice, G; Beguin, C; Saint Aman, E; Pierre, JL; Fontecave, M; Laulhere, JP				Thomas, F; Serratrice, G; Beguin, C; Saint Aman, E; Pierre, JL; Fontecave, M; Laulhere, JP			Calcein as a fluorescent probe for ferric iron - Application to iron nutrition in plant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOMATO MUTANT CHLORONERVA; MAMMALIAN-CELLS; K562 CELLS; POOL; NICOTIANAMINE; TRANSFERRIN; CHELATORS; SOYBEANS; CATIONS; ANALOGS	The recent use of calcein (CA) as a fluorescent probe for cellular iron has been shown to reflect the nutritional status of iron in mammalian cells (Breuer, W, Epsztejn, S,, and Cabantchik, Z, I. (1995) J, Biol. Chem. 270, 24209-24215), CA was claimed to be a chemosensor for iron(II), to measure the labile iron pool and the concentration of cellular free iron(II), We first study here the thermodynamic and kinetic properties of iron binding by CA. Chelation of a first iron(III) involves one aminodiacetic arm and a phenol. The overall stability constant log beta(111) of Fe(III)CAH is 33.9, The free metal ion concentration is pFe(III) = 20.3, A (Fe-III)(2) CA complex can be formed, A reversible iron(III) exchange from Fe(III)CAH to citrate and nitrilotriacetic acid is evidenced when these ligands are present in large excess. The kinetics of iron(III) exchange by CA is compatible with metabolic studies. The low reduction potential of Fe(III)CAH shows that the ferric form is highly stabilized. CA fluorescence is quenched by 85% after Fe-III chelation but by only 20% using Fe-II. Real time iron nutrition by Arabidopsis thaliana cells has been measured by fluorimetry, and the iron buffer Fe(III)CAH + CA was used as source of iron. As a siderophore, Fe(III)CAH promotes cell growth and regreening of iron-deficient cells more rapidly than Fe(III)EDTA. We conclude that CA is a good chemosensor for iron(III) in cells and biological fluids, but not for Fe(II), We discuss the interest of quantifying iron buffers in biochemical studies of iron, in vitro as well as in cells.	Univ Grenoble 1, EP 1087 CNRS, CEA, Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 9, France; Univ Grenoble 1, Lab Electrochim Organ & Photochim Redox, UMR 5630, F-38041 Grenoble 9, France; Univ Grenoble 1, UMR CNRS 5616, Lab Chim Biomimet, F-38041 Grenoble 9, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Laulhere, JP (corresponding author), Univ Grenoble 1, EP 1087 CNRS, CEA, Lab Chim & Biochim,Ctr Redox Biol, 17 Rue Martyrs, F-38054 Grenoble 9, France.	laulhere@cbcrb.ceng.cea.fr	fabrice, thomas/H-3789-2011					BARNESS E, 1992, PLANT PHYSIOL, V99, P1329, DOI 10.1104/pp.99.4.1329; BASTIAN R, 1956, ANAL CHEM, V28, P459, DOI 10.1021/ac50161a014; BECKER R, 1995, PLANT PHYSIOL, V108, P269, DOI 10.1104/pp.108.1.269; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; Breuer W, 1996, FEBS LETT, V382, P304, DOI 10.1016/0014-5793(96)00190-1; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; Breuer W, 1997, FEBS LETT, V403, P213, DOI 10.1016/S0014-5793(97)00056-2; BROWN JC, 1971, PLANT PHYSIOL, V47, P836, DOI 10.1104/pp.47.6.836; Cabantchik ZI, 1996, ANAL BIOCHEM, V233, P221, DOI 10.1006/abio.1996.0032; Caris C, 1995, BIOCHEM J, V312, P879, DOI 10.1042/bj3120879; CHABEREK S, 1959, ORGANIC SEQUESTERING, P174; CRICHTON R, 1991, INORGANIC BIOCH IRON, P131; CRUMBLISS AL, 1991, HDB MICROBIAL IRON C, P177; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Fages F, 1996, J ORG CHEM, V61, P3956, DOI 10.1021/jo960191h; FONTECAVE M, 1991, BIOL MET, V4, P133, DOI 10.1007/BF01141302; GANS P, 1985, J CHEM SOC DALTON, P1195, DOI 10.1039/dt9850001195; Glickstein H, 1996, BLOOD, V87, P4871, DOI 10.1182/blood.V87.11.4871.bloodjournal87114871; HARRIS WR, 1981, J AM CHEM SOC, V103, P2667, DOI 10.1021/ja00400a030; LAULHERE JP, 1969, PHYSIOL VEG, V7, P277; LAULHERE JP, 1972, PHYSIOL VEG, V10, P589; LONGNECKER N, 1990, PLANT PHYSIOL, V92, P17, DOI 10.1104/pp.92.1.17; Martell A. E., 1974, CRITICAL STABILITY C; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nudelman R, 1998, J MED CHEM, V41, P1671, DOI 10.1021/jm970581b; PICH A, 1991, J EXP BOT, V42, P1517, DOI 10.1093/jxb/42.12.1517; PRICE CA, 1968, ANN REV PLANT PHYSIO, V19, P239, DOI 10.1146/annurev.pp.19.060168.001323; Ringbom A., 1963, COMPLEXATION ANAL CH; SAARI LA, 1984, ANAL CHEM, V56, P810, DOI 10.1021/ac00268a051; SCHUBERT J, 1963, IR MET INT S BERL, P467; STEPHAN UW, 1995, J EXP BOT, V46, P531, DOI 10.1093/jxb/46.5.531; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Weizman H, 1996, J AM CHEM SOC, V118, P12368, DOI 10.1021/ja9610646; WILLIAMS RJP, 1982, FEBS LETT, V140, P3, DOI 10.1016/0014-5793(82)80508-5; ZHANG FS, 1991, PLANT PHYSIOL, V97, P1302, DOI 10.1104/pp.97.4.1302	35	101	103	2	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13375	13383		10.1074/jbc.274.19.13375	http://dx.doi.org/10.1074/jbc.274.19.13375			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224100	hybrid			2022-12-25	WOS:000080200400062
J	Rato, AG; Pedrero, JG; Martinez, MA; Del Rio, B; Lazo, PS; Ramos, S				Rato, AG; Pedrero, JG; Martinez, MA; Del Rio, B; Lazo, PS; Ramos, S			Melatonin blocks the activation of estrogen receptor for DNA binding	FASEB JOURNAL			English	Article						antiestrogen; breast cancer; estradiol; MCF7 cells	BREAST-CANCER-CELLS; PINEAL HORMONE MELATONIN; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; RESPONSE ELEMENTS; RETINOIC ACID; CALMODULIN; INHIBITION; ESTRADIOL; INVITRO	The present study shows that melatonin prevents, within the first cell cycle, the estradiol-induced growth of synchronized MCF7 breast cancer cells. By using nuclear extracts of these cells, we first examined the binding of estradiol-estrogen receptor complexes to estrogen-responsive elements and found that the addition of estradiol to whole cells activates the binding of the estrogen receptor to DNA whereas melatonin blocks this interaction. By contrast, melatonin neither affects the binding of estradiol to its receptor nor the receptor nuclear localization. Moreover, we also show that addition of estradiol to nuclear extracts stimulates the binding of estrogen receptor to DNA, but this activation is also prevented by melatonin. The inhibitory effect caused by melatonin is saturable at nanomolar concentrations and does not appear to be mediated by RZR nuclear receptors. The effect is also specific, since indol derivatives do not cause significant inhibition. Furthermore, we provide evidence that melatonin does not interact with the estrogen receptor in the absence of estradiol. Together, these results demonstrate that melatonin interferes with the activation of estrogen receptor by estradiol. The effect of melatonin suggests the presence of a receptor that, upon melatonin addition, destabilizes the binding of the estradiol-estrogen receptor complex to the estrogen responsive element.	Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, E-33006 Oviedo, Spain; Hosp de Jove, Gijon 33212, Spain	University of Oviedo	Rato, AG (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, E-33006 Oviedo, Spain.		Lazo, Pedro/C-4087-2008; del Rio, beatriz/L-3082-2014; Pedrero, Juana María García/AAP-4251-2021; Lazo, Pranvera/I-5299-2019	Lazo, Pedro/0000-0002-1278-6878; del Rio, beatriz/0000-0001-8107-1975; Pedrero, Juana María García/0000-0002-5891-9488; Lazo, Pranvera/0000-0002-7202-4058				BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BENITEZKING G, 1991, BRAIN RES, V557, P289, DOI 10.1016/0006-8993(91)90146-M; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; BROWN M, 1990, J BIOL CHEM, V265, P11238; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Castano E, 1997, BIOCHEM J, V326, P149, DOI 10.1042/bj3260149; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; Conway S, 1997, FEBS LETT, V407, P121, DOI 10.1016/S0014-5793(97)00315-3; COS S, 1989, J PINEAL RES, V6, P221, DOI 10.1111/j.1600-079X.1989.tb00418.x; DANFORTH DN, 1983, NATURE, V305, P323, DOI 10.1038/305323a0; DEMIRPENCE E, 1994, CANCER RES, V54, P1458; Gilad E, 1997, J CLIN ENDOCR METAB, V82, P2535, DOI 10.1210/jc.82.8.2535; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/endo.138.1.4824; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hardcastle IR, 1996, J MED CHEM, V39, P999, DOI 10.1021/jm9505472; HILL SM, 1988, CANCER RES, V48, P6121; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JORDAN VC, 1990, CANCER PREVENTION, P1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LISSONI P, 1995, BRIT J CANCER, V71, P854, DOI 10.1038/bjc.1995.164; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAESTRONI GJM, 1994, CANCER RES, V54, P4740; MEDIAVILLA MD, 1992, J PINEAL RES, V13, P13, DOI 10.1111/j.1600-079X.1992.tb00049.x; MEYER ME, 1989, CELL, V37, P432; MIGLIACCIO S, 1993, MOL ENDOCRINOL, V7, P1133, DOI 10.1210/me.7.9.1133; MOLIS TM, 1995, J PINEAL RES, V18, P93, DOI 10.1111/j.1600-079X.1995.tb00146.x; MOLLIS TM, 1994, MOL ENDOCRINOL, V8, P1681; MORREY KM, 1994, J IMMUNOL, V153, P2671; MURDOCH FE, 1991, MOL CELL ENDOCRINOL, V78, pC103, DOI 10.1016/0303-7207(91)90114-8; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; Pratt MAC, 1996, J BIOL CHEM, V271, P20346, DOI 10.1074/jbc.271.34.20346; Reiter R J, 1980, Endocr Rev, V1, P109; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; Romero MP, 1998, FASEB J, V12, P1401, DOI 10.1096/fasebj.12.13.1401; Sainz RM, 1995, J PINEAL RES, V19, P178, DOI 10.1111/j.1600-079X.1995.tb00187.x; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZBARCELO EJ, 1990, P SOC EXP BIOL MED, V194, P103, DOI 10.3181/00379727-194-43063; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay GB, 1998, CANCER RES, V58, P877; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; WILSON ST, 1992, J CLIN ENDOCR METAB, V75, P669, DOI 10.1210/jc.75.2.669; YANGMIN N, 1996, MOL ENDOCRINOL, V10, P14	49	103	104	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					857	868		10.1096/fasebj.13.8.857	http://dx.doi.org/10.1096/fasebj.13.8.857			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224229				2022-12-25	WOS:000080372500009
J	Forbes, JR; Hsi, G; Cox, DW				Forbes, JR; Hsi, G; Cox, DW			Role of the copper-binding domain in the copper transport function of ATP7B, the P-type ATPase defective in Wilson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MENKES DISEASE; CANDIDATE GENE; IRON UPTAKE; EXPRESSION; PROTEIN; YEAST; TRAFFICKING; ENCODES; IDENTIFICATION	We have analyzed the functional effect of site directed mutations and deletions in the copper-binding domain of ATP7B (the copper transporting P-type ATPase defective in Wilson disease) using a yeast complementation assay. We have shown that the sixth copper-binding motif alone is sufficient, but not essential, for normal ATP7B function. The N-terminal two or three copper-binding motifs alone are not sufficient for ATP7B function. The first two or three N-terminal motifs of the copper-binding domain are not equivalent to, and cannot replace, the C-terminal motifs when placed in the same sequence position with respect to the transmembrane channel. From our data, we propose that the copper-binding motifs closest to the channel are required for the copper-transport function of ATP7B. We propose that cooperative copper binding to the copper-binding domain of ATP7B is not critical for copper transport function, but that cooperative copper binding involving the N-terminal two or three copper-binding motifs may be involved in initiating copper-dependent intracellular trafficking. Our data also suggest a functional difference between the copper-binding domains of ATP7A and ATP7B.	Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	University of Alberta	Cox, DW (corresponding author), Univ Alberta, Dept Med Genet, 8-39 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	diane.cox@ualberta.ca						[Anonymous], 1995, METABOLIC BASIS INHE; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bingham MJ, 1996, AM J PHYSIOL-GASTR L, V271, pG741, DOI 10.1152/ajpgi.1996.271.5.G741; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DIJKSTRA M, 1995, J CLIN INVEST, V95, P412, DOI 10.1172/JCI117670; Dijkstra M, 1996, J HEPATOL, V25, P37, DOI 10.1016/S0168-8278(96)80325-4; EIBLE R, 1992, BIOTECHNIQUES, V13, P18; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SOLIOZ M, 1998, ADV MOL CEL A&B, V23, P167; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Theophilos MB, 1996, HUM MOL GENET, V5, P1619, DOI 10.1093/hmg/5.10.1619; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; ZUBENKO GS, 1980, GENETICS, V96, P137	37	129	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12408	12413		10.1074/jbc.274.18.12408	http://dx.doi.org/10.1074/jbc.274.18.12408			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212214	hybrid			2022-12-25	WOS:000080056800034
J	Jamieson, ER; Jacobson, MP; Barnes, CM; Chow, CS; Lippard, SJ				Jamieson, ER; Jacobson, MP; Barnes, CM; Chow, CS; Lippard, SJ			Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; ANTICANCER DRUG CISPLATIN; DOUBLE-STRANDED DNA; EQUILIBRIUM BINDING; CRYSTAL-STRUCTURE; MAJOR ADDUCT; DUPLEX DNA; PROTEIN; CROSS; JUNCTION	The high mobility group (HMG) domain is a DNA-binding motif found in the non-histone chromosomal proteins, HMG1 and HMG2, and some transcription factors. Experimental evidence has demonstrated that HMG-domain proteins can play a role in sensitizing cells to the anticancer drug cisplatin. Fluorescence resonance energy transfer (FRET) experiments were performed in the present study to investigate structural changes that accompany complex formation between the HMG domain B of HMG1 and a cisplatin-modified, 20-base pair double-stranded DNA probe containing fluorescein and rhodamine tethered at its two ends. The binding affinity of HMG1 domain B for the cisplatin-modified DNA probe was investigated in fluorescence titration experiments, and a value of 60 +/- 30 nM was determined for the dissociation constant. Single photon counting methods were employed to measure the fluorescence lifetime of the fluorescein donor in the presence and absence of HMG1 domain B. These FRET experiments revealed a distance change that was used to estimate a bend angle of 80-95 degrees for the cisplatin-modified DNA upon protein binding. Stopped-flow fluorescence spectroscopic experiments afforded kinetic parameters for HMG1 domain B binding to the cisplatin-modified DNA probe, with k(on) = 1.1 +/- 0.1 x 10(9) m(-1) s(-1) and k(off) = 30 +/- 4 s(-1).	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Jacobson, Matthew/Y-5161-2018	Jacobson, Matthew/0000-0001-6262-655X	NCI NIH HHS [CA34992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034992, R01CA034992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; EIS PS, 1993, BIOCHEMISTRY-US, V32, P13852, DOI 10.1021/bi00213a014; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOHLKE C, 1994, P NATL ACAD SCI USA, V91, P11660, DOI 10.1073/pnas.91.24.11660; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; HEYDUK T, 1992, BIOCHEMISTRY-US, V31, P5165, DOI 10.1021/bi00137a011; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; JaresErijman EA, 1996, J MOL BIOL, V257, P597, DOI 10.1006/jmbi.1996.0188; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; LEPRE CA, 1990, NUCL ACIDS MOL BIOL, V4, P9, DOI [DOI 10.1007/978-3-642-84150-7-2, DOI 10.1007/978-3-642-84150-7]; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Mahtab R, 1996, J AM CHEM SOC, V118, P7028, DOI 10.1021/ja961602e; McANulty MM, 1996, MUTAT RES-DNA REPAIR, V362, P75, DOI 10.1016/0921-8777(95)00037-2; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; O'Connor D. V., 1984, TIME CORRELATED SING; Ozaki H, 1997, BIOCHEM BIOPH RES CO, V231, P553, DOI 10.1006/bbrc.1997.6138; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PIL P, 1997, ENCY CANC, V1, P392; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Poklar N, 1996, P NATL ACAD SCI USA, V93, P7606, DOI 10.1073/pnas.93.15.7606; Press W., 1992, NUMERICAL RECIPES FO; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SHA M, 1995, J BIOL CHEM, V270, P19325, DOI 10.1074/jbc.270.33.19325; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TUSCHL T, 1994, SCIENCE, V266, P785, DOI 10.1126/science.7973630; URBANKE C, 1990, BIOCHEMISTRY-US, V29, P1744, DOI 10.1021/bi00459a012; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054	42	66	70	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12346	12354		10.1074/jbc.274.18.12346	http://dx.doi.org/10.1074/jbc.274.18.12346			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212205	hybrid, Green Published			2022-12-25	WOS:000080056800025
J	Sayegh, R; Auerbach, SD; Li, X; Loftus, RW; Husted, RF; Stokes, JB; Thomas, CP				Sayegh, R; Auerbach, SD; Li, X; Loftus, RW; Husted, RF; Stokes, JB; Thomas, CP			Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5 '-flanking region of the human epithelial sodium channel alpha subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	31st Congress of the American-Society-of-Nephrology	OCT 25-28, 1998	PHILADELPHIA, PENNSYLVANIA	Amer Soc Nephrol			MEDULLARY COLLECTING DUCT; SENSITIVE NA+ CHANNEL; MINERALOCORTICOID HORMONES; HOMOLOGOUS SUBUNITS; LIQUID CLEARANCE; RECEPTOR; ALDOSTERONE; ENHANCEMENT; MECHANISM; CULTURE	In airway and renal epithelia, the glucocorticoid-mediated stimulation of amiloride-sensitive Na+ transport is associated with increased expression of the epithelial Na+ channel Lu subunit (alpha ENaC), In H441 lung cells, 100 nM dexamethasone increases amiloride-sensitive short-circuit current (3.3 mu A/cm(2) to 7.5 mu A/cm(2)), correlating with a 5-fold increase in aENaC mRNA expression that could be blocked by actinomycin D, To explore transcriptional regulation of alpha ENaC, the human alpha ENaC 5'-flanking region was cloned and tested in H441 cells. By deletion analysis, a similar to 150-base pair region 5' to the upstream promoter was identified that, when stimulated with 100 nM dexamethasone, increased luciferase expression 15-fold. This region, which contains two imperfect GREs, also functioned when coupled to a heterologous promoter. When individually tested, only the downstream GRE functioned in cis and bound GR in a gel mobility shift assay. In the M-l collecting duct line Na+ transport, m alpha ENaC expression and luciferase expression from alpha ENaC genomic fragments were also increased by 100 nM dexamethasone. In a colonic cell line, HT29, trans-activation via a heterologously expressed glucocorticoid receptor restored glucocorticoid-stimulated alpha ENaC gene transcription. We conclude that glucocorticoids stimulate alpha ENaC expression in kidney and lung via activation of a hormone response element in the 5'-flanking region of h alpha ENaC and this response, in part, is the likely basis for the up-regulation of Na+ transport in these sites.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52246 USA; Vet Affairs Med Ctr, Iowa City, IA 52246 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Thomas, CP (corresponding author), Univ Iowa Hosp & Clin, Dept Internal Med, Div Nephrol, 200 Hawkins Dr, Iowa City, IA 52242 USA.			Thomas, Christie/0000-0002-5989-9685	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 52617] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; Escoubet B, 1997, AM J PHYSIOL-CELL PH, V272, pC1482, DOI 10.1152/ajpcell.1997.272.5.C1482; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GarayRojas E, 1996, GENE, V170, P173, DOI 10.1016/0378-1119(95)00896-9; GOMEZSANCHEZ EP, 1990, AM J PHYSIOL, V258, pE649, DOI 10.1152/ajpendo.1990.258.4.E649; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; HUSTED RF, 1990, J CLIN INVEST, V86, P498, DOI 10.1172/JCI114736; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; LAPLACE JR, 1992, J CLIN INVEST, V90, P1370, DOI 10.1172/JCI116003; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; ROSS ME, 1990, J NEUROSCI, V10, P520; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699; STOOS BA, 1991, KIDNEY INT, V39, P1168, DOI 10.1038/ki.1991.148; TCHEPICHEV S, 1995, AM J PHYSIOL-CELL PH, V269, pC805, DOI 10.1152/ajpcell.1995.269.3.C805; Thomas CP, 1998, AM J PHYSIOL-CELL PH, V274, pC1312, DOI 10.1152/ajpcell.1998.274.5.C1312; Thomas CP, 1996, J BIOL CHEM, V271, P26062, DOI 10.1074/jbc.271.42.26062; Venkatesh VC, 1997, AM J PHYSIOL-LUNG C, V273, pL227, DOI 10.1152/ajplung.1997.273.1.L227; Volk KA, 1995, J CLIN INVEST, V96, P2748, DOI 10.1172/JCI118344	30	127	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12431	12437		10.1074/jbc.274.18.12431	http://dx.doi.org/10.1074/jbc.274.18.12431			7	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212217	hybrid			2022-12-25	WOS:000080056800037
J	Wang, GQ; Li, SS; Lin, HN; Brumbaugh, EE; Huang, CH				Wang, GQ; Li, SS; Lin, HN; Brumbaugh, EE; Huang, CH			Effects of various numbers and positions of cis double bonds in the sn-2 acyl chain of phosphatidylethanolamine on the chain-melting temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-TRANSITION TEMPERATURES; MOLECULAR MECHANICS; HETEROACID PHOSPHATIDYLCHOLINES; UNSATURATION; HYDROCARBONS; BILAYERS; SERIES; GEL	In an attempt to investigate systematically the effects of various single and multiple cis carbon-carbon double bonds in the sn-2 acyl chains of natural phospholipids on membrane properties, we have de novo synthesized unsaturated C-20 fatty acids comprised of single or multiple methylene-interrupted cis double bonds. Subsequently, 15 molecular species of phosphatidylethanolamine (PE) with sn-l C-20-saturated and sn-2 C-20-unsaturated acyl chains were semi-synthesized by acylation of C-20-lysophosphatidylcholine with unsaturated C-20 fatty acids followed by phospholipase D-catalyzed base-exchange reaction in the presence of excess ethanolamine, The gel-to-liquid crystalline phase transitions of these 15 mixed-chain PE, in excess H2O, were investigated by high resolution differential scanning calorimetry. In addition, the energy-minimized structures of these sn-l C-20-saturated/sn-2 C-20-unsaturated PE were simulated by molecular mechanics calculations. It is shown that the successive introduction of cis double bonds into the sn-2 acyl chain of C(20):C(20)PE can affect the gel-to-liquid crystalline phase transition temperature, T-m, of the lipid bilayer in some characteristic ways; moreover, the effect depends critically on the position of cis double bonds in the sn-2 acyl chain. Specifically, we have constructed a novel T-m diagram for the 15 species of unsaturated PE, from which the effects of the number and the position of cis double bonds on T-m can be examined simultaneously in a simple, direct, and unifying manner. Interestingly, the characteristic T-m profiles exhibited by different series of mixed-chain PE with increasing degree of unsaturation can be interpreted in terms of structural changes associated with acyl chain unsaturation.	Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Huang, CH (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem, Box 440, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM-17452] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017452] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLINGER NL, 1989, J AM CHEM SOC, V111, P8551, DOI 10.1021/ja00205a001; BATTA AK, 1984, J CHROMATOGR, P284; Christie W.W., 1967, CHEM PHYS LIPIDS, V1, P407; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; COOLBEAR KP, 1983, BIOCHEMISTRY-US, V22, P1466, DOI 10.1021/bi00275a022; HITCHCOCK PB, 1974, P NATL ACAD SCI USA, V71, P3036, DOI 10.1073/pnas.71.8.3036; HUANG C, 1994, BBA-BIOMEMBRANES, V1189, P7, DOI 10.1016/0005-2736(94)90273-9; Huang C, 1998, BBA-BIOMEMBRANES, V1373, P282, DOI 10.1016/S0005-2736(98)00092-3; HUANG C, 1998, CELL PHYSL SOURCE BO, P39; Huang CH, 1997, J BIOL CHEM, V272, P21917, DOI 10.1074/jbc.272.35.21917; Huang CH, 1996, ARCH BIOCHEM BIOPHYS, V334, P135, DOI 10.1006/abbi.1996.0438; KEOUGH KMW, 1987, BIOCHIM BIOPHYS ACTA, V902, P1, DOI 10.1016/0005-2736(87)90129-5; KEOUGH KMW, 1990, BIOCHEM SOC T, V18, P835, DOI 10.1042/bst0180835; Li SS, 1996, J COMPUT CHEM, V17, P1013, DOI 10.1002/(SICI)1096-987X(199606)17:8<1013::AID-JCC10>3.0.CO;2-F; Li SS, 1998, J BIOL CHEM, V273, P19009, DOI 10.1074/jbc.273.30.19009; LI SS, 1994, BIOPHYS J, V66, P2005, DOI 10.1016/S0006-3495(94)80993-2; LIN HN, 1990, BIOCHEMISTRY-US, V29, P7063, DOI 10.1021/bi00482a017; NIEBYLSKI CD, 1994, BIOPHYS J, V67, P2387, DOI 10.1016/S0006-3495(94)80725-8; OSBOND JM, 1961, J CHEM SOC, P2779, DOI 10.1039/jr9610002779; SanchezMigallon M, 1996, BBA-BIOMEMBRANES, V1279, P251; VALICENTI AJ, 1985, LIPIDS, V20, P234, DOI 10.1007/BF02534194; Wang GQ, 1997, BIOPHYS J, V73, P283, DOI 10.1016/S0006-3495(97)78069-X; WANG ZQ, 1994, J BIOL CHEM, V269, P23491	23	17	17	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12289	12299		10.1074/jbc.274.18.12289	http://dx.doi.org/10.1074/jbc.274.18.12289			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212198	hybrid			2022-12-25	WOS:000080056800018
J	Madiai, F; Hackshaw, KV; Chiu, IM				Madiai, F; Hackshaw, KV; Chiu, IM			Characterization of the entire transcription unit of the mouse fibroblast growth factor 1 (FGF-1) gene - Tissue-specific expression of the FGF-1.A mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; SMOOTH-MUSCLE CELLS; FACTOR FAMILY; FACTOR-I; DIFFERENTIAL EXPRESSION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; CARCINOMA-CELLS; NERVOUS-SYSTEM; C-MYB	Fibroblast growth factor 1 (FGF-1, also known as acidic FGF) is a mitogen for a variety of mesoderm- and neuroectoderm-derived cells, as well as an angiogenic factor in vivo. It has been implicated in angiogenic diseases including atherosclerosis, cancer and inflammatory diseases. In the present study, the entire transcriptional unit of the mouse FGF-1 gene, including four promoters, is characterized. By nucleotide sequence and RNase protection analyses, we have determined that its 3'-end resides 3.2 kilobase pairs downstream from the stop codon. We have previously cloned and characterized the mouse homologue of the human 1B promoter, as well as a novel upstream untranslated exon. In order to elucidate the regulatory mechanism of FGF-I gene expression, the mouse promoter containing TATA and CAAT consensus sequences (FGF-1.A) was isolated from a P1 library and characterized. We further determined that the mouse heart is the most abundant source for the FGF-1.A mRNA. Finally, via both RNase protection analysis and 5'-rapid amplification of cDNA ends, we determined the transcription start site of the FGF-1.A mRNA.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.	chiu.1@osu.edu	Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [R01CA45611] Funding Source: Medline; NIAID NIH HHS [K11AI01048] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001048] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam KY, 1996, J BIOL CHEM, V271, P30263, DOI 10.1074/jbc.271.47.30263; ANDREWS DF, 1990, ONCOGENE, V5, P441; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Burgess W. H., 1996, P154; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIU IM, 1990, FID RES FDN, V3, P57; CHIU IM, 1990, ONCOGENE, V5, P755; Chotani MA, 1997, CELL GROWTH DIFFER, V8, P999; CHOTANI MA, 1995, NUCLEIC ACIDS RES, V23, P434, DOI 10.1093/nar/23.3.434; COULIER F, 1991, ANN NY ACAD SCI, V638, P53, DOI 10.1111/j.1749-6632.1991.tb49017.x; CRUMLEY G, 1990, BIOCHEM BIOPH RES CO, V171, P7, DOI 10.1016/0006-291X(90)91348-V; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; Fulton GJ, 1997, J VASC SURG, V25, P453, DOI 10.1016/S0741-5214(97)70255-6; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; Gunn J, 1997, CIRC RES, V80, P520, DOI 10.1161/01.RES.80.4.520; Hackshaw KV, 1996, GENE, V180, P131, DOI 10.1016/S0378-1119(96)00433-7; Hicks K K, 1996, P R Health Sci J, V15, P179; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; HUGHES SE, 1993, LAB INVEST, V69, P173; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; Liu Y, 1998, J BIOL CHEM, V273, P19269, DOI 10.1074/jbc.273.30.19269; LU DL, 1994, EUR J BIOCHEM, V222, P753, DOI 10.1111/j.1432-1033.1994.tb18921.x; Madiai F, 1996, GENE, V179, P231, DOI 10.1016/S0378-1119(96)00365-4; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; Philippe JM, 1996, DNA CELL BIOL, V15, P703, DOI 10.1089/dna.1996.15.703; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; PIRVOLA U, 1995, P NATL ACAD SCI USA, V92, P9269, DOI 10.1073/pnas.92.20.9269; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THOMAS D, 1991, DEV BRAIN RES, V59, P117, DOI 10.1016/0165-3806(91)90091-V; WANG WP, 1991, ONCOGENE, V6, P1521; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	61	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11937	11944		10.1074/jbc.274.17.11937	http://dx.doi.org/10.1074/jbc.274.17.11937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207015	hybrid			2022-12-25	WOS:000079834800071
J	Takasaki, A; Hayashi, N; Matsubara, M; Yamauchi, E; Taniguchi, H				Takasaki, A; Hayashi, N; Matsubara, M; Yamauchi, E; Taniguchi, H			Identification of the calmodulin-binding domain of neuron-specific protein kinase C substrate protein CAP-22/NAP-22 - Direct involvement of protein myristoylation in calmodulin-target protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-MYRISTOYLATION; CATALYTIC SUBUNIT; BOVINE BRAIN; MARCKS; PEPTIDES; PHOSPHORYLATION; MYRISTYLATION; RECOVERIN; COMPLEX; PURIFICATION	Various proteins in the signal transduction pathways as well as those of viral origin have been shown to be myristoylated, Although the modification is often essential for the proper functioning of the modified protein, the mechanism by which the modification exerts its effects is still largely unknown. Brain-specific protein kinase C substrate, CAP-23/NAP-22, which is involved in the synaptogenesis and neuronal plasticity, binds calmodulin, but the protein lacks any canonical calmodulin-binding domain. In the present report, we show that CAP-23/NAP-22 isolated from rat brain is myristoylated and that the modification is directly involved in its interaction with calmodulin. Myristoylated and non-myristoylated recombinant proteins were produced in Escherichia coli, and their calmodulin-binding properties were examined. Only the former bound to calmodulin, Synthetic peptides based on the N-terminal sequence showed similar binding properties to calmodulin, only when they were myristoylated, The calmodulin-binding site narrowed down to the myristoyl moiety together with a nine-amino acid N-terminal basic domain. Phosphorylation of a single serine residue in the N-terminal domain (Ser(5)) by protein kinase C abolished the binding. Furthermore, phosphorylation of CAP-23/NAP-22 by protein kinase C was also found myristoylation-dependent, suggesting the importance of myristoylation in protein-protein interactions.	Fujita Hlth Univ, Inst Comprehens Med Sci, Div Biomed Polymer Sci, Aichi 4701192, Japan	Fujita Health University	Taniguchi, H (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Div Biomed Polymer Sci, Aichi 4701192, Japan.		Taniguchi, Hisaaki/I-9171-2012; Hayashi, Nobuhiro/F-6088-2011; Matsubara, Mamoru/AAP-4016-2021	Hayashi, Nobuhiro/0000-0002-9950-094X; Matsubara, Mamoru/0000-0002-8893-0485				AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; Caroni P, 1997, J CELL BIOL, V136, P679, DOI 10.1083/jcb.136.3.679; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GARBER EA, 1987, P NATL ACAD SCI USA, V84, P80, DOI 10.1073/pnas.84.1.80; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KNOLL LJ, 1995, METHOD ENZYMOL, V250, P405; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; MAEKAWA S, 1994, J BIOL CHEM, V269, P19462; MAEKAWA S, 1994, BBA-GENE STRUCT EXPR, V1218, P119, DOI 10.1016/0167-4781(94)90113-9; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; Matsubara M, 1998, FEBS LETT, V421, P203, DOI 10.1016/S0014-5793(97)01557-3; Matsubara M, 1997, J BIOL CHEM, V272, P23050, DOI 10.1074/jbc.272.37.23050; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; OBRIAN CA, 1990, BIOCHEM PHARMACOL, V39, P49, DOI 10.1016/0006-2952(90)90647-4; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; SENIN II, 1995, FEBS LETT, V376, P87, DOI 10.1016/0014-5793(95)01187-2; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; Zaliani A, 1998, PROTEIN ENG, V11, P803, DOI 10.1093/protein/11.9.803; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831	41	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11848	11853		10.1074/jbc.274.17.11848	http://dx.doi.org/10.1074/jbc.274.17.11848			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207003	hybrid			2022-12-25	WOS:000079834800059
J	Yang, ZY; Mendoza, AR; Welch, TR; Zipf, WB; Yu, CY				Yang, ZY; Mendoza, AR; Welch, TR; Zipf, WB; Yu, CY			Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module) - A mechanism for gene deletions and disease associations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL ADRENAL-HYPERPLASIA; EXTRACELLULAR-MATRIX PROTEIN; EXON-INTRON STRUCTURE; ENDOGENOUS RETROVIRUSES; ANTIGENIC DETERMINANTS; MOLECULAR-GENETICS; 4TH COMPONENT; NULL ALLELES; FACTOR-B; CLASS-I	The frequent variations of human complement component C4 gene size and gene numbers, plus the extensive polymorphism of the proteins, render C4 an excellent marker for major histocompatibility complex disease associations. As shown by definitive RFLPs, the tandemly arranged genes RP, C4, CYP21, and TNX are duplicated together as a discrete genetic unit termed the RCCX module. Duplications of the RCCX modules occurred by the addition of genomic fragments containing a long (L) or a short (S) C4 gene, a CYP21A or a CYP21B gene, and the gene fragments TNXA and RP2, Four major RCCX structures with bimodular L-L, bimodular LS, monomodular L, and monomodular S are present in the Caucasian population. These modules are readily detectable by TaqI RFLPs, The RCCX modular variations appear to be a root cause for the acquisition of deleterious mutations from pseudogenes or gene segments in the RCCX to their corresponding functional genes. In a patient with congenital adrenal hyperplasia, we discovered a TNXB-TNXA recombinant with the deletion of RP2-C4B-CYP21B. Elucidation of the DNA sequence for the recombination breakpoint region and sequence analyses yielded definitive proof for an unequal crossover between TNXA om a bimodular chromosome and TNXB from a monomodular chromosome.	Childrens Hosp Res Fdn, Columbus, OH 43205 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Univ Cincinnati, Med Ctr, Cincinnati, OH 45229 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati	Yu, CY (corresponding author), Childrens Hosp Res Fdn, Room W208,700 Childrens Dr, Columbus, OH 43205 USA.		Yu, Chack-Yung/E-4360-2011	Welch, Thomas/0000-0002-5893-4020; Yu, Chack-Yung/0000-0002-5218-7503	NCRR NIH HHS [1P41 RR06009] Funding Source: Medline; NIAMS NIH HHS [R01 AR43969] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043969] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguado B, 1996, HLA MHC GENES MOL FU, P39; AHMED AR, 1991, P NATL ACAD SCI USA, V88, P5056, DOI 10.1073/pnas.88.11.5056; APPLE RJ, 1996, HLA MHC GENES MOL FU, P97; AWDEH ZL, 1980, P NATL ACAD SCI-BIOL, V77, P3576, DOI 10.1073/pnas.77.6.3576; BARBA G, 1993, J CLIN INVEST, V91, P1681, DOI 10.1172/JCI116377; BELT KT, 1984, CELL, V36, P907; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; Burch GH, 1997, NAT GENET, V17, P104, DOI 10.1038/ng0997-104; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; CARROLL MC, 1985, EMBO J, V4, P2547, DOI 10.1002/j.1460-2075.1985.tb03969.x; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; Chiquet-Ehrismann Ruth, 1993, P93; CHU XL, 1992, EXP CLIN IMMUNOGENET, V9, P80; CHU XL, 1995, EXP CLIN IMMUNOGENET, V12, P74; DANGEL AW, 1994, IMMUNOGENETICS, V40, P425; DEGLIESPOSTI MA, 1992, IMMUNOGENETICS, V36, P345; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; DONOHOUE PA, 1995, TISSUE ANTIGENS, V46, P163, DOI 10.1111/j.1399-0039.1995.tb03115.x; FIELDER AHL, 1983, BMJ-BRIT MED J, V286, P425, DOI 10.1136/bmj.286.6363.425; *GEN COMP GROUP, 1991, GCG SEQ AN SOFTW PAC; GILES CM, 1988, IMMUNOGENETICS, V27, P442, DOI 10.1007/BF00364431; GITELMAN SE, 1992, MOL CELL BIOL, V12, P2124, DOI 10.1128/MCB.12.5.2124; Gomez-Escobar N, 1998, J BIOL CHEM, V273, P30954, DOI 10.1074/jbc.273.47.30954; HARDA F, 1987, P NATL ACAD SCI USA, V84, P8091; Hauptmann G, 1988, Immunodefic Rev, V1, P3; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HOWE HS, 1991, CLIN EXP IMMUNOL, V83, P387; JENHANI F, 1992, J AUTOIMMUN, V5, P149, DOI 10.1016/0896-8411(92)90196-W; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; JOSPE N, 1987, BIOCHEM BIOPH RES CO, V142, P798, DOI 10.1016/0006-291X(87)91484-7; KAWAGUCHI H, 1991, MOL EVOLUTION MAJOR, P357; LAITINEN T, 1991, HUM REPROD, V6, P1384, DOI 10.1093/oxfordjournals.humrep.a137273; LEVISTRAUSS M, 1988, SCIENCE, V240, P201, DOI 10.1126/science.3353717; LEWIN B, 1995, CELL, V80, P1, DOI 10.1016/0092-8674(95)90442-5; Lokki ML, 1999, J IMMUNOL, V162, P3687; MATSUKI K, 1985, J CLIN INVEST, V76, P2078, DOI 10.1172/JCI112211; MATSUMOTO K, 1992, GENOMICS, V12, P485, DOI 10.1016/0888-7543(92)90438-X; MAUFF G, 1990, COMPLEMENT INFLAMMAT, V7, P193, DOI 10.1159/000463148; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; Porter R R, 1983, Mol Biol Med, V1, P161; Rathjen Fritz G., 1993, P87; RAUM D, 1984, AM J HUM GENET, V36, P72; RODRIGUES NR, 1987, EMBO J, V6, P1653, DOI 10.1002/j.1460-2075.1987.tb02414.x; RUPERT KL, 1999, IN PRESS EXP CLIN IM; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT CA, 1994, HUM MOL GENET, V3, P481, DOI 10.1093/hmg/3.3.481; SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015; Schneider P.M., 1997, COMPLEMENT PRACTICAL, P165; SCHNEIDER PM, 1986, J CLIN INVEST, V78, P650, DOI 10.1172/JCI112623; SCHNEIDER PM, 1989, EUR J PEDIATR, V149, P170, DOI 10.1007/BF01958273; SHEN LM, 1994, J BIOL CHEM, V269, P8466; SIM E, 1986, BIOCHEM J, V239, P763, DOI 10.1042/bj2390763; Simon S, 1997, HUM IMMUNOL, V57, P27, DOI 10.1016/S0198-8859(97)00177-8; SINNOTT P, 1990, P NATL ACAD SCI USA, V87, P2107, DOI 10.1073/pnas.87.6.2107; TASSABEHJI M, 1994, NUCLEIC ACIDS RES, V22, P5211, DOI 10.1093/nar/22.24.5211; Taylor JE, 1998, EUR J HUM GENET, V6, P467, DOI 10.1038/sj.ejhg.5200210; TEE MK, 1995, GENOMICS, V28, P171, DOI 10.1006/geno.1995.1128; TUSIELUNA MT, 1995, P NATL ACAD SCI USA, V92, P10796, DOI 10.1073/pnas.92.23.10796; VENNEKER GT, 1992, J INVEST DERMATOL, V99, P853, DOI 10.1111/1523-1747.ep12614826; WARREN RP, 1992, IMMUNOGENETICS, V36, P203, DOI 10.1007/BF00215048; WegRemers S, 1997, HUM GENET, V100, P548, DOI 10.1007/s004390050550; WELCH TR, 1989, HUM IMMUNOL, V26, P353, DOI 10.1016/0198-8859(89)90012-8; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; Yang ZY, 1998, GENOMICS, V53, P338, DOI 10.1006/geno.1998.5499; Yu CY, 1998, EXP CLIN IMMUNOGENET, V15, P213, DOI 10.1159/000019075; YU CY, 1986, EMBO J, V5, P2873, DOI 10.1002/j.1460-2075.1986.tb04582.x; YU CY, 1988, IMMUNOGENETICS, V27, P399, DOI 10.1007/BF00364425; YU CY, 1991, J IMMUNOL, V146, P1057; YU CY, 1987, IMMUNOGENETICS, V25, P384; YU CY, 1992, METHOD ENZYMOL, P378; ZU X, 1998, NUCLEIC ACIDS RES, V26, P4068	74	136	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12147	12156		10.1074/jbc.274.17.12147	http://dx.doi.org/10.1074/jbc.274.17.12147			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207042	hybrid			2022-12-25	WOS:000079834800098
J	Brown, BK; Li, C; Cheng, PC; Song, WX				Brown, BK; Li, C; Cheng, PC; Song, WX			Trafficking of the Ig alpha/Ig beta heterodimer with membrane Ig and bound antigen to the major histocompatibility complex class II peptide-loading compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; HLA-DM; INTRACELLULAR-TRANSPORT; INVARIANT CHAIN; B-LYMPHOCYTES; RECEPTOR; IMMUNOGLOBULIN; MOLECULES; CELLS; INTERNALIZATION	The binding of antigen to the B cell antigen receptor (BCR) initiates two major cellular events. First, upon cross linking by antigen, the BCR induces signal transduction cascades leading to the transcription of a number of genes associated with B cell activation. Second, the BCR internalizes and delivers antigens to processing compartments, where processed antigenic peptides are loaded onto major histocompatibility complex (MHC) class II molecules for presentation to T helper cells. The BCR consists of membrane Ig (mIg) and Ig alpha/ Ig beta heterodimer (Ig alpha/Ig beta). The Ig alpha/Ig beta, the signal transducing component of the BCR, has been indicated to play a role in antigen processing. In order to understand the function of the Ig alpha/Ig beta in antigen transport, we studied the intracellular trafficking pathway of the Ig alpha/Ig beta. We show that in the absence of antigen binding, the Ig alpha/Ig beta constitutively traffics with mig from the plasma membrane, through the early endosomes, to the MHC class II peptide-loading compartment. Cross-linking the BCR does not alter the trafficking pathway; however, it accelerates the transport of the Ig alpha/Ig beta to the MHC class II peptide-loading compartment. This suggests that the Ig alpha/Ig beta heterodimer is involved in BCR-mediated antigen transport through the entire antigen transport pathway.	Univ Maryland, Dept Cell Biol & Mol Genet, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	University System of Maryland; University of Maryland College Park; Northwestern University	Song, WX (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA.				NIAID NIH HHS [R29AI42093] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042093] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Aluvihare VR, 1997, EMBO J, V16, P3553, DOI 10.1093/emboj/16.12.3553; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BARNES KA, 1995, J EXP MED, V181, P1715, DOI 10.1084/jem.181.5.1715; Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; Cassard S, 1998, J IMMUNOL, V160, P1767; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CASTEN LA, 1988, J IMMUNOL, V140, P404; CASTEN LA, 1985, P NATL ACAD SCI USA, V82, P5890, DOI 10.1073/pnas.82.17.5890; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; GREEN JM, 1995, J IMMUNOL, V155, P3759; HARDING CV, 1993, J IMMUNOL, V151, P3988; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; JELACHICH ML, 1984, P NATL ACAD SCI-BIOL, V81, P5537, DOI 10.1073/pnas.81.17.5537; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Lankar D, 1998, J EXP MED, V188, P819, DOI 10.1084/jem.188.5.819; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Liljedahl M, 1998, IMMUNITY, V8, P233, DOI 10.1016/S1074-7613(00)80475-6; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MITCHELL RN, 1995, J EXP MED, V181, P1705, DOI 10.1084/jem.181.5.1705; OZATO K, 1980, J IMMUNOL, V124, P533; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; RUDENSKY AY, 1994, IMMUNITY, V1, P585, DOI 10.1016/1074-7613(94)90048-5; Schafer PH, 1996, J IMMUNOL, V157, P5487; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; Siemasko K, 1998, J IMMUNOL, V160, P5203; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SONG WX, 1994, J BIOL CHEM, V269, P29474; SONG WX, 1995, J IMMUNOL, V155, P4255; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WOLF PR, 1995, NATURE, V376, P464, DOI 10.1038/376464a0; Xu XX, 1996, INT IMMUNOL, V8, P1867, DOI 10.1093/intimm/8.12.1867; XU XX, 1995, J IMMUNOL, V155, P2984	52	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11439	11446		10.1074/jbc.274.16.11439	http://dx.doi.org/10.1074/jbc.274.16.11439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196238	hybrid			2022-12-25	WOS:000079751900106
J	Cereseto, A; Parks, RW; Rivadeneira, E; Franchini, G				Cereseto, A; Parks, RW; Rivadeneira, E; Franchini, G			Limiting amounts of p27(Kip1) correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells	ONCOGENE			English	Article						p27(Kip1); cyclin E; HTLV-I infection	DEPENDENT KINASE INHIBITOR; LEUKEMIA-LYMPHOMA VIRUS; P21(WAF1/CIP1) EXPRESSION; INTERLEUKIN-2 RECEPTOR; MOLECULAR MECHANISMS; POTENTIAL MEDIATOR; RESTRICTION POINT; BREAST-CANCER; MICE LACKING; PROTEIN	Human T-cells immortalized (interleukin-2 [IL-2] dependent) by the human T-cell lymphotropic/leukemia virus type I (HTLV-I), in time, become transformed (IL-2 independent). To understand the biochemical basis of this transition, we have used the sibling HTLV-I-infected T-cell lines, N1186 (IL-2 dependent) and N1186-94 (IL-2 independent), as models to assess the responses to antiproliferative signals. In N1186 cells arrested in G1 after serum/interleukin-2 (IL-2) deprivation, downregulation of the cyclin E-CDK2 kinase activity correlated with decreased phosphorylation of CDK2 and accumulation of p27(Kip1) bound to the cyclin E-CDK2 complex, as seen in normal activated PBMCs (peripheral blood mononuclear cells). In contrast, N1186-94 cells failed to arrest in G1 upon serum starvation, displayed constitutive cyclin E-associated kinase activity, and, although CDK2 was partially dephosphorylated, the amount of p27(Kip1) bound to the complex did not increase. This observation, extended to two other IL-2-dependent as well as to three IL-2-independent HTLV-I-infected T-cell lines, suggests that the lack of cyclin E-CDK2 kinase downregulation found in the late phase of HTLV-I transformation may correlate with insufficient amounts of p27(Kip1) associated with the cyclin E-CDK2 complex. Reconstitution experiments demonstrated that the addition of p27(Kip1) to lysates from N1186-94 starved cells resulted in the downregulation of cyclin E-associated kinase activity supporting the notion that the unresponsiveness of the cyclin E-CDK2 complex to growth inhibitory signals may be due to inadequate amounts of p27(Kip1) assembled with the complex in HTLV-I-transformed T-cells, In fact, the amount of p27(Kip1) protein was lower in most HTLV-I-transformed (IL-2-independent) than in the immortalized (IL-2-dependent) HTLV-I-infected T-cells, Furthermore, specific inhibitors of the phosphatidylinositol 3-kinase (PI3K) induced an increase of p27(Kip1) protein levels, which correlated,vith G1 arrest, in both IL-2-dependent and IL-2-independent HTLV-I-infected T-cells, Altogether, these results suggest that maintaining a low level of expression of p27(Kip1) is a key event in HTLV-I transformation.	NCI, Basic Res Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cereseto, A (corresponding author), NCI, Basic Res Lab, Div Basic Sci, Bethesda, MD 20892 USA.			Cereseto, Anna/0000-0003-4453-2597	NATIONAL CANCER INSTITUTE [ZIABC005645, Z01BC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1996, ONCOGENE, V12, P1645; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Cereseto A, 1997, LEUKEMIA, V11, P866, DOI 10.1038/sj.leu.2400665; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GONG JP, 1994, CANCER RES, V54, P4285; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOFF A, 1992, SCIENCE, V257, P1959; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEACH FS, 1993, CANCER RES, V53, P1986; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	42	33	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2441	2450		10.1038/sj.onc.1202567	http://dx.doi.org/10.1038/sj.onc.1202567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229195				2022-12-25	WOS:000079703300004
J	Fujii, GH; Morimoto, AM; Berson, AE; Bolen, JB				Fujii, GH; Morimoto, AM; Berson, AE; Bolen, JB			Transcriptional analysis of the PTEN/MMAC1 pseudogene, Psi PTEN	ONCOGENE			English	Article						MMAC; PTEN; tumor suppressor; pseudogene	TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; HOMOZYGOUS DELETION; PHOSPHATASE; PROTEIN; BREAST; BETA; CHROMOSOME-9; MUTATIONS; LOCUS	PTEN/MMAC1 is a recently characterized tumor suppressor. A pseudogene derived from the human PTEN/MMAC1 phosphatase, Psi PTEN, has been reported. Recent analysis of the pseudogene revealed conflicting results about the expression of Psi PTEN. In this study, we show that the PTEN/MMAC1 pseudogene is actively transcribed in all cells and tissues examined. In some cases, pseudogene transcripts were found to represent as much as 70% of the total PTEN/MMAC1 RNA. As Psi PTEN is transcribed, there is a potential for misinterpretation of PTEN/MMAC1 mutations when RT - PCR techniques are used, as well as potential for a Psi PTEN-encoded translation product, Although we were unable to detect a pseudogene protein product in the cell lines examined, a baculovirus produced GST pseudogene fusion protein exhibited phosphatase activity comparable to wild type. The results of this study, taken together, indicate the potential complication of PTEN/MMAC1 molecular analysis caused by the expression of Psi PTEN.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cellular Signaling, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Fujii, GH (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cellular Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cheney IW, 1998, CANCER RES, V58, P2331; CHENG JQ, 1994, CANCER RES, V54, P5547; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MORIMOTO AM, 1998, UNPUB; MORIMOTO AM, 1999, IN PRESS ONCOGENE; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rhei E, 1997, CANCER RES, V57, P3657; ROBINSON MA, 1993, P NATL ACAD SCI USA, V90, P2433, DOI 10.1073/pnas.90.6.2433; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SOLOVYEV V, 1997, ISMB, V5, P294; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; Whang YE, 1998, J NATL CANCER I, V90, P859, DOI 10.1093/jnci/90.11.859; WILDE CD, 1986, CRIT REV BIOCHEM MOL, V19, P323	27	74	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1765	1769		10.1038/sj.onc.1202492	http://dx.doi.org/10.1038/sj.onc.1202492			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208437				2022-12-25	WOS:000079025000011
J	Rojas, JM; Subleski, M; Coque, JJR; Guerrero, C; Saez, R; Li, BQ; Lopez, E; Zarich, N; Aroca, P; Kamata, T; Santos, E				Rojas, JM; Subleski, M; Coque, JJR; Guerrero, C; Saez, R; Li, BQ; Lopez, E; Zarich, N; Aroca, P; Kamata, T; Santos, E			Isoform-specific insertion near the Grb2-binding domain modulates the intrinsic guanine nucleotide exchange activity of hSos1	ONCOGENE			English	Article						hSos1; isoforms; Ras activation; GEF activity; oocyte maturation	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; OOCYTE MATURATION; FACTOR SON; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODIES; XENOPUS OOCYTES	Two human hSos1 isoforms (Isf I and Isf II; Rojas et al,, Oncogene 12, 2291-2300, 1996) defined by the presence of a distinct 15 amino acid stretch in one of them, were compared biologically and biochemically using representative NIH3T3 transfectants overexpressing either one. We showed that hSos1-Isf II is significantly more effective than hSos1-Isf I to induce proliferation or malignant transformation of rodent fibroblasts when transfected alone or in conjunction with normal H-Ras (Gly12), The hSos1-Isf II-Ras cotransfectants consistently exhibited higher saturation density, lower cell-doubling times, increased focus-forming activity and higher ability to grow on semisolid medium and at low serum concentration than their hSos1-Isf I-Ras counterparts. Furthermore, the ratio of GTP/GDP bound to cellular p21(ras) was consistently higher in the hSos1-Isf II-transfected clones, both under basal and stimulated conditions. However, no significant differences were detected in vivo between Isf I- and Isf II-transfected clones regarding the amount, stability and subcellular localization of Sos1-Grb2 complex, or the level of hSos1 phosphorylation upon cellular stimulation, Interestingly, direct Ras guanine nucleotide exchange activity assays in cellular lysates showed that Isf II transfectants consistently exhibited about threefold higher activity than Isf I transfectants under basal, unstimulated conditions. Microinjection into Xenopus oocytes of purified peptides corresponding to the C-terminal region of both isoforms (encompassing the 15 amino acid insertion area and the first Grb2-binding motif) showed that only the Isf II peptide, but not its corresponding Isf I peptide, was able to induce measurable rates of meiotic maturation, and synergyzed with insulin, but not progesterone, in induction of GVBD. Our results suggest that the increased biological potency displayed by hSos1-Isf II is due to higher intrinsic guanine nucleotide exchange activity conferred upon this isoform by the 15 a.a. insertion located in proximity to its Grb2 binding region.	NCI, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21071 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Santos, E (corresponding author), NCI, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA.		Guerrero, Carmen/F-1776-2010; Rojas, José M./AAA-3354-2021; Aroca, Pilar/P-2141-2017; Rojas, José M/D-3718-2018; Coque, Juan Jose Rubio/AAV-2049-2021	Guerrero, Carmen/0000-0002-8747-6831; Rojas, José M./0000-0002-7547-2825; Aroca, Pilar/0000-0002-7557-6931; Rojas, José M/0000-0002-5383-3482; Coque, Juan Jose Rubio/0000-0001-8221-7817; Zarich, Natasha/0000-0003-1058-6191				Aroca P, 1996, ONCOGENE, V13, P1839; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KATZAV S, 1995, ONCOGENE, V11, P1079; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; PAWSON T, 1993, CURR BIOL, V3, P4345; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rojas JM, 1996, ONCOGENE, V12, P2291; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SORRENTINO V, 1989, ONCOGENE, V4, P215; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	56	10	11	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1651	1661		10.1038/sj.onc.1202483	http://dx.doi.org/10.1038/sj.onc.1202483			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208427				2022-12-25	WOS:000079025000001
J	Cho, SW; Yoon, HY				Cho, SW; Yoon, HY			Photoaffinity labeling of brain glutamate dehydrogenase isoproteins with an azido-ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; AMINO-ACID SEQUENCE; BOVINE LIVER; CLOSTRIDIUM-SYMBIOSUM; NUCLEOTIDE ANALOG; REGULATORY SITE; IDENTIFICATION; PEPTIDES; DOMAIN; 5'-TRIPHOSPHATE	The ADP binding site within two types of bovine brain glutamate dehydrogenase isoproteins (GDH I and GDH II) was identified using photoaffinity labeling with [alpha-P-32]8-azidoadenosine 5'-diphosphate (8N(3)ADP), 8N(3)ADP, without photolysis, mimicked the activatory properties of ADP on GDH I and GDH II activities, although maximal activity with 8N(3)ADP was about 75% of maximal ADP-stimulated activity. Saturation of photoinsertion with [alpha-P-32]8N(3)ADP occurred at around 40 similar to 50 mu M photoprobe with apparent K-d values near 25 and 40 mu M for GDH I and GDH Il, respectively. Photoinsertion of [alpha-P-32]8N(3)ADP was decreased best by ADP in comparison with other nucleotides. With the combination of immobilized aluminum affinity chromatography and reversed-phase high performance liquid chromatography, photolabel-containing peptides generated by tryptic digestion were isolated. This identified a portion of the adenine ring binding domain of GDH isoproteins as in the region containing the sequence, EMSWIADT-YASTIGHYDIN. Photolabeling of the peptide was prevented over 90% by the presence of 1 mM ADP during photolysis, while other nucleotides could not reduce the amount of photoinsertion as effectively as ADP. These results demonstrate selectivity of the photoprobe for the ADP binding site and suggest that the photolabeled peptide with the residues Glu(179)-Asn(197) is within the ADP binding domain of the brain GDH isoproteins.	Univ Ulsan, Coll Med, Dept Biochem, Seoul 138736, South Korea; Yonsei Univ, Coll Hlth Sci, Dept Med Technol, Wonju 222701, South Korea	University of Ulsan; Yonsei University	Cho, SW (corresponding author), Univ Ulsan, Coll Med, Dept Biochem, 388-1 Poongnap-Dong,Songpa-Ku, Seoul 138736, South Korea.	swcho@www.amc.seoul.kr						ANDERSSON L, 1991, J CHROMATOGR, V539, P327, DOI 10.1016/S0021-9673(01)83941-8; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BATRA SP, 1986, J BIOL CHEM, V261, P5565; Bringaud F, 1997, MOL CELL BIOL, V17, P3915, DOI 10.1128/MCB.17.7.3915; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; CAMPBELL S, 1990, P NATL ACAD SCI USA, V87, P1243, DOI 10.1073/pnas.87.3.1243; Cavallaro S, 1997, P NATL ACAD SCI USA, V94, P9669, DOI 10.1073/pnas.94.18.9669; Cho SW, 1996, BIOCHIMIE, V78, P817, DOI 10.1016/S0300-9084(97)84333-7; Cho SW, 1998, J BIOL CHEM, V273, P31125, DOI 10.1074/jbc.273.47.31125; Cho SW, 1998, FEBS LETT, V426, P196, DOI 10.1016/S0014-5793(98)00335-4; Cho SW, 1996, BIOCHEMISTRY-US, V35, P13907, DOI 10.1021/bi9618575; CHO SW, 1995, EUR J BIOCHEM, V233, P340, DOI 10.1111/j.1432-1033.1995.340_1.x; CIONI P, 1989, J MOL BIOL, V207, P237, DOI 10.1016/0022-2836(89)90453-1; CROSS DG, 1970, J BIOL CHEM, V245, P2612; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; HUSSAIN MM, 1989, J BIOL CHEM, V264, P20730; JACOBSON MA, 1982, BIOCHEMISTRY-US, V21, P2177, DOI 10.1021/bi00538a029; JULLIARD JH, 1979, J BIOL CHEM, V254, P3427; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; Kim SW, 1997, J NEUROCHEM, V69, P418; KOBERSTEIN R, 1976, FEBS LETT, V64, P176, DOI 10.1016/0014-5793(76)80277-3; MAK AS, 1978, ANAL BIOCHEM, V84, P432, DOI 10.1016/0003-2697(78)90061-1; NAKATANI Y, 1987, BIOCHEM BIOPH RES CO, V149, P405, DOI 10.1016/0006-291X(87)90381-0; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; OZTURK DH, 1992, BIOCHEMISTRY-US, V31, P10544, DOI 10.1021/bi00158a018; OZTURK DH, 1991, BIOCHEMISTRY-US, V30, P7126, DOI 10.1021/bi00243a013; Peterson PE, 1997, J STRUCT BIOL, V120, P73, DOI 10.1006/jsbi.1997.3899; Plaitakis A, 1993, Can J Neurol Sci, V20 Suppl 3, pS109; PLAITAKIS A, 1982, SCIENCE, V216, P193, DOI 10.1126/science.6121377; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; PREISS T, 1993, J BIOL CHEM, V268, P24523; Rajas F, 1996, J BIOL CHEM, V271, P29882, DOI 10.1074/jbc.271.47.29882; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SCHMIDT JA, 1984, J BIOL CHEM, V259, P4515; SHASHIDHARAN P, 1994, J BIOL CHEM, V269, P16971; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Shoemaker MT, 1996, BIOCONJUGATE CHEM, V7, P302, DOI 10.1021/bc960014n; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; STILLMAN TJ, 1992, J MOL BIOL, V224, P1181, DOI 10.1016/0022-2836(92)90481-X; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; TZIMAGIORGIS G, 1991, BIOCHIM BIOPHYS ACTA, V1089, P250, DOI 10.1016/0167-4781(91)90017-G; VAILLANCOURT RR, 1995, BIOCHEM J, V311, P987, DOI 10.1042/bj3110987; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WRZESZCZYNSKI KO, 1994, BIOCHEMISTRY-US, V33, P11544, DOI 10.1021/bi00204a017; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; Zammarchi E, 1996, METABOLISM, V45, P957, DOI 10.1016/S0026-0495(96)90262-0	47	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13948	13953		10.1074/jbc.274.20.13948	http://dx.doi.org/10.1074/jbc.274.20.13948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318805	hybrid			2022-12-25	WOS:000080322200034
J	Liang, XQ; Zhu, D; Schulz, H				Liang, XQ; Zhu, D; Schulz, H			Delta(3,5,7),Delta(2,4,6)-trienoyl-CoA isomerase, a novel enzyme that functions in the beta-oxidation of polyunsaturated fatty acids with conjugated double bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-DEPENDENT PATHWAY; RAT-LIVER; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; 3-HYDROXYACYL-COA DEHYDROGENASE; MITOCHONDRIAL METABOLISM; PEROXISOMES; PURIFICATION; HYDRATASE; PROTEIN	The mitochondrial metabolism of unsaturated fatty acids with conjugated double bonds at odd-numbered positions, e.g. 9-cis,11-trans-octadecadienoic acid, was investigated. These fatty acids are substrates of beta-oxidation in isolated rat liver mitochondria and hence are expected to yield 5,7-dienoyl-CoA intermediates. 5,7-Decadienoyl-CoA was used to study the degradation of these intermediates. After introduction of a 2-trans-double bond by acyl-CoA dehydrogenase or acyl-CoA oxidase, the resultant 2,5,7-decatrienoyl-CoA can either continue its pass through the beta-oxidation cycle or be converted by Delta(3),Delta(2)-enoyl-CoA isomerase to 3,5,7-decatrienoyl-CoA. The latter compound was isomerized by a novel enzyme, named Delta(3,5,7),Delta(2,4,6)-trienoyl-CoA isomerase, to 2,4,6-decadrienoyl-CoA, which is a substrate of 2,4-dienoyl-CoA reductase (Wang, H.-Y. and Schulz, I-I. (1989) Biochem, J. 264, 47-52) and hence can be completely degraded via beta-oxidation. Delta(3,5,7),Delta(2,4,6)-Trienoyl-CoA isomerase was purified from pig heart to apparent homogeneity and found to be a component enzyme of Delta(3,5),Delta(2,4)-dienoyl-CoA isomerase. Although the direct beta-oxidation of 2,5,7-decatrienoyl-CoA seems to be the major pathway, the degradation via 2,4,6-trienoyl-CoA makes a significant contribution to the total beta-oxidation of this intermediate.	CUNY City Coll, Dept Chem, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)	Schulz, H (corresponding author), CUNY City Coll, Dept Chem, Convent Ave & 138th St, New York, NY 10031 USA.				NCRR NIH HHS [RR 03060] Funding Source: Medline; NHLBI NIH HHS [HL 30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradshaw R A, 1975, Methods Enzymol, V35, P122, DOI 10.1016/0076-6879(75)35147-1; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; DUTTON HJ, 1979, GEOMETRICAL POSITION, P1; Ellman GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI DOI 10.1016/0003-9861(59)90090-6.PMID:13650640; Filppula SA, 1998, J BIOL CHEM, V273, P349, DOI 10.1074/jbc.273.1.349; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LUO MJ, 1994, J BIOL CHEM, V269, P2384; MARTIN JC, 1998, T FATTY ACIDS HUMAN, P261; MARYANOFF BE, 1985, J AM CHEM SOC, V107, P217, DOI 10.1021/ja00287a040; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Nedergaard J, 1979, Methods Enzymol, V55, P3; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; Steinman H M, 1975, Methods Enzymol, V35, P136, DOI 10.1016/0076-6879(75)35149-5; WANG HY, 1989, BIOCHEM J, V264, P47, DOI 10.1042/bj2640047; YANG SY, 1986, J BIOL CHEM, V261, P5390	22	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13830	13835		10.1074/jbc.274.20.13830	http://dx.doi.org/10.1074/jbc.274.20.13830			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318788	hybrid			2022-12-25	WOS:000080322200017
J	Kang, SS; Kwon, T; Kwon, DY; Do, SI				Kang, SS; Kwon, T; Kwon, DY; Do, SI			Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SURVIVAL SIGNALS; TRANSFORMATION; IDENTIFICATION; AMPLIFICATION; INHIBITION; 3-KINASE	With the amino acid sequences of all reported Akt kinase physiological substrates, the possible Akt kinase substrate specificity has been suggested. The serine/threonine residue to be phosphorylated in these proteins is placed within stretches of amino acids with homology, and the arginine residues on the -5 and -3 positions and a hydrophobic amino acid on the +2 position are conserved relative to those of serine/threonine residues (XXRXRXYS/TXX). We noticed two putative Akt kinase phosphorylation sites ((220)GARRRGGSAS(229)) and ((817)AVRIRGKSYV(826)) in human telomerase reverse transcriptase (hTERT) subunit, To demonstrate that hTERT is an Akt kinase substrate protein, we performed the nonradioactive protein kinase assay with the fluorescein hTERT peptide ((817)AVRIRGKSYV(826)). We observed the phosphorylation of hTERT peptide by the human melanoma cell lysate or the activated recombinant Akt kinase proteins in vitro. With the treatment of the growth factor deprivation or okadaic acid, we also observed the up-regulation of both hTERT peptide phosphorylation and the telomerase activity. We noticed that Wortmannin down-regulates hTERT peptide phosphorylation and telomerase activity together. In addition, we observed the enhancement of telomerase activity with the pretreatment of Akt kinase in vitro. Thus, these observations suggest that Akt kinase enhances human telomerase activity through phosphorylation of hTERT subunit as one of its substrate proteins.	Shin Dong Bang R&D Ctr, Seocho Gu, Seoul 137132, South Korea; Korea Adv Inst Sci & Technol, Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kang, SS (corresponding author), Shin Dong Bang R&D Ctr, Seocho Gu, 363,Yangjae 2 Dong, Seoul 137132, South Korea.			Kwon, Taegun/0000-0002-0205-8535				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Crowder RJ, 1998, J NEUROSCI, V18, P2933; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Kang SS, 1998, J BIOCHEM MOL BIOL, V31, P339; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; RAY P, 1995, J BIOL CHEM, V270, P10680, DOI 10.1074/jbc.270.18.10680; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842	34	402	433	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13085	13090		10.1074/jbc.274.19.13085	http://dx.doi.org/10.1074/jbc.274.19.13085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224060	hybrid			2022-12-25	WOS:000080200400022
J	Torti, M; Bertoni, A; Canobbio, I; Sinigaglia, F; Lapetina, EG; Balduini, C				Torti, M; Bertoni, A; Canobbio, I; Sinigaglia, F; Lapetina, EG; Balduini, C			Rap1B and Rap2B translocation to the cytoskeleton by von Willebrand factor involves Fc gamma II receptor-mediated protein tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; IX-V COMPLEX; HUMAN-PLATELETS; GLYCOPROTEIN-IB; SIGNALING PROTEIN; ACTIVATION; ASSOCIATION; INTEGRIN; KINASE; CAMP	Stimulation of human platelets with von Willebrand factor (vWF) induced the translocation of the small GTPases Rap1B and Rap2B to the cytoskeleton. This effect was specifically prevented by an anti-glycoprotein Ib monoclonal antibody or by the omission of stirring, but was not affected by the peptide RGDS, which antagonizes binding of adhesive proteins to platelet integrins. Association of Rap2B with the cytoskeleton was very rapid, while translocation of Rap1B occurred in a later phase of platelet activation and was totally inhibited by cytochalasin D. vWF also induced the rapid tyrosine phosphorylation of several proteins that was prevented by the tyrosine kinases inhibitor genistein and by cAMP-increasing agents. Under these conditions, also the association of Rap1B and Rap2B with the cytoskeleton was prevented. Translocation of Rap proteins to the cytoskeleton induced by vWF, but not by thrombin, was inhibited by a monoclonal antibody against the Fc gamma II receptor. The same antibody inhibited vWF-induced tyrosine phosphorylation of selected substrates with molecular masses of about 75, 95, and 150 kDa. Three of these substrates were identified as the tyrosine kinase pp72(syk), the phospholipase C gamma 2, and the inositol 5-phosphatase SHIP. Our results indicate that translocation of Rap1B and Rap2B to the cytoskeleton is regulated by tyrosine kinases and suggest a novel role for the Fc gamma II receptor in the mechanism of platelet activation by vWF.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ Genoa, Inst Biol Chem, I-16132 Genoa, Italy; Case Western Reserve Univ, Sch Med, Mol Cardiovasc Res Ctr, Cleveland, OH 44106 USA	University of Pavia; University of Genoa; Case Western Reserve University	Torti, M (corresponding author), Univ Pavia, Dept Biochem, Via Bassi 21, I-27100 Pavia, Italy.		Canobbio, Ilaria/L-7414-2013	Canobbio, Ilaria/0000-0002-9643-3403				Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Asazuma N, 1997, BLOOD, V90, P4789, DOI 10.1182/blood.V90.12.4789.4789_4789_4798; BLOCKMANS D, 1995, BLOOD REV, V9, P143, DOI 10.1016/0268-960X(95)90020-9; Calverley DC, 1998, BLOOD, V91, P1295, DOI 10.1182/blood.V91.4.1295; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Clemetson KJ, 1997, THROMB HAEMOSTASIS, V78, P266; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1987, J BIOL CHEM, V262, P12627; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; OZAKI Y, 1995, BBA-GEN SUBJECTS, V1243, P482, DOI 10.1016/0304-4165(94)00178-Z; RAMASCHI G, 1994, BBA-GEN SUBJECTS, V1199, P20, DOI 10.1016/0304-4165(94)90091-4; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; Torti M, 1996, THROMB HAEMOSTASIS, V76, P444; TORTI M, 1994, THROMB HAEMOSTASIS, V71, P533; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; WINEGAR DA, 1991, J BIOL CHEM, V266, P4381	29	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13690	13697		10.1074/jbc.274.19.13690	http://dx.doi.org/10.1074/jbc.274.19.13690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224142	hybrid			2022-12-25	WOS:000080200400104
J	Zhou, GS; Lee, SC; Yao, ZB; Tan, TH				Zhou, GS; Lee, SC; Yao, ZB; Tan, TH			Hematopoietic progenitor kinase 1 is a component of transforming growth factor beta-induced c-Jun N-terminal kinase signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; BREAST-CANCER CELLS; PROTEIN-KINASE; NH2-TERMINAL KINASE; ADAPTER PROTEINS; GAMMA-RADIATION; JNK PATHWAY; KAPPA-B; ACTIVATION; TRANSDUCTION	The c-Jun N-terminal kinase (JNK) signaling pathway is involved in transforming growth factor beta (TGF-beta) signaling in a variety of cell systems, We report here that hematopoietic progenitor kinase 1 (HPK1), a novel Ste20-like protein serine/threonine kinase, serves as an upstream mediator for the TGF-beta-activated JNK1 cas cede in 293T cells. TGF-beta treatment resulted in a time-dependent activation of HPK1, which was accompanied by similar kinetics of JNK1 activation. The activation of JNK1 by TGF-beta was abrogated by a kinase-defective HPK1 mutant but not by a kinase-defective mutant of kinase homologous to Ste20/Sps1, This result indicates that HPK1 is specifically required for TGF-beta-induced activation of JNK1. We also found that TGF-beta-induced JNK1 activation was blocked by a kinase-defective mutant of TGF-beta-activated kinase 1 (TAK1), In addition, interaction between HPK1 and TAK1 was observed in transient transfection assays, and this interaction was enhanced by TGF-beta treatment. Both stress-activated protein kinase/extracellular signal-regulated kinase kinase (SEK) and mitogen-activated protein kinase kinase 7 (MKK7) are immediate upstream activators of JNK1. Although SEK and MKK7 acted downstream of TAK1, only a kinase-defective SEK mutant blocked TGF-beta-induced activation of JNK1, indicating that the TGF-beta signal is relayed solely through SEK, but not MKK7, in vivo. Furthermore, TGF-beta-induced activating protein 1 activation was blocked by a HPK1 mutant, as well as by TAK1 and SEK mutants. Taken together, these studies establish a potential cascade of TGF-beta-activated interacting kinases beginning with HPK1, a Ste20 homolog, and ending in JNK1 activation: HPK1 --> TAK1 --> SEK --> JNK1.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Amgen Inc, Boulder, CO 80301 USA	Baylor College of Medicine; Amgen	Tan, TH (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, M929 1 Baylor Plaza, Houston, TX 77030 USA.	ttan@bcm.tmc.edu	Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	NIAID NIH HHS [R01-AI38649, R01-AI42532] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; Chakrabarty S, 1998, LAB INVEST, V78, P413; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Ling P, 1999, MOL CELL BIOL, V19, P1359; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; WANG L, 1996, J BIOL CHEM, V273, P8522; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	45	71	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13133	13138		10.1074/jbc.274.19.13133	http://dx.doi.org/10.1074/jbc.274.19.13133			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224067	hybrid			2022-12-25	WOS:000080200400029
J	Binas, B; Danneberg, H; McWhir, J; Mullins, L; Clark, AJ				Binas, B; Danneberg, H; McWhir, J; Mullins, L; Clark, AJ			Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization	FASEB JOURNAL			English	Article						metabolism; heart; hypertrophy; gene targeting; mice	CARNITINE PALMITOYLTRANSFERASE-I; RAT-HEART; HYPERTROPHIC CARDIOMYOPATHY; TISSUE DISTRIBUTION; SKELETAL-MUSCLE; GENE; TRANSPORT; CLONING; SYSTEM; LIVER	Nonenzymatic cytosolic fatty acid binding proteins (FABPs) are abundantly expressed in many animal tissues with high rates of fatty acid metabolism. No physiological role has been demonstrated for any FABP, although these proteins have been implicated in transport of free long-chain fatty acids (LCFAs) and protection against LCFA toxicity, We report here that mice lacking heart-type FABP (H-FABP) exhibit a severe defect of peripheral (nonhepatic, non-fat) LCFA utilization, In these mice, the heart is unable to efficiently take up plasma LCFAs, which are normally its main fuel, and switches to glucose usage, Altered plasma levels of LCFAs, glucose, lactate and beta-hydroxybutyrate are consistent with depressed peripheral LCFA utilization, intensified carbohydrate usage, and increased hepatic LCFA oxidation; these changes are most pronounced under conditions favoring LCFA oxidation. H-FABP deficiency is only incompletely compensated, however, causing acute exercise intolerance and, at old age, a localized cardiac hypertrophy. These data establish a requirement for H-FABP in cardiac intracellular lipid transport and fuel selection and a major role in metabolic homeostasis. This new animal model should be particularly useful for investigating the significance of peripheral LCFA utilization for heart function, insulin sensitivity, and blood pressure.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Roslin Inst, Div Mol Biol, Roslin EH25 9PS, Midlothian, Scotland; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland	Helmholtz Association; Max Delbruck Center for Molecular Medicine; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh	Binas, B (corresponding author), Max Delbruck Ctr Mol Med, Franz Gross Haus 134 D,Wiltbergstr 50, D-13122 Berlin, Germany.	binasb@mdc-berlin.de		Mullins, Linda/0000-0002-6743-8707				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Baier LJ, 1996, J BIOL CHEM, V271, P10892, DOI 10.1074/jbc.271.18.10892; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Borkan SC, 1996, AM J PHYSIOL-RENAL, V271, pF527, DOI 10.1152/ajprenal.1996.271.3.F527; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLAFFEY KP, 1987, BIOCHEMISTRY-US, V26, P7900, DOI 10.1021/bi00398a054; CRISMAN TS, 1987, J MOL CELL CARDIOL, V19, P423, DOI 10.1016/S0022-2828(87)80394-2; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; KELLY DP, 1994, NEW ENGL J MED, V330, P913; Knapp F F Jr, 1996, Q J Nucl Med, V40, P252; KUSAKA Y, 1995, J MOL CELL CARDIOL, V27, P1605, DOI 10.1016/S0022-2828(95)90524-3; Kuwajima M, 1998, J MOL CELL CARDIOL, V30, P773, DOI 10.1006/jmcc.1998.0641; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MILLER WC, 1988, P SOC EXP BIOL MED, V189, P183; MISHKIN S, 1972, BIOCHEM BIOPH RES CO, V47, P997, DOI 10.1016/0006-291X(72)90931-X; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; Ohta K, 1996, CIRCULATION, V94, P785, DOI 10.1161/01.CIR.94.4.785; PANOS TC, 1953, J NUTR, V49, P397, DOI 10.1093/jn/49.3.397; PROWS DR, 1995, LIPIDS, V30, P907, DOI 10.1007/BF02537481; RUPP H, 1992, FASEB J, V6, P2349, DOI 10.1096/fasebj.6.6.1531968; SAKAI K, 1995, EUR J BIOCHEM, V229, P201, DOI 10.1111/j.1432-1033.1995.tb20456.x; Sambrook J, 1989, MOL CLONING; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; SWISLOCKI A, 1994, AM J HYPERTENS, V7, P739, DOI 10.1093/ajh/7.8.739; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; TWEEDIE S, 1989, NUCLEIC ACIDS RES, V17, P4374, DOI 10.1093/nar/17.11.4374; VORK MM, 1993, J THEOR BIOL, V160, P207, DOI 10.1006/jtbi.1993.1014; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097	35	230	245	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					805	812		10.1096/fasebj.13.8.805	http://dx.doi.org/10.1096/fasebj.13.8.805			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224224				2022-12-25	WOS:000080372500004
J	Hoidal, HK; Ertesvag, H; Skjak-Braek, G; Stokke, BT; Valla, S				Hoidal, HK; Ertesvag, H; Skjak-Braek, G; Stokke, BT; Valla, S			The recombinant Azotobacter vinelandii mannuronan C-5-epimerase AlgE4 epimerizes alginate by a nonrandom attack mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; CHEMICAL-COMPOSITION; NMR-SPECTROSCOPY; SEQUENCE; ACID; CLONING; PATTERN; STRAINS; GELS; GENE	The Ca2+-dependent mannuronan C-5-epimerase AlgE4 is a representative of a family of Azotobacter vinelandii enzymes catalyzing the polymer level epimerization of beta-D-mannuronic acid (M) to alpha-L-guluronic acid (G) in the commercially important polysaccharide alginate. The reaction product of recombinantly produced AlgE4 is predominantly characterized by an alternating sequence distribution of the M and Gr residues (MG blocks). AlgE4 was purified after intracellular overexpression in Escherichia coli, and the activity was shown to be optimal at pH values between 6.5 and 7.0, in the presence of 1-3 mM Ca2+, and at temperatures near 37 degrees C, Sr2+ was found to substitute reasonably well for Ca2+ in activation, whereas Zn2+ strongly inhibited the activity. During epimerization of alginate, the fraction of GMG blocks increased linearly as a function of the total fraction of Gr residues and comparably much faster than that of MMG blocks. These experimental data could not be accounted for by a random attack mechanism, suggesting that the enzyme either slides along the alginate chain during catalysis or recognizes a pre-existing G; residue as a preferred substrate in its consecutive attacks.	Norwegian Univ Sci & Technol, UNIGEN Ctr Mol Biol, N-7849 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Biotechnol, N-7849 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Phys, N-7849 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Valla, S (corresponding author), Norwegian Univ Sci & Technol, UNIGEN Ctr Mol Biol, N-7849 Trondheim, Norway.		Stokke, Bjørn T/C-4957-2009	Stokke, Bjørn T/0000-0003-2991-8088; Ertesvag, helga/0000-0001-9437-9469				BAYER AS, 1992, INFECT IMMUN, V60, P3979, DOI 10.1128/IAI.60.10.3979-3985.1992; BOYD A, 1994, APPL ENVIRON MICROB, V60, P2355, DOI 10.1128/AEM.60.7.2355-2359.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNISHB.A, 1974, BIOCHEM J, V139, P721, DOI 10.1042/bj1390721; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DRAGET KI, 1994, CARBOHYD POLYM, V25, P31, DOI 10.1016/0144-8617(94)90159-7; Draget KI, 1997, INT J BIOL MACROMOL, V21, P47, DOI 10.1016/S0141-8130(97)00040-8; DUBOIS M, 1956, ANAL CHEM, V28, P356; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; FETT WF, 1989, PLANT PHYSIOL, V89, P5, DOI 10.1104/pp.89.1.5; FUJIHARA M, 1992, CARBOHYD RES, V224, P343, DOI 10.1016/0008-6215(92)84123-A; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; GRANT GT, 1973, FEBS LETT, V32, P195, DOI 10.1016/0014-5793(73)80770-7; GRASDALEN H, 1979, CARBOHYD RES, V68, P23, DOI 10.1016/S0008-6215(00)84051-3; GRASDALEN H, 1981, CARBOHYD RES, V89, P179, DOI 10.1016/S0008-6215(00)85243-X; GRASDALEN H, 1983, CARBOHYD RES, V118, P255, DOI 10.1016/0008-6215(83)88053-7; Grasdalen H, 1996, CARBOHYD RES, V289, P105, DOI 10.1016/0008-6215(96)00079-1; HAUG A, 1967, ACTA CHEM SCAND, V21, P768, DOI 10.3891/acta.chem.scand.21-0768; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; HAUG A, 1969, BIOCHIM BIOPHYS ACTA, V192, P557, DOI 10.1016/0304-4165(69)90414-0; HAUG A, 1962, ACTA CHEM SCAND, V16, P1908, DOI 10.3891/acta.chem.scand.16-1908; HAUG A, 1971, CARBOHYD RES, V17, P297, DOI 10.1016/S0008-6215(00)82537-9; HAUG A, 1964, 30 NORW I SEAW RES N, P116; JOHANSEN HK, 1994, INFECT IMMUN, V62, P3146, DOI 10.1128/IAI.62.8.3146-3155.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN B, 1981, CARBOHYD RES, V92, P163, DOI 10.1016/S0008-6215(00)85994-7; LARSEN B, 1971, CARBOHYD RES, V17, P287, DOI 10.1016/S0008-6215(00)82536-7; LARSEN B, 1971, CARBOHYD RES, V20, P225, DOI 10.1016/S0008-6215(00)81375-0; LIN LP, 1968, J BACTERIOL, V95, P2336, DOI 10.1128/JB.95.6.2336-2343.1968; MARTINOU A, 1998, IN PRESS CARBOHYDR R; MINGOS DMP, 1995, ESSENTIALS INORGANIC, V1; MITCHELL ED, 1973, BIOCHIM BIOPHYS ACTA, V295, P314, DOI 10.1016/0005-2795(73)90099-8; Ofstad R., 1981, P 11 INT SEAW S GOET, P485; Onsoyen E, 1996, CARBOHYDR EUR, V46, P26; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; OTTERLEI M, 1991, J IMMUNOTHER, V10, P286, DOI 10.1097/00002371-199108000-00007; Rehm BH, 1996, J BACTERIOL, V178, P5884, DOI 10.1128/jb.178.20.5884-5889.1996; ROBYT JF, 1967, ARCH BIOCHEM BIOPHYS, V122, P8, DOI 10.1016/0003-9861(67)90118-X; SADOFF HL, 1975, BACTERIOL REV, V39, P516, DOI 10.1128/MMBR.39.4.516-539.1975; Sambrook J., 2002, MOL CLONING LAB MANU; SHERBROCKCOX V, 1984, CARBOHYD RES, V135, P147, DOI 10.1016/0008-6215(84)85012-0; SIMPSON JA, 1988, J GEN MICROBIOL, V134, P29; Skjak-Braek G, 1991, SEAWEED RESOURCES EU, P219; Skjak-Braek G, 1996, CARBOHYDR EUR, V14, P19; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; SKJAKBRAEK G, 1982, CARBOHYD RES, V103, P133, DOI 10.1016/S0008-6215(82)80013-X; SMIDSROD O, 1972, ACTA CHEM SCAND, V26, P79, DOI 10.3891/acta.chem.scand.26-0079; STOKKE BT, 1995, CAN J CHEM, V78, P1972; Svanem BIG, 1999, J BACTERIOL, V181, P68, DOI 10.1128/JB.181.1.68-77.1999; Varum KM, 1996, BBA-GEN SUBJECTS, V1291, P5, DOI 10.1016/0304-4165(96)00038-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	53	65	67	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12316	12322		10.1074/jbc.274.18.12316	http://dx.doi.org/10.1074/jbc.274.18.12316			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212201	hybrid			2022-12-25	WOS:000080056800021
J	Isshiki, S; Togayachi, A; Kudo, T; Nishihara, S; Watanabe, M; Kubota, T; Kitajima, M; Shiraishi, N; Sasaki, K; Andoh, T; Narimatsu, H				Isshiki, S; Togayachi, A; Kudo, T; Nishihara, S; Watanabe, M; Kubota, T; Kitajima, M; Shiraishi, N; Sasaki, K; Andoh, T; Narimatsu, H			Cloning, expression, and characterization of a novel UDP-galactose :beta-N-acetylglucosamine beta 1,3-galactosyltransferase (beta 3Gal-T5) responsible for synthesis of type 1 chain in colorectal and pancreatic epithelia and tumor cells derived therefrom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; CARBOHYDRATE ANTIGENS; PROGNOSTIC FACTOR; CANCER PATIENTS; GASTRIC-CANCER; LINES; GENE; ALPHA-1,3-FUCOSYL-TRANSFERASE; BIOSYNTHESIS; GANGLIOSIDE	The sialyl Lewis a antigen is a well known tumor marker, CA19-9, which is frequently elevated in the serum in gastrointestinal and pancreatic cancers. UDP-galactose:N-acetylglucosamine pl,3-galactosyltransferase(s) (beta 3Gal-Ts) are required for the synthesis of the sialyl Lewis a epitope, In the present study, a novel beta 3Gal-T, named beta 3Gal-T5, was isolated from a Colo205 cDNA library using a degenerate primer strategy based on the amino acid sequences of the four human beta 3Gal-T genes cloned to date. Transfection experiments demonstrated that HCT-15 cells transfected with the beta 3Gal-T5 gene expressed all the type 1 Lewis antigens. In gastrointestinal and pancreatic cancer cell lines, the amounts of beta 3Gal-T5 transcripts were quite well correlated with the amounts of the sialyl Lewis a antigens. The beta 1,3Gal-T activity toward agalacto-lacto-N-neotetraose was also well correlated with the amounts of beta 3Gal-T5 transcripts in a series of cultured cancer cells, and in Namalwa and HCT-15 cells transfected with the beta 3Gal-T5 gene. Thus, the beta 3Gal-T5 gene is the most probable candidate responsible for the synthesis of the type 1 Lewis antigens in gastrointestinal and pancreatic epithelia and tumor cells derived therefrom. In addition, beta 3Gal-T5 is a key enzyme that determines the amounts of the type 1 Lewis antigens including the sialyl Lewis a antigen.	Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 1928577, Japan; Soka Univ, Fac Engn, Dept Bioengn, Hachioji, Tokyo 1928577, Japan; Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608282, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan	Soka University; Soka University; Keio University; Kyowa Kirin Ltd	Narimatsu, H (corresponding author), Soka Univ, Inst Life Sci, Div Cell Biol, 1-236 Tangi Cho, Hachioji, Tokyo 1928577, Japan.	hisashi@scc1.t.soka.ac.jp	Kubota, Tomomi/J-1492-2018	Kubota, Tomomi/0000-0002-0723-135X; Nishihara, Shoko/0000-0002-1668-2603				Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRUMKIN A, 1993, DEVELOPMENT, V118, P553; HAMANAKA Y, 1994, FEBS LETT, V353, P48, DOI 10.1016/0014-5793(94)01004-8; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; HROMAS R, 1995, CANCER RES, V55, P3610; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; Kudo T, 1998, LAB INVEST, V78, P797; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MAGNANI JL, 1983, CANCER RES, V43, P5489; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; Nakamori S, 1997, J CLIN ONCOL, V15, P816, DOI 10.1200/JCO.1997.15.2.816; NAKAYAMA T, 1995, CANCER, V75, P2051, DOI 10.1002/1097-0142(19950415)75:8<2051::AID-CNCR2820750804>3.0.CO;2-4; Nakayama T, 1997, ANTICANCER RES, V17, P1379; Narimatsu H, 1998, CANCER RES, V58, P512; Narimatsu H, 1996, CANCER RES, V56, P330; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SASAKI K, 1994, Patent No. 0618759; TAKADA A, 1993, CANCER RES, V53, P354; TORRADO J, 1992, GASTROENTEROLOGY, V102, P424, DOI 10.1016/0016-5085(92)90086-E; Valli M, 1998, EUR J BIOCHEM, V256, P494, DOI 10.1046/j.1432-1327.1998.2560494.x; YAGO K, 1993, CANCER RES, V53, P5559	30	113	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12499	12507		10.1074/jbc.274.18.12499	http://dx.doi.org/10.1074/jbc.274.18.12499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212226	hybrid			2022-12-25	WOS:000080056800046
J	Raya, A; Revert, F; Navarro, S; Saus, J				Raya, A; Revert, F; Navarro, S; Saus, J			Characterization of a novel type of serine/threonine kinase that specifically phosphorylates the human goodpasture antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY DOMAINS; KAPPA-B-ALPHA; PROTEIN-KINASE; IDENTIFICATION; AUTOANTIGEN; EXPRESSION; SITE; DEGRADATION; DATABASE; COMPLEX	Goodpasture disease is an autoimmune disorder that occurs naturally only in humans. Also exclusive to humans is the phosphorylation process that targets the unique N terminal region of the Goodpasture antigen. Here we report the molecular cloning of GPBP (Goodpasture antigen-binding protein), a previously unknown 624-residue polypeptide. Although the predicted sequence does not meet the conventional structural requirements for a protein kinase, its recombinant counterpart specifically binds to and phosphorylates the exclusive N-terminal region of the human Goodpasture antigen in vitro, This novel kinase is widely expressed in human tissues but shows preferential expression in the histological structures that are targets of common autoimmune responses. The work presented in this report highlights a novel gene to be explored in human autoimmunity.	Inst Invest Citological Caja Ahorros Valencia, Fdn Valenciana Invest Biomed, Valencia 46010, Spain; Univ Valencia, Fac Med, Dept Patol, Valencia 46010, Spain	University of Valencia	Saus, J (corresponding author), Inst Invest Citological Caja Ahorros Valencia, Fdn Valenciana Invest Biomed, C Amadeo de Saboya 4, Valencia 46010, Spain.	jsaus@ochoa.fib.es	Raya, Angel/E-6205-2010; REVERT, FERNANDO/ABF-8171-2021	Raya, Angel/0000-0003-2189-9775; REVERT, FERNANDO/0000-0002-7304-5846; Saus, Juan/0000-0003-2082-1597				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BEELER JF, 1994, MOL CELL BIOL, V14, P982, DOI 10.1128/MCB.14.2.982; BERNAL D, 1993, J BIOL CHEM, V268, P12090; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Coligan JE, 1996, CURRENT PROTOCOLS PR; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; ERLICH H, 1998, MHC DIS ASS ENCY IMM, P1690; FENG LL, 1994, J BIOL CHEM, V269, P2342; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; Henderson RD, 1998, ACTA NEUROL SCAND, V98, P134; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Langelier Y, 1998, J BIOL CHEM, V273, P1435, DOI 10.1074/jbc.273.3.1435; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; PENADES JR, 1995, EUR J BIOCHEM, V229, P754, DOI 10.1111/j.1432-1033.1995.tb20524.x; Phelps RG, 1998, J BIOL CHEM, V273, P11440, DOI 10.1074/jbc.273.19.11440; Phelps RG, 1996, J BIOL CHEM, V271, P18549, DOI 10.1074/jbc.271.31.18549; QUINONES S, 1992, J BIOL CHEM, V267, P19780; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REVERT F, 1995, J BIOL CHEM, V270, P13254, DOI 10.1074/jbc.270.22.13254; ROITT I, 1994, AUTOIMMUNE DIS, P383; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUS J, 1998, GOODPASTURES SYNDROM, P1005; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334	41	71	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12642	12649		10.1074/jbc.274.18.12642	http://dx.doi.org/10.1074/jbc.274.18.12642			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212244	hybrid			2022-12-25	WOS:000080056800064
J	Valentinis, B; Romano, G; Peruzzi, F; Morrione, A; Prisco, M; Soddu, S; Cristofanelli, B; Sacchi, A; Baserga, R				Valentinis, B; Romano, G; Peruzzi, F; Morrione, A; Prisco, M; Soddu, S; Cristofanelli, B; Sacchi, A; Baserga, R			Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; IGF-I; MYOBLAST DIFFERENTIATION; RETROVIRAL VECTORS; NEURITE FORMATION; NON-SH2 DOMAINS; SOMATOMEDIN-C; SHC PROTEINS	The type 1 insulin-like growth factor receptor (IGF-IR) plays an important role in the growth of cells both in vivo and in vitro. The IGF-IR is also capable of inducing differentiation in a number of cell types, raising the question of how the same receptor can send two seemingly contradictory signals, one for growth and one for differentiation. Using 32D cells, which are murine hemopoietic cells, we show that the activated IGF-IR can induce differentiation along the granulocytic pathway in a manner similar to the granulocyte colony-stimulating factor. We find that one of the major substrates of the IGF-IR, the insulin receptor substrate-1 inhibits IGF-I-mediated differentiation of 32D cells. In the absence of insulin receptor substrate-1, functional impairment of another major substrate of the IGF-IR, the Shc proteins, is associated with a decrease in the extent of differentiation. Although the end points of the respective pathways remain to be defined, these results show for the first time that IGF-I-mediated growth or differentiation of hemopoietic cells may depend on a balance between two of its substrates.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ctr Ricersa Sperimentale, Inst Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy	Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	rbaserga@lac.jci.tju.edu	Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020; Peruzzi, Francesca/M-9804-2014	Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; 	NCI NIH HHS [CA 53484] Funding Source: Medline; NIGMS NIH HHS [GM 33694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHULER D, 1994, MOL ENDOCRINOL, V8, P1139, DOI 10.1210/me.8.9.1139; ASKEW DS, 1991, ONCOGENE, V6, P1915; BALDARI CT, 1995, ONCOGENE, V10, P1141; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DAmbrosio C, 1997, CANCER RES, V57, P3264; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; Dumenil G, 1997, BIOCHEM BIOPH RES CO, V234, P748, DOI 10.1006/bbrc.1997.6702; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAWLEY RG, 1994, GENE THER, V1, P136; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; Hongo A, 1996, ONCOGENE, V12, P1231; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI SW, 1994, J BIOL CHEM, V269, P32558; Maruoka Y, 1997, BIOCHEM BIOPH RES CO, V238, P886, DOI 10.1006/bbrc.1997.7405; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MERCHAV S, 1988, J CLIN INVEST, V81, P791, DOI 10.1172/JCI113385; METCALF D, 1985, BLOOD, V65, P357; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Miura M, 1997, BIOCHEM BIOPH RES CO, V239, P182, DOI 10.1006/bbrc.1997.7449; MYERS MG, 1994, J BIOL CHEM, V269, P28783; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RECIOPINTO E, 1984, P NATL ACAD SCI-BIOL, V81, P2562, DOI 10.1073/pnas.81.8.2562; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Romano G, 1997, VIROLOGY, V237, P23, DOI 10.1006/viro.1997.8764; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SCHMID C, 1983, FEBS LETT, V161, P117, DOI 10.1016/0014-5793(83)80742-X; SCHMID C, 1984, FEBS LETT, V173, P48, DOI 10.1016/0014-5793(84)81015-7; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yao R, 1996, ONCOGENE, V13, P343; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zamorano J, 1996, J IMMUNOL, V157, P4926	63	119	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12423	12430		10.1074/jbc.274.18.12423	http://dx.doi.org/10.1074/jbc.274.18.12423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212216	hybrid, Green Published			2022-12-25	WOS:000080056800036
J	Williams, JR; Sharp, JW; Kumari, VG; Wilson, M; Payne, JA				Williams, JR; Sharp, JW; Kumari, VG; Wilson, M; Payne, JA			The neuron-specific K-Cl cotransporter, KCC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CORTICAL-NEURONS; CEREBELLAR GRANULE CELLS; SHARK RECTAL GLAND; KCL CO-TRANSPORT; MONOCLONAL-ANTIBODIES; GABA(A) RECEPTOR; FUNCTIONAL EXPRESSION; RAT-BRAIN; SUBCELLULAR-LOCALIZATION; MOLECULAR-CLONING	The neuron-specific K-Cl cotransporter (KCC2) is hypothesized to function as an active Cl- extrusion pathway important in postsynaptic inhibition mediated by ligand-gated anion channels, like gamma-aminobutyric acid type A (GABA(A)) and glycine receptors, To understand better the functional role of KCC2 in the nervous system, we developed polyclonal antibodies to a KCC2 fusion protein and used these antibodies 60 characterize and localize KCC2 in the rat cerebellum. The antibodies specifically recognized the KCC2 protein which is an similar to 140-kDa glycoprotein detectable only within the central nervous system. The KCC2 protein displayed a robust and punctate distribution in primary cultured retinal amacrine cells known to form exclusively GABA(A)ergic synapses in culture. In immunolocalization studies, KCC2 was absent from axons and glia but was highly expressed at neuronal somata and dendrites, indicating a specific postsynaptic distribution of the protein. In the granule cell layer, KCC2 exhibited a distinct colocalization with the beta(2)/beta(3)-subunits of the GABA(A) receptor at the plasma membrane of granule cell somata and at cerebellar glomeruli, KCC2 lightly labeled the plasma membrane of Purkinje cell somata. Within the molecular layer, KCC2 exhibited a distinctly punctate distribution along dendrites, indicating it may be highly localized at inhibitory synapses along these processes. The distinct postsynaptic localization of KCC2 and its colocalization with GABA(A) receptor in the cerebellum are consistent with the putative role of KCC2 in neuronal Cl- extrusion and postsynaptic inhibition.	Univ Calif Davis, Sch Med, Dept Human Physiol, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Human Anat & Cell Biol, Davis, CA 95616 USA; Univ Calif Davis, Div Biol Sci, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Payne, JA (corresponding author), Univ Calif Davis, Sch Med, Dept Human Physiol, 1 Shields Ave, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036296, R29NS036296] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-36296] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AICKIN CC, 1984, NEUROSCI LETT, V47, P239, DOI 10.1016/0304-3940(84)90520-2; AICKIN CC, 1982, J PHYSIOL-LONDON, V329, P319, DOI 10.1113/jphysiol.1982.sp014305; ALVAREZLEEFMANS FJ, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P109; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P1138, DOI 10.1152/jn.1964.27.6.1138; BISHOP GA, 1993, ANAT EMBRYOL, V188, P287; DEBLAS AL, 1988, J NEUROSCI, V8, P602; DUNHAM PB, 1990, REGULATION POTASSIUM, P331; ECCLES JC, 1966, EXP BRAIN RES, V1, P161; EWERT M, 1992, BRAIN RES, V569, P57, DOI 10.1016/0006-8993(92)90368-J; FRERKING M, 1995, NEURON, V15, P885, DOI 10.1016/0896-6273(95)90179-5; GABBOTT PLA, 1986, J COMP NEUROL, V251, P474, DOI 10.1002/cne.902510404; GAO B, 1995, DEV BRAIN RES, V88, P1, DOI 10.1016/0165-3806(95)00062-I; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GLEASON E, 1993, J NEUROSCI, V13, P2359, DOI 10.1523/JNEUROSCI.13-06-02359.1993; GLEASON E, 1992, VISUAL NEUROSCI, V8, P315, DOI 10.1017/S0952523800005058; GUTIERREZ A, 1994, J NEUROSCI, V14, P7168; KAILA K, 1994, PROG NEUROBIOL, V42, P489, DOI 10.1016/0301-0082(94)90049-3; KING JS, 1993, ANAT EMBRYOL, V188, P299; LLANO I, 1993, J PHYSIOL-LONDON, V468, P177, DOI 10.1113/jphysiol.1993.sp019766; LLANO I, 1988, P NATL ACAD SCI USA, V85, P3221, DOI 10.1073/pnas.85.9.3221; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Nusser Z, 1998, J NEUROSCI, V18, P1693; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Plotkin MD, 1997, J NEUROBIOL, V33, P781, DOI 10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NEU6>3.0.CO;2-5; REUSS L, 1983, NATURE, V305, P723, DOI 10.1038/305723a0; RICHARDS JG, 1987, J NEUROSCI, V7, P1866; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Rohrbough J, 1996, J NEUROSCI, V16, P82; Rossi DJ, 1998, NEURON, V20, P783, DOI 10.1016/S0896-6273(00)81016-8; SAITO K, 1974, P NATL ACAD SCI USA, V71, P269, DOI 10.1073/pnas.71.2.269; SASAKI S, 1988, J CLIN INVEST, V81, P194, DOI 10.1172/JCI113294; SOMOGYI P, 1989, J NEUROSCI, V9, P2197; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; THOMPSON SM, 1988, J NEUROPHYSIOL, V60, P105, DOI 10.1152/jn.1988.60.1.105; THOMPSON SM, 1988, NEUROSCI LETT, V89, P49, DOI 10.1016/0304-3940(88)90479-X; Wisden W, 1996, NEUROPHARMACOLOGY, V35, P1139, DOI 10.1016/S0028-3908(96)00076-7; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	41	183	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12656	12664		10.1074/jbc.274.18.12656	http://dx.doi.org/10.1074/jbc.274.18.12656			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212246	hybrid			2022-12-25	WOS:000080056800066
J	Brock, TG; McNish, RW; Peters-Golden, M				Brock, TG; McNish, RW; Peters-Golden, M			Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); TUMOR-NECROSIS-FACTOR; RAT PERITONEAL-MACROPHAGES; BASOPHILIC LEUKEMIA-CELLS; NUCLEAR-ENVELOPE; MAST-CELLS; SUBCELLULAR-LOCALIZATION; ENDOPEROXIDE SYNTHASE-1; SIGNAL-TRANSDUCTION; INDUCTION	The two cyclooxygenase isoforms, cyclooxygenase-1 and cyclooxygenase-2, both metabolize arachidonic acid to prostaglandin H-2, which is subsequently processed by downstream enzymes to the various prostanoids. In the present study, we asked if the two isoforms differ in the profile of prostanoids that ultimately arise from their action on arachidonic acid. Resident peritoneal macrophages contained only cyclooxygenase-1 and synthesized (from either endogenous or exogenous arachidonic acid) a balance of four major prostanoids: prostacyclin, thromboxane A(2), prostaglandin D-2, and 12-hydroxyheptadecatrienoic acid. Prostaglandin E-2 was a minor fifth product, although these cells efficiently converted exogenous prostaglandin H-2 to prostaglandin E-2. By contrast, induction of cyclooxygenase-a with lipopolysaccharide resulted in the preferential production of prostacyclin and prostaglandin E-2. This shift in product profile was accentuated if cyclooxygenase-1 was permanently inactivated with aspirin before cyclooxygenase-2 induction. The conversion of exogenous prostaglandin H-2 to prostaglandin E-2 was only modestly increased by lipopolysaccharide treatment. Thus, cyclooxygenase-a induction leads to a shift in arachidonic acid metabolism from the production of several prostanoids with diverse effects as mediated by cyclooxygenase-1 to the preferential synthesis of two prostanoids, prostacyclin and prostaglandin E-2, which evoke common effects at the cellular level.	Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, 6301 MSRB 3, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046487, T32HL007749, R01HL047391] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07749, R01 HL47391, P50 HL46487] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BETZ M, 1991, J IMMUNOL, V146, P108; BishopBailey D, 1997, ARTERIOSCL THROM VAS, V17, P1644, DOI 10.1161/01.ATV.17.9.1644; Bjorkman David J., 1998, American Journal of Medicine, V105, p8S, DOI 10.1016/S0002-9343(98)00069-2; BROCK T, 1997, EICOSANOIDS ASPIRIN, P91; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Bustos M, 1997, J CLIN INVEST, V100, P1150, DOI 10.1172/JCI119626; CHANDLER DB, 1983, AM REV RESPIR DIS, V128, P71, DOI 10.1164/arrd.1983.128.1.71; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Fedyk ER, 1997, ADV EXP MED BIOL, V407, P237; FLETCHER JR, 1993, ANN SURG, V217, P668, DOI 10.1097/00000658-199306000-00008; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HELBIG H, 1990, CURR EYE RES, V9, P501, DOI 10.3109/02713689008999616; HERTELENDY F, 1993, AM J REPROD IMMUNOL, V30, P49, DOI 10.1111/j.1600-0897.1993.tb00601.x; HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112; KUNKEL SL, 1984, ADV INFLAMMAT RES, V7, P93; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894; Modeer T, 1996, J CLIN PERIODONTOL, V23, P927, DOI 10.1111/j.1600-051X.1996.tb00513.x; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MUKHERJEE E, 1989, PROSTAGLANDINS, V38, P557, DOI 10.1016/0090-6980(89)90149-4; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Naraba H, 1998, J IMMUNOL, V160, P2974; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P263; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; PETERSGOLDEN M, 1997, LUNG MACROPHAGES DEN, P151; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RIEDO FX, 1990, J IMMUNOL, V144, P3506; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SMITH WL, 1982, METHOD ENZYMOL, V86, P213; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V260, P521, DOI 10.1016/0003-9861(88)90477-8; URADE Y, 1989, J IMMUNOL, V143, P2982; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WHEELER AP, 1992, AM REV RESPIR DIS, V145, P632, DOI 10.1164/ajrccm/145.3.632; WILBORN J, 1995, AM J PHYSIOL-LUNG C, V268, pL294, DOI 10.1152/ajplung.1995.268.2.L294; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866; Zhang Y, 1998, J IMMUNOL, V160, P1053	41	230	241	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11660	11666		10.1074/jbc.274.17.11660	http://dx.doi.org/10.1074/jbc.274.17.11660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206978	hybrid			2022-12-25	WOS:000079834800034
J	Fischle, W; Emiliani, S; Hendzel, MJ; Nagase, T; Nomura, N; Voelter, W; Verdin, E				Fischle, W; Emiliani, S; Hendzel, MJ; Nagase, T; Nomura, N; Voelter, W; Verdin, E			A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; IN-VIVO; CHROMATIN STRUCTURE; YEAST GCN5P; N-COR; COMPLEX; ACETYLATION; RPD3; ACTIVATION; COREPRESSOR	Histone deacetylases are the catalytic subunits of multiprotein complexes that are targeted to specific pro meters through their interaction with sequence-specific DNA-binding factors. We have cloned and characterized a new human cDNA, HDAC-A, with homology to the yeast HDA1 family of histone deacetylases. Analysis of the predicted amino acid sequence of HDAC-A revealed an open reading frame of 967 amino acids containing two domains: a NH2-terminal domain with no homology to known proteins and a COOH-terminal domain with homology to known histone deacetylases (42% similarity to RPD3, 60% similarity to HDA1), Three additional human cDNAs with high homology to HDAC-A were identified in sequence data bases, indicating that HDAC-A itself is a member of a new family of human histone deacetylases. The mRNA encoding HDAC-A was differentially expressed in a variety of human tissues. The expressed protein, HDAC-Ap, exhibited histone deacetylase activity and this activity mapped to the COOH-terminal region (amino acids 495-967) with homology to HDA1p, in immunoprecipitation experiments, HDAC-A interacted specifically with several cellular proteins, indicating that it might be part of a larger multiprotein complex.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Alberta, Dept Oncol, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Kazusa DNA Res Inst, Chiba 2920812, Japan; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Alberta; Kazusa DNA Research Institute; Eberhard Karls University of Tubingen	Verdin, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.		Verdin, Eric/AAB-7999-2019; Hendzel, Michael/C-3391-2009; Emiliani, Stéphane/O-2454-2017	Hendzel, Michael/0000-0002-9603-7945; Emiliani, Stéphane/0000-0001-7344-8429; Verdin, Eric/0000-0003-3703-3183	PHS HHS [R016M516] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; AUSIO J, 1992, J CELL SCI, V102, P1; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Davie JR, 1996, J CELL BIOCHEM, V62, P149, DOI 10.1002/(SICI)1097-4644(199608)62:2<149::AID-JCB2>3.0.CO;2-S; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LOIDL P, 1994, CHROMOSOMA, V103, P441; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ohara O, 1997, DNA Res, V4, P53, DOI 10.1093/dnares/4.1.53; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sambrook J., 2002, MOL CLONING LAB MANU; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; VanLint C, 1996, GENE EXPRESSION, V5, P245; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	64	206	224	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11713	11720		10.1074/jbc.274.17.11713	http://dx.doi.org/10.1074/jbc.274.17.11713			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206986	hybrid			2022-12-25	WOS:000079834800042
J	Mathur, R; Zhou, J; Babila, T; Koren, G				Mathur, R; Zhou, J; Babila, T; Koren, G			Ile-177 and Ser-180 in the S1 segment are critically important in Kv1.1 channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIRST TRANSMEMBRANE SEGMENT; GATED POTASSIUM CHANNELS; SHAKER K+ CHANNEL; LONG-QT SYNDROME; ENDOPLASMIC-RETICULUM; EXPRESSION; GENE; CONFORMATIONS; MUTATIONS; PROTEINS	Ile-177 and Ser-180 are conserved residues in the first transmembrane segment (S1) of the Shaker, Shab, Show, and Shal subfamilies of voltage-gated K+ channels. Here we report that the mutation of these residues in Kv1.1 to leucine, proline, or arginine abolished the expression of outward potassium currents in Xenopus oocytes. Go-injection of these mutant cRNAs and wild type Kv1.1 cRNA into Xenopus oocytes exerted a potent dominant negative effect resulting in the suppression of Kv1.1-encoded currents. Transient transfection experiments of COS-7 cells revealed that the S1 mutants directed the synthesis of Kv1.1 polypeptides. Quantitative co-immunoprecipitation assays revealed that most of the S1 mutants coassembled and formed both homo- and heteromultimeric complexes. Furthermore, the mutated polypeptides could reach the plasma membranes of transfected Sol8 cells. We conclude that mutations of Ile-177 and Ser-180 do not interfere with either the assembly of multimeric channel complexes or the targeting of these complexes to the plasma membrane. It is likely that these residues are involved in helix-helix interactions that are critical to the proper functioning of voltage-gated potassium channels.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Koren, G (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	Koren@calvin.bwh.harvard.edu			NHLBI NIH HHS [HL46005] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL146005, R01HL046005] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; Bibi E, 1998, TRENDS BIOCHEM SCI, V23, P51, DOI 10.1016/S0968-0004(97)01134-1; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CHANDY KG, 1994, LIGAND VOLTAGE GATED, P1; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Folco E, 1997, J BIOL CHEM, V272, P26505, DOI 10.1074/jbc.272.42.26505; GUY HR, 1994, SOC GEN PHY, V49, P197; Harlow E, 1988, ANTIBODIES LABORATOR, P359; Hille B., 1992, IONIC CHANNELS EXCIT; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Keating MT, 1996, CURR OPIN GENET DEV, V6, P326, DOI 10.1016/S0959-437X(96)80010-4; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOREN G, 1990, NEURON, V4, P39, DOI 10.1016/0896-6273(90)90442-I; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; London B, 1998, P NATL ACAD SCI USA, V95, P2926, DOI 10.1073/pnas.95.6.2926; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PeledZehavi H, 1996, BIOCHEMISTRY-US, V35, P6828, DOI 10.1021/bi952988t; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; Ribera AB, 1996, J NEUROSCI, V16, P1123; Ribera AB, 1996, NEUROPHARMACOLOGY, V35, P1007, DOI 10.1016/0028-3908(96)00098-6; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; Stuhmer W., 1995, SINGLE CHANNEL RECOR, P341, DOI DOI 10.1007/978-1-4419-1229-9_15; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761	37	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11487	11493		10.1074/jbc.274.17.11487	http://dx.doi.org/10.1074/jbc.274.17.11487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206953	hybrid			2022-12-25	WOS:000079834800009
J	van der Sman, J; Thomas, NSB; Lam, EWF				van der Sman, J; Thomas, NSB; Lam, EWF			Modulation of E2F complexes during G(0) to S phase transition in human primary B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; RETINOBLASTOMA SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR; IN-VIVO; MYB TRANSCRIPTION; ALPHA-INTERFERON; PROTEIN FAMILY; PHORBOL ESTER; GROWTH-FACTOR; P130	The pocket protein-E2F complexes are convergence points for cell cycle signaling. In the present report, we identified and monitored the pocket protein-E2F complexes in human primary B-lymphocytes after activation by phorbol 12-myristate 13-acetate, Consistent with previous data from human and mouse fibroblasts and T-lymphocytes, E2F4 and DP1 form the predominant E2F heterodimers both in G(0) and G(1) phases of the human B-lymphocyte cell cycle, whereas E2F1 and -3 are first detected in late G(1), and their expression levels increase towards S phase. Intriguingly, the major E2F complex that we detected in quiescent human B-lymphocytes is consisted of pRB, E2F4, and DP1, Though the levels of DP1 and -2 increase when cells progress from G(0) to S, the proportion of DP1 to DP2 remains relatively constant during the cell cycle. We also observed an increase in electrophoretic mobility of the predominant E2F components, DP1 and E2F4, as B-lymphocytes progressed from G(0) into early G(1). This increase in mobility was attributable to dephosphorylation, as lambda phosphatase treatment could convert the slower migrating fortes into the corresponding faster mobility forms. We further demonstrated that this change in phosphorylation status correlates with a decrease in DNA binding activity. This modulation of DNA binding activity mediated through the dephosphorylation of DP1 and E2F4 could help to explain the lack of in vivo DNA footprinting in late G(1) and S phases of gene promoters negatively regulated through E2F sites and suggests a novel mechanism for controlling E2F transcriptional activity during the transition from quiescence to proliferation.	Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Sect Virol & Cell Biol, London W2 1PG, England; UCL, Sch Med, Dept Haematol, London WC1E 6HX, England	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; University College London; UCL Medical School	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Ludwig Inst Canc Res, London W2 1PG, England.	eric.lam@ic.ac.uk						BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Belbrahem A, 1996, EXP CELL RES, V225, P286, DOI 10.1006/excr.1996.0178; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARZYNKIEWICZ Z, 1982, J CELL PHYSIOL, V113, P465, DOI 10.1002/jcp.1041130316; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Geng Y, 1996, ONCOGENE, V12, P1173; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Huet X, 1996, MOL CELL BIOL, V16, P3789; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO J, 1993, GENE DEV, V7, P331; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; MURPHY JJ, 1993, LEUKEMIA RES, V17, P657, DOI 10.1016/0145-2126(93)90070-2; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Williams CD, 1997, BRIT J HAEMATOL, V96, P688, DOI 10.1046/j.1365-2141.1997.d01-2086.x; Williams CD, 1997, BLOOD, V90, P194; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; Zetterberg A, 1996, APOPTOSIS CELL CYCLE, P17; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	60	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12009	12016		10.1074/jbc.274.17.12009	http://dx.doi.org/10.1074/jbc.274.17.12009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207023	hybrid			2022-12-25	WOS:000079834800079
J	Kessler, R; Zacharova-Albinger, A; Laursen, NB; Kalousek, M; Klemenz, R				Kessler, R; Zacharova-Albinger, A; Laursen, NB; Kalousek, M; Klemenz, R			Attenuated expression of the serum responsive T1 gene in ras transformed fibroblasts due to the inhibition of c-fos gene activity	ONCOGENE			English	Article						AP-1; fos; fra; T1; ras; transformation; serum induction	GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; H-RAS; INTERLEUKIN-1 RECEPTOR; CELL-TRANSFORMATION; SIGNAL-TRANSDUCTION; MEDIATED INDUCTION; BINDING-PROTEINS; MAMMALIAN-CELLS; AP-1 ACTIVITY	The T1 gene encodes a protein, which shares homology with the IL-1 receptors, In fibroblasts, T1 is induced by growth factors and in response to the onset of oncogene expression. The c-fos gene is transiently activated in these situations and was shown to be the major mediator of T1 gene induction, In contrast, the sustained expression of a ras oncogene in NIH3T3 cells resulted in the downregulation of basal T1 gene activity and the attenuation of T1 gene induction in response to mitogenic signals, Likewise, the immediate early genes encoding c-Fos, FosB, and Fra-2 are repressed in these cells. T1 gene repression could be overcome by the forced expression of c-fos in ras transformed fibroblasts, Thus, the lack of c-fos gene expression is the likely cause for ns mediated T1 gene repression. Fra-1, in contrast to the other three members of the Fos family, is permanently synthesized in high amounts in ms transformed NIH3T3 fibroblasts, We show that AP-1, which is abundant in these cells throughout the whole cell cycle, consists predominantly of Fra-1/c-Jun and Fra1/JunD heterodimers, We provide evidence that Fra1/c-Jun heterodimers are responsible for the repression of c-fos gene induction following serum stimulation, The introduction of a dominant negative version of c-Jun into rns transformed fibroblasts was able to rescue c-fos gene induction in response to serum stimulation, further demonstrating that AP-1 is indeed involved in c-fos gene repression, We conclude that oncogenic ms mediates the activation of the fra-1 gene which results in elevated AP-1 activity throughout the cell cycle. Fra-1 containing AP-1 complexes repress the c-fos and possibly other immediate early genes thereby preventing the induction of certain delayed early genes such as the T1 gene in response to mitogenic stimulation.	Univ Zurich Hosp, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Klemenz, R (corresponding author), Univ Zurich Hosp, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P. E., 1994, FOS JUN FAMILIES TRA; BAR SD, 1986, SCIENCE, V233, P1061; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; BRASELMANN S, 1992, J CELL SCI, P97; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chen CY, 1996, MOL CELL BIOL, V16, P6582; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; Foulkes, 1991, HORMONAL CONTROL REG, P257; Gachter T, 1996, J BIOL CHEM, V271, P124; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GROSKOPF JC, 1994, MOL CELL BIOL, V14, P6013, DOI 10.1128/MCB.14.9.6013; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HINO O, 1995, J CANCER RES CLIN, V121, P602, DOI 10.1007/BF01197777; ITO E, 1990, ONCOGENE, V5, P1755; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Kessler R, 1997, BIOL CHEM, V378, P657; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Laursen NB, 1998, ONCOGENE, V16, P575, DOI 10.1038/sj.onc.1201522; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORITZ D, 1998, IN PRESS J IMMUNOL; Moritz DR, 1998, HYBRIDOMA, V17, P107, DOI 10.1089/hyb.1998.17.107; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; Okimoto T, 1996, ONCOGENE, V12, P1625; OSEIFRIMPONG J, 1994, MOL CARCINOGEN, V10, P72, DOI 10.1002/mc.2940100204; Rosl F, 1997, J VIROL, V71, P362; ROSSLER U, 1993, ONCOGENE, V8, P609; SANTOS E, 1984, FED PROC, V43, P2280; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUZUKI H, 1989, EXP CELL RES, V184, P524, DOI 10.1016/0014-4827(89)90350-9; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TRUB T, 1994, P NATL ACAD SCI USA, V91, P3896, DOI 10.1073/pnas.91.9.3896; Urakami S, 1997, BIOCHEM BIOPH RES CO, V241, P24, DOI 10.1006/bbrc.1997.7731; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YANAGISAWA K, 1992, FEBS LETT, V302, P51, DOI 10.1016/0014-5793(92)80282-L; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	77	14	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1733	1744		10.1038/sj.onc.1202484	http://dx.doi.org/10.1038/sj.onc.1202484			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208434				2022-12-25	WOS:000079025000008
J	Dianov, GL; Prasad, R; Wilson, SH; Bohr, VA				Dianov, GL; Prasad, R; Wilson, SH; Bohr, VA			Role of DNA polymerase beta in the excision step of long patch mammalian base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; BOVINE TESTIS; SITE REPAIR; PATHWAY; REQUIREMENT; BINDING; EXTRACT	The two base excision repair (BER) subpathways in mammalian cells are characterized by the number of nucleotides synthesized into the excision patch. They are the "single-nucleotide" BER pathway and the "long patch" (several nucleotides incorporated) BER pathway. Both of these subpathways involve excision of a damaged base and/or nearby nucleotides and DNA synthesis to fill the excision gap Whereas DNA polymerase beta (pol beta) is known to participate in the single-nucleotide BER pathway, the identity of polymerases involved in long patch BER has remained unclear. By analyzing products of long patch excision generated during BER of a uracil-containing DNA substrate in mammalian cell extracts we find that long patch excision depends on pol beta. We show that the excision of the characteristic 5'-deoxyribose phosphate containing oligonucleotide (dRP-oligo) is deficient in extracts from pol beta null cells and is rescued by addition of purified pol beta. Also, pol beta-neutralizing antibody inhibits release of the dRP-oligo in wild-type cell extracts, and the addition of pol beta after inhibition with antibody completely restores the excision reaction. The results indicate that pol beta plays an essential role in long patch BER by conducting strand displacement synthesis and controlling the size of the excised flap.	NIA, NIH, Baltimore, MD 21224 USA; NIEHS, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Dianov, GL (corresponding author), NIA, NIH, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020; Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050158, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	22	198	206	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13741	13743		10.1074/jbc.274.20.13741	http://dx.doi.org/10.1074/jbc.274.20.13741			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318775	hybrid			2022-12-25	WOS:000080322200004
J	Ingalls, RR; Monks, BG; Golenbock, DT				Ingalls, RR; Monks, BG; Golenbock, DT			Membrane expression of soluble endotoxin-binding proteins permits lipopolysaccharide signaling in Chinese hamster ovary fibroblasts independently of CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; PERMEABILITY-INCREASING PROTEIN; DECAY-ACCELERATING FACTOR; DIPHOSPHORYL LIPID-A; CD14-DEPENDENT MECHANISM; (LPS)-BINDING PROTEIN; LPS; CELLS; RECOGNITION; ACTIVATION	The activation of phagocytes by lipopolysaccharide (LPS) has been implicated in the pathogenesis of Gramnegative sepsis. Although the interaction between CD14 and LPS is a key event in the signaling cascade, the molecular mechanism by which cellular activation occurs remains obscure. We hypothesized that the main function of CD14 was to bind LPS and transfer it to a second receptor, which then initiates the subsequent signal for cellular activation. Thus, surface binding of LPS to the cell membrane would be the critical step that CD14 carries out. To test this hypothesis, we examined the activity of two other proteins known to bind LPS, lipopolysaccharide-binding protein and bactericidal/permeability-increasing protein. We found that when these normally soluble proteins were expressed in Chinese hamster ovary-gl fibroblasts as glycosylphosphatidylinositol-anchored proteins, both could substitute for CD14 in initiating LPS signaling. Pharmacological studies with synthetic lipid A analogues demonstrated that these surface expressed LPS-binding proteins had characteristics that were qualitatively identical to membrane CD14. These data support the hypothesis that a receptor distinct from CD14 functions as the actual signal transducer and suggest that surface binding of LPS to the cell membrane is the crucial first step for initiating downstream signaling events.	Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA 02118 USA	Boston Medical Center	Ingalls, RR (corresponding author), Boston Med Ctr, Maxwell Finland Lab Infect Dis, 774 Albany St, Boston, MA 02118 USA.		Monks, Brian/B-8362-2015	Monks, Brian/0000-0003-4008-3093; Ingalls, Robin/0000-0003-2197-7198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038515, K08AI001476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM054060] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01476, AI38515] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahamson SL, 1997, J BIOL CHEM, V272, P2149; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; ELSBACH P, 1993, IMMUNOBIOLOGY, V187, P417, DOI 10.1016/S0171-2985(11)80354-2; Elsbach P, 1994, Prog Clin Biol Res, V388, P41; Flaherty SF, 1997, J SURG RES, V73, P85, DOI 10.1006/jsre.1997.5195; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; GRAY PW, 1993, GENOMICS, V15, P188, DOI 10.1006/geno.1993.1030; GRAY PW, 1989, J BIOL CHEM, V264, P9505; Grunwald U, 1996, J IMMUNOL, V157, P4119; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1988, J IMMUNOL, V141, P547; HAZIOT A, 1993, J IMMUNOL, V151, P1500; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; Ingalls RR, 1998, J IMMUNOL, V161, P5413; KIRKLAND TN, 1991, INFECT IMMUN, V59, P131, DOI 10.1128/IAI.59.1.131-136.1991; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARRA MN, 1992, J IMMUNOL, V148, P532; MATHISON JC, 1992, J IMMUNOL, V149, P200; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NICHOLSONWELLER A, 1985, BLOOD, V65, P1237; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schiff DE, 1997, J LEUKOCYTE BIOL, V62, P786, DOI 10.1002/jlb.62.6.786; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Thieblemont N, 1998, IMMUNITY, V8, P771, DOI 10.1016/S1074-7613(00)80582-8; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel M M, 1995, Prog Clin Biol Res, V392, P287; Wurfel MM, 1997, J IMMUNOL, V158, P3925; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yu B, 1996, J BIOL CHEM, V271, P4100	52	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13993	13998		10.1074/jbc.274.20.13993	http://dx.doi.org/10.1074/jbc.274.20.13993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318811	hybrid			2022-12-25	WOS:000080322200040
J	Kirkman, HN; Rolfo, M; Ferraris, AM; Gaetani, GF				Kirkman, HN; Rolfo, M; Ferraris, AM; Gaetani, GF			Mechanisms of protection of catalase by NADPH - Kinetics and stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-ELECTRON OXIDATION; BOVINE LIVER CATALASE; COMPOUND-II FORMATION; PROTEUS-MIRABILIS PR; HYDROGEN-PEROXIDE; HUMAN ERYTHROCYTES; BOUND NADPH; SUPEROXIDE; DISPOSAL; RADICALS	NADPH is known to be tightly bound to mammalian catalase and to offset the ability of the substrate of catalase (H2O2) to convert the enzyme to an inactive state (compound II), In the process, the bound NADPH becomes NADP(+) and is replaced by another molecule of NADPH. This protection is believed to occur through electron tunneling between NADPH on the surface of the catalase and the heme group within the enzyme. The present study provided additional support for the concept of an intermediate state of catalase, through which NADPH serves to prevent the formation (rather than increase the removal) of compound II. In contrast, the superoxide radical seemed to bypass the intermediate state since NADPH had very little ability to prevent the superoxide radical from converting catalase to compound II. Moreover, the rate of NADPH oxidation was several times the rate of compound II formation (in the absence of NADPH) under a variety of conditions. Very little NADPH oxidation occurred when NADPH was exposed to catalase, H2O2, or the superoxide radical separately. That the ratio exceeds 1 suggests that NADPH may protect catalase from oxidative damage through actions broader than merely preventing the formation of compound II.	Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ Genoa, Dipartimento Oncol Clin & Sperimentale, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Div Hematol Oncol, I-16132 Genoa, Italy	University of North Carolina; University of North Carolina Chapel Hill; University of Genoa; University of Genoa; IRCCS AOU San Martino IST	Kirkman, HN (corresponding author), Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA.							AEBI H, 1984, METHOD ENZYMOL, V105, P121; ALMARSSON O, 1993, J AM CHEM SOC, V115, P7093, DOI 10.1021/ja00069a005; BICOUT DJ, 1995, BBA-PROTEIN STRUCT M, V1252, P172, DOI 10.1016/0167-4838(95)00123-C; BIELSKI BHJ, 1968, J PHYS CHEM-US, V72, P3836, DOI 10.1021/j100857a024; CHANCE B, 1950, BIOCHEM J, V46, P387, DOI 10.1042/bj0460387; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P404, DOI 10.1016/0003-9861(52)90469-4; COHEN G, 1961, SCIENCE, V134, P1756, DOI 10.1126/science.134.3492.1756; Eaton J W, 1972, Adv Exp Med Biol, V28, P121; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GAETANI GD, 1974, P NATL ACAD SCI USA, V71, P3584, DOI 10.1073/pnas.71.9.3584; GAETANI GF, 1994, BLOOD, V84, P325; Gaetani GF, 1996, BLOOD, V87, P1595, DOI 10.1182/blood.V87.4.1595.bloodjournal8741595; GEBICKA L, 1989, INT J RADIAT BIOL, V55, P45, DOI 10.1080/09553008914550051; GOUET P, 1995, J MOL BIOL, V249, P933, DOI 10.1006/jmbi.1995.0350; Gouet P, 1996, NAT STRUCT BIOL, V3, P951, DOI 10.1038/nsb1196-951; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HILLAR A, 1992, FEBS LETT, V314, P179, DOI 10.1016/0014-5793(92)80969-N; HILLAR A, 1994, BIOCHEM J, V300, P531, DOI 10.1042/bj3000531; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; JACOB HS, 1965, J CLIN INVEST, V44, P1187, DOI 10.1172/JCI105225; JOUVE HM, 1986, ARCH BIOCHEM BIOPHYS, V248, P71, DOI 10.1016/0003-9861(86)90402-9; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; KONO Y, 1982, J BIOL CHEM, V257, P5751; LARDINOIS OM, 1995, FREE RADICAL RES, V22, P251, DOI 10.3109/10715769509147544; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Nicholls P., 1963, ENZYMES, V8, P147; OLSON LP, 1995, BIOCHEMISTRY-US, V34, P7335, DOI 10.1021/bi00022a006; SAWADA Y, 1973, BIOCHIM BIOPHYS ACTA, V327, P257, DOI 10.1016/0005-2744(73)90408-7; SCOTT MD, 1991, J LAB CLIN MED, V118, P7; SCOTT MD, 1993, BIOCHIM BIOPHYS ACTA, V1181, P163, DOI 10.1016/0925-4439(93)90106-B; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59	36	196	202	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13908	13914		10.1074/jbc.274.20.13908	http://dx.doi.org/10.1074/jbc.274.20.13908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318800	hybrid			2022-12-25	WOS:000080322200029
J	Kwak, YG; Hu, NN; Wei, J; George, AL; Grobaski, TD; Tamkun, MM; Murray, KT				Kwak, YG; Hu, NN; Wei, J; George, AL; Grobaski, TD; Tamkun, MM; Murray, KT			Protein kinase A phosphorylation alters Kv beta 1.3 subunit-mediated inactivation of the Kv1.5 potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATRIAL MYOCYTES; RECTIFIER K+ CURRENT; BETA-SUBUNIT; MOLECULAR-CLONING; ALPHA-SUBUNIT; MODULATION; CYTOSKELETON; EXPRESSION; BINDING; DOMAIN	The human Kv1.5 potassium channel forms the I-Kur current in atrial myocytes and is functionally altered by coexpression with Kv beta subunits. To explore the role of protein kinase A (PKA) phosphorylation in beta-subunit function, we examined the effect of PKA stimulation on Kv1.5 current following coexpression with either Kv beta 1.2 or Kv beta 1.3, both of which coassemble with Kv1.5 and induce fast inactivation. In Xenopus oocytes expressing Kv1.5 and Kv beta 1.3, activation of PKA reduced macroscopic inactivation with an increase in K+ current. Similar results were obtained using HEK 293 cells which lack endogenous K+ channel subunits. These effects did not occur whom Kv1.5 was coexpressed with either KV beta 1.2 or Kv beta 1.3 lacking the amino terminus,suggesting involvement of this region of Kv beta 1.3. Removal of a consensus PKA phosphorylation site on the Kv beta 1.3 NH2 terminus (serine 24), but not alternative sites in either Kv beta 1.3 or Kv1.5, resulted in loss of the functional effects of kinase activation. The effects of phosphorylation appeared to be electrostatic, as replacement of serine 24 with a negatively charged amino acid reduced beta-mediated inactivation, while substitution with a positively charged residue enhanced it. These results indicate that Kv beta 1.3-induced inactivation is reduced by PKA activation, and that phosphorylation of serine 24 in the subunit NH2 terminus is responsible.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Vanderbilt University; Vanderbilt University; Colorado State University; Colorado State University	Murray, KT (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Rm 559,Med Res Bldg II,23rd Ave S & Pierce Ave, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL49330, HL46681] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049330, P01HL046681] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO EA, 1995, AM J PHYSIOL-HEART C, V268, pH926, DOI 10.1152/ajpheart.1995.268.2.H926; Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; Beck EJ, 1998, J GEN PHYSIOL, V112, P71, DOI 10.1085/jgp.112.1.71; Cole WC, 1996, BIOCHEM CELL BIOL, V74, P439, DOI 10.1139/o96-048; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; Feng JL, 1997, CIRC RES, V80, P572, DOI 10.1161/01.RES.80.4.572; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jing J, 1997, J BIOL CHEM, V272, P14021, DOI 10.1074/jbc.272.22.14021; KASS RS, 1993, TRENDS CARDIOVAS MED, V3, P149, DOI 10.1016/1050-1738(93)90016-Y; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; Li GR, 1996, CIRC RES, V78, P903, DOI 10.1161/01.RES.78.5.903; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MAYS DJ, 1995, J CLIN INVEST, V96, P282, DOI 10.1172/JCI118032; Morales MJ, 1996, P NATL ACAD SCI USA, V93, P15119, DOI 10.1073/pnas.93.26.15119; MURRAY KT, 1994, CIRC RES, V75, P999, DOI 10.1161/01.RES.75.6.999; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; OVERTURF KE, 1994, AM J PHYSIOL-CELL PH, V267, pC1231, DOI 10.1152/ajpcell.1994.267.5.C1231; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; UEBELE VN, 1994, FEBS LETT, V340, P104, DOI 10.1016/0014-5793(94)80181-9; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; Uebele VN, 1998, AM J PHYSIOL-CELL PH, V274, pC1485, DOI 10.1152/ajpcell.1998.274.6.C1485; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; WANG ZG, 1993, CIRC RES, V73, P1061, DOI 10.1161/01.RES.73.6.1061; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	29	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13928	13932		10.1074/jbc.274.20.13928	http://dx.doi.org/10.1074/jbc.274.20.13928			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318802	hybrid			2022-12-25	WOS:000080322200031
J	Yu, KY; Kwon, B; Ni, J; Zhai, YF; Ebner, R; Kwon, BS				Yu, KY; Kwon, B; Ni, J; Zhai, YF; Ebner, R; Kwon, BS			A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS ENTRY MEDIATOR; LYMPHOTOXIN BETA-RECEPTOR; TNF RECEPTOR; FAS LIGAND; T-CELLS; FAMILY; PROLIFERATION; INVOLVEMENT; ACTIVATION; PROTEINS	TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family. TR6 mRNA is expressed in lung tissues and colon adenocarcinoma, SW480. In addition, the expression of TR6 mRNA was shown in the endothelial cell line and induced by phorbol 12-myristate 13-acetate/ionomycin in Jurkat T leukemia cells. The open reading frame of TR6 encodes 300 amino acids with a 29-residue signal sequence but no transmembrane region. Using histidine-tagged recombinant TR6, we screened soluble forms of TNF-ligand proteins with immunoprecipitation. Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L). These bindings were confirmed with HEK 293 EBNA cells transfected with LIGHT cDNA by flow cytometry. TR6 inhibited LIGHT-induced cytotoxicity in HT29 cells. It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LT beta R) and HVEM/TR2 receptors. Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LT beta R, thereby suppressing LIGHT-mediated HT29 cell death. Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Human Genome Sci, Rockville, MD 20850 USA; Univ Ulsan, Dept Biol Sci, Ulsan 680749, South Korea; Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; GlaxoSmithKline; Human Genome Sciences Inc; University of Ulsan; University of Ulsan	Kwon, BS (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.				NIAID NIH HHS [AI28125] Funding Source: Medline; NIDCR NIH HHS [DE12156] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R44AI028125, R43AI028125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012156] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Harrop JA, 1998, J IMMUNOL, V161, P1786; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SIMMONET WS, 1997, CELL, V89, P309; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	20	331	380	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13733	13736		10.1074/jbc.274.20.13733	http://dx.doi.org/10.1074/jbc.274.20.13733			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318773	hybrid			2022-12-25	WOS:000080322200002
J	Anrather, J; Csizmadia, V; Soares, MP; Winkler, H				Anrather, J; Csizmadia, V; Soares, MP; Winkler, H			Regulation of NF-kappa B RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase C zeta in primary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; E-SELECTIN EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; IN-VIVO; CELLULAR-TRANSFORMATION; COMPLEX-FORMATION; GENE-EXPRESSION; REQUIRES RAF-1; POTENTIAL ROLE	The activity of the transcription factor NF-kappa B is thought to be regulated mainly through cytoplasmic retention by I kappa B molecules. Here we present evidence of a second mechanism of regulation acting on NF-kappa B after release from I kappa B. In endothelial cells this mechanism involves phosphorylation of the RelA subunit of NF-kappa B through a pathway involving activation of protein kinase C zeta (PKC zeta) and p21(ras). We show that transcriptional activity of RelA is dependent on phosphorylation of the N-terminal Rel homology domain but not the C-terminal transactivation domain. Inhibition of phosphorylation by dominant negative mutants of PKC zeta or p21(ras) results in loss of RelA transcriptional activity without interfering with DNA binding. Raf/MEK, small GTPases, phosphatidylinositol 3-kinase, and stress-activated protein kinase pathways are not involved in this mechanism of regulation.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Anrather, J (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, 99 Brookline Ave, Boston, MA 02115 USA.	janrathe@caregroup.harvard.edu		Soares, Miguel/0000-0002-9314-4833	NHLBI NIH HHS [1RO1HL59476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059476] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anrather J, 1997, J CLIN INVEST, V99, P763, DOI 10.1172/JCI119222; Baldassarre F, 1995, J BIOL CHEM, V270, P31244, DOI 10.1074/jbc.270.52.31244; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brostjan C, 1997, J IMMUNOL, V158, P3836; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHENG Q, 1994, J BIOL CHEM, V269, P13551; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; GEPPERT TD, 1994, MOL MED, V1, P93; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gomez J, 1997, J IMMUNOL, V158, P1516; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Min W, 1997, J IMMUNOL, V159, P3508; Min W, 1996, MOL CELL BIOL, V16, P359; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	59	171	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13594	13603		10.1074/jbc.274.19.13594	http://dx.doi.org/10.1074/jbc.274.19.13594			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224130	hybrid			2022-12-25	WOS:000080200400092
J	Maldonado, E				Maldonado, E			Transcriptional functions of a new mammalian TATA-binding protein-related factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ACTIVATION; COMPLEX; INITIATION; DOMAIN; SRB	A mammalian protein highly homologous to TATA-binding protein (TBP) has been identified and cloned. The recombinant mammalian TBP-related factor binds to the TATA box of the Ad-MLP and forms stable complexes with TFIIB on the promoter DNA. The mammalian TBP-related factor is able to substitute for TBP in supporting transcription by RNA polymerase II in an in vitro reconstituted system.	Univ Chile, Fac Med, ICBM, Program Biol Celular & Mol, Santiago 7, Chile	Universidad de Chile	Maldonado, E (corresponding author), Univ Chile, Fac Med, ICBM, Program Biol Celular & Mol, Santiago 7, Chile.	emaldona@machi.med.uchile.cl						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Buratowski S, 1997, CELL, V91, P13, DOI 10.1016/S0092-8674(01)80004-0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; Hori R, 1998, CURR BIOL, V8, pR124, DOI 10.1016/S0960-9822(98)70987-X; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5	20	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12963	12966		10.1074/jbc.274.19.12963	http://dx.doi.org/10.1074/jbc.274.19.12963			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224042	hybrid			2022-12-25	WOS:000080200400004
J	Levy, BD; Fokin, VV; Clark, JM; Wakelam, MJO; Petasis, NA; Serhan, CN				Levy, BD; Fokin, VV; Clark, JM; Wakelam, MJO; Petasis, NA; Serhan, CN			Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A(4)	FASEB JOURNAL			English	Article						eicosanoids; lipid mediators; inflammation; PMN	HUMAN-NEUTROPHILS; 15-EPI-LIPOXIN A(4); STABLE ANALOGS; LEUKOTRIENE B-4; CELLS; BIOSYNTHESIS; ACTIVATION; LEUKOCYTES; RECEPTORS; OXIDASE	It is of wide interest to understand how opposing extracellular signals (positive or negative) are translated into intracellular signaling events. Receptor-ligand interactions initiate the generation of bioactive lipids by human neutrophils (PMN), which serve as signals to orchestrate cellular responses important in host defense and inflammation. We recently identified a novel polyisoprenyl phosphate (PIPP) signaling pathway and found that one of its components, presqualene diphosphate (PSDP), is a potent negative intracellular signal in PMN that regulates superoxide anion generation by several stimuli, including phosphatidic acid, We determined intracellular PIPP signaling by autocoids with opposing actions on PMN: leukotriene B-4 (LTB4), a potent chemoattractant, and lipoxin A(4) (IXA(4)), a 'stop signal' for recruitment, LTB4 receptor activation initiated a rapid decrease in PSDP levels concurrent with activation of PLD and cellular responses. In sharp contrast, activation of the LXA(4) receptor reversed LTB4-initiated PSDP remodeling, leading to an accumulation of PSDP and potent inhibition of both PLD and superoxide anion generation, Thus, an inverse relationship was established for PSDP levers and PLD activity with two PMN ligands that evoke opposing responses. In addition, PSDP directly inhibited both isolated human recombinant (K-i = 6 nM) and plant (K-i = 20 nM) PLD, Together, these findings link PIPP remodeling to intracellular regulation of PMN function and suggest a role for PIPPs as lipid repressors in signal transduction, a novel mechanism that may also explain aspirin's suppressive actions in vivo in cell signaling.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; Univ Birmingham, Inst Canc Studies, Birmingham B15 2TH, W Midlands, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Southern California; University of Birmingham	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St,Thorn 724, Boston, MA 02115 USA.		Petasis, Nicos/B-3162-2009	Petasis, Nicos/0000-0002-8864-4446; Wakelam, Michael/0000-0003-4059-9276	NHLBI NIH HHS [HL-56383] Funding Source: Medline; NIDDK NIH HHS [DK-50305] Funding Source: Medline; NIGMS NIH HHS [GM-38765] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R29GM038765, R01GM038765] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSALHAM A, 1993, BIOCHIM BIOPHYS ACTA, V1158, P1, DOI 10.1016/0304-4165(93)90088-P; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BACH TJ, 1995, LIPIDS, V30, P191, DOI 10.1007/BF02537822; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BORGEAT P, 1990, CLIN BIOCHEM, V23, P459, DOI 10.1016/0009-9120(90)90272-V; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; FIORE S, 1993, BLOOD, V81, P3395; GOMEZCAMBRONERO J, 1995, J INTERF CYTOK RES, V15, P877, DOI 10.1089/jir.1995.15.877; Herschman HR, 1998, TRENDS CARDIOVAS MED, V8, P145, DOI 10.1016/S1050-1738(98)00004-8; ISAKSON P, 1995, ADV PROSTAG THROMB L, V23, P49; Jarstfer MB, 1996, J AM CHEM SOC, V118, P13089, DOI 10.1021/ja963308s; Levy BD, 1997, NATURE, V389, P985, DOI 10.1038/40180; MARCUS AJ, 1995, NEW ENGL J MED, V333, P656, DOI 10.1056/NEJM199509073331011; Martin A, 1997, BIOCHEM SOC T, V25, P1157, DOI 10.1042/bst0251157; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; Owman C, 1998, P NATL ACAD SCI USA, V95, P9530, DOI 10.1073/pnas.95.16.9530; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; RABINOWITZ JL, 1992, LIPIDS, V27, P311, DOI 10.1007/BF02536483; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SHECHTER I, 1980, J LIPID RES, V21, P277; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578; Vainio H, 1997, PHARMACOL TOXICOL, V81, P151, DOI 10.1111/j.1600-0773.1997.tb02060.x; Wakelam MJO, 1997, ADV ENZYME REGUL, V37, P29, DOI 10.1016/S0065-2571(96)00023-4; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; ZHOU HL, 1993, BIOCHEM PHARMACOL, V46, P139	35	92	94	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					903	911		10.1096/fasebj.13.8.903	http://dx.doi.org/10.1096/fasebj.13.8.903			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224233				2022-12-25	WOS:000080372500013
J	Schett, G; Steiner, CW; Groger, M; Winkler, S; Graninger, W; Smolen, J; Xu, QB; Steiner, G				Schett, G; Steiner, CW; Groger, M; Winkler, S; Graninger, W; Smolen, J; Xu, QB; Steiner, G			Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70	FASEB JOURNAL			English	Article						Fas activation; antibody; heat shock element; apoptosis hsp	TUMOR-NECROSIS-FACTOR; STRESS-INDUCED APOPTOSIS; SHOCK-PROTEIN HSP70; MEDIATED APOPTOSIS; MONOCLONAL-ANTIBODY; ICE/CED-3 PROTEASE; DEATH FACTOR; ICE-LIKE; CELLS; EXPRESSION	Activation of heat shock factor (HSF) 1-DNA binding and inducible heat shock protein (hsp) 70 (also called hsp72) expression enables cells to resist various forms of stress and survive. Fas, a membrane-bound protein, is a central proapoptotic factor; its activation leads to a cascade of events, resulting in programmed cell death. These two mechanisms with contradictory functions, promoting either cell survival or death, were examined for their potential to inhibit each other's activation. Induction of FAS-mediated signaling was followed by a rapid decrease in HSF1-DNA binding and inducible hsp70 expression. Inhibition of HSF1-DNA binding was demonstrated to be based on absent hyperphosphorylation of HSF1 during FAS signaling. These effects of FAS activation on the HSF1/hsp70 stress response were blocked by ICE (caspase 1) inhibitors, suggesting an ICE-mediated process. Furthermore, inhibition of HSF1/hsp70 was accompanied by an increase in apoptosis rates from 20% to 50% in response to heat stress. When analyzing the effects of HSF1/hsp70 activation on Fas-mediated apoptosis, protection from apoptosis was seen in cells with induced hsp70 protein levels, but not in cells that were just induced for HSF1-DNA binding. Thus, we conclude that inhibition of HSF1/hsp70 stress response during Fas-mediated apoptosis and vice versa may facilitate a cell. to pass a previously chosen pathway, stress resistance or apoptosis, without the influence of inhibitory signals.	Univ Vienna, Div Rheumatol, Dept Internal Med 3, A-1090 Vienna, Austria; Univ Vienna, Dept Immunodermatol, A-1090 Vienna, Austria; Univ Vienna, Div Infectiol, Dept Internal Med 1, A-1090 Vienna, Austria; Austrian Acad Sci, Inst Biomed Aging Res, Innsbruck, Austria; Ludwig Boltzmann Inst Rheumatol & Balneol, Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; Austrian Academy of Sciences; Ludwig Boltzmann Institute	Schett, G (corresponding author), Univ Vienna, Div Rheumatol, Dept Internal Med 3, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Graninger, Winfried/AAI-7192-2020	Graninger, Winfried/0000-0002-3489-3439; Steiner, Guenter/0000-0002-5089-7405				BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Chant ID, 1996, BRIT J HAEMATOL, V93, P898, DOI 10.1046/j.1365-2141.1996.d01-1737.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Ding XZ, 1998, FASEB J, V12, P451, DOI 10.1096/fasebj.12.6.451; Ding XZ, 1997, J CLIN INVEST, V99, P136, DOI 10.1172/JCI119124; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FILIPPOVICH I, 1994, BIOCHEM BIOPH RES CO, V198, P257, DOI 10.1006/bbrc.1994.1036; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Kuo ML, 1997, MOL CARCINOGEN, V18, P221, DOI 10.1002/(SICI)1098-2744(199704)18:4<221::AID-MC6>3.0.CO;2-G; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Liossis SNC, 1998, CLIN IMMUNOL IMMUNOP, V86, P235, DOI 10.1006/clin.1997.4482; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Morimoto RI, 1990, STRESS PROTEINS BIOL; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OguriHyakumachi N, 1995, INT J IMMUNOPHARMACO, V17, P913, DOI 10.1016/0192-0561(95)00082-8; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Schett G, 1995, J CLIN INVEST, V96, P2569, DOI 10.1172/JCI118320; Schett G, 1998, J CLIN INVEST, V102, P302, DOI 10.1172/JCI2465; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; WEI YQ, 1994, CANCER RES, V54, P4952; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; Xu QB, 1996, LAB INVEST, V74, P178; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	43	67	72	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					833	842		10.1096/fasebj.13.8.833	http://dx.doi.org/10.1096/fasebj.13.8.833			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224227	Bronze			2022-12-25	WOS:000080372500007
J	Calvo, PA; Frank, DW; Bieler, BM; Berson, JF; Marks, MS				Calvo, PA; Frank, DW; Bieler, BM; Berson, JF; Marks, MS			A cytoplasmic sequence in human tyrosinase defines a second class of Di-leucine-based sorting signals for late endosomal and lysosomal delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II INVARIANT CHAIN; TRANS-GOLGI NETWORK; MEMBRANE-PROTEIN; ENDOCYTIC PATHWAY; OCULOCUTANEOUS ALBINISM; STRUCTURAL REQUIREMENTS; PLASMA-MEMBRANE; DOWN-REGULATION; CELL-SURFACE; LIMP-II	Distinct cytoplasmic sorting signals target integral membrane proteins to late endosomal compartments, but it is not known whether different signals direct targeting by different pathways. The availability of multiple pathways may permit some cell types to divert proteins to specialized compartments, such as the melanosome of pigmented cells. To address this issue, we characterized sorting determinants of tyrosinase, a tissue-specific resident protein of the melanosome. The cytoplasmic domain of tyrosinase was both necessary and sufficient for internalization and steady state localization to late endosomes and lysosomes in HeLa cells. Mutagenesis of two leucine residues within a conventional di leucine motif ablated late endosomal localization. However, the properties of this di-leucine-based signal were distinguished from that of CD3 gamma by overexpression studies; overexpression of the tyrosinase signal, but not the well characterized CD3 gamma signal, induced a 4-fold enlargement of late endosomes and lysosomes and interfered with endosomal sorting mediated by both tyrosine- and other di-leucine-based signals. These properties suggest that the tyrosinase and CD3 gamma dileucine signals are distinctly recognized and sorted by distinct pathways to late endosomes in non-pigmented cells. We speculate that melanocytic cells utilize the second pathway to divert proteins to the melanosome.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Marks, MS (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 277 John Morgan Bldg6082,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		Marks, Michael S/Q-7223-2019	Marks, Michael S/0000-0001-7435-7262	NATIONAL CANCER INSTITUTE [T32CA009671] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [T32EY007131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009946] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09671] Funding Source: Medline; NEI NIH HHS [T32-EY07131-06] Funding Source: Medline; NIAID NIH HHS [1F32-AI09946] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUNACHALAM B, 1994, INT IMMUNOL, V6, P439, DOI 10.1093/intimm/6.3.439; BEERMANN F, 1995, EXP EYE RES, V61, P599, DOI 10.1016/S0014-4835(05)80053-3; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Borovansky J, 1997, ARCH DERMATOL RES, V289, P145, DOI 10.1007/s004030050170; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHEN YT, 1995, P NATL ACAD SCI USA, V92, P8125, DOI 10.1073/pnas.92.18.8125; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; COWLES CR, 1997, EMBO J, V16, P2768; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; GIEBEL LB, 1991, AM J HUM GENET, V48, P1159; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hansen HJ, 1996, BIOCHEM J, V320, P293, DOI 10.1042/bj3200293; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kang S, 1998, J BIOL CHEM, V273, P20644, DOI 10.1074/jbc.273.32.20644; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Karlsson K, 1998, J BIOL CHEM, V273, P18966, DOI 10.1074/jbc.273.30.18966; Keller P, 1997, J CELL SCI, V110, P3001; KING RA, 1991, MOL BIOL MED, V8, P19; KING RA, 1995, METABOLIC MOL BASES, V3, P4353; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kondoh H, 1996, ZOOL SCI, V13, P825, DOI 10.2108/zsj.13.825; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAMB CA, 1992, J IMMUNOL, V148, P3478; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1993, J CELL SCI, V106, P831; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; SCHRAERMEYER U, 1995, PIGM CELL RES, V8, P209, DOI 10.1111/j.1600-0749.1995.tb00665.x; Schraermeyer U, 1996, HISTOL HISTOPATHOL, V11, P445; SEIJI M, 1961, J INVEST DERMATOL, V36, P243, DOI 10.1038/jid.1961.42; SEYMOUR AS, 1997, MOL BIOL CELL, V8, P227; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; Song WX, 1997, INT IMMUNOL, V9, P1709, DOI 10.1093/intimm/9.11.1709; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; Warren RA, 1997, J BIOL CHEM, V272, P2116; Warren RA, 1998, J BIOL CHEM, V273, P17056, DOI 10.1074/jbc.273.27.17056; Wilson JM, 1997, J CELL BIOL, V136, P319, DOI 10.1083/jcb.136.2.319; Xu YQ, 1997, J INVEST DERMATOL, V109, P788, DOI 10.1111/1523-1747.ep12340971; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	74	96	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12780	12789		10.1074/jbc.274.18.12780	http://dx.doi.org/10.1074/jbc.274.18.12780			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212263	hybrid			2022-12-25	WOS:000080056800083
J	Ishii, TM; Takano, M; Xie, LH; Noma, A; Ohmori, H				Ishii, TM; Takano, M; Xie, LH; Noma, A; Ohmori, H			Molecular characterization of the hyperpolarization-activated cation channel in rabbit heart sinoatrial node	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINO-ATRIAL NODE; CURRENT IF; CELLS; IDENTIFICATION; DEPOLARIZATION; FAMILY; BLOCK; CLAMP; BRAIN; NA+	We cloned a cDNA (HAC4) that encodes the hyperpolarization-activated cation channel (I-f or I-h) by screening a rabbit sinoatrial (SA) node cDNA library using a fragment of rat brain I-f cDNA. HAC I is composed of 1150 amino acid residues, and its cytoplasmic N- and C-terminal regions are longer than those of HAC1-3. The transmembrane region of HAC4 was most homologous to partially cloned mouse I-f BCNG-3 (96%), whereas the C-terminal region of HAC4 showed low homology to all HAC family members so far cloned. Northern blotting revealed that HAC4 mRNA was the most highly expressed in the SA node among the rabbit cardiac tissues examined. The electrophysiological properties of HAC4 were examined using the whole cell patch-clamp technique. In COS-7 cells transfected with HAC4 cDNA, hyperpolarizing voltage steps activated slowly developing inward currents. The half-maximal activation was obtained at -87.2 +/- 2.8 mV under control conditions and at -64.4 +/- 2.6 mV in the presence of intracellular 0.3 mM cAMP. The reversal potential was -34.2 +/- 0.9 mV in 140 mM Na-o(+) and 5 mM K-o(+) versus 10 mM Na-i(+) and 145 mM K-i(+). These results indicate that HAC4 forms I-f in rabbit heart SA node.	Kyoto Univ, Fac Med, Dept Physiol, Kyoto 6068501, Japan	Kyoto University	Ohmori, H (corresponding author), Kyoto Univ, Fac Med, Dept Physiol, Kyoto 6068501, Japan.			Ohmori, Harunori/0000-0002-4319-4947				Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; DENYER JC, 1990, J PHYSIOL-LONDON, V429, P401, DOI 10.1113/jphysiol.1990.sp018264; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1980, J PHYSIOL-LONDON, V308, P353, DOI 10.1113/jphysiol.1980.sp013475; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOERR T, 1989, PFLUG ARCH EUR J PHY, V413, P599, DOI 10.1007/BF00581808; FRACE AM, 1992, PFLUG ARCH EUR J PHY, V421, P97; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; GINNEKEN ACG, 1991, J PHYSIOL-LONDON, V434, P57; GUO JQ, 1995, J PHYSIOL-LONDON, V483, P1; HO WK, 1994, PFLUG ARCH EUR J PHY, V426, P68, DOI 10.1007/BF00374672; ISHII T, 1993, J BIOL CHEM, V268, P2836; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; MARUOKA F, 1994, J PHYSIOL-LONDON, V477, P423, DOI 10.1113/jphysiol.1994.sp020204; NOMA A, 1983, PFLUG ARCH EUR J PHY, V397, P190, DOI 10.1007/BF00584356; ONO K, 1994, PFLUG ARCH EUR J PHY, V427, P437, DOI 10.1007/BF00374258; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; WATANABE E, 1995, AM J PHYSIOL, V269, pH1753; YANAGIHARA K, 1980, JPN J PHYSIOL, V30, P841; YANAGIHARA K, 1980, PFLUG ARCH EUR J PHY, V385, P11, DOI 10.1007/BF00583909; YANAGIHARA K, 1980, PFLUG ARCH EUR J PHY, V388, P255, DOI 10.1007/BF00658491	23	218	237	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12835	12839		10.1074/jbc.274.18.12835	http://dx.doi.org/10.1074/jbc.274.18.12835			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212270	hybrid			2022-12-25	WOS:000080056800090
J	Le Gouill, C; Parent, JL; Caron, CA; Gaudreau, R; Volkov, L; Rola-Pleszczynski, M; Stankova, J				Le Gouill, C; Parent, JL; Caron, CA; Gaudreau, R; Volkov, L; Rola-Pleszczynski, M; Stankova, J			Selective modulation of wild type receptor functions by mutants of G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; TRANSMEMBRANE DOMAIN; BETA(2)-ADRENERGIC RECEPTOR; MUSCARINIC RECEPTORS; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; DIMERIZATION; MUTATIONS; IDENTIFICATION; EXPRESSION	Members of the G-protein-coupled receptor (GPCR) family are involved in most aspects of higher eukaryote biology, and mutations in their coding sequence have been linked to several diseases. In the present study, we report that mutant GPCR can affect the functional properties of the co-expressed wild type (WT) receptor. Mutants of the human platelet-activating factor receptor that fail to show any detectable ligand binding (N285I and K298stop) or coupling to a G-protein (D63N, D289A, and Y293A) were co-expressed with the WT receptor in Chinese hamster ovary and COS-7 cells. In this context, N285I and K298stop mutant receptors inhibited H-3-WEB2086 binding and surface expression. Co-transfection with D63N resulted in a constitutively active receptor phenotype. Platelet-activating factor-induced inositol phosphate production in cells transfected with a 1:1 ratio of WT:D63N was higher than with the WT cDNA alone but was abolished with a 1:3 ratio. We confirmed that these findings could be extended to other GPCRs by showing that co-expression of the WT C-C chemokine receptor 2b with a carboxyl-terminal deletion mutant (K311stop), resulted in a decreased affinity and responsiveness to MCP-1. A better understanding of this phenomenon could lead to important tools for the prevention or treatment of certain diseases.	Univ Sherbrooke, Fac Med, Div Immunol, Dept Pediat, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Stankova, J (corresponding author), Univ Sherbrooke, Fac Med, Div Immunol, Dept Pediat, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.							ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALI H, 1994, J BIOL CHEM, V269, P24557; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; FAR DF, 1994, CYTOMETRY, V15, P327, DOI 10.1002/cyto.990150408; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; Horan TP, 1997, J BIOCHEM-TOKYO, V121, P370; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KOTANI M, 1995, MOL PHARMACOL, V48, P869; Kuang YN, 1996, J BIOL CHEM, V271, P3975; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; LEMON MA, 1997, EMBO J, V16, P281; LIU K, 1994, J BIOL CHEM, V269, P29220; Maclennan KM, 1996, PROG NEUROBIOL, V50, P585, DOI 10.1016/S0301-0082(96)00047-0; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Naville D, 1996, J CLIN ENDOCR METAB, V81, P1442, DOI 10.1210/jc.81.4.1442; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; OkudaAshitaka E, 1996, J BIOL CHEM, V271, P31255, DOI 10.1074/jbc.271.49.31255; Parent JL, 1996, BIOCHEM BIOPH RES CO, V219, P968, DOI 10.1006/bbrc.1996.0341; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Paschke R, 1996, EXP CLIN ENDOCR DIAB, V104, P129, DOI 10.1055/s-0029-1211720; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SHUKLA SD, 1997, ADV EXP MED BIOL, V416, P153; SNYDER F, 1982, ANNU REP MED CHEM, V517, P243; Spiegel AM, 1997, J INHERIT METAB DIS, V20, P113, DOI 10.1023/A:1005393501786; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Watson S., 1994, G PROTEIN LINKED REC; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; Yano K, 1996, BIOCHEM BIOPH RES CO, V220, P1036, DOI 10.1006/bbrc.1996.0528	44	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12548	12554		10.1074/jbc.274.18.12548	http://dx.doi.org/10.1074/jbc.274.18.12548			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212233	hybrid			2022-12-25	WOS:000080056800053
J	Felinski, EA; Quinn, PG				Felinski, EA; Quinn, PG			The CREB constitutive activation domain interacts with TATA-binding protein-associated factor 110 (TAF110) through specific hydrophobic residues in one of the three subdomains required for both activation and TAF110 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CAMP RESPONSE ELEMENT; MEDIATES TRANSCRIPTIONAL ACTIVATION; THYROID-HORMONE RECEPTORS; DROSOPHILA TFIID-COMPLEX; ALPHA-SUBUNIT GENE; DTAF(II)110 COMPONENT; SOMATOSTATIN GENE; HUMAN TAF(II)135; COACTIVATORS	The cAMP response element-binding protein (CREB) mediates both basal and PKA-inducible transcription through two separate and independently active domains, the constitutive activation domain (CAD) and the kinase-inducible domain, respectively. The CREB CAD interacts with the general transcription factor TFIID through one or more of the TATA-binding protein-associated factors (TAFs), one of which is TAF110, The CAD is composed of three subdomains, rich in either serine, hydrophobic amino acids, or glutamine, In the present study, analysis of deletion mutants of the CAD showed that all three CAD subdomains were required for effective interaction with TAF110 in a yeast two-hybrid assay, Therefore, a library of random point mutations within the CAD was analyzed in a reverse two-hybrid screen to identify amino acids that are essential for interaction with the TAF. Interaction defects resulted solely from mutations of hydrophobic amino acid residues within the hydrophobic cluster to charged amino acid residues. Together, the deletion and mutation analyses suggest that the entire CAD provides an environment for a specific hydrophobic interaction with TAF110 that is crucial for interaction. Our results provide further evidence for a model of basal activation by CREB involving interaction with TAF110 that promotes recruitment or stabilization of TFIID binding to the promoter, which facilitates pre-initiation complex assembly.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Cell & Mol Biol Program, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Quinn, PG (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, H166,500 Univ Dr, Hershey, PA 17033 USA.	pquinn@psu.edu						Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Coustry F, 1998, BIOCHEM J, V331, P291, DOI 10.1042/bj3310291; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KIM KS, 1993, J BIOL CHEM, V268, P15689; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NASMYTH KM, 1986, P NATL ACAD SCI USA, V77, P2119; NILSON JH, 1989, ANN NY ACAD SCI, V564, P77, DOI 10.1111/j.1749-6632.1989.tb25889.x; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Parker D, 1996, MOL CELL BIOL, V16, P694; Petty KJ, 1996, MOL ENDOCRINOL, V10, P1632, DOI 10.1210/me.10.12.1632; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHULTZ LD, 1987, GENE, V61, P123, DOI 10.1016/0378-1119(87)90107-7; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; WEIL PA, 1979, CELL, V18, P469; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; XING LP, 1994, J BIOL CHEM, V269, P28732; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	62	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11672	11678		10.1074/jbc.274.17.11672	http://dx.doi.org/10.1074/jbc.274.17.11672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206980	hybrid			2022-12-25	WOS:000079834800036
J	Qian, YM; Varlamov, O; Fricker, LD				Qian, YM; Varlamov, O; Fricker, LD			Glu(300) of rat carboxypeptidase E is essential for enzymatic activity but not substrate binding or routing to the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY CELL-LINE; B VIRUS-PARTICLES; C-TERMINAL REGION; GENE FAMILY; MOLECULAR-CLONING; CPE(FAT)/CPE(FAT) MICE; SEQUENCE-ANALYSIS; SORTING RECEPTOR; MEMBRANE-BINDING; CDNA CLONING	Several recently discovered members of the carboxypeptidase E (CPE) gene family lack critical active site residues that are conserved in other family members. For example, three CPE-like proteins contain a Tyr in place of Glu(300) (equivalent to Glu(270) Of carboxypeptidase A and B). To investigate the importance of this position, Glu(300) Of rat CPE was converted into Gin, Lys, or Tyr, and the proteins expressed in Sf9 cells using the baculovirus system. All three mutants were secreted from the cells, but the media showed no enzyme activity above background levels. Wild-type CPE and the Gln(300) point mutant bound to ap-aminobenzoyl-Arg-Sepharose affinity resin, and this binding was competed by an active site-directed inhibitor, guanidinoethylmercaptosuccinic acid. The affinity purified mutant CPE protein showed no detectable enzyme activity (<0.004% of wildtype CPE) toward dansyl-Phe-Ala-Arg. Expression of the Gln(300) and Lys(300) mutant CPE proteins in the NIT3 mouse pancreatic beta-cell line showed that these mutants are routed into secretory vesicles and secreted via the regulated pathway. Taken together, these results indicate that Glu(300) Of CPE is essential for enzyme activity, but not required for substrate binding or for routing into the regulated secretory pathway.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	fricker@aecom.yu.edu			NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000194] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIDA NIH HHS [DA-00194, R01 DA-04494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1995, METH NEUROSCI; Battey, 1986, BASIC METHODS MOL BI; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONE RI, 1982, NEUROPEPTIDES, V3, P97, DOI 10.1016/0143-4179(82)90005-1; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; DEVI L, 1989, MOL ENDOCRINOL, V3, P1852, DOI 10.1210/mend-3-11-1852; DEVI L, 1989, J NEUROENDOCRINOL, V1, P363, DOI 10.1111/j.1365-2826.1989.tb00130.x; EATON DL, 1991, J BIOL CHEM, V266, P21833; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1983, BIOCHEM BIOPH RES CO, V111, P994, DOI 10.1016/0006-291X(83)91398-0; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; MITRA A, 1994, J BIOL CHEM, V269, P19876; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NALAMACHU SR, 1994, J BIOL CHEM, V269, P11192; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; Philippon A, 1998, CELL MOL LIFE SCI, V54, P341, DOI 10.1007/s000180050161; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; ROBERTS RM, 1995, ADV EXP MED BIOL, V362, P231; Sagane K, 1998, BIOCHEM J, V334, P93, DOI 10.1042/bj3340093; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; Song LX, 1997, J BIOL CHEM, V272, P10543; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1997, BIOCHEM J, V323, P265, DOI 10.1042/bj3230265; TAN FL, 1989, J BIOL CHEM, V264, P13165; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; van Huijsduijnen RH, 1998, GENE, V206, P273, DOI 10.1016/S0378-1119(97)00597-0; Varlamov O, 1996, J BIOL CHEM, V271, P6077, DOI 10.1074/jbc.271.11.6077; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; Xie S, 1997, P NATL ACAD SCI USA, V94, P12809, DOI 10.1073/pnas.94.24.12809; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; Xin XN, 1998, DNA CELL BIOL, V17, P897, DOI 10.1089/dna.1998.17.897; ZHANG FM, 1991, J BIOL CHEM, V266, P24606; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7	46	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11582	11586		10.1074/jbc.274.17.11582	http://dx.doi.org/10.1074/jbc.274.17.11582			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206965	hybrid			2022-12-25	WOS:000079834800021
J	Makihira, S; Yan, WQ; Ohno, S; Kawamoto, T; Fujimoto, K; Okimura, A; Yoshida, E; Noshiro, M; Hamada, T; Kato, Y				Makihira, S; Yan, WQ; Ohno, S; Kawamoto, T; Fujimoto, K; Okimura, A; Yoshida, E; Noshiro, M; Hamada, T; Kato, Y			Enhancement of cell adhesion and spreading by a cartilage-specific noncollagenous protein, cartilage matrix protein (CMP/matrilin-1), via integrin alpha(1)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; EXTRACELLULAR-MATRIX; OSTEOARTHRITIC CARTILAGE; ARTICULAR CHONDROCYTES; VONWILLEBRAND-FACTOR; SUBSTRATE ADHESION; DIVALENT-CATIONS; EXPRESSION; RECEPTOR; ALPHA-3-BETA-1	Cartilage matrix protein (CMP; also known as matrilin-1), one of the major noncollagenous proteins in most cartilages, binds to aggrecan and type II collagen. We examined the effect of CMP on the adhesion of chondrocytes and fibroblasts using CMP-coated dishes. The CMP coating at 10-20 mu g/ml enhanced the adhesion and spreading of rabbit growth plate, resting and articular chondrocytes, and fibroblasts and human epiphyseal chondrocytes and MRC5 fibroblasts. The effect of CMP on the spreading of chondrocytes was synergistically increased by native, but not heated, type II collagen (gelatin). The monoclonal antibody to integrin alpha(1) or beta(1) abolished CMP-induced cell adhesion and spreading, whereas the antibody to integrin alpha(2), alpha(3), alpha(5), beta(2), alpha(5)beta(1), or alpha(v)beta(5) had little effect on cell adhesion or spreading. The antibody to integrin alpha(1), but not to other subunits, coprecipitated I-125-CMP that was added to MRC5 cell lysates, indicating the association of CMP with the integrin a, subunit. Unlabeled CMP competed for the binding to integrin alpha(1), with I-125-CMP. These findings suggest that CMP is a potent adhesion factor for chondrocytes, particularly in the presence of type II collagen, and that integrin alpha(1)beta(1) is involved in CMP-mediated cell adhesion and spreading, Since CMP is expressed almost exclusively in cartilage, this adhesion factor, unlike fibronectin or laminin, may play a special role in the development and remodeling of cartilage.	Hiroshima Univ, Sch Dent, Dept Biochem, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Sch Dent, Dept Prosthet Dent, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Sch Dent, Dept Orthodont, Minami Ku, Hiroshima 7348553, Japan; Norman Bethune Univ Med Sci, Inst Endem Dis, Dept Biochem, Changchun 130021, Peoples R China	Hiroshima University; Hiroshima University; Hiroshima University; Jilin University	Kato, Y (corresponding author), Hiroshima Univ, Sch Dent, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	ykato@ipc.hiroshima-u.ac.jp	, 河本健/D-7938-2015	, 河本健/0000-0003-3337-1775				ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Deak F, 1997, J BIOL CHEM, V272, P9268; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Hauser N, 1995, ACTA ORTHOP SCAND, V66, P19, DOI 10.3109/17453679509157641; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KATO Y, 1993, J CLIN INVEST, V92, P2323, DOI 10.1172/JCI116836; KISS I, 1989, J BIOL CHEM, V264, P8126; LOESER RF, 1995, EXP CELL RES, V217, P248, DOI 10.1006/excr.1995.1084; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; Meulenbelt I, 1997, ARTHRITIS RHEUM, V40, P1760, DOI 10.1002/art.1780401006; OKADA Y, 1992, LAB INVEST, V66, P680; Okimura A, 1997, ARTHRITIS RHEUM, V40, P1029, DOI 10.1002/art.1780400606; Pattaramalai S, 1996, EXP CELL RES, V222, P281, DOI 10.1006/excr.1996.0036; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; PAULSSON M, 1984, BIOCHEM J, V221, P623, DOI 10.1042/bj2210623; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SALTER DM, 1995, J HISTOCHEM CYTOCHEM, V43, P447, DOI 10.1177/43.4.7897185; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; STIRPE NS, 1989, DEVELOPMENT, V107, P23; Towbin H, 1992, Biotechnology, V24, P145; TSONIS PA, 1988, EXP EYE RES, V46, P753, DOI 10.1016/S0014-4835(88)80061-7; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; WOODS VL, 1994, ARTHRITIS RHEUM, V37, P537, DOI 10.1002/art.1780370414; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012	38	60	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11417	11423		10.1074/jbc.274.16.11417	http://dx.doi.org/10.1074/jbc.274.16.11417			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196235	hybrid			2022-12-25	WOS:000079751900103
J	Miura, R; Aspberg, A; Ethell, IM; Hagihara, K; Schnaar, RL; Ruoslahti, E; Yamaguchi, Y				Miura, R; Aspberg, A; Ethell, IM; Hagihara, K; Schnaar, RL; Ruoslahti, E; Yamaguchi, Y			The proteoglycan lectin domain binds sulfated cell surface glycolipids and promotes cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE; NERVOUS-SYSTEM; CARBOHYDRATE-BINDING; CORE PROTEIN; TENASCIN-R; L-SELECTIN; RAT-BRAIN; L2/HNK-1 CARBOHYDRATE; EXPRESSION CLONING; NEURITE OUTGROWTH	The lecticans are a group of chondroitin sulfate proteoglycans characterized by the presence of C-type lectin domains. Despite the suggestion that their lectin domains interact with carbohydrate ligands, the identity of such ligands has not been elucidated. We previously showed that brevican, a nervous system-specific lectican, binds the surface of B28 glial cells (Yamada, H., Fredette, B., Shitara, K., Hagihara, K., Miura, R., Ranscht, B., Stallcup, W, B., and Yamaguchi, Y. (1997) J. Neurosci, 17, 7784-7795), In this paper, we demonstrate that two classes of sulfated glycolipids, sulfatides and HNK-1-reactive sulfoglucuronylglycolipids (SGGLs), act as cell surface receptors for brevican. The lectin domain of brevican binds sulfatides and SGGLs in a calcium-dependent manner as expected of a C-type lectin domain. Intact, full-length brevican also binds both sulfatides and SGGLs. The lectin domain immobilized as a substrate supports adhesion of cells expressing SGGLs or sulfatides, which was inhibited by monoclonal antibodies against these glycolipids or by treatment of the substrate with SGGLs or sulfatides, Our findings demonstrate that the interaction between the lectin domains of lecticans and sulfated glycolipids comprises a novel cell substrate recognition system, and suggest that lecticans in extracellular matrices serve as substrate for adhesion and migration of cells expressing these glycolipids in vivo.	Burnham Inst, La Jolla, CA 92037 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Neurosci, Baltimore, MD 21205 USA	Sanford Burnham Prebys Medical Discovery Institute; Johns Hopkins University	Yamaguchi, Y (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Ethell, Iryna/0000-0002-1324-6611; Aspberg, Anders/0000-0002-6588-6944	NCI NIH HHS [CA28896] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline; NINDS NIH HHS [NS32717] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA028896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Chou DKH, 1998, J BIOL CHEM, V273, P8508, DOI 10.1074/jbc.273.14.8508; COOLING LLW, 1995, GLYCOBIOLOGY, V5, P571, DOI 10.1093/glycob/5.6.571; Courel MN, 1998, J NEUROCYTOL, V27, P27, DOI 10.1023/A:1006982802778; CROSSIN KL, 1992, J NEUROSCI RES, V33, P631, DOI 10.1002/jnr.490330416; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FRYXELL KJ, 1980, J NEUROCHEM, V35, P1461, DOI 10.1111/j.1471-4159.1980.tb09026.x; GERSTEN DM, 1978, J IMMUNOL METHODS, V24, P305, DOI 10.1016/0022-1759(78)90133-3; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HALL H, 1995, GLYCOBIOLOGY, V5, P435, DOI 10.1093/glycob/5.4.435; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; Jahnke W, 1997, ANGEW CHEM INT EDIT, V36, P2603, DOI 10.1002/anie.199726031; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; Lebaron RG, 1996, PERSPECT DEV NEUROBI, V3, P261; Li H, 1996, MOL BRAIN RES, V36, P309, DOI 10.1016/0169-328X(95)00269-X; MCEVER RP, 1995, J BIOL CHEM, V270, P1125; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; Miura Y, 1997, BIOCHEM BIOPH RES CO, V241, P698, DOI 10.1006/bbrc.1997.7876; Nair SM, 1997, J NEUROCHEM, V68, P1286; NEEDHAM LK, 1993, J CELL BIOL, V121, P397, DOI 10.1083/jcb.121.2.397; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1339; NIIMURA Y, 1990, BIOCHIM BIOPHYS ACTA, V1052, P248, DOI 10.1016/0167-4889(90)90218-3; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; Pesheva P, 1997, J NEUROSCI, V17, P4642; PODUSLO SE, 1985, NEUROCHEM RES, V10, P1285, DOI 10.1007/BF00964847; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; Schwartz NB, 1996, PERSPECT DEV NEUROBI, V3, P291; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; Seidenbecher CI, 1998, EUR J NEUROSCI, V10, P1621, DOI 10.1046/j.1460-9568.1998.00166.x; STALLCUP WB, 1976, EXP CELL RES, V98, P285, DOI 10.1016/0014-4827(76)90440-7; TAKI T, 1991, CANCER RES, V51, P1701; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; UJITA M, 1994, J BIOL CHEM, V269, P27603; Wong CH, 1997, J AM CHEM SOC, V119, P8152, DOI 10.1021/ja970920q; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 1996, PERSPECT DEV NEUROBI, V3, P307; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	63	96	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11431	11438		10.1074/jbc.274.16.11431	http://dx.doi.org/10.1074/jbc.274.16.11431			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196237	hybrid			2022-12-25	WOS:000079751900105
J	Rosenwald, IB; Chen, JJ; Wang, ST; Savas, L; London, IM; Pullman, J				Rosenwald, IB; Chen, JJ; Wang, ST; Savas, L; London, IM; Pullman, J			Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis	ONCOGENE			English	Article						eIF-4E; translation factors; cyclins; protein synthesis; transformation; colon cancer	CAP-BINDING PROTEIN; RNA 5' CAP; TRANSLATION INITIATION; FACTOR 4E; MESSENGER-RNA; CYCLIN D1; CELL-CYCLE; C-MYC; ORNITHINE DECARBOXYLASE; RETINOBLASTOMA PROTEIN	A general increase in protein synthesis and a specific increase in the synthesis of growth-promoting proteins are necessary for mitogenesis, Regulation of protein synthesis, as well as preferential translation of some mRNAs coding for growth promoting proteins (e.g. cyclin D1), involves the essential protein synthesis initiation factor eIF-4E. This factor is induced by various oncoproteins, and, when overexpressed, it can transform cultured cells. In this report we explore the roles of eIF-4E in human neoplastic disorders of the colon and in the regulation of general and specific protein synthesis, We find that eIF-4E is increased in colon adenomas and carcinomas, and this increase is accompanied in most but not all cases by elevation of cyclin D1 levels. While general protein synthesis is increased by eIF-4E overexpression in cultured cells, only a small proportion of proteins is preferentially upregulated by eIF-4E, as revealed by two-dimensional gel electrophoresis. These results are consistent with the view that eIF-4E plays a role in carcinogenesis by increasing general protein synthesis and by preferentially upregulating a subset of putative growth promoting proteins. Our results, taken together with the recent findings that c-myc transcription is negatively regulated by APC and our earlier data on transcriptional activation of eIF-4E expression by c-Myc suggest that eIF-4E is a downstream target of the APC/beta-catenin/Tcf-4 pathway, and is strongly involved in colon tumorigenesis.	Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA; MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts Institute of Technology (MIT)	Rosenwald, IB (corresponding author), Univ Massachusetts, Med Ctr, Dept Pathol, 55 Lake Ave N, Worcester, MA 01655 USA.				NIDDK NIH HHS [DK 16272, R01 DK016272] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Epifanova O I, 1977, Int Rev Cytol Suppl, P303; GRAFF JR, 1995, INT J CANCER, V60, P255; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERSHKO A, 1971, NATURE-NEW BIOL, V232, P206, DOI 10.1038/newbio232206a0; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Maeda K, 1997, INT J CANCER, V74, P310, DOI 10.1002/(SICI)1097-0215(19970620)74:3<310::AID-IJC13>3.0.CO;2-F; MAKIN CA, 1984, J CLIN PATHOL, V37, P975, DOI 10.1136/jcp.37.9.975; MELHEM MF, 1992, CANCER RES, V52, P5853; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; RHOADS RE, 1994, BIOCHIMIE, V76, P831, DOI 10.1016/0300-9084(94)90184-8; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Rosenwald IB, 1995, CANCER LETT, V98, P77, DOI 10.1016/0304-3835(95)90206-6; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Shantz LM, 1996, CANCER RES, V56, P3265; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	44	154	173	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	1999	18	15					2507	2517		10.1038/sj.onc.1202563	http://dx.doi.org/10.1038/sj.onc.1202563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229202				2022-12-25	WOS:000079703300011
J	Bertin, J; Nir, WJ; Fischer, CM; Tayber, OV; Errada, PR; Grant, JR; Keilty, JJ; Gosselin, ML; Robison, KE; Wong, GHW; Glucksmann, MA; DiStefano, PS				Bertin, J; Nir, WJ; Fischer, CM; Tayber, OV; Errada, PR; Grant, JR; Keilty, JJ; Gosselin, ML; Robison, KE; Wong, GHW; Glucksmann, MA; DiStefano, PS			Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; RECEPTOR; ELEGANS; KINASE	The nematode CED-4 protein and its human homolog Apaf-1 play a central role in apoptosis by functioning as direct activators of death-inducing caspases. A novel human CED-4/Apaf-1 family member called CARD4 was identified that has a domain structure strikingly similar to the cytoplasmic, receptor-like proteins that mediate disease resistance in plants. CARD4 interacted with the serine-threonine kinase RICK and potently induced NF-kappa B activity through TRAF-6 and NIK signaling molecules. In addition, coexpression of CARD4 augmented caspase-9-induced apoptosis. Thus, CARD4 coordinates downstream NF-kappa B and apoptotic signaling pathways and may be a component of the host innate immune response.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Bertin, J (corresponding author), Millennium Pharmaceut Inc, 640 Med Dr, Cambridge, MA 02139 USA.	bertin@mpi.com						Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; INOHARA N, 1998, P NATL ACAD SCI USA, V273, P12296; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	16	302	324	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12955	12958		10.1074/jbc.274.19.12955	http://dx.doi.org/10.1074/jbc.274.19.12955			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224040	hybrid			2022-12-25	WOS:000080200400002
J	Chen, LL; Whitty, A; Lobb, RR; Adams, SP; Pepinsky, RB				Chen, LL; Whitty, A; Lobb, RR; Adams, SP; Pepinsky, RB			Multiple activation states of integrin alpha(4)beta(1) detected through their different affinities for a small molecule ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; CONFORMATIONAL-CHANGES; SIGNAL-TRANSDUCTION; LEUKOCYTE ADHESION; ALPHA-4 INTEGRINS; CRYSTAL-STRUCTURE; DIVALENT-CATIONS; BINDING REGION; CROSS-LINKING; T-CELLS	We have used the highly specific alpha(4)beta(1) inhibitor 4-((N'-2-methylphenyl)ureido)- phenylacetyl-leucine-aspartic acid-valine-proline (BIO1211) as a model LDV-containing ligand to study integrin-ligand interactions on Jurkat cells under diverse conditions that affect the activation state of alpha(4)beta(1). Observed K-D values for BIO1211 binding ranged from a value of 20-40 NM in the nonactivated state of the integrin that exists in 1 mM Mg2+, I mM Ca2+ to 100 pM in the activated state seen in 2 mM Mn2+ to 18 pM when binding was measured after coactivation by 2 mM Mn2+ plus 10 mu g/ml of the integrin-activating monoclonal antibody TS2/16. The large range in RD values was governed almost exclusively by differences in the dissociation rates of the integrin-BIO1211 complex, which ranged from 0.17 x 10(-4) s(-1) to >140 x 10(-4) s(-1). Association rate constants varied only slightly under the same conditions, all falling in the narrow range from 0.9 to 2.7 x 10(6) M-1 s(-1). The further increase in affinity observed upon co-activation by divalent cations and TS2/16 compared with that observed at saturating concentrations of metal ions or TS2/16 alone indicates that the mechanism by which these factors bring about activation are distinct and identified a previously unrecognized high affinity state on alpha(4)beta(1) that had not been detected by conventional assay methods. Similar changes in affinity were observed when the binding properties of vascular cell adhesion molecule-1 and CS1 to alpha(4)beta(1) were studied, indicating that the different affinity states detected with BIO1211 are an inherent property of the integrin.	Biogen Inc, Cambridge, MA 02142 USA	Biogen	Pepinsky, RB (corresponding author), Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.							ANWAR ARE, 1994, IMMUNOLOGY, V82, P222; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; CHAN BMC, 1991, J IMMUNOL, V147, P398; Chen LL, 1998, BIOCHEMISTRY-US, V37, P8743, DOI 10.1021/bi980311a; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GULINO D, 1992, J BIOL CHEM, V267, P1001; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MOLOSSI S, 1995, J CLIN INVEST, V95, P2601, DOI 10.1172/JCI117962; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Newham P, 1998, J IMMUNOL, V160, P4508; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PERELSON AS, 1980, MATH BIOSCI, V48, P71, DOI 10.1016/0025-5564(80)90017-6; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Udagawa T, 1996, J IMMUNOL, V157, P1965; WAHL SM, 1994, J CLIN INVEST, V94, P655, DOI 10.1172/JCI117382; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WAYER EA, 1992, J CELL BIOL, V116, P489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; Yoshikawa H, 1996, J IMMUNOL, V156, P1832	41	67	68	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13167	13175		10.1074/jbc.274.19.13167	http://dx.doi.org/10.1074/jbc.274.19.13167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224072	hybrid			2022-12-25	WOS:000080200400034
J	Liu, Y; Thor, A; Shtivelman, E; Cao, YH; Tu, GH; Heath, TD; Debs, RJ				Liu, Y; Thor, A; Shtivelman, E; Cao, YH; Tu, GH; Heath, TD; Debs, RJ			Systemic gene delivery expands the repertoire of effective antiangiogenic agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TUMOR ANGIOGENESIS; IN-VIVO; LUNG-CARCINOMA; CANCER; METASTASIS; THERAPY; GROWTH; SUPPRESSION; ANGIOSTATIN	Cationic liposome-DNA complex (CLDC)-based intravenous gene delivery targets gene expression to vascular endothelial cells, macrophages and tumor cells. We used systemic gene delivery to identify anti-angiogenic gene products effective against metastatic spread in tumor-bearing mice, Specifically, CLDC-based intravenous delivery of the p53 and GM-CSF genes were each as effective as the potent antiangiogenic gene, angiostatin, in reducing both tumor metastasis and tumor angiogenesis, Combined delivery of these genes did not increase anti-tumor activity, further suggesting that each gene appeared to produce its antimetastatic activity through a common antiangiogenic pathway. CLDC-based intravenous delivery of the human wild type p53 gene transfected up to 80% of tumor cells metastatic to lung. Furthermore, it specifically induced the expression of the potent antiangiogenic gene, thrombospondin-l, indicating that p53 gene delivery in vivo may inhibit angiogenesis by inducing endogenous thrombospondin-l expression. CLDC-based delivery also identified a novel antitumor activity for the metastasis suppressor gene CC3, Thus, CLDC-based intravenous gene delivery can produce systemic antiangiogenic gene therapy using a variety of different genes and may be used to assess potential synergy of combined anti-tumor gene delivery and to identify novel activities for existing anti-tumor genes.	Calif Pacific Med Ctr, Res Inst, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA; Northwestern Univ, Sch Med, Dept Pathol, Evanston, IL 60201 USA; Karolinska Inst, Lab Angiogenesis Res, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; Northwestern University; Karolinska Institutet; University of Wisconsin System; University of Wisconsin Madison	Debs, RJ (corresponding author), Calif Pacific Med Ctr, Res Inst, Geraldine Brush Canc Res Inst, 2330 Clay St,Stern Bldg, San Francisco, CA 94115 USA.				NATIONAL CANCER INSTITUTE [R01CA058914, P50CA058207, R01CA071422] Funding Source: NIH RePORTER; NCI NIH HHS [CA58914, CA58207, CA71422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIKFALVI A, 1994, LEUKEMIA, V8, P523; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cao YH, 1998, J CLIN INVEST, V101, P1055, DOI 10.1172/JCI1558; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CRAFT PS, 1994, ANN ONCOL, V5, P305, DOI 10.1093/oxfordjournals.annonc.a058829; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hartikka J, 1996, HUM GENE THER, V7, P1205, DOI 10.1089/hum.1996.7.10-1205; HEIDENREICH O, 1995, MOL MED TODAY, V1, P128, DOI 10.1016/S1357-4310(95)80090-5; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; Kijima H, 1995, PHARMACOL THERAPEUT, V68, P247, DOI 10.1016/0163-7258(95)02008-X; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIOTTA LA, 1993, PRINCIPLES MOL CELL, P134; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; McLean JW, 1997, AM J PHYSIOL-HEART C, V273, pH387, DOI 10.1152/ajpheart.1997.273.1.H387; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Soldi R, 1997, BLOOD, V89, P863, DOI 10.1182/blood.V89.3.863; Song YK, 1997, HUM GENE THER, V8, P1585, DOI 10.1089/hum.1997.8.13-1585; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TSUIMOTO Y, 1987, P NATL ACAD SCI USA, V83, P5214; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xu M, 1997, HUM GENE THER, V8, P177, DOI 10.1089/hum.1997.8.2-177	36	76	91	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13338	13344		10.1074/jbc.274.19.13338	http://dx.doi.org/10.1074/jbc.274.19.13338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224095	hybrid			2022-12-25	WOS:000080200400057
J	Nakamura, T; Takeuchi, K; Muraoka, S; Takezoe, H; Takahashi, N; Mori, N				Nakamura, T; Takeuchi, K; Muraoka, S; Takezoe, H; Takahashi, N; Mori, N			A neurally enriched coronin-like protein, ClipinC, is a novel candidate for an actin cytoskeleton-cortical membrane-linking protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; FOCAL ADHESIONS; BETA-1 INTEGRIN; CELL MOTILITY; STRESS FIBERS; GROWTH CONES; WD-REPEAT; DICTYOSTELIUM; FILOPODIA; SUBUNIT	Brain-enriched human FC96 protein shows a close sequence similarity to the Dictyostelium actin-binding protein coronin, which has been implicated in cell motility, cytokinesis, and phagocytosis, A phylogenetic tree analysis revealed that FC96 and two other mammalian molecules (p57 and IR10) form a new protein family, the coronin-like protein (Clipin) family; thus hereafter we refer to FC96 as ClipinC, A WD domain and a succeeding cu-helical region are conserved among coronin and Clipin family members. ClipinC is predominantly expressed in the brain, and discrete areas in the mouse brain were intensely labeled with anti-ClipinC antibodies. ClipinC was also shown to bind directly to F-actin in vitro. Immunocytochemical analysis revealed that ClipinC accumulated at focal adhesions as well as at neurite tips and stress fibers. Furthermore, ClipinC was associated with vinculin, which is a major component of focal contacts. These results indicate that ClipinC is also a component part of the cross-bridge between the actin cytoskeleton and the plasma membrane. These findings and the previously reported function of coronin suggest that ClipinC may play specific roles in the reorganization of neuronal actin structure, a change that has been implicated in both cell motility and growth cone advance.	Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, Ikoma, Nara 6300101, Japan; Sci & Technol Corp Japan, PRESTO, Inheritance & Variat Grp, Kyoto 61902, Japan; Sci & Technol Corp Japan, CREST, Program Protecting Brain, Oobu, Aichi 4748522, Japan; Natl Inst Longev Sci, Dept Mol Genet Res, Oobu, Aichi 4748522, Japan	Sumitomo Electric Industries; Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Nakamura, T (corresponding author), Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan.		Takeuchi, Kosei/AAV-3577-2021	Takeuchi, Kosei/0000-0001-6397-2243				Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Grabham PW, 1997, J NEUROSCI, V17, P5455; Grogan A, 1997, J CELL SCI, V110, P3071; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Nakamura T, 1996, ONCOGENE, V13, P1111; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OUIMET CC, 1990, J NEUROSCI, V10, P1683; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rakic Pasko, 1994, Current Opinion in Neurobiology, V4, P63, DOI 10.1016/0959-4388(94)90033-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sasaki Y F, 1994, DNA Res, V1, P91, DOI 10.1093/dnares/1.2.91; SCHMIDT CE, 1995, J NEUROSCI, V15, P3400; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TANABE Y, 1988, MOL CELL BIOL, V8, P466; VARNUMFINNEY B, 1994, J CELL BIOL, V127, P1071, DOI 10.1083/jcb.127.4.1071; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; Wu DY, 1996, J NEUROSCI, V16, P1470; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; ZAPHIROPOULOS PG, 1996, DNA CELL BIOL, V15	33	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13322	13327		10.1074/jbc.274.19.13322	http://dx.doi.org/10.1074/jbc.274.19.13322			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224093	hybrid			2022-12-25	WOS:000080200400055
J	Spiegelberg, BD; Xiong, JP; Smith, JJ; Gu, RF; York, JD				Spiegelberg, BD; Xiong, JP; Smith, JJ; Gu, RF; York, JD			Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3 '-nucleotidase inhibited by inositol 1,4-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHATE 1-PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; 3'(2'),5'-BISPHOSPHATE NUCLEOTIDASE; PAPS TRANSLOCASE; SALT TOLERANCE; YEAST; GENE; FRUCTOSE-1,6-BISPHOSPHATASE; MONOPHOSPHATASE; IDENTIFICATION	Discovery of a structurally conserved metal-dependent lithium-inhibited phosphomonoesterase protein family has identified several potential cellular targets of lithium as used to treat manic depression. Here we describe identification of a novel family member using a "computer cloning" strategy, Human and murine cDNA clones encoded proteins sharing 92% identity and were highly expressed in kidney. Native and recombinant protein harbored intrinsic magnesium-dependent bisphosphate nucleotidase activity (BPntase), which removed the S'-phosphate from 3'-5' bisphosphate nucleosides and 3'-phosphoadenosine 5'-phosphosulfate with K-m and V-max values of 0.5 mu M and 40 mu mol/min/mg. Lithium uncompetitively inhibited activity with a K-i of 157 mu M interestingly, BPntase was competitively inhibited by inositol 1,4-bisphosphate with a K-i of 15 mu M Expression of mammalian BPntase complemented defects in hal2/met22 mutant yeast. These data suggest that BPntase's physiologic role in nucleotide metabolism may be regulated by inositol signaling pathways. The presence of high levels of BPntase in the kidney are provocative in Light of the roles of bisphosphorylated nucleotides in regulating salt tolerance, sulfur assimilation, detoxification, and lithium toxicity. We propose that inhibition of human BPntase may account for Lithium-induced nephrotoxicity, which may be overcome by supplementation of current therapeutic regimes with inhibitors of nucleotide biosynthesis, such as methionine.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University	York, JD (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA.				NHLBI NIH HHS [R01-HL 55672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharya JK, 1998, NEURON, V20, P1219, DOI 10.1016/S0896-6273(00)80502-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; BONE R, 1994, BIOCHEMISTRY-US, V33, P9468, DOI 10.1021/bi00198a012; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEREST H, 1971, Journal of Bacteriology, V106, P758; Depiereux E, 1997, COMPUT APPL BIOSCI, V13, P249; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; INHORN RC, 1987, J BIOL CHEM, V262, P15946; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; KE HM, 1989, P NATL ACAD SCI USA, V86, P1475, DOI 10.1073/pnas.86.5.1475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moore DD, 1995, GLOB MOB SURV; MURGUIA JR, 1995, SCIENCE, V267, P232; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; NEUWALD AF, 1992, J BACTERIOL, V174, P415, DOI 10.1128/jb.174.2.415-425.1992; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3695, DOI 10.1021/bi951303m; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3685, DOI 10.1021/bi951302u; PENG ZH, 1995, J BIOL CHEM, V270, P29105, DOI 10.1074/jbc.270.49.29105; POLLACK SJ, 1993, EUR J BIOCHEM, V217, P281, DOI 10.1111/j.1432-1033.1993.tb18244.x; Quintero FJ, 1996, PLANT CELL, V8, P529, DOI 10.1105/tpc.8.3.529; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER SS, 1979, ANAL BIOCHEM, V96, P34, DOI 10.1016/0003-2697(79)90550-5; Stolz LE, 1998, GENETICS, V148, P1715; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P8916, DOI 10.1073/pnas.92.19.8916; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149; YORK JD, 1994, BIOCHEMISTRY-US, V33, P13164, DOI 10.1021/bi00249a002; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i	34	72	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13619	13628		10.1074/jbc.274.19.13619	http://dx.doi.org/10.1074/jbc.274.19.13619			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224133	hybrid			2022-12-25	WOS:000080200400095
J	Fagan, KA; Rich, TC; Tolman, S; Schaack, J; Karpen, JW; Cooper, DMF				Fagan, KA; Rich, TC; Tolman, S; Schaack, J; Karpen, JW; Cooper, DMF			Adenovirus-mediated expression of an olfactory cyclic nucleotide-gated channel regulates the endogenous Ca2+-inhibitable adenylyl cyclase in C6-2B glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; FUNCTIONAL EXPRESSION; LIGHT ADAPTATION; CALCIUM; NEURONS; CLONING; INHIBITION; METABOLISM; SYNAPSES; MUSCLE	Previous studies have established that Ca2+-sensitive adenylyl cyclases, whether endogenously or heterologously expressed, are preferentially regulated by capacitative Ca2+ entry, compared with other means of elevating cytosolic Ca2+ (Chiono, M,, Mahey, R,, Tate, G,, and Cooper, D, Ni. F. (1995) J. Biol. Chem, 270, 1149-1155; Fagan, K, A, Mahey, R,, and Cooper, D, M. F, (1996) J, Biol, Chem, 271, 12438-12444; Fagan, K, A., Mons, N,, and Cooper, D, M. F, (1998) J. Biol. Chem. 273, 9297-9305), These findings led to the suggestion that adenylyl cyclases and capacitative Ca2+ entry channels were localized in the same functional domain of the plasma membrane, In the present study, we have asked whether a heterologously expressed Ca2+-permeable channel could regulate the Ca2+-inhibitable adenylyl cyclase of C6-2B glioma cells. The cDNA coding for the rat olfactory cyclic nucleotide-gated channel was inserted into an adenovirus construct to achieve high levels of expression. Electrophysiological measurements confirmed the preservation of the properties of the expressed olfactory channel. Stimulation of the channel with cGMP analogs yielded a robust elevation in cytosolic Ca2+, which was associated with an inhibition of cAMP accumulation, comparable with that elicited by capacitative Ca2+ entry. These findings not only extend the means whereby Ca2+-sensitive adenylyl cyclases may be regulated, they also suggest that in tissues where they co-exist, cyclic nucleotidegated channels and Ca2+ sensitive adenylyl cyclases may reciprocally modulate each other's activity.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.				NHLBI NIH HHS [HL58344] Funding Source: Medline; NIGMS NIH HHS [GM 32483] Funding Source: Medline; NINDS NIH HHS [NS 28389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANHOLT RRH, 1993, CRIT REV NEUROBIOL, V7, P1; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; Bradley J, 1997, J NEUROSCI, V17, P1993; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Ding CL, 1997, AM J PHYSIOL-CELL PH, V272, pC1335, DOI 10.1152/ajpcell.1997.272.4.C1335; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Feng L, 1996, FEBS LETT, V395, P77, DOI 10.1016/0014-5793(96)01011-3; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; FRINGS S, 1995, NEURON, V15, P169, DOI 10.1016/0896-6273(95)90074-8; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Ishikawa Y, 1997, CIRC RES, V80, P297, DOI 10.1161/01.RES.80.3.297; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kingston PA, 1996, P NATL ACAD SCI USA, V93, P10440, DOI 10.1073/pnas.93.19.10440; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; Parent A, 1998, J NEUROPHYSIOL, V79, P3295, DOI 10.1152/jn.1998.79.6.3295; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; Ruiz ML, 1996, J MOL CELL CARDIOL, V28, P1453, DOI 10.1006/jmcc.1996.0136; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Savchenko A, 1997, NATURE, V390, P694, DOI 10.1038/37803; SCHAACK J, 1995, J VIROL, V69, P3920, DOI 10.1128/JVI.69.6.3920-3923.1995; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	37	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12445	12453		10.1074/jbc.274.18.12445	http://dx.doi.org/10.1074/jbc.274.18.12445			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212219	hybrid			2022-12-25	WOS:000080056800039
J	Pizard, A; Blaukat, A; Muller-Esterl, W; Alhenc-Gelas, F; Rajerison, RM				Pizard, A; Blaukat, A; Muller-Esterl, W; Alhenc-Gelas, F; Rajerison, RM			Bradykinin-induced internalization of the human B-2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; B2 RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE RESIDUE; BETA-ARRESTIN; AGONIST; DESENSITIZATION; SEQUESTRATION	The binding of bradykinin (BK) to B-2 receptor triggers the internalization of the agonist-receptor complex, To investigate the mechanisms and the receptor structures involved in this fundamental process of receptor regulation, the human B-2 receptor was mutated within its cytoplasmic tail by complementary strategies of truncation, deletion, and amino acid substitution. Ligand binding, signal transduction, internalization as well as phosphorylation were studied for the mutated receptors expressed in COS, CHO, and HEK 293 cells, Truncation of 44 out of 55 amino acid residues of the receptor's cytoplasmic tail corresponding to positions 321-364 did not alter the kinetics of BK binding and the receptor coupling to phospholipase C and phospholipase A(2). By contrast, truncations after positions 320 and 334, deletions within the segment covering positions 335-351, as well as alanine substitution of serine and threonine residues within segment 335-351 diminished the internalization capacity of the mutant receptors. Mutants with a markedly reduced internalization potential failed to produce BK-induced receptor phosphorylation suggesting that phosphorylation may be involved in receptor internalization. The mutagenesis approaches converged at the conclusion that three serines in positions 339, 346, and 348 and two threonines in positions 342 and 345, contained in a sequence segment that is highly conserved between species, have a critical role in the ligand-dependent internalization and phosphorylation of kinin receptors and can intervene in these processes iii an alternative manner. However, mutants lacking these residues were still sensitive to dominant-negative forms of p-arrestin and dynamin, suggesting the existence of additional receptor structure(s) involved in the receptor sequestration through clathrin-coated vesicles.	INSERM, U367, F-75005 Paris, France; Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Johannes Gutenberg University of Mainz	Pizard, A (corresponding author), INSERM, U367, 17 Rue Fer Moulin, F-75005 Paris, France.		Pizard, Anne CM/P-4754-2016; Alhenc-Gelas, Francois/F-9511-2017	Pizard, Anne CM/0000-0003-2705-6365; 				Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BASCANDS JL, 1994, AM J PHYSIOL, V36, pF871; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Blaukat A, 1997, IMMUNOPHARMACOLOGY, V36, P115, DOI 10.1016/S0162-3109(97)00009-X; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHEN CC, 1995, MOL PHARMACOL, V39, P39; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Faussner A, 1998, J BIOL CHEM, V273, P2617, DOI 10.1074/jbc.273.5.2617; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Haasemann M, 1998, J CELL SCI, V111, P917; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Hess J. F., 1993, MOL PHARMACOL, V45, P1; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hill AV, 1910, J PHYSIOL-LONDON, V40, piv; JAFFA AA, 1997, AM J PHYSIOL, V273, pF9126; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MENKE JG, 1994, J BIOL CHEM, V269, P21583; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; Pizard A, 1998, J BIOL CHEM, V273, P1309, DOI 10.1074/jbc.273.3.1309; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; Rao RV, 1997, MOL PHARMACOL, V51, P185, DOI 10.1124/mol.51.2.185; REGOLI D, 1980, PHARMACOL REV, V32, P1; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schroeder C, 1997, J BIOL CHEM, V272, P12475, DOI 10.1074/jbc.272.19.12475; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Widmann C, 1997, MOL ENDOCRINOL, V11, P1094, DOI 10.1210/me.11.8.1094; WOLSING DH, 1991, J PHARMACOL EXP THER, V257, P621; YANG J, 1995, MOL PHARMACOL, V48, P477; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	43	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12738	12747		10.1074/jbc.274.18.12738	http://dx.doi.org/10.1074/jbc.274.18.12738			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212257	hybrid			2022-12-25	WOS:000080056800077
J	Rogers, GW; Richter, NJ; Merrick, WC				Rogers, GW; Richter, NJ; Merrick, WC			Biochemical and kinetic characterization of the RNA helicase activity of eukaryotic initiation factor 4A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX PROTEIN EIF4A; MESSENGER-RNA; SECONDARY STRUCTURE; ESCHERICHIA-COLI; TRANSLATION; BINDING; NUCLEOTIDE; MECHANISM; FAMILY; REGION	Eukaryotic initiation factor (eIF) 4A is the prototypic member of the DEAD box family of proteins and has been proposed to act as an RNA helicase to unwind secondary structure in the 5'-untranslated region of eukaryotic mRNAs, Previous studies have shown that the RNA helicase activity of eIF4A is dependent on the presence of a second initiation factor, eIF4B, In this report, eIF4A has been demonstrated to function independently of eIF4B as an ATP-dependent RNA helicase, The bio chemical and kinetic properties of this activity were examined. By using a family of RNA duplexes with an unstructured single-stranded region followed by a duplex region of increasing length and stability, it was observed that the initial rate of duplex unwinding decreased with increasing stability of the duplex. Furthermore, the maximum amount of duplex unwound also decreased with increasing stability. Results suggest that eIF4A acts in a non-processive manner. eIF4B and eIF4H were shown to stimulate the helicase activity of eIF4A, allowing eIF4A to unwind longer, more stable duplexes with both an increase in initial rate and maximum amount of duplex unwound. A simple kinetic model is proposed to explain the mechanism by which eIF4A unwinds RNA duplex structures in an ATP-dependent manner.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07319] Funding Source: Medline; NIGMS NIH HHS [GM08056, GM26796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; CARBERRY SE, 1992, BIOCHEMISTRY-US, V31, P1427, DOI 10.1021/bi00120a020; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; GOSS DJ, 1987, BIOCHEMISTRY-US, V26, P1551, DOI 10.1021/bi00380a009; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Merrick WC., 1996, TRANSLATION CONTROL, P31; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; Richter-Cook NJ, 1998, J BIOL CHEM, V273, P7579, DOI 10.1074/jbc.273.13.7579; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SHUMAN S, 1993, J BIOL CHEM, V268, P11798; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069	37	244	248	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12236	12244		10.1074/jbc.274.18.12236	http://dx.doi.org/10.1074/jbc.274.18.12236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212190	hybrid			2022-12-25	WOS:000080056800010
J	Vezza, R; Habib, A; FitzGerald, GA				Vezza, R; Habib, A; FitzGerald, GA			Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, G(h)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	70th Scientific Session of the American-Heart-Association Meeting	NOV 09-13, 1997	ORLANDO, FLORIDA	Amer Heart Assoc			PHOSPHOLIPASE-C; HUMAN PLATELETS; A(2) RECEPTOR; TRANSGLUTAMINASE ACTIVITY; THROMBIN RECEPTORS; ALPHA-SUBUNITS; TERMINAL TAIL; KINASE-C; IN-VIVO; IDENTIFICATION	Thromboxane A(2) acts via G protein-coupled receptors; two splice variants of the thromboxane A(2) receptor (TP alpha and TP beta) have been cloned. It is unknown whether they differ in their capacity to activate intracellular signaling pathways. Recently, a high molecular weight G protein, G(h), that can also function as a tissue transglutaminase, has been described. We investigated whether G(h) functions as a signaling protein in association with thromboxane receptors, First, we sought G(h) expression in cells known to express TPs, Reverse transcription-polymerase chain reaction and immunoblotting demonstrated G(h) expression in platelets, megakaryocytic cell lines, and endothelial and vascular smooth muscle cells. Second, immunoprecipitation of both TP alpha and TP beta in transfected COS-7 cells resulted in the co-immunoprecipitation of G(h), indicating that TPs may associate G(h) in vice. Finally, agonist activation of TP alpha, but not of TP beta, resulted in stimulation of phospholipase C-mediated inositol phosphate production in cells cotransfected with G(h), By contrast, agonist activation of both TP iso forms resulted in G(h)-mediated inositol phosphate signaling. G(h) is expressed in platelets and vascular cells and may associate with both TP isoforms. However, stimulation of TP isoforms results in differential activation of downstream signaling pathways via this novel G protein.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania	FitzGerald, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, 153 Johnson Pavil,3600 Hamilton Walk, Philadelphia, PA 19104 USA.		FitzGerald, Garret A/A-4222-2010; Habib, Aida/H-8647-2019	Habib, Aida/0000-0001-6027-0043	NHLBI NIH HHS [HL4500] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan CJ, 1996, J PHARMACOL EXP THER, V277, P1132; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; DANGELO DD, 1994, J PHARMACOL EXP THER, V271, P1034; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FITZGERALD GA, 1991, AM J CARDIOL, V68, pB11, DOI 10.1016/0002-9149(91)90379-Y; GENTILE V, 1991, J BIOL CHEM, V266, P478; HABIB A, 1993, J BIOL CHEM, V268, P23448; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HALUSHKA PV, 1995, J LIPID MEDIAT CELL, V12, P361, DOI 10.1016/0929-7855(95)00023-J; HERRMANN HC, 1993, ARTERIOSCLER THROMB, V13, P924, DOI 10.1161/01.ATV.13.6.924; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HIRATA T, 1994, J CLIN INVEST, V94, P1662, DOI 10.1172/JCI117510; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; IM JM, 1990, J BIOL CHEM, V265, P18944; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; MORAN N, 1990, CIRCULATION, V82, P461; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; SHENKER A, 1991, J BIOL CHEM, V266, P9309; Shibata T, 1996, BIOCHEM BIOPH RES CO, V218, P383, DOI 10.1006/bbrc.1996.0067; SHIRAI H, 1995, HYPERTENSION, V25, P726, DOI 10.1161/01.HYP.25.4.726; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Thomas DW, 1998, J CLIN INVEST, V102, P1994, DOI 10.1172/JCI5116; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808; VANWILLIGEN G, 1995, BIOCHEM BIOPH RES CO, V214, P254, DOI 10.1006/bbrc.1995.2282; Vezza R, 1996, J BIOL CHEM, V271, P30028, DOI 10.1074/jbc.271.47.30028; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828	46	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12774	12779		10.1074/jbc.274.18.12774	http://dx.doi.org/10.1074/jbc.274.18.12774			6	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212262	hybrid			2022-12-25	WOS:000080056800082
J	Yujiri, T; Fanger, GR; Garrington, TP; Schlesinger, TK; Gibson, S; Johnson, GL				Yujiri, T; Fanger, GR; Garrington, TP; Schlesinger, TK; Gibson, S; Johnson, GL			MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID SHEAR-STRESS; CELL-SHAPE CHANGE; PROTEIN-KINASE; ENDOTHELIAL-CELLS; GENE-EXPRESSION; JNK; PATHWAYS; RAC1; ERK; INTERLEUKIN-1	Cell shape change and the restructuring of the cytoskeleton are important regulatory responses that influence the growth, differentiation, and commitment to apoptosis of different cell types. MEK kinase 1 (MEKK1) activates the c-Jun NH2-terminal kinase (JNK) pathway in response to exposure of cells to microtubule toxins, including taxol, MEKK1 expression is elevated 3-fold in mitosis and microtubule toxin-treated cells accumulated at G(2)/M of the cell cycle. Targeted disruption of MEKK1 expression in embryonic stem cells resulted in the loss of JNK activation and increased apoptosis in response to taxol. Targeted disruption of the MEK kinase 2 gene had no effect on activation of the JNK pathway in response to microtubule toxins demonstrating a specific role of MEKK1 in this response. Cytochalasin D-mediated disruption of actin fibers activates JNK and stimulates apoptosis similarly in MEKK1(-/-) and wild type cells. The results show that MEKK1 is required for JNK activation in response to microtubule but not actin fiber toxins in embryonic stem cells. MEKK1 activation can protect cells from apoptosis in response to change in the integrity of the microtubule cytoskeleton.	Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, 1400 Jackson St, Denver, CO 80206 USA.		Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456; Gibson, Spencer/0000-0003-0119-732X	NIDDK NIH HHS [DK37871, DK48845] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048845, R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Best A, 1996, J BIOL CHEM, V271, P3756; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CLEVELAND DW, 1985, ANNU REV BIOCHEM, V54, P331, DOI 10.1146/annurev.bi.54.070185.001555; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FERRUA B, 1990, CELL IMMUNOL, V131, P391, DOI 10.1016/0008-8749(90)90263-Q; FOLKMAN J, 1973, J EXP MED, V138, P745, DOI 10.1084/jem.138.4.745; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Ishida T, 1997, ANN NY ACAD SCI, V811, P12, DOI 10.1111/j.1749-6632.1997.tb51984.x; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Li YS, 1996, MOL CELL BIOL, V16, P5947; Malek AM, 1996, J CELL SCI, V109, P713; MANIE S, 1993, J BIOL CHEM, V268, P13675; MAROUDAS NG, 1973, EXP CELL RES, V81, P104, DOI 10.1016/0014-4827(73)90116-X; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RIDLEY AJ, 1994, EMBO J, V13, P260; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	25	109	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12605	12610		10.1074/jbc.274.18.12605	http://dx.doi.org/10.1074/jbc.274.18.12605			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212239	hybrid			2022-12-25	WOS:000080056800059
J	Iguchi, G; Okimura, Y; Takahashi, T; Mizuno, I; Fumoto, M; Takahashi, Y; Kaji, H; Abe, H; Chihara, K				Iguchi, G; Okimura, Y; Takahashi, T; Mizuno, I; Fumoto, M; Takahashi, Y; Kaji, H; Abe, H; Chihara, K			Cloning and characterization of the 5 '-flanking region of the human growth hormone-releasing hormone receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-TYPES; EXPRESSION; PIT-1; SECRETION; RESPONSES; PROMOTER; BINDING; MOUSE; DNA	We cloned the 5'-flanking region of the human growth hormone-releasing hormone receptor (GHRH-R) gene and determined the nucleotide sequence of 2.7 kilobases upstream from the translation start site. RNase protection analysis showed the major transcription start site is 122 base pairs upstream from the translation start site. The 5'-end of the longest product of 5'-rapid amplification of cDNA ends was close to the site. There were no typical TATA homologies but several putative regulatory elements including Pit-1-binding site-like element. Transient transfection studies using a luciferase reporter gene demonstrated that 5'-flanking region had promoter activity in GH3 cells (derived from rat pituitary tumor) but not in nonpituitary cells, BeWo and HeLa cells. However, co-transfection of Pit-1 expression vector increased luciferase activity in BeWo cells. Deletion study showed that the regions from -310 to -130 and from -130 to -120 were important for the GHRH-R gene expression in GH3 cells, although the latter contributed less to the gene expression. In BeWo cells cotransfected with Pit-1 expression vector, the region from -310 to -130 was essential for the Pit-1-dependent expression of GHRH-R gene. The region from -310 to -120 has two putative Pit-1-binding sites, P1 and P2, located from -129 to -123 and from -171 to -160, respectively. Both mobility shift assay and DNase-I footprint analysis showed that P2 had much higher Pit-1 binding affinity than P1. Mutation of P2 decreased GHRH-R gene expression in GH3 cells. These findings were consistent with the results that the region from -310 to -130 is an important element for Pit-1-dependent expression of GHRH-R gene.	Kobe Univ, Sch Med, Dept Med, Div 3,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Okimura, Y (corresponding author), Kobe Univ, Sch Med, Dept Med, Div 3,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BANCROFT FC, 1969, J CELL BIOL, V43, P432, DOI 10.1083/jcb.43.3.432; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASANUEVA FF, 1990, J CLIN ENDOCR METAB, V70, P234, DOI 10.1210/jcem-70-1-234; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GAYLINN BD, 1993, MOL ENDOCRINOL, V7, P77, DOI 10.1210/me.7.1.77; GILMAN M, 1993, CURRENT PROTOCOLS MO; Horikawa R, 1996, ENDOCRINOLOGY, V137, P2642, DOI 10.1210/en.137.6.2642; HSIUNG HM, 1993, NEUROPEPTIDES, V25, P1, DOI 10.1016/0143-4179(93)90062-F; IRANMANESH A, 1992, ENDOCRIN METAB CLIN, V21, P783, DOI 10.1016/S0889-8529(18)30189-0; Lam KSL, 1996, NEUROENDOCRINOLOGY, V63, P475, DOI 10.1159/000127075; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1743; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; Petersenn S, 1998, MOL ENDOCRINOL, V12, P233, DOI 10.1210/me.12.2.233; PETERSENN S, 1996, 10 INT C END JUN 12, P623; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; STEPHANOU A, 1992, J MOL ENDOCRINOL, V9, P273, DOI 10.1677/jme.0.0090273; TAKAHASHI T, 1996, 10 INT C END JUN 12, P621; TAKAHASHI T, 1997, 79 ANN M END SOC JUN, P527; TAKAHASHI T, 1995, ENDOCRINOLOGY, V136, P4271; VALE W, 1983, ENDOCRINOLOGY, V112, P1553, DOI 10.1210/endo-112-4-1553; Wajnrajch MP, 1996, NAT GENET, V12, P88, DOI 10.1038/ng0196-88	29	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12108	12114		10.1074/jbc.274.17.12108	http://dx.doi.org/10.1074/jbc.274.17.12108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207037	hybrid			2022-12-25	WOS:000079834800093
J	Kimball, SR; Shantz, LM; Horetsky, RL; Jefferson, LS				Kimball, SR; Shantz, LM; Horetsky, RL; Jefferson, LS			Leucine regulates translation of specific mRNAs in L6 myoblasts through mTOR-mediated changes in availability of eIF4E and phosphorylation of ribosomal protein S6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4E; MESSENGER-RNA TRANSLATION; ORNITHINE DECARBOXYLASE; AMINO-ACIDS; SIGNAL-TRANSDUCTION; SECONDARY STRUCTURE; CELL-PROLIFERATION; MAMMALIAN TARGET; RAT-LIVER; PHAS-I	Regulation of translation of mRNAs coding for specific proteins plays an important role in controlling cell growth, differentiation, and transformation. Two proteins have been implicated in the regulation of specific mRNA translation: eukaryotic initiation factor eIF4E and ribosomal protein S6. Increased phosphorylation of eIF4E as well as its overexpression are associated with stimulation of translation of mRNAs with highly structured 5'-untranslated regions. Similarly, phosphorylation of S6 results in preferential translation of mRNAs containing an oligopyrimidine tract at the 5'-end of the message, In the present study, leucine stimulated phosphorylation of the eIF4E-binding protein, 4E-BP1, in L6 myoblasts, resulting in dissociation of eIF4E from the inactive eIF4E 4E-BP1 complex. The increased availability of eIF4E was associated with a 1.6-fold elevation in ornithine decarboxylase relative to global protein synthesis. Leucine also stimulated phosphorylation of the ribosomal protein Se kinase, p70(S6k), resulting in increased phosphorylation of S6. Hyperphosphorylation of S6 was associated with a 4-fold increase in synthesis of elongation factor eEF1A Rapamycin, an inhibitor of the protein kinase mTOR, prevented all of the leucine-induced effects. Thus, leucine acting through an mTOR-dependent pathway stimulates the translation of specific mRNAs both by increasing the availability of eIF4E and by stimulating phosphorylation of S6.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kimball, SR (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.	skimball@psu.edu		Shantz, Lisa/0000-0001-8814-4022	NIDDK NIH HHS [DK-15658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BOMMER UA, 1994, CELL MOL BIOL RES, V40, P633; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Coffer PJ, 1998, BIOCHEM J, V335, P1; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; FLAIM KE, 1982, J BIOL CHEM, V257, P2939; Flynn A, 1996, CANCER SURV, V27, P293; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JEFFERIES HBJ, 1996, COLD SPRING HARBOR M, V30, P389; KAHANA C, 1985, J BIOL CHEM, V260, P5390; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; KIMBALL SR, 1994, BBA-GEN SUBJECTS, V1201, P473, DOI 10.1016/0304-4165(94)90079-5; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; Meyuhas Oded, 1996, V30, P363; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shama Silvian, 1995, Gene Expression, V4, P241; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1996, CANCER RES, V56, P3265; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VANVENRO.WJ, 1972, BIOCHIM BIOPHYS ACTA, V259, P127, DOI 10.1016/0005-2787(72)90480-7; VAUGHAN MH, 1973, J BIOL CHEM, V248, P7087; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	43	282	290	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11647	11652		10.1074/jbc.274.17.11647	http://dx.doi.org/10.1074/jbc.274.17.11647			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206976	hybrid			2022-12-25	WOS:000079834800032
J	Blomgren, K; Hallin, U; Andersson, AL; Puka-Sundvall, M; Bahr, BA; McRae, A; Saido, TC; Kawashima, S; Hagberg, H				Blomgren, K; Hallin, U; Andersson, AL; Puka-Sundvall, M; Bahr, BA; McRae, A; Saido, TC; Kawashima, S; Hagberg, H			Calpastatin is up-regulated in response to hypoxia and is a suicide substrate to calpain after neonatal cerebral hypoxia-ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; RAT-BRAIN; SUBCELLULAR-DISTRIBUTION; POSTISCHEMIC HIPPOCAMPUS; CALCIUM ACCUMULATION; MOLECULAR DIVERSITY; FODRIN PROTEOLYSIS; SPATIAL-RESOLUTION; NEURONAL DAMAGE; APOPTOTIC CELLS	In a model of cerebral hypoxia-ischemia in the immature rat, widespread brain injury is produced in the ipsilateral hemisphere, whereas the contralateral hemisphere is left undamaged. Previously, we found that calpains were equally translocated to cellular membranes (a prerequisite for protease activation) in the ipsilateral and contralateral hemispheres. However, activation, as judged by degradation of fodrin, occurred only in the ipsilateral hemisphere. In this study we demonstrate that calpastatin, the specific, endogenous inhibitor protein to calpain, is up-regulated in response to hypoxia and may be responsible for the halted calpain activation in the contralateral hemisphere. Concomitantly, extensive degradation of calpastatin occurred in the ipsilateral hemisphere, as demonstrated by the appearance of a membrane-bound 50-kDa calpastatin breakdown produce. The calpastatin breakdown product accumulated in the synaptosomal fraction, displaying a peak 24 h post-insult, but was not detectable in the cytosolic fraction. The degradation of calpastatin was blocked by administration of CX295, a calpain inhibitor, indicating that calpastatin acts as a suicide substrate to calpain during hypoxia-ischemia. In summary, calpastatin was up-regulated in areas that remain undamaged and degraded in areas where excessive activation of calpains and infarction occurs.	Univ Gothenburg, Perinatal Ctr, Inst Physiol & Pharmacol, SE-40530 Gothenburg, Sweden; Sahlgrens Univ Hosp, Perinatal Ctr, Dept Pediat, SE-41685 Gothenburg, Sweden; Univ Gothenburg, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA; Univ Connecticut, Neurosci Program, Storrs, CT 06269 USA; Cortex Pharmaceut Inc, Irvine, CA 92618 USA; Univ W Indies, Dept Anat & Cell Biol, St Augustine, Trinidad Tobago; RIKEN, Proteolyt Neurosci Lab, Wako, Saitama 35101, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Biol, Bunkyo Ku, Tokyo 113, Japan; Sahlgrens Univ Hosp, Dept Obstet Gynecol, Perinatal Ctr, SE-41685 Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; University of Connecticut; University of Connecticut; University West Indies Mona Jamaica; University West Indies Saint Augustine; RIKEN; Tokyo Metropolitan Institute of Medical Science; Sahlgrenska University Hospital	Blomgren, K (corresponding author), Univ Gothenburg, Perinatal Ctr, Inst Physiol & Pharmacol, POB 432, SE-40530 Gothenburg, Sweden.	klas.blomgren@fysiologi.gu.se	Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Blomgren, Klas/0000-0002-0476-7271; Hagberg, Henrik/0000-0003-3962-1448				ADACHI Y, 1991, J BIOL CHEM, V266, P3968; BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BLOMGREN K, 1995, BRAIN RES, V684, P136, DOI 10.1016/0006-8993(95)00398-A; BLOMGREN K, 1995, BRAIN RES, V684, P143, DOI 10.1016/0006-8993(95)00399-B; BLOMGREN K, 1989, NEUROCHEM RES, V14, P1149, DOI 10.1007/BF00965622; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cong M, 1998, J BIOL CHEM, V273, P660, DOI 10.1074/jbc.273.1.660; COTMAN CW, 1974, J CELL BIOL, V63, P441, DOI 10.1083/jcb.63.2.441; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DELUCA CI, 1993, BIOCHIM BIOPHYS ACTA, V1216, P81, DOI 10.1016/0167-4781(93)90040-K; DEMARTINO GN, 1984, ARCH BIOCHEM BIOPHYS, V232, P713, DOI 10.1016/0003-9861(84)90592-7; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; Hagberg B, 1993, RECENT ADV PAEDIATRI, P67; HAGBERG H, 1994, BIOL NEONATE, V66, P205; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; HU BR, 1994, J NEUROCHEM, V62, P1357; INOMATA M, 1989, J BIOL CHEM, V264, P18838; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KARLSSON JO, 1994, ANAL BIOCHEM, V219, P144, DOI 10.1006/abio.1994.1243; KASAI Y, 1986, J BIOCHEM-TOKYO, V100, P183, DOI 10.1093/oxfordjournals.jbchem.a121691; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LEE WJ, 1992, J BIOL CHEM, V267, P8437; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; MAKI M, 1987, BIOCHEM BIOPH RES CO, V143, P300, DOI 10.1016/0006-291X(87)90665-6; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1986, ARCH BIOCHEM BIOPHYS, V246, P233, DOI 10.1016/0003-9861(86)90468-6; MELLGREN RL, 1988, BIOCHEM BIOPH RES CO, V150, P170, DOI 10.1016/0006-291X(88)90501-3; Melloni E, 1998, FEBS LETT, V431, P55, DOI 10.1016/S0014-5793(98)00724-8; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; OSTWALD K, 1994, J NEUROCHEM, V63, P1069; OSTWALD K, 1993, BRAIN RES, V630, P289, DOI 10.1016/0006-8993(93)90668-D; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; PUKASUNDVALL M, 1994, DEV BRAIN RES, V77, P146, DOI 10.1016/0165-3806(94)90223-2; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saido TC, 1997, NEUROSCI LETT, V227, P75, DOI 10.1016/S0304-3940(97)00309-1; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO Y, 1994, FEBS LETT, V353, P327, DOI 10.1016/0014-5793(94)01075-7; Salamino F, 1997, FEBS LETT, V412, P433, DOI 10.1016/S0014-5793(97)00819-3; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; STEIN DT, 1988, J CEREBR BLOOD F MET, V8, P834, DOI 10.1038/jcbfm.1988.140; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VANNUCCI RC, 1989, MANAGEMENT LABOR, P186; VOLPE JJ, 1995, NEUROLOGY NEWBORN, P314; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748	61	98	100	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14046	14052		10.1074/jbc.274.20.14046	http://dx.doi.org/10.1074/jbc.274.20.14046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318818	hybrid			2022-12-25	WOS:000080322200047
J	Wadgaonkar, R; Collins, T				Wadgaonkar, R; Collins, T			Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTIONAL COACTIVATORS; P300/CBP-ASSOCIATED FACTOR; SYNERGISTIC ACTIVATION; ONCOPROTEIN MDM2; TERMINAL DOMAIN; P53 PROTEIN; WILD-TYPE; REPRESSION	The ability of the p53 tumor suppressor to induce cell cycle arrest and cell death is closely regulated under normal conditions. The transcriptional activity of p53 is negatively controlled by murine double minute (MDM2). p53 requires the coactivator CREB-binding protein (CBP), or its structural homolog, p300, to stimulate transcription of responsive genes. Here we find that the transactivation domain of p53 selectively interacts with the N- and C-terminal regions of CBP/p300. A mutant CBP lacking the N terminus failed to stimulate p53-dependent transactivation. In both p53 null Saos2 cells, and in UV-irradiated MCF7 cells, we observed that MDM2 associates with the N-terminal region of CBP/p300. Because p53 interacts with both MDM2 and CBP/p300 through its trans-activation domain, we examined the role of MDM2 in p53-coactivator interactions. MDM2 blocked CBP/p300 recruitment in vitro and inhibited the interaction of the transactivating region of p53 with both the N- or C-terminal regions of CBP/p300 in a mammalian two-hybrid assay. These observations suggest that MDM2 may be inhibiting p53 trans-activation by shielding its activation domain from the coactivators, a new mechanism for the inhibition of p53-dependent gene expression.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Collins, T (corresponding author), Brigham & Womens Hosp, Dept Pathol, 221 Longwood Ave, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, P01HL036028, R37HL035716] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 36028, HL 45462, HL 35716] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDIERY WS, 1993, CELL, V75, P817; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Scolnick DM, 1997, CANCER RES, V57, P3693; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	39	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13760	13767		10.1074/jbc.274.20.13760	http://dx.doi.org/10.1074/jbc.274.20.13760			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318779	hybrid			2022-12-25	WOS:000080322200008
J	Ishii, T; Matsunaga, T; Pellerin, P; O'Neill, MA; Darvill, A; Albersheim, P				Ishii, T; Matsunaga, T; Pellerin, P; O'Neill, MA; Darvill, A; Albersheim, P			The plant cell wall polysaccharide rhamnogalacturonan II self-assembles into a covalently cross-linked dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PECTIC POLYSACCHARIDE; BORON REQUIREMENT; STRUCTURAL ROLE; SUGAR-BEET; COMPLEX; OLIGOSACCHARIDES; HYDROLYSIS; COMPONENT; TOBACCO; ESTER	The location of the 1:2 borate-diol ester cross-link in the dimer of the plant cell wall polysaccharide rhamnogalacturonan II (RG-II) has been determined. The ester cross-links the apiofuranosyl residue of the 2-O-methyl-D-xylose-containing side chains in each of the subunits of the dimer. The apiofuranosyl residue in each of the two aceric acid-containing side chains is not esterified. The site of borate esterification is identical in naturally occurring and in in vitro synthesized dimer. Pb2+, La3+, and Ca2+ increase dimer formation in vitro in a concentration- and pH-dependent manner. Pb2+ is the most effective cation. The dimer accounts for 55% of the RG-II when the monomer (0.5 mM) is treated for 5 min at pH 3.5 with boric acid (1 mM) and Pb2+ (0.5 mM); at pH 5 the rate of conversion is somewhat slower. Hg2+ does not increase the rate of dimer formation. A cation's charge density and its ability to form a coordination complex with RG-II, in addition to steric factors, may regulate the rate and stability of dimer formation in vitro. Our data provide evidence that the structure of RG-II itself determines which apiofuranosyl residues are esterified with borate and that in the presence of boric acid and certain cations, two RG-II monomers self-assemble to form a dimer.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 3058687, Japan; Kyushu Natl Agr Expt Stn, Kumamoto 8611192, Japan; INRA, Inst Produits de la Vigne, Unite Rech Biopolymeres & Aromes, F-34060 Montpellier, France	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Forestry & Forest Products Research Institute - Japan; National Agriculture & Food Research Organization - Japan; INRAE	O'Neill, MA (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.							[Anonymous], 1997, PLANT NUTR SUSTAINAB; Brown PH, 1997, PLANT SOIL, V196, P211, DOI 10.1023/A:1004245823080; Dell B, 1997, PLANT SOIL, V193, P103, DOI 10.1023/A:1004264009230; Findeklee P, 1996, BOT ACTA, V109, P463, DOI 10.1111/j.1438-8677.1996.tb00599.x; Fleischer A, 1998, PLANT PHYSIOL, V117, P1401, DOI 10.1104/pp.117.4.1401; Frausto da Silva J.J.R., 1991, BIOL CHEM ELEMENTS I; HIRSCH AM, 1980, CAN J BOT, V58, P856, DOI 10.1139/b80-110; HU HI, 1994, PLANT PHYSIOL, V105, P681, DOI 10.1104/pp.105.2.681; Hu HN, 1996, J EXP BOT, V47, P227, DOI 10.1093/jxb/47.2.227; Ishii T, 1996, CARBOHYD RES, V284, P1, DOI 10.1016/0008-6215(96)00010-9; Ishii T, 1997, PLANT PHYSIOL, V113, P1265, DOI 10.1104/pp.113.4.1265; Ishii T, 1998, PHYTOCHEMISTRY, V49, P1195, DOI 10.1016/S0031-9422(98)00119-8; JARVIS MC, 1992, PLANT CELL ENVIRON, V15, P1, DOI 10.1111/j.1365-3040.1992.tb01452.x; Kaneko S, 1997, PHYTOCHEMISTRY, V44, P243, DOI 10.1016/S0031-9422(96)00539-0; Kobayashi M, 1996, PLANT PHYSIOL, V110, P1017, DOI 10.1104/pp.110.3.1017; Kobayashi M, 1997, PLANT CELL PHYSIOL, V38, P676, DOI 10.1093/oxfordjournals.pcp.a029220; Kouchi H., 1975, Soil Science and Plant Nutrition, V21, P137, DOI 10.1080/00380768.1975.10432630; LOOMIS WD, 1992, BIOFACTORS, V3, P229; MACDOUGALL AJ, 1995, PLANT PHYSIOL, V108, P1679, DOI 10.1104/pp.108.4.1679; Matoh T, 1997, PLANT SOIL, V193, P59, DOI 10.1023/A:1004207824251; Matoh T, 1996, PLANT CELL PHYSIOL, V37, P636, DOI 10.1093/oxfordjournals.pcp.a028992; MCNEIL M, 1982, METHOD ENZYMOL, V83, P3; O'Neill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI DOI 10.1016/B978-0-12-461012-5.50018-5; ONeill MA, 1996, J BIOL CHEM, V271, P22923, DOI 10.1074/jbc.271.37.22923; Pellerin P, 1996, CARBOHYD RES, V290, P183, DOI 10.1016/0008-6215(96)00139-5; Pellerin  P, 1998, ANALUSIS, V26, pM32; Shin KS, 1998, CARBOHYD RES, V307, P97, DOI 10.1016/S0008-6215(98)00016-0; STEVENSON TT, 1988, CARBOHYD RES, V179, P269, DOI 10.1016/0008-6215(88)84124-7; VANDUIN M, 1987, CARBOHYD RES, V162, P65, DOI 10.1016/0008-6215(87)80201-X; WEAST RC, 1983, CRC HDB CHEM PHYSICS, pF170; WHITCOMBE AJ, 1995, CARBOHYD RES, V271, P15, DOI 10.1016/0008-6215(94)00002-W; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9	32	148	154	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13098	13104		10.1074/jbc.274.19.13098	http://dx.doi.org/10.1074/jbc.274.19.13098			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224062	hybrid			2022-12-25	WOS:000080200400024
J	Jang, MH; Basran, J; Scrutton, NS; Hille, R				Jang, MH; Basran, J; Scrutton, NS; Hille, R			The reaction of trimethylamine dehydrogenase with trimethylamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; COVALENTLY BOUND COENZYME; MONOAMINE-OXIDASE; BACTERIUM W3A1; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIUM; PROSTHETIC GROUPS; FLAVOPROTEIN; SUBSTRATE; CATALYSIS	The reductive half-reaction of trimethylamine dehydrogenase with its physiological substrate trimethylamine has been examined by stopped-flow spectroscopy over the pH range 6.0-11.0, with attention focusing on the fastest of the three kinetic phases of the reaction, the flavin reduction/substrate oxidation process. As in previous work with the slow substrate diethylmethylamine, the reaction is found to consist of three well resolved kinetic phases. The observed rate constant for the fast phase exhibits hyperbolic dependence on the substrate concentration with an extrapolated limiting rate constant (k(lim)) greater than 1000 s(-1) at pH above 8.5, 10 degrees C, The kinetic parameter k(lim)/K-d for the fast phase exhibits a bell-shaped pH dependence, with two pK(a) values of 9.3 +/- 0.1 and 10.0 +/- 0.1 attributed to a basic residue in the enzyme active site and the ionization of the free substrate, respectively. The sigmoidal pH profile for k(lim) gives a single pK(a) value of 7.1 +/- 0.2. The observed rate constants for both the intermediate and slow phases are found to decrease as the substrate concentration is increased. The steady-state kinetic behavior of trimethylamine dehydrogenase with trimethylamine has also been examined, and is found to be adequately described without invoking a second, inhibitory substrate-binding site. The present results demonstrate that: (a) substrate must be protonated in order to bind to the enzyme; (b) an ionization group on the enzyme is involved in substrate binding; (c) an active site general base is involved, but not strictly required, in the oxidation of substrate; (d) the fast phase of the reaction with native enzyme is considerably faster than observed with enzyme isolated from Methylophilus methylotrophus that has been grown up on dimethylamine; and (e) a discrete inhibitory substrate-binding site is not required to account for excess substrate inhibition, the kinetic behavior of trimethylamine dehydrogenase can be readily explained in the context of the known properties of the enzyme.	Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University System of Ohio; Ohio State University; University of Leicester	Hille, R (corresponding author), Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA.							ARMSTRONG JM, 1964, BIOCHIM BIOPHYS ACTA, V86, P194; Basran J, 1999, J BIOL CHEM, V274, P13155, DOI 10.1074/jbc.274.19.13155; Basran J, 1997, BIOCHEMISTRY-US, V36, P1989, DOI 10.1021/bi962623o; BELLAMY HD, 1989, J BIOL CHEM, V264, P11887; COLBY J, 1974, BIOCHEM J, V143, P555, DOI 10.1042/bj1430555; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; EDMONDSON DE, 1995, XENOBIOTICA, V25, P735, DOI 10.3109/00498259509061889; Falzon L, 1996, BIOCHEMISTRY-US, V35, P2445, DOI 10.1021/bi951550q; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HILLE R, 1984, J BIOL CHEM, V259, P1570; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KIM JM, 1993, J AM CHEM SOC, V115, P10591, DOI 10.1021/ja00076a017; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SILVERMAN RB, 1995, ACCOUNTS CHEM RES, V28, P335, DOI 10.1021/ar00056a003; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STANKOVICH MT, 1987, FLAVINS FLAVOPROTEIN, P687; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHEM BIOPH RES CO, V71, P1289, DOI 10.1016/0006-291X(76)90794-4; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1985, BIOCHEM BIOPH RES CO, V132, P352, DOI 10.1016/0006-291X(85)91029-0; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; WEAST RC, 1968, HDB CHEM PHYSICS, pD89	31	33	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13147	13154		10.1074/jbc.274.19.13147	http://dx.doi.org/10.1074/jbc.274.19.13147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224069	hybrid			2022-12-25	WOS:000080200400031
J	Fry, M; Loeb, LA				Fry, M; Loeb, LA			Human Werner syndrome DNA helicase unwinds tetrahelical structures of the fragile X syndrome repeat sequence d(CGG)(n)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME PROTEIN; HAIRPIN STRUCTURES; ESCHERICHIA-COLI; HUMAN GENOME; CGG REPEAT; INSTABILITY; FORM; RECOMBINATION; EXONUCLEASE; CELLS	Formation of hairpin and tetrahelical structures by a d(CGG) trinucleotide repeat sequence is thought to cause expansion of this sequence and to engender fragile X syndrome. Here we show that human Werner syndrome DNA helicase (WRN), a member of the RecQ family of helicases, efficiently unwinds G'2 bimolecular tetraplex structures of d(CGG),. Unwinding of d(CGG), by WRN requires hydrolyzable ATP and Mg2+ and is proportional to the amount of added helicase and to the time of incubation. The efficiencies of unwinding of G'2 d(CGG)(7) tetraplex with 7 nucleotide-long single-stranded tails at their 3' or 5' ends are, respectively, 3.5- and a-fold greater than that of double-stranded DNA. By contrast, WRN is unable to unwind a blunt-ended d(CGG), tetraplex, bimolecular tetraplex structures of a telomeric sequence 5'-d(TAGACATG(TTAGGG)(2)TTA)-3', or tetramolecular quadruplex forms of an IgG switch region sequence 5'-d(TACAGGGGAGCTGGGGTAGA)-3'. The ability of WRN to selectively unwind specific tetra-helices may reflect a specific role of this helicase in DNA metabolism.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; Univ Washington, Dept Pathol, Joseph Gottstein Canc Res Mem Lab, Seattle, WA 98195 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Washington; University of Washington Seattle	Fry, M (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001751] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-39909] Funding Source: Medline; NIAID NIH HHS [AI-01751] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baran N, 1997, NUCLEIC ACIDS RES, V25, P297, DOI 10.1093/nar/25.2.297; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; COURCELLE J, 1997, FASEB J, V11, P1358; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FRY M, 1988, NUCLEIC ACIDS RES, V16, P199, DOI 10.1093/nar/16.1.199; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GACY AM, 1995, CELL, V81, P533; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HAN J, 1994, NUCLEIC ACIDS RES, V22, P1735, DOI 10.1093/nar/22.9.1735; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HENDERSON E, 1995, TELOMERES, P11; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644; Mangel L, 1998, J BIOL CHEM, V273, P30466, DOI 10.1074/jbc.273.46.30466; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SEKI M, 1995, MOL CELL BIOL, V15, P165, DOI 10.1128/MCB.15.1.165; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VIJAYALAXMI H J E, 1983, Science (Washington D C), V221, P851; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	41	302	313	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12797	12802		10.1074/jbc.274.18.12797	http://dx.doi.org/10.1074/jbc.274.18.12797			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212265	hybrid			2022-12-25	WOS:000080056800085
J	Grimm, SL; Nordeen, SK				Grimm, SL; Nordeen, SK			A composite enhancer element directing tissue-specific expression of mouse mammary tumor virus requires both ubiquitous and tissue-restricted factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; MULTIPLE REGULATORY ELEMENTS; BINDING-PROTEIN; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; CELL-LINE; GLAND; PROMOTER; DNA; FAMILY	Mouse mammary tumor virus (MMTV) expression is restricted primarily to mammary epithelial cells. Sequences responsible for both the mammary-specific expression of MMTV and the activation of cellular oncogenes are located within two enhancer elements at the 5'-end of the long terminal repeat. Whereas the Ban2 enhancer (-1075 to -978) has been well characterized, the mammary-specific enhancer of MMTV from -956 to -862 has only recently been recognized as a key determinant of mammary-specific oncogene activation by MMTV. The present study identifies and characterizes three binding sites located within this element. Transient transfection of deletion and mutation constructs shows that all three sites contribute to the basal expression of MMTV in mammary cells. One of the binding activities (footprint I) is restricted to mammary cells, whereas the other two sites bind factors found in both mammary and nonmammary cells. The multimerized mammary-specific enhancer of MMTV on its own can enhance a minimal promoter in a mammary-specific fashion. However, the FpI binding site alone cannot mediate this effect. Thus, it is the binding of multiple factors in a combinatorial fashion that mediates the mammary-restricted expression of MMTV.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nordeen, SK (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, 4200 E 9th Ave,Box B216, Denver, CO 80262 USA.	Steve.Nordeen@uchsc.edu						BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; Golovkina TV, 1998, J VIROL, V72, P3066, DOI 10.1128/JVI.72.4.3066-3071.1998; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Grimm SL, 1998, J VIROL, V72, P9428, DOI 10.1128/JVI.72.12.9428-9435.1998; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; Kusk P, 1996, J BIOL CHEM, V271, P31269, DOI 10.1074/jbc.271.49.31269; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MOK E, 1992, J VIROL, V66, P7529, DOI 10.1128/JVI.66.12.7529-7532.1992; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; MORRIS VL, 1977, J MOL BIOL, V114, P73, DOI 10.1016/0022-2836(77)90284-4; NANDI S, 1973, ADV CANCER RES, V17, P353; Nikolajczyk BS, 1997, MOL CELL BIOL, V17, P3527, DOI 10.1128/MCB.17.7.3527; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Qin W, 1999, J VIROL, V73, P368, DOI 10.1128/JVI.73.1.368-376.1999; Rosen JM, 1998, BIOCHEM SOC SYMP, P101; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; SALMONS B, 1987, VIRUS RES, V8, P81, DOI 10.1016/0168-1702(87)90022-0; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991	40	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12790	12796		10.1074/jbc.274.18.12790	http://dx.doi.org/10.1074/jbc.274.18.12790			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212264	hybrid			2022-12-25	WOS:000080056800084
J	Hanna, AN; Chan, EYW; Xu, J; Stone, JC; Brindley, DN				Hanna, AN; Chan, EYW; Xu, J; Stone, JC; Brindley, DN			A novel pathway for tumor necrosis factor-alpha and ceramide signaling involving sequential activation of tyrosine kinase, p21(ras), and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PERMEABLE CERAMIDES; FOCAL ADHESION KINASE; SPHINGOMYELIN TURNOVER; PROTEIN-KINASE; TNF-ALPHA; PHOSPHOINOSITIDE 3-KINASE; ARACHIDONIC-ACID; PHOSPHOLIPASE-D; GLUCOSE-UPTAKE; DNA-SYNTHESIS	Treatment of confluent rata fibroblasts with C-2-ceramide (N-acetylsphingosine), sphingomyelinase, or tumor necrosis factor-alpha (TNF alpha) increased phosphatidylinositol (PI) 3-kinase activity by 3-6-fold after 10 min. This effect of C-2-ceramide depended on tyrosine kinase activity and an increase in Ras-GTP levels. Increased PI 3-kinase activity was also accompanied by its translocation to the membrane fraction, increases in tyrosine phosphorylation of the p85 subunit, and physical association with Pas, Activation of PI 3-kinase by TNF alpha, sphingomyelinase, and C-2-ceramide was inhibited by tyrosine kinase inhibitors (genistein and PP1). The stimulation of PI S-kinase by sphingomyelinase and C-2-ceramide was not observed in fibroblasts expressing dominant-negative Pas (N17) and the stimulation by TNF alpha was decreased by 70%. PI 3-kinase activation by C-2-ceramide was not modified by inhibitors of acidic and neutral ceramidases, and it was not observed with the relatively inactive analog, dihydro-C-2-ceramide It is proposed that activation of Pas and PI 3-kinase by ceramide can contribute to signaling effects of TNF alpha that occur downstream of sphingomyelinase activation and result in increased fibroblasts proliferation.	Univ Alberta, Signal Transduct Labs, Lipid & Lipoprot Res Grp, Heritage Med Res Ctr 357, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Brindley, DN (corresponding author), Univ Alberta, Signal Transduct Labs, Lipid & Lipoprot Res Grp, Heritage Med Res Ctr 357, Edmonton, AB T6G 2S2, Canada.		Chan, Edmond Y.W./A-1940-2013	Chan, Edmond Y.W./0000-0001-9777-0252				AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; BATTEGAY EJ, 1995, J IMMUNOL, V154, P6040; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CIFONE MG, 1993, J EXP MED, V177, P1547; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; EVANS DA, 1989, AM J PHYSIOL, V257, pR1182, DOI 10.1152/ajpregu.1989.257.5.R1182; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Gerritsen ME, 1998, AM J PATHOL, V152, P505; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1997, SPHINGOLIPID MEDIATE, P103; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jobson TM, 1998, J CLIN INVEST, V101, P2650, DOI 10.1172/JCI1876; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM MY, 1991, J BIOL CHEM, V266, P484; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Lu G, 1997, NEUROCHEM INT, V30, P401, DOI 10.1016/S0197-0186(96)00075-7; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; McGowan KM, 1997, J BIOL CHEM, V272, P1331, DOI 10.1074/jbc.272.2.1331; MIYAZAKI Y, 1995, J CLIN INVEST, V96, P250, DOI 10.1172/JCI118029; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHTA H, 1994, ANAL BIOCHEM, V222, P489, DOI 10.1006/abio.1994.1522; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V189, P1503, DOI 10.1016/0006-291X(92)90245-G; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; WARNER LC, 1993, ONCOGENE, V8, P3249; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	67	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12722	12729		10.1074/jbc.274.18.12722	http://dx.doi.org/10.1074/jbc.274.18.12722			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212255	hybrid			2022-12-25	WOS:000080056800075
J	Tang, H; Zhao, ZZJ; Huang, XY; Landon, EJ; Inagami, T				Tang, H; Zhao, ZZJ; Huang, XY; Landon, EJ; Inagami, T			Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by G(i) protein-coupled receptors in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SRC FAMILY KINASE; PHOSPHOTYROSINE PHOSPHATASE; RAS ACTIVATION; MAP KINASE; PHOSPHORYLATION; INSULIN; ASSOCIATION; SH-PTP2; SHPTP2	SHP-2, an SH2 domain-containing protein-tyrosine phosphatase, plays an important role in receptor tyrosine kinase-regulated cell proliferation and differentiation, Little is known about the activation mechanisms and the participation of SHP-2 in the activity of G protein-coupled receptors lacking intrinsic tyrosine kinase activity. We show that the activity of SHP-2 (but not SHP-1) is specifically stimulated by the selective alpha(2A)-adrenergic receptor agonist UK14304 and by lysophosphatidic acid (LPA) in Madin-Darby canine kidney (MDCK) cells. UK14304 and LPA promote the tyrosine phosphorylation of SHP-2 and its association with Grb2, The agonist-induced direct interaction of Grb2 with SHP-2 is mediated by the SH2 domain of Grb2 and the tyrosine phosphorylation of SHP-2. Rapid activation of Src family kinase by UK14304 preceded the SHP-2 activation. Among the Src family members (Src, Fyn, Lck, Yes, and Lyn) present in MDCK cells, Fyn was the only one specifically associated with SHP-2, and the physical interaction between them, which requires the Src family kinase activity, was increased in response to the agonists, Pertussis toxin, PP1 (a selective Src family kinase inhibitor), or overexpression of a catalytically inactive mutant of Fyn blocked the UK14304- or LPA-stimulated activity of SHP-2, SHP-2 tyrosine phosphorylation, and SHP-2 association with Grb2. Therefore, we have demonstrated for the first time that the activation of SHP-2 by these G(i) protein-coupled receptors requires Fyn kinase and that there is a specific physical interaction of Fyn kinase with SHP-2 in MDCK cells.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Hematol, Nashville, TN 37232 USA; Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Cornell University	Inagami, T (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 663 Light Hall, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL-57393, HL-58205] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058205, R01HL057393, R37HL058205] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi M, 1996, CELL, V85, P15; Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHENG HC, 1991, J BIOL CHEM, V266, P17919; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TAKATA M, 1995, FEBS LETT, V374, P407, DOI 10.1016/0014-5793(95)01160-G; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12401	12407		10.1074/jbc.274.18.12401	http://dx.doi.org/10.1074/jbc.274.18.12401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212213	hybrid			2022-12-25	WOS:000080056800033
J	Volonte, D; Galbiati, F; Li, SW; Nishiyama, K; Okamoto, T; Lisanti, MP				Volonte, D; Galbiati, F; Li, SW; Nishiyama, K; Okamoto, T; Lisanti, MP			Flotillins/cavatellins are differentially expressed in cells and tissues and form a hetero-oligomeric complex with caveolins in vivo - Characterization and epitope-mapping of a novel flotillin-1 monoclonal antibody probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; PLASMA-MEMBRANE DOMAINS; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; ROUS-SARCOMA VIRUS; TYROSINE KINASES; GENE FAMILY; RECOMBINANT EXPRESSION; BIOLOGICAL-MEMBRANES; SIGNAL-TRANSDUCTION	Caveolae are vesicular organelles that represent a subcompartment of the plasma membrane, Caveolins and flotillins are two families of mammalian caveolae-associated integral membrane proteins. However, it remains unknown whether flotillins interact with caveolin proteins to form a stable caveolar complex or if expression of flotillins can drive vesicle formation, Here, we examine the cell type and tissue-specific expression of the flotillin gene family. For this purpose, we generated a novel monoclonal antibody probe that recognizes only flotillin-1. A survey of cell and tissue types demonstrates that flotillins 1 and 2 have a complementary tissue distribution. At the cellular level, flotillin-2 was ubiquitously expressed, whereas flotillin-1 was most abundant in A498 kidney cells, muscle cell lines, and fibroblasts, Using three different models of cellular differentiation, we next examined the expression of flotillins 1 and 2, Taken together, our data suggest that the expression levels of flotillins 1 and 2 are independently regulated and does not strictly correlate with known expression patterns of caveolin family members. However, when caveolins and flotillins are co-expressed within the same cell, as in A498 cells, they form a stable hetero-oligomeric "caveolar complex." In support of these observations, we show that heterologous expression of murine flotillin-1 in Sf21 insect cells using baculovirus-based vectors is sufficient to drive the formation of caveolae-like vesicles. These results suggest that flotillins may participate functionally in the formation of caveolae or caveolae-like vesicles in vivo. Thus, flotillin-1 represents a new integral membrane protein marker for the slightly larger caveolae-related domains (50-200 nm) that are observed in cell types that fail to express caveolin-1, As a consequence of these findings, we propose the term "cavatellins" be used (instead of flotillins) to describe this gene family.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Cleveland Clinic Foundation	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael/B-6131-2018	Li, Shengwen Calvin/0000-0002-9699-9204; Lisanti, Michael/0000-0003-2034-1382	NATIONAL CANCER INSTITUTE [F32CA071326, R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056036] Funding Source: NIH RePORTER; NCI NIH HHS [CA-71326, F32 CA071326, R01-CA-80250] Funding Source: Medline; NIMH NIH HHS [MH-56036] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COLE F, 1993, J BIOL CHEM, V268, P1580; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAN JY, 1983, J CELL SCI, V61, P219; FORBES MS, 1979, J ULTRA MOL STRUCT R, V67, P325, DOI 10.1016/S0022-5320(79)80032-5; Galbiati F, 1998, GENE, V210, P229, DOI 10.1016/S0378-1119(98)00064-X; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Harlow E., 1988, ANTIBODIES LAB MANUA; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Puertollano R, 1997, J BIOL CHEM, V272, P18311, DOI 10.1074/jbc.272.29.18311; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHROEDER WT, 1994, J BIOL CHEM, V269, P19983; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1983, HISTOLOGY CELL TISSU, P371; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7	53	177	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12702	12709		10.1074/jbc.274.18.12702	http://dx.doi.org/10.1074/jbc.274.18.12702			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212252	hybrid			2022-12-25	WOS:000080056800072
J	Harmer, SL; DeFranco, AL				Harmer, SL; DeFranco, AL			The Src homology domain 2-containing inositol phosphatase SHIP forms a ternary complex with Shc and Grb2 in antigen receptor-stimulated B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEINS; FC-GAMMA RECEPTORS; CROSS-LINKING; PHOSPHATIDYLINOSITOL 3-KINASE; POLYPHOSPHATE 5-PHOSPHATASE; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; CO-LIGATION; CELL; KINASE	The inositol phosphatase SHIP has been implicated in signaling events downstream of a variety of receptors and is thought to play an inhibitory role in stimulated B cells. we and others have reported that SHIP is rapidly tyrosine phosphorylated upon B cell antigen receptor (BCR) cross-linking and forms a complex with the adapter protein Shc. Here, we report that cross-linking of the BCR induces association between Grb2 and SHIP as well as association between Shc and SHIP. We made use of a Grb2-deficient B cell line to demonstrate both in vitro and in vivo that Grb2 expression is required for the efficient association between Shc and SHIP. The results indicate that SHIP, Shc, and Grb2 form a ternary complex in stimulated B cells, with Grb2 stabilizing the interaction between Shc and SHIP, The interactions between Shc, Grb2, and SHIP are therefore analogous to the interactions between Shc, Grb2, and SOS. Shc and Grb2 may help to localize SHIP to the cell membrane, regulating SHIP's inhibitory function following BCR stimulation.	Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	DeFranco, AL (corresponding author), Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA.		Harmer, Sarah/G-5572-2016	Harmer, Sarah/0000-0002-5627-5500; Harmer, Stacey/0000-0001-6813-6682				Chacko GW, 1996, J IMMUNOL, V157, P2234; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; Earl PL, 1998, CURRENT PROTOCOLS MO; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FAHEY KA, 1987, J IMMUNOL, V138, P3935; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOLD MR, 1992, BIOCHEM J, V287, P269, DOI 10.1042/bj2870269; GOLD MR, 1994, J IMMUNOL, V152, P42; GOLD MR, 1992, J IMMUNOL, V148, P2012; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Okada H, 1998, J IMMUNOL, V161, P5129; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; Pradhan M, 1997, J CELL BIOCHEM, V67, P32, DOI 10.1002/(SICI)1097-4644(19971001)67:1<32::AID-JCB4>3.0.CO;2-X; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; SALCINI AE, 1994, ONCOGENE, V9, P2827; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sarmay G, 1997, IMMUNOL LETT, V57, P159, DOI 10.1016/S0165-2478(97)00055-2; Sarmay G, 1996, J BIOL CHEM, V271, P30499; SAXTON TM, 1994, J IMMUNOL, V153, P623; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SMIT L, 1994, J BIOL CHEM, V269, P20209; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Tridandapani S, 1997, J IMMUNOL, V158, P1125; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8	61	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12183	12191		10.1074/jbc.274.17.12183	http://dx.doi.org/10.1074/jbc.274.17.12183			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207047	hybrid			2022-12-25	WOS:000079834800103
J	Oosterhuis, JH; van der Hoorn, FA				Oosterhuis, JH; van der Hoorn, FA			Testis-specific TTF-D binds to single-stranded DNA in the c-mos and Odf1 promoters and activates Odf1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H1T GENE; GERM-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR; NUCLEAR PROTEINS; TRANSGENIC MICE; PGK-2 GENE; SPERMATOGENESIS; CREM; EXPRESSION; ELEMENT	We recently identified testis-specific nuclear factor binding sites in the testis-specific promoters of the cmos gene and the Odf1 gene, which are 80% identical. Here we characterize a testis-specific nuclear factor, TTF-D, which is able to complex with both binding sites and stimulates Odf1 promoter activity. TTF-D is detectable in mouse testis as early as day 11 postpartum and contains three peptides of 22, 25, and 35 kDa in size. Surprisingly, TTF-D binds specifically to its cognate double-stranded DNA binding site as well as to its single-stranded DNA binding site. Both double-stranded and single-stranded binding site oligonucleotide DNA can specifically repress Odf1 promoter activity. Our results suggest that TTF-D is involved in positive transcription regulation of a pre-meiotic and a post-meiotic gene in the testis.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	van der Hoorn, FA (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	fvdhoorn@ucalgary.ca						BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BOISSONNEAULT G, 1993, MOL CELL BIOL, V13, P4323, DOI 10.1128/MCB.13.7.4323; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; BudhramMahadeo V, 1996, J BIOL CHEM, V271, P9108, DOI 10.1074/jbc.271.15.9108; CUNLIFFE V, 1990, GENOMICS, V8, P331, DOI 10.1016/0888-7543(90)90290-B; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DENNY P, 1991, GENE, V106, P221, DOI 10.1016/0378-1119(91)90202-M; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GOTO M, 1993, NUCLEIC ACIDS RES, V21, P209, DOI 10.1093/nar/21.2.209; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; Grimes SR, 1997, MOL BIOL REP, V24, P175, DOI 10.1023/A:1006807716339; GRIMES SR, 1992, EXP CELL RES, V201, P216, DOI 10.1016/0014-4827(92)90366-G; GRIMES SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P402, DOI 10.1016/0003-9861(92)90590-S; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; HIGGY NA, 1995, DEV GENET, V16, P190, DOI 10.1002/dvg.1020160211; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Lindsey S, 1996, J ASSIST REPROD GEN, V13, P182, DOI 10.1007/BF02072542; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NIKOLAJCZYK BS, 1995, BIOL REPROD, V52, P524, DOI 10.1095/biolreprod52.3.524; PESCHON JJ, 1989, ANN NY ACAD SCI, V564, P186, DOI 10.1111/j.1749-6632.1989.tb25897.x; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; VANDERHOORN FA, 1987, J MOL BIOL, V193, P255, DOI 10.1016/0022-2836(87)90217-8; VANDERHOORN FA, 1992, ONCOGENE, V7, P1093; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; Yiu GK, 1997, BIOL REPROD, V56, P1439, DOI 10.1095/biolreprod56.6.1439; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	41	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11708	11712		10.1074/jbc.274.17.11708	http://dx.doi.org/10.1074/jbc.274.17.11708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206985	hybrid			2022-12-25	WOS:000079834800041
J	Shimizu, H; Hosokawa, H; Ninomiya, H; Miner, JH; Masaki, T				Shimizu, H; Hosokawa, H; Ninomiya, H; Miner, JH; Masaki, T			Adhesion of cultured bovine aortic endothelial cells to laminin-1 mediated by dystroglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; CENTRAL-NERVOUS-SYSTEM; ADULT-MOUSE TISSUES; EXTRACELLULAR-MATRIX; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; PERIPHERAL-NERVE; MUSCULAR-DYSTROPHY; CONVERTING ENZYME; BINDING-PROTEIN	Expression of dystroglycan (DG) by cultured bovine aortic endothelial (BAE) cells was confirmed by cDNA cloning from a BAE cDNA library, Northern blotting of mRNA, Western blotting of membrane proteins, and double immunostaining with antibodies against beta DG and platelet endothelial cell adhesion molecule-1. Immunocytochemical analysis revealed localization of DG in multiple plaques on the basal side of resting cells. This patchy distribution was obscured in migrating cells, in which the most prominent staining was observed in the trailing edge anchoring the cells to the substratum. Biotin-labeled laminin-1 overlay assay of dissociated BAE membrane proteins indicated the interaction of laminin-l with alpha DG, The laminin alpha 5 globular domain fragment expressed in bacteria and labeled with biotin could also bind alpha DG on the membrane blot, and the unlabeled fragment disrupted the binding of biotin-laminin-1 to alpha DG. The interaction of biotin-laminin-1 with alpha DG was inhibited by soluble alpha DG contained in the conditioned medium from DG cDNA-transfected BAE cells and by a series of glycosaminoglycans (heparin, dextran sulfate, and fucoidan), Soluble alpha DG in the conditioned medium inhibited the adhesion of BAE cells to laminin-1-coated dishes, whereas it had no effect on their adhesion to fibronectin, All three glycosaminoglycans that disrupted the biotin-laminin-1 binding to alpha DG inhibited BAE cell adhesion to laminin-1, whereas they failed to inhibit the adhesion to fibronectin, These results indicate a role of DG as a non-integrin laminin receptor involved in vascular endothelial cell adhesion to the extracellular matrix.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Kyoto University; Washington University (WUSTL)	Masaki, T (corresponding author), Natl Cardiovasc Res Inst, 5-7-1 Fujishirodai, Osaka 5658565, Japan.							ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; AZIZKHAN RG, 1980, J EXP MED, V152, P931, DOI 10.1084/jem.152.4.931; BASSON CT, 1990, J CELL BIOL, V110, P789, DOI 10.1083/jcb.110.3.789; Belkin AM, 1996, CELL ADHES COMMUN, V4, P281, DOI 10.3109/15419069609010772; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; BRUCE GW, 1990, J NEUROSCI, V10, P3576; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHENG YF, 1989, J CELL PHYSIOL, V139, P275, DOI 10.1002/jcp.1041390209; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Drenckhahn D, 1996, NEUROSCIENCE, V73, P605, DOI 10.1016/0306-4522(96)00069-3; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; Durbeej M, 1997, EXP LUNG RES, V23, P109, DOI 10.3109/01902149709074024; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Matsumura K, 1997, J BIOL CHEM, V272, P13904, DOI 10.1074/jbc.272.21.13904; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Osawa M, 1997, EUR J CELL BIOL, V72, P229; Powell SK, 1997, INT J BIOCHEM CELL B, V29, P401, DOI 10.1016/S1357-2725(96)00110-0; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V169, P1138, DOI 10.1016/0006-291X(90)92014-Q; SOROKIN L, 1994, EUR J BIOCHEM, V223, P603, DOI 10.1111/j.1432-1033.1994.tb19031.x; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Sugawara F, 1996, MOL PHARMACOL, V49, P447; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; Tian M, 1996, EUR J NEUROSCI, V8, P2739, DOI 10.1111/j.1460-9568.1996.tb01568.x; Tressler R J, 1989, Cancer Commun, V1, P55; Uchino M, 1996, INTERNAL MED, V35, P189, DOI 10.2169/internalmedicine.35.189; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; Yamamoto T, 1997, ACTA NEUROPATHOL, V94, P173, DOI 10.1007/s004010050690; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	46	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11995	12000		10.1074/jbc.274.17.11995	http://dx.doi.org/10.1074/jbc.274.17.11995			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207021	hybrid, Green Submitted			2022-12-25	WOS:000079834800077
J	Gerbitz, A; Mautner, J; Geltinger, C; Hortnagel, K; Christoph, B; Asenbauer, H; Klobeck, G; Polack, A; Bornkamm, GW				Gerbitz, A; Mautner, J; Geltinger, C; Hortnagel, K; Christoph, B; Asenbauer, H; Klobeck, G; Polack, A; Bornkamm, GW			Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma	ONCOGENE			English	Article						c-myc; lambda enhancer; gene regulation; Burkitt's lymphoma; Na-Butyrate	LOCUS-CONTROL REGION; EPSTEIN-BARR-VIRUS; IMMUNOGLOBULIN-KAPPA-ENHANCERS; HEAVY-CHAIN LOCUS; PROMOTER SHIFT; CHROMOSOMAL TRANSLOCATIONS; HYPERSENSITIVE SITES; GENE-EXPRESSION; SODIUM-BUTYRATE; DOWN-REGULATION	In Burkitt's lymphoma (BL) cells the proto-oncogene c-myc is juxtaposed to one of the immunoglobulin (Ig) loci on chromosomes 2, 14, or 22, The c-myc gene becomes transcriptionally activated as a consequence of the chromosomal translocation and shows preferential usage of promoter P1 over P2, a phenomenon referred to as promoter shift. In order to define the responsible regulatory elements within the Ig lambda locus, we studied the effect of the human Ig lambda enhancer (HuE lambda) on c-myc expression after stable transfection into BL cells. A 12 kb genomic fragment encompassing HuE lambda, but not HuE lambda alone, strongly activated c-myc expression and induced the promoter shift. To identify additional elements involved in c-myc deregulation, we mapped DNaseI hypersensitive sites within the 12 kb lambda fragment on the construct. Besides one hypersensitive site corresponding to HuE lambda, three additional sites were detected, Two of these elements displayed enhancer activity after transient transfection. The third element did not activate c-myc transcription, but was required for full c-myc activation and promoter shift. Deletion analyses of the c-myc promoter identified the immediate promoter region as sufficient for activation by the Ig lambda locus, but also revealed that induction of the promoter shift requires additional upstream elements.	Dana Farber Canc Inst, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumor Genet, D-81377 Munich, Germany; Univ Munich, Genet Inst, D-80336 Munich, Germany; Adolf Butenandt Inst Physiol Chem, D-80336 Munich, Germany	Harvard University; Dana-Farber Cancer Institute; Johns Hopkins University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich	Gerbitz, A (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.							ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ANISIMOVA E, 1982, J GEN VIROL, V58, P163, DOI 10.1099/0022-1317-58-1-163; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; Asenbauer H, 1996, EUR J IMMUNOL, V26, P142, DOI 10.1002/eji.1830260122; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BLOMBERG BB, 1991, J IMMUNOL, V147, P2354; BORNKAMM GW, 1988, G KLEIN, P223; BREZNICK EH, 1997, P NATL ACAD SCI USA, V94, P4566; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; COMBRIATO G, 1991, EUR J IMMUNOL, V21, P1513, DOI 10.1002/eji.1830210627; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; Geltinger C, 1996, GENE EXPRESSION, V6, P113; Glozak MA, 1996, MOL IMMUNOL, V33, P427, DOI 10.1016/0161-5890(95)00146-8; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; JOOS S, 1992, CANCER RES, V52, P6547; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MAGRATH I, 1990, ADV CANCER RES, V55, P134; Mautner J, 1996, ONCOGENE, V12, P1299; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; NOWELL PC, 1960, SCIENCE, V132, P1497; NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; PULVERTAFT RJV, 1964, LANCET, V1, P238; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROTTLEB C, 1995, INT J CANCER, V62, P697, DOI 10.1002/ijc.2910620609; ROTTLEB C, 1996, INT J CANCER, V67, P1; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STIEF A, 1989, NATURE, V341, P341; STROBL LJ, 1993, ONCOGENE, V8, P1437; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	55	45	50	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1745	1753		10.1038/sj.onc.1202468	http://dx.doi.org/10.1038/sj.onc.1202468			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208435				2022-12-25	WOS:000079025000009
J	Gabrielli, BG; Sarcevic, B; Sinnamon, J; Walker, G; Castellano, M; Wang, XQ; Ellem, KAO				Gabrielli, BG; Sarcevic, B; Sinnamon, J; Walker, G; Castellano, M; Wang, XQ; Ellem, KAO			A cyclin D-Cdk4 activity required for G(2) phase cell cycle progression is inhibited in ultraviolet radiation-induced G(2) phase delay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-CDK COMPLEXES; DEPENDENT KINASES; RETINOBLASTOMA-PROTEIN; DNA-DAMAGE; HUMAN KERATINOCYTES; HUMAN FIBROBLASTS; G1 ARREST; P16; PHOSPHORYLATION; P53	Cyclin D-Cdk4 complexes have a demonstrated role in G(1) phase, regulating the function of the retinoblastoma susceptibility gene product (Rb). Previously, we have shown that following treatment with low doses of UV radiation, cell lines that express wild-type pie and Cdk4 responded with a Gz phase cell. cycle delay. The UV-responsive lines contained elevated levels of p16 posttreatment, and the accumulation of pie correlated with the G(2) delay, Here we report that in UV-irradiated HeLa and A2058 cells, pie bound Cdk4 and Cdk6 complexes with increased avidity and inhibited a cyclin D3-Cdk4 compiler normally activated in late S/early G(2) phase. Activation of this complex was correlated with the caffeine-induced release from the UV-induced G(2) delay and a decrease in the level of pie bound to Cdk4, Finally, overexpression of a dominant-negative mutant of Cdk4 blocked cells in G(2) phase. These data indicate that the cyclin D3-Cdk4 activity is necessary for cell cycle progression through G(2) phase into mitosis and that the increased binding of p16 blocks this activity and G(2), phase progression after UV exposure.	Univ Queensland, Queensland Inst Med Res, Queensland Canc Fund Res Unit, Brisbane, Qld 4029, Australia; Univ Queensland, Joint Expt Oncol Program, Brisbane, Qld 4029, Australia; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Gabrielli, BG (corresponding author), Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.	brianG@qimr.edu.au	Gabrielli, Brian G/B-3655-2011; Wang, Xue-Qing/F-1758-2010	Gabrielli, Brian G/0000-0003-3933-1651; Sarcevic, Boris/0000-0002-8063-1050				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BATES S, 1994, ONCOGENE, V9, P1633; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Castellano M, 1997, CANCER RES, V57, P4868; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HERZINGER T, 1995, ONCOGENE, V11, P2151; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, ONCOGENE, V9, P2261; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Petrocelli T, 1996, ONCOGENE, V12, P1387; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TAM SW, 1994, CANCER RES, V54, P5816; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wang XQ, 1996, CANCER RES, V56, P2510; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weller EM, 1996, INT J RADIAT BIOL, V69, P371, DOI 10.1080/095530096145931	45	63	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13961	13969		10.1074/jbc.274.20.13961	http://dx.doi.org/10.1074/jbc.274.20.13961			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318807	hybrid			2022-12-25	WOS:000080322200036
J	Oh, H; Park, Y; Park, C				Oh, H; Park, Y; Park, C			A mutated PtsG, the glucose transporter, allows uptake of D-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; TRANSCRIPTIONAL ACTIVATOR; PHOSPHOTRANSFERASE SYSTEM; PHOSPHORYLATION; GENE; EXPRESSION; CLONING; OPERON; OVEREXPRESSION; PURIFICATION	Mutations arose from an Escherichia coli strain defective in the high (Rbs/ribose) and low (Als/allose and Xyl/xylose) affinity D-ribose transporters, which allow cells to grow on D-ribose. Genetic tagging and mapping of the mutations revealed that two loci in the E. coli linkage map are involved in creating a novel ribose transport mechanism. One mutation was found in ptsG, the glucose-specific transporter of phosphoenolpyruvate:carbohydrate phosphotransferase system and the other in mlc, recently reported to be involved in the regulation of ptsG. Five different mutations in ptsG were characterized, whose growth on D-ribose medium was about 80% that of the high affinity system (Rbs(+)). Two of them were found in the predicted periplasmic loops, whereas three others are in the transmembrane region. Ribose uptakes in the mutants, competitively inhibited by D-glucose, D-xylose, or D-allose, were much lower than that of the high affinity transporter but higher than those of the Als and Xyl systems. Further analyses of the mutants revealed that the rbsK (ribokinase) and rbsD (function unknown) genes are involved in the ribose transport through PtsG, indicating that the phosphorylation of ribose is not mediated by PtsG and that some unknown metabolic function mediated by RbsD is-required. It was also found that D-xylose, another sugar not involved in phosphorylation, was efficiently transported through the wild-type or mutant PtsG in mlc-negative background, The efficiencies of xylose add glucose transports are variable in the PtsG mutants, depending on their locations, either in the periplasm or in the membrane. In an extreme case of the transmembrane change (I283T), xylose transport is virtually abolished, indicating that the residue is directly involved in determining sugar specificity. We propose that there are at least two domains for substrate specificity in PtsG with slightly altered recognition properties.	Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Behav Genet, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Park, C (corresponding author), Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Behav Genet, Dept Biol Sci, Yusong-Ku, Taejon 305701, South Korea.		Park, Chankyu/C-1936-2011					AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; Begley GS, 1996, J BACTERIOL, V178, P940, DOI 10.1128/jb.178.3.940-942.1996; BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1992, J BIOL CHEM, V267, P3847; BUHR A, 1994, J BIOL CHEM, V269, P23437; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; DAVIS EO, 1987, J BIOL CHEM, V262, P13928; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; Declan D. A., 1998, SCIENCE, V280, P69; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HOPE JN, 1986, J BIOL CHEM, V261, P7663; IIDA A, 1984, J BACTERIOL, V158, P674, DOI 10.1128/JB.158.2.674-682.1984; Kim CH, 1997, J BACTERIOL, V179, P7631, DOI 10.1128/jb.179.24.7631-7637.1997; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; LOPILATO JE, 1984, J BACTERIOL, V158, P665, DOI 10.1128/JB.158.2.665-673.1984; MEINS M, 1993, J BIOL CHEM, V268, P11604; MESIBOV R, 1973, J GEN PHYSIOL, V62, P203, DOI 10.1085/jgp.62.2.203; Miller J.H., 1972, EXPT MOL GENETICS; MOWBRAY SL, 1992, J MOL BIOL, V225, P693; PARK C, 1986, J BACTERIOL, V167, P101, DOI 10.1128/jb.167.1.101-109.1986; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; RIEDL J, 1991, J BACTERIOL, V173, P4862; RUIJTER GJG, 1992, J BACTERIOL, V174, P2843, DOI 10.1128/JB.174.9.2843-2850.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Song SG, 1998, FEMS MICROBIOL LETT, V163, P255, DOI 10.1111/j.1574-6968.1998.tb13054.x; Song SG, 1997, J BACTERIOL, V179, P7025, DOI 10.1128/jb.179.22.7025-7032.1997; WILEMSRIESENBER.MR, 1992, J BACTERIOL, V174, P4558	33	36	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14006	14011		10.1074/jbc.274.20.14006	http://dx.doi.org/10.1074/jbc.274.20.14006			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318813	hybrid			2022-12-25	WOS:000080322200042
J	Yang, YK; Dickinson, CJ; Zeng, Q; Li, JY; Thompson, DK; Gantz, I				Yang, YK; Dickinson, CJ; Zeng, Q; Li, JY; Thompson, DK; Gantz, I			Contribution of melanocortin receptor exoloops to Agouti-related protein binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING-HORMONE RECEPTOR; MOLECULAR-CLONING; COUPLED RECEPTORS; LIGAND-BINDING; EXPRESSION; ANTAGONISM; OBESITY; FAMILY; MICE; ART	Agouti-related protein (AGRP) is an endogenous antagonist of melanocortin action that functions in the hypothalamic control of feeding behavior. Although previous studies have shown that AGRP binds three of the five known subtypes of melanocortin receptor, the receptor domains participating in binding and the molecular interactions involved are presently unknown, The present studies were designed to examine the contribution of extracytoplasmic domains of the melanocortin-4 receptor (MC4R) to AGRP binding by making chimerical receptor constructs of the human melanocortin-1 receptor (MC1R; a receptor that is not inhibited by AGRP) and the human MC4R (a receptor that is potently inhibited by AGRP). Substitutions of the extracytoplasmic NH2 terminus and the first extracytoplasmic: loop (exoloop) of the MC4R, with homologous domains of the MC1R had no effect on AGRP (87-132) binding affinity or inhibitory activity (the ability to inhibit melanocortin-stimulated cAMP generation). In contrast, cassette substitutions of exoloops 2 and 3 of the MC4R with the homologous exoloops of the MC1R resulted in a substantial loss of AGRP binding affinity and inhibitory activity. Conversely, the exchange of exoloops 2 land 3 of the MC1R with the homologous exoloops of the MC4R was found to confer AGRP binding and inhibitory activity to the basic structure of the MC1R. Importantly, these substitutions did not affect the ability of the alpha-melanocyte stimulating: hormone analogue [Nle(4),D-Phe(7)] melanocyte stimulating hormone to bind or activate the chimeric receptors. These data indicate that exoloops 2 and 3 of the melanocortin receptors are important for AGRP binding.	Univ Michigan, Sch Med, Dept Gen Surg, Ann Arbor, MI 48109 USA; Ann Arbor Vet Adm Hosp, Dept Gen Surg, Ann Arbor, MI 48109 USA; Gryphon Sci, S San Francisco, CA 94080 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Gantz, I (corresponding author), 6504 MSRB I,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.			Thompson, Darren/0000-0002-3725-7112	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054032, P30DK034933, R01DK047398] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1 DK54032-01, P30DK34933, R01 DK47398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Chhajlani V, 1996, BIOCHEM BIOPH RES CO, V219, P521, DOI 10.1006/bbrc.1996.0266; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; EBERLE AN, 1988, MELANOTROPINS CHEM P, P210; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Fong TM, 1997, BIOCHEM BIOPH RES CO, V237, P629, DOI 10.1006/bbrc.1997.7200; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Haskell-Luevano C, 1996, Drug Des Discov, V14, P197; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Schioth HB, 1996, BIOCHEM BIOPH RES CO, V229, P687, DOI 10.1006/bbrc.1996.1866; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Tatro JB, 1996, NEUROIMMUNOMODULAT, V3, P259, DOI 10.1159/000097281; Yang YK, 1997, J BIOL CHEM, V272, P23000, DOI 10.1074/jbc.272.37.23000; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148	23	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14100	14106		10.1074/jbc.274.20.14100	http://dx.doi.org/10.1074/jbc.274.20.14100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318826	hybrid			2022-12-25	WOS:000080322200055
J	Bochar, DA; Pan, ZQ; Knights, R; Fisher, RP; Shilatifard, A; Shiekhattar, R				Bochar, DA; Pan, ZQ; Knights, R; Fisher, RP; Shilatifard, A; Shiekhattar, R			Inhibition of transcription by the trimeric cyclin-dependent kinase 7 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; RNA-POLYMERASE-II; RING FINGER PROTEIN; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; EXCISION-REPAIR; FACTOR TFIIH; IN-VITRO; CAK	Cyclin-dependent kinase 7 (CDK7) can be isolated as a subunit of a trimeric kinase complex functional in activation of the mitotic promoting factor. In this study, we demonstrate that the trimeric cdk-activating kinase (CAK) acts as a transcriptional repressor of class II promoters and show that repression results from CAK impeding the entry of RNA polymerase II and basal transcription factor IIF into a competent preinitiation complex. This repression is independent of CDK7 kinase activity. We find that the p36/mAT1 subunit of CAK, is required for transcriptional repression and the repression is independent of the promoter used. Our results demonstrate a central role for CAK in regulation of messenger RNA synthesis by either inhibition of RNA polymerase II-catalyzed transcription or stimulation of transcription through association with basal transcription repair factor IIH.	Wistar Inst, Philadelphia, PA 19104 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	The Wistar Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Saint Louis University	Shiekhattar, R (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.		Bochar, Daniel A/A-9224-2009		NIGMS NIH HHS [GM55059] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Fisher RP, 1997, METHOD ENZYMOL, V283, P256; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SUN P, 1992, MOL ENDOCRINOL, V11, P1858; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288	31	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13162	13166		10.1074/jbc.274.19.13162	http://dx.doi.org/10.1074/jbc.274.19.13162			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224071	hybrid			2022-12-25	WOS:000080200400033
J	Devine, JH; Eubank, DW; Clouthier, DE; Tontonoz, P; Spiegelman, BM; Hammer, RE; Beale, EG				Devine, JH; Eubank, DW; Clouthier, DE; Tontonoz, P; Spiegelman, BM; Hammer, RE; Beale, EG			Adipose expression of the phosphoenolpyruvate carboxykinase promoter requires peroxisome proliferator-activated receptor gamma and 9-cis-retinoic acid receptor binding to an adipocyte-specific enhancer in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; HUMAN GROWTH-HORMONE; GENE-EXPRESSION; TRANSGENIC MICE; PPAR-GAMMA; COUP-TF; GTP; TRANSCRIPTION; UPSTREAM; PATHWAY	A putative adipocyte-specific enhancer has been mapped to approximately 1 kilobase pair upstream of the cytosolic phosphoenolpyruvate carboxykinase (PEPCK) gene, In the present study, we used transgenic mice to identify and characterize the 413-base pair (bp) region between -1242 and -828 bp as a bona fide adipocyte-specific enhancer in vivo. This enhancer functioned most efficiently in the context of the PEPCK promoter. The nuclear receptors peroxisome proliferator-activated receptor gamma (PPAR gamma) and g-cis-retinoic acid receptor (RXR) are required for enhancer function in vivo because: 1) a 3-bp mutation in the PPAR gamma-/RXR-binding element centered at -992 bp, PCK2, completely abolished transgene expression in adipose tissue; and 2) electrophoretic mobility supershift experiments with specific antibodies indicated that PPAR gamma and RXR are the only factors in adipocyte nuclear extracts which bind PCK2, In contrast, a second PPAR gamma/RXR-binding element centered at -446 bp, PCK1, is not involved in adipocyte specificity because inactivation of this site did not affect transgene expression, Moreover, electrophoretic mobility shift experiments indicated that, unlike PCK2, PCK1 is not selective for PPAR gamma/RXR-binding. To characterize the enhancer further, the rat and human PEPCK 5'-flanking DNA sequences were compared by computer and found to have significant similarities in the enhancer region. This high level of conservation suggests that additional transcription factors are probably involved in enhancer function. A putative human PCK2 element was identified by this sequence comparison. The human and rat PCK2 elements bound PPAR gamma/RXR with the same affinities. This work provides the first in vivo evidence that the binding of PPAR gamma to its target sequences is absolutely required for adipocyte-specific gene expression.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA; Univ Texas, SW Med Ctr, Dept Biochem, Howard Hughes Med Inst, Dallas, TX 75235 USA; Harvard Univ, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Beale, EG (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA.	bioegb@ttusc.edu	Beale, Elmus/GNM-8181-2022	Hammer, Robert E./0000-0001-5487-7551; Beale, Elmus/0000-0002-7758-0600	NIGMS NIH HHS [R01GM39895] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039895] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTRASFERRY J, 1994, BIOCHEM BIOPH RES CO, V203, P385, DOI 10.1006/bbrc.1994.2194; BEALE EG, 1985, J BIOL CHEM, V260, P748; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHEYETTE TE, 1992, NUCLEIC ACIDS RES, V20, P3427, DOI 10.1093/nar/20.13.3427; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; Ghosh D, 1999, NUCLEIC ACIDS RES, V27, P315, DOI 10.1093/nar/27.1.315; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HANSON RW, 1973, AM J CLIN NUTR, V26, P55, DOI 10.1093/ajcn/26.1.55; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; VAUGHAN M, 1962, J BIOL CHEM, V237, P3354; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703	36	75	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13604	13612		10.1074/jbc.274.19.13604	http://dx.doi.org/10.1074/jbc.274.19.13604			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224131	hybrid			2022-12-25	WOS:000080200400093
J	Friesen, JA; Campbell, HA; Kent, C				Friesen, JA; Campbell, HA; Kent, C			Enzymatic and cellular characterization of a catalytic fragment of CTP : phosphocholine cytidylyltransferase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; RAT-LIVER; DOMAIN; IDENTIFICATION; EXPRESSION; SITES	To probe the mechanism of lipid activation of CTP: phosphocholine cytidylyltransferase (CCT alpha), we have characterized a catalytic fragment of the enzyme that lacks the membrane-binding segment. The kinetic properties of the purified fragment, CCT alpha 236, were characterized, as well as the effects of expressing the fragment in cultured cells. CCT alpha 236 was truncated after residue 236, which corresponds to the end of the highly conserved catalytic domain. The activity of purified CCT alpha 236 was independent of lipids and about 50-fold higher than the activity of wild-type CCT alpha assayed in the absence of lipids, supporting a model in which the membrane-binding segment functions as an inhibitor of the catalytic domain. The k(cat)/K-m values for CCT alpha 236 were only slightly lower than those for lipid-activated CCT alpha. The importance of the membrane-binding segment in vivo was tested by expression of CCT alpha 236 in CHO58 cells, a cell line that is temperature-sensitive for growth and CCT alpha activity. Expression of wild-type CCT alpha in these cells complemented the defective growth phenotype when the cells were cultured in complete or delipidated fetal bovine serum. Expression of CCT alpha 236, however, did not complement the growth phenotype in the absence of serum lipids. These cells were capable of making phosphatidylcholine in the delipidated medium, so the inability of the cells to grow was not due to defective phosphatidylcholine synthesis. Supplementation of the delipidated medium with an unsaturated fatty acid allowed growth of CHO58 cells expressing CCT alpha 236, These results indicate that the membrane-binding segment of CCT alpha has an important role in cellular lipid metabolism.	Univ Michigan, Dept Biol Chem, Sch Med, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kent, C (corresponding author), Univ Michigan, Dept Biol Chem, Sch Med, Med Ctr, 4417 Med Sci 1, Ann Arbor, MI 48109 USA.			Adams, Heidi/0000-0001-7563-3126	NATIONAL CANCER INSTITUTE [R01CA064159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019286] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA64159] Funding Source: Medline; NIDDK NIH HHS [5P60DK-20572] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM19286-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KYTE J, 1995, MECH PROTEIN CHEM, P149; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; PARK YS, 1993, J BIOL CHEM, V268, P16648; PLESNER IW, 1986, BIOCHEM J, V239, P175, DOI 10.1042/bj2390175; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; [No title captured]	19	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13384	13389		10.1074/jbc.274.19.13384	http://dx.doi.org/10.1074/jbc.274.19.13384			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224101	hybrid			2022-12-25	WOS:000080200400063
J	Gurrola, GB; Rosati, B; Rocchetti, M; Pimienta, G; Zaza, A; Arcangeli, A; Olivotto, M; Possani, LD; Wanke, E				Gurrola, GB; Rosati, B; Rocchetti, M; Pimienta, G; Zaza, A; Arcangeli, A; Olivotto, M; Possani, LD; Wanke, E			A toxin to nervous, cardiac, and endocrine ERG K+ channels isolated from Centruroides noxius scorpion venom	FASEB JOURNAL			English	Article						eag gene family; erg gene; ergtoxin; scorpion toxin; action potential	III ANTIARRHYTHMIC AGENT; POTASSIUM-CHANNEL; CELL-LINE; NEUROBLASTOMA-CELLS; I-KR; FUNCTIONAL EXPRESSION; INWARD RECTIFIER; XENOPUS OOCYTES; HERG ENCODES; BLOCK	Toxins isolated from a variety of venoms are tools for probing the physiological function and structure of ion channels. The ether-a-go-go-related genes (erg) codify for the K+ channels (ERG), which are crucial in neurons and are impaired in human long-QT syndrome and Drosophila 'seizure' mutants. We have isolated a peptide from the scorpion Centruroides noxius Hoffmann that has no sequence homologies with other toxins, and demonstrate that it specifically inhibits (IC50=16+/-1 nM) only ERG channels of different species and distinct histogenesis. These results open up the possibility of investigating ERG channel structure-function relationships and novel pharmacological tools with potential therapeutic efficacy.	Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; Univ Milan, Dept Gen Physiol & Biochem, Lab Electrophysiol, I-20133 Milan, Italy; Natl Autonomous Univ Mexico, Inst Biotechnol, Dept Mol Recognit & Struct Biol, Cuernavaca 62271, Morelos, Mexico; Univ Florence, Inst Gen Pathol, I-50134 Florence, Italy	University of Milan; University of Milano-Bicocca; University of Milan; Universidad Nacional Autonoma de Mexico; University of Florence	Wanke, E (corresponding author), Univ Milan, Dipartimento Fisiol & Biochim Gen, Via Celoria 26, I-20133 Milan, Italy.		Zaza, Antonio/N-2646-2019; Possani, Lourival D/J-2397-2013; Pimienta, Genaro/A-2714-2011	Zaza, Antonio/0000-0001-9355-4958; 	Telethon [1046] Funding Source: Medline	Telethon(Fondazione Telethon)		Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; ARCANGELI A, 1993, J CELL BIOL, V122, P1131, DOI 10.1083/jcb.122.5.1131; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1998, CANCER RES, V58, P815; Busch AE, 1996, PFLUG ARCH EUR J PHY, V432, P1094, DOI 10.1007/s004240050240; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; CURRAN ME, 1995, CELL, V80, P95; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; GARCIA ML, 1997, ADV PHARMACOL, V39, P426; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; JUDD AM, 1988, ENDOCRINOLOGY, V123, P2341, DOI 10.1210/endo-123-5-2341; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MAGISTRETTI J, 1996, TRENDS NEUROSCI, V19, P531; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Meyer R, 1998, J PHYSIOL-LONDON, V508, P49, DOI 10.1111/j.1469-7793.1998.049br.x; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; POLLO A, 1993, PFLUG ARCH EUR J PHY, V423, P462, DOI 10.1007/BF00374942; Possani L. D., 1984, HDB NATURAL TOXINS, V2, P513; RORSMAN P, 1986, AM J PHYSIOL, V251, P912; ROSATI B, 1998, SFN ANN M, V792, P2; Sanguinetti MC, 1997, MOL PHARMACOL, V51, P491; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1996, NATURE, V384, P78; SCHAFER R, 1998, SFN ANN M, V330, P17; SCHAFER R, 1997, SOC NEUROSCI, V23, pA856; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; Selisko B, 1998, EUR J BIOCHEM, V254, P468, DOI 10.1046/j.1432-1327.1998.2540468.x; Shi WM, 1997, J NEUROSCI, V17, P9423; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; SPINELLI W, 1993, CARDIOVASC RES, V27, P1580, DOI 10.1093/cvr/27.9.1580; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; Suessbrich H, 1997, BRIT J PHARMACOL, V120, P968, DOI 10.1038/sj.bjp.0700989; Suessbrich H, 1996, FEBS LETT, V385, P77, DOI 10.1016/0014-5793(96)00355-9; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Titus SA, 1997, J NEUROSCI, V17, P875; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TYGAT J, 1998, BIOPHYS J, V74, pA229; Wang XJ, 1997, J NEUROSCI, V17, P882; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Weinsberg F, 1997, PFLUG ARCH EUR J PHY, V434, P1, DOI 10.1007/s004240050356; Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261; Zaza A, 1998, CIRC RES, V82, P947, DOI 10.1161/01.RES.82.9.947	53	94	97	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					953	962		10.1096/fasebj.13.8.953	http://dx.doi.org/10.1096/fasebj.13.8.953			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224238				2022-12-25	WOS:000080372500018
J	Banhegyi, G; Lusini, L; Puskas, F; Rossi, R; Fulceri, R; Braun, L; Mile, V; di Simplicio, P; Mandl, J; Benedetti, A				Banhegyi, G; Lusini, L; Puskas, F; Rossi, R; Fulceri, R; Braun, L; Mile, V; di Simplicio, P; Mandl, J; Benedetti, A			Preferential transport of glutathione versus glutathione disulfide in rat liver microsomal vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN; OXIDATION; DEHYDROASCORBATE; PERMEABILITY; GLUCOSE; SYSTEM; CELL	A bi directional, saturable transport of glutathione (GSH) was found in rat liver microsomal vesicles. GSH transport could be inhibited by the anion transport blockers flufenamic acid and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid. A part of GSH taken up by the vesicles was metabolized to glutathione disulfide (GSSG) in the lumen. Microsomal membrane was virtually nonpermeable toward GSSG; accordingly, GSSG generated in the microsomal lumen could hardly exit. Therefore, GSH transport, contrary to previous assumptions, is preferred in the endoplasmic reticulum, and GSSG entrapped and accumulated in the lumen creates the oxidized state of its redox buffer.	Univ Siena, Inst Gen Pathol, I-53100 Siena, Italy; Semmelweis Univ, Dept Med Chem, H-1444 Budapest, Hungary; Univ Siena, Inst Nervous & Mental Dis, I-53100 Siena, Italy	University of Siena; Semmelweis University; University of Siena	Benedetti, A (corresponding author), Univ Siena, Inst Gen Pathol, Via Laterina 8, I-53100 Siena, Italy.	benedetti@unisi.it	Rossi, Ranieri/C-8743-2011; Bánhegyi, Gábor/A-1476-2014	Rossi, Ranieri/0000-0002-0187-4530; 				Banhegyi G, 1998, J BIOL CHEM, V273, P2758, DOI 10.1074/jbc.273.5.2758; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Banhegyi G, 1996, BIOCHEM J, V315, P171, DOI 10.1042/bj3150171; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; COUSIN JL, 1982, BIOCHIM BIOPHYS ACTA, V687, P147, DOI 10.1016/0005-2736(82)90540-5; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; FULCERI R, 1992, BIOCHEM J, V286, P813, DOI 10.1042/bj2860813; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENNE V, 1986, FEBS LETT, V202, P267, DOI 10.1016/0014-5793(86)80699-8; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ISSACS J, 1977, BIOCHIM BIOPHYS ACTA, V497, P192; JANOLINO VG, 1987, ARCH BIOCHEM BIOPHYS, V258, P265, DOI 10.1016/0003-9861(87)90344-4; Marcolongo P, 1996, BIOCHEM BIOPH RES CO, V219, P916, DOI 10.1006/bbrc.1996.0333; MEISSNER G, 1988, METHOD ENZYMOL, V157, P417; MINOTTI G, 1991, J BIOL CHEM, V266, P20011; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Puskas F, 1998, FEBS LETT, V430, P293, DOI 10.1016/S0014-5793(98)00678-4; SOLING HD, 1994, FALK SYMP, V74, P127; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WELLS WW, 1990, J BIOL CHEM, V265, P15361; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1	24	104	107	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12213	12216		10.1074/jbc.274.18.12213	http://dx.doi.org/10.1074/jbc.274.18.12213			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212186	hybrid, Green Published			2022-12-25	WOS:000080056800006
J	Boiziau, C; Dausse, E; Yurchenko, L; Toulme, JJ				Boiziau, C; Dausse, E; Yurchenko, L; Toulme, JJ			DNA aptamers selected against the HIV-1 trans-activation-responsive RNA element form RNA-DNA kissing complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; HIGH-AFFINITY; TAR RNA; ANTISENSE OLIGONUCLEOTIDES; SECONDARY STRUCTURES; HAIRPIN COMPLEX; BINDING PROTEIN; INHIBITION; REGION; LOOP	In vitro selection was performed in a DNA library, made of oligonucleotides with a 30-nucleotide random sequence, to identify ligands of the human immunodeficiency virus type-1 trans-activation-responsive (TAR) RNA element. Aptamers, extracted after 15 rounds of selection-amplification, either from a classical library of sequences or from virtual combinatorial libraries, displayed an imperfect stem-loop structure and presented a consensus motif 5'ACTCCCAT in the apical loop. The six central bases of the consensus were complementary to the TAR apical region, giving rise to the formation of RNA-DNA kissing complexes, without disrupting the secondary structure of TAR. The RNA-DNA kissing complex was a poor substrate for Escherichia coli RNase H, likely due to steric and conformational constraints of the DNA/RNA heteroduplex, 2'-O-Methyl derivatives of a selected aptamer were binders of lower efficiency than the parent aptamer in contrast to regular sense/antisense hybrids, indicating that the RNA/DNA loop-loop region adopted a non-canonical heteroduplex structure. These results, which allowed the identification of a new type of complex, DNA-RNA kissing complex, demonstrate the interest of in vitro selection for identifying non antisense oligonucleotide ligands of RNA structures that are of potential value for artificially modulating gene expression.	Univ Victor Segalen, IFR Pathol Infect, INSERM U386, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Toulme, JJ (corresponding author), Univ Victor Segalen, IFR Pathol Infect, INSERM U386, 146 Rue Leo Saignat, F-33076 Bordeaux, France.		Boiziau, Claudine/AAM-3463-2021	Boiziau, Claudine/0000-0002-0475-2571; Toulme, Jean-jacques/0000-0002-8432-5034				Boiziau C, 1997, ANTISENSE NUCLEIC A, V7, P369, DOI 10.1089/oli.1.1997.7.369; CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705; Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; Gatignol A, 1996, GENE EXPRESSION, V5, P217; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GRAEBLE MA, 1993, P NATL ACAD SCI USA, V90, P6184, DOI 10.1073/pnas.90.13.6184; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HJALT TAH, 1995, NUCLEIC ACIDS RES, V23, P580, DOI 10.1093/nar/23.4.580; HUE I, 1997, P NATL ACAD SCI USA, V94, P2106; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; IRIBARREN AM, 1990, P NATL ACAD SCI USA, V87, P7747, DOI 10.1073/pnas.87.19.7747; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; LARROUY B, 1995, NUCLEIC ACIDS RES, V23, P3434, DOI 10.1093/nar/23.17.3434; Le Tinevez R, 1998, NUCLEIC ACIDS RES, V26, P2273, DOI 10.1093/nar/26.10.2273; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, J BIOL CHEM, V272, P27513, DOI 10.1074/jbc.272.44.27513; MARINO JP, 1995, SCIENCE, V268, P1448, DOI 10.1126/science.7539549; Mishra RK, 1996, P NATL ACAD SCI USA, V93, P10679, DOI 10.1073/pnas.93.20.10679; MORIKAWA K, 1998, CRYSTAL STRUCTURES R, P181; Paillart JC, 1996, BIOCHIMIE, V78, P639, DOI 10.1016/S0300-9084(96)80010-1; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; Toulme JJ, 1996, BIOCHIMIE, V78, P663, DOI 10.1016/S0300-9084(96)80012-5; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128	33	95	122	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12730	12737		10.1074/jbc.274.18.12730	http://dx.doi.org/10.1074/jbc.274.18.12730			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212256	hybrid			2022-12-25	WOS:000080056800076
J	Dickinson, LA; Trauger, JW; Baird, EE; Dervan, PB; Graves, BJ; Gottesfeld, JM				Dickinson, LA; Trauger, JW; Baird, EE; Dervan, PB; Graves, BJ; Gottesfeld, JM			Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-kappa B, and DNA by a designed DNA-binding ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLE-IMIDAZOLE POLYAMIDES; MINOR-GROOVE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; ALPHA-ENHANCER; PHYSICAL INTERACTIONS; CRYSTAL-STRUCTURE; VIRUS ENHANCER; MURINE ETS-1; HMG PROTEIN	Sequence-specific pyrrole-imidazole polyamides can be designed to interfere with transcription factor binding and to regulate gene expression, both in vitro and in living cells. Polyamides bound adjacent to the recognition sites for TBP, Ets-l, and LEF-1 in the human immunodeficiency virus, type 1 (HnT-1), long terminal repeat inhibited transcription in cell-free assays and viral rep lication in human peripheral blood lymphocytes. The DNA binding activity of the transcription factor Ets-l is specifically inhibited by a polyamide bound in the minor groove. Ets-l is a member of the winged-helix-turn-helix family of transcription factors and binds DNA through a recognition helix bound in the major groove with additional phosphate contacts on either side of this major groove interaction. The inhibitory polyamide possibly interferes with phosphate contacts made by Ets-l, by occupying the adjacent minor groove. Full-length Ets-l binds the HIV-1 enhancer through cooperative interactions with the p50 subunit of NF-kappa B, and the Ets-inhibitory polyamide also blocks formation of ternary Ets-1 NF-kappa B DNA complexes on the HIV-1 enhancer. A polyamide bound adjacent to the recognition site for NF-kappa B also inhibits NF-kappa B binding and ternary complex formation. These results broaden the application range of minor groove-binding polyamides and demonstrate that these DNA ligands are powerful inhibitors of DNA-binding proteins that predominantly use major groove contacts and of cooperative protein-DNA ternary complexes.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92087 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA; Univ Utah, Sch Med, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84132 USA	Scripps Research Institute; California Institute of Technology; California Institute of Technology; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Gottesfeld, JM (corresponding author), Scripps Res Inst, Dept Biol Mol, 10550 N Torrey Pines Rd, La Jolla, CA 92087 USA.			Gottesfeld, Joel/0000-0002-4643-5777	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038663, R01GM057148] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-57148, R01 GM038663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bremer RE, 1998, CHEM BIOL, V5, P119, DOI 10.1016/S1074-5521(98)90057-6; Dickinson LA, 1998, P NATL ACAD SCI USA, V95, P12890, DOI 10.1073/pnas.95.22.12890; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kielkopf CL, 1998, NAT STRUCT BIOL, V5, P104, DOI 10.1038/nsb0298-104; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; STARR DB, 1995, J MOL BIOL, V250, P434; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Turner JM, 1998, J AM CHEM SOC, V120, P6219, DOI 10.1021/ja980147e; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; White S, 1998, NATURE, V391, P468, DOI 10.1038/35106; White S, 1997, CHEM BIOL, V4, P569, DOI 10.1016/S1074-5521(97)90243-X	37	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12765	12773		10.1074/jbc.274.18.12765	http://dx.doi.org/10.1074/jbc.274.18.12765			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212261	Green Accepted, hybrid			2022-12-25	WOS:000080056800081
J	Ghose, S; Porzig, H; Baltensperger, K				Ghose, S; Porzig, H; Baltensperger, K			Induction of erythroid differentiation by altered G(alpha 16) activity as detected by a reporter gene assay in MB-02 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-DEFICIENT G-ALPHA(16); PROTEIN-COUPLED RECEPTORS; EMBRYONAL CARCINOMA-CELLS; SIGNAL-TRANSDUCTION; ERYTHROLEUKEMIA-CELLS; KINASE CASCADES; ALPHA-SUBUNITS; RETINOIC ACID; B-CELL; EXPRESSION	Heterotrimeric G proteins may assume modulatory roles in cellular proliferation and differentiation. The G protein alpha-subunit G(alpha 16) which is specifically expressed in hematopoietic cells, is highly regulated during differentiation of normal and leukemic cells. In human erythroleukemia cells, suppression of G(alpha 16) inhibited cellular growth rates. A reporter gene system was established to assess the role of G(alpha 16) on erythroid differentiation of MB-02 erythroleukemia cells. It is based on transient transfection with a plasmid that expresses green fluorescent protein under the control of the beta-globin promoter. Expression of G(alpha 16) led to a significant increase in green fluorescent protein-positive cells, as did transfection with a G(alpha 16) antisense plasmid (154 and 156% of controls, respectively). The GTPase-deficient, constitutively active mutant of G(alpha 16), G(alpha 16)R186C, further stimulated differentiation to 195% of control values. Because the effect of G(alpha 16) is triggered most efficiently by the GTP-bound protein, an indirect action through interference of overexpressed G(alpha 16) with G protein beta gamma-subunits can be excluded, The corresponding mutant of G(alpha q) (G(alpha q)R182C), the phylogenetically closest family member of G(alpha 16), had no effect. The data define a specific role for G(alpha 16)-dependent signal transduction in cellular differentiation: deviations from optimal levels of G(alpha 16) functional activity lead to reduced growth rates and promote differentiation in hematopoietic cells.	Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Baltensperger, K (corresponding author), Univ Bern, Inst Pharmacol, Postfach 51,Friedbuhlstr 49, CH-3010 Bern, Switzerland.	kurt.baltensperger@pki.unibe.ch						AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Baltensperger H, 1997, J BIOL CHEM, V272, P10151; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; Grant KR, 1997, IMMUNOLOGY, V90, P564, DOI 10.1046/j.1365-2567.1997.00196.x; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HOOPER WC, 1991, LEUKEMIA RES, V15, P753, DOI 10.1016/0145-2126(91)90079-9; HUPPERTZ C, 1993, EUR J BIOCHEM, V215, P611, DOI 10.1111/j.1432-1033.1993.tb18072.x; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lippert E, 1997, FEBS LETT, V417, P292, DOI 10.1016/S0014-5793(97)01308-2; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAPARA MY, 1995, BLOOD, V85, P1836, DOI 10.1182/blood.V85.7.1836.bloodjournal8571836; NEEDHAM M, 1995, PROTEIN EXPRES PURIF, V6, P124, DOI 10.1006/prep.1995.1015; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU T, 1987, BLOOD, V70, P1764; Pfeilstocker M, 1996, LEUKEMIA, V10, P1117; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; QIAN NX, 1994, J BIOL CHEM, V269, P17417; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; SU HL, 1993, AM J PHYSIOL, V265, pC1729, DOI 10.1152/ajpcell.1993.265.6.C1729; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Tenailleau S, 1997, EXP HEMATOL, V25, P927; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	33	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12848	12854		10.1074/jbc.274.18.12848	http://dx.doi.org/10.1074/jbc.274.18.12848			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212272	hybrid			2022-12-25	WOS:000080056800092
J	Wang, J; White, AL				Wang, J; White, AL			6-aminohexanoic acid as a chemical chaperone for apolipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) CONCENTRATIONS; PRIMARY BABOON HEPATOCYTES; LOW-DENSITY-LIPOPROTEIN; APO(A) MESSENGER-RNA; MOLECULAR-BASIS; ENDOPLASMIC-RETICULUM; SIZE POLYMORPHISM; BINDING SITES; PROTEIN; PLASMINOGEN	Apolipoprotein (a) (apo(a)) is a component of the atherogenic lipoprotein, Lp(a), The efficiency with which apo(a) escapes the endoplasmic reticulum (ER) and is secreted by the liver is a major determinant of plasma Lp(a) levels. Apo(a) contains a series of domains homologous to plasminogen kringle (K) 4, each of which possesses a potential lysine-binding site. By using primary mouse hepatocytes expressing a 17K4 human apo(a) protein, we found that high concentrations (25-200 mM) of the lysine analog, 6-aminohexanoic acid (6AHA), increased apo(a) secretion 8-14-fold. This was accompanied by a decrease in apo(a) presecretory degradation. 6AHA inhibited accumulation of apo(a) in the ER induced by the proteasome inhibitor, lactacystin. Thus, 6AHA appeared to inhibit degradation by increasing apo(a) export from the ER. Significantly, 6AHA overcame the block in apo(a) secretion induced by the ER glucosidase inhibitor, castanospermine. 6AHA may therefore circumvent the requirement for calnexin and calreticulin interaction in apo(a) secretion. Sucrose gradients and a gel-based folding assay were unable to detect any influence of 6AHA on apo(a) folding. However, non-covalent or small, disulfide-dependent changes in apo(a) conformation would not be detected in these assays. Proline also increased the efficiency of apo(a) secretion. We propose that 6AHA and proline can act as chemical chaperones for apo(a).	Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	White, AL (corresponding author), Univ Texas, SW Med Ctr, Ctr Human Nutr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059541, R29HL059541] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COHEN JC, 1993, J CLIN INVEST, V91, P1630, DOI 10.1172/JCI116370; Cox LA, 1998, J LIPID RES, V39, P1319; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; Fless GM, 1996, BIOCHEMISTRY-US, V35, P2289, DOI 10.1021/bi951792q; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; Gaubatz J W, 1986, Methods Enzymol, V129, P167; GETHING MJ, 1992, NATURE, V355, P3; GUEVARA J, 1993, BIOPHYS J, V64, P686, DOI 10.1016/S0006-3495(93)81428-0; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; HOOVERPLOW JL, 1993, BIOCHEMISTRY-US, V32, P13681, DOI 10.1021/bi00212a037; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MAKINO K, 1991, LIPIDS, V26, P679, DOI 10.1007/BF02535613; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MORRISETT JD, 1990, LIPOPROTEIN A, P53; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; RAINWATER DL, 1989, BIOCHIM BIOPHYS ACTA, V1003, P30, DOI 10.1016/0005-2760(89)90094-5; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; SANDHOLZER C, 1991, HUM GENET, V86, P607; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WHITE AL, 1994, J BIOL CHEM, V269, P9060; White AL, 1997, CLIN GENET, V52, P326; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1994, J BIOL CHEM, V269, P28716; WHITE AL, 1994, CHEM PHYS LIPIDS, V67-8, P123, DOI 10.1016/0009-3084(94)90131-7; White AL, 1999, J LIPID RES, V40, P275; White AL, 1997, J BIOL CHEM, V272, P5048, DOI 10.1074/jbc.272.8.5048; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; ZYSOW BR, 1995, ARTERIOSCL THROM VAS, V15, P58, DOI 10.1161/01.ATV.15.1.58	50	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12883	12889		10.1074/jbc.274.18.12883	http://dx.doi.org/10.1074/jbc.274.18.12883			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212277	hybrid			2022-12-25	WOS:000080056800097
J	Babenko, AP; Gonzalez, G; Bryan, J				Babenko, AP; Gonzalez, G; Bryan, J			Two regions of sulfonylurea receptor specify the spontaneous bursting and ATP inhibition of K-ATP channel isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC B-CELLS; POTASSIUM CHANNELS; INSULIN-SECRETION; SUBUNIT; SUR1; REGULATOR; DIAZOXIDE; BINDING; MGADP	K-ATP channels are heteromultimers of K(IR)6.2 and a sulfonylurea receptor, SUR, an ATP binding cassette (ABC) protein with several isoforms. K(IR)6.2 forms a channel pore whose spontaneous activity and ATP sensitivity are modulated by the receptor via an unknown interaction(s), Side by side comparison of single-channel kinetics and steady-state ATP inhibition of human beta-cell, SUR1/K(IR)6.2, versus cardiac, SUR2A/K(IR)6.2 channels demonstrate that the latter have a greater mean burst duration and open probability in the absence of nucleotides and similar to 4-fold higher IC50(ATP). We have used matched chimeras of SUR1 and SUR2A to show that the kinetics, which determine the maximal open probability (Po-max), and the ATP sensitivity are functionally separable and to identify the two segments of SUR responsible for these isoform differences. A region within the first five transmembrane domains specifies the interburst kinetics, whereas a C-terminal segment determines the sensitivity to inhibitory ATP, The separable effects of SUR on ATP inhibition and channel kinetics implies that the cytoplasmic C terminus of SUR either directly modulates the affinity of a weak ATP binding site on the inward rectifier or affects linkage between the binding site and the gate. This is the first identification of parts of an ABC protein that interact with an ion channel subunit to modulate the spontaneous activity and ATP sensitivity of the heteromeric channel.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Babenko, AP (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052771, R01DK044311] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44311, DK52771] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; GILLIS KD, 1989, AM J PHYSIOL, V257, pC1119, DOI 10.1152/ajpcell.1989.257.6.C1119; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; John SA, 1998, J PHYSIOL-LONDON, V510, P333, DOI 10.1111/j.1469-7793.1998.333bk.x; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; SCHWAPPACH B, 1999, IN PRESS NEURON; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; TAKANO M, 1993, PROG NEUROBIOL, V41, P21, DOI 10.1016/0301-0082(93)90039-U; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; ZILBERTER Y, 1988, PFLUG ARCH EUR J PHY, V411, P584, DOI 10.1007/BF00582382	26	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11587	11592		10.1074/jbc.274.17.11587	http://dx.doi.org/10.1074/jbc.274.17.11587			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206966	hybrid			2022-12-25	WOS:000079834800022
J	Davies, DR; Braam, LM; Reznikoff, WS; Rayment, I				Davies, DR; Braam, LM; Reznikoff, WS; Rayment, I			The three-dimensional structure of a Tn5 transposase-related protein determined to 2.9-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA VIRUS INTEGRASE; RAY-DIFFRACTION DATA; CATALYTIC DOMAIN; MACROMOLECULAR STRUCTURES; ESCHERICHIA-COLI; HIV-1 INTEGRASE; ACTIVE-SITE; POLYNUCLEOTIDYL TRANSFER; RETROVIRAL INTEGRATION; CRYSTAL-STRUCTURE	Transposon Tn5 employs a unique means of self-regulation by expressing a truncated version of the transposase enzyme that acts as an inhibitor. The inhibitor protein differs from the full-length transposase only by the absence of the first 55 N-terminal amino acid residues. It contains the catalytic active site of transposase and a C-terminal domain involved in protein-protein interactions. The three-dimensional structure of Tn5 inhibitor determined to 2.9-Angstrom resolution is reported here. A portion of the protein fold of the catalytic core domain is similar to the folds of human immunodeficiency virus-1 integrase, avian sarcoma virus integrase, and bacteriophage Mu transposase, The Tn5 inhibitor contains an insertion that extends the beta-sheet of the catalytic core from 5 to 9 strands. All three of the conserved residues that make up the "DDE" motif of the active site are visible in the structure. An arginine residue that is strictly conserved among the IS4 family of bacterial transposases is present at the center of the active site, suggesting a catalytic motif of "DDRE," A novel C-terminal domain forms a dimer interface across a crystallographic 2-fold axis, Although this dimer represents the structure of the inhibited complex, it provides insight into the structure of the synaptic complex.	Univ Wisconsin, Inst Enzyme Res, Madison, WI 53705 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Inst Enzyme Res, 1710 Univ Ave, Madison, WI 53705 USA.	ivan@enzyme.wisc.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NIAMS NIH HHS [AR35186] Funding Source: Medline; NIGMS NIH HHS [GM50692, GM08349] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BERG DE, 1983, P NATL ACAD SCI-BIOL, V80, P792, DOI 10.1073/pnas.80.3.792; BERG DE, 1989, MOBILE DNA, P186; BERG DE, 1989, MOBILE DNA, P185; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Braam LAM, 1998, J BIOL CHEM, V273, P10908, DOI 10.1074/jbc.273.18.10908; Braam LAM, 1999, J BIOL CHEM, V274, P86, DOI 10.1074/jbc.274.1.86; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DELACRUZ NB, 1993, J BACTERIOL, V175, P6932, DOI 10.1128/jb.175.21.6932-6938.1993; DELONG A, 1991, P NATL ACAD SCI USA, V88, P6072, DOI 10.1073/pnas.88.14.6072; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; FISHER AJ, 1996, MOLDED; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; NAVAZA J, 1993, ACTA CRYSTALLOGR D, V49, P588, DOI 10.1107/S0907444993005141; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1986, THESIS YALE U; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REZNIKOFF WS, 1993, ANNU REV MICROBIOL, V47, P945, DOI 10.1146/annurev.mi.47.100193.004501; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SCHALLER H, 1979, COLD SPRING HARB SYM, V43, P401, DOI 10.1101/SQB.1979.043.01.046; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WEINREICH MD, 1994, J MOL BIOL, V241, P166, DOI 10.1006/jmbi.1994.1486; WEINREICH MD, 1994, GENE DEV, V8, P2363, DOI 10.1101/gad.8.19.2363; WIEGAND TW, 1994, J MOL BIOL, V235, P486, DOI 10.1006/jmbi.1994.1008; WIEGAND TW, 1992, J BACTERIOL, V174, P1229, DOI 10.1128/jb.174.4.1229-1239.1992; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; York D, 1996, NUCLEIC ACIDS RES, V24, P3790, DOI 10.1093/nar/24.19.3790; Yurieva O, 1996, BIOCHEM MOL BIOL INT, V38, P15; Zhou M, 1997, J MOL BIOL, V271, P362, DOI 10.1006/jmbi.1997.1188	71	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11904	11913		10.1074/jbc.274.17.11904	http://dx.doi.org/10.1074/jbc.274.17.11904			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207011	hybrid			2022-12-25	WOS:000079834800067
J	Esser, K; Nelson, T; Lupa-Kimball, V; Blough, E				Esser, K; Nelson, T; Lupa-Kimball, V; Blough, E			The CACC box and myocyte enhancer factor-2 sites within the myosin light chain 2 slow promoter cooperate in regulating nerve-specific transcription in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN GENE-EXPRESSION; TRANSGENIC MICE; FIBER-TYPE; LIGHT-CHAIN-2 GENE; ACTIN GENE; ELEMENTS; DIFFERENTIATION; MYOGENESIS; ACTIVATION; CELLS	Previous experiments showed that activity of the -800-base pair MLC2slow promoter was 75-fold higher in the innervated soleus (SOL) compared with the noninnervated SOL muscles, Using in vivo DNA injection of MLC2slow promoter-luciferase constructs, the aim of this project was to identify regulatory sites and potential transcription factors important for slow nerve-dependent gene expression. Three sites within the proximal promoter (myocyte enhancer factor-2 (MEF2), E-box, and CACC box) were individually mutated, and the effect on luciferase expression was determined. There was no change in luciferase expression in the SOL and extensor digitorum longus (EDL) muscles when the E-box was mutated. In contrast, the MEF2 mutation resulted in a 30-fold decrease in expression in the innervated SOL muscles (10.3 versus 0.36 normalized relative light units (RLUs)). Transactivation of the MLC2slow promoter by overexpressing MEF2 was only seen in the innervated SOL (676,340 versus 2,225,957 RLUs; p < 0.01) with no effect in noninnervated SOL or EDL muscles. These findings suggest that the active MLC2slow promoter is sensitive to MEF2 levels, but MEF2 levels alone do not determine nerve-dependent expression. Mutation of the CACC box resulted in a significant up-regulation in the EDL muscles (0.23 versus 4.08 normalized RLUs), With the CACC box mutated, overexpression of MEF2 was sufficient to transactivate the MLC2slow promoter in noninnervated SOL muscles (27,536 versus 1,605,797 RLUs), Results from electrophoretic mobility shift and supershift assays confirm MEF2 protein binding to the MEF2 site and demonstrate specific binding to the CACC sequence. These results suggest a model for nerve-dependent regulation of the MLC2slow promoter in which derepression occurs through the CACC box followed by quantitative expression through enhanced MEF2 activation.	Univ Illinois, Sch Kinesiol MC 194, Chicago, IL 60608 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60608 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Esser, K (corresponding author), Univ Illinois, Sch Kinesiol MC 194, 901 W Roosevelt Rd, Chicago, IL 60608 USA.	kryn.esser@uic.edu			NHLBI NIH HHS [HL07692-08] Funding Source: Medline; NIAMS NIH HHS [AR43349] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043349, R29AR043349] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; Blough E, 1999, BIOTECHNIQUES, V26, P202, DOI 10.2144/99262bm05; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BULLER AJ, 1965, J PHYSIOL-LONDON, V178, P343, DOI 10.1113/jphysiol.1965.sp007631; Calvo S, 1996, DEV GENET, V19, P169, DOI 10.1002/(SICI)1520-6408(1996)19:2<169::AID-DVG9>3.3.CO;2-T; CARLSON BM, 1981, PHYSIOL BOHEMOSLOV, V30, P505; CARSON J, 1996, AM J PHYSIOL, V39, pC1624; CARSON JA, 1995, AM J PHYSIOL-CELL PH, V268, pC918, DOI 10.1152/ajpcell.1995.268.4.C918; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; COHEN A, 1988, NUCLEIC ACIDS RES, V16, P10037, DOI 10.1093/nar/16.21.10037; CORIN SJ, 1995, P NATL ACAD SCI USA, V92, P6185, DOI 10.1073/pnas.92.13.6185; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; Dhar M, 1997, J BIOL CHEM, V272, P18490, DOI 10.1074/jbc.272.29.18490; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; ESSER K, 1993, DEV BIOL, V159, P173, DOI 10.1006/dbio.1993.1231; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Jerkovic R, 1997, J MUSCLE RES CELL M, V18, P369, DOI 10.1023/A:1018630311208; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; Kraus W E, 1994, Exerc Sport Sci Rev, V22, P313; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LEVITT LK, 1995, DNA CELL BIOL, V14, P599, DOI 10.1089/dna.1995.14.599; Lupa-Kimball VA, 1998, AM J PHYSIOL-CELL PH, V274, pC229, DOI 10.1152/ajpcell.1998.274.1.C229; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MATHISEN PM, 1987, GENE DEV, V1, P1107, DOI 10.1101/gad.1.10.1107; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MINTY A, 1986, MOL CELL BIOL, V6, P2137, DOI 10.1128/MCB.6.6.2137; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ONTELL MP, 1993, DEV DYNAM, V198, P203, DOI 10.1002/aja.1001980306; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; Sambrook J., 1989, MOL CLONING, pA1; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SUTHERLAND CJ, 1993, DEV DYNAM, V196, P25, DOI 10.1002/aja.1001960104; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	54	42	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12095	12102		10.1074/jbc.274.17.12095	http://dx.doi.org/10.1074/jbc.274.17.12095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207035	hybrid			2022-12-25	WOS:000079834800091
J	Gotoh, I; Fukuda, M; Adachi, M; Nishida, E				Gotoh, I; Fukuda, M; Adachi, M; Nishida, E			Control of the cell morphology and the S phase entry by mitogen-activated protein kinase kinase - A regulatory role of its N-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; NIH 3T3 CELLS; MAP-KINASE; MESODERM INDUCTION; PHOSPHORYLATION SITES; DNA-SYNTHESIS; RAS; CASCADE; TRANSFORMATION; PROLIFERATION	The mitogen-activated protein kinase kinase (MAPKK)/MAP kinase (MAPK) cascade plays an important role in the growth control of mammalian cells. We have found that expression of constitutively active MAPKK induces rapid morphological changes of fibroblastic cells, which are accompanied by disruption of stress fibers and disappearance of focal adhesions. These changes took place under the conditions that inhibited cellular Pas function, suggesting a linkage between the MAPK cascade and the control of cell morphology. We further show that constitutively active MAPKK can induce expression of endogenous Fos protein, an immediately early gene product, and cause the S phase entry of G(0)-arrested cells. Finally, expression of the N-terminal fragment of MAPKK which encompasses the nuclear export signal sequence and the MAPK-binding site blocked both the serum-induced S phase entry of quiescent cells and the oncogenic Ras induced morphological changes. All these results demonstrate that MAPKK is one of key molecules involved in the control of both cell morphology and cell proliferation and suggest an important role for the N-terminal region of MAPKK in the regulation of the MAPK signaling.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Fukuda, Makoto/S-9748-2019; Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HATTORI S, 1985, MOL CELL BIOL, V5, P1449, DOI 10.1128/MCB.5.6.1449; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SEGER R, 1994, J BIOL CHEM, V269, P25699; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	41	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11874	11880		10.1074/jbc.274.17.11874	http://dx.doi.org/10.1074/jbc.274.17.11874			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207007	hybrid			2022-12-25	WOS:000079834800063
J	Chandrasekaran, S; Guo, NH; Rodrigues, RG; Kaiser, J; Roberts, DD				Chandrasekaran, S; Guo, NH; Rodrigues, RG; Kaiser, J; Roberts, DD			Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha(3)beta(1) integrin and regulated by insulin-like growth factor-1 and CD98	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; HEPARIN-BINDING DOMAIN; CANCER CELLS; I REPEATS; PLATELET THROMBOSPONDIN; ENDOTHELIAL-CELLS; MELANOMA-CELLS; TUMOR-GROWTH; RECEPTOR; ANGIOGENESIS	Thrombospondin-1 (TSP1) is a matricellular protein that displays both pro- and anti-adhesive activities. Binding to sulfated glycoconjugates mediates most high affinity binding of soluble TSP1 to MDA-MB-435 cells, but attachment and spreading of these cells on immobilized TSP1 is primarily beta(1) integrin-dependent. The integrin alpha(3)beta(1) is the major mediator of breast carcinoma cell adhesion and chemotaxis to TSP1. This integrin is partially active in MDA-MB-435 cells but is mostly inactive in MDA-MB-231 and MCF-7 cells, which require beta(1) integrin activation to induce spreading on TSP1. Integrin-mediated cell spreading on TSP1 is accompanied by extension of filopodia containing beta(1) integrins. TSP1 binding activity of the alpha(3)beta(1) integrin is not stimulated by CD47-binding peptides from TSP1 or by protein kinase C activation, which activate alpha(v)beta(3) integrin function in the same cells. In MDA-MB-231 but not MDA-MB-435 cells, this integrin is activated by pertussis toxin, whereas serum, insulin, insulin-like growth factor-1, and ligation of CD98 increase activity of this integrin in both cell lines. Serum stimulation is accompanied by increased surface expression of CD98, whereas insulinlike growth factor-1 does not increase CD98 expression. Thus, the pro-adhesive activity of TSP1 for breast carcinoma cells is controlled by several signals that regulate activity of the alpha(3)beta(1) integrin.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.		Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				ADAMS JC, 1995, J CELL SCI, V108, P1977; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Genersch E, 1996, J MOL MED-JMM, V74, P609, DOI 10.1007/s001090050064; GUO NH, 1992, J BIOL CHEM, V267, P19349; Guo NH, 1997, J PEPT RES, V50, P210; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; GUO NH, 1992, J BIOL CHEM, V267, P17743; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hotchkiss KA, 1996, BIOCHEMISTRY-US, V35, P9761, DOI 10.1021/bi9603938; Hsu SC, 1996, CANCER RES, V56, P5684; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Incardona F, 1996, J CELL BIOCHEM, V62, P431, DOI 10.1002/(SICI)1097-4644(19960915)62:4<431::AID-JCB1>3.0.CO;2-N; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Lasky LA, 1997, NATURE, V390, P15, DOI 10.1038/36204; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; PEYRAT JP, 1989, B CANCER, V76, P311; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TUSZYNSKI GP, 1991, J CLIN INVEST, V87, P1387, DOI 10.1172/JCI115144; van der Pluijm G, 1997, LAB INVEST, V77, P665; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; VOURI K, 1994, SCIENCE, V266, P1576; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; YABKOWITZ R, 1993, J IMMUNOL, V151, P149	45	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11408	11416		10.1074/jbc.274.16.11408	http://dx.doi.org/10.1074/jbc.274.16.11408			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196234	hybrid			2022-12-25	WOS:000079751900102
J	Okomoto, T; Minamikawa, T; Edward, G; Vakharia, V; Herman, E				Okomoto, T; Minamikawa, T; Edward, G; Vakharia, V; Herman, E			Posttranslational removal of the carboxyl-terminal KDEL of the cysteine protease SH-EP occurs prior to maturation of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUXIN-BINDING PROTEIN; LUMINAL ER PROTEINS; MUNG-BEAN SEEDLINGS; RAT PROCATHEPSIN-B; ENDOPLASMIC-RETICULUM; CATHEPSIN-L; VIGNA-MUNGO; MOLECULAR-CLONING; SULFHYDRYL-ENDOPEPTIDASE; VICILIN PEPTIDOHYDROLASE	SH-EP is a cysteine protease from germinating mung bean (Vigna mungo) that possesses a carboxyl-terminal endoplasmic reticulum (ER) retention sequence, KDEL. In order to examine the function of the ER retention sequence, we expressed a full-length cDNA of SH-EP and a minus-KDEL control in insect Sf-9 cells using the baculovirus system. Our observations on the synthesis, processing, and trafficking of SH-EP in Sf-9 cells suggest that the KDEL ER-retention sequence is posttranslationally removed either while the protein is still in the ER or immediately after its exit from the ER, resulting in the accumulation of proSH-EP minus its KDEL signal. It is this intermediate form that appears to progress through the endomembrane system and is subsequently processed to form mature active SH-EP, The removal of an ER retention may regulate protein delivery to a functional site and present an alternative role for ER retention sequences in addition to their well established role in maintaining the protein composition of the ER lumen.	Tokyo Metropolitan Univ, Dept Biol Sci, Tokyo 1920397, Japan; Univ Maryland, Ctr Agr Biotechnol, College Pk, MD 20742 USA; ARS, Climate Stress Lab, USDA, Beltsville, MD 20705 USA	Tokyo Metropolitan University; University System of Maryland; University of Maryland College Park; United States Department of Agriculture (USDA)	Okomoto, T (corresponding author), Tokyo Metropolitan Univ, Dept Biol Sci, Minami Osawa, Tokyo 1920397, Japan.			Vakharia, Vikram/0000-0002-0955-3010				AKASOFU H, 1989, NUCLEIC ACIDS RES, V17, P6733, DOI 10.1093/nar/17.16.6733; BAKER EN, 1977, J MOL BIOL, V115, P263, DOI 10.1016/0022-2836(77)90154-1; BAUMGARTNER B, 1978, J CELL BIOL, V79, P10, DOI 10.1083/jcb.79.1.10; BAUMGARTNER B, 1977, EUR J BIOCHEM, V77, P223, DOI 10.1111/j.1432-1033.1977.tb11661.x; BECKER C, 1995, EUR J BIOCHEM, V228, P456, DOI 10.1111/j.1432-1033.1995.tb20284.x; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BOYLAN MT, 1987, PLANTA, V170, P343, DOI 10.1007/BF00395026; BUSTOS MM, 1988, PLANT MOL BIOL, V10, P475, DOI 10.1007/BF00033603; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; CHRISPEELS MJ, 1976, P NATL ACAD SCI USA, V73, P3168, DOI 10.1073/pnas.73.9.3168; CHRISPEELS MJ, 1975, PLANT PHYSIOL, V55, P1031, DOI 10.1104/pp.55.6.1031; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; DENECKE J, 1992, EMBO J, V11, P2345, DOI 10.1002/j.1460-2075.1992.tb05294.x; DENECKE J, 1991, PLANT CELL, V3, P1025, DOI 10.1105/tpc.3.9.1025; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; Gomord V, 1997, PLANT J, V11, P313, DOI 10.1046/j.1365-313X.1997.11020313.x; Guerrero C, 1998, PLANT MOL BIOL, V36, P565, DOI 10.1023/A:1005952005739; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; Henderson J, 1997, PLANTA, V202, P313, DOI 10.1007/s004250050133; HERMAN EM, 1990, PLANTA, V182, P305, DOI 10.1007/BF00197126; HESSE T, 1989, EMBO J, V8, P2453, DOI 10.1002/j.1460-2075.1989.tb08380.x; HICKS GR, 1989, P NATL ACAD SCI USA, V86, P4948, DOI 10.1073/pnas.86.13.4948; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; HIRANO H, 1992, J BIOCHEM-TOKYO, V111, P754, DOI 10.1093/oxfordjournals.jbchem.a123831; HOLWERDA BC, 1990, PLANT CELL, V2, P1091, DOI 10.1105/tpc.2.11.1091; HOLWERDA BC, 1992, PLANT CELL, V4, P307, DOI 10.1105/tpc.4.3.307; INOHARA N, 1989, P NATL ACAD SCI USA, V86, P3564, DOI 10.1073/pnas.86.10.3564; JONES AM, 1993, PLANT PHYSIOL, V101, P595, DOI 10.1104/pp.101.2.595; Jones CG, 1996, BBA-PROTEIN STRUCT M, V1296, P13, DOI 10.1016/0167-4838(96)00098-2; KALINSKI A, 1992, J BIOL CHEM, V267, P12068; Kalinski A, 1997, PLANT PHYSIOL BIOCH, V35, P795; KALINSKI AJ, 1994, PLANTA, V195, P611; Kardailsky IV, 1996, MOL PLANT MICROBE IN, V9, P689, DOI 10.1094/MPMI-9-0689; KASSELL B, 1973, SCIENCE, V180, P1022, DOI 10.1126/science.180.4090.1022; KOEHLER SM, 1990, PLANT CELL, V2, P769, DOI 10.1105/tpc.2.8.769; LEE HI, 1993, P NATL ACAD SCI USA, V90, P11433, DOI 10.1073/pnas.90.23.11433; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; MACDONALD H, 1994, PLANT PHYSIOL, V105, P1049, DOI 10.1104/pp.105.4.1049; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; MITSUHASHI W, 1986, PLANT PHYSIOL, V80, P628, DOI 10.1104/pp.80.3.628; MITSUHASHI W, 1989, PLANT PHYSIOL, V89, P274, DOI 10.1104/pp.89.1.274; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Muntz K, 1996, J EXP BOT, V47, P605, DOI 10.1093/jxb/47.5.605; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NAPIER RM, 1990, PLANTA, V182, P313, DOI 10.1007/BF00197128; NAPIER RM, 1992, J CELL SCI, V102, P261; NISHIMURA M, 1982, PLANT PHYSIOL, V70, P742, DOI 10.1104/pp.70.3.742; NONG VH, 1995, BBA-GENE STRUCT EXPR, V1261, P435, DOI 10.1016/0167-4781(95)00038-I; NORTH MJ, 1986, BIOCHEM J, V238, P623, DOI 10.1042/bj2380623; OKAMOTO T, 1994, FEBS LETT, V351, P31, DOI 10.1016/0014-5793(94)00809-4; OKAMOTO T, 1995, EUR J BIOCHEM, V231, P300, DOI 10.1111/j.1432-1033.1995.tb20700.x; Okamoto T, 1999, PLANT MOL BIOL, V39, P63, DOI 10.1023/A:1006170518002; Okita TW, 1996, ANNU REV PLANT PHYS, V47, P327, DOI 10.1146/annurev.arplant.47.1.327; Paris N, 1997, PLANT PHYSIOL, V115, P29, DOI 10.1104/pp.115.1.29; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PUEYO JJ, 1995, PLANTA, V196, P586, DOI 10.1007/BF00203660; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TANAKA T, 1991, PLANT MOL BIOL, V16, P1083, DOI 10.1007/BF00016081; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; VITALE A, 1993, J EXP BOT, V44, P390; WANDELT CI, 1992, PLANT J, V2, P181; WEIST DL, 1995, EMBO J, V14, P3425; WEIST DL, 1997, P NATL ACAD SCI USA, V94, P1884; YAMAUCHI D, 1992, PLANT CELL PHYSIOL, V33, P789; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	81	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11390	11398		10.1074/jbc.274.16.11390	http://dx.doi.org/10.1074/jbc.274.16.11390			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196232	hybrid			2022-12-25	WOS:000079751900100
J	Care, A; Valtieri, M; Mattia, G; Meccia, E; Masella, B; Luchetti, L; Felicetti, F; Colombo, MP; Peschle, C				Care, A; Valtieri, M; Mattia, G; Meccia, E; Masella, B; Luchetti, L; Felicetti, F; Colombo, MP; Peschle, C			Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation	ONCOGENE			English	Article						homeobox genes; hematopoietic progenitors; retroviral vector expression	NATURAL-KILLER LYMPHOCYTES; FIBROBLAST GROWTH-FACTOR; HUMAN PERIPHERAL-BLOOD; HOMEOBOX GENES; FUNCTIONAL-ROLE; LEUKEMIA; OVEREXPRESSION; EXPANSION	Hematopoietic progenitor/stem cells (HPCs/HSCs) purified from human adult peripheral blood (PB) were triggered into cycling, retrovirally transduced with HOXB7 and then functionally assayed in vitro. HPCs were assayed in multi- and unilineage differentiation cultures in either liquid phase or semisolid medium, primitive HPCs in the high proliferative potential colony-forming cell (HPP-CFC) evaluation system and putative HSCs in Dexter type long-term culture (LTC) as LTC initiating cells (LTC-ICs), Control experiments ensured that the exogenous HOXB7 gene was constantly expressed, while the endogenous one was barely or not transcribed. Enforced expression of the gene markedly modulated the proliferation/differentiation program of the entire HSC/HPC population, Enforced HOXB7 expression exerted a potent stimulatory effect on the proliferation of the primitive HPC and putative HSC subsets, assayed as HPP-CFCs and LTC-ICs respectively. While not modifying the total number of HPCs, exogenous HOXB7 induced an increase of the number of granulo-monocytic (GM) HPCs [colony-forming unit GM (CFU-GM) CFU-GM, CFU-C and CFU-M, as evaluated by clonogenic assays] and markedly amplified the progeny of both CFU-G and CFU-M, which showed a sustained proliferation through at least 1-2 months (as evaluated in liquid suspension culture). The prolonged proliferative stimulus induced by HOXB7 transfer into LTC, primitive and GM oriented HPC culture was characterized by persistent proliferation of a discrete population of blast cells and a large pool of differentiated myeloid precursors. Altogether, these results suggest the hypothesis that the proliferative stimulus exerted by exogenous HOXB7 in primitive and GM-oriented HPCs may represent a preleukemic immortalization step. Consistent with the functional role of HOXB7 in the initial ontogenetic phase, these studies indicate that ectopic HOXB7 expression in early HPCs and HSCs from adult PB stimulates their self renewal, sustained proliferation and myeloid differentiation.	Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Ist Nazl Tumori, I-20133 Milan, Italy; T Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA	Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Care, A (corresponding author), Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy.		Felicetti, Federica/N-7077-2017; CARE', Alessandra/H-5090-2016; felli, nadia/G-2088-2012; Mattia, Gianfranco/K-5194-2016; Colombo, Mario P./V-7166-2017; valtieri, mauro/H-1044-2016	Felicetti, Federica/0000-0003-4628-0696; CARE', Alessandra/0000-0003-4106-3342; felli, nadia/0000-0001-6763-3361; Mattia, Gianfranco/0000-0001-7047-6360; Colombo, Mario P./0000-0003-0042-7955; valtieri, mauro/0000-0002-9139-6754; meccia, ettore/0000-0003-2076-5951				BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; DEGUCHI Y, 1991, BLOOD, V78, P445; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LICHTY BD, 1995, LEUKEMIA LYMPHOMA, V16, P209, DOI 10.3109/10428199509049759; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PETRINI M, 1992, BLOOD, V80, P185; Quaranta MT, 1996, J IMMUNOL, V157, P2462; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Shimamoto T, 1998, INT J HEMATOL, V67, P339; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Tocci A, 1996, BLOOD, V88, P2878, DOI 10.1182/blood.V88.8.2878.bloodjournal8882878; UDOMSAKDI C, 1992, BLOOD, V80, P2513; VALTIERI M, 1994, CANCER RES, V54, P4398; Valtieri M, 1998, CANCER RES, V58, P562; Ziegler B, 1998, Stem Cells, V16 Suppl 1, P51	32	53	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1993	2001		10.1038/sj.onc.1202498	http://dx.doi.org/10.1038/sj.onc.1202498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208421				2022-12-25	WOS:000079191300009
J	Guldberg, P; Straten, PT; Ahrenkiel, V; Seremet, T; Kirkin, AF; Zeuthen, J				Guldberg, P; Straten, PT; Ahrenkiel, V; Seremet, T; Kirkin, AF; Zeuthen, J			Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma	ONCOGENE			English	Article						STK11; LKB1; tumour suppressor; malignant melanoma; Peutz-Jeghers syndrome; serine/threonine kinase	CUTANEOUS MELANOMA; CELL-LINES; CANCER; IDENTIFICATION; BREAST; PTEN	Mutations in LKB1/STK11, a gene mapping to chromosome 19p13.3 and encoding a widely expressed serine/threonine kinase, were recently identified as the cause of Peutz-Jeghers syndrome. Despite the hamartomatous polyps and increased cancer risk associated with this syndrome, somatic alterations in LKB1/STK11 have not been identified in human tumours. Prompted by another feature of the syndrome, lentigines of the lips and oral mucosa, we evaluated the status of LKB1/STK11 expression, deletion, and mutation in cell lines and tumour samples from 35 patients with sporadic malignant melanoma, Two somatic mutations were identified, a nonsense mutation (Glu170Stop) causing exon skipping and intron retention, and a missense mutation (Asp194Tyr) affecting an invariant residue in the catalytic subunit of LKB1/STK11. Our data suggest that LKB1/STK11 may contribute to tumorigenesis in a small fraction of malignant melanomas.	Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.							ABRAMS ES, 1992, METHOD ENZYMOL, V212, P71; Albino Anthony P., 1995, Current Opinion in Oncology, V7, P162, DOI 10.1097/00001622-199503000-00012; Avizienyte E, 1998, CANCER RES, V58, P2087; Bartkova J, 1996, CANCER RES, V56, P5475; Bignell GR, 1998, CANCER RES, V58, P1384; BRAITMAN M, 1979, CUTIS, V23, P617; Castellano M, 1997, CANCER RES, V57, P4868; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; Guldberg P, 1997, CANCER RES, V57, P3660; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Healy E, 1996, CANCER RES, V56, P589; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hoffmeyer S, 1998, AM J HUM GENET, V62, P269, DOI 10.1086/301715; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; KAMP A, 1994, SCIENCE, V264, P436; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; PARMITER AH, 1986, CANCER RES, V46, P1526; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Welch DR, 1997, PATHOBIOLOGY, V65, P311, DOI 10.1159/000164143; Wong SS, 1996, BRIT J DERMATOL, V135, P439, DOI 10.1046/j.1365-2133.1996.d01-1017.x	28	96	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1777	1780		10.1038/sj.onc.1202486	http://dx.doi.org/10.1038/sj.onc.1202486			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208439				2022-12-25	WOS:000079025000013
J	Kelm, RJ; Cogan, JG; Elder, PK; Strauch, AR; Getz, MJ				Kelm, RJ; Cogan, JG; Elder, PK; Strauch, AR; Getz, MJ			Molecular interactions between single-stranded DNA-binding proteins associated with all essential MCAT element in the mouse smooth muscle alpha-actin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN GENE PROMOTER; FAR UPSTREAM ELEMENT; PUR-ALPHA; MESSENGER-RNA; GLIAL-CELLS; Y-BOX; TRANSCRIPTIONAL REGULATION; STIMULATES TRANSCRIPTION; SEQUENCE; YB-1	Transcriptional activity of the mouse vascular smooth muscle alpha-actin gene in fibroblasts is regulated, in part, by a 30-base pair asymmetric polypurine-polypyrimidine tract containing an essential MCAT enhancer motif. The double-stranded form of this sequence serves as a binding site for a transcription enhancer factor 1-related protein while the separated single strands interact with two distinct DNA binding activities termed VACssBF1 and 2 (Cogan, J. G., Sun, S., Stoflet, E. S., Schmidt, L. J., Getz, M. J., and Strauch, A. R. (1995) J, Biol. Chem. 270, 11310-11321; Sun, S., Stoflet, E. S., Cogan, J. G., Strauch, A. R., and Getz, M. J. (1995) Mol.. Cell. Biol. 15, 2429-2936), VACssBF2 has been recently cloned and shown to consist of two closely related proteins, Pur alpha and Pur beta (Kelm, R. J., Elder, P. K., Strauch, A. R., and Getz, M. J, (1997) J. Biol. Chem. 272, 26727-26733). In this study, we demonstrate that Pur alpha and Pur beta interact with each other via highly specific protein-protein interactions and bind to the purine-rich strand of the MCAT enhancer in the form of both homo- and heteromeric complexes. Moreover, both Pur proteins interact with MSY1, a VACssBF1-like protein cloned by virtue of its affinity for the pyrimidine-rich strand of the enhancer. Interactions between Pur alpha, Pur beta, and MSY1 do not require the participation of DNA, Combinatorial interactions between these three single-stranded DNA-binding proteins may be important in regulating activity of the smooth muscle alpha-actin MCAT enhancer in fibroblasts.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Ohio State Univ, Coll Med, Dept Physiol, Columbus, OH 43210 USA	Mayo Clinic; University System of Ohio; Ohio State University	Getz, MJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.				NHLBI NIH HHS [R01 HL54281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; Chang CF, 1996, J VIROL, V70, P4150, DOI 10.1128/JVI.70.6.4150-4156.1996; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; CLOWES AW, 1988, J CELL BIOL, V107, P1939, DOI 10.1083/jcb.107.5.1939; Cogan J. G., 1994, Molecular Biology of the Cell, V5, p164A; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Muralidharan V, 1997, J CELL BIOCHEM, V66, P524, DOI 10.1002/(SICI)1097-4644(19970915)66:4<524::AID-JCB11>3.0.CO;2-B; OZER J, 1990, J BIOL CHEM, V265, P22143; Saito H, 1996, J BIOL CHEM, V271, P8911, DOI 10.1074/jbc.271.15.8911; SAKURA H, 1988, GENE, V73, P499; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1992, NEW BIOL, V4, P349; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; Thatikunta P, 1997, J CELL BIOCHEM, V67, P466, DOI 10.1002/(SICI)1097-4644(19971215)67:4<466::AID-JCB5>3.0.CO;2-Q; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	40	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14238	14245		10.1074/jbc.274.20.14238	http://dx.doi.org/10.1074/jbc.274.20.14238			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318844	hybrid			2022-12-25	WOS:000080322200073
J	Shifrin, VI; Anderson, P				Shifrin, VI; Anderson, P			Trichothecene mycotoxins trigger a ribotoxic stress response that activates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-II EVALUATION; CANCER STUDY-GROUP; MAMMALIAN-CELLS; POLY(ADP-RIBOSE) POLYMERASE; SIGNALING PATHWAY; T-2 TOXIN; DNA FRAGMENTATION; MAPKAP KINASE-2; INHIBITION; BINDING	The trichothecene family of mycotoxins inhibit protein synthesis by binding to the ribosomal peptidyltransferase site. Inhibitors of the peptidyltransferase reaction (e.g. anisomycin) can trigger a ribotoxic stress response that activates c-Jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinases, components of a signaling cascade that regulates cell survival in response to stress. We have found that selected trichothecenes strongly activate JNK/p38 kinases and induce rapid apoptosis in Jurkat T cells. Although the ability of individual trichothecenes to inhibit protein synthesis and activate JNK/p38 kinases are dissociable, both effects contribute to the induction of apoptosis. Among trichothecenes that strongly activate JNK/p38 kinases, induction of apoptosis increases linearly with inhibition of protein synthesis. Among trichothecenes that strongly inhibit protein synthesis, induction of apoptosis increases linearly with activation of JNK/p38 kinases. Trichothecenes that inhibit protein synthesis without activating JNK/p38 kinases inhibit the function (i.e. activation of JNK/p38 kinases and induction of apoptosis) of apoptotic trichothecenes and anisomycin. Harringtonine, a structurally unrelated protein synthesis inhibitor that competes with trichothecenes (and anisomycin) for ribosome binding, also inhibits the activation of JNK/p38 kinases and induction of apoptosis by trichothecenes and anisomycin. Taken together,these results implicate the peptidyltransferase site as a regulator of both JNK/p38 kinase activation and apoptosis.	Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Anderson, P (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA067929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033660] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67929] Funding Source: Medline; NIAID NIH HHS [AI 33660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER SS, 1984, CANCER TREAT REP, V68, P423; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Ausbel F.M., 1995, CURRENT PROTOCOLS MO; BALLESTRA J, 1991, TRANSLATION EUKARYOT; Budihardjo II, 1998, MOL CELL BIOCHEM, V178, P245, DOI 10.1023/A:1006808001462; BUKOWSKI R, 1982, CANCER TREAT REP, V66, P381; Cahill MA, 1996, ONCOGENE, V13, P2087; CANNON M, 1976, BIOCHEM J, V160, P137, DOI 10.1042/bj1600137; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cano E, 1996, ONCOGENE, V12, P805; CARTER CJ, 1976, BIOCHEM J, V154, P171, DOI 10.1042/bj1540171; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; CROW T, 1990, P NATL ACAD SCI USA, V87, P4490, DOI 10.1073/pnas.87.12.4490; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DESIMONE PA, 1986, AM J CLIN ONCOL-CANC, V9, P187, DOI 10.1097/00000421-198606000-00002; FRESNO M, 1977, EUR J BIOCHEM, V72, P323, DOI 10.1111/j.1432-1033.1977.tb11256.x; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOODWIN JW, 1983, CANCER TREAT REP, V67, P285; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harlow E., 1988, ANTIBODIES LAB MANUA; HOBDEN AN, 1980, BIOCHEM J, V190, P765, DOI 10.1042/bj1900765; Iordanov MS, 1998, J BIOL CHEM, V273, P15794, DOI 10.1074/jbc.273.25.15794; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Iordanov MS, 1998, J BIOL CHEM, V273, P3528, DOI 10.1074/jbc.273.6.3528; JIMENEZ A, 1975, EUR J BIOCHEM, V54, P483, DOI 10.1111/j.1432-1033.1975.tb04160.x; JIMENEZ A, 1975, BIOCHIM BIOPHYS ACTA, V383, P427, DOI 10.1016/0005-2787(75)90312-3; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEATHERMAN DL, 1993, J PHARMACOL EXP THER, V266, P741; LEATHERMAN DL, 1993, J PHARMACOL EXP THER, V266, P732; LEIST M, 1994, J IMMUNOL, V153, P1778; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Li L., 1994, Yaoxue Xuebao, V29, P667; MIDDLEBROOK JL, 1989, BIOCHEM PHARMACOL, V38, P3103, DOI 10.1016/0006-2952(89)90021-X; MIDDLEBROOK JL, 1989, J PHARMACOL EXP THER, V250, P860; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; SUGITA M, 1995, ZOOL SCI, V12, P419, DOI 10.2108/zsj.12.419; SYNETOS D, 1986, BIOCHIM BIOPHYS ACTA, V868, P249, DOI 10.1016/0167-4781(86)90061-8; TEJEDOR F, 1985, BIOCHEMISTRY-US, V24, P3667, DOI 10.1021/bi00335a040; THIGPEN JT, 1981, CANCER TREAT REP, V65, P881; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu WP, 1998, MOL CARCINOGEN, V22, P247, DOI 10.1002/(SICI)1098-2744(199808)22:4<247::AID-MC6>3.3.CO;2-P	56	344	358	3	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13985	13992		10.1074/jbc.274.20.13985	http://dx.doi.org/10.1074/jbc.274.20.13985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318810	hybrid			2022-12-25	WOS:000080322200039
J	Galvez, T; Parmentier, ML; Joly, C; Malitschek, B; Kaupmann, K; Kuhn, R; Bittiger, H; Froestl, W; Bettler, B; Pin, JP				Galvez, T; Parmentier, ML; Joly, C; Malitschek, B; Kaupmann, K; Kuhn, R; Bittiger, H; Froestl, W; Bettler, B; Pin, JP			Mutagenesis and modeling of the GABA(B) receptor extracellular domain support a Venus flytrap mechanism for ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; PUTATIVE PHEROMONE RECEPTORS; AGONIST SELECTIVITY; PROTEIN-STRUCTURE; MULTIGENE FAMILY; PHOSPHOLIPASE-C; ACTIVATION; SPECIFICITY; LEUCINE; SITE	The gamma-aminobutyric acid type B (GABA(B)) receptor is distantly related to the metabotropic glutamate receptor-like family of G-protein-coupled receptors (family 3), Sequence comparison revealed that, like metabotropic glutamate receptors, the extracellular domain of the two GABA(B) receptor splice variants possesses an identical region homologous to the bacterial periplasmic leucine-binding protein (LBP), but lacks the cysteine-rich region common to all other family 3 receptors. A three dimensional model of the LBP-like domain of the GABA(B) receptor was constructed based on the known structure of LBP, This model predicts that four of the five cysteine residues found in this GABA(B) receptor domain are important for its correct folding. This conclusion is supported by analysis of mutations of these Cys residues and a decrease in the thermostability of the binding site after dithiothreitol treatment. Additionally, Ser-246 was found to be critical for CGP64213 binding. Interestingly, this residue aligns with Ser-79 of LBP, which forms a hydrogen bond with the ligand, The mutation of Ser-269 was found to differently affect the affinity of various ligands, indicating that this residue is involved in the selectivity of recognition of GABA(B) re ceptor ligands, Finally, the mutation of two residues, Ser-247 and Gln-312, was found to increase the affinity for agonists and to decrease the affinity for antagonists. Such an effect of point mutations can be explained by the Venus flytrap model for receptor activation. This model proposes that the initial step in the activation of the receptor by agonist results from the closure of the two lobes of the binding domain.	CNRS UPR 9023, INSERM, Ctr Pharmacol Endocrinol Mecanismes Mol Commun Ce, F-34094 Montpellier 5, France; Novartis Pharma AG, Therapuet Area, Nervous Syst, CH-4002 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Novartis	Pin, JP (corresponding author), CNRS UPR 9023, INSERM, Ctr Pharmacol Endocrinol Mecanismes Mol Commun Ce, 141 Rue Cardonille, F-34094 Montpellier 5, France.		bettler, bernhard/AAO-8018-2020; Parmentier, Marie-Laure/N-9915-2017; Pin, Jean-Philippe/Y-6668-2019	Parmentier, Marie-Laure/0000-0001-6133-3413; Pin, Jean-Philippe/0000-0002-1423-345X; Kaupmann, Klemens/0000-0001-8903-2508; Bettler, Bernhard/0000-0003-0842-8207				BITTIGER H, 1993, TRENDS PHARMACOL SCI, V14, P391, DOI 10.1016/0165-6147(93)90056-P; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; FROESTL W, 1995, J MED CHEM, V38, P3297, DOI 10.1021/jm00017a015; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Hawrot E, 1998, FEBS LETT, V432, P103, DOI 10.1016/S0014-5793(98)00794-7; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Malitschek B, 1998, MOL CELL NEUROSCI, V12, P56, DOI 10.1006/mcne.1998.0698; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; MAO B, 1982, J BIOL CHEM, V257, P1131; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OH BH, 1994, J BIOL CHEM, V269, P4135; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; OLAH GA, 1993, J BIOL CHEM, V268, P16241; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; WOLF A, 1994, J BIOL CHEM, V269, P23051; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; Wolf A, 1996, J BIOL CHEM, V271, P21243, DOI 10.1074/jbc.271.35.21243	43	166	171	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13362	13369		10.1074/jbc.274.19.13362	http://dx.doi.org/10.1074/jbc.274.19.13362			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224098	hybrid			2022-12-25	WOS:000080200400060
J	Lum, L; Wong, BR; Josien, R; Becherer, JD; Erdjument-Bromage, H; Schlondorff, J; Tempst, P; Choi, Y; Blobel, CP				Lum, L; Wong, BR; Josien, R; Becherer, JD; Erdjument-Bromage, H; Schlondorff, J; Tempst, P; Choi, Y; Blobel, CP			Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITORY FACTOR; T-CELLS; LIGAND; OSTEOPROTEGERIN; DISINTEGRIN; METALLOPROTEINASE; CYTOKINE; DIFFERENTIATION; ACTIVATION; PRECURSOR	Tumor necrosis factor (TNF)-related activation-induced cytokine (TRANCE), a member of the TNF family, is a dendritic cell survival factor and is essential for osteoclastogenesis and osteoclast activation. In this report we demonstrate (i) that TRANCE, like TNF-a, is made as a membrane-anchored precursor, which is released from the plasma membrane by a metalloprotease; (ii) that soluble TRANCE has potent dendritic cell survival and osteoclastogenic activity; (iii) that the metalloprotease-disintegrin TNF-alpha convertase (TACE) can cleave immunoprecipitated TRANCE in vitro in a fashion that mimics the cleavage observed in tissue culture cells; and (iv) that in vitro cleavage of a TRANCE ectodomain/CD8 fusion protein and of a peptide corresponding to the TRANCE cleavage site by TACE occurs at the same site that is used when TRANCE is shed from cells into the supernatant. We propose that the TRANCE ectodomain is released from cells by TACE or a related metalloprotease-disintegrin, and that this release is an important component of the function of TRANCE in bone and immune homeostasis.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Tri Inst Cornell Rockefeller Univ, Mem Sloan Kettering Canc Ctr, MD PHD Training Program, New York, NY USA; Glaxo Wellcome Res & Dev Ltd, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Rockefeller Univ, Immunobiol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Cellular Physiol & Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; GlaxoSmithKline; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, 1275 York Ave,Box 368, New York, NY 10021 USA.		Josien, Regis/L-7468-2015; Josien, Regis/U-4405-2019	Josien, Regis/0000-0001-7900-7413; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Schlondorff, Johannes/0000-0002-9973-9731	NIAID NIH HHS [AI44264] Funding Source: Medline; NIGMS NIH HHS [5T32GM07739-17] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BECHERER JD, 1991, J CELL BIOCH G S, V15, P139; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Botos I, 1996, P NATL ACAD SCI USA, V93, P2749, DOI 10.1073/pnas.93.7.2749; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	29	339	356	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13613	13618		10.1074/jbc.274.19.13613	http://dx.doi.org/10.1074/jbc.274.19.13613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224132	hybrid			2022-12-25	WOS:000080200400094
J	Walker, KW; Bradshaw, RA				Walker, KW; Bradshaw, RA			Yeast methionine aminopeptidase I - Alteration of substrate specificity by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MYCOBACTERIUM-LEPRAE; AMINO-ACID; PROTEIN; GENE; CLONING; TRANSFORMATION; ORGANIZATION	In eukaryotes, two isozymes (I and II) of methionine aminopeptidase (MetAP) catalyze the removal of the initiator methionine if the penultimate residue has a small radius of gyration (glycine, alanine, serine, threonine, proline, valine, and cysteine), Using site-directed mutagenesis, recombinant yeast MetAP I derivatives that are able to cleave N-terminal methionine from substrates that have larger penultimate residues have been expressed. A Met to Ala change at 329 (Met(206) in Escherichia coli enzyme) produces an average catalytic efficiency Id-fold higher than the native enzyme on normal substrates and cleaves substrates containing penultimate asparagine, glutamine, isoleucine, leucine, methionine, and phenylalanine, Interestingly, the native enzyme also has significant activity with the asparagine peptide not previously identified as a substrate. Mutation of Gln(356) (Gln(233) in E coli MetAP) to alanine results in a catalytic efficiency about one-third that of native with normal substrates but which can cleave methionine from substrates with penultimate histidine, asparagine, glutamine, leucine, methionine, phenylalanine, and tryptophan. Mutation of Ser(195) to alanine had no effect on substrate specificity. None of the altered enzymes produced cleaved substrates with a fully charged residue (lysine, arginine, aspartic acid, or glutamic acid) or tyrosine in the penultimate position.	Univ Calif Irvine, Dept Physiol & Biophys, Coll Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Coll Med, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Bradshaw, RA (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Coll Med, Irvine, CA 92697 USA.		Bradshaw, Ralph A/K-1515-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032465] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32465] Funding Source: Medline; NIGMS NIH HHS [GM18940] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CHANG YH, 1992, J BIOL CHEM, V267, P8007; EIGLMEIER K, 1993, MOL MICROBIOL, V7, P197, DOI 10.1111/j.1365-2958.1993.tb01111.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hilbert H, 1996, NUCLEIC ACIDS RES, V24, P628, DOI 10.1093/nar/24.4.628; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Klinkenberg M, 1997, ARCH BIOCHEM BIOPHYS, V347, P193, DOI 10.1006/abbi.1997.0345; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Lowther WT, 1998, P NATL ACAD SCI USA, V95, P12153, DOI 10.1073/pnas.95.21.12153; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MOVVA NR, 1990, MOL GEN GENET, V223, P345; Newton DL, 1998, BIOCHEMISTRY-US, V37, P5173, DOI 10.1021/bi972147h; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; Sensen CW, 1996, MOL MICROBIOL, V22, P175, DOI 10.1111/j.1365-2958.1996.tb02666.x; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Suh JW, 1996, GENE, V169, P17, DOI 10.1016/0378-1119(95)00757-1; Tahirov TH, 1998, J STRUCT BIOL, V121, P68, DOI 10.1006/jsbi.1997.3940; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; Walker KW, 1998, PROTEIN SCI, V7, P2684, DOI 10.1002/pro.5560071224; Walker KW, 1999, BIOTECHNOL APPL BIOC, V29, P157; WU SY, 1993, J BIOL CHEM, V268, P10796; ZUO SL, 1995, MOL GEN GENET, V246, P247, DOI 10.1007/BF00294688	41	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13403	13409		10.1074/jbc.274.19.13403	http://dx.doi.org/10.1074/jbc.274.19.13403			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224104	hybrid			2022-12-25	WOS:000080200400066
J	Fleming, IN; Elliott, CM; Buchanan, FG; Downes, CP; Exton, JH				Fleming, IN; Elliott, CM; Buchanan, FG; Downes, CP; Exton, JH			Ca2+/calmodulin-dependent protein kinase II regulates Tiam1 by reversible protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; SWISS 3T3 CELLS; PLECKSTRIN HOMOLOGY DOMAINS; ACTIN STRESS FIBERS; PHOSPHOLIPASE-D; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; RAS TRANSFORMATION; GDP/GTP EXCHANGE; CDC42 GTPASES	A number of guanine nucleotide exchange factors have been identified that activate Rho family GTPases, by promoting the binding of GTP to these proteins. We have recently demonstrated that lysophosphatidic acid and several other agonists stimulate phosphorylation of the Rac1-specific exchange factor Tiam1 in Swiss 3T3 fibroblasts, and that protein kinase C is involved in Tiam1 phosphorylation (Fleming, I. N,, Elliott, C, M,, Collard, J, G,, and Exton, J, H. (1997) J, BioA Chem. 272, 33105-33110), We now show, through manipulation of intracellular [Ca2+] and the use of protein kinase inhibitors, that both protein kinase C alpha and Ca2+/calmodulindependent protein kinase II are involved in the phosphorylation of Tiam1 in vivo, Furthermore, we show that Ca2+/calmodulin-dependent protein kinase II phosphorylates Tiam1 in vitro, producing an electrophoretic retardation on SDS-polyacrylamide gel electrophoresis, Significantly, phosphorylation of Tiam1 by Ca2+/calmodulin-dependent protein kinase II, but not by protein kinase C, enhanced its nucleotide exchange activity toward Rad, by approximately a-fold. Furthermore, Tiam1 was preferentially dephosphorylated by protein phosphatase 1 in vitro, and treatment with this phosphatase abolished the Ca2+/calmodulin-dependent protein kinase II activation of Tiam1, These data demonstrate that protein kinase Ca and Ca2+/calmodulin-dependent protein kinase II phosphorylate Tiam1 in vivo, and that the latter kinase plays a key role in regulating the activity of this exchange factor in vitro.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ Dundee, Inst Med Sci, Dept Biochem, Dundee DD1 4HN, Scotland	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; University of Dundee	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.			Fleming, Ian/0000-0001-9505-6418				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1998, FEBS LETT, V429, P229, DOI 10.1016/S0014-5793(98)00566-3; FUJISAWA H, 1990, BIOESSAYS, V12, P27, DOI 10.1002/bies.950120106; GRAZIANI G, 1989, ONCOGENE, V4, P823; HABETS GGM, 1995, ONCOGENE, V10, P1371; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	39	133	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12753	12758		10.1074/jbc.274.18.12753	http://dx.doi.org/10.1074/jbc.274.18.12753			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212259	hybrid			2022-12-25	WOS:000080056800079
J	Huang, CS; Ma, WY; Maxiner, A; Sun, Y; Dong, ZG				Huang, CS; Ma, WY; Maxiner, A; Sun, Y; Dong, ZG			p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; ULTRAVIOLET-RADIATION; AP-1 TRANSACTIVATION; GAMMA-RADIATION; IN-VITRO; ACTIVATION; GROWTH; DAMAGE; PATHWAY	The p53 tumor suppressor protein is a transcription factor that plays a key role in the process of apoptosis and the cell's defense against tumor development. Activation of p53 occurs, at least in part, by phosphorylation of its protein. Very recently it has been reported that UV induced a functional activation of p53 via phosphorylation at serine 389. Here, we report that the UV-induced phosphorylation of p53 at serine 389 is mediated by p38 kinase. WC-induced phosphorylation of p53 at serine 389 was markedly impaired by either pretreatment of cells with p38 kinase inhibitor, SB202190, or stable expression of a dominant negative mutant of p38 kinase. In contrast, there was no inhibition observed in cells treated with specific MEK1 inhibitor, PD98059, or with stable expression of a dominant negative mutant of ERK2 or JNK1. Most importantly, p38 kinase could be co-immunoprecipitated with p53 by using antibodies against p53. Incubation of active p38 kinase with p53 protein caused the phosphorylation of p53 protein at serine 389 in. vitro, while no phosphorylation of p53 at serine 389 was observed when p53 was incubated with activated JNK2 or ERK2. Furthermore, pretreatment of cells with SB202190 blocked the p53 DNA binding activity and p53-dependent transcription. These results strongly suggest that the p38 kinase is at least one of the most important mediators of p53 phosphorylation at serine 389 induced by UVC radiation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Parke Davis Pharmaceut Res, Dept Biol Mol, Ann Arbor, MI 48105 USA	University of Minnesota System; Pfizer	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16Th Ave NE, Austin, MN 55912 USA.	zgdong@smig.net		Huang, Chuanshu/0000-0003-4133-5096	NCI NIH HHS [CA74916] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; APPEL K, 1995, ONCOGENE, V11, P1971; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huang CS, 1998, CANCER RES, V58, P4102; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MAYR GA, 1995, CANCER RES, V55, P2410; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	48	249	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12229	12235		10.1074/jbc.274.18.12229	http://dx.doi.org/10.1074/jbc.274.18.12229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212189	hybrid			2022-12-25	WOS:000080056800009
J	Rao, GN; Madamanchi, NR; Lele, M; Gadiparthi, L; Gingras, AC; Eling, TE; Sonenberg, N				Rao, GN; Madamanchi, NR; Lele, M; Gadiparthi, L; Gingras, AC; Eling, TE; Sonenberg, N			A potential role for extracellular signal-regulated kinases in prostaglandin F-2 alpha-induced protein synthesis in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; P70 S6 KINASE; INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; TRANSLATION INITIATION; VENTRICULAR MYOCYTES; CARDIAC-HYPERTROPHY; MESSENGER-RNA; PHAS-I	To understand the mechanisms of prostaglandin F-2 alpha (PGF(2 alpha))-induced protein synthesis in vascular smooth muscle cells (VSMC), we have studied its effect on two major signal transduction pathways: mitogen-activated protein kinases and phosphatidylinositol 3-kinase (PI3-kinase) and their downstream targets ribosomal protein S6 kinase (p70(S6k)) and eukaryotic initiation factor eIF4E and its regulator 4E-BP1, PGF(2 alpha) induced the activities of extracellular signal-regulated kinase 2 (ERK2) and Jun N-terminal kinase 1 (JNK1) groups of mitogen-activated protein kinases, PI3-kinase, and p70(S6k) in a time-dependent manner in growth-arrested VSMC. PGF(2 alpha) also induced eIF4E and 4E-BP1 phosphorylation, global protein synthesis, and basic fibroblast growth factor-a (bFGF-2) expression in VSMC, Whereas inhibition of PI3-kinase by wortmannin completely blocked the p70(S6k) activation, it only partially decreased the ERK2 activity, and had no significant effect on global protein synthesis and bFGF-2 expression induced by PGF(2 alpha), Rapamycin, a potent inhibitor of p70(S6k), also failed to prevent PGF(2 alpha)-induced global protein synthesis and bFGF-2 expression, although it partially decreased ERK2 activity. In contrast, inhibition of ERK2 activity by PD 098059 led to a significant loss of PGF(2 alpha)-induced eIF4E and 4E-BP1 phosphorylation, global protein synthesis, and bFGF-2 expression. PGF(2 alpha)-induced phosphorylation of eIF4E and 4E-BP1 was also found to be sensitive to inhibition by both wortmannin and rapamycin, These findings demonstrate that 1) PI3-kinase-dependent and independent mechanisms appear to be involved in PGF(2 alpha)-induced activation of ERK2; 2) PGF(2 alpha)-induced eIF4E and 4E-BP1 phosphorylation appear to be mediated by both ERK-dependent and PI3-kinase-dependent rapamycin-sensitive mechanisms; and 3) ERK-dependent eIF4E phosphorylation but not PIS-kinase-dependent p70S6k activation correlates with PGF(2 alpha)-induced global protein synthesis and bFGF-2 expression in VSMC.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Medical Branch Galveston; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Rao, GN (corresponding author), Univ Texas, Med Branch, Old John Sealy Hosp 4 124B, 301 Univ Blvd,Route 0567, Galveston, TX 77555 USA.		Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; Madamanchi, Nageswara/0000-0003-0590-0908				Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BROWN EJ, 1995, NATURE, V377, P411; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DORN GW, 1992, J BIOL CHEM, V267, P24897; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FLEMING JW, 1992, CIRCULATION, V85, P420, DOI 10.1161/01.CIR.85.2.420; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KRIEG J, 1988, J BIOL CHEM, V263, P11473; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; MYERS MG, 1994, J BIOL CHEM, V269, P28783; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAO GN, 1994, J BIOL CHEM, V269, P7180; Rao GN, 1996, ONCOGENE, V13, P713; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Seva C, 1997, BIOCHEM BIOPH RES CO, V238, P202, DOI 10.1006/bbrc.1997.7163; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; VANMANTEUFFEL S, 1996, P NATL ACAD SCI USA, V93, P4076; VANMANTEUFFEL SR, 1997, MOL CELL BIOL, V17, P5426; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	59	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12925	12932		10.1074/jbc.274.18.12925	http://dx.doi.org/10.1074/jbc.274.18.12925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212283	hybrid			2022-12-25	WOS:000080056800103
J	Chaika, OV; Chaika, N; Volle, DJ; Hayashi, H; Ebina, Y; Wang, LM; Pierce, JH; Lewis, RE				Chaika, OV; Chaika, N; Volle, DJ; Hayashi, H; Ebina, Y; Wang, LM; Pierce, JH; Lewis, RE			Mutation of tyrosine 960 within the insulin receptor juxtamembrane domain impairs glucose transport but does not inhibit ligand-mediated phosphorylation of insulin receptor substrate-2 in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PROTEIN; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; CSF-1 RECEPTOR; CELLS; IRS-2; REGION; FAMILY; MICE; IDENTIFICATION	CSF-1 is equipotent to insulin in its ability to stimulate 2[H-3]deoxyglucose uptake in 3T3-L1 adipocytes expressing the colony stimulating factor-1 receptor/insulin receptor chimera (CSF1R/IR), However, CSF-1-stimulated glucose uptake and glycogen synthesis is reduced by 50% in comparison to insulin in 3T3-L1 cells expressing a CSF1R/IR mutated at Tyr(960) (CSF1R/IRA960), CSF-1-treated adipocytes expressing the CSF1R/IRA960 were impaired in their ability to phosphorylate insulin receptor substrate 1 (IRS-1) but not in their ability to phosphorylate IRS-2, Immunoprecipitation of IRS proteins followed by Western blotting revealed that the intact CSF1R/IR co-precipitates with IRS-2 from CSF-1-treated cells. In contrast, the CSF1R/IRA960 co-precipitates poorly with IRS-S, These observations suggest that Tyr(960) is important for interaction of the insulin receptor cytoplasmic domain with IRS-2, but it is not essential to the ability of the insulin receptor tyrosine kinase to use IRS-2 as a substrate. These observations also suggest that in 3T3-L1 adipocytes, tyrosine phosphorylation of IRS-2 by the insulin receptor tyrosine kinase is not sufficient for maximal stimulation of receptor-regulated glucose transport or glycogen synthesis.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Tokushima, Inst Enzyme Res, Dept Enzyme Genet, Tokushima 770, Japan; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Tokushima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lewis, RE (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.		Lewis, Robert E./H-3404-2019	Hayashi, Hideki/0000-0003-4585-6542	NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052809] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727] Funding Source: Medline; NIDDK NIH HHS [DK52809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; Boehm JE, 1998, J BIOL CHEM, V273, P7169, DOI 10.1074/jbc.273.12.7169; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FROST SC, 1985, J BIOL CHEM, V260, P2646; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KABURAGI Y, 1995, ENDOCRINOLOGY, V136, P3437, DOI 10.1210/en.136.8.3437; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SHERR CJ, 1989, BLOOD, V73, P1786; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; THEIS RS, 1989, J BIOL CHEM, V264, P12820; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829	44	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12075	12080		10.1074/jbc.274.17.12075	http://dx.doi.org/10.1074/jbc.274.17.12075			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207032	hybrid			2022-12-25	WOS:000079834800088
J	Yue, JB; Frey, RS; Mulder, KM				Yue, JB; Frey, RS; Mulder, KM			Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF beta	ONCOGENE			English	Article						Ras/MEK; TGF beta; Smad1	GROWTH-FACTOR-BETA; FAMILY MEDIATOR SMAD1; BREAST-CANCER CELLS; EPITHELIAL-CELLS; PROTEIN; KINASE; MAD; ACTIVATION; PHOSPHORYLATION; BMP	Our previous data demonstrated that Ras activation was necessary and sufficient for transforming growth factor-p (TGF beta)-mediated Erk1 activation, and,vas required for TGF beta up-regulation of the Cdk inhibitors (CKI's) p27(Kip1) and p21(Cip1) (KM Mulder and SL Morris, J, Biol, Chem., 267, 5029-5031, 1992; MT Hartsough and KM Mulder, J, Biol, Chem., 270, 7117-7124, 1995; MT Hartsough ef nl,, J, Biol, Chem., 271, 22368-22375, 1996 and J Yue et al., Oncogene, 17, 47-55, 1998), Here we examined the role of Res in TGF beta-mediated effects on a rat homolog of Smad1 (termed RSmad1), We demonstrate that both TGF beta and bone morphogenetic protein (BMP) can induce endogenous Smad1 phosphorylation in intestinal epithelial cells (IECs), The combination of transient expression of RSmad1 and TGF beta treatment had an additive effect on induction of the TGF beta-responsive reporter 3TP-lux, Either inactivation of Ras by stable, inducible expression of a dominant-negative mutant of Ras (RasN17) or addition of MAP and ERK kinase (MEK) inhibitor PD98059 to cells significantly decreased the ability of both TGF beta and BMP to induce phosphorylation of endogenous Smad1 in IECs, Moreover, either inactivation of Ras or addition of PD98059 to IEC 4-1 cells inhibited the ability of RSmad1 to regulate 3TP luciferase activity in both the presence and absence of TGF beta, Collectively, our data indicate that TGF beta can regulate RSmad1 function in epithelial cells, and that the Ras/MEK pathway is partially required for TGF beta-mediated regulation of RSmad1.	Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.		Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NCI NIH HHS [CA51425, CA68444, CA54816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068444, R01CA051425, R01CA054816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; CHEN Y, 1997, P NATL ACAD SCI USA, V94, P12939; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; RAFTERY LA, 1995, GENETICS, V139, P241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; YUE J, 1999, IN PRESS J CELL PHYS; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903	29	85	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2033	2037		10.1038/sj.onc.1202521	http://dx.doi.org/10.1038/sj.onc.1202521			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208426	Bronze			2022-12-25	WOS:000079191300014
J	Schmidt, M; Maurer-Gebhard, M; Groner, B; Kohler, G; Brochmann-Santos, G; Wels, W				Schmidt, M; Maurer-Gebhard, M; Groner, B; Kohler, G; Brochmann-Santos, G; Wels, W			Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors	ONCOGENE			English	Article						epidermal growth factor receptor; EGFR-vIII; monoclonal antibody 14E1; single chain Fv; immunotoxin	GROWTH-FACTOR RECEPTOR; PSEUDOMONAS EXOTOXIN; MONOCLONAL-ANTIBODIES; LUNG CARCINOMAS; TYROSINE KINASE; FV-FRAGMENTS; EXPRESSION; MUTANT; TUMORS; CELLS	Cytotoxic strategies which are directed to tumor-associated antigens might be most beneficial for cancer patients with minimal tumor load such as in an adjuvant setting after initial therapy, We have recently described a highly potent single chain antibody-toxin, scFv(14E1)-ETA, which consists of the variable domains of the antibody 14E1 genetically fused to a truncated form of Pseudomonas exotoxin A. ScFv(14E1)-ETA specifically recognizes the human epidermal growth factor receptor (EGFR) and the oncogenically activated receptor variant EGFRvIII, which have been implicated in the development of various human malignancies. Here we have investigated the antimetastatic activity of bacterially expressed scFv(14E1)-ETA and its disulfide-stabilized derivative ds-scFv(14E1)-ETA in a novel model for disseminated disease which is based on murine renal carcinoma cells subsequently transfected with the E. coli P-galactosidase gene, and human full-length or variant EGFR cDNAs, Intravenous injection of these Renca-lacZ/EGFR and Renca-lacZ/EGFRvIII cells in syngenic Balb/c mice led to the formation of pulmonary metastases which were readily detectable upon excision of the lungs and X-gal staining, Systemic treatment of mice with scFv(14E1)-ETA resulted in the complete suppression of Renca-lacZ/EGFRvIII metastasis formation and drastically reduced the number of pulmonary Renca-lacZ/EGFR tumor nodules, The ds-scFv(14E1)-ETA derivative where the antibody variable regions are connected by an artificial disulfide bond displayed improved thermal stability at physiological temperature but due to reduced cytotoxic activity was less potent than the original scFv(14E1)-ETA in metastasis suppression.	Georg Speyer Haus Inst Biomed Res, D-60596 Frankfurt, Germany; Tumor Biol Ctr, Inst Expt Canc Res, D-79106 Freiburg, Germany; Univ Freiburg, Dept Pathol, D-79104 Freiburg, Germany	University of Freiburg	Wels, W (corresponding author), Georg Speyer Haus Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.			Wels, Winfried/0000-0001-9858-3643				Altenschmidt U, 1997, INT J CANCER, V73, P117, DOI 10.1002/(SICI)1097-0215(19970926)73:1<117::AID-IJC18>3.0.CO;2-D; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; Groner B, 1997, INT J CANCER, V70, P682, DOI 10.1002/(SICI)1097-0215(19970317)70:6<682::AID-IJC10>3.0.CO;2-C; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; HUMPHREY PA, 1988, CANCER RES, V48, P2231; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; Kabat EA, 1991, SEQUENCES PROTEINS I; Lorimer IAJ, 1996, P NATL ACAD SCI USA, V93, P14815, DOI 10.1073/pnas.93.25.14815; Luo Dong, 1995, Journal of Biochemistry (Tokyo), V118, P825; Maurer-Gebhard M, 1998, CANCER RES, V58, P2661; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; OGATA M, 1992, J BIOL CHEM, V267, P25396; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; Pantel K, 1996, CURR TOP MICROBIOL, V213, P1; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; Reiter Y, 1996, NAT BIOTECHNOL, V14, P1239, DOI 10.1038/nbt1096-1239; Schmidt M, 1998, INT J CANCER, V75, P878, DOI 10.1002/(SICI)1097-0215(19980316)75:6<878::AID-IJC10>3.3.CO;2-U; Schmidt M, 1997, BRIT J CANCER, V75, P1575, DOI 10.1038/bjc.1997.270; Spyridonidis A, 1998, BLOOD, V91, P1820, DOI 10.1182/blood.V91.5.1820.1820_1820_1827; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; Wels W, 1996, CURR TOP MICROBIOL, V213, P113; WELS W, 1992, CANCER RES, V52, P6310; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; Young NM, 1995, FEBS LETT, V377, P135, DOI 10.1016/0014-5793(95)01325-3	32	49	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1711	1721		10.1038/sj.onc.1202489	http://dx.doi.org/10.1038/sj.onc.1202489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208432				2022-12-25	WOS:000079025000006
J	Pelosi, M; Di Bartolo, V; Mounier, V; Mege, D; Pascussi, JM; Dufour, E; Blondel, A; Acuto, O				Pelosi, M; Di Bartolo, V; Mounier, V; Mege, D; Pascussi, JM; Dufour, E; Blondel, A; Acuto, O			Tyrosine 319 in the interdomain B of ZAP-70 is a binding site for the Src homology 2 domain of Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; KINASE-ACTIVITY; SH2 DOMAIN; SIGNAL-TRANSDUCTION; FAMILY; PHOSPHORYLATION; ACTIVATION; SYK; IDENTIFICATION; PROTEINS	T-cell antigen receptor-induced signaling requires both ZAP-70 and Lck protein-tyrosine kinases, One essential function of Lck in this process is to phosphorylate ZAP-70 and up-regulate its catalytic activity. We have previously shown that after T-cell antigen receptor stimulation, Lck binds to ZAP-70 via its Src homology 2 (SH2) domain (LckSH2) and, more recently, that Tyr(319) of ZAP-70 is phosphorylated in vivo and plays a positive regulatory role. Here, we investigated the possibility that Tyr(319) mediates the SH2-dependent interaction between Lck and ZAP-70. We show that a phosphopeptide encompassing the motif harboring Tyr(319), YSDP, interacted with LckSH2, although with a lower affinity compared with a phosphopeptide containing the optimal binding motif, YEEI. Moreover, mutation of Tyr(319) to phenylalanine prevented the interaction of ZAP-70 with LckSH2. Based on these results, a gain-of-function mutant of ZAP-70 was generated by changing the sequence (YSDP)-S-319 into (YEEI)-E-319. As a result of its increased ability to bind LckSH2, this mutant induced a dramatic increase in NFAT activity in Jurkat T-cells, was hyperphosphorylated, and displayed a higher catalytic activity compared with wild-type ZAP-70. Collectively, our findings indicate that Tyr(319)-mediated binding of the SH2 domain of Lck is crucial for ZAP-70 activation and consequently for the propagation of the signaling cascade leading to T-cell activation.	Inst Pasteur, Dept Immunol, Mol Immunol Unit, F-75724 Paris 15, France; Inst Pasteur, Cellular Biochem Unit, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Acuto, O (corresponding author), Inst Pasteur, Dept Immunol, Mol Immunol Unit, 25 Rue Docteur Roux, F-75724 Paris 15, France.	oacuto@pasteur.fr	pascussi, jean marc/F-9311-2013; Di Bartolo, Vincenzo/AAL-6834-2020	pascussi, jean marc/0000-0002-5168-5383; Di Bartolo, Vincenzo/0000-0002-5453-947X				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; ALCOVER A, 1990, J BIOL CHEM, V265, P4131; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; Couture C, 1997, EUR J BIOCHEM, V246, P447, DOI 10.1111/j.1432-1033.1997.00447.x; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Di Bartolo V, 1999, J BIOL CHEM, V274, P6285, DOI 10.1074/jbc.274.10.6285; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Grazioli L, 1998, J BIOL CHEM, V273, P8916, DOI 10.1074/jbc.273.15.8916; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KATZAV S, 1994, J BIOL CHEM, V269, P32579; Kong GH, 1996, MOL CELL BIOL, V16, P5026; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LUO K, 1990, ONCOGENE, V5, P921; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Zeitlmann L, 1998, J BIOL CHEM, V273, P15445, DOI 10.1074/jbc.273.25.15445; Zhao QH, 1996, MOL CELL BIOL, V16, P6765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	103	107	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14229	14237		10.1074/jbc.274.20.14229	http://dx.doi.org/10.1074/jbc.274.20.14229			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318843	hybrid			2022-12-25	WOS:000080322200072
J	Qu, ZQ; Zhu, GY; Yang, ZJ; Cui, NR; Li, YJ; Chanchevalap, S; Sulaiman, S; Haynie, H; Jiang, C				Qu, ZQ; Zhu, GY; Yang, ZJ; Cui, NR; Li, YJ; Chanchevalap, S; Sulaiman, S; Haynie, H; Jiang, C			Identification of a critical motif responsible for gating of Kir2.3 channel by intracellular protons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT MEDULLA; CENTRAL CHEMOSENSITIVITY; POTASSIUM CHANNELS; CULTIVATED NEURONS; K(IR)1.1 CHANNELS; CARBON-DIOXIDE; PH; SENSITIVITY; K+; CURRENTS	Protons are involved in gating Kir2.3. To identify the molecular motif in the Kir2.3 channel protein that is responsible for this process, experiments were performed using wild-type and mutated Kir2.3 and Kir2.1. CO2 and low pH(i) strongly inhibited wild-type Kir2.3 but not Kir2.1 in whole cell voltage clamp and excised inside-out patches, This CO2/pH sensitivity was completely eliminated in a mutant Kir2.3 in which the N terminus was substituted with that in Kir2.1, whereas a similar replacement of its C terminus had no effect. Site-specific mutations of all titratable residues in the N terminus, however, did not change the CO2/pH sensitivity. Using several chimeras generated systematically in the N terminus, a 10-residue motif near the M1 region was identified in which only three amino acids are different between Kir2.3 and Kir2.1. Mutations of these residues, especially Thr(53), dramatically reduced the pH sensitivity of Kir2.3. Introducing these residues or even a single threonine to the corresponding positions of Kir2.1 made the mutant channel pH-sensitive. Thus, a critical motif responsible for gating Kir2.3 by protons was identified in the N terminus, which contained about 10 residues centered by Thr(53).	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Cent Ave, Atlanta, GA 30303 USA.	biocjj@panther.gsu.edu		Yang, Zhenjiang/0000-0002-9315-154X	NHLBI NIH HHS [R01 HL058410, HL58410-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bukauskas FF, 1997, BIOPHYS J, V72, P2137, DOI 10.1016/S0006-3495(97)78856-8; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; DEAN JB, 1990, NEUROSCIENCE, V36, P207, DOI 10.1016/0306-4522(90)90363-9; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; FELDMAN JL, 1986, HDB PHYSL 1, V4, P463; Fitzherald RS, 1986, HDB PHYSL 3, P313; HAYASHI F, 1992, ABSTR SOC NEUR, V18; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; JIANG C, 1994, J NEUROSCI, V14, P5590; JIANG C, 1992, J PHYSIOL-LONDON, V448, P697, DOI 10.1113/jphysiol.1992.sp019065; JIANG C, 1997, ABSTR SOC NEUR, V23; JIANG C, 1996, TISSUE OXYGEN DEPRIV, P595; Karschin C, 1997, MOL CELL NEUROSCI, V10, P131, DOI 10.1006/mcne.1997.0655; Krishek BJ, 1996, J PHYSIOL-LONDON, V492, P431, DOI 10.1113/jphysiol.1996.sp021319; LOESCHCKE HH, 1982, J PHYSIOL-LONDON, V332, P1; MITCHELL RA, 1975, AM REV RESPIR DIS, V111, P206; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; Pineda J, 1997, NEUROSCIENCE, V77, P723, DOI 10.1016/S0306-4522(96)00485-X; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Scheid P, 1998, FASEB J, V12, pA50; Schlaefke M E, 1981, Rev Physiol Biochem Pharmacol, V90, P171, DOI 10.1007/BFb0034080; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; Wellner-Kienitz MC, 1998, NEUROSCIENCE, V87, P109, DOI 10.1016/S0306-4522(98)00159-6; Wellner-Kienitz MC, 1998, J NEUROPHYSIOL, V79, P2885, DOI 10.1152/jn.1998.79.6.2885; Widdicombe J.G., 1986, HDB PHYS, P1; XU HX, 1998, ABSTR SOC NEUR, V24; Zhu GY, 1999, J BIOL CHEM, V274, P11643, DOI 10.1074/jbc.274.17.11643; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x	34	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13783	13789		10.1074/jbc.274.20.13783	http://dx.doi.org/10.1074/jbc.274.20.13783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318782	hybrid			2022-12-25	WOS:000080322200011
J	Ma, YS; Cunningham, ME; Wang, XM; Ghosh, I; Regan, L; Longley, BJ				Ma, YS; Cunningham, ME; Wang, XM; Ghosh, I; Regan, L; Longley, BJ			Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE C-KIT; STEM-CELL FACTOR; TYROSINE KINASE; SIGNAL TRANSDUCTION; FUNCTION MUTATIONS; ACTIVATION; LIGAND; IDENTIFICATION; DIMERIZATION; MASTOCYTOSIS	KIT receptor kinase activity is repressed, prior to stem cell factor binding, by unknown structural constraints. Using site-directed mutagenesis, we examined the role of KIT intracellular juxtamembrane residues Met-552 through Ile-563 in controlling receptor autophosphorylation, Alanine substitution for Tyr-553, Trp-557, Val-559, or Val-560, all sitting along the hydrophobic side of an amphipathic alpha-helix (Tyr-553-Ile-563) predicted by the Chou-Fasman algorithm, resulted in substantially increased spontaneous receptor phosphorylation, revealing inhibitory roles for these residues Alanine substitution for other residues, most of which are on the hydrophilic side of the helix, caused no or slightly increased basal receptor phosphorylation, Converting Tyr-553 or Trp-557 to phenylalanine generated slight or no elevation, respectively, in basal KIT phosphorylation, indicating that the phenyl ring of Tyr-553 and the hydrophobicity of Trp-557 are critical for the inhibition. Although alanine substitution for Lys-558 had no effect on receptor phosphorylation, its substitution with proline produced high spontaneous receptor phosphorylation, suggesting that the predicted alpha-helical conformation is involved in the inhibition. A synthetic peptide comprising Tyr-553 through Ile-563 showed circular dichroism spectra characteristic of alpha-helix, supporting the structural prediction. Thus, the KIT intracellular juxtamembrane region contains important residues which, in a putative alpha-helical conformation, exert inhibitory control on the kinase activity of ligand-unoccupied receptor.	Columbia Univ Coll Phys & Surg, Dept Dermatol, Sect Dermatopathol, Vanderbilt Clin, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Columbia University; Vanderbilt University; Columbia University; Yale University	Longley, BJ (corresponding author), Columbia Univ Coll Phys & Surg, Dept Dermatol, Sect Dermatopathol, Vanderbilt Clin, 630 W 168th St,15-221, New York, NY 10032 USA.		Cunningham, Matthew/AAA-4994-2022	Cunningham, Matthew/0000-0003-3723-062X	NIAMS NIH HHS [R01 AR43356, AR44535] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535, R01AR043356] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; LEV S, 1992, J BIOL CHEM, V267, P15970; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Ma YS, 1999, J INVEST DERMATOL, V112, P165, DOI 10.1046/j.1523-1747.1999.00488.x; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016	20	105	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13399	13402		10.1074/jbc.274.19.13399	http://dx.doi.org/10.1074/jbc.274.19.13399			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224103	hybrid			2022-12-25	WOS:000080200400065
J	Paul-Soto, R; Bauer, R; Frere, JM; Galleni, M; Meyer-Klaucke, W; Nolting, H; Rossolini, GM; de Seny, D; Hernandez-Valladares, M; Zeppezauer, M; Adolph, HW				Paul-Soto, R; Bauer, R; Frere, JM; Galleni, M; Meyer-Klaucke, W; Nolting, H; Rossolini, GM; de Seny, D; Hernandez-Valladares, M; Zeppezauer, M; Adolph, HW			Mono- and binuclear Zn2+-beta-lactamase - Role of the conserved cysteine in the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLO-BETA-LACTAMASE; BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; BINDING; SITES	When expressed by pathogenic bacteria, Zn2+-beta-lactamases induce resistance to most beta-lactam antibiotics. A possible strategy to fight these bacteria would be a combined therapy with non-toxic inhibitors of Zn2+-beta-lactamases together with standard antibiotics. For this purpose, it is important to verify that the inhibitor is effective under all clinical conditions. We have investigated the correlation between the number of zinc ions bound to the Zn2+-beta-lactamase from Bacillus cereus and hydrolysis of benzylpenicillin and nitrocefin for the wild type and a mutant where cysteine 168 is replaced by alanine. It is shown that both the mono-Zn2+ (mononuclear) and di-Zn2+ (binuclear) Zn2+-beta-lactamases are catalytically active but with different kinetic properties, The mono-Zn2+-beta-lactamase requires the conserved cysteine residue for hydrolysis of the beta-lactam ring in contrast to the binuclear enzyme where the cysteine residue is not essential. Substrate affinity is not significantly affected by the mutation for the mononuclear enzyme but is decreased for the binuclear enzyme. These results were derived from kinetic studies on two wild types and the mutant enzyme with benzylpenicillin and nitrocefin as substrates. Thus, targeting drug design to modify this residue might represent an efficient strategy, the more so if it also interferes with the formation of the binuclear enzyme.	Univ Saarlandes, Fachrichtung Biochem 12 4, D-66041 Saarbrucken, Germany; Univ Liege, Inst Chim B6, Ctr Ingn Prot, B-4000 Liege, Belgium; DESY, EMBL, Outstn Hamburg, D-22603 Hamburg, Germany; Royal Vet & Agr Univ, Dept Phys, DK-1871 Frederiksberg, Denmark; Univ Siena, Dipartimento Biol Mol, Sez Microbiol, I-53100 Siena, Italy	Saarland University; University of Liege; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Copenhagen; University of Siena	Adolph, HW (corresponding author), Univ Saarlandes, Fachrichtung Biochem 12 4, D-66041 Saarbrucken, Germany.		Meyer-Klaucke, Wolfram/G-1148-2010; Hernandez-Valladares, Maria del Carmen/GXF-7320-2022; Adolph, Hans W/A-2104-2008	Hernandez-Valladares, Maria del Carmen/0000-0001-9347-7841; ROSSOLINI, Gian Maria/0000-0002-9386-0434				AULD DS, 1988, METHOD ENZYMOL, V158, P1; BALDWIN GS, 1978, BIOCHEM J, V175, P441, DOI 10.1042/bj1750441; BALDWIN GS, 1980, J INORG BIOCHEM, V13, P189, DOI 10.1016/S0162-0134(00)80068-9; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crowder MW, 1996, BIOCHEMISTRY-US, V35, P12126, DOI 10.1021/bi960976h; DAVIES RB, 1974, BIOCHEM J, V143, P129, DOI 10.1042/bj1430129; DEMEESTER F, 1987, BIOCHEM PHARMACOL, V36, P2393, DOI 10.1016/0006-2952(87)90609-5; FEITERS MC, 1990, COMMENTS INORG CHEM, V11, P131; FEITERS MC, 1986, J PHYS, P1169; HERMES C, 1984, NUCL INSTRUM METH A, V222, P207, DOI 10.1016/0167-5087(84)90532-5; MeyerKlaucke W, 1996, EUR J BIOCHEM, V241, P432, DOI 10.1111/j.1432-1033.1996.00432.x; PAYNE DJ, 1993, J MED MICROBIOL, V39, P93, DOI 10.1099/00222615-39-2-93; Shaw R W, 1991, Protein Expr Purif, V2, P151, DOI 10.1016/1046-5928(91)90064-P; SOTO RP, 1998, FEBS LETT, V438, P137; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402	21	117	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13242	13249		10.1074/jbc.274.19.13242	http://dx.doi.org/10.1074/jbc.274.19.13242			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224083	hybrid			2022-12-25	WOS:000080200400045
J	van de Water, B; Nagelkerke, JF; Stevens, JL				van de Water, B; Nagelkerke, JF; Stevens, JL			Dephosphorylation of focal adhesion kinase (FAK) and loss of focal contacts precede caspase-mediated cleavage of FAK during apoptosis in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PROXIMAL TUBULAR CELLS; RAT-KIDNEY; PHOSPHATIDYLINOSITOL 3-KINASE; C-MYC; POLY(ADP-RIBOSE) POLYMERASE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; PP125(FAK); ACTIVATION	The relationship between focal adhesion protein (FAK) activity and loss of cell-matrix contact during apoptosis is not entirely clear nor has the role of FAK in chemically induced apoptosis been studied. We investigated the status of FAK phosphorylation and cleavage in renal epithelial cells during apoptosis caused by the nephrotoxicant dichlorovinylcysteine (DCVC). DCVC treatment caused a loss of cell-matrix contact which was preceded by a dissociation of FAK from the focal adhesions and tyrosine dephosphorylation of FAK. Paxillin was also dephosphorylated at tyrosine. DCVC treatment activated caspase-3 which was associated with cleavage of FAK. However, FAK cleavage occurred after cells had already lost focal adhesions indicating that cleavage of FAK by caspases is not responsible for loss of FAK from focal adhesions. Accordingly, although inhibition of caspase activity with zVAD-fmk blocked activation of caspase-3, FAK cleavage, and apoptosis, it neither affected dephosphorylation nor translocation of FAK or paxillin, However, zVAD-fmk completely blocked the cell detachment caused by DCVC treatment. Orthovanadate prevented DCVC-induced tyrosine dephosphorylation of both FAK and paxillin; however, it did not inhibit DCVC-induced apoptosis and actually potentiated focal adhesion disorganization and cell detachment. Thus, FAK dephosphorylation and loss of focal adhesions are not due to caspase activation; however, caspases are required for FAK proteolysis and cell detachment.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, NL-2300 RA Leiden, Netherlands; Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA	Leiden University; Leiden University - Excl LUMC; University of Vermont	van de Water, B (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, POB 9503, NL-2300 RA Leiden, Netherlands.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007847] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46267] Funding Source: Medline; NIEHS NIH HHS [ES07847] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BOOGAARD PJ, 1989, TOXICOL APPL PHARM, V101, P135, DOI 10.1016/0041-008X(89)90219-6; Brady H.R., 1996, KIDNEY, P1200; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN Q, 1990, J BIOL CHEM, V265, P21603; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEPESO L, 1997, SCIENCE, V278, P687; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAILIT J, 1993, AM J PHYSIOL, V264, pF149, DOI 10.1152/ajprenal.1993.264.1.F149; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; GOLDSTEIN RS, 1996, TOXICOLOGY, P417; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HATZINGER PB, 1989, IN VITRO CELL DEV B, V25, P205; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kruidering M, 1998, CELL DEATH DIFFER, V5, P601, DOI 10.1038/sj.cdd.4400392; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; Maravei DV, 1997, CELL DEATH DIFFER, V4, P707, DOI 10.1038/sj.cdd.4400311; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; OSBORNE BA, 1995, SEMIN CANCER BIOL, V6, P27, DOI 10.1006/scbi.1995.0004; RACUSEN LC, 1991, LAB INVEST, V64, P546; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Sanders EJ, 1995, INT REV CYTOL, V163, P105, DOI 10.1016/S0074-7696(08)62210-X; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; VANDEWATER B, 1994, AM J PHYSIOL-RENAL, V267, pF888, DOI 10.1152/ajprenal.1994.267.5.F888; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; VUORI K, 1993, J BIOL CHEM, V268, P21459; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YU KF, 1994, J CELL PHYSIOL, V161, P303, DOI 10.1002/jcp.1041610215; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	68	125	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13328	13337		10.1074/jbc.274.19.13328	http://dx.doi.org/10.1074/jbc.274.19.13328			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224094	hybrid, Green Published			2022-12-25	WOS:000080200400056
J	Zhang, W; Mannan, I; Schulz, S; Parkinson, SJ; Alekseev, AE; Gomez, LA; Terzic, A; Waldman, SA				Zhang, W; Mannan, I; Schulz, S; Parkinson, SJ; Alekseev, AE; Gomez, LA; Terzic, A; Waldman, SA			Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea	FASEB JOURNAL			English	Article						E-coli heat-stable enterotoxin; intestinal cell water secretion; cyclic GMP; 2-substituted adenine nucleotides; CFTR-mediated chloride current	HEAT-STABLE ENTEROTOXIN; GUANYLYL CYCLASE-C; DEPENDENT PROTEIN-KINASE; CELL-LINE CACO-2; ESCHERICHIA-COLI; RAT INTESTINE; CYCLIC-GMP; RECEPTOR; SECRETION; CHANNELS	Bacteria that produce heat-stable enterotoxins (STs), a leading cause of secretory diarrhea, are a major cause of morbidity and mortality worldwide. ST stimulates guanylyl cyclase C (GCC) and accumulation of intracellular cyclic GMP ([cGMP](i)), which opens the cystic fibrosis transmembrane conductance regulator (CFTR)-related chloride channel, triggering intestinal secretion. Although the signaling cascade mediating ST-induced diarrhea is well characterized, antisecretory therapy targeting this pathway has not been developed. 2-ChloroATP (2ClATP) and its cell-permeant precursor, 2-chloroadenosine (2ClAdo), disrupt ST-dependent signaling in intestinal cells. However, whether the ability to disrupt guanylyl cyclase signaling translates into effective antisecretory therapy remains untested. In this study, the efficacy of 2ClAdo to prevent ST-induced water secretion by human intestinal cells was examined. In Caco-2 human intestinal cells, ST increased [cGMP](i), induced a chloride current, and stimulated net basolateral-to-apical water secretion. This effect on chloride current and water secretion was mimicked by the cell-permeant analog of cGMP, 8-bromo-cGMP. Treatment of Caco-2 cells with 2C1Ado prevented ST-induced increases in [cGMP](i), chloride current and water secretion. Inhibition of the downstream consequences of ST-GCC interaction reflects proximal disruption of cGMP production because 8-bromo-cGMP stimulated chloride current and water secretion in 2ClAdo-treated cells. Thus, this study demonstrates that disruption of guanylyl cyclase signaling is an effective strategy for antisecretory therapy and provides the basis for developing mechanism-based treatments for enterotoxigenic diarrhea.	Thomas Jefferson Univ, Div Clin Pharmacol, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Div Clin Pharmacol, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Div Cardiovasc Dis, Rochester, MN 55905 USA	Jefferson University; Jefferson University; Mayo Clinic; Mayo Clinic	Waldman, SA (corresponding author), Thomas Jefferson Univ, Div Clin Pharmacol, Dept Med, MOB 813,1100 Walnut St, Philadelphia, PA 19107 USA.	waldmans@jeflin.tju.edu	Alekseev, Alexey/I-5346-2013	Waldman, Scott/0000-0001-6619-175X	NATIONAL CANCER INSTITUTE [R01CA075123] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059214] Funding Source: NIH RePORTER; NCI NIH HHS [CA75123] Funding Source: Medline; NHLBI NIH HHS [HL59214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alekseev AE, 1996, BIOPHYS J, V70, P786, DOI 10.1016/S0006-3495(96)79618-2; Alekseev AE, 1996, J MOL CELL CARDIOL, V28, P1193, DOI 10.1006/jmcc.1996.0110; Alekseev AE, 1997, J MEMBRANE BIOL, V157, P203, DOI 10.1007/s002329900229; BLACK RE, 1982, AM J EPIDEMIOL, V115, P315, DOI 10.1093/oxfordjournals.aje.a113308; Carrithers SL, 1996, P NATL ACAD SCI USA, V93, P14827, DOI 10.1073/pnas.93.25.14827; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; CRAVIOTO A, 1988, EPIDEMIOL INFECT, V101, P123, DOI 10.1017/S0950268800029289; Dorr RA, 1997, COMPUT METH PROG BIO, V53, P9, DOI 10.1016/S0169-2607(96)01801-9; DREYFUS LA, 1984, INFECT IMMUN, V46, P537, DOI 10.1128/IAI.46.2.537-543.1984; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GRASSET E, 1985, AM J PHYSIOL, V248, pC410, DOI 10.1152/ajpcell.1985.248.5.C410; GUERRANT RL, 1990, REV INFECT DIS, V12, pS41; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; Mann EA, 1996, BBA-GENE STRUCT EXPR, V1305, P7, DOI 10.1016/0167-4781(95)00190-5; Mann EA, 1997, BIOCHEM BIOPH RES CO, V239, P463, DOI 10.1006/bbrc.1997.7487; NATH SK, 1990, J DIARRHOEAL DIS RES, V8, P133; PARISI M, 1995, J MEMBRANE BIOL, V143, P237; PARISI M, 1993, PFLUG ARCH EUR J PHY, V423, P1, DOI 10.1007/BF00374953; Parkinson SJ, 1997, J BIOL CHEM, V272, P754, DOI 10.1074/jbc.272.2.754; PARKINSON SJ, 1994, J BIOL CHEM, V269, P22683; Parkinson SJ, 1996, BIOCHEMISTRY-US, V35, P3213, DOI 10.1021/bi9524326; PINTO M, 1983, BIOL CELL, V47, P323; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RUBAS W, 1993, PHARMACEUT RES, V10, P113, DOI 10.1023/A:1018937416447; SAVARINO SJ, 1991, J CLIN INVEST, V87, P1450, DOI 10.1172/JCI115151; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Schulz S, 1997, J CLIN INVEST, V100, P1590, DOI 10.1172/JCI119683; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; Vaandrager AB, 1997, GASTROENTEROLOGY, V112, P437, DOI 10.1053/gast.1997.v112.pm9024297; Waldman SA, 1998, CANCER EPIDEM BIOMAR, V7, P505; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359; 1985, TRAVELERS DIARRHEA, V5, P1	35	21	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					913	922		10.1096/fasebj.13.8.913	http://dx.doi.org/10.1096/fasebj.13.8.913			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224234				2022-12-25	WOS:000080372500014
J	Blumenthal, SG; Aichele, G; Wirth, T; Czernilofsky, AP; Nordheim, A; Dittmer, J				Blumenthal, SG; Aichele, G; Wirth, T; Czernilofsky, AP; Nordheim, A; Dittmer, J			Regulation of the human interleukin-5 promoter by Ets transcription factors - Ets1 and Ets2, but not Elf-1, cooperate with GATA3 and HTLV-I Tax(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-I; CREB BINDING-PROTEIN; NF-KAPPA-B; HORMONE-RELATED PROTEIN; GM-CSF PROMOTER; HUMAN T-CELLS; DNA-BINDING; C-JUN; TRANSACTIVATOR TAX; GENE-EXPRESSION	Interleukin-5 (IL-5), expressed primarily by type-2 T helper (Th2) cells, plays an important role in the development of allergic diseases, such as allergic asthma. Studying the regulation of IL-5 gene expression by Ets transcription factors, we found that Ets1 and Ets2, but not Elf-1, were able to activate the human IL-5 promoter in Jurkat T-cells. This required the presence of either phorbol 12-myristate acetate (PMA) plus ionomycin or PMA plus the viral protein HTLV-I Tax,. By mutation studies, it could be shown that Ets1 and Ets2 exerted their effects on the IL-5 promoter through a GGAA motif within the Cle0 element. In myeloid Kasumi cells, Ets1 and Ets2 failed to stimulate IL-5 promoter activity, unless the T-cell specific transcription factor GATA3 was added. These results show, for the first time, that Ets1 and Ets2 are able to cooperate with GATA3. Both ionomycin and Tax, increased the combined effect of GATA3 with Ets1 and Ets2 in the presence of PMA. The data further demonstrate that, in addition to Ets1, Ets2 is also able to functionally cooperate with Tax,. The synergism of GATA3 with either Ets1 or Ets2 may play an important role in calcium- or Tax(1)-dependent regulation of IL-5 expression in Th2 cells or in HTLV-I transformed adult T-cell leukemia cells, respectively.	Univ Tubingen, Inst Zellbiol, Mol Biol Abt, D-72076 Tubingen, Germany; Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Bender & Co Gesell MBH, A-1121 Vienna, Austria	Eberhard Karls University of Tubingen	Dittmer, J (corresponding author), Univ Tubingen, Inst Zellbiol, Mol Biol Abt, Morgenstelle 15, D-72076 Tubingen, Germany.		Dittmer, Juergen/G-1160-2011; Wirth, Thomas/X-7172-2019					ALEXANDRE C, 1991, ONCOGENE, V6, P543; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; Foster PS, 1997, MEM I OSWALDO CRUZ, V92, P55, DOI 10.1590/S0074-02761997000800009; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Gitlin Scott D., 1993, P159; Good L, 1997, J BIOL CHEM, V272, P1425, DOI 10.1074/jbc.272.3.1425; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; HOOPER WC, 1991, BIOCHEM BIOPH RES CO, V181, P976, DOI 10.1016/0006-291X(91)92032-F; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KVANTA A, 1992, CELL SIGNAL, V4, P275, DOI 10.1016/0898-6568(92)90067-I; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Luo C, 1996, MOL CELL BIOL, V16, P3955; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MAKOVER D, 1991, ONCOGENE, V6, P455; MURATA K, 1992, CANCER, V69, P966, DOI 10.1002/1097-0142(19920215)69:4&lt;966::AID-CNCR2820690422&gt;3.0.CO;2-H; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NOMA T, 1989, J EXP MED, V169, P1853, DOI 10.1084/jem.169.5.1853; Patton SE, 1998, CANCER RES, V58, P2253; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; Rincon M, 1997, CURR BIOL, V7, pR729, DOI 10.1016/S0960-9822(06)00368-X; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S M, 1989, New Biologist, V1, P275; SACCHI N, 1988, LEUKEMIA, V2, P12; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Stranick KS, 1997, J BIOL CHEM, V272, P16453, DOI 10.1074/jbc.272.26.16453; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TOMINAGA A, 1988, J IMMUNOL, V140, P1175; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WARREN DJ, 1985, IMMUNOLOGY, V54, P615; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	86	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12910	12916		10.1074/jbc.274.18.12910	http://dx.doi.org/10.1074/jbc.274.18.12910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212281	hybrid			2022-12-25	WOS:000080056800101
J	Yang, VWC; LaBrenz, SR; Rosenberg, LC; McQuillan, D; Hook, M				Yang, VWC; LaBrenz, SR; Rosenberg, LC; McQuillan, D; Hook, M			Decorin is a Zn2+ metalloprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; DERMATAN SULFATE PROTEOGLYCANS; GROWTH-FACTOR-BETA; CORE PROTEIN; MATRIX METALLOPROTEINASES; COLLAGEN FIBRILLOGENESIS; PROTEODERMATAN SULFATE; ESCHERICHIA-COLI; SKIN FRAGILITY; LINK PROTEIN	Decorin is ubiquitously distributed in the extracellular matrix of mammals and a member of the proteoglycan family characterized by a core protein dominated by leucine-rich repeat motifs. We show here that decorin extracted from bovine tissues under denaturing conditions or produced in recombinant "native" form by cultured mammalian cells has a high affinity for Zn2+ as demonstrated by equilibrium dialyses. The Zn2+-binding sites are localized to the N-terminal domain of the core protein that contains 4 Cys residues in a spacing reminiscent of a zinc finger. A recombinant 41-amino acid long peptide representing the N-terminal domain of decorin has full Zn2+ binding activity and binds two Zn2+ ions with an average H-D, of 3 x 10(-7) (M). Binding of Zn2+ to this peptide results in a change in secondary structure as shown by circular dichroism spectroscopy. Biglycan, a proteoglycan that is structurally closely related to decorin contains a similar high affinity Zn2+-binding segment, whereas the structurally more distantly related proteoglycans, epiphycan and osteoglycin, do not bind Zn2+ with high affinity.	Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77030 USA; Montefiore Med Ctr, Orthopaed Res Lab, Bronx, NY 10467 USA	University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Hook, M (corresponding author), Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, Houston, TX 77030 USA.	mhook@ibt.tamu.edu			NIAMS NIH HHS [AR42919, AR42826] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919, R01AR042826] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ancsin JB, 1996, J BIOL CHEM, V271, P6845, DOI 10.1074/jbc.271.12.6845; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CHOI HU, 1989, J BIOL CHEM, V264, P2876; DAMLE SP, 1982, J BIOL CHEM, V257, P5523; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; EMONARD H, 1990, CELL MOL BIOL, V36, P131; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1985, CHEM BIOL MINERALIZE, P188; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P654; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hering TM, 1996, ANAL BIOCHEM, V240, P98, DOI 10.1006/abio.1996.0335; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JEZOREK JR, 1979, ANAL CHEM, V51, P373, DOI 10.1021/ac50039a012; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LIU J, 1994, J BIOL CHEM, V269, P28366; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKAMURA T, 1983, BIOCHEM J, V213, P289, DOI 10.1042/bj2130289; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; POOLE AR, 1986, J HISTOCHEM CYTOCHEM, V34, P619, DOI 10.1177/34.5.3701029; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; REINHARDT D, 1993, J BIOL CHEM, V268, P10881; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VARELAS JB, 1995, ARCH BIOCHEM BIOPHYS, V321, P21, DOI 10.1006/abbi.1995.1363; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	44	29	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12454	12460		10.1074/jbc.274.18.12454	http://dx.doi.org/10.1074/jbc.274.18.12454			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212220	Green Submitted, hybrid			2022-12-25	WOS:000080056800040
J	Salinas, M; Reyes, R; Lesage, F; Fosset, M; Heurteaux, C; Romey, G; Lazdunski, M				Salinas, M; Reyes, R; Lesage, F; Fosset, M; Heurteaux, C; Romey, G; Lazdunski, M			Cloning of a new mouse two-P domain channel subunit and a human homologue with a unique pore structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; LONG-QT SYNDROME; CALCIUM-MODULATED PROTEINS; RECTIFYING K+-CHANNEL; SENSITIVE NA+ CHANNEL; POTASSIUM CHANNEL; SULFONYLUREA RECEPTOR; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE	Mouse KCNK6 is a new subunit belonging to the TWIK channel family. This 335-amino acid polypeptide has four transmembrane segments, two pore-forming domains, and a Ca2+-binding EF-hand motif. Expression of KCNK6 transcripts is principally observed in eyes, lung, stomach and embryo. In the eyes, immunohistochemistry reveals protein expression only in some of the retina neurons. Although KCNK6 is able to dimerize as other functional two-P domain K+ channels when it is expressed in COS-7 cells, it remains in the endoplasmic reticulum and is unable to generate ionic channel activity. Deletions, mutations, and chimera constructions suggest that KCNK6 is not an intracellular channel but rather a subunit that needs to associate with a partner, which remains to be discovered, in order to reach the plasma membrane, A closely related human KCNK7-A subunit has been cloned. KCNK7 displays an intriguing GLE sequence in its filter region instead of the G(Y/F/L)G sequence, which is considered to be the K+ channel signature. This subunit is alternatively spliced and gives rise to the shorter forms KCNK7-B and -C, None of the KCNR7 structures can generate channel activity by itself. The KCNK7 gene is situated on chromosome 11, in the q13 region, where several candidate diseases have been identified.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	SALINAS, Miguel/N-6380-2016; Lesage, Florian/P-9780-2019; HEURTEAUX, Catherine/M-4947-2016; Lesage, Florian/D-5097-2011	SALINAS, Miguel/0000-0002-7445-123X; Lesage, Florian/0000-0002-4406-7106; HEURTEAUX, Catherine/0000-0002-9741-9777; Lesage, Florian/0000-0002-4406-7106				ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; Attali B, 1996, NATURE, V384, P24, DOI 10.1038/384024a0; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Czempinski K, 1997, EMBO J, V16, P2565, DOI 10.1093/emboj/16.10.2565; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drici MD, 1998, CIRC RES, V83, P95, DOI 10.1161/01.RES.83.1.95; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HAY M, 1994, NEUROSCI LETT, V167, P179, DOI 10.1016/0304-3940(94)91056-1; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Hille B., 1992, IONIC CHANNELS EXCIT; Hille Bertil, 1994, P75; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Jaskiewicz E, 1997, ACTA BIOCHIM POL, V44, P173; John SA, 1998, J PHYSIOL-LONDON, V510, P333, DOI 10.1111/j.1469-7793.1998.333bk.x; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; Leonoudakis D, 1998, J NEUROSCI, V18, P868; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1997, FEBS LETT, V402, P28, DOI 10.1016/S0014-5793(96)01491-3; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 1997, EMBO J, V16, P6615, DOI 10.1093/emboj/16.22.6615; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Post MA, 1996, FEBS LETT, V399, P177, DOI 10.1016/S0014-5793(96)01316-6; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; SKRE H, 1974, CLIN GENET, V5, P196; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; WONG ROL, 1995, NATURE, V374, P716, DOI 10.1038/374716a0; WONG SH, 1993, J BIOL CHEM, V268, P22853; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu ZL, 1996, J VIROL, V70, P6563, DOI 10.1128/JVI.70.10.6563-6575.1996	79	111	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11751	11760		10.1074/jbc.274.17.11751	http://dx.doi.org/10.1074/jbc.274.17.11751			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206991	hybrid			2022-12-25	WOS:000079834800047
J	Wilson, HA; Waldrip, JB; Nielson, KH; Judd, AM; Han, SK; Cho, WW; Sims, PJ; Bell, JD				Wilson, HA; Waldrip, JB; Nielson, KH; Judd, AM; Han, SK; Cho, WW; Sims, PJ; Bell, JD			Mechanisms by which elevated intracellular calcium induces S49 cell membranes to become susceptible to the action of secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; PLASMA-MEMBRANE; LAURDAN FLUORESCENCE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; PALMITIC ACID; MAST-CELLS; IN-VITRO; LYSOPHOSPHATIDYLCHOLINE	Exposure of S49 lymphoma cells to exogenous group IIA or V secretory phospholipase A(2) (sPLA(2)) caused an initial release of fatty acid followed by resistance to further hydrolysis by the enzyme. This refractoriness was overcome by exposing cells to palmitoyl lysolecithin. This effect was specific in terms of lysophospholipid structure, Induction of membrane susceptibility by lysolecithin involved an increase in cytosolic calcium and was duplicated by incubating the cells with calcium ionophores such as ionomycin. Lysolecithin also activated cytosolic phospholipase A(2) (cPLA(2)). Inhibition of this enzyme attenuated the ability of lysolecithin (but not ionomycin) to induce susceptibility to sPLC(2). Lysolecithin or ionomycin caused concurrent hydrolysis of both phosphatidylethanolamine and phosphatidylcholine implying that transbilayer movement of phosphatidylethanolamine occurred upon exposure to these agents but that susceptibility is not simply due to exposure of a preferred substrate (i.e. phosphatidylethanolamine) to the enzyme. Microvesicles were apparently released from the cells upon addition of lysolecithin or ionomycin. Both these vesicles and the remnant cell membranes were susceptible to sPLA(2). Together these data suggest that lysolecithin induces susceptibility through both cPLA(2)-dependent and -independent pathways. Whereas elevated cytosolic calcium was required for both pathways, it was sufficient only for the cPLA(2)-independent pathway. This cPLA(2)-independent pathway involved changes in cell membrane structure associated with transbilayer phospholipid migration and microvesicle release.	Brigham Young Univ, Dept Zool, Provo, UT 84602 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Brigham Young University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Scripps Research Institute	Bell, JD (corresponding author), Brigham Young Univ, Dept Zool, Provo, UT 84602 USA.	john_bell@byu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049710, R01GM052598] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36946] Funding Source: Medline; NIGMS NIH HHS [GM52598, GM49710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; ARNDTJOVIN DJ, 1989, METHOD CELL BIOL, V30, P417; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASSE F, 1994, BBA-BIOMEMBRANES, V1190, P217, DOI 10.1016/0005-2736(94)90077-9; BELL JD, 1995, BIOCHEMISTRY-US, V34, P11551, DOI 10.1021/bi00036a031; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURACK WR, 1995, BIOCHEMISTRY-US, V34, P14819, DOI 10.1021/bi00045a024; CHANG CP, 1993, J BIOL CHEM, V268, P7171; CHAP HJ, 1977, BIOCHIM BIOPHYS ACTA, V467, P146, DOI 10.1016/0005-2736(77)90192-4; Chen L, 1997, J LIPID RES, V38, P546; CHONG PLG, 1993, BIOCHIM BIOPHYS ACTA, V1149, P260, DOI 10.1016/0005-2736(93)90209-I; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; COX DA, 1996, AM J PHYS, V40, pH1706; DUMASWALA UJ, 1984, TRANSFUSION, V24, P490, DOI 10.1046/j.1537-2995.1984.24685066807.x; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GHERIANIGRUSZKA N, 1988, J BIOL CHEM, V263, P11808; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; HARA S, 1993, J BIOCHEM-TOKYO, V114, P509, DOI 10.1093/oxfordjournals.jbchem.a124208; Henshaw JB, 1998, BIOCHEMISTRY-US, V37, P10709, DOI 10.1021/bi9728809; Honger T, 1996, BIOCHEMISTRY-US, V35, P9003, DOI 10.1021/bi960866a; Hoque ANE, 1997, CIRC RES, V80, P95, DOI 10.1161/01.RES.80.1.95; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V980, P23, DOI 10.1016/0005-2736(89)90195-8; KIKUCHIYANOSHITA R, 1993, J BIOCHEM-TOKYO, V114, P33, DOI 10.1093/oxfordjournals.jbchem.a124135; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Magishi K, 1996, PFLUG ARCH EUR J PHY, V432, P345, DOI 10.1007/s004240050142; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAG MK, 1995, MEDIAT INFLAMM, V4, P90, DOI 10.1155/S0962935195000147; OGITA T, 1997, AM J PHYS, V41, pH17; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; PARASASSI T, 1994, BIOPHYS J, V66, P120, DOI 10.1016/S0006-3495(94)80763-5; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RICHIERI GV, 1989, J IMMUNOL, V143, P2302; RICHIERI GV, 1995, ANAL BIOCHEM, V229, P256, DOI 10.1006/abio.1995.1410; Romano M, 1998, ARTERIOSCL THROM VAS, V18, P519, DOI 10.1161/01.ATV.18.4.519; RYBORG AK, 1995, BRIT J DERMATOL, V133, P398, DOI 10.1111/j.1365-2133.1995.tb02667.x; SCOLDING NJ, 1992, NEUROSCI LETT, V135, P95, DOI 10.1016/0304-3940(92)90144-V; SEVANIAN A, 1988, BIOCHIM BIOPHYS ACTA, V961, P316, DOI 10.1016/0005-2760(88)90079-3; Shander GS, 1996, J MOL CELL CARDIOL, V28, P743, DOI 10.1006/jmcc.1996.0069; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Spangelo BL, 1996, ENDOCRINOLOGY, V137, P4419, DOI 10.1210/en.137.10.4419; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; SWEETMAN LL, 1995, ARCH BIOCHEM BIOPHYS, V323, P97, DOI 10.1006/abbi.1995.0014; VADAS P, 1993, CIRC SHOCK, V39, P160; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WIEDMER T, 1991, BLOOD, V78, P2880; Wilson HA, 1997, BBA-LIPID LIPID MET, V1349, P142, DOI 10.1016/S0005-2760(97)00089-1; WOLF A, 1991, LIPIDS, V26, P223, DOI 10.1007/BF02543975; Wong JT, 1998, J BIOL CHEM, V273, P6830, DOI 10.1074/jbc.273.12.6830; Wu RH, 1998, ARTERIOSCL THROM VAS, V18, P626, DOI 10.1161/01.ATV.18.4.626; Yu LP, 1998, J PHARMACOL EXP THER, V286, P1; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	61	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11494	11504		10.1074/jbc.274.17.11494	http://dx.doi.org/10.1074/jbc.274.17.11494			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206954	hybrid			2022-12-25	WOS:000079834800010
J	Wu, MY; Wang, PY; Han, SH; Hsieh, SL				Wu, MY; Wang, PY; Han, SH; Hsieh, SL			The cytoplasmic domain of the lymphotoxin-beta receptor mediates cell death in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; PERIPHERAL LYMPHOID ORGANS; FACTOR TNF RECEPTOR; VIRUS CORE PROTEIN; KAPPA-B ACTIVATION; MONOCLONAL-ANTIBODIES; SIGNALING COMPLEX; APOPTOSIS; EXPRESSION; INTERACTS	Activation of lymphotoxin-beta receptor (LT-beta R) by conjugation with heterotrimeric lymphotoxin, LT-alpha 1/beta 2, or by cross-linking with anti-LT-beta R antibodies can trigger apoptosis. We have observed that overexpression of either LT-beta R or the cytoplasmic domain of LT-beta R (LT-beta R(CD)) also induces apoptosis, which may be attributed to the tendency of LT-beta R(CD) to self associate. The self-association domain of LT-beta R(CD) was mapped to amino acids 324-377, a region of the protein that is also essential for LT-beta R-induced apoptosis. Furthermore, we have shown that LT-beta R(CD)-induced apoptosis could be inhibited by a TRAF3 dominant negative mutant and by the caspase inhibitors Z-VAD-FMK, DEVD -FMK, and CrmA. The ligand-independent apoptosis induced by LT-beta R(CD) will help us to further dissect LT-beta R signaling pathway.	Natl Yang Ming Univ, Sch Med, Inst Microbiol & Immunol, Taipei 11221, Taiwan; Natl Yang Ming Univ, Sch Med, Immunol Res Ctr, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Hsieh, SL (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Microbiol & Immunol, Taipei 11221, Taiwan.		Hsieh, Shie-Liang Edmond/ABA-9184-2021					BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; FORCE WR, 1995, J IMMUNOL, V155, P5280; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Haridas V, 1998, J IMMUNOL, V160, P3152; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Mackay F, 1996, J BIOL CHEM, V271, P24934, DOI 10.1074/jbc.271.40.24934; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; Wu MY, 1997, J BIOL CHEM, V272, P17154, DOI 10.1074/jbc.272.27.17154; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	41	38	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11868	11873		10.1074/jbc.274.17.11868	http://dx.doi.org/10.1074/jbc.274.17.11868			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207006	hybrid			2022-12-25	WOS:000079834800062
J	Catteau, A; Harris, WH; Xu, CF; Solomon, E				Catteau, A; Harris, WH; Xu, CF; Solomon, E			Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics	ONCOGENE			English	Article						breast cancer; ovarian cancer; BRCA1 promoter; methylation	TUMOR-SUPPRESSOR GENE; ESTROGEN-RECEPTOR GENE; DNA METHYLATION; CPG ISLAND; HYPERMETHYLATION; EXPRESSION; CARCINOMAS; RETINOBLASTOMA; MUTATIONS; IDENTIFICATION	Reduced expression of BRCA1 has been reported in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. Abnormal methylation leading to silencing of tumour suppressor genes has been implicated in tumorigenesis in a wide range of sporadic cancers. Therefore, we sought to determine the frequency of methylation within the BRCA1 promoter region in a large group of sporadic invasive breast (n=96) and ovarian (n=43) carcinomas using Southern analyses. Overall, methylation was detected in 11% of breast cancer cases and in 5% of ovarian tumours, Methylation of the BRCA1 promoter region was strongly correlated with lack of estrogen and progesterone receptor expression. It is clear from the frequency of abnormal methylation of the BRCA1 promoter region, that this cannot be the sole mechanism mediating the reduced expression of BRCA1 that has previously been reported to occur in the majority of invasive sporadic breast tumours, Nevertheless this study suggests that abnormal methylation of the BRCA1 promoter may be important in tumorigenesis in a subset of sporadic breast and ovarian cancers.	UMDS, Div Med & Mol Genet, Guys Hosp, London SE1 9RT, England; Guys Hosp, Hedley Atkins ICRF Breast Pathol Lab, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Catteau, A (corresponding author), UMDS, Div Med & Mol Genet, Guys Hosp, 8th Floor,Guys Tower, London SE1 9RT, England.			Xu, Chun-Fang/0000-0002-8747-0683	Medical Research Council [G9600577] Funding Source: Medline; MRC [G9600577] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Barnes DM, 1996, BRIT J CANCER, V74, P1445, DOI 10.1038/bjc.1996.563; BARNES DM, 1995, PROG PATHOL, V2, P89; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brown MA, 1996, ONCOGENE, V12, P2507; CATTEAU A, 1999, IN PRESS BR J CANC; CLIBY W, 1993, CANCER RES, V53, P2393; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; CROPP CS, 1993, CANCER RES, V53, P5617; Dobrovic A, 1997, CANCER RES, V57, P3347; FERGUSON AT, 1995, CANCER RES, V55, P2279; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GRAFF JR, 1995, CANCER RES, V55, P5195; GREGER V, 1994, HUM GENET, V94, P491; Hakkarainen M, 1996, INT J CANCER, V69, P471, DOI 10.1002/(SICI)1097-0215(19961220)69:6<471::AID-IJC9>3.3.CO;2-A; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Huang THM, 1997, CANCER RES, V57, P1030; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAITO H, 1993, CANCER RES, V53, P3382; SAKAI T, 1991, AM J HUM GENET, V48, P880; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405	44	286	301	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1957	1965		10.1038/sj.onc.1202509	http://dx.doi.org/10.1038/sj.onc.1202509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208417				2022-12-25	WOS:000079191300005
J	Walter, AO; Peng, ZY; Cartwright, CA				Walter, AO; Peng, ZY; Cartwright, CA			The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism	ONCOGENE			English	Article						Src; Shp-2; tyrosine kinase; tyrosine phosphatase	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FACTOR RECEPTOR-BETA; PROTEIN-KINASE; SH3 DOMAIN; C-SRC; CELL-TRANSFORMATION; BINDING-SITE; 3T3 CELLS; FAMILY; PHOSPHORYLATION	Previously, we demonstrated that the Src tyrosine kinase interacts with the Shp-2 tyrosine phosphatase. To determine whether Shp-2 regulates Src kinase activity, we measured Src activity in cells overexpressing wild-type or catalytically-inactive C463S Shp-2, We observed a 2-3-fold increase in the specific activity of Src in both cell types and the increase did not appear to be due to dephosphorylation of Tyr 527 or phosphorylation of Tyr 416 on Src. Conversely, we observed a 2-3-fold decrease in the specific activity of Src when Shp-2 expression was inhibited. Using glutathione S-transferase-fusion proteins, we demonstrated that Shp-2 binds to the SH3 domain of Src, Our findings reveal that the Shp-2 tyrosine phosphatase can regulate the Src tyrosine kinase by a non-enzymatic mechanism. We also found that the phosphatase activity of Shp-2 immunoprecipitates is downregulated in cells transformed by Src or other proteins, and that Shp-2, preferentially associates with the membrane fraction of transformed cells. We suggest that membrane-association of Shp-2 is important for regulating Shp-2 activity.	Stanford Univ, Dept Med, Sch Med, Med Sch Lab, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, Med Sch Lab, Surge Bldg,P304, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007056, R01DK043743] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01 DK43743-07, T32 DK07056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOONG AC, 1994, CANCER RES, V54, P5273; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARK J, 1995, MOL CELL BIOL, V15, P2374; PENG ZY, 1995, ONCOGENE, V11, P1955; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	48	66	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1911	1920		10.1038/sj.onc.1202513	http://dx.doi.org/10.1038/sj.onc.1202513			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208413				2022-12-25	WOS:000079191300001
J	Parolini, I; Topa, S; Sorice, M; Pace, A; Ceddia, P; Montesoro, E; Pavan, A; Lisanti, MP; Peschle, C; Sargiacomo, M				Parolini, I; Topa, S; Sorice, M; Pace, A; Ceddia, P; Montesoro, E; Pavan, A; Lisanti, MP; Peschle, C; Sargiacomo, M			Phorbol ester-induced disruption of the CD4-Lck complex occurs within a detergent-resistant microdomain of the plasma membrane - Involvement of the translocation of activated protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; TYROSINE KINASE; SIGNAL-TRANSDUCTION; LYMPHOCYTES-T; MYRISTATE ACETATE; ANCHORED PROTEINS; CD4 RECEPTOR; COATED PITS; CAVEOLAE; DOMAINS	Recent studies have highlighted the existence of discrete microdomains at the cell surface that are distinct from caveolae. The function of these microdomains remains unknown. However, recent evidence suggests that they may participate in a subset of transmembrane signaling events. In hematopoietic cells, these low density Triton-insoluble (LDTI) microdomains (also called caveolae-related domains) are dramatically enriched in signaling molecules, such as cell surface receptors (CD4 and CD55), Src family tyrosine kinases (Lyn, Lck, Hck, and Fyn), heterotrimeric G proteins, and gangliosides (GM(1) and GM(3)). Human T lymphocytes have become a well established model system for studying the process of phorbol ester-induced down-regulation of CD4. Here, we present evidence that phorbol 12-myristate 13-acetate (PMA)-induced down-regulation of the cell surface pool of CD4 occurs within the LDTI microdomains of T cells. Localization of CD4 in LDTI microdomains was confirmed by immunoelectron microscopy,PMA-induced disruption of the CD4-Lck complex was rapid (within 5 min), and this disruption occurred within LDTI microdomains, Because PMA is an activator of protein kinase C (PKC), we next evaluated the possible roles of different PKC isoforms in this process. Our results indicate that PMA induced the rapid translocation of cytosolic PKCs to LDTI microdomains. We identified PKC alpha as the major isoform involved in this translocation event. Taken together, our results support the hypothesis that LDTI microdomains represent a functionally important plasma membrane compartment in T cells.	Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Univ La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Istituto Superiore di Sanita (ISS); University of L'Aquila; Sapienza University Rome; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Jefferson University	Sargiacomo, M (corresponding author), Ist Super Sanita, Dept Hematol Oncol, Viale Regina Elena 299, I-00161 Rome, Italy.		Sorice, Maurizio/Q-5079-2019; Sousa, Maria/HCI-9642-2022; Lisanti, Michael P/C-6866-2013; parolini, Isabella/J-9955-2016; Lisanti, Michael/B-6131-2018	parolini, Isabella/0000-0001-9863-1051; Lisanti, Michael/0000-0003-2034-1382; Sorice, Maurizio/0000-0003-3534-1502; Sargiacomo, Massimo/0000-0003-4040-706X	NCI NIH HHS [R01-CA-80250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ALEXANDER DR, 1989, IMMUNOL TODAY, V10, P200, DOI 10.1016/0167-5699(89)90325-3; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BERRY N, 1989, J IMMUNOL, V143, P1407; BIJLMAKERS MJ, 1997, J CELL BIOL, V137, P1019; BLUE ML, 1987, J IMMUNOL, V139, P3949; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DOYLE C, 1989, IMMUNOL REV, V109, P17, DOI 10.1111/j.1600-065X.1989.tb00018.x; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1994, J BIOL CHEM, V269, P30745; GAY D, 1988, P NATL ACAD SCI USA, V85, P5629, DOI 10.1073/pnas.85.15.5629; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUPTA S, 1994, ADV EXP MED BIOL, V365, P143; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HOESSLI DC, 1983, P NATL ACAD SCI-BIOL, V80, P439, DOI 10.1073/pnas.80.2.439; HOESSLI DC, 1996, CURR OPIN CELL BIOL, V8, P168; HOXIE JA, 1986, J IMMUNOL, V137, P1194; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P8, DOI 10.1093/oxfordjournals.jbchem.a123016; KISHORE K, 1998, CELL, V94, P625; LEHEL C, 1994, J BIOL CHEM, V269, P4761; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; PETERSEN CM, 1992, EXP CELL RES, V201, P160, DOI 10.1016/0014-4827(92)90360-K; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Sorice M, 1997, J LIPID RES, V38, P969; SORICE M, 1995, SCAND J IMMUNOL, V41, P148, DOI 10.1111/j.1365-3083.1995.tb03547.x; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	65	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14176	14187		10.1074/jbc.274.20.14176	http://dx.doi.org/10.1074/jbc.274.20.14176			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318836	hybrid			2022-12-25	WOS:000080322200065
J	Guo, SL; Stolz, LE; Lemrow, SM; York, JD				Guo, SL; Stolz, LE; Lemrow, SM; York, JD			SAC1-like domains of yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL POLYPHOSPHATE 5-PHOSPHATASES; PHOSPHOLIPASE-D ACTIVITY; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; VACUOLE; FAB1P; PHOSPHOINOSITIDES; IDENTIFICATION; 2ND-MESSENGER; PURIFICATION	The SAC1 gene product has been implicated in the regulation of actin cytoskeleton, secretion from the Golgi, and microsomal ATP transport; yet its function is unknown. Within SAC1 is an evolutionarily conserved 300-amino acid region, designated a SAC1-like domain, that is also present at the amino termini of the inositol polyphosphate 5-phosphatases, mammalian synaptojanin, and certain yeast INP5 gene products. Here we report that SAC1-like domains have intrinsic enzymatic activity that defines a new class of polyphosphoinositide phosphatase (PPIPase), Purified recombinant SAC1-like domains convert yeast lipids phosphatidylinositol (PI) S-phosphate, PI 4-phosphate, and PI 3,5-bisphosphate to PI, whereas PI 4,5-bisphosphate is not a substrate. Yeast lacking Sac1p exhibit 10-, 2.5-, and a-fold increases in the cellular levels of PI 4-phosphate, PI 3,5-bisphosphate, and PI 3-phosphate, respectively. The 5-phosphatase domains of synaptojanin, Inp52p, and Inp53p are also catalytic, thus representing the first examples of an inositol signaling protein with two distinct lipid phosphatase active sites within a single polypeptide chain. Together, our data provide a long sought mechanism as to how defects in Sac1p overcome certain actin mutants and bypass the requirement for yeast phosphatidylinositol/phosphatidylcholine transfer protein, Sec14p. We demonstrate that PPIPase activity is a key regulator of membrane trafficking and actin cytoskeleton organization and suggest signaling roles for phosphoinositides other than PI 4,5-bisphosphate in these processes. Additionally, the tethering of PPIPase and B-phosphatase activities indicate a novel mechanism by which concerted phosphoinositide hydrolysis participates in membrane trafficking.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University	York, JD (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL 55672] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; ERNEUX G, 1998, BIOCHIM BIOPHYS ACTA, V1436, P185; ESTEVEZ F, 1994, BIOCHEM J, V302, P709, DOI 10.1042/bj3020709; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; HOPE HMR, 1994, J BIOL CHEM, V269, P23648; Kandzari D E, 1996, Subcell Biochem, V26, P97; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; NOVICK P, 1989, GENETICS, V121, P659; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Stolz LE, 1998, GENETICS, V148, P1715; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346	38	296	304	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12990	12995		10.1074/jbc.274.19.12990	http://dx.doi.org/10.1074/jbc.274.19.12990			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224048	hybrid			2022-12-25	WOS:000080200400010
J	Mukherjee, S; Palczewski, K; Gurevich, VV; Hunzicker-Dunn, M				Mukherjee, S; Palczewski, K; Gurevich, VV; Hunzicker-Dunn, M			beta-arrestin-dependent desensitization of luteinizing hormone choriogonadotropin receptor is prevented by a synthetic peptide corresponding to the third intracellular loop of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN ADENYLATE-CYCLASE; HUMAN BETA-2-ADRENERGIC RECEPTOR; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; GONADOTROPIN RECEPTOR; CYTOPLASMIC DOMAINS; GRANULOSA-CELLS; LIGAND-BINDING; CORPUS-LUTEUM; LH RECEPTORS; ACTIVATE GS	Desensitization is a ubiquitous response of guanine nucleotide-binding protein-coupled receptors (GPCRs) characterized by the waning of effector activity despite continued presence of agonist, Binding of an arrestin to the activated, often phosphorylated GPCR triggers desensitization. We reported for the luteinizing hormone/choriogonadotropin receptor (LH/CG R) that beta-arrestin tightly bound to porcine ovarian follicular membranes mediates agonist-dependent desensitization of LH/CG R-stimulated adenylyl cyclase (AC) activity (Mukherjee, S,, Palczewski, K,, Gurevich, V, V., Benovic, J, L,, Banga, J, P., and Hunzicker-Dunn, M. (1999) Proc. Natl, Acad, Sci. U, S, A. 96, 493-498). We now show that addition of a synthetic peptide corresponding to the entire third intracellular loop (3i) of the LH/CG R completely and specifically reverses desensitization of AC activity, with an ED50 of 10 mu M but does not modulate basal, hCG-stimulated, or forskolin-stimulated AC activities. beta-Arrestin binds selectively to the 3i peptide coupled to activated Sepharose, Desensitization of LH/CG R-stimulated AC activity is rescued when the 3i peptide is preincubated with exogenous beta-arrestin, These results show that endogenous beta-arrestin participates in cell-free desensitization of agonist-dependent LH/CG R-stimulated AC activity in follicular membranes by interacting directly with the 3i loop of the receptor, thereby preventing G(s) activation.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Univ Washington, Sch Med, Dept Ophthalmol Pharmacol & Chem, Seattle, WA 98195 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Res, Sun City, AZ 85372 USA	Northwestern University; University of Washington; University of Washington Seattle; Banner Research; Banner Health; Banner Sun Health Research Institute	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [R01 EY 09339, R01 EY 11500] Funding Source: Medline; NICHD NIH HHS [P01 HD 21921] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011500, R01EY009339] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abell AN, 1997, J BIOL CHEM, V272, P14586, DOI 10.1074/jbc.272.23.14586; Abell AN, 1998, MOL ENDOCRINOL, V12, P1857, DOI 10.1210/me.12.12.1857; AMSTERDAM A, 1980, P NATL ACAD SCI-BIOL, V77, P3440, DOI 10.1073/pnas.77.6.3440; Beau I, 1998, J BIOL CHEM, V273, P18610, DOI 10.1074/jbc.273.29.18610; BENDER FE, 1982, STAT METHODS FOOD AG; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; Chan WY, 1998, MOL GENET METAB, V63, P75, DOI 10.1006/mgme.1997.2650; CONTI M, 1976, J BIOL CHEM, V251, P7729; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1992, J BIOL CHEM, V267, P22183; EKSTROM RC, 1990, ENDOCRINOLOGY, V127, P2578, DOI 10.1210/endo-127-5-2578; EKSTROM RC, 1990, ENDOCRINOLOGY, V126, P1191, DOI 10.1210/endo-126-2-1191; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; EZRA E, 1980, J BIOL CHEM, V255, P653; EZRA E, 1981, J BIOL CHEM, V256, P5377; FERGUSON SSG, 1996, CAN J PHYSL PHARM, V74, P1094; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUNZICKERDUNN M, 1981, BIOL REPROD, V24, P279, DOI 10.1095/biolreprod24.2.279; HUNZICKERDUNN M, 1981, ENDOCRINOLOGY, V109, P345, DOI 10.1210/endo-109-2-345; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P185, DOI 10.1210/endo-99-1-185; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P198, DOI 10.1210/endo-99-1-198; JONASSEN JA, 1980, ENDOCRINOLOGY, V106, P1786, DOI 10.1210/endo-106-6-1786; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; LAMM MLG, 1994, ENDOCRINOLOGY, V134, P1745, DOI 10.1210/en.134.4.1745; LAMM MLG, 1994, MOL ENDOCRINOL, V8, P1537, DOI 10.1210/me.8.11.1537; LAMPRECHT SA, 1977, J CYCLIC NUCL PROT, V3, P69; LAMPRECHT SA, 1973, J ENDOCRINOL, V57, P217, DOI 10.1677/joe.0.0570217; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH JM, 1973, BIOCHIM BIOPHYS ACTA, V304, P197, DOI 10.1016/0304-4165(73)90128-1; MARSH JM, 1970, J BIOL CHEM, V245, P1596; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Meduri G, 1996, J ENDOCRINOL, V148, P435, DOI 10.1677/joe.0.1480435; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P4201; Rajagopalan-Gupta RM, 1999, ENDOCRINOLOGY, V140, P1612, DOI 10.1210/en.140.4.1612; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; SCHWALL RH, 1984, ENDOCRINOLOGY, V114, P1114, DOI 10.1210/endo-114-4-1114; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WONG SKF, 1990, J BIOL CHEM, V265, P6219; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; ZOR U, 1976, BIOCHIM BIOPHYS ACTA, V428, P761, DOI 10.1016/0304-4165(76)90206-3	54	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					12984	12989		10.1074/jbc.274.19.12984	http://dx.doi.org/10.1074/jbc.274.19.12984			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224047	hybrid			2022-12-25	WOS:000080200400009
J	Prezeau, L; Richman, JG; Edwards, SW; Limbird, LE				Prezeau, L; Richman, JG; Edwards, SW; Limbird, LE			The zeta isoform of 14-3-3 proteins interacts with the third intracellular loop of different alpha(2)-adrenergic receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; AGONIST-PROMOTED DESENSITIZATION; CANINE KIDNEY-CELLS; ADRENERGIC-RECEPTOR; ALPHA(2A)-ADRENERGIC RECEPTOR; ALPHA-2-ADRENERGIC RECEPTORS; BASOLATERAL MEMBRANE; COUPLED RECEPTORS; BINDING PROTEINS; NA+/H+ EXCHANGE	The alpha(2)-adrenergic receptors (alpha(2)ARs) are localized to and function on the basolateral surface in polarized renal epithelial cells via a mechanism involving the third cytoplasmic loop. To identify proteins that may contribute to this retention, [S-35]Met-labeled Gen10 fusion proteins with the 3i loops of the alpha(2A)AR (Val(217)-Ala(377)), alpha(2B)AR (Lys(210)-Trp(354)) and alpha(2C)AR (Arg(248)-Val(363)) were used as ligands in gel overlay assays. A protein doublet of similar to 30 kDa in Madin-Darby canine kidney cells or pig brain cytosol (alpha(2B) greater than or equal to alpha(2C) >> alpha(2A)) was identified. The interacting protein was purified by sequential DEAE and size exclusion chromatography, and subsequent microsequencing revealed that they are the zeta isoform of 14-3-3 proteins. [S-35]Met-14-3-3 zeta binds to all three native alpha(2)AR subtypes, assessed using a solid phase binding assay (alpha(2A) greater than or equal to alpha(2B) > alpha(2C)), and this binding depends on the presence of the 3i loops. Attenuation of the alpha(2)AR-14-3-3 interactions in the presence of a phosphorylated Raf-l peptide corresponding to its 14-3-3 interacting domain (residues 251-266), but not by its non-phosphorylated counterpart, provides evidence for the functional specificity of these interactions and suggests one potential interface for the alpha(2)AR and 14-3-3 interactions. These studies represent the first evidence for G protein-coupled receptor interactions with 14-3-3 proteins and may provide a mechanism for receptor localization and/or coordination of signal transduction.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Rm 468, Nashville, TN 37232 USA.	Lee.Limbird@mcmail.vanderbilt.edu		Edwards, Stephen/0000-0002-7985-111X	NIDDK NIH HHS [DK13499, DK15658, DK 43185] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, R01DK015658, R13DK043185, R01DK013499] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; EASON MG, 1992, J BIOL CHEM, V267, P25473; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GUYER CA, 1990, J BIOL CHEM, V265, P17307; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HERTEL C, 1990, J BIOL CHEM, V265, P17988; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; Jinsi A, 1996, EUR J PHARMACOL, V302, P183, DOI 10.1016/0014-2999(96)00049-0; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NUNNARI JM, 1987, J BIOL CHEM, V262, P12387; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; RICHMAN JG, 1998, AM J PHYSIOL, V43, pC654; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; Wade SM, 1996, MOL PHARMACOL, V50, P351; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	57	75	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13462	13469		10.1074/jbc.274.19.13462	http://dx.doi.org/10.1074/jbc.274.19.13462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224112	hybrid			2022-12-25	WOS:000080200400074
J	Pazirandeh, A; Xue, YT; Rafter, I; Sjovall, J; Jondal, M; Okret, S				Pazirandeh, A; Xue, YT; Rafter, I; Sjovall, J; Jondal, M; Okret, S			Paracrine glucocorticoid activity produced by mouse thymic epithelial cells	FASEB JOURNAL			English	Article						steroid biosynthesis; thymocyte development; cytochrome P450; reporter cells; paracrine signaling	NEGATIVE SELECTION; POSITIVE SELECTION; TRANSGENIC MICE; RECEPTOR; APOPTOSIS; THYMOCYTES; NEUROSTEROIDS; ANTAGONIST; EXPRESSION; SYSTEM	Previous data have suggested that glucocorticoids (GCs) are involved in the differentiation of thymocytes into mature T cells, In this report we demonstrate that the mouse thymic epithelial cells (TEC) express the cytochrome P450 hydroxylases Cyp11A1, Cyp21, and Cyp11B1, These enzymes, in combination with 3 beta-hydroxysteroid dehydrogenase (3 beta HSD), convert cholesterol into corticosterone, the major GC in rodents. In addition, when TEC were cocultured with 'reporter cells' containing the glucocorticoid receptor (GR) and a GR-dependent reporter gene, a specific induction of reporter gene activity was observed, Induction of reporter gene activity was blocked when the TEC and reporter cells were incubated in the presence of the Cyp11B1 inhibitor metyrapone or the 3 beta HSD inhibitor trilostane, as well as by the GR antagonist RU486, Coculturing of TEC with thymocytes induced apoptosis in the latter, which was partially blocked by the enzyme inhibitors and RU486, We conclude that TEC secrete a GC hormone activity and suggest a paracrine role for this in thymocyte development.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, Novum F60, S-14186 Huddinge, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, MBB, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Okret, S (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, Novum F60, S-14186 Huddinge, Sweden.							AIRD F, 1993, P NATL ACAD SCI USA, V90, P7104, DOI 10.1073/pnas.90.15.7104; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BATANERO E, 1992, BRAIN BEHAV IMMUN, V6, P249, DOI 10.1016/0889-1591(92)90047-R; Baulieu E E, 1997, Aging (Milano), V9, P12; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELL DA, 1991, NUCLEIC ACIDS RES, V19, P5079, DOI 10.1093/nar/19.18.5079; Bevan MJ, 1997, IMMUNITY, V7, P175, DOI 10.1016/S1074-7613(00)80520-8; BLALOCK JE, 1994, IMMUNOLOGIST, V2, P8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cascio C, 1998, P NATL ACAD SCI USA, V95, P2862, DOI 10.1073/pnas.95.6.2862; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; ERNST B, 1995, J EXP MED, V182, P961, DOI 10.1084/jem.182.4.961; Ernst BB, 1996, J EXP MED, V183, P1235, DOI 10.1084/jem.183.3.1235; FELTEN SY, 1992, NEUROIMMUNOENDOCRINO, V52, P25; FERLINI C, 1995, CYTOMETRY, V21, P282; GUENNOUN R, 1995, MOL BRAIN RES, V30, P287, DOI 10.1016/0169-328X(95)00016-L; HAAPARANTA T, 1982, BIOCHIM BIOPHYS ACTA, V716, P79, DOI 10.1016/0304-4165(82)90205-7; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JANEWAY C, 1992, Current Biology, V2, P26, DOI 10.1016/0960-9822(92)90419-B; JONDAL M, 1993, EUR J IMMUNOL, V23, P1246, DOI 10.1002/eji.1830230608; Jondal M, 1995, Curr Top Microbiol Immunol, V200, P67; JONDAL M, 1993, EUR J IMMUNOL, V23, P2734; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Lewis JC, 1998, ANAL CHEM, V70, p579A, DOI 10.1021/ac9819638; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Miller WL., 1995, ENDOCRINOL METAB, P555; MORALE MC, 1995, ENDOCRINOLOGY, V136, P3949, DOI 10.1210/en.136.9.3949; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; Sambrook J., 2002, MOL CLONING LAB MANU; Schreiber L, 1996, SCAND J IMMUNOL, V44, P314, DOI 10.1046/j.1365-3083.1996.d01-312.x; Schumacher M, 1996, DEV NEUROSCI-BASEL, V18, P6, DOI 10.1159/000111391; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; SKINNER MA, 1992, INT J DEV BIOL, V36, P573; STROMSTEDT M, 1995, MOL BRAIN RES, V34, P75, DOI 10.1016/0169-328X(95)00140-N; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Vacchio M S, 1996, Behring Inst Mitt, P24; Vacchio MS, 1997, J EXP MED, V185, P2033, DOI 10.1084/jem.185.11.2033; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; VONBOEHMER H, 1997, IMMUNOLOGIST, V5, P185; WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307; Xue YT, 1996, EUR J IMMUNOL, V26, P428, DOI 10.1002/eji.1830260224; Zhang J, 1997, BIOCHEM J, V322, P175, DOI 10.1042/bj3220175; Zilberman Y, 1996, CELL IMMUNOL, V170, P78, DOI 10.1006/cimm.1996.0136	50	102	105	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					893	901		10.1096/fasebj.13.8.893	http://dx.doi.org/10.1096/fasebj.13.8.893			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224232	Bronze			2022-12-25	WOS:000080372500012
J	Pacheco-Rodriguez, G; Patton, WA; Adamik, R; Yoo, HS; Lee, FJS; Zhang, GF; Moss, J; Vaughan, M				Pacheco-Rodriguez, G; Patton, WA; Adamik, R; Yoo, HS; Lee, FJS; Zhang, GF; Moss, J; Vaughan, M			Structural elements of ADP-ribosylation factor 1 required for functional interaction with cytohesin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GTP-BINDING PROTEIN; SEC7 DOMAIN; CHOLERA-TOXIN; PHOSPHOLIPASE-D; GOLGI-COMPLEX; FACTOR ARNO; ARF GTPASE; ACTIVATION; TRANSPORT	ADP-ribosylation factor 1 (ARF1) is a 20-kDa guanine nucleotide-binding protein involved in vesicular trafficking. Conversion of inactive ARF-G;DP to active ARF-GTP is catalyzed by guanine nucleotide exchange proteins such as cytohesin-1. Cytohesin-1 and its Sec7 domain (C-1Sec7) exhibit guanine nucleotide exchange protein activity with ARF1 but not ARF-like protein 1 (ARL1), which is 57% identical in amino acid sequence. With chimeric proteins composed of ARF1 (F) and ARL1 (L) sequences we identified three structural elements responsible for this specificity. Cytohesin-1 increased [S-35]guanosine 5'-(gamma-thio)triphosphate binding to L28/F first 28 residues of L, remainder Fl and to a much lesser extent F139L, and mut13F139/L (F139/L with random sequence in the first 13 positions) but not Delta 13ARF1 that lacks the first 13 amino acids; therefore, a nonspecific ARF N terminus was required for cytohesin-1 action. The N terminus was not, however, required for that of C-1Sec7. Both C-1Sec7 and cytohesin-1 effectively released guanosine 5'-(gamma-thio)triphosphate from ARF1, but only C-1Sec7 displaced the nonhydrolyzable GTP analog bound to mut13F139/L, again indicating that structure in addition to the Sec7 domain is involved in cytohesin-1 interaction. Some element(s) of the C-terminal region is also involved, because replacement of the last 42 amino acids with ARL sequence in F139L decreased markedly the interaction with cytohesin-1. Participation of both termini is consistent with the crystallographic structure of ARF in which the two terminal a-helices are in close proximity. ARF1 residues 28-50 are also important in the interaction with cytohesin-1; replacement of Lys-38 with Gin, the corresponding residue in ARL1, abolished the ability to serve as substrate for cytohesin-1 or C-1Sec7. These studies have defined multiple structural elements in ARF1, including switch 1 and the N and C termini, that participate in functional interactions with cytohesin-1 (or its catalytic domain C-1Sec7), which were not apparent from crystallographic analysis.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Pacheco-Rodriguez, G (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.		Pacheco, Gustavo/Q-6956-2019	LEE, FANG-JEN/0000-0002-2167-2426	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000638, ZIAHL000627, Z01HL000656, Z01HL000627] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Hong JX, 1998, J BIOL CHEM, V273, P15872, DOI 10.1074/jbc.273.25.15872; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1992, J BIOL CHEM, V267, P13039; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Liang JO, 1997, J BIOL CHEM, V272, P33001, DOI 10.1074/jbc.272.52.33001; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Losonczi JA, 1998, BIOCHEMISTRY-US, V37, P706, DOI 10.1021/bi9717791; Lowe SL, 1996, J CELL SCI, V109, P209; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PATTON WA, 1997, BACTERIAL TOXINS TOO, P15; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Vitale N, 1997, J BIOL CHEM, V272, P25077, DOI 10.1074/jbc.272.40.25077; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	48	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12438	12444		10.1074/jbc.274.18.12438	http://dx.doi.org/10.1074/jbc.274.18.12438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212218	hybrid			2022-12-25	WOS:000080056800038
J	Parsley, TB; Cornell, CT; Semler, BL				Parsley, TB; Cornell, CT; Semler, BL			Modulation of the RNA binding and protein processing activities of poliovirus polypeptide 3CD by the viral RNA polymerase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; CLEAVAGE SITES; REPLICATION; PRECURSOR; POLYPROTEIN; MUTATIONS; COMPLEX; INVITRO; TRANSLATION; EXPRESSION	To study the role of the RNA polymerase domain (3D) in the proteinase substrate recognition and RNA binding properties of poliovirus polypeptide 3CD, we generated recombinant 3C and 3CD polypeptides and purified them to near homogeneity. By using these purified proteins in in vitro cleavage assays with structural and non-structural viral polyprotein substrates, we found that 3CD processes the poliovirus structural polyprotein precursor (P1) 100 to 1000 times more efficiently than 3C processes P1, We also found that trans-cleavage of other 3CD molecules and sites within the non-structural P3 precursor is more efficiently mediated by 3CD than 3C, However, 3C and 3CD appear to be equally efficient in the processing of a non-structural polyprotein precursor, 2C3AB, Four mutated 3CD polyproteins with site-directed lesions in the 3D domain of the proteinase were analyzed for their ability to process viral polyprotein precursors and to form a ternary complex with RNA sequences encoded in the 5' terminus of the viral genome. Analysis of mutated 3CD polypeptides revealed that specific mutations within the 3D amino acid sequences of 3CD confer differential effects on 3CD activity. All four mutated 3CD proteins tested were able to process the P1 structural precursor with wild type or near wild type efficiency. However, three of the mutated enzymes demonstrated an impaired ability to process some sites within the P3 non-structural precursor, relative to wild type 3CD, One of the mutant 3CD polypeptides, 3CD-3DK127A, also displayed a defect in its ability to form a ternary ribonucleoprotein complex with poliovirus 5' RNA sequences.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine	Semler, BL (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.	blsemler@uci.edu	Semler, Bert/AAV-8795-2020	Semler, Bert/0000-0002-2424-5155	NIAID NIH HHS [R01 AI022693, AI 22693] Funding Source: Medline; NIGMS NIH HHS [GM 07311] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022693] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Barton DJ, 1996, VIROLOGY, V217, P459, DOI 10.1006/viro.1996.0140; Blair WS, 1998, RNA, V4, P215; Blair WS, 1996, VIROLOGY, V218, P1, DOI 10.1006/viro.1996.0160; BROWN BA, 1979, VIROLOGY, V97, P396, DOI 10.1016/0042-6822(79)90350-7; BURNS CC, 1992, VIROLOGY, V189, P568, DOI 10.1016/0042-6822(92)90580-I; BURNS CC, 1989, J VIROL, V63, P4866, DOI 10.1128/JVI.63.11.4866-4874.1989; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; HANECAK R, 1982, P NATL ACAD SCI-BIOL, V79, P3973, DOI 10.1073/pnas.79.13.3973; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN GR, 1982, J VIROL, V41, P340, DOI 10.1128/JVI.41.1.340-344.1982; LAWSON MA, 1990, CURR TOP MICROBIOL, V161, P49; LAWSON MA, 1991, P NATL ACAD SCI USA, V88, P9919, DOI 10.1073/pnas.88.22.9919; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306; NELSON M, 1992, METHOD ENZYMOL, V216, P279; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; PALLANSCH MA, 1984, J VIROL, V49, P873, DOI 10.1128/JVI.49.3.873-880.1984; Parsley TB, 1997, RNA, V3, P1124; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; SEMLER BL, 1987, J CELL BIOCHEM, V33, P39, DOI 10.1002/jcb.240330105; SEMLER BL, 1981, P NATL ACAD SCI-BIOL, V78, P3464, DOI 10.1073/pnas.78.6.3464; SEMLER BL, 1981, VIROLOGY, V114, P589, DOI 10.1016/0042-6822(81)90242-7; Todd S, 1997, VIROLOGY, V229, P90, DOI 10.1006/viro.1996.8416; Towner JS, 1998, J VIROL, V72, P7191, DOI 10.1128/JVI.72.9.7191-7200.1998; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Xiang WK, 1997, SEMIN VIROL, V8, P256, DOI 10.1006/smvy.1997.0128; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9; YPMAWONG MF, 1988, J BIOL CHEM, V263, P17846	35	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12867	12876		10.1074/jbc.274.18.12867	http://dx.doi.org/10.1074/jbc.274.18.12867			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212275	hybrid			2022-12-25	WOS:000080056800095
J	Sternsdorf, T; Jensen, K; Reich, B; Will, H				Sternsdorf, T; Jensen, K; Reich, B; Will, H			The nuclear dot protein Sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; GTPASE-ACTIVATING PROTEIN; PML-RAR-ALPHA; NF-KAPPA-B; RETINOIC ACID; SUMO-1 MODIFICATION; COVALENT MODIFICATION; GROWTH-SUPPRESSOR; ARSENIC TRIOXIDE	The Sp100 and promyelocytic leukemia proteins (PML) are constituents of nuclear domains, known as nuclear dots (NDs) or PML bodies, and are both covalently modified by the small ubiquitin-related protein SUMO-1. NDs play a role in autoimmunity, virus infections, and in the etiology of acute promyelocytic leukemia. To date, little is known about the function of the Sp100 protein. Here we analyzed Sp100 domains that determine its subcellular localization, dimerization, and SUMOylation. A functional nuclear localization signal and an ND-targeting region that coincides with an Sp100 homodimerization domain were mapped. Sequences similar to the Sp100 homodimerization/ND-targeting region occur in several other proteins and constitute a novel protein motif, termed HSR domain. The lysine residue of the Sp100 protein, to which SUMO-1 is covalently linked, was mapped within and may therefore modulate the previously described HP1 protein-binding site. A consensus sequence for SUMOylation of proteins in general is suggested. SUMOylation strictly depended on a functional nuclear localization signal but was not necessary for nuclear import or ND targeting. A three-dimensional structure of Sp100, which supports the mapping data and provides additional information on Sp100 structure/function relationships, was generated by computer modeling. Taken together, our studies indicate the existence of well defined Sp100 domains with functions in ND targeting, nuclear import, nuclear SUMOylation, and protein-protein interaction.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Sternsdorf, T (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	sternsdo@hpi.uni-hamburg.de						Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; AHN MJ, 1995, ONCOGENE, V10, P2307; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; Andre C, 1996, EXP CELL RES, V229, P253, DOI 10.1006/excr.1996.0368; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; BERNSTEIN RM, 1984, CLIN EXP IMMUNOL, V55, P553; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1996, BLOOD, V88, P1052; DANIEL MT, 1993, BLOOD, V82, P1858; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Dent AL, 1996, BLOOD, V88, P1423, DOI 10.1182/blood.V88.4.1423.bloodjournal8841423; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ECKERT WA, 1991, MOL CELL BIOL, V11, P2229, DOI 10.1128/MCB.11.4.2229; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Gibson TJ, 1998, TRENDS BIOCHEM SCI, V23, P242, DOI 10.1016/S0968-0004(98)01231-6; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Grotzinger T, 1996, MOL CELL BIOL, V16, P1150; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Guldner HH, 1999, J CELL SCI, V112, P733; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KADEREIT S, 1993, J BIOL CHEM, V268, P24432; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; Kwong YL, 1997, BLOOD, V89, P3487, DOI 10.1182/blood.V89.9.3487; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okura T, 1996, J IMMUNOL, V157, P4277; PLASS C, 1995, HEREDITAS, V122, P245, DOI 10.1111/j.1601-5223.1995.00245.x; POWELL F, 1984, LANCET, V1, P288; RASKA I, 1992, CELL BIOL INT REP, V16, P771, DOI 10.1016/S0309-1651(05)80021-9; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Sambrook J, 1989, MOL CLONING LAB MANU, V3; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1997, J CELL BIOL, V138, P435, DOI 10.1083/jcb.138.2.435; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; STERNSDORF T, 1995, SCAND J IMMUNOL, V42, P257, DOI 10.1111/j.1365-3083.1995.tb03652.x; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1992, J CELL SCI, V101, P773; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; SZOSTECKI C, 1992, SCAND J IMMUNOL, V36, P555, DOI 10.1111/j.1365-3083.1992.tb03224.x; SZOSTECKI C, 1987, CLIN EXP IMMUNOL, V68, P108; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Weichenhan D, 1998, CYTOGENET CELL GENET, V80, P226, DOI 10.1159/000014985; Weichenhan D, 1997, GENOMICS, V43, P298, DOI 10.1006/geno.1997.4834; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170	73	215	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12555	12566		10.1074/jbc.274.18.12555	http://dx.doi.org/10.1074/jbc.274.18.12555			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212234	hybrid			2022-12-25	WOS:000080056800054
J	Vogler, O; Nolte, B; Voss, M; Schmidt, M; Jakobs, KH; van Koppen, CJ				Vogler, O; Nolte, B; Voss, M; Schmidt, M; Jakobs, KH; van Koppen, CJ			Regulation of muscarinic acetylcholine receptor sequestration and function by beta-arrestin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; SYNERGISTIC REGULATION; NEUROBLASTOMA-CELLS; PLASMA-MEMBRANE; PROTEIN-KINASE; INTERNALIZATION; RESENSITIZATION; DYNAMIN; DESENSITIZATION; PHOSPHORYLATION	After activation, agonist-occupied G; protein-coupled receptors are phosphorylated by G protein-coupled receptor kinases and bind cytosolic beta-arrestins, which uncouple the receptors from their cognate G;proteins, Recent studies on the beta(2)-adrenerse receptor have demonstrated that beta-arrestin also targets the receptors to clathrin-coated pits for subsequent internalization and activation of mitogen-activated protein kinases, We and others have previously shown that muscarinic acetylcholine receptors (mAChRs) of the mi, m3, and m4 subtype require functional dynamin to sequester into HEK-293 tsA201 cells, whereas m2 mAChRs sequester in a dynamin-independent manner. To investigate the role of beta-arrestin in mAChR sequestration, we determined the effect of overexpressing beta-arrestin-1 and the dominant-negative inhibitor of beta-arrestin-mediated receptor sequestration, beta-arrestin-1 V53D, on mAChR sequestration and function. Sequestration of mi, m3, and m4 mAChRs was suppressed by 60-75% in cells overexpressing beta-arrestin-1 V53D, whereas m2 mAChR sequestration was affected by less than 10%. In addition, overexpression of beta-arrestin-1 V53D as well as dynamin K44A significantly suppressed mi mAChR-mediated activation of mitogen-activated protein kinases, Finally, we investigated whether mAChRs sequester into clathrin-coated vesicles by overexpressing Hub, a dominant-negative clathrin mutant. Although sequestration of mi, m3, and m4 mAChRs was inhibited by 50-70%, m2 mAChR sequestration was suppressed by less than 10%, We conclude that mi, m3, and m4 mAChRs expressed in HEK-293 tsA201 cells sequester into clathrin-coated vesicles in a beta-arrestin- and dynamin-dependent manner, whereas sequestration of m2 mAChRs in these cells is largely independent of these proteins.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany	University of Duisburg Essen	van Koppen, CJ (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany.		Vögler, Oliver/D-7658-2011					Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; Szekeres PG, 1998, J NEUROCHEM, V70, P1694; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VANKOPPEN CJ, 1993, BIOCHIM BIOPHYS ACTA, V1173, P342, DOI 10.1016/0167-4781(93)90135-Z; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YANG J, 1995, MOL PHARMACOL, V48, P477; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	35	98	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12333	12338		10.1074/jbc.274.18.12333	http://dx.doi.org/10.1074/jbc.274.18.12333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212203	hybrid			2022-12-25	WOS:000080056800023
J	Gamper, M; Kim, E; Howard, PK; Ma, H; Hunter, T; Firtel, RA				Gamper, M; Kim, E; Howard, PK; Ma, H; Hunter, T; Firtel, RA			Regulation of Dictyostelium protein-tyrosine phosphatase-3 (PTP3) through osmotic shock and stress stimulation and identification of pp130 as a PTP3 substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATF1 TRANSCRIPTION FACTOR; MAP KINASE CASCADE; FISSION YEAST; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; AP-1 ACTIVITY; MYOSIN-II; PHOSPHORYLATION; DISCOIDEUM	Osmotic shock and growth-medium stimulation of Dictyostelium cells results in rapid cell rounding, a reduction in cell volume, and a rearrangement of the cytoskeleton that leads to resistance to osmotic shock. Osmotic shock induces the activation of guanylyl cyclase, a rise in cGMP mediating the phosphorylation of myosin II, and the tyrosine phosphorylation of actin and the similar to 130-kDa protein (p130), We present data suggesting that signaling pathways leading to these different responses are, at least in part, independent. We show that a variety of stresses induce the SerPThr phosphorylation of the protein-tyrosine phosphatase-3 (PTP3), This modification does not alter PTP3 catalytic activity but correlates with its translocation from the cytosol to subcellular structures that co-localize to endosomal vesicles. This translocation is independent of PTP3 activity. Mutation of the catalytically essential Cys to a Ser results in inactive PTP3 that forms a stable complex with tyrosine-phosphorylated p130 (pp130) in vivo and in vitro, suggesting that PTP3 has a substrate specificity for pp130. The data suggest that stresses activate several interacting signaling pathways controlled by Ser/Thr and Tyr phosphorylation, which, along with the activation of guanylyl cyclase, mediate the ability of this organism to respond to adverse changes in the external environment.	Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA; Salk Inst Biol Studies, Mol Biol & Virol Lab, San Diego, CA 92186 USA	University of California System; University of California San Diego; Salk Institute	Firtel, RA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Biol, Rm 225,9500 Gilman Dr, La Jolla, CA 92093 USA.	rafirtel@ucsd.edu						AbuElneel K, 1996, J BIOL CHEM, V271, P977, DOI 10.1074/jbc.271.2.977; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CHENG HC, 1992, J BIOL CHEM, V267, P9248; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dembinsky A, 1996, J CELL BIOL, V134, P911, DOI 10.1083/jcb.134.4.911; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; Gamper M, 1996, MOL CELL BIOL, V16, P2431; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOWARD PK, 1993, SCIENCE, V259, P241, DOI 10.1126/science.7678470; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; JUNGBLUTH A, 1994, J CELL SCI, V107, P117; JUNGBLUTH A, 1995, FEBS LETT, V375, P87, DOI 10.1016/0014-5793(95)01165-B; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Kuwayama H, 1996, SCIENCE, V271, P207, DOI 10.1126/science.271.5246.207; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; Ma H, 1997, EMBO J, V16, P4317, DOI 10.1093/emboj/16.14.4317; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANN SKO, 1987, MOL CELL BIOL, V7, P458, DOI 10.1128/MCB.7.1.458; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MIZUNO T, 1982, J BIOL CHEM, V257, P13692; Oyama M, 1996, J BIOL CHEM, V271, P5574; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Schuster SC, 1996, EMBO J, V15, P3880, DOI 10.1002/j.1460-2075.1996.tb00762.x; SCHWEIGER A, 1992, J CELL SCI, V102, P601; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Temesvari LA, 1996, J CELL SCI, V109, P663; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Woodgett JR, 1996, PHILOS T R SOC B, V351, P135, DOI 10.1098/rstb.1996.0009; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007; Zhu QL, 1997, P NATL ACAD SCI USA, V94, P7308, DOI 10.1073/pnas.94.14.7308	48	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12129	12138		10.1074/jbc.274.17.12129	http://dx.doi.org/10.1074/jbc.274.17.12129			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207040	hybrid			2022-12-25	WOS:000079834800096
J	Kang, S; Lee, H; Han, JS; Hwang, DS				Kang, S; Lee, H; Han, JS; Hwang, DS			Interaction of SeqA and Dam methylase on the hemimethylated origin of Escherichia coli chromosomal DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH CORRECTION; INITIATION; PROTEIN; METHYLTRANSFERASE; GENE; PROMOTER; MUTANTS; EXPRESSION; SEQUENCE; PREVENTS	Preferential binding of SeqA protein to hemimethylated oriC, the origin of Escherichia coli chromosomal replication, delays methylation by Dam methylase. Because the SeqA-oriC interaction appears to be essential in timing of chromosomal replication initiation, the biochemical functions of SeqA protein and Dam methylase at the 13-mer L, M, and R region containing 4 GATC sequences at the left end of oriC were examined. We found that SeqA protein preferentially bound hemimethylated 13-mers but not fully nor unmethylated 13-mers. Regardless of strand methylation, the binding of SeqA protein to the hemimethylated GATC sequence of 13-mer L was followed by additional binding to other hemimethylated GATC sequences of 13-mer M and R. On the other hand, Dam methylase did not discriminate binding of 13-mers in different methylation patterns and was not specific to GATC sequences. The binding specificity and higher affinity of SeqA protein over Dam methylase to the hemimethylated 13-mers along with the reported cellular abundance of this protein explains the dominant action of SeqA protein over Dam methylase to the newly replicated oriC for the sequestration of chromosomal replication. Furthermore, SeqA protein bound to hemimethylated 13-mers was not dissociated by Dam methylase, and most SeqA protein spontaneously dissociated 10 min after binding. Also, SeqA protein delayed the in vitro methylation of hemimethylated 13-mers by Dam methylase. These in vitro results suggest that the intrinsic binding instability of SeqA protein results in release of sequestrated hemimethylated oriC.	Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Dept Microbiol, Seoul 151742, South Korea; Seoul Natl Univ, Interdisciplinary Program Genet Engn, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Hwang, DS (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea.			Kang, Sukhyun/0000-0002-7567-0231				BALE A, 1979, MUTAT RES, V59, P157, DOI 10.1016/0027-5107(79)90153-2; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Boye E, 1996, P NATL ACAD SCI USA, V93, P12206, DOI 10.1073/pnas.93.22.12206; BOYE E, 1992, J BACTERIOL, V174, P1682, DOI 10.1128/jb.174.5.1682-1685.1992; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAUN RE, 1986, MOL GEN GENET, V202, P246, DOI 10.1007/BF00331644; BRENDLER T, 1995, EMBO J, V14, P4083, DOI 10.1002/j.1460-2075.1995.tb00080.x; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HATTMAN S, 1982, P NATL ACAD SCI-BIOL, V79, P5518, DOI 10.1073/pnas.79.18.5518; HERMAN GE, 1982, J BIOL CHEM, V257, P2605; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1988, J BIOL CHEM, V263, P10633; KIMURA T, 1989, MOL GEN GENET, V219, P69, DOI 10.1007/BF00261159; Kornberg A., 1992, DNA REPLICATION; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; Lee YS, 1997, J BIOL CHEM, V272, P83; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MARINUS MG, 1973, J BACTERIOL, V114, P1143, DOI 10.1128/JB.114.3.1143-1150.1973; MARINUS MG, 1996, ESCHERICHIA COLI SAL, V1, P782; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; NWOSU VU, 1992, BIOCHEM J, V283, P745, DOI 10.1042/bj2830745; Papavassiliou AG., 1994, DNA-protein interactions, P43, DOI 10.1385/0-89603-256-6:43; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Sambrook J., 2002, MOL CLONING LAB MANU; SLASTER S, 1995, CELL, V82, P927; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, V2, P1555; WAGNER R, 1976, P NATL ACAD SCI USA, V73, P4135, DOI 10.1073/pnas.73.11.4135; Wold S, 1998, EMBO J, V17, P4158, DOI 10.1093/emboj/17.14.4158; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	34	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11463	11468		10.1074/jbc.274.17.11463	http://dx.doi.org/10.1074/jbc.274.17.11463			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206949	hybrid			2022-12-25	WOS:000079834800005
J	Theodorakis, NG; Drujan, D; De Maio, A				Theodorakis, NG; Drujan, D; De Maio, A			Thermotolerant cells show an attenuated expression of Hsp70 after heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROTEIN-SYNTHESIS; TRANSLATIONAL THERMOTOLERANCE; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; DNAK; HSP104; STABILIZATION; MECHANISMS; INHIBITION	Expression of heat shock proteins (hsps) results in the protection of cells from subsequent stresses. However, hsps are also toxic when present within cells for a prolonged time period, Thus, the expression of hsps should be tightly regulated. In the present study, the expression of Hsp70 after heat shock was compared between thermotolerant cells, which contain a large concentration of Hsp70, and nonthermotolerant cells (naive), Accumulation of Hsp70, assessed by Western blotting, was negligible when thermotolerant cells were heat-shocked a second time. Hsp70 transcription was similar between thermotolerant and naive cells during heat shock. However, Hsp70 transcription was attenuated more rapidly in thermotolerant than naive cells immediately upon return to non-heat shock conditions. In addition, Hsp70 mRNA stability was reduced in thermotolerant cells as compared with naive cells following the stress. New synthesis of Hsp70 and the efficiency of Hsp70 mRNA translation were similar between thermotolerant and naive cells during the post-stress period. These results suggest that thermotolerant cells limit Hsp70 expression by transcriptional and pretranslational mechanisms, perhaps to avoid the potential cytotoxic effect of these proteins.	Johns Hopkins Univ, Sch Med, Div Pediat Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	De Maio, A (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Surg, 720 Rutland Ave, Baltimore, MD 21205 USA.			Theodorakis, Nicholas/0000-0002-3119-4990	NIGMS NIH HHS [GM-50878] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050878] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANATHAN J, 1986, SCIENCE, V232, P252; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BECK SC, 1994, J BIOL CHEM, V269, P21803; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; De Maio A, 1995, New Horiz, V3, P198; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DEMAIO A, 1993, CIRC SHOCK, V40, P177; DEMAIO A, 1993, EUR J BIOCHEM, V218, P413; DIDOMENICO BJ, 1982, P NATL ACAD SCI-BIOL, V79, P6181, DOI 10.1073/pnas.79.20.6181; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; Feder ME, 1996, J EXP BIOL, V199, P1837; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; HEADS RJ, 1994, J MOL CELL CARDIOL, V26, P695, DOI 10.1006/jmcc.1994.1084; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; VIDAIR CA, 1995, J CELL PHYSIOL, V163, P194, DOI 10.1002/jcp.1041630122; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; YOST HJ, 1991, MOL CELL BIOL, V11, P1062, DOI 10.1128/MCB.11.2.1062	38	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12081	12086		10.1074/jbc.274.17.12081	http://dx.doi.org/10.1074/jbc.274.17.12081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207033	hybrid			2022-12-25	WOS:000079834800089
J	Wood, LC; Ashby, MN; Grunfeld, C; Feingold, KR				Wood, LC; Ashby, MN; Grunfeld, C; Feingold, KR			Cloning of murine translation initiation factor 6 and functional analysis of the homologous sequence YPR016c in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REV ACTIVATION DOMAIN; CAP-BINDING PROTEIN; CELL-PROLIFERATION; SUBUNIT BIOGENESIS; BARRIER DISRUPTION; GROWTH-FACTOR; DNA-SYNTHESIS; YEAST; GENE; EXPRESSION	The cDNA sequence of a murine gene whose expression was up-regulated after epidermal injury was cloned utilizing differential display. The full-length cDNA was isolated by 3' and 5' rapid amplification of cDNA ends from mouse liver. The predicted protein is >97% identical to the human sequence for eukaryotic translation initiation factor (eIF) 6, thus identifying the gene as murine eIF6, Functional studies of the yeast eIF6 homolog, YPR016c, were initiated in Saccharomyces cerevisiae to determine the cellular role(s) of eIF6. Complete deletion of the YPR016c coding sequence was lethal. Viability was restored in the presence of either YPR016c of murine eIF6, when either was expressed as aminoterminal green fluorescent protein fusion protein. Moreover, both fusion proteins localized to nuclear/perinuclear compartments in their respective yeast strains. When the expression of YPR016c-green fluorescent protein was repressed, there was a dramatic reduction in the 60 S ribosomal subunit and polysome content and decreased 80S monosome content. Additionally, the YPR016c-depleted cells arrested in G(1). These studies show that YPR016c, which encodes yeast eIF6, is necessary for maximal polysome formation and plays an important role in determining free 60 S ribosomal subunit content.	Dept Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA; Dept Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Acacia Biosci Inc, Richmond, CA 94806 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wood, LC (corresponding author), Dept Vet Affairs Med Ctr, Dermatol Serv, 4150 Clement St,111F, San Francisco, CA 94121 USA.				NIAMS NIH HHS [AR 39639] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039639] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V2; Benard L, 1998, MOL CELL BIOL, V18, P2688, DOI 10.1128/MCB.18.5.2688; BENNE R, 1978, J BIOL CHEM, V253, P3078; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BURKE DJ, 1991, MOL CELL BIOL, V11, P3691, DOI 10.1128/MCB.11.7.3691; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; Denda M, 1996, ARCH DERMATOL RES, V288, P230, DOI 10.1007/BF02530090; ELIAS PM, 1991, ADV LIPID RES, V24, P1; FEINGOLD KR, 1991, ADV LIPID RES, V24, P57; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; HANICJOYCE PJ, 1987, EXP CELL RES, V172, P134, DOI 10.1016/0014-4827(87)90100-5; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG HA, 1994, J BIOL CHEM, V269, P3934; Kovarik P, 1998, CURR GENET, V33, P100, DOI 10.1007/s002940050314; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Liou A, 1997, J INVEST DERMATOL, V108, P73, DOI 10.1111/1523-1747.ep12285638; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MOLL R, 1995, BBA-GENE STRUCT EXPR, V1261, P315, DOI 10.1016/0167-4781(95)00024-B; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; POPOLO L, 1982, EXP CELL RES, V142, P69, DOI 10.1016/0014-4827(82)90410-4; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; PROKSCH E, 1991, J CLIN INVEST, V87, P1668, DOI 10.1172/JCI115183; RAYCHAUDHURI P, 1984, J BIOL CHEM, V259, P1930; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; Si K, 1997, P NATL ACAD SCI USA, V94, P14285, DOI 10.1073/pnas.94.26.14285; SIKORSKI RS, 1989, GENETICS, V122, P19; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; Wood L C, 1994, Exp Dermatol, V3, P56, DOI 10.1111/j.1600-0625.1994.tb00047.x; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Wood LC, 1996, J INVEST DERMATOL, V106, P397, DOI 10.1111/1523-1747.ep12343392; Zanchin NIT, 1997, MOL CELL BIOL, V17, P5001, DOI 10.1128/MCB.17.9.5001	42	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11653	11659		10.1074/jbc.274.17.11653	http://dx.doi.org/10.1074/jbc.274.17.11653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206977	hybrid			2022-12-25	WOS:000079834800033
J	Mashima, T; Naito, M; Tsuruo, T				Mashima, T; Naito, M; Tsuruo, T			Caspase-mediated cleavage of cytoskeletal actin plays a positive role in the process of morphological apoptosis	ONCOGENE			English	Article						caspase; actin; etoposide; morphology; apoptosis	INTERLEUKIN 1-BETA-CONVERTING ENZYME; AGENT-INDUCED APOPTOSIS; ICE-LIKE PROTEASES; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CELL-DEATH; CYTOCHROME-C; PHOSPHATIDYLSERINE EXTERNALIZATION; DNA FRAGMENTATION; ACTIVATION; GELSOLIN	Tumors result from the imbalance between cell growth and apoptosis. One of the characteristic changes in cancers is the abnormality in cytoskeleton, which suggests some roles of cytoskeletal proteins in tumorigenesis or the maintenance of tumor cells. Previously we showed that cytoskeletal actin is the substrate of caspases, the proteases responsible for apoptosis, while the role of actin cleavage in apoptosis remained unknown. To examine the cleavage of actin in vivo, we extensively performed immunoblot analysis using actin fragment-specific antibody. Here, we showed that, in some solid tumor cells, induction of apoptosis was accompanied by caspase-dependent actin-cleavage to 15 and 31 kDa fragments in vivo. To elucidate the role of actin-cleavage further, we introduced actin cleaved-fragments. We found that ectopic expression of an actin 15 kDa fragment induces morphological changes resembling those of apoptotic cells, The expression of the actin fragment induced a dramatic change of cellular actin localization, as visualized by enhanced green fluorescent protein (EGFP)-tagged actin, while the actin fragment expression did not cause caspase activation nor the cleavage of a marker substrate protein, poly (ADP-ribose) polymerase. These results indicate that actin cleavage could play a positive role in the morphological changes of apoptosis downstream of caspase activation.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Asch HL, 1996, CANCER RES, V56, P4841; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; Chen ZH, 1996, CANCER RES, V56, P5224; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; COTTER TG, 1992, CANCER RES, V52, P997; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NEAMATI N, 1995, J IMMUNOL, V154, P3788; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; TANAKA M, 1995, CANCER RES, V55, P3228; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANDEKERCKHOVE J, 1980, CELL, V22, P893, DOI 10.1016/0092-8674(80)90566-8; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Wong WW, 1998, AGENT ACTION SUPPL, V49, P5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	164	171	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2423	2430		10.1038/sj.onc.1202558	http://dx.doi.org/10.1038/sj.onc.1202558			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229193				2022-12-25	WOS:000079703300002
J	Sciacca, L; Costantino, A; Pandini, G; Mineo, R; Frasca, F; Scalia, P; Sbraccia, P; Goldfine, ID; Vigneri, R; Belfiore, A				Sciacca, L; Costantino, A; Pandini, G; Mineo, R; Frasca, F; Scalia, P; Sbraccia, P; Goldfine, ID; Vigneri, R; Belfiore, A			Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism	ONCOGENE			English	Article						insulin receptor; IGF-I receptor; IGF-I; IGF-II; breast cancer	HAMSTER OVARY CELLS; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; TRANSFORMED PHENOTYPE; OVEREXPRESSION; EXPRESSION; INHIBITION; BINDING; CDNA	IGF-II, produced by breast cancer epithelial and stromal cells, enhances tumor growth by activating the IGF-I receptor (IGF-I-R) via autocrine and paracrine mechanisms. Previously we found that the insulin receptor (IR), which is related to the IGF-I-R, is overexpressed in breast cancer cells. Herein, we find that, in breast cancer the IR is activated by IGF-II, In eight human breast cancer cell lines studied there,vas high affinity ICF-II binding to the IR, with subsequent IR activation, In these lints, IGF-II had a potency up to 63% that of insulin. In contrast, in non malignant human breast cells, IGF-II was less than 1% potent as insulin. Via activation of the IR tyrosine kinase IGF-II stimulated breast cancer cell growth. However, IGF-II also activated the IR in breast cancer tissue specimens; IGF-II was 10-100% as potent as insulin. The IR occurs in two isoforms generated by alternative splicing of exon 11; these isoforms are IR-A (Ex11-) and IR-B (Ex11+). IR-A was predominantly expressed in breast cancer cells and specimens and the potency of IGF-II was correlated to the expression of this isoform (P<0.0001). These data indicate, therefore, that the IR-A, which binds IGF-II with high affinity, is predominantly expressed in breast cancer cells and represents a new autocrine/paracrine loop involved in tumor biology.	Univ Catania, Osped Garibaldi, Ist Med Interna Malattie Endocrine & Metab, I-95123 Catania, Italy; Univ La Sapienza, Policlin Umberto I, Cattedra Endocrinol 1, I-00161 Rome, Italy; Univ Calif San Francisco, Div Diabet & Endocrine Res, San Francisco, CA 94115 USA	University of Catania; Sapienza University Rome; University Hospital Sapienza Rome; University of California System; University of California San Francisco	Belfiore, A (corresponding author), Univ Catania, Osped Garibaldi, Ist Med Interna Malattie Endocrine & Metab, I-95123 Catania, Italy.		Pandini, Giuseppe/AAB-9650-2019; SCIACCA, Laura/AAS-2896-2020; Scalia, Pierluigi/AAH-8443-2019; Belfiore, Antonino/B-4652-2011; Sciacca, Laura/B-9368-2014; Frasca, Francesco/J-1332-2018; Vigneri, Riccardo/M-3968-2017	Pandini, Giuseppe/0000-0003-3747-7649; SCIACCA, Laura/0000-0002-3258-7200; Scalia, Pierluigi/0000-0002-5911-1640; Belfiore, Antonino/0000-0002-6181-4193; Sciacca, Laura/0000-0002-3258-7200; Frasca, Francesco/0000-0002-5556-3201; Vigneri, Riccardo/0000-0002-4401-3140				ARTEAGA CL, 1989, CANCER RES, V49, P6237; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; CARMICHAEL J, 1987, CANCER RES, V47, P943; CULLEN K, 1997, ASSIST TECHN RES SER, V2, P1; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ENJOH T, 1993, J CLIN ENDOCR METAB, V77, P510, DOI 10.1210/jc.77.2.510; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; FRASCA F, 1999, IN PRESS MOL CELL BI, V19; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; JONAS HA, 1990, ENDOCRINOLOGY, V127, P1301, DOI 10.1210/endo-127-3-1301; JONAS HA, 1989, BIOCHEM J, V257, P101, DOI 10.1042/bj2570101; JONAS HA, 1992, BIOCHEM J, V266, P737; KULL FC, 1983, J BIOL CHEM, V258, P6561; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Mathieu MC, 1997, P ASSOC AM PHYSICIAN, V109, P565; MILAZZO G, 1992, CANCER RES, V52, P3924; MILAZZO G, 1992, J CLIN INVEST, V89, P899, DOI 10.1172/JCI115670; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Papa V, 1996, J ENDOCRINOL INVEST, V19, P324, DOI 10.1007/BF03347871; PODSKALNY JM, 1986, J BIOL CHEM, V261, P14076; SOOS MA, 1992, J BIOL CHEM, V267, P12955; Steller MA, 1996, CANCER RES, V56, P1761; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058	31	215	224	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2471	2479		10.1038/sj.onc.1202600	http://dx.doi.org/10.1038/sj.onc.1202600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229198				2022-12-25	WOS:000079703300007
J	Shirane, M; Harumiya, Y; Ishida, N; Hirai, A; Miyamoto, C; Hatakeyama, S; Nakayama, K; Kitagawa, M				Shirane, M; Harumiya, Y; Ishida, N; Hirai, A; Miyamoto, C; Hatakeyama, S; Nakayama, K; Kitagawa, M			Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; NF-KAPPA-B; CELL-CYCLE; PROTEASOME PATHWAY; PROTEIN-DEGRADATION; BREAST-CANCER; FRTL-5 CELLS; MICE LACKING; S-PHASE; ACTIVATION	The intracellular level of p27(Kip1), a cyclin-dependent kinase (CDK) inhibitory protein, is rapidly reduced at the G(1)/S transition phase when the cell cycle pause ceases. In this study, we demonstrated that two posttranslational mechanisms were involved in p27(Kip1) breakdown: degradation via the ubiquitin (Ub)-proteasome pathway and proteolytic processing that rapidly eliminates the cyclin-binding domain. We confirmed that p27(Kip1) was ubiquitinated in vitro as well as in vivo. The p27(Kip1) -ubiquitination activity was higher at the G(1)/S boundary than during the G(0)/G(1) phase, and p27(Kip1) ubiquitination was reduced significantly when the lysine residues at positions 134, 153, and 165 were replaced by arginine, suggesting that these lysine residues are the targets for Ub conjugation. In parallel with its Uh-dependent degradation, p27(Kip1) was processed rapidly at its N terminus, reducing its molecular mass from 27 to 22 kDa, by a ubiquitination-independent but adenosine triphosphate (ATP)-dependent mechanism with higher activity during the S than the G(0)/G(1) phase. This 22-kDa intermediate had no cyclin-binding domain at its N terminus and virtually no CDK2 kinase inhibitory activity. These results suggest that p27(Kip1) is eliminated by two independent mechanisms, ubiquitin-mediated degradation and ubiquitin-independent processing, during progression from the G(1) to S phase.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Japanese Fdn Canc Res, Inst Canc, Ctr Canc Chemotherapy, Dept Mol Biotherapy Res, Tokyo 1708455, Japan; Chiba Univ, Sch Med, Dept Internal Med 2, Chiba 2600856, Japan; Chiba Prefectural Togane Hosp, Togane 2838588, Japan; Nippon Roche Res Ctr, Kamakura, Kanagawa 2470063, Japan	Kyushu University; Japan Science & Technology Agency (JST); Japanese Foundation for Cancer Research; Chiba University; Roche Holding	Nakayama, K (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	高, 雨莉/HGU-8187-2022; Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hirai A, 1997, J BIOL CHEM, V272, P13; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITAGAWA M, 1994, ONCOGENE, V9, P2549; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Steeg PS, 1997, NAT MED, V3, P152, DOI 10.1038/nm0297-152; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tokumoto T, 1997, J CELL BIOL, V138, P1313, DOI 10.1083/jcb.138.6.1313; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036	47	214	221	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13886	13893		10.1074/jbc.274.20.13886	http://dx.doi.org/10.1074/jbc.274.20.13886			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318797	hybrid			2022-12-25	WOS:000080322200026
J	Abu-Elneel, K; Kapeller, I; Shlomai, J				Abu-Elneel, K; Kapeller, I; Shlomai, J			Universal minicircle sequence-binding protein, a sequence-specific DNA-binding protein that recognizes the two replication origins of the kinetoplast DNA minicircle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; CRITHIDIA-FASCICULATA; TRYPANOSOMA-EQUIPERDUM; GENOMIC ORGANIZATION; NETWORKS; DISCONTINUITIES; TRANSCRIPTION; PURIFICATION; SITES; GAP	Replication of the kinetoplast DNA minicircle lagging (heavy (H)) strand initiates at, or near, a unique hexameric sequence (5'-ACGCCC-3') that is conserved in the minicircles of trypanosomatid species. A protein from the trypanosomatid Crithidia fasciculata binds specifically a 14-mer sequence, consisting of the complementary strand hexamer and eight flanking nucleotides at the H-strand replication origin, This protein was identified as the previously described universal minicircle sequence (UMS)-binding protein (UMSBP) (Tzfati, Y,, Abeliovich, H,, Avrahami, D,, and Shlomai, J, (1995) J. Biol. Chem, 270, 21339-21345), This CCHC-type zinc finger protein binds the single-stranded form of both the 12-mer (UMS) and 14-mer sequences, at the replication origins of the minicircle L-strand and H-strand, respectively. The attribution of the two different DNA binding activities to the same protein relies on their co-purification from C, fasciculata cell extracts and on the high affinity of recombinant UMSBP to the two origin-associated sequences. Both the conserved H-strand hexamer and its nanking nucleotides at the replication origin are required for binding. Neither the hexameric sequence per se nor this sequence flanked by different sequences could support the generation of specific nucleoprotein complexes, Stoichiometry analysis indicates that each UMSBP molecule binds either of the two origin-associated sequences in the nucleoprotein complex but not both simultaneously.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Shlomai, J (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, IL-91120 Jerusalem, Israel.							ABELIOVICH H, 1995, ANAL BIOCHEM, V228, P351, DOI 10.1006/abio.1995.1363; ABELIOVICH H, 1993, MOL CELL BIOL, V13, P7766, DOI 10.1128/MCB.13.12.7766; AVRAHAMI D, 1995, P NATL ACAD SCI USA, V92, P10511, DOI 10.1073/pnas.92.23.10511; BIRKENMEYER L, 1986, J BIOL CHEM, V261, P2362; BIRKENMEYER L, 1987, J BIOL CHEM, V262, P2384; BRACK C, 1972, P NATL ACAD SCI USA, V69, P1642, DOI 10.1073/pnas.69.6.1642; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; Englund Paul T., 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P147; ENGLUND PT, 1977, J BIOL CHEM, V252, P6208; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; ENGLUND PT, 1982, ANNU REV BIOCHEM, V51, P695, DOI 10.1146/annurev.bi.51.070182.003403; ENGLUND PT, 1979, J BIOL CHEM, V254, P4895; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KITCHIN PA, 1985, J BIOL CHEM, V260, P3844; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KORNBERG A, 1991, DNA REPLICATION, P511; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; NTAMBI JM, 1985, J BIOL CHEM, V260, P5574; NTAMBI JM, 1986, J BIOL CHEM, V261, P1890; PEREZMORGA D, 1993, J CELL BIOL, V123, P1069, DOI 10.1083/jcb.123.5.1069; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1989, J BIOL CHEM, V264, P823; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; RYAN KA, 1989, MOL CELL BIOL, V9, P3212, DOI 10.1128/MCB.9.8.3212; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SHELINE C, 1989, MOL BIOCHEM PARASIT, V37, P151, DOI 10.1016/0166-6851(89)90147-3; SHELINE C, 1989, MOL CELL BIOL, V9, P169, DOI 10.1128/MCB.9.1.169; SHLOMAI J, 1986, J BIOL CHEM, V261, P6219; SHLOMAI J, 1994, PARASITOL TODAY, V10, P341, DOI 10.1016/0169-4758(94)90244-5; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; TORRI AL, 1996, DNA REPLICATION EUKA, P1029; TZFATI Y, 1992, P NATL ACAD SCI USA, V89, P6891, DOI 10.1073/pnas.89.15.6891; TZFATI Y, 1995, J BIOL CHEM, V270, P21339, DOI 10.1074/jbc.270.36.21339; Tzfati Y, 1998, MOL BIOCHEM PARASIT, V94, P137, DOI 10.1016/S0166-6851(98)00052-8	45	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13419	13426		10.1074/jbc.274.19.13419	http://dx.doi.org/10.1074/jbc.274.19.13419			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224106	hybrid			2022-12-25	WOS:000080200400068
J	Cho, WL; Tsao, SM; Hays, AR; Walter, R; Chen, JS; Snigirevskaya, ES; Raikhel, AS				Cho, WL; Tsao, SM; Hays, AR; Walter, R; Chen, JS; Snigirevskaya, ES; Raikhel, AS			Mosquito cathepsin B-like protease involved in embryonic degradation of vitellin is produced as a latent extraovarian precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							29-KDA HEMOCYTE PROTEINASE; AMINO-ACID-SEQUENCES; CYSTEINE PROTEINASE; FAT-BODY; YOLK DEGRADATION; AEDES-AEGYPTI; MOLECULAR-CLONING; PROCATHEPSIN-B; BOMBYX-MORI; HAEMONCHUS-CONTORTUS	Here we report identification of a novel member of the thiol protease superfamily in the yellow fever mosquito, Aedes aegypti. It is synthesized and secreted as a latent proenzyme in a sex-, stage-, and tissue-specific manner by the fat body, an insect metabolic tissue, of female mosquitoes during vitellogenesis in response to blood feeding. The secreted, hemolymph form of the enzyme is a large molecule, likely a hexamer, consisting of 44-kDa subunits. The deduced amino acid sequence of this 44-kDa precursor shares high similarity with cathepsin B but not with other mammalian cathepsins. We have named this mosquito enzyme vitellogenic cathepsin B (VCB). VCB decreases to 42 kDa after internalization by oocytes, In mature yolk bodies, VCB is located in the matrix surrounding the crystalline yolk protein, vitellin. At the onset of embryogenesis, VCB is further processed to 33 kDa. The embryo extract containing the 33-kDa VCB is active toward benzoyloxycarbonyl-Arg-Arg-para-nitroanilide, a cathepsin B-specific substrate, and degrades vitellogenin, the vitellin precursor. Both of these enzymatic activities are prevented by trans-epoxysuccinyl-L-leucylamido- (4-guanidino)butane (E-64), a thiol protease inhibitor. Furthermore, addition of the anti-VCB antibody to the embryonic extract prevented cleavage of vitellogenin, strongly indicating that the activated VCB is involved in embryonic degradation of vitellin.	Michigan State Univ, Dept Entomol, E Lansing, MI 48824 USA; Natl Yang Ming Univ, Dept Parasitol, Taipei 112, Taiwan; Michigan State Univ, Genet Program, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Russian Acad Sci, Inst Cytol, Electron Microscopy Lab, St Petersburg 194064, Russia	Michigan State University; National Yang Ming Chiao Tung University; Michigan State University; Michigan State University; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Raikhel, AS (corresponding author), Michigan State Univ, Dept Entomol, S-150 Plant Biol Bldg, E Lansing, MI 48824 USA.	araikhel@pilot.msu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032154, R37AI024716, R01AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24716, AI-32154] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BECHET DM, 1991, J BIOL CHEM, V266, P14104; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; Brinke A, 1997, GENOMICS, V45, P105, DOI 10.1006/geno.1997.4902; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; Chen JS, 1997, J MOL EVOL, V44, P440, DOI 10.1007/PL00006164; Chiou JY, 1998, J BIOMED SCI, V5, P120; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cho WL, 1997, INSECT BIOCHEM MOLEC, V27, P351, DOI 10.1016/S0965-1748(97)00017-9; CHO WL, 1992, J BIOL CHEM, V267, P21823; CHO WL, 1995, INSECT BIOCHEM MOLEC, V25, P19, DOI 10.1016/0965-1748(94)00045-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX GN, 1990, MOL BIOCHEM PARASIT, V41, P25, DOI 10.1016/0166-6851(90)90093-2; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEITSCH KW, 1995, INSECT BIOCHEM MOLEC, V25, P449, DOI 10.1016/0965-1748(94)00082-A; DHADIALLA TS, 1990, J BIOL CHEM, V265, P9924; FAGOTTO F, 1994, J CELL BIOL, V125, P1047, DOI 10.1083/jcb.125.5.1047; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P237, DOI 10.1002/arch.940140404; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P217, DOI 10.1002/arch.940140403; FELLEISEN R, 1990, EMBO J, V9, P371, DOI 10.1002/j.1460-2075.1990.tb08120.x; Giorgi F, 1997, TISSUE CELL, V29, P293, DOI 10.1016/S0040-8166(97)80005-5; HAGEDORN HH, 1977, J INSECT PHYSIOL, V23, P203, DOI 10.1016/0022-1910(77)90030-0; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; KAWOOYA JK, 1986, J BIOL CHEM, V261, P844; Khan A, 1998, MODERN PATHOL, V11, P704; Kim K, 1998, INT J CANCER, V79, P324, DOI 10.1002/(SICI)1097-0215(19980821)79:4<324::AID-IJC4>3.3.CO;2-N; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KULAKOSKY PC, 1987, INSECT BIOCHEM, V19, P367; KURATA S, 1992, DEV BIOL, V153, P115, DOI 10.1016/0012-1606(92)90096-Y; KURATA S, 1992, EUR J BIOCHEM, V204, P911, DOI 10.1111/j.1432-1033.1992.tb16711.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XD, 1996, J BIOL CHEM, V271, P33344, DOI 10.1074/jbc.271.52.33344; Loukas A, 1998, MOL BIOCHEM PARASIT, V92, P275, DOI 10.1016/S0166-6851(97)00245-4; MACH L, 1994, J BIOL CHEM, V269, P13030; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MEDINA M, 1989, DEV GROWTH DIFFER, V31, P241; MEDINA M, 1988, ARCH BIOCHEM BIOPHYS, V263, P355, DOI 10.1016/0003-9861(88)90646-7; MERCKELBACH A, 1994, TROP MED PARASITOL, V45, P193; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; PRATT D, 1992, MOL BIOCHEM PARASIT, V56, P39, DOI 10.1016/0166-6851(92)90152-A; PRATT D, 1990, MOL BIOCHEM PARASIT, V43, P181, DOI 10.1016/0166-6851(90)90143-A; QIAN F, 1991, DNA CELL BIOL, V10, P159, DOI 10.1089/dna.1991.10.159; Raikhel A. S., 1997, The molecular biology of insect disease vectors: a methods manual., P507; RAIKHEL AS, 1987, TISSUE CELL, V19, P515, DOI 10.1016/0040-8166(87)90045-0; RAIKHEL AS, 1991, TISSUE CELL, V23, P577, DOI 10.1016/0040-8166(91)90015-L; RAIKHEL AS, 1983, TISSUE CELL, V15, P281, DOI 10.1016/0040-8166(83)90023-X; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; RIBOLLA PEM, 1993, INSECT BIOCHEM MOLEC, V23, P217, DOI 10.1016/0965-1748(93)90002-A; ROBERTSON CD, 1993, MOL BIOCHEM PARASIT, V62, P271, DOI 10.1016/0166-6851(93)90116-F; ROSENBERG K, 1989, NEW STATESMAN SOC, V2, P35; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sappington T. W., 1997, The molecular biology of insect disease vectors: a methods manual., P523; Sappington TW, 1998, INSECT BIOCHEM MOLEC, V28, P277, DOI 10.1016/S0965-1748(97)00110-0; SAPPINGTON TW, 1995, INSECT BIOCHEM MOLEC, V25, P807, DOI 10.1016/0965-1748(95)00016-O; Seroussi E, 1998, GENE, V212, P13, DOI 10.1016/S0378-1119(98)00098-5; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; SLOANE BF, 1990, CANCER METAST REV, V9, P333, DOI 10.1007/BF00049523; Snigirevskaya ES, 1997, CELL TISSUE RES, V290, P129, DOI 10.1007/s004410050915; STEPHENS H, 1982, J HISTOCHEM CYTOCHEM, V30, P605; TAKAHASHI N, 1993, FEBS LETT, V334, P153, DOI 10.1016/0014-5793(93)81702-2; TAKAHASHI SY, 1993, J BIOCHEM, V114, P267, DOI 10.1093/oxfordjournals.jbchem.a124165; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; TERRA WR, 1988, INSECT BIOCHEM, V18, P423, DOI 10.1016/0020-1790(88)90058-3; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; Xing RY, 1998, BIOCHEM J, V332, P499, DOI 10.1042/bj3320499; YAMAMOTO Y, 1994, J BIOCHEM, V116, P1330, DOI 10.1093/oxfordjournals.jbchem.a124683; YAMAMOTO Y, 1993, COMP BIOCHEM PHYS B, V106, P35, DOI 10.1016/0305-0491(93)90004-O; YAMAMOTO Y, 1994, J INSECT PHYSIOL, V40, P447, DOI 10.1016/0022-1910(94)90163-5; Yoshizaki N, 1998, COMP BIOCHEM PHYS B, V119, P571, DOI 10.1016/S0305-0491(98)00030-3; Yu YL, 1998, FEBS LETT, V429, P9, DOI 10.1016/S0014-5793(98)00548-1; ZHU J, 1986, Biochimica et Biophysica Acta, V882, P427, DOI 10.1016/0304-4165(86)90267-9	83	161	177	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13311	13321		10.1074/jbc.274.19.13311	http://dx.doi.org/10.1074/jbc.274.19.13311			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224092	hybrid			2022-12-25	WOS:000080200400054
J	Hajduch, E; Rencurel, F; Balendran, A; Batty, IH; Downes, CP; Hundal, HS				Hajduch, E; Rencurel, F; Balendran, A; Batty, IH; Downes, CP; Hundal, HS			Serotonin (5-hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; AMINO-ACID-TRANSPORT; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; DEVELOPMENTAL REGULATION; SUBCELLULAR-DISTRIBUTION; COUPLED RECEPTORS; 3T3-L1 CELLS	In this study we show that serotonin (5-hydroxytryptamine (5-HT)) causes a rapid stimulation in glucose uptake by similar to 50% in both L6 myotubes and isolated rat skeletal muscle. This activation is mediated via the 5-HT2A receptor, which is expressed in L6, rat, and human skeletal muscle. In L6 cells, expression of the 5-HT2A receptor is developmentally regulated based on the finding that receptor abundance increases by over 3-fold during differentiation from myoblasts to myotubes, Stimulation of the 5-HT2A receptor using methylserotonin (m-HT), a selective 5-HT2A agonist, increased muscle glucose uptake in a manner similar to that seen in response to 5-HT. The agonist-mediated stimulation in glucose uptake was attributable to an increase in the plasma membrane content of GLUT1, GLUT3, and GLUT4. The stimulatory effects of 5-HT and m-HT were suppressed in the presence of submicromolar concentrations of ketanserin (a selective 5-HT2A antagonist) providing further evidence that the increase in glucose uptake was specifically mediated via the 5-HT2A receptor. Treatment of L6 cells with insulin resulted in tyrosine phosphorylation of IRS1, increased cellular production of phosphatidylinositol 3,4,5-phosphate and a 41-fold activation in protein kinase B (PKB/Akt) activity. In contrast, m-HT did not modulate IRS1, phosphoinositide 3-kinase, or PKB activity. The present results indicate that rat and human skeletal muscle both express the 5-HT2A receptor and that 5-HT and specific 5-HT2A agonists can rapidly stimulate glucose uptake in skeletal muscle by a mechanism which does not depend upon components that participate in the insulin signaling pathway.	Univ Dundee, Dept Anat & Physiol, Dundee DD1 4HN, Scotland; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	University of Dundee; University of Dundee; University of Dundee	Hundal, HS (corresponding author), Univ Dundee, Dept Anat & Physiol, Dundee DD1 4HN, Scotland.		Hundal, Hari/A-8990-2008; Hajduch, Eric/B-7332-2008	Hundal, Hari/0000-0002-7621-4932; Hajduch, Eric/0000-0002-0125-7751				Aledo JC, 1997, BIOCHEM J, V325, P727, DOI 10.1042/bj3250727; BILAN PJ, 1992, FEBS LETT, V298, P285, DOI 10.1016/0014-5793(92)80078-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CONN PJ, 1986, P NATL ACAD SCI USA, V83, P4086, DOI 10.1073/pnas.83.11.4086; Coulie B, 1998, AM J PHYSIOL-ENDOC M, V274, pE317, DOI 10.1152/ajpendo.1998.274.2.E317; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; EATON MJ, 1995, DEV BIOL, V170, P169, DOI 10.1006/dbio.1995.1205; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FISCHER Y, 1995, BIOCHEM J, V311, P575, DOI 10.1042/bj3110575; FURMAN BL, 1980, DIABETOLOGIA, V19, P386, DOI 10.1007/BF00280525; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HOYER D, 1994, PHARMACOL REV, V46, P157; HUNDAL HS, 1994, MOL MEMBR BIOL, V11, P255, DOI 10.3109/09687689409160435; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LUNDQUIST I, 1971, DIABETOLOGIA, V7, P414, DOI 10.1007/BF01212056; Martin F. J., 1995, Life Sciences, V56, P51; McDowell HE, 1997, EUR J BIOCHEM, V247, P306, DOI 10.1111/j.1432-1033.1997.00306.x; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MONOPOLI A, 1990, CARDIOVASC DRUG THER, V4, P59, DOI 10.1007/BF00053428; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Newsholme EA, 1995, ADV EXP MED BIOL, V384, P315; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PEROUTKA SJ, 1995, TRENDS NEUROSCI, V18, P68; SMITH SA, 1977, BIOCHEM J, V168, P495, DOI 10.1042/bj1680495; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TECOTT L, 1995, MOL CELL NEUROSCI, V6, P43, DOI 10.1006/mcne.1995.1005; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; UvnasMoberg K, 1996, NEUROENDOCRINOLOGY, V63, P269, DOI 10.1159/000126970; VanEppsFung M, 1997, ENDOCRINOLOGY, V138, P5170, DOI 10.1210/en.138.12.5170; WILSON JP, 1974, AM J PHYSIOL, V227, P305, DOI 10.1152/ajplegacy.1974.227.2.305; WOZNIAK KM, 1991, LIFE SCI, V49, P101, DOI 10.1016/0024-3205(91)90023-5; YAMADA J, 1989, LIFE SCI, V45, P1931, DOI 10.1016/0024-3205(89)90547-X; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125	39	95	101	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13563	13568		10.1074/jbc.274.19.13563	http://dx.doi.org/10.1074/jbc.274.19.13563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224126	hybrid			2022-12-25	WOS:000080200400088
J	Jacob, A; Cooney, D; Tridandapani, S; Kelley, T; Coggeshall, KM				Jacob, A; Cooney, D; Tridandapani, S; Kelley, T; Coggeshall, KM			Fc gamma RIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SH2-CONTAINING INOSITOL PHOSPHATASE; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; HEMATOPOIETIC-CELLS; NEGATIVE REGULATION; MULTIPLE CYTOKINES	We examined activation of the serine/threonine kinase Akt in the murine B cell line A20. Akt is activated in a phosphoinositide 3-kinase (PtdIns 3-kinase)-dependent manner upon stimulation of the antigen receptor, surface immunoglobulin (sIg). In contrast, Akt induction is reduced upon co-clustering of sig with the B cell IgG receptor, Fc gamma RIIb. Go-clustering of sIg-Fc gamma RIIb transmits a dominant negative signal and is associated with reduced accumulation of the PtdIns 3-kinase product phosphatidylinositol 3,4,5-trisphosphate (PtdIns 3,4,5-P-3), known to be a potent activator of Akt. PtdIns 3-kinase is activated to the same extent with and without Fc gamma RIIb co-ligation, indicating conditions supporting the generation of PtdIns 3,4,5-P-3. We hypothesized that the decreased Akt activity arises from the consumption of PtdIns 3,4,5-P-3 by the inositol-5-phosphatase Src homology 2-containing inositol B-phosphatase (SHIP), which has been shown by us to be tyrosine-phosphorylated and associated with Fc gamma RIIb when the latter is co-ligated. In direct support of this hypothesis, we report here that Akt induction is greatly reduced in fibroblasts expressing catalytically active but not inactive SHIP. Likewise, the reduction in Akt activity upon sIgFc gamma RIIb co-clustering is absent from avian B cells lacking expression of SHIP. These findings indicate that SHIP acts as a negative regulator of Akt activation.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Coggeshall, KM (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.	coggeshall.1@osu.edu	Cooney, Damon/J-4762-2014; Tridandapani, Susheela/E-4209-2011	Cooney, Damon/0000-0002-2786-287X; 	NATIONAL CANCER INSTITUTE [R01CA064268, P30CA016058, R29CA064268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041147] Funding Source: NIH RePORTER; NCI NIH HHS [CA64268, P30 CA16058] Funding Source: Medline; NIAID NIH HHS [AI41147] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Ashman RF, 1996, J IMMUNOL, V157, P5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chacko GW, 1996, J IMMUNOL, V157, P2234; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; delPeso L, 1997, SCIENCE, V278, P687; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOLD MR, 1994, J IMMUNOL, V152, P42; GOLD MR, 1992, J IMMUNOL, V148, P2012; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Hunter MG, 1998, J IMMUNOL, V160, P4979; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Sarkar S, 1996, J BIOL CHEM, V271, P20182, DOI 10.1074/jbc.271.33.20182; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tridandapani S, 1997, J IMMUNOL, V158, P1125; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Yamashita Y, 1996, J EXP MED, V184, P113, DOI 10.1084/jem.184.1.113; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	56	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13704	13710		10.1074/jbc.274.19.13704	http://dx.doi.org/10.1074/jbc.274.19.13704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224144	hybrid			2022-12-25	WOS:000080200400106
J	Kawasaki, H; Fujii, H; Gotoh, Y; Morooka, T; Shimohama, S; Nishida, E; Hirano, T				Kawasaki, H; Fujii, H; Gotoh, Y; Morooka, T; Shimohama, S; Nishida, E; Hirano, T			Requirement for mitogen-activated protein kinase in cerebellar long term depression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHOSPHORYLATION SITES; PURKINJE-CELLS; OSMOTIC SHOCK; CALCIUM; POTENTIATION; CASCADE; RAS; INVOLVEMENT; MECHANISMS	The mitogen-activated protein kinase (MAPK) cascade has been shown to play an essential role in regulation of cell proliferation and cell differentiation. Although mammalian MAPKs are most abundantly expressed in postmitotic and terminally differentiated neuronal cells, their function in the central nervous system is still largely undefined. We present evidence here for a role of the MAPK cascade in cerebellar long term depression (LTD), which is a widely studied form of synaptic plasticity in mammalian brain. In cultured Purkinje cells, LTD is known to be induced by iontophoretic application of glutamate and depolarization of Purkinje cells. We found that MAPK was activated in Purkinje cells by treatment of primary cultures of rat embryonic cerebella with glutamate and a depolarization-inducing agent, KCl. Application of PD98059, a specific inhibitor of MAPK kinase (MAPKK/MEK), inhibited both the activation of MAPK and the induction of LTD in Purkinje cells. Furthermore, the induction of LTD was completely blocked by introduction into Purkinje cells of anti-active MAPK antibody, which was found to specifically and potently inhibit the activity of MAPK. These results suggest that postsynaptic activation of the MAPK cascade is essential for the induction of cerebellar LTD.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Inst Virus Res, Dept Genet & Mol Biol, Sakyo Ku, Kyoto 606, Japan; Japan Sci & Technol Corp, CRESt, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto University; Japan Science & Technology Agency (JST)	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		KAWASAKI, Hiroshi/L-3736-2015; Kawasaki, Hiroshi/C-4404-2015	Kawasaki, Hiroshi/0000-0002-2514-1497; Fujii, Hiroaki/0000-0002-0013-5891				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KASONO K, 1995, NEUROREPORT, V6, P569, DOI 10.1097/00001756-199502000-00040; KASONO K, 1994, NEUROREPORT, V6, P17, DOI 10.1097/00001756-199412300-00006; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; Linden D J, 1994, Learn Mem, V1, P121; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1994, J NEUROPHYSIOL, V71, P1992, DOI 10.1152/jn.1994.71.5.1992; Linden DJ, 1996, NEURON, V17, P483, DOI 10.1016/S0896-6273(00)80180-4; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519	33	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13498	13502		10.1074/jbc.274.19.13498	http://dx.doi.org/10.1074/jbc.274.19.13498			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224117	hybrid			2022-12-25	WOS:000080200400079
J	Madge, LA; Sierra-Honigmann, MR; Pober, JS				Madge, LA; Sierra-Honigmann, MR; Pober, JS			Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1) - A nonpharmacological explanation for inhibition of TNF-mediated activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; PROTEIN-KINASE ACTIVATION; HUMAN ENDOTHELIAL-CELLS; SOLUBLE FORM; ALPHA PHOSPHORYLATION; FACTOR-BINDING; COMPLEX; CLEAVAGE; DEATH	Several chemical compounds not known to interact with tumor necrosis factor (TNF) signal transducing proteins inhibit TNF-mediated activation of vascular endothelial cells (EC), Four structurally diverse agents, arachidonyl trifluoromethylketone, staurosporine, sodium salicylate, and C-6-ceramide, were studied. All four agents caused EC apoptosis at concentrations that inhibited TNF-induced I kappa B alpha degradation. However, evidence of apoptosis was not evident until after several (e.g, 3-12) hours of treatment, whereas 2 h of treatment was sufficient to inhibit TNF responses. IL-l-induced I kappa B alpha degradation was unaffected by these treatments. Inhibition of TNF signaling could not be prevented with either of the broad spectrum caspase inhibitors zVADfmk or yVADcmk, The inhibition of p38 kinase with SB203580 prevented the inhibition of TNF signaling by all agents except arachidonyl trifluoromethylketone,No changes in the levels or molecular weights of the adaptor proteins TRADD (TNF receptor-associated death domain), RIP (receptor-interacting protein), or TRAF2 (TNF receptor-associated factor-alpha) were caused by apoptogenic drugs. However, TNF receptor 1 (TNFR1) surface expression was significantly reduced by all four agents, Furthermore, TNF-dependent recruitment of TRADD to surface TNFR1 was also inhibited. These data suggest that several putative inhibitors of TNF signaling work by triggering apoptosis and that an early event coincident with the initiation of apoptosis, preceding evidence of injury, is loss of TNFR1, Consistent with this hypothesis, cotreatment of EC with the metalloproteinase inhibitor Tapi (TNF-alpha proteinase inhibitor) blocked the reduction in surface TNFR1 by apoptogenic drugs and prevented inhibition of TNF-induced I kappa B alpha degradation without blocking apoptosis. TNFR1 loss could be a mechanism to limit inflammation in response to apoptotic cell death.	Yale Univ, Sch Med, Mol Cardiobiol Program, Boyer Ctr Mol Med, New Haven, CT 06536 USA	Yale University	Pober, JS (corresponding author), Yale Univ, Sch Med, Mol Cardiobiol Program, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06536 USA.				NHLBI NIH HHS [HL-36007] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; Bjornberg F, 1998, BIOCHEM BIOPH RES CO, V244, P594, DOI 10.1006/bbrc.1998.8302; BRADLEY JR, 1995, AM J PATHOL, V146, P27; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COPE AP, 1992, ARTHRITIS RHEUM, V35, P1160, DOI 10.1002/art.1780351008; CROWE PD, 1993, J IMMUNOL, V151, P6882; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Haridas V, 1998, J IMMUNOL, V160, P3152; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE TA, 1990, BIOCHEM BIOPH RES CO, V172, P1273, DOI 10.1016/0006-291X(90)91587-I; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LANTZ M, 1994, J IMMUNOL, V152, P1362; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Pierce JW, 1996, J IMMUNOL, V156, P3961; Pinckard JK, 1997, J BIOL CHEM, V272, P10784; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; Slowik MR, 1996, CIRC RES, V79, P736, DOI 10.1161/01.RES.79.4.736; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stuhlmeier KM, 1997, J BIOL CHEM, V272, P24679, DOI 10.1074/jbc.272.39.24679; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	61	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13643	13649		10.1074/jbc.274.19.13643	http://dx.doi.org/10.1074/jbc.274.19.13643			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224136	hybrid			2022-12-25	WOS:000080200400098
J	Shinohara, H; Balboa, MA; Johnson, CA; Balsinde, J; Dennis, EA				Shinohara, H; Balboa, MA; Johnson, CA; Balsinde, J; Dennis, EA			Regulation of delayed prostaglandin production in activated P388D(1) macrophages by Group IV cytosolic and Group V secretory phospholipase A(2)s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID MOBILIZATION; MAST-CELLS; D-2 GENERATION; E-2 GENERATION; EXPRESSION; INHIBITION; SYNTHASE-2; METABOLISM; ENZYMES; IIA	Group V secretory phospholipase A(2) (sPLA(2)) rather than Group IIA sPLA(2) is involved in short term, immediate arachidonic acid mobilization and prostaglandin E-2 (PGE(2)) production in the macrophage-like cell line P388D(1). When a new clone of these cells, P388D(1)/MAB, selected on the basis of high responsivity to lipopolysaccharide plus platelet-activating factor, was studied, delayed PGE(2) production (6-24 h) in response to lipopolysaccharide alone occurred in parallel with the induction of Group V sPLA(2) and cyclooxygenase-a (COX-2), No changes in the level of cytosolic phospholipase A(2) (cPLA(2)) or COX-1 were observed, and Group IIA sPLA(2) was not detectable. Use of a potent and selective sPLA(2) inhibitor, 3-(3-acetamide 1-benzyl-2-ethylindolyl-5-oxy)-propanesulfonic acid (LY311727), and an antisense oligonucleotide specific for Group V sPLA(2) revealed that delayed PGE, was largely dependent on the induction of Group V sPLA(2). Also, COX-2, not COX-1, was found to mediate delayed PGE(2) production because the response was completely blocked by the specific COX-2 inhibitor NS-398, Delayed PGE(2) production and Group V sPLA(2) expression were also found to be blunted by the inhibitor methylarachidonyl fluorophosphonate, Because inhibition of Ca2+-independent PLA(2) by an antisense technique did not have any effect on the arachidonic acid release, the data using methylarachidonyl fluorophosphonate suggest a key role for the cPLA(2) in the response as well. Collectively, the results suggest a model whereby cPLA(2) activation regulates Group V sPLA(2) expression, which in turn is responsible for delayed PGE(2) production via COX-2.	Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Revelle Coll, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA.		Dennis, Edward A./M-5554-2019; Balboa, María A./V-9493-2018; Balsinde, Jesús/C-7833-2018	Dennis, Edward A./0000-0003-3738-3140; Balboa, María A./0000-0002-2130-5298; Balsinde, Jesús/0000-0002-4157-6714	NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GLASER KB, 1990, J BIOL CHEM, V265, P8658; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Surette ME, 1998, BIOCHEM J, V330, P915; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247	27	142	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12263	12268		10.1074/jbc.274.18.12263	http://dx.doi.org/10.1074/jbc.274.18.12263			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212194	hybrid, Green Published			2022-12-25	WOS:000080056800014
J	Dhanabal, M; Ramchandran, R; Waterman, MJF; Lu, H; Knebelmann, B; Segal, M; Sukhatme, VP				Dhanabal, M; Ramchandran, R; Waterman, MJF; Lu, H; Knebelmann, B; Segal, M; Sukhatme, VP			Endostatin induces endothelial cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOW CYTOMETRIC DETECTION; ANNEXIN-V; PHOSPHATIDYLSERINE EXPRESSION; SOLID TUMORS; BCL-2; ANGIOGENESIS; DEATH; VASCULATURE; THERAPY; BAX	Endostatin, a carboxyl-terminal fragment of collagen XVIII, has been shown to regress tumors in mice. In this study, we have analyzed the mechanism of endostatin action on endothelial cells and nonendothelial cells. Endostatin treatment of cow pulmonary artery endothelial cells caused apoptosis, as demonstrated by three methods, annexin V-fluorescein isothiocyanate staining, caspase 3, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling assay. Moreover, addition of endostatin led to a marked reduction of the Bcl-2 and Bcl-X-L anti-apoptotic protein, whereas Bax protein levels were unaffected. These effects were not seen in several nonendothelial cells. Collectively, these findings provide important mechanistic insight into endostatin action.	Beth Israel Deaconess Med Ctr, Dept Med, Div Renal, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Sukhatme, VP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Renal, Dana 517,330 Brookline Ave, Boston, MA 02215 USA.	vsukhatm@bidmc.harvard.edu	Sukhatme, Vikas/W-2776-2019					Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; BAILLIE CT, 1995, BRIT J CANCER, V72, P257, DOI 10.1038/bjc.1995.323; BICKNELL R, 1994, ANN ONCOL, V5, pS45, DOI 10.1093/annonc/5.suppl_4.S45; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Cho JH, 1998, PATHOL RES PRACT, V194, P309, DOI 10.1016/S0344-0338(98)80054-X; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Dhanabal M, 1999, CANCER RES, V59, P189; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; THORPE PE, 1995, BREAST CANCER RES TR, V36, P237, DOI 10.1007/BF00666044; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01	26	510	614	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11721	11726		10.1074/jbc.274.17.11721	http://dx.doi.org/10.1074/jbc.274.17.11721			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206987	hybrid			2022-12-25	WOS:000079834800043
J	Obin, M; Mesco, E; Gong, X; Haas, AL; Joseph, J; Taylor, A				Obin, M; Mesco, E; Gong, X; Haas, AL; Joseph, J; Taylor, A			Neurite outgrowth in PC12 cells - Distinguishing the roles of ubiquitylation and ubiquitin-dependent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							END RULE PATHWAY; NERVE GROWTH-FACTOR; PROTEIN-DEGRADATION; CONJUGATING ENZYMES; NEURONAL DIFFERENTIATION; PROTEASOME; GENE; LACTACYSTIN; INHIBITORS; COMPLEX	Nerve growth factor (NGF)-induced neurite outgrowth from rat PC12 cells was coincident with elevated (ra-fold) levels of endogenous ubiquitin (Ub) protein conjugates, elevated rates of formation of I-125-labeled Ub similar to E1 (Ub-activating enzyme) thiol esters and I-125-labeled Ub similar to E2 (Ub carrier protein) thiol esters in vitro, and enhanced capacity to synthesize I-125-labeled Ub-protein conjugates de novo. Activities of at least four E2s were increased in NGF-treated cells, including E2(14K), a component of the N-end rule pathway. Ubiquitylation of I-125-labeled beta-lactoglobulin was up to 4-fold greater in supernatants from NGF-treated cells versus untreated cells and was selectively inhibited by the dipeptide Leu-Ala, an inhibitor of Ub isopeptide ligase (E3), However, Uh-dependent proteolysis of I-125-labeled beta-lactoglobulin was not increased in supernatants from NGF-treated cells, suggesting that neurite outgrowth is promoted by enhanced rates of synthesis (rather than degradation) of Uh-protein conjugates, Consistent with this observation, neurite outgrowth was induced by proteasome inhibitors (lactacystin and clasto-lactacystin beta-lactone) and was associated with elevated levels of ubiquitylated protein and stabilization of the Uh-dependent substrate, p53. Lactacystin-induced neurite outgrowth was blocked by the dipeptide Leu-Ala (2 mM) but not by His-Ala These data 1) demonstrate that the enhanced pool of ubiquitylated protein observed during neuritogenesis in PC12 cells reflects coordinated up-regulation of Ub-conjugating activity, 2) suggest that Ub-dependent proteolysis is a negative regulator of neurite outgrowth in vitro, and 3) support a role for E2(14K)/E3-mediated protein ubiquitylation in PC12 cell neurite outgrowth.	Tufts Univ, JMUSDA, HNRCA, Lab Nutr & Vis Res, Boston, MA 02111 USA; Tufts Univ, JMUSDA, HNRCA, Neurosci Lab, Boston, MA 02111 USA; Savannah State Univ, Dept Biol & Life Sci, Savannah, GA 31404 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA); University System of Georgia; Savannah State University; Medical College of Wisconsin	Obin, M (corresponding author), Tufts Univ, JMUSDA, HNRCA, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.				NEI NIH HHS [EY11703] Funding Source: Medline; NIGMS NIH HHS [GM34009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIELLO LP, 1986, BIOCHEMISTRY-US, V25, P3944, DOI 10.1021/bi00361a031; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BONFANTI L, 1992, J COMP NEUROL, V322, P35, DOI 10.1002/cne.903220104; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; FAHRBACH SE, 1994, J COMP NEUROL, V343, P464, DOI 10.1002/cne.903430309; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Flann S, 1997, NEUROSCIENCE, V81, P173, DOI 10.1016/S0306-4522(97)00196-6; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280, DOI 10.1016/0006-291X(92)91555-5; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Maufroid JP, 1996, INT J DEV BIOL, V40, P609; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; OBIN M, 1995, CURR EYE RES, V14, P751, DOI 10.3109/02713689508995796; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; OH CE, 1994, J NEUROSCI, V14, P3166; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMITHTHOMAS LC, 1994, DEV BRAIN RES, V81, P171, DOI 10.1016/0165-3806(94)90303-4; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; Taban CH, 1996, EXPERIENTIA, V52, P865, DOI 10.1007/BF01938871; TAKADA K, 1994, NEUROCHEM RES, V19, P391, DOI 10.1007/BF00967315; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Wang YM, 1997, NEUROCHEM RES, V22, P1453, DOI 10.1023/A:1021998227237; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; WING SS, 1992, J BIOL CHEM, V267, P6495	45	86	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11789	11795		10.1074/jbc.274.17.11789	http://dx.doi.org/10.1074/jbc.274.17.11789			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206996	hybrid			2022-12-25	WOS:000079834800052
J	Witkowski, A; Joshi, AK; Rangan, VS; Falick, AM; Witkowska, HE; Smith, S				Witkowski, A; Joshi, AK; Rangan, VS; Falick, AM; Witkowska, HE; Smith, S			Dibromopropanone cross-linking of the phosphopantetheine and active-site cysteine thiols of the animal fatty acid synthase can occur both inter- and intrasubunit - Reevaluation of the side-by-side, antiparallel subunit model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAMMARY-GLAND; MASS-SPECTROMETRY; MULTIFUNCTIONAL ENZYME; MOLECULAR-CLONING; CHICKEN LIVER; IN-VITRO; SYNTHETASE; DOMAINS; CDNA; COMPLEMENTATION	The objective of this study was to test a new model for the homodimeric animal FAS which implies that the condensation reaction can be catalyzed by the aminoterminal beta-ketoacyl synthase domain in cooperation with the penultimate carboxyl-terminal acyl carrier protein domain of either subunit, Treatment of animal fatty acid synthase dimers with dibromopropanone generates three new molecular species with decreased electrophoretic mobilities; none of these species are formed by fatty acid synthase mutant dimers lacking either the active-site cysteine of the beta-ketoacyl synthase domain (C161A) or the phosphopantetheine thiol of the acyl carrier protein domain (S2151A), A double affinity-labeling strategy was used to isolate dimers that carried one or both mutations on one or both subunits; the heterodimers were treated with dibromopropanone and analyzed by a combination of sodium dodecyl sulfate/polyacrylamide gel electrophoresis, Western blotting, gel filtration, and matrix-assisted laser desorption mass spectrometry, Thus the two slowest moving of these species, which accounted for 45 and 15% of the total, were identified as doubly and singly cross-linked dimers, respectively, whereas the fastest moving species, which accounted for 35% of the total, was identified as originating from internally cross-linked subunits, These results show that the two polypeptides of the fatty acid synthase are oriented such that head-to-tail contacts are formed both between and within subunits, and provide the first structural evidence in support of the new model.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; PE Biosyst, S San Francisco, CA 94080 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Smith, S (corresponding author), Childrens Hosp Oakland, Res Inst, 747 52nd St, Oakland, CA 94609 USA.			Witkowski, Andrzej/0000-0002-0442-4586	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; CHANG SI, 1990, ACCOUNTS CHEM RES, V23, P363, DOI 10.1021/ar00179a003; CHANG SI, 1989, P NATL ACAD SCI USA, V86, P8373, DOI 10.1073/pnas.86.21.8373; FERNANDEZPATRON C, 1992, BIOTECHNIQUES, V12, P564; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; Joshi AK, 1998, BIOCHEMISTRY-US, V37, P2515, DOI 10.1021/bi971886v; JOSHI AK, 1993, BIOCHEM J, V296, P143, DOI 10.1042/bj2960143; Joshi AK, 1998, J BIOL CHEM, V273, P4937, DOI 10.1074/jbc.273.9.4937; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; KUMAR S, 1970, BIOCHEM BIOPH RES CO, V40, P825, DOI 10.1016/0006-291X(70)90977-0; MOCK KK, 1992, RAPID COMMUN MASS SP, V6, P233, DOI 10.1002/rcm.1290060402; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PETITHORY JR, 1993, BIOCHEM J, V292, P361, DOI 10.1042/bj2920361; Rangan VS, 1998, J BIOL CHEM, V273, P34949, DOI 10.1074/jbc.273.52.34949; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SINGH N, 1984, J BIOL CHEM, V259, P3605; Smith S, 1975, Methods Enzymol, V35, P65, DOI 10.1016/0076-6879(75)35139-2; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH S, 1985, EUR J BIOCHEM, V152, P547, DOI 10.1111/j.1432-1033.1985.tb09230.x; SMITH S, 1971, J BIOL CHEM, V246, P6428; STOOPS JK, 1982, J BIOL CHEM, V257, P3230; STOOPS JK, 1981, J BIOL CHEM, V256, P5128; STRUPAT K, 1994, ANAL CHEM, V66, P464, DOI 10.1021/ac00076a008; VESTAL ML, 1995, RAPID COMMUN MASS SP, V9, P1044, DOI 10.1002/rcm.1290091115; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Witkowski A, 1996, BIOCHEMISTRY-US, V35, P10569, DOI 10.1021/bi960910m; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; Witkowski A, 1997, BIOCHEMISTRY-US, V36, P16338, DOI 10.1021/bi972242q	31	32	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11557	11563		10.1074/jbc.274.17.11557	http://dx.doi.org/10.1074/jbc.274.17.11557			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206962	hybrid			2022-12-25	WOS:000079834800018
J	Zhu, HJ; Sizeland, AM				Zhu, HJ; Sizeland, AM			A pivotal role for the transmembrane domain in transforming growth factor-beta receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTOR; HETEROOLIGOMERIC COMPLEXES; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION; EXPRESSION; KINASE; TRANSPHOSPHORYLATION; PHOSPHORYLATION; SUPERFAMILY; PROTEINS	Transforming growth factor-beta (TGF-beta) delivers diverse growth and differentiation signals by binding two distantly related transmembrane serine/threonine kinase receptors: the type I receptor (T beta RI) and the type II receptor (T beta RII), In an attempt to establish the role of the transmembrane domain in receptor signaling, two chimeric TGF-beta receptors, T beta RI-II-I and T beta RII-I-II, containing the opposite transmembrane domain were generated. When transfected into a mutant mink lung epithelial cell line R1B, which lacks functional T beta RI, T beta RI-II-I restored TGF-beta 1-induced transcriptional activation of a TGF-beta reporter p3TP-Lux to similar to 25% of the levels restored by wild-type T beta RI, In the mutant mink lung epithelial cell line DR26, which contains a truncated, nonfunctional T beta RII, wild-type receptor T beta RII restored the TGF-beta responsiveness, while the T beta RII-I-II cDNA was inactive, When both T beta RI and T beta RII were transfected into R1B, DR26, or Mv1Lu cells, a low level of constitutive p3TP-Lux activity was observed. However, cotransfection of both transmembrane chimeric receptors, T beta RI-II-I and T beta RII-I-II, or the wild-type T beta RI with the transmembrane chimeric T beta RII-I-II resulted in high levels of ligand-independent receptor activation. These results suggest that the transmembrane domains of both TGF-beta receptors are essential and play a pivotal role in receptor activation. To investigate the role of the transmembrane domain further, four type II transmembrane mutants were generated: T beta RII Delta-1, T beta RII Delta-2, T beta RII Delta-3, and T beta RII Delta-4, which have one, two, three, or four amino acids deleted at the N terminus of the transmembrane domain, respectively. Interestingly, co expression of T beta RII Delta-1 with the wild-type T beta RI in DR26 cells resulted in high levels of constitutive activation, while only low levels of the activation were observed when T beta RII Delta-2, T beta RII Delta-3, or T beta RII Delta-4 were co-expressed with the wildtype T beta RI, However, T beta RII Delta-1 restored very little the TGF-beta responsiveness in DR26cells, Expression of T beta RII Delta-2, T beta RII Delta-3, and T beta RII Delta-4 resulted in a progressive increase in TGF-P responsiveness, with T beta RII Delta-4 reaching the level of activity of the wild-type T beta RII, Furthermore, like T beta RII-I-II, co-expression of T beta RII Delta-1 with T beta RI-II-I also resulted in high levels of constitutive activation. These results are consistent with an important role for the transmembrane region of the receptors, We further propose a model of receptor activation in which receptor activation occurs via relative orientational rotation.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Zhu, HJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.			Zhu, Hong-Jian/0000-0002-1478-995X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; MIYAZONO K, 1993, GROWTH FACTORS, V8, P11, DOI 10.3109/08977199309029130; OKADOME T, 1994, J BIOL CHEM, V269, P30753; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	31	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11773	11781		10.1074/jbc.274.17.11773	http://dx.doi.org/10.1074/jbc.274.17.11773			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206994	hybrid			2022-12-25	WOS:000079834800050
J	Dorn, C; Ou, QL; Svaren, J; Crawford, PA; Sadovsky, Y				Dorn, C; Ou, QL; Svaren, J; Crawford, PA; Sadovsky, Y			Activation of luteinizing hormone beta gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL HYPOPLASIA CONGENITA; VENTROMEDIAL HYPOTHALAMIC NUCLEUS; PROTEIN-KINASE-C; FACTOR-I SF-1; SUBUNIT GENE; TRANSGENIC MICE; DNA-BINDING; NGFI-A; GNRH RECEPTOR; DIFFERENTIAL REGULATION	We have previously shown that early growth response (Egr) 1-deficient mice exhibit female infertility, reflecting a luteinizing hormone (LH) beta deficiency. Egr-1 activates the LH beta gene in vitro through synergy with steroidogenic factor-1 (SF-1), a protein required for gonadotrope function, To test if this synergy is essential for gonadotropin-releasing hormone (GnRH) stimulation of LH beta, we examined the activity of the LH beta promoter in the gonadotrope cell line L beta T2. GnRH markedly stimulated the LH beta promoter (15-fold). Mutation of either Egr-1 or SF-1 elements within the LH beta promoter attenuated this stimulation, whereas mutation of both promoter elements abrogated GnRH induction of the LH beta promoter. Furthermore, GnRH stimulated Egr-1 but not SF-1 expression in L beta T2 cells. Importantly, overexpression of Egr-1 alone was sufficient to enhance LH beta expression. Although other Egr proteins are expressed in L beta T2 cells and are capable of interacting with SF-1, GnRH stimulation of Egr-1 was the most robust, We also found that the nuclear receptor DAX-1, a repressor of SF-1 activity, reduced Egr-1-SF-1 synergy and diminished GnRH stimulation of the LH beta promoter. We conclude that the synergy between Egr-1 and SF-1 is essential for GnRH stimulation of the LH beta gene and plays a central role in the dynamic regulation of LH beta expression.	Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Sadovsky, Y (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, POB 8064,4911 Barnes Jewish Hosp Plaza, St Louis, MO 63110 USA.	sadovskyy@msnotes.wustl.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921; Crawford, Peter/0000-0001-8597-4426				Alarid ET, 1996, DEVELOPMENT, V122, P3319; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANDREWS WV, 1988, J BIOL CHEM, V263, P13755; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BELCHETZ PE, 1978, SCIENCE, V202, P631, DOI 10.1126/science.100883; Brown P, 1997, INT J BIOCHEM CELL B, V29, P1513, DOI 10.1016/S1357-2725(97)00082-4; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAYTON RN, 1991, MOL CELL ENDOCRINOL, V80, P193, DOI 10.1016/0303-7207(91)90156-M; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Ehrengruber MU, 1998, METHOD ENZYMOL, V293, P483; FALLEST PC, 1995, BIOL REPROD, V53, P103, DOI 10.1095/biolreprod53.1.103; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; HAISENLEDER DJ, 1991, ENDOCRINOLOGY, V128, P509, DOI 10.1210/endo-128-1-509; Haisenleder DJ, 1996, ENDOCRINOLOGY, V137, P5719, DOI 10.1210/en.137.12.5719; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ikuyama S, 1998, CLIN ENDOCRINOL, V48, P647, DOI 10.1046/j.1365-2265.1998.00477.x; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Kaiser UB, 1998, J BIOL CHEM, V273, P12943, DOI 10.1074/jbc.273.21.12943; Kaiser UB, 1995, P NATL ACAD SCI USA, V92, P12280, DOI 10.1073/pnas.92.26.12280; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; Keri RA, 1996, J BIOL CHEM, V271, P10782, DOI 10.1074/jbc.271.18.10782; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; Lanctot C, 1997, DEVELOPMENT, V124, P2807; LeDrean Y, 1996, MOL ENDOCRINOL, V10, P217, DOI 10.1210/me.10.3.217; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARSHALL JC, 1991, RECENT PROG HORM RES, V47, P155; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Naor Z, 1998, FRONT NEUROENDOCRIN, V19, P1, DOI 10.1006/frne.1997.0162; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SAADE G, 1989, ENDOCRINOLOGY, V124, P1744, DOI 10.1210/endo-124-4-1744; Sadovsky Y, 1998, J SOC GYNECOL INVEST, V5, P6, DOI 10.1016/S1071-5576(97)00096-8; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; SHUPNIK MA, 1991, J BIOL CHEM, V266, P17084; SHUPNIK MA, 1990, MOL ENDOCRINOL, V4, P1444, DOI 10.1210/mend-4-10-1444; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; Thomas P, 1996, ENDOCRINOLOGY, V137, P2979, DOI 10.1210/en.137.7.2979; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tourtellotte WG, 1998, NAT GENET, V20, P87, DOI 10.1038/1757; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; WATSON MA, 1990, DEVELOPMENT, V110, P173; Weck J, 1998, MOL ENDOCRINOL, V12, P451, DOI 10.1210/me.12.3.451; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	65	151	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13870	13876		10.1074/jbc.274.20.13870	http://dx.doi.org/10.1074/jbc.274.20.13870			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318795	hybrid			2022-12-25	WOS:000080322200024
J	Hanlon, M; Sealy, L				Hanlon, M; Sealy, L			Ras regulates the association of serum response factor and CCAAT/enhancer-binding protein beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; LONG TERMINAL REPEAT; C/EBP-BETA; FACTOR SRF; ELEMENT; FAMILY; SEQUENCE; COMPLEX; NF-IL6; MEMBER	The serum response element (SRE) is a promoter element essential for transcriptional activation of immediate early genes, such as c-fos and early growth response-1, by mitogenic signals, Several transcription factors bind the SRE, including the serum response factor (SRF), the ternary complex factor, and the CCAAT/enhancer-binding protein beta (C/EBP beta). The C/EBP beta mRNA encodes three translation products of 38, 35, and 20 kDa, p35-C/EBP beta activates transcription of the SRE in an SRF-dependent fashion, whereas p20-C/EBP beta, which initiates at an internal in-frame methionine, lacks a transactivation domain and inhibits transcription. We show that SRF and C/EBP beta interact in vivo through the DNA binding domain of SRF and the C terminus of C/EEP beta common to p35/38 and p20. Therefore, like the ternary complex factor, C/EBP beta may be recruited to the SRE not only by binding to the DNA, which is not a high affinity site, but also by protein-protein interactions with SRF, Strikingly, in both the mammalian two-hybrid assay and in vivo coimmunoprecipitations, the association of SRF and p35-C/EBP beta but not p20-C/EBP beta is dramatically stimulated by activated Ras, Furthermore, mutation of the threonine within a mitogen-activated protein kinase consensus motif in the C terminus of C/EBP beta eliminates the response to Ras, These results suggest a new mechanism by which mitogenic signals may influence transcription activity of the SRE by selectively promoting protein-protein interactions between SRF and the transactivator p35-C/EBP beta.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Sealy, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NIGMS NIH HHS [GM29826, 5T32GM08554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029826, T32GM008554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Mobley CM, 1998, J VIROL, V72, P6592, DOI 10.1128/JVI.72.8.6592-6601.1998; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Pelech S L, 1995, Prog Cell Cycle Res, V1, P33; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIESMAN R, 1987, EMBO J, V6, P2711; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	23	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14224	14228		10.1074/jbc.274.20.14224	http://dx.doi.org/10.1074/jbc.274.20.14224			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318842	hybrid			2022-12-25	WOS:000080322200071
J	Hirata, K; Dichek, HL; Cioffi, JA; Choi, SY; Leeper, NJ; Quintana, L; Kronmal, GS; Cooper, AD; Quertermous, T				Hirata, K; Dichek, HL; Cioffi, JA; Choi, SY; Leeper, NJ; Quintana, L; Kronmal, GS; Cooper, AD; Quertermous, T			Cloning of a unique lipase from endothelial cells extends the lipase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY-LIKE STRUCTURES; LIPOPROTEIN-LIPASE; HEPATIC LIPASE; PANCREATIC LIPASE; DIFFERENTIATION; ANGIOGENESIS; ATHEROSCLEROSIS; HYBRIDIZATION; METABOLISM; RECEPTOR	A new lipoprotein lipase-like gene has been cloned from endothelial cells through a subtraction methodology aimed at characterizing genes that are expressed with in vitro differentiation of this cell type. The conceptual endothelial cell-derived lipase protein contains 500 amino acids, including an 18-amino acid hydrophobic signal sequence, and is 44% identical to lipoprotein lipase and 41% identical to hepatic lipase. Comparison of primary sequence to that of lipoprotein and hepatic lipase reveals conservation of the serine, aspartic acid, and histidine catalytic residues as well as the 10 cysteine residues involved in disulfide bond formation. Expression was identified in cultured human umbilical vein endothelial cells, human coronary artery endothelial cells, and murine endothelial-like yolk sac cells by Northern blot. In addition, Northern blot and in situ hybridization analysis revealed expression of the endothelial-derived lipase in placenta, liver, lung, ovary, thyroid gland, and testis. A c-Myc-tagged protein secreted from transfected COS7 cells had phospholipase Al activity but no triglyceride lipase activity. Its tissue-restricted pattern of expression and its ability to be expressed by endothelial cells, suggests that endothelial cell-derived lipase may have unique functions in lipoprotein metabolism and in vascular disease.	Stanford Univ, Sch Med, Div Cardiol, Stanford, CA 94305 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Progenitor Inc, Menlo Park, CA 94025 USA; Palo Alto Med Fdn, Palo Alto, CA 94301 USA; Stanford Univ, Sch Med, Div Gastroenterol, Stanford, CA 94305 USA	Stanford University; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; Palo Alto Medical Foundation Research Institute; Stanford University	Quertermous, T (corresponding author), Stanford Univ, Sch Med, Div Cardiol, Falk Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.			Quertermous, Thomas/0000-0002-7645-9067	NHLBI NIH HHS [KO8 HL 03865 01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATENBURG JJ, 1992, AM J PHYSIOL, V262, P367; BELFRAGE P, 1969, J LIPID RES, V10, P341; BIEZENSKI JJ, 1969, AM J OBSTET GYNECOL, V104, P1177, DOI 10.1016/S0002-9378(16)34293-4; BRAUN JEA, 1992, BIOCHEM J, V287, P337, DOI 10.1042/bj2870337; Corn BJ, 1991, CLIN BIOTECHNOL, V3, P15; CRYER A, 1987, LIPOPROTEIN LIPASE; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DICHEK HL, 1993, J LIPID RES, V34, P1393; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; HIDE WA, 1992, J LIPID RES, V33, P167; HOGAN B, 1994, MANIPULATING MOUSE E, P325; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Mallampalli RK, 1997, J CLIN INVEST, V99, P2020, DOI 10.1172/JCI119370; OBRIEN KD, 1994, AM J PATHOL, V144, P538; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; QUINN DM, 1982, BIOCHEMISTRY-US, V21, P6872, DOI 10.1021/bi00269a038; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P112; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WEI YZ, 1995, STEM CELLS, V13, P541, DOI 10.1002/stem.5530130512; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	31	257	295	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14170	14175		10.1074/jbc.274.20.14170	http://dx.doi.org/10.1074/jbc.274.20.14170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318835	hybrid			2022-12-25	WOS:000080322200064
J	Holz, GG; Leech, CA; Heller, RS; Castonguay, M; Habener, JF				Holz, GG; Leech, CA; Heller, RS; Castonguay, M; Habener, JF			cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells - A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INOSITOL 1,4,5-TRISPHOSPHATE; RELEASE CHANNEL; PEPTIDE-I; SARCOPLASMIC-RETICULUM; PEPTIDE-1(7-36) AMIDE; PHOSPHOLIPASE-C; CALCIUM-RELEASE; SECRETING CELLS; CARDIAC-MUSCLE	Glucagon-like peptide-1 (GLP-1) is an intestinally derived insulinotropic hormone currently under investigation for use as a novel therapeutic agent in the treatment of type 2 diabetes mellitus, In vitro studies of pancreatic islets of Langerhans demonstrated that GLP-1 interacts with specific beta-cell G protein-coupled receptors, thereby facilitating insulin exocytosis by raising intracellular levels of cAMP and Ca2+. Here we report that the stimulatory influence of GLP-1 on Ca2+ signaling results, in part, from cAMP-dependent mobilization of ryanodine-sensitive Ca2+ stores. Studies of human, rat, and mouse beta-cells demonstrate that the binding of a fluorescent derivative of ryanodine (BODIPY FL-X ryanodine) to its receptors is specific, reversible, and of high affinity. Rat islets and BTC3 insulinoma cells are shown by reverse transcriptase polymerase chain reaction analyses to express mRNA corresponding to the type 2 isoform of ryanodine receptor-intracellular Ca2+ release channel (RYR2), Single-cell measurements of [Ca2+](i) using primary cultures of rat and human beta-cells indicate that GLP-1 facilitates Ca2+-induced Ca2+ release (CICR), whereby mobilization of Ca2+ stores is triggered by influx of Ca2+ through L-type Ca2+ channels, In these cells, GLP-1 is shown to interact with metabolism of D-glucose to produce a fast transient increase of [Ca2+](i). This effect is reproduced by 8-Br-cAMP, but is blocked by a GLP-1 receptor antagonist (exendin-(9-39)), a cAMP antagonist ((Rp)-cAMPS), an L-type Ca2+ channel antagonist (nimodipine), an antagonist of the sarco(endo)plasmic reticulum Ca2+ ATPase (thapsigargin), or by ryanodine, Characterization of the CICR mechanism by voltage clamp analysis also demonstrates a stimulation of Ca2+ release by caffeine. These findings provide new support for a model of beta-cell signal transduction whereby GLP-1 promotes CICR by sensitizing intracellular Ca2+ release channels to the stimulatory influence of cytosolic Ca2+.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Endocrinol Lab, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Holz, GG (corresponding author), NYU, Med Ctr, Dept Physiol & Neurosci, New York, NY 10016 USA.		Holz, George G/A-3386-2012; Heller, R.Scott/A-7279-2008	Holz, George/0000-0002-1781-3580	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045817, R01DK052166, R01DK045817, R01DK030834] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45817, R01 DK045817, DK-52166, DK-30834, R01 DK030834] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; AYABE T, 1995, DEVELOPMENT, V121, P2233; BARKER CJ, 1994, BIOCHEM J, V297, P265, DOI 10.1042/bj2970265; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; Chatton JY, 1998, BIOCHEM J, V330, P1411, DOI 10.1042/bj3301411; Chen TH, 1996, LIFE SCI, V58, P983, DOI 10.1016/0024-3205(96)00046-X; CHOW RH, 1995, J PHYSIOL-LONDON, V485, P607, DOI 10.1113/jphysiol.1995.sp020756; CULLINAN CA, 1994, CELL CALCIUM, V15, P391, DOI 10.1016/0143-4160(94)90014-0; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; FRIDOLF T, 1991, DIABETES RES CLIN EX, V16, P185; FRIDOLF T, 1993, MOL CELL ENDOCRINOL, V96, P85, DOI 10.1016/0303-7207(93)90098-5; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; Gromada J, 1998, FEBS LETT, V425, P277, DOI 10.1016/S0014-5793(98)00254-3; GROMADA J, 1995, DIABETES, V44, P767, DOI 10.2337/diabetes.44.7.767; Gromada J, 1998, DIABETES, V47, P57, DOI 10.2337/diabetes.47.1.57; Gromada J, 1997, PFLUG ARCH EUR J PHY, V434, P515, DOI 10.1007/s004240050431; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Gromada J, 1996, BRIT J PHARMACOL, V118, P769, DOI 10.1111/j.1476-5381.1996.tb15466.x; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; Islam MS, 1997, DIABETOLOGIA, V40, P1480, DOI 10.1007/s001250050853; Islam MS, 1997, BIOCHEM J, V321, P347, DOI 10.1042/bj3210347; ISLAM MS, 1993, SCIENCE, V262, P584, DOI 10.1126/science.8211188; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Kato M, 1996, REGUL PEPTIDES, V62, P23, DOI 10.1016/0167-0115(95)00164-6; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; KREYMANN B, 1987, LANCET, V2, P1300; LACY PE, 1967, DIABETES, V16, P335; Leech CA, 1997, J BIOL CHEM, V272, P17987, DOI 10.1074/jbc.272.29.17987; Leech CA, 1996, ANN NY ACAD SCI, V805, P81; Liu YJ, 1996, ARCH BIOCHEM BIOPHYS, V334, P295, DOI 10.1006/abbi.1996.0458; LU M, 1993, ENDOCRINOLOGY, V132, P94, DOI 10.1210/en.132.1.94; Malaisse WJ, 1997, BIOCHEM BIOPH RES CO, V231, P546, DOI 10.1006/bbrc.1996.5715; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NATHAN DM, 1992, DIABETES CARE, V15, P270, DOI 10.2337/diacare.15.2.270; Nauck MA, 1997, EXP CLIN ENDOCR DIAB, V105, P187, DOI 10.1055/s-0029-1211750; Okamoto H, 1997, DIABETOLOGIA, V40, P1485, DOI 10.1007/s001250050854; OTSU K, 1990, J BIOL CHEM, V265, P13472; Ozawa T, 1998, BIOCHEM BIOPH RES CO, V246, P422, DOI 10.1006/bbrc.1998.8636; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TANIGUCHI T, 1996, ENDOCRINOL METAB, V3, P135; Tengholm A, 1998, DIABETES, V47, P1224, DOI 10.2337/diabetes.47.8.1224; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; WANG JL, 1993, J BIOL CHEM, V268, P7785; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; WILLMOTT NJ, 1995, FEBS LETT, V371, P99, DOI 10.1016/0014-5793(95)00848-4; WILLMOTT NJ, 1995, CELL CALCIUM, V18, P411, DOI 10.1016/0143-4160(95)90056-X; WOLF BA, 1985, BIOCHEM J, V227, P965, DOI 10.1042/bj2270965; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YADA T, 1993, ENDOCRINOLOGY, V133, P1685, DOI 10.1210/en.133.4.1685; ZAWALICH WS, 1993, REGUL PEPTIDES, V44, P277, DOI 10.1016/0167-0115(93)90137-W	69	188	201	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14147	14156		10.1074/jbc.274.20.14147	http://dx.doi.org/10.1074/jbc.274.20.14147			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318832	Green Accepted, hybrid			2022-12-25	WOS:000080322200061
J	Huang, CYF; Chang, CPB; Huang, CL; Ferrell, JE				Huang, CYF; Chang, CPB; Huang, CL; Ferrell, JE			M phase phosphorylation of cytoplasmic dynein intermediate chain and p150(Glued)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTE MATURATION; MAP KINASE CASCADE; MOS PROTO-ONCOGENE; CELL-CYCLE; MEIOTIC MATURATION; MITOTIC SPINDLE; IN-VIVO; TYROSINE PHOSPHORYLATION; MOTOR PROTEINS; CHROMOSOME SEGREGATION	To understand how the dramatic cell biological changes of oocyte maturation are brought about, we have begun to identify proteins whose phosphorylation state changes during Xenopus oocyte maturation. Here we have focused on one such protein, p83. We partially purified p83, obtained peptide sequence, and identified it as the intermediate chain of cytoplasmic dynein. During oocyte maturation, dynein intermediate chain became hyperphosphorylated at the time of germinal vesicle breakdown and remained hyperphosphorylated throughout the rest of meiosis and early embryogenesis. p150(Glued), a subunit of dynactin that has been shown to bind to dynein intermediate chain, underwent similar changes in its phosphorylation, Both dynein intermediate chain and p150(Glued) also became hyperphosphorylated during M phase in XTC-2 cells and HeLa cells. Thus, two components of the dynein-dynactin complex undergo coordinated phosphorylation changes at two G(2)/M transitions (maturation in oocytes and mitosis in cells in culture) but remain constitutively in their M phase forms during early embryogenesis. Dynein intermediate chain and p150(Glued) phosphorylation may positively regulate mitotic processes, such as spindle assembly or orientation, or negatively regulate interphase processes such as minus-end-directed organelle trafficking.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan	Stanford University; National Health Research Institutes - Taiwan	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	ferrell@cmgm.stanford.edu	Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937	NIGMS NIH HHS [GM46383] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046383] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DILLMAN JF, 1995, BIOPHYS J, V68, pS226; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Farshori P, 1997, BIOCHEM BIOPH RES CO, V232, P810, DOI 10.1006/bbrc.1997.6379; Faulkner NE, 1998, HUM MOL GENET, V7, P671, DOI 10.1093/hmg/7.4.671; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Gotoh Y, 1995, Prog Cell Cycle Res, V1, P287; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JESSUS C, 1991, DEVELOPMENT, V111, P813; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Murray AW, 1998, CELL, V92, P157, DOI 10.1016/S0092-8674(00)80910-1; MURRAY AW, 1991, SCI AM, V264, P56, DOI 10.1038/scientificamerican0391-56; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; NORBURY C, 1990, CIBA F SYMP, V150, P168; NORBURY C, 1990, CIBA F SYMP, V150, P177; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Saredi A, 1997, J CELL SCI, V110, P1287; SCHROER TA, 1994, CURR OPIN CELL BIOL, V6, P69, DOI 10.1016/0955-0674(94)90118-X; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	63	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14262	14269		10.1074/jbc.274.20.14262	http://dx.doi.org/10.1074/jbc.274.20.14262			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318847	hybrid			2022-12-25	WOS:000080322200076
J	Matsumoto, T; Yokote, K; Tamura, K; Takemoto, M; Ueno, S; Saito, Y; Mori, S				Matsumoto, T; Yokote, K; Tamura, K; Takemoto, M; Ueno, S; Saito, Y; Mori, S			Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA-RECEPTOR; FACTOR BETA-RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; LIGAND-MEDIATED ENDOCYTOSIS; HEAT-SHOCK PROTEIN-27; MAP KINASE; C-JUN; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; CDC42 GTPASES	Members of the mitogen activated protein (MAP) kinase family, extracellular signal-regulated kinase, stress-activated protein kinase 1/c-Jun NH2-terminal kinase, and p38, are central elements that transduce the signal generated by growth factors, cytokines, and stressing agents. It is well known that the plaleletrderived growth factor (PDGF) activates extracellular signal-regulated kinase, which leads to cellular mitogenic response. On the other hand, the role of the other MAP kinases in mediating the cellular function of PDGF remains unclear. In the present study, we have investigated the functional role of the other MAP kinases in PDGF-mediated cellular responses. We show that ligand stimulation of PDGF receptors leads to the activation of p38 but not stress-activated protein kinase-1/c-Jun NH2-terminal kinase. Experiments using a specific inhibitor of p38, SB203580, show that the activation of p38 is required for PDGF-induced cell motility responses such as cell migration and actin reorganization but not required for PDGF-stimulated DNA synthesis. Analyses of tyrosine residue-mutated PDGF receptors show that Src homology 2 domain-containing proteins including Src family kinases, phosphatidylinositol 3-kinase, the GTPase-activating protein of Ras, the Src homology 2 domain-containing phosphatase SHP-2, phospholipase C-gamma, and Crk do not play a major role in mediating the PDGF-induced activation of p38. Finally, the expression of dominant-negative Ras but not dominant-negative Rac inhibited p38 activation by PDGF, suggesting that Ras is a potent mediator in the p38 activation pathway downstream of PDGF receptors, Taken together, our present study proposes the existence of a Ras-dependent pathway for the activation of p38, which is important for cell motility responses elicited by PDGF stimulation.	Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Chiba 2600856, Japan; Kyushu Univ, Sch Med, Dept Cardiol, Mol Cardiol Unit,Higashi Ku, Fukuoka 8128582, Japan	Chiba University; Kyushu University	Matsumoto, T (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 1-8-1 Inohana, Chiba 2600856, Japan.							ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; Guay J, 1997, J CELL SCI, V110, P357; HELDIN CH, 1994, GUIDEBOOK CYTOKINES, P249; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Huot J, 1996, CANCER RES, V56, P273; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORI S, 1994, J BIOL CHEM, V269, P4917; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Ueno H, 1997, ARTERIOSCL THROM VAS, V17, P898, DOI 10.1161/01.ATV.17.5.898; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WENNSTROM S, 1994, ONCOGENE, V9, P651; Yokote K, 1996, J BIOL CHEM, V271, P5101; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	44	147	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13954	13960		10.1074/jbc.274.20.13954	http://dx.doi.org/10.1074/jbc.274.20.13954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318806	hybrid			2022-12-25	WOS:000080322200035
J	Wang, YX; Dhulipala, PDK; Li, L; Benovic, JL; Kotlikoff, MI				Wang, YX; Dhulipala, PDK; Li, L; Benovic, JL; Kotlikoff, MI			Coupling of M-2 muscarinic receptors to membrane ion channels via phosphoinositide 3-kinase gamma and atypical protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; POTASSIUM CHANNEL; K+ CHANNEL; INTRACELLULAR CALCIUM; SYMPATHETIC NEURONS; SIGNAL-TRANSDUCTION; PLATELET CYTOSOL; INWARD CURRENT; ACTIVATION; IDENTIFICATION	We report a novel signaling pathway linking M-2 muscarinic receptors to metabotropic ion channels. Stimulation of heterologously expressed M-2 receptors, but not other G(i)/G(o)-associated receptors (M-4 or alpha(2c)), activates a calcium- and voltage-independent chloride current in Xenopus oocytes. We show that the stimulatory pathway linking M-2 receptors to these chloride channels consists of G beta gamma stimulation of phosphoinositide 3-kinase gamma (PI-3K gamma), formation of phosphatidylinositol 3,4,5-trisphosphate (PIP3), and activation of atypical protein kinase C (PKC). The chloride current is activated in the absence of M-2 receptor stimulation by the injection of PIP3, and PIP3 current activation is blocked by a pseudosubstrate inhibitory peptide of atypical PKC but not other PKCs. Moreover, the current is activated by injection of recombinant PKC zeta at concentrations as low as 1 mM. M-2 receptor-current coupling was disrupted by inhibiton of PI-3K and by injection of beta gamma binding peptides, but it was not affected by expression of dominant negative p85 cRNA. We also show that this pathway mediates M-2 receptor coupling to metabotropic nonselective cation channels in mammalian smooth muscle cells, thus demonstrating the broad relevance of this signaling cascade in neurotransmitter signaling.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	University of Pennsylvania; Jefferson University	Kotlikoff, MI (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL41084, HL45239] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045239, R01HL041084, R29HL041084] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENHAM CD, 1985, NATURE, V316, P345, DOI 10.1038/316345a0; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BYRNE NG, 1987, BRIT J PHARMACOL, V92, P371, DOI 10.1111/j.1476-5381.1987.tb11333.x; Cantrell AR, 1996, NEURON, V16, P1019, DOI 10.1016/S0896-6273(00)80125-7; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; Gadbut AP, 1996, J BIOL CHEM, V271, P6398, DOI 10.1074/jbc.271.11.6398; Gailly P, 1997, J PHYSIOL-LONDON, V500, P95, DOI 10.1113/jphysiol.1997.sp022002; HARE K, 1994, P NATL ACAD SCI USA, V91, P7415; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INOUE R, 1990, J PHYSIOL-LONDON, V424, P73, DOI 10.1113/jphysiol.1990.sp018056; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARSH SJ, 1995, NEURON, V15, P729, DOI 10.1016/0896-6273(95)90160-4; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOCHIDA S, 1988, NEUROSCI LETT, V86, P201, DOI 10.1016/0304-3940(88)90571-X; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PACAUD P, 1991, J PHYSIOL-LONDON, V441, P477, DOI 10.1113/jphysiol.1991.sp018763; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; Wang YX, 1997, P NATL ACAD SCI USA, V94, P14918, DOI 10.1073/pnas.94.26.14918; Wang YX, 1997, AM J PHYSIOL-CELL PH, V273, pC500, DOI 10.1152/ajpcell.1997.273.2.C500; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	41	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					13859	13864		10.1074/jbc.274.20.13859	http://dx.doi.org/10.1074/jbc.274.20.13859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318793	hybrid			2022-12-25	WOS:000080322200022
J	Ferrari, D; Stroh, C; Schulze-Osthoff, K				Ferrari, D; Stroh, C; Schulze-Osthoff, K			P2X(7)/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; NUCLEAR FACTOR; EXTRACELLULAR ATP; KAPPA-B; PURINERGIC RECEPTORS; PLASMA-MEMBRANE; NERVOUS-SYSTEM; CYCLOSPORINE-A; GENE FAMILY; CALCINEURIN	ATP is released from neurons and other cell types during several physiological and stress conditions under which it exerts various biological effects upon binding to purinoreceptors, A rather peculiar purinoreceptor called P2X(7)/P2Z is expressed on microglial and other myeloic cells. Although increasing evidence implicates an important role for P2Z in inflammatory processes, little information exists about underlying signaling pathways. Here, we report that in N9 microglial cells, extracellular ATP potently activates nuclear factor of activated T cells (NFAT), a central transcription factor involved in cytokine gene expression. ATP activated NFAT rapidly (within 1 min), whereas activation of nuclear factor kappa B was much delayed, with strikingly distinct kinetics, During ATP stimulation, both NFAT-1 and NFAT-2 were activated by a calcineurin dependent pathway that required the influx of extracellular calcium ions. Based on the pharmacological profile, NFAT activation was specifically mediated by P2Z and not by other purinoreceptors. Ne cells that lacked P2Z but still expressed P2Y purinoreceptors failed to respond to NFAT activation. We conclude that P2Z-mediated NFAT activation may represent a novel mechanism by which extracellular ATP can modulate early inflammatory gene expression within the nervous and immune system.	Univ Tubingen, Med Clin, Dept Internal Med 1, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schulze-Osthoff, K (corresponding author), Univ Tubingen, Med Clin, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013; Ferrari, Davide/F-5644-2015	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Ferrari, Davide/0000-0002-5727-9204				APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; Burnstock G, 1996, CURR OPIN NEUROBIOL, V6, P526, DOI 10.1016/S0959-4388(96)80060-2; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Chuvpilo S, 1999, IMMUNITY, V10, P261, DOI 10.1016/S1074-7613(00)80026-6; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; FERRARI D, 1997, J EXP MED, V185, P1; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRIFFITHS RJ, 1995, J IMMUNOL, V154, P2821; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HICKMAN SE, 1994, BLOOD, V84, P2452; HO AM, 1994, J BIOL CHEM, V269, P28181; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Humphreys BD, 1996, J IMMUNOL, V157, P5627; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; MURGIA M, 1993, J BIOL CHEM, V268, P8199; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Park JC, 1996, J BIOL CHEM, V271, P20914, DOI 10.1074/jbc.271.34.20914; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	51	126	128	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13205	13210		10.1074/jbc.274.19.13205	http://dx.doi.org/10.1074/jbc.274.19.13205			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224077	hybrid			2022-12-25	WOS:000080200400039
J	Gradin, K; Toftgard, R; Poellinger, L; Berghard, A				Gradin, K; Toftgard, R; Poellinger, L; Berghard, A			Repression of dioxin signal transduction in fibroblasts - Identification of a putative repressor associated with Arnt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; AH-RECEPTOR; HISTONE ACETYLATION; TRANSCRIPTIONAL REPRESSION; CHROMATIN STRUCTURE; MESSENGER-RNA; GENE FAMILY; EXPRESSION; PROTEIN; RECRUITMENT	Heterodimeric complexes of basic helix-loop-helix/PAS transcription factors are involved in regulation of diverse physiological phenomena such as circadian rhythms, reaction to low oxygen tension, and detoxification, In fibroblasts, the basic helix-loop-helix/PAS heterodimer consisting of the ligand-inducible dioxin receptor and Arnt shows DNA-binding activity, and the receptor and Arnt are able to activate transcription when fused to a heterologous DNA-binding domain. However, fibroblasts are nonresponsive to dioxin with regard to induction mediated by the DNA response element recognized by the receptor and Arnt. Here we demonstrate that Arnt is associated with a fibroblast-specific factor, forming a complex that is capable of binding the dioxin response element. This factor may function as a repressor since negative regulation of target gene induction appears to be abolished by inhibition of histone deacetylase activity by trichostatin A. Finally, the negative regulatory function of this factor appears to be restricted for dioxin signaling since Ar-nt was able to mediate, together with hypoxia-inducible factor-la, transcriptional activation in hypoxic cells. Taken together, these data suggest that fibroblast-specific inhibition of dioxin responsiveness involves recruitment by Arnt of a cell type- and signaling pathway-specific corepressor associated with a histone deacetylase.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Nutr & Toxicol, S-14157 Huddinge, Sweden; Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden	Karolinska Institutet; Karolinska Institutet; Umea University	Gradin, K (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, Box 285, S-17177 Stockholm, Sweden.	katarina.gradin@cmb.ki.se						AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Basu A, 1997, J BIOL CHEM, V272, P5899, DOI 10.1074/jbc.272.9.5899; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Campbell SJ, 1996, J CELL SCI, V109, P2619; CHEN H, 1995, NAT GENET, V10, P9, DOI 10.1038/ng0595-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1996, MOL CELL BIOL, V16, P5865; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GRADIN K, 1994, J BIOL CHEM, V269, P23800; GRADIN K, 1993, J BIOL CHEM, V268, P4061; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; IOANNIDES C, 1990, DRUG METAB REV, V22, P1, DOI 10.3109/03602539008991444; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Kobayashi A, 1997, J BIOCHEM, V122, P703; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OMIECINSKI CJ, 1990, CANCER RES, V50, P4315; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; REICK M, 1994, MOL CELL BIOL, V14, P5653, DOI 10.1128/MCB.14.9.5653; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; STRUHL K, 1990, CURRENT PROTOCOLS S, V11; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang G L, 1996, Curr Opin Hematol, V3, P156; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	53	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13511	13518		10.1074/jbc.274.19.13511	http://dx.doi.org/10.1074/jbc.274.19.13511			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224119	hybrid			2022-12-25	WOS:000080200400081
J	Pye, DA; Gallagher, JT				Pye, DA; Gallagher, JT			Monomer complexes of basic fibroblast growth factor and heparan sulfate oligosaccharides are the minimal functional unit for cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RECEPTOR-BINDING; MITOGENIC ACTIVITY; EXTRACELLULAR DOMAIN; BIOLOGICAL-ACTIVITY; FGF RECEPTORS; DIMERIZATION; AFFINITY; IDENTIFICATION; EXPRESSION	The interaction of basic fibroblast growth factor (bFGF) with heparan sulfate (HS)/heparin has been shown to strongly enhance the activity of the growth factor although the mechanism of activation is unclear. We have addressed the issue of the minimal stoichiometry of an active HS oligosaccharide bFGF complex by chemically cross-linking the two components to form novel covalent conjugates. The cross-linking procedure produced both monomeric and dimeric bFGF oligosaccharide complexes, which were purified to homogeneity. Dimer conjugates were shown to have been formed as a result of disulfide bridging of monomer conjugates. These monomer conjugates were subsequently found to be biologically active in a mitogenesis assay. We therefore conclude that a monomeric bFGF oligosaccharide complex is the minimal functional unit required for mitogenic stimulation.	Univ Manchester, Paterson Inst Canc Res, Dept Med Oncol, Canc Res Campaign,Christie Hosp, Manchester M20 4BX, Lancs, England; Univ Manchester, Paterson Inst Canc Res, Dept drug Dev & Imaging, Canc Res Campaign,Christie Hosp, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Pye, DA (corresponding author), Univ Manchester, Paterson Inst Canc Res, Dept Med Oncol, Canc Res Campaign,Christie Hosp, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							ARAKAWA T, 1989, BIOCHEM BIOPH RES CO, V161, P335, DOI 10.1016/0006-291X(89)91601-X; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P576; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOX GM, 1988, J BIOL CHEM, V263, P18452; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; HEIDIN CH, 1995, CELL, V80, P213; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; Miao HQ, 1996, J BIOL CHEM, V271, P4879; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MOSES MA, 1991, BIO-TECHNOL, V9, P630, DOI 10.1038/nbt0791-630; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PRESTA M, 1992, BIOCHEM BIOPH RES CO, V185, P1098, DOI 10.1016/0006-291X(92)91739-D; PYE DA, 1995, BBA-MOL CELL RES, V1266, P235, DOI 10.1016/0167-4889(95)00012-H; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1998, BIOCHEM BIOPH RES CO, V248, P889, DOI 10.1006/bbrc.1998.9081; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SENO M, 1988, BIOCHEM BIOPH RES CO, V151, P701, DOI 10.1016/S0006-291X(88)80337-1; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; UENO H, 1992, J BIOL CHEM, V267, P1470; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; WALKER A, 1994, J BIOL CHEM, V269, P931; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	59	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	1999	274	19					13456	13461		10.1074/jbc.274.19.13456	http://dx.doi.org/10.1074/jbc.274.19.13456			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194NL	10224111	hybrid			2022-12-25	WOS:000080200400073
J	Bras, A; Ruiz-Vela, A; De Buitrago, GG; Martinez, C				Bras, A; Ruiz-Vela, A; De Buitrago, GG; Martinez, C			Caspase activation by BCR cross-linking in immature B cells: differential effects on growth arrest and apoptosis	FASEB JOURNAL			English	Article						caspases; cell cycle; PARP	LYMPHOMA-CELLS; CYTOCHROME-C; NEGATIVE SELECTION; CLONAL DELETION; GENE-PRODUCT; BONE-MARROW; DEATH; BCL-2; RECEPTOR; WEHI-231	The B cell lymphoma WEHI-231 has been used as a model to study immature B cell tolerance, based on its capacity to undergo growth arrest and programmed cell death on B cell receptor (BCR) cross-linking. Using this model to identify the molecular mechanisms underlying these processes, we found that BCR cross-linking results in the selective activation of caspase 7/Mch3, but not of the other two members of the CPP32 family, caspase 2/Nedd2 and caspase 3/CPP32. This was evidenced by the induction of proteolytic activity against the substrate for the CPP32 subfamily of caspases (z-DVED-AMC) in vitro, as well as PARP proteolysis in vivo and by the processing of the 35 kDa Mch3 into a 32 kDa species, which was later further proteolyzed. The general caspase inhibitor z-VAD-fmk, but not the CPP32 family inhibitor Ac-DEVD-CHO, blocked anti-lu-induced apoptosis, indicating that a caspase not belonging to the CPP32-like family is also implicated in anti-mu-triggered apoptosis. In contrast, z-VAD-fmk was not able to counteract growth arrest induced by anti-En. treatment, suggesting that caspase activation is not necessary for induction of growth arrest. Neither of the inhibitors prevented Mch3 processing; however, z-VAD-fmk prevented proteolysis of the p32 subunit, suggesting that further processing of this subunit is associated with apoptosis. Bcl-2 overexpression prevented anti-mu induction of CPP32-like activity and apoptosis, and blocked further processing of the Mch3 p32 subunit. In contrast, CD40 stimulation completely blocked the appearance of the p32 subunit in addition to blocking CPP32-like activity and apoptosis induced by BCR cross-linking. Moreover, only CD40 stimulation was able to prevent anti-mu-induced growth arrest, which was correlated with inhibition of retinoblastoma and of cyclin A down-regulation. In splenic B cells, Mch3 is also specifically proteolyzed ex vivo after induction of apoptosis by BCR cross-linking, demonstrating the specific involvement of caspase-7/Mch3 in apoptosis induced in B cell tolerance.	Univ Autonoma Madrid, Dept Immunol & Oncol, Ctr Nacl Biotecnol, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bras, A (corresponding author), Univ Autonoma Madrid, Dept Immunol & Oncol, Ctr Nacl Biotecnol, CSIC, Campus de Cantoblanco, E-28049 Madrid, Spain.	abras@cnb.uam.es		Ruiz-Vela, Antonio/0000-0002-4410-6208				BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BOYD AW, 1981, J IMMUNOL, V126, P2466; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLAVERIA C, 1998, IN PRESS EMBO J, V17; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HARTLEY SB, 1993, CELL, V3, P3265; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Hertz M, 1998, CURR OPIN IMMUNOL, V10, P208, DOI 10.1016/S0952-7915(98)80250-1; ISHIDA T, 1995, J IMMUNOL, V155, P5527; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LeBein TW, 1998, CURR OPIN IMMUNOL, V10, P188, DOI 10.1016/S0952-7915(98)80248-3; MacLennan ICM, 1998, CURR OPIN IMMUNOL, V10, P220, DOI 10.1016/S0952-7915(98)80252-5; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; MERINO R, 1995, J IMMUNOL, V155, P3830; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NISITANI S, 1993, J EXP MED, V178, P1247, DOI 10.1084/jem.178.4.1247; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; ONEL KB, 1995, EUR J IMMUNOL, V25, P2940, DOI 10.1002/eji.1830251034; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RUSSELL DM, 1991, NATURE, V6351, P308; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	47	45	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					931	944		10.1096/fasebj.13.8.931	http://dx.doi.org/10.1096/fasebj.13.8.931			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224236				2022-12-25	WOS:000080372500016
J	Bogdanov, M; Umeda, M; Dowhan, W				Bogdanov, M; Umeda, M; Dowhan, W			Phospholipid-assisted refolding of an integral membrane protein - Minimum structural features for phosphatidylethanolamine to act as a molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC PHASE-BEHAVIOR; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; LACTOSE PERMEASE; P-31 NMR; PHOSPHATIDYLSERINE DECARBOXYLASE; INTERMEDIATE; TRANSITIONS; BILAYER; TRANSPORT	Escherichia coli-derived phosphatidylethanolamine (PE) or PE with fully saturated fatty acids was able to correct in vitro a defect in folding in the lipid dependent epitope 4B1 of lactose permease (LacY) resulting from in vivo assembly in the absence of PE. PE plasmalogen, PE with two unsaturated fatty acids, and lyso-PE, which all do not favor bilayer organization, did not support proper refolding, Proper refolding occurred when these latter lipids were mixed with a bilayer-forming lipid (phosphatidylglycerol), which alone could not support refolding, L-Phosphatidylserine (PS; natural diastereomer) did support proper refolding, PE derivatives of increasing degrees of methylation were progressively less effective in supporting refolding, with phosphatidylcholine being completely ineffective. Therefore, the properties of nonmethylated aminophospholipids capable of organization into a bilayer configuration are essential for the recovery of the native state of epitope 4B1 after misassembly in vivo in the absence of PE, Neither D-PS (sn-glycero-l-phosphate backbone) nor P-D-S (D-serine in the head group) is competent in supporting proper refolding unless used in binary mixtures with phosphatidylglycerol. The detailed characterization of phospholipid-assisted refolding reported here further supports a specific rather than nonspecific role for PE in structural maturation of lactose permease in vivo (Bogdanov, RI., and Dowhan, W, (1998) EMBO J, 17, 5255-5264).	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Tokyo 113, Japan	University of Texas System; Tokyo Metropolitan Institute of Medical Science	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	wdowhan@bmb.med.uth.tmc.edu	Bogdanov, Mikhail/J-3695-2017		NIGMS NIH HHS [GM24078] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn T, 1998, J BIOL CHEM, V273, P21692, DOI 10.1074/jbc.273.34.21692; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5; BROWNING JL, 1980, BIOCHEMISTRY-US, V19, P1262, DOI 10.1021/bi00547a034; CHEN CC, 1984, J BIOL CHEM, V259, P150; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; CULLIS PR, 1991, LIPID POLYMORPHISM M, P35; de Cock H, 1999, J BIOL CHEM, V274, P5114, DOI 10.1074/jbc.274.8.5114; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; DORSET DL, 1990, BIOCHIM BIOPHYS ACTA, V1028, P299, DOI 10.1016/0005-2736(90)90179-R; DOWHAN W, 1992, METHOD ENZYMOL, V209, P348; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; EPAND RM, 1990, CHEM PHYS LIPIDS, V52, P227, DOI 10.1016/0009-3084(90)90118-B; Epand RM, 1998, BIOCHEMISTRY-US, V37, P12068, DOI 10.1021/bi980527c; FARREN SB, 1980, BIOCHEM BIOPH RES CO, V97, P182, DOI 10.1016/S0006-291X(80)80152-5; FINE JB, 1982, J LIPID RES, V23, P660; GRUNER SM, 1988, BIOCHEMISTRY-US, V27, P2853, DOI 10.1021/bi00408a029; HARLOS K, 1981, BIOCHEMISTRY-US, V20, P2888, DOI 10.1021/bi00513a027; HAWROT E, 1978, J BIOL CHEM, V253, P8213; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; LEWIS RNAH, 1993, BIOPHYS J, V64, P1081, DOI 10.1016/S0006-3495(93)81474-7; LI L, 1995, CHEM PHYS LIPIDS, V76, P135, DOI 10.1016/0009-3084(95)02437-N; LOHNER K, 1991, BIOCHIM BIOPHYS ACTA, V1061, P132, DOI 10.1016/0005-2736(91)90277-F; MANNOCK DA, 1992, BIOPHYS J, V63, P1355, DOI 10.1016/S0006-3495(92)81713-7; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Marsh D., 1993, PROTEIN LIPID INTERA, P41; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; PAGE MGP, 1988, J BIOL CHEM, V263, P15897; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SEDDON JM, 1983, BIOCHEMISTRY-US, V22, P1280, DOI 10.1021/bi00274a045; SELINSKY BS, 1992, STRUCTURE BIOL MEMBR, P603; SkorkoGlonek J, 1997, J BIOL CHEM, V272, P8974; Starling AP, 1996, BIOCHEM J, V320, P309, DOI 10.1042/bj3200309; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P274, DOI 10.1021/bi962292f; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TILCOCK CPS, 1982, BIOCHIM BIOPHYS ACTA, V684, P212, DOI 10.1016/0005-2736(82)90008-6; TILCOCK CPS, 1986, BIOCHEMISTRY-US, V25, P816, DOI 10.1021/bi00352a013; UJWAL ML, 1994, MOL MEMBR BIOL, V11, P9, DOI 10.3109/09687689409161024; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8; Voss J, 1997, BIOCHEMISTRY-US, V36, P15055, DOI 10.1021/bi971726j; ZARDENETA G, 1993, BIOCHEMISTRY-US, V32, P13941, DOI 10.1021/bi00213a025; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811; ZARDENETA G, 1992, EUR J BIOCHEM, V210, P831, DOI 10.1111/j.1432-1033.1992.tb17486.x	50	111	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12339	12345		10.1074/jbc.274.18.12339	http://dx.doi.org/10.1074/jbc.274.18.12339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212204	hybrid			2022-12-25	WOS:000080056800024
J	Groh, S; Marty, I; Ottolia, M; Prestipino, G; Chapel, A; Villaz, M; Ronjat, M				Groh, S; Marty, I; Ottolia, M; Prestipino, G; Chapel, A; Villaz, M; Ronjat, M			Functional interaction of the cytoplasmic domain of triadin with the skeletal ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; CA2+ RELEASE; DIHYDROPYRIDINE RECEPTOR; GLYCOPROTEIN TRIADIN; CA-2+ RELEASE; MUSCLE; CALSEQUESTRIN; VESICLES; PROTEIN	Triadin has been shown to co-localize with the ryanodine receptor in the sarcoplasmic reticulum membrane. We show that immunoprecipitation of solubilized sarcoplasmic reticulum membrane with antibodies directed against triadin or ryanodine receptor, leads to the coimmunoprecipitation of ryanodine receptor and triadin, We then investigated the functional importance of the cytoplasmic domain of triadin (residues 1-47) in the control of Ca2+ release from sarcoplasmic reticulum, We show that antibodies directed against a synthetic peptide encompassing residues 2-17, induce a decrease in the rate of Ca2+ release from sarcoplasmic reticulum vesicles as well as a decrease in the open probability of the ryanodine receptor Ca2+ channel incorporated in lipid bilayers, Using surface plasmon resonance spectroscopy, we defined a discrete domain (residues 18-46) of the cytoplasmic part of triadin interacting with the purified ryanodine receptor. This interaction is optimal at low Ca2+ concentration (up to pCa 5) and inhibited by increasing calcium concentration (IC50 of 300 mu M). The direct molecular interaction of this triadin domain with the ryanodine receptor was confirmed by overlay assay and shown to induce the inhibition of the Ca2+ channel activity of purified RyR in bilayer, We propose that this interaction plays a critical role in the control, by triadin, of the Ca2+ channel behavior of the ryanodine receptor and therefore may represent an important step in the regulation process of excitation-contraction coupling in skeletal muscle.	CEA, DBMS, Lab Canaux Ion & Signalisat, F-38054 Grenoble, France; CNR, Ist Cibernet & Biofis, I-16149 Genoa, Italy; CEA, DBMS, Lab Chim Prot, F-38054 Grenoble, France	CEA; Consiglio Nazionale delle Ricerche (CNR); CEA	Ronjat, M (corresponding author), CEA, DBMS, Lab Canaux Ion & Signalisat, 17 Rue Martyrs, F-38054 Grenoble, France.	mronjat@cea.fr	Marty, Isabelle/ABF-5362-2020; Marty, Isabelle/N-7114-2017	Marty, Isabelle/0000-0003-3625-913X; Ronjat, Michel/0000-0002-9728-6425				BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRANDT NR, 1992, FEBS LETT, V299, P57, DOI 10.1016/0014-5793(92)80100-U; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BURATTI R, 1995, BIOCHEM BIOPH RES CO, V213, P1082, DOI 10.1006/bbrc.1995.2238; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; IKEMOTO N, 1989, J BIOENERG BIOMEMBR, V21, P247, DOI 10.1007/BF00812071; IKEMOTO N, 1984, J BIOL CHEM, V259, P3151; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEUNG AT, 1988, J BIOL CHEM, V263, P994; LIU GH, 1994, J BIOL CHEM, V269, P33028; MARSILI V, 1992, J MUSCLE RES CELL M, V13, P511, DOI 10.1007/BF01737993; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARTY I, 1995, BIOCHEM J, V307, P769, DOI 10.1042/bj3070769; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MOUTIN MJ, 1988, J BIOL CHEM, V263, P4228; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Treves S, 1997, BIOCHEMISTRY-US, V36, P11496, DOI 10.1021/bi970160w; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	36	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	1999	274	18					12278	12283		10.1074/jbc.274.18.12278	http://dx.doi.org/10.1074/jbc.274.18.12278			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192BC	10212196	hybrid			2022-12-25	WOS:000080056800016
J	Bertero, MG; Gonzales, B; Tarricone, C; Ceciliani, F; Galizzi, A				Bertero, MG; Gonzales, B; Tarricone, C; Ceciliani, F; Galizzi, A			Overproduction and characterization of the Bacillus subtilis anti-sigma factor FlgM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SIGMA(F); COLI RNA-POLYMERASE; FLAGELLUM-SPECIFIC SIGMA; SALMONELLA-TYPHIMURIUM; GENE-EXPRESSION; BACTERIOPHAGE-T4 ASIA; NEGATIVE REGULATOR; FACTOR SPOIIAB; PROTEIN; INHIBITION	FlgM is an anti-sigma factor of the flagellar-specific sigma (sigma) subunit of RNA polymerase in Bacillus subtilis, and it is responsible of the coupling of late flagellar gene expression to the completion of the hook-basal body structure. We have overproduced the protein in soluble form and characterized it. FlgM forms dimers as shown by gel exclusion chromatography and native polyacrylamide gel electrophoresis and interacts in vitro with the cognate sigma(D) factor. The FlgM .sigma(D) complex is a stable heterodimer as demonstrated by gel exclusion chromatography, chemical cross-linking, native polyacrylamide gel electrophoresis, and isoelectric focusing. sigma(D) belongs to the group of sigma factors able to bind to the promoter sequence even in the absence of core RNA polymerase. The FlgM .sigma(D) complex gave a shift in a DNA mobility shift assay with a probe containing a sigma(D)-dependent promoter sequence. Limited proteolysis studies indicate the presence of two structural motifs, corresponding to the N- and C-terminal regions, respectively.	Univ Pavia, Dipartimento Genet & Microbiol A Buzzati Traverso, I-27100 Pavia, Italy; Univ Milan, Dipartimento Fisiol Vet & Biochim, I-20133 Milan, Italy	University of Pavia; University of Milan	Galizzi, A (corresponding author), Univ Pavia, Dipartimento Genet & Microbiol A Buzzati Traverso, Via Abbiategrasso 207, I-27100 Pavia, Italy.		Ceciliani, Fabrizio/Q-6551-2017	Ceciliani, Fabrizio/0000-0002-9199-5757; Bertero, Michela/0000-0002-2012-6706				Adelman K, 1997, J BIOL CHEM, V272, P27435, DOI 10.1074/jbc.272.43.27435; ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; Alper S, 1996, J MOL BIOL, V260, P165, DOI 10.1006/jmbi.1996.0390; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BROWN KL, 1995, MOL MICROBIOL, V16, P397, DOI 10.1111/j.1365-2958.1995.tb02405.x; Caramori T, 1996, J BACTERIOL, V178, P3113, DOI 10.1128/jb.178.11.3113-3118.1996; Chadsey MS, 1998, GENE DEV, V12, P3123, DOI 10.1101/gad.12.19.3123; CHEN YF, 1995, J MOL BIOL, V249, P743, DOI 10.1006/jmbi.1995.0333; Colland F, 1998, MOL MICROBIOL, V27, P819, DOI 10.1046/j.1365-2958.1998.00729.x; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; Decatur AL, 1996, GENE DEV, V10, P2348, DOI 10.1101/gad.10.18.2348; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DUFOUR A, 1994, J BACTERIOL, V176, P1813, DOI 10.1128/jb.176.7.1813-1820.1994; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; Fredrick K, 1996, J BACTERIOL, V178, P7010, DOI 10.1128/jb.178.23.7010-7013.1996; GILLEN KL, 1991, J BACTERIOL, V173, P6453, DOI 10.1128/jb.173.20.6453-6459.1991; Gorham HC, 1996, MOL MICROBIOL, V19, P171, DOI 10.1046/j.1365-2958.1996.360888.x; Huang XJ, 1998, J BACTERIOL, V180, P3765, DOI 10.1128/JB.180.15.3765-3770.1998; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; Iyoda S, 1995, MOL GEN GENET, V249, P417; KUTSUKAKE K, 1994, MOL GEN GENET, V243, P605, DOI 10.1007/BF00279569; KUTSUKAKE K, 1994, EMBO J, V13, P4568, DOI 10.1002/j.1460-2075.1994.tb06778.x; Magnin T, 1996, MOL MICROBIOL, V19, P901, DOI 10.1046/j.1365-2958.1996.434964.x; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; MIREL DB, 1994, J BACTERIOL, V176, P4492, DOI 10.1128/JB.176.15.4492-4500.1994; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; ORSINI G, 1993, J BACTERIOL, V175, P85, DOI 10.1128/JB.175.1.85-93.1993; Schurr MJ, 1996, J BACTERIOL, V178, P4997, DOI 10.1128/jb.178.16.4997-5004.1996; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Severinova E, 1998, J MOL BIOL, V279, P9, DOI 10.1006/jmbi.1998.1742; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Xie ZD, 1996, J BACTERIOL, V178, P4990, DOI 10.1128/jb.178.16.4990-4996.1996	35	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12103	12107		10.1074/jbc.274.17.12103	http://dx.doi.org/10.1074/jbc.274.17.12103			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207036	hybrid			2022-12-25	WOS:000079834800092
J	Hayman, ML; Read, LK				Hayman, ML; Read, LK			Trypanosoma brucei RBP16 is a mitochondrial Y-box family protein with guide RNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-SHOCK DOMAIN; MESSENGER-RNA; RIBONUCLEOPROTEIN COMPLEXES; KINETOPLASTID MITOCHONDRIA; IN-VITRO; LEISHMANIA-TARENTOLAE; ESCHERICHIA-COLI; LIFE-CYCLE; IDENTIFICATION; MOLECULES	Trypanosoma brucei mitochondria possess a unique mechanism of mRNA maturation called RNA editing, In this process, uridylate residues are inserted and deleted posttranscriptionally into pre-mRNA to create translatable messages. The genetic information for RNA editing resides in small RNA molecules called guide RNAs (gRNAs), Thus, proteins in direct contact with gRNA are likely to catalyze or influence RNA editing. Herein we characterize an abundant gRNA-binding protein from T, brucei mitochondria. This protein, which we term RBP16 (for RNA-binding protein of 16 kDa), binds to different gRNA molecules. The major determinant of this interaction is the oligo(U) tail, present on the 3'-ends of gRNAs. RBP16 forms multiple, stable complexes with gRNA in vitro, and immunoprecipitation experiments provide evidence for an association between RBP16 and gRNA within T, brucei mitochondria. Mature RBP16 contains a cold shock domain at the N terminus and a C-terminal region rich in arginine and glycine, The presence of the cold shock domain places RBP16 as the first organellar member of the highly conserved Y-box protein family. The arginine and glycine rich C terminus in combination with the cold shock domain predicts that RBP16 will be involved in the regulation of gene expression at the posttranscriptional level.	SUNY Buffalo, Sch Med, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med, Ctr Microbial Pathogenesis, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Read, LK (corresponding author), SUNY Buffalo, Sch Med, Dept Microbiol, 138 Farber Hall, Buffalo, NY 14214 USA.	lread@acsu.buffalo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053502] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53502] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER BK, 1991, MOL CELL BIOL, V11, P5878, DOI 10.1128/MCB.11.12.5878; Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; Allen TE, 1998, MOL CELL BIOL, V18, P6014, DOI 10.1128/MCB.18.10.6014; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; Arts GJ, 1996, BBA-GENE STRUCT EXPR, V1307, P39; AUSABEL F, 1995, CURRENT PROTOCOLS MO; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; Bringaud F, 1997, MOL CELL BIOL, V17, P3915, DOI 10.1128/MCB.17.7.3915; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; BRUN R, 1979, ACTA TROP, V36, P289; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Franco GR, 1997, GENE, V198, P5, DOI 10.1016/S0378-1119(97)00261-8; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; Graumann P, 1997, MOL MICROBIOL, V25, P741, DOI 10.1046/j.1365-2958.1997.5121878.x; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; HANCOCK K, 1992, J BIOL CHEM, V267, P23963; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Hermann T, 1997, NUCLEIC ACIDS RES, V25, P2311, DOI 10.1093/nar/25.12.2311; JASMER DP, 1985, MOL CELL BIOL, V5, P3041, DOI 10.1128/MCB.5.11.3041; Jiang WN, 1997, J BIOL CHEM, V272, P196; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; KOLLER J, 1994, NUCLEIC ACIDS RES, V22, P1988, DOI 10.1093/nar/22.11.1988; Koller J, 1997, J BIOL CHEM, V272, P3749, DOI 10.1074/jbc.272.6.3749; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LEEGWATER P, 1995, EUR J BIOCHEM, V227, P780, DOI 10.1111/j.1432-1033.1995.tb20201.x; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; PARSONS M, 1991, EXP PARASITOL, V73, P101, DOI 10.1016/0014-4894(91)90012-L; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Salvetti A, 1998, DEV BIOL, V201, P217, DOI 10.1006/dbio.1998.8996; SCHMID B, 1995, NUCLEIC ACIDS RES, V23, P3093, DOI 10.1093/nar/23.16.3093; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SKEHEL PA, 1994, GENE, V145, P231, DOI 10.1016/0378-1119(94)90011-6; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; Thieringer HA, 1997, NUCLEIC ACIDS RES, V25, P4764, DOI 10.1093/nar/25.23.4764; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vanhamme L, 1998, J BIOL CHEM, V273, P21825, DOI 10.1074/jbc.273.34.21825	48	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12067	12074		10.1074/jbc.274.17.12067	http://dx.doi.org/10.1074/jbc.274.17.12067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207031	hybrid			2022-12-25	WOS:000079834800087
J	Suetomi, K; Lu, ZJ; Heck, T; Wood, TG; Prusak, DJ; Dunn, KJ; Navarro, J				Suetomi, K; Lu, ZJ; Heck, T; Wood, TG; Prusak, DJ; Dunn, KJ; Navarro, J			Differential mechanisms of recognition and activation of interleukin-8 receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; AMINO TERMINUS; PROTEIN; BINDING; CHEMOKINES; EXPRESSION; NEUTROPHIL; SURFACE; IDENTIFICATION; SPECIFICITY	We have probed an epitope sequence (His(18)-Pro(19)- Lys(20)-Phe(21)) in interleukin-8 (IL-8) by site-directed mutagenesis, This work shows that single and double Ala substitutions of His(18) and Phe(21) in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen. These Ala mutants triggered neutrophil degranulation and induced calcium responses mediated by CXCR1 and CXCR2, Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to CXCR1, CXCR2, and the Duffy antigen, Interestingly, double mutants with charged residue substitutions failed to trigger degranulation or to induce wildtype calcium responses mediated by CXCR1, Except for the H18A and F21A mutants, all other IL-8 mutants failed to induce superoxide production in neutrophils, This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Genet Inst, Cambridge, MA 02140 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Navarro, J (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA.		Wood, Thomas/GWZ-2481-2022; Wood, Thomas/B-6172-2012	Wood, Thomas/0000-0001-8962-8571; Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034031] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34031] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Baly D, 1997, METHOD ENZYMOL, V287, P69; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1994, J BIOL CHEM, V269, P17730; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SKLAR LA, 1985, J BIOL CHEM, V260, P1461; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; WILLIAMSON K, 1988, BIOCHEMISTRY-US, V27, P5371, DOI 10.1021/bi00414a062; WOOD TG, 1994, CHALL MOD MED, V3, P217; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3	29	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11768	11772		10.1074/jbc.274.17.11768	http://dx.doi.org/10.1074/jbc.274.17.11768			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206993	hybrid			2022-12-25	WOS:000079834800049
J	Tan, MJ; Li, SJ; Swaroop, MJ; Guan, KL; Oberley, LW; Sun, Y				Tan, MJ; Li, SJ; Swaroop, MJ; Guan, KL; Oberley, LW; Sun, Y			Transcriptional activation of the human glutathione peroxidase promoter by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; NUCLEAR ANTIGEN PROMOTER; TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINES; NASOPHARYNGEAL CARCINOMA; ANTIOXIDANT ENZYMES; TISSUE INHIBITOR; CYCLE CONTROL; BINDING-SITE; DNA-DAMAGE	Glutathione peroxidase (GPX) is a primary antioxidant enzyme that scavenges hydrogen peroxide or organic hydroperoxides. We have recently found that GPX is induced by etoposide, a topoisomerase II inhibitor and a p53 activator. In a search for a cis-element that confers potential p53 regulation of GPX, we identified a p53 binding site in the promoter of the GPX gene. This site bound to purified p53 as well as p53 in nuclear extract activated by etoposide. A luciferase reporter driven by a 262-base pair GPX promoter fragment was transcriptionally activated by wild type p53 in a p53 binding site-dependent manner. The same reporter was also activated in a p53 binding site-independent manner by several p53 mutants. The p53 binding and transactivation of the GPX promoter were enhanced by etoposide in p53-positive U2-OS cells. Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter, Furthermore, expression of endogenous GPX was induced significantly at both mRNA and enzyme activity levels by etoposide in U2-OS cells but not in p53-negative Saos-2 cells. This is the first report demonstrating that GPX is a novel p53 target gene. The finding links the p53 tumor suppressor to an antioxidant enzyme and will facilitate study of the p53 signaling pathway and antioxidant enzyme regulation.	Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Univ Iowa, Radiat Res Lab, Iowa City, IA 52242 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Pfizer; University of Iowa; University of Michigan System; University of Michigan	Sun, Y (corresponding author), Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA.		Guan, Kun-Liang/ADK-7088-2022	Swaroop, Manju/0000-0002-0576-1664				ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHU FF, 1993, J BIOL CHEM, V268, P2571; COWAN DB, 1992, J MOL CELL CARDIOL, V24, P423, DOI 10.1016/0022-2828(92)93196-Q; COWAN DB, 1993, J BIOL CHEM, V268, P26904; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; FRANK L, 1984, PEDIATR RES, V18, P240, DOI 10.1203/00006450-198403000-00004; Fuchs EJ, 1997, CANCER RES, V57, P2550; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOLDSMITH ME, 1995, J BIOL CHEM, V270, P2894; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IGRISHI T, 1985, J BIOCH, V9, P117; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; LAI GM, 1991, INT J CANCER, V49, P688, DOI 10.1002/ijc.2910490511; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBMANN J, 1995, CANCER RES, V55, P4465; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, COLD SPRING HARB SYM, V59, P419, DOI 10.1101/SQB.1994.059.01.047; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Masanek U, 1997, ANTI-CANCER DRUG, V8, P189, DOI 10.1097/00001813-199702000-00010; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLS GC, 1957, J BIOL CHEM, V229, P189; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; OGAWA J, 1993, CANCER-AM CANCER SOC, V71, P2204, DOI 10.1002/1097-0142(19930401)71:7<2204::AID-CNCR2820710707>3.0.CO;2-O; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAGILA DE, 1967, J LAB CLIN MED, V70, P158; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SPALLHOLZ JE, 1991, PEROXIDASES CHEM BIO, V1, P259; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1994, CANCER RES, V54, P1139; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; VOLM M, 1995, INT J CANCER, V63, P193, DOI 10.1002/ijc.2910630208; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang YX, 1999, FEBS LETT, V445, P269, DOI 10.1016/S0014-5793(99)00136-2; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	73	185	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					12061	12066		10.1074/jbc.274.17.12061	http://dx.doi.org/10.1074/jbc.274.17.12061			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10207030	hybrid			2022-12-25	WOS:000079834800086
J	Zhu, GY; Qu, ZQ; Cui, NG; Jiang, C				Zhu, GY; Qu, ZQ; Cui, NG; Jiang, C			Suppression of Kir2.3 activity by protein kinase C phosphorylation of the channel protein at threonine 53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNEL; RECTIFYING K+ CHANNEL; XENOPUS OOCYTES; DUAL MODULATION; INHIBITION; NEURONS; ATP; CONDUCTANCE; CELLS	Kir2.3 plays an important part in the maintenance of membrane potential in neurons and myocardium. Identification of intracellular signaling molecules controlling this channel thus may lead to an understanding of the regulation of membrane excitability. To determine whether Kir2.3 is modulated by direct phosphorylation of its channel protein and identify the phosphorylation site of protein kinase C (PKC), we performed experiments using several recombinant and mutant Kir2.3 channels, Whole-cell Kir2.3 currents were inhibited by phorbol la-myristate 13-acetate (PMA) in Xenopus oocytes. When the N-terminal region of Kir2.3 was replaced with that of Kir2.1, another member in the Kir2 family that is insensitive to PMA, the chimerical channel lost its PMA sensitivity. However, substitution of the C terminus was ineffective. Four potential PKC phosphorylation sites in the N terminus were studied by comparing mutations of serine or threonine with their counterpart residues in Kir2.1. Whereas substitutions of serine residues at positions 5, 36, and 39 had no effect on the channel sensitivity to PMA, mutation of threonine 53 completely eliminated the channel response to PMA. Interestingly, creation of this threonine residue at the corresponding position (I79T) in Kir2.1 lent the mutant channel a PMA sensitivity almost identical to the wildtype Kir2.3. These results therefore indicate that Kir2.3 is directly modulated by PKC phosphorylation of its channel protein and threonine 53 is the PKC phosphorylation site in Kir2.3.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Cent Ave, Atlanta, GA 30303 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58410-01, R01 HL058410] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cohen NA, 1996, J BIOL CHEM, V271, P32301, DOI 10.1074/jbc.271.50.32301; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; DiMagno L, 1996, PFLUG ARCH EUR J PHY, V431, P335, DOI 10.1007/BF02207270; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Garcia DE, 1998, J NEUROSCI, V18, P2834; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jiang C, 1997, J NEUROPHYSIOL, V77, P93, DOI 10.1152/jn.1997.77.1.93; JIANG C, 1994, J NEUROSCI, V14, P5590; Jones SVP, 1997, NEUROPHARMACOLOGY, V36, P209, DOI 10.1016/S0028-3908(96)00142-6; Macica CM, 1998, AM J PHYSIOL-RENAL, V274, pF175, DOI 10.1152/ajprenal.1998.274.1.F175; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; SATO R, 1995, J MEMBRANE BIOL, V148, P185; SCHWAB A, 1993, J MEMBRANE BIOL, V132, P125; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; SULLIVAN SK, 1990, P NATL ACAD SCI USA, V87, P4553, DOI 10.1073/pnas.87.12.4553; TABCHARANI JA, 1994, J MEMBRANE BIOL, V142, P255; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; TANG WM, 1994, FEBS LETT, V348, P239, DOI 10.1016/0014-5793(94)00612-1; Visentin S, 1997, J NEUROSCI RES, V47, P233; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; Welling PA, 1997, AM J PHYSIOL-RENAL, V273, pF825, DOI 10.1152/ajprenal.1997.273.5.F825; WU T, 1995, NEUROSCI LETT, V184, P121, DOI 10.1016/0304-3940(94)11185-L	25	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11643	11646		10.1074/jbc.274.17.11643	http://dx.doi.org/10.1074/jbc.274.17.11643			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206975	hybrid			2022-12-25	WOS:000079834800031
J	Zou, H; Li, YC; Liu, HS; Wang, XD				Zou, H; Li, YC; Liu, HS; Wang, XD			An APAF-1 center dot cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; ELEGANS CED-4; PROTEASE; PATHWAYS; OLIGOMERIZATION; REQUIREMENT; CASPASE-3; APAF-1; DATP	We report here the reconstitution of the de novo procaspase-9 activation pathway using highly purified cytochrome c, recombinant APAF-1, and recombinant procaspase-9, APAF-1 binds and hydrolyzes ATP or dATP to ADP or dADP, respectively. The hydrolysis of ATP/dATP and the binding of cytochrome c promote APAF-1 oligomerization, forming a large multimeric APAF-1 cytochrome c complex. Such a complex can be isolated using gel filtration chromatography and is by itself sufficient to recruit and activate procaspase-9, The stoichiometric ratio of procaspase-9 to APAF-1 is approximately 1 to 1 in the complex. Once activated, caspase-9 disassociates from the complex and becomes available to cleave and activate downstream caspases such as caspase-3.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	xwang@biochem.swmed.edu		Wang, Xiaodong/0000-0001-9885-356X	NIGMS NIH HHS [GMRO1-57158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; SKOOG L, 1974, J BIOL CHEM, V249, P6434; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	31	1693	1782	4	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	1999	274	17					11549	11556		10.1074/jbc.274.17.11549	http://dx.doi.org/10.1074/jbc.274.17.11549			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	188EX	10206961	hybrid			2022-12-25	WOS:000079834800017
